Eigene Vorlage

Dossier zur Nutzenbewertung gemäß § 35a SGB V

Belantamab-Mafodotin (BLENREP)

GlaxoSmithKline GmbH & Co.KG

Separater Anhang 4-G zu Modul 4A

Tabellen und Abbildungen

Stand: 31.03.2023

Inhaltsverzeichnis

Protocol: 207495 Page 1 of 1
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 1.001110
Summary of Subject Status and Subject Disposition for the Study Conclusion Record

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)	Total (N=44)
Subject Status			
Died	4 (27%)	16 (55%)	20 (45%)
Ongoing	9 (60%)	13 (45%)	22 (50%)
On study treatment	1 (7%)	5 (17%)	6 (14%)
In follow-up	8 (53%)	8 (28%)	16 (36%)
Withdrawn from study	2 (13%)	0	2 (5%)
Primary Reason [1]/Subreason [2] for Study Withdrawal			
Protocol deviation	0	0	0
Study terminated by sponsor	0	0	0
Lost to follow-up	0	0	0
Subject relocated	0	0	0
Subject was incarcerated	0	0	0
Other	0	0	0
Site terminated by sponsor	0	0	0
Physician decision	0	0	0
Withdrawal by subject	2 (13%)	0	2 (5%)
Burden of procedure	0	0	0
Subject relocated	0	0	0
Other	2 (13%)	0	2 (5%)

[1] Subjects may have only one primary reason.
[2] Percentages for subreasons may sum to more or less than 100%. Subjects may have more than one subreason underneath a single primary reason. Subjects are not required to indicate subreasons.
Note: A subject is considered on study treatment until they discontinue all components of their study treatment.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_sp_es8.sas 16DEC2022 08:46

Table 1.002110
Summary of Treatment Status and Reasons for Discontinuation of Study Treatment

	Pom (N=15)	Dex (N=15)	Belantamab mafodotin (N=29)
Treatment Status			
Not Treated	1 (7%)	1 (7%)	0
Ongoing	1 (7%)	1 (7%)	5 (17%)
Discontinued	13 (87%)	13 (87%)	24 (83%)

[1] Subjects may have only one primary reason.
[2] Percentages for subreasons may sum to more or less than 100%. Subjects may have more than one subreason underneath a single primary reason. Subjects are not required to indicate subreasons.
Note: Number of subjects for Pom and Dex is the number of subjects in the Pom/Dex treatment group.
Note: Reasons for treatment discontinuation are only presented for treated subjects. Subjects that are assigned as 'discontinued' due to death may or may not have a reason for study treatment discontinuation.
Note: There is 1 subject who died that is not included in the primary reason for treatment discontinuation section, but is recorded as discontinued.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_sp_sd4.sas 16DEC2022 05:42

Table 1.002110
Summary of Treatment Status and Reasons for Discontinuation of Study Treatment

	Pom (N=15)	Dex (N=15)	Belantamab mafodotin (N=29)
Primary Reason [1]/Subreason [2] for Treatment Discontinuation			
Progressive disease	6 (40%)	7 (47%)	13 (45%)
Adverse event	2 (13%)	2 (13%)	1 (3%)
Lack of efficacy	0	0	0
Protocol deviation	0	0	0
Study terminated by sponsor	0	0	0
Lost to follow-up	0	0	0
Subject relocated	0	0	0
Subject was incarcerated	0	0	0
Other	0	0	0
Site terminated by sponsor	0	0	0
Physician decision	4 (27%)	3 (20%)	10 (34%)
Clinical relapse	1 (7%)	1 (7%)	3 (10%)
Other	3 (20%)	2 (13%)	7 (24%)
Withdrawal by subject	1 (7%)	1 (7%)	0
Burden of procedure	0	0	0
Subject relocated	0	0	0
Other	1 (7%)	1 (7%)	0
Sponsor terminated study treatment	0	0	0

[1] Subjects may have only one primary reason.
[2] Percentages for subreasons may sum to more or less than 100%. Subjects may have more than one subreason underneath a single primary reason. Subjects are not required to indicate subreasons.
Note: Number of subjects for Pom and Dex is the number of subjects in the Pom/Dex treatment group.
Note: Reasons for treatment discontinuation are only presented for treated subjects. Subjects that are assigned as 'discontinued' due to death may or may not have a reason for study treatment discontinuation.
Note: There is 1 subject who died that is not included in the primary reason for treatment discontinuation section, but is recorded as discontinued.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_sp_sd4.sas 16DEC2022 05:42

Table 1.002110
Summary of Treatment Status and Reasons for Discontinuation of Study Treatment

	Pom (N=15)	Dex (N=15)	Belantamab mafodotin (N=29)
Treatment discontinuation related to study treatment?/Primary Reason [1]			
No	2 (13%)	2 (13%)	6 (21%)
Yes	5 (33%)	4 (27%)	2 (7%)
Adverse event	1 (7%)	1 (7%)	1 (3%)
Lack of efficacy	0	0	0
Protocol deviation	0	0	0
Physician decision	3 (20%)	2 (13%)	1 (3%)
Withdrawal by subject	1 (7%)	1 (7%)	0

[1] Subjects may have only one primary reason.
[2] Percentages for subreasons may sum to more or less than 100%. Subjects may have more than one subreason underneath a single primary reason. Subjects are not required to indicate subreasons.
Note: Number of subjects for Pom and Dex is the number of subjects in the Pom/Dex treatment group.
Note: Reasons for treatment discontinuation are only presented for treated subjects. Subjects that are assigned as 'discontinued' due to death may or may not have a reason for study treatment discontinuation.
Note: There is 1 subject who died that is not included in the primary reason for treatment discontinuation section, but is recorded as discontinued.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_sp_sd4.sas 16DEC2022 05:42

Protocol: 207495 Page 1 of 1
Population: All Screened (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 1.003110
Summary of Screening Status and Reasons for Screen Failure

	Screened Subjects (N=45)
Screening Status	
ENTERED INTO TRIAL	44 (98%)
FAILED	1 (2%)
Primary Reason for Failure	
DID NOT MEET INCLUSION/EXCLUSION CRITERIA	0
ADVERSE EVENT	0
PROTOCOL DEVIATION	0
STUDY TERMINATED BY SPONSOR	0
LOST TO FOLLOW-UP	0
PHYSICIAN DECISION	1 (2%)
WITHDRAWAL BY SUBJECT	0

Note: Subjects may have only one primary reason for screen failure.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_sp_es6.sas 21DEC2022 06:08

Protocol: 207495 Page 1 of 1
Population: All Screened (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 1.005110
Summary of Study Populations

Population	Screen Failure (N=1)	Pom/Dex (N=15)	Belantamab mafodotin (N=29)	Total (N=45)
All Screened	1 (100%)	15 (100%)	29 (100%)	45 (100%)
Enrolled	0	15 (100%)	29 (100%)	44 (98%)
Intent-to-Treat	0	15 (100%)	29 (100%)	44 (98%)
Modified Intent-to-Treat	0	14 (93%)	29 (100%)	43 (96%)
Safety	0	14 (93%)	29 (100%)	43 (96%)
Pharmacokinetic	0	0	29 (100%)	29 (64%)
Ocular Sub-study	0	0	2 (7%)	2 (4%)
Modified Ocular Sub-study	0	0	1 (3%)	1 (2%)

PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_sp_sp1.sas 15DEC2022 07:44

Protocol: 207495 Page 1 of 3
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 1.006110
Summary of Demographic Characteristics

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)	Total (N=44)
Sex			
n	15	29	44
Female	7 (47%)	12 (41%)	19 (43%)
Male	8 (53%)	17 (59%)	25 (57%)
Age (years) [1]			
n	15	29	44
Mean	66.5	63.4	64.5
SD	8.35	10.35	9.73
Median	67.0	64.0	66.0
Min.	51	43	43
Max.	79	84	84
Age Group 1 (years) [1]			
n	15	29	44
<65	6 (40%)	15 (52%)	21 (48%)
>=65 to <75	7 (47%)	10 (34%)	17 (39%)
>=75	2 (13%)	4 (14%)	6 (14%)
Age Group 2 (years) [1]			
n	15	29	44
<=18	0	0	0
19-64	6 (40%)	15 (52%)	21 (48%)
>=65	9 (60%)	14 (48%)	23 (52%)
Ethnicity			
n	15	29	44
HISPANIC OR LATINO	1 (7%)	5 (17%)	6 (14%)
NOT HISPANIC OR LATINO	14 (93%)	24 (83%)	38 (86%)

[1] Age is imputed when full date of birth is not provided.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_sp_dm.sas 15DEC2022 07:54

Protocol: 207495 Page 2 of 3
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 1.006110
Summary of Demographic Characteristics

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)	Total (N=44)
High Level Race			
n	15	29	44
AMERICAN INDIAN OR ALASKA NATIVE	0	0	0
ASIAN	3 (20%)	5 (17%)	8 (18%)
BLACK OR AFRICAN AMERICAN	0	1 (3%)	1 (2%)
NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER	0	0	0
WHITE	12 (80%)	23 (79%)	35 (80%)
MIXED RACE	0	0	0
Race Detail			
n	15	29	44
AMERICAN INDIAN OR ALASKA NATIVE	0	0	0
ASIAN - CENTRAL/SOUTH ASIAN HERITAGE	0	0	0
ASIAN - EAST ASIAN HERITAGE	2 (13%)	0	2 (5%)
ASIAN - JAPANESE HERITAGE	1 (7%)	5 (17%)	6 (14%)
ASIAN - SOUTH EAST ASIAN HERITAGE	0	0	0
BLACK OR AFRICAN AMERICAN	0	1 (3%)	1 (2%)
NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER	0	0	0
WHITE - ARABIC/NORTH AFRICAN HERITAGE	0	0	0
WHITE - WHITE/CAUCASIAN/EUROPEAN HERITAGE	12 (80%)	23 (79%)	35 (80%)
MIXED ASIAN RACE	0	0	0
MIXED WHITE RACE	0	0	0
MIXED RACE	0	0	0
Height (cm)			
n	15	29	44
Mean	164.95	165.75	165.48
SD	9.188	10.651	10.075
Median	164.00	165.00	164.50
Min.	150.0	142.3	142.3
Max.	181.0	183.0	183.0

[1] Age is imputed when full date of birth is not provided.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_sp_dm.sas 15DEC2022 07:54

Protocol: 207495 Page 3 of 3
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 1.006110
Summary of Demographic Characteristics

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)	Total (N=44)
Weight (kg)			
n	15	29	44
Mean	74.11	76.65	75.78
SD	14.888	15.817	15.380
Median	70.60	77.30	75.85
Min.	49.3	37.0	37.0
Max.	104.5	102.0	104.5
BMI (kg/m2)			
n	15	29	44
Mean	27.11	27.67	27.48
SD	4.207	4.259	4.201
Median	27.14	28.05	28.00
Min.	21.9	18.3	18.3
Max.	35.4	36.4	36.4

[1] Age is imputed when full date of birth is not provided.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_sp_dm.sas 15DEC2022 07:54

Protocol: 207495 Page 1 of 1
Population: Enrolled (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 1.007110
Summary of Age Ranges

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)	Total (N=44)
Age Ranges [1]			
Adult (18-64 years)	6 (40%)	15 (52%)	21 (48%)
>=65-84 years	9 (60%)	14 (48%)	23 (52%)
>=85 years	0	0	0

[1] Age is imputed when full date of birth is not provided.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_sp_dm11.sas 16DEC2022 04:48

Protocol: 207495 Page 1 of 1
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 1.025110
Summary of Number of Subjects in Subgroups

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)	Total (N=44)
ISS (International Staging System) staging [1]			
n	15	29	44
I/II	10 (67%)	19 (66%)	29 (66%)
III	5 (33%)	10 (34%)	15 (34%)
Age Group (years) [2]			
n	15	29	44
<65	6 (40%)	15 (52%)	21 (48%)
>=65 to <75	7 (47%)	10 (34%)	17 (39%)
>=75	2 (13%)	4 (14%)	6 (14%)
Sex			
n	15	29	44
Female	7 (47%)	12 (41%)	19 (43%)
Male	8 (53%)	17 (59%)	25 (57%)
Region of Enrolment			
n	15	29	44
North America	0	0	0
Europe	10 (67%)	18 (62%)	28 (64%)
North East Asia	3 (20%)	5 (17%)	8 (18%)
Rest of the world	2 (13%)	6 (21%)	8 (18%)

[1] ISS staging at Screening as collected on the eCRF.
[2] Age is imputed when full date of birth is not provided.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_sp_dm_sub.sas 30JAN2023 04:17

Protocol: 207495 Page 1 of 1
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 1.008110
Summary of Race and Racial Combinations

Race	Race Detail	Pom/Dex (N=15)		Belantamab mafodotin (N=29)		Total (N=44)	
n		15		29		44	
AMERICAN INDIAN OR ALASKA NATIVE		0		0		0	
ASIAN		3	(20%)	5	(17%)	8	(18%)
	CENTRAL/SOUTH ASIAN HERITAGE	0		0		0	
	EAST ASIAN HERITAGE	2	(13%)	0		2	(5%)
	JAPANESE HERITAGE	1	(7%)	5	(17%)	6	(14%)
	SOUTH EAST ASIAN HERITAGE	0		0		0	
	MIXED ASIAN RACE	0		0		0	
BLACK OR AFRICAN AMERICAN		0		1	(3%)	1	(2%)
NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER		0		0		0	
WHITE		12	(80%)	23	(79%)	35	(80%)
	ARABIC/NORTH AFRICAN HERITAGE	0		0		0	
	WHITE/CAUCASIAN/EUROPEAN HERITAGE	12	(80%)	23	(79%)	35	(80%)

PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_sp_dm6.sas 04JAN2023 11:09

Protocol: 207495 Page 1 of 1
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 1.002210
Summary of ECOG Performance Status at Baseline

	Pom/Dex (N=15)		Belantamab mafodotin (N=29)	
Baseline				
n	15		29	
0	4	(27%)	9	(31%)
1	10	(67%)	16	(55%)
2	1	(7%)	4	(14%)
3	0		0	
4-5	0		0	

Note: Performance Status:
0 = Fully active.
1 = Restricted in strenuous activity but able to carry out light work activities.
2 = Capable of self care but unable to carry out any work activities.
3 = Capable of limited self care, confined to bed/chair more than 50% of waking hours.
4 = Completely disabled; can’t carry on any self care; totally confined to bed/chair.
5 = Dead.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_sp_ecog_bsln_can.sas 27JAN2023 04:39

Protocol: 207495 Page 1 of 4
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 1.009110
Summary of Disease Characteristics at Screening

	Pom/Dex (N=15)		Belantamab mafodotin (N=29)		Total (N=44)	
Stage at Screening						
n	15		29		44	
I	4	(27%)	5	(17%)	9	(20%)
II	6	(40%)	14	(48%)	20	(45%)
III	5	(33%)	10	(34%)	15	(34%)
Unknown	0		0		0	
Type of multiple myeloma						
n	15		29		44	
Nonsecretory	0		0		0	
Secretory	15	(100%)	29	(100%)	44	(100%)
Myeloma light chain						
n	13		25		38	
Kappa Light Chain	10	(77%)	21	(84%)	31	(82%)
Lambda Light Chain	3	(23%)	4	(16%)	7	(18%)
Myeloma immunoglobulin						
n	12		24		36	
IgA	2	(17%)	4	(17%)	6	(17%)
IgD	0		0		0	
IgE	0		0		0	
IgG	10	(83%)	20	(83%)	30	(83%)
IgM	0		0		0	
Extramedullary Disease						
n	15		29		44	
No	11	(73%)	20	(69%)	31	(70%)
Yes	4	(27%)	9	(31%)	13	(30%)

[1] Subjects may be included in more than one category.
[2] If the subject has any of the following cytogenetics: t(4;14), t(14;16) or 17p13del.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_sp_dc_scrn.sas 21DEC2022 06:35

Table 1.009110
Summary of Disease Characteristics at Screening

	Pom/Dex (N=15)		Belantamab mafodotin (N=29)		Total (N=44)	
Lytic Bone Lesions						
n	15		29		44	
No	3	(20%)	6	(21%)	9	(20%)
Yes	12	(80%)	23	(79%)	35	(80%)
Lines of therapy completed prior to screening						
n	15		29		44	
No Lines	0		0		0	
1 Line	0		0		0	
2 Lines	0		0		0	
3 Lines	0		0		0	
4 Lines	5	(33%)	13	(45%)	18	(41%)
5 Lines	6	(40%)	5	(17%)	11	(25%)
6 Lines	1	(7%)	4	(14%)	5	(11%)
7 Lines	0		6	(21%)	6	(14%)
8 Lines	2	(13%)	0		2	(5%)
9 Lines	0		1	(3%)	1	(2%)
10 Lines	0		0		0	
More Than 10 Lines	1	(7%)	0		1	(2%)
Lines of therapy completed prior to screening						
n	15		29		44	
Mean	5.7		5.2		5.4	
SD	2.41		1.41		1.79	
Median	5.0		5.0		5.0	
Min.	4		4		4	
Max.	13		9		13	

[1] Subjects may be included in more than one category.
[2] If the subject has any of the following cytogenetics: t(4;14), t(14;16) or 17p13del.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_sp_dc_scrn.sas 21DEC2022 06:35

Protocol: 207495 Page 3 of 4
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 1.009110
Summary of Disease Characteristics at Screening

	Pom/Dex (N=15)		Belantamab mafodotin (N=29)		Total (N=44)	
Prior stem cell transplant						
n	15		29		44	
No	5	(33%)	13	(45%)	18	(41%)
Yes	10	(67%)	16	(55%)	26	(59%)
Genetics [1]						
t(4;14)	1	(7%)	0		1	(2%)
t(14;16)	0		0		0	
amp(1q)	3	(20%)	4	(14%)	7	(16%)
1pdel	0		0		0	
17p13del	1	(7%)	2	(7%)	3	(7%)
Other	3	(20%)	2	(7%)	5	(11%)
High Risk Cytogenetics						
n	15		29		44	
High Risk [2]	2	(13%)	2	(7%)	4	(9%)
Other (non-high risk, negative, not evaluable, not done)	13	(87%)	27	(93%)	40	(91%)
Baseline renal impairment status per eGFR (ml/min/1.73 m2)						
n	15		28		43	
Normal (>=90)	5	(33%)	5	(18%)	10	(23%)
Mild (>=60, <90)	7	(47%)	15	(54%)	22	(51%)
Moderate (>=30, <60)	3	(20%)	8	(29%)	11	(26%)
Severe (>=15, <30)	0		0		0	

[1] Subjects may be included in more than one category.
[2] If the subject has any of the following cytogenetics: t(4;14), t(14;16) or 17p13del.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_sp_dc_scrn.sas 21DEC2022 06:35

Protocol: 207495 Page 4 of 4
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 1.009110
Summary of Disease Characteristics at Screening

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)	Total (N=44)
Baseline renal impairment status per eGFR (ml/min/1.73 m2)			
n	15	29	44
Mean	75.9	71.4	72.9
SD	22.16	24.26	23.40
Median	74.0	66.2	71.5
Min.	30	13	13
Max.	119	132	132

[1] Subjects may be included in more than one category.
[2] If the subject has any of the following cytogenetics: t(4;14), t(14;16) or 17p13del.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_sp_dc_scrn.sas 21DEC2022 06:35

Protocol: 207495 Page 1 of 5
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 1.010110
Summary of Current Medical Conditions

Condition	Pom/Dex (N=15)		Belantamab mafodotin (N=29)		Total (N=44)	
Any condition	15	(100%)	28	(97%)	43	(98%)
HYPERTENSION	9	(60%)	14	(48%)	23	(52%)
ANEMIA	3	(20%)	5	(17%)	8	(18%)
THROMBOCYTOPENIA	0		8	(28%)	8	(18%)
BONE PAIN	1	(7%)	4	(14%)	5	(11%)
CATARACT	1	(7%)	4	(14%)	5	(11%)
BACK PAIN	1	(7%)	3	(10%)	4	(9%)
HYPERLIPIDEMIA	1	(7%)	3	(10%)	4	(9%)
ANAEMIA	1	(7%)	2	(7%)	3	(7%)
DEPRESSION	2	(13%)	1	(3%)	3	(7%)
PERIPHERAL NEUROPATHY	3	(20%)	0		3	(7%)
ANXIETY	0		2	(7%)	2	(5%)
ATRIAL FIBRILLATION	1	(7%)	1	(3%)	2	(5%)
BILATERAL CATARACT	1	(7%)	1	(3%)	2	(5%)
BILATERAL CATARACTS	2	(13%)	0		2	(5%)
CHRONIC GASTRITIS	1	(7%)	1	(3%)	2	(5%)
CHRONIC PANCREATITIS	2	(13%)	0		2	(5%)
DRY EYE	1	(7%)	1	(3%)	2	(5%)
HEART FAILURE	0		2	(7%)	2	(5%)
HYPERURICEMIA	1	(7%)	1	(3%)	2	(5%)
INSOMNIA	0		2	(7%)	2	(5%)
OSTEOPOROSIS	1	(7%)	1	(3%)	2	(5%)
PLEURAL EFFUSION	0		2	(7%)	2	(5%)
SPLENOMEGALIA	0		2	(7%)	2	(5%)
6,8 RIBS LEFT CONSOLIDATED FRACTURES	1	(7%)	0		1	(2%)
ACUTE KIDNEY INJURY	0		1	(3%)	1	(2%)
AGE-RELATED MACULAR DEGENERATION	0		1	(3%)	1	(2%)
ALOPECIA	0		1	(3%)	1	(2%)
AMBLYOPIA	1	(7%)	0		1	(2%)
AMD(AGE-RELATED MACULAR DEGENERATION)	1	(7%)	0		1	(2%)
ANISOMETROPIA	0		1	(3%)	1	(2%)

PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_sp_mh1_curr.sas 16DEC2022 09:01

Protocol: 207495 Page 2 of 5
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 1.010110
Summary of Current Medical Conditions

Condition	Pom/Dex (N=15)		Belantamab mafodotin (N=29)		Total (N=44)	
ANOREXIA	1	(7%)	0		1	(2%)
ASCITES	0		1	(3%)	1	(2%)
ATHEROSCLEROSIS	0		1	(3%)	1	(2%)
BENIGN PROSTATIC HYPERPLASI	1	(7%)	0		1	(2%)
BILATERAL CATARACTA	1	(7%)	0		1	(2%)
BILATERAL POSTERIOR CAPSULAR CATARACT	0		1	(3%)	1	(2%)
BLURRY VISION	1	(7%)	0		1	(2%)
BORTEZOMIB-INDUCED PERIPHERAL NEUROPATHY SENSORY	1	(7%)	0		1	(2%)
BOTH EYES CATARACT	1	(7%)	0		1	(2%)
BOTH LEG PAIN	1	(7%)	0		1	(2%)
CATARACT (BOTH EYES)	0		1	(3%)	1	(2%)
CATARACT OF LEFT EYE	1	(7%)	0		1	(2%)
CATARACTA (LEFT EYE)	0		1	(3%)	1	(2%)
CATARACTA (RIGHT EYE)	0		1	(3%)	1	(2%)
CATARACTA ON BOTH EYES	0		1	(3%)	1	(2%)
CHRONIC DIARRHEA POST COVID-19	1	(7%)	0		1	(2%)
CHRONIC HEART FAILURE	0		1	(3%)	1	(2%)
CHRONIC HEMORRHOIDS WITHOUT EXACERBATION	1	(7%)	0		1	(2%)
COMPLETE RIGHT BUNDLE BRANCH BLOCK	0		1	(3%)	1	(2%)
CONSPITATION	1	(7%)	0		1	(2%)
CONSTIPATION	0		1	(3%)	1	(2%)
CORONARY ARTERY DISEASE	0		1	(3%)	1	(2%)
CYTOPENIA	0		1	(3%)	1	(2%)
DEEP VEIN THROMBOSIS	0		1	(3%)	1	(2%)
DIABETES	0		1	(3%)	1	(2%)
DIFFUSE AND VISCERAL EDEMA	0		1	(3%)	1	(2%)
DIVERTICULAR DISEASE	1	(7%)	0		1	(2%)
DIVERTICULOSIS	0		1	(3%)	1	(2%)
DRY EYE (INTERMITTENT)	0		1	(3%)	1	(2%)
DRY EYE (LEFT EYE)	0		1	(3%)	1	(2%)
DRY EYE (RIGHT EYE)	0		1	(3%)	1	(2%)
DRY SKIN	1	(7%)	0		1	(2%)

PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_sp_mh1_curr.sas 16DEC2022 09:01

Protocol: 207495 Page 3 of 5
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 1.010110
Summary of Current Medical Conditions

Condition	Pom/Dex (N=15)		Belantamab mafodotin (N=29)		Total (N=44)	
DYSPNEA	1	(7%)	0		1	(2%)
ECZEMA ASTEATOTIC	0		1	(3%)	1	(2%)
ELEVATED LDH	0		1	(3%)	1	(2%)
EPIGASTRIC PAIN	1	(7%)	0		1	(2%)
FACIAL PARALYSIS	0		1	(3%)	1	(2%)
FATIGUE	0		1	(3%)	1	(2%)
FOREIGN BODY SENSATION	0		1	(3%)	1	(2%)
FRACTURE	0		1	(3%)	1	(2%)
GASTRIC ULCER	1	(7%)	0		1	(2%)
GASTROESOPHAGEAL REFLUX DISEASE	0		1	(3%)	1	(2%)
GENERAL PAIN BONE PAIN	0		1	(3%)	1	(2%)
GENERALIZED WHOLE BODY PAIN	1	(7%)	0		1	(2%)
GERD GASTRO-OESOPHAGEALIS REFLUX 02.03.2006	1	(7%)	0		1	(2%)
GLAUCOMA	1	(7%)	0		1	(2%)
HEMORRHOIDS	1	(7%)	0		1	(2%)
HIP PAIN	0		1	(3%)	1	(2%)
HUMERUS DIAPHYSISE FREACTURE (RIGHT UPPER ARM)(TO AUG.2020)	1	(7%)	0		1	(2%)
HYPERMETROPIA (BOTH EYES)	0		1	(3%)	1	(2%)
HYPEROPIA OF THE LEFT EYE	0		1	(3%)	1	(2%)
HYPERTONIC RETINOPATHY	0		1	(3%)	1	(2%)
HYPERURICAEMIA	1	(7%)	0		1	(2%)
HYPOMAGNESEMIA	0		1	(3%)	1	(2%)
HYPOTHYROIDISM	0		1	(3%)	1	(2%)
INAPETENCE	0		1	(3%)	1	(2%)
INTERVERTEBRAL DISK HERNIA	0		1	(3%)	1	(2%)
KIDNEY CALCULUS	0		1	(3%)	1	(2%)
LEG CRAMPS	1	(7%)	0		1	(2%)
LOMBAR PAIN	0		1	(3%)	1	(2%)
LT PELVIS BONE FRACTURE	1	(7%)	0		1	(2%)
LYMPHOPENIA	0		1	(3%)	1	(2%)
MILD SENSORY POLYNEUROPATHY	1	(7%)	0		1	(2%)

PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_sp_mh1_curr.sas 16DEC2022 09:01

Table 1.010110
Summary of Current Medical Conditions

Condition	Pom/Dex (N=15)		Belantamab mafodotin (N=29)		Total (N=44)	
MITRAL VALVE INSUFFICIENCY	1	(7%)	0		1	(2%)
MODERATE SYSTOLIC IMPAIRMENT	0		1	(3%)	1	(2%)
MUSCLE CRAMPS 2021 YEAR	0		1	(3%)	1	(2%)
MYELOMA MULTIPLEX 10.06.2007	1	(7%)	0		1	(2%)
MYOPIA OF THE RIGHT EYE	0		1	(3%)	1	(2%)
MYOPIC ASTIGMATISM	0		1	(3%)	1	(2%)
NAIL TINEA	0		1	(3%)	1	(2%)
NEUROCIRCULATORY DYSTONIA, CARDIAC TYPE	1	(7%)	0		1	(2%)
NEUROPATHY	0		1	(3%)	1	(2%)
NEUTROPENIA	0		1	(3%)	1	(2%)
ORAL AND ESOPHAGEAL MONILIASE	0		1	(3%)	1	(2%)
OSTEOCHONDROSIS OF THE CERVICAL AND LUMBAR SPINE	1	(7%)	0		1	(2%)
OSTEONECROSIS OF JAW	0		1	(3%)	1	(2%)
PAIN LOWER BACK, PAIN NECK, THORAX, LUMBAL SPINE	0		1	(3%)	1	(2%)
PAIN ON LOW EXTREMITIES	1	(7%)	0		1	(2%)
PALPITATIONS	1	(7%)	0		1	(2%)
PANCREAS CYST	1	(7%)	0		1	(2%)
PARAPLEGIA	0		1	(3%)	1	(2%)
PAROXYSMAL TACHYCARDIA CONTROLLED	1	(7%)	0		1	(2%)
PEDAL OEDEMA INTO THIGHS	0		1	(3%)	1	(2%)
PELVIC PAIN 2021 YEAR	0		1	(3%)	1	(2%)
PERIPHERAL NEUROPATHY (FEET)	0		1	(3%)	1	(2%)
PERIPHERAL SENSORY NEUROPATHY	0		1	(3%)	1	(2%)
POLYNEUROPATHY	0		1	(3%)	1	(2%)
POSTERIOR SUBCAPSULAR CATARACT GRADE 1 AT RIGHT EYE	0		1	(3%)	1	(2%)
PREMACULAR MEMBRANE (RIGHT EYE)	0		1	(3%)	1	(2%)
PRESBYOPIA	0		1	(3%)	1	(2%)
PROSTATIC HYPERPLASIA	0		1	(3%)	1	(2%)
PROTEINURIA	0		1	(3%)	1	(2%)
PRURITUS	0		1	(3%)	1	(2%)
PRURITUS FACIAL	0		1	(3%)	1	(2%)

PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_sp_mh1_curr.sas 16DEC2022 09:01

Protocol: 207495 Page 5 of 5
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 1.010110
Summary of Current Medical Conditions

Condition	Pom/Dex (N=15)		Belantamab mafodotin (N=29)		Total (N=44)	
PSEUDOPHAKIA	0		1	(3%)	1	(2%)
PUNCTATE KERATOPATHY (LEFT)	1	(7%)	0		1	(2%)
PYREXIA	0		1	(3%)	1	(2%)
RENAL FAILURE	0		1	(3%)	1	(2%)
RETINAL ANGIOSCLEROSIS	0		1	(3%)	1	(2%)
RIGHT EYE CATARACT	0		1	(3%)	1	(2%)
RIGHT INGUINAL HERNIA	0		1	(3%)	1	(2%)
RIGHT LEG PAIN	0		1	(3%)	1	(2%)
RIGHT NEPHROPTOSIS	1	(7%)	0		1	(2%)
ROOT FRACTURE	0		1	(3%)	1	(2%)
SCHWANOMA	0		1	(3%)	1	(2%)
SENILE XEROSIS	0		1	(3%)	1	(2%)
SENSORY NEUROPATHY	0		1	(3%)	1	(2%)
SENSORY POLYNEUROPATHY 2010	0		1	(3%)	1	(2%)
SHORTNESS OF BREATH	0		1	(3%)	1	(2%)
SLEEP DISORDER	1	(7%)	0		1	(2%)
SPINAL STENOSIS	0		1	(3%)	1	(2%)
STABLE CHOLECYSTOLITHIASIS	1	(7%)	0		1	(2%)
TACHYCARDIA	1	(7%)	0		1	(2%)
TH7, TH8, TH9, TH10, TH11, TH12, L1, L2, L3 COMPRESSION FRACTURES	1	(7%)	0		1	(2%)
UPPER BACK PAIN	0		1	(3%)	1	(2%)
VISION DECREASED	0		1	(3%)	1	(2%)
WEAKNESS	0		1	(3%)	1	(2%)

PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_sp_mh1_curr.sas 16DEC2022 09:01

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 1.011110
Summary of Past Medical Conditions

Condition	Pom/Dex (N=15)	Belantamab mafodotin (N=29)	Total (N=44)
Any condition	7 (47%)	21 (72%)	28 (64%)
CATARACT	1 (7%)	3 (10%)	4 (9%)
DIABETES	2 (13%)	1 (3%)	3 (7%)
ASTHMA	1 (7%)	1 (3%)	2 (5%)
HERPES ZOSTER	1 (7%)	1 (3%)	2 (5%)
ACUTE RENAL FAILURE (2017)	0	1 (3%)	1 (2%)
ACUTE RENAL FALURE (2014)	0	1 (3%)	1 (2%)
ANGINA PECTORIS	0	1 (3%)	1 (2%)
ANKLE SURGERY 1983 (RIGHT RIBBON RUPTURE) ST BORBALA HOSPITAL	0	1 (3%)	1 (2%)
ANOPAPILLA	0	1 (3%)	1 (2%)
AUTOLOGOUS PERIPHERAL STEM CELL TRANSPLANTATION (2014.03.11)	0	1 (3%)	1 (2%)
AUTOLOGOUS STEM CELL TRANSPLANTATION FROM 16.04.2007 TO 11.05.2007	1 (7%)	0	1 (2%)
BACTERIAL SEPSE	0	1 (3%)	1 (2%)
BENIGN SALIVARY GLAND TUMOUR	1 (7%)	0	1 (2%)
BONE FRACTURE	0	1 (3%)	1 (2%)
BONE PAIN	0	1 (3%)	1 (2%)
CATARACT (RIGHT EYE)	0	1 (3%)	1 (2%)
CATARACT SURGERIES ON BOTH EYES	0	1 (3%)	1 (2%)
CATARACT SURGERY IN 2016	0	1 (3%)	1 (2%)
CATARACT SURGERY IN BOTH EYES	0	1 (3%)	1 (2%)
CATARACT SURGERY JULY 2021	0	1 (3%)	1 (2%)
CHOLECYSTECTOMY SURGERY TO 26.10.1998-FROM 29.10.1998	1 (7%)	0	1 (2%)
CHRONIC BRONCHITIS WITHOUT EXACERBATION	1 (7%)	0	1 (2%)
CHRONIC KIDNEY DISEASE	0	1 (3%)	1 (2%)
CHRONIC PYELONEPHRITIS, WITHOUT EXACERBATION	1 (7%)	0	1 (2%)
CIRCUMFLEX ARTERY STENTING	0	1 (3%)	1 (2%)
CORONARY ANGIOGRAPHY	0	1 (3%)	1 (2%)

PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_sp_mh1_past.sas 16DEC2022 09:01

Table 1.011110
Summary of Past Medical Conditions

Condition	Pom/Dex (N=15)	Belantamab mafodotin (N=29)	Total (N=44)
DEEP VEIN THROMBOSIS	0	1 (3%)	1 (2%)
DEEP VENOUS THROMBOSIS OF THE LEFT LOWER LIMB	0	1 (3%)	1 (2%)
DUODENO-GASTRIC REFLUX	1 (7%)	0	1 (2%)
DYSPEPSIA	0	1 (3%)	1 (2%)
DYSPEPSIA (HEARTBURN)	0	1 (3%)	1 (2%)
ESSENTIAL THROMBOCYTOSIS 2003 YEAR	0	1 (3%)	1 (2%)
FESS SURGERY (FUNCTIONAL ENDOSCOPIC PARANASAL SINUS SURGERY)RIGHT SINUS DUE TO CYST TO 05.12.2002-FROM 09.12.2002	1 (7%)	0	1 (2%)
GALL-BLADDER (STONE)	0	1 (3%)	1 (2%)
HEMORRHOID SURGERY FROM 07.12.1998-TO 12.12.1998	1 (7%)	0	1 (2%)
HERPES SIMPLEX	0	1 (3%)	1 (2%)
HIGH HOMOCYSTEINE	1 (7%)	0	1 (2%)
HIGH-DOSE-RATE INTRACAVITARY RADIOTHERAPY IN THE MANAGEMENT OF CERVICAL INTRAEPITHELIAL NEOPLASIA CIN III FROM 26.03.1986-TO 29.03.1986 (MYOMA DUE TO UTERINE SURGERY (CERVITIS UTERI)	1 (7%)	0	1 (2%)
HYPERPLASIA PROSTATE	1 (7%)	0	1 (2%)
HYPERTENSION	0	1 (3%)	1 (2%)
HYPERURICEMIA	0	1 (3%)	1 (2%)
ILEUS	0	1 (3%)	1 (2%)
INTESTINAL GIARDIASIS	1 (7%)	0	1 (2%)
KYPHOPLASTY	0	1 (3%)	1 (2%)
LACUNAR INFARCTION	0	1 (3%)	1 (2%)
LEFT CORONARY ARTERY STENTING	0	1 (3%)	1 (2%)
LEFT EYE CATARACT	0	1 (3%)	1 (2%)
LEFT HAND II. FINGER TENDON SURGERY	0	1 (3%)	1 (2%)
LEFT SHOULDER FRACTURE	0	1 (3%)	1 (2%)
MULITNODULAR GOITRE	0	1 (3%)	1 (2%)
MYOCARDIAL INFARCTION	0	1 (3%)	1 (2%)
MYOMA UTERI DUE TO SURGERY FROM 27.02. 1986- TO 05.03.1986	1 (7%)	0	1 (2%)

PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_sp_mh1_past.sas 16DEC2022 09:01

Table 1.011110
Summary of Past Medical Conditions

Condition	Pom/Dex (N=15)		Belantamab mafodotin (N=29)		Total (N=44)	
NEUTROPENIA	0		1	(3%)	1	(2%)
PANCREATITIS (OPUS TREATMENT)	0		1	(3%)	1	(2%)
PATHOLOGICAL FRACTURE OF RIGHT ARM	0		1	(3%)	1	(2%)
PITVARFIBRILATION TO 08.07.2006-FROM 10.08.2006 SURGERY (PROPAFENON CARDIOVERSIO)	1	(7%)	0		1	(2%)
PLEURITITIS	0		1	(3%)	1	(2%)
PNEUMONIA	0		1	(3%)	1	(2%)
POLYNEUROPATHY	1	(7%)	0		1	(2%)
RAT BITE	0		1	(3%)	1	(2%)
RECTAL PERFORATED PERITOUITIS	0		1	(3%)	1	(2%)
REFRACTIVE SURGERY 2002	0		1	(3%)	1	(2%)
RENAL DYSFUNCTION	0		1	(3%)	1	(2%)
RIGHT CHRONIC CATARRHALIS OTITIS DUE TO SURGERY GROMMET INSERTION FROM 23.03.2009-TO 25.03.2009.	1	(7%)	0		1	(2%)
SENSORY NEUROPATHY	0		1	(3%)	1	(2%)
SINGLE SUPRAVENTRICULAR EXTRASYSTOLES	0		1	(3%)	1	(2%)
STROKE	0		1	(3%)	1	(2%)
SURGEY CATARACT, BOTH EYES	1	(7%)	0		1	(2%)
TENSION STRESS (NERVE)	1	(7%)	0		1	(2%)
THROMBOEMBOLIC EVENT	0		1	(3%)	1	(2%)
THROMBOPHLEBITIS	1	(7%)	0		1	(2%)
THROMBOSIS VENA TIBIALIS POSTERIOR LEFT	0		1	(3%)	1	(2%)
THROMBOYTOPENIA	0		1	(3%)	1	(2%)
TIBIAL EDEMA	0		1	(3%)	1	(2%)
TONSILLECTOMY	0		1	(3%)	1	(2%)
TOTAL ABDOMINAL HYSTERECTOMY	1	(7%)	0		1	(2%)
TOTAL ENDOPROTESIS ON LEFT HIP IN 2003 NATIONAL INSTITUTE OF ORTHOPEDICS	0		1	(3%)	1	(2%)
TOTAL ENDOPROTESIS ON RIGHT HIPIN 2004 NATIONAL INSTITUTE OF ORTHOPEDICS	0		1	(3%)	1	(2%)
TRANSITORY ISCHEMIC ATTACK (TIA) 2007 YEAR	0		1	(3%)	1	(2%)
TRANSITORY ISCHEMIC ATTACK(TIA) 1999 YEAR	0		1	(3%)	1	(2%)

PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_sp_mh1_past.sas 16DEC2022 09:01

Protocol: 207495 Page 4 of 4
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 1.011110
Summary of Past Medical Conditions

Condition	Pom/Dex (N=15)	Belantamab mafodotin (N=29)	Total (N=44)
TUBERCULOSIS	1 (7%)	0	1 (2%)
URINARY INFECTION	0	1 (3%)	1 (2%)
VERTEBROPLASTY	0	1 (3%)	1 (2%)
VILLOUS ADENOMA OF THE COLON	0	1 (3%)	1 (2%)

PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_sp_mh1_past.sas 16DEC2022 09:01

Protocol: 207495 Page 1 of 9
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 1.012110
Summary of Concomitant Medications

Ingredient	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Any medication	14 (93%)	28 (97%)
ACYCLOVIR	6 (40%)	16 (55%)
PARACETAMOL	3 (20%)	14 (48%)
ACETYLSALICYLIC ACID	10 (67%)	5 (17%)
SULFAMETHOXAZOLE	5 (33%)	10 (34%)
TRIMETHOPRIM	5 (33%)	9 (31%)
TRAMADOL	4 (27%)	8 (28%)
ALLOPURINOL	1 (7%)	10 (34%)
OMEPRAZOLE	5 (33%)	6 (21%)
PANTOPRAZOLE	2 (13%)	9 (31%)
MORPHINE	2 (13%)	7 (24%)
ZOLEDRONIC ACID	5 (33%)	4 (14%)
AMOXICILLIN	4 (27%)	4 (14%)
DEXAMETHASONE	1 (7%)	7 (24%)
BISOPROLOL	2 (13%)	5 (17%)
FUROSEMIDE	2 (13%)	5 (17%)
LANSOPRAZOLE	1 (7%)	6 (21%)
AMLODIPINE	1 (7%)	5 (17%)
COLECALCIFEROL	2 (13%)	4 (14%)
ONDANSETRON	0	6 (21%)
CLAVULANIC ACID	2 (13%)	3 (10%)
ENALAPRIL	2 (13%)	3 (10%)
FAMOTIDINE	4 (27%)	1 (3%)
GABAPENTIN	2 (13%)	3 (10%)
POTASSIUM NOS	1 (7%)	4 (14%)
PREGABALIN	0	5 (17%)
TOZINAMERAN	3 (20%)	2 (7%)
CHLORPHENAMINE	1 (7%)	3 (10%)
FEBUXOSTAT	1 (7%)	3 (10%)
FENTANYL	0	4 (14%)
LEVOFLOXACIN	3 (20%)	1 (3%)

PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_sp_cm8.sas 16DEC2022 09:21

Table 1.012110
Summary of Concomitant Medications

Ingredient	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
MAGNESIUM	2 (13%)	2 (7%)
METOCLOPRAMIDE	1 (7%)	3 (10%)
METOPROLOL	1 (7%)	3 (10%)
OXYCODONE	1 (7%)	3 (10%)
RIVAROXABAN	2 (13%)	2 (7%)
SPIRONOLACTONE	0	4 (14%)
CALCIUM	1 (7%)	2 (7%)
CALCIUM CARBONATE	2 (13%)	1 (3%)
CALCIVID (NOS)	0	3 (10%)
CEFEPIME	1 (7%)	2 (7%)
CYANOCOBALAMIN	2 (13%)	1 (3%)
DICLOFENAC	2 (13%)	1 (3%)
DOXAZOSIN	1 (7%)	2 (7%)
ENOXAPARIN	2 (13%)	1 (3%)
ESOMEPRAZOLE	2 (13%)	1 (3%)
FLUCONAZOLE	0	3 (10%)
FOLIC ACID	2 (13%)	1 (3%)
GRANULOCYTE COLONY STIMULATING FACTOR	1 (7%)	2 (7%)
MACROGOL	0	3 (10%)
MAGNESIUM SULFATE	0	3 (10%)
METAMIZOLE SODIUM	0	3 (10%)
PYRIDOXINE	3 (20%)	0
SODIUM CHLORIDE	1 (7%)	2 (7%)
AMIKACIN	1 (7%)	1 (3%)
AMPHOTERICIN B	1 (7%)	1 (3%)
APIXABAN	1 (7%)	1 (3%)
ATORVASTATIN	0	2 (7%)
CIPROFIBRATE	0	2 (7%)
CIPROFLOXACIN	0	2 (7%)
CITALOPRAM	1 (7%)	1 (3%)
CLOPIDOGREL	1 (7%)	1 (3%)
DEXCHLORPHENIRAMINE	1 (7%)	1 (3%)

PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_sp_cm8.sas 16DEC2022 09:21

Table 1.012110
Summary of Concomitant Medications

Ingredient	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
DIHYDROCODEINE	1 (7%)	1 (3%)
DIPHENHYDRAMINE	0	2 (7%)
DOXYCYCLINE	1 (7%)	1 (3%)
DULOXETINE	0	2 (7%)
GLUCOSE	0	2 (7%)
HEPARINOID	1 (7%)	1 (3%)
HYDROCORTISONE	0	2 (7%)
KETOPROFEN	1 (7%)	1 (3%)
LIDOCAINE	0	2 (7%)
LORATADINE	0	2 (7%)
MAGNESIUM OXIDE	1 (7%)	1 (3%)
MECOBALAMIN	1 (7%)	1 (3%)
MEGESTROL	2 (13%)	0
METHADONE	0	2 (7%)
METHYLPREDNISOLONE	0	2 (7%)
NUTRITIONAL SUPPLEMENT NOS	1 (7%)	1 (3%)
PENTAMIDINE	0	2 (7%)
PERINDOPRIL	1 (7%)	1 (3%)
PIPERACILLIN	1 (7%)	1 (3%)
PREDNISOLONE	1 (7%)	1 (3%)
RIBOFLAVIN	2 (13%)	0
SENNOSIDES	1 (7%)	1 (3%)
TAZOBACTAM	1 (7%)	1 (3%)
THIAMINE	2 (13%)	0
TRANEXAMIC ACID	0	2 (7%)
VALACICLOVIR	0	2 (7%)
ZOLPIDEM	1 (7%)	1 (3%)
ADENINE	1 (7%)	0
ADENOSINE TRIPHOSPHATE	0	1 (3%)
ALBUMIN NORMAL HUMAN SERUM	0	1 (3%)
ALGOPYRIN (NOS)	0	1 (3%)
ALIZAPRIDE	0	1 (3%)

PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_sp_cm8.sas 16DEC2022 09:21

Protocol: 207495 Page 4 of 9
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 1.012110
Summary of Concomitant Medications

Ingredient	Pom/Dex (N=15)		Belantamab mafodotin (N=29)	
ALMAGATE	1	(7%)	0	
ALPRAZOLAM	1	(7%)	0	
AMBROXOL	1	(7%)	0	
AMITRIPTYLINE	1	(7%)	0	
AMMONIUM CHLORIDE	1	(7%)	0	
AMOROLFINE	1	(7%)	0	
AMPICILLIN	1	(7%)	0	
ANIDULAFUNGIN	0		1	(3%)
ANNONA MURICATA EXTRACT	1	(7%)	0	
ARGININE	1	(7%)	0	
ATROPINE	1	(7%)	0	
AZELASTINE	1	(7%)	0	
AZITHROMYCIN	0		1	(3%)
BENFOTIAMINE	1	(7%)	0	
BETAMETHASONE	0		1	(3%)
BICARBONATE	0		1	(3%)
BIFIDOBACTERIUM LONGUM	1	(7%)	0	
BILASTINE	1	(7%)	0	
BIPHENYLDIMETHYLDICARBOXYLATE	1	(7%)	0	
BROTIZOLAM	0		1	(3%)
BUDESONIDE	0		1	(3%)
CALCIUM CHLORIDE	0		1	(3%)
CALCIUM GLUCONATE	0		1	(3%)
CALCIUM LACTATE	0		1	(3%)
CALCIUM POLYSTYRENE SULFONATE	1	(7%)	0	
CANDESARTAN	0		1	(3%)
CARBAZOCHROME	0		1	(3%)
CARNITINE OROTATE	1	(7%)	0	
CARVEDILOL	1	(7%)	0	
CEFALEXIN	1	(7%)	0	
CEFTRIAXONE	0		1	(3%)
CEFUROXIME	0		1	(3%)

PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_sp_cm8.sas 16DEC2022 09:21

Protocol: 207495 Page 5 of 9
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 1.012110
Summary of Concomitant Medications

Ingredient	Pom/Dex (N=15)		Belantamab mafodotin (N=29)	
CELECOXIB	1	(7%)	0	
CHLORAMPHENICOL	1	(7%)	0	
CHLORHEXIDINE	1	(7%)	0	
CHLOROPYRAMINE	0		1	(3%)
CILASTATIN	1	(7%)	0	
CITRATE	0		1	(3%)
CLOTRIMAZOLE	0		1	(3%)
COCONUT OIL	1	(7%)	0	
CODEINE	0		1	(3%)
COVID-19 VACCINE	1	(7%)	0	
CYCLIZINE	0		1	(3%)
CYCLOBENZAPRINE	0		1	(3%)
DABIGATRAN	0		1	(3%)
DAPAGLIFLOZIN	1	(7%)	0	
DENOSUMAB	1	(7%)	0	
DESVENLAFAXINE	0		1	(3%)
DEXKETOPROFEN	1	(7%)	0	
DEXLANSOPRAZOLE	1	(7%)	0	
DIGITOXIN	1	(7%)	0	
DIMENHYDRINATE	0		1	(3%)
DIMETINDENE	0		1	(3%)
DOCUSATE	0		1	(3%)
DOMPERIDONE	0		1	(3%)
DROSPIRENONE	1	(7%)	0	
DUTASTERIDE	0		1	(3%)
EDOXABAN	0		1	(3%)
EFINACONAZOLE	0		1	(3%)
ELASOMERAN	0		1	(3%)
ELDECALCITOL	0		1	(3%)
EPERISONE	1	(7%)	0	
EPINEPHRINE	0		1	(3%)
ERGOCALCIFEROL	0		1	(3%)

PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_sp_cm8.sas 16DEC2022 09:21

Table 1.012110
Summary of Concomitant Medications

Ingredient	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
ERYTHROMYCIN	0	1 (3%)
ERYTHROPOIETIN HUMAN	0	1 (3%)
ESCITALOPRAM	1 (7%)	0
ESTRADIOL	1 (7%)	0
ESZOPICLONE	0	1 (3%)
ETORICOXIB	0	1 (3%)
FELODIPINE	0	1 (3%)
FEXOFENADINE	1 (7%)	0
FORMOTEROL	0	1 (3%)
FOSINOPRIL	0	1 (3%)
GINSENG	1 (7%)	0
GLICLAZIDE	0	1 (3%)
GLUCONIC ACID	0	1 (3%)
GLYCEROL	0	1 (3%)
GLYCERYL TRINITRATE	0	1 (3%)
GLYCYRRHIZA (NOS)	1 (7%)	0
GRANISETRON	0	1 (3%)
GUAIAZULENE	0	1 (3%)
GUALENIC ACID	0	1 (3%)
HAMAMELIS VIRGINIANA	1 (7%)	0
HEPARIN (NOS)	1 (7%)	0
HYDROCHLOROTHIAZIDE	1 (7%)	0
HYDROXYZINE	1 (7%)	0
IMIPENEM	1 (7%)	0
IRBESARTAN	1 (7%)	0
ISOSORBIDE DINITRATE	0	1 (3%)
ITOPRIDE	1 (7%)	0
IVABRADINE	1 (7%)	0
KETOCONAZOLE	0	1 (3%)
KETOROLAC	0	1 (3%)
LACTIC ACID	0	1 (3%)
LACTULOSE	0	1 (3%)

PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_sp_cm8.sas 16DEC2022 09:21

Protocol: 207495 Page 7 of 9
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 1.012110
Summary of Concomitant Medications

Ingredient	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
LEVODROPROPIZINE	1 (7%)	0
LEVOTHYROXINE	0	1 (3%)
LISINOPRIL	0	1 (3%)
LIVER EXTRACT	1 (7%)	0
LORAZEPAM	1 (7%)	0
LOSARTAN	0	1 (3%)
LOXOPROFEN	1 (7%)	0
MAGNESIUM GLUCONATE	0	1 (3%)
MAGNESIUM HYDROXIDE	1 (7%)	0
MAGNESIUM PIDOLATE	0	1 (3%)
MEROPENEM	0	1 (3%)
METARAMINOL	0	1 (3%)
METHYLEPHEDRINE	1 (7%)	0
MIDAZOLAM	0	1 (3%)
MINERALS NOS	0	1 (3%)
MIROGABALIN	1 (7%)	0
MIRTAZAPINE	0	1 (3%)
MIYARI BACTERIA	1 (7%)	0
MOSAPRIDE	1 (7%)	0
NALOXONE	1 (7%)	0
NAPHAZOLINE	1 (7%)	0
NAPROXEN	1 (7%)	0
NEBIVOLOL	0	1 (3%)
NITROFURANTOIN	0	1 (3%)
NOREPINEPHRINE	0	1 (3%)
NYSTATIN	0	1 (3%)
OLMESARTAN	0	1 (3%)
OXYGEN	0	1 (3%)
PAEONIA (NOS)	1 (7%)	0
PALONOSETRON	0	1 (3%)
PAMIDRONIC ACID	1 (7%)	0
PEGFILGRASTIM	1 (7%)	0

PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_sp_cm8.sas 16DEC2022 09:21

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 1.012110
Summary of Concomitant Medications

Ingredient	Pom/Dex (N=15)		Belantamab mafodotin (N=29)	
PENTOXIFYLLINE	1	(7%)	0	
PHOSPHATE-SANDOZ (NOS)	0		1	(3%)
PHYTOMENADIONE	0		1	(3%)
PIOGLITAZONE	1	(7%)	0	
PITAVASTATIN	1	(7%)	0	
PLANTAGO OVATA	0		1	(3%)
POLAPREZINC	0		1	(3%)
POSACONAZOLE	1	(7%)	0	
POTASSIUM MAGNESIUM ASPARTATE	0		1	(3%)
PRASUGREL	1	(7%)	0	
PROPOFOL	0		1	(3%)
PROPYLENE GLYCOL	0		1	(3%)
PROTEINS NOS	0		1	(3%)
QUININE	1	(7%)	0	
RABEPRAZOLE	0		1	(3%)
RAMIPRIL	0		1	(3%)
RASBURICASE	0		1	(3%)
ROCURONIUM	0		1	(3%)
ROSUVASTATIN	1	(7%)	0	
SALBUTAMOL	0		1	(3%)
SENNA	0		1	(3%)
SERENOA REPENS	0		1	(3%)
SILYBUM MARIANUM	1	(7%)	0	
SIMVASTATIN	0		1	(3%)
SITAGLIPTIN	1	(7%)	0	
SODIUM BICARBONATE	0		1	(3%)
SODIUM GLYCEROPHOSPHATE	0		1	(3%)
SODIUM LACTATE	0		1	(3%)
SODIUM PHOSPHATE DIBASIC	0		1	(3%)
SODIUM PHOSPHATE MONOBASIC	0		1	(3%)
SULBACTAM	1	(7%)	0	
SULFAMETHIZOLE	1	(7%)	0	

PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_sp_cm8.sas 16DEC2022 09:21

Table 1.012110
Summary of Concomitant Medications

Ingredient	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
TELMISARTAN	1 (7%)	0
TEPRENONE	0	1 (3%)
TOCOPHEROL	0	1 (3%)
TOLVAPTAN	0	1 (3%)
TRIMEPERIDINE	1 (7%)	0
TRIMETAZIDINE	1 (7%)	0
UMECLIDINIUM	1 (7%)	0
URSODEOXYCHOLIC ACID	1 (7%)	0
VANCOMYCIN	0	1 (3%)
VILANTEROL	1 (7%)	0
VITAMIN D NOS	1 (7%)	0
VITIS VINIFERA EXTRACT	1 (7%)	0
ZANTHOXYLUM PIPERITUM	1 (7%)	0
ZINGIBER OFFICINALE	1 (7%)	0

PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_sp_cm8.sas 16DEC2022 09:21

Protocol: 207495 Page 1 of 4
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 1.013110
Summary of Prophylactic Medication for Infusion-Related Reactions
by Drug Class and Drug Name

Drug Class Drug	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Any medication	0	16 (55%)
Anilides		
Any medication	0	10 (34%)
PARACETAMOL	0	10 (34%)
Glucocorticoids		
Any medication	0	8 (28%)
DEXAMETHASONE	0	7 (24%)
METHYLPREDNISOLONE	0	1 (3%)
Corticosteroids		
Any medication	0	7 (24%)
DEXAMETHASONE	0	7 (24%)
Corticosteroids For Local Oral Treatment		
Any medication	0	7 (24%)
DEXAMETHASONE	0	7 (24%)
Corticosteroids, Moderately Potent (Group II)		
Any medication	0	7 (24%)
DEXAMETHASONE	0	7 (24%)
Other Antiemetics		
Any medication	0	6 (21%)
ONDANSETRON	0	3 (10%)
DIPHENHYDRAMINE	0	2 (7%)
DIPHENHYDRAMINE HYDROCHLORIDE	0	1 (3%)

Note: Subjects may be included in more than one category for 'Drug Class' and 'Drug'.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_sp_med_irr.sas 16DEC2022 09:27

Protocol: 207495 Page 2 of 4
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 1.013110
Summary of Prophylactic Medication for Infusion-Related Reactions
by Drug Class and Drug Name

Drug Class Drug	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Serotonin (5ht3) Antagonists		
Any medication	0	5 (17%)
ONDANSETRON	0	3 (10%)
GRANISETRON HYDROCHLORIDE	0	1 (3%)
PALONOSETRON HYDROCHLORIDE	0	1 (3%)
Substituted Alkylamines		
Any medication	0	5 (17%)
CHLORPHENAMINE	0	3 (10%)
CHLORPHENAMINE MALEATE	0	1 (3%)
DIMETINDENE MALEATE	0	1 (3%)
Antihistamines For Topical Use		
Any medication	0	4 (14%)
DIPHENHYDRAMINE	0	2 (7%)
DIMETINDENE MALEATE	0	1 (3%)
DIPHENHYDRAMINE HYDROCHLORIDE	0	1 (3%)
Aminoalkyl Ethers		
Any medication	0	3 (10%)
DIPHENHYDRAMINE	0	2 (7%)
DIPHENHYDRAMINE HYDROCHLORIDE	0	1 (3%)
Ethers Chemically Close To Antihistamines		
Any medication	0	3 (10%)
DIPHENHYDRAMINE	0	2 (7%)
DIPHENHYDRAMINE HYDROCHLORIDE	0	1 (3%)

Note: Subjects may be included in more than one category for 'Drug Class' and 'Drug'.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_sp_med_irr.sas 16DEC2022 09:27

Protocol: 207495 Page 3 of 4
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 1.013110
Summary of Prophylactic Medication for Infusion-Related Reactions
by Drug Class and Drug Name

Drug Class Drug	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Other Hypnotics And Sedatives		
Any medication	0	3 (10%)
DIPHENHYDRAMINE	0	2 (7%)
DIPHENHYDRAMINE HYDROCHLORIDE	0	1 (3%)
Other Antihistamines For Systemic Use		
Any medication	0	2 (7%)
LORATADINE	0	2 (7%)
Corticosteroids, Combinations For Treatment Of Acne		
Any medication	0	1 (3%)
METHYLPREDNISOLONE	0	1 (3%)
Corticosteroids, Plain		
Any medication	0	1 (3%)
METHYLPREDNISOLONE	0	1 (3%)
Corticosteroids, Potent (Group III)		
Any medication	0	1 (3%)
METHYLPREDNISOLONE	0	1 (3%)
Corticosteroids, Weak (Group I)		
Any medication	0	1 (3%)
METHYLPREDNISOLONE	0	1 (3%)
H2-Receptor Antagonists		
Any medication	0	1 (3%)
FAMOTIDINE	0	1 (3%)

Note: Subjects may be included in more than one category for 'Drug Class' and 'Drug'.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_sp_med_irr.sas 16DEC2022 09:27

Protocol: 207495 Page 4 of 4
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 1.013110
Summary of Prophylactic Medication for Infusion-Related Reactions
by Drug Class and Drug Name

Drug Class Drug	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Preparations Inhibiting Uric Acid Production		
Any medication	0	1 (3%)
ALLOPURINOL	0	1 (3%)
Propulsives		
Any medication	0	1 (3%)
METOCLOPRAMIDE	0	1 (3%)

Note: Subjects may be included in more than one category for 'Drug Class' and 'Drug'.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_sp_med_irr.sas 16DEC2022 09:27

Protocol: 207495 Page 1 of 47
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 1.014110
Summary of Ocular Therapy Medications

Ocular Therapy Medication: Topical antibiotic

Cycle	Pom/Dex (N=15)	Belantamab mafodotin (N=29)	
Cycle 1	0/14	1/29	(3%)
<4 times a day	0/14	0/29	
4 - 5 times a day	0/14	0/29	
6 - 12 times a day	0/14	0/29	
>12 times a day	0/14	0/29	
Missing	0/14	1/29	(3%)
Cycle 2	0/13	2/25	(8%)
<4 times a day	0/13	0/25	
4 - 5 times a day	0/13	0/25	
6 - 12 times a day	0/13	0/25	
>12 times a day	0/13	0/25	
Missing	0/13	2/25	(8%)
Cycle 3	0/13	1/15	(7%)
<4 times a day	0/13	0/15	
4 - 5 times a day	0/13	0/15	
6 - 12 times a day	0/13	0/15	
>12 times a day	0/13	0/15	
Missing	0/13	1/15	(7%)
Cycle 4	0/13	0/10	
<4 times a day	0/13	0/10	
4 - 5 times a day	0/13	0/10	
6 - 12 times a day	0/13	0/10	
>12 times a day	0/13	0/10	
Missing	0/13	0/10	

Note: Subjects may have more than one ocular therapy medication.
Note: A subject can take a medication more than once within a cycle and so can therefore be included in more than one frequency category.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_sp_med_oth.sas 21DEC2022 02:45

Table 1.014110
Summary of Ocular Therapy Medications

Ocular Therapy Medication: Topical antibiotic

Cycle	Pom/Dex (N=15)		Belantamab mafodotin (N=29)
Cycle 5	1/13	(8%)	0/ 8
<4 times a day	0/13		0/ 8
4 - 5 times a day	0/13		0/ 8
6 - 12 times a day	0/13		0/ 8
>12 times a day	0/13		0/ 8
Missing	1/13	(8%)	0/ 8
Cycle 6	1/11	(9%)	0/ 6
<4 times a day	0/11		0/ 6
4 - 5 times a day	0/11		0/ 6
6 - 12 times a day	0/11		0/ 6
>12 times a day	0/11		0/ 6
Missing	1/11	(9%)	0/ 6
Cycle 7	1/ 8	(13%)	0/ 5
<4 times a day	0/ 8		0/ 5
4 - 5 times a day	0/ 8		0/ 5
6 - 12 times a day	0/ 8		0/ 5
>12 times a day	0/ 8		0/ 5
Missing	1/ 8	(13%)	0/ 5
Cycle 8	0/ 6		0/ 5
<4 times a day	0/ 6		0/ 5
4 - 5 times a day	0/ 6		0/ 5
6 - 12 times a day	0/ 6		0/ 5
>12 times a day	0/ 6		0/ 5
Missing	0/ 6		0/ 5

Note: Subjects may have more than one ocular therapy medication.
Note: A subject can take a medication more than once within a cycle and so can therefore be included in more than one frequency category.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_sp_med_oth.sas 21DEC2022 02:45

Protocol: 207495 Page 3 of 47
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 1.014110
Summary of Ocular Therapy Medications

Ocular Therapy Medication: Topical antibiotic

Cycle	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Cycle 9	0/ 5	0/ 5
<4 times a day	0/ 5	0/ 5
4 - 5 times a day	0/ 5	0/ 5
6 - 12 times a day	0/ 5	0/ 5
>12 times a day	0/ 5	0/ 5
Missing	0/ 5	0/ 5
Cycle 10	0/ 3	0/ 5
<4 times a day	0/ 3	0/ 5
4 - 5 times a day	0/ 3	0/ 5
6 - 12 times a day	0/ 3	0/ 5
>12 times a day	0/ 3	0/ 5
Missing	0/ 3	0/ 5
Cycle 11	0/ 3	0/ 3
<4 times a day	0/ 3	0/ 3
4 - 5 times a day	0/ 3	0/ 3
6 - 12 times a day	0/ 3	0/ 3
>12 times a day	0/ 3	0/ 3
Missing	0/ 3	0/ 3
Cycle 12	0/ 3	0/ 3
<4 times a day	0/ 3	0/ 3
4 - 5 times a day	0/ 3	0/ 3
6 - 12 times a day	0/ 3	0/ 3
>12 times a day	0/ 3	0/ 3
Missing	0/ 3	0/ 3

Note: Subjects may have more than one ocular therapy medication.
Note: A subject can take a medication more than once within a cycle and so can therefore be included in more than one frequency category.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_sp_med_oth.sas 21DEC2022 02:45

Protocol: 207495 Page 4 of 47
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 1.014110
Summary of Ocular Therapy Medications

Ocular Therapy Medication: Topical antibiotic

Cycle	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Cycle 13	0/ 3	0/ 3
<4 times a day	0/ 3	0/ 3
4 - 5 times a day	0/ 3	0/ 3
6 - 12 times a day	0/ 3	0/ 3
>12 times a day	0/ 3	0/ 3
Missing	0/ 3	0/ 3
Cycle 14	0/ 3	0/ 3
<4 times a day	0/ 3	0/ 3
4 - 5 times a day	0/ 3	0/ 3
6 - 12 times a day	0/ 3	0/ 3
>12 times a day	0/ 3	0/ 3
Missing	0/ 3	0/ 3
Cycle 15	0/ 2	0/ 2
<4 times a day	0/ 2	0/ 2
4 - 5 times a day	0/ 2	0/ 2
6 - 12 times a day	0/ 2	0/ 2
>12 times a day	0/ 2	0/ 2
Missing	0/ 2	0/ 2
Cycle 16	0/ 2	0/ 1
<4 times a day	0/ 2	0/ 1
4 - 5 times a day	0/ 2	0/ 1
6 - 12 times a day	0/ 2	0/ 1
>12 times a day	0/ 2	0/ 1
Missing	0/ 2	0/ 1

Note: Subjects may have more than one ocular therapy medication.
Note: A subject can take a medication more than once within a cycle and so can therefore be included in more than one frequency category.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_sp_med_oth.sas 21DEC2022 02:45

Protocol: 207495 Page 5 of 47
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 1.014110
Summary of Ocular Therapy Medications

Ocular Therapy Medication: Topical antibiotic

Cycle	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Cycle 17	0/ 2	0/ 1
<4 times a day	0/ 2	0/ 1
4 - 5 times a day	0/ 2	0/ 1
6 - 12 times a day	0/ 2	0/ 1
>12 times a day	0/ 2	0/ 1
Missing	0/ 2	0/ 1
Cycle 18	0/ 2	0/ 1
<4 times a day	0/ 2	0/ 1
4 - 5 times a day	0/ 2	0/ 1
6 - 12 times a day	0/ 2	0/ 1
>12 times a day	0/ 2	0/ 1
Missing	0/ 2	0/ 1
Cycle 19	0/ 2	0/ 1
<4 times a day	0/ 2	0/ 1
4 - 5 times a day	0/ 2	0/ 1
6 - 12 times a day	0/ 2	0/ 1
>12 times a day	0/ 2	0/ 1
Missing	0/ 2	0/ 1
Cycle 20	0/ 2	0/ 1
<4 times a day	0/ 2	0/ 1
4 - 5 times a day	0/ 2	0/ 1
6 - 12 times a day	0/ 2	0/ 1
>12 times a day	0/ 2	0/ 1
Missing	0/ 2	0/ 1

Note: Subjects may have more than one ocular therapy medication.
Note: A subject can take a medication more than once within a cycle and so can therefore be included in more than one frequency category.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_sp_med_oth.sas 21DEC2022 02:45

Protocol: 207495 Page 6 of 47
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 1.014110
Summary of Ocular Therapy Medications

Ocular Therapy Medication: Topical antibiotic

Cycle	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Cycle 21	0/ 2	0/ 1
<4 times a day	0/ 2	0/ 1
4 - 5 times a day	0/ 2	0/ 1
6 - 12 times a day	0/ 2	0/ 1
>12 times a day	0/ 2	0/ 1
Missing	0/ 2	0/ 1
Cycle 22	0/ 2	0/ 1
<4 times a day	0/ 2	0/ 1
4 - 5 times a day	0/ 2	0/ 1
6 - 12 times a day	0/ 2	0/ 1
>12 times a day	0/ 2	0/ 1
Missing	0/ 2	0/ 1
Cycle 23	0/ 2	0/ 1
<4 times a day	0/ 2	0/ 1
4 - 5 times a day	0/ 2	0/ 1
6 - 12 times a day	0/ 2	0/ 1
>12 times a day	0/ 2	0/ 1
Missing	0/ 2	0/ 1
Cycle 24	0/ 1	0/ 1
<4 times a day	0/ 1	0/ 1
4 - 5 times a day	0/ 1	0/ 1
6 - 12 times a day	0/ 1	0/ 1
>12 times a day	0/ 1	0/ 1
Missing	0/ 1	0/ 1

Note: Subjects may have more than one ocular therapy medication.
Note: A subject can take a medication more than once within a cycle and so can therefore be included in more than one frequency category.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_sp_med_oth.sas 21DEC2022 02:45

Table 1.014110
Summary of Ocular Therapy Medications

Ocular Therapy Medication: Topical antibiotic

Cycle	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Cycle 25	0/ 0	0/ 1
<4 times a day	0/ 0	0/ 1
4 - 5 times a day	0/ 0	0/ 1
6 - 12 times a day	0/ 0	0/ 1
>12 times a day	0/ 0	0/ 1
Missing	0/ 0	0/ 1
Cycle 26	0/ 0	0/ 1
<4 times a day	0/ 0	0/ 1
4 - 5 times a day	0/ 0	0/ 1
6 - 12 times a day	0/ 0	0/ 1
>12 times a day	0/ 0	0/ 1
Missing	0/ 0	0/ 1
Cycle 27	0/ 0	0/ 1
<4 times a day	0/ 0	0/ 1
4 - 5 times a day	0/ 0	0/ 1
6 - 12 times a day	0/ 0	0/ 1
>12 times a day	0/ 0	0/ 1
Missing	0/ 0	0/ 1
Cycle 28	0/ 0	0/ 1
<4 times a day	0/ 0	0/ 1
4 - 5 times a day	0/ 0	0/ 1
6 - 12 times a day	0/ 0	0/ 1
>12 times a day	0/ 0	0/ 1
Missing	0/ 0	0/ 1

Note: Subjects may have more than one ocular therapy medication.
Note: A subject can take a medication more than once within a cycle and so can therefore be included in more than one frequency category.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_sp_med_oth.sas 21DEC2022 02:45

Table 1.014110
Summary of Ocular Therapy Medications

Ocular Therapy Medication: Topical antibiotic

Cycle	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Cycle 29	0/ 0	0/ 1
<4 times a day	0/ 0	0/ 1
4 - 5 times a day	0/ 0	0/ 1
6 - 12 times a day	0/ 0	0/ 1
>12 times a day	0/ 0	0/ 1
Missing	0/ 0	0/ 1
Cycle 30	0/ 0	0/ 1
<4 times a day	0/ 0	0/ 1
4 - 5 times a day	0/ 0	0/ 1
6 - 12 times a day	0/ 0	0/ 1
>12 times a day	0/ 0	0/ 1
Missing	0/ 0	0/ 1
Cycle 31	0/ 0	0/ 1
<4 times a day	0/ 0	0/ 1
4 - 5 times a day	0/ 0	0/ 1
6 - 12 times a day	0/ 0	0/ 1
>12 times a day	0/ 0	0/ 1
Missing	0/ 0	0/ 1
Cycle 32	0/ 0	0/ 1
<4 times a day	0/ 0	0/ 1
4 - 5 times a day	0/ 0	0/ 1
6 - 12 times a day	0/ 0	0/ 1
>12 times a day	0/ 0	0/ 1
Missing	0/ 0	0/ 1

Note: Subjects may have more than one ocular therapy medication.
Note: A subject can take a medication more than once within a cycle and so can therefore be included in more than one frequency category.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_sp_med_oth.sas 21DEC2022 02:45

Table 1.014110
Summary of Ocular Therapy Medications

Ocular Therapy Medication: Topical antibiotic

Cycle	Pom/Dex (N=15)		Belantamab mafodotin (N=29)	
Cycle 33	0/ 0		0/ 1	
<4 times a day	0/ 0		0/ 1	
4 - 5 times a day	0/ 0		0/ 1	
6 - 12 times a day	0/ 0		0/ 1	
>12 times a day	0/ 0		0/ 1	
Missing	0/ 0		0/ 1	
Overall	1/14	(7%)	2/29	(7%)
<4 times a day	0/14		0/29	
4 - 5 times a day	0/14		0/29	
6 - 12 times a day	0/14		0/29	
>12 times a day	0/14		0/29	
Missing	1/14	(7%)	2/29	(7%)

Note: Subjects may have more than one ocular therapy medication.
Note: A subject can take a medication more than once within a cycle and so can therefore be included in more than one frequency category.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_sp_med_oth.sas 21DEC2022 02:45

Table 1.014110
Summary of Ocular Therapy Medications

Ocular Therapy Medication: Topical corticosteroids

Cycle	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Cycle 1	0/14	0/29
<4 times a day	0/14	0/29
4 - 5 times a day	0/14	0/29
6 - 12 times a day	0/14	0/29
>12 times a day	0/14	0/29
Missing	0/14	0/29
Cycle 2	0/13	1/25 (4%)
<4 times a day	0/13	0/25
4 - 5 times a day	0/13	0/25
6 - 12 times a day	0/13	0/25
>12 times a day	0/13	0/25
Missing	0/13	1/25 (4%)
Cycle 3	0/13	1/15 (7%)
<4 times a day	0/13	0/15
4 - 5 times a day	0/13	0/15
6 - 12 times a day	0/13	0/15
>12 times a day	0/13	0/15
Missing	0/13	1/15 (7%)
Cycle 4	0/13	1/10 (10%)
<4 times a day	0/13	0/10
4 - 5 times a day	0/13	0/10
6 - 12 times a day	0/13	0/10
>12 times a day	0/13	0/10
Missing	0/13	1/10 (10%)

Note: Subjects may have more than one ocular therapy medication.
Note: A subject can take a medication more than once within a cycle and so can therefore be included in more than one frequency category.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_sp_med_oth.sas 21DEC2022 02:45

Table 1.014110
Summary of Ocular Therapy Medications

Ocular Therapy Medication: Topical corticosteroids

Cycle	Pom/Dex (N=15)		Belantamab mafodotin (N=29)	
Cycle 5	1/13	(8%)	1/ 8	(13%)
<4 times a day	0/13		0/ 8	
4 - 5 times a day	0/13		0/ 8	
6 - 12 times a day	0/13		0/ 8	
>12 times a day	0/13		0/ 8	
Missing	1/13	(8%)	1/ 8	(13%)
Cycle 6	1/11	(9%)	0/ 6	
<4 times a day	0/11		0/ 6	
4 - 5 times a day	0/11		0/ 6	
6 - 12 times a day	0/11		0/ 6	
>12 times a day	0/11		0/ 6	
Missing	1/11	(9%)	0/ 6	
Cycle 7	1/ 8	(13%)	0/ 5	
<4 times a day	0/ 8		0/ 5	
4 - 5 times a day	0/ 8		0/ 5	
6 - 12 times a day	0/ 8		0/ 5	
>12 times a day	0/ 8		0/ 5	
Missing	1/ 8	(13%)	0/ 5	
Cycle 8	0/ 6		0/ 5	
<4 times a day	0/ 6		0/ 5	
4 - 5 times a day	0/ 6		0/ 5	
6 - 12 times a day	0/ 6		0/ 5	
>12 times a day	0/ 6		0/ 5	
Missing	0/ 6		0/ 5	

Note: Subjects may have more than one ocular therapy medication.
Note: A subject can take a medication more than once within a cycle and so can therefore be included in more than one frequency category.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_sp_med_oth.sas 21DEC2022 02:45

Table 1.014110
Summary of Ocular Therapy Medications

Ocular Therapy Medication: Topical corticosteroids

Cycle	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Cycle 9	0/ 5	0/ 5
<4 times a day	0/ 5	0/ 5
4 - 5 times a day	0/ 5	0/ 5
6 - 12 times a day	0/ 5	0/ 5
>12 times a day	0/ 5	0/ 5
Missing	0/ 5	0/ 5
Cycle 10	0/ 3	0/ 5
<4 times a day	0/ 3	0/ 5
4 - 5 times a day	0/ 3	0/ 5
6 - 12 times a day	0/ 3	0/ 5
>12 times a day	0/ 3	0/ 5
Missing	0/ 3	0/ 5
Cycle 11	0/ 3	0/ 3
<4 times a day	0/ 3	0/ 3
4 - 5 times a day	0/ 3	0/ 3
6 - 12 times a day	0/ 3	0/ 3
>12 times a day	0/ 3	0/ 3
Missing	0/ 3	0/ 3
Cycle 12	0/ 3	0/ 3
<4 times a day	0/ 3	0/ 3
4 - 5 times a day	0/ 3	0/ 3
6 - 12 times a day	0/ 3	0/ 3
>12 times a day	0/ 3	0/ 3
Missing	0/ 3	0/ 3

Note: Subjects may have more than one ocular therapy medication.
Note: A subject can take a medication more than once within a cycle and so can therefore be included in more than one frequency category.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_sp_med_oth.sas 21DEC2022 02:45

Protocol: 207495 Page 13 of 47
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 1.014110
Summary of Ocular Therapy Medications

Ocular Therapy Medication: Topical corticosteroids

Cycle	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Cycle 13	0/ 3	0/ 3
<4 times a day	0/ 3	0/ 3
4 - 5 times a day	0/ 3	0/ 3
6 - 12 times a day	0/ 3	0/ 3
>12 times a day	0/ 3	0/ 3
Missing	0/ 3	0/ 3
Cycle 14	0/ 3	0/ 3
<4 times a day	0/ 3	0/ 3
4 - 5 times a day	0/ 3	0/ 3
6 - 12 times a day	0/ 3	0/ 3
>12 times a day	0/ 3	0/ 3
Missing	0/ 3	0/ 3
Cycle 15	0/ 2	0/ 2
<4 times a day	0/ 2	0/ 2
4 - 5 times a day	0/ 2	0/ 2
6 - 12 times a day	0/ 2	0/ 2
>12 times a day	0/ 2	0/ 2
Missing	0/ 2	0/ 2
Cycle 16	0/ 2	0/ 1
<4 times a day	0/ 2	0/ 1
4 - 5 times a day	0/ 2	0/ 1
6 - 12 times a day	0/ 2	0/ 1
>12 times a day	0/ 2	0/ 1
Missing	0/ 2	0/ 1

Note: Subjects may have more than one ocular therapy medication.
Note: A subject can take a medication more than once within a cycle and so can therefore be included in more than one frequency category.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_sp_med_oth.sas 21DEC2022 02:45

Protocol: 207495 Page 14 of 47
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 1.014110
Summary of Ocular Therapy Medications

Ocular Therapy Medication: Topical corticosteroids

Cycle	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Cycle 17	0/ 2	0/ 1
<4 times a day	0/ 2	0/ 1
4 - 5 times a day	0/ 2	0/ 1
6 - 12 times a day	0/ 2	0/ 1
>12 times a day	0/ 2	0/ 1
Missing	0/ 2	0/ 1
Cycle 18	0/ 2	0/ 1
<4 times a day	0/ 2	0/ 1
4 - 5 times a day	0/ 2	0/ 1
6 - 12 times a day	0/ 2	0/ 1
>12 times a day	0/ 2	0/ 1
Missing	0/ 2	0/ 1
Cycle 19	0/ 2	0/ 1
<4 times a day	0/ 2	0/ 1
4 - 5 times a day	0/ 2	0/ 1
6 - 12 times a day	0/ 2	0/ 1
>12 times a day	0/ 2	0/ 1
Missing	0/ 2	0/ 1
Cycle 20	0/ 2	0/ 1
<4 times a day	0/ 2	0/ 1
4 - 5 times a day	0/ 2	0/ 1
6 - 12 times a day	0/ 2	0/ 1
>12 times a day	0/ 2	0/ 1
Missing	0/ 2	0/ 1

Note: Subjects may have more than one ocular therapy medication.
Note: A subject can take a medication more than once within a cycle and so can therefore be included in more than one frequency category.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_sp_med_oth.sas 21DEC2022 02:45

Table 1.014110
Summary of Ocular Therapy Medications

Ocular Therapy Medication: Topical corticosteroids

Cycle	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Cycle 21	0/ 2	0/ 1
<4 times a day	0/ 2	0/ 1
4 - 5 times a day	0/ 2	0/ 1
6 - 12 times a day	0/ 2	0/ 1
>12 times a day	0/ 2	0/ 1
Missing	0/ 2	0/ 1
Cycle 22	0/ 2	0/ 1
<4 times a day	0/ 2	0/ 1
4 - 5 times a day	0/ 2	0/ 1
6 - 12 times a day	0/ 2	0/ 1
>12 times a day	0/ 2	0/ 1
Missing	0/ 2	0/ 1
Cycle 23	0/ 2	0/ 1
<4 times a day	0/ 2	0/ 1
4 - 5 times a day	0/ 2	0/ 1
6 - 12 times a day	0/ 2	0/ 1
>12 times a day	0/ 2	0/ 1
Missing	0/ 2	0/ 1
Cycle 24	0/ 1	0/ 1
<4 times a day	0/ 1	0/ 1
4 - 5 times a day	0/ 1	0/ 1
6 - 12 times a day	0/ 1	0/ 1
>12 times a day	0/ 1	0/ 1
Missing	0/ 1	0/ 1

Note: Subjects may have more than one ocular therapy medication.
Note: A subject can take a medication more than once within a cycle and so can therefore be included in more than one frequency category.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_sp_med_oth.sas 21DEC2022 02:45

Protocol: 207495 Page 16 of 47
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 1.014110
Summary of Ocular Therapy Medications

Ocular Therapy Medication: Topical corticosteroids

Cycle	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Cycle 25	0/ 0	0/ 1
<4 times a day	0/ 0	0/ 1
4 - 5 times a day	0/ 0	0/ 1
6 - 12 times a day	0/ 0	0/ 1
>12 times a day	0/ 0	0/ 1
Missing	0/ 0	0/ 1
Cycle 26	0/ 0	0/ 1
<4 times a day	0/ 0	0/ 1
4 - 5 times a day	0/ 0	0/ 1
6 - 12 times a day	0/ 0	0/ 1
>12 times a day	0/ 0	0/ 1
Missing	0/ 0	0/ 1
Cycle 27	0/ 0	0/ 1
<4 times a day	0/ 0	0/ 1
4 - 5 times a day	0/ 0	0/ 1
6 - 12 times a day	0/ 0	0/ 1
>12 times a day	0/ 0	0/ 1
Missing	0/ 0	0/ 1
Cycle 28	0/ 0	0/ 1
<4 times a day	0/ 0	0/ 1
4 - 5 times a day	0/ 0	0/ 1
6 - 12 times a day	0/ 0	0/ 1
>12 times a day	0/ 0	0/ 1
Missing	0/ 0	0/ 1

Note: Subjects may have more than one ocular therapy medication.
Note: A subject can take a medication more than once within a cycle and so can therefore be included in more than one frequency category.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_sp_med_oth.sas 21DEC2022 02:45

Protocol: 207495 Page 17 of 47
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 1.014110
Summary of Ocular Therapy Medications

Ocular Therapy Medication: Topical corticosteroids

Cycle	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Cycle 29	0/ 0	0/ 1
<4 times a day	0/ 0	0/ 1
4 - 5 times a day	0/ 0	0/ 1
6 - 12 times a day	0/ 0	0/ 1
>12 times a day	0/ 0	0/ 1
Missing	0/ 0	0/ 1
Cycle 30	0/ 0	0/ 1
<4 times a day	0/ 0	0/ 1
4 - 5 times a day	0/ 0	0/ 1
6 - 12 times a day	0/ 0	0/ 1
>12 times a day	0/ 0	0/ 1
Missing	0/ 0	0/ 1
Cycle 31	0/ 0	0/ 1
<4 times a day	0/ 0	0/ 1
4 - 5 times a day	0/ 0	0/ 1
6 - 12 times a day	0/ 0	0/ 1
>12 times a day	0/ 0	0/ 1
Missing	0/ 0	0/ 1
Cycle 32	0/ 0	0/ 1
<4 times a day	0/ 0	0/ 1
4 - 5 times a day	0/ 0	0/ 1
6 - 12 times a day	0/ 0	0/ 1
>12 times a day	0/ 0	0/ 1
Missing	0/ 0	0/ 1

Note: Subjects may have more than one ocular therapy medication.
Note: A subject can take a medication more than once within a cycle and so can therefore be included in more than one frequency category.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_sp_med_oth.sas 21DEC2022 02:45

Table 1.014110
Summary of Ocular Therapy Medications

Ocular Therapy Medication: Topical corticosteroids

Cycle	Pom/Dex (N=15)		Belantamab mafodotin (N=29)	
Cycle 33	0/ 0		0/ 1	
<4 times a day	0/ 0		0/ 1	
4 - 5 times a day	0/ 0		0/ 1	
6 - 12 times a day	0/ 0		0/ 1	
>12 times a day	0/ 0		0/ 1	
Missing	0/ 0		0/ 1	
Overall	1/14	(7%)	1/29	(3%)
<4 times a day	0/14		0/29	
4 - 5 times a day	0/14		0/29	
6 - 12 times a day	0/14		0/29	
>12 times a day	0/14		0/29	
Missing	1/14	(7%)	1/29	(3%)

Note: Subjects may have more than one ocular therapy medication.
Note: A subject can take a medication more than once within a cycle and so can therefore be included in more than one frequency category.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_sp_med_oth.sas 21DEC2022 02:45

Protocol: 207495 Page 19 of 47
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 1.014110
Summary of Ocular Therapy Medications

Ocular Therapy Medication: Artificial Tears (preservative free)

Cycle	Pom/Dex (N=15)		Belantamab mafodotin (N=29)	
Cycle 1	1/14	(7%)	24/29	(83%)
<4 times a day	0/14		0/29	
4 - 5 times a day	0/14		1/29	(3%)
6 - 12 times a day	0/14		4/29	(14%)
>12 times a day	0/14		0/29	
Missing	1/14	(7%)	19/29	(66%)
Cycle 2	1/13	(8%)	18/25	(72%)
<4 times a day	0/13		0/25	
4 - 5 times a day	0/13		0/25	
6 - 12 times a day	0/13		3/25	(12%)
>12 times a day	0/13		0/25	
Missing	1/13	(8%)	16/25	(64%)
Cycle 3	1/13	(8%)	7/15	(47%)
<4 times a day	0/13		0/15	
4 - 5 times a day	0/13		0/15	
6 - 12 times a day	0/13		2/15	(13%)
>12 times a day	0/13		0/15	
Missing	1/13	(8%)	5/15	(33%)
Cycle 4	1/13	(8%)	6/10	(60%)
<4 times a day	0/13		0/10	
4 - 5 times a day	0/13		0/10	
6 - 12 times a day	0/13		1/10	(10%)
>12 times a day	0/13		0/10	
Missing	1/13	(8%)	5/10	(50%)

Note: Subjects may have more than one ocular therapy medication.
Note: A subject can take a medication more than once within a cycle and so can therefore be included in more than one frequency category.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_sp_med_oth.sas 21DEC2022 02:45

Protocol: 207495 Page 20 of 47
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 1.014110
Summary of Ocular Therapy Medications

Ocular Therapy Medication: Artificial Tears (preservative free)

Cycle	Pom/Dex (N=15)	Belantamab mafodotin (N=29)	
Cycle 5	0/13	5/ 8	(63%)
<4 times a day	0/13	0/ 8	
4 - 5 times a day	0/13	0/ 8	
6 - 12 times a day	0/13	0/ 8	
>12 times a day	0/13	0/ 8	
Missing	0/13	5/ 8	(63%)
Cycle 6	0/11	2/ 6	(33%)
<4 times a day	0/11	0/ 6	
4 - 5 times a day	0/11	0/ 6	
6 - 12 times a day	0/11	0/ 6	
>12 times a day	0/11	0/ 6	
Missing	0/11	2/ 6	(33%)
Cycle 7	0/ 8	2/ 5	(40%)
<4 times a day	0/ 8	0/ 5	
4 - 5 times a day	0/ 8	0/ 5	
6 - 12 times a day	0/ 8	0/ 5	
>12 times a day	0/ 8	0/ 5	
Missing	0/ 8	2/ 5	(40%)
Cycle 8	0/ 6	2/ 5	(40%)
<4 times a day	0/ 6	0/ 5	
4 - 5 times a day	0/ 6	0/ 5	
6 - 12 times a day	0/ 6	0/ 5	
>12 times a day	0/ 6	0/ 5	
Missing	0/ 6	2/ 5	(40%)

Note: Subjects may have more than one ocular therapy medication.
Note: A subject can take a medication more than once within a cycle and so can therefore be included in more than one frequency category.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_sp_med_oth.sas 21DEC2022 02:45

Table 1.014110
Summary of Ocular Therapy Medications

Ocular Therapy Medication: Artificial Tears (preservative free)

Cycle	Pom/Dex (N=15)	Belantamab mafodotin (N=29)	
Cycle 9	0/ 5	2/ 5	(40%)
<4 times a day	0/ 5	0/ 5	
4 - 5 times a day	0/ 5	0/ 5	
6 - 12 times a day	0/ 5	0/ 5	
>12 times a day	0/ 5	0/ 5	
Missing	0/ 5	2/ 5	(40%)
Cycle 10	0/ 3	2/ 5	(40%)
<4 times a day	0/ 3	0/ 5	
4 - 5 times a day	0/ 3	0/ 5	
6 - 12 times a day	0/ 3	0/ 5	
>12 times a day	0/ 3	0/ 5	
Missing	0/ 3	2/ 5	(40%)
Cycle 11	0/ 3	0/ 3	
<4 times a day	0/ 3	0/ 3	
4 - 5 times a day	0/ 3	0/ 3	
6 - 12 times a day	0/ 3	0/ 3	
>12 times a day	0/ 3	0/ 3	
Missing	0/ 3	0/ 3	
Cycle 12	0/ 3	0/ 3	
<4 times a day	0/ 3	0/ 3	
4 - 5 times a day	0/ 3	0/ 3	
6 - 12 times a day	0/ 3	0/ 3	
>12 times a day	0/ 3	0/ 3	
Missing	0/ 3	0/ 3	

Note: Subjects may have more than one ocular therapy medication.
Note: A subject can take a medication more than once within a cycle and so can therefore be included in more than one frequency category.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_sp_med_oth.sas 21DEC2022 02:45

Protocol: 207495 Page 22 of 47
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 1.014110
Summary of Ocular Therapy Medications

Ocular Therapy Medication: Artificial Tears (preservative free)

Cycle	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Cycle 13	0/ 3	0/ 3
<4 times a day	0/ 3	0/ 3
4 - 5 times a day	0/ 3	0/ 3
6 - 12 times a day	0/ 3	0/ 3
>12 times a day	0/ 3	0/ 3
Missing	0/ 3	0/ 3
Cycle 14	0/ 3	0/ 3
<4 times a day	0/ 3	0/ 3
4 - 5 times a day	0/ 3	0/ 3
6 - 12 times a day	0/ 3	0/ 3
>12 times a day	0/ 3	0/ 3
Missing	0/ 3	0/ 3
Cycle 15	0/ 2	0/ 2
<4 times a day	0/ 2	0/ 2
4 - 5 times a day	0/ 2	0/ 2
6 - 12 times a day	0/ 2	0/ 2
>12 times a day	0/ 2	0/ 2
Missing	0/ 2	0/ 2
Cycle 16	0/ 2	0/ 1
<4 times a day	0/ 2	0/ 1
4 - 5 times a day	0/ 2	0/ 1
6 - 12 times a day	0/ 2	0/ 1
>12 times a day	0/ 2	0/ 1
Missing	0/ 2	0/ 1

Note: Subjects may have more than one ocular therapy medication.
Note: A subject can take a medication more than once within a cycle and so can therefore be included in more than one frequency category.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_sp_med_oth.sas 21DEC2022 02:45

Protocol: 207495 Page 23 of 47
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 1.014110
Summary of Ocular Therapy Medications

Ocular Therapy Medication: Artificial Tears (preservative free)

Cycle	Pom/Dex (N=15)		Belantamab mafodotin (N=29)
Cycle 17	0/ 2		0/ 1
<4 times a day	0/ 2		0/ 1
4 - 5 times a day	0/ 2		0/ 1
6 - 12 times a day	0/ 2		0/ 1
>12 times a day	0/ 2		0/ 1
Missing	0/ 2		0/ 1
Cycle 18	0/ 2		0/ 1
<4 times a day	0/ 2		0/ 1
4 - 5 times a day	0/ 2		0/ 1
6 - 12 times a day	0/ 2		0/ 1
>12 times a day	0/ 2		0/ 1
Missing	0/ 2		0/ 1
Cycle 19	1/ 2	(50%)	0/ 1
<4 times a day	0/ 2		0/ 1
4 - 5 times a day	0/ 2		0/ 1
6 - 12 times a day	0/ 2		0/ 1
>12 times a day	0/ 2		0/ 1
Missing	1/ 2	(50%)	0/ 1
Cycle 20	1/ 2	(50%)	0/ 1
<4 times a day	0/ 2		0/ 1
4 - 5 times a day	0/ 2		0/ 1
6 - 12 times a day	0/ 2		0/ 1
>12 times a day	0/ 2		0/ 1
Missing	1/ 2	(50%)	0/ 1

Note: Subjects may have more than one ocular therapy medication.
Note: A subject can take a medication more than once within a cycle and so can therefore be included in more than one frequency category.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_sp_med_oth.sas 21DEC2022 02:45

Protocol: 207495 Page 24 of 47
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 1.014110
Summary of Ocular Therapy Medications

Ocular Therapy Medication: Artificial Tears (preservative free)

Cycle	Pom/Dex (N=15)		Belantamab mafodotin (N=29)
Cycle 21	1/ 2	(50%)	0/ 1
<4 times a day	0/ 2		0/ 1
4 - 5 times a day	0/ 2		0/ 1
6 - 12 times a day	0/ 2		0/ 1
>12 times a day	0/ 2		0/ 1
Missing	1/ 2	(50%)	0/ 1
Cycle 22	1/ 2	(50%)	0/ 1
<4 times a day	0/ 2		0/ 1
4 - 5 times a day	0/ 2		0/ 1
6 - 12 times a day	0/ 2		0/ 1
>12 times a day	0/ 2		0/ 1
Missing	1/ 2	(50%)	0/ 1
Cycle 23	0/ 2		0/ 1
<4 times a day	0/ 2		0/ 1
4 - 5 times a day	0/ 2		0/ 1
6 - 12 times a day	0/ 2		0/ 1
>12 times a day	0/ 2		0/ 1
Missing	0/ 2		0/ 1
Cycle 24	0/ 1		0/ 1
<4 times a day	0/ 1		0/ 1
4 - 5 times a day	0/ 1		0/ 1
6 - 12 times a day	0/ 1		0/ 1
>12 times a day	0/ 1		0/ 1
Missing	0/ 1		0/ 1

Note: Subjects may have more than one ocular therapy medication.
Note: A subject can take a medication more than once within a cycle and so can therefore be included in more than one frequency category.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_sp_med_oth.sas 21DEC2022 02:45

Table 1.014110
Summary of Ocular Therapy Medications

Ocular Therapy Medication: Artificial Tears (preservative free)

Cycle	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Cycle 25	0/ 0	0/ 1
<4 times a day	0/ 0	0/ 1
4 - 5 times a day	0/ 0	0/ 1
6 - 12 times a day	0/ 0	0/ 1
>12 times a day	0/ 0	0/ 1
Missing	0/ 0	0/ 1
Cycle 26	0/ 0	0/ 1
<4 times a day	0/ 0	0/ 1
4 - 5 times a day	0/ 0	0/ 1
6 - 12 times a day	0/ 0	0/ 1
>12 times a day	0/ 0	0/ 1
Missing	0/ 0	0/ 1
Cycle 27	0/ 0	0/ 1
<4 times a day	0/ 0	0/ 1
4 - 5 times a day	0/ 0	0/ 1
6 - 12 times a day	0/ 0	0/ 1
>12 times a day	0/ 0	0/ 1
Missing	0/ 0	0/ 1
Cycle 28	0/ 0	0/ 1
<4 times a day	0/ 0	0/ 1
4 - 5 times a day	0/ 0	0/ 1
6 - 12 times a day	0/ 0	0/ 1
>12 times a day	0/ 0	0/ 1
Missing	0/ 0	0/ 1

Note: Subjects may have more than one ocular therapy medication.
Note: A subject can take a medication more than once within a cycle and so can therefore be included in more than one frequency category.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_sp_med_oth.sas 21DEC2022 02:45

Table 1.014110
Summary of Ocular Therapy Medications

Ocular Therapy Medication: Artificial Tears (preservative free)

Cycle	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Cycle 29	0/ 0	0/ 1
<4 times a day	0/ 0	0/ 1
4 - 5 times a day	0/ 0	0/ 1
6 - 12 times a day	0/ 0	0/ 1
>12 times a day	0/ 0	0/ 1
Missing	0/ 0	0/ 1
Cycle 30	0/ 0	0/ 1
<4 times a day	0/ 0	0/ 1
4 - 5 times a day	0/ 0	0/ 1
6 - 12 times a day	0/ 0	0/ 1
>12 times a day	0/ 0	0/ 1
Missing	0/ 0	0/ 1
Cycle 31	0/ 0	0/ 1
<4 times a day	0/ 0	0/ 1
4 - 5 times a day	0/ 0	0/ 1
6 - 12 times a day	0/ 0	0/ 1
>12 times a day	0/ 0	0/ 1
Missing	0/ 0	0/ 1
Cycle 32	0/ 0	0/ 1
<4 times a day	0/ 0	0/ 1
4 - 5 times a day	0/ 0	0/ 1
6 - 12 times a day	0/ 0	0/ 1
>12 times a day	0/ 0	0/ 1
Missing	0/ 0	0/ 1

Note: Subjects may have more than one ocular therapy medication.
Note: A subject can take a medication more than once within a cycle and so can therefore be included in more than one frequency category.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_sp_med_oth.sas 21DEC2022 02:45

Table 1.014110
Summary of Ocular Therapy Medications

Ocular Therapy Medication: Artificial Tears (preservative free)

Cycle	Pom/Dex (N=15)		Belantamab mafodotin (N=29)	
Cycle 33	0/ 0		0/ 1	
<4 times a day	0/ 0		0/ 1	
4 - 5 times a day	0/ 0		0/ 1	
6 - 12 times a day	0/ 0		0/ 1	
>12 times a day	0/ 0		0/ 1	
Missing	0/ 0		0/ 1	
Overall	2/14	(14%)	26/29	(90%)
<4 times a day	0/14		0/29	
4 - 5 times a day	0/14		1/29	(3%)
6 - 12 times a day	0/14		4/29	(14%)
>12 times a day	0/14		0/29	
Missing	2/14	(14%)	22/29	(76%)

Note: Subjects may have more than one ocular therapy medication.
Note: A subject can take a medication more than once within a cycle and so can therefore be included in more than one frequency category.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_sp_med_oth.sas 21DEC2022 02:45

Table 1.014110
Summary of Ocular Therapy Medications

Ocular Therapy Medication: Autologous serum eye drops

Cycle	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Cycle 1	0/14	0/29
<4 times a day	0/14	0/29
4 – 5 times a day	0/14	0/29
6 – 12 times a day	0/14	0/29
>12 times a day	0/14	0/29
Missing	0/14	0/29
Cycle 2	0/13	0/25
<4 times a day	0/13	0/25
4 – 5 times a day	0/13	0/25
6 – 12 times a day	0/13	0/25
>12 times a day	0/13	0/25
Missing	0/13	0/25
Cycle 3	0/13	0/15
<4 times a day	0/13	0/15
4 – 5 times a day	0/13	0/15
6 – 12 times a day	0/13	0/15
>12 times a day	0/13	0/15
Missing	0/13	0/15
Cycle 4	0/13	0/10
<4 times a day	0/13	0/10
4 – 5 times a day	0/13	0/10
6 – 12 times a day	0/13	0/10
>12 times a day	0/13	0/10
Missing	0/13	0/10

Note: Subjects may have more than one ocular therapy medication.
Note: A subject can take a medication more than once within a cycle and so can therefore be included in more than one frequency category.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_sp_med_oth.sas 21DEC2022 02:45

Table 1.014110
Summary of Ocular Therapy Medications

Ocular Therapy Medication: Autologous serum eye drops

Cycle	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Cycle 5	0/13	0/ 8
<4 times a day	0/13	0/ 8
4 – 5 times a day	0/13	0/ 8
6 – 12 times a day	0/13	0/ 8
>12 times a day	0/13	0/ 8
Missing	0/13	0/ 8
Cycle 6	0/11	0/ 6
<4 times a day	0/11	0/ 6
4 – 5 times a day	0/11	0/ 6
6 – 12 times a day	0/11	0/ 6
>12 times a day	0/11	0/ 6
Missing	0/11	0/ 6
Cycle 7	0/ 8	0/ 5
<4 times a day	0/ 8	0/ 5
4 – 5 times a day	0/ 8	0/ 5
6 – 12 times a day	0/ 8	0/ 5
>12 times a day	0/ 8	0/ 5
Missing	0/ 8	0/ 5
Cycle 8	0/ 6	0/ 5
<4 times a day	0/ 6	0/ 5
4 – 5 times a day	0/ 6	0/ 5
6 – 12 times a day	0/ 6	0/ 5
>12 times a day	0/ 6	0/ 5
Missing	0/ 6	0/ 5

Note: Subjects may have more than one ocular therapy medication.
Note: A subject can take a medication more than once within a cycle and so can therefore be included in more than one frequency category.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_sp_med_oth.sas 21DEC2022 02:45

Protocol: 207495 Page 30 of 47
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 1.014110
Summary of Ocular Therapy Medications

Ocular Therapy Medication: Autologous serum eye drops

Cycle	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Cycle 9	0/ 5	0/ 5
<4 times a day	0/ 5	0/ 5
4 - 5 times a day	0/ 5	0/ 5
6 - 12 times a day	0/ 5	0/ 5
>12 times a day	0/ 5	0/ 5
Missing	0/ 5	0/ 5
Cycle 10	0/ 3	0/ 5
<4 times a day	0/ 3	0/ 5
4 - 5 times a day	0/ 3	0/ 5
6 - 12 times a day	0/ 3	0/ 5
>12 times a day	0/ 3	0/ 5
Missing	0/ 3	0/ 5
Cycle 11	0/ 3	0/ 3
<4 times a day	0/ 3	0/ 3
4 - 5 times a day	0/ 3	0/ 3
6 - 12 times a day	0/ 3	0/ 3
>12 times a day	0/ 3	0/ 3
Missing	0/ 3	0/ 3
Cycle 12	0/ 3	0/ 3
<4 times a day	0/ 3	0/ 3
4 - 5 times a day	0/ 3	0/ 3
6 - 12 times a day	0/ 3	0/ 3
>12 times a day	0/ 3	0/ 3
Missing	0/ 3	0/ 3

Note: Subjects may have more than one ocular therapy medication.
Note: A subject can take a medication more than once within a cycle and so can therefore be included in more than one frequency category.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_sp_med_oth.sas 21DEC2022 02:45

Protocol: 207495 Page 31 of 47
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 1.014110
Summary of Ocular Therapy Medications

Ocular Therapy Medication: Autologous serum eye drops

Cycle	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Cycle 13	0/ 3	0/ 3
<4 times a day	0/ 3	0/ 3
4 - 5 times a day	0/ 3	0/ 3
6 - 12 times a day	0/ 3	0/ 3
>12 times a day	0/ 3	0/ 3
Missing	0/ 3	0/ 3
Cycle 14	0/ 3	0/ 3
<4 times a day	0/ 3	0/ 3
4 - 5 times a day	0/ 3	0/ 3
6 - 12 times a day	0/ 3	0/ 3
>12 times a day	0/ 3	0/ 3
Missing	0/ 3	0/ 3
Cycle 15	0/ 2	0/ 2
<4 times a day	0/ 2	0/ 2
4 - 5 times a day	0/ 2	0/ 2
6 - 12 times a day	0/ 2	0/ 2
>12 times a day	0/ 2	0/ 2
Missing	0/ 2	0/ 2
Cycle 16	0/ 2	0/ 1
<4 times a day	0/ 2	0/ 1
4 - 5 times a day	0/ 2	0/ 1
6 - 12 times a day	0/ 2	0/ 1
>12 times a day	0/ 2	0/ 1
Missing	0/ 2	0/ 1

Note: Subjects may have more than one ocular therapy medication.
Note: A subject can take a medication more than once within a cycle and so can therefore be included in more than one frequency category.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_sp_med_oth.sas 21DEC2022 02:45

Protocol: 207495 Page 32 of 47
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 1.014110
Summary of Ocular Therapy Medications

Ocular Therapy Medication: Autologous serum eye drops

Cycle	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Cycle 17	0/ 2	0/ 1
<4 times a day	0/ 2	0/ 1
4 - 5 times a day	0/ 2	0/ 1
6 - 12 times a day	0/ 2	0/ 1
>12 times a day	0/ 2	0/ 1
Missing	0/ 2	0/ 1
Cycle 18	0/ 2	0/ 1
<4 times a day	0/ 2	0/ 1
4 - 5 times a day	0/ 2	0/ 1
6 - 12 times a day	0/ 2	0/ 1
>12 times a day	0/ 2	0/ 1
Missing	0/ 2	0/ 1
Cycle 19	0/ 2	0/ 1
<4 times a day	0/ 2	0/ 1
4 - 5 times a day	0/ 2	0/ 1
6 - 12 times a day	0/ 2	0/ 1
>12 times a day	0/ 2	0/ 1
Missing	0/ 2	0/ 1
Cycle 20	0/ 2	0/ 1
<4 times a day	0/ 2	0/ 1
4 - 5 times a day	0/ 2	0/ 1
6 - 12 times a day	0/ 2	0/ 1
>12 times a day	0/ 2	0/ 1
Missing	0/ 2	0/ 1

Note: Subjects may have more than one ocular therapy medication.
Note: A subject can take a medication more than once within a cycle and so can therefore be included in more than one frequency category.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_sp_med_oth.sas 21DEC2022 02:45

Protocol: 207495 Page 33 of 47
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 1.014110
Summary of Ocular Therapy Medications

Ocular Therapy Medication: Autologous serum eye drops

Cycle	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Cycle 21	0/ 2	0/ 1
<4 times a day	0/ 2	0/ 1
4 - 5 times a day	0/ 2	0/ 1
6 - 12 times a day	0/ 2	0/ 1
>12 times a day	0/ 2	0/ 1
Missing	0/ 2	0/ 1
Cycle 22	0/ 2	0/ 1
<4 times a day	0/ 2	0/ 1
4 - 5 times a day	0/ 2	0/ 1
6 - 12 times a day	0/ 2	0/ 1
>12 times a day	0/ 2	0/ 1
Missing	0/ 2	0/ 1
Cycle 23	0/ 2	0/ 1
<4 times a day	0/ 2	0/ 1
4 - 5 times a day	0/ 2	0/ 1
6 - 12 times a day	0/ 2	0/ 1
>12 times a day	0/ 2	0/ 1
Missing	0/ 2	0/ 1
Cycle 24	0/ 1	0/ 1
<4 times a day	0/ 1	0/ 1
4 - 5 times a day	0/ 1	0/ 1
6 - 12 times a day	0/ 1	0/ 1
>12 times a day	0/ 1	0/ 1
Missing	0/ 1	0/ 1

Note: Subjects may have more than one ocular therapy medication.
Note: A subject can take a medication more than once within a cycle and so can therefore be included in more than one frequency category.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_sp_med_oth.sas 21DEC2022 02:45

Protocol: 207495 Page 34 of 47
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 1.014110
Summary of Ocular Therapy Medications

Ocular Therapy Medication: Autologous serum eye drops

Cycle	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Cycle 25	0/ 0	0/ 1
<4 times a day	0/ 0	0/ 1
4 - 5 times a day	0/ 0	0/ 1
6 - 12 times a day	0/ 0	0/ 1
>12 times a day	0/ 0	0/ 1
Missing	0/ 0	0/ 1
Cycle 26	0/ 0	0/ 1
<4 times a day	0/ 0	0/ 1
4 - 5 times a day	0/ 0	0/ 1
6 - 12 times a day	0/ 0	0/ 1
>12 times a day	0/ 0	0/ 1
Missing	0/ 0	0/ 1
Cycle 27	0/ 0	0/ 1
<4 times a day	0/ 0	0/ 1
4 - 5 times a day	0/ 0	0/ 1
6 - 12 times a day	0/ 0	0/ 1
>12 times a day	0/ 0	0/ 1
Missing	0/ 0	0/ 1
Cycle 28	0/ 0	0/ 1
<4 times a day	0/ 0	0/ 1
4 - 5 times a day	0/ 0	0/ 1
6 - 12 times a day	0/ 0	0/ 1
>12 times a day	0/ 0	0/ 1
Missing	0/ 0	0/ 1

Note: Subjects may have more than one ocular therapy medication.
Note: A subject can take a medication more than once within a cycle and so can therefore be included in more than one frequency category.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_sp_med_oth.sas 21DEC2022 02:45

Protocol: 207495 Page 35 of 47
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 1.014110
Summary of Ocular Therapy Medications

Ocular Therapy Medication: Autologous serum eye drops

Cycle	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Cycle 29	0/ 0	0/ 1
<4 times a day	0/ 0	0/ 1
4 - 5 times a day	0/ 0	0/ 1
6 - 12 times a day	0/ 0	0/ 1
>12 times a day	0/ 0	0/ 1
Missing	0/ 0	0/ 1
Cycle 30	0/ 0	0/ 1
<4 times a day	0/ 0	0/ 1
4 - 5 times a day	0/ 0	0/ 1
6 - 12 times a day	0/ 0	0/ 1
>12 times a day	0/ 0	0/ 1
Missing	0/ 0	0/ 1
Cycle 31	0/ 0	0/ 1
<4 times a day	0/ 0	0/ 1
4 - 5 times a day	0/ 0	0/ 1
6 - 12 times a day	0/ 0	0/ 1
>12 times a day	0/ 0	0/ 1
Missing	0/ 0	0/ 1
Cycle 32	0/ 0	0/ 1
<4 times a day	0/ 0	0/ 1
4 - 5 times a day	0/ 0	0/ 1
6 - 12 times a day	0/ 0	0/ 1
>12 times a day	0/ 0	0/ 1
Missing	0/ 0	0/ 1

Note: Subjects may have more than one ocular therapy medication.
Note: A subject can take a medication more than once within a cycle and so can therefore be included in more than one frequency category.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_sp_med_oth.sas 21DEC2022 02:45

Table 1.014110
Summary of Ocular Therapy Medications

Ocular Therapy Medication: Autologous serum eye drops

Cycle	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Cycle 33	0/ 0	0/ 1
<4 times a day	0/ 0	0/ 1
4 - 5 times a day	0/ 0	0/ 1
6 - 12 times a day	0/ 0	0/ 1
>12 times a day	0/ 0	0/ 1
Missing	0/ 0	0/ 1
Overall	0/14	0/29
<4 times a day	0/14	0/29
4 - 5 times a day	0/14	0/29
6 - 12 times a day	0/14	0/29
>12 times a day	0/14	0/29
Missing	0/14	0/29

Note: Subjects may have more than one ocular therapy medication.
Note: A subject can take a medication more than once within a cycle and so can therefore be included in more than one frequency category.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_sp_med_oth.sas 21DEC2022 02:45

Protocol: 207495 Page 37 of 47
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 1.014110
Summary of Ocular Therapy Medications

Ocular Therapy Medication: Other Ocular Therapy Medication

Cycle	Pom/Dex (N=15)		Belantamab mafodotin (N=29)	
Cycle 1	1/14	(7%)	6/29	(21%)
<4 times a day	0/14		1/29	(3%)
4 - 5 times a day	0/14		1/29	(3%)
6 - 12 times a day	0/14		0/29	
>12 times a day	0/14		1/29	(3%)
Missing	1/14	(7%)	3/29	(10%)
Cycle 2	1/13	(8%)	6/25	(24%)
<4 times a day	0/13		0/25	
4 - 5 times a day	0/13		1/25	(4%)
6 - 12 times a day	0/13		0/25	
>12 times a day	0/13		1/25	(4%)
Missing	1/13	(8%)	4/25	(16%)
Cycle 3	1/13	(8%)	4/15	(27%)
<4 times a day	0/13		0/15	
4 - 5 times a day	0/13		1/15	(7%)
6 - 12 times a day	0/13		0/15	
>12 times a day	0/13		1/15	(7%)
Missing	1/13	(8%)	2/15	(13%)
Cycle 4	1/13	(8%)	3/10	(30%)
<4 times a day	0/13		0/10	
4 - 5 times a day	0/13		0/10	
6 - 12 times a day	0/13		0/10	
>12 times a day	0/13		0/10	
Missing	1/13	(8%)	3/10	(30%)

Note: Subjects may have more than one ocular therapy medication.
Note: A subject can take a medication more than once within a cycle and so can therefore be included in more than one frequency category.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_sp_med_oth.sas 21DEC2022 02:45

Protocol: 207495 Page 38 of 47
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 1.014110
Summary of Ocular Therapy Medications

Ocular Therapy Medication: Other Ocular Therapy Medication

Cycle	Pom/Dex (N=15)		Belantamab mafodotin (N=29)	
Cycle 5	2/13	(15%)	4/ 8	(50%)
<4 times a day	0/13		0/ 8	
4 - 5 times a day	0/13		0/ 8	
6 - 12 times a day	0/13		0/ 8	
>12 times a day	0/13		0/ 8	
Missing	2/13	(15%)	4/ 8	(50%)
Cycle 6	2/11	(18%)	2/ 6	(33%)
<4 times a day	0/11		0/ 6	
4 - 5 times a day	0/11		0/ 6	
6 - 12 times a day	0/11		0/ 6	
>12 times a day	0/11		0/ 6	
Missing	2/11	(18%)	2/ 6	(33%)
Cycle 7	2/ 8	(25%)	2/ 5	(40%)
<4 times a day	0/ 8		0/ 5	
4 - 5 times a day	0/ 8		0/ 5	
6 - 12 times a day	0/ 8		0/ 5	
>12 times a day	0/ 8		0/ 5	
Missing	2/ 8	(25%)	2/ 5	(40%)
Cycle 8	2/ 6	(33%)	2/ 5	(40%)
<4 times a day	0/ 6		0/ 5	
4 - 5 times a day	0/ 6		0/ 5	
6 - 12 times a day	0/ 6		0/ 5	
>12 times a day	0/ 6		0/ 5	
Missing	2/ 6	(33%)	2/ 5	(40%)

Note: Subjects may have more than one ocular therapy medication.
Note: A subject can take a medication more than once within a cycle and so can therefore be included in more than one frequency category.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_sp_med_oth.sas 21DEC2022 02:45

Protocol: 207495 Page 39 of 47
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 1.014110
Summary of Ocular Therapy Medications

Ocular Therapy Medication: Other Ocular Therapy Medication

Cycle	Pom/Dex (N=15)	Belantamab mafodotin (N=29)	
Cycle 9	0/ 5	1/ 5	(20%)
<4 times a day	0/ 5	0/ 5	
4 - 5 times a day	0/ 5	0/ 5	
6 - 12 times a day	0/ 5	0/ 5	
>12 times a day	0/ 5	0/ 5	
Missing	0/ 5	1/ 5	(20%)
Cycle 10	0/ 3	1/ 5	(20%)
<4 times a day	0/ 3	0/ 5	
4 - 5 times a day	0/ 3	0/ 5	
6 - 12 times a day	0/ 3	0/ 5	
>12 times a day	0/ 3	0/ 5	
Missing	0/ 3	1/ 5	(20%)
Cycle 11	0/ 3	0/ 3	
<4 times a day	0/ 3	0/ 3	
4 - 5 times a day	0/ 3	0/ 3	
6 - 12 times a day	0/ 3	0/ 3	
>12 times a day	0/ 3	0/ 3	
Missing	0/ 3	0/ 3	
Cycle 12	0/ 3	0/ 3	
<4 times a day	0/ 3	0/ 3	
4 - 5 times a day	0/ 3	0/ 3	
6 - 12 times a day	0/ 3	0/ 3	
>12 times a day	0/ 3	0/ 3	
Missing	0/ 3	0/ 3	

Note: Subjects may have more than one ocular therapy medication.
Note: A subject can take a medication more than once within a cycle and so can therefore be included in more than one frequency category.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_sp_med_oth.sas 21DEC2022 02:45

Table 1.014110
Summary of Ocular Therapy Medications

Ocular Therapy Medication: Other Ocular Therapy Medication

Cycle	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Cycle 13	0/ 3	0/ 3
<4 times a day	0/ 3	0/ 3
4 - 5 times a day	0/ 3	0/ 3
6 - 12 times a day	0/ 3	0/ 3
>12 times a day	0/ 3	0/ 3
Missing	0/ 3	0/ 3
Cycle 14	0/ 3	0/ 3
<4 times a day	0/ 3	0/ 3
4 - 5 times a day	0/ 3	0/ 3
6 - 12 times a day	0/ 3	0/ 3
>12 times a day	0/ 3	0/ 3
Missing	0/ 3	0/ 3
Cycle 15	0/ 2	0/ 2
<4 times a day	0/ 2	0/ 2
4 - 5 times a day	0/ 2	0/ 2
6 - 12 times a day	0/ 2	0/ 2
>12 times a day	0/ 2	0/ 2
Missing	0/ 2	0/ 2
Cycle 16	0/ 2	0/ 1
<4 times a day	0/ 2	0/ 1
4 - 5 times a day	0/ 2	0/ 1
6 - 12 times a day	0/ 2	0/ 1
>12 times a day	0/ 2	0/ 1
Missing	0/ 2	0/ 1

Note: Subjects may have more than one ocular therapy medication.
Note: A subject can take a medication more than once within a cycle and so can therefore be included in more than one frequency category.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_sp_med_oth.sas 21DEC2022 02:45

Protocol: 207495 Page 41 of 47
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 1.014110
Summary of Ocular Therapy Medications

Ocular Therapy Medication: Other Ocular Therapy Medication

Cycle	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Cycle 17	0/ 2	0/ 1
<4 times a day	0/ 2	0/ 1
4 - 5 times a day	0/ 2	0/ 1
6 - 12 times a day	0/ 2	0/ 1
>12 times a day	0/ 2	0/ 1
Missing	0/ 2	0/ 1
Cycle 18	0/ 2	0/ 1
<4 times a day	0/ 2	0/ 1
4 - 5 times a day	0/ 2	0/ 1
6 - 12 times a day	0/ 2	0/ 1
>12 times a day	0/ 2	0/ 1
Missing	0/ 2	0/ 1
Cycle 19	0/ 2	0/ 1
<4 times a day	0/ 2	0/ 1
4 - 5 times a day	0/ 2	0/ 1
6 - 12 times a day	0/ 2	0/ 1
>12 times a day	0/ 2	0/ 1
Missing	0/ 2	0/ 1
Cycle 20	0/ 2	0/ 1
<4 times a day	0/ 2	0/ 1
4 - 5 times a day	0/ 2	0/ 1
6 - 12 times a day	0/ 2	0/ 1
>12 times a day	0/ 2	0/ 1
Missing	0/ 2	0/ 1

Note: Subjects may have more than one ocular therapy medication.
Note: A subject can take a medication more than once within a cycle and so can therefore be included in more than one frequency category.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_sp_med_oth.sas 21DEC2022 02:45

Table 1.014110
Summary of Ocular Therapy Medications

Ocular Therapy Medication: Other Ocular Therapy Medication

Cycle	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Cycle 21	0/ 2	0/ 1
<4 times a day	0/ 2	0/ 1
4 - 5 times a day	0/ 2	0/ 1
6 - 12 times a day	0/ 2	0/ 1
>12 times a day	0/ 2	0/ 1
Missing	0/ 2	0/ 1
Cycle 22	0/ 2	0/ 1
<4 times a day	0/ 2	0/ 1
4 - 5 times a day	0/ 2	0/ 1
6 - 12 times a day	0/ 2	0/ 1
>12 times a day	0/ 2	0/ 1
Missing	0/ 2	0/ 1
Cycle 23	0/ 2	0/ 1
<4 times a day	0/ 2	0/ 1
4 - 5 times a day	0/ 2	0/ 1
6 - 12 times a day	0/ 2	0/ 1
>12 times a day	0/ 2	0/ 1
Missing	0/ 2	0/ 1
Cycle 24	0/ 1	0/ 1
<4 times a day	0/ 1	0/ 1
4 - 5 times a day	0/ 1	0/ 1
6 - 12 times a day	0/ 1	0/ 1
>12 times a day	0/ 1	0/ 1
Missing	0/ 1	0/ 1

Note: Subjects may have more than one ocular therapy medication.
Note: A subject can take a medication more than once within a cycle and so can therefore be included in more than one frequency category.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_sp_med_oth.sas 21DEC2022 02:45

Protocol: 207495 Page 43 of 47
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 1.014110
Summary of Ocular Therapy Medications

Ocular Therapy Medication: Other Ocular Therapy Medication

Cycle	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Cycle 25	0/ 0	0/ 1
<4 times a day	0/ 0	0/ 1
4 - 5 times a day	0/ 0	0/ 1
6 - 12 times a day	0/ 0	0/ 1
>12 times a day	0/ 0	0/ 1
Missing	0/ 0	0/ 1
Cycle 26	0/ 0	0/ 1
<4 times a day	0/ 0	0/ 1
4 - 5 times a day	0/ 0	0/ 1
6 - 12 times a day	0/ 0	0/ 1
>12 times a day	0/ 0	0/ 1
Missing	0/ 0	0/ 1
Cycle 27	0/ 0	0/ 1
<4 times a day	0/ 0	0/ 1
4 - 5 times a day	0/ 0	0/ 1
6 - 12 times a day	0/ 0	0/ 1
>12 times a day	0/ 0	0/ 1
Missing	0/ 0	0/ 1
Cycle 28	0/ 0	0/ 1
<4 times a day	0/ 0	0/ 1
4 - 5 times a day	0/ 0	0/ 1
6 - 12 times a day	0/ 0	0/ 1
>12 times a day	0/ 0	0/ 1
Missing	0/ 0	0/ 1

Note: Subjects may have more than one ocular therapy medication.
Note: A subject can take a medication more than once within a cycle and so can therefore be included in more than one frequency category.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_sp_med_oth.sas 21DEC2022 02:45

Protocol: 207495 Page 44 of 47
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 1.014110
Summary of Ocular Therapy Medications

Ocular Therapy Medication: Other Ocular Therapy Medication

Cycle	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Cycle 29	0/ 0	0/ 1
<4 times a day	0/ 0	0/ 1
4 - 5 times a day	0/ 0	0/ 1
6 - 12 times a day	0/ 0	0/ 1
>12 times a day	0/ 0	0/ 1
Missing	0/ 0	0/ 1
Cycle 30	0/ 0	0/ 1
<4 times a day	0/ 0	0/ 1
4 - 5 times a day	0/ 0	0/ 1
6 - 12 times a day	0/ 0	0/ 1
>12 times a day	0/ 0	0/ 1
Missing	0/ 0	0/ 1
Cycle 31	0/ 0	0/ 1
<4 times a day	0/ 0	0/ 1
4 - 5 times a day	0/ 0	0/ 1
6 - 12 times a day	0/ 0	0/ 1
>12 times a day	0/ 0	0/ 1
Missing	0/ 0	0/ 1
Cycle 32	0/ 0	0/ 1
<4 times a day	0/ 0	0/ 1
4 - 5 times a day	0/ 0	0/ 1
6 - 12 times a day	0/ 0	0/ 1
>12 times a day	0/ 0	0/ 1
Missing	0/ 0	0/ 1

Note: Subjects may have more than one ocular therapy medication.
Note: A subject can take a medication more than once within a cycle and so can therefore be included in more than one frequency category.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_sp_med_oth.sas 21DEC2022 02:45

Table 1.014110
Summary of Ocular Therapy Medications

Ocular Therapy Medication: Other Ocular Therapy Medication

Cycle	Pom/Dex (N=15)		Belantamab mafodotin (N=29)	
Cycle 33	0/ 0		0/ 1	
<4 times a day	0/ 0		0/ 1	
4 - 5 times a day	0/ 0		0/ 1	
6 - 12 times a day	0/ 0		0/ 1	
>12 times a day	0/ 0		0/ 1	
Missing	0/ 0		0/ 1	
Overall	3/14	(21%)	9/29	(31%)
<4 times a day	0/14		1/29	(3%)
4 - 5 times a day	0/14		1/29	(3%)
6 - 12 times a day	0/14		0/29	
>12 times a day	0/14		1/29	(3%)
Missing	3/14	(21%)	6/29	(21%)

Note: Subjects may have more than one ocular therapy medication.
Note: A subject can take a medication more than once within a cycle and so can therefore be included in more than one frequency category.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_sp_med_oth.sas 21DEC2022 02:45

Protocol: 207495 Page 46 of 47
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 1.014110
Summary of Ocular Therapy Medications

Ocular Therapy Medication: No Ocular Therapy Medication

Cycle	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Cycle 1	12/14 (86%)	2/29 (7%)
Cycle 2	11/13 (85%)	6/25 (24%)
Cycle 3	11/13 (85%)	7/15 (47%)
Cycle 4	11/13 (85%)	3/10 (30%)
Cycle 5	11/13 (85%)	2/ 8 (25%)
Cycle 6	9/11 (82%)	3/ 6 (50%)
Cycle 7	6/ 8 (75%)	2/ 5 (40%)
Cycle 8	4/ 6 (67%)	2/ 5 (40%)
Cycle 9	5/ 5 (100%)	3/ 5 (60%)
Cycle 10	3/ 3 (100%)	3/ 5 (60%)
Cycle 11	3/ 3 (100%)	3/ 3 (100%)
Cycle 12	3/ 3 (100%)	3/ 3 (100%)
Cycle 13	3/ 3 (100%)	3/ 3 (100%)
Cycle 14	3/ 3 (100%)	3/ 3 (100%)
Cycle 15	2/ 2 (100%)	2/ 2 (100%)
Cycle 16	2/ 2 (100%)	1/ 1 (100%)
Cycle 17	2/ 2 (100%)	1/ 1 (100%)
Cycle 18	2/ 2 (100%)	1/ 1 (100%)
Cycle 19	1/ 2 (50%)	1/ 1 (100%)
Cycle 20	1/ 2 (50%)	1/ 1 (100%)
Cycle 21	1/ 2 (50%)	1/ 1 (100%)
Cycle 22	1/ 2 (50%)	1/ 1 (100%)
Cycle 23	2/ 2 (100%)	1/ 1 (100%)
Cycle 24	1/ 1 (100%)	1/ 1 (100%)
Cycle 25	0/ 0	1/ 1 (100%)
Cycle 26	0/ 0	1/ 1 (100%)
Cycle 27	0/ 0	1/ 1 (100%)
Cycle 28	0/ 0	1/ 1 (100%)

Note: Subjects may have more than one ocular therapy medication.
Note: A subject can take a medication more than once within a cycle and so can therefore be included in more than one frequency category.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_sp_med_oth.sas 21DEC2022 02:45

Table 1.014110
Summary of Ocular Therapy Medications

Ocular Therapy Medication: No Ocular Therapy Medication

Cycle	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Cycle 29	0/ 0	1/ 1 (100%)
Cycle 30	0/ 0	1/ 1 (100%)
Cycle 31	0/ 0	1/ 1 (100%)
Cycle 32	0/ 0	1/ 1 (100%)
Cycle 33	0/ 0	1/ 1 (100%)
Overall	13/14 (93%)	8/29 (28%)

Note: Subjects may have more than one ocular therapy medication.
Note: A subject can take a medication more than once within a cycle and so can therefore be included in more than one frequency category.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_sp_med_oth.sas 21DEC2022 02:45

Protocol: 207495 Page 1 of 10
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 1.015110
Summary of Ocular Therapy Procedures

Ocular Therapy Procedure: Cooling Eye Mask

Cycle	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Cycle 1	0/14	5/29 (17%)
Cycle 2	0/13	5/25 (20%)
Cycle 3	0/13	1/15 (7%)
Cycle 4	0/13	1/10 (10%)
Cycle 5	0/13	0/ 8
Cycle 6	0/11	0/ 6
Cycle 7	0/ 8	0/ 5
Cycle 8	0/ 6	0/ 5
Cycle 9	0/ 5	0/ 5
Cycle 10	0/ 3	0/ 5
Cycle 11	0/ 3	0/ 3
Cycle 12	0/ 3	0/ 3
Cycle 13	0/ 3	0/ 3
Cycle 14	0/ 3	0/ 3
Cycle 15	0/ 2	0/ 2
Cycle 16	0/ 2	0/ 1
Cycle 17	0/ 2	0/ 1
Cycle 18	0/ 2	0/ 1
Cycle 19	0/ 2	0/ 1
Cycle 20	0/ 2	0/ 1
Cycle 21	0/ 2	0/ 1
Cycle 22	0/ 2	0/ 1
Cycle 23	0/ 2	0/ 1
Cycle 24	0/ 1	0/ 1
Cycle 25	0/ 0	0/ 1
Cycle 26	0/ 0	0/ 1
Cycle 27	0/ 0	0/ 1
Cycle 28	0/ 0	0/ 1
Cycle 29	0/ 0	0/ 1
Cycle 30	0/ 0	0/ 1

Note: Subjects may have more than one ocular therapy procedure.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_sp_proc_oc.sas 21DEC2022 04:43

Table 1.015110
Summary of Ocular Therapy Procedures

Ocular Therapy Procedure: Cooling Eye Mask

Cycle	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Cycle 31	0/ 0	0/ 1
Cycle 32	0/ 0	0/ 1
Cycle 33	0/ 0	0/ 1
Overall	0/14	5/29 (17%)

Note: Subjects may have more than one ocular therapy procedure.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_sp_proc_oc.sas 21DEC2022 04:43

Protocol: 207495 Page 3 of 10
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 1.015110
Summary of Ocular Therapy Procedures

Ocular Therapy Procedure: Punctal Plugs (Lacrimal Plugs)

Cycle	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Cycle 1	1/14 (7%)	2/29 (7%)
Cycle 2	0/13	1/25 (4%)
Cycle 3	0/13	1/15 (7%)
Cycle 4	0/13	1/10 (10%)
Cycle 5	0/13	1/ 8 (13%)
Cycle 6	0/11	1/ 6 (17%)
Cycle 7	0/ 8	1/ 5 (20%)
Cycle 8	0/ 6	1/ 5 (20%)
Cycle 9	0/ 5	1/ 5 (20%)
Cycle 10	0/ 3	1/ 5 (20%)
Cycle 11	0/ 3	0/ 3
Cycle 12	0/ 3	0/ 3
Cycle 13	0/ 3	0/ 3
Cycle 14	0/ 3	0/ 3
Cycle 15	0/ 2	0/ 2
Cycle 16	0/ 2	0/ 1
Cycle 17	0/ 2	0/ 1
Cycle 18	0/ 2	0/ 1
Cycle 19	0/ 2	0/ 1
Cycle 20	0/ 2	0/ 1
Cycle 21	0/ 2	0/ 1
Cycle 22	0/ 2	0/ 1
Cycle 23	0/ 2	0/ 1
Cycle 24	0/ 1	0/ 1
Cycle 25	0/ 0	0/ 1
Cycle 26	0/ 0	0/ 1
Cycle 27	0/ 0	0/ 1
Cycle 28	0/ 0	0/ 1
Cycle 29	0/ 0	0/ 1
Cycle 30	0/ 0	0/ 1

Note: Subjects may have more than one ocular therapy procedure.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_sp_proc_oc.sas 21DEC2022 04:43

Table 1.015110
Summary of Ocular Therapy Procedures

Ocular Therapy Procedure: Punctal Plugs (Lacrimal Plugs)

Cycle	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Cycle 31	0/ 0	0/ 1
Cycle 32	0/ 0	0/ 1
Cycle 33	0/ 0	0/ 1
Overall	1/14 (7%)	2/29 (7%)

Note: Subjects may have more than one ocular therapy procedure.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_sp_proc_oc.sas 21DEC2022 04:43

Table 1.015110
Summary of Ocular Therapy Procedures

Ocular Therapy Procedure: Bandage Contact Lenses

Cycle	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Cycle 1	0/14	0/29
Cycle 2	0/13	0/25
Cycle 3	0/13	0/15
Cycle 4	0/13	0/10
Cycle 5	0/13	0/ 8
Cycle 6	0/11	0/ 6
Cycle 7	0/ 8	0/ 5
Cycle 8	0/ 6	0/ 5
Cycle 9	0/ 5	0/ 5
Cycle 10	0/ 3	0/ 5
Cycle 11	0/ 3	0/ 3
Cycle 12	0/ 3	0/ 3
Cycle 13	0/ 3	0/ 3
Cycle 14	0/ 3	0/ 3
Cycle 15	0/ 2	0/ 2
Cycle 16	0/ 2	0/ 1
Cycle 17	0/ 2	0/ 1
Cycle 18	0/ 2	0/ 1
Cycle 19	0/ 2	0/ 1
Cycle 20	0/ 2	0/ 1
Cycle 21	0/ 2	0/ 1
Cycle 22	0/ 2	0/ 1
Cycle 23	0/ 2	0/ 1
Cycle 24	0/ 1	0/ 1
Cycle 25	0/ 0	0/ 1
Cycle 26	0/ 0	0/ 1
Cycle 27	0/ 0	0/ 1
Cycle 28	0/ 0	0/ 1
Cycle 29	0/ 0	0/ 1
Cycle 30	0/ 0	0/ 1

Note: Subjects may have more than one ocular therapy procedure.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_sp_proc_oc.sas 21DEC2022 04:43

Table 1.015110
Summary of Ocular Therapy Procedures

Ocular Therapy Procedure: Bandage Contact Lenses

Cycle	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Cycle 31	0/ 0	0/ 1
Cycle 32	0/ 0	0/ 1
Cycle 33	0/ 0	0/ 1
Overall	0/14	0/29

Note: Subjects may have more than one ocular therapy procedure.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_sp_proc_oc.sas 21DEC2022 04:43

Protocol: 207495 Page 7 of 10
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 1.015110
Summary of Ocular Therapy Procedures

Ocular Therapy Procedure: Other Ocular Therapy Procedure

Cycle	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Cycle 1	0/14	0/29
Cycle 2	1/13 (8%)	0/25
Cycle 3	0/13	0/15
Cycle 4	1/13 (8%)	0/10
Cycle 5	0/13	1/ 8 (13%)
Cycle 6	0/11	0/ 6
Cycle 7	1/ 8 (13%)	0/ 5
Cycle 8	1/ 6 (17%)	0/ 5
Cycle 9	0/ 5	0/ 5
Cycle 10	0/ 3	0/ 5
Cycle 11	0/ 3	0/ 3
Cycle 12	0/ 3	0/ 3
Cycle 13	0/ 3	0/ 3
Cycle 14	0/ 3	0/ 3
Cycle 15	0/ 2	0/ 2
Cycle 16	0/ 2	0/ 1
Cycle 17	0/ 2	0/ 1
Cycle 18	0/ 2	0/ 1
Cycle 19	0/ 2	0/ 1
Cycle 20	0/ 2	0/ 1
Cycle 21	0/ 2	0/ 1
Cycle 22	0/ 2	0/ 1
Cycle 23	0/ 2	0/ 1
Cycle 24	0/ 1	0/ 1
Cycle 25	0/ 0	0/ 1
Cycle 26	0/ 0	0/ 1
Cycle 27	0/ 0	0/ 1
Cycle 28	0/ 0	0/ 1
Cycle 29	0/ 0	0/ 1
Cycle 30	0/ 0	0/ 1

Note: Subjects may have more than one ocular therapy procedure.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_sp_proc_oc.sas 21DEC2022 04:43

Table 1.015110
Summary of Ocular Therapy Procedures

Ocular Therapy Procedure: Other Ocular Therapy Procedure

Cycle	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Cycle 31	0/ 0	0/ 1
Cycle 32	0/ 0	0/ 1
Cycle 33	0/ 0	0/ 1
Overall	2/14 (14%)	1/29 (3%)

Note: Subjects may have more than one ocular therapy procedure.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_sp_proc_oc.sas 21DEC2022 04:43

Protocol: 207495 Page 9 of 10
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 1.015110
Summary of Ocular Therapy Procedures

Ocular Therapy Procedure: No Ocular Therapy Procedure

Cycle	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Cycle 1	13/14 (93%)	22/29 (76%)
Cycle 2	12/13 (92%)	19/25 (76%)
Cycle 3	13/13 (100%)	13/15 (87%)
Cycle 4	12/13 (92%)	8/10 (80%)
Cycle 5	13/13 (100%)	6/ 8 (75%)
Cycle 6	11/11 (100%)	5/ 6 (83%)
Cycle 7	7/ 8 (88%)	4/ 5 (80%)
Cycle 8	5/ 6 (83%)	4/ 5 (80%)
Cycle 9	5/ 5 (100%)	4/ 5 (80%)
Cycle 10	3/ 3 (100%)	4/ 5 (80%)
Cycle 11	3/ 3 (100%)	3/ 3 (100%)
Cycle 12	3/ 3 (100%)	3/ 3 (100%)
Cycle 13	3/ 3 (100%)	3/ 3 (100%)
Cycle 14	3/ 3 (100%)	3/ 3 (100%)
Cycle 15	2/ 2 (100%)	2/ 2 (100%)
Cycle 16	2/ 2 (100%)	1/ 1 (100%)
Cycle 17	2/ 2 (100%)	1/ 1 (100%)
Cycle 18	2/ 2 (100%)	1/ 1 (100%)
Cycle 19	2/ 2 (100%)	1/ 1 (100%)
Cycle 20	2/ 2 (100%)	1/ 1 (100%)
Cycle 21	2/ 2 (100%)	1/ 1 (100%)
Cycle 22	2/ 2 (100%)	1/ 1 (100%)
Cycle 23	2/ 2 (100%)	1/ 1 (100%)
Cycle 24	1/ 1 (100%)	1/ 1 (100%)
Cycle 25	0/ 0	1/ 1 (100%)
Cycle 26	0/ 0	1/ 1 (100%)
Cycle 27	0/ 0	1/ 1 (100%)
Cycle 28	0/ 0	1/ 1 (100%)
Cycle 29	0/ 0	1/ 1 (100%)
Cycle 30	0/ 0	1/ 1 (100%)

Note: Subjects may have more than one ocular therapy procedure.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_sp_proc_oc.sas 21DEC2022 04:43

Table 1.015110
Summary of Ocular Therapy Procedures

Ocular Therapy Procedure: No Ocular Therapy Procedure

Cycle	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Cycle 31	0/ 0	1/ 1 (100%)
Cycle 32	0/ 0	1/ 1 (100%)
Cycle 33	0/ 0	1/ 1 (100%)
Overall	14/14 (100%)	23/29 (79%)

Note: Subjects may have more than one ocular therapy procedure.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_sp_proc_oc.sas 21DEC2022 04:43

Protocol: 207495 Page 1 of 1
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 1.023110
Summary of Blood Products

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Any Blood Product	3 (20%)	11 (38%)
Red Blood Cells	3 (20%)	10 (34%)
Platelets	2 (13%)	9 (31%)
Other Blood Product	0	1 (3%)
Whole Blood	1 (7%)	0

Note: Includes all blood products with onset date within on-treatment window.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_sp_bp1a.sas 16DEC2022 09:54

Protocol: 207495 Page 1 of 1
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 1.024110
Summary of Blood Supportive Care Products

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Any Blood Supportive Care Product	1 (7%)	0
Other Blood Supportive Care Product	1 (7%)	0

Note: Includes all blood supportive care products with onset date within on-treatment window.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_sp_bp1c.sas 16DEC2022 09:54

Protocol: 207495 Page 1 of 1
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 1.016110
Summary of Prior Anti-Cancer Therapy by Drug Class of Agents

Drug Class Base Component	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Chemotherapy	15 (100%)	29 (100%)
Immunomodulator	15 (100%)	29 (100%)
LENALIDOMIDE	15 (100%)	29 (100%)
THALIDOMIDE	9 (60%)	19 (66%)
Monoclonal Antibody	15 (100%)	29 (100%)
Anti-CD38 antibodies	15 (100%)	29 (100%)
DARATUMUMAB	15 (100%)	27 (93%)
ISATUXIMAB	1 (7%)	2 (7%)
Proteasome Inhibitor	15 (100%)	29 (100%)
BORTEZOMIB	15 (100%)	29 (100%)
CARFILZOMIB	5 (33%)	19 (66%)
IXAZOMIB	3 (20%)	8 (28%)
Steroids	15 (100%)	29 (100%)
Radioactive Therapy	3 (20%)	9 (31%)
HDAC Inhibitor	0	4 (14%)
Other	1 (7%)	2 (7%)

Note: Multiple categories per subject possible, total may add to more than 100%.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_sp_ctx_class_pr.sas 16JAN2023 10:30

Protocol: 207495 Page 1 of 1
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 1.017110
Summary of Prior Dictionary Coded Anti-Cancer Therapy

Ingredient	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Any medication	15 (100%)	29 (100%)
BORTEZOMIB	15 (100%)	29 (100%)
DEXAMETHASONE	15 (100%)	29 (100%)
LENALIDOMIDE	15 (100%)	29 (100%)
DARATUMUMAB	15 (100%)	27 (93%)
CYCLOPHOSPHAMIDE	12 (80%)	24 (83%)
MELPHALAN	10 (67%)	18 (62%)
THALIDOMIDE	9 (60%)	19 (66%)
CARFILZOMIB	5 (33%)	19 (66%)
DOXORUBICIN	7 (47%)	9 (31%)
IXAZOMIB	2 (13%)	6 (21%)
BENDAMUSTINE	2 (13%)	5 (17%)
CISPLATIN	0	6 (21%)
PREDNISOLONE	3 (20%)	3 (10%)
VINCRISTINE	4 (27%)	2 (7%)
ETOPOSIDE	0	5 (17%)
MELPHALAN FLUFENAMIDE	1 (7%)	4 (14%)
METHYLPREDNISOLONE	3 (20%)	2 (7%)
PREDNISONE	2 (13%)	2 (7%)
ISATUXIMAB	1 (7%)	2 (7%)
IXAZOMIB CITRATE	1 (7%)	2 (7%)
PANOBINOSTAT	0	3 (10%)
BUSULFAN	1 (7%)	1 (3%)
VENETOCLAX	0	2 (7%)
CARMUSTINE	1 (7%)	0
DOXORUBICIN HYDROCHLORIDE	1 (7%)	0
HYDROCORTISONE	1 (7%)	0
INTERFERON ALPHA (NOS)	1 (7%)	0
PANOBINOSTAT LACTATE	0	1 (3%)
RANIMUSTINE	1 (7%)	0

PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_sp_ctx_prior.sas 03JAN2023 03:09

Protocol: 207495 Page 1 of 1
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 1.018110
Summary of Number of Prior Anti-Cancer Therapy Regimens

Number of Lines	Pom/Dex (N=15)		Belantamab mafodotin (N=29)	
n	15		29	
No Lines	0		0	
1 Line	0		0	
2 Lines	0		0	
3 Lines	0		0	
4 Lines	5	(33%)	13	(45%)
5 Lines	6	(40%)	5	(17%)
6 Lines	1	(7%)	4	(14%)
7 Lines	0		6	(21%)
8 Lines	2	(13%)	0	
9 Lines	0		1	(3%)
10 Lines	0		0	
More Than 10 Lines	1	(7%)	0	

PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_sp_ac3.sas 19DEC2022 07:26

Protocol: 207495 Page 1 of 1
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 1.021110
Summary of Subjects Refractory to Prior Anti-Cancer Therapy by Drug Class of Agents

Drug Class Base Component	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Immunomodulator	15 (100%)	29 (100%)
LENALIDOMIDE	14 (93%)	28 (97%)
THALIDOMIDE	7 (47%)	8 (28%)
Monoclonal Antibody	15 (100%)	29 (100%)
Anti-CD38 antibodies	15 (100%)	29 (100%)
DARATUMUMAB	15 (100%)	27 (93%)
ISATUXIMAB	1 (7%)	2 (7%)
Proteasome Inhibitor	15 (100%)	29 (100%)
BORTEZOMIB	13 (87%)	28 (97%)
CARFILZOMIB	5 (33%)	17 (59%)
IXAZOMIB	3 (20%)	6 (21%)
Steroids	15 (100%)	28 (97%)
Chemotherapy	9 (60%)	22 (76%)
HDAC Inhibitor	0	3 (10%)
Other	1 (7%)	2 (7%)

Note: Multiple categories per subject possible, total may add to more than 100%.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_sp_ctx_refr_prior.sas 16JAN2023 10:31

Protocol: 207495 Page 1 of 1
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 1.020110
Summary of Follow-Up Anti-Cancer Therapy

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Any Anti-Cancer Therapy		
Yes	9 (60%)	16 (55%)
No	6 (40%)	13 (45%)
Type of Anti-Cancer Therapy		
Steroids	6 (40%)	15 (52%)
Immunomodulator	3 (20%)	15 (52%)
Proteasome Inhibitor	3 (20%)	8 (28%)
Chemotherapy	5 (33%)	5 (17%)
Monoclonal Antibody	1 (7%)	5 (17%)
Missing	2 (13%)	0
Other	1 (7%)	1 (3%)
Bi-Specific Antibody (BiTE)	0	1 (3%)
Engineered T/NK Cell Therapy	0	1 (3%)
Time from Study Treatment Discontinuation to Start of Subsequent Anti-Cancer Therapy (days)[1]		
n	9	15
Min.	8	5
1st Quartile	31.0	14.0
Median	42.0	29.0
3rd Quartile	63.0	64.0
Max.	163	231

[1] Time from Study Treatment Discontinuation to Start of Subsequent Systemic Anti-Cancer Therapy (radiotherapy and surgeries are not considered as systemic anti-cancer therapy).

PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_sp_ctx_post.sas 19DEC2022 04:15

Protocol: 207495 Page 1 of 1
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.001112
Summary of Duration of Exposure to Belantamab Mafodotin

		Belantamab mafodotin (N=29)
Time on Study Treatment (months) [1]	n	29
	Mean	4.15
	SD	4.963
	Median	2.07
	Min.	0.7
	Max.	22.9

[1] The time on study treatment does not exclude dose interruptions.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_dur_bm.sas 27FEB2023 05:04

Protocol: 207495 Page 1 of 4
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.001210
Summary of Dose Intensity and Dose Exposure of Belantamab Mafodotin Delivered by Cycle

Exposure Endpoint: Dose Intensity (mg/kg/3 weeks) [1][2]

Treatment	N	Cycle	n	Mean	SD	Median	Min.	Max.
Belantamab mafodotin	29	Cycle 1	29	2.321	0.5194	2.500	0.35	2.78
		Cycle 2	25	2.333	0.6581	2.500	0.33	3.88
		Cycle 3	15	2.057	0.6912	2.179	0.44	2.67
		Cycle 4	10	2.082	0.6337	2.355	0.54	2.50
		Cycle 5	8	2.040	0.6608	2.314	0.62	2.50
		Cycle 6	6	2.293	0.3687	2.461	1.56	2.50
		Cycle 7	5	2.200	0.3702	2.231	1.59	2.50
		Cycle 8	5	2.206	0.3584	2.223	1.62	2.50
		Cycle 9	5	2.218	0.3489	2.237	1.65	2.50
		Cycle 10	5	2.231	0.3409	2.250	1.67	2.50
		Cycle 11	3	2.420	0.1387	2.500	2.26	2.50
		Cycle 12	3	2.428	0.1239	2.500	2.29	2.50
		Cycle 13	3	2.428	0.1250	2.500	2.28	2.50
		Cycle 14	3	2.427	0.1260	2.500	2.28	2.50
		Cycle 15	2	2.467	0.0464	2.467	2.43	2.50
		Cycle 16	1	2.500		2.500	2.50	2.50
		Cycle 17	1	2.500		2.500	2.50	2.50
		Cycle 18	1	2.500		2.500	2.50	2.50
		Cycle 19	1	2.500		2.500	2.50	2.50
		Cycle 20	1	2.500		2.500	2.50	2.50
		Cycle 21	1	2.511		2.511	2.51	2.51
		Cycle 22	1	2.500		2.500	2.50	2.50
		Cycle 23	1	2.500		2.500	2.50	2.50
		Cycle 24	1	2.500		2.500	2.50	2.50

[1] The dose intensity for each cycle is calculated as the cumulative actual dose (mg/kg) up to the cycle divided by expected duration of exposure up to the end of the cycle per 3 weeks.
[2] Overall dose intensity is the cumulative actual dose (mg/kg) divided by the total duration of exposure per 3 weeks.
[3] The dose exposure for each cycle is the total dose (mg/kg) received of the study treatment within the cycle.
[4] Overall dose exposure is the cumulative actual dose received (mg/kg).
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_int_bm.sas 24JAN2023 06:44

Table 3.001210
Summary of Dose Intensity and Dose Exposure of Belantamab Mafodotin Delivered by Cycle

Exposure Endpoint: Dose Intensity (mg/kg/3 weeks) [1][2]

Treatment	N	Cycle	n	Mean	SD	Median	Min.	Max.
Belantamab mafodotin	29	Cycle 25	1	2.500		2.500	2.50	2.50
		Cycle 26	1	2.500		2.500	2.50	2.50
		Cycle 27	1	2.504		2.504	2.50	2.50
		Cycle 28	1	2.500		2.500	2.50	2.50
		Cycle 29	1	2.500		2.500	2.50	2.50
		Cycle 30	1	2.500		2.500	2.50	2.50
		Cycle 31	1	2.508		2.508	2.51	2.51
		Cycle 32	1	2.414		2.414	2.41	2.41
		Cycle 33	1	2.486		2.486	2.49	2.49
		Overall	29	2.321	0.6573	2.500	0.44	3.88

[1] The dose intensity for each cycle is calculated as the cumulative actual dose (mg/kg) up to the cycle divided by expected duration of exposure up to the end of the cycle per 3 weeks.
[2] Overall dose intensity is the cumulative actual dose (mg/kg) divided by the total duration of exposure per 3 weeks.
[3] The dose exposure for each cycle is the total dose (mg/kg) received of the study treatment within the cycle.
[4] Overall dose exposure is the cumulative actual dose received (mg/kg).
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_int_bm.sas 24JAN2023 06:44

Protocol: 207495 Page 3 of 4
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.001210
Summary of Dose Intensity and Dose Exposure of Belantamab Mafodotin Delivered by Cycle

Exposure Endpoint: Dose Exposure (mg/kg) [3][4]

Treatment	N	Cycle	n	Mean	SD	Median	Min.	Max.
Belantamab mafodotin	29	Cycle 1	29	2.508	0.0355	2.500	2.46	2.66
		Cycle 2	25	2.452	0.1730	2.500	1.86	2.58
		Cycle 3	15	2.324	0.2773	2.494	1.82	2.52
		Cycle 4	10	2.436	0.1890	2.499	1.90	2.52
		Cycle 5	8	2.346	0.2718	2.500	1.90	2.50
		Cycle 6	6	2.395	0.2367	2.500	1.91	2.50
		Cycle 7	5	2.354	0.2599	2.500	1.90	2.50
		Cycle 8	5	2.354	0.2599	2.500	1.90	2.50
		Cycle 9	5	2.295	0.2517	2.368	1.90	2.50
		Cycle 10	5	2.362	0.2660	2.500	1.90	2.54
		Cycle 11	3	2.456	0.0760	2.500	2.37	2.50
		Cycle 12	3	2.456	0.0760	2.500	2.37	2.50
		Cycle 13	3	2.456	0.0760	2.500	2.37	2.50
		Cycle 14	3	2.456	0.0760	2.500	2.37	2.50
		Cycle 15	2	2.434	0.0930	2.434	2.37	2.50
		Cycle 16	1	2.500		2.500	2.50	2.50
		Cycle 17	1	2.500		2.500	2.50	2.50
		Cycle 18	1	2.500		2.500	2.50	2.50
		Cycle 19	1	2.500		2.500	2.50	2.50
		Cycle 20	1	2.500		2.500	2.50	2.50
		Cycle 21	1	2.500		2.500	2.50	2.50
		Cycle 22	1	2.500		2.500	2.50	2.50
		Cycle 23	1	2.500		2.500	2.50	2.50
		Cycle 24	1	2.500		2.500	2.50	2.50

[1] The dose intensity for each cycle is calculated as the cumulative actual dose (mg/kg) up to the cycle divided by expected duration of exposure up to the end of the cycle per 3 weeks.
[2] Overall dose intensity is the cumulative actual dose (mg/kg) divided by the total duration of exposure per 3 weeks.
[3] The dose exposure for each cycle is the total dose (mg/kg) received of the study treatment within the cycle.
[4] Overall dose exposure is the cumulative actual dose received (mg/kg).
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_int_bm.sas 24JAN2023 06:44

Table 3.001210
Summary of Dose Intensity and Dose Exposure of Belantamab Mafodotin Delivered by Cycle

Exposure Endpoint: Dose Exposure (mg/kg) [3][4]

Treatment	N	Cycle	n	Mean	SD	Median	Min.	Max.
Belantamab mafodotin	29	Cycle 25	1	2.500		2.500	2.50	2.50
		Cycle 26	1	2.500		2.500	2.50	2.50
		Cycle 27	1	2.500		2.500	2.50	2.50
		Cycle 28	1	2.500		2.500	2.50	2.50
		Cycle 29	1	2.500		2.500	2.50	2.50
		Cycle 30	1	2.500		2.500	2.50	2.50
		Cycle 31	1	2.500		2.500	2.50	2.50
		Cycle 32	1	2.500		2.500	2.50	2.50
		Cycle 33	1	2.500		2.500	2.50	2.50
		Overall	29	12.156	16.1726	6.250	2.50	82.50

[1] The dose intensity for each cycle is calculated as the cumulative actual dose (mg/kg) up to the cycle divided by expected duration of exposure up to the end of the cycle per 3 weeks.
[2] Overall dose intensity is the cumulative actual dose (mg/kg) divided by the total duration of exposure per 3 weeks.
[3] The dose exposure for each cycle is the total dose (mg/kg) received of the study treatment within the cycle.
[4] Overall dose exposure is the cumulative actual dose received (mg/kg).
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_int_bm.sas 24JAN2023 06:44

Protocol: 207495 Page 1 of 1
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.002112
Summary of Exposure to Belantamab Mafodotin

		Belantamab mafodotin (N=29)
Number of cycles	n	29
	Mean	5.0
	SD	6.52
	Median	3.0
	Min.	1
	Max.	33

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ex_bm.sas 27FEB2023 05:18

Protocol: 207495 Page 1 of 1
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.003112
Summary of Exposure to Pomalidomide

		Pom/Dex (N=14)
Subject Daily Dose (mg/day) [1]	n	14
	Mean	3.97
	SD	0.109
	Median	4.00
	Min.	3.6
	Max.	4.0
Cumulative Actual Dose (mg)	n	14
	Mean	751.0
	SD	541.31
	Median	576.0
	Min.	40
	Max.	1936
Time on Study Treatment (months) [2]	n	14
	Mean	8.71
	SD	6.273
	Median	6.55
	Min.	0.9
	Max.	22.0
	< 3 months	1 (7%)
	3 months to 6 months	5 (36%)
	> 6 months to 12 months	5 (36%)
	> 12 months	3 (21%)

[1] The subject daily dose (the cumulative actual dose divided by the duration of exposure) is calculated for each subject first and the summary statistics are calculated based on the subject average daily dose.
[2] The time on study drug does not exclude dose interruptions.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ex_pm.sas 27FEB2023 05:22

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.004112
Summary of Dose Exposure, Cumulative Dose, Average Daily Dose, Dose Intensity and Relative Dose Intensity of Pomalidomide Delivered by Cycle

Exposure Endpoint: Dose Exposure (Days)

Treatment	N	Time Unit	n	Mean	SD	Median	Min.	Max.
Pom/Dex	14	Cycle 1	14	20.3	2.97	21.0	10	22
		Cycle 2	13	20.7	1.80	21.0	15	23
		Cycle 3	13	21.3	7.43	21.0	9	43
		Cycle 4	12	21.1	0.29	21.0	21	22
		Cycle 5	13	20.3	1.80	21.0	15	21
		Cycle 6	11	20.9	2.30	21.0	15	25
		Cycle 7	8	20.9	0.35	21.0	20	21
		Cycle 8	6	21.0	0.00	21.0	21	21
		Cycle 9	5	21.0	0.00	21.0	21	21
		Cycle 10	3	21.0	0.00	21.0	21	21
		Cycle 11	3	21.0	0.00	21.0	21	21
		Cycle 12	3	21.0	0.00	21.0	21	21
		Cycle 13	3	21.0	0.00	21.0	21	21
		Cycle 14	3	21.0	0.00	21.0	21	21
		Cycle 15	2	21.0	0.00	21.0	21	21
		Cycle 16	2	21.0	0.00	21.0	21	21
		Cycle 17	2	21.0	0.00	21.0	21	21
		Cycle 18	2	21.0	0.00	21.0	21	21
		Cycle 19	2	21.0	0.00	21.0	21	21
		Cycle 20	2	21.0	0.00	21.0	21	21
		Cycle 21	2	21.0	0.00	21.0	21	21
		Cycle 22	2	14.0	9.90	14.0	7	21
		Cycle 23	2	17.5	4.95	17.5	14	21
		Cycle 24	1	1.0		1.0	1	1
		Overall	14	189.1	135.51	148.5	10	484

[1] The dose intensity for each cycle is calculated as the cumulative dose (mg) during the cycle divided by duration of exposure for the cycle.
[2] Overall dose intensity is the cumulative actual dose (mg) divided by the total duration of exposure.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_dos_cyc_pom.sas 27FEB2023 06:11

Table 3.004112
Summary of Dose Exposure, Cumulative Dose, Average Daily Dose, Dose Intensity and Relative Dose Intensity of Pomalidomide Delivered by Cycle

Exposure Endpoint: Cumulative Dose (mg)

Treatment	N	Time Unit	n	Mean	SD	Median	Min.	Max.
Pom/Dex	14	Cycle 1	14	81.1	11.89	84.0	40	88
		Cycle 2	13	82.8	7.19	84.0	60	92
		Cycle 3	13	85.2	29.73	84.0	36	172
		Cycle 4	12	84.3	1.15	84.0	84	88
		Cycle 5	13	81.2	7.19	84.0	60	84
		Cycle 6	11	81.6	10.46	84.0	60	100
		Cycle 7	8	80.9	7.36	84.0	63	84
		Cycle 8	6	80.5	8.57	84.0	63	84
		Cycle 9	5	84.0	0.00	84.0	84	84
		Cycle 10	3	84.0	0.00	84.0	84	84
		Cycle 11	3	84.0	0.00	84.0	84	84
		Cycle 12	3	84.0	0.00	84.0	84	84
		Cycle 13	3	84.0	0.00	84.0	84	84
		Cycle 14	3	84.0	0.00	84.0	84	84
		Cycle 15	2	84.0	0.00	84.0	84	84
		Cycle 16	2	84.0	0.00	84.0	84	84
		Cycle 17	2	84.0	0.00	84.0	84	84
		Cycle 18	2	84.0	0.00	84.0	84	84
		Cycle 19	2	84.0	0.00	84.0	84	84
		Cycle 20	2	84.0	0.00	84.0	84	84
		Cycle 21	2	84.0	0.00	84.0	84	84
		Cycle 22	2	56.0	39.60	56.0	28	84
		Cycle 23	2	63.0	29.70	63.0	42	84
		Cycle 24	1	4.0		4.0	4	4
		Overall	14	751.0	541.31	576.0	40	1936

[1] The dose intensity for each cycle is calculated as the cumulative dose (mg) during the cycle divided by duration of exposure for the cycle.
[2] Overall dose intensity is the cumulative actual dose (mg) divided by the total duration of exposure.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_dos_cyc_pom.sas 27FEB2023 06:11

Protocol: 207495 Page 3 of 5
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.004112
Summary of Dose Exposure, Cumulative Dose, Average Daily Dose, Dose Intensity and Relative Dose Intensity of Pomalidomide Delivered by Cycle

Exposure Endpoint: Average Daily Dose (mg/day)

Treatment	N	Time Unit	n	Mean	SD	Median	Min.	Max.
Pom/Dex	14	Cycle 1	14	4.00	0.000	4.00	4.0	4.0
		Cycle 2	13	4.00	0.000	4.00	4.0	4.0
		Cycle 3	13	4.00	0.000	4.00	4.0	4.0
		Cycle 4	12	4.00	0.000	4.00	4.0	4.0
		Cycle 5	13	4.00	0.000	4.00	4.0	4.0
		Cycle 6	11	3.91	0.302	4.00	3.0	4.0
		Cycle 7	8	3.88	0.354	4.00	3.0	4.0
		Cycle 8	6	3.83	0.408	4.00	3.0	4.0
		Cycle 9	5	4.00	0.000	4.00	4.0	4.0
		Cycle 10	3	4.00	0.000	4.00	4.0	4.0
		Cycle 11	3	4.00	0.000	4.00	4.0	4.0
		Cycle 12	3	4.00	0.000	4.00	4.0	4.0
		Cycle 13	3	4.00	0.000	4.00	4.0	4.0
		Cycle 14	3	4.00	0.000	4.00	4.0	4.0
		Cycle 15	2	4.00	0.000	4.00	4.0	4.0
		Cycle 16	2	4.00	0.000	4.00	4.0	4.0
		Cycle 17	2	4.00	0.000	4.00	4.0	4.0
		Cycle 18	2	4.00	0.000	4.00	4.0	4.0
		Cycle 19	2	4.00	0.000	4.00	4.0	4.0
		Cycle 20	2	4.00	0.000	4.00	4.0	4.0
		Cycle 21	2	4.00	0.000	4.00	4.0	4.0
		Cycle 22	2	4.00	0.000	4.00	4.0	4.0
		Cycle 23	2	3.50	0.707	3.50	3.0	4.0
		Cycle 24	1	4.00		4.00	4.0	4.0
		Overall	14	3.97	0.109	4.00	3.6	4.0

[1] The dose intensity for each cycle is calculated as the cumulative dose (mg) during the cycle divided by duration of exposure for the cycle.
[2] Overall dose intensity is the cumulative actual dose (mg) divided by the total duration of exposure.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_dos_cyc_pom.sas 27FEB2023 06:11

Table 3.004112
Summary of Dose Exposure, Cumulative Dose, Average Daily Dose, Dose Intensity and Relative Dose Intensity of Pomalidomide Delivered by Cycle

Exposure Endpoint: Dose Intensity (mg/day) [1][2]

Treatment	N	Time Unit	n	Mean	SD	Median	Min.	Max.
Pom/Dex	14	Cycle 1	14	2.89	0.444	3.00	1.4	3.2
		Cycle 2	13	3.06	0.442	3.00	2.3	4.4
		Cycle 3	13	2.83	0.547	3.00	1.3	3.5
		Cycle 4	12	2.94	0.205	3.00	2.4	3.3
		Cycle 5	13	3.02	0.355	3.00	2.5	4.0
		Cycle 6	11	2.73	0.639	3.00	1.6	3.6
		Cycle 7	8	2.90	0.243	3.00	2.4	3.2
		Cycle 8	6	2.65	0.680	3.00	1.4	3.2
		Cycle 9	5	3.02	0.050	3.00	3.0	3.1
		Cycle 10	3	2.97	0.060	3.00	2.9	3.0
		Cycle 11	3	3.00	0.000	3.00	3.0	3.0
		Cycle 12	3	3.00	0.000	3.00	3.0	3.0
		Cycle 13	3	2.97	0.060	3.00	2.9	3.0
		Cycle 14	3	2.82	0.306	3.00	2.5	3.0
		Cycle 15	2	3.33	0.461	3.33	3.0	3.7
		Cycle 16	2	3.06	0.079	3.06	3.0	3.1
		Cycle 17	2	3.06	0.079	3.06	3.0	3.1
		Cycle 18	2	2.90	0.141	2.90	2.8	3.0
		Cycle 19	2	2.95	0.073	2.95	2.9	3.0
		Cycle 20	2	3.25	0.354	3.25	3.0	3.5
		Cycle 21	2	2.43	0.667	2.43	2.0	2.9
		Cycle 22	2	1.49	1.387	1.49	0.5	2.5
		Cycle 23	2	2.25	1.061	2.25	1.5	3.0
		Cycle 24	1	4.00		4.00	4.0	4.0
		Overall	14	2.77	0.459	2.90	1.4	3.4

[1] The dose intensity for each cycle is calculated as the cumulative dose (mg) during the cycle divided by duration of exposure for the cycle.
[2] Overall dose intensity is the cumulative actual dose (mg) divided by the total duration of exposure.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_dos_cyc_pom.sas 27FEB2023 06:11

Table 3.004112
Summary of Dose Exposure, Cumulative Dose, Average Daily Dose, Dose Intensity and Relative Dose Intensity of Pomalidomide Delivered by Cycle

Exposure Endpoint: Relative Dose Intensity

Treatment	N	Time Unit	n	Mean	SD	Median	Min.	Max.
Pom/Dex	14	Cycle 1	14	0.963	0.1478	1.000	0.48	1.08
		Cycle 2	13	1.021	0.1475	1.000	0.77	1.46
		Cycle 3	13	0.944	0.1822	1.000	0.43	1.17
		Cycle 4	12	0.979	0.0683	1.000	0.80	1.09
		Cycle 5	13	1.007	0.1183	1.000	0.82	1.33
		Cycle 6	11	0.911	0.2129	1.000	0.52	1.19
		Cycle 7	8	0.968	0.0811	1.000	0.81	1.08
		Cycle 8	6	0.885	0.2265	1.000	0.48	1.08
		Cycle 9	5	1.007	0.0166	1.000	1.00	1.04
		Cycle 10	3	0.989	0.0199	1.000	0.97	1.00
		Cycle 11	3	1.000	0.0000	1.000	1.00	1.00
		Cycle 12	3	1.000	0.0000	1.000	1.00	1.00
		Cycle 13	3	0.989	0.0199	1.000	0.97	1.00
		Cycle 14	3	0.941	0.1019	1.000	0.82	1.00
		Cycle 15	2	1.109	0.1537	1.109	1.00	1.22
		Cycle 16	2	1.019	0.0262	1.019	1.00	1.04
		Cycle 17	2	1.019	0.0262	1.019	1.00	1.04
		Cycle 18	2	0.967	0.0471	0.967	0.93	1.00
		Cycle 19	2	0.983	0.0244	0.983	0.97	1.00
		Cycle 20	2	1.083	0.1179	1.083	1.00	1.17
		Cycle 21	2	0.808	0.2223	0.808	0.65	0.97
		Cycle 22	2	0.497	0.4623	0.497	0.17	0.82
		Cycle 23	2	0.750	0.3536	0.750	0.50	1.00
		Cycle 24	1	1.333		1.333	1.33	1.33
		Overall	14	0.925	0.1531	0.967	0.48	1.12

[1] The dose intensity for each cycle is calculated as the cumulative dose (mg) during the cycle divided by duration of exposure for the cycle.
[2] Overall dose intensity is the cumulative actual dose (mg) divided by the total duration of exposure.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_dos_cyc_pom.sas 27FEB2023 06:11

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.005112
Summary of Exposure to Dexamethasone

Age Group: <75 years

		Pom/Dex (N=14)
Number of Subjects in Subgroup		13
Subject Daily Dose (mg/day) [1]	n	13
	Mean	33.63
	SD	8.601
	Median	40.00
	Min.	18.6
	Max.	40.0
Cumulative Actual Dose (mg)	n	13
	Mean	1150.77
	SD	888.880
	Median	920.00
	Min.	80.0
	Max.	3340.0
Time on Study Treatment (months) [2]	n	13
	Mean	8.60
	SD	6.515
	Median	6.44
	Min.	0.9
	Max.	22.0
	< 3 months	1 (8%)
	3 months to 6 months	5 (38%)
	> 6 months to 12 months	4 (31%)
	> 12 months	3 (23%)

[1] The subject daily dose (the cumulative actual dose divided by the duration of exposure) is calculated for each subject first and the summary statistics are calculated based on the subject average daily dose.
[2] The time on study drug does not exclude dose interruptions.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ex_dx.sas 27FEB2023 09:14

Protocol: 207495 Page 2 of 2
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.005112
Summary of Exposure to Dexamethasone

Age Group: >=75 years

		Pom/Dex (N=14)
Number of Subjects in Subgroup		1
Subject Daily Dose (mg/day) [1]	n	1
	Mean	20.00
	SD	
	Median	20.00
	Min.	20.0
	Max.	20.0
Cumulative Actual Dose (mg)	n	1
	Mean	720.00
	SD	
	Median	720.00
	Min.	720.0
	Max.	720.0
Time on Study Treatment (months) [2]	n	1
	Mean	10.12
	SD	
	Median	10.12
	Min.	10.1
	Max.	10.1
	< 3 months	0
	3 months to 6 months	0
	> 6 months to 12 months	1 (100%)
	> 12 months	0

[1] The subject daily dose (the cumulative actual dose divided by the duration of exposure) is calculated for each subject first and the summary statistics are calculated based on the subject average daily dose.
[2] The time on study drug does not exclude dose interruptions.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ex_dx.sas 27FEB2023 09:14

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.006112
Summary of Dose Exposure, Cumulative Dose, Average Daily Dose, Dose Intensity and Relative Dose Intensity of Dexamethasone Delivered by Cycle

Age Group: < 75 years
Exposure Endpoint: Dose Exposure (Days)

Treatment	N	Time Unit	n	Mean	SD	Median	Min.	Max.
Pom/Dex	13	Cycle 1	13	3.8	0.55	4.0	2	4
		Cycle 2	12	4.0	0.43	4.0	3	5
		Cycle 3	12	3.8	0.87	4.0	2	5
		Cycle 4	12	3.9	0.29	4.0	3	4
		Cycle 5	12	3.8	0.39	4.0	3	4
		Cycle 6	10	3.9	0.32	4.0	3	4
		Cycle 7	7	3.9	0.38	4.0	3	4
		Cycle 8	5	4.0	0.00	4.0	4	4
		Cycle 9	4	3.8	0.50	4.0	3	4
		Cycle 10	3	3.3	1.15	4.0	2	4
		Cycle 11	3	4.0	0.00	4.0	4	4
		Cycle 12	3	4.0	0.00	4.0	4	4
		Cycle 13	3	4.0	0.00	4.0	4	4
		Cycle 14	3	4.0	0.00	4.0	4	4
		Cycle 15	2	3.5	0.71	3.5	3	4
		Cycle 16	2	4.0	0.00	4.0	4	4
		Cycle 17	2	4.0	0.00	4.0	4	4
		Cycle 18	2	4.0	0.00	4.0	4	4
		Cycle 19	2	4.0	0.00	4.0	4	4
		Cycle 20	2	4.0	0.00	4.0	4	4
		Cycle 21	2	4.0	0.00	4.0	4	4
		Cycle 22	2	2.5	2.12	2.5	1	4
		Cycle 23	2	3.0	1.41	3.0	2	4
		Cycle 24	1	1.0		1.0	1	1
		Overall	13	35.5	26.42	27.0	2	90

[1] The dose intensity for each cycle is calculated as the cumulative dose (mg) during the cycle divided by duration of exposure for the cycle.
[2] Overall dose intensity is the cumulative actual dose (mg) divided by the total duration of exposure.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_dos_cyc_dex.sas 03MAR2023 08:50

Table 3.006112
Summary of Dose Exposure, Cumulative Dose, Average Daily Dose, Dose Intensity and Relative Dose Intensity of Dexamethasone Delivered by Cycle

Age Group: < 75 years
Exposure Endpoint: Cumulative Dose (mg)

Treatment	N	Time Unit	n	Mean	SD	Median	Min.	Max.
Pom/Dex	13	Cycle 1	13	152.31	22.418	160.00	80.0	160.0
		Cycle 2	12	140.00	40.000	160.00	80.0	200.0
		Cycle 3	12	128.33	39.505	160.00	80.0	160.0
		Cycle 4	12	136.67	36.013	160.00	80.0	160.0
		Cycle 5	12	123.33	43.345	140.00	40.0	160.0
		Cycle 6	10	112.00	45.412	100.00	40.0	160.0
		Cycle 7	7	102.86	45.356	80.00	40.0	160.0
		Cycle 8	5	112.00	43.818	80.00	80.0	160.0
		Cycle 9	4	115.00	52.599	120.00	60.0	160.0
		Cycle 10	3	120.00	69.282	160.00	40.0	160.0
		Cycle 11	3	133.33	46.188	160.00	80.0	160.0
		Cycle 12	3	133.33	46.188	160.00	80.0	160.0
		Cycle 13	3	133.33	46.188	160.00	80.0	160.0
		Cycle 14	3	133.33	46.188	160.00	80.0	160.0
		Cycle 15	2	110.00	70.711	110.00	60.0	160.0
		Cycle 16	2	120.00	56.569	120.00	80.0	160.0
		Cycle 17	2	120.00	56.569	120.00	80.0	160.0
		Cycle 18	2	120.00	56.569	120.00	80.0	160.0
		Cycle 19	2	120.00	56.569	120.00	80.0	160.0
		Cycle 20	2	120.00	56.569	120.00	80.0	160.0
		Cycle 21	2	80.00	0.000	80.00	80.0	80.0
		Cycle 22	2	50.00	42.426	50.00	20.0	80.0
		Cycle 23	2	60.00	28.284	60.00	40.0	80.0
		Cycle 24	1	20.00		20.00	20.0	20.0
		Overall	13	1150.77	888.880	920.00	80.0	3340.0

[1] The dose intensity for each cycle is calculated as the cumulative dose (mg) during the cycle divided by duration of exposure for the cycle.
[2] Overall dose intensity is the cumulative actual dose (mg) divided by the total duration of exposure.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_dos_cyc_dex.sas 03MAR2023 08:50

Protocol: 207495 Page 3 of 10
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.006112
Summary of Dose Exposure, Cumulative Dose, Average Daily Dose, Dose Intensity and Relative Dose Intensity of Dexamethasone Delivered by Cycle

Age Group: < 75 years
Exposure Endpoint: Average Daily Dose (mg/day)

Treatment	N	Time Unit	n	Mean	SD	Median	Min.	Max.
Pom/Dex	13	Cycle 1	13	39.62	1.387	40.00	35.0	40.0
		Cycle 2	12	35.00	9.045	40.00	20.0	40.0
		Cycle 3	12	35.00	9.045	40.00	20.0	40.0
		Cycle 4	12	35.00	9.045	40.00	20.0	40.0
		Cycle 5	12	32.50	11.382	40.00	10.0	40.0
		Cycle 6	10	29.00	11.972	30.00	10.0	40.0
		Cycle 7	7	27.14	12.536	20.00	10.0	40.0
		Cycle 8	5	28.00	10.954	20.00	20.0	40.0
		Cycle 9	4	30.00	11.547	30.00	20.0	40.0
		Cycle 10	3	33.33	11.547	40.00	20.0	40.0
		Cycle 11	3	33.33	11.547	40.00	20.0	40.0
		Cycle 12	3	33.33	11.547	40.00	20.0	40.0
		Cycle 13	3	33.33	11.547	40.00	20.0	40.0
		Cycle 14	3	33.33	11.547	40.00	20.0	40.0
		Cycle 15	2	30.00	14.142	30.00	20.0	40.0
		Cycle 16	2	30.00	14.142	30.00	20.0	40.0
		Cycle 17	2	30.00	14.142	30.00	20.0	40.0
		Cycle 18	2	30.00	14.142	30.00	20.0	40.0
		Cycle 19	2	30.00	14.142	30.00	20.0	40.0
		Cycle 20	2	30.00	14.142	30.00	20.0	40.0
		Cycle 21	2	20.00	0.000	20.00	20.0	20.0
		Cycle 22	2	20.00	0.000	20.00	20.0	20.0
		Cycle 23	2	20.00	0.000	20.00	20.0	20.0
		Cycle 24	1	20.00		20.00	20.0	20.0
		Overall	13	33.63	8.601	40.00	18.6	40.0

[1] The dose intensity for each cycle is calculated as the cumulative dose (mg) during the cycle divided by duration of exposure for the cycle.
[2] Overall dose intensity is the cumulative actual dose (mg) divided by the total duration of exposure.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_dos_cyc_dex.sas 03MAR2023 08:50

Protocol: 207495 Page 4 of 10
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.006112
Summary of Dose Exposure, Cumulative Dose, Average Daily Dose, Dose Intensity and Relative Dose Intensity of Dexamethasone Delivered by Cycle

Age Group: < 75 years
Exposure Endpoint: Dose Intensity (mg/day) [1][2]

Treatment	N	Time Unit	n	Mean	SD	Median	Min.	Max.
Pom/Dex	13	Cycle 1	13	5.40	0.802	5.71	2.9	6.2
		Cycle 2	12	5.01	1.414	5.71	2.9	7.1
		Cycle 3	12	4.75	1.625	5.71	2.9	7.6
		Cycle 4	12	4.95	1.427	5.71	2.3	6.0
		Cycle 5	12	4.68	1.846	5.52	1.4	8.0
		Cycle 6	10	4.02	1.877	3.57	1.4	6.7
		Cycle 7	7	3.63	1.498	3.08	1.4	5.7
		Cycle 8	5	4.09	1.692	2.86	2.9	6.2
		Cycle 9	4	4.16	1.941	4.29	2.1	5.9
		Cycle 10	3	4.22	2.419	5.52	1.4	5.7
		Cycle 11	3	4.76	1.650	5.71	2.9	5.7
		Cycle 12	3	4.76	1.650	5.71	2.9	5.7
		Cycle 13	3	4.70	1.596	5.52	2.9	5.7
		Cycle 14	3	4.43	1.449	4.71	2.9	5.7
		Cycle 15	2	4.55	3.404	4.55	2.1	7.0
		Cycle 16	2	4.39	2.170	4.39	2.9	5.9
		Cycle 17	2	4.39	2.170	4.39	2.9	5.9
		Cycle 18	2	4.10	1.751	4.10	2.9	5.3
		Cycle 19	2	4.19	1.881	4.19	2.9	5.5
		Cycle 20	2	4.76	2.694	4.76	2.9	6.7
		Cycle 21	2	2.31	0.635	2.31	1.9	2.8
		Cycle 22	2	1.36	1.407	1.36	0.4	2.4
		Cycle 23	2	2.14	1.010	2.14	1.4	2.9
		Cycle 24	1	20.00		20.00	20.0	20.0
		Overall	13	4.44	1.317	4.99	2.6	6.3

[1] The dose intensity for each cycle is calculated as the cumulative dose (mg) during the cycle divided by duration of exposure for the cycle.
[2] Overall dose intensity is the cumulative actual dose (mg) divided by the total duration of exposure.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_dos_cyc_dex.sas 03MAR2023 08:50

Protocol: 207495 Page 5 of 10
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.006112
Summary of Dose Exposure, Cumulative Dose, Average Daily Dose, Dose Intensity and Relative Dose Intensity of Dexamethasone Delivered by Cycle

Age Group: < 75 years
Exposure Endpoint: Relative Dose Intensity

Treatment	N	Time Unit	n	Mean	SD	Median	Min.	Max.
Pom/Dex	13	Cycle 1	13	0.945	0.1403	1.000	0.50	1.08
		Cycle 2	12	0.877	0.2475	1.000	0.50	1.25
		Cycle 3	12	0.831	0.2844	1.000	0.50	1.33
		Cycle 4	12	0.866	0.2497	1.000	0.40	1.05
		Cycle 5	12	0.819	0.3231	0.967	0.25	1.40
		Cycle 6	10	0.704	0.3284	0.625	0.25	1.17
		Cycle 7	7	0.635	0.2622	0.538	0.25	1.00
		Cycle 8	5	0.715	0.2962	0.500	0.50	1.08
		Cycle 9	4	0.728	0.3396	0.750	0.38	1.04
		Cycle 10	3	0.739	0.4234	0.966	0.25	1.00
		Cycle 11	3	0.833	0.2887	1.000	0.50	1.00
		Cycle 12	3	0.833	0.2887	1.000	0.50	1.00
		Cycle 13	3	0.822	0.2793	0.966	0.50	1.00
		Cycle 14	3	0.775	0.2536	0.824	0.50	1.00
		Cycle 15	2	0.796	0.5957	0.796	0.38	1.22
		Cycle 16	2	0.769	0.3797	0.769	0.50	1.04
		Cycle 17	2	0.769	0.3797	0.769	0.50	1.04
		Cycle 18	2	0.717	0.3064	0.717	0.50	0.93
		Cycle 19	2	0.733	0.3292	0.733	0.50	0.97
		Cycle 20	2	0.833	0.4714	0.833	0.50	1.17
		Cycle 21	2	0.404	0.1111	0.404	0.33	0.48
		Cycle 22	2	0.238	0.2462	0.238	0.06	0.41
		Cycle 23	2	0.375	0.1768	0.375	0.25	0.50
		Cycle 24	1	3.500		3.500	3.50	3.50
		Overall	13	0.776	0.2304	0.874	0.45	1.11

[1] The dose intensity for each cycle is calculated as the cumulative dose (mg) during the cycle divided by duration of exposure for the cycle.
[2] Overall dose intensity is the cumulative actual dose (mg) divided by the total duration of exposure.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_dos_cyc_dex.sas 03MAR2023 08:50

Table 3.006112
Summary of Dose Exposure, Cumulative Dose, Average Daily Dose, Dose Intensity and Relative Dose Intensity of Dexamethasone Delivered by Cycle

Age Group: >= 75 years
Exposure Endpoint: Dose Exposure (Days)

Treatment	N	Time Unit	n	Mean	SD	Median	Min.	Max.
Pom/Dex	1	Cycle 1	1	4.0		4.0	4	4
		Cycle 2	1	4.0		4.0	4	4
		Cycle 3	1	4.0		4.0	4	4
		Cycle 4	1	4.0		4.0	4	4
		Cycle 5	1	4.0		4.0	4	4
		Cycle 6	1	4.0		4.0	4	4
		Cycle 7	1	4.0		4.0	4	4
		Cycle 8	1	4.0		4.0	4	4
		Cycle 9	1	4.0		4.0	4	4
		Overall	1	36.0		36.0	36	36

[1] The dose intensity for each cycle is calculated as the cumulative dose (mg) during the cycle divided by duration of exposure for the cycle.
[2] Overall dose intensity is the cumulative actual dose (mg) divided by the total duration of exposure.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_dos_cyc_dex.sas 03MAR2023 08:50

Table 3.006112
Summary of Dose Exposure, Cumulative Dose, Average Daily Dose, Dose Intensity and Relative Dose Intensity of Dexamethasone Delivered by Cycle

Age Group: >= 75 years
Exposure Endpoint: Cumulative Dose (mg)

Treatment	N	Time Unit	n	Mean	SD	Median	Min.	Max.
Pom/Dex	1	Cycle 1	1	80.00		80.00	80.0	80.0
		Cycle 2	1	80.00		80.00	80.0	80.0
		Cycle 3	1	80.00		80.00	80.0	80.0
		Cycle 4	1	80.00		80.00	80.0	80.0
		Cycle 5	1	80.00		80.00	80.0	80.0
		Cycle 6	1	80.00		80.00	80.0	80.0
		Cycle 7	1	80.00		80.00	80.0	80.0
		Cycle 8	1	80.00		80.00	80.0	80.0
		Cycle 9	1	80.00		80.00	80.0	80.0
		Overall	1	720.00		720.00	720.0	720.0

[1] The dose intensity for each cycle is calculated as the cumulative dose (mg) during the cycle divided by duration of exposure for the cycle.
[2] Overall dose intensity is the cumulative actual dose (mg) divided by the total duration of exposure.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_dos_cyc_dex.sas 03MAR2023 08:50

Table 3.006112
Summary of Dose Exposure, Cumulative Dose, Average Daily Dose, Dose Intensity and Relative Dose Intensity of Dexamethasone Delivered by Cycle

Age Group: >= 75 years
Exposure Endpoint: Average Daily Dose (mg/day)

Treatment	N	Time Unit	n	Mean	SD	Median	Min.	Max.
Pom/Dex	1	Cycle 1	1	20.00		20.00	20.0	20.0
		Cycle 2	1	20.00		20.00	20.0	20.0
		Cycle 3	1	20.00		20.00	20.0	20.0
		Cycle 4	1	20.00		20.00	20.0	20.0
		Cycle 5	1	20.00		20.00	20.0	20.0
		Cycle 6	1	20.00		20.00	20.0	20.0
		Cycle 7	1	20.00		20.00	20.0	20.0
		Cycle 8	1	20.00		20.00	20.0	20.0
		Cycle 9	1	20.00		20.00	20.0	20.0
		Overall	1	20.00		20.00	20.0	20.0

[1] The dose intensity for each cycle is calculated as the cumulative dose (mg) during the cycle divided by duration of exposure for the cycle.
[2] Overall dose intensity is the cumulative actual dose (mg) divided by the total duration of exposure.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_dos_cyc_dex.sas 03MAR2023 08:50

Table 3.006112
Summary of Dose Exposure, Cumulative Dose, Average Daily Dose, Dose Intensity and Relative Dose Intensity of Dexamethasone Delivered by Cycle

Age Group: >= 75 years
Exposure Endpoint: Dose Intensity (mg/day) [1][2]

Treatment	N	Time Unit	n	Mean	SD	Median	Min.	Max.
Pom/Dex	1	Cycle 1	1	2.86		2.86	2.9	2.9
		Cycle 2	1	2.86		2.86	2.9	2.9
		Cycle 3	1	2.86		2.86	2.9	2.9
		Cycle 4	1	2.86		2.86	2.9	2.9
		Cycle 5	1	2.35		2.35	2.4	2.4
		Cycle 6	1	1.60		1.60	1.6	1.6
		Cycle 7	1	3.08		3.08	3.1	3.1
		Cycle 8	1	1.38		1.38	1.4	1.4
		Cycle 9	1	2.86		2.86	2.9	2.9
		Overall	1	2.34		2.34	2.3	2.3

[1] The dose intensity for each cycle is calculated as the cumulative dose (mg) during the cycle divided by duration of exposure for the cycle.
[2] Overall dose intensity is the cumulative actual dose (mg) divided by the total duration of exposure.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_dos_cyc_dex.sas 03MAR2023 08:50

Table 3.006112
Summary of Dose Exposure, Cumulative Dose, Average Daily Dose, Dose Intensity and Relative Dose Intensity of Dexamethasone Delivered by Cycle

Age Group: >= 75 years
Exposure Endpoint: Relative Dose Intensity

Treatment	N	Time Unit	n	Mean	SD	Median	Min.	Max.
Pom/Dex	1	Cycle 1	1	1.000		1.000	1.00	1.00
		Cycle 2	1	1.000		1.000	1.00	1.00
		Cycle 3	1	1.000		1.000	1.00	1.00
		Cycle 4	1	1.000		1.000	1.00	1.00
		Cycle 5	1	0.824		0.824	0.82	0.82
		Cycle 6	1	0.560		0.560	0.56	0.56
		Cycle 7	1	1.077		1.077	1.08	1.08
		Cycle 8	1	0.483		0.483	0.48	0.48
		Cycle 9	1	1.000		1.000	1.00	1.00
		Overall	1	0.818		0.818	0.82	0.82

[1] The dose intensity for each cycle is calculated as the cumulative dose (mg) during the cycle divided by duration of exposure for the cycle.
[2] Overall dose intensity is the cumulative actual dose (mg) divided by the total duration of exposure.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_dos_cyc_dex.sas 03MAR2023 08:50

Table 3.002210
Summary of Dose Reductions of Belantamab Mafodotin

	Belantamab mafodotin (N=29)	
Subjects with Any Reduction	5	(17%)
Total Number of Dose Reductions	5	
Number of Dose Reductions		
0	24	(83%)
1	5	(17%)
2	0	
3 or more	0	
Reasons for Reduction [1]		
n	5	
Adverse event	5	(100%)
Adverse event resolved	0	
Subject non-compliance	0	
Corneal event	0	
Other	0	

[1] Subjects may be counted multiple times in the same 'reason' row if the subject had multiple reductions for the same reason.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_dosred_bm.sas 24JAN2023 07:08

Table 3.002210
Summary of Dose Reductions of Belantamab Mafodotin

	Belantamab mafodotin (N=29)
Number of Subjects with Dose Reduction by Planned Time	
Cycle 1 Day 1	0/29
Cycle 2 Day 1	2/25 (8%)
Cycle 3 Day 1	2/15 (13%)
Cycle 4 Day 1	0/10
Cycle 5 Day 1	1/ 8 (13%)
Cycle 6 Day 1	0/ 6
Cycle 7 Day 1	0/ 5
Cycle 8 Day 1	0/ 5
Cycle 9 Day 1	0/ 5
Cycle 10 Day 1	0/ 5
Cycle 11 Day 1	0/ 3
Cycle 12 Day 1	0/ 3
Cycle 13 Day 1	0/ 3
Cycle 14 Day 1	0/ 3
Cycle 15 Day 1	0/ 2
Cycle 16 Day 1	0/ 1
Cycle 17 Day 1	0/ 1
Cycle 18 Day 1	0/ 1
Cycle 19 Day 1	0/ 1
Cycle 20 Day 1	0/ 1
Cycle 21 Day 1	0/ 1
Cycle 22 Day 1	0/ 1
Cycle 23 Day 1	0/ 1
Cycle 24 Day 1	0/ 1
Cycle 25 Day 1	0/ 1
Cycle 26 Day 1	0/ 1
Cycle 27 Day 1	0/ 1
Cycle 28 Day 1	0/ 1
Cycle 29 Day 1	0/ 1
Cycle 30 Day 1	0/ 1

[1] Subjects may be counted multiple times in the same 'reason' row if the subject had multiple reductions for the same reason.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_dosred_bm.sas 24JAN2023 07:08

Table 3.002210
Summary of Dose Reductions of Belantamab Mafodotin

	Belantamab mafodotin (N=29)
Cycle 31 Day 1	0/ 1
Cycle 32 Day 1	0/ 1
Cycle 33 Day 1	0/ 1

[1] Subjects may be counted multiple times in the same 'reason' row if the subject had multiple reductions for the same reason.

Protocol: 207495 Page 1 of 3
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.003210
Summary of Reported Dose Delays of Belantamab Mafodotin

	Belantamab mafodotin (N=29)	
Subjects with Any Dose Delay	3	(10%)
Total Number of Dose Delays	3	
Number of Dose Delays		
0	26	(90%)
1	3	(10%)
2	0	
3 or more	0	
Delay Duration (days)		
n	3	
0	0	
1-21	2	(67%)
22-42	0	
>42	1	(33%)
Min.	11	
Max.	208	
1st Quartile	11.0	
3rd Quartile	208.0	
Median	18.0	
Reasons for Delay [1]		
n	3	
Adverse event	3	(100%)
Adverse event resolved	0	
Subject non-compliance	0	
Corneal event	0	
Other	0	

[1] Subjects may be counted multiple times in the same 'reason' row if the subject had multiple delays with the same reason.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_dosdel_bm.sas 24JAN2023 07:28

Table 3.003210
Summary of Reported Dose Delays of Belantamab Mafodotin

	Belantamab mafodotin (N=29)
Number of Subjects with Dose Delays by Planned Time	
Cycle 1 Day 1	0/29
Cycle 2 Day 1	2/25 (8%)
Cycle 3 Day 1	0/15
Cycle 4 Day 1	1/10 (10%)
Cycle 5 Day 1	0/ 8
Cycle 6 Day 1	0/ 6
Cycle 7 Day 1	0/ 5
Cycle 8 Day 1	0/ 5
Cycle 9 Day 1	0/ 5
Cycle 10 Day 1	0/ 5
Cycle 11 Day 1	0/ 3
Cycle 12 Day 1	0/ 3
Cycle 13 Day 1	0/ 3
Cycle 14 Day 1	0/ 3
Cycle 15 Day 1	0/ 2
Cycle 16 Day 1	0/ 1
Cycle 17 Day 1	0/ 1
Cycle 18 Day 1	0/ 1
Cycle 19 Day 1	0/ 1
Cycle 20 Day 1	0/ 1
Cycle 21 Day 1	0/ 1
Cycle 22 Day 1	0/ 1
Cycle 23 Day 1	0/ 1
Cycle 24 Day 1	0/ 1
Cycle 25 Day 1	0/ 1
Cycle 26 Day 1	0/ 1
Cycle 27 Day 1	0/ 1
Cycle 28 Day 1	0/ 1
Cycle 29 Day 1	0/ 1
Cycle 30 Day 1	0/ 1

[1] Subjects may be counted multiple times in the same 'reason' row if the subject had multiple delays with the same reason.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_dosdel_bm.sas 24JAN2023 07:28

Table 3.003210
Summary of Reported Dose Delays of Belantamab Mafodotin

	Belantamab mafodotin (N=29)
Cycle 31 Day 1	0/ 1
Cycle 32 Day 1	0/ 1
Cycle 33 Day 1	0/ 1

[1] Subjects may be counted multiple times in the same 'reason' row if the subject had multiple delays with the same reason.

Table 3.010112
Summary of Dose Reductions of Pomalidomide

	Pom/Dex (N=14)	
Subjects with Any Reduction	1	(7%)
Total Number of Dose Reductions	1	
Number of Dose Reductions		
0	13	(93%)
1	1	(7%)
2	0	
3 or more	0	
Reasons for Reduction [1]		
n	1	
Adverse event	1	(100%)
Adverse event resolved	0	
Subject non-compliance	0	
Corneal event	0	
Other	0	

[1] Subjects may be counted multiple times in the same 'reason' row if the subject had multiple reductions for the same reason.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_dosred_pom.sas 17MAR2023 09:30

Table 3.010112
Summary of Dose Reductions of Pomalidomide

	Pom/Dex (N=14)	
Number of Subjects with Dose Reduction by Planned Time		
Cycle 1 Day 1	0/14	
Cycle 2 Day 1	0/13	
Cycle 3 Day 1	0/13	
Cycle 3 Day 22	0/ 1	
Cycle 4 Day 1	0/12	
Cycle 5 Day 1	0/13	
Cycle 6 Day 1	1/11	(9%)
Cycle 7 Day 1	0/ 8	
Cycle 8 Day 1	0/ 6	
Cycle 9 Day 1	0/ 5	
Cycle 10 Day 1	0/ 3	
Cycle 11 Day 1	0/ 3	
Cycle 12 Day 1	0/ 3	
Cycle 13 Day 1	0/ 3	
Cycle 14 Day 1	0/ 3	
Cycle 15 Day 1	0/ 2	
Cycle 16 Day 1	0/ 2	
Cycle 17 Day 1	0/ 2	
Cycle 18 Day 1	0/ 2	
Cycle 19 Day 1	0/ 2	
Cycle 20 Day 1	0/ 2	
Cycle 21 Day 1	0/ 2	
Cycle 22 Day 1	0/ 2	
Cycle 23 Day 1	0/ 2	
Cycle 24 Day 1	0/ 1	

[1] Subjects may be counted multiple times in the same 'reason' row if the subject had multiple reductions for the same reason.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_dosred_pom.sas 17MAR2023 09:30

Table 3.011112
Summary of Dose Reductions of Dexamethasone

	Pom/Dex (N=14)	
Subjects with Any Reduction	6	(43%)
Total Number of Dose Reductions	7	
Number of Dose Reductions		
0	8	(57%)
1	5	(36%)
2	1	(7%)
3 or more	0	
Reasons for Reduction [1]		
n	7	
Adverse event	5	(71%)
Adverse event resolved	0	
Subject non-compliance	0	
Corneal event	0	
Other	2	(29%)

[1] Subjects may be counted multiple times in the same 'reason' row if the subject had multiple reductions for the same reason.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_dosred_dex.sas 17MAR2023 09:32

Table 3.011112
Summary of Dose Reductions of Dexamethasone

	Pom/Dex (N=14)
Number of Subjects with Dose Reduction by Planned Time	
Cycle 1 Day 1	0/14
Cycle 1 Day 8	0/14
Cycle 1 Day 15	0/13
Cycle 1 Day 22	1/13 (8%)
Cycle 2 Day 1	2/13 (15%)
Cycle 2 Day 8	0/13
Cycle 2 Day 15	0/12
Cycle 2 Day 22	0/12
Cycle 3 Day 1	0/12
Cycle 3 Day 8	0/13
Cycle 3 Day 15	0/11
Cycle 3 Day 22	0/12
Cycle 4 Day 1	0/12
Cycle 4 Day 8	0/13
Cycle 4 Day 15	0/13
Cycle 4 Day 22	0/13
Cycle 5 Day 1	2/13 (15%)
Cycle 5 Day 8	0/13
Cycle 5 Day 15	0/13
Cycle 5 Day 22	0/11
Cycle 6 Day 1	1/11 (9%)
Cycle 6 Day 8	0/11
Cycle 6 Day 15	0/11
Cycle 6 Day 22	0/10
Cycle 7 Day 1	0/ 8
Cycle 7 Day 8	0/ 8
Cycle 7 Day 15	0/ 8
Cycle 7 Day 22	0/ 7
Cycle 8 Day 1	0/ 6
Cycle 8 Day 8	0/ 6

[1] Subjects may be counted multiple times in the same 'reason' row if the subject had multiple reductions for the same reason.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_dosred_dex.sas 17MAR2023 09:32

Table 3.011112
Summary of Dose Reductions of Dexamethasone

	Pom/Dex (N=14)
Cycle 8 Day 15	0/ 6
Cycle 8 Day 22	0/ 6
Cycle 9 Day 1	0/ 5
Cycle 9 Day 8	0/ 5
Cycle 9 Day 15	0/ 5
Cycle 9 Day 22	0/ 4
Cycle 10 Day 1	0/ 3
Cycle 10 Day 8	0/ 3
Cycle 10 Day 15	0/ 2
Cycle 10 Day 22	0/ 2
Cycle 11 Day 1	0/ 3
Cycle 11 Day 8	0/ 3
Cycle 11 Day 15	0/ 3
Cycle 11 Day 22	0/ 3
Cycle 12 Day 1	0/ 3
Cycle 12 Day 8	0/ 3
Cycle 12 Day 15	0/ 3
Cycle 12 Day 22	0/ 3
Cycle 13 Day 1	0/ 3
Cycle 13 Day 8	0/ 3
Cycle 13 Day 15	0/ 3
Cycle 13 Day 22	0/ 3
Cycle 14 Day 1	0/ 3
Cycle 14 Day 8	0/ 3
Cycle 14 Day 15	0/ 3
Cycle 14 Day 22	0/ 3
Cycle 15 Day 1	0/ 2
Cycle 15 Day 8	0/ 2
Cycle 15 Day 15	0/ 1
Cycle 15 Day 22	0/ 2
Cycle 16 Day 1	0/ 2

[1] Subjects may be counted multiple times in the same 'reason' row if the subject had multiple reductions for the same reason.

Table 3.011112
Summary of Dose Reductions of Dexamethasone

	Pom/Dex (N=14)
Cycle 16 Day 8	0/ 2
Cycle 16 Day 15	0/ 2
Cycle 16 Day 22	0/ 2
Cycle 17 Day 1	0/ 2
Cycle 17 Day 8	0/ 2
Cycle 17 Day 15	0/ 2
Cycle 17 Day 22	0/ 2
Cycle 18 Day 1	0/ 2
Cycle 18 Day 8	0/ 2
Cycle 18 Day 15	0/ 2
Cycle 18 Day 22	0/ 2
Cycle 19 Day 1	0/ 2
Cycle 19 Day 8	0/ 2
Cycle 19 Day 15	0/ 2
Cycle 19 Day 22	0/ 2
Cycle 20 Day 1	0/ 2
Cycle 20 Day 8	0/ 2
Cycle 20 Day 15	0/ 2
Cycle 20 Day 22	0/ 2
Cycle 21 Day 1	1/ 2 (50%)
Cycle 21 Day 8	0/ 2
Cycle 21 Day 15	0/ 2
Cycle 21 Day 22	0/ 2
Cycle 22 Day 1	0/ 2
Cycle 22 Day 8	0/ 1
Cycle 22 Day 15	0/ 1
Cycle 22 Day 22	0/ 1
Cycle 23 Day 1	0/ 2
Cycle 23 Day 8	0/ 2
Cycle 23 Day 15	0/ 1
Cycle 23 Day 22	0/ 1

[1] Subjects may be counted multiple times in the same 'reason' row if the subject had multiple reductions for the same reason.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_dosred_dex.sas 17MAR2023 09:32

Table 3.011112
Summary of Dose Reductions of Dexamethasone

	Pom/Dex (N=14)
Cycle 24 Day 1	0/ 1

[1] Subjects may be counted multiple times in the same 'reason' row if the subject had multiple reductions for the same reason.

Protocol: 207495 Page 1 of 2
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.008112
Summary of Reported Dose Delays of Pomalidomide

	Pom/Dex (N=14)	
Subjects with Any Dose Delay	3	(21%)
Total Number of Dose Delays	5	
Number of Dose Delays		
0	11	(79%)
1	1	(7%)
2	2	(14%)
3 or more	0	
Delay Duration (days)		
n	0	
0	0	
1	0	
2	0	
>2	0	
Min.	0	
Max.	0	
1st Quartile	0	
3rd Quartile	0	
Median	0	
Reasons for Delay [1]		
n	5	
Adverse event	5	(100%)
Adverse event resolved	0	
Subject non-compliance	0	
Corneal event	0	
Other	0	

[1] Subjects may be counted multiple times in the same 'reason' row if the subject had multiple delays with the same reason.
Note: Dose interruptions for pomalidomide are entered as delays on the CRF. If a dose begins earlier than scheduled and is recorded as a delay on the CRF then the duration of delay is set to missing.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_dosdel_pom.sas 17MAR2023 09:14

Protocol: 207495 Page 2 of 2
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.008112
Summary of Reported Dose Delays of Pomalidomide

	Pom/Dex (N=14)	
Number of Subjects with Dose Delays by Planned Time		
Cycle 1 Day 1	1/14	(7%)
Cycle 2 Day 1	0/13	
Cycle 3 Day 1	1/13	(8%)
Cycle 3 Day 22	0/ 1	
Cycle 4 Day 1	0/12	
Cycle 5 Day 1	1/13	(8%)
Cycle 6 Day 1	0/11	
Cycle 7 Day 1	0/ 8	
Cycle 8 Day 1	0/ 6	
Cycle 9 Day 1	0/ 5	
Cycle 10 Day 1	0/ 3	
Cycle 11 Day 1	0/ 3	
Cycle 12 Day 1	0/ 3	
Cycle 13 Day 1	0/ 3	
Cycle 14 Day 1	0/ 3	
Cycle 15 Day 1	0/ 2	
Cycle 16 Day 1	0/ 2	
Cycle 17 Day 1	0/ 2	
Cycle 18 Day 1	0/ 2	
Cycle 19 Day 1	0/ 2	
Cycle 20 Day 1	0/ 2	
Cycle 21 Day 1	0/ 2	
Cycle 22 Day 1	1/ 2	(50%)
Cycle 23 Day 1	1/ 2	(50%)
Cycle 24 Day 1	0/ 1	

[1] Subjects may be counted multiple times in the same 'reason' row if the subject had multiple delays with the same reason.
Note: Dose interruptions for pomalidomide are entered as delays on the CRF. If a dose begins earlier than scheduled and is recorded as a delay on the CRF then the duration of delay is set to missing.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_dosdel_pom.sas 17MAR2023 09:14

Protocol: 207495 Page 1 of 1
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.009112
Summary of Reported Dose Delays of Dexamethasone

No data to report

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_dosdel_dex.sas 17MAR2023 12:15

Protocol: 207495 Page 1 of 2
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 1.022110
Summary of Duration of Follow-up

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Duration of Follow-up (Months) [1]		
n	15	29
Min.	0.1	0.9
1st Quartile	7.95	4.90
Median	12.94	9.46
3rd Quartile	17.08	15.70
Max.	24.1	22.9
<30 days	1 (7%)	2 (7%)
>=30 days and <60 days	1 (7%)	3 (10%)
>=60 days and <90 days	0	2 (7%)
>=90 days and <120 days	0	0
>=120 days and <180 days	1 (7%)	6 (21%)
>=180 days and <240 days	0	1 (3%)
>=240 days and <360 days	3 (20%)	4 (14%)
>=360 days	9 (60%)	11 (38%)

[1] Duration of Follow-up is defined as the time from randomization to last contact or death.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_sp_fup1.sas 15DEC2022 08:12

Protocol: 207495 Page 2 of 2
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 1.022110
Summary of Duration of Follow-up

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Duration of Follow-up (Months) for subjects with ongoing follow-up		
n	9	13
Min.	8.4	9.7
1st Quartile	12.94	11.99
Median	15.77	15.70
3rd Quartile	17.25	18.83
Max.	24.1	22.9
<30 days	0	0
>=30 days and <60 days	0	0
>=60 days and <90 days	0	0
>=90 days and <120 days	0	0
>=120 days and <180 days	0	0
>=180 days and <240 days	0	0
>=240 days and <360 days	1 (11%)	3 (23%)
>=360 days	8 (89%)	10 (77%)

[1] Duration of Follow-up is defined as the time from randomization to last contact or death.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_sp_fup1.sas 15DEC2022 08:12

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.007112
Summary of Duration of Follow-up (Safety Population)

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Duration of Follow-Up [1] (months)		
n	14	28
Median	7.72	2.81
1st Quartile	5.85	1.72
3rd Quartile	10.45	6.88
Min.	1.1	0.8
Max.	23.7	22.9

[1] Duration of Follow-up is defined as the time from randomization to last on-treatment contact with AE assessment or ocular examination including Ocular Surface Disease Index (OSDI) and Patient-Reported Outcome Version of the Common Term Criteria for Adverse Events (PRO-CTCAE). Subject 701 was excluded as no such data exists for this subject to determine the duration of Follow-up.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_fup_saf.sas 20MAR2023 11:34

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 1.002112
Duration of Observation of Overall Survival

		Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Time (Months) [1]	n	15	29
	Median	12.94	9.46
	1st Quartile	7.95	4.90
	3rd Quartile	17.08	15.70
	Min.	0.1	0.9
	Max.	24.1	22.9

[1] Survival times are calculated from date of randomization to death or date of last contact.
These are descriptive summary of survival times and no KM analysis applied.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_sp_osurv.sas 17MAR2023 08:55

Protocol: 207495 Page 1 of 2
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 2.012110
Summary of Overall Survival

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Died (event)	4 (27%)	16 (55%)
Censored, follow-up ended	2 (13%)	0
Censored, follow-up ongoing	9 (60%)	13 (45%)
Event Summary		
Death	4 (27%)	16 (55%)
Estimates for Time Variable (Months) [1]		
1st Quartile	13.5	4.9
95% CI	(1.1,-)	(1.0,5.7)
Median	-	9.5
95% CI	(9.5,-)	(5.1,-)
3rd Quartile	-	-
95% CI	(-,-)	(18.7,-)
Survival Probability		
Time-to-Event Endpoint at 6 Months	0.93	0.55
95% CI	(0.59,0.99)	(0.36,0.71)
Time-to-Event Endpoint at 12 Months	0.77	0.48
95% CI	(0.43,0.92)	(0.29,0.65)
Time-to-Event Endpoint at 18 Months	0.66	0.48
95% CI	(0.31,0.86)	(0.29,0.65)

[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Hazard ratios are estimated using the Cox Proportional Hazards. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex. Hazard ratio and two sided p-value from stratified log-rank test are adjusted for previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and CRF reported number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...).
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_e_tte1_os.sas 04JAN2023 10:46

Protocol: 207495 Page 2 of 2
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 2.012110
Summary of Overall Survival

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Stratified Hazard Ratio [2]		
Estimate		2.02
95% CI		(0.52,7.85)
Stratified Log-Rank [2]		
P-Value		0.304

[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Hazard ratios are estimated using the Cox Proportional Hazards. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex. Hazard ratio and two sided p-value from stratified log-rank test are adjusted for previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and CRF reported number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...).

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_e_tte1_os.sas 04JAN2023 10:46

Protocol: 207495 Page 1 of 2
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 2.013110

Summary of Overall Survival (using Stratification Data from the Clinical Database as Reported on the CRF)

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Died (event)	4 (27%)	16 (55%)
Censored, follow-up ended	2 (13%)	0
Censored, follow-up ongoing	9 (60%)	13 (45%)
Event Summary		
Death	4 (27%)	16 (55%)
Estimates for Time Variable (Months) [1]		
1st Quartile	13.5	4.9
95% CI	(1.1,-)	(1.0,5.7)
Median	-	9.5
95% CI	(9.5,-)	(5.1,-)
3rd Quartile	-	-
95% CI	(-,-)	(18.7,-)
Survival Probability		
Time-to-Event Endpoint at 6 Months	0.93	0.55
95% CI	(0.59,0.99)	(0.36,0.71)
Time-to-Event Endpoint at 12 Months	0.77	0.48
95% CI	(0.43,0.92)	(0.29,0.65)
Time-to-Event Endpoint at 18 Months	0.66	0.48
95% CI	(0.31,0.86)	(0.29,0.65)

[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Hazard ratios are estimated using the Cox Proportional Hazards. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex. Hazard ratio and two sided p-value from stratified log-rank test are adjusted for previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) as reported on the CRF.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_e_tte1_os_strat.sas 15MAR2023 09:10

Table 2.013110

Summary of Overall Survival (using Stratification Data from the Clinical Database as Reported on the CRF)

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Stratified Hazard Ratio [2]		
Number of Subjects in the Model	15	29
Estimate		2.33
95% CI		(0.60,8.98)
Stratified Log-Rank [2]		
P-Value		0.210

[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Hazard ratios are estimated using the Cox Proportional Hazards. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex. Hazard ratio and two sided p-value from stratified log-rank test are adjusted for previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) as reported on the CRF.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_e_tte1_os_strat.sas 15MAR2023 09:10

Protocol: 207495 Page 1 of 2
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 2.002112
Summary of Overall Survival by Response Category
(based on Investigator-Assessed Response with Confirmation) and Treatment Arm

Treatment: Pom/Dex (N=15)

	PR or better	MR or better	SD	PD or NE
n	9	9	4	2
Number of Subjects				
Died (event)	2 (22%)	2 (22%)	1 (25%)	1 (50%)
Censored, follow-up ended	0	0	1 (25%)	1 (50%)
Censored, follow-up ongoing	7 (78%)	7 (78%)	2 (50%)	0
Event Summary				
Death	2 (22%)	2 (22%)	1 (25%)	1 (50%)
Estimates for Time Variable (Months) [1]				
1st Quartile	13.5	13.5	8.0	1.1
95% CI	(9.5,-)	(9.5,-)	(8.0,-)	(-,-)
Median	-	-	-	1.1
95% CI	(9.5,-)	(9.5,-)	(8.0,-)	(-,-)
3rd Quartile	-	-	-	1.1
95% CI	(-,-)	(-,-)	(8.0,-)	(-,-)
Survival Probability				
Time-to-Event Endpoint at 6 months	1.00	1.00	1.00	0.00
95% CI	(-,-)	(-,-)	(-,-)	(-,-)
Time-to-Event Endpoint at 12 months	0.89	0.89	0.67	0.00
95% CI	(0.43,0.98)	(0.43,0.98)	(0.05,0.95)	(-,-)
Time-to-Event Endpoint at 18 months	0.74	0.74	0.67	0.00
95% CI	(0.29,0.93)	(0.29,0.93)	(0.05,0.95)	(-,-)

[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_e_os_rsp_irc.sas 01MAR2023 11:01

Table 2.002112
Summary of Overall Survival by Response Category
(based on Investigator-Assessed Response with Confirmation) and Treatment Arm

Treatment: Belantamab mafodotin (N=29)

	PR or better	MR or better	SD	PD or NE
n	6	8	13	8
Number of Subjects				
Died (event)	2 (33%)	2 (25%)	7 (54%)	7 (88%)
Censored, follow-up ended	0	0	0	0
Censored, follow-up ongoing	4 (67%)	6 (75%)	6 (46%)	1 (13%)
Event Summary				
Death	2 (33%)	2 (25%)	7 (54%)	7 (88%)
Estimates for Time Variable (Months) [1]				
1st Quartile	18.7	18.7	5.5	1.0
95% CI	(4.9,-)	(4.9,-)	(1.2,9.5)	(0.9,2.9)
Median	18.7	-	9.5	2.0
95% CI	(4.9,-)	(4.9,-)	(5.1,-)	(0.9,6.6)
3rd Quartile	-	-	-	5.8
95% CI	(18.7,-)	(18.7,-)	(5.7,-)	(1.0,-)
Survival Probability				
Time-to-Event Endpoint at 6 months	0.83	0.88	0.54	0.25
95% CI	(0.27,0.97)	(0.39,0.98)	(0.25,0.76)	(0.04,0.56)
Time-to-Event Endpoint at 12 months	0.83	0.88	0.46	-
95% CI	(0.27,0.97)	(0.39,0.98)	(0.19,0.70)	(-,-)
Time-to-Event Endpoint at 18 months	0.83	0.88	0.46	-
95% CI	(0.27,0.97)	(0.39,0.98)	(0.19,0.70)	(-,-)

[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 2.017110
Summary of Investigator-Assessed Best Response with Confirmation (IMWG 2016 Criteria)

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Best Response		
Stringent Complete Response (sCR)	0	0
Complete Response (CR)	0	1 (3%)
Very Good Partial Response (VGPR)	2 (13%)	3 (10%)
Partial Response (PR)	7 (47%)	2 (7%)
Minimal Response (MR)	0	2 (7%)
Stable Disease (SD)	4 (27%)	13 (45%)
Progressive Disease (PD)	0	6 (21%)
Not Evaluable (NE)	2 (13%)	2 (7%)
Overall Response Rate		
sCR+CR+VGPR+PR	9 (60%)	6 (21%)
95% Confidence Interval	(32.3%,83.7%)	(8.0%,39.7%)
97.5% Confidence Interval	(29.1%,85.9%)	(6.9%,42.4%)
Difference in Overall Response Rate		
Difference		-39%
95% CI for Difference		(-65.7%,-8.6%)
97.5% CI for Difference		(-68.7%,-4.3%)
Clinical Benefit Rate		
sCR+CR+VGPR+PR+MR	9 (60%)	8 (28%)
95% Confidence Interval	(32.3%,83.7%)	(12.7%,47.2%)
97.5% Confidence Interval	(29.1%,85.9%)	(11.3%,49.9%)
Difference in Clinical Benefit Rate		
Difference		-32%
95% CI for Difference		(-59.7%,-1.1%)
97.5% CI for Difference		(-63.0%,3.2%)

Note: The confidence intervals are based on exact method.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_e_re1ac_inv.sas 03JAN2023 11:13

Protocol: 207495 Page 1 of 1
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 2.022110
Overall Response Rate Summary based on Investigator-Assessed Response

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
n	15	29
Responder (PR or better)	9 (60%)	6 (21%)
Inverse OR (95% CI) [1] vs. Pom/Dex		5.75 (1.46,22.61)
P-value [1]		0.0123
Inverse RR (95% CI) vs. Pom/Dex		2.90 (1.27,6.61)
ARD (95% CI) vs. Pom/Dex		-0.39 (-0.68,-0.10)
P-value [2]		0.0174

PR=Partial Response, OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
[1] Inverse Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact Test.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_e_orr_lr.sas 18JAN2023 09:10

Protocol: 207495 Page 1 of 1
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 2.026110
Clinical Benefit Rate Summary based on Investigator-Assessed Response

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
n	15	29
Clinical Benefit (MR or better)	9 (60%)	8 (28%)
Inverse OR (95% CI) [1] vs. Pom/Dex		3.94 (1.06,14.67)
P-value [1]		0.0411
Inverse RR (95% CI) vs. Pom/Dex		2.18 (1.06,4.47)
ARD (95% CI) vs. Pom/Dex		-0.32 (-0.62,-0.03)
P-value [2]		0.0526

MR=Minimal Response, OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
[1] Inverse Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact Test.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_e_cbr_summ.sas 20FEB2023 11:34

Protocol: 207495 Page 1 of 1
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 2.025110
Summary of Time to Response Based on Investigator-Assessed Response

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Response (event)	9 (60%)	6 (21%)
Estimates for Time Variable (Months) [1]		
1st Quartile	0.8	0.7
95% CI	(0.7,1.4)	(0.7,0.9)
Median	1.4	0.8
95% CI	(0.7,2.1)	(0.7,12.5)
3rd Quartile	1.4	5.6
95% CI	(0.8,3.1)	(0.7,12.5)
Stratified Inverse Hazard Ratio [2]		
Estimate		1.10
95% CI		(0.23,5.15)
Stratified Log-Rank [2]		
P-Value		0.846

Note: Analysis only includes subjects with response (PR or better).
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Inverse hazard ratios are estimated using the Cox Proportional Hazards. An inverse hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex. Inverse hazard ratio and two sided p-value from stratified log-rank test are adjusted for previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) as reported on the CRF.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_e_t3_ttr_inv.sas 28FEB2023 08:16

Protocol: 207495 Page 1 of 1
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 2.024110
Summary of Time to Best Response Based on Investigator-Assessed Response

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Best Response (event)	9 (60%)	6 (21%)
Estimates for Time Variable (Months) [1]		
1st Quartile	0.8	0.9
95% CI	(0.7,1.4)	(0.8,2.7)
Median	1.4	2.4
95% CI	(0.7,3.1)	(0.8,12.5)
3rd Quartile	2.1	5.6
95% CI	(1.4,7.0)	(0.9,12.5)
Stratified Inverse Hazard Ratio [2]		
Estimate		1.43
95% CI		(0.31,6.57)
Stratified Log-Rank [2]		
P-Value		0.644

Note: Analysis only includes subjects with response (PR or better).
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Inverse hazard ratios are estimated using the Cox Proportional Hazards. An inverse hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex. Inverse hazard ratio and two sided p-value from stratified log-rank test are adjusted for previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) as reported on the CRF.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_e_t3_ttbr_inv.sas 28FEB2023 08:15

Protocol: 207495 Page 1 of 2
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 2.010110
Summary of Duration of Response Based on Investigator-Assessed Response

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
n	9	6
Progressed or Died (event)	5 (56%)	2 (33%)
Censored, follow-up ended	2 (22%)	0
Censored, follow-up ongoing	2 (22%)	4 (67%)
Event Summary		
Disease Progression	5 (56%)	2 (33%)
Death due to PD	0	0
Death not due to PD	0	0
Estimates for Time Variable (Months) - Disease progression + PD deaths [1]		
1st Quartile	4.9	9.7
95% CI	(2.1,8.5)	(2.1,-)
Median	8.2	-
95% CI	(2.1,-)	(2.1,-)
3rd Quartile	-	-
95% CI	(8.2,-)	(9.7,-)
Estimates for Time Variable (Months) - Disease progression + all deaths [1]		
1st Quartile	4.9	9.7
95% CI	(2.1,8.5)	(2.1,-)
Median	8.2	-
95% CI	(2.1,-)	(2.1,-)
3rd Quartile	-	-
95% CI	(8.2,-)	(9.7,-)

[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Hazard ratios are estimated using the Cox Proportional Hazards. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex. Hazard ratio and two sided p-value from stratified log-rank test are adjusted for previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) as reported on the CRF.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_e_tte1a_dor_inv.sas 21FEB2023 06:27

Protocol: 207495 Page 2 of 2
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 2.010110
Summary of Duration of Response Based on Investigator-Assessed Response

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Stratified Hazard Ratio [2]		
Estimate		0.47
95% CI		(0.04,5.68)
Stratified Log-Rank [2]		
P-Value		0.549

[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Hazard ratios are estimated using the Cox Proportional Hazards. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex. Hazard ratio and two sided p-value from stratified log-rank test are adjusted for previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) as reported on the CRF.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_e_tte1a_dor_inv.sas 21FEB2023 06:27

Protocol: 207495 Page 1 of 2
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 2.001110
Summary of Progression-Free Survival Based on Investigator-Assessed Response and Primary Censoring Rule

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Progressed or Died (event)	8 (53%)	20 (69%)
Censored, follow-up ended	4 (27%)	4 (14%)
Censored, follow-up ongoing	3 (20%)	5 (17%)
Event Summary		
Disease Progression	7 (47%)	16 (55%)
Death	1 (7%)	4 (14%)
Estimates for Time Variable (Months) [1]		
1st Quartile	3.8	1.2
95% CI	(1.1,9.3)	(0.7,1.8)
Median	9.3	2.6
95% CI	(3.5,-)	(1.4,5.7)
3rd Quartile	-	10.3
95% CI	(6.3,-)	(2.8,-)
Progression-Free Survival Probability		
Time-to-Event Endpoint at 6 Months	0.63	0.31
95% CI	(0.32,0.83)	(0.14,0.49)
Stratified Hazard Ratio [2]		
Estimate		2.89
95% CI		(0.91,9.20)

[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Hazard ratios are estimated using the Cox Proportional Hazards. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex. Hazard ratio and two sided p-value from stratified log-rank test are adjusted for previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and CRF reported number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...).
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_e_tte1_pfs_inv.sas 04JAN2023 10:45

Protocol: 207495 Page 2 of 2
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 2.001110
Summary of Progression-Free Survival Based on Investigator-Assessed Response and Primary Censoring Rule

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Stratified Log-Rank [2]		
P-Value		0.063
Unstratified Hazard Ratio		
Estimate		2.07
95% CI		(0.90,4.72)

[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Hazard ratios are estimated using the Cox Proportional Hazards. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex. Hazard ratio and two sided p-value from stratified log-rank test are adjusted for previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and CRF reported number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...).
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_e_tte1_pfs_inv.sas 04JAN2023 10:45

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 2.015110

Summary of Progression-Free Survival Based on Investigator-Assessed Response and Primary Censoring Rule (using Stratification Data from the Clinical Database as Reported on the CRF)

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Progressed or Died (event)	8 (53%)	20 (69%)
Censored, follow-up ended	4 (27%)	4 (14%)
Censored, follow-up ongoing	3 (20%)	5 (17%)
Event Summary		
Disease Progression	7 (47%)	16 (55%)
Death	1 (7%)	4 (14%)
Estimates for Time Variable (Months) [1]		
1st Quartile	3.8	1.2
95% CI	(1.1,9.3)	(0.7,1.8)
Median	9.3	2.6
95% CI	(3.5,-)	(1.4,5.7)
3rd Quartile	-	10.3
95% CI	(6.3,-)	(2.8,-)
Progression-Free Survival Probability		
Time-to-Event Endpoint at 6 Months	0.63	0.31
95% CI	(0.32,0.83)	(0.14,0.49)
Stratified Hazard Ratio [2]		
Number of Subjects in the Model	15	29
Estimate		3.01
95% CI		(0.94,9.66)

[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Hazard ratios are estimated using the Cox Proportional Hazards. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex. Hazard ratio and two sided p-value from stratified log-rank test are adjusted for previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) as reported on the CRF.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_e_tte1_pfs_in_str.sas 15MAR2023 09:10

Table 2.015110

Summary of Progression-Free Survival Based on Investigator-Assessed Response and Primary Censoring Rule (using Stratification Data from the Clinical Database as Reported on the CRF)

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Stratified Log-Rank [2] P-Value		0.055

[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Hazard ratios are estimated using the Cox Proportional Hazards. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex. Hazard ratio and two sided p-value from stratified log-rank test are adjusted for previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) as reported on the CRF.

Protocol: 207495 Page 1 of 2
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 2.002110
Summary of Progression-Free Survival Based on Investigator-Assessed Response and Alternative Censoring Rule 1

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Progressed or Died (event)	8 (53%)	20 (69%)
Censored, follow-up ended	4 (27%)	4 (14%)
Censored, follow-up ongoing	3 (20%)	5 (17%)
Event Summary		
Disease Progression	7 (47%)	16 (55%)
Death	1 (7%)	4 (14%)
Estimates for Time Variable (Months) [1]		
1st Quartile	4.2	1.3
95% CI	(1.1,9.8)	(0.7,2.1)
Median	9.8	2.8
95% CI	(3.5,-)	(1.4,5.7)
3rd Quartile	-	10.3
95% CI	(6.3,-)	(2.8,-)
Progression-Free Survival Probability		
Time-to-Event Endpoint at 6 Months	0.63	0.31
95% CI	(0.32,0.83)	(0.14,0.49)
Stratified Hazard Ratio [2]		
Estimate		2.89
95% CI		(0.91,9.20)

[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Hazard ratios are estimated using the Cox Proportional Hazards. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex. Hazard ratio and two sided p-value from stratified log-rank test are adjusted for previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and CRF reported number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...).

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_e_tte1_pfs_inv_c1.sas 14MAR2023 11:43

Table 2.002110
Summary of Progression-Free Survival Based on Investigator-Assessed Response and Alternative Censoring Rule 1

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Stratified Log-Rank [2] P-Value		0.063

[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Hazard ratios are estimated using the Cox Proportional Hazards. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex. Hazard ratio and two sided p-value from stratified log-rank test are adjusted for previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and CRF reported number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...).

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 2.003110
Summary of Progression-Free Survival Based on Investigator-Assessed Response and Alternative Censoring Rule 2

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Progressed or Died (event)	11 (73%)	24 (83%)
Censored, follow-up ended	2 (13%)	0
Censored, follow-up ongoing	2 (13%)	5 (17%)
Event Summary		
Disease Progression	7 (47%)	15 (52%)
Disease Progression (after extended loss to follow-up)	0	0
Death	1 (7%)	3 (10%)
Death (after extended loss to follow-up)	0	0
Start of new anti-cancer therapy	2 (13%)	3 (10%)
Treatment discontinuation	1 (7%)	3 (10%)
Estimates for Time Variable (Months) [1]		
1st Quartile	3.8	1.0
95% CI	(1.1,6.4)	(0.8,1.4)
Median	6.4	1.6
95% CI	(3.5,11.3)	(1.1,3.8)
3rd Quartile	11.3	5.7
95% CI	(6.4,-)	(2.6,-)

Note: Start of new anti-cancer therapy and treatment discontinuation are considered as an event.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Hazard ratios are estimated using the Cox Proportional Hazards. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex. Hazard ratio and two sided p-value from stratified log-rank test are adjusted for previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and CRF reported number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...).
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_e_tte1_pfs_inv_c2.sas 14MAR2023 11:43

Protocol: 207495 Page 2 of 2
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 2.003110
Summary of Progression-Free Survival Based on Investigator-Assessed Response and Alternative Censoring Rule 2

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Progression-Free Survival Probability		
Time-to-Event Endpoint at 6 Months	0.63	0.24
95% CI	(0.32,0.83)	(0.11,0.41)
Stratified Hazard Ratio [2]		
Estimate		2.00
95% CI		(0.75,5.38)
Stratified Log-Rank [2]		
P-Value		0.161

Note: Start of new anti-cancer therapy and treatment discontinuation are considered as an event.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Hazard ratios are estimated using the Cox Proportional Hazards. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex. Hazard ratio and two sided p-value from stratified log-rank test are adjusted for previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and CRF reported number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...).
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_e_tte1_pfs_inv_c2.sas 14MAR2023 11:43

Protocol: 207495 Page 1 of 2
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 2.027110
Summary of Progression-Free Survival Based on Investigator-Assessed Response and Alternative Censoring Rule 1
(using Stratification Data from the Clinical Database as Reported on the CRF)

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Progressed or Died (event)	8 (53%)	20 (69%)
Censored, follow-up ended	4 (27%)	4 (14%)
Censored, follow-up ongoing	3 (20%)	5 (17%)
Event Summary		
Disease Progression	7 (47%)	16 (55%)
Death	1 (7%)	4 (14%)
Estimates for Time Variable (Months) [1]		
1st Quartile	4.2	1.3
95% CI	(1.1,9.8)	(0.7,2.1)
Median	9.8	2.8
95% CI	(3.5,-)	(1.4,5.7)
3rd Quartile	-	10.3
95% CI	(6.3,-)	(2.8,-)
Progression-Free Survival Probability		
Time-to-Event Endpoint at 6 Months	0.63	0.31
95% CI	(0.32,0.83)	(0.14,0.49)
Stratified Hazard Ratio [2]		
Estimate		3.01
95% CI		(0.94,9.66)

[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Hazard ratios are estimated using the Cox Proportional Hazards. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex. Hazard ratio and two sided p-value from stratified log-rank test are adjusted for previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) as reported on the CRF.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_e_tte1_pfs_crf_cr1.sas 13MAR2023 06:3

Protocol: 207495 Page 2 of 2
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 2.027110
Summary of Progression-Free Survival Based on Investigator-Assessed Response
and Alternative Censoring Rule 1
(using Stratification Data from the Clinical Database as Reported on the CRF)

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Stratified Log-Rank [2]		
P-Value		0.058

[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Hazard ratios are estimated using the Cox Proportional Hazards. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex. Hazard ratio and two sided p-value from stratified log-rank test are adjusted for previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) as reported on the CRF.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_e_tte1_pfs_crf_cr1.sas 13MAR2023 06:3

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 2.028110
Summary of Progression-Free Survival Based on Investigator-Assessed Response and Alternative Censoring Rule 2
(using Stratification Data from the Clinical Database as Reported on the CRF)

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Progressed or Died (event)	11 (73%)	24 (83%)
Censored, follow-up ended	2 (13%)	0
Censored, follow-up ongoing	2 (13%)	5 (17%)
Event Summary		
Disease Progression	7 (47%)	15 (52%)
Disease Progression (after extended loss to follow-up)	0	0
Death	1 (7%)	3 (10%)
Death (after extended loss to follow-up)	0	0
Start of new anti-cancer therapy	2 (13%)	3 (10%)
Treatment discontinuation	1 (7%)	3 (10%)
Estimates for Time Variable (Months) [1]		
1st Quartile	3.8	1.0
95% CI	(1.1,6.4)	(0.8,1.4)
Median	6.4	1.6
95% CI	(3.5,11.3)	(1.1,3.8)
3rd Quartile	11.3	5.7
95% CI	(6.4,-)	(2.6,-)

Note: Start of new anti-cancer therapy and treatment discontinuation are considered as an event.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Hazard ratios are estimated using the Cox Proportional Hazards. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex. Hazard ratio and two sided p-value from stratified log-rank test are adjusted for previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) as reported on the CRF.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_e_tte1_pfs_crf_cr2.sas 13MAR2023 06:3

Protocol: 207495 Page 2 of 2
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 2.028110
Summary of Progression-Free Survival Based on Investigator-Assessed Response and Alternative Censoring Rule 2
(using Stratification Data from the Clinical Database as Reported on the CRF)

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Progression-Free Survival Probability		
Time-to-Event Endpoint at 6 Months	0.63	0.24
95% CI	(0.32,0.83)	(0.11,0.41)
Stratified Hazard Ratio [2]		
Estimate		2.04
95% CI		(0.76,5.47)
Stratified Log-Rank [2]		
P-Value		0.152

Note: Start of new anti-cancer therapy and treatment discontinuation are considered as an event.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Hazard ratios are estimated using the Cox Proportional Hazards. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex. Hazard ratio and two sided p-value from stratified log-rank test are adjusted for previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) as reported on the CRF.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_e_tte1_pfs_crf_cr2.sas 13MAR2023 06:3

Protocol: 207495 Page 1 of 1
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 2.004110
Summary of Restricted Mean Survival Time of Progression-Free Survival Based on Investigator-Assessed Response and Primary Censoring Rule

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Progressed or Died (event)	8 (53%)	20 (69%)
Censored, follow-up ended	4 (27%)	4 (14%)
Censored, follow-up ongoing	3 (20%)	5 (17%)
Event Summary		
Disease Progression	7 (47%)	16 (55%)
Death	1 (7%)	4 (14%)
RMST Estimates at t* (22.9) (months)		
Estimate	11.3	7.0
95% CI	(6.5,16.2)	(3.6,10.4)
Difference between RMST at t* (22.9) from Pom/Dex (months)		
Estimated Difference		-4.3
95% CI		(-10.4, 1.8)
Ratio of RMST at t* (22.9)		
Belamaf Mafodotin RMST / Pom/Dex RMST		0.62
95% CI		(0.32, 1.20)
RMST Test		
P-Value [1]		0.152

Note: The RMST is the expected survival time restricted to a specific time horizon t*. The cutoff t* for determining the RMST is the smallest value among the largest observed time across study interventions.
[1] Two sided P-value from RMST test.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_e_tte6_pfs_inv.sas 05JAN2023 11:57

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 2.003112
Summary of Progression-Free Survival by Response Category
(based on Investigator-Assessed Response with Confirmation) and Treatment Arm

Treatment: Pom/Dex (N=15)

	PR or better	MR or better	SD	PD or NE
n	9	9	4	2
Number of Subjects				
Progressed or Died (event)	5 (56%)	5 (56%)	2 (50%)	1 (50%)
Censored, follow-up ended	2 (22%)	2 (22%)	1 (25%)	1 (50%)
Censored, follow-up ongoing	2 (22%)	2 (22%)	1 (25%)	0
Event Summary				
Disease Progression	5 (56%)	5 (56%)	2 (50%)	0
Death	0	0	0	1 (50%)
Estimates for Time Variable (Months) [1]				
1st Quartile	6.3	6.3	3.8	1.1
95% CI	(2.8,11.3)	(2.8,11.3)	(3.8,-)	(-,-)
Median	9.3	9.3	4.2	1.1
95% CI	(2.8,-)	(2.8,-)	(3.8,-)	(-,-)
3rd Quartile	-	-	-	1.1
95% CI	(9.3,-)	(9.3,-)	(3.8,-)	(-,-)
Progression-Free Survival Probability				
Time-to-Event Endpoint at 6 months	0.78	0.78	0.33	0.00
95% CI	(0.36,0.94)	(0.36,0.94)	(0.01,0.77)	(-,-)
Time-to-Event Endpoint at 12 months	0.32	0.32	0.33	0.00
95% CI	(0.05,0.65)	(0.05,0.65)	(0.01,0.77)	(-,-)
Time-to-Event Endpoint at 18 months	0.32	0.32	0.33	0.00
95% CI	(0.05,0.65)	(0.05,0.65)	(0.01,0.77)	(-,-)

[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_e_pfs_rsp_irc.sas 01MAR2023 11:18

Table 2.003112
Summary of Progression-Free Survival by Response Category
(based on Investigator-Assessed Response with Confirmation) and Treatment Arm

Treatment: Belantamab mafodotin (N=29)

	PR or better	MR or better	SD	PD or NE
n	6	8	13	8
Number of Subjects				
Progressed or Died (event)	2 (33%)	4 (50%)	9 (69%)	7 (88%)
Censored, follow-up ended	0	0	3 (23%)	1 (13%)
Censored, follow-up ongoing	4 (67%)	4 (50%)	1 (8%)	0
Event Summary				
Disease Progression	2 (33%)	4 (50%)	6 (46%)	6 (75%)
Death	0	0	3 (23%)	1 (13%)
Estimates for Time Variable (Months) [1]				
1st Quartile	10.3	6.3	1.4	0.7
95% CI	(2.8,-)	(2.8,-)	(1.2,2.1)	(0.7,1.0)
Median	-	10.3	2.1	1.0
95% CI	(2.8,-)	(2.8,-)	(1.4,5.7)	(0.7,1.0)
3rd Quartile	-	-	5.7	1.0
95% CI	(10.3,-)	(7.0,-)	(2.1,-)	(0.9,1.1)
Progression-Free Survival Probability				
Time-to-Event Endpoint at 6 months	0.83	0.75	0.13	0.00
95% CI	(0.27,0.97)	(0.31,0.93)	(0.01,0.43)	(-,-)
Time-to-Event Endpoint at 12 months	0.63	0.47	-	0.00
95% CI	(0.14,0.89)	(0.12,0.76)	(-,-)	(-,-)
Time-to-Event Endpoint at 18 months	0.63	0.47	-	0.00
95% CI	(0.14,0.89)	(0.12,0.76)	(-,-)	(-,-)

[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 2.016110
Summary of Progression-Free Survival 2 Based on Investigator-Assessed Response

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Progressed or Died (event)	7 (47%)	21 (72%)
Censored, follow-up ended	2 (13%)	0
Censored, follow-up ongoing	6 (40%)	8 (28%)
Event Summary		
Disease Progression	5 (33%)	12 (41%)
Death	2 (13%)	9 (31%)
Estimates for Time Variable (Months) [1]		
1st Quartile	8.6	2.1
95% CI	(1.1,10.4)	(1.0,4.0)
Median	13.5	5.7
95% CI	(8.6,-)	(3.1,13.7)
3rd Quartile	-	18.7
95% CI	(10.4,-)	(7.5,-)
Progression-Free Survival Probability		
Time-to-Event Endpoint at 6 Months	0.93	0.45
95% CI	(0.59,0.99)	(0.27,0.62)
Stratified Hazard Ratio [2]		
Estimate		1.74
95% CI		(0.63,4.77)

[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Hazard ratios are estimated using the Cox Proportional Hazards. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex. Hazard ratio and two-sided p-value from stratified log-rank test are adjusted for previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) as reported on the CRF.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_e_tte1_pfs2_inv.sas 21FEB2023 06:28

Protocol: 207495 Page 2 of 2
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 2.016110
Summary of Progression-Free Survival 2 Based on Investigator-Assessed Response

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Stratified Log-Rank [2]		
P-Value		0.277

[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Hazard ratios are estimated using the Cox Proportional Hazards. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex. Hazard ratio and two-sided p-value from stratified log-rank test are adjusted for previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) as reported on the CRF.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_e_tte1_pfs2_inv.sas 21FEB2023 06:28

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 2.005110
Summary of Reasons for Censoring for Time-to-Event Endpoints
Based on Investigator-Assessed Response

		Pom/Dex (N=15)		Belantamab mafodotin (N=29)	
Progression Free Survival (PFS)	n	7		9	
	Date of last adequate asmt	4	(57%)	5	(56%)
	Date of randomization	1	(14%)	1	(11%)
	Last adeq asmt on or prior to new CTX	2	(29%)	3	(33%)
Progression Free Survival (PFS) Secondary Reasons	n	4		4	
	Extended LTFU: Death	0		0	
	Extended LTFU: Progression	0		0	
	Inadequate baseline	0		0	
	New subsequent anti-cancer therapy	2	(50%)	3	(75%)
	No adequate post-baseline disease FU assessments	0		1	(25%)
	Randomized and not dosed (and no adequate disease FU assessments)	1	(25%)	0	
	Study discontinuation: LTFU	0		0	
	Study discontinuation: Withdrawal by subject	0		0	
	Unconfirmed PD	1	(25%)	0	
Progression Free Survival (PFS) SA1	n	7		9	
	Date of last adequate asmt	4	(57%)	5	(56%)
	Date of randomization	1	(14%)	1	(11%)
	Last adeq asmt on or prior to new CTX	2	(29%)	3	(33%)

Note: n is the number of subjects who were censored, which is used as the denominator to calculate the percentage.
Note: CTX = Anti-cancer therapy.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_e_censor_reasons.sas 06JAN2023 10:45

Table 2.005110
Summary of Reasons for Censoring for Time-to-Event Endpoints
Based on Investigator-Assessed Response

		Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Progression Free Survival (PFS) SA2	n	4	5
	Date of last adequate asmt	3 (75%)	5 (100%)
	Date of randomization	1 (25%)	0
Overall Survival (OS)	n	11	13
	Last contact date	11 (100%)	13 (100%)
Duration of Response (DOR)	n	4	4
	Date of last adequate asmt	2 (50%)	4 (100%)
	Last adeq asmt on or prior to new CTX	2 (50%)	0
Duration of Response (DOR) Secondary Reasons	n	2	0
	Death (other causes)	0	0
	Extended LTFU: Death	0	0
	Extended LTFU: Progression	0	0
	Inadequate baseline	0	0
	New subsequent anti-cancer therapy	2 (100%)	0
	No adequate post-baseline disease FU assessments	0	0
	Randomized and not dosed (and no adequate disease FU assessments)	0	0
	Study discontinuation: LTFU	0	0
	Study discontinuation: Withdrawal by subject	0	0
	Unconfirmed PD	0	0

Note: n is the number of subjects who were censored, which is used as the denominator to calculate the percentage.
Note: CTX = Anti-cancer therapy.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_e_censor_reasons.sas 06JAN2023 10:45

Table 2.005110
Summary of Reasons for Censoring for Time-to-Event Endpoints
Based on Investigator-Assessed Response

		Pom/Dex (N=15)		Belantamab mafodotin (N=29)	
Time to Progression (TTP)	n	8		9	
	Date of death (other causes)	1	(13%)	0	
	Date of last adequate asmt	4	(50%)	5	(56%)
	Date of randomization	1	(13%)	1	(11%)
	Last adeq asmt on or prior to new CTX	2	(25%)	3	(33%)
Time to Progression (TTP) Secondary Reasons	n	5		4	
	Death (other causes)	0		0	
	Extended LTFU: Death	0		0	
	Extended LTFU: Progression	0		0	
	Inadequate baseline	0		0	
	New subsequent anti-cancer therapy	2	(40%)	3	(75%)
	No adequate post-baseline disease FU assessments	1	(20%)	1	(25%)
	Randomized and not dosed (and no adequate disease FU assessments)	1	(20%)	0	
	Study discontinuation: LTFU	0		0	
	Study discontinuation: Withdrawal by subject	0		0	
	Unconfirmed PD	1	(20%)	0	
Progression Free Survival 2 (PFS2)	n	8		8	
	Last contact date	8	(100%)	8	(100%)

Note: n is the number of subjects who were censored, which is used as the denominator to calculate the percentage.
Note: CTX = Anti-cancer therapy.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_e_censor_reasons.sas 06JAN2023 10:45

Table 4.002110
Summary of Compliance of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L, FACT-GP5, PGIS and PGIC by Visit

Timepoint		Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Baseline	# of subjects remaining in study	15	29
	# of subjects with PRO-CTCAE score (%)	13 (87%)	17 (59%)
	# of subjects with OSDI summary score (%)	13 (87%)	25 (86%)
	# of subjects with QLQ-C30 summary score (%)	13 (87%)	27 (93%)
	# of subjects with QLQ-MY20 domain score (%)	13 (87%)	26 (90%)
	# of subjects with QLQ-IL52 domain score (%)	13 (87%)	26 (90%)
	# of subjects with EQ-5D-3L (%)	13 (87%)	25 (86%)
	# of subjects with FACT-GP5 score (%)	13 (87%)	25 (86%)
	# of subjects with PGIS score (%)	13 (87%)	25 (86%)
Week 4	# of subjects remaining in study	13	28
	# of subjects with PRO-CTCAE score (%)	13 (100%)	22 (79%)
	# of subjects with OSDI summary score (%)	13 (100%)	23 (82%)
	# of subjects with QLQ-C30 summary score (%)	13 (100%)	23 (82%)
	# of subjects with QLQ-MY20 domain score (%)	12 (92%)	23 (82%)
	# of subjects with QLQ-IL52 domain score (%)	12 (92%)	23 (82%)
	# of subjects with FACT-GP5 score (%)	13 (100%)	23 (82%)

Note: Percentage is calculated using # of subjects remaining in the study at given timepoint as denominator.
Note: Subjects are counted as remaining in the study at last follow-up visit if they have at least one recorded follow-up visit.
Note: The overall compliance rate is the number of subjects with an evaluable baseline form and at least one evaluable post-baseline form. For PGIC score the overall compliance rate is the number of subjects with an evaluable post-baseline form.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t4_comp1.sas 05JAN2023 13:31

Table 4.002110
Summary of Compliance of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L, FACT-GP5, PGIS and PGIC by Visit

Timepoint		Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 7	# of subjects remaining in study	13	21
	# of subjects with PRO-CTCAE score (%)	12 (92%)	16 (76%)
	# of subjects with OSDI summary score (%)	12 (92%)	15 (71%)
	# of subjects with QLQ-C30 summary score (%)	12 (92%)	17 (81%)
	# of subjects with QLQ-MY20 domain score (%)	12 (92%)	17 (81%)
	# of subjects with QLQ-IL52 domain score (%)	12 (92%)	17 (81%)
	# of subjects with EQ-5D-3L (%)	12 (92%)	14 (67%)
	# of subjects with FACT-GP5 score (%)	12 (92%)	15 (71%)
	# of subjects with PGIS score (%)	12 (92%)	14 (67%)
	# of subjects with PGIC score (%)	12 (92%)	14 (67%)
Week 10	# of subjects remaining in study	13	15
	# of subjects with PRO-CTCAE score (%)	13 (100%)	11 (73%)
	# of subjects with OSDI summary score (%)	13 (100%)	12 (80%)
	# of subjects with QLQ-C30 summary score (%)	13 (100%)	12 (80%)
	# of subjects with QLQ-MY20 domain score (%)	13 (100%)	12 (80%)
	# of subjects with QLQ-IL52 domain score (%)	13 (100%)	12 (80%)
	# of subjects with FACT-GP5 score (%)	13 (100%)	12 (80%)

Note: Percentage is calculated using # of subjects remaining in the study at given timepoint as denominator.
Note: Subjects are counted as remaining in the study at last follow-up visit if they have at least one recorded follow-up visit.
Note: The overall compliance rate is the number of subjects with an evaluable baseline form and at least one evaluable post-baseline form. For PGIC score the overall compliance rate is the number of subjects with an evaluable post-baseline form.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t4_comp1.sas 05JAN2023 13:31

Table 4.002110
Summary of Compliance of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L, FACT-GP5, PGIS and PGIC by Visit

Timepoint		Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 13	# of subjects remaining in study	13	11
	# of subjects with PRO-CTCAE score (%)	13 (100%)	9 (82%)
	# of subjects with OSDI summary score (%)	13 (100%)	9 (82%)
	# of subjects with QLQ-C30 summary score (%)	13 (100%)	9 (82%)
	# of subjects with QLQ-MY20 domain score (%)	13 (100%)	9 (82%)
	# of subjects with QLQ-IL52 domain score (%)	13 (100%)	9 (82%)
	# of subjects with EQ-5D-3L (%)	13 (100%)	7 (64%)
	# of subjects with FACT-GP5 score (%)	13 (100%)	9 (82%)
	# of subjects with PGIS score (%)	13 (100%)	7 (64%)
	# of subjects with PGIC score (%)	13 (100%)	7 (64%)
Week 16	# of subjects remaining in study	13	10
	# of subjects with PRO-CTCAE score (%)	12 (92%)	7 (70%)
	# of subjects with OSDI summary score (%)	12 (92%)	8 (80%)
	# of subjects with QLQ-C30 summary score (%)	12 (92%)	8 (80%)
	# of subjects with QLQ-MY20 domain score (%)	12 (92%)	8 (80%)
	# of subjects with QLQ-IL52 domain score (%)	12 (92%)	8 (80%)
	# of subjects with FACT-GP5 score (%)	12 (92%)	8 (80%)

Note: Percentage is calculated using # of subjects remaining in the study at given timepoint as denominator.
Note: Subjects are counted as remaining in the study at last follow-up visit if they have at least one recorded follow-up visit.
Note: The overall compliance rate is the number of subjects with an evaluable baseline form and at least one evaluable post-baseline form. For PGIC score the overall compliance rate is the number of subjects with an evaluable post-baseline form.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t4_comp1.sas 05JAN2023 13:31

Table 4.002110
Summary of Compliance of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L, FACT-GP5, PGIS and PGIC by Visit

Timepoint		Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 19	# of subjects remaining in study	12	9
	# of subjects with PRO-CTCAE score (%)	12 (100%)	6 (67%)
	# of subjects with OSDI summary score (%)	12 (100%)	7 (78%)
	# of subjects with QLQ-C30 summary score (%)	12 (100%)	7 (78%)
	# of subjects with QLQ-MY20 domain score (%)	12 (100%)	7 (78%)
	# of subjects with QLQ-IL52 domain score (%)	12 (100%)	7 (78%)
	# of subjects with EQ-5D-3L (%)	12 (100%)	7 (78%)
	# of subjects with FACT-GP5 score (%)	12 (100%)	7 (78%)
	# of subjects with PGIS score (%)	12 (100%)	7 (78%)
	# of subjects with PGIC score (%)	12 (100%)	7 (78%)
Week 22	# of subjects remaining in study	10	8
	# of subjects with PRO-CTCAE score (%)	7 (70%)	6 (75%)
	# of subjects with OSDI summary score (%)	7 (70%)	7 (88%)
	# of subjects with QLQ-C30 summary score (%)	7 (70%)	7 (88%)
	# of subjects with QLQ-MY20 domain score (%)	7 (70%)	7 (88%)
	# of subjects with QLQ-IL52 domain score (%)	7 (70%)	7 (88%)
	# of subjects with FACT-GP5 score (%)	7 (70%)	7 (88%)

Note: Percentage is calculated using # of subjects remaining in the study at given timepoint as denominator.
Note: Subjects are counted as remaining in the study at last follow-up visit if they have at least one recorded follow-up visit.
Note: The overall compliance rate is the number of subjects with an evaluable baseline form and at least one evaluable post-baseline form. For PGIC score the overall compliance rate is the number of subjects with an evaluable post-baseline form.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t4_comp1.sas 05JAN2023 13:31

Table 4.002110
Summary of Compliance of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L, FACT-GP5, PGIS and PGIC by Visit

Timepoint		Pom/Dex (N=15)		Belantamab mafodotin (N=29)	
Week 25	# of subjects remaining in study	10		7	
	# of subjects with PRO-CTCAE score (%)	7	(70%)	7	(100%)
	# of subjects with OSDI summary score (%)	7	(70%)	7	(100%)
	# of subjects with QLQ-C30 summary score (%)	7	(70%)	7	(100%)
	# of subjects with QLQ-MY20 domain score (%)	7	(70%)	7	(100%)
	# of subjects with QLQ-IL52 domain score (%)	7	(70%)	7	(100%)
	# of subjects with EQ-5D-3L (%)	6	(60%)	6	(86%)
	# of subjects with FACT-GP5 score (%)	7	(70%)	7	(100%)
	# of subjects with PGIS score (%)	6	(60%)	6	(86%)
	# of subjects with PGIC score (%)	6	(60%)	6	(86%)
Week 28	# of subjects remaining in study	8		7	
	# of subjects with PRO-CTCAE score (%)	7	(88%)	6	(86%)
	# of subjects with OSDI summary score (%)	7	(88%)	6	(86%)
	# of subjects with QLQ-C30 summary score (%)	7	(88%)	6	(86%)
	# of subjects with QLQ-MY20 domain score (%)	7	(88%)	6	(86%)
	# of subjects with QLQ-IL52 domain score (%)	7	(88%)	6	(86%)
	# of subjects with FACT-GP5 score (%)	7	(88%)	6	(86%)

Note: Percentage is calculated using # of subjects remaining in the study at given timepoint as denominator.
Note: Subjects are counted as remaining in the study at last follow-up visit if they have at least one recorded follow-up visit.
Note: The overall compliance rate is the number of subjects with an evaluable baseline form and at least one evaluable post-baseline form. For PGIC score the overall compliance rate is the number of subjects with an evaluable post-baseline form.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t4_comp1.sas 05JAN2023 13:31

Table 4.002110
Summary of Compliance of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L, FACT-GP5, PGIS and PGIC by Visit

Timepoint		Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 31	# of subjects remaining in study	7	7
	# of subjects with PRO-CTCAE score (%)	7 (100%)	6 (86%)
	# of subjects with OSDI summary score (%)	7 (100%)	6 (86%)
	# of subjects with QLQ-C30 summary score (%)	7 (100%)	6 (86%)
	# of subjects with QLQ-MY20 domain score (%)	7 (100%)	6 (86%)
	# of subjects with QLQ-IL52 domain score (%)	7 (100%)	6 (86%)
	# of subjects with EQ-5D-3L (%)	7 (100%)	6 (86%)
	# of subjects with FACT-GP5 score (%)	7 (100%)	6 (86%)
	# of subjects with PGIS score (%)	7 (100%)	6 (86%)
	# of subjects with PGIC score (%)	7 (100%)	6 (86%)
Week 34	# of subjects remaining in study	5	7
	# of subjects with PRO-CTCAE score (%)	5 (100%)	6 (86%)
	# of subjects with OSDI summary score (%)	5 (100%)	6 (86%)
	# of subjects with QLQ-C30 summary score (%)	5 (100%)	6 (86%)
	# of subjects with QLQ-MY20 domain score (%)	5 (100%)	6 (86%)
	# of subjects with QLQ-IL52 domain score (%)	5 (100%)	6 (86%)
	# of subjects with FACT-GP5 score (%)	5 (100%)	6 (86%)

Note: Percentage is calculated using # of subjects remaining in the study at given timepoint as denominator.
Note: Subjects are counted as remaining in the study at last follow-up visit if they have at least one recorded follow-up visit.
Note: The overall compliance rate is the number of subjects with an evaluable baseline form and at least one evaluable post-baseline form. For PGIC score the overall compliance rate is the number of subjects with an evaluable post-baseline form.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t4_comp1.sas 05JAN2023 13:31

Table 4.002110
Summary of Compliance of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L, FACT-GP5, PGIS and PGIC by Visit

Timepoint		Pom/Dex (N=15)		Belantamab mafodotin (N=29)	
Week 37	# of subjects remaining in study	5		6	
	# of subjects with PRO-CTCAE score (%)	4	(80%)	6	(100%)
	# of subjects with OSDI summary score (%)	4	(80%)	6	(100%)
	# of subjects with QLQ-C30 summary score (%)	4	(80%)	6	(100%)
	# of subjects with QLQ-MY20 domain score (%)	4	(80%)	6	(100%)
	# of subjects with QLQ-IL52 domain score (%)	4	(80%)	6	(100%)
	# of subjects with EQ-5D-3L (%)	4	(80%)	6	(100%)
	# of subjects with FACT-GP5 score (%)	4	(80%)	6	(100%)
	# of subjects with PGIS score (%)	4	(80%)	6	(100%)
	# of subjects with PGIC score (%)	4	(80%)	6	(100%)
Week 40	# of subjects remaining in study	5		6	
	# of subjects with PRO-CTCAE score (%)	4	(80%)	5	(83%)
	# of subjects with OSDI summary score (%)	4	(80%)	5	(83%)
	# of subjects with QLQ-C30 summary score (%)	4	(80%)	5	(83%)
	# of subjects with QLQ-MY20 domain score (%)	4	(80%)	5	(83%)
	# of subjects with QLQ-IL52 domain score (%)	4	(80%)	5	(83%)
	# of subjects with FACT-GP5 score (%)	4	(80%)	5	(83%)

Note: Percentage is calculated using # of subjects remaining in the study at given timepoint as denominator.
Note: Subjects are counted as remaining in the study at last follow-up visit if they have at least one recorded follow-up visit.
Note: The overall compliance rate is the number of subjects with an evaluable baseline form and at least one evaluable post-baseline form. For PGIC score the overall compliance rate is the number of subjects with an evaluable post-baseline form.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t4_comp1.sas 05JAN2023 13:31

Table 4.002110
Summary of Compliance of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L, FACT-GP5, PGIS and PGIC by Visit

Timepoint		Pom/Dex (N=15)		Belantamab mafodotin (N=29)	
Week 43	# of subjects remaining in study	5		5	
	# of subjects with PRO-CTCAE score (%)	4	(80%)	4	(80%)
	# of subjects with OSDI summary score (%)	4	(80%)	4	(80%)
	# of subjects with QLQ-C30 summary score (%)	4	(80%)	4	(80%)
	# of subjects with QLQ-MY20 domain score (%)	4	(80%)	4	(80%)
	# of subjects with QLQ-IL52 domain score (%)	4	(80%)	4	(80%)
	# of subjects with EQ-5D-3L (%)	4	(80%)	4	(80%)
	# of subjects with FACT-GP5 score (%)	4	(80%)	4	(80%)
	# of subjects with PGIS score (%)	4	(80%)	4	(80%)
	# of subjects with PGIC score (%)	4	(80%)	4	(80%)
Week 46	# of subjects remaining in study	3		5	
	# of subjects with PRO-CTCAE score (%)	3	(100%)	4	(80%)
	# of subjects with OSDI summary score (%)	3	(100%)	4	(80%)
	# of subjects with QLQ-C30 summary score (%)	3	(100%)	4	(80%)
	# of subjects with QLQ-MY20 domain score (%)	3	(100%)	4	(80%)
	# of subjects with QLQ-IL52 domain score (%)	3	(100%)	4	(80%)
	# of subjects with FACT-GP5 score (%)	3	(100%)	4	(80%)

Note: Percentage is calculated using # of subjects remaining in the study at given timepoint as denominator.
Note: Subjects are counted as remaining in the study at last follow-up visit if they have at least one recorded follow-up visit.
Note: The overall compliance rate is the number of subjects with an evaluable baseline form and at least one evaluable post-baseline form. For PGIC score the overall compliance rate is the number of subjects with an evaluable post-baseline form.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t4_comp1.sas 05JAN2023 13:31

Table 4.002110
Summary of Compliance of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L, FACT-GP5, PGIS and PGIC by Visit

Timepoint		Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 49	# of subjects remaining in study	3	4
	# of subjects with PRO-CTCAE score (%)	3 (100%)	4 (100%)
	# of subjects with OSDI summary score (%)	3 (100%)	4 (100%)
	# of subjects with QLQ-C30 summary score (%)	3 (100%)	4 (100%)
	# of subjects with QLQ-MY20 domain score (%)	3 (100%)	4 (100%)
	# of subjects with QLQ-IL52 domain score (%)	3 (100%)	4 (100%)
	# of subjects with EQ-5D-3L (%)	3 (100%)	4 (100%)
	# of subjects with FACT-GP5 score (%)	3 (100%)	4 (100%)
	# of subjects with PGIS score (%)	3 (100%)	4 (100%)
	# of subjects with PGIC score (%)	3 (100%)	4 (100%)
Week 52	# of subjects remaining in study	3	4
	# of subjects with PRO-CTCAE score (%)	3 (100%)	4 (100%)
	# of subjects with OSDI summary score (%)	3 (100%)	4 (100%)
	# of subjects with QLQ-C30 summary score (%)	3 (100%)	4 (100%)
	# of subjects with QLQ-MY20 domain score (%)	3 (100%)	4 (100%)
	# of subjects with QLQ-IL52 domain score (%)	3 (100%)	4 (100%)
	# of subjects with FACT-GP5 score (%)	3 (100%)	4 (100%)

Note: Percentage is calculated using # of subjects remaining in the study at given timepoint as denominator.
Note: Subjects are counted as remaining in the study at last follow-up visit if they have at least one recorded follow-up visit.
Note: The overall compliance rate is the number of subjects with an evaluable baseline form and at least one evaluable post-baseline form. For PGIC score the overall compliance rate is the number of subjects with an evaluable post-baseline form.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t4_comp1.sas 05JAN2023 13:31

Table 4.002110
Summary of Compliance of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L, FACT-GP5, PGIS and PGIC by Visit

Timepoint		Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 55	# of subjects remaining in study	3	3
	# of subjects with PRO-CTCAE score (%)	3 (100%)	3 (100%)
	# of subjects with OSDI summary score (%)	3 (100%)	3 (100%)
	# of subjects with QLQ-C30 summary score (%)	3 (100%)	3 (100%)
	# of subjects with QLQ-MY20 domain score (%)	3 (100%)	3 (100%)
	# of subjects with QLQ-IL52 domain score (%)	3 (100%)	3 (100%)
	# of subjects with EQ-5D-3L (%)	3 (100%)	3 (100%)
	# of subjects with FACT-GP5 score (%)	3 (100%)	3 (100%)
	# of subjects with PGIS score (%)	3 (100%)	3 (100%)
	# of subjects with PGIC score (%)	3 (100%)	3 (100%)
Week 58	# of subjects remaining in study	2	2
	# of subjects with PRO-CTCAE score (%)	2 (100%)	2 (100%)
	# of subjects with OSDI summary score (%)	2 (100%)	2 (100%)
	# of subjects with QLQ-C30 summary score (%)	2 (100%)	2 (100%)
	# of subjects with QLQ-MY20 domain score (%)	2 (100%)	2 (100%)
	# of subjects with QLQ-IL52 domain score (%)	2 (100%)	2 (100%)
	# of subjects with FACT-GP5 score (%)	2 (100%)	2 (100%)

Note: Percentage is calculated using # of subjects remaining in the study at given timepoint as denominator.
Note: Subjects are counted as remaining in the study at last follow-up visit if they have at least one recorded follow-up visit.
Note: The overall compliance rate is the number of subjects with an evaluable baseline form and at least one evaluable post-baseline form. For PGIC score the overall compliance rate is the number of subjects with an evaluable post-baseline form.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t4_comp1.sas 05JAN2023 13:31

Table 4.002110
Summary of Compliance of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L, FACT-GP5, PGIS and PGIC by Visit

Timepoint		Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 61	# of subjects remaining in study	2	2
	# of subjects with PRO-CTCAE score (%)	2 (100%)	2 (100%)
	# of subjects with OSDI summary score (%)	2 (100%)	2 (100%)
	# of subjects with QLQ-C30 summary score (%)	2 (100%)	2 (100%)
	# of subjects with QLQ-MY20 domain score (%)	2 (100%)	2 (100%)
	# of subjects with QLQ-IL52 domain score (%)	2 (100%)	2 (100%)
	# of subjects with EQ-5D-3L (%)	2 (100%)	2 (100%)
	# of subjects with FACT-GP5 score (%)	2 (100%)	2 (100%)
	# of subjects with PGIS score (%)	2 (100%)	2 (100%)
	# of subjects with PGIC score (%)	2 (100%)	2 (100%)
Week 64	# of subjects remaining in study	2	2
	# of subjects with PRO-CTCAE score (%)	2 (100%)	2 (100%)
	# of subjects with OSDI summary score (%)	2 (100%)	2 (100%)
	# of subjects with QLQ-C30 summary score (%)	2 (100%)	2 (100%)
	# of subjects with QLQ-MY20 domain score (%)	2 (100%)	2 (100%)
	# of subjects with QLQ-IL52 domain score (%)	2 (100%)	2 (100%)
	# of subjects with FACT-GP5 score (%)	2 (100%)	2 (100%)

Note: Percentage is calculated using # of subjects remaining in the study at given timepoint as denominator.
Note: Subjects are counted as remaining in the study at last follow-up visit if they have at least one recorded follow-up visit.
Note: The overall compliance rate is the number of subjects with an evaluable baseline form and at least one evaluable post-baseline form. For PGIC score the overall compliance rate is the number of subjects with an evaluable post-baseline form.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t4_comp1.sas 05JAN2023 13:31

Table 4.002110
Summary of Compliance of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L, FACT-GP5, PGIS and PGIC by Visit

Timepoint		Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 67	# of subjects remaining in study	2	2
	# of subjects with PRO-CTCAE score (%)	2 (100%)	2 (100%)
	# of subjects with OSDI summary score (%)	2 (100%)	2 (100%)
	# of subjects with QLQ-C30 summary score (%)	2 (100%)	2 (100%)
	# of subjects with QLQ-MY20 domain score (%)	2 (100%)	2 (100%)
	# of subjects with QLQ-IL52 domain score (%)	2 (100%)	2 (100%)
	# of subjects with EQ-5D-3L (%)	2 (100%)	2 (100%)
	# of subjects with FACT-GP5 score (%)	2 (100%)	2 (100%)
	# of subjects with PGIS score (%)	2 (100%)	2 (100%)
	# of subjects with PGIC score (%)	2 (100%)	2 (100%)
Week 70	# of subjects remaining in study	2	1
	# of subjects with PRO-CTCAE score (%)	2 (100%)	1 (100%)
	# of subjects with OSDI summary score (%)	2 (100%)	1 (100%)
	# of subjects with QLQ-C30 summary score (%)	2 (100%)	1 (100%)
	# of subjects with QLQ-MY20 domain score (%)	2 (100%)	1 (100%)
	# of subjects with QLQ-IL52 domain score (%)	2 (100%)	1 (100%)
	# of subjects with FACT-GP5 score (%)	2 (100%)	1 (100%)

Note: Percentage is calculated using # of subjects remaining in the study at given timepoint as denominator.
Note: Subjects are counted as remaining in the study at last follow-up visit if they have at least one recorded follow-up visit.
Note: The overall compliance rate is the number of subjects with an evaluable baseline form and at least one evaluable post-baseline form. For PGIC score the overall compliance rate is the number of subjects with an evaluable post-baseline form.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t4_comp1.sas 05JAN2023 13:31

Table 4.002110
Summary of Compliance of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L, FACT-GP5, PGIS and PGIC by Visit

Timepoint		Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 73	# of subjects remaining in study	2	1
	# of subjects with PRO-CTCAE score (%)	1 (50%)	1 (100%)
	# of subjects with OSDI summary score (%)	1 (50%)	1 (100%)
	# of subjects with QLQ-C30 summary score (%)	1 (50%)	1 (100%)
	# of subjects with QLQ-MY20 domain score (%)	1 (50%)	1 (100%)
	# of subjects with QLQ-IL52 domain score (%)	1 (50%)	1 (100%)
	# of subjects with EQ-5D-3L (%)	1 (50%)	1 (100%)
	# of subjects with FACT-GP5 score (%)	1 (50%)	1 (100%)
	# of subjects with PGIS score (%)	1 (50%)	1 (100%)
	# of subjects with PGIC score (%)	1 (50%)	1 (100%)
Week 76	# of subjects remaining in study	2	1
	# of subjects with PRO-CTCAE score (%)	2 (100%)	1 (100%)
	# of subjects with OSDI summary score (%)	2 (100%)	1 (100%)
	# of subjects with QLQ-C30 summary score (%)	2 (100%)	1 (100%)
	# of subjects with QLQ-MY20 domain score (%)	2 (100%)	1 (100%)
	# of subjects with QLQ-IL52 domain score (%)	2 (100%)	1 (100%)
	# of subjects with FACT-GP5 score (%)	2 (100%)	1 (100%)

Note: Percentage is calculated using # of subjects remaining in the study at given timepoint as denominator.
Note: Subjects are counted as remaining in the study at last follow-up visit if they have at least one recorded follow-up visit.
Note: The overall compliance rate is the number of subjects with an evaluable baseline form and at least one evaluable post-baseline form. For PGIC score the overall compliance rate is the number of subjects with an evaluable post-baseline form.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t4_comp1.sas 05JAN2023 13:31

Table 4.002110
Summary of Compliance of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L, FACT-GP5, PGIS and PGIC by Visit

Timepoint		Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 79	# of subjects remaining in study	2	1
	# of subjects with PRO-CTCAE score (%)	2 (100%)	1 (100%)
	# of subjects with OSDI summary score (%)	2 (100%)	1 (100%)
	# of subjects with QLQ-C30 summary score (%)	2 (100%)	1 (100%)
	# of subjects with QLQ-MY20 domain score (%)	2 (100%)	1 (100%)
	# of subjects with QLQ-IL52 domain score (%)	2 (100%)	1 (100%)
	# of subjects with EQ-5D-3L (%)	2 (100%)	1 (100%)
	# of subjects with FACT-GP5 score (%)	2 (100%)	1 (100%)
	# of subjects with PGIS score (%)	2 (100%)	1 (100%)
	# of subjects with PGIC score (%)	2 (100%)	1 (100%)
Week 82	# of subjects remaining in study	2	1
	# of subjects with PRO-CTCAE score (%)	2 (100%)	1 (100%)
	# of subjects with OSDI summary score (%)	2 (100%)	1 (100%)
	# of subjects with QLQ-C30 summary score (%)	2 (100%)	1 (100%)
	# of subjects with QLQ-MY20 domain score (%)	2 (100%)	1 (100%)
	# of subjects with QLQ-IL52 domain score (%)	2 (100%)	1 (100%)
	# of subjects with FACT-GP5 score (%)	2 (100%)	1 (100%)

Note: Percentage is calculated using # of subjects remaining in the study at given timepoint as denominator.
Note: Subjects are counted as remaining in the study at last follow-up visit if they have at least one recorded follow-up visit.
Note: The overall compliance rate is the number of subjects with an evaluable baseline form and at least one evaluable post-baseline form. For PGIC score the overall compliance rate is the number of subjects with an evaluable post-baseline form.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t4_comp1.sas 05JAN2023 13:31

Table 4.002110
Summary of Compliance of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L, FACT-GP5, PGIS and PGIC by Visit

Timepoint		Pom/Dex (N=15)		Belantamab mafodotin (N=29)	
Week 85	# of subjects remaining in study	2		1	
	# of subjects with PRO-CTCAE score (%)	1	(50%)	1	(100%)
	# of subjects with OSDI summary score (%)	1	(50%)	1	(100%)
	# of subjects with QLQ-C30 summary score (%)	1	(50%)	1	(100%)
	# of subjects with QLQ-MY20 domain score (%)	1	(50%)	1	(100%)
	# of subjects with QLQ-IL52 domain score (%)	1	(50%)	1	(100%)
	# of subjects with EQ-5D-3L (%)	1	(50%)	1	(100%)
	# of subjects with FACT-GP5 score (%)	1	(50%)	1	(100%)
	# of subjects with PGIS score (%)	1	(50%)	1	(100%)
	# of subjects with PGIC score (%)	1	(50%)	1	(100%)
Week 88	# of subjects remaining in study	2		1	
	# of subjects with PRO-CTCAE score (%)	1	(50%)	1	(100%)
	# of subjects with OSDI summary score (%)	1	(50%)	1	(100%)
	# of subjects with QLQ-C30 summary score (%)	1	(50%)	1	(100%)
	# of subjects with QLQ-MY20 domain score (%)	1	(50%)	1	(100%)
	# of subjects with QLQ-IL52 domain score (%)	1	(50%)	1	(100%)
	# of subjects with FACT-GP5 score (%)	1	(50%)	1	(100%)

Note: Percentage is calculated using # of subjects remaining in the study at given timepoint as denominator.
Note: Subjects are counted as remaining in the study at last follow-up visit if they have at least one recorded follow-up visit.
Note: The overall compliance rate is the number of subjects with an evaluable baseline form and at least one evaluable post-baseline form. For PGIC score the overall compliance rate is the number of subjects with an evaluable post-baseline form.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t4_comp1.sas 05JAN2023 13:31

Table 4.002110
Summary of Compliance of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L, FACT-GP5, PGIS and PGIC by Visit

Timepoint		Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 91	# of subjects remaining in study	2	1
	# of subjects with PRO-CTCAE score (%)	1 (50%)	1 (100%)
	# of subjects with OSDI summary score (%)	1 (50%)	1 (100%)
	# of subjects with QLQ-C30 summary score (%)	2 (100%)	1 (100%)
	# of subjects with QLQ-MY20 domain score (%)	1 (50%)	1 (100%)
	# of subjects with QLQ-IL52 domain score (%)	1 (50%)	1 (100%)
	# of subjects with EQ-5D-3L (%)	1 (50%)	1 (100%)
	# of subjects with FACT-GP5 score (%)	1 (50%)	1 (100%)
	# of subjects with PGIS score (%)	1 (50%)	1 (100%)
	# of subjects with PGIC score (%)	1 (50%)	1 (100%)
Week 94	# of subjects remaining in study	2	1
	# of subjects with PRO-CTCAE score (%)	2 (100%)	1 (100%)
	# of subjects with OSDI summary score (%)	2 (100%)	1 (100%)
	# of subjects with QLQ-C30 summary score (%)	2 (100%)	1 (100%)
	# of subjects with QLQ-MY20 domain score (%)	2 (100%)	1 (100%)
	# of subjects with QLQ-IL52 domain score (%)	2 (100%)	1 (100%)
	# of subjects with FACT-GP5 score (%)	2 (100%)	1 (100%)

Note: Percentage is calculated using # of subjects remaining in the study at given timepoint as denominator.
Note: Subjects are counted as remaining in the study at last follow-up visit if they have at least one recorded follow-up visit.
Note: The overall compliance rate is the number of subjects with an evaluable baseline form and at least one evaluable post-baseline form. For PGIC score the overall compliance rate is the number of subjects with an evaluable post-baseline form.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t4_comp1.sas 05JAN2023 13:31

Table 4.002110
Summary of Compliance of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L, FACT-GP5, PGIS and PGIC by Visit

Timepoint		Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 97	# of subjects remaining in study	1	1
	# of subjects with PRO-CTCAE score (%)	1 (100%)	0
	# of subjects with OSDI summary score (%)	1 (100%)	0
	# of subjects with QLQ-C30 summary score (%)	1 (100%)	0
	# of subjects with QLQ-MY20 domain score (%)	1 (100%)	0
	# of subjects with QLQ-IL52 domain score (%)	1 (100%)	0
	# of subjects with EQ-5D-3L (%)	1 (100%)	0
	# of subjects with FACT-GP5 score (%)	1 (100%)	0
	# of subjects with PGIS score (%)	1 (100%)	0
	# of subjects with PGIC score (%)	1 (100%)	0
Week 100	# of subjects remaining in study	1	1
	# of subjects with PRO-CTCAE score (%)	0	1 (100%)
	# of subjects with OSDI summary score (%)	0	1 (100%)
	# of subjects with QLQ-C30 summary score (%)	0	1 (100%)
	# of subjects with QLQ-MY20 domain score (%)	0	1 (100%)
	# of subjects with QLQ-IL52 domain score (%)	0	1 (100%)
	# of subjects with FACT-GP5 score (%)	0	1 (100%)

Note: Percentage is calculated using # of subjects remaining in the study at given timepoint as denominator.
Note: Subjects are counted as remaining in the study at last follow-up visit if they have at least one recorded follow-up visit.
Note: The overall compliance rate is the number of subjects with an evaluable baseline form and at least one evaluable post-baseline form. For PGIC score the overall compliance rate is the number of subjects with an evaluable post-baseline form.

Table 4.002110
Summary of Compliance of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L, FACT-GP5, PGIS and PGIC by Visit

Timepoint		Pom/Dex (N=15)		Belantamab mafodotin (N=29)	
End of Treatment	# of subjects remaining in study	13		24	
	# of subjects with PRO-CTCAE score (%)	10	(77%)	11	(46%)
	# of subjects with OSDI summary score (%)	9	(69%)	11	(46%)
	# of subjects with QLQ-C30 summary score (%)	10	(77%)	11	(46%)
	# of subjects with QLQ-MY20 domain score (%)	10	(77%)	11	(46%)
	# of subjects with QLQ-IL52 domain score (%)	10	(77%)	11	(46%)
	# of subjects with EQ-5D-3L (%)	10	(77%)	11	(46%)
	# of subjects with FACT-GP5 score (%)	10	(77%)	11	(46%)
	# of subjects with PGIS score (%)	10	(77%)	11	(46%)
	# of subjects with PGIC score (%)	10	(77%)	11	(46%)
Last Follow-up	# of subjects remaining in study	11		23	
	# of subjects with PRO-CTCAE score (%)	0		0	
	# of subjects with OSDI summary score (%)	0		5	(22%)
	# of subjects with QLQ-C30 summary score (%)	3	(27%)	5	(22%)
	# of subjects with QLQ-MY20 domain score (%)	3	(27%)	2	(9%)
	# of subjects with QLQ-IL52 domain score (%)	3	(27%)	2	(9%)
	# of subjects with EQ-5D-3L (%)	3	(27%)	5	(22%)
	# of subjects with FACT-GP5 score (%)	0		0	
	# of subjects with PGIS score (%)	1	(9%)	1	(4%)
	# of subjects with PGIC score (%)	1	(9%)	1	(4%)

Note: Percentage is calculated using # of subjects remaining in the study at given timepoint as denominator.
Note: Subjects are counted as remaining in the study at last follow-up visit if they have at least one recorded follow-up visit.
Note: The overall compliance rate is the number of subjects with an evaluable baseline form and at least one evaluable post-baseline form. For PGIC score the overall compliance rate is the number of subjects with an evaluable post-baseline form.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t4_comp1.sas 05JAN2023 13:31

Protocol: 207495 Page 19 of 19
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.002110
Summary of Compliance of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L, FACT-GP5, PGIS and PGIC by Visit

Timepoint		Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Overall Compliance	# of subjects with PRO-CTCAE score (%)	12 (80%)	16 (55%)
	# of subjects with OSDI summary score (%)	12 (80%)	23 (79%)
	# of subjects with QLQ-C30 summary score (%)	12 (80%)	25 (86%)
	# of subjects with QLQ-MY20 domain score (%)	12 (80%)	24 (83%)
	# of subjects with QLQ-IL52 domain score (%)	12 (80%)	24 (83%)
	# of subjects with EQ-5D-3L (%)	12 (80%)	19 (66%)
	# of subjects with FACT-GP5 score (%)	12 (80%)	23 (79%)
	# of subjects with PGIS score (%)	12 (80%)	19 (66%)
	# of subjects with PGIC score (%)	13 (87%)	20 (69%)

Note: Percentage is calculated using # of subjects remaining in the study at given timepoint as denominator.
Note: Subjects are counted as remaining in the study at last follow-up visit if they have at least one recorded follow-up visit.
Note: The overall compliance rate is the number of subjects with an evaluable baseline form and at least one evaluable post-baseline form. For PGIC score the overall compliance rate is the number of subjects with an evaluable post-baseline form.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t4_comp1.sas 05JAN2023 13:31

Table 4.117110
Summary of Compliance of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L, FACT-GP5, PGIS and PGIC by Visit

Timepoint		Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Baseline	# of subjects remaining in study	14	29
	# of subjects with PRO-CTCAE score (%)	13 (93%)	17 (59%)
	# of subjects with OSDI summary score (%)	13 (93%)	25 (86%)
	# of subjects with QLQ-C30 summary score (%)	13 (93%)	27 (93%)
	# of subjects with QLQ-MY20 domain score (%)	13 (93%)	26 (90%)
	# of subjects with QLQ-IL52 domain score (%)	13 (93%)	26 (90%)
	# of subjects with EQ-5D-3L (%)	13 (93%)	25 (86%)
	# of subjects with FACT-GP5 score (%)	13 (93%)	25 (86%)
	# of subjects with PGIS score (%)	13 (93%)	25 (86%)
Week 4	# of subjects remaining in study	13	28
	# of subjects with PRO-CTCAE score (%)	13 (100%)	22 (79%)
	# of subjects with OSDI summary score (%)	13 (100%)	23 (82%)
	# of subjects with QLQ-C30 summary score (%)	13 (100%)	23 (82%)
	# of subjects with QLQ-MY20 domain score (%)	12 (92%)	23 (82%)
	# of subjects with QLQ-IL52 domain score (%)	12 (92%)	23 (82%)
	# of subjects with FACT-GP5 score (%)	13 (100%)	23 (82%)

Note: Percentage is calculated using # of subjects remaining in the study at given timepoint as denominator.
Note: Subjects are counted as remaining in the study at last follow-up visit if they have at least one recorded follow-up visit.
Note: The overall compliance rate is the number of subjects with an evaluable baseline form and at least one evaluable post-baseline form. For PGIC score the overall compliance rate is the number of subjects with an evaluable post-baseline form.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t4_comp1_sfty.sas 15MAR2023 05:49

Table 4.117110
Summary of Compliance of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L, FACT-GP5, PGIS and PGIC by Visit

Timepoint		Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 7	# of subjects remaining in study	13	21
	# of subjects with PRO-CTCAE score (%)	12 (92%)	16 (76%)
	# of subjects with OSDI summary score (%)	12 (92%)	15 (71%)
	# of subjects with QLQ-C30 summary score (%)	12 (92%)	17 (81%)
	# of subjects with QLQ-MY20 domain score (%)	12 (92%)	17 (81%)
	# of subjects with QLQ-IL52 domain score (%)	12 (92%)	17 (81%)
	# of subjects with EQ-5D-3L (%)	12 (92%)	14 (67%)
	# of subjects with FACT-GP5 score (%)	12 (92%)	15 (71%)
	# of subjects with PGIS score (%)	12 (92%)	14 (67%)
	# of subjects with PGIC score (%)	12 (92%)	14 (67%)
Week 10	# of subjects remaining in study	13	15
	# of subjects with PRO-CTCAE score (%)	13 (100%)	11 (73%)
	# of subjects with OSDI summary score (%)	13 (100%)	12 (80%)
	# of subjects with QLQ-C30 summary score (%)	13 (100%)	12 (80%)
	# of subjects with QLQ-MY20 domain score (%)	13 (100%)	12 (80%)
	# of subjects with QLQ-IL52 domain score (%)	13 (100%)	12 (80%)
	# of subjects with FACT-GP5 score (%)	13 (100%)	12 (80%)

Note: Percentage is calculated using # of subjects remaining in the study at given timepoint as denominator.
Note: Subjects are counted as remaining in the study at last follow-up visit if they have at least one recorded follow-up visit.
Note: The overall compliance rate is the number of subjects with an evaluable baseline form and at least one evaluable post-baseline form. For PGIC score the overall compliance rate is the number of subjects with an evaluable post-baseline form.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t4_comp1_sfty.sas 15MAR2023 05:49

Table 4.117110
Summary of Compliance of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L, FACT-GP5, PGIS and PGIC by Visit

Timepoint		Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 13	# of subjects remaining in study	13	11
	# of subjects with PRO-CTCAE score (%)	13 (100%)	9 (82%)
	# of subjects with OSDI summary score (%)	13 (100%)	9 (82%)
	# of subjects with QLQ-C30 summary score (%)	13 (100%)	9 (82%)
	# of subjects with QLQ-MY20 domain score (%)	13 (100%)	9 (82%)
	# of subjects with QLQ-IL52 domain score (%)	13 (100%)	9 (82%)
	# of subjects with EQ-5D-3L (%)	13 (100%)	7 (64%)
	# of subjects with FACT-GP5 score (%)	13 (100%)	9 (82%)
	# of subjects with PGIS score (%)	13 (100%)	7 (64%)
	# of subjects with PGIC score (%)	13 (100%)	7 (64%)
Week 16	# of subjects remaining in study	13	10
	# of subjects with PRO-CTCAE score (%)	12 (92%)	7 (70%)
	# of subjects with OSDI summary score (%)	12 (92%)	8 (80%)
	# of subjects with QLQ-C30 summary score (%)	12 (92%)	8 (80%)
	# of subjects with QLQ-MY20 domain score (%)	12 (92%)	8 (80%)
	# of subjects with QLQ-IL52 domain score (%)	12 (92%)	8 (80%)
	# of subjects with FACT-GP5 score (%)	12 (92%)	8 (80%)

Note: Percentage is calculated using # of subjects remaining in the study at given timepoint as denominator.
Note: Subjects are counted as remaining in the study at last follow-up visit if they have at least one recorded follow-up visit.
Note: The overall compliance rate is the number of subjects with an evaluable baseline form and at least one evaluable post-baseline form. For PGIC score the overall compliance rate is the number of subjects with an evaluable post-baseline form.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t4_comp1_sfty.sas 15MAR2023 05:49

Table 4.117110
Summary of Compliance of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L, FACT-GP5, PGIS and PGIC by Visit

Timepoint		Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 19	# of subjects remaining in study	12	9
	# of subjects with PRO-CTCAE score (%)	12 (100%)	6 (67%)
	# of subjects with OSDI summary score (%)	12 (100%)	7 (78%)
	# of subjects with QLQ-C30 summary score (%)	12 (100%)	7 (78%)
	# of subjects with QLQ-MY20 domain score (%)	12 (100%)	7 (78%)
	# of subjects with QLQ-IL52 domain score (%)	12 (100%)	7 (78%)
	# of subjects with EQ-5D-3L (%)	12 (100%)	7 (78%)
	# of subjects with FACT-GP5 score (%)	12 (100%)	7 (78%)
	# of subjects with PGIS score (%)	12 (100%)	7 (78%)
	# of subjects with PGIC score (%)	12 (100%)	7 (78%)
Week 22	# of subjects remaining in study	10	8
	# of subjects with PRO-CTCAE score (%)	7 (70%)	6 (75%)
	# of subjects with OSDI summary score (%)	7 (70%)	7 (88%)
	# of subjects with QLQ-C30 summary score (%)	7 (70%)	7 (88%)
	# of subjects with QLQ-MY20 domain score (%)	7 (70%)	7 (88%)
	# of subjects with QLQ-IL52 domain score (%)	7 (70%)	7 (88%)
	# of subjects with FACT-GP5 score (%)	7 (70%)	7 (88%)

Note: Percentage is calculated using # of subjects remaining in the study at given timepoint as denominator.
Note: Subjects are counted as remaining in the study at last follow-up visit if they have at least one recorded follow-up visit.
Note: The overall compliance rate is the number of subjects with an evaluable baseline form and at least one evaluable post-baseline form. For PGIC score the overall compliance rate is the number of subjects with an evaluable post-baseline form.

Table 4.117110
Summary of Compliance of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L, FACT-GP5, PGIS and PGIC by Visit

Timepoint		Pom/Dex (N=14)		Belantamab mafodotin (N=29)	
Week 25	# of subjects remaining in study	10		7	
	# of subjects with PRO-CTCAE score (%)	7	(70%)	7	(100%)
	# of subjects with OSDI summary score (%)	7	(70%)	7	(100%)
	# of subjects with QLQ-C30 summary score (%)	7	(70%)	7	(100%)
	# of subjects with QLQ-MY20 domain score (%)	7	(70%)	7	(100%)
	# of subjects with QLQ-IL52 domain score (%)	7	(70%)	7	(100%)
	# of subjects with EQ-5D-3L (%)	6	(60%)	6	(86%)
	# of subjects with FACT-GP5 score (%)	7	(70%)	7	(100%)
	# of subjects with PGIS score (%)	6	(60%)	6	(86%)
	# of subjects with PGIC score (%)	6	(60%)	6	(86%)
Week 28	# of subjects remaining in study	8		7	
	# of subjects with PRO-CTCAE score (%)	7	(88%)	6	(86%)
	# of subjects with OSDI summary score (%)	7	(88%)	6	(86%)
	# of subjects with QLQ-C30 summary score (%)	7	(88%)	6	(86%)
	# of subjects with QLQ-MY20 domain score (%)	7	(88%)	6	(86%)
	# of subjects with QLQ-IL52 domain score (%)	7	(88%)	6	(86%)
	# of subjects with FACT-GP5 score (%)	7	(88%)	6	(86%)

Note: Percentage is calculated using # of subjects remaining in the study at given timepoint as denominator.
Note: Subjects are counted as remaining in the study at last follow-up visit if they have at least one recorded follow-up visit.
Note: The overall compliance rate is the number of subjects with an evaluable baseline form and at least one evaluable post-baseline form. For PGIC score the overall compliance rate is the number of subjects with an evaluable post-baseline form.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t4_comp1_sfty.sas 15MAR2023 05:49

Table 4.117110
Summary of Compliance of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L, FACT-GP5, PGIS and PGIC by Visit

Timepoint		Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 31	# of subjects remaining in study	7	7
	# of subjects with PRO-CTCAE score (%)	7 (100%)	6 (86%)
	# of subjects with OSDI summary score (%)	7 (100%)	6 (86%)
	# of subjects with QLQ-C30 summary score (%)	7 (100%)	6 (86%)
	# of subjects with QLQ-MY20 domain score (%)	7 (100%)	6 (86%)
	# of subjects with QLQ-IL52 domain score (%)	7 (100%)	6 (86%)
	# of subjects with EQ-5D-3L (%)	7 (100%)	6 (86%)
	# of subjects with FACT-GP5 score (%)	7 (100%)	6 (86%)
	# of subjects with PGIS score (%)	7 (100%)	6 (86%)
	# of subjects with PGIC score (%)	7 (100%)	6 (86%)
Week 34	# of subjects remaining in study	5	7
	# of subjects with PRO-CTCAE score (%)	5 (100%)	6 (86%)
	# of subjects with OSDI summary score (%)	5 (100%)	6 (86%)
	# of subjects with QLQ-C30 summary score (%)	5 (100%)	6 (86%)
	# of subjects with QLQ-MY20 domain score (%)	5 (100%)	6 (86%)
	# of subjects with QLQ-IL52 domain score (%)	5 (100%)	6 (86%)
	# of subjects with FACT-GP5 score (%)	5 (100%)	6 (86%)

Note: Percentage is calculated using # of subjects remaining in the study at given timepoint as denominator.
Note: Subjects are counted as remaining in the study at last follow-up visit if they have at least one recorded follow-up visit.
Note: The overall compliance rate is the number of subjects with an evaluable baseline form and at least one evaluable post-baseline form. For PGIC score the overall compliance rate is the number of subjects with an evaluable post-baseline form.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t4_comp1_sfty.sas 15MAR2023 05:49

Table 4.117110
Summary of Compliance of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L, FACT-GP5, PGIS and PGIC by Visit

Timepoint		Pom/Dex (N=14)		Belantamab mafodotin (N=29)	
Week 37	# of subjects remaining in study	5		6	
	# of subjects with PRO-CTCAE score (%)	4	(80%)	6	(100%)
	# of subjects with OSDI summary score (%)	4	(80%)	6	(100%)
	# of subjects with QLQ-C30 summary score (%)	4	(80%)	6	(100%)
	# of subjects with QLQ-MY20 domain score (%)	4	(80%)	6	(100%)
	# of subjects with QLQ-IL52 domain score (%)	4	(80%)	6	(100%)
	# of subjects with EQ-5D-3L (%)	4	(80%)	6	(100%)
	# of subjects with FACT-GP5 score (%)	4	(80%)	6	(100%)
	# of subjects with PGIS score (%)	4	(80%)	6	(100%)
	# of subjects with PGIC score (%)	4	(80%)	6	(100%)
Week 40	# of subjects remaining in study	5		6	
	# of subjects with PRO-CTCAE score (%)	4	(80%)	5	(83%)
	# of subjects with OSDI summary score (%)	4	(80%)	5	(83%)
	# of subjects with QLQ-C30 summary score (%)	4	(80%)	5	(83%)
	# of subjects with QLQ-MY20 domain score (%)	4	(80%)	5	(83%)
	# of subjects with QLQ-IL52 domain score (%)	4	(80%)	5	(83%)
	# of subjects with FACT-GP5 score (%)	4	(80%)	5	(83%)

Note: Percentage is calculated using # of subjects remaining in the study at given timepoint as denominator.
Note: Subjects are counted as remaining in the study at last follow-up visit if they have at least one recorded follow-up visit.
Note: The overall compliance rate is the number of subjects with an evaluable baseline form and at least one evaluable post-baseline form. For PGIC score the overall compliance rate is the number of subjects with an evaluable post-baseline form.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t4_comp1_sfty.sas 15MAR2023 05:49

Table 4.117110
Summary of Compliance of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L, FACT-GP5, PGIS and PGIC by Visit

Timepoint		Pom/Dex (N=14)		Belantamab mafodotin (N=29)	
Week 43	# of subjects remaining in study	5		5	
	# of subjects with PRO-CTCAE score (%)	4	(80%)	4	(80%)
	# of subjects with OSDI summary score (%)	4	(80%)	4	(80%)
	# of subjects with QLQ-C30 summary score (%)	4	(80%)	4	(80%)
	# of subjects with QLQ-MY20 domain score (%)	4	(80%)	4	(80%)
	# of subjects with QLQ-IL52 domain score (%)	4	(80%)	4	(80%)
	# of subjects with EQ-5D-3L (%)	4	(80%)	4	(80%)
	# of subjects with FACT-GP5 score (%)	4	(80%)	4	(80%)
	# of subjects with PGIS score (%)	4	(80%)	4	(80%)
	# of subjects with PGIC score (%)	4	(80%)	4	(80%)
Week 46	# of subjects remaining in study	3		5	
	# of subjects with PRO-CTCAE score (%)	3	(100%)	4	(80%)
	# of subjects with OSDI summary score (%)	3	(100%)	4	(80%)
	# of subjects with QLQ-C30 summary score (%)	3	(100%)	4	(80%)
	# of subjects with QLQ-MY20 domain score (%)	3	(100%)	4	(80%)
	# of subjects with QLQ-IL52 domain score (%)	3	(100%)	4	(80%)
	# of subjects with FACT-GP5 score (%)	3	(100%)	4	(80%)

Note: Percentage is calculated using # of subjects remaining in the study at given timepoint as denominator.
Note: Subjects are counted as remaining in the study at last follow-up visit if they have at least one recorded follow-up visit.
Note: The overall compliance rate is the number of subjects with an evaluable baseline form and at least one evaluable post-baseline form. For PGIC score the overall compliance rate is the number of subjects with an evaluable post-baseline form.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t4_comp1_sfty.sas 15MAR2023 05:49

Table 4.117110
Summary of Compliance of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L, FACT-GP5, PGIS and PGIC by Visit

Timepoint		Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 49	# of subjects remaining in study	3	4
	# of subjects with PRO-CTCAE score (%)	3 (100%)	4 (100%)
	# of subjects with OSDI summary score (%)	3 (100%)	4 (100%)
	# of subjects with QLQ-C30 summary score (%)	3 (100%)	4 (100%)
	# of subjects with QLQ-MY20 domain score (%)	3 (100%)	4 (100%)
	# of subjects with QLQ-IL52 domain score (%)	3 (100%)	4 (100%)
	# of subjects with EQ-5D-3L (%)	3 (100%)	4 (100%)
	# of subjects with FACT-GP5 score (%)	3 (100%)	4 (100%)
	# of subjects with PGIS score (%)	3 (100%)	4 (100%)
	# of subjects with PGIC score (%)	3 (100%)	4 (100%)
Week 52	# of subjects remaining in study	3	4
	# of subjects with PRO-CTCAE score (%)	3 (100%)	4 (100%)
	# of subjects with OSDI summary score (%)	3 (100%)	4 (100%)
	# of subjects with QLQ-C30 summary score (%)	3 (100%)	4 (100%)
	# of subjects with QLQ-MY20 domain score (%)	3 (100%)	4 (100%)
	# of subjects with QLQ-IL52 domain score (%)	3 (100%)	4 (100%)
	# of subjects with FACT-GP5 score (%)	3 (100%)	4 (100%)

Note: Percentage is calculated using # of subjects remaining in the study at given timepoint as denominator.
Note: Subjects are counted as remaining in the study at last follow-up visit if they have at least one recorded follow-up visit.
Note: The overall compliance rate is the number of subjects with an evaluable baseline form and at least one evaluable post-baseline form. For PGIC score the overall compliance rate is the number of subjects with an evaluable post-baseline form.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t4_comp1_sfty.sas 15MAR2023 05:49

Table 4.117110
Summary of Compliance of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L, FACT-GP5, PGIS and PGIC by Visit

Timepoint		Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 55	# of subjects remaining in study	3	3
	# of subjects with PRO-CTCAE score (%)	3 (100%)	3 (100%)
	# of subjects with OSDI summary score (%)	3 (100%)	3 (100%)
	# of subjects with QLQ-C30 summary score (%)	3 (100%)	3 (100%)
	# of subjects with QLQ-MY20 domain score (%)	3 (100%)	3 (100%)
	# of subjects with QLQ-IL52 domain score (%)	3 (100%)	3 (100%)
	# of subjects with EQ-5D-3L (%)	3 (100%)	3 (100%)
	# of subjects with FACT-GP5 score (%)	3 (100%)	3 (100%)
	# of subjects with PGIS score (%)	3 (100%)	3 (100%)
	# of subjects with PGIC score (%)	3 (100%)	3 (100%)
Week 58	# of subjects remaining in study	2	2
	# of subjects with PRO-CTCAE score (%)	2 (100%)	2 (100%)
	# of subjects with OSDI summary score (%)	2 (100%)	2 (100%)
	# of subjects with QLQ-C30 summary score (%)	2 (100%)	2 (100%)
	# of subjects with QLQ-MY20 domain score (%)	2 (100%)	2 (100%)
	# of subjects with QLQ-IL52 domain score (%)	2 (100%)	2 (100%)
	# of subjects with FACT-GP5 score (%)	2 (100%)	2 (100%)

Note: Percentage is calculated using # of subjects remaining in the study at given timepoint as denominator.
Note: Subjects are counted as remaining in the study at last follow-up visit if they have at least one recorded follow-up visit.
Note: The overall compliance rate is the number of subjects with an evaluable baseline form and at least one evaluable post-baseline form. For PGIC score the overall compliance rate is the number of subjects with an evaluable post-baseline form.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t4_comp1_sfty.sas 15MAR2023 05:49

Table 4.117110
Summary of Compliance of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L, FACT-GP5, PGIS and PGIC by Visit

Timepoint		Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 61	# of subjects remaining in study	2	2
	# of subjects with PRO-CTCAE score (%)	2 (100%)	2 (100%)
	# of subjects with OSDI summary score (%)	2 (100%)	2 (100%)
	# of subjects with QLQ-C30 summary score (%)	2 (100%)	2 (100%)
	# of subjects with QLQ-MY20 domain score (%)	2 (100%)	2 (100%)
	# of subjects with QLQ-IL52 domain score (%)	2 (100%)	2 (100%)
	# of subjects with EQ-5D-3L (%)	2 (100%)	2 (100%)
	# of subjects with FACT-GP5 score (%)	2 (100%)	2 (100%)
	# of subjects with PGIS score (%)	2 (100%)	2 (100%)
	# of subjects with PGIC score (%)	2 (100%)	2 (100%)
Week 64	# of subjects remaining in study	2	2
	# of subjects with PRO-CTCAE score (%)	2 (100%)	2 (100%)
	# of subjects with OSDI summary score (%)	2 (100%)	2 (100%)
	# of subjects with QLQ-C30 summary score (%)	2 (100%)	2 (100%)
	# of subjects with QLQ-MY20 domain score (%)	2 (100%)	2 (100%)
	# of subjects with QLQ-IL52 domain score (%)	2 (100%)	2 (100%)
	# of subjects with FACT-GP5 score (%)	2 (100%)	2 (100%)

Note: Percentage is calculated using # of subjects remaining in the study at given timepoint as denominator.
Note: Subjects are counted as remaining in the study at last follow-up visit if they have at least one recorded follow-up visit.
Note: The overall compliance rate is the number of subjects with an evaluable baseline form and at least one evaluable post-baseline form. For PGIC score the overall compliance rate is the number of subjects with an evaluable post-baseline form.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t4_comp1_sfty.sas 15MAR2023 05:49

Table 4.117110
Summary of Compliance of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L, FACT-GP5, PGIS and PGIC by Visit

Timepoint		Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 67	# of subjects remaining in study	2	2
	# of subjects with PRO-CTCAE score (%)	2 (100%)	2 (100%)
	# of subjects with OSDI summary score (%)	2 (100%)	2 (100%)
	# of subjects with QLQ-C30 summary score (%)	2 (100%)	2 (100%)
	# of subjects with QLQ-MY20 domain score (%)	2 (100%)	2 (100%)
	# of subjects with QLQ-IL52 domain score (%)	2 (100%)	2 (100%)
	# of subjects with EQ-5D-3L (%)	2 (100%)	2 (100%)
	# of subjects with FACT-GP5 score (%)	2 (100%)	2 (100%)
	# of subjects with PGIS score (%)	2 (100%)	2 (100%)
	# of subjects with PGIC score (%)	2 (100%)	2 (100%)
Week 70	# of subjects remaining in study	2	1
	# of subjects with PRO-CTCAE score (%)	2 (100%)	1 (100%)
	# of subjects with OSDI summary score (%)	2 (100%)	1 (100%)
	# of subjects with QLQ-C30 summary score (%)	2 (100%)	1 (100%)
	# of subjects with QLQ-MY20 domain score (%)	2 (100%)	1 (100%)
	# of subjects with QLQ-IL52 domain score (%)	2 (100%)	1 (100%)
	# of subjects with FACT-GP5 score (%)	2 (100%)	1 (100%)

Note: Percentage is calculated using # of subjects remaining in the study at given timepoint as denominator.
Note: Subjects are counted as remaining in the study at last follow-up visit if they have at least one recorded follow-up visit.
Note: The overall compliance rate is the number of subjects with an evaluable baseline form and at least one evaluable post-baseline form. For PGIC score the overall compliance rate is the number of subjects with an evaluable post-baseline form.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t4_comp1_sfty.sas 15MAR2023 05:49

Table 4.117110
Summary of Compliance of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L, FACT-GP5, PGIS and PGIC by Visit

Timepoint		Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 73	# of subjects remaining in study	2	1
	# of subjects with PRO-CTCAE score (%)	1 (50%)	1 (100%)
	# of subjects with OSDI summary score (%)	1 (50%)	1 (100%)
	# of subjects with QLQ-C30 summary score (%)	1 (50%)	1 (100%)
	# of subjects with QLQ-MY20 domain score (%)	1 (50%)	1 (100%)
	# of subjects with QLQ-IL52 domain score (%)	1 (50%)	1 (100%)
	# of subjects with EQ-5D-3L (%)	1 (50%)	1 (100%)
	# of subjects with FACT-GP5 score (%)	1 (50%)	1 (100%)
	# of subjects with PGIS score (%)	1 (50%)	1 (100%)
	# of subjects with PGIC score (%)	1 (50%)	1 (100%)
Week 76	# of subjects remaining in study	2	1
	# of subjects with PRO-CTCAE score (%)	2 (100%)	1 (100%)
	# of subjects with OSDI summary score (%)	2 (100%)	1 (100%)
	# of subjects with QLQ-C30 summary score (%)	2 (100%)	1 (100%)
	# of subjects with QLQ-MY20 domain score (%)	2 (100%)	1 (100%)
	# of subjects with QLQ-IL52 domain score (%)	2 (100%)	1 (100%)
	# of subjects with FACT-GP5 score (%)	2 (100%)	1 (100%)

Note: Percentage is calculated using # of subjects remaining in the study at given timepoint as denominator.
Note: Subjects are counted as remaining in the study at last follow-up visit if they have at least one recorded follow-up visit.
Note: The overall compliance rate is the number of subjects with an evaluable baseline form and at least one evaluable post-baseline form. For PGIC score the overall compliance rate is the number of subjects with an evaluable post-baseline form.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t4_comp1_sfty.sas 15MAR2023 05:49

Table 4.117110
Summary of Compliance of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L, FACT-GP5, PGIS and PGIC by Visit

Timepoint		Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 79	# of subjects remaining in study	2	1
	# of subjects with PRO-CTCAE score (%)	2 (100%)	1 (100%)
	# of subjects with OSDI summary score (%)	2 (100%)	1 (100%)
	# of subjects with QLQ-C30 summary score (%)	2 (100%)	1 (100%)
	# of subjects with QLQ-MY20 domain score (%)	2 (100%)	1 (100%)
	# of subjects with QLQ-IL52 domain score (%)	2 (100%)	1 (100%)
	# of subjects with EQ-5D-3L (%)	2 (100%)	1 (100%)
	# of subjects with FACT-GP5 score (%)	2 (100%)	1 (100%)
	# of subjects with PGIS score (%)	2 (100%)	1 (100%)
	# of subjects with PGIC score (%)	2 (100%)	1 (100%)
Week 82	# of subjects remaining in study	2	1
	# of subjects with PRO-CTCAE score (%)	2 (100%)	1 (100%)
	# of subjects with OSDI summary score (%)	2 (100%)	1 (100%)
	# of subjects with QLQ-C30 summary score (%)	2 (100%)	1 (100%)
	# of subjects with QLQ-MY20 domain score (%)	2 (100%)	1 (100%)
	# of subjects with QLQ-IL52 domain score (%)	2 (100%)	1 (100%)
	# of subjects with FACT-GP5 score (%)	2 (100%)	1 (100%)

Note: Percentage is calculated using # of subjects remaining in the study at given timepoint as denominator.
Note: Subjects are counted as remaining in the study at last follow-up visit if they have at least one recorded follow-up visit.
Note: The overall compliance rate is the number of subjects with an evaluable baseline form and at least one evaluable post-baseline form. For PGIC score the overall compliance rate is the number of subjects with an evaluable post-baseline form.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t4_comp1_sfty.sas 15MAR2023 05:49

Table 4.117110
Summary of Compliance of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L, FACT-GP5, PGIS and PGIC by Visit

Timepoint		Pom/Dex (N=14)		Belantamab mafodotin (N=29)	
Week 85	# of subjects remaining in study	2		1	
	# of subjects with PRO-CTCAE score (%)	1	(50%)	1	(100%)
	# of subjects with OSDI summary score (%)	1	(50%)	1	(100%)
	# of subjects with QLQ-C30 summary score (%)	1	(50%)	1	(100%)
	# of subjects with QLQ-MY20 domain score (%)	1	(50%)	1	(100%)
	# of subjects with QLQ-IL52 domain score (%)	1	(50%)	1	(100%)
	# of subjects with EQ-5D-3L (%)	1	(50%)	1	(100%)
	# of subjects with FACT-GP5 score (%)	1	(50%)	1	(100%)
	# of subjects with PGIS score (%)	1	(50%)	1	(100%)
	# of subjects with PGIC score (%)	1	(50%)	1	(100%)
Week 88	# of subjects remaining in study	2		1	
	# of subjects with PRO-CTCAE score (%)	1	(50%)	1	(100%)
	# of subjects with OSDI summary score (%)	1	(50%)	1	(100%)
	# of subjects with QLQ-C30 summary score (%)	1	(50%)	1	(100%)
	# of subjects with QLQ-MY20 domain score (%)	1	(50%)	1	(100%)
	# of subjects with QLQ-IL52 domain score (%)	1	(50%)	1	(100%)
	# of subjects with FACT-GP5 score (%)	1	(50%)	1	(100%)

Note: Percentage is calculated using # of subjects remaining in the study at given timepoint as denominator.
Note: Subjects are counted as remaining in the study at last follow-up visit if they have at least one recorded follow-up visit.
Note: The overall compliance rate is the number of subjects with an evaluable baseline form and at least one evaluable post-baseline form. For PGIC score the overall compliance rate is the number of subjects with an evaluable post-baseline form.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t4_comp1_sfty.sas 15MAR2023 05:49

Table 4.117110
Summary of Compliance of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L, FACT-GP5, PGIS and PGIC by Visit

Timepoint		Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 91	# of subjects remaining in study	2	1
	# of subjects with PRO-CTCAE score (%)	1 (50%)	1 (100%)
	# of subjects with OSDI summary score (%)	1 (50%)	1 (100%)
	# of subjects with QLQ-C30 summary score (%)	2 (100%)	1 (100%)
	# of subjects with QLQ-MY20 domain score (%)	1 (50%)	1 (100%)
	# of subjects with QLQ-IL52 domain score (%)	1 (50%)	1 (100%)
	# of subjects with EQ-5D-3L (%)	1 (50%)	1 (100%)
	# of subjects with FACT-GP5 score (%)	1 (50%)	1 (100%)
	# of subjects with PGIS score (%)	1 (50%)	1 (100%)
	# of subjects with PGIC score (%)	1 (50%)	1 (100%)
Week 94	# of subjects remaining in study	2	1
	# of subjects with PRO-CTCAE score (%)	2 (100%)	1 (100%)
	# of subjects with OSDI summary score (%)	2 (100%)	1 (100%)
	# of subjects with QLQ-C30 summary score (%)	2 (100%)	1 (100%)
	# of subjects with QLQ-MY20 domain score (%)	2 (100%)	1 (100%)
	# of subjects with QLQ-IL52 domain score (%)	2 (100%)	1 (100%)
	# of subjects with FACT-GP5 score (%)	2 (100%)	1 (100%)

Note: Percentage is calculated using # of subjects remaining in the study at given timepoint as denominator.
Note: Subjects are counted as remaining in the study at last follow-up visit if they have at least one recorded follow-up visit.
Note: The overall compliance rate is the number of subjects with an evaluable baseline form and at least one evaluable post-baseline form. For PGIC score the overall compliance rate is the number of subjects with an evaluable post-baseline form.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t4_comp1_sfty.sas 15MAR2023 05:49

Table 4.117110
Summary of Compliance of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L, FACT-GP5, PGIS and PGIC by Visit

Timepoint		Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 97	# of subjects remaining in study	1	1
	# of subjects with PRO-CTCAE score (%)	1 (100%)	0
	# of subjects with OSDI summary score (%)	1 (100%)	0
	# of subjects with QLQ-C30 summary score (%)	1 (100%)	0
	# of subjects with QLQ-MY20 domain score (%)	1 (100%)	0
	# of subjects with QLQ-IL52 domain score (%)	1 (100%)	0
	# of subjects with EQ-5D-3L (%)	1 (100%)	0
	# of subjects with FACT-GP5 score (%)	1 (100%)	0
	# of subjects with PGIS score (%)	1 (100%)	0
	# of subjects with PGIC score (%)	1 (100%)	0
Week 100	# of subjects remaining in study	1	1
	# of subjects with PRO-CTCAE score (%)	0	1 (100%)
	# of subjects with OSDI summary score (%)	0	1 (100%)
	# of subjects with QLQ-C30 summary score (%)	0	1 (100%)
	# of subjects with QLQ-MY20 domain score (%)	0	1 (100%)
	# of subjects with QLQ-IL52 domain score (%)	0	1 (100%)
	# of subjects with FACT-GP5 score (%)	0	1 (100%)

Note: Percentage is calculated using # of subjects remaining in the study at given timepoint as denominator.
Note: Subjects are counted as remaining in the study at last follow-up visit if they have at least one recorded follow-up visit.
Note: The overall compliance rate is the number of subjects with an evaluable baseline form and at least one evaluable post-baseline form. For PGIC score the overall compliance rate is the number of subjects with an evaluable post-baseline form.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t4_comp1_sfty.sas 15MAR2023 05:49

Table 4.117110
Summary of Compliance of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L, FACT-GP5, PGIS and PGIC by Visit

Timepoint		Pom/Dex (N=14)		Belantamab mafodotin (N=29)	
End of Treatment	# of subjects remaining in study	13		24	
	# of subjects with PRO-CTCAE score (%)	10	(77%)	11	(46%)
	# of subjects with OSDI summary score (%)	9	(69%)	11	(46%)
	# of subjects with QLQ-C30 summary score (%)	10	(77%)	11	(46%)
	# of subjects with QLQ-MY20 domain score (%)	10	(77%)	11	(46%)
	# of subjects with QLQ-IL52 domain score (%)	10	(77%)	11	(46%)
	# of subjects with EQ-5D-3L (%)	10	(77%)	11	(46%)
	# of subjects with FACT-GP5 score (%)	10	(77%)	11	(46%)
	# of subjects with PGIS score (%)	10	(77%)	11	(46%)
	# of subjects with PGIC score (%)	10	(77%)	11	(46%)
Last Follow-up	# of subjects remaining in study	11		23	
	# of subjects with PRO-CTCAE score (%)	0		0	
	# of subjects with OSDI summary score (%)	0		5	(22%)
	# of subjects with QLQ-C30 summary score (%)	3	(27%)	5	(22%)
	# of subjects with QLQ-MY20 domain score (%)	3	(27%)	2	(9%)
	# of subjects with QLQ-IL52 domain score (%)	3	(27%)	2	(9%)
	# of subjects with EQ-5D-3L (%)	3	(27%)	5	(22%)
	# of subjects with FACT-GP5 score (%)	0		0	
	# of subjects with PGIS score (%)	1	(9%)	1	(4%)
	# of subjects with PGIC score (%)	1	(9%)	1	(4%)

Note: Percentage is calculated using # of subjects remaining in the study at given timepoint as denominator.
Note: Subjects are counted as remaining in the study at last follow-up visit if they have at least one recorded follow-up visit.
Note: The overall compliance rate is the number of subjects with an evaluable baseline form and at least one evaluable post-baseline form. For PGIC score the overall compliance rate is the number of subjects with an evaluable post-baseline form.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t4_comp1_sfty.sas 15MAR2023 05:49

Table 4.117110
Summary of Compliance of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L, FACT-GP5, PGIS and PGIC by Visit

Timepoint		Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Overall Compliance	# of subjects with PRO-CTCAE score (%)	12 (86%)	16 (55%)
	# of subjects with OSDI summary score (%)	12 (86%)	23 (79%)
	# of subjects with QLQ-C30 summary score (%)	12 (86%)	25 (86%)
	# of subjects with QLQ-MY20 domain score (%)	12 (86%)	24 (83%)
	# of subjects with QLQ-IL52 domain score (%)	12 (86%)	24 (83%)
	# of subjects with EQ-5D-3L (%)	12 (86%)	19 (66%)
	# of subjects with FACT-GP5 score (%)	12 (86%)	23 (79%)
	# of subjects with PGIS score (%)	12 (86%)	19 (66%)
	# of subjects with PGIC score (%)	13 (93%)	20 (69%)

Note: Percentage is calculated using # of subjects remaining in the study at given timepoint as denominator.
Note: Subjects are counted as remaining in the study at last follow-up visit if they have at least one recorded follow-up visit.
Note: The overall compliance rate is the number of subjects with an evaluable baseline form and at least one evaluable post-baseline form. For PGIC score the overall compliance rate is the number of subjects with an evaluable post-baseline form.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t4_comp1_sfty.sas 15MAR2023 05:49

Table 4.115110
Summary of Compliance of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L, FACT-GP5, PGIS and PGIC by Visit 2

Timepoint		Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Baseline	# of subjects remaining in study	15 (100%)	29 (100%)
	# of subjects with PRO-CTCAE score (%)	13 (87%)	17 (59%)
	# of subjects with OSDI summary score (%)	13 (87%)	25 (86%)
	# of subjects with QLQ-C30 summary score (%)	13 (87%)	27 (93%)
	# of subjects with QLQ-MY20 domain score (%)	13 (87%)	26 (90%)
	# of subjects with QLQ-IL52 domain score (%)	13 (87%)	26 (90%)
	# of subjects with EQ-5D-3L (%)	13 (87%)	25 (86%)
	# of subjects with FACT-GP5 score (%)	13 (87%)	25 (86%)
	# of subjects with PGIS score (%)	13 (87%)	25 (86%)
Week 4	# of subjects remaining in study	13 (87%)	28 (97%)
	# of subjects with PRO-CTCAE score (%)	13 (87%)	22 (76%)
	# of subjects with OSDI summary score (%)	13 (87%)	23 (79%)
	# of subjects with QLQ-C30 summary score (%)	13 (87%)	23 (79%)
	# of subjects with QLQ-MY20 domain score (%)	12 (80%)	23 (79%)
	# of subjects with QLQ-IL52 domain score (%)	12 (80%)	23 (79%)
	# of subjects with FACT-GP5 score (%)	13 (87%)	23 (79%)

Note: Percentage is calculated using the number of subjects in each treatment group as denominator.
Note: Subjects are counted as remaining in the study at last follow-up visit if they have at least one recorded follow-up visit.
Note: The overall compliance rate is the number of subjects with an evaluable baseline form and at least one evaluable post-baseline form. For PGIC score the overall compliance rate is the number of subjects with an evaluable post-baseline form.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t4_comp1_2.sas 07MAR2023 08:00

Table 4.115110
Summary of Compliance of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L, FACT-GP5, PGIS and PGIC by Visit 2

Timepoint		Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 7	# of subjects remaining in study	13 (87%)	21 (72%)
	# of subjects with PRO-CTCAE score (%)	12 (80%)	16 (55%)
	# of subjects with OSDI summary score (%)	12 (80%)	15 (52%)
	# of subjects with QLQ-C30 summary score (%)	12 (80%)	17 (59%)
	# of subjects with QLQ-MY20 domain score (%)	12 (80%)	17 (59%)
	# of subjects with QLQ-IL52 domain score (%)	12 (80%)	17 (59%)
	# of subjects with EQ-5D-3L (%)	12 (80%)	14 (48%)
	# of subjects with FACT-GP5 score (%)	12 (80%)	15 (52%)
	# of subjects with PGIS score (%)	12 (80%)	14 (48%)
	# of subjects with PGIC score (%)	12 (80%)	14 (48%)
Week 10	# of subjects remaining in study	13 (87%)	15 (52%)
	# of subjects with PRO-CTCAE score (%)	13 (87%)	11 (38%)
	# of subjects with OSDI summary score (%)	13 (87%)	12 (41%)
	# of subjects with QLQ-C30 summary score (%)	13 (87%)	12 (41%)
	# of subjects with QLQ-MY20 domain score (%)	13 (87%)	12 (41%)
	# of subjects with QLQ-IL52 domain score (%)	13 (87%)	12 (41%)
	# of subjects with FACT-GP5 score (%)	13 (87%)	12 (41%)

Note: Percentage is calculated using the number of subjects in each treatment group as denominator.
Note: Subjects are counted as remaining in the study at last follow-up visit if they have at least one recorded follow-up visit.
Note: The overall compliance rate is the number of subjects with an evaluable baseline form and at least one evaluable post-baseline form. For PGIC score the overall compliance rate is the number of subjects with an evaluable post-baseline form.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t4_comp1_2.sas 07MAR2023 08:00

Table 4.115110
Summary of Compliance of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L, FACT-GP5, PGIS and PGIC by Visit 2

Timepoint		Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 13	# of subjects remaining in study	13 (87%)	11 (38%)
	# of subjects with PRO-CTCAE score (%)	13 (87%)	9 (31%)
	# of subjects with OSDI summary score (%)	13 (87%)	9 (31%)
	# of subjects with QLQ-C30 summary score (%)	13 (87%)	9 (31%)
	# of subjects with QLQ-MY20 domain score (%)	13 (87%)	9 (31%)
	# of subjects with QLQ-IL52 domain score (%)	13 (87%)	9 (31%)
	# of subjects with EQ-5D-3L (%)	13 (87%)	7 (24%)
	# of subjects with FACT-GP5 score (%)	13 (87%)	9 (31%)
	# of subjects with PGIS score (%)	13 (87%)	7 (24%)
	# of subjects with PGIC score (%)	13 (87%)	7 (24%)
Week 16	# of subjects remaining in study	13 (87%)	10 (34%)
	# of subjects with PRO-CTCAE score (%)	12 (80%)	7 (24%)
	# of subjects with OSDI summary score (%)	12 (80%)	8 (28%)
	# of subjects with QLQ-C30 summary score (%)	12 (80%)	8 (28%)
	# of subjects with QLQ-MY20 domain score (%)	12 (80%)	8 (28%)
	# of subjects with QLQ-IL52 domain score (%)	12 (80%)	8 (28%)
	# of subjects with FACT-GP5 score (%)	12 (80%)	8 (28%)

Note: Percentage is calculated using the number of subjects in each treatment group as denominator.
Note: Subjects are counted as remaining in the study at last follow-up visit if they have at least one recorded follow-up visit.
Note: The overall compliance rate is the number of subjects with an evaluable baseline form and at least one evaluable post-baseline form. For PGIC score the overall compliance rate is the number of subjects with an evaluable post-baseline form.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t4_comp1_2.sas 07MAR2023 08:00

Table 4.115110
Summary of Compliance of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L, FACT-GP5, PGIS and PGIC by Visit 2

Timepoint		Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 19	# of subjects remaining in study	12 (80%)	9 (31%)
	# of subjects with PRO-CTCAE score (%)	12 (80%)	6 (21%)
	# of subjects with OSDI summary score (%)	12 (80%)	7 (24%)
	# of subjects with QLQ-C30 summary score (%)	12 (80%)	7 (24%)
	# of subjects with QLQ-MY20 domain score (%)	12 (80%)	7 (24%)
	# of subjects with QLQ-IL52 domain score (%)	12 (80%)	7 (24%)
	# of subjects with EQ-5D-3L (%)	12 (80%)	7 (24%)
	# of subjects with FACT-GP5 score (%)	12 (80%)	7 (24%)
	# of subjects with PGIS score (%)	12 (80%)	7 (24%)
	# of subjects with PGIC score (%)	12 (80%)	7 (24%)
Week 22	# of subjects remaining in study	10 (67%)	8 (28%)
	# of subjects with PRO-CTCAE score (%)	7 (47%)	6 (21%)
	# of subjects with OSDI summary score (%)	7 (47%)	7 (24%)
	# of subjects with QLQ-C30 summary score (%)	7 (47%)	7 (24%)
	# of subjects with QLQ-MY20 domain score (%)	7 (47%)	7 (24%)
	# of subjects with QLQ-IL52 domain score (%)	7 (47%)	7 (24%)
	# of subjects with FACT-GP5 score (%)	7 (47%)	7 (24%)

Note: Percentage is calculated using the number of subjects in each treatment group as denominator.
Note: Subjects are counted as remaining in the study at last follow-up visit if they have at least one recorded follow-up visit.
Note: The overall compliance rate is the number of subjects with an evaluable baseline form and at least one evaluable post-baseline form. For PGIC score the overall compliance rate is the number of subjects with an evaluable post-baseline form.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t4_comp1_2.sas 07MAR2023 08:00

Table 4.115110
Summary of Compliance of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L, FACT-GP5, PGIS and PGIC by Visit 2

Timepoint		Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 25	# of subjects remaining in study	10 (67%)	7 (24%)
	# of subjects with PRO-CTCAE score (%)	7 (47%)	7 (24%)
	# of subjects with OSDI summary score (%)	7 (47%)	7 (24%)
	# of subjects with QLQ-C30 summary score (%)	7 (47%)	7 (24%)
	# of subjects with QLQ-MY20 domain score (%)	7 (47%)	7 (24%)
	# of subjects with QLQ-IL52 domain score (%)	7 (47%)	7 (24%)
	# of subjects with EQ-5D-3L (%)	6 (40%)	6 (21%)
	# of subjects with FACT-GP5 score (%)	7 (47%)	7 (24%)
	# of subjects with PGIS score (%)	6 (40%)	6 (21%)
	# of subjects with PGIC score (%)	6 (40%)	6 (21%)
Week 28	# of subjects remaining in study	8 (53%)	7 (24%)
	# of subjects with PRO-CTCAE score (%)	7 (47%)	6 (21%)
	# of subjects with OSDI summary score (%)	7 (47%)	6 (21%)
	# of subjects with QLQ-C30 summary score (%)	7 (47%)	6 (21%)
	# of subjects with QLQ-MY20 domain score (%)	7 (47%)	6 (21%)
	# of subjects with QLQ-IL52 domain score (%)	7 (47%)	6 (21%)
	# of subjects with FACT-GP5 score (%)	7 (47%)	6 (21%)

Note: Percentage is calculated using the number of subjects in each treatment group as denominator.
Note: Subjects are counted as remaining in the study at last follow-up visit if they have at least one recorded follow-up visit.
Note: The overall compliance rate is the number of subjects with an evaluable baseline form and at least one evaluable post-baseline form. For PGIC score the overall compliance rate is the number of subjects with an evaluable post-baseline form.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t4_comp1_2.sas 07MAR2023 08:00

Table 4.115110
Summary of Compliance of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L, FACT-GP5, PGIS and PGIC by Visit 2

Timepoint		Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 31	# of subjects remaining in study	7 (47%)	7 (24%)
	# of subjects with PRO-CTCAE score (%)	7 (47%)	6 (21%)
	# of subjects with OSDI summary score (%)	7 (47%)	6 (21%)
	# of subjects with QLQ-C30 summary score (%)	7 (47%)	6 (21%)
	# of subjects with QLQ-MY20 domain score (%)	7 (47%)	6 (21%)
	# of subjects with QLQ-IL52 domain score (%)	7 (47%)	6 (21%)
	# of subjects with EQ-5D-3L (%)	7 (47%)	6 (21%)
	# of subjects with FACT-GP5 score (%)	7 (47%)	6 (21%)
	# of subjects with PGIS score (%)	7 (47%)	6 (21%)
	# of subjects with PGIC score (%)	7 (47%)	6 (21%)
Week 34	# of subjects remaining in study	5 (33%)	7 (24%)
	# of subjects with PRO-CTCAE score (%)	5 (33%)	6 (21%)
	# of subjects with OSDI summary score (%)	5 (33%)	6 (21%)
	# of subjects with QLQ-C30 summary score (%)	5 (33%)	6 (21%)
	# of subjects with QLQ-MY20 domain score (%)	5 (33%)	6 (21%)
	# of subjects with QLQ-IL52 domain score (%)	5 (33%)	6 (21%)
	# of subjects with FACT-GP5 score (%)	5 (33%)	6 (21%)

Note: Percentage is calculated using the number of subjects in each treatment group as denominator.
Note: Subjects are counted as remaining in the study at last follow-up visit if they have at least one recorded follow-up visit.
Note: The overall compliance rate is the number of subjects with an evaluable baseline form and at least one evaluable post-baseline form. For PGIC score the overall compliance rate is the number of subjects with an evaluable post-baseline form.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t4_comp1_2.sas 07MAR2023 08:00

Table 4.115110
Summary of Compliance of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L, FACT-GP5, PGIS and PGIC by Visit 2

Timepoint		Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 37	# of subjects remaining in study	5 (33%)	6 (21%)
	# of subjects with PRO-CTCAE score (%)	4 (27%)	6 (21%)
	# of subjects with OSDI summary score (%)	4 (27%)	6 (21%)
	# of subjects with QLQ-C30 summary score (%)	4 (27%)	6 (21%)
	# of subjects with QLQ-MY20 domain score (%)	4 (27%)	6 (21%)
	# of subjects with QLQ-IL52 domain score (%)	4 (27%)	6 (21%)
	# of subjects with EQ-5D-3L (%)	4 (27%)	6 (21%)
	# of subjects with FACT-GP5 score (%)	4 (27%)	6 (21%)
	# of subjects with PGIS score (%)	4 (27%)	6 (21%)
	# of subjects with PGIC score (%)	4 (27%)	6 (21%)
Week 40	# of subjects remaining in study	5 (33%)	6 (21%)
	# of subjects with PRO-CTCAE score (%)	4 (27%)	5 (17%)
	# of subjects with OSDI summary score (%)	4 (27%)	5 (17%)
	# of subjects with QLQ-C30 summary score (%)	4 (27%)	5 (17%)
	# of subjects with QLQ-MY20 domain score (%)	4 (27%)	5 (17%)
	# of subjects with QLQ-IL52 domain score (%)	4 (27%)	5 (17%)
	# of subjects with FACT-GP5 score (%)	4 (27%)	5 (17%)

Note: Percentage is calculated using the number of subjects in each treatment group as denominator.
Note: Subjects are counted as remaining in the study at last follow-up visit if they have at least one recorded follow-up visit.
Note: The overall compliance rate is the number of subjects with an evaluable baseline form and at least one evaluable post-baseline form. For PGIC score the overall compliance rate is the number of subjects with an evaluable post-baseline form.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t4_comp1_2.sas 07MAR2023 08:00

Table 4.115110
Summary of Compliance of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L, FACT-GP5, PGIS and PGIC by Visit 2

Timepoint		Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 43	# of subjects remaining in study	5 (33%)	5 (17%)
	# of subjects with PRO-CTCAE score (%)	4 (27%)	4 (14%)
	# of subjects with OSDI summary score (%)	4 (27%)	4 (14%)
	# of subjects with QLQ-C30 summary score (%)	4 (27%)	4 (14%)
	# of subjects with QLQ-MY20 domain score (%)	4 (27%)	4 (14%)
	# of subjects with QLQ-IL52 domain score (%)	4 (27%)	4 (14%)
	# of subjects with EQ-5D-3L (%)	4 (27%)	4 (14%)
	# of subjects with FACT-GP5 score (%)	4 (27%)	4 (14%)
	# of subjects with PGIS score (%)	4 (27%)	4 (14%)
	# of subjects with PGIC score (%)	4 (27%)	4 (14%)
Week 46	# of subjects remaining in study	3 (20%)	5 (17%)
	# of subjects with PRO-CTCAE score (%)	3 (20%)	4 (14%)
	# of subjects with OSDI summary score (%)	3 (20%)	4 (14%)
	# of subjects with QLQ-C30 summary score (%)	3 (20%)	4 (14%)
	# of subjects with QLQ-MY20 domain score (%)	3 (20%)	4 (14%)
	# of subjects with QLQ-IL52 domain score (%)	3 (20%)	4 (14%)
	# of subjects with FACT-GP5 score (%)	3 (20%)	4 (14%)

Note: Percentage is calculated using the number of subjects in each treatment group as denominator.
Note: Subjects are counted as remaining in the study at last follow-up visit if they have at least one recorded follow-up visit.
Note: The overall compliance rate is the number of subjects with an evaluable baseline form and at least one evaluable post-baseline form. For PGIC score the overall compliance rate is the number of subjects with an evaluable post-baseline form.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t4_comp1_2.sas 07MAR2023 08:00

Table 4.115110
Summary of Compliance of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L, FACT-GP5, PGIS and PGIC by Visit 2

Timepoint		Pom/Dex (N=15)		Belantamab mafodotin (N=29)	
Week 49	# of subjects remaining in study	3	(20%)	4	(14%)
	# of subjects with PRO-CTCAE score (%)	3	(20%)	4	(14%)
	# of subjects with OSDI summary score (%)	3	(20%)	4	(14%)
	# of subjects with QLQ-C30 summary score (%)	3	(20%)	4	(14%)
	# of subjects with QLQ-MY20 domain score (%)	3	(20%)	4	(14%)
	# of subjects with QLQ-IL52 domain score (%)	3	(20%)	4	(14%)
	# of subjects with EQ-5D-3L (%)	3	(20%)	4	(14%)
	# of subjects with FACT-GP5 score (%)	3	(20%)	4	(14%)
	# of subjects with PGIS score (%)	3	(20%)	4	(14%)
	# of subjects with PGIC score (%)	3	(20%)	4	(14%)
Week 52	# of subjects remaining in study	3	(20%)	4	(14%)
	# of subjects with PRO-CTCAE score (%)	3	(20%)	4	(14%)
	# of subjects with OSDI summary score (%)	3	(20%)	4	(14%)
	# of subjects with QLQ-C30 summary score (%)	3	(20%)	4	(14%)
	# of subjects with QLQ-MY20 domain score (%)	3	(20%)	4	(14%)
	# of subjects with QLQ-IL52 domain score (%)	3	(20%)	4	(14%)
	# of subjects with FACT-GP5 score (%)	3	(20%)	4	(14%)

Note: Percentage is calculated using the number of subjects in each treatment group as denominator.
Note: Subjects are counted as remaining in the study at last follow-up visit if they have at least one recorded follow-up visit.
Note: The overall compliance rate is the number of subjects with an evaluable baseline form and at least one evaluable post-baseline form. For PGIC score the overall compliance rate is the number of subjects with an evaluable post-baseline form.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t4_comp1_2.sas 07MAR2023 08:00

Table 4.115110
Summary of Compliance of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L, FACT-GP5, PGIS and PGIC by Visit 2

Timepoint		Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 55	# of subjects remaining in study	3 (20%)	3 (10%)
	# of subjects with PRO-CTCAE score (%)	3 (20%)	3 (10%)
	# of subjects with OSDI summary score (%)	3 (20%)	3 (10%)
	# of subjects with QLQ-C30 summary score (%)	3 (20%)	3 (10%)
	# of subjects with QLQ-MY20 domain score (%)	3 (20%)	3 (10%)
	# of subjects with QLQ-IL52 domain score (%)	3 (20%)	3 (10%)
	# of subjects with EQ-5D-3L (%)	3 (20%)	3 (10%)
	# of subjects with FACT-GP5 score (%)	3 (20%)	3 (10%)
	# of subjects with PGIS score (%)	3 (20%)	3 (10%)
	# of subjects with PGIC score (%)	3 (20%)	3 (10%)
Week 58	# of subjects remaining in study	2 (13%)	2 (7%)
	# of subjects with PRO-CTCAE score (%)	2 (13%)	2 (7%)
	# of subjects with OSDI summary score (%)	2 (13%)	2 (7%)
	# of subjects with QLQ-C30 summary score (%)	2 (13%)	2 (7%)
	# of subjects with QLQ-MY20 domain score (%)	2 (13%)	2 (7%)
	# of subjects with QLQ-IL52 domain score (%)	2 (13%)	2 (7%)
	# of subjects with FACT-GP5 score (%)	2 (13%)	2 (7%)

Note: Percentage is calculated using the number of subjects in each treatment group as denominator.
Note: Subjects are counted as remaining in the study at last follow-up visit if they have at least one recorded follow-up visit.
Note: The overall compliance rate is the number of subjects with an evaluable baseline form and at least one evaluable post-baseline form. For PGIC score the overall compliance rate is the number of subjects with an evaluable post-baseline form.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t4_comp1_2.sas 07MAR2023 08:00

Table 4.115110
Summary of Compliance of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L, FACT-GP5, PGIS and PGIC by Visit 2

Timepoint		Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 61	# of subjects remaining in study	2 (13%)	2 (7%)
	# of subjects with PRO-CTCAE score (%)	2 (13%)	2 (7%)
	# of subjects with OSDI summary score (%)	2 (13%)	2 (7%)
	# of subjects with QLQ-C30 summary score (%)	2 (13%)	2 (7%)
	# of subjects with QLQ-MY20 domain score (%)	2 (13%)	2 (7%)
	# of subjects with QLQ-IL52 domain score (%)	2 (13%)	2 (7%)
	# of subjects with EQ-5D-3L (%)	2 (13%)	2 (7%)
	# of subjects with FACT-GP5 score (%)	2 (13%)	2 (7%)
	# of subjects with PGIS score (%)	2 (13%)	2 (7%)
	# of subjects with PGIC score (%)	2 (13%)	2 (7%)
Week 64	# of subjects remaining in study	2 (13%)	2 (7%)
	# of subjects with PRO-CTCAE score (%)	2 (13%)	2 (7%)
	# of subjects with OSDI summary score (%)	2 (13%)	2 (7%)
	# of subjects with QLQ-C30 summary score (%)	2 (13%)	2 (7%)
	# of subjects with QLQ-MY20 domain score (%)	2 (13%)	2 (7%)
	# of subjects with QLQ-IL52 domain score (%)	2 (13%)	2 (7%)
	# of subjects with FACT-GP5 score (%)	2 (13%)	2 (7%)

Note: Percentage is calculated using the number of subjects in each treatment group as denominator.
Note: Subjects are counted as remaining in the study at last follow-up visit if they have at least one recorded follow-up visit.
Note: The overall compliance rate is the number of subjects with an evaluable baseline form and at least one evaluable post-baseline form. For PGIC score the overall compliance rate is the number of subjects with an evaluable post-baseline form.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t4_comp1_2.sas 07MAR2023 08:00

Table 4.115110
Summary of Compliance of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L, FACT-GP5, PGIS and PGIC by Visit 2

Timepoint		Pom/Dex (N=15)		Belantamab mafodotin (N=29)	
Week 67	# of subjects remaining in study	2	(13%)	2	(7%)
	# of subjects with PRO-CTCAE score (%)	2	(13%)	2	(7%)
	# of subjects with OSDI summary score (%)	2	(13%)	2	(7%)
	# of subjects with QLQ-C30 summary score (%)	2	(13%)	2	(7%)
	# of subjects with QLQ-MY20 domain score (%)	2	(13%)	2	(7%)
	# of subjects with QLQ-IL52 domain score (%)	2	(13%)	2	(7%)
	# of subjects with EQ-5D-3L (%)	2	(13%)	2	(7%)
	# of subjects with FACT-GP5 score (%)	2	(13%)	2	(7%)
	# of subjects with PGIS score (%)	2	(13%)	2	(7%)
	# of subjects with PGIC score (%)	2	(13%)	2	(7%)
Week 70	# of subjects remaining in study	2	(13%)	1	(3%)
	# of subjects with PRO-CTCAE score (%)	2	(13%)	1	(3%)
	# of subjects with OSDI summary score (%)	2	(13%)	1	(3%)
	# of subjects with QLQ-C30 summary score (%)	2	(13%)	1	(3%)
	# of subjects with QLQ-MY20 domain score (%)	2	(13%)	1	(3%)
	# of subjects with QLQ-IL52 domain score (%)	2	(13%)	1	(3%)
	# of subjects with FACT-GP5 score (%)	2	(13%)	1	(3%)

Note: Percentage is calculated using the number of subjects in each treatment group as denominator.
Note: Subjects are counted as remaining in the study at last follow-up visit if they have at least one recorded follow-up visit.
Note: The overall compliance rate is the number of subjects with an evaluable baseline form and at least one evaluable post-baseline form. For PGIC score the overall compliance rate is the number of subjects with an evaluable post-baseline form.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t4_comp1_2.sas 07MAR2023 08:00

Table 4.115110
Summary of Compliance of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L, FACT-GP5, PGIS and PGIC by Visit 2

Timepoint		Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 73	# of subjects remaining in study	2 (13%)	1 (3%)
	# of subjects with PRO-CTCAE score (%)	1 (7%)	1 (3%)
	# of subjects with OSDI summary score (%)	1 (7%)	1 (3%)
	# of subjects with QLQ-C30 summary score (%)	1 (7%)	1 (3%)
	# of subjects with QLQ-MY20 domain score (%)	1 (7%)	1 (3%)
	# of subjects with QLQ-IL52 domain score (%)	1 (7%)	1 (3%)
	# of subjects with EQ-5D-3L (%)	1 (7%)	1 (3%)
	# of subjects with FACT-GP5 score (%)	1 (7%)	1 (3%)
	# of subjects with PGIS score (%)	1 (7%)	1 (3%)
	# of subjects with PGIC score (%)	1 (7%)	1 (3%)
Week 76	# of subjects remaining in study	2 (13%)	1 (3%)
	# of subjects with PRO-CTCAE score (%)	2 (13%)	1 (3%)
	# of subjects with OSDI summary score (%)	2 (13%)	1 (3%)
	# of subjects with QLQ-C30 summary score (%)	2 (13%)	1 (3%)
	# of subjects with QLQ-MY20 domain score (%)	2 (13%)	1 (3%)
	# of subjects with QLQ-IL52 domain score (%)	2 (13%)	1 (3%)
	# of subjects with FACT-GP5 score (%)	2 (13%)	1 (3%)

Note: Percentage is calculated using the number of subjects in each treatment group as denominator.
Note: Subjects are counted as remaining in the study at last follow-up visit if they have at least one recorded follow-up visit.
Note: The overall compliance rate is the number of subjects with an evaluable baseline form and at least one evaluable post-baseline form. For PGIC score the overall compliance rate is the number of subjects with an evaluable post-baseline form.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t4_comp1_2.sas 07MAR2023 08:00

Table 4.115110
Summary of Compliance of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L, FACT-GP5, PGIS and PGIC by Visit 2

Timepoint		Pom/Dex (N=15)		Belantamab mafodotin (N=29)	
Week 79	# of subjects remaining in study	2	(13%)	1	(3%)
	# of subjects with PRO-CTCAE score (%)	2	(13%)	1	(3%)
	# of subjects with OSDI summary score (%)	2	(13%)	1	(3%)
	# of subjects with QLQ-C30 summary score (%)	2	(13%)	1	(3%)
	# of subjects with QLQ-MY20 domain score (%)	2	(13%)	1	(3%)
	# of subjects with QLQ-IL52 domain score (%)	2	(13%)	1	(3%)
	# of subjects with EQ-5D-3L (%)	2	(13%)	1	(3%)
	# of subjects with FACT-GP5 score (%)	2	(13%)	1	(3%)
	# of subjects with PGIS score (%)	2	(13%)	1	(3%)
	# of subjects with PGIC score (%)	2	(13%)	1	(3%)
Week 82	# of subjects remaining in study	2	(13%)	1	(3%)
	# of subjects with PRO-CTCAE score (%)	2	(13%)	1	(3%)
	# of subjects with OSDI summary score (%)	2	(13%)	1	(3%)
	# of subjects with QLQ-C30 summary score (%)	2	(13%)	1	(3%)
	# of subjects with QLQ-MY20 domain score (%)	2	(13%)	1	(3%)
	# of subjects with QLQ-IL52 domain score (%)	2	(13%)	1	(3%)
	# of subjects with FACT-GP5 score (%)	2	(13%)	1	(3%)

Note: Percentage is calculated using the number of subjects in each treatment group as denominator.
Note: Subjects are counted as remaining in the study at last follow-up visit if they have at least one recorded follow-up visit.
Note: The overall compliance rate is the number of subjects with an evaluable baseline form and at least one evaluable post-baseline form. For PGIC score the overall compliance rate is the number of subjects with an evaluable post-baseline form.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t4_comp1_2.sas 07MAR2023 08:00

Table 4.115110
Summary of Compliance of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L, FACT-GP5, PGIS and PGIC by Visit 2

Timepoint		Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 85	# of subjects remaining in study	2 (13%)	1 (3%)
	# of subjects with PRO-CTCAE score (%)	1 (7%)	1 (3%)
	# of subjects with OSDI summary score (%)	1 (7%)	1 (3%)
	# of subjects with QLQ-C30 summary score (%)	1 (7%)	1 (3%)
	# of subjects with QLQ-MY20 domain score (%)	1 (7%)	1 (3%)
	# of subjects with QLQ-IL52 domain score (%)	1 (7%)	1 (3%)
	# of subjects with EQ-5D-3L (%)	1 (7%)	1 (3%)
	# of subjects with FACT-GP5 score (%)	1 (7%)	1 (3%)
	# of subjects with PGIS score (%)	1 (7%)	1 (3%)
	# of subjects with PGIC score (%)	1 (7%)	1 (3%)
Week 88	# of subjects remaining in study	2 (13%)	1 (3%)
	# of subjects with PRO-CTCAE score (%)	1 (7%)	1 (3%)
	# of subjects with OSDI summary score (%)	1 (7%)	1 (3%)
	# of subjects with QLQ-C30 summary score (%)	1 (7%)	1 (3%)
	# of subjects with QLQ-MY20 domain score (%)	1 (7%)	1 (3%)
	# of subjects with QLQ-IL52 domain score (%)	1 (7%)	1 (3%)
	# of subjects with FACT-GP5 score (%)	1 (7%)	1 (3%)

Note: Percentage is calculated using the number of subjects in each treatment group as denominator.
Note: Subjects are counted as remaining in the study at last follow-up visit if they have at least one recorded follow-up visit.
Note: The overall compliance rate is the number of subjects with an evaluable baseline form and at least one evaluable post-baseline form. For PGIC score the overall compliance rate is the number of subjects with an evaluable post-baseline form.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t4_comp1_2.sas 07MAR2023 08:00

Table 4.115110
Summary of Compliance of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L, FACT-GP5, PGIS and PGIC by Visit 2

Timepoint		Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 91	# of subjects remaining in study	2 (13%)	1 (3%)
	# of subjects with PRO-CTCAE score (%)	1 (7%)	1 (3%)
	# of subjects with OSDI summary score (%)	1 (7%)	1 (3%)
	# of subjects with QLQ-C30 summary score (%)	2 (13%)	1 (3%)
	# of subjects with QLQ-MY20 domain score (%)	1 (7%)	1 (3%)
	# of subjects with QLQ-IL52 domain score (%)	1 (7%)	1 (3%)
	# of subjects with EQ-5D-3L (%)	1 (7%)	1 (3%)
	# of subjects with FACT-GP5 score (%)	1 (7%)	1 (3%)
	# of subjects with PGIS score (%)	1 (7%)	1 (3%)
	# of subjects with PGIC score (%)	1 (7%)	1 (3%)
Week 94	# of subjects remaining in study	2 (13%)	1 (3%)
	# of subjects with PRO-CTCAE score (%)	2 (13%)	1 (3%)
	# of subjects with OSDI summary score (%)	2 (13%)	1 (3%)
	# of subjects with QLQ-C30 summary score (%)	2 (13%)	1 (3%)
	# of subjects with QLQ-MY20 domain score (%)	2 (13%)	1 (3%)
	# of subjects with QLQ-IL52 domain score (%)	2 (13%)	1 (3%)
	# of subjects with FACT-GP5 score (%)	2 (13%)	1 (3%)

Note: Percentage is calculated using the number of subjects in each treatment group as denominator.
Note: Subjects are counted as remaining in the study at last follow-up visit if they have at least one recorded follow-up visit.
Note: The overall compliance rate is the number of subjects with an evaluable baseline form and at least one evaluable post-baseline form. For PGIC score the overall compliance rate is the number of subjects with an evaluable post-baseline form.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t4_comp1_2.sas 07MAR2023 08:00

Table 4.115110
Summary of Compliance of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L, FACT-GP5, PGIS and PGIC by Visit 2

Timepoint		Pom/Dex (N=15)		Belantamab mafodotin (N=29)	
Week 97	# of subjects remaining in study	1	(7%)	1	(3%)
	# of subjects with PRO-CTCAE score (%)	1	(7%)	0	
	# of subjects with OSDI summary score (%)	1	(7%)	0	
	# of subjects with QLQ-C30 summary score (%)	1	(7%)	0	
	# of subjects with QLQ-MY20 domain score (%)	1	(7%)	0	
	# of subjects with QLQ-IL52 domain score (%)	1	(7%)	0	
	# of subjects with EQ-5D-3L (%)	1	(7%)	0	
	# of subjects with FACT-GP5 score (%)	1	(7%)	0	
	# of subjects with PGIS score (%)	1	(7%)	0	
	# of subjects with PGIC score (%)	1	(7%)	0	
Week 100	# of subjects remaining in study	1	(7%)	1	(3%)
	# of subjects with PRO-CTCAE score (%)	0		1	(3%)
	# of subjects with OSDI summary score (%)	0		1	(3%)
	# of subjects with QLQ-C30 summary score (%)	0		1	(3%)
	# of subjects with QLQ-MY20 domain score (%)	0		1	(3%)
	# of subjects with QLQ-IL52 domain score (%)	0		1	(3%)
	# of subjects with FACT-GP5 score (%)	0		1	(3%)

Note: Percentage is calculated using the number of subjects in each treatment group as denominator.
Note: Subjects are counted as remaining in the study at last follow-up visit if they have at least one recorded follow-up visit.
Note: The overall compliance rate is the number of subjects with an evaluable baseline form and at least one evaluable post-baseline form. For PGIC score the overall compliance rate is the number of subjects with an evaluable post-baseline form.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t4_comp1_2.sas 07MAR2023 08:00

Table 4.115110
Summary of Compliance of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L, FACT-GP5, PGIS and PGIC by Visit 2

Timepoint		Pom/Dex (N=15)	Belantamab mafodotin (N=29)
End of Treatment	# of subjects remaining in study	13 (87%)	24 (83%)
	# of subjects with PRO-CTCAE score (%)	10 (67%)	11 (38%)
	# of subjects with OSDI summary score (%)	9 (60%)	11 (38%)
	# of subjects with QLQ-C30 summary score (%)	10 (67%)	11 (38%)
	# of subjects with QLQ-MY20 domain score (%)	10 (67%)	11 (38%)
	# of subjects with QLQ-IL52 domain score (%)	10 (67%)	11 (38%)
	# of subjects with EQ-5D-3L (%)	10 (67%)	11 (38%)
	# of subjects with FACT-GP5 score (%)	10 (67%)	11 (38%)
	# of subjects with PGIS score (%)	10 (67%)	11 (38%)
	# of subjects with PGIC score (%)	10 (67%)	11 (38%)
Last Follow-up	# of subjects remaining in study	11 (73%)	23 (79%)
	# of subjects with PRO-CTCAE score (%)	0	0
	# of subjects with OSDI summary score (%)	0	5 (17%)
	# of subjects with QLQ-C30 summary score (%)	3 (20%)	5 (17%)
	# of subjects with QLQ-MY20 domain score (%)	3 (20%)	2 (7%)
	# of subjects with QLQ-IL52 domain score (%)	3 (20%)	2 (7%)
	# of subjects with EQ-5D-3L (%)	3 (20%)	5 (17%)
	# of subjects with FACT-GP5 score (%)	0	0
	# of subjects with PGIS score (%)	1 (7%)	1 (3%)
	# of subjects with PGIC score (%)	1 (7%)	1 (3%)

Note: Percentage is calculated using the number of subjects in each treatment group as denominator.
Note: Subjects are counted as remaining in the study at last follow-up visit if they have at least one recorded follow-up visit.
Note: The overall compliance rate is the number of subjects with an evaluable baseline form and at least one evaluable post-baseline form. For PGIC score the overall compliance rate is the number of subjects with an evaluable post-baseline form.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t4_comp1_2.sas 07MAR2023 08:00

Table 4.115110
Summary of Compliance of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L, FACT-GP5, PGIS and PGIC by Visit 2

Timepoint		Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Overall Compliance	# of subjects with PRO-CTCAE score (%)	12 (80%)	16 (55%)
	# of subjects with OSDI summary score (%)	12 (80%)	23 (79%)
	# of subjects with QLQ-C30 summary score (%)	12 (80%)	25 (86%)
	# of subjects with QLQ-MY20 domain score (%)	12 (80%)	24 (83%)
	# of subjects with QLQ-IL52 domain score (%)	12 (80%)	24 (83%)
	# of subjects with EQ-5D-3L (%)	12 (80%)	19 (66%)
	# of subjects with FACT-GP5 score (%)	12 (80%)	23 (79%)
	# of subjects with PGIS score (%)	12 (80%)	19 (66%)
	# of subjects with PGIC score (%)	13 (87%)	20 (69%)

Note: Percentage is calculated using the number of subjects in each treatment group as denominator.
Note: Subjects are counted as remaining in the study at last follow-up visit if they have at least one recorded follow-up visit.
Note: The overall compliance rate is the number of subjects with an evaluable baseline form and at least one evaluable post-baseline form. For PGIC score the overall compliance rate is the number of subjects with an evaluable post-baseline form.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t4_comp1_2.sas 07MAR2023 08:00

Table 4.116110
Summary of Compliance of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L, FACT-GP5, PGIS and PGIC by Visit 2

Timepoint		Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Baseline	# of subjects remaining in study	14 (100%)	29 (100%)
	# of subjects with PRO-CTCAE score (%)	13 (93%)	17 (59%)
	# of subjects with OSDI summary score (%)	13 (93%)	25 (86%)
	# of subjects with QLQ-C30 summary score (%)	13 (93%)	27 (93%)
	# of subjects with QLQ-MY20 domain score (%)	13 (93%)	26 (90%)
	# of subjects with QLQ-IL52 domain score (%)	13 (93%)	26 (90%)
	# of subjects with EQ-5D-3L (%)	13 (93%)	25 (86%)
	# of subjects with FACT-GP5 score (%)	13 (93%)	25 (86%)
	# of subjects with PGIS score (%)	13 (93%)	25 (86%)
Week 4	# of subjects remaining in study	13 (93%)	28 (97%)
	# of subjects with PRO-CTCAE score (%)	13 (93%)	22 (76%)
	# of subjects with OSDI summary score (%)	13 (93%)	23 (79%)
	# of subjects with QLQ-C30 summary score (%)	13 (93%)	23 (79%)
	# of subjects with QLQ-MY20 domain score (%)	12 (86%)	23 (79%)
	# of subjects with QLQ-IL52 domain score (%)	12 (86%)	23 (79%)
	# of subjects with FACT-GP5 score (%)	13 (93%)	23 (79%)

Note: Percentage is calculated using the number of subjects in each treatment group as denominator.
Note: Subjects are counted as remaining in the study at last follow-up visit if they have at least one recorded follow-up visit.
Note: The overall compliance rate is the number of subjects with an evaluable baseline form and at least one evaluable post-baseline form. For PGIC score the overall compliance rate is the number of subjects with an evaluable post-baseline form.

Table 4.116110
Summary of Compliance of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L, FACT-GP5, PGIS and PGIC by Visit 2

Timepoint		Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 7	# of subjects remaining in study	13 (93%)	21 (72%)
	# of subjects with PRO-CTCAE score (%)	12 (86%)	16 (55%)
	# of subjects with OSDI summary score (%)	12 (86%)	15 (52%)
	# of subjects with QLQ-C30 summary score (%)	12 (86%)	17 (59%)
	# of subjects with QLQ-MY20 domain score (%)	12 (86%)	17 (59%)
	# of subjects with QLQ-IL52 domain score (%)	12 (86%)	17 (59%)
	# of subjects with EQ-5D-3L (%)	12 (86%)	14 (48%)
	# of subjects with FACT-GP5 score (%)	12 (86%)	15 (52%)
	# of subjects with PGIS score (%)	12 (86%)	14 (48%)
	# of subjects with PGIC score (%)	12 (86%)	14 (48%)
Week 10	# of subjects remaining in study	13 (93%)	15 (52%)
	# of subjects with PRO-CTCAE score (%)	13 (93%)	11 (38%)
	# of subjects with OSDI summary score (%)	13 (93%)	12 (41%)
	# of subjects with QLQ-C30 summary score (%)	13 (93%)	12 (41%)
	# of subjects with QLQ-MY20 domain score (%)	13 (93%)	12 (41%)
	# of subjects with QLQ-IL52 domain score (%)	13 (93%)	12 (41%)
	# of subjects with FACT-GP5 score (%)	13 (93%)	12 (41%)

Note: Percentage is calculated using the number of subjects in each treatment group as denominator.
Note: Subjects are counted as remaining in the study at last follow-up visit if they have at least one recorded follow-up visit.
Note: The overall compliance rate is the number of subjects with an evaluable baseline form and at least one evaluable post-baseline form. For PGIC score the overall compliance rate is the number of subjects with an evaluable post-baseline form.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t4_comp1_saf.sas 07MAR2023 09:18

Table 4.116110
Summary of Compliance of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L, FACT-GP5, PGIS and PGIC by Visit 2

Timepoint		Pom/Dex (N=14)		Belantamab mafodotin (N=29)	
Week 13	# of subjects remaining in study	13	(93%)	11	(38%)
	# of subjects with PRO-CTCAE score (%)	13	(93%)	9	(31%)
	# of subjects with OSDI summary score (%)	13	(93%)	9	(31%)
	# of subjects with QLQ-C30 summary score (%)	13	(93%)	9	(31%)
	# of subjects with QLQ-MY20 domain score (%)	13	(93%)	9	(31%)
	# of subjects with QLQ-IL52 domain score (%)	13	(93%)	9	(31%)
	# of subjects with EQ-5D-3L (%)	13	(93%)	7	(24%)
	# of subjects with FACT-GP5 score (%)	13	(93%)	9	(31%)
	# of subjects with PGIS score (%)	13	(93%)	7	(24%)
	# of subjects with PGIC score (%)	13	(93%)	7	(24%)
Week 16	# of subjects remaining in study	13	(93%)	10	(34%)
	# of subjects with PRO-CTCAE score (%)	12	(86%)	7	(24%)
	# of subjects with OSDI summary score (%)	12	(86%)	8	(28%)
	# of subjects with QLQ-C30 summary score (%)	12	(86%)	8	(28%)
	# of subjects with QLQ-MY20 domain score (%)	12	(86%)	8	(28%)
	# of subjects with QLQ-IL52 domain score (%)	12	(86%)	8	(28%)
	# of subjects with FACT-GP5 score (%)	12	(86%)	8	(28%)

Note: Percentage is calculated using the number of subjects in each treatment group as denominator.
Note: Subjects are counted as remaining in the study at last follow-up visit if they have at least one recorded follow-up visit.
Note: The overall compliance rate is the number of subjects with an evaluable baseline form and at least one evaluable post-baseline form. For PGIC score the overall compliance rate is the number of subjects with an evaluable post-baseline form.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t4_comp1_saf.sas 07MAR2023 09:18

Table 4.116110
Summary of Compliance of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L, FACT-GP5, PGIS and PGIC by Visit 2

Timepoint		Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 19	# of subjects remaining in study	12 (86%)	9 (31%)
	# of subjects with PRO-CTCAE score (%)	12 (86%)	6 (21%)
	# of subjects with OSDI summary score (%)	12 (86%)	7 (24%)
	# of subjects with QLQ-C30 summary score (%)	12 (86%)	7 (24%)
	# of subjects with QLQ-MY20 domain score (%)	12 (86%)	7 (24%)
	# of subjects with QLQ-IL52 domain score (%)	12 (86%)	7 (24%)
	# of subjects with EQ-5D-3L (%)	12 (86%)	7 (24%)
	# of subjects with FACT-GP5 score (%)	12 (86%)	7 (24%)
	# of subjects with PGIS score (%)	12 (86%)	7 (24%)
	# of subjects with PGIC score (%)	12 (86%)	7 (24%)
Week 22	# of subjects remaining in study	10 (71%)	8 (28%)
	# of subjects with PRO-CTCAE score (%)	7 (50%)	6 (21%)
	# of subjects with OSDI summary score (%)	7 (50%)	7 (24%)
	# of subjects with QLQ-C30 summary score (%)	7 (50%)	7 (24%)
	# of subjects with QLQ-MY20 domain score (%)	7 (50%)	7 (24%)
	# of subjects with QLQ-IL52 domain score (%)	7 (50%)	7 (24%)
	# of subjects with FACT-GP5 score (%)	7 (50%)	7 (24%)

Note: Percentage is calculated using the number of subjects in each treatment group as denominator.
Note: Subjects are counted as remaining in the study at last follow-up visit if they have at least one recorded follow-up visit.
Note: The overall compliance rate is the number of subjects with an evaluable baseline form and at least one evaluable post-baseline form. For PGIC score the overall compliance rate is the number of subjects with an evaluable post-baseline form.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t4_comp1_saf.sas 07MAR2023 09:18

Table 4.116110
Summary of Compliance of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L, FACT-GP5, PGIS and PGIC by Visit 2

Timepoint		Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 25	# of subjects remaining in study	10 (71%)	7 (24%)
	# of subjects with PRO-CTCAE score (%)	7 (50%)	7 (24%)
	# of subjects with OSDI summary score (%)	7 (50%)	7 (24%)
	# of subjects with QLQ-C30 summary score (%)	7 (50%)	7 (24%)
	# of subjects with QLQ-MY20 domain score (%)	7 (50%)	7 (24%)
	# of subjects with QLQ-IL52 domain score (%)	7 (50%)	7 (24%)
	# of subjects with EQ-5D-3L (%)	6 (43%)	6 (21%)
	# of subjects with FACT-GP5 score (%)	7 (50%)	7 (24%)
	# of subjects with PGIS score (%)	6 (43%)	6 (21%)
	# of subjects with PGIC score (%)	6 (43%)	6 (21%)
Week 28	# of subjects remaining in study	8 (57%)	7 (24%)
	# of subjects with PRO-CTCAE score (%)	7 (50%)	6 (21%)
	# of subjects with OSDI summary score (%)	7 (50%)	6 (21%)
	# of subjects with QLQ-C30 summary score (%)	7 (50%)	6 (21%)
	# of subjects with QLQ-MY20 domain score (%)	7 (50%)	6 (21%)
	# of subjects with QLQ-IL52 domain score (%)	7 (50%)	6 (21%)
	# of subjects with FACT-GP5 score (%)	7 (50%)	6 (21%)

Note: Percentage is calculated using the number of subjects in each treatment group as denominator.
Note: Subjects are counted as remaining in the study at last follow-up visit if they have at least one recorded follow-up visit.
Note: The overall compliance rate is the number of subjects with an evaluable baseline form and at least one evaluable post-baseline form. For PGIC score the overall compliance rate is the number of subjects with an evaluable post-baseline form.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t4_comp1_saf.sas 07MAR2023 09:18

Table 4.116110
Summary of Compliance of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L, FACT-GP5, PGIS and PGIC by Visit 2

Timepoint		Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 31	# of subjects remaining in study	7 (50%)	7 (24%)
	# of subjects with PRO-CTCAE score (%)	7 (50%)	6 (21%)
	# of subjects with OSDI summary score (%)	7 (50%)	6 (21%)
	# of subjects with QLQ-C30 summary score (%)	7 (50%)	6 (21%)
	# of subjects with QLQ-MY20 domain score (%)	7 (50%)	6 (21%)
	# of subjects with QLQ-IL52 domain score (%)	7 (50%)	6 (21%)
	# of subjects with EQ-5D-3L (%)	7 (50%)	6 (21%)
	# of subjects with FACT-GP5 score (%)	7 (50%)	6 (21%)
	# of subjects with PGIS score (%)	7 (50%)	6 (21%)
	# of subjects with PGIC score (%)	7 (50%)	6 (21%)
Week 34	# of subjects remaining in study	5 (36%)	7 (24%)
	# of subjects with PRO-CTCAE score (%)	5 (36%)	6 (21%)
	# of subjects with OSDI summary score (%)	5 (36%)	6 (21%)
	# of subjects with QLQ-C30 summary score (%)	5 (36%)	6 (21%)
	# of subjects with QLQ-MY20 domain score (%)	5 (36%)	6 (21%)
	# of subjects with QLQ-IL52 domain score (%)	5 (36%)	6 (21%)
	# of subjects with FACT-GP5 score (%)	5 (36%)	6 (21%)

Note: Percentage is calculated using the number of subjects in each treatment group as denominator.
Note: Subjects are counted as remaining in the study at last follow-up visit if they have at least one recorded follow-up visit.
Note: The overall compliance rate is the number of subjects with an evaluable baseline form and at least one evaluable post-baseline form. For PGIC score the overall compliance rate is the number of subjects with an evaluable post-baseline form.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t4_comp1_saf.sas 07MAR2023 09:18

Table 4.116110
Summary of Compliance of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L, FACT-GP5, PGIS and PGIC by Visit 2

Timepoint		Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 37	# of subjects remaining in study	5 (36%)	6 (21%)
	# of subjects with PRO-CTCAE score (%)	4 (29%)	6 (21%)
	# of subjects with OSDI summary score (%)	4 (29%)	6 (21%)
	# of subjects with QLQ-C30 summary score (%)	4 (29%)	6 (21%)
	# of subjects with QLQ-MY20 domain score (%)	4 (29%)	6 (21%)
	# of subjects with QLQ-IL52 domain score (%)	4 (29%)	6 (21%)
	# of subjects with EQ-5D-3L (%)	4 (29%)	6 (21%)
	# of subjects with FACT-GP5 score (%)	4 (29%)	6 (21%)
	# of subjects with PGIS score (%)	4 (29%)	6 (21%)
	# of subjects with PGIC score (%)	4 (29%)	6 (21%)
Week 40	# of subjects remaining in study	5 (36%)	6 (21%)
	# of subjects with PRO-CTCAE score (%)	4 (29%)	5 (17%)
	# of subjects with OSDI summary score (%)	4 (29%)	5 (17%)
	# of subjects with QLQ-C30 summary score (%)	4 (29%)	5 (17%)
	# of subjects with QLQ-MY20 domain score (%)	4 (29%)	5 (17%)
	# of subjects with QLQ-IL52 domain score (%)	4 (29%)	5 (17%)
	# of subjects with FACT-GP5 score (%)	4 (29%)	5 (17%)

Note: Percentage is calculated using the number of subjects in each treatment group as denominator.
Note: Subjects are counted as remaining in the study at last follow-up visit if they have at least one recorded follow-up visit.
Note: The overall compliance rate is the number of subjects with an evaluable baseline form and at least one evaluable post-baseline form. For PGIC score the overall compliance rate is the number of subjects with an evaluable post-baseline form.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t4_comp1_saf.sas 07MAR2023 09:18

Table 4.116110
Summary of Compliance of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L, FACT-GP5, PGIS and PGIC by Visit 2

Timepoint		Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 43	# of subjects remaining in study	5 (36%)	5 (17%)
	# of subjects with PRO-CTCAE score (%)	4 (29%)	4 (14%)
	# of subjects with OSDI summary score (%)	4 (29%)	4 (14%)
	# of subjects with QLQ-C30 summary score (%)	4 (29%)	4 (14%)
	# of subjects with QLQ-MY20 domain score (%)	4 (29%)	4 (14%)
	# of subjects with QLQ-IL52 domain score (%)	4 (29%)	4 (14%)
	# of subjects with EQ-5D-3L (%)	4 (29%)	4 (14%)
	# of subjects with FACT-GP5 score (%)	4 (29%)	4 (14%)
	# of subjects with PGIS score (%)	4 (29%)	4 (14%)
	# of subjects with PGIC score (%)	4 (29%)	4 (14%)
Week 46	# of subjects remaining in study	3 (21%)	5 (17%)
	# of subjects with PRO-CTCAE score (%)	3 (21%)	4 (14%)
	# of subjects with OSDI summary score (%)	3 (21%)	4 (14%)
	# of subjects with QLQ-C30 summary score (%)	3 (21%)	4 (14%)
	# of subjects with QLQ-MY20 domain score (%)	3 (21%)	4 (14%)
	# of subjects with QLQ-IL52 domain score (%)	3 (21%)	4 (14%)
	# of subjects with FACT-GP5 score (%)	3 (21%)	4 (14%)

Note: Percentage is calculated using the number of subjects in each treatment group as denominator.
Note: Subjects are counted as remaining in the study at last follow-up visit if they have at least one recorded follow-up visit.
Note: The overall compliance rate is the number of subjects with an evaluable baseline form and at least one evaluable post-baseline form. For PGIC score the overall compliance rate is the number of subjects with an evaluable post-baseline form.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t4_comp1_saf.sas 07MAR2023 09:18

Table 4.116110
Summary of Compliance of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L, FACT-GP5, PGIS and PGIC by Visit 2

Timepoint		Pom/Dex (N=14)		Belantamab mafodotin (N=29)	
Week 49	# of subjects remaining in study	3	(21%)	4	(14%)
	# of subjects with PRO-CTCAE score (%)	3	(21%)	4	(14%)
	# of subjects with OSDI summary score (%)	3	(21%)	4	(14%)
	# of subjects with QLQ-C30 summary score (%)	3	(21%)	4	(14%)
	# of subjects with QLQ-MY20 domain score (%)	3	(21%)	4	(14%)
	# of subjects with QLQ-IL52 domain score (%)	3	(21%)	4	(14%)
	# of subjects with EQ-5D-3L (%)	3	(21%)	4	(14%)
	# of subjects with FACT-GP5 score (%)	3	(21%)	4	(14%)
	# of subjects with PGIS score (%)	3	(21%)	4	(14%)
	# of subjects with PGIC score (%)	3	(21%)	4	(14%)
Week 52	# of subjects remaining in study	3	(21%)	4	(14%)
	# of subjects with PRO-CTCAE score (%)	3	(21%)	4	(14%)
	# of subjects with OSDI summary score (%)	3	(21%)	4	(14%)
	# of subjects with QLQ-C30 summary score (%)	3	(21%)	4	(14%)
	# of subjects with QLQ-MY20 domain score (%)	3	(21%)	4	(14%)
	# of subjects with QLQ-IL52 domain score (%)	3	(21%)	4	(14%)
	# of subjects with FACT-GP5 score (%)	3	(21%)	4	(14%)

Note: Percentage is calculated using the number of subjects in each treatment group as denominator.
Note: Subjects are counted as remaining in the study at last follow-up visit if they have at least one recorded follow-up visit.
Note: The overall compliance rate is the number of subjects with an evaluable baseline form and at least one evaluable post-baseline form. For PGIC score the overall compliance rate is the number of subjects with an evaluable post-baseline form.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t4_comp1_saf.sas 07MAR2023 09:18

Table 4.116110
Summary of Compliance of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L, FACT-GP5, PGIS and PGIC by Visit 2

Timepoint		Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 55	# of subjects remaining in study	3 (21%)	3 (10%)
	# of subjects with PRO-CTCAE score (%)	3 (21%)	3 (10%)
	# of subjects with OSDI summary score (%)	3 (21%)	3 (10%)
	# of subjects with QLQ-C30 summary score (%)	3 (21%)	3 (10%)
	# of subjects with QLQ-MY20 domain score (%)	3 (21%)	3 (10%)
	# of subjects with QLQ-IL52 domain score (%)	3 (21%)	3 (10%)
	# of subjects with EQ-5D-3L (%)	3 (21%)	3 (10%)
	# of subjects with FACT-GP5 score (%)	3 (21%)	3 (10%)
	# of subjects with PGIS score (%)	3 (21%)	3 (10%)
	# of subjects with PGIC score (%)	3 (21%)	3 (10%)
Week 58	# of subjects remaining in study	2 (14%)	2 (7%)
	# of subjects with PRO-CTCAE score (%)	2 (14%)	2 (7%)
	# of subjects with OSDI summary score (%)	2 (14%)	2 (7%)
	# of subjects with QLQ-C30 summary score (%)	2 (14%)	2 (7%)
	# of subjects with QLQ-MY20 domain score (%)	2 (14%)	2 (7%)
	# of subjects with QLQ-IL52 domain score (%)	2 (14%)	2 (7%)
	# of subjects with FACT-GP5 score (%)	2 (14%)	2 (7%)

Note: Percentage is calculated using the number of subjects in each treatment group as denominator.
Note: Subjects are counted as remaining in the study at last follow-up visit if they have at least one recorded follow-up visit.
Note: The overall compliance rate is the number of subjects with an evaluable baseline form and at least one evaluable post-baseline form. For PGIC score the overall compliance rate is the number of subjects with an evaluable post-baseline form.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t4_comp1_saf.sas 07MAR2023 09:18

Table 4.116110
Summary of Compliance of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L, FACT-GP5, PGIS and PGIC by Visit 2

Timepoint		Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 61	# of subjects remaining in study	2 (14%)	2 (7%)
	# of subjects with PRO-CTCAE score (%)	2 (14%)	2 (7%)
	# of subjects with OSDI summary score (%)	2 (14%)	2 (7%)
	# of subjects with QLQ-C30 summary score (%)	2 (14%)	2 (7%)
	# of subjects with QLQ-MY20 domain score (%)	2 (14%)	2 (7%)
	# of subjects with QLQ-IL52 domain score (%)	2 (14%)	2 (7%)
	# of subjects with EQ-5D-3L (%)	2 (14%)	2 (7%)
	# of subjects with FACT-GP5 score (%)	2 (14%)	2 (7%)
	# of subjects with PGIS score (%)	2 (14%)	2 (7%)
	# of subjects with PGIC score (%)	2 (14%)	2 (7%)
Week 64	# of subjects remaining in study	2 (14%)	2 (7%)
	# of subjects with PRO-CTCAE score (%)	2 (14%)	2 (7%)
	# of subjects with OSDI summary score (%)	2 (14%)	2 (7%)
	# of subjects with QLQ-C30 summary score (%)	2 (14%)	2 (7%)
	# of subjects with QLQ-MY20 domain score (%)	2 (14%)	2 (7%)
	# of subjects with QLQ-IL52 domain score (%)	2 (14%)	2 (7%)
	# of subjects with FACT-GP5 score (%)	2 (14%)	2 (7%)

Note: Percentage is calculated using the number of subjects in each treatment group as denominator.
Note: Subjects are counted as remaining in the study at last follow-up visit if they have at least one recorded follow-up visit.
Note: The overall compliance rate is the number of subjects with an evaluable baseline form and at least one evaluable post-baseline form. For PGIC score the overall compliance rate is the number of subjects with an evaluable post-baseline form.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t4_comp1_saf.sas 07MAR2023 09:18

Table 4.116110
Summary of Compliance of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L, FACT-GP5, PGIS and PGIC by Visit 2

Timepoint		Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 67	# of subjects remaining in study	2 (14%)	2 (7%)
	# of subjects with PRO-CTCAE score (%)	2 (14%)	2 (7%)
	# of subjects with OSDI summary score (%)	2 (14%)	2 (7%)
	# of subjects with QLQ-C30 summary score (%)	2 (14%)	2 (7%)
	# of subjects with QLQ-MY20 domain score (%)	2 (14%)	2 (7%)
	# of subjects with QLQ-IL52 domain score (%)	2 (14%)	2 (7%)
	# of subjects with EQ-5D-3L (%)	2 (14%)	2 (7%)
	# of subjects with FACT-GP5 score (%)	2 (14%)	2 (7%)
	# of subjects with PGIS score (%)	2 (14%)	2 (7%)
	# of subjects with PGIC score (%)	2 (14%)	2 (7%)
Week 70	# of subjects remaining in study	2 (14%)	1 (3%)
	# of subjects with PRO-CTCAE score (%)	2 (14%)	1 (3%)
	# of subjects with OSDI summary score (%)	2 (14%)	1 (3%)
	# of subjects with QLQ-C30 summary score (%)	2 (14%)	1 (3%)
	# of subjects with QLQ-MY20 domain score (%)	2 (14%)	1 (3%)
	# of subjects with QLQ-IL52 domain score (%)	2 (14%)	1 (3%)
	# of subjects with FACT-GP5 score (%)	2 (14%)	1 (3%)

Note: Percentage is calculated using the number of subjects in each treatment group as denominator.
Note: Subjects are counted as remaining in the study at last follow-up visit if they have at least one recorded follow-up visit.
Note: The overall compliance rate is the number of subjects with an evaluable baseline form and at least one evaluable post-baseline form. For PGIC score the overall compliance rate is the number of subjects with an evaluable post-baseline form.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t4_comp1_saf.sas 07MAR2023 09:18

Table 4.116110
Summary of Compliance of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L, FACT-GP5, PGIS and PGIC by Visit 2

Timepoint		Pom/Dex (N=14)		Belantamab mafodotin (N=29)	
Week 73	# of subjects remaining in study	2	(14%)	1	(3%)
	# of subjects with PRO-CTCAE score (%)	1	(7%)	1	(3%)
	# of subjects with OSDI summary score (%)	1	(7%)	1	(3%)
	# of subjects with QLQ-C30 summary score (%)	1	(7%)	1	(3%)
	# of subjects with QLQ-MY20 domain score (%)	1	(7%)	1	(3%)
	# of subjects with QLQ-IL52 domain score (%)	1	(7%)	1	(3%)
	# of subjects with EQ-5D-3L (%)	1	(7%)	1	(3%)
	# of subjects with FACT-GP5 score (%)	1	(7%)	1	(3%)
	# of subjects with PGIS score (%)	1	(7%)	1	(3%)
	# of subjects with PGIC score (%)	1	(7%)	1	(3%)
Week 76	# of subjects remaining in study	2	(14%)	1	(3%)
	# of subjects with PRO-CTCAE score (%)	2	(14%)	1	(3%)
	# of subjects with OSDI summary score (%)	2	(14%)	1	(3%)
	# of subjects with QLQ-C30 summary score (%)	2	(14%)	1	(3%)
	# of subjects with QLQ-MY20 domain score (%)	2	(14%)	1	(3%)
	# of subjects with QLQ-IL52 domain score (%)	2	(14%)	1	(3%)
	# of subjects with FACT-GP5 score (%)	2	(14%)	1	(3%)

Note: Percentage is calculated using the number of subjects in each treatment group as denominator.
Note: Subjects are counted as remaining in the study at last follow-up visit if they have at least one recorded follow-up visit.
Note: The overall compliance rate is the number of subjects with an evaluable baseline form and at least one evaluable post-baseline form. For PGIC score the overall compliance rate is the number of subjects with an evaluable post-baseline form.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t4_comp1_saf.sas 07MAR2023 09:18

Table 4.116110
Summary of Compliance of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L, FACT-GP5, PGIS and PGIC by Visit 2

Timepoint		Pom/Dex (N=14)		Belantamab mafodotin (N=29)	
Week 79	# of subjects remaining in study	2	(14%)	1	(3%)
	# of subjects with PRO-CTCAE score (%)	2	(14%)	1	(3%)
	# of subjects with OSDI summary score (%)	2	(14%)	1	(3%)
	# of subjects with QLQ-C30 summary score (%)	2	(14%)	1	(3%)
	# of subjects with QLQ-MY20 domain score (%)	2	(14%)	1	(3%)
	# of subjects with QLQ-IL52 domain score (%)	2	(14%)	1	(3%)
	# of subjects with EQ-5D-3L (%)	2	(14%)	1	(3%)
	# of subjects with FACT-GP5 score (%)	2	(14%)	1	(3%)
	# of subjects with PGIS score (%)	2	(14%)	1	(3%)
	# of subjects with PGIC score (%)	2	(14%)	1	(3%)
Week 82	# of subjects remaining in study	2	(14%)	1	(3%)
	# of subjects with PRO-CTCAE score (%)	2	(14%)	1	(3%)
	# of subjects with OSDI summary score (%)	2	(14%)	1	(3%)
	# of subjects with QLQ-C30 summary score (%)	2	(14%)	1	(3%)
	# of subjects with QLQ-MY20 domain score (%)	2	(14%)	1	(3%)
	# of subjects with QLQ-IL52 domain score (%)	2	(14%)	1	(3%)
	# of subjects with FACT-GP5 score (%)	2	(14%)	1	(3%)

Note: Percentage is calculated using the number of subjects in each treatment group as denominator.
Note: Subjects are counted as remaining in the study at last follow-up visit if they have at least one recorded follow-up visit.
Note: The overall compliance rate is the number of subjects with an evaluable baseline form and at least one evaluable post-baseline form. For PGIC score the overall compliance rate is the number of subjects with an evaluable post-baseline form.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t4_comp1_saf.sas 07MAR2023 09:18

Table 4.116110
Summary of Compliance of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L, FACT-GP5, PGIS and PGIC by Visit 2

Timepoint		Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 85	# of subjects remaining in study	2 (14%)	1 (3%)
	# of subjects with PRO-CTCAE score (%)	1 (7%)	1 (3%)
	# of subjects with OSDI summary score (%)	1 (7%)	1 (3%)
	# of subjects with QLQ-C30 summary score (%)	1 (7%)	1 (3%)
	# of subjects with QLQ-MY20 domain score (%)	1 (7%)	1 (3%)
	# of subjects with QLQ-IL52 domain score (%)	1 (7%)	1 (3%)
	# of subjects with EQ-5D-3L (%)	1 (7%)	1 (3%)
	# of subjects with FACT-GP5 score (%)	1 (7%)	1 (3%)
	# of subjects with PGIS score (%)	1 (7%)	1 (3%)
	# of subjects with PGIC score (%)	1 (7%)	1 (3%)
Week 88	# of subjects remaining in study	2 (14%)	1 (3%)
	# of subjects with PRO-CTCAE score (%)	1 (7%)	1 (3%)
	# of subjects with OSDI summary score (%)	1 (7%)	1 (3%)
	# of subjects with QLQ-C30 summary score (%)	1 (7%)	1 (3%)
	# of subjects with QLQ-MY20 domain score (%)	1 (7%)	1 (3%)
	# of subjects with QLQ-IL52 domain score (%)	1 (7%)	1 (3%)
	# of subjects with FACT-GP5 score (%)	1 (7%)	1 (3%)

Note: Percentage is calculated using the number of subjects in each treatment group as denominator.
Note: Subjects are counted as remaining in the study at last follow-up visit if they have at least one recorded follow-up visit.
Note: The overall compliance rate is the number of subjects with an evaluable baseline form and at least one evaluable post-baseline form. For PGIC score the overall compliance rate is the number of subjects with an evaluable post-baseline form.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t4_comp1_saf.sas 07MAR2023 09:18

Table 4.116110
Summary of Compliance of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L, FACT-GP5, PGIS and PGIC by Visit 2

Timepoint		Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 91	# of subjects remaining in study	2 (14%)	1 (3%)
	# of subjects with PRO-CTCAE score (%)	1 (7%)	1 (3%)
	# of subjects with OSDI summary score (%)	1 (7%)	1 (3%)
	# of subjects with QLQ-C30 summary score (%)	2 (14%)	1 (3%)
	# of subjects with QLQ-MY20 domain score (%)	1 (7%)	1 (3%)
	# of subjects with QLQ-IL52 domain score (%)	1 (7%)	1 (3%)
	# of subjects with EQ-5D-3L (%)	1 (7%)	1 (3%)
	# of subjects with FACT-GP5 score (%)	1 (7%)	1 (3%)
	# of subjects with PGIS score (%)	1 (7%)	1 (3%)
	# of subjects with PGIC score (%)	1 (7%)	1 (3%)
Week 94	# of subjects remaining in study	2 (14%)	1 (3%)
	# of subjects with PRO-CTCAE score (%)	2 (14%)	1 (3%)
	# of subjects with OSDI summary score (%)	2 (14%)	1 (3%)
	# of subjects with QLQ-C30 summary score (%)	2 (14%)	1 (3%)
	# of subjects with QLQ-MY20 domain score (%)	2 (14%)	1 (3%)
	# of subjects with QLQ-IL52 domain score (%)	2 (14%)	1 (3%)
	# of subjects with FACT-GP5 score (%)	2 (14%)	1 (3%)

Note: Percentage is calculated using the number of subjects in each treatment group as denominator.
Note: Subjects are counted as remaining in the study at last follow-up visit if they have at least one recorded follow-up visit.
Note: The overall compliance rate is the number of subjects with an evaluable baseline form and at least one evaluable post-baseline form. For PGIC score the overall compliance rate is the number of subjects with an evaluable post-baseline form.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t4_comp1_saf.sas 07MAR2023 09:18

Table 4.116110
Summary of Compliance of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L, FACT-GP5, PGIS and PGIC by Visit 2

Timepoint		Pom/Dex (N=14)		Belantamab mafodotin (N=29)	
Week 97	# of subjects remaining in study	1	(7%)	1	(3%)
	# of subjects with PRO-CTCAE score (%)	1	(7%)	0	
	# of subjects with OSDI summary score (%)	1	(7%)	0	
	# of subjects with QLQ-C30 summary score (%)	1	(7%)	0	
	# of subjects with QLQ-MY20 domain score (%)	1	(7%)	0	
	# of subjects with QLQ-IL52 domain score (%)	1	(7%)	0	
	# of subjects with EQ-5D-3L (%)	1	(7%)	0	
	# of subjects with FACT-GP5 score (%)	1	(7%)	0	
	# of subjects with PGIS score (%)	1	(7%)	0	
	# of subjects with PGIC score (%)	1	(7%)	0	
Week 100	# of subjects remaining in study	1	(7%)	1	(3%)
	# of subjects with PRO-CTCAE score (%)	0		1	(3%)
	# of subjects with OSDI summary score (%)	0		1	(3%)
	# of subjects with QLQ-C30 summary score (%)	0		1	(3%)
	# of subjects with QLQ-MY20 domain score (%)	0		1	(3%)
	# of subjects with QLQ-IL52 domain score (%)	0		1	(3%)
	# of subjects with FACT-GP5 score (%)	0		1	(3%)

Note: Percentage is calculated using the number of subjects in each treatment group as denominator.
Note: Subjects are counted as remaining in the study at last follow-up visit if they have at least one recorded follow-up visit.
Note: The overall compliance rate is the number of subjects with an evaluable baseline form and at least one evaluable post-baseline form. For PGIC score the overall compliance rate is the number of subjects with an evaluable post-baseline form.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t4_comp1_saf.sas 07MAR2023 09:18

Table 4.116110
Summary of Compliance of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L, FACT-GP5, PGIS and PGIC by Visit 2

Timepoint		Pom/Dex (N=14)	Belantamab mafodotin (N=29)
End of Treatment	# of subjects remaining in study	13 (93%)	24 (83%)
	# of subjects with PRO-CTCAE score (%)	10 (71%)	11 (38%)
	# of subjects with OSDI summary score (%)	9 (64%)	11 (38%)
	# of subjects with QLQ-C30 summary score (%)	10 (71%)	11 (38%)
	# of subjects with QLQ-MY20 domain score (%)	10 (71%)	11 (38%)
	# of subjects with QLQ-IL52 domain score (%)	10 (71%)	11 (38%)
	# of subjects with EQ-5D-3L (%)	10 (71%)	11 (38%)
	# of subjects with FACT-GP5 score (%)	10 (71%)	11 (38%)
	# of subjects with PGIS score (%)	10 (71%)	11 (38%)
	# of subjects with PGIC score (%)	10 (71%)	11 (38%)
Last Follow-up	# of subjects remaining in study	11 (79%)	23 (79%)
	# of subjects with PRO-CTCAE score (%)	0	0
	# of subjects with OSDI summary score (%)	0	5 (17%)
	# of subjects with QLQ-C30 summary score (%)	3 (21%)	5 (17%)
	# of subjects with QLQ-MY20 domain score (%)	3 (21%)	2 (7%)
	# of subjects with QLQ-IL52 domain score (%)	3 (21%)	2 (7%)
	# of subjects with EQ-5D-3L (%)	3 (21%)	5 (17%)
	# of subjects with FACT-GP5 score (%)	0	0
	# of subjects with PGIS score (%)	1 (7%)	1 (3%)
	# of subjects with PGIC score (%)	1 (7%)	1 (3%)

Note: Percentage is calculated using the number of subjects in each treatment group as denominator.
Note: Subjects are counted as remaining in the study at last follow-up visit if they have at least one recorded follow-up visit.
Note: The overall compliance rate is the number of subjects with an evaluable baseline form and at least one evaluable post-baseline form. For PGIC score the overall compliance rate is the number of subjects with an evaluable post-baseline form.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t4_comp1_saf.sas 07MAR2023 09:18

Table 4.116110
Summary of Compliance of PRO-CTCAE, OSDI, EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-IL52, EQ-5D-3L, FACT-GP5, PGIS and PGIC by Visit 2

Timepoint		Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Overall Compliance	# of subjects with PRO-CTCAE score (%)	12 (86%)	16 (55%)
	# of subjects with OSDI summary score (%)	12 (86%)	23 (79%)
	# of subjects with QLQ-C30 summary score (%)	12 (86%)	25 (86%)
	# of subjects with QLQ-MY20 domain score (%)	12 (86%)	24 (83%)
	# of subjects with QLQ-IL52 domain score (%)	12 (86%)	24 (83%)
	# of subjects with EQ-5D-3L (%)	12 (86%)	19 (66%)
	# of subjects with FACT-GP5 score (%)	12 (86%)	23 (79%)
	# of subjects with PGIS score (%)	12 (86%)	19 (66%)
	# of subjects with PGIC score (%)	13 (93%)	20 (69%)

Note: Percentage is calculated using the number of subjects in each treatment group as denominator.
Note: Subjects are counted as remaining in the study at last follow-up visit if they have at least one recorded follow-up visit.
Note: The overall compliance rate is the number of subjects with an evaluable baseline form and at least one evaluable post-baseline form. For PGIC score the overall compliance rate is the number of subjects with an evaluable post-baseline form.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t4_comp1_saf.sas 07MAR2023 09:18

Table 4.020110
Summary of EQ-5D-3L VAS Value and Change from Baseline by Visit

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Baseline	Actual Score	n	13	25
		Mean	58.2	56.5
		SD	16.73	19.24
		Median	60.0	56.0
		Min.	31	20
		Max.	81	95
Week 4	Actual Score	n	0	1
		Mean		60.0
		SD		
		Median		60.0
		Min.		60
		Max.		60
	Change from Baseline	n	0	1
		Mean		0.0
		SD		
		Median		0.0
		Min.		0
		Max.		0
	Worsening in EQ VAS score >=15 from Baseline	n (%)	0	0
	Improvement in EQ VAS score >=15 from Baseline	n (%)	0	0

Table 4.020110
Summary of EQ-5D-3L VAS Value and Change from Baseline by Visit

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 7	Actual Score	n	12	14
		Mean	58.6	59.1
		SD	21.39	21.71
		Median	55.5	67.0
		Min.	28	18
		Max.	92	90
	Change from Baseline	n	11	13
		Mean	0.6	-1.6
		SD	10.07	14.58
		Median	1.0	-1.0
		Min.	-17	-27
		Max.	16	29
	Worsening in EQ VAS score >=15 from Baseline	n (%)	1 (9%)	3 (23%)
	Improvement in EQ VAS score >=15 from Baseline	n (%)	1 (9%)	1 (8%)

Table 4.020110
Summary of EQ-5D-3L VAS Value and Change from Baseline by Visit

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 10	Actual Score	n	0	2
		Mean		60.5
		SD		27.58
		Median		60.5
		Min.		41
		Max.		80
	Change from Baseline	n	0	2
		Mean		5.0
		SD		21.21
		Median		5.0
		Min.		-10
		Max.		20
	Worsening in EQ VAS score >=15 from Baseline	n (%)	0	0
	Improvement in EQ VAS score >=15 from Baseline	n (%)	0	1 (50%)

Table 4.020110
Summary of EQ-5D-3L VAS Value and Change from Baseline by Visit

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 13	Actual Score	n	13	7
		Mean	56.5	72.3
		SD	23.14	13.23
		Median	58.0	70.0
		Min.	10	49
		Max.	90	88
	Change from Baseline	n	12	7
		Mean	-1.8	5.0
		SD	24.46	9.24
		Median	4.5	2.0
		Min.	-51	-7
		Max.	29	20
	Worsening in EQ VAS score >=15 from Baseline	n (%)	3 (25%)	0
	Improvement in EQ VAS score >=15 from Baseline	n (%)	3 (25%)	1 (14%)

Table 4.020110
Summary of EQ-5D-3L VAS Value and Change from Baseline by Visit

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 16	Actual Score	n	0	1
		Mean		70.0
		SD		
		Median		70.0
		Min.		70
		Max.		70
	Change from Baseline	n	0	1
		Mean		10.0
		SD		
		Median		10.0
		Min.		10
		Max.		10
	Worsening in EQ VAS score >=15 from Baseline	n (%)	0	0
	Improvement in EQ VAS score >=15 from Baseline	n (%)	0	0

Table 4.020110
Summary of EQ-5D-3L VAS Value and Change from Baseline by Visit

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 19	Actual Score	n	12	7
		Mean	70.9	66.9
		SD	17.15	17.81
		Median	78.0	70.0
		Min.	40	38
		Max.	93	90
	Change from Baseline	n	11	7
		Mean	14.0	-2.6
		SD	13.48	13.53
		Median	13.0	0.0
		Min.	-4	-27
		Max.	34	11
	Worsening in EQ VAS score >=15 from Baseline	n (%)	0	1 (14%)
	Improvement in EQ VAS score >=15 from Baseline	n (%)	5 (45%)	0

Table 4.020110
Summary of EQ-5D-3L VAS Value and Change from Baseline by Visit

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 22	Actual Score	n	0	2
		Mean		85.0
		SD		7.07
		Median		85.0
		Min.		80
		Max.		90
	Change from Baseline	n	0	2
		Mean		15.0
		SD		7.07
		Median		15.0
		Min.		10
		Max.		20
	Worsening in EQ VAS score >=15 from Baseline	n (%)	0	0
	Improvement in EQ VAS score >=15 from Baseline	n (%)	0	1 (50%)

Table 4.020110
Summary of EQ-5D-3L VAS Value and Change from Baseline by Visit

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 25	Actual Score	n	6	6
		Mean	65.3	73.2
		SD	23.97	19.47
		Median	73.5	76.5
		Min.	21	50
		Max.	88	95
	Change from Baseline	n	6	5
		Mean	1.5	2.0
		SD	16.98	9.59
		Median	-1.5	0.0
		Min.	-16	-12
		Max.	31	12
	Worsening in EQ VAS score >=15 from Baseline	n (%)	1 (17%)	0
	Improvement in EQ VAS score >=15 from Baseline	n (%)	1 (17%)	0

Table 4.020110
Summary of EQ-5D-3L VAS Value and Change from Baseline by Visit

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 28	Actual Score	n	0	1
		Mean		80.0
		SD		
		Median		80.0
		Min.		80
		Max.		80
	Change from Baseline	n	0	1
		Mean		20.0
		SD		
		Median		20.0
		Min.		20
		Max.		20
	Worsening in EQ VAS score >=15 from Baseline	n (%)	0	0
	Improvement in EQ VAS score >=15 from Baseline	n (%)	0	1 (100%)

Table 4.020110
Summary of EQ-5D-3L VAS Value and Change from Baseline by Visit

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 31	Actual Score	n	7	6
		Mean	74.9	81.7
		SD	11.45	14.43
		Median	79.0	83.5
		Min.	51	58
		Max.	85	100
	Change from Baseline	n	7	6
		Mean	9.3	8.5
		SD	23.86	11.81
		Median	5.0	10.5
		Min.	-22	-5
		Max.	54	20
	Worsening in EQ VAS score >=15 from Baseline	n (%)	1 (14%)	0
	Improvement in EQ VAS score >=15 from Baseline	n (%)	2 (29%)	3 (50%)

Table 4.020110
Summary of EQ-5D-3L VAS Value and Change from Baseline by Visit

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 34	Actual Score	n	0	1
		Mean		80.0
		SD		
		Median		80.0
		Min.		80
		Max.		80
	Change from Baseline	n	0	1
		Mean		20.0
		SD		
		Median		20.0
		Min.		20
		Max.		20
	Worsening in EQ VAS score >=15 from Baseline	n (%)	0	0
	Improvement in EQ VAS score >=15 from Baseline	n (%)	0	1 (100%)

Table 4.020110
Summary of EQ-5D-3L VAS Value and Change from Baseline by Visit

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 37	Actual Score	n	4	6
		Mean	80.3	84.3
		SD	7.80	14.08
		Median	81.0	86.5
		Min.	70	61
		Max.	89	100
	Change from Baseline	n	4	6
		Mean	11.5	11.2
		SD	9.04	12.24
		Median	12.0	9.5
		Min.	0	-2
		Max.	22	30
	Worsening in EQ VAS score >=15 from Baseline	n (%)	0	0
	Improvement in EQ VAS score >=15 from Baseline	n (%)	1 (25%)	2 (33%)

Table 4.020110
Summary of EQ-5D-3L VAS Value and Change from Baseline by Visit

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 43	Actual Score	n	4	4
		Mean	74.8	87.3
		SD	23.87	12.82
		Median	83.0	90.5
		Min.	40	69
		Max.	93	99
	Change from Baseline	n	4	4
		Mean	6.0	10.0
		SD	12.94	7.12
		Median	7.5	8.0
		Min.	-8	4
		Max.	17	20
	Worsening in EQ VAS score >=15 from Baseline	n (%)	0	0
	Improvement in EQ VAS score >=15 from Baseline	n (%)	2 (50%)	1 (25%)

Table 4.020110
Summary of EQ-5D-3L VAS Value and Change from Baseline by Visit

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 49	Actual Score	n	3	4
		Mean	81.3	82.8
		SD	12.66	15.56
		Median	79.0	88.0
		Min.	70	61
		Max.	95	94
	Change from Baseline	n	3	4
		Mean	13.0	5.5
		SD	13.08	8.19
		Median	19.0	5.0
		Min.	-2	-2
		Max.	22	14
	Worsening in EQ VAS score >=15 from Baseline	n (%)	0	0
	Improvement in EQ VAS score >=15 from Baseline	n (%)	2 (67%)	0

Table 4.020110
Summary of EQ-5D-3L VAS Value and Change from Baseline by Visit

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 55	Actual Score	n	3	3
		Mean	81.3	90.3
		SD	10.26	5.03
		Median	84.0	91.0
		Min.	70	85
		Max.	90	95
	Change from Baseline	n	3	3
		Mean	13.0	8.3
		SD	9.54	7.37
		Median	14.0	11.0
		Min.	3	0
		Max.	22	14
	Worsening in EQ VAS score >=15 from Baseline	n (%)	0	0
	Improvement in EQ VAS score >=15 from Baseline	n (%)	1 (33%)	0

Table 4.020110
Summary of EQ-5D-3L VAS Value and Change from Baseline by Visit

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 61	Actual Score	n	2	2
		Mean	54.5	87.0
		SD	4.95	5.66
		Median	54.5	87.0
		Min.	51	83
		Max.	58	91
	Change from Baseline	n	2	2
		Mean	-7.5	4.0
		SD	14.85	11.31
		Median	-7.5	4.0
		Min.	-18	-4
		Max.	3	12
	Worsening in EQ VAS score >=15 from Baseline	n (%)	1 (50%)	0
	Improvement in EQ VAS score >=15 from Baseline	n (%)	0	0

Table 4.020110
Summary of EQ-5D-3L VAS Value and Change from Baseline by Visit

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 67	Actual Score	n	2	2
		Mean	80.0	84.5
		SD	14.14	7.78
		Median	80.0	84.5
		Min.	70	79
		Max.	90	90
	Change from Baseline	n	2	2
		Mean	18.0	1.5
		SD	5.66	9.19
		Median	18.0	1.5
		Min.	14	-5
		Max.	22	8
	Worsening in EQ VAS score >=15 from Baseline	n (%)	0	0
	Improvement in EQ VAS score >=15 from Baseline	n (%)	1 (50%)	0

Table 4.020110
Summary of EQ-5D-3L VAS Value and Change from Baseline by Visit

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 73	Actual Score	n	1	1
		Mean	70.0	93.0
		SD		
		Median	70.0	93.0
		Min.	70	93
		Max.	70	93
	Change from Baseline	n	1	1
		Mean	22.0	-2.0
		SD		
		Median	22.0	-2.0
		Min.	22	-2
		Max.	22	-2
	Worsening in EQ VAS score >=15 from Baseline	n (%)	0	0
	Improvement in EQ VAS score >=15 from Baseline	n (%)	1 (100%)	0

Table 4.020110
Summary of EQ-5D-3L VAS Value and Change from Baseline by Visit

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 79	Actual Score	n	2	1
		Mean	76.5	96.0
		SD	23.33	
		Median	76.5	96.0
		Min.	60	96
		Max.	93	96
	Change from Baseline	n	2	1
		Mean	14.5	1.0
		SD	3.54	
		Median	14.5	1.0
		Min.	12	1
		Max.	17	1
	Worsening in EQ VAS score >=15 from Baseline	n (%)	0	0
	Improvement in EQ VAS score >=15 from Baseline	n (%)	1 (50%)	0

Table 4.020110
Summary of EQ-5D-3L VAS Value and Change from Baseline by Visit

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 85	Actual Score	n	1	1
		Mean	50.0	88.0
		SD		
		Median	50.0	88.0
		Min.	50	88
		Max.	50	88
	Change from Baseline	n	1	1
		Mean	2.0	-7.0
		SD		
		Median	2.0	-7.0
		Min.	2	-7
		Max.	2	-7
	Worsening in EQ VAS score >=15 from Baseline	n (%)	0	0
	Improvement in EQ VAS score >=15 from Baseline	n (%)	0	0

Table 4.020110
Summary of EQ-5D-3L VAS Value and Change from Baseline by Visit

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 91	Actual Score	n	1	1
		Mean	50.0	79.0
		SD		
		Median	50.0	79.0
		Min.	50	79
		Max.	50	79
	Change from Baseline	n	1	1
		Mean	2.0	-16.0
		SD		
		Median	2.0	-16.0
		Min.	2	-16
		Max.	2	-16
	Worsening in EQ VAS score >=15 from Baseline	n (%)	0	1 (100%)
	Improvement in EQ VAS score >=15 from Baseline	n (%)	0	0

Table 4.020110
Summary of EQ-5D-3L VAS Value and Change from Baseline by Visit

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 97	Actual Score	n	1	0
		Mean	80.0	
		SD		
		Median	80.0	
		Min.	80	
		Max.	80	
	Change from Baseline	n	1	0
		Mean	32.0	
		SD		
		Median	32.0	
		Min.	32	
		Max.	32	
	Worsening in EQ VAS score >=15 from Baseline	n (%)	0	0
	Improvement in EQ VAS score >=15 from Baseline	n (%)	1 (100%)	0

Table 4.020110
Summary of EQ-5D-3L VAS Value and Change from Baseline by Visit

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
End of Treatment	Actual Score	n	10	11
		Mean	57.5	46.6
		SD	16.83	25.92
		Median	57.5	39.0
		Min.	30	10
		Max.	81	95
	Change from Baseline	n	9	11
		Mean	1.4	-13.3
		SD	22.53	15.38
		Median	5.0	-15.0
		Min.	-29	-46
		Max.	31	15
	Worsening in EQ VAS score >=15 from Baseline	n (%)	3 (33%)	6 (55%)
	Improvement in EQ VAS score >=15 from Baseline	n (%)	3 (33%)	1 (9%)

Protocol: 207495 Page 24 of 30
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.020110
Summary of EQ-5D-3L VAS Value and Change from Baseline by Visit

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 1	Actual Score	n	3	5
		Mean	55.3	44.6
		SD	27.39	27.58
		Median	50.0	50.0
		Min.	31	0
		Max.	85	74
	Change from Baseline	n	2	5
		Mean	12.0	-10.2
		SD	9.90	14.87
		Median	12.0	-8.0
		Min.	5	-34
		Max.	19	7
	Worsening in EQ VAS score >=15 from Baseline	n (%)	0	1 (20%)
	Improvement in EQ VAS score >=15 from Baseline	n (%)	1 (50%)	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t6_vas.sas 10MAR2023 10:20

Table 4.020110
Summary of EQ-5D-3L VAS Value and Change from Baseline by Visit

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 2	Actual Score	n	3	3
		Mean	53.7	46.0
		SD	14.84	28.21
		Median	50.0	42.0
		Min.	41	20
		Max.	70	76
	Change from Baseline	n	2	3
		Mean	4.5	-8.7
		SD	48.79	5.03
		Median	4.5	-8.0
		Min.	-30	-14
		Max.	39	-4
	Worsening in EQ VAS score >=15 from Baseline	n (%)	1 (50%)	0
	Improvement in EQ VAS score >=15 from Baseline	n (%)	1 (50%)	0

Table 4.020110
Summary of EQ-5D-3L VAS Value and Change from Baseline by Visit

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 4	Actual Score	n	0	2
		Mean		62.5
		SD		17.68
		Median		62.5
		Min.		50
		Max.		75
	Change from Baseline	n	0	2
		Mean		-2.5
		SD		3.54
		Median		-2.5
		Min.		-5
		Max.		0
	Worsening in EQ VAS score >=15 from Baseline	n (%)	0	0
	Improvement in EQ VAS score >=15 from Baseline	n (%)	0	0

Table 4.020110
Summary of EQ-5D-3L VAS Value and Change from Baseline by Visit

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
PFS Follow-Up 2	Actual Score	n	1	1
		Mean	66.0	81.0
		SD		
		Median	66.0	81.0
		Min.	66	81
		Max.	66	81
	Change from Baseline	n	1	1
		Mean	-14.0	1.0
		SD		
		Median	-14.0	1.0
		Min.	-14	1
		Max.	-14	1
	Worsening in EQ VAS score >=15 from Baseline	n (%)	0	0
	Improvement in EQ VAS score >=15 from Baseline	n (%)	0	0

Protocol: 207495 Page 28 of 30
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.020110
Summary of EQ-5D-3L VAS Value and Change from Baseline by Visit

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
PFS Follow-Up 4	Actual Score	n	0	1
		Mean		85.0
		SD		
		Median		85.0
		Min.		85
		Max.		85
	Change from Baseline	n	0	1
		Mean		5.0
		SD		
		Median		5.0
		Min.		5
		Max.		5
	Worsening in EQ VAS score >=15 from Baseline	n (%)	0	0
	Improvement in EQ VAS score >=15 from Baseline	n (%)	0	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t6_vas.sas 10MAR2023 10:20

Table 4.020110
Summary of EQ-5D-3L VAS Value and Change from Baseline by Visit

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Last Follow-up	Actual Score	n	3	5
		Mean	53.7	47.4
		SD	14.84	19.72
		Median	50.0	50.0
		Min.	41	20
		Max.	70	75
	Change from Baseline	n	2	5
		Mean	4.5	-7.4
		SD	48.79	5.27
		Median	4.5	-8.0
		Min.	-30	-14
		Max.	39	0
	Worsening in EQ VAS score >=15 from Baseline	n (%)	1 (50%)	0
	Improvement in EQ VAS score >=15 from Baseline	n (%)	1 (50%)	0

Table 4.020110
Summary of EQ-5D-3L VAS Value and Change from Baseline by Visit

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Worst Case Post-Baseline	Actual Score	n	13	21
		Mean	42.3	49.9
		SD	21.33	23.32
		Median	44.0	50.0
		Min.	10	0
		Max.	78	90
	Change from Baseline	n	12	20
		Mean	-15.6	-10.4
		SD	18.75	16.48
		Median	-11.5	-11.0
		Min.	-51	-46
		Max.	13	29
	Worsening in EQ VAS score >=15 from Baseline	n (%)	5 (42%)	8 (40%)
	Improvement in EQ VAS score >=15 from Baseline	n (%)	0	1 (5%)

Table 4.021110
Analysis of EQ-5D-3L VAS Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: EQ VAS Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 7		
n [1]	12	19
n [2]	11	18
LS Mean (SE)	63.7 (4.74)	57.1 (3.72)
95% C.I.	(53.9, 73.5)	(49.5, 64.7)
LS Mean Change from Baseline (SE)	0.2 (4.74)	-6.4 (3.72)
95% C.I.	(-9.6, 9.9)	(-14.1, 1.2)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-6.6 (5.99)
95% C.I.		(-18.9, 5.7)
Corrected Hedges' g Statistic		-0.41
95% C.I.		(-1.16, 0.35)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_eq_vas.sas 13MAR2023 08:07

Table 4.021110
Analysis of EQ-5D-3L VAS Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: EQ VAS Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 13		
n [1]	12	19
n [2]	12	10
LS Mean (SE)	60.8 (6.62)	64.1 (6.07)
95% C.I.	(46.9, 74.8)	(51.5, 76.8)
LS Mean Change from Baseline (SE)	-2.7 (6.62)	0.6 (6.07)
95% C.I.	(-16.6, 11.3)	(-12.0, 13.2)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		3.3 (8.96)
95% C.I.		(-15.5, 22.1)
Corrected Hedges' g Statistic		0.15
95% C.I.		(-0.69, 0.99)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_eq_vas.sas 13MAR2023 08:07

Table 4.021110
Analysis of EQ-5D-3L VAS Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: EQ VAS Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 19		
n [1]	12	19
n [2]	12	12
LS Mean (SE)	73.6 (5.50)	58.3 (4.92)
95% C.I.	(62.0, 85.2)	(48.1, 68.6)
LS Mean Change from Baseline (SE)	10.1 (5.50)	-5.2 (4.92)
95% C.I.	(-1.5, 21.7)	(-15.4, 5.1)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-15.2 (7.40)
95% C.I.		(-30.7, 0.3)
Corrected Hedges' g Statistic		-0.81
95% C.I.		(-1.65, 0.02)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_eq_vas.sas 13MAR2023 08:07

Table 4.021110
Analysis of EQ-5D-3L VAS Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: EQ VAS Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 25		
n [1]	12	19
n [2]	8	6
LS Mean (SE)	68.1 (6.54)	54.7 (7.47)
95% C.I.	(53.5, 82.6)	(38.5, 70.9)
LS Mean Change from Baseline (SE)	4.6 (6.54)	-8.8 (7.47)
95% C.I.	(-10.0, 19.1)	(-25.0, 7.4)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-13.3 (10.30)
95% C.I.		(-35.8, 9.2)
Corrected Hedges' g Statistic		-0.68
95% C.I.		(-1.77, 0.41)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_eq_vas.sas 13MAR2023 08:07

Table 4.021110
Analysis of EQ-5D-3L VAS Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: EQ VAS Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 31		
n [1]	12	19
n [2]	7	8
LS Mean (SE)	70.5 (6.20)	62.1 (5.41)
95% C.I.	(57.3, 83.6)	(50.8, 73.5)
LS Mean Change from Baseline (SE)	7.0 (6.20)	-1.4 (5.41)
95% C.I.	(-6.2, 20.1)	(-12.8, 10.0)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-8.3 (8.22)
95% C.I.		(-25.7, 9.0)
Corrected Hedges' g Statistic		-0.50
95% C.I.		(-1.53, 0.53)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_eq_vas.sas 13MAR2023 08:07

Table 4.021110
Analysis of EQ-5D-3L VAS Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: EQ VAS Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 37		
n [1]	12	19
n [2]	4	7
LS Mean (SE)	71.8 (6.13)	69.9 (5.39)
95% C.I.	(58.1, 85.5)	(57.9, 81.9)
LS Mean Change from Baseline (SE)	8.3 (6.13)	6.4 (5.39)
95% C.I.	(-5.4, 22.0)	(-5.6, 18.4)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-1.9 (7.68)
95% C.I.		(-19.0, 15.3)
Corrected Hedges' g Statistic		-0.13
95% C.I.		(-1.36, 1.10)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_eq_vas.sas 13MAR2023 08:07

Table 4.021110
Analysis of EQ-5D-3L VAS Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: EQ VAS Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 43		
n [1]	12	19
n [2]	6	4
LS Mean (SE)	61.3 (9.26)	58.2 (10.97)
95% C.I.	(39.7, 82.8)	(33.4, 82.9)
LS Mean Change from Baseline (SE)	-2.3 (9.26)	-5.3 (10.97)
95% C.I.	(-23.8, 19.3)	(-30.1, 19.4)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-3.1 (14.26)
95% C.I.		(-35.6, 29.4)
Corrected Hedges' g Statistic		-0.12
95% C.I.		(-1.39, 1.14)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_eq_vas.sas 13MAR2023 08:07

Table 4.021110
Analysis of EQ-5D-3L VAS Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: EQ VAS Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 49		
n [1]	12	19
n [2]	4	5

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_eq_vas.sas 13MAR2023 08:07

Table 4.021110
Analysis of EQ-5D-3L VAS Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: EQ VAS Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 55		
n [1]	12	19
n [2]	4	4

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_eq_vas.sas 13MAR2023 08:07

Table 4.021110
Analysis of EQ-5D-3L VAS Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: EQ VAS Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 61		
n [1]	12	19
n [2]	3	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_eq_vas.sas 13MAR2023 08:07

Table 4.021110
Analysis of EQ-5D-3L VAS Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: EQ VAS Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 67		
n [1]	12	19
n [2]	2	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_eq_vas.sas 13MAR2023 08:07

Table 4.021110
Analysis of EQ-5D-3L VAS Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: EQ VAS Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 73		
n [1]	12	19
n [2]	2	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_eq_vas.sas 13MAR2023 08:07

Table 4.021110
Analysis of EQ-5D-3L VAS Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: EQ VAS Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 79		
n [1]	12	19
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_eq_vas.sas 13MAR2023 08:07

Table 4.021110
Analysis of EQ-5D-3L VAS Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: EQ VAS Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 85		
n [1]	12	19
n [2]	1	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_eq_vas.sas 13MAR2023 08:07

Table 4.021110
Analysis of EQ-5D-3L VAS Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: EQ VAS Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 91		
n [1]	12	19
n [2]	1	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_eq_vas.sas 13MAR2023 08:07

Table 4.021110
Analysis of EQ-5D-3L VAS Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: EQ VAS Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 97		
n [1]	12	19
n [2]	1	0

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_eq_vas.sas 13MAR2023 08:07

Table 4.021110
Analysis of EQ-5D-3L VAS Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: EQ VAS Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
End of Treatment		
n [1]	12	19
n [2]	9	11
LS Mean (SE)	61.7 (5.27)	54.2 (4.63)
95% C.I.	(50.8, 72.6)	(44.7, 63.7)
LS Mean Change from Baseline (SE)	-1.8 (5.27)	-9.4 (4.63)
95% C.I.	(-12.7, 9.1)	(-18.9, 0.1)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-7.5 (6.96)
95% C.I.		(-21.9, 6.8)
Corrected Hedges' g Statistic		-0.46
95% C.I.		(-1.36, 0.43)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_eq_vas.sas 13MAR2023 08:07

Table 4.021110
Analysis of EQ-5D-3L VAS Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: EQ VAS Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 1		
n [1]	12	19
n [2]	2	5

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_eq_vas.sas 13MAR2023 08:07

Table 4.021110
Analysis of EQ-5D-3L VAS Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: EQ VAS Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 2		
n [1]	12	19
n [2]	2	3

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_eq_vas.sas 13MAR2023 08:07

Table 4.021110
Analysis of EQ-5D-3L VAS Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: EQ VAS Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 4		
n [1]	12	19
n [2]	0	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_eq_vas.sas 13MAR2023 08:07

Table 4.021110
Analysis of EQ-5D-3L VAS Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: EQ VAS Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
PFS Follow-Up 2		
n [1]	12	19
n [2]	1	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_eq_vas.sas 13MAR2023 08:07

Table 4.021110
Analysis of EQ-5D-3L VAS Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: EQ VAS Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
PFS Follow-Up 4		
n [1]	12	19
n [2]	0	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_eq_vas.sas 13MAR2023 08:07

Protocol: 207495 Page 1 of 1
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.080110
Summary of EQ-5D-3L VAS Time to first Improvement
(Up to and including Last Follow-Up)

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Improved (event)	7 (47%)	4 (14%)
Censored, follow-up ended	4 (27%)	14 (48%)
Censored, follow-up ongoing	4 (27%)	11 (38%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	2.9 (1.4, 4.2)	7.0 (1.6, -)
Median (95% CI)	7.0 (2.8, -)	- (6.9, -)
3rd Quartile (95% CI)	- (4.2, -)	- (-, -)
Log-Rank P-value [2]		0.0804
Inverse Hazard Ratio (95% CI) [3]		3.55 (0.80, 15.77)
P-value [3]		0.0964

Note: If a subject has not improved, they are censored at the latest assessment or at randomization if no assessments.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Inverse hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. Inverse hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_vas_tfi.sas 13MAR2023 14:07

Protocol: 207495 Page 1 of 1
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.077110
Summary of EQ-5D-3L VAS Time to first Deterioration 1
(Up to and including Last Follow-Up)

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated or Died (event)	7 (47%)	19 (66%)
Censored, follow-up ended	1 (7%)	0
Censored, follow-up ongoing	7 (47%)	10 (34%)
Event Summary		
Deterioration	5 (33%)	8 (28%)
Death	2 (13%)	11 (38%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	2.9 (1.1, 13.5)	1.4 (1.0, 1.6)
Median (95% CI)	13.5 (2.9, -)	2.1 (1.4, 9.5)
3rd Quartile (95% CI)	13.9 (10.3, -)	18.7 (5.1, 20.7)
Log-Rank P-value [2]		0.6180
Hazard Ratio (95% CI) [3]		1.33 (0.44, 4.04)
P-value [3]		0.6190

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessments.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_vas_tfd1.sas 13MAR2023 14:07

Protocol: 207495 Page 1 of 1
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.078110
Summary of EQ-5D-3L VAS Time to first Deterioration 2
(Up to and including Last Follow-Up)

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated (event)	5 (33%)	8 (28%)
Censored, follow-up ended	3 (20%)	11 (38%)
Censored, follow-up ongoing	7 (47%)	10 (34%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	6.6 (1.4, 13.9)	1.6 (1.4, 20.7)
Median (95% CI)	13.9 (2.9, -)	20.7 (1.6, 20.7)
3rd Quartile (95% CI)	- (13.9, -)	20.7 (-, -)
Log-Rank P-value [2]		0.5966
Hazard Ratio (95% CI) [3]		0.65 (0.13, 3.28)
P-value [3]		0.5993

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessments.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_vas_tfd2.sas 13MAR2023 14:07

Protocol: 207495 Page 1 of 2
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.081110
Summary of EQ-5D-3L VAS Time to permanent Deterioration 1
(Up to and including End of Treatment)

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated or Died (event)	2 (13%)	9 (31%)
Censored, follow-up ended	4 (27%)	7 (24%)
Censored, follow-up ongoing	9 (60%)	13 (45%)
Event Summary		
Deterioration	1 (7%)	0
Death	1 (7%)	9 (31%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (1.1, -)	5.1 (1.0, 9.5)
Median (95% CI)	- (5.6, -)	9.5 (5.1, -)
3rd Quartile (95% CI)	- (-, -)	- (9.5, -)
Log-Rank P-value [2]		0.1558
Hazard Ratio (95% CI) [3]		4.58 (0.48, 43.50)
P-value [3]		0.1847

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd1_vas_eot.sas 14MAR2023 17:28

Protocol: 207495 Page 2 of 2
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.081110
Summary of EQ-5D-3L VAS Time to permanent Deterioration 1
(Up to and including End of Treatment)

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of subsequent visits with confirmation for subjects who permanently deteriorated or died		
n	2	9
0	1 / 2 (50%)	9 / 9 (100%)
1	0 / 2	0 / 9
2	1 / 2 (50%)	0 / 9
3	0 / 2	0 / 9
>=4	0 / 2	0 / 9
Number of subsequent visits with confirmation for subjects who deteriorated towards end of observation period [4]		
n	2	7
0	1 / 2 (50%)	5 / 7 (71%)
1	1 / 2 (50%)	2 / 7 (29%)

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd1_vas_eot.sas 14MAR2023 17:28

Protocol: 207495 Page 1 of 2
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.082110
Summary of EQ-5D-3L VAS Time to permanent Deterioration 2
(Up to and including End of Treatment)

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated (event)	1 (7%)	0
Censored, follow-up ended	5 (33%)	16 (55%)
Censored, follow-up ongoing	9 (60%)	13 (45%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (5.6, -)	- (-, -)
Median (95% CI)	- (5.6, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		-
Hazard Ratio (95% CI) [3]		- (-, -)
P-value [3]		-
Number of subsequent visits with confirmation for subjects who permanently deteriorated		
n	1	0
0	0 / 1	0
1	0 / 1	0
2	1 / 1 (100%)	0
3	0 / 1	0
>=4	0 / 1	0

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd2_vas_eot.sas 14MAR2023 17:29

Protocol: 207495 Page 2 of 2
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.082110
Summary of EQ-5D-3L VAS Time to permanent Deterioration 2
(Up to and including End of Treatment)

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of subsequent visits with confirmation for subjects who deteriorated towards end of observation period [4]		
n	2	8
0	1 / 2 (50%)	6 / 8 (75%)
1	1 / 2 (50%)	2 / 8 (25%)

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd2_vas_eot.sas 14MAR2023 17:29

Protocol: 207495 Page 1 of 2
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.083110
Summary of EQ-5D-3L VAS Time to permanent Deterioration 1
(Up to and including Last Follow-Up)

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated or Died (event)	4 (27%)	16 (55%)
Censored, follow-up ended	2 (13%)	0
Censored, follow-up ongoing	9 (60%)	13 (45%)
Event Summary		
Deterioration	1 (7%)	0
Death	3 (20%)	16 (55%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	8.0 (1.1, -)	2.9 (1.0, 5.5)
Median (95% CI)	- (5.6, -)	5.7 (4.9, 18.7)
3rd Quartile (95% CI)	- (13.5, -)	18.7 (6.6, -)
Log-Rank P-value [2]		0.0864
Hazard Ratio (95% CI) [3]		3.69 (0.76, 17.85)
P-value [3]		0.1046

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd1_vas_lf.sas 14MAR2023 17:30

Protocol: 207495 Page 2 of 2
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.083110
Summary of EQ-5D-3L VAS Time to permanent Deterioration 1
(Up to and including Last Follow-Up)

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of subsequent visits with confirmation for subjects who permanently deteriorated or died		
n	4	16
0	3 / 4 (75%)	16 / 16 (100%)
1	0 / 4	0 / 16
2	1 / 4 (25%)	0 / 16
3	0 / 4	0 / 16
>=4	0 / 4	0 / 16
Number of subsequent visits with confirmation for subjects who deteriorated towards end of observation period [4]		
n	1	1
0	1 / 1 (100%)	1 / 1 (100%)
1	0 / 1	0 / 1

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd1_vas_lf.sas 14MAR2023 17:30

Protocol: 207495 Page 1 of 2
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.084110
Summary of EQ-5D-3L VAS Time to permanent Deterioration 2
(Up to and including Last Follow-Up)

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated (event)	1 (7%)	0
Censored, follow-up ended	5 (33%)	16 (55%)
Censored, follow-up ongoing	9 (60%)	13 (45%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (5.6, -)	- (-, -)
Median (95% CI)	- (5.6, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		-
Hazard Ratio (95% CI) [3]		- (-, -)
P-value [3]		-
Number of subsequent visits with confirmation for subjects who permanently deteriorated		
n	1	0
0	0 / 1	0
1	0 / 1	0
2	1 / 1 (100%)	0
3	0 / 1	0
>=4	0 / 1	0

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd2_vas_lf.sas 14MAR2023 17:30

Protocol: 207495 Page 2 of 2
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.084110
Summary of EQ-5D-3L VAS Time to permanent Deterioration 2
(Up to and including Last Follow-Up)

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of subsequent visits with confirmation for subjects who deteriorated towards end of observation period [4]		
n	2	4
0	1 / 2 (50%)	4 / 4 (100%)
1	1 / 2 (50%)	0 / 4

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd2_vas_lf.sas 14MAR2023 17:30

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Global Health Status Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Baseline	Actual Score	n	13	27
		Mean	59.62	51.85
		SD	21.204	25.772
		Median	58.33	50.00
		Min.	33.3	8.3
		Max.	100.0	100.0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Global Health Status Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 4	Actual Score	n	13	23
		Mean	54.49	51.09
		SD	27.975	26.980
		Median	66.67	50.00
		Min.	8.3	0.0
		Max.	91.7	100.0
	Change from Baseline	n	12	23
		Mean	-2.78	-3.99
		SD	25.950	21.301
		Median	4.17	0.00
		Min.	-66.7	-41.7
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	6 (50%)	8 (35%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (25%)	7 (30%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	4 (33%)	10 (43%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	4 (33%)	8 (35%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Global Health Status Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 7	Actual Score	n	12	17
		Mean	62.50	59.31
		SD	23.969	27.145
		Median	58.33	66.67
		Min.	33.3	16.7
		Max.	100.0	100.0
	Change from Baseline	n	11	17
		Mean	1.52	1.96
		SD	23.517	14.887
		Median	0.00	0.00
		Min.	-33.3	-16.7
		Max.	50.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (36%)	5 (29%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (18%)	3 (18%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	5 (45%)	4 (24%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	3 (27%)	4 (24%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Global Health Status Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 10	Actual Score	n	13	12
		Mean	63.46	61.81
		SD	19.702	31.474
		Median	66.67	58.33
		Min.	16.7	16.7
		Max.	91.7	100.0
	Change from Baseline	n	12	12
		Mean	6.25	2.08
		SD	18.844	17.087
		Median	8.33	0.00
		Min.	-25.0	-25.0
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	7 (58%)	4 (33%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	5 (42%)	4 (33%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	3 (25%)	3 (25%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	3 (25%)	2 (17%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Global Health Status Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 13	Actual Score	n	13	9
		Mean	53.21	67.59
		SD	23.209	20.175
		Median	50.00	75.00
		Min.	25.0	33.3
		Max.	91.7	91.7
	Change from Baseline	n	12	9
		Mean	-7.64	-0.93
		SD	29.827	21.828
		Median	-4.17	0.00
		Min.	-58.3	-33.3
		Max.	50.0	41.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (25%)	3 (33%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (25%)	2 (22%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	6 (50%)	4 (44%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	5 (42%)	3 (33%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Global Health Status Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 16	Actual Score	n	12	8
		Mean	60.42	59.38
		SD	19.177	29.357
		Median	54.17	66.67
		Min.	33.3	8.3
		Max.	91.7	91.7
	Change from Baseline	n	11	8
		Mean	-2.27	-13.54
		SD	22.077	34.485
		Median	0.00	-12.50
		Min.	-33.3	-75.0
		Max.	50.0	41.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (27%)	2 (25%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (9%)	1 (13%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	4 (36%)	5 (63%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	4 (36%)	4 (50%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Global Health Status Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 19	Actual Score	n	12	7
		Mean	61.11	65.48
		SD	24.187	19.501
		Median	66.67	66.67
		Min.	16.7	33.3
		Max.	91.7	83.3
	Change from Baseline	n	11	7
		Mean	-1.52	-5.95
		SD	29.538	17.817
		Median	0.00	-8.33
		Min.	-50.0	-33.3
		Max.	50.0	25.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	5 (45%)	1 (14%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	4 (36%)	1 (14%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	4 (36%)	4 (57%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	3 (27%)	2 (29%)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_c30_dom.sas 10MAR2023 10:38

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Global Health Status Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 22	Actual Score	n	7	7
		Mean	63.10	76.19
		SD	21.973	16.265
		Median	66.67	83.33
		Min.	25.0	50.0
		Max.	91.7	100.0
	Change from Baseline	n	7	7
		Mean	-3.57	-3.57
		SD	27.995	20.331
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	50.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (14%)	1 (14%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (14%)	1 (14%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	3 (43%)	3 (43%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	2 (29%)	2 (29%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Global Health Status Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 25	Actual Score	n	7	7
		Mean	59.52	75.00
		SD	20.086	18.634
		Median	66.67	83.33
		Min.	25.0	50.0
		Max.	83.3	100.0
	Change from Baseline	n	7	7
		Mean	-14.29	4.76
		SD	20.813	24.465
		Median	-8.33	0.00
		Min.	-58.3	-25.0
		Max.	0.0	41.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	2 (29%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	2 (29%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	4 (57%)	2 (29%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	3 (43%)	2 (29%)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_c30_dom.sas 10MAR2023 10:38

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Global Health Status Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 28	Actual Score	n	7	6
		Mean	63.10	77.78
		SD	24.465	13.608
		Median	66.67	75.00
		Min.	33.3	66.7
		Max.	91.7	100.0
	Change from Baseline	n	7	6
		Mean	-10.71	-1.39
		SD	22.420	18.572
		Median	-8.33	-4.17
		Min.	-50.0	-16.7
		Max.	16.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (29%)	1 (17%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (14%)	1 (17%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	4 (57%)	3 (50%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	3 (43%)	2 (33%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Global Health Status Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 31	Actual Score	n	7	6
		Mean	58.33	83.33
		SD	21.517	14.907
		Median	66.67	83.33
		Min.	25.0	66.7
		Max.	83.3	100.0
	Change from Baseline	n	7	6
		Mean	-15.48	4.17
		SD	23.780	14.672
		Median	-8.33	0.00
		Min.	-50.0	-8.3
		Max.	16.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (14%)	1 (17%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (14%)	1 (17%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	4 (57%)	1 (17%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	3 (43%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Global Health Status Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 34	Actual Score	n	5	6
		Mean	76.67	84.72
		SD	9.129	16.173
		Median	83.33	87.50
		Min.	66.7	58.3
		Max.	83.3	100.0
	Change from Baseline	n	5	6
		Mean	1.67	5.56
		SD	20.750	19.484
		Median	8.33	0.00
		Min.	-33.3	-16.7
		Max.	16.7	41.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (60%)	2 (33%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (40%)	1 (17%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (20%)	1 (17%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (20%)	1 (17%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Global Health Status Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 37	Actual Score	n	4	6
		Mean	68.75	84.72
		SD	29.167	18.572
		Median	83.33	91.67
		Min.	25.0	58.3
		Max.	83.3	100.0
	Change from Baseline	n	4	6
		Mean	-8.33	5.56
		SD	21.517	17.213
		Median	-8.33	0.00
		Min.	-33.3	-16.7
		Max.	16.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (25%)	2 (33%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (25%)	2 (33%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	2 (50%)	1 (17%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	2 (50%)	1 (17%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Global Health Status Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 40	Actual Score	n	4	5
		Mean	64.58	80.00
		SD	21.916	18.257
		Median	66.67	66.67
		Min.	41.7	66.7
		Max.	83.3	100.0
	Change from Baseline	n	4	5
		Mean	-12.50	1.67
		SD	24.056	19.003
		Median	-12.50	0.00
		Min.	-41.7	-16.7
		Max.	16.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (25%)	1 (20%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (25%)	1 (20%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	3 (75%)	2 (40%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	2 (50%)	1 (20%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Global Health Status Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 43	Actual Score	n	4	4
		Mean	68.75	83.33
		SD	25.797	20.412
		Median	75.00	87.50
		Min.	33.3	58.3
		Max.	91.7	100.0
	Change from Baseline	n	4	4
		Mean	-8.33	6.25
		SD	24.533	24.884
		Median	-8.33	0.00
		Min.	-33.3	-16.7
		Max.	16.7	41.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (50%)	1 (25%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (25%)	1 (25%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	2 (50%)	1 (25%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	2 (50%)	1 (25%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Global Health Status Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 46	Actual Score	n	3	4
		Mean	77.78	85.42
		SD	25.459	19.691
		Median	83.33	91.67
		Min.	50.0	58.3
		Max.	100.0	100.0
	Change from Baseline	n	3	4
		Mean	-2.78	8.33
		SD	17.347	28.868
		Median	-8.33	0.00
		Min.	-16.7	-16.7
		Max.	16.7	50.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (33%)	1 (25%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (33%)	1 (25%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	2 (67%)	1 (25%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (33%)	1 (25%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Global Health Status Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 49	Actual Score	n	3	4
		Mean	80.56	81.25
		SD	12.729	21.916
		Median	83.33	83.33
		Min.	66.7	58.3
		Max.	91.7	100.0
	Change from Baseline	n	3	4
		Mean	0.00	4.17
		SD	14.434	20.972
		Median	8.33	0.00
		Min.	-16.7	-16.7
		Max.	8.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (67%)	1 (25%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (25%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (33%)	1 (25%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (33%)	1 (25%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Global Health Status Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 52	Actual Score	n	3	4
		Mean	80.56	87.50
		SD	12.729	15.957
		Median	83.33	91.67
		Min.	66.7	66.7
		Max.	91.7	100.0
	Change from Baseline	n	3	4
		Mean	0.00	10.42
		SD	14.434	26.680
		Median	8.33	0.00
		Min.	-16.7	-8.3
		Max.	8.3	50.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (67%)	1 (25%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (25%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (33%)	1 (25%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (33%)	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_c30_dom.sas 10MAR2023 10:38

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Global Health Status Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 55	Actual Score	n	3	3
		Mean	72.22	88.89
		SD	19.245	19.245
		Median	83.33	100.00
		Min.	50.0	66.7
		Max.	83.3	100.0
	Change from Baseline	n	3	3
		Mean	-8.33	11.11
		SD	8.333	19.245
		Median	-8.33	0.00
		Min.	-16.7	0.0
		Max.	0.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (33%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (33%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	2 (67%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (33%)	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_c30_dom.sas 10MAR2023 10:38

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Global Health Status Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 58	Actual Score	n	2	2
		Mean	66.67	83.33
		SD	23.570	23.570
		Median	66.67	83.33
		Min.	50.0	66.7
		Max.	83.3	100.0
	Change from Baseline	n	2	2
		Mean	-4.17	16.67
		SD	5.893	23.570
		Median	-4.17	16.67
		Min.	-8.3	0.0
		Max.	0.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (50%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Global Health Status Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 61	Actual Score	n	2	2
		Mean	33.33	83.33
		SD	11.785	23.570
		Median	33.33	83.33
		Min.	25.0	66.7
		Max.	41.7	100.0
	Change from Baseline	n	2	2
		Mean	-37.50	16.67
		SD	29.463	23.570
		Median	-37.50	16.67
		Min.	-58.3	0.0
		Max.	-16.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (50%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	2 (100%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	2 (100%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Global Health Status Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 64	Actual Score	n	2	2
		Mean	62.50	87.50
		SD	29.463	17.678
		Median	62.50	87.50
		Min.	41.7	75.0
		Max.	83.3	100.0
	Change from Baseline	n	2	2
		Mean	-8.33	20.83
		SD	11.785	29.463
		Median	-8.33	20.83
		Min.	-16.7	0.0
		Max.	0.0	41.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (50%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_c30_dom.sas 10MAR2023 10:38

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Global Health Status Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 67	Actual Score	n	2	2
		Mean	79.17	87.50
		SD	17.678	17.678
		Median	79.17	87.50
		Min.	66.7	75.0
		Max.	91.7	100.0
	Change from Baseline	n	2	2
		Mean	8.33	20.83
		SD	0.000	29.463
		Median	8.33	20.83
		Min.	8.3	0.0
		Max.	8.3	41.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (100%)	1 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (50%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_c30_dom.sas 10MAR2023 10:38

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Global Health Status Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 70	Actual Score	n	2	1
		Mean	75.00	100.00
		SD	23.570	
		Median	75.00	100.00
		Min.	58.3	100.0
		Max.	91.7	100.0
	Change from Baseline	n	2	1
		Mean	4.17	0.00
		SD	5.893	
		Median	4.17	0.00
		Min.	0.0	0.0
		Max.	8.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Global Health Status Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 73	Actual Score	n	1	1
		Mean	33.33	100.00
		SD		
		Median	33.33	100.00
		Min.	33.3	100.0
		Max.	33.3	100.0
	Change from Baseline	n	1	1
		Mean	-25.00	0.00
		SD		
		Median	-25.00	0.00
		Min.	-25.0	0.0
		Max.	-25.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (100%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (100%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Global Health Status Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 76	Actual Score	n	2	1
		Mean	66.67	100.00
		SD	0.000	
		Median	66.67	100.00
		Min.	66.7	100.0
		Max.	66.7	100.0
	Change from Baseline	n	2	1
		Mean	-4.17	0.00
		SD	17.678	
		Median	-4.17	0.00
		Min.	-16.7	0.0
		Max.	8.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Global Health Status Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 79	Actual Score	n	2	1
		Mean	75.00	100.00
		SD	11.785	
		Median	75.00	100.00
		Min.	66.7	100.0
		Max.	83.3	100.0
	Change from Baseline	n	2	1
		Mean	4.17	0.00
		SD	5.893	
		Median	4.17	0.00
		Min.	0.0	0.0
		Max.	8.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Global Health Status Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 82	Actual Score	n	2	1
		Mean	75.00	100.00
		SD	11.785	
		Median	75.00	100.00
		Min.	66.7	100.0
		Max.	83.3	100.0
	Change from Baseline	n	2	1
		Mean	4.17	0.00
		SD	5.893	
		Median	4.17	0.00
		Min.	0.0	0.0
		Max.	8.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Global Health Status Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 85	Actual Score	n	1	1
		Mean	33.33	66.67
		SD		
		Median	33.33	66.67
		Min.	33.3	66.7
		Max.	33.3	66.7
	Change from Baseline	n	1	1
		Mean	-25.00	-33.33
		SD		
		Median	-25.00	-33.33
		Min.	-25.0	-33.3
		Max.	-25.0	-33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (100%)	1 (100%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (100%)	1 (100%)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_c30_dom.sas 10MAR2023 10:38

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Global Health Status Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 88	Actual Score	n	1	1
		Mean	83.33	100.00
		SD		
		Median	83.33	100.00
		Min.	83.3	100.0
		Max.	83.3	100.0
	Change from Baseline	n	1	1
		Mean	0.00	0.00
		SD		
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Global Health Status Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 91	Actual Score	n	2	1
		Mean	54.17	83.33
		SD	53.033	
		Median	54.17	83.33
		Min.	16.7	83.3
		Max.	91.7	83.3
	Change from Baseline	n	2	1
		Mean	-16.67	-16.67
		SD	35.355	
		Median	-16.67	-16.67
		Min.	-41.7	-16.7
		Max.	8.3	-16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	1 (100%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	1 (100%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Global Health Status Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 94	Actual Score	n	2	1
		Mean	62.50	100.00
		SD	41.248	
		Median	62.50	100.00
		Min.	33.3	100.0
		Max.	91.7	100.0
	Change from Baseline	n	2	1
		Mean	-8.33	0.00
		SD	23.570	
		Median	-8.33	0.00
		Min.	-25.0	0.0
		Max.	8.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Global Health Status Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 97	Actual Score	n	1	0
		Mean	41.67	
		SD		
		Median	41.67	
		Min.	41.7	
		Max.	41.7	
	Change from Baseline	n	1	0
		Mean	-16.67	
		SD		
		Median	-16.67	
		Min.	-16.7	
		Max.	-16.7	
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (100%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (100%)	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_c30_dom.sas 10MAR2023 10:38

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Global Health Status Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 100	Actual Score	n	0	1
		Mean		83.33
		SD		
		Median		83.33
		Min.		83.3
		Max.		83.3
	Change from Baseline	n	0	1
		Mean		-16.67
		SD		
		Median		-16.67
		Min.		-16.7
		Max.		-16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (100%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (100%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Global Health Status Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
End of Treatment	Actual Score	n	10	11
		Mean	50.00	38.64
		SD	24.845	32.972
		Median	50.00	50.00
		Min.	16.7	0.0
		Max.	83.3	100.0
	Change from Baseline	n	9	11
		Mean	-4.63	-16.67
		SD	30.932	21.082
		Median	-16.67	-16.67
		Min.	-50.0	-58.3
		Max.	33.3	8.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (44%)	1 (9%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	4 (44%)	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	5 (56%)	6 (55%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	5 (56%)	6 (55%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Global Health Status Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 1	Actual Score	n	3	5
		Mean	44.44	30.00
		SD	34.694	27.386
		Median	33.33	16.67
		Min.	16.7	0.0
		Max.	83.3	66.7
	Change from Baseline	n	2	5
		Mean	-16.67	-16.67
		SD	47.140	23.570
		Median	-16.67	0.00
		Min.	-50.0	-50.0
		Max.	16.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	2 (40%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	2 (40%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Global Health Status Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 2	Actual Score	n	3	3
		Mean	55.56	38.89
		SD	9.623	25.459
		Median	50.00	33.33
		Min.	50.0	16.7
		Max.	66.7	66.7
	Change from Baseline	n	2	3
		Mean	-16.67	-5.56
		SD	0.000	9.623
		Median	-16.67	0.00
		Min.	-16.7	-16.7
		Max.	-16.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	2 (100%)	1 (33%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	2 (100%)	1 (33%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Global Health Status Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 4	Actual Score	n	0	2
		Mean		54.17
		SD		17.678
		Median		54.17
		Min.		41.7
		Max.		66.7
	Change from Baseline	n	0	2
		Mean		-4.17
		SD		5.893
		Median		-4.17
		Min.		-8.3
		Max.		0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (50%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Global Health Status Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
PFS Follow-Up 2	Actual Score	n	1	1
		Mean	66.67	58.33
		SD		
		Median	66.67	58.33
		Min.	66.7	58.3
		Max.	66.7	58.3
	Change from Baseline	n	1	1
		Mean	0.00	-8.33
		SD		
		Median	0.00	-8.33
		Min.	0.0	-8.3
		Max.	0.0	-8.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (100%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Global Health Status Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
PFS Follow-Up 4	Actual Score	n	0	1
		Mean		66.67
		SD		
		Median		66.67
		Min.		66.7
		Max.		66.7
	Change from Baseline	n	0	1
		Mean		0.00
		SD		
		Median		0.00
		Min.		0.0
		Max.		0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Global Health Status Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Last Follow-up	Actual Score	n	3	5
		Mean	55.56	28.33
		SD	9.623	26.087
		Median	50.00	16.67
		Min.	50.0	0.0
		Max.	66.7	66.7
	Change from Baseline	n	2	5
		Mean	-16.67	-18.33
		SD	0.000	22.361
		Median	-16.67	-8.33
		Min.	-16.7	-50.0
		Max.	-16.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	2 (100%)	3 (60%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	2 (100%)	2 (40%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Global Health Status Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Worst Case Post-Baseline	Actual Score	n	13	25
		Mean	32.05	33.00
		SD	21.204	23.383
		Median	25.00	33.33
		Min.	8.3	0.0
		Max.	66.7	83.3
	Change from Baseline	n	12	25
		Mean	-27.08	-20.33
		SD	28.455	23.333
		Median	-33.33	-16.67
		Min.	-66.7	-75.0
		Max.	33.3	25.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (8%)	2 (8%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (8%)	2 (8%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	9 (75%)	17 (68%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	9 (75%)	16 (64%)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_c30_dom.sas 10MAR2023 10:38

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Physical Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Baseline	Actual Score	n	13	27
		Mean	62.56	54.24
		SD	25.609	29.165
		Median	66.67	60.00
		Min.	6.7	6.7
		Max.	93.3	100.0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Physical Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 4	Actual Score	n	13	23
		Mean	60.51	54.78
		SD	30.118	34.522
		Median	66.67	53.33
		Min.	6.7	0.0
		Max.	100.0	100.0
	Change from Baseline	n	12	23
		Mean	-2.22	-2.80
		SD	16.412	19.422
		Median	-3.33	0.00
		Min.	-26.7	-60.0
		Max.	33.3	26.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (25%)	8 (35%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (25%)	5 (22%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	6 (50%)	11 (48%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	4 (33%)	6 (26%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Physical Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 7	Actual Score	n	12	17
		Mean	62.78	60.78
		SD	29.468	38.721
		Median	70.00	73.33
		Min.	6.7	0.0
		Max.	100.0	100.0
	Change from Baseline	n	11	17
		Mean	0.61	3.92
		SD	9.167	17.648
		Median	0.00	0.00
		Min.	-6.7	-26.7
		Max.	20.0	40.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (27%)	7 (41%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (18%)	5 (29%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	5 (45%)	7 (41%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	3 (18%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Physical Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 10	Actual Score	n	13	12
		Mean	57.44	58.89
		SD	32.265	35.486
		Median	60.00	66.67
		Min.	6.7	6.7
		Max.	100.0	100.0
	Change from Baseline	n	12	12
		Mean	-4.44	0.00
		SD	16.657	14.771
		Median	0.00	3.33
		Min.	-40.0	-26.7
		Max.	20.0	26.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (33%)	6 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (17%)	2 (17%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	5 (42%)	4 (33%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	4 (33%)	3 (25%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Physical Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 13	Actual Score	n	13	9
		Mean	61.54	62.96
		SD	27.642	21.373
		Median	66.67	66.67
		Min.	13.3	33.3
		Max.	100.0	86.7
	Change from Baseline	n	12	9
		Mean	1.11	5.19
		SD	13.584	9.876
		Median	3.33	6.67
		Min.	-20.0	-6.7
		Max.	20.0	20.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	6 (50%)	6 (67%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	4 (33%)	3 (33%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	4 (33%)	3 (33%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	3 (25%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Physical Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 16	Actual Score	n	12	8
		Mean	67.22	67.50
		SD	24.364	27.241
		Median	66.67	70.00
		Min.	20.0	20.0
		Max.	100.0	100.0
	Change from Baseline	n	11	8
		Mean	4.85	0.83
		SD	23.681	13.540
		Median	6.67	3.33
		Min.	-33.3	-20.0
		Max.	60.0	20.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	6 (55%)	4 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (27%)	2 (25%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	3 (27%)	3 (38%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	2 (18%)	2 (25%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Physical Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 19	Actual Score	n	12	7
		Mean	70.56	62.86
		SD	25.813	29.023
		Median	73.33	53.33
		Min.	20.0	20.0
		Max.	100.0	100.0
	Change from Baseline	n	11	7
		Mean	8.48	-1.90
		SD	25.314	7.418
		Median	6.67	0.00
		Min.	-40.0	-13.3
		Max.	60.0	6.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	8 (73%)	2 (29%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	5 (45%)	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	2 (18%)	3 (43%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	2 (18%)	1 (14%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Physical Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 22	Actual Score	n	7	7
		Mean	73.33	76.19
		SD	14.402	27.449
		Median	66.67	80.00
		Min.	60.0	26.7
		Max.	100.0	100.0
	Change from Baseline	n	7	7
		Mean	7.62	5.71
		SD	25.943	20.522
		Median	6.67	6.67
		Min.	-20.0	-33.3
		Max.	60.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (57%)	5 (71%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (29%)	2 (29%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	2 (29%)	1 (14%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	2 (29%)	1 (14%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Physical Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 25	Actual Score	n	7	7
		Mean	76.19	72.38
		SD	23.048	28.656
		Median	80.00	86.67
		Min.	33.3	40.0
		Max.	100.0	100.0
	Change from Baseline	n	7	7
		Mean	5.71	6.67
		SD	16.966	18.856
		Median	6.67	0.00
		Min.	-20.0	-20.0
		Max.	26.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	5 (71%)	3 (43%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (43%)	3 (43%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	2 (29%)	2 (29%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	2 (29%)	1 (14%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Physical Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 28	Actual Score	n	7	6
		Mean	81.90	82.22
		SD	13.174	26.218
		Median	80.00	93.33
		Min.	60.0	33.3
		Max.	100.0	100.0
	Change from Baseline	n	7	6
		Mean	11.43	10.00
		SD	33.046	21.807
		Median	6.67	13.33
		Min.	-20.0	-26.7
		Max.	80.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (57%)	4 (67%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (29%)	3 (50%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	2 (29%)	1 (17%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	2 (29%)	1 (17%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Physical Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 31	Actual Score	n	7	6
		Mean	82.86	80.00
		SD	13.254	24.585
		Median	80.00	86.67
		Min.	66.7	40.0
		Max.	100.0	100.0
	Change from Baseline	n	7	6
		Mean	12.38	7.78
		SD	27.603	17.596
		Median	6.67	10.00
		Min.	-13.3	-20.0
		Max.	66.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (57%)	4 (67%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (43%)	3 (50%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	2 (29%)	1 (17%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	2 (29%)	1 (17%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Physical Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 34	Actual Score	n	5	6
		Mean	84.00	76.67
		SD	12.111	27.889
		Median	80.00	86.67
		Min.	73.3	40.0
		Max.	100.0	100.0
	Change from Baseline	n	5	6
		Mean	2.67	4.44
		SD	8.944	18.217
		Median	6.67	3.33
		Min.	-6.7	-20.0
		Max.	13.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (60%)	3 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (20%)	2 (33%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	2 (40%)	2 (33%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (17%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Physical Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 37	Actual Score	n	4	6
		Mean	78.33	72.22
		SD	19.149	33.841
		Median	83.33	83.33
		Min.	53.3	20.0
		Max.	93.3	100.0
	Change from Baseline	n	4	6
		Mean	-8.33	0.00
		SD	14.782	23.851
		Median	-6.67	3.33
		Min.	-26.7	-40.0
		Max.	6.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (25%)	3 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (17%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	2 (50%)	2 (33%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	2 (50%)	1 (17%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Physical Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 40	Actual Score	n	4	5
		Mean	78.33	86.67
		SD	18.359	20.548
		Median	76.67	100.00
		Min.	60.0	53.3
		Max.	100.0	100.0
	Change from Baseline	n	4	5
		Mean	-8.33	10.67
		SD	13.744	16.055
		Median	-10.00	6.67
		Min.	-20.0	-6.7
		Max.	6.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (25%)	3 (60%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	2 (40%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	2 (50%)	1 (20%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	2 (50%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Physical Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 43	Actual Score	n	4	4
		Mean	85.00	83.33
		SD	22.027	22.111
		Median	93.33	90.00
		Min.	53.3	53.3
		Max.	100.0	100.0
	Change from Baseline	n	4	4
		Mean	-1.67	11.67
		SD	17.533	18.359
		Median	3.33	10.00
		Min.	-26.7	-6.7
		Max.	13.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (50%)	2 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (25%)	2 (50%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (25%)	1 (25%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (25%)	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_c30_dom.sas 10MAR2023 10:38

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Physical Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 46	Actual Score	n	3	4
		Mean	75.56	81.67
		SD	42.339	22.690
		Median	100.00	86.67
		Min.	26.7	53.3
		Max.	100.0	100.0
	Change from Baseline	n	3	4
		Mean	-11.11	10.00
		SD	36.717	17.638
		Median	6.67	6.67
		Min.	-53.3	-6.7
		Max.	13.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (67%)	2 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (33%)	2 (50%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (33%)	1 (25%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (33%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Physical Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 49	Actual Score	n	3	4
		Mean	86.67	80.00
		SD	23.094	25.531
		Median	100.00	86.67
		Min.	60.0	46.7
		Max.	100.0	100.0
	Change from Baseline	n	3	4
		Mean	0.00	8.33
		SD	17.638	19.907
		Median	6.67	6.67
		Min.	-20.0	-13.3
		Max.	13.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (67%)	2 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (33%)	2 (50%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (33%)	1 (25%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (33%)	1 (25%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Physical Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 52	Actual Score	n	3	4
		Mean	86.67	78.33
		SD	23.094	23.960
		Median	100.00	83.33
		Min.	60.0	46.7
		Max.	100.0	100.0
	Change from Baseline	n	3	4
		Mean	0.00	6.67
		SD	17.638	17.213
		Median	6.67	6.67
		Min.	-20.0	-13.3
		Max.	13.3	26.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (67%)	2 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (33%)	2 (50%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (33%)	1 (25%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (33%)	1 (25%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Physical Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 55	Actual Score	n	3	3
		Mean	95.56	88.89
		SD	7.698	13.878
		Median	100.00	93.33
		Min.	86.7	73.3
		Max.	100.0	100.0
	Change from Baseline	n	3	3
		Mean	8.89	13.33
		SD	3.849	13.333
		Median	6.67	13.33
		Min.	6.7	0.0
		Max.	13.3	26.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (100%)	2 (67%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (33%)	2 (67%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Physical Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 58	Actual Score	n	2	2
		Mean	76.67	86.67
		SD	32.998	18.856
		Median	76.67	86.67
		Min.	53.3	73.3
		Max.	100.0	100.0
	Change from Baseline	n	2	2
		Mean	-6.67	6.67
		SD	28.284	9.428
		Median	-6.67	6.67
		Min.	-26.7	0.0
		Max.	13.3	13.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	1 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	1 (50%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Physical Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 61	Actual Score	n	2	2
		Mean	46.67	86.67
		SD	0.000	18.856
		Median	46.67	86.67
		Min.	46.7	73.3
		Max.	46.7	100.0
	Change from Baseline	n	2	2
		Mean	-36.67	6.67
		SD	4.714	9.428
		Median	-36.67	6.67
		Min.	-40.0	0.0
		Max.	-33.3	13.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (50%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	2 (100%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	2 (100%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Physical Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 64	Actual Score	n	2	2
		Mean	70.00	90.00
		SD	32.998	14.142
		Median	70.00	90.00
		Min.	46.7	80.0
		Max.	93.3	100.0
	Change from Baseline	n	2	2
		Mean	-13.33	10.00
		SD	28.284	14.142
		Median	-13.33	10.00
		Min.	-33.3	0.0
		Max.	6.7	20.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	1 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (50%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Physical Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 67	Actual Score	n	2	2
		Mean	76.67	86.67
		SD	23.570	18.856
		Median	76.67	86.67
		Min.	60.0	73.3
		Max.	93.3	100.0
	Change from Baseline	n	2	2
		Mean	-6.67	6.67
		SD	18.856	9.428
		Median	-6.67	6.67
		Min.	-20.0	0.0
		Max.	6.7	13.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	1 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (50%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Physical Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 70	Actual Score	n	2	1
		Mean	70.00	100.00
		SD	32.998	
		Median	70.00	100.00
		Min.	46.7	100.0
		Max.	93.3	100.0
	Change from Baseline	n	2	1
		Mean	-13.33	0.00
		SD	28.284	
		Median	-13.33	0.00
		Min.	-33.3	0.0
		Max.	6.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_c30_dom.sas 10MAR2023 10:38

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Physical Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 73	Actual Score	n	1	1
		Mean	60.00	100.00
		SD		
		Median	60.00	100.00
		Min.	60.0	100.0
		Max.	60.0	100.0
	Change from Baseline	n	1	1
		Mean	-20.00	0.00
		SD		
		Median	-20.00	0.00
		Min.	-20.0	0.0
		Max.	-20.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (100%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (100%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Physical Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 76	Actual Score	n	2	1
		Mean	66.67	100.00
		SD	28.284	
		Median	66.67	100.00
		Min.	46.7	100.0
		Max.	86.7	100.0
	Change from Baseline	n	2	1
		Mean	-16.67	0.00
		SD	23.570	
		Median	-16.67	0.00
		Min.	-33.3	0.0
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Physical Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 79	Actual Score	n	2	1
		Mean	70.00	100.00
		SD	32.998	
		Median	70.00	100.00
		Min.	46.7	100.0
		Max.	93.3	100.0
	Change from Baseline	n	2	1
		Mean	-13.33	0.00
		SD	28.284	
		Median	-13.33	0.00
		Min.	-33.3	0.0
		Max.	6.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_c30_dom.sas 10MAR2023 10:38

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Physical Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 82	Actual Score	n	2	1
		Mean	70.00	100.00
		SD	32.998	
		Median	70.00	100.00
		Min.	46.7	100.0
		Max.	93.3	100.0
	Change from Baseline	n	2	1
		Mean	-13.33	0.00
		SD	28.284	
		Median	-13.33	0.00
		Min.	-33.3	0.0
		Max.	6.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_c30_dom.sas 10MAR2023 10:38

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Physical Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 85	Actual Score	n	1	1
		Mean	60.00	100.00
		SD		
		Median	60.00	100.00
		Min.	60.0	100.0
		Max.	60.0	100.0
	Change from Baseline	n	1	1
		Mean	-20.00	0.00
		SD		
		Median	-20.00	0.00
		Min.	-20.0	0.0
		Max.	-20.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (100%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (100%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Physical Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 88	Actual Score	n	1	1
		Mean	93.33	100.00
		SD		
		Median	93.33	100.00
		Min.	93.3	100.0
		Max.	93.3	100.0
	Change from Baseline	n	1	1
		Mean	6.67	0.00
		SD		
		Median	6.67	0.00
		Min.	6.7	0.0
		Max.	6.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (100%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_c30_dom.sas 10MAR2023 10:38

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Physical Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 91	Actual Score	n	2	1
		Mean	73.33	93.33
		SD	28.284	
		Median	73.33	93.33
		Min.	53.3	93.3
		Max.	93.3	93.3
	Change from Baseline	n	2	1
		Mean	-10.00	-6.67
		SD	23.570	
		Median	-10.00	-6.67
		Min.	-26.7	-6.7
		Max.	6.7	-6.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	1 (100%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Physical Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 94	Actual Score	n	2	1
		Mean	60.00	100.00
		SD	37.712	
		Median	60.00	100.00
		Min.	33.3	100.0
		Max.	86.7	100.0
	Change from Baseline	n	2	1
		Mean	-23.33	0.00
		SD	32.998	
		Median	-23.33	0.00
		Min.	-46.7	0.0
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Physical Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 97	Actual Score	n	1	0
		Mean	80.00	
		SD		
		Median	80.00	
		Min.	80.0	
		Max.	80.0	
	Change from Baseline	n	1	0
		Mean	0.00	
		SD		
		Median	0.00	
		Min.	0.0	
		Max.	0.0	
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Physical Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 100	Actual Score	n	0	1
		Mean		100.00
		SD		
		Median		100.00
		Min.		100.0
		Max.		100.0
	Change from Baseline	n	0	1
		Mean		0.00
		SD		
		Median		0.00
		Min.		0.0
		Max.		0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_c30_dom.sas 10MAR2023 10:38

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Physical Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
End of Treatment	Actual Score	n	10	11
		Mean	56.67	56.77
		SD	32.848	39.282
		Median	63.33	73.33
		Min.	0.0	6.7
		Max.	100.0	100.0
	Change from Baseline	n	9	11
		Mean	5.19	-9.90
		SD	23.040	30.100
		Median	6.67	-6.67
		Min.	-33.3	-82.2
		Max.	53.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	6 (67%)	3 (27%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (22%)	2 (18%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	2 (22%)	6 (55%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	2 (22%)	4 (36%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Physical Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 1	Actual Score	n	3	5
		Mean	48.89	54.67
		SD	37.908	38.701
		Median	60.00	73.33
		Min.	6.7	6.7
		Max.	80.0	93.3
	Change from Baseline	n	2	5
		Mean	36.67	-10.67
		SD	23.570	10.111
		Median	36.67	-13.33
		Min.	20.0	-20.0
		Max.	53.3	6.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (100%)	1 (20%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (100%)	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	4 (80%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	4 (80%)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_c30_dom.sas 10MAR2023 10:38

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Physical Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 2	Actual Score	n	3	3
		Mean	42.22	57.78
		SD	27.756	36.717
		Median	33.33	60.00
		Min.	20.0	20.0
		Max.	73.3	93.3
	Change from Baseline	n	2	3
		Mean	20.00	-13.33
		SD	9.428	17.638
		Median	20.00	-20.00
		Min.	13.3	-26.7
		Max.	26.7	6.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (100%)	1 (33%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (100%)	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	2 (67%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	2 (67%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Physical Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 4	Actual Score	n	0	2
		Mean		80.00
		SD		9.428
		Median		80.00
		Min.		73.3
		Max.		86.7
	Change from Baseline	n	0	2
		Mean		-6.67
		SD		9.428
		Median		-6.67
		Min.		-13.3
		Max.		0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (50%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (50%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Physical Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
PFS Follow-Up 2	Actual Score	n	1	1
		Mean	66.67	93.33
		SD		
		Median	66.67	93.33
		Min.	66.7	93.3
		Max.	66.7	93.3
	Change from Baseline	n	1	1
		Mean	6.67	6.67
		SD		
		Median	6.67	6.67
		Min.	6.7	6.7
		Max.	6.7	6.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (100%)	1 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_c30_dom.sas 10MAR2023 10:38

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Physical Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
PFS Follow-Up 4	Actual Score	n	0	1
		Mean		100.00
		SD		
		Median		100.00
		Min.		100.0
		Max.		100.0
	Change from Baseline	n	0	1
		Mean		13.33
		SD		
		Median		13.33
		Min.		13.3
		Max.		13.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (100%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Physical Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Last Follow-up	Actual Score	n	3	5
		Mean	42.22	53.33
		SD	27.756	37.118
		Median	33.33	73.33
		Min.	20.0	6.7
		Max.	73.3	86.7
	Change from Baseline	n	2	5
		Mean	20.00	-12.00
		SD	9.428	7.303
		Median	20.00	-13.33
		Min.	13.3	-20.0
		Max.	26.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (100%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (100%)	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	4 (80%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	4 (80%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Physical Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Worst Case Post-Baseline	Actual Score	n	13	25
		Mean	40.00	39.91
		SD	29.059	33.020
		Median	46.67	26.67
		Min.	0.0	0.0
		Max.	93.3	93.3
	Change from Baseline	n	12	25
		Mean	-20.56	-14.67
		SD	18.740	19.288
		Median	-20.00	-13.33
		Min.	-53.3	-82.2
		Max.	6.7	20.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (8%)	2 (8%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (4%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	9 (75%)	20 (80%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	8 (67%)	14 (56%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Role Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Baseline	Actual Score	n	13	27
		Mean	58.97	52.47
		SD	31.634	37.469
		Median	66.67	50.00
		Min.	0.0	0.0
		Max.	100.0	100.0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Role Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 4	Actual Score	n	13	23
		Mean	53.85	51.45
		SD	37.978	41.106
		Median	66.67	66.67
		Min.	0.0	0.0
		Max.	100.0	100.0
	Change from Baseline	n	12	23
		Mean	-4.17	-5.07
		SD	28.538	22.153
		Median	0.00	0.00
		Min.	-66.7	-66.7
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (33%)	4 (17%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	4 (33%)	4 (17%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	5 (42%)	7 (30%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	5 (42%)	7 (30%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Role Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 7	Actual Score	n	11	17
		Mean	54.55	50.00
		SD	35.032	40.825
		Median	66.67	50.00
		Min.	0.0	0.0
		Max.	100.0	100.0
	Change from Baseline	n	10	17
		Mean	-1.67	-5.88
		SD	30.882	17.620
		Median	0.00	0.00
		Min.	-66.7	-33.3
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (40%)	2 (12%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	4 (40%)	2 (12%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	3 (30%)	6 (35%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	3 (30%)	6 (35%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Role Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 10	Actual Score	n	13	12
		Mean	56.41	43.06
		SD	30.076	41.107
		Median	66.67	41.67
		Min.	0.0	0.0
		Max.	100.0	100.0
	Change from Baseline	n	12	12
		Mean	-2.78	-13.89
		SD	33.207	25.459
		Median	0.00	-8.33
		Min.	-66.7	-66.7
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	5 (42%)	1 (8%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	5 (42%)	1 (8%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	4 (33%)	6 (50%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	4 (33%)	6 (50%)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_c30_dom.sas 10MAR2023 10:38

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Role Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 13	Actual Score	n	13	9
		Mean	56.41	66.67
		SD	35.052	38.188
		Median	66.67	66.67
		Min.	0.0	0.0
		Max.	100.0	100.0
	Change from Baseline	n	12	9
		Mean	-1.39	3.70
		SD	32.144	13.889
		Median	0.00	0.00
		Min.	-66.7	-16.7
		Max.	50.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	5 (42%)	2 (22%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	5 (42%)	2 (22%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	4 (33%)	1 (11%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	4 (33%)	1 (11%)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_c30_dom.sas 10MAR2023 10:38

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Role Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 16	Actual Score	n	12	8
		Mean	68.06	56.25
		SD	28.831	29.463
		Median	75.00	66.67
		Min.	0.0	0.0
		Max.	100.0	100.0
	Change from Baseline	n	11	8
		Mean	12.12	-16.67
		SD	30.814	39.841
		Median	16.67	0.00
		Min.	-50.0	-100.0
		Max.	66.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	6 (55%)	1 (13%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	6 (55%)	1 (13%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	2 (18%)	3 (38%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	2 (18%)	3 (38%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Role Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 19	Actual Score	n	12	7
		Mean	70.83	59.52
		SD	33.428	30.211
		Median	75.00	66.67
		Min.	0.0	0.0
		Max.	100.0	100.0
	Change from Baseline	n	11	7
		Mean	15.15	-9.52
		SD	21.672	25.198
		Median	16.67	0.00
		Min.	-33.3	-33.3
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	9 (82%)	1 (14%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	9 (82%)	1 (14%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	2 (18%)	3 (43%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	2 (18%)	3 (43%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Role Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 22	Actual Score	n	7	7
		Mean	66.67	76.19
		SD	21.517	25.198
		Median	66.67	66.67
		Min.	33.3	33.3
		Max.	100.0	100.0
	Change from Baseline	n	7	7
		Mean	4.76	0.00
		SD	35.635	21.517
		Median	16.67	0.00
		Min.	-50.0	-33.3
		Max.	50.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (57%)	2 (29%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	4 (57%)	2 (29%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	2 (29%)	2 (29%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	2 (29%)	2 (29%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Role Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 25	Actual Score	n	7	7
		Mean	66.67	69.05
		SD	28.868	41.308
		Median	66.67	100.00
		Min.	33.3	0.0
		Max.	100.0	100.0
	Change from Baseline	n	7	7
		Mean	2.38	7.14
		SD	37.796	16.265
		Median	16.67	0.00
		Min.	-50.0	-16.7
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (57%)	3 (43%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	4 (57%)	3 (43%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	2 (29%)	1 (14%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	2 (29%)	1 (14%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Role Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 28	Actual Score	n	7	6
		Mean	78.57	80.56
		SD	23.002	34.021
		Median	83.33	100.00
		Min.	33.3	16.7
		Max.	100.0	100.0
	Change from Baseline	n	7	6
		Mean	14.29	8.33
		SD	44.544	25.276
		Median	16.67	8.33
		Min.	-66.7	-33.3
		Max.	83.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	5 (71%)	3 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	5 (71%)	3 (50%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (14%)	1 (17%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (14%)	1 (17%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Role Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 31	Actual Score	n	7	6
		Mean	73.81	77.78
		SD	16.265	27.217
		Median	66.67	83.33
		Min.	50.0	33.3
		Max.	100.0	100.0
	Change from Baseline	n	7	6
		Mean	9.52	5.56
		SD	26.972	17.213
		Median	0.00	0.00
		Min.	-33.3	-16.7
		Max.	50.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (43%)	2 (33%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (43%)	2 (33%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (14%)	1 (17%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (14%)	1 (17%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Role Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 34	Actual Score	n	5	6
		Mean	86.67	69.44
		SD	18.257	37.143
		Median	100.00	83.33
		Min.	66.7	16.7
		Max.	100.0	100.0
	Change from Baseline	n	5	6
		Mean	13.33	-2.78
		SD	27.386	16.387
		Median	16.67	0.00
		Min.	-33.3	-33.3
		Max.	33.3	16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (80%)	1 (17%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	4 (80%)	1 (17%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (20%)	1 (17%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (20%)	1 (17%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Role Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 37	Actual Score	n	4	6
		Mean	83.33	75.00
		SD	33.333	39.087
		Median	100.00	91.67
		Min.	33.3	0.0
		Max.	100.0	100.0
	Change from Baseline	n	4	6
		Mean	4.17	2.78
		SD	47.871	28.707
		Median	25.00	8.33
		Min.	-66.7	-50.0
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (75%)	3 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (75%)	3 (50%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (25%)	1 (17%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (25%)	1 (17%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Role Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 40	Actual Score	n	4	5
		Mean	66.67	80.00
		SD	38.490	44.721
		Median	66.67	100.00
		Min.	33.3	0.0
		Max.	100.0	100.0
	Change from Baseline	n	4	5
		Mean	-12.50	0.00
		SD	45.896	31.180
		Median	-8.33	0.00
		Min.	-66.7	-50.0
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (50%)	2 (40%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (50%)	2 (40%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	2 (50%)	1 (20%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	2 (50%)	1 (20%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Role Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 43	Actual Score	n	4	4
		Mean	70.83	83.33
		SD	47.871	33.333
		Median	91.67	100.00
		Min.	0.0	33.3
		Max.	100.0	100.0
	Change from Baseline	n	4	4
		Mean	-8.33	8.33
		SD	63.099	21.517
		Median	16.67	8.33
		Min.	-100.0	-16.7
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (50%)	2 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (50%)	2 (50%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (25%)	1 (25%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (25%)	1 (25%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Role Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 46	Actual Score	n	3	4
		Mean	66.67	83.33
		SD	57.735	33.333
		Median	100.00	100.00
		Min.	0.0	33.3
		Max.	100.0	100.0
	Change from Baseline	n	3	4
		Mean	-11.11	8.33
		SD	76.980	21.517
		Median	33.33	8.33
		Min.	-100.0	-16.7
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (67%)	2 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (67%)	2 (50%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (33%)	1 (25%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (33%)	1 (25%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Role Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 49	Actual Score	n	3	4
		Mean	88.89	79.17
		SD	19.245	41.667
		Median	100.00	100.00
		Min.	66.7	16.7
		Max.	100.0	100.0
	Change from Baseline	n	3	4
		Mean	11.11	4.17
		SD	38.490	28.464
		Median	33.33	8.33
		Min.	-33.3	-33.3
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (67%)	2 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (67%)	2 (50%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (33%)	1 (25%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (33%)	1 (25%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Role Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 52	Actual Score	n	3	4
		Mean	88.89	70.83
		SD	19.245	39.382
		Median	100.00	83.33
		Min.	66.7	16.7
		Max.	100.0	100.0
	Change from Baseline	n	3	4
		Mean	11.11	-4.17
		SD	38.490	20.972
		Median	33.33	0.00
		Min.	-33.3	-33.3
		Max.	33.3	16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (67%)	1 (25%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (67%)	1 (25%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (33%)	1 (25%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (33%)	1 (25%)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_c30_dom.sas 10MAR2023 10:38

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Role Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 55	Actual Score	n	3	3
		Mean	83.33	100.00
		SD	16.667	0.000
		Median	83.33	100.00
		Min.	66.7	100.0
		Max.	100.0	100.0
	Change from Baseline	n	3	3
		Mean	5.56	16.67
		SD	34.694	16.667
		Median	16.67	16.67
		Min.	-33.3	0.0
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (67%)	2 (67%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (67%)	2 (67%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (33%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (33%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Role Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 58	Actual Score	n	2	2
		Mean	41.67	100.00
		SD	58.926	0.000
		Median	41.67	100.00
		Min.	0.0	100.0
		Max.	83.3	100.0
	Change from Baseline	n	2	2
		Mean	-41.67	16.67
		SD	82.496	23.570
		Median	-41.67	16.67
		Min.	-100.0	0.0
		Max.	16.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	1 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	1 (50%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_c30_dom.sas 10MAR2023 10:38

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Role Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 61	Actual Score	n	2	2
		Mean	50.00	83.33
		SD	0.000	23.570
		Median	50.00	83.33
		Min.	50.0	66.7
		Max.	50.0	100.0
	Change from Baseline	n	2	2
		Mean	-33.33	0.00
		SD	23.570	0.000
		Median	-33.33	0.00
		Min.	-50.0	0.0
		Max.	-16.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	2 (100%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	2 (100%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Role Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 64	Actual Score	n	2	2
		Mean	66.67	83.33
		SD	23.570	23.570
		Median	66.67	83.33
		Min.	50.0	66.7
		Max.	83.3	100.0
	Change from Baseline	n	2	2
		Mean	-16.67	0.00
		SD	47.140	0.000
		Median	-16.67	0.00
		Min.	-50.0	0.0
		Max.	16.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Role Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 67	Actual Score	n	2	2
		Mean	58.33	100.00
		SD	35.355	0.000
		Median	58.33	100.00
		Min.	33.3	100.0
		Max.	83.3	100.0
	Change from Baseline	n	2	2
		Mean	-25.00	16.67
		SD	58.926	23.570
		Median	-25.00	16.67
		Min.	-66.7	0.0
		Max.	16.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	1 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	1 (50%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Role Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 70	Actual Score	n	2	1
		Mean	83.33	100.00
		SD	23.570	
		Median	83.33	100.00
		Min.	66.7	100.0
		Max.	100.0	100.0
	Change from Baseline	n	2	1
		Mean	0.00	0.00
		SD	47.140	
		Median	0.00	0.00
		Min.	-33.3	0.0
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Role Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 73	Actual Score	n	1	1
		Mean	33.33	100.00
		SD		
		Median	33.33	100.00
		Min.	33.3	100.0
		Max.	33.3	100.0
	Change from Baseline	n	1	1
		Mean	-66.67	0.00
		SD		
		Median	-66.67	0.00
		Min.	-66.7	0.0
		Max.	-66.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (100%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (100%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Role Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 76	Actual Score	n	2	1
		Mean	58.33	100.00
		SD	35.355	
		Median	58.33	100.00
		Min.	33.3	100.0
		Max.	83.3	100.0
	Change from Baseline	n	2	1
		Mean	-25.00	0.00
		SD	58.926	
		Median	-25.00	0.00
		Min.	-66.7	0.0
		Max.	16.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Role Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 79	Actual Score	n	2	1
		Mean	50.00	100.00
		SD	23.570	
		Median	50.00	100.00
		Min.	33.3	100.0
		Max.	66.7	100.0
	Change from Baseline	n	2	1
		Mean	-33.33	0.00
		SD	47.140	
		Median	-33.33	0.00
		Min.	-66.7	0.0
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Role Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 82	Actual Score	n	2	1
		Mean	66.67	100.00
		SD	47.140	
		Median	66.67	100.00
		Min.	33.3	100.0
		Max.	100.0	100.0
	Change from Baseline	n	2	1
		Mean	-16.67	0.00
		SD	70.711	
		Median	-16.67	0.00
		Min.	-66.7	0.0
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Role Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 85	Actual Score	n	1	1
		Mean	100.00	100.00
		SD		
		Median	100.00	100.00
		Min.	100.0	100.0
		Max.	100.0	100.0
	Change from Baseline	n	1	1
		Mean	0.00	0.00
		SD		
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_c30_dom.sas 10MAR2023 10:38

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Role Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 88	Actual Score	n	1	1
		Mean	100.00	100.00
		SD		
		Median	100.00	100.00
		Min.	100.0	100.0
		Max.	100.0	100.0
	Change from Baseline	n	1	1
		Mean	33.33	0.00
		SD		
		Median	33.33	0.00
		Min.	33.3	0.0
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (100%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (100%)	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Role Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 91	Actual Score	n	2	1
		Mean	58.33	100.00
		SD	35.355	
		Median	58.33	100.00
		Min.	33.3	100.0
		Max.	83.3	100.0
	Change from Baseline	n	2	1
		Mean	-25.00	0.00
		SD	58.926	
		Median	-25.00	0.00
		Min.	-66.7	0.0
		Max.	16.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Role Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 94	Actual Score	n	2	1
		Mean	66.67	100.00
		SD	47.140	
		Median	66.67	100.00
		Min.	33.3	100.0
		Max.	100.0	100.0
	Change from Baseline	n	2	1
		Mean	-16.67	0.00
		SD	70.711	
		Median	-16.67	0.00
		Min.	-66.7	0.0
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Role Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 97	Actual Score	n	1	0
		Mean	50.00	
		SD		
		Median	50.00	
		Min.	50.0	
		Max.	50.0	
	Change from Baseline	n	1	0
		Mean	-50.00	
		SD		
		Median	-50.00	
		Min.	-50.0	
		Max.	-50.0	
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (100%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (100%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Role Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 100	Actual Score	n	0	1
		Mean		100.00
		SD		
		Median		100.00
		Min.		100.0
		Max.		100.0
	Change from Baseline	n	0	1
		Mean		0.00
		SD		
		Median		0.00
		Min.		0.0
		Max.		0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_c30_dom.sas 10MAR2023 10:38

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Role Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
End of Treatment	Actual Score	n	10	11
		Mean	56.67	46.97
		SD	34.427	41.378
		Median	66.67	33.33
		Min.	0.0	0.0
		Max.	100.0	100.0
	Change from Baseline	n	9	11
		Mean	9.26	-16.67
		SD	37.371	32.489
		Median	16.67	0.00
		Min.	-66.7	-66.7
		Max.	66.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	5 (56%)	2 (18%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	5 (56%)	2 (18%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	2 (22%)	5 (45%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	2 (22%)	5 (45%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Role Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 1	Actual Score	n	3	4
		Mean	38.89	41.67
		SD	34.694	28.868
		Median	50.00	50.00
		Min.	0.0	0.0
		Max.	66.7	66.7
	Change from Baseline	n	2	4
		Mean	33.33	-8.33
		SD	23.570	21.517
		Median	33.33	-8.33
		Min.	16.7	-33.3
		Max.	50.0	16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (100%)	1 (25%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (100%)	1 (25%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	2 (50%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	2 (50%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Role Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 2	Actual Score	n	3	3
		Mean	38.89	50.00
		SD	25.459	16.667
		Median	33.33	50.00
		Min.	16.7	33.3
		Max.	66.7	66.7
	Change from Baseline	n	2	3
		Mean	25.00	-5.56
		SD	11.785	9.623
		Median	25.00	0.00
		Min.	16.7	-16.7
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (100%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (100%)	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (33%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (33%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Role Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 4	Actual Score	n	0	2
		Mean		58.33
		SD		11.785
		Median		58.33
		Min.		50.0
		Max.		66.7
	Change from Baseline	n	0	2
		Mean		-8.33
		SD		11.785
		Median		-8.33
		Min.		-16.7
		Max.		0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (50%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (50%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Role Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
PFS Follow-Up 2	Actual Score	n	1	1
		Mean	50.00	66.67
		SD		
		Median	50.00	66.67
		Min.	50.0	66.7
		Max.	50.0	66.7
	Change from Baseline	n	1	1
		Mean	0.00	0.00
		SD		
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Role Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
PFS Follow-Up 4	Actual Score	n	0	1
		Mean		66.67
		SD		
		Median		66.67
		Min.		66.7
		Max.		66.7
	Change from Baseline	n	0	1
		Mean		0.00
		SD		
		Median		0.00
		Min.		0.0
		Max.		0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_c30_dom.sas 10MAR2023 10:38

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Role Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Last Follow-up	Actual Score	n	3	4
		Mean	38.89	37.50
		SD	25.459	28.464
		Median	33.33	41.67
		Min.	16.7	0.0
		Max.	66.7	66.7
	Change from Baseline	n	2	4
		Mean	25.00	-12.50
		SD	11.785	15.957
		Median	25.00	-8.33
		Min.	16.7	-33.3
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (100%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (100%)	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	2 (50%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	2 (50%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Role Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Worst Case Post-Baseline	Actual Score	n	13	25
		Mean	26.92	30.00
		SD	25.036	37.577
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	66.7	100.0
	Change from Baseline	n	12	25
		Mean	-33.33	-22.00
		SD	33.333	29.155
		Median	-25.00	-16.67
		Min.	-100.0	-100.0
		Max.	0.0	16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (4%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (4%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	8 (67%)	13 (52%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	8 (67%)	13 (52%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Emotional Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Baseline	Actual Score	n	13	27
		Mean	78.21	72.84
		SD	19.406	25.063
		Median	83.33	75.00
		Min.	25.0	0.0
		Max.	100.0	100.0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Emotional Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 4	Actual Score	n	13	23
		Mean	76.92	75.00
		SD	31.023	25.500
		Median	83.33	83.33
		Min.	0.0	8.3
		Max.	100.0	100.0
	Change from Baseline	n	12	23
		Mean	5.56	0.72
		SD	18.577	16.071
		Median	8.33	0.00
		Min.	-33.3	-33.3
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	7 (58%)	9 (39%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	5 (42%)	5 (22%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	3 (25%)	7 (30%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	2 (17%)	4 (17%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Emotional Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 7	Actual Score	n	12	17
		Mean	72.22	74.18
		SD	27.371	27.895
		Median	79.17	83.33
		Min.	8.3	8.3
		Max.	100.0	100.0
	Change from Baseline	n	11	17
		Mean	2.27	2.12
		SD	18.292	13.873
		Median	0.00	0.00
		Min.	-33.3	-25.0
		Max.	25.0	25.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	5 (45%)	8 (47%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (27%)	4 (24%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	2 (18%)	5 (29%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	2 (18%)	3 (18%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Emotional Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 10	Actual Score	n	13	12
		Mean	80.77	72.22
		SD	30.691	27.371
		Median	91.67	83.33
		Min.	0.0	16.7
		Max.	100.0	100.0
	Change from Baseline	n	12	12
		Mean	9.72	0.00
		SD	15.825	19.462
		Median	8.33	0.00
		Min.	-16.7	-33.3
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	8 (67%)	4 (33%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	5 (42%)	3 (25%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	3 (25%)	4 (33%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (8%)	3 (25%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Emotional Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 13	Actual Score	n	13	9
		Mean	75.64	86.11
		SD	31.080	23.936
		Median	83.33	100.00
		Min.	0.0	33.3
		Max.	100.0	100.0
	Change from Baseline	n	12	9
		Mean	4.17	15.74
		SD	22.332	12.805
		Median	12.50	16.67
		Min.	-41.7	0.0
		Max.	25.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	7 (58%)	7 (78%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	6 (50%)	5 (56%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	4 (33%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	4 (33%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Emotional Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 16	Actual Score	n	12	8
		Mean	78.47	78.13
		SD	28.968	31.477
		Median	87.50	95.83
		Min.	0.0	25.0
		Max.	100.0	100.0
	Change from Baseline	n	11	8
		Mean	7.58	8.33
		SD	24.567	19.920
		Median	8.33	8.33
		Min.	-33.3	-25.0
		Max.	41.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	6 (55%)	5 (63%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	5 (45%)	3 (38%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	2 (18%)	2 (25%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	2 (18%)	1 (13%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Emotional Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 19	Actual Score	n	12	7
		Mean	81.94	86.90
		SD	30.533	23.987
		Median	100.00	91.67
		Min.	0.0	33.3
		Max.	100.0	100.0
	Change from Baseline	n	11	7
		Mean	11.36	14.29
		SD	21.171	13.363
		Median	16.67	8.33
		Min.	-33.3	0.0
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	8 (73%)	6 (86%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	6 (55%)	2 (29%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	2 (18%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	2 (18%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Emotional Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 22	Actual Score	n	7	7
		Mean	89.29	85.71
		SD	13.363	7.927
		Median	91.67	91.67
		Min.	66.7	75.0
		Max.	100.0	91.7
	Change from Baseline	n	7	7
		Mean	14.29	-1.19
		SD	22.420	13.968
		Median	16.67	-8.33
		Min.	-25.0	-16.7
		Max.	41.7	25.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	5 (71%)	2 (29%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	4 (57%)	1 (14%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (14%)	4 (57%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (14%)	1 (14%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Emotional Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 25	Actual Score	n	7	7
		Mean	85.71	90.48
		SD	21.897	8.909
		Median	100.00	91.67
		Min.	41.7	75.0
		Max.	100.0	100.0
	Change from Baseline	n	7	7
		Mean	8.33	2.38
		SD	19.245	16.467
		Median	16.67	0.00
		Min.	-25.0	-16.7
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	5 (71%)	3 (43%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	4 (57%)	1 (14%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	2 (29%)	3 (43%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (14%)	1 (14%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Emotional Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 28	Actual Score	n	7	6
		Mean	89.29	87.50
		SD	21.362	11.487
		Median	100.00	91.67
		Min.	41.7	66.7
		Max.	100.0	100.0
	Change from Baseline	n	7	6
		Mean	11.90	0.00
		SD	39.924	9.129
		Median	8.33	0.00
		Min.	-58.3	-8.3
		Max.	75.0	16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	5 (71%)	1 (17%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (43%)	1 (17%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (14%)	2 (33%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (14%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Emotional Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 31	Actual Score	n	7	6
		Mean	90.48	90.28
		SD	13.968	13.351
		Median	100.00	95.83
		Min.	66.7	66.7
		Max.	100.0	100.0
	Change from Baseline	n	7	6
		Mean	13.10	2.78
		SD	21.440	4.303
		Median	8.33	0.00
		Min.	-25.0	0.0
		Max.	41.7	8.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	6 (86%)	2 (33%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (43%)	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (14%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (14%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Emotional Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 34	Actual Score	n	5	6
		Mean	86.67	84.72
		SD	15.138	15.290
		Median	91.67	91.67
		Min.	66.7	58.3
		Max.	100.0	100.0
	Change from Baseline	n	5	6
		Mean	0.00	-2.78
		SD	15.590	6.804
		Median	0.00	-4.17
		Min.	-25.0	-8.3
		Max.	16.7	8.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (40%)	1 (17%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (20%)	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (20%)	3 (50%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (20%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Emotional Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 37	Actual Score	n	4	6
		Mean	83.33	88.89
		SD	28.054	8.607
		Median	95.83	91.67
		Min.	41.7	75.0
		Max.	100.0	100.0
	Change from Baseline	n	4	6
		Mean	-8.33	1.39
		SD	34.021	13.351
		Median	4.17	0.00
		Min.	-58.3	-16.7
		Max.	16.7	16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (50%)	2 (33%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (25%)	2 (33%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (25%)	2 (33%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (25%)	1 (17%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Emotional Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 40	Actual Score	n	4	5
		Mean	83.33	91.67
		SD	28.054	5.893
		Median	95.83	91.67
		Min.	41.7	83.3
		Max.	100.0	100.0
	Change from Baseline	n	4	5
		Mean	-8.33	3.33
		SD	34.021	17.280
		Median	4.17	0.00
		Min.	-58.3	-8.3
		Max.	16.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (50%)	1 (20%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (25%)	1 (20%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (25%)	2 (40%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (25%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Emotional Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 43	Actual Score	n	4	4
		Mean	79.17	91.67
		SD	36.324	6.804
		Median	95.83	91.67
		Min.	25.0	83.3
		Max.	100.0	100.0
	Change from Baseline	n	4	4
		Mean	-12.50	4.17
		SD	42.219	8.333
		Median	4.17	0.00
		Min.	-75.0	0.0
		Max.	16.7	16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (50%)	1 (25%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (25%)	1 (25%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (25%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (25%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Emotional Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 46	Actual Score	n	3	4
		Mean	88.89	87.50
		SD	19.245	14.434
		Median	100.00	91.67
		Min.	66.7	66.7
		Max.	100.0	100.0
	Change from Baseline	n	3	4
		Mean	-2.78	0.00
		SD	26.788	24.533
		Median	8.33	-4.17
		Min.	-33.3	-25.0
		Max.	16.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (67%)	1 (25%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (33%)	1 (25%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (33%)	2 (50%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (33%)	1 (25%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Emotional Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 49	Actual Score	n	3	4
		Mean	88.89	81.25
		SD	19.245	12.500
		Median	100.00	83.33
		Min.	66.7	66.7
		Max.	100.0	91.7
	Change from Baseline	n	3	4
		Mean	-2.78	-6.25
		SD	26.788	7.979
		Median	8.33	-4.17
		Min.	-33.3	-16.7
		Max.	16.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (67%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (33%)	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (33%)	2 (50%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (33%)	1 (25%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Emotional Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 52	Actual Score	n	3	4
		Mean	88.89	93.75
		SD	19.245	7.979
		Median	100.00	95.83
		Min.	66.7	83.3
		Max.	100.0	100.0
	Change from Baseline	n	3	4
		Mean	-2.78	6.25
		SD	26.788	18.478
		Median	8.33	0.00
		Min.	-33.3	-8.3
		Max.	16.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (67%)	1 (25%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (33%)	1 (25%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (33%)	1 (25%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (33%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Emotional Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 55	Actual Score	n	3	3
		Mean	100.00	97.22
		SD	0.000	4.811
		Median	100.00	100.00
		Min.	100.0	91.7
		Max.	100.0	100.0
	Change from Baseline	n	3	3
		Mean	8.33	11.11
		SD	8.333	19.245
		Median	8.33	0.00
		Min.	0.0	0.0
		Max.	16.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (67%)	1 (33%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (33%)	1 (33%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Emotional Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 58	Actual Score	n	2	2
		Mean	70.83	87.50
		SD	41.248	5.893
		Median	70.83	87.50
		Min.	41.7	83.3
		Max.	100.0	91.7
	Change from Baseline	n	2	2
		Mean	-25.00	8.33
		SD	47.140	11.785
		Median	-25.00	8.33
		Min.	-58.3	0.0
		Max.	8.3	16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	1 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (50%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Emotional Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 61	Actual Score	n	2	2
		Mean	79.17	87.50
		SD	5.893	5.893
		Median	79.17	87.50
		Min.	75.0	83.3
		Max.	83.3	91.7
	Change from Baseline	n	2	2
		Mean	-16.67	8.33
		SD	0.000	11.785
		Median	-16.67	8.33
		Min.	-16.7	0.0
		Max.	-16.7	16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (50%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	2 (100%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	2 (100%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Emotional Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 64	Actual Score	n	2	2
		Mean	95.83	87.50
		SD	5.893	5.893
		Median	95.83	87.50
		Min.	91.7	83.3
		Max.	100.0	91.7
	Change from Baseline	n	2	2
		Mean	0.00	8.33
		SD	11.785	11.785
		Median	0.00	8.33
		Min.	-8.3	0.0
		Max.	8.3	16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	1 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (50%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Emotional Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 67	Actual Score	n	2	2
		Mean	75.00	70.83
		SD	35.355	29.463
		Median	75.00	70.83
		Min.	50.0	50.0
		Max.	100.0	91.7
	Change from Baseline	n	2	2
		Mean	-20.83	-8.33
		SD	41.248	11.785
		Median	-20.83	-8.33
		Min.	-50.0	-16.7
		Max.	8.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	1 (50%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	1 (50%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Emotional Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 70	Actual Score	n	2	1
		Mean	91.67	91.67
		SD	11.785	
		Median	91.67	91.67
		Min.	83.3	91.7
		Max.	100.0	91.7
	Change from Baseline	n	2	1
		Mean	-4.17	0.00
		SD	17.678	
		Median	-4.17	0.00
		Min.	-16.7	0.0
		Max.	8.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_c30_dom.sas 10MAR2023 10:38

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Emotional Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 73	Actual Score	n	1	1
		Mean	50.00	91.67
		SD		
		Median	50.00	91.67
		Min.	50.0	91.7
		Max.	50.0	91.7
	Change from Baseline	n	1	1
		Mean	-50.00	0.00
		SD		
		Median	-50.00	0.00
		Min.	-50.0	0.0
		Max.	-50.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (100%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (100%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Emotional Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 76	Actual Score	n	2	1
		Mean	79.17	91.67
		SD	29.463	
		Median	79.17	91.67
		Min.	58.3	91.7
		Max.	100.0	91.7
	Change from Baseline	n	2	1
		Mean	-16.67	0.00
		SD	35.355	
		Median	-16.67	0.00
		Min.	-41.7	0.0
		Max.	8.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Emotional Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 79	Actual Score	n	2	1
		Mean	79.17	91.67
		SD	29.463	
		Median	79.17	91.67
		Min.	58.3	91.7
		Max.	100.0	91.7
	Change from Baseline	n	2	1
		Mean	-16.67	0.00
		SD	35.355	
		Median	-16.67	0.00
		Min.	-41.7	0.0
		Max.	8.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Emotional Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 82	Actual Score	n	2	1
		Mean	79.17	100.00
		SD	29.463	
		Median	79.17	100.00
		Min.	58.3	100.0
		Max.	100.0	100.0
	Change from Baseline	n	2	1
		Mean	-16.67	8.33
		SD	35.355	
		Median	-16.67	8.33
		Min.	-41.7	8.3
		Max.	8.3	8.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	1 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Emotional Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 85	Actual Score	n	1	1
		Mean	50.00	100.00
		SD		
		Median	50.00	100.00
		Min.	50.0	100.0
		Max.	50.0	100.0
	Change from Baseline	n	1	1
		Mean	-50.00	8.33
		SD		
		Median	-50.00	8.33
		Min.	-50.0	8.3
		Max.	-50.0	8.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (100%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (100%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Emotional Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 88	Actual Score	n	1	1
		Mean	100.00	91.67
		SD		
		Median	100.00	91.67
		Min.	100.0	91.7
		Max.	100.0	91.7
	Change from Baseline	n	1	1
		Mean	8.33	0.00
		SD		
		Median	8.33	0.00
		Min.	8.3	0.0
		Max.	8.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (100%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Emotional Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 91	Actual Score	n	2	1
		Mean	66.67	100.00
		SD	47.140	
		Median	66.67	100.00
		Min.	33.3	100.0
		Max.	100.0	100.0
	Change from Baseline	n	2	1
		Mean	-29.17	8.33
		SD	53.033	
		Median	-29.17	8.33
		Min.	-66.7	8.3
		Max.	8.3	8.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	1 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Emotional Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 94	Actual Score	n	2	1
		Mean	91.67	91.67
		SD	11.785	
		Median	91.67	91.67
		Min.	83.3	91.7
		Max.	100.0	91.7
	Change from Baseline	n	2	1
		Mean	-4.17	0.00
		SD	17.678	
		Median	-4.17	0.00
		Min.	-16.7	0.0
		Max.	8.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Emotional Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 97	Actual Score	n	1	0
		Mean	58.33	
		SD		
		Median	58.33	
		Min.	58.3	
		Max.	58.3	
	Change from Baseline	n	1	0
		Mean	-41.67	
		SD		
		Median	-41.67	
		Min.	-41.7	
		Max.	-41.7	
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (100%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (100%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Emotional Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 100	Actual Score	n	0	1
		Mean		91.67
		SD		
		Median		91.67
		Min.		91.7
		Max.		91.7
	Change from Baseline	n	0	1
		Mean		0.00
		SD		
		Median		0.00
		Min.		0.0
		Max.		0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_c30_dom.sas 10MAR2023 10:38

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Emotional Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
End of Treatment	Actual Score	n	10	11
		Mean	77.50	56.82
		SD	32.406	27.085
		Median	91.67	50.00
		Min.	0.0	25.0
		Max.	100.0	100.0
	Change from Baseline	n	9	11
		Mean	14.81	-10.61
		SD	18.993	25.574
		Median	16.67	-16.67
		Min.	-25.0	-41.7
		Max.	41.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	8 (89%)	3 (27%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	5 (56%)	3 (27%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (11%)	7 (64%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (11%)	6 (55%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Emotional Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 1	Actual Score	n	3	5
		Mean	66.67	78.33
		SD	38.188	9.501
		Median	75.00	75.00
		Min.	25.0	66.7
		Max.	100.0	91.7
	Change from Baseline	n	2	5
		Mean	41.67	1.67
		SD	11.785	10.865
		Median	41.67	0.00
		Min.	33.3	-8.3
		Max.	50.0	16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (100%)	2 (40%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (100%)	1 (20%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	2 (40%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Emotional Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 2	Actual Score	n	3	3
		Mean	55.56	72.22
		SD	45.896	17.347
		Median	58.33	66.67
		Min.	8.3	58.3
		Max.	100.0	91.7
	Change from Baseline	n	2	3
		Mean	33.33	-2.78
		SD	0.000	9.623
		Median	33.33	-8.33
		Min.	33.3	-8.3
		Max.	33.3	8.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (100%)	1 (33%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (100%)	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	2 (67%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Emotional Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 4	Actual Score	n	0	2
		Mean		87.50
		SD		17.678
		Median		87.50
		Min.		75.0
		Max.		100.0
	Change from Baseline	n	0	2
		Mean		0.00
		SD		0.000
		Median		0.00
		Min.		0.0
		Max.		0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Emotional Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
PFS Follow-Up 2	Actual Score	n	1	1
		Mean	91.67	83.33
		SD		
		Median	91.67	83.33
		Min.	91.7	83.3
		Max.	91.7	83.3
	Change from Baseline	n	1	1
		Mean	25.00	-16.67
		SD		
		Median	25.00	-16.67
		Min.	25.0	-16.7
		Max.	25.0	-16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (100%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (100%)	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (100%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (100%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Emotional Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
PFS Follow-Up 4	Actual Score	n	0	1
		Mean		100.00
		SD		
		Median		100.00
		Min.		100.0
		Max.		100.0
	Change from Baseline	n	0	1
		Mean		0.00
		SD		
		Median		0.00
		Min.		0.0
		Max.		0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_c30_dom.sas 10MAR2023 10:38

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Emotional Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Last Follow-up	Actual Score	n	3	5
		Mean	55.56	78.33
		SD	45.896	15.138
		Median	58.33	75.00
		Min.	8.3	58.3
		Max.	100.0	100.0
	Change from Baseline	n	2	5
		Mean	33.33	1.67
		SD	0.000	6.972
		Median	33.33	0.00
		Min.	33.3	-8.3
		Max.	33.3	8.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (100%)	2 (40%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (100%)	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (20%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Emotional Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Worst Case Post-Baseline	Actual Score	n	13	25
		Mean	58.33	55.11
		SD	28.666	24.594
		Median	66.67	58.33
		Min.	0.0	8.3
		Max.	100.0	91.7
	Change from Baseline	n	12	25
		Mean	-14.58	-16.89
		SD	27.781	15.935
		Median	-4.17	-16.67
		Min.	-75.0	-41.7
		Max.	25.0	19.4
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (25%)	3 (12%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (8%)	1 (4%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	6 (50%)	21 (84%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	5 (42%)	15 (60%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Cognitive Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Baseline	Actual Score	n	13	27
		Mean	80.77	74.69
		SD	22.408	24.183
		Median	83.33	83.33
		Min.	33.3	16.7
		Max.	100.0	100.0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Cognitive Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 4	Actual Score	n	13	23
		Mean	76.92	75.36
		SD	19.882	22.957
		Median	83.33	83.33
		Min.	50.0	33.3
		Max.	100.0	100.0
	Change from Baseline	n	12	23
		Mean	0.00	0.00
		SD	23.570	24.618
		Median	0.00	0.00
		Min.	-33.3	-66.7
		Max.	50.0	66.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (33%)	7 (30%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	4 (33%)	7 (30%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	4 (33%)	5 (22%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	4 (33%)	5 (22%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Cognitive Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 7	Actual Score	n	12	17
		Mean	79.17	78.43
		SD	22.613	26.197
		Median	83.33	83.33
		Min.	33.3	16.7
		Max.	100.0	100.0
	Change from Baseline	n	11	17
		Mean	3.03	-2.94
		SD	34.816	26.507
		Median	0.00	0.00
		Min.	-50.0	-66.7
		Max.	66.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (36%)	6 (35%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	4 (36%)	6 (35%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	3 (27%)	6 (35%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	3 (27%)	6 (35%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Cognitive Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 10	Actual Score	n	13	12
		Mean	83.33	86.11
		SD	28.054	22.285
		Median	100.00	100.00
		Min.	16.7	33.3
		Max.	100.0	100.0
	Change from Baseline	n	12	12
		Mean	9.72	1.39
		SD	28.831	15.006
		Median	0.00	0.00
		Min.	-50.0	-33.3
		Max.	66.7	16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	5 (42%)	4 (33%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	5 (42%)	4 (33%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (8%)	2 (17%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (8%)	2 (17%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Cognitive Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 13	Actual Score	n	13	9
		Mean	78.21	88.89
		SD	27.542	22.048
		Median	83.33	100.00
		Min.	16.7	33.3
		Max.	100.0	100.0
	Change from Baseline	n	12	9
		Mean	4.17	-3.70
		SD	32.664	24.689
		Median	0.00	0.00
		Min.	-50.0	-66.7
		Max.	66.7	16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	5 (42%)	2 (22%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	5 (42%)	2 (22%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	4 (33%)	1 (11%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	4 (33%)	1 (11%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Cognitive Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 16	Actual Score	n	12	8
		Mean	73.61	89.58
		SD	29.694	23.465
		Median	83.33	100.00
		Min.	0.0	33.3
		Max.	100.0	100.0
	Change from Baseline	n	11	8
		Mean	-1.52	-8.33
		SD	29.302	25.198
		Median	0.00	0.00
		Min.	-33.3	-66.7
		Max.	66.7	16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (27%)	1 (13%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (27%)	1 (13%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	4 (36%)	2 (25%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	4 (36%)	2 (25%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Cognitive Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 19	Actual Score	n	12	7
		Mean	79.17	85.71
		SD	23.704	26.227
		Median	83.33	100.00
		Min.	16.7	33.3
		Max.	100.0	100.0
	Change from Baseline	n	11	7
		Mean	3.03	-11.90
		SD	27.707	28.406
		Median	0.00	0.00
		Min.	-33.3	-66.7
		Max.	66.7	16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (27%)	1 (14%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (27%)	1 (14%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	4 (36%)	2 (29%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	4 (36%)	2 (29%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Cognitive Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 22	Actual Score	n	7	7
		Mean	78.57	90.48
		SD	12.599	18.898
		Median	83.33	100.00
		Min.	66.7	50.0
		Max.	100.0	100.0
	Change from Baseline	n	7	7
		Mean	-9.52	-4.76
		SD	21.207	20.893
		Median	-16.67	0.00
		Min.	-33.3	-50.0
		Max.	33.3	16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (14%)	1 (14%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (14%)	1 (14%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	5 (71%)	1 (14%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	5 (71%)	1 (14%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Cognitive Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 25	Actual Score	n	7	7
		Mean	80.95	95.24
		SD	17.817	8.133
		Median	83.33	100.00
		Min.	50.0	83.3
		Max.	100.0	100.0
	Change from Baseline	n	7	7
		Mean	-7.14	4.76
		SD	23.288	8.133
		Median	0.00	0.00
		Min.	-33.3	0.0
		Max.	33.3	16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (14%)	2 (29%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (14%)	2 (29%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	3 (43%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	3 (43%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Cognitive Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 28	Actual Score	n	7	6
		Mean	78.57	100.00
		SD	20.893	0.000
		Median	83.33	100.00
		Min.	50.0	100.0
		Max.	100.0	100.0
	Change from Baseline	n	7	6
		Mean	-9.52	5.56
		SD	26.972	8.607
		Median	0.00	0.00
		Min.	-50.0	0.0
		Max.	33.3	16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (14%)	2 (33%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (14%)	2 (33%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	3 (43%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	3 (43%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Cognitive Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 31	Actual Score	n	7	6
		Mean	85.71	97.22
		SD	14.996	6.804
		Median	83.33	100.00
		Min.	66.7	83.3
		Max.	100.0	100.0
	Change from Baseline	n	7	6
		Mean	-2.38	2.78
		SD	11.501	12.546
		Median	0.00	0.00
		Min.	-16.7	-16.7
		Max.	16.7	16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (14%)	2 (33%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (14%)	2 (33%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	2 (29%)	1 (17%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	2 (29%)	1 (17%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Cognitive Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 34	Actual Score	n	5	6
		Mean	83.33	100.00
		SD	11.785	0.000
		Median	83.33	100.00
		Min.	66.7	100.0
		Max.	100.0	100.0
	Change from Baseline	n	5	6
		Mean	-3.33	5.56
		SD	13.944	8.607
		Median	0.00	0.00
		Min.	-16.7	0.0
		Max.	16.7	16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (20%)	2 (33%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (20%)	2 (33%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	2 (40%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	2 (40%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Cognitive Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 37	Actual Score	n	4	6
		Mean	87.50	97.22
		SD	15.957	6.804
		Median	91.67	100.00
		Min.	66.7	83.3
		Max.	100.0	100.0
	Change from Baseline	n	4	6
		Mean	-8.33	2.78
		SD	21.517	12.546
		Median	-8.33	0.00
		Min.	-33.3	-16.7
		Max.	16.7	16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (25%)	2 (33%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (25%)	2 (33%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	2 (50%)	1 (17%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	2 (50%)	1 (17%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Cognitive Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 40	Actual Score	n	4	5
		Mean	91.67	100.00
		SD	9.623	0.000
		Median	91.67	100.00
		Min.	83.3	100.0
		Max.	100.0	100.0
	Change from Baseline	n	4	5
		Mean	-4.17	6.67
		SD	8.333	9.129
		Median	0.00	0.00
		Min.	-16.7	0.0
		Max.	0.0	16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	2 (40%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	2 (40%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (25%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (25%)	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_c30_dom.sas 10MAR2023 10:38

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Cognitive Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 43	Actual Score	n	4	4
		Mean	83.33	95.83
		SD	33.333	8.333
		Median	100.00	100.00
		Min.	33.3	83.3
		Max.	100.0	100.0
	Change from Baseline	n	4	4
		Mean	-12.50	4.17
		SD	36.956	8.333
		Median	0.00	0.00
		Min.	-66.7	0.0
		Max.	16.7	16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (25%)	1 (25%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (25%)	1 (25%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (25%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (25%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Cognitive Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 46	Actual Score	n	3	4
		Mean	88.89	95.83
		SD	9.623	8.333
		Median	83.33	100.00
		Min.	83.3	83.3
		Max.	100.0	100.0
	Change from Baseline	n	3	4
		Mean	-5.56	4.17
		SD	9.623	15.957
		Median	0.00	8.33
		Min.	-16.7	-16.7
		Max.	0.0	16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	2 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	2 (50%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (33%)	1 (25%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (33%)	1 (25%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Cognitive Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 49	Actual Score	n	3	4
		Mean	88.89	91.67
		SD	9.623	16.667
		Median	83.33	100.00
		Min.	83.3	66.7
		Max.	100.0	100.0
	Change from Baseline	n	3	4
		Mean	-5.56	0.00
		SD	9.623	23.570
		Median	0.00	8.33
		Min.	-16.7	-33.3
		Max.	0.0	16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	2 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	2 (50%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (33%)	1 (25%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (33%)	1 (25%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Cognitive Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 52	Actual Score	n	3	4
		Mean	88.89	95.83
		SD	9.623	8.333
		Median	83.33	100.00
		Min.	83.3	83.3
		Max.	100.0	100.0
	Change from Baseline	n	3	4
		Mean	-5.56	4.17
		SD	9.623	8.333
		Median	0.00	0.00
		Min.	-16.7	0.0
		Max.	0.0	16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (25%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (25%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (33%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (33%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Cognitive Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 55	Actual Score	n	3	3
		Mean	94.44	100.00
		SD	9.623	0.000
		Median	100.00	100.00
		Min.	83.3	100.0
		Max.	100.0	100.0
	Change from Baseline	n	3	3
		Mean	0.00	11.11
		SD	0.000	9.623
		Median	0.00	16.67
		Min.	0.0	0.0
		Max.	0.0	16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	2 (67%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	2 (67%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Cognitive Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 58	Actual Score	n	2	2
		Mean	75.00	100.00
		SD	11.785	0.000
		Median	75.00	100.00
		Min.	66.7	100.0
		Max.	83.3	100.0
	Change from Baseline	n	2	2
		Mean	-16.67	8.33
		SD	23.570	11.785
		Median	-16.67	8.33
		Min.	-33.3	0.0
		Max.	0.0	16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (50%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Cognitive Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 61	Actual Score	n	2	2
		Mean	66.67	100.00
		SD	23.570	0.000
		Median	66.67	100.00
		Min.	50.0	100.0
		Max.	83.3	100.0
	Change from Baseline	n	2	2
		Mean	-25.00	8.33
		SD	35.355	11.785
		Median	-25.00	8.33
		Min.	-50.0	0.0
		Max.	0.0	16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (50%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Cognitive Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 64	Actual Score	n	2	2
		Mean	66.67	100.00
		SD	23.570	0.000
		Median	66.67	100.00
		Min.	50.0	100.0
		Max.	83.3	100.0
	Change from Baseline	n	2	2
		Mean	-25.00	8.33
		SD	35.355	11.785
		Median	-25.00	8.33
		Min.	-50.0	0.0
		Max.	0.0	16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (50%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_c30_dom.sas 10MAR2023 10:38

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Cognitive Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 67	Actual Score	n	2	2
		Mean	83.33	91.67
		SD	0.000	11.785
		Median	83.33	91.67
		Min.	83.3	83.3
		Max.	83.3	100.0
	Change from Baseline	n	2	2
		Mean	-8.33	0.00
		SD	11.785	0.000
		Median	-8.33	0.00
		Min.	-16.7	0.0
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Cognitive Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 70	Actual Score	n	2	1
		Mean	91.67	100.00
		SD	11.785	
		Median	91.67	100.00
		Min.	83.3	100.0
		Max.	100.0	100.0
	Change from Baseline	n	2	1
		Mean	0.00	0.00
		SD	0.000	
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_c30_dom.sas 10MAR2023 10:38

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Cognitive Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 73	Actual Score	n	1	1
		Mean	83.33	100.00
		SD		
		Median	83.33	100.00
		Min.	83.3	100.0
		Max.	83.3	100.0
	Change from Baseline	n	1	1
		Mean	-16.67	0.00
		SD		
		Median	-16.67	0.00
		Min.	-16.7	0.0
		Max.	-16.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (100%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (100%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Cognitive Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 76	Actual Score	n	2	1
		Mean	75.00	100.00
		SD	11.785	
		Median	75.00	100.00
		Min.	66.7	100.0
		Max.	83.3	100.0
	Change from Baseline	n	2	1
		Mean	-16.67	0.00
		SD	23.570	
		Median	-16.67	0.00
		Min.	-33.3	0.0
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Cognitive Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 79	Actual Score	n	2	1
		Mean	83.33	100.00
		SD	23.570	
		Median	83.33	100.00
		Min.	66.7	100.0
		Max.	100.0	100.0
	Change from Baseline	n	2	1
		Mean	-8.33	0.00
		SD	35.355	
		Median	-8.33	0.00
		Min.	-33.3	0.0
		Max.	16.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Cognitive Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 82	Actual Score	n	2	1
		Mean	83.33	100.00
		SD	23.570	
		Median	83.33	100.00
		Min.	66.7	100.0
		Max.	100.0	100.0
	Change from Baseline	n	2	1
		Mean	-8.33	0.00
		SD	35.355	
		Median	-8.33	0.00
		Min.	-33.3	0.0
		Max.	16.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Cognitive Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 85	Actual Score	n	1	1
		Mean	50.00	100.00
		SD		
		Median	50.00	100.00
		Min.	50.0	100.0
		Max.	50.0	100.0
	Change from Baseline	n	1	1
		Mean	-50.00	0.00
		SD		
		Median	-50.00	0.00
		Min.	-50.0	0.0
		Max.	-50.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (100%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (100%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Cognitive Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 88	Actual Score	n	1	1
		Mean	83.33	100.00
		SD		
		Median	83.33	100.00
		Min.	83.3	100.0
		Max.	83.3	100.0
	Change from Baseline	n	1	1
		Mean	0.00	0.00
		SD		
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Cognitive Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 91	Actual Score	n	2	1
		Mean	58.33	100.00
		SD	35.355	
		Median	58.33	100.00
		Min.	33.3	100.0
		Max.	83.3	100.0
	Change from Baseline	n	2	1
		Mean	-33.33	0.00
		SD	47.140	
		Median	-33.33	0.00
		Min.	-66.7	0.0
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Cognitive Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 94	Actual Score	n	2	1
		Mean	91.67	100.00
		SD	11.785	
		Median	91.67	100.00
		Min.	83.3	100.0
		Max.	100.0	100.0
	Change from Baseline	n	2	1
		Mean	0.00	0.00
		SD	0.000	
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Cognitive Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 97	Actual Score	n	1	0
		Mean	83.33	
		SD		
		Median	83.33	
		Min.	83.3	
		Max.	83.3	
	Change from Baseline	n	1	0
		Mean	-16.67	
		SD		
		Median	-16.67	
		Min.	-16.7	
		Max.	-16.7	
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (100%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (100%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Cognitive Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 100	Actual Score	n	0	1
		Mean		100.00
		SD		
		Median		100.00
		Min.		100.0
		Max.		100.0
	Change from Baseline	n	0	1
		Mean		0.00
		SD		
		Median		0.00
		Min.		0.0
		Max.		0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_c30_dom.sas 10MAR2023 10:38

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Cognitive Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
End of Treatment	Actual Score	n	10	11
		Mean	71.67	62.12
		SD	34.292	28.955
		Median	83.33	66.67
		Min.	0.0	16.7
		Max.	100.0	100.0
	Change from Baseline	n	9	11
		Mean	3.70	-6.06
		SD	24.689	29.129
		Median	0.00	0.00
		Min.	-16.7	-66.7
		Max.	66.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (11%)	4 (36%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (11%)	4 (36%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	2 (22%)	4 (36%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	2 (22%)	4 (36%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Cognitive Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 1	Actual Score	n	3	5
		Mean	72.22	76.67
		SD	9.623	9.129
		Median	66.67	83.33
		Min.	66.7	66.7
		Max.	83.3	83.3
	Change from Baseline	n	2	5
		Mean	8.33	16.67
		SD	35.355	11.785
		Median	8.33	16.67
		Min.	-16.7	0.0
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	4 (80%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	4 (80%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Cognitive Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 2	Actual Score	n	3	3
		Mean	44.44	61.11
		SD	25.459	9.623
		Median	50.00	66.67
		Min.	16.7	50.0
		Max.	66.7	66.7
	Change from Baseline	n	2	3
		Mean	-25.00	5.56
		SD	58.926	9.623
		Median	-25.00	0.00
		Min.	-66.7	0.0
		Max.	16.7	16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	1 (33%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	1 (33%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Cognitive Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 4	Actual Score	n	0	2
		Mean		75.00
		SD		11.785
		Median		75.00
		Min.		66.7
		Max.		83.3
	Change from Baseline	n	0	2
		Mean		8.33
		SD		11.785
		Median		8.33
		Min.		0.0
		Max.		16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (50%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Cognitive Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
PFS Follow-Up 2	Actual Score	n	1	1
		Mean	50.00	66.67
		SD		
		Median	50.00	66.67
		Min.	50.0	66.7
		Max.	50.0	66.7
	Change from Baseline	n	1	1
		Mean	0.00	0.00
		SD		
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_c30_dom.sas 10MAR2023 10:38

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Cognitive Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
PFS Follow-Up 4	Actual Score	n	0	1
		Mean		66.67
		SD		
		Median		66.67
		Min.		66.7
		Max.		66.7
	Change from Baseline	n	0	1
		Mean		0.00
		SD		
		Median		0.00
		Min.		0.0
		Max.		0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Cognitive Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Last Follow-up	Actual Score	n	3	5
		Mean	44.44	70.00
		SD	25.459	13.944
		Median	50.00	66.67
		Min.	16.7	50.0
		Max.	66.7	83.3
	Change from Baseline	n	2	5
		Mean	-25.00	10.00
		SD	58.926	9.129
		Median	-25.00	16.67
		Min.	-66.7	0.0
		Max.	16.7	16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	3 (60%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	3 (60%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Cognitive Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Worst Case Post-Baseline	Actual Score	n	13	25
		Mean	55.13	60.67
		SD	29.957	26.300
		Median	66.67	66.67
		Min.	0.0	16.7
		Max.	100.0	100.0
	Change from Baseline	n	12	25
		Mean	-19.44	-12.67
		SD	33.207	25.129
		Median	-16.67	0.00
		Min.	-66.7	-66.7
		Max.	50.0	16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (8%)	5 (20%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (8%)	5 (20%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	7 (58%)	11 (44%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	7 (58%)	11 (44%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Social Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Baseline	Actual Score	n	13	27
		Mean	67.95	60.49
		SD	30.778	35.551
		Median	66.67	66.67
		Min.	0.0	0.0
		Max.	100.0	100.0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Social Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 4	Actual Score	n	13	23
		Mean	65.38	61.59
		SD	42.197	36.734
		Median	83.33	66.67
		Min.	0.0	0.0
		Max.	100.0	100.0
	Change from Baseline	n	12	23
		Mean	-2.78	-3.62
		SD	24.447	19.434
		Median	0.00	0.00
		Min.	-66.7	-50.0
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (25%)	4 (17%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (25%)	4 (17%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	3 (25%)	7 (30%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	3 (25%)	7 (30%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Social Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 7	Actual Score	n	12	17
		Mean	68.06	68.63
		SD	25.084	31.115
		Median	66.67	66.67
		Min.	33.3	16.7
		Max.	100.0	100.0
	Change from Baseline	n	11	17
		Mean	-1.52	5.88
		SD	15.731	17.620
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	16.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (27%)	6 (35%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (27%)	6 (35%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	3 (27%)	2 (12%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	3 (27%)	2 (12%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Social Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 10	Actual Score	n	13	12
		Mean	66.67	58.33
		SD	31.914	37.268
		Median	66.67	66.67
		Min.	0.0	0.0
		Max.	100.0	100.0
	Change from Baseline	n	12	12
		Mean	-2.78	-4.17
		SD	13.914	27.639
		Median	0.00	0.00
		Min.	-33.3	-66.7
		Max.	16.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (17%)	3 (25%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (17%)	3 (25%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	3 (25%)	4 (33%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	3 (25%)	4 (33%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Social Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 13	Actual Score	n	13	9
		Mean	62.82	74.07
		SD	33.440	31.304
		Median	66.67	83.33
		Min.	0.0	33.3
		Max.	100.0	100.0
	Change from Baseline	n	12	9
		Mean	-5.56	1.85
		SD	22.845	15.466
		Median	0.00	0.00
		Min.	-66.7	-16.7
		Max.	16.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (25%)	2 (22%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (25%)	2 (22%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	4 (33%)	2 (22%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	4 (33%)	2 (22%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Social Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 16	Actual Score	n	11	8
		Mean	65.15	66.67
		SD	37.605	34.503
		Median	66.67	75.00
		Min.	0.0	16.7
		Max.	100.0	100.0
	Change from Baseline	n	10	8
		Mean	1.67	-6.25
		SD	28.814	26.633
		Median	0.00	0.00
		Min.	-66.7	-66.7
		Max.	33.3	16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (40%)	2 (25%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	4 (40%)	2 (25%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	2 (20%)	2 (25%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	2 (20%)	2 (25%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Social Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 19	Actual Score	n	12	7
		Mean	70.83	73.81
		SD	36.324	30.211
		Median	83.33	83.33
		Min.	0.0	33.3
		Max.	100.0	100.0
	Change from Baseline	n	11	7
		Mean	6.06	4.76
		SD	28.159	15.853
		Median	16.67	0.00
		Min.	-66.7	-16.7
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	7 (64%)	2 (29%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	7 (64%)	2 (29%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	2 (18%)	1 (14%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	2 (18%)	1 (14%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Social Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 22	Actual Score	n	7	7
		Mean	66.67	76.19
		SD	33.333	31.706
		Median	66.67	100.00
		Min.	0.0	33.3
		Max.	100.0	100.0
	Change from Baseline	n	7	7
		Mean	0.00	-7.14
		SD	34.694	30.211
		Median	0.00	0.00
		Min.	-66.7	-66.7
		Max.	50.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (29%)	1 (14%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (29%)	1 (14%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (14%)	2 (29%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (14%)	2 (29%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Social Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 25	Actual Score	n	7	7
		Mean	71.43	71.43
		SD	40.500	40.500
		Median	100.00	100.00
		Min.	0.0	0.0
		Max.	100.0	100.0
	Change from Baseline	n	7	7
		Mean	0.00	2.38
		SD	31.914	14.996
		Median	0.00	0.00
		Min.	-66.7	-16.7
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (43%)	1 (14%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (43%)	1 (14%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (14%)	1 (14%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (14%)	1 (14%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Social Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 28	Actual Score	n	7	6
		Mean	83.33	80.56
		SD	37.268	26.701
		Median	100.00	91.67
		Min.	0.0	33.3
		Max.	100.0	100.0
	Change from Baseline	n	7	6
		Mean	11.90	0.00
		SD	41.627	10.541
		Median	16.67	0.00
		Min.	-66.7	-16.7
		Max.	66.7	16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (57%)	1 (17%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	4 (57%)	1 (17%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (14%)	1 (17%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (14%)	1 (17%)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_c30_dom.sas 10MAR2023 10:38

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Social Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 31	Actual Score	n	7	6
		Mean	85.71	80.56
		SD	26.227	19.484
		Median	100.00	83.33
		Min.	33.3	50.0
		Max.	100.0	100.0
	Change from Baseline	n	7	6
		Mean	14.29	0.00
		SD	27.936	10.541
		Median	16.67	0.00
		Min.	-33.3	-16.7
		Max.	50.0	16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (57%)	1 (17%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	4 (57%)	1 (17%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (14%)	1 (17%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (14%)	1 (17%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Social Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 34	Actual Score	n	5	6
		Mean	76.67	83.33
		SD	27.889	21.082
		Median	83.33	91.67
		Min.	33.3	50.0
		Max.	100.0	100.0
	Change from Baseline	n	5	6
		Mean	-3.33	2.78
		SD	18.257	6.804
		Median	0.00	0.00
		Min.	-33.3	0.0
		Max.	16.7	16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (20%)	1 (17%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (20%)	1 (17%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (20%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (20%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Social Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 37	Actual Score	n	4	6
		Mean	83.33	80.56
		SD	23.570	26.701
		Median	91.67	91.67
		Min.	50.0	33.3
		Max.	100.0	100.0
	Change from Baseline	n	4	6
		Mean	0.00	0.00
		SD	23.570	10.541
		Median	-8.33	0.00
		Min.	-16.7	-16.7
		Max.	33.3	16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (25%)	1 (17%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (25%)	1 (17%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	2 (50%)	1 (17%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	2 (50%)	1 (17%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Social Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 40	Actual Score	n	4	5
		Mean	66.67	83.33
		SD	38.490	23.570
		Median	66.67	100.00
		Min.	33.3	50.0
		Max.	100.0	100.0
	Change from Baseline	n	4	5
		Mean	-16.67	6.67
		SD	43.033	14.907
		Median	-16.67	0.00
		Min.	-66.7	0.0
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (25%)	1 (20%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (25%)	1 (20%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	2 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	2 (50%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Social Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 43	Actual Score	n	4	4
		Mean	75.00	75.00
		SD	50.000	31.914
		Median	100.00	83.33
		Min.	0.0	33.3
		Max.	100.0	100.0
	Change from Baseline	n	4	4
		Mean	-8.33	4.17
		SD	41.944	20.972
		Median	0.00	0.00
		Min.	-66.7	-16.7
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (25%)	1 (25%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (25%)	1 (25%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (25%)	1 (25%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (25%)	1 (25%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Social Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 46	Actual Score	n	3	4
		Mean	72.22	79.17
		SD	48.113	25.000
		Median	100.00	83.33
		Min.	16.7	50.0
		Max.	100.0	100.0
	Change from Baseline	n	3	4
		Mean	-16.67	8.33
		SD	28.868	16.667
		Median	0.00	0.00
		Min.	-50.0	0.0
		Max.	0.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (25%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (25%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (33%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (33%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Social Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 49	Actual Score	n	3	4
		Mean	77.78	87.50
		SD	38.490	25.000
		Median	100.00	100.00
		Min.	33.3	50.0
		Max.	100.0	100.0
	Change from Baseline	n	3	4
		Mean	-11.11	16.67
		SD	19.245	19.245
		Median	0.00	16.67
		Min.	-33.3	0.0
		Max.	0.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	2 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	2 (50%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (33%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (33%)	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_c30_dom.sas 10MAR2023 10:38

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Social Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 52	Actual Score	n	3	4
		Mean	77.78	79.17
		SD	38.490	25.000
		Median	100.00	83.33
		Min.	33.3	50.0
		Max.	100.0	100.0
	Change from Baseline	n	3	4
		Mean	-11.11	8.33
		SD	19.245	16.667
		Median	0.00	0.00
		Min.	-33.3	0.0
		Max.	0.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (25%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (25%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (33%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (33%)	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_c30_dom.sas 10MAR2023 10:38

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Social Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 55	Actual Score	n	3	3
		Mean	100.00	88.89
		SD	0.000	19.245
		Median	100.00	100.00
		Min.	100.0	66.7
		Max.	100.0	100.0
	Change from Baseline	n	3	3
		Mean	11.11	11.11
		SD	19.245	19.245
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (33%)	1 (33%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (33%)	1 (33%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Social Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 58	Actual Score	n	2	2
		Mean	50.00	83.33
		SD	70.711	23.570
		Median	50.00	83.33
		Min.	0.0	66.7
		Max.	100.0	100.0
	Change from Baseline	n	2	2
		Mean	-33.33	16.67
		SD	47.140	23.570
		Median	-33.33	16.67
		Min.	-66.7	0.0
		Max.	0.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (50%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Social Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 61	Actual Score	n	2	2
		Mean	50.00	83.33
		SD	23.570	23.570
		Median	50.00	83.33
		Min.	33.3	66.7
		Max.	66.7	100.0
	Change from Baseline	n	2	2
		Mean	-33.33	16.67
		SD	0.000	23.570
		Median	-33.33	16.67
		Min.	-33.3	0.0
		Max.	-33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (50%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	2 (100%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	2 (100%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Social Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 64	Actual Score	n	2	2
		Mean	50.00	100.00
		SD	23.570	0.000
		Median	50.00	100.00
		Min.	33.3	100.0
		Max.	66.7	100.0
	Change from Baseline	n	2	2
		Mean	-33.33	33.33
		SD	0.000	0.000
		Median	-33.33	33.33
		Min.	-33.3	33.3
		Max.	-33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	2 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	2 (100%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	2 (100%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	2 (100%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Social Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 67	Actual Score	n	2	2
		Mean	66.67	83.33
		SD	0.000	23.570
		Median	66.67	83.33
		Min.	66.7	66.7
		Max.	66.7	100.0
	Change from Baseline	n	2	2
		Mean	-16.67	16.67
		SD	23.570	23.570
		Median	-16.67	16.67
		Min.	-33.3	0.0
		Max.	0.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (50%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Social Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 70	Actual Score	n	2	1
		Mean	66.67	100.00
		SD	47.140	
		Median	66.67	100.00
		Min.	33.3	100.0
		Max.	100.0	100.0
	Change from Baseline	n	2	1
		Mean	-16.67	33.33
		SD	23.570	
		Median	-16.67	33.33
		Min.	-33.3	33.3
		Max.	0.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (100%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Social Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 73	Actual Score	n	1	1
		Mean	50.00	66.67
		SD		
		Median	50.00	66.67
		Min.	50.0	66.7
		Max.	50.0	66.7
	Change from Baseline	n	1	1
		Mean	-16.67	0.00
		SD		
		Median	-16.67	0.00
		Min.	-16.7	0.0
		Max.	-16.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (100%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (100%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Social Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 76	Actual Score	n	2	1
		Mean	75.00	66.67
		SD	35.355	
		Median	75.00	66.67
		Min.	50.0	66.7
		Max.	100.0	66.7
	Change from Baseline	n	2	1
		Mean	-8.33	0.00
		SD	11.785	
		Median	-8.33	0.00
		Min.	-16.7	0.0
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Social Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 79	Actual Score	n	2	1
		Mean	58.33	66.67
		SD	11.785	
		Median	58.33	66.67
		Min.	50.0	66.7
		Max.	66.7	66.7
	Change from Baseline	n	2	1
		Mean	-25.00	0.00
		SD	11.785	
		Median	-25.00	0.00
		Min.	-33.3	0.0
		Max.	-16.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	2 (100%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	2 (100%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Social Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 82	Actual Score	n	2	1
		Mean	75.00	66.67
		SD	35.355	
		Median	75.00	66.67
		Min.	50.0	66.7
		Max.	100.0	66.7
	Change from Baseline	n	2	1
		Mean	-8.33	0.00
		SD	11.785	
		Median	-8.33	0.00
		Min.	-16.7	0.0
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Social Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 85	Actual Score	n	1	1
		Mean	66.67	100.00
		SD		
		Median	66.67	100.00
		Min.	66.7	100.0
		Max.	66.7	100.0
	Change from Baseline	n	1	1
		Mean	0.00	33.33
		SD		
		Median	0.00	33.33
		Min.	0.0	33.3
		Max.	0.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (100%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Social Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 88	Actual Score	n	1	1
		Mean	100.00	100.00
		SD		
		Median	100.00	100.00
		Min.	100.0	100.0
		Max.	100.0	100.0
	Change from Baseline	n	1	1
		Mean	0.00	33.33
		SD		
		Median	0.00	33.33
		Min.	0.0	33.3
		Max.	0.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (100%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_c30_dom.sas 10MAR2023 10:38

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Social Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 91	Actual Score	n	2	1
		Mean	66.67	66.67
		SD	47.140	
		Median	66.67	66.67
		Min.	33.3	66.7
		Max.	100.0	66.7
	Change from Baseline	n	2	1
		Mean	-16.67	0.00
		SD	23.570	
		Median	-16.67	0.00
		Min.	-33.3	0.0
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Social Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 94	Actual Score	n	2	1
		Mean	83.33	66.67
		SD	23.570	
		Median	83.33	66.67
		Min.	66.7	66.7
		Max.	100.0	66.7
	Change from Baseline	n	2	1
		Mean	0.00	0.00
		SD	0.000	
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_c30_dom.sas 10MAR2023 10:38

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Social Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 97	Actual Score	n	1	0
		Mean	66.67	
		SD		
		Median	66.67	
		Min.	66.7	
		Max.	66.7	
	Change from Baseline	n	1	0
		Mean	0.00	
		SD		
		Median	0.00	
		Min.	0.0	
		Max.	0.0	
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_c30_dom.sas 10MAR2023 10:38

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Social Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 100	Actual Score	n	0	1
		Mean		66.67
		SD		
		Median		66.67
		Min.		66.7
		Max.		66.7
	Change from Baseline	n	0	1
		Mean		0.00
		SD		
		Median		0.00
		Min.		0.0
		Max.		0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_c30_dom.sas 10MAR2023 10:38

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Social Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
End of Treatment	Actual Score	n	10	11
		Mean	68.33	45.45
		SD	33.747	42.224
		Median	66.67	66.67
		Min.	0.0	0.0
		Max.	100.0	100.0
	Change from Baseline	n	9	11
		Mean	5.56	-21.21
		SD	34.359	22.473
		Median	0.00	-33.33
		Min.	-66.7	-50.0
		Max.	50.0	16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (44%)	1 (9%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	4 (44%)	1 (9%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	2 (22%)	7 (64%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	2 (22%)	7 (64%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Social Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 1	Actual Score	n	3	4
		Mean	55.56	41.67
		SD	25.459	31.914
		Median	50.00	50.00
		Min.	33.3	0.0
		Max.	83.3	66.7
	Change from Baseline	n	2	4
		Mean	25.00	-16.67
		SD	11.785	30.429
		Median	25.00	-16.67
		Min.	16.7	-50.0
		Max.	33.3	16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (100%)	1 (25%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (100%)	1 (25%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	2 (50%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	2 (50%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Social Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 2	Actual Score	n	3	3
		Mean	61.11	44.44
		SD	41.944	41.944
		Median	66.67	50.00
		Min.	16.7	0.0
		Max.	100.0	83.3
	Change from Baseline	n	2	3
		Mean	41.67	-16.67
		SD	58.926	16.667
		Median	41.67	-16.67
		Min.	0.0	-33.3
		Max.	83.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	2 (67%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	2 (67%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Social Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 4	Actual Score	n	0	2
		Mean		66.67
		SD		0.000
		Median		66.67
		Min.		66.7
		Max.		66.7
	Change from Baseline	n	0	2
		Mean		-8.33
		SD		35.355
		Median		-8.33
		Min.		-33.3
		Max.		16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (50%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (50%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (50%)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_c30_dom.sas 10MAR2023 10:38

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Social Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
PFS Follow-Up 2	Actual Score	n	1	1
		Mean	66.67	66.67
		SD		
		Median	66.67	66.67
		Min.	66.7	66.7
		Max.	66.7	66.7
	Change from Baseline	n	1	1
		Mean	0.00	-33.33
		SD		
		Median	0.00	-33.33
		Min.	0.0	-33.3
		Max.	0.0	-33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (100%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (100%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Social Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
PFS Follow-Up 4	Actual Score	n	0	1
		Mean		100.00
		SD		
		Median		100.00
		Min.		100.0
		Max.		100.0
	Change from Baseline	n	0	1
		Mean		0.00
		SD		
		Median		0.00
		Min.		0.0
		Max.		0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Social Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Last Follow-up	Actual Score	n	3	4
		Mean	61.11	33.33
		SD	41.944	38.490
		Median	66.67	33.33
		Min.	16.7	0.0
		Max.	100.0	66.7
	Change from Baseline	n	2	4
		Mean	41.67	-25.00
		SD	58.926	28.868
		Median	41.67	-33.33
		Min.	0.0	-50.0
		Max.	83.3	16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	1 (25%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	1 (25%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	3 (75%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	3 (75%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Social Functioning Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Worst Case Post-Baseline	Actual Score	n	13	25
		Mean	44.87	44.00
		SD	35.606	38.454
		Median	33.33	33.33
		Min.	0.0	0.0
		Max.	100.0	100.0
	Change from Baseline	n	12	25
		Mean	-25.00	-18.67
		SD	32.177	24.683
		Median	-16.67	-16.67
		Min.	-66.7	-66.7
		Max.	16.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (8%)	1 (4%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (8%)	1 (4%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	7 (58%)	14 (56%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	7 (58%)	14 (56%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Fatigue Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Baseline	Actual Score	n	12	27
		Mean	47.22	50.82
		SD	24.675	29.506
		Median	44.44	55.56
		Min.	0.0	0.0
		Max.	77.8	100.0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Fatigue Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 4	Actual Score	n	13	23
		Mean	47.86	49.28
		SD	23.300	33.304
		Median	44.44	44.44
		Min.	11.1	0.0
		Max.	88.9	100.0
	Change from Baseline	n	11	23
		Mean	0.00	1.21
		SD	27.217	17.404
		Median	0.00	0.00
		Min.	-33.3	-22.2
		Max.	66.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	5 (45%)	8 (35%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	5 (45%)	8 (35%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	3 (27%)	9 (39%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	3 (27%)	9 (39%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Fatigue Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 7	Actual Score	n	12	17
		Mean	46.30	45.10
		SD	24.542	38.384
		Median	44.44	33.33
		Min.	0.0	0.0
		Max.	88.9	100.0
	Change from Baseline	n	10	17
		Mean	2.22	-2.29
		SD	27.617	19.150
		Median	0.00	0.00
		Min.	-33.3	-44.4
		Max.	55.6	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (40%)	4 (24%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	4 (40%)	4 (24%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	4 (40%)	6 (35%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	4 (40%)	5 (29%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Fatigue Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 10	Actual Score	n	13	12
		Mean	46.15	41.67
		SD	28.991	36.430
		Median	44.44	33.33
		Min.	0.0	0.0
		Max.	88.9	100.0
	Change from Baseline	n	11	12
		Mean	1.01	-1.39
		SD	27.422	23.466
		Median	0.00	0.00
		Min.	-33.3	-44.4
		Max.	44.4	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	5 (45%)	4 (33%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	5 (45%)	4 (33%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	4 (36%)	4 (33%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	4 (36%)	4 (33%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Fatigue Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 13	Actual Score	n	13	9
		Mean	49.57	30.86
		SD	20.090	24.074
		Median	44.44	33.33
		Min.	22.2	0.0
		Max.	88.9	77.8
	Change from Baseline	n	11	9
		Mean	3.03	-11.73
		SD	20.543	23.314
		Median	11.11	-22.22
		Min.	-33.3	-44.4
		Max.	33.3	22.2
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (36%)	6 (67%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	4 (36%)	6 (67%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	6 (55%)	3 (33%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	6 (55%)	3 (33%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Fatigue Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 16	Actual Score	n	12	8
		Mean	36.11	38.89
		SD	23.748	40.717
		Median	27.78	22.22
		Min.	11.1	0.0
		Max.	100.0	100.0
	Change from Baseline	n	10	8
		Mean	-13.33	3.47
		SD	19.458	37.906
		Median	-11.11	-5.56
		Min.	-44.4	-44.4
		Max.	11.1	77.8
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	6 (60%)	4 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	6 (60%)	4 (50%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	2 (20%)	3 (38%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	2 (20%)	3 (38%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Fatigue Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 19	Actual Score	n	12	7
		Mean	41.67	38.10
		SD	30.011	28.586
		Median	38.89	33.33
		Min.	0.0	0.0
		Max.	88.9	88.9
	Change from Baseline	n	10	7
		Mean	-4.44	0.79
		SD	35.602	20.394
		Median	-16.67	0.00
		Min.	-44.4	-33.3
		Max.	55.6	27.8
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	7 (70%)	2 (29%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	7 (70%)	2 (29%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	3 (30%)	2 (29%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	3 (30%)	2 (29%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Fatigue Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 22	Actual Score	n	7	7
		Mean	28.57	19.05
		SD	17.982	20.998
		Median	33.33	22.22
		Min.	0.0	0.0
		Max.	44.4	55.6
	Change from Baseline	n	6	7
		Mean	-22.22	-7.14
		SD	14.055	19.435
		Median	-27.78	0.00
		Min.	-33.3	-33.3
		Max.	0.0	22.2
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	5 (83%)	3 (43%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	5 (83%)	3 (43%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	2 (29%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (14%)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_c30_dom.sas 10MAR2023 10:38

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Fatigue Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 25	Actual Score	n	7	7
		Mean	31.75	25.40
		SD	20.716	29.197
		Median	33.33	11.11
		Min.	0.0	0.0
		Max.	66.7	66.7
	Change from Baseline	n	6	7
		Mean	-14.81	-3.17
		SD	15.181	24.607
		Median	-11.11	0.00
		Min.	-33.3	-44.4
		Max.	0.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (67%)	2 (29%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	4 (67%)	2 (29%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	2 (29%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	2 (29%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Fatigue Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 28	Actual Score	n	7	6
		Mean	30.16	14.81
		SD	17.817	24.003
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	55.6	55.6
	Change from Baseline	n	6	6
		Mean	-16.67	-12.96
		SD	28.760	26.682
		Median	-16.67	-11.11
		Min.	-55.6	-55.6
		Max.	22.2	22.2
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (50%)	3 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (50%)	3 (50%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (17%)	1 (17%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (17%)	1 (17%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Fatigue Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 31	Actual Score	n	7	6
		Mean	22.22	25.93
		SD	18.144	26.912
		Median	33.33	22.22
		Min.	0.0	0.0
		Max.	44.4	66.7
	Change from Baseline	n	6	6
		Mean	-20.37	-1.85
		SD	21.564	21.564
		Median	-27.78	-5.56
		Min.	-44.4	-22.2
		Max.	11.1	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (67%)	3 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	4 (67%)	3 (50%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (17%)	2 (33%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (17%)	2 (33%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Fatigue Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 34	Actual Score	n	5	6
		Mean	28.89	22.22
		SD	16.851	23.307
		Median	33.33	16.67
		Min.	0.0	0.0
		Max.	44.4	55.6
	Change from Baseline	n	4	6
		Mean	-13.89	-5.56
		SD	22.906	18.257
		Median	-16.67	0.00
		Min.	-33.3	-33.3
		Max.	11.1	11.1
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (50%)	2 (33%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (50%)	2 (33%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (25%)	2 (33%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (25%)	2 (33%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Fatigue Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 37	Actual Score	n	4	6
		Mean	30.56	16.67
		SD	16.667	23.040
		Median	33.33	5.56
		Min.	11.1	0.0
		Max.	44.4	55.6
	Change from Baseline	n	3	6
		Mean	3.70	-11.11
		SD	23.130	23.307
		Median	11.11	-11.11
		Min.	-22.2	-44.4
		Max.	22.2	22.2
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (33%)	3 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (33%)	3 (50%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	2 (67%)	1 (17%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	2 (67%)	1 (17%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Fatigue Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 40	Actual Score	n	4	5
		Mean	30.56	15.56
		SD	30.598	14.907
		Median	27.78	22.22
		Min.	0.0	0.0
		Max.	66.7	33.3
	Change from Baseline	n	3	5
		Mean	7.41	-6.67
		SD	39.021	21.660
		Median	11.11	0.00
		Min.	-33.3	-33.3
		Max.	44.4	22.2
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (33%)	2 (40%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (33%)	2 (40%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	2 (67%)	1 (20%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	2 (67%)	1 (20%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Fatigue Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 43	Actual Score	n	4	4
		Mean	38.89	8.33
		SD	26.450	10.638
		Median	27.78	5.56
		Min.	22.2	0.0
		Max.	77.8	22.2
	Change from Baseline	n	3	4
		Mean	14.81	-19.44
		SD	25.660	18.976
		Median	0.00	-16.67
		Min.	0.0	-44.4
		Max.	44.4	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	3 (75%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	3 (75%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (33%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (33%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Fatigue Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 46	Actual Score	n	3	4
		Mean	29.63	16.67
		SD	32.075	14.344
		Median	11.11	16.67
		Min.	11.1	0.0
		Max.	66.7	33.3
	Change from Baseline	n	3	4
		Mean	0.00	-11.11
		SD	29.397	30.089
		Median	-11.11	0.00
		Min.	-22.2	-55.6
		Max.	33.3	11.1
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (67%)	1 (25%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (67%)	1 (25%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (33%)	1 (25%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (33%)	1 (25%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Fatigue Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 49	Actual Score	n	3	4
		Mean	22.22	22.22
		SD	11.111	20.286
		Median	22.22	22.22
		Min.	11.1	0.0
		Max.	33.3	44.4
	Change from Baseline	n	3	4
		Mean	-7.41	-5.56
		SD	12.830	14.344
		Median	0.00	-5.56
		Min.	-22.2	-22.2
		Max.	0.0	11.1
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (33%)	2 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (33%)	2 (50%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (25%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (25%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Fatigue Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 52	Actual Score	n	3	3
		Mean	25.93	22.22
		SD	6.415	19.245
		Median	22.22	11.11
		Min.	22.2	11.1
		Max.	33.3	44.4
	Change from Baseline	n	3	3
		Mean	-3.70	-7.41
		SD	6.415	32.075
		Median	0.00	11.11
		Min.	-11.1	-44.4
		Max.	0.0	11.1
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (33%)	1 (33%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (33%)	1 (33%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	2 (67%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	2 (67%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Fatigue Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 55	Actual Score	n	3	3
		Mean	29.63	7.41
		SD	6.415	6.415
		Median	33.33	11.11
		Min.	22.2	0.0
		Max.	33.3	11.1
	Change from Baseline	n	3	3
		Mean	0.00	-18.52
		SD	0.000	27.962
		Median	0.00	-22.22
		Min.	0.0	-44.4
		Max.	0.0	11.1
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	2 (67%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	2 (67%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (33%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (33%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Fatigue Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 58	Actual Score	n	2	2
		Mean	50.00	5.56
		SD	39.284	7.857
		Median	50.00	5.56
		Min.	22.2	0.0
		Max.	77.8	11.1
	Change from Baseline	n	2	2
		Mean	22.22	-22.22
		SD	31.427	31.427
		Median	22.22	-22.22
		Min.	0.0	-44.4
		Max.	44.4	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (50%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Fatigue Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 61	Actual Score	n	2	2
		Mean	66.67	16.67
		SD	31.427	23.570
		Median	66.67	16.67
		Min.	44.4	0.0
		Max.	88.9	33.3
	Change from Baseline	n	2	2
		Mean	38.89	-11.11
		SD	39.284	15.713
		Median	38.89	-11.11
		Min.	11.1	-22.2
		Max.	66.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (50%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	2 (100%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	2 (100%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Fatigue Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 64	Actual Score	n	2	2
		Mean	38.89	11.11
		SD	7.857	15.713
		Median	38.89	11.11
		Min.	33.3	0.0
		Max.	44.4	22.2
	Change from Baseline	n	2	2
		Mean	11.11	-16.67
		SD	0.000	23.570
		Median	11.11	-16.67
		Min.	11.1	-33.3
		Max.	11.1	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (50%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	2 (100%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	2 (100%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Fatigue Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 67	Actual Score	n	2	2
		Mean	38.89	16.67
		SD	7.857	7.857
		Median	38.89	16.67
		Min.	33.3	11.1
		Max.	44.4	22.2
	Change from Baseline	n	2	2
		Mean	11.11	-11.11
		SD	15.713	31.427
		Median	11.11	-11.11
		Min.	0.0	-33.3
		Max.	22.2	11.1
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (50%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	1 (50%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	1 (50%)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_c30_dom.sas 10MAR2023 10:38

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Fatigue Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 70	Actual Score	n	2	1
		Mean	44.44	0.00
		SD	15.713	
		Median	44.44	0.00
		Min.	33.3	0.0
		Max.	55.6	0.0
	Change from Baseline	n	2	1
		Mean	16.67	0.00
		SD	7.857	
		Median	16.67	0.00
		Min.	11.1	0.0
		Max.	22.2	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	2 (100%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	2 (100%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Fatigue Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 73	Actual Score	n	1	1
		Mean	77.78	11.11
		SD		
		Median	77.78	11.11
		Min.	77.8	11.1
		Max.	77.8	11.1
	Change from Baseline	n	1	1
		Mean	44.44	11.11
		SD		
		Median	44.44	11.11
		Min.	44.4	11.1
		Max.	44.4	11.1
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (100%)	1 (100%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (100%)	1 (100%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Fatigue Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 76	Actual Score	n	2	1
		Mean	44.44	0.00
		SD	15.713	
		Median	44.44	0.00
		Min.	33.3	0.0
		Max.	55.6	0.0
	Change from Baseline	n	2	1
		Mean	16.67	0.00
		SD	7.857	
		Median	16.67	0.00
		Min.	11.1	0.0
		Max.	22.2	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	2 (100%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	2 (100%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Fatigue Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 79	Actual Score	n	2	1
		Mean	38.89	11.11
		SD	23.570	
		Median	38.89	11.11
		Min.	22.2	11.1
		Max.	55.6	11.1
	Change from Baseline	n	2	1
		Mean	11.11	11.11
		SD	15.713	
		Median	11.11	11.11
		Min.	0.0	11.1
		Max.	22.2	11.1
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	1 (100%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	1 (100%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Fatigue Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 82	Actual Score	n	2	1
		Mean	38.89	0.00
		SD	23.570	
		Median	38.89	0.00
		Min.	22.2	0.0
		Max.	55.6	0.0
	Change from Baseline	n	2	1
		Mean	11.11	0.00
		SD	15.713	
		Median	11.11	0.00
		Min.	0.0	0.0
		Max.	22.2	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Fatigue Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 85	Actual Score	n	1	1
		Mean	55.56	22.22
		SD		
		Median	55.56	22.22
		Min.	55.6	22.2
		Max.	55.6	22.2
	Change from Baseline	n	1	1
		Mean	22.22	22.22
		SD		
		Median	22.22	22.22
		Min.	22.2	22.2
		Max.	22.2	22.2
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (100%)	1 (100%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (100%)	1 (100%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Fatigue Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 88	Actual Score	n	1	1
		Mean	33.33	0.00
		SD		
		Median	33.33	0.00
		Min.	33.3	0.0
		Max.	33.3	0.0
	Change from Baseline	n	1	1
		Mean	11.11	0.00
		SD		
		Median	11.11	0.00
		Min.	11.1	0.0
		Max.	11.1	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (100%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (100%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Fatigue Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 91	Actual Score	n	2	1
		Mean	44.44	0.00
		SD	31.427	
		Median	44.44	0.00
		Min.	22.2	0.0
		Max.	66.7	0.0
	Change from Baseline	n	2	1
		Mean	16.67	0.00
		SD	23.570	
		Median	16.67	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Fatigue Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 94	Actual Score	n	2	1
		Mean	44.44	0.00
		SD	47.140	
		Median	44.44	0.00
		Min.	11.1	0.0
		Max.	77.8	0.0
	Change from Baseline	n	2	1
		Mean	16.67	0.00
		SD	39.284	
		Median	16.67	0.00
		Min.	-11.1	0.0
		Max.	44.4	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Fatigue Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 97	Actual Score	n	1	0
		Mean	66.67	
		SD		
		Median	66.67	
		Min.	66.7	
		Max.	66.7	
	Change from Baseline	n	1	0
		Mean	33.33	
		SD		
		Median	33.33	
		Min.	33.3	
		Max.	33.3	
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (100%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (100%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Fatigue Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 100	Actual Score	n	0	1
		Mean		22.22
		SD		
		Median		22.22
		Min.		22.2
		Max.		22.2
	Change from Baseline	n	0	1
		Mean		22.22
		SD		
		Median		22.22
		Min.		22.2
		Max.		22.2
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (100%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (100%)

Protocol: 207495 Page 287 of 630
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Fatigue Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
End of Treatment	Actual Score	n	10	10
		Mean	42.22	50.00
		SD	35.058	33.230
		Median	33.33	44.44
		Min.	0.0	0.0
		Max.	100.0	100.0
	Change from Baseline	n	8	10
		Mean	-11.11	2.22
		SD	30.861	20.150
		Median	-22.22	0.00
		Min.	-44.4	-22.2
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	5 (63%)	4 (40%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	5 (63%)	4 (40%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	2 (25%)	4 (40%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	2 (25%)	4 (40%)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_c30_dom.sas 10MAR2023 10:38

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Fatigue Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 1	Actual Score	n	3	5
		Mean	48.15	53.33
		SD	35.717	27.666
		Median	33.33	44.44
		Min.	22.2	33.3
		Max.	88.9	100.0
	Change from Baseline	n	2	5
		Mean	-50.00	0.00
		SD	7.857	24.845
		Median	-50.00	0.00
		Min.	-55.6	-33.3
		Max.	-44.4	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (100%)	2 (40%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (100%)	2 (40%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	2 (40%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	2 (40%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Fatigue Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 2	Actual Score	n	3	3
		Mean	77.78	62.96
		SD	22.222	27.962
		Median	77.78	66.67
		Min.	55.6	33.3
		Max.	100.0	88.9
	Change from Baseline	n	2	3
		Mean	0.00	3.70
		SD	31.427	6.415
		Median	0.00	0.00
		Min.	-22.2	0.0
		Max.	22.2	11.1
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	1 (33%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	1 (33%)

Protocol: 207495 Page 290 of 630
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Fatigue Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 4	Actual Score	n	0	2
		Mean		50.00
		SD		23.570
		Median		50.00
		Min.		33.3
		Max.		66.7
	Change from Baseline	n	0	2
		Mean		5.56
		SD		7.857
		Median		5.56
		Min.		0.0
		Max.		11.1
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (50%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (50%)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_c30_dom.sas 10MAR2023 10:38

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Fatigue Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
PFS Follow-Up 2	Actual Score	n	1	1
		Mean	55.56	33.33
		SD		
		Median	55.56	33.33
		Min.	55.6	33.3
		Max.	55.6	33.3
	Change from Baseline	n	1	1
		Mean	-22.22	0.00
		SD		
		Median	-22.22	0.00
		Min.	-22.2	0.0
		Max.	-22.2	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (100%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (100%)	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Fatigue Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
PFS Follow-Up 4	Actual Score	n	0	1
		Mean		33.33
		SD		
		Median		33.33
		Min.		33.3
		Max.		33.3
	Change from Baseline	n	0	1
		Mean		0.00
		SD		
		Median		0.00
		Min.		0.0
		Max.		0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_c30_dom.sas 10MAR2023 10:38

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Fatigue Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Last Follow-up	Actual Score	n	3	5
		Mean	77.78	64.44
		SD	22.222	30.832
		Median	77.78	66.67
		Min.	55.6	33.3
		Max.	100.0	100.0
	Change from Baseline	n	2	5
		Mean	0.00	11.11
		SD	31.427	13.608
		Median	0.00	11.11
		Min.	-22.2	0.0
		Max.	22.2	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	3 (60%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	3 (60%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Fatigue Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Worst Case Post-Baseline	Actual Score	n	13	25
		Mean	70.09	67.11
		SD	24.167	29.306
		Median	77.78	66.67
		Min.	33.3	22.2
		Max.	100.0	100.0
	Change from Baseline	n	11	25
		Mean	25.25	16.22
		SD	30.263	19.106
		Median	22.22	11.11
		Min.	-22.2	-22.2
		Max.	66.7	77.8
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (9%)	1 (4%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (9%)	1 (4%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	7 (64%)	18 (72%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	7 (64%)	18 (72%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Nausea and Vomiting Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Baseline	Actual Score	n	13	26
		Mean	2.56	10.26
		SD	6.259	22.646
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	16.7	100.0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Nausea and Vomiting Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 4	Actual Score	n	13	23
		Mean	3.85	10.14
		SD	7.309	22.326
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	16.7	100.0
	Change from Baseline	n	12	22
		Mean	1.39	0.76
		SD	11.143	14.065
		Median	0.00	0.00
		Min.	-16.7	-33.3
		Max.	16.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (17%)	2 (9%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (17%)	2 (9%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	3 (25%)	4 (18%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	3 (25%)	4 (18%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Nausea and Vomiting Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 7	Actual Score	n	12	17
		Mean	0.00	4.90
		SD	0.000	11.433
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	33.3
	Change from Baseline	n	11	16
		Mean	-1.52	-2.08
		SD	5.025	19.124
		Median	0.00	0.00
		Min.	-16.7	-50.0
		Max.	0.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (9%)	3 (19%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (9%)	3 (19%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	3 (19%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	3 (19%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Nausea and Vomiting Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 10	Actual Score	n	13	12
		Mean	0.00	9.72
		SD	0.000	15.006
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	33.3
	Change from Baseline	n	12	11
		Mean	-2.78	0.00
		SD	6.487	21.082
		Median	0.00	0.00
		Min.	-16.7	-50.0
		Max.	0.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (17%)	2 (18%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (17%)	2 (18%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	3 (27%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	3 (27%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Nausea and Vomiting Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 13	Actual Score	n	13	9
		Mean	1.28	5.56
		SD	4.623	11.785
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	16.7	33.3
	Change from Baseline	n	12	8
		Mean	-2.78	-4.17
		SD	6.487	19.416
		Median	0.00	0.00
		Min.	-16.7	-50.0
		Max.	0.0	16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (17%)	1 (13%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (17%)	1 (13%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (13%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (13%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Nausea and Vomiting Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 16	Actual Score	n	12	8
		Mean	1.39	0.00
		SD	4.811	0.000
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	16.7	0.0
	Change from Baseline	n	11	7
		Mean	-3.03	-9.52
		SD	6.742	18.898
		Median	0.00	0.00
		Min.	-16.7	-50.0
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (18%)	2 (29%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (18%)	2 (29%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Nausea and Vomiting Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 19	Actual Score	n	12	7
		Mean	2.78	2.38
		SD	6.487	6.299
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	16.7	16.7
	Change from Baseline	n	11	6
		Mean	-1.52	0.00
		SD	8.989	0.000
		Median	0.00	0.00
		Min.	-16.7	0.0
		Max.	16.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (18%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (18%)	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (9%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (9%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Nausea and Vomiting Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 22	Actual Score	n	7	7
		Mean	0.00	0.00
		SD	0.000	0.000
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Change from Baseline	n	7	6
		Mean	0.00	0.00
		SD	0.000	0.000
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_c30_dom.sas 10MAR2023 10:38

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Nausea and Vomiting Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 25	Actual Score	n	7	7
		Mean	0.00	4.76
		SD	0.000	12.599
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	33.3
	Change from Baseline	n	7	7
		Mean	0.00	4.76
		SD	0.000	12.599
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (14%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (14%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Nausea and Vomiting Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 28	Actual Score	n	7	6
		Mean	7.14	0.00
		SD	18.898	0.000
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	50.0	0.0
	Change from Baseline	n	7	6
		Mean	7.14	0.00
		SD	18.898	0.000
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	50.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (14%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (14%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Nausea and Vomiting Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 31	Actual Score	n	7	6
		Mean	4.76	0.00
		SD	12.599	0.000
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Change from Baseline	n	7	6
		Mean	4.76	0.00
		SD	12.599	0.000
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (14%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (14%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Nausea and Vomiting Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 34	Actual Score	n	5	6
		Mean	0.00	0.00
		SD	0.000	0.000
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Change from Baseline	n	5	6
		Mean	0.00	0.00
		SD	0.000	0.000
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_c30_dom.sas 10MAR2023 10:38

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Nausea and Vomiting Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 37	Actual Score	n	4	6
		Mean	8.33	0.00
		SD	16.667	0.000
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Change from Baseline	n	4	6
		Mean	8.33	0.00
		SD	16.667	0.000
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (25%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (25%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Nausea and Vomiting Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 40	Actual Score	n	4	5
		Mean	4.17	0.00
		SD	8.333	0.000
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	16.7	0.0
	Change from Baseline	n	4	5
		Mean	4.17	0.00
		SD	8.333	0.000
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	16.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (25%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (25%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Nausea and Vomiting Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 43	Actual Score	n	4	4
		Mean	4.17	0.00
		SD	8.333	0.000
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	16.7	0.0
	Change from Baseline	n	4	4
		Mean	4.17	0.00
		SD	8.333	0.000
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	16.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (25%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (25%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Nausea and Vomiting Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 46	Actual Score	n	3	4
		Mean	5.56	0.00
		SD	9.623	0.000
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	16.7	0.0
	Change from Baseline	n	3	4
		Mean	5.56	0.00
		SD	9.623	0.000
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	16.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (33%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (33%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Nausea and Vomiting Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 49	Actual Score	n	3	4
		Mean	0.00	0.00
		SD	0.000	0.000
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Change from Baseline	n	3	4
		Mean	0.00	0.00
		SD	0.000	0.000
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_c30_dom.sas 10MAR2023 10:38

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Nausea and Vomiting Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 52	Actual Score	n	3	4
		Mean	0.00	0.00
		SD	0.000	0.000
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Change from Baseline	n	3	4
		Mean	0.00	0.00
		SD	0.000	0.000
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_c30_dom.sas 10MAR2023 10:38

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Nausea and Vomiting Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 55	Actual Score	n	3	3
		Mean	0.00	0.00
		SD	0.000	0.000
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Change from Baseline	n	3	3
		Mean	0.00	0.00
		SD	0.000	0.000
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_c30_dom.sas 10MAR2023 10:38

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Nausea and Vomiting Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 58	Actual Score	n	2	2
		Mean	8.33	0.00
		SD	11.785	0.000
		Median	8.33	0.00
		Min.	0.0	0.0
		Max.	16.7	0.0
	Change from Baseline	n	2	2
		Mean	8.33	0.00
		SD	11.785	0.000
		Median	8.33	0.00
		Min.	0.0	0.0
		Max.	16.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_c30_dom.sas 10MAR2023 10:38

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Nausea and Vomiting Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 61	Actual Score	n	2	2
		Mean	16.67	0.00
		SD	23.570	0.000
		Median	16.67	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Change from Baseline	n	2	2
		Mean	16.67	0.00
		SD	23.570	0.000
		Median	16.67	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_c30_dom.sas 10MAR2023 10:38

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Nausea and Vomiting Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 64	Actual Score	n	2	2
		Mean	16.67	0.00
		SD	23.570	0.000
		Median	16.67	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Change from Baseline	n	2	2
		Mean	16.67	0.00
		SD	23.570	0.000
		Median	16.67	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_c30_dom.sas 10MAR2023 10:38

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Nausea and Vomiting Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 67	Actual Score	n	2	2
		Mean	8.33	0.00
		SD	11.785	0.000
		Median	8.33	0.00
		Min.	0.0	0.0
		Max.	16.7	0.0
	Change from Baseline	n	2	2
		Mean	8.33	0.00
		SD	11.785	0.000
		Median	8.33	0.00
		Min.	0.0	0.0
		Max.	16.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Nausea and Vomiting Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 70	Actual Score	n	2	1
		Mean	0.00	0.00
		SD	0.000	
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Change from Baseline	n	2	1
		Mean	0.00	0.00
		SD	0.000	
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Nausea and Vomiting Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 73	Actual Score	n	1	1
		Mean	16.67	0.00
		SD		
		Median	16.67	0.00
		Min.	16.7	0.0
		Max.	16.7	0.0
	Change from Baseline	n	1	1
		Mean	16.67	0.00
		SD		
		Median	16.67	0.00
		Min.	16.7	0.0
		Max.	16.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (100%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (100%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Nausea and Vomiting Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 76	Actual Score	n	2	1
		Mean	8.33	0.00
		SD	11.785	
		Median	8.33	0.00
		Min.	0.0	0.0
		Max.	16.7	0.0
	Change from Baseline	n	2	1
		Mean	8.33	0.00
		SD	11.785	
		Median	8.33	0.00
		Min.	0.0	0.0
		Max.	16.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Nausea and Vomiting Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 79	Actual Score	n	2	1
		Mean	8.33	0.00
		SD	11.785	
		Median	8.33	0.00
		Min.	0.0	0.0
		Max.	16.7	0.0
	Change from Baseline	n	2	1
		Mean	8.33	0.00
		SD	11.785	
		Median	8.33	0.00
		Min.	0.0	0.0
		Max.	16.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Nausea and Vomiting Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 82	Actual Score	n	2	1
		Mean	8.33	0.00
		SD	11.785	
		Median	8.33	0.00
		Min.	0.0	0.0
		Max.	16.7	0.0
	Change from Baseline	n	2	1
		Mean	8.33	0.00
		SD	11.785	
		Median	8.33	0.00
		Min.	0.0	0.0
		Max.	16.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Nausea and Vomiting Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 85	Actual Score	n	1	1
		Mean	0.00	0.00
		SD		
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Change from Baseline	n	1	1
		Mean	0.00	0.00
		SD		
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_c30_dom.sas 10MAR2023 10:38

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Nausea and Vomiting Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 88	Actual Score	n	1	1
		Mean	0.00	0.00
		SD		
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Change from Baseline	n	1	1
		Mean	0.00	0.00
		SD		
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Nausea and Vomiting Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 91	Actual Score	n	2	1
		Mean	8.33	0.00
		SD	11.785	
		Median	8.33	0.00
		Min.	0.0	0.0
		Max.	16.7	0.0
	Change from Baseline	n	2	1
		Mean	8.33	0.00
		SD	11.785	
		Median	8.33	0.00
		Min.	0.0	0.0
		Max.	16.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Nausea and Vomiting Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 94	Actual Score	n	2	1
		Mean	8.33	0.00
		SD	11.785	
		Median	8.33	0.00
		Min.	0.0	0.0
		Max.	16.7	0.0
	Change from Baseline	n	2	1
		Mean	8.33	0.00
		SD	11.785	
		Median	8.33	0.00
		Min.	0.0	0.0
		Max.	16.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Nausea and Vomiting Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 97	Actual Score	n	1	0
		Mean	16.67	
		SD		
		Median	16.67	
		Min.	16.7	
		Max.	16.7	
	Change from Baseline	n	1	0
		Mean	16.67	
		SD		
		Median	16.67	
		Min.	16.7	
		Max.	16.7	
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (100%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (100%)	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_c30_dom.sas 10MAR2023 10:38

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Nausea and Vomiting Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 100	Actual Score	n	0	1
		Mean		0.00
		SD		
		Median		0.00
		Min.		0.0
		Max.		0.0
	Change from Baseline	n	0	1
		Mean		0.00
		SD		
		Median		0.00
		Min.		0.0
		Max.		0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_c30_dom.sas 10MAR2023 10:38

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Nausea and Vomiting Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
End of Treatment	Actual Score	n	10	11
		Mean	8.33	10.61
		SD	21.155	25.025
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	66.7	83.3
	Change from Baseline	n	9	11
		Mean	5.56	1.52
		SD	23.570	31.140
		Median	0.00	0.00
		Min.	-16.7	-50.0
		Max.	66.7	83.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (11%)	2 (18%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (11%)	2 (18%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (11%)	1 (9%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (11%)	1 (9%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Nausea and Vomiting Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 1	Actual Score	n	3	5
		Mean	5.56	6.67
		SD	9.623	14.907
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	16.7	33.3
	Change from Baseline	n	2	5
		Mean	0.00	0.00
		SD	0.000	23.570
		Median	0.00	0.00
		Min.	0.0	-33.3
		Max.	0.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (20%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (20%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (20%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (20%)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_c30_dom.sas 10MAR2023 10:38

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Nausea and Vomiting Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 2	Actual Score	n	3	3
		Mean	11.11	0.00
		SD	19.245	0.000
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Change from Baseline	n	2	3
		Mean	0.00	-11.11
		SD	0.000	19.245
		Median	0.00	0.00
		Min.	0.0	-33.3
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (33%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (33%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Nausea and Vomiting Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 4	Actual Score	n	0	2
		Mean		8.33
		SD		11.785
		Median		8.33
		Min.		0.0
		Max.		16.7
	Change from Baseline	n	0	2
		Mean		-8.33
		SD		11.785
		Median		-8.33
		Min.		-16.7
		Max.		0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (50%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Nausea and Vomiting Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
PFS Follow-Up 2	Actual Score	n	1	1
		Mean	0.00	0.00
		SD		
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Change from Baseline	n	1	1
		Mean	0.00	-33.33
		SD		
		Median	0.00	-33.33
		Min.	0.0	-33.3
		Max.	0.0	-33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (100%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_c30_dom.sas 10MAR2023 10:38

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Nausea and Vomiting Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
PFS Follow-Up 4	Actual Score	n	0	1
		Mean		16.67
		SD		
		Median		16.67
		Min.		16.7
		Max.		16.7
	Change from Baseline	n	0	1
		Mean		-16.67
		SD		
		Median		-16.67
		Min.		-16.7
		Max.		-16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (100%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Nausea and Vomiting Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Last Follow-up	Actual Score	n	3	5
		Mean	11.11	10.00
		SD	19.245	14.907
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	33.3
	Change from Baseline	n	2	5
		Mean	0.00	3.33
		SD	0.000	18.257
		Median	0.00	0.00
		Min.	0.0	-16.7
		Max.	0.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (20%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (20%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (20%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (20%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Nausea and Vomiting Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Worst Case Post-Baseline	Actual Score	n	13	25
		Mean	15.38	16.00
		SD	22.008	26.123
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	66.7	100.0
	Change from Baseline	n	12	24
		Mean	11.11	6.94
		SD	24.958	21.376
		Median	0.00	0.00
		Min.	-16.7	-33.3
		Max.	66.7	83.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (17%)	2 (8%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (17%)	2 (8%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	5 (42%)	7 (29%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	5 (42%)	7 (29%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Pain Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Baseline	Actual Score	n	13	27
		Mean	50.00	52.47
		SD	40.254	36.311
		Median	50.00	50.00
		Min.	0.0	0.0
		Max.	100.0	100.0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Pain Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 4	Actual Score	n	13	23
		Mean	41.03	48.55
		SD	38.858	40.487
		Median	33.33	33.33
		Min.	0.0	0.0
		Max.	100.0	100.0
	Change from Baseline	n	12	23
		Mean	-9.72	1.45
		SD	21.856	20.666
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	16.7	50.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	5 (42%)	6 (26%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	5 (42%)	6 (26%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	3 (25%)	6 (26%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	3 (25%)	6 (26%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Pain Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 7	Actual Score	n	12	17
		Mean	36.11	46.08
		SD	34.694	37.514
		Median	33.33	33.33
		Min.	0.0	0.0
		Max.	100.0	100.0
	Change from Baseline	n	11	17
		Mean	-19.70	-3.92
		SD	35.604	15.057
		Median	-16.67	0.00
		Min.	-100.0	-33.3
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	7 (64%)	6 (35%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	7 (64%)	6 (35%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	2 (18%)	2 (12%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	2 (18%)	2 (12%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Pain Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 10	Actual Score	n	13	12
		Mean	33.33	51.39
		SD	35.355	42.911
		Median	33.33	58.33
		Min.	0.0	0.0
		Max.	100.0	100.0
	Change from Baseline	n	12	12
		Mean	-16.67	6.94
		SD	22.473	22.983
		Median	-16.67	0.00
		Min.	-66.7	-16.7
		Max.	16.7	66.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	7 (58%)	2 (17%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	7 (58%)	2 (17%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (8%)	3 (25%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (8%)	3 (25%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Pain Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 13	Actual Score	n	13	9
		Mean	38.46	46.30
		SD	35.606	35.136
		Median	33.33	50.00
		Min.	0.0	0.0
		Max.	100.0	83.3
	Change from Baseline	n	12	9
		Mean	-12.50	1.85
		SD	25.746	30.556
		Median	-16.67	0.00
		Min.	-66.7	-33.3
		Max.	33.3	50.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	7 (58%)	3 (33%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	7 (58%)	3 (33%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	2 (17%)	2 (22%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	2 (17%)	2 (22%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Pain Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 16	Actual Score	n	12	8
		Mean	22.22	35.42
		SD	30.429	44.932
		Median	0.00	8.33
		Min.	0.0	0.0
		Max.	66.7	100.0
	Change from Baseline	n	11	8
		Mean	-22.73	2.08
		SD	28.159	33.850
		Median	-33.33	0.00
		Min.	-66.7	-50.0
		Max.	33.3	50.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	7 (64%)	3 (38%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	7 (64%)	3 (38%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (9%)	2 (25%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (9%)	2 (25%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Pain Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 19	Actual Score	n	12	7
		Mean	27.78	33.33
		SD	31.248	36.004
		Median	25.00	16.67
		Min.	0.0	0.0
		Max.	100.0	100.0
	Change from Baseline	n	11	7
		Mean	-19.70	2.38
		SD	26.686	11.501
		Median	-16.67	0.00
		Min.	-66.7	-16.7
		Max.	16.7	16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	6 (55%)	1 (14%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	6 (55%)	1 (14%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (9%)	2 (29%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (9%)	2 (29%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Pain Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 22	Actual Score	n	7	7
		Mean	21.43	19.05
		SD	29.991	24.398
		Median	16.67	16.67
		Min.	0.0	0.0
		Max.	83.3	66.7
	Change from Baseline	n	7	7
		Mean	-19.05	-2.38
		SD	52.200	22.420
		Median	-16.67	0.00
		Min.	-83.3	-33.3
		Max.	66.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (57%)	3 (43%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	4 (57%)	3 (43%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	2 (29%)	2 (29%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	2 (29%)	2 (29%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Pain Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 25	Actual Score	n	7	7
		Mean	14.29	30.95
		SD	24.398	39.002
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	66.7	83.3
	Change from Baseline	n	7	7
		Mean	-23.81	-4.76
		SD	30.211	31.497
		Median	-33.33	0.00
		Min.	-66.7	-33.3
		Max.	16.7	50.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (57%)	3 (43%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	4 (57%)	3 (43%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (14%)	2 (29%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (14%)	2 (29%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Pain Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 28	Actual Score	n	7	6
		Mean	16.67	22.22
		SD	19.245	40.369
		Median	16.67	0.00
		Min.	0.0	0.0
		Max.	50.0	100.0
	Change from Baseline	n	7	6
		Mean	-21.43	-2.78
		SD	32.934	37.143
		Median	-16.67	-8.33
		Min.	-83.3	-33.3
		Max.	16.7	66.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (57%)	3 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	4 (57%)	3 (50%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (14%)	1 (17%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (14%)	1 (17%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Pain Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 31	Actual Score	n	7	6
		Mean	16.67	25.00
		SD	13.608	34.561
		Median	16.67	8.33
		Min.	0.0	0.0
		Max.	33.3	83.3
	Change from Baseline	n	7	6
		Mean	-21.43	0.00
		SD	28.406	27.889
		Median	-33.33	0.00
		Min.	-66.7	-33.3
		Max.	16.7	50.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (57%)	2 (33%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	4 (57%)	2 (33%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (14%)	1 (17%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (14%)	1 (17%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Pain Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 34	Actual Score	n	5	6
		Mean	13.33	27.78
		SD	18.257	37.515
		Median	0.00	8.33
		Min.	0.0	0.0
		Max.	33.3	83.3
	Change from Baseline	n	5	6
		Mean	-16.67	2.78
		SD	16.667	28.707
		Median	-16.67	0.00
		Min.	-33.3	-33.3
		Max.	0.0	50.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (60%)	2 (33%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (60%)	2 (33%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	2 (33%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	2 (33%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Pain Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 37	Actual Score	n	4	6
		Mean	33.33	22.22
		SD	36.004	32.773
		Median	25.00	8.33
		Min.	0.0	0.0
		Max.	83.3	83.3
	Change from Baseline	n	4	6
		Mean	12.50	-2.78
		SD	15.957	28.707
		Median	8.33	-8.33
		Min.	0.0	-33.3
		Max.	33.3	50.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	3 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	3 (50%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	2 (50%)	1 (17%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	2 (50%)	1 (17%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Pain Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 40	Actual Score	n	4	5
		Mean	25.00	16.67
		SD	21.517	28.868
		Median	25.00	0.00
		Min.	0.0	0.0
		Max.	50.0	66.7
	Change from Baseline	n	4	5
		Mean	4.17	-3.33
		SD	15.957	24.721
		Median	8.33	0.00
		Min.	-16.7	-33.3
		Max.	16.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (25%)	2 (40%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (25%)	2 (40%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	2 (50%)	1 (20%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	2 (50%)	1 (20%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Pain Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 43	Actual Score	n	4	4
		Mean	29.17	16.67
		SD	47.871	23.570
		Median	8.33	8.33
		Min.	0.0	0.0
		Max.	100.0	50.0
	Change from Baseline	n	4	4
		Mean	8.33	-8.33
		SD	34.694	21.517
		Median	8.33	-8.33
		Min.	-33.3	-33.3
		Max.	50.0	16.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (25%)	2 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (25%)	2 (50%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	2 (50%)	1 (25%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	2 (50%)	1 (25%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Pain Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 46	Actual Score	n	3	4
		Mean	22.22	25.00
		SD	38.490	28.868
		Median	0.00	16.67
		Min.	0.0	0.0
		Max.	66.7	66.7
	Change from Baseline	n	3	4
		Mean	-5.56	0.00
		SD	25.459	23.570
		Median	0.00	-8.33
		Min.	-33.3	-16.7
		Max.	16.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (33%)	2 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (33%)	2 (50%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (33%)	1 (25%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (33%)	1 (25%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Pain Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 49	Actual Score	n	3	4
		Mean	16.67	33.33
		SD	28.868	36.004
		Median	0.00	25.00
		Min.	0.0	0.0
		Max.	50.0	83.3
	Change from Baseline	n	3	4
		Mean	-11.11	8.33
		SD	19.245	28.868
		Median	0.00	0.00
		Min.	-33.3	-16.7
		Max.	0.0	50.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (33%)	1 (25%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (33%)	1 (25%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (25%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (25%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Pain Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 52	Actual Score	n	3	4
		Mean	22.22	29.17
		SD	25.459	28.464
		Median	16.67	25.00
		Min.	0.0	0.0
		Max.	50.0	66.7
	Change from Baseline	n	3	4
		Mean	-5.56	4.17
		SD	9.623	20.972
		Median	0.00	0.00
		Min.	-16.7	-16.7
		Max.	0.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (33%)	1 (25%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (33%)	1 (25%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (25%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (25%)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_c30_dom.sas 10MAR2023 10:38

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Pain Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 55	Actual Score	n	3	3
		Mean	11.11	16.67
		SD	19.245	16.667
		Median	0.00	16.67
		Min.	0.0	0.0
		Max.	33.3	33.3
	Change from Baseline	n	3	3
		Mean	-16.67	-5.56
		SD	16.667	9.623
		Median	-16.67	0.00
		Min.	-33.3	-16.7
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (67%)	1 (33%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (67%)	1 (33%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Pain Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 58	Actual Score	n	2	2
		Mean	41.67	8.33
		SD	58.926	11.785
		Median	41.67	8.33
		Min.	0.0	0.0
		Max.	83.3	16.7
	Change from Baseline	n	2	2
		Mean	0.00	-8.33
		SD	47.140	11.785
		Median	0.00	-8.33
		Min.	-33.3	-16.7
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	1 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	1 (50%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Pain Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 61	Actual Score	n	2	2
		Mean	58.33	16.67
		SD	35.355	23.570
		Median	58.33	16.67
		Min.	33.3	0.0
		Max.	83.3	33.3
	Change from Baseline	n	2	2
		Mean	16.67	0.00
		SD	47.140	0.000
		Median	16.67	0.00
		Min.	-16.7	0.0
		Max.	50.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Pain Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 64	Actual Score	n	2	2
		Mean	33.33	16.67
		SD	47.140	23.570
		Median	33.33	16.67
		Min.	0.0	0.0
		Max.	66.7	33.3
	Change from Baseline	n	2	2
		Mean	-8.33	0.00
		SD	35.355	0.000
		Median	-8.33	0.00
		Min.	-33.3	0.0
		Max.	16.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Pain Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 67	Actual Score	n	2	2
		Mean	16.67	0.00
		SD	23.570	0.000
		Median	16.67	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Change from Baseline	n	2	2
		Mean	-25.00	-16.67
		SD	11.785	23.570
		Median	-25.00	-16.67
		Min.	-33.3	-33.3
		Max.	-16.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (100%)	1 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (100%)	1 (50%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Pain Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 70	Actual Score	n	2	1
		Mean	16.67	0.00
		SD	23.570	
		Median	16.67	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Change from Baseline	n	2	1
		Mean	-25.00	0.00
		SD	11.785	
		Median	-25.00	0.00
		Min.	-33.3	0.0
		Max.	-16.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (100%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (100%)	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Pain Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 73	Actual Score	n	1	1
		Mean	50.00	0.00
		SD		
		Median	50.00	0.00
		Min.	50.0	0.0
		Max.	50.0	0.0
	Change from Baseline	n	1	1
		Mean	0.00	0.00
		SD		
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Pain Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 76	Actual Score	n	2	1
		Mean	50.00	0.00
		SD	23.570	
		Median	50.00	0.00
		Min.	33.3	0.0
		Max.	66.7	0.0
	Change from Baseline	n	2	1
		Mean	8.33	0.00
		SD	11.785	
		Median	8.33	0.00
		Min.	0.0	0.0
		Max.	16.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Pain Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 79	Actual Score	n	2	1
		Mean	33.33	0.00
		SD	47.140	
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	66.7	0.0
	Change from Baseline	n	2	1
		Mean	-8.33	0.00
		SD	35.355	
		Median	-8.33	0.00
		Min.	-33.3	0.0
		Max.	16.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Pain Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 82	Actual Score	n	2	1
		Mean	33.33	0.00
		SD	47.140	
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	66.7	0.0
	Change from Baseline	n	2	1
		Mean	-8.33	0.00
		SD	35.355	
		Median	-8.33	0.00
		Min.	-33.3	0.0
		Max.	16.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Pain Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 85	Actual Score	n	1	1
		Mean	50.00	0.00
		SD		
		Median	50.00	0.00
		Min.	50.0	0.0
		Max.	50.0	0.0
	Change from Baseline	n	1	1
		Mean	0.00	0.00
		SD		
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Pain Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 88	Actual Score	n	1	1
		Mean	0.00	0.00
		SD		
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Change from Baseline	n	1	1
		Mean	-33.33	0.00
		SD		
		Median	-33.33	0.00
		Min.	-33.3	0.0
		Max.	-33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (100%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (100%)	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_c30_dom.sas 10MAR2023 10:38

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Pain Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 91	Actual Score	n	2	1
		Mean	33.33	0.00
		SD	47.140	
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	66.7	0.0
	Change from Baseline	n	2	1
		Mean	-8.33	0.00
		SD	35.355	
		Median	-8.33	0.00
		Min.	-33.3	0.0
		Max.	16.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Pain Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 94	Actual Score	n	2	1
		Mean	16.67	0.00
		SD	23.570	
		Median	16.67	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Change from Baseline	n	2	1
		Mean	-25.00	0.00
		SD	11.785	
		Median	-25.00	0.00
		Min.	-33.3	0.0
		Max.	-16.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (100%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (100%)	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Pain Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 97	Actual Score	n	1	0
		Mean	50.00	
		SD		
		Median	50.00	
		Min.	50.0	
		Max.	50.0	
	Change from Baseline	n	1	0
		Mean	0.00	
		SD		
		Median	0.00	
		Min.	0.0	
		Max.	0.0	
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_c30_dom.sas 10MAR2023 10:38

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Pain Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 100	Actual Score	n	0	1
		Mean		0.00
		SD		
		Median		0.00
		Min.		0.0
		Max.		0.0
	Change from Baseline	n	0	1
		Mean		0.00
		SD		
		Median		0.00
		Min.		0.0
		Max.		0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_c30_dom.sas 10MAR2023 10:38

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Pain Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
End of Treatment	Actual Score	n	10	10
		Mean	28.33	46.67
		SD	36.047	28.109
		Median	16.67	33.33
		Min.	0.0	16.7
		Max.	100.0	100.0
	Change from Baseline	n	9	10
		Mean	-31.48	8.33
		SD	25.610	23.895
		Median	-33.33	0.00
		Min.	-66.7	-16.7
		Max.	0.0	50.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	7 (78%)	3 (30%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	7 (78%)	3 (30%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	4 (40%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	4 (40%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Pain Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 1	Actual Score	n	3	5
		Mean	50.00	30.00
		SD	44.096	7.454
		Median	33.33	33.33
		Min.	16.7	16.7
		Max.	100.0	33.3
	Change from Baseline	n	2	5
		Mean	-58.33	3.33
		SD	11.785	18.257
		Median	-58.33	0.00
		Min.	-66.7	-16.7
		Max.	-50.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (100%)	1 (20%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (100%)	1 (20%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (20%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (20%)

Protocol: 207495 Page 373 of 630
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Pain Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 2	Actual Score	n	3	3
		Mean	44.44	38.89
		SD	50.918	25.459
		Median	33.33	33.33
		Min.	0.0	16.7
		Max.	100.0	66.7
	Change from Baseline	n	2	3
		Mean	-66.67	5.56
		SD	47.140	25.459
		Median	-66.67	0.00
		Min.	-100.0	-16.7
		Max.	-33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (100%)	1 (33%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (100%)	1 (33%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (33%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (33%)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_c30_dom.sas 10MAR2023 10:38

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Pain Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 4	Actual Score	n	0	2
		Mean		33.33
		SD		0.000
		Median		33.33
		Min.		33.3
		Max.		33.3
	Change from Baseline	n	0	2
		Mean		0.00
		SD		0.000
		Median		0.00
		Min.		0.0
		Max.		0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Pain Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
PFS Follow-Up 2	Actual Score	n	1	1
		Mean	33.33	33.33
		SD		
		Median	33.33	33.33
		Min.	33.3	33.3
		Max.	33.3	33.3
	Change from Baseline	n	1	1
		Mean	-33.33	0.00
		SD		
		Median	-33.33	0.00
		Min.	-33.3	0.0
		Max.	-33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (100%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (100%)	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Pain Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
PFS Follow-Up 4	Actual Score	n	0	1
		Mean		33.33
		SD		
		Median		33.33
		Min.		33.3
		Max.		33.3
	Change from Baseline	n	0	1
		Mean		0.00
		SD		
		Median		0.00
		Min.		0.0
		Max.		0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_c30_dom.sas 10MAR2023 10:38

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Pain Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Last Follow-up	Actual Score	n	3	5
		Mean	44.44	36.67
		SD	50.918	18.257
		Median	33.33	33.33
		Min.	0.0	16.7
		Max.	100.0	66.7
	Change from Baseline	n	2	5
		Mean	-66.67	10.00
		SD	47.140	22.361
		Median	-66.67	0.00
		Min.	-100.0	-16.7
		Max.	-33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (100%)	1 (20%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (100%)	1 (20%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	2 (40%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	2 (40%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Pain Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Worst Case Post-Baseline	Actual Score	n	13	25
		Mean	58.97	67.33
		SD	37.028	35.837
		Median	66.67	83.33
		Min.	0.0	0.0
		Max.	100.0	100.0
	Change from Baseline	n	12	25
		Mean	9.72	16.00
		SD	32.920	21.773
		Median	8.33	0.00
		Min.	-33.3	0.0
		Max.	66.7	66.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (33%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	4 (33%)	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	6 (50%)	11 (44%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	6 (50%)	11 (44%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Dyspnea Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Baseline	Actual Score	n	13	27
		Mean	17.95	23.46
		SD	25.875	25.844
		Median	0.00	33.33
		Min.	0.0	0.0
		Max.	66.7	100.0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Dyspnea Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 4	Actual Score	n	13	23
		Mean	28.21	28.99
		SD	32.903	35.254
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	100.0	100.0
	Change from Baseline	n	12	23
		Mean	5.56	5.80
		SD	37.155	27.802
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	66.7	66.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (33%)	4 (17%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	4 (33%)	4 (17%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	4 (33%)	6 (26%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	4 (33%)	6 (26%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Dyspnea Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 7	Actual Score	n	11	17
		Mean	18.18	15.69
		SD	22.918	23.914
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	66.7	66.7
	Change from Baseline	n	10	17
		Mean	3.33	0.00
		SD	18.922	23.570
		Median	0.00	0.00
		Min.	-33.3	-66.7
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (10%)	2 (12%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (10%)	2 (12%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	2 (20%)	3 (18%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	2 (20%)	3 (18%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Dyspnea Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 10	Actual Score	n	13	12
		Mean	25.64	19.44
		SD	30.894	26.432
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	100.0	66.7
	Change from Baseline	n	12	12
		Mean	5.56	5.56
		SD	34.329	23.925
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	66.7	66.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (25%)	1 (8%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (25%)	1 (8%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	3 (25%)	2 (17%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	3 (25%)	2 (17%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Dyspnea Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 13	Actual Score	n	13	9
		Mean	28.21	14.81
		SD	29.957	24.216
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	100.0	66.7
	Change from Baseline	n	12	9
		Mean	8.33	3.70
		SD	28.868	26.058
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	66.7	66.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (17%)	1 (11%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (17%)	1 (11%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	4 (33%)	1 (11%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	4 (33%)	1 (11%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Dyspnea Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 16	Actual Score	n	12	8
		Mean	27.78	8.33
		SD	31.248	15.430
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	100.0	33.3
	Change from Baseline	n	11	8
		Mean	6.06	-4.17
		SD	29.129	27.817
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	66.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (18%)	3 (38%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (18%)	3 (38%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	3 (27%)	2 (25%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	3 (27%)	2 (25%)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_c30_dom.sas 10MAR2023 10:38

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Dyspnea Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 19	Actual Score	n	12	7
		Mean	27.78	19.05
		SD	31.248	26.227
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	100.0	66.7
	Change from Baseline	n	11	7
		Mean	9.09	9.52
		SD	39.696	25.198
		Median	0.00	0.00
		Min.	-66.7	-33.3
		Max.	66.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (18%)	1 (14%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (18%)	1 (14%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	4 (36%)	3 (43%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	4 (36%)	3 (43%)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_c30_dom.sas 10MAR2023 10:38

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Dyspnea Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 22	Actual Score	n	7	7
		Mean	23.81	4.76
		SD	25.198	12.599
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	66.7	33.3
	Change from Baseline	n	7	7
		Mean	4.76	-4.76
		SD	23.002	12.599
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (14%)	1 (14%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (14%)	1 (14%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	2 (29%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	2 (29%)	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_c30_dom.sas 10MAR2023 10:38

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Dyspnea Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 25	Actual Score	n	7	7
		Mean	38.10	14.29
		SD	23.002	26.227
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	66.7	66.7
	Change from Baseline	n	7	7
		Mean	14.29	4.76
		SD	32.530	12.599
		Median	0.00	0.00
		Min.	-33.3	0.0
		Max.	66.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (14%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (14%)	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	3 (43%)	1 (14%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	3 (43%)	1 (14%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Dyspnea Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 28	Actual Score	n	7	6
		Mean	23.81	0.00
		SD	25.198	0.000
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	66.7	0.0
	Change from Baseline	n	7	6
		Mean	0.00	-5.56
		SD	33.333	13.608
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	66.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (29%)	1 (17%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (29%)	1 (17%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (14%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (14%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Dyspnea Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 31	Actual Score	n	7	6
		Mean	23.81	11.11
		SD	25.198	17.213
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	66.7	33.3
	Change from Baseline	n	7	6
		Mean	0.00	5.56
		SD	27.217	13.608
		Median	0.00	0.00
		Min.	-33.3	0.0
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (29%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (29%)	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	2 (29%)	1 (17%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	2 (29%)	1 (17%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Dyspnea Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 34	Actual Score	n	5	6
		Mean	20.00	16.67
		SD	18.257	27.889
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	33.3	66.7
	Change from Baseline	n	5	6
		Mean	-6.67	11.11
		SD	27.889	17.213
		Median	0.00	0.00
		Min.	-33.3	0.0
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (40%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (40%)	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (20%)	2 (33%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (20%)	2 (33%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Dyspnea Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 37	Actual Score	n	4	6
		Mean	25.00	11.11
		SD	31.914	17.213
		Median	16.67	0.00
		Min.	0.0	0.0
		Max.	66.7	33.3
	Change from Baseline	n	4	6
		Mean	8.33	5.56
		SD	41.944	13.608
		Median	0.00	0.00
		Min.	-33.3	0.0
		Max.	66.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (25%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (25%)	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (25%)	1 (17%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (25%)	1 (17%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Dyspnea Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 40	Actual Score	n	4	5
		Mean	33.33	6.67
		SD	38.490	14.907
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	66.7	33.3
	Change from Baseline	n	4	5
		Mean	16.67	6.67
		SD	43.033	14.907
		Median	16.67	0.00
		Min.	-33.3	0.0
		Max.	66.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (25%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (25%)	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	2 (50%)	1 (20%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	2 (50%)	1 (20%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Dyspnea Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 43	Actual Score	n	4	4
		Mean	33.33	8.33
		SD	47.140	16.667
		Median	16.67	0.00
		Min.	0.0	0.0
		Max.	100.0	33.3
	Change from Baseline	n	4	4
		Mean	16.67	8.33
		SD	57.735	16.667
		Median	0.00	0.00
		Min.	-33.3	0.0
		Max.	100.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (25%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (25%)	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (25%)	1 (25%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (25%)	1 (25%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Dyspnea Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 46	Actual Score	n	3	4
		Mean	22.22	8.33
		SD	38.490	16.667
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	66.7	33.3
	Change from Baseline	n	3	4
		Mean	0.00	8.33
		SD	57.735	16.667
		Median	-33.33	0.00
		Min.	-33.3	0.0
		Max.	66.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (67%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (67%)	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (33%)	1 (25%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (33%)	1 (25%)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_c30_dom.sas 10MAR2023 10:38

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Dyspnea Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 49	Actual Score	n	3	4
		Mean	22.22	8.33
		SD	38.490	16.667
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	66.7	33.3
	Change from Baseline	n	3	4
		Mean	0.00	8.33
		SD	57.735	16.667
		Median	-33.33	0.00
		Min.	-33.3	0.0
		Max.	66.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (67%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (67%)	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (33%)	1 (25%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (33%)	1 (25%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Dyspnea Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 52	Actual Score	n	3	4
		Mean	33.33	8.33
		SD	33.333	16.667
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	66.7	33.3
	Change from Baseline	n	3	4
		Mean	11.11	8.33
		SD	50.918	16.667
		Median	0.00	0.00
		Min.	-33.3	0.0
		Max.	66.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (33%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (33%)	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (33%)	1 (25%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (33%)	1 (25%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Dyspnea Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 55	Actual Score	n	3	3
		Mean	33.33	11.11
		SD	0.000	19.245
		Median	33.33	0.00
		Min.	33.3	0.0
		Max.	33.3	33.3
	Change from Baseline	n	3	3
		Mean	11.11	11.11
		SD	19.245	19.245
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (33%)	1 (33%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (33%)	1 (33%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Dyspnea Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 58	Actual Score	n	2	2
		Mean	66.67	16.67
		SD	47.140	23.570
		Median	66.67	16.67
		Min.	33.3	0.0
		Max.	100.0	33.3
	Change from Baseline	n	2	2
		Mean	50.00	16.67
		SD	70.711	23.570
		Median	50.00	16.67
		Min.	0.0	0.0
		Max.	100.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	1 (50%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	1 (50%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Dyspnea Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 61	Actual Score	n	2	2
		Mean	33.33	16.67
		SD	0.000	23.570
		Median	33.33	16.67
		Min.	33.3	0.0
		Max.	33.3	33.3
	Change from Baseline	n	2	2
		Mean	16.67	16.67
		SD	23.570	23.570
		Median	16.67	16.67
		Min.	0.0	0.0
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	1 (50%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	1 (50%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Dyspnea Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 64	Actual Score	n	2	2
		Mean	33.33	16.67
		SD	0.000	23.570
		Median	33.33	16.67
		Min.	33.3	0.0
		Max.	33.3	33.3
	Change from Baseline	n	2	2
		Mean	16.67	16.67
		SD	23.570	23.570
		Median	16.67	16.67
		Min.	0.0	0.0
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	1 (50%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	1 (50%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Dyspnea Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 67	Actual Score	n	2	2
		Mean	33.33	16.67
		SD	0.000	23.570
		Median	33.33	16.67
		Min.	33.3	0.0
		Max.	33.3	33.3
	Change from Baseline	n	2	2
		Mean	16.67	16.67
		SD	23.570	23.570
		Median	16.67	16.67
		Min.	0.0	0.0
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	1 (50%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	1 (50%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Dyspnea Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 70	Actual Score	n	2	1
		Mean	50.00	0.00
		SD	23.570	
		Median	50.00	0.00
		Min.	33.3	0.0
		Max.	66.7	0.0
	Change from Baseline	n	2	1
		Mean	33.33	0.00
		SD	47.140	
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	66.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Dyspnea Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 73	Actual Score	n	1	1
		Mean	66.67	0.00
		SD		
		Median	66.67	0.00
		Min.	66.7	0.0
		Max.	66.7	0.0
	Change from Baseline	n	1	1
		Mean	66.67	0.00
		SD		
		Median	66.67	0.00
		Min.	66.7	0.0
		Max.	66.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (100%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (100%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Dyspnea Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 76	Actual Score	n	2	1
		Mean	50.00	0.00
		SD	23.570	
		Median	50.00	0.00
		Min.	33.3	0.0
		Max.	66.7	0.0
	Change from Baseline	n	2	1
		Mean	33.33	0.00
		SD	47.140	
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	66.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Dyspnea Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 79	Actual Score	n	2	1
		Mean	50.00	0.00
		SD	23.570	
		Median	50.00	0.00
		Min.	33.3	0.0
		Max.	66.7	0.0
	Change from Baseline	n	2	1
		Mean	33.33	0.00
		SD	47.140	
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	66.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Dyspnea Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 82	Actual Score	n	2	1
		Mean	50.00	0.00
		SD	23.570	
		Median	50.00	0.00
		Min.	33.3	0.0
		Max.	66.7	0.0
	Change from Baseline	n	2	1
		Mean	33.33	0.00
		SD	47.140	
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	66.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Dyspnea Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 85	Actual Score	n	1	1
		Mean	0.00	0.00
		SD		
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Change from Baseline	n	1	1
		Mean	0.00	0.00
		SD		
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Dyspnea Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 88	Actual Score	n	1	1
		Mean	33.33	0.00
		SD		
		Median	33.33	0.00
		Min.	33.3	0.0
		Max.	33.3	0.0
	Change from Baseline	n	1	1
		Mean	0.00	0.00
		SD		
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Dyspnea Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 91	Actual Score	n	2	1
		Mean	50.00	0.00
		SD	23.570	
		Median	50.00	0.00
		Min.	33.3	0.0
		Max.	66.7	0.0
	Change from Baseline	n	2	1
		Mean	33.33	0.00
		SD	47.140	
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	66.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Dyspnea Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 94	Actual Score	n	2	1
		Mean	50.00	0.00
		SD	23.570	
		Median	50.00	0.00
		Min.	33.3	0.0
		Max.	66.7	0.0
	Change from Baseline	n	2	1
		Mean	33.33	0.00
		SD	47.140	
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	66.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Dyspnea Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 97	Actual Score	n	1	0
		Mean	33.33	
		SD		
		Median	33.33	
		Min.	33.3	
		Max.	33.3	
	Change from Baseline	n	1	0
		Mean	33.33	
		SD		
		Median	33.33	
		Min.	33.3	
		Max.	33.3	
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (100%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (100%)	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_c30_dom.sas 10MAR2023 10:38

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Dyspnea Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 100	Actual Score	n	0	1
		Mean		0.00
		SD		
		Median		0.00
		Min.		0.0
		Max.		0.0
	Change from Baseline	n	0	1
		Mean		0.00
		SD		
		Median		0.00
		Min.		0.0
		Max.		0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_c30_dom.sas 10MAR2023 10:38

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Dyspnea Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
End of Treatment	Actual Score	n	10	11
		Mean	30.00	30.30
		SD	33.148	34.816
		Median	16.67	33.33
		Min.	0.0	0.0
		Max.	66.7	100.0
	Change from Baseline	n	9	11
		Mean	3.70	0.00
		SD	20.031	33.333
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	33.3	66.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (11%)	4 (36%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (11%)	4 (36%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	2 (22%)	3 (27%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	2 (22%)	3 (27%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Dyspnea Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 1	Actual Score	n	3	4
		Mean	33.33	58.33
		SD	33.333	31.914
		Median	33.33	50.00
		Min.	0.0	33.3
		Max.	66.7	100.0
	Change from Baseline	n	2	4
		Mean	0.00	16.67
		SD	47.140	19.245
		Median	0.00	16.67
		Min.	-33.3	0.0
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	2 (50%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	2 (50%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Dyspnea Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 2	Actual Score	n	3	3
		Mean	55.56	33.33
		SD	50.918	33.333
		Median	66.67	33.33
		Min.	0.0	0.0
		Max.	100.0	66.7
	Change from Baseline	n	2	3
		Mean	33.33	11.11
		SD	47.140	19.245
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	66.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	1 (33%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	1 (33%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Dyspnea Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 4	Actual Score	n	0	2
		Mean		33.33
		SD		0.000
		Median		33.33
		Min.		33.3
		Max.		33.3
	Change from Baseline	n	0	2
		Mean		16.67
		SD		23.570
		Median		16.67
		Min.		0.0
		Max.		33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (50%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (50%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Dyspnea Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
PFS Follow-Up 2	Actual Score	n	1	1
		Mean	66.67	0.00
		SD		
		Median	66.67	0.00
		Min.	66.7	0.0
		Max.	66.7	0.0
	Change from Baseline	n	1	1
		Mean	0.00	0.00
		SD		
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Dyspnea Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
PFS Follow-Up 4	Actual Score	n	0	1
		Mean		0.00
		SD		
		Median		0.00
		Min.		0.0
		Max.		0.0
	Change from Baseline	n	0	1
		Mean		0.00
		SD		
		Median		0.00
		Min.		0.0
		Max.		0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_c30_dom.sas 10MAR2023 10:38

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Dyspnea Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Last Follow-up	Actual Score	n	3	4
		Mean	55.56	58.33
		SD	50.918	31.914
		Median	66.67	50.00
		Min.	0.0	33.3
		Max.	100.0	100.0
	Change from Baseline	n	2	4
		Mean	33.33	16.67
		SD	47.140	19.245
		Median	33.33	16.67
		Min.	0.0	0.0
		Max.	66.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	2 (50%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	2 (50%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Dyspnea Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Worst Case Post-Baseline	Actual Score	n	13	25
		Mean	53.85	36.00
		SD	32.026	35.901
		Median	66.67	33.33
		Min.	0.0	0.0
		Max.	100.0	100.0
	Change from Baseline	n	12	25
		Mean	33.33	12.00
		SD	34.816	31.740
		Median	33.33	0.00
		Min.	0.0	-66.7
		Max.	100.0	66.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	3 (12%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	3 (12%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	7 (58%)	10 (40%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	7 (58%)	10 (40%)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_c30_dom.sas 10MAR2023 10:38

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Insomnia Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Baseline	Actual Score	n	12	26
		Mean	33.33	25.64
		SD	31.782	31.704
		Median	33.33	16.67
		Min.	0.0	0.0
		Max.	100.0	100.0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Insomnia Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 4	Actual Score	n	13	23
		Mean	35.90	24.64
		SD	37.172	32.126
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	100.0	100.0
	Change from Baseline	n	11	22
		Mean	-3.03	0.00
		SD	40.701	27.217
		Median	0.00	0.00
		Min.	-66.7	-33.3
		Max.	66.7	66.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (36%)	6 (27%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	4 (36%)	6 (27%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	2 (18%)	5 (23%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	2 (18%)	5 (23%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Insomnia Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 7	Actual Score	n	12	17
		Mean	33.33	29.41
		SD	37.605	33.087
		Median	33.33	33.33
		Min.	0.0	0.0
		Max.	100.0	100.0
	Change from Baseline	n	10	16
		Mean	0.00	12.50
		SD	35.136	23.960
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	66.7	66.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (40%)	1 (6%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	4 (40%)	1 (6%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	3 (30%)	6 (38%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	3 (30%)	6 (38%)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_c30_dom.sas 10MAR2023 10:38

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Insomnia Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 10	Actual Score	n	13	12
		Mean	30.77	19.44
		SD	41.859	30.011
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	100.0	100.0
	Change from Baseline	n	11	11
		Mean	-9.09	0.00
		SD	36.790	14.907
		Median	0.00	0.00
		Min.	-66.7	-33.3
		Max.	66.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	5 (45%)	1 (9%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	5 (45%)	1 (9%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	2 (18%)	1 (9%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	2 (18%)	1 (9%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Insomnia Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 13	Actual Score	n	13	9
		Mean	30.77	22.22
		SD	34.592	23.570
		Median	33.33	33.33
		Min.	0.0	0.0
		Max.	100.0	66.7
	Change from Baseline	n	11	8
		Mean	-9.09	-12.50
		SD	30.151	17.252
		Median	0.00	0.00
		Min.	-66.7	-33.3
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (36%)	3 (38%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	4 (36%)	3 (38%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	2 (18%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	2 (18%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Insomnia Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 16	Actual Score	n	12	8
		Mean	25.00	25.00
		SD	37.939	38.832
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	100.0	100.0
	Change from Baseline	n	10	7
		Mean	-16.67	0.00
		SD	28.328	47.140
		Median	-16.67	0.00
		Min.	-66.7	-33.3
		Max.	33.3	100.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	5 (50%)	3 (43%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	5 (50%)	3 (43%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (10%)	1 (14%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (10%)	1 (14%)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_c30_dom.sas 10MAR2023 10:38

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Insomnia Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 19	Actual Score	n	12	7
		Mean	19.44	28.57
		SD	38.817	35.635
		Median	0.00	33.33
		Min.	0.0	0.0
		Max.	100.0	100.0
	Change from Baseline	n	10	6
		Mean	-23.33	-5.56
		SD	22.498	13.608
		Median	-33.33	0.00
		Min.	-66.7	-33.3
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	6 (60%)	1 (17%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	6 (60%)	1 (17%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_c30_dom.sas 10MAR2023 10:38

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Insomnia Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 22	Actual Score	n	7	7
		Mean	19.05	14.29
		SD	37.796	17.817
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	100.0	33.3
	Change from Baseline	n	6	6
		Mean	-5.56	-11.11
		SD	53.403	17.213
		Median	-33.33	0.00
		Min.	-33.3	-33.3
		Max.	100.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (67%)	2 (33%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	4 (67%)	2 (33%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (17%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (17%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Insomnia Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 25	Actual Score	n	7	7
		Mean	23.81	14.29
		SD	41.786	17.817
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	100.0	33.3
	Change from Baseline	n	6	7
		Mean	11.11	-4.76
		SD	50.185	23.002
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	100.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (33%)	2 (29%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (33%)	2 (29%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	2 (33%)	1 (14%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	2 (33%)	1 (14%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Insomnia Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 28	Actual Score	n	7	6
		Mean	19.05	0.00
		SD	26.227	0.000
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	66.7	0.0
	Change from Baseline	n	6	6
		Mean	5.56	-22.22
		SD	38.968	27.217
		Median	0.00	-16.67
		Min.	-33.3	-66.7
		Max.	66.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (33%)	3 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (33%)	3 (50%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	2 (33%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	2 (33%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Insomnia Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 31	Actual Score	n	7	6
		Mean	9.52	11.11
		SD	25.198	17.213
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	66.7	33.3
	Change from Baseline	n	6	6
		Mean	-5.56	-11.11
		SD	38.968	27.217
		Median	-16.67	-16.67
		Min.	-33.3	-33.3
		Max.	66.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (50%)	3 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (50%)	3 (50%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (17%)	1 (17%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (17%)	1 (17%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Insomnia Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 34	Actual Score	n	5	6
		Mean	13.33	0.00
		SD	29.814	0.000
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	66.7	0.0
	Change from Baseline	n	4	6
		Mean	0.00	-22.22
		SD	47.140	27.217
		Median	-16.67	-16.67
		Min.	-33.3	-66.7
		Max.	66.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (50%)	3 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (50%)	3 (50%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (25%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (25%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Insomnia Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 37	Actual Score	n	4	6
		Mean	25.00	5.56
		SD	50.000	13.608
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	100.0	33.3
	Change from Baseline	n	3	6
		Mean	22.22	-16.67
		SD	69.389	18.257
		Median	0.00	-16.67
		Min.	-33.3	-33.3
		Max.	100.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (33%)	3 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (33%)	3 (50%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (33%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (33%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Insomnia Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 40	Actual Score	n	4	5
		Mean	25.00	13.33
		SD	50.000	18.257
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	100.0	33.3
	Change from Baseline	n	3	5
		Mean	22.22	-6.67
		SD	69.389	27.889
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	100.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (33%)	2 (40%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (33%)	2 (40%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (33%)	1 (20%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (33%)	1 (20%)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_c30_dom.sas 10MAR2023 10:38

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Insomnia Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 43	Actual Score	n	4	4
		Mean	25.00	0.00
		SD	50.000	0.000
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	100.0	0.0
	Change from Baseline	n	3	4
		Mean	22.22	-25.00
		SD	69.389	31.914
		Median	0.00	-16.67
		Min.	-33.3	-66.7
		Max.	100.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (33%)	2 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (33%)	2 (50%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (33%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (33%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Insomnia Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 46	Actual Score	n	3	4
		Mean	33.33	16.67
		SD	57.735	33.333
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	100.0	66.7
	Change from Baseline	n	3	4
		Mean	22.22	-8.33
		SD	69.389	16.667
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	100.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (33%)	1 (25%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (33%)	1 (25%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (33%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (33%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Insomnia Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 49	Actual Score	n	3	4
		Mean	33.33	16.67
		SD	33.333	19.245
		Median	33.33	16.67
		Min.	0.0	0.0
		Max.	66.7	33.3
	Change from Baseline	n	3	4
		Mean	22.22	-8.33
		SD	38.490	31.914
		Median	0.00	-16.67
		Min.	0.0	-33.3
		Max.	66.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	2 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	2 (50%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (33%)	1 (25%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (33%)	1 (25%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Insomnia Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 52	Actual Score	n	3	3
		Mean	22.22	0.00
		SD	38.490	0.000
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	66.7	0.0
	Change from Baseline	n	3	3
		Mean	11.11	-22.22
		SD	50.918	38.490
		Median	0.00	0.00
		Min.	-33.3	-66.7
		Max.	66.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (33%)	1 (33%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (33%)	1 (33%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (33%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (33%)	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_c30_dom.sas 10MAR2023 10:38

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Insomnia Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 55	Actual Score	n	3	3
		Mean	11.11	0.00
		SD	19.245	0.000
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Change from Baseline	n	3	3
		Mean	0.00	-11.11
		SD	0.000	19.245
		Median	0.00	0.00
		Min.	0.0	-33.3
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (33%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (33%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Insomnia Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 58	Actual Score	n	2	2
		Mean	50.00	0.00
		SD	70.711	0.000
		Median	50.00	0.00
		Min.	0.0	0.0
		Max.	100.0	0.0
	Change from Baseline	n	2	2
		Mean	50.00	0.00
		SD	70.711	0.000
		Median	50.00	0.00
		Min.	0.0	0.0
		Max.	100.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Insomnia Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 61	Actual Score	n	2	2
		Mean	16.67	0.00
		SD	23.570	0.000
		Median	16.67	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Change from Baseline	n	2	2
		Mean	16.67	0.00
		SD	23.570	0.000
		Median	16.67	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Insomnia Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 64	Actual Score	n	2	2
		Mean	16.67	0.00
		SD	23.570	0.000
		Median	16.67	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Change from Baseline	n	2	2
		Mean	16.67	0.00
		SD	23.570	0.000
		Median	16.67	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Insomnia Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 67	Actual Score	n	2	2
		Mean	50.00	0.00
		SD	70.711	0.000
		Median	50.00	0.00
		Min.	0.0	0.0
		Max.	100.0	0.0
	Change from Baseline	n	2	2
		Mean	50.00	0.00
		SD	70.711	0.000
		Median	50.00	0.00
		Min.	0.0	0.0
		Max.	100.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Insomnia Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 70	Actual Score	n	2	1
		Mean	33.33	0.00
		SD	47.140	
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	66.7	0.0
	Change from Baseline	n	2	1
		Mean	33.33	0.00
		SD	47.140	
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	66.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Insomnia Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 73	Actual Score	n	1	1
		Mean	66.67	0.00
		SD		
		Median	66.67	0.00
		Min.	66.7	0.0
		Max.	66.7	0.0
	Change from Baseline	n	1	1
		Mean	66.67	0.00
		SD		
		Median	66.67	0.00
		Min.	66.7	0.0
		Max.	66.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (100%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (100%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Insomnia Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 76	Actual Score	n	2	1
		Mean	50.00	0.00
		SD	23.570	
		Median	50.00	0.00
		Min.	33.3	0.0
		Max.	66.7	0.0
	Change from Baseline	n	2	1
		Mean	50.00	0.00
		SD	23.570	
		Median	50.00	0.00
		Min.	33.3	0.0
		Max.	66.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	2 (100%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	2 (100%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Insomnia Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 79	Actual Score	n	2	1
		Mean	33.33	0.00
		SD	47.140	
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	66.7	0.0
	Change from Baseline	n	2	1
		Mean	33.33	0.00
		SD	47.140	
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	66.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Insomnia Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 82	Actual Score	n	2	1
		Mean	33.33	0.00
		SD	47.140	
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	66.7	0.0
	Change from Baseline	n	2	1
		Mean	33.33	0.00
		SD	47.140	
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	66.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Insomnia Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 85	Actual Score	n	1	1
		Mean	66.67	0.00
		SD		
		Median	66.67	0.00
		Min.	66.7	0.0
		Max.	66.7	0.0
	Change from Baseline	n	1	1
		Mean	66.67	0.00
		SD		
		Median	66.67	0.00
		Min.	66.7	0.0
		Max.	66.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (100%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (100%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Insomnia Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 88	Actual Score	n	1	1
		Mean	0.00	0.00
		SD		
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Change from Baseline	n	1	1
		Mean	0.00	0.00
		SD		
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Insomnia Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 91	Actual Score	n	2	1
		Mean	33.33	0.00
		SD	47.140	
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	66.7	0.0
	Change from Baseline	n	2	1
		Mean	33.33	0.00
		SD	47.140	
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	66.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Insomnia Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 94	Actual Score	n	2	1
		Mean	0.00	0.00
		SD	0.000	
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Change from Baseline	n	2	1
		Mean	0.00	0.00
		SD	0.000	
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Insomnia Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 97	Actual Score	n	1	0
		Mean	100.00	
		SD		
		Median	100.00	
		Min.	100.0	
		Max.	100.0	
	Change from Baseline	n	1	0
		Mean	100.00	
		SD		
		Median	100.00	
		Min.	100.0	
		Max.	100.0	
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (100%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (100%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Insomnia Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 100	Actual Score	n	0	1
		Mean		33.33
		SD		
		Median		33.33
		Min.		33.3
		Max.		33.3
	Change from Baseline	n	0	1
		Mean		33.33
		SD		
		Median		33.33
		Min.		33.3
		Max.		33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (100%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (100%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Insomnia Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
End of Treatment	Actual Score	n	10	10
		Mean	30.00	23.33
		SD	33.148	35.312
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	100.0	100.0
	Change from Baseline	n	8	10
		Mean	-12.50	-6.67
		SD	30.538	21.082
		Median	0.00	0.00
		Min.	-66.7	-33.3
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (38%)	3 (30%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (38%)	3 (30%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (13%)	1 (10%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (13%)	1 (10%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Insomnia Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 1	Actual Score	n	3	5
		Mean	44.44	20.00
		SD	50.918	29.814
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	100.0	66.7
	Change from Baseline	n	2	5
		Mean	-16.67	6.67
		SD	23.570	14.907
		Median	-16.67	0.00
		Min.	-33.3	0.0
		Max.	0.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (20%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (20%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Insomnia Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 2	Actual Score	n	3	3
		Mean	22.22	44.44
		SD	38.490	19.245
		Median	0.00	33.33
		Min.	0.0	33.3
		Max.	66.7	66.7
	Change from Baseline	n	2	3
		Mean	-33.33	22.22
		SD	0.000	19.245
		Median	-33.33	33.33
		Min.	-33.3	0.0
		Max.	-33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (100%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (100%)	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	2 (67%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	2 (67%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Insomnia Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 4	Actual Score	n	0	2
		Mean		50.00
		SD		23.570
		Median		50.00
		Min.		33.3
		Max.		66.7
	Change from Baseline	n	0	2
		Mean		16.67
		SD		23.570
		Median		16.67
		Min.		0.0
		Max.		33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (50%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (50%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Insomnia Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
PFS Follow-Up 2	Actual Score	n	1	1
		Mean	0.00	0.00
		SD		
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Change from Baseline	n	1	1
		Mean	-33.33	0.00
		SD		
		Median	-33.33	0.00
		Min.	-33.3	0.0
		Max.	-33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (100%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (100%)	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Insomnia Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
PFS Follow-Up 4	Actual Score	n	0	1
		Mean		0.00
		SD		
		Median		0.00
		Min.		0.0
		Max.		0.0
	Change from Baseline	n	0	1
		Mean		0.00
		SD		
		Median		0.00
		Min.		0.0
		Max.		0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Insomnia Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Last Follow-up	Actual Score	n	3	5
		Mean	22.22	33.33
		SD	38.490	23.570
		Median	0.00	33.33
		Min.	0.0	0.0
		Max.	66.7	66.7
	Change from Baseline	n	2	5
		Mean	-33.33	20.00
		SD	0.000	18.257
		Median	-33.33	33.33
		Min.	-33.3	0.0
		Max.	-33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (100%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (100%)	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	3 (60%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	3 (60%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Insomnia Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Worst Case Post-Baseline	Actual Score	n	13	25
		Mean	58.97	46.67
		SD	33.758	34.694
		Median	66.67	33.33
		Min.	0.0	0.0
		Max.	100.0	100.0
	Change from Baseline	n	11	24
		Mean	24.24	22.22
		SD	39.696	28.937
		Median	0.00	33.33
		Min.	-33.3	-33.3
		Max.	100.0	100.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (9%)	1 (4%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (9%)	1 (4%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	5 (45%)	13 (54%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	5 (45%)	13 (54%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Appetite Loss Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Baseline	Actual Score	n	13	26
		Mean	15.38	37.18
		SD	25.875	36.911
		Median	0.00	33.33
		Min.	0.0	0.0
		Max.	66.7	100.0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Appetite Loss Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 4	Actual Score	n	13	23
		Mean	12.82	34.78
		SD	21.681	32.533
		Median	0.00	33.33
		Min.	0.0	0.0
		Max.	66.7	100.0
	Change from Baseline	n	12	22
		Mean	-2.78	4.55
		SD	22.285	21.320
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (25%)	3 (14%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (25%)	3 (14%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	2 (17%)	6 (27%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	2 (17%)	6 (27%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Appetite Loss Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 7	Actual Score	n	12	17
		Mean	8.33	29.41
		SD	15.076	33.087
		Median	0.00	33.33
		Min.	0.0	0.0
		Max.	33.3	100.0
	Change from Baseline	n	11	16
		Mean	-9.09	0.00
		SD	15.570	32.203
		Median	0.00	0.00
		Min.	-33.3	-100.0
		Max.	0.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (27%)	2 (13%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (27%)	2 (13%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	4 (25%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	4 (25%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Appetite Loss Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 10	Actual Score	n	13	12
		Mean	10.26	25.00
		SD	21.014	28.868
		Median	0.00	16.67
		Min.	0.0	0.0
		Max.	66.7	66.7
	Change from Baseline	n	12	11
		Mean	-5.56	-6.06
		SD	23.925	35.957
		Median	0.00	0.00
		Min.	-66.7	-100.0
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (17%)	2 (18%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (17%)	2 (18%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (8%)	2 (18%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (8%)	2 (18%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Appetite Loss Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 13	Actual Score	n	13	9
		Mean	2.56	18.52
		SD	9.245	24.216
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	66.7
	Change from Baseline	n	12	8
		Mean	-16.67	-12.50
		SD	26.591	39.591
		Median	0.00	0.00
		Min.	-66.7	-100.0
		Max.	0.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (33%)	2 (25%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	4 (33%)	2 (25%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (13%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (13%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Appetite Loss Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 16	Actual Score	n	12	8
		Mean	2.78	12.50
		SD	9.623	24.801
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	66.7
	Change from Baseline	n	11	7
		Mean	-15.15	-9.52
		SD	31.140	31.706
		Median	0.00	0.00
		Min.	-66.7	-66.7
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (36%)	2 (29%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	4 (36%)	2 (29%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (9%)	1 (14%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (9%)	1 (14%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Appetite Loss Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 19	Actual Score	n	12	7
		Mean	0.00	19.05
		SD	0.000	26.227
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	66.7
	Change from Baseline	n	11	6
		Mean	-18.18	-5.56
		SD	27.340	13.608
		Median	0.00	0.00
		Min.	-66.7	-33.3
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (36%)	1 (17%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	4 (36%)	1 (17%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Appetite Loss Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 22	Actual Score	n	7	7
		Mean	4.76	9.52
		SD	12.599	16.265
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	33.3
	Change from Baseline	n	7	6
		Mean	-9.52	0.00
		SD	16.265	0.000
		Median	0.00	0.00
		Min.	-33.3	0.0
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (29%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (29%)	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Appetite Loss Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 25	Actual Score	n	7	7
		Mean	4.76	9.52
		SD	12.599	16.265
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	33.3
	Change from Baseline	n	7	7
		Mean	-4.76	-4.76
		SD	12.599	12.599
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (14%)	1 (14%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (14%)	1 (14%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Appetite Loss Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 28	Actual Score	n	7	6
		Mean	9.52	5.56
		SD	25.198	13.608
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	66.7	33.3
	Change from Baseline	n	7	6
		Mean	0.00	-5.56
		SD	38.490	13.608
		Median	0.00	0.00
		Min.	-66.7	-33.3
		Max.	66.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (14%)	1 (17%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (14%)	1 (17%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (14%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (14%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Appetite Loss Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 31	Actual Score	n	7	6
		Mean	9.52	11.11
		SD	16.265	17.213
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	33.3
	Change from Baseline	n	7	6
		Mean	0.00	0.00
		SD	19.245	0.000
		Median	0.00	0.00
		Min.	-33.3	0.0
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (14%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (14%)	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (14%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (14%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Appetite Loss Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 34	Actual Score	n	5	6
		Mean	6.67	11.11
		SD	14.907	17.213
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	33.3
	Change from Baseline	n	5	6
		Mean	6.67	0.00
		SD	14.907	0.000
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (20%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (20%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Appetite Loss Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 37	Actual Score	n	4	6
		Mean	8.33	5.56
		SD	16.667	13.608
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	33.3
	Change from Baseline	n	4	6
		Mean	8.33	-5.56
		SD	16.667	13.608
		Median	0.00	0.00
		Min.	0.0	-33.3
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (17%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (17%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (25%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (25%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Appetite Loss Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 40	Actual Score	n	4	5
		Mean	25.00	6.67
		SD	31.914	14.907
		Median	16.67	0.00
		Min.	0.0	0.0
		Max.	66.7	33.3
	Change from Baseline	n	4	5
		Mean	25.00	0.00
		SD	31.914	0.000
		Median	16.67	0.00
		Min.	0.0	0.0
		Max.	66.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	2 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	2 (50%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Appetite Loss Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 43	Actual Score	n	4	4
		Mean	8.33	8.33
		SD	16.667	16.667
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	33.3
	Change from Baseline	n	4	4
		Mean	8.33	0.00
		SD	16.667	0.000
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (25%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (25%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Appetite Loss Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 46	Actual Score	n	3	4
		Mean	11.11	16.67
		SD	19.245	33.333
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	66.7
	Change from Baseline	n	3	4
		Mean	11.11	8.33
		SD	19.245	16.667
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (33%)	1 (25%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (33%)	1 (25%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Appetite Loss Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 49	Actual Score	n	3	4
		Mean	11.11	8.33
		SD	19.245	16.667
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	33.3
	Change from Baseline	n	3	4
		Mean	11.11	0.00
		SD	19.245	0.000
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (33%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (33%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Appetite Loss Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 52	Actual Score	n	3	4
		Mean	11.11	0.00
		SD	19.245	0.000
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Change from Baseline	n	3	4
		Mean	11.11	-8.33
		SD	19.245	16.667
		Median	0.00	0.00
		Min.	0.0	-33.3
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (25%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (25%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (33%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (33%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Appetite Loss Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 55	Actual Score	n	3	3
		Mean	11.11	0.00
		SD	19.245	0.000
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Change from Baseline	n	3	3
		Mean	11.11	0.00
		SD	19.245	0.000
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (33%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (33%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Appetite Loss Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 58	Actual Score	n	2	2
		Mean	33.33	0.00
		SD	47.140	0.000
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	66.7	0.0
	Change from Baseline	n	2	2
		Mean	33.33	0.00
		SD	47.140	0.000
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	66.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Appetite Loss Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 61	Actual Score	n	2	2
		Mean	33.33	0.00
		SD	0.000	0.000
		Median	33.33	0.00
		Min.	33.3	0.0
		Max.	33.3	0.0
	Change from Baseline	n	2	2
		Mean	33.33	0.00
		SD	0.000	0.000
		Median	33.33	0.00
		Min.	33.3	0.0
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	2 (100%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	2 (100%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Appetite Loss Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 64	Actual Score	n	2	2
		Mean	33.33	0.00
		SD	47.140	0.000
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	66.7	0.0
	Change from Baseline	n	2	2
		Mean	33.33	0.00
		SD	47.140	0.000
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	66.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Appetite Loss Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 67	Actual Score	n	2	2
		Mean	16.67	0.00
		SD	23.570	0.000
		Median	16.67	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Change from Baseline	n	2	2
		Mean	16.67	0.00
		SD	23.570	0.000
		Median	16.67	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Appetite Loss Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 70	Actual Score	n	2	1
		Mean	0.00	0.00
		SD	0.000	
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Change from Baseline	n	2	1
		Mean	0.00	0.00
		SD	0.000	
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Appetite Loss Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 73	Actual Score	n	1	1
		Mean	0.00	0.00
		SD		
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Change from Baseline	n	1	1
		Mean	0.00	0.00
		SD		
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Appetite Loss Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 76	Actual Score	n	2	1
		Mean	16.67	0.00
		SD	23.570	
		Median	16.67	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Change from Baseline	n	2	1
		Mean	16.67	0.00
		SD	23.570	
		Median	16.67	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Appetite Loss Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 79	Actual Score	n	2	1
		Mean	16.67	0.00
		SD	23.570	
		Median	16.67	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Change from Baseline	n	2	1
		Mean	16.67	0.00
		SD	23.570	
		Median	16.67	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Appetite Loss Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 82	Actual Score	n	2	1
		Mean	16.67	0.00
		SD	23.570	
		Median	16.67	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Change from Baseline	n	2	1
		Mean	16.67	0.00
		SD	23.570	
		Median	16.67	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Appetite Loss Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 85	Actual Score	n	1	1
		Mean	33.33	0.00
		SD		
		Median	33.33	0.00
		Min.	33.3	0.0
		Max.	33.3	0.0
	Change from Baseline	n	1	1
		Mean	33.33	0.00
		SD		
		Median	33.33	0.00
		Min.	33.3	0.0
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (100%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (100%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Appetite Loss Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 88	Actual Score	n	1	1
		Mean	0.00	0.00
		SD		
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Change from Baseline	n	1	1
		Mean	0.00	0.00
		SD		
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Appetite Loss Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 91	Actual Score	n	2	1
		Mean	33.33	0.00
		SD	47.140	
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	66.7	0.0
	Change from Baseline	n	2	1
		Mean	33.33	0.00
		SD	47.140	
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	66.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Appetite Loss Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 94	Actual Score	n	2	1
		Mean	0.00	0.00
		SD	0.000	
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Change from Baseline	n	2	1
		Mean	0.00	0.00
		SD	0.000	
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Appetite Loss Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 97	Actual Score	n	1	0
		Mean	0.00	
		SD		
		Median	0.00	
		Min.	0.0	
		Max.	0.0	
	Change from Baseline	n	1	0
		Mean	0.00	
		SD		
		Median	0.00	
		Min.	0.0	
		Max.	0.0	
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_c30_dom.sas 10MAR2023 10:38

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Appetite Loss Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 100	Actual Score	n	0	1
		Mean		0.00
		SD		
		Median		0.00
		Min.		0.0
		Max.		0.0
	Change from Baseline	n	0	1
		Mean		0.00
		SD		
		Median		0.00
		Min.		0.0
		Max.		0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Appetite Loss Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
End of Treatment	Actual Score	n	10	11
		Mean	13.33	33.33
		SD	23.307	36.515
		Median	0.00	33.33
		Min.	0.0	0.0
		Max.	66.7	100.0
	Change from Baseline	n	9	11
		Mean	-11.11	6.06
		SD	37.268	29.129
		Median	0.00	0.00
		Min.	-66.7	-33.3
		Max.	66.7	66.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (44%)	2 (18%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	4 (44%)	2 (18%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (11%)	3 (27%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (11%)	3 (27%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Appetite Loss Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 1	Actual Score	n	3	5
		Mean	0.00	26.67
		SD	0.000	14.907
		Median	0.00	33.33
		Min.	0.0	0.0
		Max.	0.0	33.3
	Change from Baseline	n	2	5
		Mean	-33.33	0.00
		SD	47.140	23.570
		Median	-33.33	0.00
		Min.	-66.7	-33.3
		Max.	0.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	1 (20%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	1 (20%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (20%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (20%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Appetite Loss Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 2	Actual Score	n	3	3
		Mean	33.33	44.44
		SD	33.333	19.245
		Median	33.33	33.33
		Min.	0.0	33.3
		Max.	66.7	66.7
	Change from Baseline	n	2	3
		Mean	0.00	22.22
		SD	0.000	19.245
		Median	0.00	33.33
		Min.	0.0	0.0
		Max.	0.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	2 (67%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	2 (67%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Appetite Loss Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 4	Actual Score	n	0	2
		Mean		0.00
		SD		0.000
		Median		0.00
		Min.		0.0
		Max.		0.0
	Change from Baseline	n	0	2
		Mean		-16.67
		SD		23.570
		Median		-16.67
		Min.		-33.3
		Max.		0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (50%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_c30_dom.sas 10MAR2023 10:38

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Appetite Loss Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
PFS Follow-Up 2	Actual Score	n	1	1
		Mean	0.00	33.33
		SD		
		Median	0.00	33.33
		Min.	0.0	33.3
		Max.	0.0	33.3
	Change from Baseline	n	1	1
		Mean	0.00	0.00
		SD		
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Appetite Loss Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
PFS Follow-Up 4	Actual Score	n	0	1
		Mean		0.00
		SD		
		Median		0.00
		Min.		0.0
		Max.		0.0
	Change from Baseline	n	0	1
		Mean		-33.33
		SD		
		Median		-33.33
		Min.		-33.3
		Max.		-33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (100%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Appetite Loss Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Last Follow-up	Actual Score	n	3	5
		Mean	33.33	26.67
		SD	33.333	27.889
		Median	33.33	33.33
		Min.	0.0	0.0
		Max.	66.7	66.7
	Change from Baseline	n	2	5
		Mean	0.00	0.00
		SD	0.000	33.333
		Median	0.00	0.00
		Min.	0.0	-33.3
		Max.	0.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	2 (40%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	2 (40%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	2 (40%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	2 (40%)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_c30_dom.sas 10MAR2023 10:38

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Appetite Loss Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Worst Case Post-Baseline	Actual Score	n	13	25
		Mean	33.33	48.00
		SD	30.429	33.444
		Median	33.33	33.33
		Min.	0.0	0.0
		Max.	66.7	100.0
	Change from Baseline	n	12	24
		Mean	16.67	13.89
		SD	33.333	23.909
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	66.7	66.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (8%)	2 (8%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (8%)	2 (8%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	4 (33%)	11 (46%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	4 (33%)	11 (46%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Constipation Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Baseline	Actual Score	n	13	26
		Mean	2.56	24.36
		SD	9.245	30.634
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	100.0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Constipation Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 4	Actual Score	n	13	23
		Mean	25.64	20.29
		SD	36.398	31.365
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	100.0	100.0
	Change from Baseline	n	12	22
		Mean	19.44	-1.52
		SD	33.207	24.075
		Median	0.00	0.00
		Min.	0.0	-33.3
		Max.	100.0	66.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	5 (23%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	5 (23%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	4 (33%)	3 (14%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	4 (33%)	3 (14%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Constipation Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 7	Actual Score	n	12	17
		Mean	19.44	19.61
		SD	30.011	31.311
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	100.0	100.0
	Change from Baseline	n	11	16
		Mean	15.15	-2.08
		SD	34.524	30.957
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	100.0	100.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (9%)	4 (25%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (9%)	4 (25%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	4 (36%)	1 (6%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	4 (36%)	1 (6%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Constipation Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 10	Actual Score	n	13	12
		Mean	23.08	16.67
		SD	34.385	22.473
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	100.0	66.7
	Change from Baseline	n	12	11
		Mean	19.44	-6.06
		SD	38.817	25.025
		Median	0.00	0.00
		Min.	-33.3	-66.7
		Max.	100.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (8%)	2 (18%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (8%)	2 (18%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	4 (33%)	1 (9%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	4 (33%)	1 (9%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Constipation Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 13	Actual Score	n	13	9
		Mean	25.64	11.11
		SD	33.758	16.667
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	100.0	33.3
	Change from Baseline	n	12	8
		Mean	22.22	-12.50
		SD	38.490	17.252
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	100.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (8%)	3 (38%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (8%)	3 (38%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	5 (42%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	5 (42%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Constipation Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 16	Actual Score	n	12	8
		Mean	25.00	8.33
		SD	32.177	23.570
		Median	16.67	0.00
		Min.	0.0	0.0
		Max.	100.0	66.7
	Change from Baseline	n	11	7
		Mean	21.21	0.00
		SD	34.230	0.000
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	100.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	4 (36%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	4 (36%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Constipation Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 19	Actual Score	n	12	7
		Mean	25.00	14.29
		SD	35.176	26.227
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	100.0	66.7
	Change from Baseline	n	11	6
		Mean	21.21	5.56
		SD	40.202	13.608
		Median	0.00	0.00
		Min.	-33.3	0.0
		Max.	100.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (9%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (9%)	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	4 (36%)	1 (17%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	4 (36%)	1 (17%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Constipation Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 22	Actual Score	n	7	7
		Mean	14.29	4.76
		SD	26.227	12.599
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	66.7	33.3
	Change from Baseline	n	7	6
		Mean	9.52	0.00
		SD	31.706	21.082
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	66.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (14%)	1 (17%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (14%)	1 (17%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	2 (29%)	1 (17%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	2 (29%)	1 (17%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Constipation Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 25	Actual Score	n	7	7
		Mean	19.05	9.52
		SD	26.227	16.265
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	66.7	33.3
	Change from Baseline	n	7	7
		Mean	14.29	-4.76
		SD	32.530	29.991
		Median	0.00	0.00
		Min.	-33.3	-66.7
		Max.	66.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (14%)	1 (14%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (14%)	1 (14%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	3 (43%)	1 (14%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	3 (43%)	1 (14%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Constipation Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 28	Actual Score	n	7	6
		Mean	19.05	0.00
		SD	26.227	0.000
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	66.7	0.0
	Change from Baseline	n	7	6
		Mean	14.29	-5.56
		SD	32.530	13.608
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	66.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (14%)	1 (17%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (14%)	1 (17%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	3 (43%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	3 (43%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Constipation Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 31	Actual Score	n	7	6
		Mean	14.29	0.00
		SD	17.817	0.000
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Change from Baseline	n	7	6
		Mean	9.52	-5.56
		SD	25.198	13.608
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (14%)	1 (17%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (14%)	1 (17%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	3 (43%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	3 (43%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Constipation Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 34	Actual Score	n	5	6
		Mean	13.33	0.00
		SD	18.257	0.000
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Change from Baseline	n	5	6
		Mean	13.33	-5.56
		SD	18.257	13.608
		Median	0.00	0.00
		Min.	0.0	-33.3
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (17%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (17%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	2 (40%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	2 (40%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Constipation Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 37	Actual Score	n	4	6
		Mean	41.67	0.00
		SD	41.944	0.000
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	100.0	0.0
	Change from Baseline	n	4	6
		Mean	41.67	-5.56
		SD	41.944	13.608
		Median	33.33	0.00
		Min.	0.0	-33.3
		Max.	100.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (17%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (17%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	3 (75%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	3 (75%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Constipation Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 40	Actual Score	n	4	5
		Mean	16.67	0.00
		SD	19.245	0.000
		Median	16.67	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Change from Baseline	n	4	5
		Mean	16.67	-6.67
		SD	19.245	14.907
		Median	16.67	0.00
		Min.	0.0	-33.3
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (20%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (20%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	2 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	2 (50%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Constipation Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 43	Actual Score	n	4	4
		Mean	16.67	0.00
		SD	33.333	0.000
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	66.7	0.0
	Change from Baseline	n	4	4
		Mean	16.67	-8.33
		SD	33.333	16.667
		Median	0.00	0.00
		Min.	0.0	-33.3
		Max.	66.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (25%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (25%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (25%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (25%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Constipation Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 46	Actual Score	n	3	4
		Mean	22.22	0.00
		SD	19.245	0.000
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Change from Baseline	n	3	4
		Mean	22.22	-8.33
		SD	19.245	16.667
		Median	33.33	0.00
		Min.	0.0	-33.3
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (25%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (25%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	2 (67%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	2 (67%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Constipation Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 49	Actual Score	n	3	4
		Mean	33.33	0.00
		SD	33.333	0.000
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	66.7	0.0
	Change from Baseline	n	3	4
		Mean	33.33	-8.33
		SD	33.333	16.667
		Median	33.33	0.00
		Min.	0.0	-33.3
		Max.	66.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (25%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (25%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	2 (67%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	2 (67%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Constipation Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 52	Actual Score	n	3	4
		Mean	22.22	0.00
		SD	38.490	0.000
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	66.7	0.0
	Change from Baseline	n	3	4
		Mean	22.22	-8.33
		SD	38.490	16.667
		Median	0.00	0.00
		Min.	0.0	-33.3
		Max.	66.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (25%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (25%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (33%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (33%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Constipation Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 55	Actual Score	n	3	3
		Mean	11.11	0.00
		SD	19.245	0.000
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Change from Baseline	n	3	3
		Mean	11.11	-11.11
		SD	19.245	19.245
		Median	0.00	0.00
		Min.	0.0	-33.3
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (33%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (33%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (33%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (33%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Constipation Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 58	Actual Score	n	2	2
		Mean	66.67	0.00
		SD	47.140	0.000
		Median	66.67	0.00
		Min.	33.3	0.0
		Max.	100.0	0.0
	Change from Baseline	n	2	2
		Mean	66.67	0.00
		SD	47.140	0.000
		Median	66.67	0.00
		Min.	33.3	0.0
		Max.	100.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	2 (100%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	2 (100%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Constipation Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 61	Actual Score	n	2	2
		Mean	66.67	0.00
		SD	0.000	0.000
		Median	66.67	0.00
		Min.	66.7	0.0
		Max.	66.7	0.0
	Change from Baseline	n	2	2
		Mean	66.67	0.00
		SD	0.000	0.000
		Median	66.67	0.00
		Min.	66.7	0.0
		Max.	66.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	2 (100%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	2 (100%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Constipation Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 64	Actual Score	n	2	2
		Mean	50.00	0.00
		SD	23.570	0.000
		Median	50.00	0.00
		Min.	33.3	0.0
		Max.	66.7	0.0
	Change from Baseline	n	2	2
		Mean	50.00	0.00
		SD	23.570	0.000
		Median	50.00	0.00
		Min.	33.3	0.0
		Max.	66.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	2 (100%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	2 (100%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Constipation Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 67	Actual Score	n	2	2
		Mean	66.67	0.00
		SD	47.140	0.000
		Median	66.67	0.00
		Min.	33.3	0.0
		Max.	100.0	0.0
	Change from Baseline	n	2	2
		Mean	66.67	0.00
		SD	47.140	0.000
		Median	66.67	0.00
		Min.	33.3	0.0
		Max.	100.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	2 (100%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	2 (100%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Constipation Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 70	Actual Score	n	2	1
		Mean	66.67	0.00
		SD	0.000	
		Median	66.67	0.00
		Min.	66.7	0.0
		Max.	66.7	0.0
	Change from Baseline	n	2	1
		Mean	66.67	0.00
		SD	0.000	
		Median	66.67	0.00
		Min.	66.7	0.0
		Max.	66.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	2 (100%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	2 (100%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Constipation Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 73	Actual Score	n	1	1
		Mean	66.67	0.00
		SD		
		Median	66.67	0.00
		Min.	66.7	0.0
		Max.	66.7	0.0
	Change from Baseline	n	1	1
		Mean	66.67	0.00
		SD		
		Median	66.67	0.00
		Min.	66.7	0.0
		Max.	66.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (100%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (100%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Constipation Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 76	Actual Score	n	2	1
		Mean	66.67	0.00
		SD	0.000	
		Median	66.67	0.00
		Min.	66.7	0.0
		Max.	66.7	0.0
	Change from Baseline	n	2	1
		Mean	66.67	0.00
		SD	0.000	
		Median	66.67	0.00
		Min.	66.7	0.0
		Max.	66.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	2 (100%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	2 (100%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Constipation Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 79	Actual Score	n	2	1
		Mean	50.00	0.00
		SD	23.570	
		Median	50.00	0.00
		Min.	33.3	0.0
		Max.	66.7	0.0
	Change from Baseline	n	2	1
		Mean	50.00	0.00
		SD	23.570	
		Median	50.00	0.00
		Min.	33.3	0.0
		Max.	66.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	2 (100%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	2 (100%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Constipation Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 82	Actual Score	n	2	1
		Mean	50.00	0.00
		SD	23.570	
		Median	50.00	0.00
		Min.	33.3	0.0
		Max.	66.7	0.0
	Change from Baseline	n	2	1
		Mean	50.00	0.00
		SD	23.570	
		Median	50.00	0.00
		Min.	33.3	0.0
		Max.	66.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	2 (100%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	2 (100%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Constipation Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 85	Actual Score	n	1	1
		Mean	66.67	0.00
		SD		
		Median	66.67	0.00
		Min.	66.7	0.0
		Max.	66.7	0.0
	Change from Baseline	n	1	1
		Mean	66.67	0.00
		SD		
		Median	66.67	0.00
		Min.	66.7	0.0
		Max.	66.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (100%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (100%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Constipation Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 88	Actual Score	n	1	1
		Mean	33.33	0.00
		SD		
		Median	33.33	0.00
		Min.	33.3	0.0
		Max.	33.3	0.0
	Change from Baseline	n	1	1
		Mean	33.33	0.00
		SD		
		Median	33.33	0.00
		Min.	33.3	0.0
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (100%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (100%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Constipation Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 91	Actual Score	n	2	1
		Mean	50.00	0.00
		SD	23.570	
		Median	50.00	0.00
		Min.	33.3	0.0
		Max.	66.7	0.0
	Change from Baseline	n	2	1
		Mean	50.00	0.00
		SD	23.570	
		Median	50.00	0.00
		Min.	33.3	0.0
		Max.	66.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	2 (100%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	2 (100%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Constipation Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 94	Actual Score	n	2	1
		Mean	16.67	0.00
		SD	23.570	
		Median	16.67	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Change from Baseline	n	2	1
		Mean	16.67	0.00
		SD	23.570	
		Median	16.67	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Constipation Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 97	Actual Score	n	1	0
		Mean	33.33	
		SD		
		Median	33.33	
		Min.	33.3	
		Max.	33.3	
	Change from Baseline	n	1	0
		Mean	33.33	
		SD		
		Median	33.33	
		Min.	33.3	
		Max.	33.3	
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (100%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (100%)	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_c30_dom.sas 10MAR2023 10:38

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Constipation Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 100	Actual Score	n	0	1
		Mean		0.00
		SD		
		Median		0.00
		Min.		0.0
		Max.		0.0
	Change from Baseline	n	0	1
		Mean		0.00
		SD		
		Median		0.00
		Min.		0.0
		Max.		0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_c30_dom.sas 10MAR2023 10:38

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Constipation Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
End of Treatment	Actual Score	n	10	11
		Mean	13.33	27.27
		SD	32.203	29.129
		Median	0.00	33.33
		Min.	0.0	0.0
		Max.	100.0	66.7
	Change from Baseline	n	9	11
		Mean	0.00	9.09
		SD	16.667	26.208
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	33.3	66.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (11%)	1 (9%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (11%)	1 (9%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (11%)	3 (27%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (11%)	3 (27%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Constipation Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 1	Actual Score	n	3	5
		Mean	33.33	33.33
		SD	33.333	33.333
		Median	33.33	33.33
		Min.	0.0	0.0
		Max.	66.7	66.7
	Change from Baseline	n	2	5
		Mean	16.67	20.00
		SD	23.570	29.814
		Median	16.67	0.00
		Min.	0.0	0.0
		Max.	33.3	66.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	2 (40%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	2 (40%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Constipation Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 2	Actual Score	n	3	3
		Mean	33.33	11.11
		SD	33.333	19.245
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	66.7	33.3
	Change from Baseline	n	2	3
		Mean	33.33	0.00
		SD	47.140	33.333
		Median	33.33	0.00
		Min.	0.0	-33.3
		Max.	66.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (33%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (33%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	1 (33%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	1 (33%)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_c30_dom.sas 10MAR2023 10:38

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Constipation Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 4	Actual Score	n	0	2
		Mean		0.00
		SD		0.000
		Median		0.00
		Min.		0.0
		Max.		0.0
	Change from Baseline	n	0	2
		Mean		-16.67
		SD		23.570
		Median		-16.67
		Min.		-33.3
		Max.		0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (50%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Constipation Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
PFS Follow-Up 2	Actual Score	n	1	1
		Mean	33.33	33.33
		SD		
		Median	33.33	33.33
		Min.	33.3	33.3
		Max.	33.3	33.3
	Change from Baseline	n	1	1
		Mean	33.33	0.00
		SD		
		Median	33.33	0.00
		Min.	33.3	0.0
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (100%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (100%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Constipation Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
PFS Follow-Up 4	Actual Score	n	0	1
		Mean		0.00
		SD		
		Median		0.00
		Min.		0.0
		Max.		0.0
	Change from Baseline	n	0	1
		Mean		-33.33
		SD		
		Median		-33.33
		Min.		-33.3
		Max.		-33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (100%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Constipation Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Last Follow-up	Actual Score	n	3	5
		Mean	33.33	33.33
		SD	33.333	33.333
		Median	33.33	33.33
		Min.	0.0	0.0
		Max.	66.7	66.7
	Change from Baseline	n	2	5
		Mean	33.33	20.00
		SD	47.140	38.006
		Median	33.33	33.33
		Min.	0.0	-33.3
		Max.	66.7	66.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (20%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (20%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	3 (60%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	3 (60%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Constipation Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Worst Case Post-Baseline	Actual Score	n	13	25
		Mean	53.85	37.33
		SD	39.764	35.119
		Median	66.67	33.33
		Min.	0.0	0.0
		Max.	100.0	100.0
	Change from Baseline	n	12	24
		Mean	47.22	13.89
		SD	38.817	27.657
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	100.0	100.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	9 (75%)	6 (25%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	9 (75%)	6 (25%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Diarrhea Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Baseline	Actual Score	n	13	26
		Mean	15.38	15.38
		SD	22.008	21.563
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	66.7	66.7

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Diarrhea Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 4	Actual Score	n	13	23
		Mean	7.69	13.04
		SD	14.618	21.879
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	66.7
	Change from Baseline	n	12	22
		Mean	-8.33	-3.03
		SD	25.126	25.006
		Median	0.00	0.00
		Min.	-66.7	-66.7
		Max.	33.3	66.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (25%)	4 (18%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (25%)	4 (18%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (8%)	2 (9%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (8%)	2 (9%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Diarrhea Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 7	Actual Score	n	11	17
		Mean	0.00	19.61
		SD	0.000	33.456
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	100.0
	Change from Baseline	n	10	17
		Mean	-20.00	5.88
		SD	23.307	31.700
		Median	-16.67	0.00
		Min.	-66.7	-33.3
		Max.	0.0	100.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	5 (50%)	3 (18%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	5 (50%)	3 (18%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	4 (24%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	4 (24%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Diarrhea Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 10	Actual Score	n	13	12
		Mean	0.00	13.89
		SD	0.000	30.011
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	100.0
	Change from Baseline	n	12	12
		Mean	-16.67	0.00
		SD	22.473	14.213
		Median	0.00	0.00
		Min.	-66.7	-33.3
		Max.	0.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	5 (42%)	1 (8%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	5 (42%)	1 (8%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (8%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (8%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Diarrhea Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 13	Actual Score	n	13	9
		Mean	5.13	11.11
		SD	18.490	33.333
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	66.7	100.0
	Change from Baseline	n	12	9
		Mean	-11.11	-3.70
		SD	25.950	26.058
		Median	0.00	0.00
		Min.	-66.7	-66.7
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (33%)	1 (11%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	4 (33%)	1 (11%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (8%)	1 (11%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (8%)	1 (11%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Diarrhea Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 16	Actual Score	n	11	8
		Mean	3.03	12.50
		SD	10.050	35.355
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	100.0
	Change from Baseline	n	10	8
		Mean	-13.33	-4.17
		SD	28.109	27.817
		Median	0.00	0.00
		Min.	-66.7	-66.7
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (40%)	1 (13%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	4 (40%)	1 (13%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (10%)	1 (13%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (10%)	1 (13%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Diarrhea Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 19	Actual Score	n	12	7
		Mean	2.78	9.52
		SD	9.623	25.198
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	66.7
	Change from Baseline	n	11	7
		Mean	-12.12	-9.52
		SD	22.473	25.198
		Median	0.00	0.00
		Min.	-66.7	-66.7
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (27%)	1 (14%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (27%)	1 (14%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_c30_dom.sas 10MAR2023 10:38

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Diarrhea Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 22	Actual Score	n	7	7
		Mean	0.00	14.29
		SD	0.000	37.796
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	100.0
	Change from Baseline	n	7	7
		Mean	-23.81	-4.76
		SD	25.198	29.991
		Median	-33.33	0.00
		Min.	-66.7	-66.7
		Max.	0.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	4 (57%)	1 (14%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	4 (57%)	1 (14%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (14%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (14%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Diarrhea Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 25	Actual Score	n	7	7
		Mean	0.00	14.29
		SD	0.000	37.796
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	100.0
	Change from Baseline	n	7	7
		Mean	-19.05	-4.76
		SD	26.227	29.991
		Median	0.00	0.00
		Min.	-66.7	-66.7
		Max.	0.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (43%)	1 (14%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (43%)	1 (14%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (14%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (14%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Diarrhea Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 28	Actual Score	n	7	6
		Mean	0.00	5.56
		SD	0.000	13.608
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	33.3
	Change from Baseline	n	7	6
		Mean	-19.05	-16.67
		SD	26.227	27.889
		Median	0.00	0.00
		Min.	-66.7	-66.7
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (43%)	2 (33%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (43%)	2 (33%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Diarrhea Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 31	Actual Score	n	7	6
		Mean	4.76	11.11
		SD	12.599	27.217
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	66.7
	Change from Baseline	n	7	6
		Mean	-14.29	-11.11
		SD	26.227	27.217
		Median	0.00	0.00
		Min.	-66.7	-66.7
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (29%)	1 (17%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (29%)	1 (17%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_c30_dom.sas 10MAR2023 10:38

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Diarrhea Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 34	Actual Score	n	5	6
		Mean	0.00	22.22
		SD	0.000	40.369
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	100.0
	Change from Baseline	n	5	6
		Mean	-13.33	0.00
		SD	18.257	21.082
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	0.0	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (40%)	1 (17%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (40%)	1 (17%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (17%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (17%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Diarrhea Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 37	Actual Score	n	4	6
		Mean	8.33	22.22
		SD	16.667	40.369
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	100.0
	Change from Baseline	n	4	6
		Mean	0.00	0.00
		SD	27.217	21.082
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (25%)	1 (17%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (25%)	1 (17%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (25%)	1 (17%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (25%)	1 (17%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Diarrhea Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 40	Actual Score	n	4	5
		Mean	0.00	13.33
		SD	0.000	29.814
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	66.7
	Change from Baseline	n	4	5
		Mean	-8.33	0.00
		SD	16.667	0.000
		Median	0.00	0.00
		Min.	-33.3	0.0
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (25%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (25%)	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Diarrhea Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 43	Actual Score	n	4	4
		Mean	8.33	16.67
		SD	16.667	33.333
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	66.7
	Change from Baseline	n	4	4
		Mean	0.00	0.00
		SD	27.217	0.000
		Median	0.00	0.00
		Min.	-33.3	0.0
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (25%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (25%)	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (25%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (25%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Diarrhea Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 46	Actual Score	n	3	4
		Mean	0.00	8.33
		SD	0.000	16.667
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	33.3
	Change from Baseline	n	3	4
		Mean	-11.11	-8.33
		SD	19.245	16.667
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (33%)	1 (25%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (33%)	1 (25%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Diarrhea Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 49	Actual Score	n	3	4
		Mean	11.11	8.33
		SD	19.245	16.667
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	33.3
	Change from Baseline	n	3	4
		Mean	0.00	-8.33
		SD	0.000	16.667
		Median	0.00	0.00
		Min.	0.0	-33.3
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (25%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (25%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Diarrhea Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 52	Actual Score	n	3	4
		Mean	11.11	8.33
		SD	19.245	16.667
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	33.3
	Change from Baseline	n	3	4
		Mean	0.00	-8.33
		SD	0.000	16.667
		Median	0.00	0.00
		Min.	0.0	-33.3
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (25%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (25%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_c30_dom.sas 10MAR2023 10:38

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Diarrhea Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 55	Actual Score	n	3	3
		Mean	0.00	0.00
		SD	0.000	0.000
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Change from Baseline	n	3	3
		Mean	-11.11	0.00
		SD	19.245	0.000
		Median	0.00	0.00
		Min.	-33.3	0.0
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (33%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (33%)	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Diarrhea Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 58	Actual Score	n	2	2
		Mean	16.67	0.00
		SD	23.570	0.000
		Median	16.67	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Change from Baseline	n	2	2
		Mean	16.67	0.00
		SD	23.570	0.000
		Median	16.67	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Diarrhea Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 61	Actual Score	n	2	2
		Mean	16.67	0.00
		SD	23.570	0.000
		Median	16.67	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Change from Baseline	n	2	2
		Mean	16.67	0.00
		SD	23.570	0.000
		Median	16.67	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Diarrhea Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 64	Actual Score	n	2	2
		Mean	0.00	0.00
		SD	0.000	0.000
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Change from Baseline	n	2	2
		Mean	0.00	0.00
		SD	0.000	0.000
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_c30_dom.sas 10MAR2023 10:38

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Diarrhea Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 67	Actual Score	n	2	2
		Mean	16.67	0.00
		SD	23.570	0.000
		Median	16.67	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Change from Baseline	n	2	2
		Mean	16.67	0.00
		SD	23.570	0.000
		Median	16.67	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Diarrhea Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 70	Actual Score	n	2	1
		Mean	0.00	0.00
		SD	0.000	
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Change from Baseline	n	2	1
		Mean	0.00	0.00
		SD	0.000	
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Diarrhea Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 73	Actual Score	n	1	1
		Mean	33.33	0.00
		SD		
		Median	33.33	0.00
		Min.	33.3	0.0
		Max.	33.3	0.0
	Change from Baseline	n	1	1
		Mean	33.33	0.00
		SD		
		Median	33.33	0.00
		Min.	33.3	0.0
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (100%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (100%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Diarrhea Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 76	Actual Score	n	2	1
		Mean	0.00	0.00
		SD	0.000	
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Change from Baseline	n	2	1
		Mean	0.00	0.00
		SD	0.000	
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Diarrhea Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 79	Actual Score	n	2	1
		Mean	0.00	0.00
		SD	0.000	
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Change from Baseline	n	2	1
		Mean	0.00	0.00
		SD	0.000	
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Diarrhea Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 82	Actual Score	n	2	1
		Mean	0.00	0.00
		SD	0.000	
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Change from Baseline	n	2	1
		Mean	0.00	0.00
		SD	0.000	
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Diarrhea Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 85	Actual Score	n	1	1
		Mean	0.00	0.00
		SD		
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Change from Baseline	n	1	1
		Mean	0.00	0.00
		SD		
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Diarrhea Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 88	Actual Score	n	1	1
		Mean	0.00	0.00
		SD		
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Change from Baseline	n	1	1
		Mean	0.00	0.00
		SD		
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Diarrhea Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 91	Actual Score	n	2	1
		Mean	0.00	0.00
		SD	0.000	
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Change from Baseline	n	2	1
		Mean	0.00	0.00
		SD	0.000	
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Diarrhea Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 94	Actual Score	n	2	1
		Mean	16.67	0.00
		SD	23.570	
		Median	16.67	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Change from Baseline	n	2	1
		Mean	16.67	0.00
		SD	23.570	
		Median	16.67	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Diarrhea Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 97	Actual Score	n	1	0
		Mean	0.00	
		SD		
		Median	0.00	
		Min.	0.0	
		Max.	0.0	
	Change from Baseline	n	1	0
		Mean	0.00	
		SD		
		Median	0.00	
		Min.	0.0	
		Max.	0.0	
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_c30_dom.sas 10MAR2023 10:38

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Diarrhea Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 100	Actual Score	n	0	1
		Mean		0.00
		SD		
		Median		0.00
		Min.		0.0
		Max.		0.0
	Change from Baseline	n	0	1
		Mean		0.00
		SD		
		Median		0.00
		Min.		0.0
		Max.		0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_c30_dom.sas 10MAR2023 10:38

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Diarrhea Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
End of Treatment	Actual Score	n	10	10
		Mean	10.00	13.33
		SD	22.498	23.307
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	66.7	66.7
	Change from Baseline	n	9	10
		Mean	-11.11	0.00
		SD	28.868	15.713
		Median	0.00	0.00
		Min.	-66.7	-33.3
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	3 (33%)	1 (10%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	3 (33%)	1 (10%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (11%)	1 (10%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (11%)	1 (10%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Diarrhea Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 1	Actual Score	n	3	5
		Mean	0.00	26.67
		SD	0.000	27.889
		Median	0.00	33.33
		Min.	0.0	0.0
		Max.	0.0	66.7
	Change from Baseline	n	2	5
		Mean	-50.00	6.67
		SD	23.570	27.889
		Median	-50.00	0.00
		Min.	-66.7	-33.3
		Max.	-33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (100%)	1 (20%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (100%)	1 (20%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	2 (40%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	2 (40%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Diarrhea Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 2	Actual Score	n	3	3
		Mean	11.11	44.44
		SD	19.245	19.245
		Median	0.00	33.33
		Min.	0.0	33.3
		Max.	33.3	66.7
	Change from Baseline	n	2	3
		Mean	-33.33	22.22
		SD	0.000	19.245
		Median	-33.33	33.33
		Min.	-33.3	0.0
		Max.	-33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (100%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (100%)	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	2 (67%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	2 (67%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Diarrhea Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 4	Actual Score	n	0	2
		Mean		0.00
		SD		0.000
		Median		0.00
		Min.		0.0
		Max.		0.0
	Change from Baseline	n	0	2
		Mean		-16.67
		SD		23.570
		Median		-16.67
		Min.		-33.3
		Max.		0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (50%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Diarrhea Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
PFS Follow-Up 2	Actual Score	n	1	1
		Mean	0.00	0.00
		SD		
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Change from Baseline	n	1	1
		Mean	-33.33	0.00
		SD		
		Median	-33.33	0.00
		Min.	-33.3	0.0
		Max.	-33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (100%)	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (100%)	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Diarrhea Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
PFS Follow-Up 4	Actual Score	n	0	1
		Mean		0.00
		SD		
		Median		0.00
		Min.		0.0
		Max.		0.0
	Change from Baseline	n	0	1
		Mean		0.00
		SD		
		Median		0.00
		Min.		0.0
		Max.		0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_c30_dom.sas 10MAR2023 10:38

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Diarrhea Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Last Follow-up	Actual Score	n	3	5
		Mean	11.11	13.33
		SD	19.245	29.814
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	33.3	66.7
	Change from Baseline	n	2	5
		Mean	-33.33	-6.67
		SD	0.000	27.889
		Median	-33.33	0.00
		Min.	-33.3	-33.3
		Max.	-33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (100%)	2 (40%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (100%)	2 (40%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (20%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (20%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Diarrhea Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Worst Case Post-Baseline	Actual Score	n	13	25
		Mean	17.95	25.33
		SD	22.008	32.318
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	66.7	100.0
	Change from Baseline	n	12	24
		Mean	2.78	11.11
		SD	17.164	30.561
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	33.3	100.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (8%)	3 (13%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (8%)	3 (13%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	2 (17%)	8 (33%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	2 (17%)	8 (33%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Financial Difficulties Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Baseline	Actual Score	n	13	27
		Mean	15.38	38.27
		SD	25.875	35.450
		Median	0.00	33.33
		Min.	0.0	0.0
		Max.	66.7	100.0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Financial Difficulties Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 4	Actual Score	n	13	23
		Mean	20.51	27.54
		SD	39.764	38.471
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	100.0	100.0
	Change from Baseline	n	12	23
		Mean	2.78	-4.35
		SD	36.121	30.657
		Median	0.00	0.00
		Min.	-66.7	-66.7
		Max.	66.7	66.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (17%)	7 (30%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (17%)	7 (30%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	2 (17%)	3 (13%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	2 (17%)	3 (13%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Financial Difficulties Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 7	Actual Score	n	12	17
		Mean	19.44	15.69
		SD	22.285	23.914
		Median	16.67	0.00
		Min.	0.0	0.0
		Max.	66.7	66.7
	Change from Baseline	n	11	17
		Mean	3.03	-19.61
		SD	23.355	31.311
		Median	0.00	0.00
		Min.	-33.3	-100.0
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (18%)	8 (47%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (18%)	8 (47%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	3 (27%)	1 (6%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	3 (27%)	1 (6%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Financial Difficulties Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 10	Actual Score	n	13	12
		Mean	20.51	25.00
		SD	34.797	28.868
		Median	0.00	16.67
		Min.	0.0	0.0
		Max.	100.0	66.7
	Change from Baseline	n	12	12
		Mean	2.78	-8.33
		SD	26.432	20.719
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	66.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (17%)	4 (33%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (17%)	4 (33%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	2 (17%)	1 (8%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	2 (17%)	1 (8%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Financial Difficulties Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 13	Actual Score	n	13	9
		Mean	15.38	18.52
		SD	22.008	29.397
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	66.7	66.7
	Change from Baseline	n	12	9
		Mean	0.00	-14.81
		SD	20.101	44.444
		Median	0.00	0.00
		Min.	-33.3	-100.0
		Max.	33.3	66.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (17%)	4 (44%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (17%)	4 (44%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	2 (17%)	1 (11%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	2 (17%)	1 (11%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Financial Difficulties Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 16	Actual Score	n	11	8
		Mean	21.21	25.00
		SD	40.202	34.503
		Median	0.00	16.67
		Min.	0.0	0.0
		Max.	100.0	100.0
	Change from Baseline	n	10	8
		Mean	0.00	-8.33
		SD	27.217	42.725
		Median	0.00	0.00
		Min.	-33.3	-100.0
		Max.	66.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (20%)	2 (25%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (20%)	2 (25%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (10%)	2 (25%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (10%)	2 (25%)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_c30_dom.sas 10MAR2023 10:38

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Financial Difficulties Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 19	Actual Score	n	12	7
		Mean	16.67	23.81
		SD	30.151	25.198
		Median	0.00	33.33
		Min.	0.0	0.0
		Max.	100.0	66.7
	Change from Baseline	n	11	7
		Mean	-3.03	-14.29
		SD	17.979	32.530
		Median	0.00	0.00
		Min.	-33.3	-66.7
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (18%)	3 (43%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (18%)	3 (43%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (9%)	1 (14%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (9%)	1 (14%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Financial Difficulties Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 22	Actual Score	n	7	7
		Mean	19.05	23.81
		SD	37.796	25.198
		Median	0.00	33.33
		Min.	0.0	0.0
		Max.	100.0	66.7
	Change from Baseline	n	7	7
		Mean	0.00	0.00
		SD	33.333	19.245
		Median	0.00	0.00
		Min.	-33.3	-33.3
		Max.	66.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (29%)	1 (14%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (29%)	1 (14%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (14%)	1 (14%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (14%)	1 (14%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Financial Difficulties Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 25	Actual Score	n	7	7
		Mean	23.81	14.29
		SD	37.090	17.817
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	100.0	33.3
	Change from Baseline	n	7	7
		Mean	4.76	-14.29
		SD	35.635	42.414
		Median	0.00	0.00
		Min.	-33.3	-100.0
		Max.	66.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (29%)	2 (29%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (29%)	2 (29%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	2 (29%)	1 (14%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	2 (29%)	1 (14%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Financial Difficulties Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 28	Actual Score	n	7	6
		Mean	14.29	16.67
		SD	37.796	18.257
		Median	0.00	16.67
		Min.	0.0	0.0
		Max.	100.0	33.3
	Change from Baseline	n	7	6
		Mean	-4.76	-11.11
		SD	40.500	34.427
		Median	0.00	0.00
		Min.	-66.7	-66.7
		Max.	66.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (29%)	2 (33%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (29%)	2 (33%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (14%)	1 (17%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (14%)	1 (17%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Financial Difficulties Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 31	Actual Score	n	7	6
		Mean	14.29	16.67
		SD	37.796	18.257
		Median	0.00	16.67
		Min.	0.0	0.0
		Max.	100.0	33.3
	Change from Baseline	n	7	6
		Mean	-4.76	-11.11
		SD	40.500	34.427
		Median	0.00	0.00
		Min.	-66.7	-66.7
		Max.	66.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (29%)	2 (33%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (29%)	2 (33%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (14%)	1 (17%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (14%)	1 (17%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Financial Difficulties Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 34	Actual Score	n	5	6
		Mean	26.67	16.67
		SD	43.461	18.257
		Median	0.00	16.67
		Min.	0.0	0.0
		Max.	100.0	33.3
	Change from Baseline	n	5	6
		Mean	0.00	-11.11
		SD	52.705	34.427
		Median	0.00	0.00
		Min.	-66.7	-66.7
		Max.	66.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (40%)	2 (33%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (40%)	2 (33%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	2 (40%)	1 (17%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	2 (40%)	1 (17%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Financial Difficulties Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 37	Actual Score	n	4	6
		Mean	25.00	16.67
		SD	50.000	18.257
		Median	0.00	16.67
		Min.	0.0	0.0
		Max.	100.0	33.3
	Change from Baseline	n	4	6
		Mean	-8.33	-11.11
		SD	56.928	34.427
		Median	-16.67	0.00
		Min.	-66.7	-66.7
		Max.	66.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (50%)	2 (33%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (50%)	2 (33%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (25%)	1 (17%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (25%)	1 (17%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Financial Difficulties Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 40	Actual Score	n	4	5
		Mean	25.00	20.00
		SD	50.000	18.257
		Median	0.00	33.33
		Min.	0.0	0.0
		Max.	100.0	33.3
	Change from Baseline	n	4	5
		Mean	-8.33	-6.67
		SD	56.928	36.515
		Median	-16.67	0.00
		Min.	-66.7	-66.7
		Max.	66.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (50%)	1 (20%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (50%)	1 (20%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (25%)	1 (20%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (25%)	1 (20%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Financial Difficulties Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 43	Actual Score	n	4	4
		Mean	25.00	33.33
		SD	50.000	27.217
		Median	0.00	33.33
		Min.	0.0	0.0
		Max.	100.0	66.7
	Change from Baseline	n	4	4
		Mean	-8.33	0.00
		SD	56.928	27.217
		Median	-16.67	0.00
		Min.	-66.7	-33.3
		Max.	66.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (50%)	1 (25%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (50%)	1 (25%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (25%)	1 (25%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (25%)	1 (25%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Financial Difficulties Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 46	Actual Score	n	3	4
		Mean	33.33	16.67
		SD	57.735	19.245
		Median	0.00	16.67
		Min.	0.0	0.0
		Max.	100.0	33.3
	Change from Baseline	n	3	4
		Mean	11.11	-16.67
		SD	50.918	57.735
		Median	0.00	0.00
		Min.	-33.3	-100.0
		Max.	66.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (33%)	1 (25%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (33%)	1 (25%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (33%)	1 (25%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (33%)	1 (25%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Financial Difficulties Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 49	Actual Score	n	3	4
		Mean	22.22	16.67
		SD	38.490	19.245
		Median	0.00	16.67
		Min.	0.0	0.0
		Max.	66.7	33.3
	Change from Baseline	n	3	4
		Mean	0.00	-16.67
		SD	33.333	43.033
		Median	0.00	-16.67
		Min.	-33.3	-66.7
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (33%)	2 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (33%)	2 (50%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (33%)	1 (25%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (33%)	1 (25%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Financial Difficulties Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 52	Actual Score	n	3	4
		Mean	22.22	25.00
		SD	38.490	16.667
		Median	0.00	33.33
		Min.	0.0	0.0
		Max.	66.7	33.3
	Change from Baseline	n	3	4
		Mean	0.00	-8.33
		SD	33.333	41.944
		Median	0.00	0.00
		Min.	-33.3	-66.7
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	1 (33%)	1 (25%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	1 (33%)	1 (25%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (33%)	1 (25%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (33%)	1 (25%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Financial Difficulties Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 55	Actual Score	n	3	3
		Mean	0.00	22.22
		SD	0.000	19.245
		Median	0.00	33.33
		Min.	0.0	0.0
		Max.	0.0	33.3
	Change from Baseline	n	3	3
		Mean	-22.22	-22.22
		SD	19.245	38.490
		Median	-33.33	0.00
		Min.	-33.3	-66.7
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (67%)	1 (33%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (67%)	1 (33%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Financial Difficulties Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 58	Actual Score	n	2	2
		Mean	50.00	33.33
		SD	70.711	0.000
		Median	50.00	33.33
		Min.	0.0	33.3
		Max.	100.0	33.3
	Change from Baseline	n	2	2
		Mean	33.33	-33.33
		SD	47.140	47.140
		Median	33.33	-33.33
		Min.	0.0	-66.7
		Max.	66.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (50%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Financial Difficulties Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 61	Actual Score	n	2	2
		Mean	33.33	33.33
		SD	47.140	0.000
		Median	33.33	33.33
		Min.	0.0	33.3
		Max.	66.7	33.3
	Change from Baseline	n	2	2
		Mean	16.67	-33.33
		SD	23.570	47.140
		Median	16.67	-33.33
		Min.	0.0	-66.7
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (50%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Financial Difficulties Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 64	Actual Score	n	2	2
		Mean	33.33	16.67
		SD	47.140	23.570
		Median	33.33	16.67
		Min.	0.0	0.0
		Max.	66.7	33.3
	Change from Baseline	n	2	2
		Mean	16.67	-50.00
		SD	23.570	23.570
		Median	16.67	-50.00
		Min.	0.0	-66.7
		Max.	33.3	-33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	2 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	2 (100%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Financial Difficulties Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 67	Actual Score	n	2	2
		Mean	50.00	33.33
		SD	70.711	0.000
		Median	50.00	33.33
		Min.	0.0	33.3
		Max.	100.0	33.3
	Change from Baseline	n	2	2
		Mean	33.33	-33.33
		SD	47.140	47.140
		Median	33.33	-33.33
		Min.	0.0	-66.7
		Max.	66.7	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (50%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (50%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Financial Difficulties Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 70	Actual Score	n	2	1
		Mean	33.33	0.00
		SD	47.140	
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	66.7	0.0
	Change from Baseline	n	2	1
		Mean	16.67	-33.33
		SD	23.570	
		Median	16.67	-33.33
		Min.	0.0	-33.3
		Max.	33.3	-33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (100%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_c30_dom.sas 10MAR2023 10:38

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Financial Difficulties Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 73	Actual Score	n	1	1
		Mean	66.67	33.33
		SD		
		Median	66.67	33.33
		Min.	66.7	33.3
		Max.	66.7	33.3
	Change from Baseline	n	1	1
		Mean	33.33	0.00
		SD		
		Median	33.33	0.00
		Min.	33.3	0.0
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (100%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (100%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Financial Difficulties Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 76	Actual Score	n	2	1
		Mean	33.33	0.00
		SD	47.140	
		Median	33.33	0.00
		Min.	0.0	0.0
		Max.	66.7	0.0
	Change from Baseline	n	2	1
		Mean	16.67	-33.33
		SD	23.570	
		Median	16.67	-33.33
		Min.	0.0	-33.3
		Max.	33.3	-33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (100%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Financial Difficulties Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 79	Actual Score	n	2	1
		Mean	33.33	33.33
		SD	47.140	
		Median	33.33	33.33
		Min.	0.0	33.3
		Max.	66.7	33.3
	Change from Baseline	n	2	1
		Mean	16.67	0.00
		SD	23.570	
		Median	16.67	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Financial Difficulties Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 82	Actual Score	n	2	1
		Mean	33.33	33.33
		SD	47.140	
		Median	33.33	33.33
		Min.	0.0	33.3
		Max.	66.7	33.3
	Change from Baseline	n	2	1
		Mean	16.67	0.00
		SD	23.570	
		Median	16.67	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Financial Difficulties Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 85	Actual Score	n	1	1
		Mean	33.33	0.00
		SD		
		Median	33.33	0.00
		Min.	33.3	0.0
		Max.	33.3	0.0
	Change from Baseline	n	1	1
		Mean	0.00	-33.33
		SD		
		Median	0.00	-33.33
		Min.	0.0	-33.3
		Max.	0.0	-33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (100%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_c30_dom.sas 10MAR2023 10:38

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Financial Difficulties Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 88	Actual Score	n	1	1
		Mean	0.00	0.00
		SD		
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Change from Baseline	n	1	1
		Mean	0.00	-33.33
		SD		
		Median	0.00	-33.33
		Min.	0.0	-33.3
		Max.	0.0	-33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (100%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (100%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Financial Difficulties Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 91	Actual Score	n	2	1
		Mean	33.33	33.33
		SD	47.140	
		Median	33.33	33.33
		Min.	0.0	33.3
		Max.	66.7	33.3
	Change from Baseline	n	2	1
		Mean	16.67	0.00
		SD	23.570	
		Median	16.67	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Financial Difficulties Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 94	Actual Score	n	2	1
		Mean	16.67	33.33
		SD	23.570	
		Median	16.67	33.33
		Min.	0.0	33.3
		Max.	33.3	33.3
	Change from Baseline	n	2	1
		Mean	0.00	0.00
		SD	0.000	
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Financial Difficulties Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 97	Actual Score	n	1	0
		Mean	66.67	
		SD		
		Median	66.67	
		Min.	66.7	
		Max.	66.7	
	Change from Baseline	n	1	0
		Mean	33.33	
		SD		
		Median	33.33	
		Min.	33.3	
		Max.	33.3	
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (100%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (100%)	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_c30_dom.sas 10MAR2023 10:38

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Financial Difficulties Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 100	Actual Score	n	0	1
		Mean		33.33
		SD		
		Median		33.33
		Min.		33.3
		Max.		33.3
	Change from Baseline	n	0	1
		Mean		0.00
		SD		
		Median		0.00
		Min.		0.0
		Max.		0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_c30_dom.sas 10MAR2023 10:38

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Financial Difficulties Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
End of Treatment	Actual Score	n	10	11
		Mean	20.00	36.36
		SD	35.832	31.463
		Median	0.00	33.33
		Min.	0.0	0.0
		Max.	100.0	100.0
	Change from Baseline	n	9	11
		Mean	0.00	3.03
		SD	37.268	23.355
		Median	0.00	0.00
		Min.	-66.7	-33.3
		Max.	66.7	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (22%)	2 (18%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (22%)	2 (18%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	2 (22%)	3 (27%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	2 (22%)	3 (27%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Financial Difficulties Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 1	Actual Score	n	3	4
		Mean	33.33	33.33
		SD	33.333	27.217
		Median	33.33	33.33
		Min.	0.0	0.0
		Max.	66.7	66.7
	Change from Baseline	n	2	4
		Mean	16.67	0.00
		SD	23.570	27.217
		Median	16.67	0.00
		Min.	0.0	-33.3
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (25%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (25%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	1 (25%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	1 (25%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Financial Difficulties Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 2	Actual Score	n	3	3
		Mean	33.33	22.22
		SD	33.333	19.245
		Median	33.33	33.33
		Min.	0.0	0.0
		Max.	66.7	33.3
	Change from Baseline	n	2	3
		Mean	16.67	-11.11
		SD	23.570	19.245
		Median	16.67	0.00
		Min.	0.0	-33.3
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	1 (33%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	1 (33%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Financial Difficulties Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 4	Actual Score	n	0	2
		Mean		33.33
		SD		47.140
		Median		33.33
		Min.		0.0
		Max.		66.7
	Change from Baseline	n	0	2
		Mean		0.00
		SD		0.000
		Median		0.00
		Min.		0.0
		Max.		0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Financial Difficulties Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
PFS Follow-Up 2	Actual Score	n	1	1
		Mean	33.33	0.00
		SD		
		Median	33.33	0.00
		Min.	33.3	0.0
		Max.	33.3	0.0
	Change from Baseline	n	1	1
		Mean	33.33	0.00
		SD		
		Median	33.33	0.00
		Min.	33.3	0.0
		Max.	33.3	0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (100%)	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (100%)	0

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Financial Difficulties Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
PFS Follow-Up 4	Actual Score	n	0	1
		Mean		0.00
		SD		
		Median		0.00
		Min.		0.0
		Max.		0.0
	Change from Baseline	n	0	1
		Mean		0.00
		SD		
		Median		0.00
		Min.		0.0
		Max.		0.0
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	0	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_c30_dom.sas 10MAR2023 10:38

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Financial Difficulties Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Last Follow-up	Actual Score	n	3	4
		Mean	33.33	41.67
		SD	33.333	31.914
		Median	33.33	50.00
		Min.	0.0	0.0
		Max.	66.7	66.7
	Change from Baseline	n	2	4
		Mean	16.67	8.33
		SD	23.570	16.667
		Median	16.67	0.00
		Min.	0.0	0.0
		Max.	33.3	33.3
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	1 (50%)	1 (25%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	1 (50%)	1 (25%)

Table 4.049110
Summary of Change in EORTC QLQ-C30 Domain Scores from Baseline

Item Score: Financial Difficulties Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Worst Case Post-Baseline	Actual Score	n	13	25
		Mean	35.90	44.00
		SD	37.172	34.319
		Median	33.33	33.33
		Min.	0.0	0.0
		Max.	100.0	100.0
	Change from Baseline	n	12	25
		Mean	19.44	10.67
		SD	36.121	26.736
		Median	16.67	0.00
		Min.	-33.3	-33.3
		Max.	66.7	66.7
	Improvement in EORTC QLQ-C30 domain score >=5	n (%)	2 (17%)	2 (8%)
	Improvement in EORTC QLQ-C30 domain score >=10	n (%)	2 (17%)	2 (8%)
	Worsening in EORTC QLQ-C30 domain score >=5	n (%)	6 (50%)	7 (28%)
	Worsening in EORTC QLQ-C30 domain score >=10	n (%)	6 (50%)	7 (28%)

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Global Health Status Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 4		
n [1]	12	25
n [2]	12	23
LS Mean (SE)	60.8 (6.43)	57.3 (4.83)
95% C.I.	(48.1, 73.6)	(47.7, 66.9)
LS Mean Change from Baseline (SE)	-4.2 (6.43)	-7.8 (4.83)
95% C.I.	(-17.0, 8.6)	(-17.3, 1.8)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-3.5 (7.91)
95% C.I.		(-19.2, 12.2)
Corrected Hedges' g Statistic		-0.15
95% C.I.		(-0.85, 0.55)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Global Health Status Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 7		
n [1]	12	25
n [2]	11	21
LS Mean (SE)	65.1 (6.52)	56.2 (4.93)
95% C.I.	(52.2, 78.0)	(46.4, 65.9)
LS Mean Change from Baseline (SE)	0.1 (6.52)	-8.9 (4.93)
95% C.I.	(-12.9, 13.0)	(-18.7, 0.9)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-8.9 (8.04)
95% C.I.		(-24.9, 7.0)
Corrected Hedges' g Statistic		-0.39
95% C.I.		(-1.13, 0.34)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Global Health Status Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 10		
n [1]	12	25
n [2]	12	12
LS Mean (SE)	70.5 (6.43)	56.8 (5.60)
95% C.I.	(57.8, 83.3)	(45.7, 67.9)
LS Mean Change from Baseline (SE)	5.5 (6.43)	-8.2 (5.60)
95% C.I.	(-7.3, 18.3)	(-19.3, 2.8)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-13.7 (8.43)
95% C.I.		(-30.4, 3.0)
Corrected Hedges' g Statistic		-0.63
95% C.I.		(-1.45, 0.19)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Global Health Status Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 13		
n [1]	12	25
n [2]	12	10
LS Mean (SE)	55.6 (6.44)	56.6 (6.02)
95% C.I.	(42.8, 68.4)	(44.7, 68.5)
LS Mean Change from Baseline (SE)	-9.5 (6.44)	-8.4 (6.02)
95% C.I.	(-22.3, 3.3)	(-20.3, 3.5)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		1.1 (8.80)
95% C.I.		(-16.4, 18.5)
Corrected Hedges' g Statistic		0.05
95% C.I.		(-0.79, 0.89)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Global Health Status Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 16		
n [1]	12	25
n [2]	11	10
LS Mean (SE)	62.7 (6.52)	50.0 (6.17)
95% C.I.	(49.8, 75.6)	(37.9, 62.2)
LS Mean Change from Baseline (SE)	-2.3 (6.52)	-15.0 (6.17)
95% C.I.	(-15.3, 10.6)	(-27.2, -2.8)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-12.7 (8.96)
95% C.I.		(-30.4, 5.1)
Corrected Hedges' g Statistic		-0.59
95% C.I.		(-1.46, 0.29)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Global Health Status Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 19		
n [1]	12	25
n [2]	12	9
LS Mean (SE)	64.4 (6.45)	51.7 (6.47)
95% C.I.	(51.6, 77.2)	(38.9, 64.5)
LS Mean Change from Baseline (SE)	-0.6 (6.45)	-13.3 (6.47)
95% C.I.	(-13.4, 12.2)	(-26.1, -0.5)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-12.7 (9.17)
95% C.I.		(-30.9, 5.4)
Corrected Hedges' g Statistic		-0.58
95% C.I.		(-1.46, 0.30)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Global Health Status Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 22		
n [1]	12	25
n [2]	8	8
LS Mean (SE)	58.2 (6.98)	55.8 (6.87)
95% C.I.	(44.4, 72.0)	(42.2, 69.4)
LS Mean Change from Baseline (SE)	-6.9 (6.98)	-9.2 (6.87)
95% C.I.	(-20.7, 6.9)	(-22.8, 4.3)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-2.4 (9.77)
95% C.I.		(-21.7, 17.0)
Corrected Hedges' g Statistic		-0.11
95% C.I.		(-1.09, 0.87)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Global Health Status Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 25		
n [1]	12	25
n [2]	9	8
LS Mean (SE)	56.4 (7.03)	60.4 (7.06)
95% C.I.	(42.4, 70.3)	(46.5, 74.4)
LS Mean Change from Baseline (SE)	-8.7 (7.03)	-4.6 (7.06)
95% C.I.	(-22.6, 5.3)	(-18.6, 9.3)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		4.1 (9.95)
95% C.I.		(-15.6, 23.7)
Corrected Hedges' g Statistic		0.19
95% C.I.		(-0.77, 1.14)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Global Health Status Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 28		
n [1]	12	25
n [2]	7	7
LS Mean (SE)	58.5 (7.88)	56.4 (7.65)
95% C.I.	(42.9, 74.1)	(41.3, 71.5)
LS Mean Change from Baseline (SE)	-6.6 (7.88)	-8.7 (7.65)
95% C.I.	(-22.1, 9.0)	(-23.8, 6.4)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-2.1 (10.70)
95% C.I.		(-23.2, 19.1)
Corrected Hedges' g Statistic		-0.10
95% C.I.		(-1.14, 0.95)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Global Health Status Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 31		
n [1]	12	25
n [2]	7	7
LS Mean (SE)	53.6 (8.21)	62.8 (7.81)
95% C.I.	(37.4, 69.9)	(47.4, 78.3)
LS Mean Change from Baseline (SE)	-11.4 (8.21)	-2.2 (7.81)
95% C.I.	(-27.7, 4.8)	(-17.6, 13.2)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		9.2 (11.15)
95% C.I.		(-12.8, 31.2)
Corrected Hedges' g Statistic		0.41
95% C.I.		(-0.65, 1.47)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Global Health Status Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 34		
n [1]	12	25
n [2]	6	6
LS Mean (SE)	63.1 (8.93)	69.0 (8.84)
95% C.I.	(45.4, 80.7)	(51.6, 86.4)
LS Mean Change from Baseline (SE)	-2.0 (8.93)	4.0 (8.84)
95% C.I.	(-19.6, 15.7)	(-13.5, 21.4)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		5.9 (11.79)
95% C.I.		(-17.4, 29.2)
Corrected Hedges' g Statistic		0.25
95% C.I.		(-0.88, 1.39)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Global Health Status Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 37		
n [1]	12	25
n [2]	4	6
LS Mean (SE)	53.2 (10.06)	64.8 (9.13)
95% C.I.	(33.4, 73.1)	(46.8, 82.8)
LS Mean Change from Baseline (SE)	-11.8 (10.06)	-0.2 (9.13)
95% C.I.	(-31.7, 8.0)	(-18.2, 17.8)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		11.6 (12.55)
95% C.I.		(-13.2, 36.4)
Corrected Hedges' g Statistic		0.49
95% C.I.		(-0.80, 1.77)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Global Health Status Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 40		
n [1]	12	25
n [2]	4	6
LS Mean (SE)	52.1 (10.00)	65.3 (9.00)
95% C.I.	(32.4, 71.8)	(47.6, 83.1)
LS Mean Change from Baseline (SE)	-12.9 (10.00)	0.3 (9.00)
95% C.I.	(-32.7, 6.8)	(-17.5, 18.0)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		13.2 (12.39)
95% C.I.		(-11.2, 37.7)
Corrected Hedges' g Statistic		0.56
95% C.I.		(-0.73, 1.85)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Global Health Status Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 43		
n [1]	12	25
n [2]	6	4
LS Mean (SE)	56.8 (8.76)	66.8 (10.06)
95% C.I.	(39.5, 74.1)	(46.9, 86.6)
LS Mean Change from Baseline (SE)	-8.3 (8.76)	1.7 (10.06)
95% C.I.	(-25.6, 9.0)	(-18.1, 21.6)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		10.0 (12.05)
95% C.I.		(-13.8, 33.8)
Corrected Hedges' g Statistic		0.43
95% C.I.		(-0.85, 1.71)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Global Health Status Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 46		
n [1]	12	25
n [2]	4	4

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Global Health Status Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 49		
n [1]	12	25
n [2]	4	4

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Global Health Status Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 52		
n [1]	12	25
n [2]	3	6

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Global Health Status Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 55		
n [1]	12	25
n [2]	4	3

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Global Health Status Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 58		
n [1]	12	25
n [2]	2	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Global Health Status Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 61		
n [1]	12	25
n [2]	2	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Global Health Status Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 64		
n [1]	12	25
n [2]	3	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Global Health Status Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 67		
n [1]	12	25
n [2]	2	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Global Health Status Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 70		
n [1]	12	25
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Global Health Status Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 73		
n [1]	12	25
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Global Health Status Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 76		
n [1]	12	25
n [2]	2	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Global Health Status Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 79		
n [1]	12	25
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Global Health Status Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 82		
n [1]	12	25
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Global Health Status Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 85		
n [1]	12	25
n [2]	1	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Global Health Status Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 88		
n [1]	12	25
n [2]	1	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Global Health Status Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 91		
n [1]	12	25
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Global Health Status Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 94		
n [1]	12	25
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Global Health Status Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 97		
n [1]	12	25
n [2]	1	0

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Global Health Status Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 100		
n [1]	12	25
n [2]	0	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Global Health Status Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
End of Treatment		
n [1]	12	25
n [2]	9	11
LS Mean (SE)	58.6 (7.15)	47.7 (6.67)
95% C.I.	(44.5, 72.8)	(34.5, 60.9)
LS Mean Change from Baseline (SE)	-6.4 (7.15)	-17.3 (6.67)
95% C.I.	(-20.6, 7.8)	(-30.5, -4.1)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-10.9 (9.57)
95% C.I.		(-29.9, 8.1)
Corrected Hedges' g Statistic		-0.48
95% C.I.		(-1.37, 0.41)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Global Health Status Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 1		
n [1]	12	25
n [2]	2	5

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Global Health Status Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 2		
n [1]	12	25
n [2]	2	3

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Global Health Status Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 4		
n [1]	12	25
n [2]	0	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Global Health Status Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
PFS Follow-Up 2		
n [1]	12	25
n [2]	1	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Global Health Status Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
PFS Follow-Up 4		
n [1]	12	25
n [2]	0	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Physical Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 4		
n [1]	12	25
n [2]	12	23
LS Mean (SE)	63.1 (6.13)	62.1 (4.49)
95% C.I.	(50.9, 75.3)	(53.2, 71.0)
LS Mean Change from Baseline (SE)	-2.3 (6.13)	-3.3 (4.49)
95% C.I.	(-14.5, 9.9)	(-12.2, 5.7)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-1.0 (7.57)
95% C.I.		(-16.0, 14.1)
Corrected Hedges' g Statistic		-0.04
95% C.I.		(-0.74, 0.65)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Physical Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 7		
n [1]	12	25
n [2]	11	21
LS Mean (SE)	64.2 (6.21)	63.6 (4.58)
95% C.I.	(51.8, 76.5)	(54.5, 72.8)
LS Mean Change from Baseline (SE)	-1.2 (6.21)	-1.7 (4.58)
95% C.I.	(-13.5, 11.2)	(-10.8, 7.4)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-0.5 (7.68)
95% C.I.		(-15.8, 14.7)
Corrected Hedges' g Statistic		-0.03
95% C.I.		(-0.76, 0.70)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Physical Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 10		
n [1]	12	25
n [2]	12	12
LS Mean (SE)	61.2 (6.13)	62.3 (5.26)
95% C.I.	(49.0, 73.4)	(51.9, 72.7)
LS Mean Change from Baseline (SE)	-4.2 (6.13)	-3.1 (5.26)
95% C.I.	(-16.4, 8.0)	(-13.5, 7.3)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		1.1 (8.05)
95% C.I.		(-14.9, 17.1)
Corrected Hedges' g Statistic		0.05
95% C.I.		(-0.75, 0.85)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Physical Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 13		
n [1]	12	25
n [2]	12	10
LS Mean (SE)	66.4 (6.13)	62.8 (5.69)
95% C.I.	(54.2, 78.6)	(51.6, 74.1)
LS Mean Change from Baseline (SE)	1.0 (6.13)	-2.6 (5.69)
95% C.I.	(-11.2, 13.2)	(-13.8, 8.7)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-3.6 (8.34)
95% C.I.		(-20.1, 13.0)
Corrected Hedges' g Statistic		-0.17
95% C.I.		(-1.01, 0.67)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Physical Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 16		
n [1]	12	25
n [2]	11	10
LS Mean (SE)	67.6 (6.21)	62.5 (5.82)
95% C.I.	(55.2, 79.9)	(51.0, 74.0)
LS Mean Change from Baseline (SE)	2.2 (6.21)	-2.9 (5.82)
95% C.I.	(-10.2, 14.5)	(-14.4, 8.6)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-5.0 (8.50)
95% C.I.		(-21.9, 11.8)
Corrected Hedges' g Statistic		-0.25
95% C.I.		(-1.11, 0.61)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Physical Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 19		
n [1]	12	25
n [2]	12	9
LS Mean (SE)	70.2 (6.13)	59.2 (6.09)
95% C.I.	(57.9, 82.4)	(47.1, 71.2)
LS Mean Change from Baseline (SE)	4.8 (6.13)	-6.2 (6.09)
95% C.I.	(-7.4, 17.0)	(-18.2, 5.8)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-11.0 (8.64)
95% C.I.		(-28.1, 6.1)
Corrected Hedges' g Statistic		-0.53
95% C.I.		(-1.41, 0.35)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Physical Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 22		
n [1]	12	25
n [2]	8	8
LS Mean (SE)	65.0 (6.62)	63.8 (6.40)
95% C.I.	(51.9, 78.2)	(51.2, 76.5)
LS Mean Change from Baseline (SE)	-0.3 (6.62)	-1.6 (6.40)
95% C.I.	(-13.5, 12.8)	(-14.2, 11.1)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-1.2 (9.20)
95% C.I.		(-19.4, 17.0)
Corrected Hedges' g Statistic		-0.06
95% C.I.		(-1.04, 0.92)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Physical Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 25		
n [1]	12	25
n [2]	9	8
LS Mean (SE)	66.1 (6.69)	63.7 (6.64)
95% C.I.	(52.8, 79.3)	(50.6, 76.8)
LS Mean Change from Baseline (SE)	0.7 (6.69)	-1.7 (6.64)
95% C.I.	(-12.6, 14.0)	(-14.8, 11.4)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-2.4 (9.42)
95% C.I.		(-21.0, 16.3)
Corrected Hedges' g Statistic		-0.12
95% C.I.		(-1.07, 0.84)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Physical Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 28		
n [1]	12	25
n [2]	7	7
LS Mean (SE)	75.3 (7.32)	69.9 (7.12)
95% C.I.	(60.8, 89.8)	(55.8, 84.0)
LS Mean Change from Baseline (SE)	9.9 (7.32)	4.5 (7.12)
95% C.I.	(-4.6, 24.4)	(-9.6, 18.6)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-5.4 (10.13)
95% C.I.		(-25.5, 14.6)
Corrected Hedges' g Statistic		-0.27
95% C.I.		(-1.32, 0.79)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Physical Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 31		
n [1]	12	25
n [2]	7	7
LS Mean (SE)	74.9 (7.64)	65.9 (7.34)
95% C.I.	(59.8, 90.1)	(51.4, 80.4)
LS Mean Change from Baseline (SE)	9.6 (7.64)	0.5 (7.34)
95% C.I.	(-5.6, 24.7)	(-14.0, 15.0)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-9.1 (10.54)
95% C.I.		(-29.9, 11.8)
Corrected Hedges' g Statistic		-0.43
95% C.I.		(-1.49, 0.63)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Protocol: 207495 Page 50 of 585
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Physical Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 34		
n [1]	12	25
n [2]	6	6
LS Mean (SE)	74.3 (8.03)	62.1 (7.87)
95% C.I.	(58.4, 90.2)	(46.6, 77.6)
LS Mean Change from Baseline (SE)	8.9 (8.03)	-3.3 (7.87)
95% C.I.	(-7.0, 24.8)	(-18.8, 12.3)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-12.2 (11.16)
95% C.I.		(-34.2, 9.9)
Corrected Hedges' g Statistic		-0.58
95% C.I.		(-1.73, 0.58)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Physical Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 37		
n [1]	12	25
n [2]	4	6
LS Mean (SE)	59.3 (10.81)	56.0 (8.21)
95% C.I.	(38.0, 80.6)	(39.8, 72.3)
LS Mean Change from Baseline (SE)	-6.1 (10.81)	-9.3 (8.21)
95% C.I.	(-27.4, 15.2)	(-25.6, 6.9)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-3.2 (12.48)
95% C.I.		(-27.8, 21.4)
Corrected Hedges' g Statistic		-0.14
95% C.I.		(-1.41, 1.13)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Physical Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 40		
n [1]	12	25
n [2]	4	6
LS Mean (SE)	67.2 (11.13)	69.0 (8.66)
95% C.I.	(45.3, 89.1)	(51.9, 86.1)
LS Mean Change from Baseline (SE)	1.8 (11.13)	3.6 (8.66)
95% C.I.	(-20.1, 23.7)	(-13.4, 20.7)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		1.8 (12.21)
95% C.I.		(-22.3, 25.9)
Corrected Hedges' g Statistic		0.08
95% C.I.		(-1.19, 1.34)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Physical Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 43		
n [1]	12	25
n [2]	6	4
LS Mean (SE)	70.9 (7.55)	67.3 (8.66)
95% C.I.	(56.0, 85.8)	(50.3, 84.4)
LS Mean Change from Baseline (SE)	5.5 (7.55)	2.0 (8.66)
95% C.I.	(-9.4, 20.4)	(-15.1, 19.0)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-3.5 (11.46)
95% C.I.		(-26.2, 19.1)
Corrected Hedges' g Statistic		-0.18
95% C.I.		(-1.44, 1.09)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Physical Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 46		
n [1]	12	25
n [2]	4	4

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Physical Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 49		
n [1]	12	25
n [2]	4	4

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Physical Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 52		
n [1]	12	25
n [2]	3	6

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Physical Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 55		
n [1]	12	25
n [2]	4	3

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Physical Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 58		
n [1]	12	25
n [2]	2	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Physical Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 61		
n [1]	12	25
n [2]	2	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Physical Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 64		
n [1]	12	25
n [2]	3	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Physical Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 67		
n [1]	12	25
n [2]	2	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Physical Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 70		
n [1]	12	25
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Physical Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 73		
n [1]	12	25
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Physical Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 76		
n [1]	12	25
n [2]	2	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Physical Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 79		
n [1]	12	25
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Physical Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 82		
n [1]	12	25
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Physical Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 85		
n [1]	12	25
n [2]	1	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Physical Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 88		
n [1]	12	25
n [2]	1	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Physical Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 91		
n [1]	12	25
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Physical Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 94		
n [1]	12	25
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Physical Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 97		
n [1]	12	25
n [2]	1	0

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Physical Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 100		
n [1]	12	25
n [2]	0	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Physical Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
End of Treatment		
n [1]	12	25
n [2]	9	11
LS Mean (SE)	67.2 (6.82)	57.7 (6.14)
95% C.I.	(53.7, 80.8)	(45.5, 69.9)
LS Mean Change from Baseline (SE)	1.8 (6.82)	-7.7 (6.14)
95% C.I.	(-11.7, 15.4)	(-19.8, 4.5)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-9.5 (9.21)
95% C.I.		(-27.8, 8.8)
Corrected Hedges' g Statistic		-0.45
95% C.I.		(-1.34, 0.45)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Physical Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 1		
n [1]	12	25
n [2]	2	5

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Physical Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 2		
n [1]	12	25
n [2]	2	3

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Physical Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 4		
n [1]	12	25
n [2]	0	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Physical Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
PFS Follow-Up 2		
n [1]	12	25
n [2]	1	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Physical Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
PFS Follow-Up 4		
n [1]	12	25
n [2]	0	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Role Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 4		
n [1]	12	25
n [2]	12	23
LS Mean (SE)	58.8 (8.01)	56.2 (5.79)
95% C.I.	(42.9, 74.7)	(44.7, 67.7)
LS Mean Change from Baseline (SE)	-4.2 (8.01)	-6.8 (5.79)
95% C.I.	(-20.1, 11.6)	(-18.3, 4.6)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-2.6 (9.88)
95% C.I.		(-22.2, 17.0)
Corrected Hedges' g Statistic		-0.09
95% C.I.		(-0.79, 0.61)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Protocol: 207495 Page 80 of 585
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Role Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 7		
n [1]	12	25
n [2]	10	21
LS Mean (SE)	58.4 (8.28)	51.7 (5.95)
95% C.I.	(42.0, 74.7)	(39.9, 63.5)
LS Mean Change from Baseline (SE)	-4.7 (8.28)	-11.4 (5.95)
95% C.I.	(-21.1, 11.7)	(-23.2, 0.4)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-6.7 (10.17)
95% C.I.		(-26.8, 13.5)
Corrected Hedges' g Statistic		-0.24
95% C.I.		(-1.00, 0.51)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Role Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 10		
n [1]	12	25
n [2]	12	12
LS Mean (SE)	60.1 (8.01)	45.8 (6.99)
95% C.I.	(44.2, 76.0)	(31.9, 59.6)
LS Mean Change from Baseline (SE)	-3.0 (8.01)	-17.3 (6.99)
95% C.I.	(-18.8, 12.9)	(-31.1, -3.5)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-14.3 (10.62)
95% C.I.		(-35.4, 6.7)
Corrected Hedges' g Statistic		-0.53
95% C.I.		(-1.35, 0.28)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Role Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 13		
n [1]	12	25
n [2]	12	10
LS Mean (SE)	61.5 (8.01)	58.9 (7.63)
95% C.I.	(45.7, 77.4)	(43.8, 73.9)
LS Mean Change from Baseline (SE)	-1.5 (8.01)	-4.2 (7.63)
95% C.I.	(-17.4, 14.4)	(-19.2, 10.9)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-2.7 (11.06)
95% C.I.		(-24.5, 19.2)
Corrected Hedges' g Statistic		-0.10
95% C.I.		(-0.94, 0.74)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Role Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 16		
n [1]	12	25
n [2]	11	10
LS Mean (SE)	68.7 (8.13)	51.9 (7.94)
95% C.I.	(52.6, 84.8)	(36.2, 67.6)
LS Mean Change from Baseline (SE)	5.6 (8.13)	-11.1 (7.94)
95% C.I.	(-10.5, 21.7)	(-26.8, 4.5)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-16.7 (11.37)
95% C.I.		(-39.2, 5.7)
Corrected Hedges' g Statistic		-0.62
95% C.I.		(-1.49, 0.26)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Role Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 19		
n [1]	12	25
n [2]	12	8
LS Mean (SE)	71.2 (8.01)	53.0 (8.56)
95% C.I.	(55.3, 87.1)	(36.1, 69.9)
LS Mean Change from Baseline (SE)	8.2 (8.01)	-10.1 (8.56)
95% C.I.	(-7.7, 24.0)	(-27.0, 6.8)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-18.2 (11.72)
95% C.I.		(-41.4, 5.0)
Corrected Hedges' g Statistic		-0.66
95% C.I.		(-1.58, 0.26)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Protocol: 207495 Page 85 of 585
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Role Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 22		
n [1]	12	25
n [2]	8	8
LS Mean (SE)	61.6 (8.78)	60.1 (8.80)
95% C.I.	(44.3, 79.0)	(42.7, 77.5)
LS Mean Change from Baseline (SE)	-1.4 (8.78)	-2.9 (8.80)
95% C.I.	(-18.8, 16.0)	(-20.3, 14.4)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-1.5 (12.44)
95% C.I.		(-26.1, 23.0)
Corrected Hedges' g Statistic		-0.06
95% C.I.		(-1.04, 0.92)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Role Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 25		
n [1]	12	25
n [2]	9	8
LS Mean (SE)	62.1 (8.90)	61.5 (8.90)
95% C.I.	(44.5, 79.7)	(44.0, 79.1)
LS Mean Change from Baseline (SE)	-1.0 (8.90)	-1.5 (8.90)
95% C.I.	(-18.6, 16.6)	(-19.1, 16.1)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-0.5 (12.59)
95% C.I.		(-25.4, 24.4)
Corrected Hedges' g Statistic		-0.02
95% C.I.		(-0.97, 0.93)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Role Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 28		
n [1]	12	25
n [2]	7	7
LS Mean (SE)	74.9 (9.73)	65.6 (9.53)
95% C.I.	(55.7, 94.2)	(46.8, 84.4)
LS Mean Change from Baseline (SE)	11.9 (9.73)	2.6 (9.53)
95% C.I.	(-7.3, 31.1)	(-16.2, 21.4)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-9.3 (13.59)
95% C.I.		(-36.2, 17.5)
Corrected Hedges' g Statistic		-0.34
95% C.I.		(-1.40, 0.71)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Role Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 31		
n [1]	12	25
n [2]	7	7
LS Mean (SE)	68.9 (10.10)	61.7 (9.84)
95% C.I.	(48.9, 88.9)	(42.3, 81.1)
LS Mean Change from Baseline (SE)	5.9 (10.10)	-1.4 (9.84)
95% C.I.	(-14.1, 25.8)	(-20.8, 18.1)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-7.2 (14.07)
95% C.I.		(-35.0, 20.6)
Corrected Hedges' g Statistic		-0.26
95% C.I.		(-1.31, 0.80)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Role Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 34		
n [1]	12	25
n [2]	6	6
LS Mean (SE)	80.2 (10.67)	54.9 (10.61)
95% C.I.	(59.1, 101.3)	(34.0, 75.9)
LS Mean Change from Baseline (SE)	17.2 (10.67)	-8.1 (10.61)
95% C.I.	(-3.9, 38.3)	(-29.1, 12.8)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-25.3 (15.09)
95% C.I.		(-55.1, 4.5)
Corrected Hedges' g Statistic		-0.90
95% C.I.		(-2.08, 0.29)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Role Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 37		
n [1]	12	25
n [2]	4	6
LS Mean (SE)	73.1 (12.88)	64.3 (10.90)
95% C.I.	(47.7, 98.5)	(42.8, 85.8)
LS Mean Change from Baseline (SE)	10.0 (12.88)	1.2 (10.90)
95% C.I.	(-15.4, 35.4)	(-20.3, 22.8)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-8.8 (16.20)
95% C.I.		(-40.7, 23.2)
Corrected Hedges' g Statistic		-0.30
95% C.I.		(-1.57, 0.97)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Role Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 40		
n [1]	12	25
n [2]	4	6
LS Mean (SE)	44.7 (13.18)	58.6 (11.52)
95% C.I.	(18.8, 70.7)	(35.9, 81.3)
LS Mean Change from Baseline (SE)	-18.3 (13.18)	-4.4 (11.52)
95% C.I.	(-44.3, 7.7)	(-27.1, 18.3)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		13.9 (16.15)
95% C.I.		(-18.0, 45.7)
Corrected Hedges' g Statistic		0.45
95% C.I.		(-0.83, 1.74)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Role Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 43		
n [1]	12	25
n [2]	6	4
LS Mean (SE)	56.7 (10.14)	71.8 (12.03)
95% C.I.	(36.7, 76.7)	(48.1, 95.6)
LS Mean Change from Baseline (SE)	-6.3 (10.14)	8.8 (12.03)
95% C.I.	(-26.4, 13.7)	(-14.9, 32.5)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		15.1 (15.96)
95% C.I.		(-16.3, 46.6)
Corrected Hedges' g Statistic		0.56
95% C.I.		(-0.73, 1.85)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Role Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 46		
n [1]	12	25
n [2]	4	4

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Role Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 49		
n [1]	12	25
n [2]	4	4

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Role Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 52		
n [1]	12	25
n [2]	3	6

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Role Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 55		
n [1]	12	25
n [2]	4	3

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Role Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 58		
n [1]	12	25
n [2]	2	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Role Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 61		
n [1]	12	25
n [2]	2	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Role Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 64		
n [1]	12	25
n [2]	3	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Role Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 67		
n [1]	12	25
n [2]	2	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Role Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 70		
n [1]	12	25
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Role Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 73		
n [1]	12	25
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Role Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 76		
n [1]	12	25
n [2]	2	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Role Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 79		
n [1]	12	25
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Role Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 82		
n [1]	12	25
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Role Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 85		
n [1]	12	25
n [2]	1	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Role Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 88		
n [1]	12	25
n [2]	1	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Role Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 91		
n [1]	12	25
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Role Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 94		
n [1]	12	25
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Role Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 97		
n [1]	12	25
n [2]	1	0

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Role Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 100		
n [1]	12	25
n [2]	0	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Role Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
End of Treatment		
n [1]	12	25
n [2]	9	11
LS Mean (SE)	65.5 (9.05)	47.7 (8.10)
95% C.I.	(47.6, 83.4)	(31.7, 63.7)
LS Mean Change from Baseline (SE)	2.4 (9.05)	-15.4 (8.10)
95% C.I.	(-15.5, 20.4)	(-31.4, 0.7)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-17.8 (12.19)
95% C.I.		(-41.9, 6.3)
Corrected Hedges' g Statistic		-0.63
95% C.I.		(-1.53, 0.27)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Role Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 1		
n [1]	12	25
n [2]	2	4

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Role Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 2		
n [1]	12	25
n [2]	2	3

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Role Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 4		
n [1]	12	25
n [2]	0	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Role Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
PFS Follow-Up 2		
n [1]	12	25
n [2]	1	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Role Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
PFS Follow-Up 4		
n [1]	12	25
n [2]	0	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Emotional Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 4		
n [1]	12	25
n [2]	12	23
LS Mean (SE)	83.1 (5.00)	76.5 (3.59)
95% C.I.	(73.2, 93.0)	(69.4, 83.6)
LS Mean Change from Baseline (SE)	5.6 (5.00)	-1.0 (3.59)
95% C.I.	(-4.3, 15.5)	(-8.1, 6.1)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-6.6 (6.16)
95% C.I.		(-18.8, 5.6)
Corrected Hedges' g Statistic		-0.37
95% C.I.		(-1.08, 0.33)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Emotional Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 7		
n [1]	12	25
n [2]	11	21
LS Mean (SE)	78.6 (5.09)	71.9 (3.71)
95% C.I.	(68.5, 88.7)	(64.6, 79.3)
LS Mean Change from Baseline (SE)	1.1 (5.09)	-5.6 (3.71)
95% C.I.	(-9.0, 11.2)	(-12.9, 1.8)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-6.7 (6.29)
95% C.I.		(-19.1, 5.8)
Corrected Hedges' g Statistic		-0.38
95% C.I.		(-1.12, 0.35)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Emotional Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 10		
n [1]	12	25
n [2]	12	12
LS Mean (SE)	87.3 (5.00)	73.3 (4.50)
95% C.I.	(77.4, 97.2)	(64.4, 82.2)
LS Mean Change from Baseline (SE)	9.8 (5.00)	-4.2 (4.50)
95% C.I.	(-0.1, 19.7)	(-13.1, 4.6)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-14.0 (6.73)
95% C.I.		(-27.3, -0.7)
Corrected Hedges' g Statistic		-0.82
95% C.I.		(-1.66, 0.01)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Emotional Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 13		
n [1]	12	25
n [2]	12	10
LS Mean (SE)	81.8 (5.00)	84.2 (4.92)
95% C.I.	(71.9, 91.7)	(74.5, 93.9)
LS Mean Change from Baseline (SE)	4.3 (5.00)	6.7 (4.92)
95% C.I.	(-5.6, 14.2)	(-3.0, 16.4)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		2.4 (7.02)
95% C.I.		(-11.5, 16.3)
Corrected Hedges' g Statistic		0.14
95% C.I.		(-0.70, 0.98)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Emotional Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 16		
n [1]	12	25
n [2]	11	10
LS Mean (SE)	82.0 (5.09)	81.1 (5.04)
95% C.I.	(71.9, 92.1)	(71.1, 91.0)
LS Mean Change from Baseline (SE)	4.5 (5.09)	3.6 (5.04)
95% C.I.	(-5.6, 14.5)	(-6.4, 13.5)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-0.9 (7.17)
95% C.I.		(-15.1, 13.3)
Corrected Hedges' g Statistic		-0.05
95% C.I.		(-0.91, 0.80)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Emotional Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 19		
n [1]	12	25
n [2]	12	9
LS Mean (SE)	86.0 (5.00)	83.6 (5.24)
95% C.I.	(76.1, 95.9)	(73.2, 93.9)
LS Mean Change from Baseline (SE)	8.4 (5.00)	6.0 (5.24)
95% C.I.	(-1.4, 18.3)	(-4.3, 16.4)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-2.4 (7.25)
95% C.I.		(-16.7, 11.9)
Corrected Hedges' g Statistic		-0.14
95% C.I.		(-1.00, 0.73)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Emotional Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 22		
n [1]	12	25
n [2]	8	8
LS Mean (SE)	84.9 (5.61)	77.4 (5.64)
95% C.I.	(73.8, 96.0)	(66.3, 88.5)
LS Mean Change from Baseline (SE)	7.4 (5.61)	-0.1 (5.64)
95% C.I.	(-3.7, 18.5)	(-11.2, 11.0)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-7.5 (8.03)
95% C.I.		(-23.3, 8.4)
Corrected Hedges' g Statistic		-0.44
95% C.I.		(-1.44, 0.55)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Emotional Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 25		
n [1]	12	25
n [2]	9	8
LS Mean (SE)	83.7 (5.59)	83.0 (6.13)
95% C.I.	(72.7, 94.8)	(70.9, 95.1)
LS Mean Change from Baseline (SE)	6.2 (5.59)	5.5 (6.13)
95% C.I.	(-4.9, 17.2)	(-6.6, 17.6)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-0.7 (8.35)
95% C.I.		(-17.2, 15.8)
Corrected Hedges' g Statistic		-0.04
95% C.I.		(-0.99, 0.91)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Emotional Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 28		
n [1]	12	25
n [2]	7	7
LS Mean (SE)	87.8 (6.18)	83.9 (6.30)
95% C.I.	(75.6, 100.0)	(71.4, 96.3)
LS Mean Change from Baseline (SE)	10.2 (6.18)	6.3 (6.30)
95% C.I.	(-2.0, 22.4)	(-6.1, 18.8)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-3.9 (8.85)
95% C.I.		(-21.4, 13.6)
Corrected Hedges' g Statistic		-0.22
95% C.I.		(-1.27, 0.83)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Emotional Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 31		
n [1]	12	25
n [2]	7	7
LS Mean (SE)	89.9 (6.40)	81.2 (6.34)
95% C.I.	(77.3, 102.6)	(68.7, 93.7)
LS Mean Change from Baseline (SE)	12.4 (6.40)	3.7 (6.34)
95% C.I.	(-0.3, 25.0)	(-8.8, 16.2)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-8.7 (9.02)
95% C.I.		(-26.5, 9.1)
Corrected Hedges' g Statistic		-0.48
95% C.I.		(-1.55, 0.58)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Emotional Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 34		
n [1]	12	25
n [2]	6	6
LS Mean (SE)	83.0 (6.80)	76.6 (7.03)
95% C.I.	(69.6, 96.5)	(62.8, 90.5)
LS Mean Change from Baseline (SE)	5.5 (6.80)	-0.9 (7.03)
95% C.I.	(-7.9, 19.0)	(-14.8, 13.0)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-6.4 (9.83)
95% C.I.		(-25.8, 13.0)
Corrected Hedges' g Statistic		-0.35
95% C.I.		(-1.49, 0.79)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Emotional Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 37		
n [1]	12	25
n [2]	4	6
LS Mean (SE)	90.1 (10.02)	92.1 (8.33)
95% C.I.	(70.4, 109.9)	(75.7, 108.5)
LS Mean Change from Baseline (SE)	12.6 (10.02)	14.6 (8.33)
95% C.I.	(-7.1, 32.4)	(-1.9, 31.0)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		1.9 (10.59)
95% C.I.		(-19.0, 22.8)
Corrected Hedges' g Statistic		0.09
95% C.I.		(-1.18, 1.35)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Emotional Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 40		
n [1]	12	25
n [2]	4	6
LS Mean (SE)	93.3 (9.88)	98.9 (8.80)
95% C.I.	(73.8, 112.8)	(81.5, 116.2)
LS Mean Change from Baseline (SE)	15.8 (9.88)	21.4 (8.80)
95% C.I.	(-3.7, 35.3)	(4.0, 38.7)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		5.6 (10.49)
95% C.I.		(-15.1, 26.3)
Corrected Hedges' g Statistic		0.24
95% C.I.		(-1.03, 1.51)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Emotional Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 43		
n [1]	12	25
n [2]	6	4
LS Mean (SE)	80.0 (6.50)	90.8 (8.00)
95% C.I.	(67.1, 92.8)	(75.0, 106.5)
LS Mean Change from Baseline (SE)	2.4 (6.50)	13.3 (8.00)
95% C.I.	(-10.4, 15.3)	(-2.5, 29.0)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		10.8 (10.46)
95% C.I.		(-9.8, 31.4)
Corrected Hedges' g Statistic		0.61
95% C.I.		(-0.68, 1.91)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Emotional Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 46		
n [1]	12	25
n [2]	4	4

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Emotional Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 49		
n [1]	12	25
n [2]	4	4

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Emotional Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 52		
n [1]	12	25
n [2]	3	6

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Emotional Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 55		
n [1]	12	25
n [2]	4	3

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Emotional Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 58		
n [1]	12	25
n [2]	2	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Emotional Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 61		
n [1]	12	25
n [2]	2	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Emotional Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 64		
n [1]	12	25
n [2]	3	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Emotional Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 67		
n [1]	12	25
n [2]	2	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Emotional Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 70		
n [1]	12	25
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Emotional Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 73		
n [1]	12	25
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Emotional Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 76		
n [1]	12	25
n [2]	2	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Emotional Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 79		
n [1]	12	25
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Emotional Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 82		
n [1]	12	25
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Emotional Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 85		
n [1]	12	25
n [2]	1	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Emotional Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 88		
n [1]	12	25
n [2]	1	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Emotional Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 91		
n [1]	12	25
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Emotional Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 94		
n [1]	12	25
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Emotional Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 97		
n [1]	12	25
n [2]	1	0

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Emotional Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 100		
n [1]	12	25
n [2]	0	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Emotional Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
End of Treatment		
n [1]	12	25
n [2]	9	11
LS Mean (SE)	86.4 (5.67)	61.5 (5.28)
95% C.I.	(75.2, 97.6)	(51.1, 72.0)
LS Mean Change from Baseline (SE)	8.9 (5.67)	-16.0 (5.28)
95% C.I.	(-2.3, 20.1)	(-26.4, -5.5)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-24.9 (7.64)
95% C.I.		(-40.0, -9.7)
Corrected Hedges' g Statistic		-1.38
95% C.I.		(-2.36, -0.40)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Emotional Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 1		
n [1]	12	25
n [2]	2	5

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Emotional Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 2		
n [1]	12	25
n [2]	2	3

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Emotional Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 4		
n [1]	12	25
n [2]	0	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Emotional Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
PFS Follow-Up 2		
n [1]	12	25
n [2]	1	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Emotional Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
PFS Follow-Up 4		
n [1]	12	25
n [2]	0	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Cognitive Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 4		
n [1]	12	25
n [2]	12	23
LS Mean (SE)	80.9 (6.25)	78.4 (4.60)
95% C.I.	(68.5, 93.3)	(69.2, 87.5)
LS Mean Change from Baseline (SE)	-2.2 (6.25)	-4.8 (4.60)
95% C.I.	(-14.6, 10.2)	(-13.9, 4.3)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-2.6 (7.65)
95% C.I.		(-17.8, 12.6)
Corrected Hedges' g Statistic		-0.12
95% C.I.		(-0.81, 0.58)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Cognitive Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 7		
n [1]	12	25
n [2]	11	21
LS Mean (SE)	82.7 (6.33)	71.8 (4.68)
95% C.I.	(70.2, 95.3)	(62.5, 81.1)
LS Mean Change from Baseline (SE)	-0.4 (6.33)	-11.3 (4.68)
95% C.I.	(-13.0, 12.2)	(-20.6, -2.0)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-10.9 (7.77)
95% C.I.		(-26.4, 4.5)
Corrected Hedges' g Statistic		-0.50
95% C.I.		(-1.24, 0.24)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Cognitive Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 10		
n [1]	12	25
n [2]	12	12
LS Mean (SE)	91.4 (6.26)	77.9 (5.36)
95% C.I.	(79.0, 103.9)	(67.3, 88.5)
LS Mean Change from Baseline (SE)	8.3 (6.26)	-5.2 (5.36)
95% C.I.	(-4.2, 20.7)	(-15.8, 5.4)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-13.5 (8.20)
95% C.I.		(-29.7, 2.8)
Corrected Hedges' g Statistic		-0.65
95% C.I.		(-1.47, 0.18)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Cognitive Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 13		
n [1]	12	25
n [2]	12	10
LS Mean (SE)	84.0 (6.27)	83.8 (5.90)
95% C.I.	(71.5, 96.4)	(72.2, 95.4)
LS Mean Change from Baseline (SE)	0.8 (6.27)	0.6 (5.90)
95% C.I.	(-11.6, 13.3)	(-11.0, 12.3)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-0.2 (8.65)
95% C.I.		(-17.3, 16.9)
Corrected Hedges' g Statistic		-0.01
95% C.I.		(-0.85, 0.83)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Cognitive Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 16		
n [1]	12	25
n [2]	11	10
LS Mean (SE)	79.8 (6.34)	83.7 (6.10)
95% C.I.	(67.3, 92.4)	(71.6, 95.7)
LS Mean Change from Baseline (SE)	-3.3 (6.34)	0.5 (6.10)
95% C.I.	(-15.9, 9.3)	(-11.5, 12.6)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		3.8 (8.81)
95% C.I.		(-13.6, 21.2)
Corrected Hedges' g Statistic		0.18
95% C.I.		(-0.68, 1.04)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Cognitive Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 19		
n [1]	12	25
n [2]	12	9
LS Mean (SE)	81.8 (6.28)	78.5 (6.43)
95% C.I.	(69.4, 94.3)	(65.8, 91.2)
LS Mean Change from Baseline (SE)	-1.3 (6.28)	-4.6 (6.43)
95% C.I.	(-13.8, 11.1)	(-17.3, 8.1)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-3.3 (9.09)
95% C.I.		(-21.3, 14.7)
Corrected Hedges' g Statistic		-0.15
95% C.I.		(-1.02, 0.71)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Cognitive Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 22		
n [1]	12	25
n [2]	8	8
LS Mean (SE)	75.8 (6.86)	78.6 (6.69)
95% C.I.	(62.2, 89.4)	(65.4, 91.8)
LS Mean Change from Baseline (SE)	-7.4 (6.86)	-4.6 (6.69)
95% C.I.	(-21.0, 6.2)	(-17.8, 8.6)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		2.8 (9.44)
95% C.I.		(-15.9, 21.4)
Corrected Hedges' g Statistic		0.14
95% C.I.		(-0.84, 1.12)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Cognitive Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 25		
n [1]	12	25
n [2]	9	8
LS Mean (SE)	79.8 (6.84)	80.6 (6.86)
95% C.I.	(66.2, 93.3)	(67.0, 94.2)
LS Mean Change from Baseline (SE)	-3.4 (6.84)	-2.6 (6.86)
95% C.I.	(-16.9, 10.2)	(-16.1, 11.0)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		0.8 (9.70)
95% C.I.		(-18.4, 20.0)
Corrected Hedges' g Statistic		0.04
95% C.I.		(-0.91, 0.99)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Cognitive Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 28		
n [1]	12	25
n [2]	7	7
LS Mean (SE)	77.9 (7.56)	86.1 (7.43)
95% C.I.	(63.0, 92.9)	(71.4, 100.7)
LS Mean Change from Baseline (SE)	-5.2 (7.56)	2.9 (7.43)
95% C.I.	(-20.2, 9.7)	(-11.8, 17.6)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		8.2 (10.41)
95% C.I.		(-12.4, 28.7)
Corrected Hedges' g Statistic		0.38
95% C.I.		(-0.67, 1.44)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Cognitive Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 31		
n [1]	12	25
n [2]	7	7
LS Mean (SE)	83.1 (7.86)	80.7 (7.57)
95% C.I.	(67.5, 98.6)	(65.7, 95.6)
LS Mean Change from Baseline (SE)	-0.1 (7.86)	-2.5 (7.57)
95% C.I.	(-15.6, 15.5)	(-17.5, 12.5)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-2.4 (10.83)
95% C.I.		(-23.8, 19.0)
Corrected Hedges' g Statistic		-0.11
95% C.I.		(-1.16, 0.94)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Cognitive Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 34		
n [1]	12	25
n [2]	6	6
LS Mean (SE)	80.9 (8.27)	86.7 (8.64)
95% C.I.	(64.5, 97.2)	(69.7, 103.8)
LS Mean Change from Baseline (SE)	-2.3 (8.27)	3.6 (8.64)
95% C.I.	(-18.6, 14.1)	(-13.5, 20.6)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		5.9 (11.70)
95% C.I.		(-17.3, 29.0)
Corrected Hedges' g Statistic		0.26
95% C.I.		(-0.88, 1.40)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Cognitive Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 37		
n [1]	12	25
n [2]	4	6
LS Mean (SE)	88.3 (11.36)	91.8 (9.90)
95% C.I.	(65.9, 110.7)	(72.3, 111.3)
LS Mean Change from Baseline (SE)	5.2 (11.36)	8.7 (9.90)
95% C.I.	(-17.2, 27.6)	(-10.8, 28.2)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		3.5 (12.41)
95% C.I.		(-21.0, 28.0)
Corrected Hedges' g Statistic		0.13
95% C.I.		(-1.13, 1.40)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Cognitive Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 40		
n [1]	12	25
n [2]	4	6
LS Mean (SE)	80.9 (10.76)	86.1 (8.38)
95% C.I.	(59.7, 102.1)	(69.6, 102.6)
LS Mean Change from Baseline (SE)	-2.3 (10.76)	3.0 (8.38)
95% C.I.	(-23.5, 18.9)	(-13.6, 19.5)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		5.3 (12.53)
95% C.I.		(-19.5, 30.0)
Corrected Hedges' g Statistic		0.23
95% C.I.		(-1.04, 1.50)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Cognitive Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 43		
n [1]	12	25
n [2]	6	4
LS Mean (SE)	77.1 (7.77)	84.4 (9.01)
95% C.I.	(61.7, 92.4)	(66.6, 102.2)
LS Mean Change from Baseline (SE)	-6.1 (7.77)	1.3 (9.01)
95% C.I.	(-21.5, 9.3)	(-16.5, 19.0)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		7.4 (11.78)
95% C.I.		(-15.9, 30.6)
Corrected Hedges' g Statistic		0.36
95% C.I.		(-0.92, 1.63)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Cognitive Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 46		
n [1]	12	25
n [2]	4	4

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Protocol: 207495 Page 172 of 585
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Cognitive Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 49		
n [1]	12	25
n [2]	4	4

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Cognitive Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 52		
n [1]	12	25
n [2]	3	6

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Cognitive Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 55		
n [1]	12	25
n [2]	4	3

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Cognitive Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 58		
n [1]	12	25
n [2]	2	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Cognitive Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 61		
n [1]	12	25
n [2]	2	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Cognitive Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 64		
n [1]	12	25
n [2]	3	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Cognitive Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 67		
n [1]	12	25
n [2]	2	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Cognitive Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 70		
n [1]	12	25
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Cognitive Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 73		
n [1]	12	25
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Cognitive Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 76		
n [1]	12	25
n [2]	2	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Cognitive Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 79		
n [1]	12	25
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Cognitive Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 82		
n [1]	12	25
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Cognitive Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 85		
n [1]	12	25
n [2]	1	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Cognitive Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 88		
n [1]	12	25
n [2]	1	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Cognitive Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 91		
n [1]	12	25
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Cognitive Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 94		
n [1]	12	25
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Cognitive Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 97		
n [1]	12	25
n [2]	1	0

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Cognitive Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 100		
n [1]	12	25
n [2]	0	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Cognitive Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
End of Treatment		
n [1]	12	25
n [2]	9	11
LS Mean (SE)	80.4 (6.95)	71.4 (6.78)
95% C.I.	(66.7, 94.2)	(58.0, 84.8)
LS Mean Change from Baseline (SE)	-2.7 (6.95)	-11.8 (6.78)
95% C.I.	(-16.5, 11.1)	(-25.2, 1.7)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-9.1 (9.39)
95% C.I.		(-27.7, 9.6)
Corrected Hedges' g Statistic		-0.40
95% C.I.		(-1.29, 0.49)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Cognitive Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 1		
n [1]	12	25
n [2]	2	5

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Cognitive Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 2		
n [1]	12	25
n [2]	2	3

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Cognitive Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 4		
n [1]	12	25
n [2]	0	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Cognitive Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
PFS Follow-Up 2		
n [1]	12	25
n [2]	1	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Cognitive Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
PFS Follow-Up 4		
n [1]	12	25
n [2]	0	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Social Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 4		
n [1]	12	25
n [2]	12	23
LS Mean (SE)	68.4 (7.31)	68.0 (5.29)
95% C.I.	(54.0, 82.9)	(57.5, 78.4)
LS Mean Change from Baseline (SE)	-2.7 (7.31)	-3.1 (5.29)
95% C.I.	(-17.1, 11.8)	(-13.6, 7.3)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-0.5 (9.06)
95% C.I.		(-18.4, 17.4)
Corrected Hedges' g Statistic		-0.02
95% C.I.		(-0.72, 0.68)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Social Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 7		
n [1]	12	25
n [2]	11	21
LS Mean (SE)	68.8 (7.47)	65.3 (5.51)
95% C.I.	(54.1, 83.6)	(54.4, 76.2)
LS Mean Change from Baseline (SE)	-2.2 (7.47)	-5.7 (5.51)
95% C.I.	(-17.0, 12.5)	(-16.6, 5.1)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-3.5 (9.32)
95% C.I.		(-21.9, 14.9)
Corrected Hedges' g Statistic		-0.14
95% C.I.		(-0.87, 0.59)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Social Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 10		
n [1]	12	25
n [2]	12	12
LS Mean (SE)	68.6 (7.31)	60.6 (6.79)
95% C.I.	(54.1, 83.0)	(47.2, 74.0)
LS Mean Change from Baseline (SE)	-2.5 (7.31)	-10.5 (6.79)
95% C.I.	(-17.0, 12.0)	(-23.9, 2.9)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-8.0 (10.03)
95% C.I.		(-27.8, 11.8)
Corrected Hedges' g Statistic		-0.32
95% C.I.		(-1.12, 0.49)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Social Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 13		
n [1]	12	25
n [2]	12	10
LS Mean (SE)	66.0 (7.32)	66.0 (7.40)
95% C.I.	(51.5, 80.5)	(51.4, 80.6)
LS Mean Change from Baseline (SE)	-5.1 (7.32)	-5.1 (7.40)
95% C.I.	(-19.6, 9.4)	(-19.7, 9.5)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		0.0 (10.40)
95% C.I.		(-20.5, 20.5)
Corrected Hedges' g Statistic		0.00
95% C.I.		(-0.84, 0.84)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Social Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 16		
n [1]	12	25
n [2]	10	10
LS Mean (SE)	67.9 (7.67)	57.7 (7.57)
95% C.I.	(52.7, 83.0)	(42.8, 72.7)
LS Mean Change from Baseline (SE)	-3.2 (7.67)	-13.3 (7.57)
95% C.I.	(-18.4, 11.9)	(-28.3, 1.6)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-10.1 (10.78)
95% C.I.		(-31.4, 11.2)
Corrected Hedges' g Statistic		-0.40
95% C.I.		(-1.29, 0.48)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Social Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 19		
n [1]	12	25
n [2]	12	8
LS Mean (SE)	71.9 (7.32)	69.4 (8.25)
95% C.I.	(57.5, 86.4)	(53.2, 85.7)
LS Mean Change from Baseline (SE)	0.9 (7.32)	-1.7 (8.25)
95% C.I.	(-13.6, 15.3)	(-17.9, 14.6)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-2.5 (11.02)
95% C.I.		(-24.3, 19.2)
Corrected Hedges' g Statistic		-0.10
95% C.I.		(-0.99, 0.80)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Social Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 22		
n [1]	12	25
n [2]	8	8
LS Mean (SE)	58.2 (8.30)	66.2 (8.46)
95% C.I.	(41.8, 74.6)	(49.6, 82.9)
LS Mean Change from Baseline (SE)	-12.9 (8.30)	-4.8 (8.46)
95% C.I.	(-29.3, 3.5)	(-21.5, 11.9)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		8.1 (11.92)
95% C.I.		(-15.5, 31.6)
Corrected Hedges' g Statistic		0.32
95% C.I.		(-0.67, 1.31)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Social Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 25		
n [1]	12	25
n [2]	9	8
LS Mean (SE)	70.0 (8.25)	67.1 (8.49)
95% C.I.	(53.7, 86.3)	(50.4, 83.9)
LS Mean Change from Baseline (SE)	-1.0 (8.25)	-3.9 (8.49)
95% C.I.	(-17.3, 15.3)	(-20.7, 12.8)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-2.9 (11.86)
95% C.I.		(-26.3, 20.5)
Corrected Hedges' g Statistic		-0.11
95% C.I.		(-1.07, 0.84)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Social Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 28		
n [1]	12	25
n [2]	7	7
LS Mean (SE)	82.3 (9.16)	67.0 (9.07)
95% C.I.	(64.2, 100.4)	(49.1, 84.9)
LS Mean Change from Baseline (SE)	11.2 (9.16)	-4.1 (9.07)
95% C.I.	(-6.9, 29.3)	(-22.0, 13.8)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-15.3 (12.88)
95% C.I.		(-40.7, 10.1)
Corrected Hedges' g Statistic		-0.59
95% C.I.		(-1.66, 0.48)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Social Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 31		
n [1]	12	25
n [2]	7	7
LS Mean (SE)	84.6 (9.44)	64.8 (9.30)
95% C.I.	(66.0, 103.3)	(46.5, 83.2)
LS Mean Change from Baseline (SE)	13.6 (9.44)	-6.2 (9.30)
95% C.I.	(-5.1, 32.2)	(-24.6, 12.1)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-19.8 (13.25)
95% C.I.		(-45.9, 6.4)
Corrected Hedges' g Statistic		-0.75
95% C.I.		(-1.83, 0.34)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Social Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 34		
n [1]	12	25
n [2]	6	6
LS Mean (SE)	75.8 (10.05)	70.4 (10.24)
95% C.I.	(55.9, 95.6)	(50.2, 90.6)
LS Mean Change from Baseline (SE)	4.7 (10.05)	-0.7 (10.24)
95% C.I.	(-15.2, 24.5)	(-20.9, 19.5)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-5.3 (14.41)
95% C.I.		(-33.8, 23.1)
Corrected Hedges' g Statistic		-0.20
95% C.I.		(-1.33, 0.94)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Social Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 37		
n [1]	12	25
n [2]	4	6
LS Mean (SE)	78.7 (12.42)	68.9 (10.68)
95% C.I.	(54.3, 103.2)	(47.9, 90.0)
LS Mean Change from Baseline (SE)	7.7 (12.42)	-2.1 (10.68)
95% C.I.	(-16.8, 32.2)	(-23.2, 19.0)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-9.8 (15.55)
95% C.I.		(-40.5, 20.9)
Corrected Hedges' g Statistic		-0.34
95% C.I.		(-1.62, 0.93)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Social Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 40		
n [1]	12	25
n [2]	4	6
LS Mean (SE)	67.0 (12.43)	76.2 (10.69)
95% C.I.	(42.5, 91.5)	(55.1, 97.3)
LS Mean Change from Baseline (SE)	-4.1 (12.43)	5.2 (10.69)
95% C.I.	(-28.6, 20.4)	(-15.9, 26.3)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		9.2 (15.53)
95% C.I.		(-21.4, 39.9)
Corrected Hedges' g Statistic		0.32
95% C.I.		(-0.95, 1.60)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Social Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 43		
n [1]	12	25
n [2]	6	4
LS Mean (SE)	67.3 (9.68)	70.0 (11.65)
95% C.I.	(48.3, 86.4)	(47.0, 93.0)
LS Mean Change from Baseline (SE)	-3.7 (9.68)	-1.1 (11.65)
95% C.I.	(-22.8, 15.4)	(-24.0, 21.9)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		2.7 (15.22)
95% C.I.		(-27.4, 32.7)
Corrected Hedges' g Statistic		0.10
95% C.I.		(-1.16, 1.37)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Social Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 46		
n [1]	12	25
n [2]	4	4

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Social Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 49		
n [1]	12	25
n [2]	4	4

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Social Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 52		
n [1]	12	25
n [2]	3	6

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Social Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 55		
n [1]	12	25
n [2]	4	3

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Social Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 58		
n [1]	12	25
n [2]	2	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Social Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 61		
n [1]	12	25
n [2]	2	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Social Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 64		
n [1]	12	25
n [2]	3	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Social Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 67		
n [1]	12	25
n [2]	2	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Social Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 70		
n [1]	12	25
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Social Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 73		
n [1]	12	25
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Social Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 76		
n [1]	12	25
n [2]	2	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Social Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 79		
n [1]	12	25
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Social Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 82		
n [1]	12	25
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Social Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 85		
n [1]	12	25
n [2]	1	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Social Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 88		
n [1]	12	25
n [2]	1	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Social Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 91		
n [1]	12	25
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Social Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 94		
n [1]	12	25
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Social Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 97		
n [1]	12	25
n [2]	1	0

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Social Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 100		
n [1]	12	25
n [2]	0	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Social Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
End of Treatment		
n [1]	12	25
n [2]	9	11
LS Mean (SE)	72.8 (8.23)	50.4 (7.56)
95% C.I.	(56.6, 89.1)	(35.5, 65.4)
LS Mean Change from Baseline (SE)	1.8 (8.23)	-20.7 (7.56)
95% C.I.	(-14.5, 18.0)	(-35.6, -5.7)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-22.4 (11.20)
95% C.I.		(-44.6, -0.3)
Corrected Hedges' g Statistic		-0.86
95% C.I.		(-1.78, 0.06)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Social Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 1		
n [1]	12	25
n [2]	2	4

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Social Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 2		
n [1]	12	25
n [2]	2	3

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Social Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 4		
n [1]	12	25
n [2]	0	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Social Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
PFS Follow-Up 2		
n [1]	12	25
n [2]	1	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Social Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
PFS Follow-Up 4		
n [1]	12	25
n [2]	0	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Fatigue Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 4		
n [1]	11	25
n [2]	11	23
LS Mean (SE)	43.9 (6.78)	46.4 (4.67)
95% C.I.	(30.5, 57.4)	(37.1, 55.6)
LS Mean Change from Baseline (SE)	0.4 (6.78)	2.8 (4.67)
95% C.I.	(-13.1, 13.8)	(-6.5, 12.1)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		2.4 (8.21)
95% C.I.		(-13.9, 18.7)
Corrected Hedges' g Statistic		0.11
95% C.I.		(-0.61, 0.82)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Fatigue Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 7		
n [1]	11	25
n [2]	10	21
LS Mean (SE)	48.0 (6.90)	48.2 (4.79)
95% C.I.	(34.3, 61.7)	(38.7, 57.6)
LS Mean Change from Baseline (SE)	4.4 (6.90)	4.6 (4.79)
95% C.I.	(-9.2, 18.1)	(-4.9, 14.1)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		0.1 (8.38)
95% C.I.		(-16.5, 16.7)
Corrected Hedges' g Statistic		0.01
95% C.I.		(-0.75, 0.76)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Fatigue Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 10		
n [1]	11	25
n [2]	11	12
LS Mean (SE)	45.0 (6.78)	44.0 (5.69)
95% C.I.	(31.6, 58.5)	(32.7, 55.2)
LS Mean Change from Baseline (SE)	1.4 (6.78)	0.4 (5.69)
95% C.I.	(-12.0, 14.9)	(-10.8, 11.6)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-1.1 (8.84)
95% C.I.		(-18.6, 16.5)
Corrected Hedges' g Statistic		-0.05
95% C.I.		(-0.87, 0.77)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Fatigue Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 13		
n [1]	11	25
n [2]	11	10
LS Mean (SE)	47.4 (6.78)	38.8 (6.23)
95% C.I.	(34.0, 60.9)	(26.5, 51.1)
LS Mean Change from Baseline (SE)	3.8 (6.78)	-4.8 (6.23)
95% C.I.	(-9.6, 17.3)	(-17.1, 7.5)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-8.7 (9.22)
95% C.I.		(-26.9, 9.6)
Corrected Hedges' g Statistic		-0.39
95% C.I.		(-1.26, 0.47)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Fatigue Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 16		
n [1]	11	25
n [2]	10	10
LS Mean (SE)	33.5 (6.90)	43.5 (6.41)
95% C.I.	(19.8, 47.2)	(30.8, 56.1)
LS Mean Change from Baseline (SE)	-10.1 (6.90)	-0.1 (6.41)
95% C.I.	(-23.8, 3.6)	(-12.8, 12.5)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		10.0 (9.43)
95% C.I.		(-8.7, 28.6)
Corrected Hedges' g Statistic		0.45
95% C.I.		(-0.43, 1.34)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Fatigue Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 19		
n [1]	11	25
n [2]	11	9
LS Mean (SE)	43.4 (6.78)	47.1 (6.77)
95% C.I.	(30.0, 56.9)	(33.7, 60.4)
LS Mean Change from Baseline (SE)	-0.1 (6.78)	3.5 (6.77)
95% C.I.	(-13.6, 13.3)	(-9.9, 16.9)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		3.6 (9.62)
95% C.I.		(-15.4, 22.7)
Corrected Hedges' g Statistic		0.16
95% C.I.		(-0.72, 1.04)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Fatigue Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 22		
n [1]	11	25
n [2]	7	8
LS Mean (SE)	35.6 (7.80)	36.9 (7.28)
95% C.I.	(20.2, 51.0)	(22.5, 51.3)
LS Mean Change from Baseline (SE)	-8.0 (7.80)	-6.7 (7.28)
95% C.I.	(-23.4, 7.5)	(-21.0, 7.7)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		1.3 (10.97)
95% C.I.		(-20.4, 23.0)
Corrected Hedges' g Statistic		0.06
95% C.I.		(-0.95, 1.07)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Fatigue Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 25		
n [1]	11	25
n [2]	8	8
LS Mean (SE)	36.9 (7.59)	43.4 (7.65)
95% C.I.	(21.8, 51.9)	(28.3, 58.5)
LS Mean Change from Baseline (SE)	-6.7 (7.59)	-0.2 (7.65)
95% C.I.	(-21.7, 8.3)	(-15.3, 14.9)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		6.5 (10.79)
95% C.I.		(-14.8, 27.8)
Corrected Hedges' g Statistic		0.29
95% C.I.		(-0.70, 1.27)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Fatigue Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 28		
n [1]	11	25
n [2]	6	7
LS Mean (SE)	34.2 (8.44)	33.0 (7.99)
95% C.I.	(17.5, 50.9)	(17.2, 48.7)
LS Mean Change from Baseline (SE)	-9.4 (8.44)	-10.6 (7.99)
95% C.I.	(-26.1, 7.3)	(-26.4, 5.2)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-1.2 (11.71)
95% C.I.		(-24.4, 21.9)
Corrected Hedges' g Statistic		-0.05
95% C.I.		(-1.15, 1.04)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Fatigue Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 31		
n [1]	11	25
n [2]	6	7
LS Mean (SE)	27.8 (8.64)	48.2 (7.97)
95% C.I.	(10.7, 44.9)	(32.5, 63.9)
LS Mean Change from Baseline (SE)	-15.7 (8.64)	4.6 (7.97)
95% C.I.	(-32.8, 1.3)	(-11.1, 20.4)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		20.4 (11.82)
95% C.I.		(-3.0, 43.7)
Corrected Hedges' g Statistic		0.90
95% C.I.		(-0.25, 2.04)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Fatigue Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 34		
n [1]	11	25
n [2]	5	6
LS Mean (SE)	26.7 (8.93)	41.1 (8.95)
95% C.I.	(9.1, 44.4)	(23.4, 58.7)
LS Mean Change from Baseline (SE)	-16.8 (8.93)	-2.5 (8.95)
95% C.I.	(-34.5, 0.8)	(-20.2, 15.2)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		14.3 (13.07)
95% C.I.		(-11.5, 40.1)
Corrected Hedges' g Statistic		0.62
95% C.I.		(-0.59, 1.84)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Fatigue Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 37		
n [1]	11	25
n [2]	3	6

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Fatigue Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 40		
n [1]	11	25
n [2]	3	6

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Fatigue Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 43		
n [1]	11	25
n [2]	5	4

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Fatigue Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 46		
n [1]	11	25
n [2]	3	4

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Fatigue Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 49		
n [1]	11	25
n [2]	4	4

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Fatigue Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 52		
n [1]	11	25
n [2]	3	5

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Fatigue Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 55		
n [1]	11	25
n [2]	4	3

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Fatigue Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 58		
n [1]	11	25
n [2]	2	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Fatigue Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 61		
n [1]	11	25
n [2]	2	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Fatigue Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 64		
n [1]	11	25
n [2]	3	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Fatigue Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 67		
n [1]	11	25
n [2]	2	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Fatigue Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 70		
n [1]	11	25
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Fatigue Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 73		
n [1]	11	25
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Fatigue Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 76		
n [1]	11	25
n [2]	2	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Fatigue Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 79		
n [1]	11	25
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Fatigue Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 82		
n [1]	11	25
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Fatigue Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 85		
n [1]	11	25
n [2]	1	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Fatigue Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 88		
n [1]	11	25
n [2]	1	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Fatigue Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 91		
n [1]	11	25
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Fatigue Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 94		
n [1]	11	25
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Fatigue Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 97		
n [1]	11	25
n [2]	1	0

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Fatigue Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 100		
n [1]	11	25
n [2]	0	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Fatigue Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
End of Treatment		
n [1]	11	25
n [2]	8	10
LS Mean (SE)	38.4 (7.80)	45.4 (6.89)
95% C.I.	(23.0, 53.9)	(31.8, 59.1)
LS Mean Change from Baseline (SE)	-5.2 (7.80)	1.9 (6.89)
95% C.I.	(-20.6, 10.3)	(-11.8, 15.5)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		7.0 (10.32)
95% C.I.		(-13.4, 27.5)
Corrected Hedges' g Statistic		0.31
95% C.I.		(-0.63, 1.24)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Fatigue Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 1		
n [1]	11	25
n [2]	2	5

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Fatigue Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 2		
n [1]	11	25
n [2]	2	3

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Fatigue Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 4		
n [1]	11	25
n [2]	0	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Fatigue Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
PFS Follow-Up 2		
n [1]	11	25
n [2]	1	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Fatigue Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
PFS Follow-Up 4		
n [1]	11	25
n [2]	0	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Nausea and vomiting Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 4		
n [1]	12	24
n [2]	12	22
LS Mean (SE)	5.0 (5.16)	6.7 (3.81)
95% C.I.	(-5.3, 15.4)	(-0.9, 14.3)
LS Mean Change from Baseline (SE)	1.1 (5.16)	2.8 (3.81)
95% C.I.	(-9.2, 11.4)	(-4.8, 10.4)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		1.7 (6.44)
95% C.I.		(-11.2, 14.5)
Corrected Hedges' g Statistic		0.09
95% C.I.		(-0.61, 0.79)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Nausea and vomiting Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 7		
n [1]	12	24
n [2]	11	20
LS Mean (SE)	-0.2 (5.21)	8.3 (3.84)
95% C.I.	(-10.6, 10.2)	(0.7, 16.0)
LS Mean Change from Baseline (SE)	-4.1 (5.21)	4.4 (3.84)
95% C.I.	(-14.5, 6.3)	(-3.3, 12.0)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		8.5 (6.50)
95% C.I.		(-4.5, 21.5)
Corrected Hedges' g Statistic		0.48
95% C.I.		(-0.26, 1.23)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Nausea and vomiting Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 10		
n [1]	12	24
n [2]	12	11
LS Mean (SE)	0.5 (5.17)	11.9 (4.35)
95% C.I.	(-9.8, 10.8)	(3.2, 20.5)
LS Mean Change from Baseline (SE)	-3.4 (5.17)	7.9 (4.35)
95% C.I.	(-13.8, 6.9)	(-0.7, 16.5)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		11.3 (6.80)
95% C.I.		(-2.2, 24.9)
Corrected Hedges' g Statistic		0.67
95% C.I.		(-0.17, 1.51)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Nausea and vomiting Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 13		
n [1]	12	24
n [2]	12	9
LS Mean (SE)	0.4 (5.17)	10.9 (4.76)
95% C.I.	(-9.9, 10.7)	(1.4, 20.3)
LS Mean Change from Baseline (SE)	-3.5 (5.17)	6.9 (4.76)
95% C.I.	(-13.9, 6.8)	(-2.5, 16.3)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		10.5 (7.08)
95% C.I.		(-3.6, 24.5)
Corrected Hedges' g Statistic		0.61
95% C.I.		(-0.27, 1.49)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Nausea and vomiting Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 16		
n [1]	12	24
n [2]	11	9
LS Mean (SE)	2.8 (5.20)	7.1 (4.80)
95% C.I.	(-7.6, 13.2)	(-2.4, 16.6)
LS Mean Change from Baseline (SE)	-1.1 (5.20)	3.2 (4.80)
95% C.I.	(-11.5, 9.3)	(-6.3, 12.7)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		4.3 (7.13)
95% C.I.		(-9.9, 18.5)
Corrected Hedges' g Statistic		0.26
95% C.I.		(-0.63, 1.14)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Nausea and vomiting Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 19		
n [1]	12	24
n [2]	12	8
LS Mean (SE)	6.9 (5.17)	10.2 (4.99)
95% C.I.	(-3.4, 17.3)	(0.3, 20.1)
LS Mean Change from Baseline (SE)	3.0 (5.17)	6.2 (4.99)
95% C.I.	(-7.4, 13.3)	(-3.6, 16.1)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		3.2 (7.23)
95% C.I.		(-11.1, 17.6)
Corrected Hedges' g Statistic		0.19
95% C.I.		(-0.71, 1.08)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Nausea and vomiting Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 22		
n [1]	12	24
n [2]	8	7
LS Mean (SE)	4.9 (5.54)	9.7 (5.73)
95% C.I.	(-6.1, 16.0)	(-1.6, 21.0)
LS Mean Change from Baseline (SE)	1.0 (5.54)	5.8 (5.73)
95% C.I.	(-10.0, 12.0)	(-5.5, 17.1)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		4.8 (7.65)
95% C.I.		(-10.4, 20.0)
Corrected Hedges' g Statistic		0.29
95% C.I.		(-0.73, 1.31)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Nausea and vomiting Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 25		
n [1]	12	24
n [2]	9	8
LS Mean (SE)	6.1 (5.74)	10.5 (5.28)
95% C.I.	(-5.3, 17.5)	(0.0, 21.0)
LS Mean Change from Baseline (SE)	2.2 (5.74)	6.6 (5.28)
95% C.I.	(-9.2, 13.6)	(-3.9, 17.0)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		4.4 (7.80)
95% C.I.		(-11.1, 19.9)
Corrected Hedges' g Statistic		0.26
95% C.I.		(-0.70, 1.21)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Nausea and vomiting Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 28		
n [1]	12	24
n [2]	7	7
LS Mean (SE)	- (-)	- (-)
95% C.I.	(-,-)	(-,-)
LS Mean Change from Baseline (SE)	- (-)	- (-)
95% C.I.	(-,-)	(-,-)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-3.6 (8.14)
95% C.I.		(-19.7, 12.6)
Corrected Hedges' g Statistic		-
95% C.I.		(-,-)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Nausea and vomiting Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 31		
n [1]	12	24
n [2]	7	7
LS Mean (SE)	- (-)	- (-)
95% C.I.	(-,-)	(-,-)
LS Mean Change from Baseline (SE)	- (-)	- (-)
95% C.I.	(-,-)	(-,-)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-1.7 (8.40)
95% C.I.		(-18.4, 14.9)
Corrected Hedges' g Statistic		-
95% C.I.		(-,-)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Nausea and vomiting Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 34		
n [1]	12	24
n [2]	6	6
LS Mean (SE)	- (-)	- (-)
95% C.I.	(-,-)	(-,-)
LS Mean Change from Baseline (SE)	- (-)	- (-)
95% C.I.	(-,-)	(-,-)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		3.1 (8.79)
95% C.I.		(-14.3, 20.5)
Corrected Hedges' g Statistic		-
95% C.I.		(-,-)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Nausea and vomiting Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 37		
n [1]	12	24
n [2]	4	6
LS Mean (SE)	- (-)	- (-)
95% C.I.	(-,-)	(-,-)
LS Mean Change from Baseline (SE)	- (-)	- (-)
95% C.I.	(-,-)	(-,-)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-5.4 (9.25)
95% C.I.		(-23.7, 12.9)
Corrected Hedges' g Statistic		-
95% C.I.		(-,-)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Nausea and vomiting Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 40		
n [1]	12	24
n [2]	4	6
LS Mean (SE)	6.0 (6.87)	4.8 (6.02)
95% C.I.	(-7.6, 19.6)	(-7.1, 16.7)
LS Mean Change from Baseline (SE)	2.1 (6.87)	0.9 (6.02)
95% C.I.	(-11.5, 15.7)	(-11.0, 12.8)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-1.2 (9.31)
95% C.I.		(-19.6, 17.2)
Corrected Hedges' g Statistic		-0.08
95% C.I.		(-1.34, 1.19)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Nausea and vomiting Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 43		
n [1]	12	24
n [2]	6	4
LS Mean (SE)	- (-)	- (-)
95% C.I.	(-,-)	(-,-)
LS Mean Change from Baseline (SE)	- (-)	- (-)
95% C.I.	(-,-)	(-,-)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-0.9 (8.91)
95% C.I.		(-18.6, 16.7)
Corrected Hedges' g Statistic		-
95% C.I.		(-,-)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Nausea and vomiting Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 46		
n [1]	12	24
n [2]	4	4

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Nausea and vomiting Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 49		
n [1]	12	24
n [2]	4	4

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Nausea and vomiting Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 52		
n [1]	12	24
n [2]	3	6

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Nausea and vomiting Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 55		
n [1]	12	24
n [2]	4	3

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Nausea and vomiting Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 58		
n [1]	12	24
n [2]	2	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Nausea and vomiting Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 61		
n [1]	12	24
n [2]	2	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Nausea and vomiting Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 64		
n [1]	12	24
n [2]	3	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Nausea and vomiting Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 67		
n [1]	12	24
n [2]	2	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Nausea and vomiting Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 70		
n [1]	12	24
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Nausea and vomiting Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 73		
n [1]	12	24
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Nausea and vomiting Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 76		
n [1]	12	24
n [2]	2	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Nausea and vomiting Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 79		
n [1]	12	24
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Nausea and vomiting Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 82		
n [1]	12	24
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Nausea and vomiting Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 85		
n [1]	12	24
n [2]	1	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Nausea and vomiting Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 88		
n [1]	12	24
n [2]	1	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Nausea and vomiting Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 91		
n [1]	12	24
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Nausea and vomiting Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 94		
n [1]	12	24
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Nausea and vomiting Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 97		
n [1]	12	24
n [2]	1	0

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Nausea and vomiting Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 100		
n [1]	12	24
n [2]	0	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Nausea and vomiting Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
End of Treatment		
n [1]	12	24
n [2]	9	11
LS Mean (SE)	7.5 (5.61)	9.4 (5.19)
95% C.I.	(-3.7, 18.7)	(-0.9, 19.7)
LS Mean Change from Baseline (SE)	3.5 (5.61)	5.4 (5.19)
95% C.I.	(-7.6, 14.7)	(-4.9, 15.8)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		1.9 (7.75)
95% C.I.		(-13.5, 17.3)
Corrected Hedges' g Statistic		0.11
95% C.I.		(-0.78, 0.99)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Nausea and vomiting Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 1		
n [1]	12	24
n [2]	2	5

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Nausea and vomiting Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 2		
n [1]	12	24
n [2]	2	3

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Nausea and vomiting Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 4		
n [1]	12	24
n [2]	0	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Nausea and vomiting Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
PFS Follow-Up 2		
n [1]	12	24
n [2]	1	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Nausea and vomiting Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
PFS Follow-Up 4		
n [1]	12	24
n [2]	0	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Pain Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 4		
n [1]	12	25
n [2]	12	23
LS Mean (SE)	30.3 (6.73)	42.3 (4.87)
95% C.I.	(16.9, 43.6)	(32.7, 52.0)
LS Mean Change from Baseline (SE)	-9.2 (6.73)	2.9 (4.87)
95% C.I.	(-22.5, 4.1)	(-6.8, 12.5)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		12.1 (8.23)
95% C.I.		(-4.2, 28.3)
Corrected Hedges' g Statistic		0.51
95% C.I.		(-0.20, 1.21)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Pain Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 7		
n [1]	12	25
n [2]	11	21
LS Mean (SE)	23.8 (6.91)	44.5 (5.00)
95% C.I.	(10.2, 37.5)	(34.6, 54.4)
LS Mean Change from Baseline (SE)	-15.6 (6.91)	5.0 (5.00)
95% C.I.	(-29.3, -2.0)	(-4.8, 14.9)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		20.7 (8.44)
95% C.I.		(4.0, 37.3)
Corrected Hedges' g Statistic		0.88
95% C.I.		(0.12, 1.64)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Protocol: 207495 Page 315 of 585
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Pain Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 10		
n [1]	12	25
n [2]	12	12
LS Mean (SE)	24.0 (6.74)	52.9 (6.07)
95% C.I.	(10.6, 37.3)	(40.9, 64.8)
LS Mean Change from Baseline (SE)	-15.5 (6.74)	13.4 (6.07)
95% C.I.	(-28.9, -2.2)	(1.4, 25.4)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		28.9 (9.02)
95% C.I.		(11.1, 46.7)
Corrected Hedges' g Statistic		1.26
95% C.I.		(0.38, 2.13)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Pain Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 13		
n [1]	12	25
n [2]	12	10
LS Mean (SE)	29.3 (6.75)	43.6 (6.66)
95% C.I.	(16.0, 42.7)	(30.4, 56.7)
LS Mean Change from Baseline (SE)	-10.2 (6.75)	4.1 (6.66)
95% C.I.	(-23.5, 3.2)	(-9.0, 17.2)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		14.3 (9.45)
95% C.I.		(-4.4, 32.9)
Corrected Hedges' g Statistic		0.61
95% C.I.		(-0.24, 1.47)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Pain Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 16		
n [1]	12	25
n [2]	11	10
LS Mean (SE)	18.8 (6.87)	40.0 (6.86)
95% C.I.	(5.3, 32.4)	(26.5, 53.5)
LS Mean Change from Baseline (SE)	-20.6 (6.87)	0.5 (6.86)
95% C.I.	(-34.2, -7.1)	(-13.0, 14.0)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		21.2 (9.75)
95% C.I.		(1.9, 40.4)
Corrected Hedges' g Statistic		0.91
95% C.I.		(0.01, 1.81)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Pain Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 19		
n [1]	12	25
n [2]	12	9
LS Mean (SE)	22.3 (6.76)	40.8 (7.17)
95% C.I.	(9.0, 35.7)	(26.6, 54.9)
LS Mean Change from Baseline (SE)	-17.1 (6.76)	1.3 (7.17)
95% C.I.	(-30.5, -3.8)	(-12.8, 15.5)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		18.5 (9.95)
95% C.I.		(-1.2, 38.1)
Corrected Hedges' g Statistic		0.78
95% C.I.		(-0.11, 1.68)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Pain Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 22		
n [1]	12	25
n [2]	8	8
LS Mean (SE)	17.9 (7.56)	23.8 (7.93)
95% C.I.	(2.9, 32.8)	(8.2, 39.4)
LS Mean Change from Baseline (SE)	-21.6 (7.56)	-15.7 (7.93)
95% C.I.	(-36.5, -6.7)	(-31.3, -0.1)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		5.9 (11.00)
95% C.I.		(-15.8, 27.6)
Corrected Hedges' g Statistic		0.26
95% C.I.		(-0.73, 1.24)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Pain Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 25		
n [1]	12	25
n [2]	9	8
LS Mean (SE)	12.9 (7.59)	35.5 (7.71)
95% C.I.	(-2.1, 27.9)	(20.2, 50.7)
LS Mean Change from Baseline (SE)	-26.6 (7.59)	-4.0 (7.71)
95% C.I.	(-41.6, -11.6)	(-19.2, 11.2)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		22.6 (10.90)
95% C.I.		(1.0, 44.1)
Corrected Hedges' g Statistic		0.96
95% C.I.		(-0.05, 1.96)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Pain Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 28		
n [1]	12	25
n [2]	7	7
LS Mean (SE)	15.8 (8.37)	30.3 (8.52)
95% C.I.	(-0.7, 32.3)	(13.5, 47.1)
LS Mean Change from Baseline (SE)	-23.6 (8.37)	-9.2 (8.52)
95% C.I.	(-40.1, -7.1)	(-26.0, 7.6)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		14.5 (11.92)
95% C.I.		(-9.0, 38.0)
Corrected Hedges' g Statistic		0.61
95% C.I.		(-0.46, 1.68)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Pain Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 31		
n [1]	12	25
n [2]	7	7
LS Mean (SE)	15.3 (8.63)	37.3 (8.89)
95% C.I.	(-1.8, 32.3)	(19.7, 54.8)
LS Mean Change from Baseline (SE)	-24.2 (8.63)	-2.2 (8.89)
95% C.I.	(-41.2, -7.2)	(-19.7, 15.3)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		22.0 (12.33)
95% C.I.		(-2.3, 46.4)
Corrected Hedges' g Statistic		0.89
95% C.I.		(-0.21, 1.99)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Pain Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 34		
n [1]	12	25
n [2]	6	6
LS Mean (SE)	15.0 (9.17)	41.0 (9.57)
95% C.I.	(-3.1, 33.1)	(22.1, 59.9)
LS Mean Change from Baseline (SE)	-24.5 (9.17)	1.5 (9.57)
95% C.I.	(-42.6, -6.4)	(-17.4, 20.4)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		26.0 (13.32)
95% C.I.		(-0.3, 52.3)
Corrected Hedges' g Statistic		1.04
95% C.I.		(-0.16, 2.25)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Pain Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 37		
n [1]	12	25
n [2]	4	6
LS Mean (SE)	42.4 (11.85)	38.2 (10.11)
95% C.I.	(19.1, 65.8)	(18.2, 58.1)
LS Mean Change from Baseline (SE)	3.0 (11.85)	-1.3 (10.11)
95% C.I.	(-20.4, 26.3)	(-21.2, 18.6)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-4.3 (14.19)
95% C.I.		(-32.2, 23.7)
Corrected Hedges' g Statistic		-0.16
95% C.I.		(-1.42, 1.11)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Protocol: 207495 Page 325 of 585
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Pain Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 40		
n [1]	12	25
n [2]	4	6
LS Mean (SE)	23.0 (12.02)	28.2 (10.49)
95% C.I.	(-0.7, 46.7)	(7.5, 48.8)
LS Mean Change from Baseline (SE)	-16.5 (12.02)	-11.3 (10.49)
95% C.I.	(-40.1, 7.2)	(-32.0, 9.4)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		5.2 (14.13)
95% C.I.		(-22.7, 33.0)
Corrected Hedges' g Statistic		0.19
95% C.I.		(-1.08, 1.45)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Pain Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 43		
n [1]	12	25
n [2]	6	4
LS Mean (SE)	25.8 (8.81)	27.2 (10.72)
95% C.I.	(8.4, 43.2)	(6.1, 48.3)
LS Mean Change from Baseline (SE)	-13.7 (8.81)	-12.3 (10.72)
95% C.I.	(-31.0, 3.7)	(-33.4, 8.9)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		1.4 (14.03)
95% C.I.		(-26.3, 29.1)
Corrected Hedges' g Statistic		0.06
95% C.I.		(-1.21, 1.32)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Pain Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 46		
n [1]	12	25
n [2]	4	4

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Pain Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 49		
n [1]	12	25
n [2]	4	4

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Pain Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 52		
n [1]	12	25
n [2]	3	6

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Pain Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 55		
n [1]	12	25
n [2]	4	3

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Pain Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 58		
n [1]	12	25
n [2]	2	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Pain Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 61		
n [1]	12	25
n [2]	2	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Pain Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 64		
n [1]	12	25
n [2]	3	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Pain Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 67		
n [1]	12	25
n [2]	2	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Pain Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 70		
n [1]	12	25
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Pain Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 73		
n [1]	12	25
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Pain Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 76		
n [1]	12	25
n [2]	2	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Pain Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 79		
n [1]	12	25
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Pain Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 82		
n [1]	12	25
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Pain Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 85		
n [1]	12	25
n [2]	1	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Pain Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 88		
n [1]	12	25
n [2]	1	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Pain Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 91		
n [1]	12	25
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Pain Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 94		
n [1]	12	25
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Pain Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 97		
n [1]	12	25
n [2]	1	0

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Pain Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 100		
n [1]	12	25
n [2]	0	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Protocol: 207495 Page 346 of 585
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Pain Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
End of Treatment		
n [1]	12	25
n [2]	9	10
LS Mean (SE)	16.2 (7.74)	47.1 (7.19)
95% C.I.	(0.9, 31.5)	(32.9, 61.3)
LS Mean Change from Baseline (SE)	-23.3 (7.74)	7.6 (7.19)
95% C.I.	(-38.6, -8.0)	(-6.6, 21.8)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		30.9 (10.62)
95% C.I.		(9.9, 51.9)
Corrected Hedges' g Statistic		1.28
95% C.I.		(0.30, 2.27)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Pain Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 1		
n [1]	12	25
n [2]	2	5

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Pain Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 2		
n [1]	12	25
n [2]	2	3

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Pain Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 4		
n [1]	12	25
n [2]	0	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Pain Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
PFS Follow-Up 2		
n [1]	12	25
n [2]	1	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Pain Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
PFS Follow-Up 4		
n [1]	12	25
n [2]	0	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Dyspnoea Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 4		
n [1]	12	25
n [2]	12	23
LS Mean (SE)	24.1 (7.99)	24.7 (5.73)
95% C.I.	(8.3, 40.0)	(13.3, 36.1)
LS Mean Change from Baseline (SE)	6.2 (7.99)	6.7 (5.73)
95% C.I.	(-9.7, 22.0)	(-4.7, 18.1)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		0.6 (9.80)
95% C.I.		(-18.9, 20.0)
Corrected Hedges' g Statistic		0.02
95% C.I.		(-0.68, 0.72)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Dyspnoea Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 7		
n [1]	12	25
n [2]	10	21
LS Mean (SE)	22.5 (8.22)	20.5 (5.85)
95% C.I.	(6.2, 38.8)	(8.9, 32.1)
LS Mean Change from Baseline (SE)	4.5 (8.22)	2.5 (5.85)
95% C.I.	(-11.8, 20.9)	(-9.1, 14.1)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-2.1 (10.08)
95% C.I.		(-22.1, 17.9)
Corrected Hedges' g Statistic		-0.08
95% C.I.		(-0.83, 0.68)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Dyspnoea Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 10		
n [1]	12	25
n [2]	12	12
LS Mean (SE)	24.2 (7.99)	20.3 (6.86)
95% C.I.	(8.4, 40.1)	(6.8, 33.9)
LS Mean Change from Baseline (SE)	6.2 (7.99)	2.3 (6.86)
95% C.I.	(-9.6, 22.1)	(-11.2, 15.9)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-3.9 (10.53)
95% C.I.		(-24.8, 17.0)
Corrected Hedges' g Statistic		-0.15
95% C.I.		(-0.95, 0.65)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Dyspnoea Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 13		
n [1]	12	25
n [2]	12	10
LS Mean (SE)	26.7 (7.99)	23.6 (7.55)
95% C.I.	(10.8, 42.5)	(8.7, 38.5)
LS Mean Change from Baseline (SE)	8.7 (7.99)	5.6 (7.55)
95% C.I.	(-7.2, 24.5)	(-9.3, 20.5)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-3.1 (11.01)
95% C.I.		(-24.9, 18.7)
Corrected Hedges' g Statistic		-0.11
95% C.I.		(-0.95, 0.73)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Dyspnoea Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 16		
n [1]	12	25
n [2]	11	10
LS Mean (SE)	26.3 (8.10)	16.9 (7.77)
95% C.I.	(10.2, 42.4)	(1.6, 32.3)
LS Mean Change from Baseline (SE)	8.3 (8.10)	-1.0 (7.77)
95% C.I.	(-7.8, 24.4)	(-16.4, 14.3)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-9.3 (11.20)
95% C.I.		(-31.5, 12.8)
Corrected Hedges' g Statistic		-0.35
95% C.I.		(-1.21, 0.52)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Dyspnoea Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 19		
n [1]	12	25
n [2]	12	8
LS Mean (SE)	29.9 (7.99)	25.2 (8.49)
95% C.I.	(14.0, 45.8)	(8.5, 42.0)
LS Mean Change from Baseline (SE)	11.9 (7.99)	7.3 (8.49)
95% C.I.	(-4.0, 27.8)	(-9.5, 24.0)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-4.7 (11.69)
95% C.I.		(-27.8, 18.5)
Corrected Hedges' g Statistic		-0.17
95% C.I.		(-1.07, 0.73)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Dyspnoea Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 22		
n [1]	12	25
n [2]	8	8
LS Mean (SE)	25.1 (8.77)	20.0 (8.68)
95% C.I.	(7.7, 42.5)	(2.8, 37.1)
LS Mean Change from Baseline (SE)	7.1 (8.77)	2.0 (8.68)
95% C.I.	(-10.3, 24.5)	(-15.2, 19.1)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-5.1 (12.46)
95% C.I.		(-29.7, 19.5)
Corrected Hedges' g Statistic		-0.20
95% C.I.		(-1.18, 0.79)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Dyspnoea Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 25		
n [1]	12	25
n [2]	9	8
LS Mean (SE)	32.9 (8.79)	20.2 (9.04)
95% C.I.	(15.5, 50.3)	(2.4, 38.1)
LS Mean Change from Baseline (SE)	14.9 (8.79)	2.2 (9.04)
95% C.I.	(-2.5, 32.3)	(-15.6, 20.1)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-12.7 (12.66)
95% C.I.		(-37.7, 12.3)
Corrected Hedges' g Statistic		-0.46
95% C.I.		(-1.43, 0.50)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Dyspnoea Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 28		
n [1]	12	25
n [2]	7	7
LS Mean (SE)	20.2 (9.70)	12.6 (9.55)
95% C.I.	(1.0, 39.3)	(-6.3, 31.4)
LS Mean Change from Baseline (SE)	2.2 (9.70)	-5.4 (9.55)
95% C.I.	(-17.0, 21.3)	(-24.2, 13.5)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-7.6 (13.83)
95% C.I.		(-34.9, 19.8)
Corrected Hedges' g Statistic		-0.28
95% C.I.		(-1.33, 0.77)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Dyspnoea Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 31		
n [1]	12	25
n [2]	7	7
LS Mean (SE)	18.5 (10.13)	27.6 (9.97)
95% C.I.	(-1.5, 38.5)	(7.9, 47.2)
LS Mean Change from Baseline (SE)	0.5 (10.13)	9.6 (9.97)
95% C.I.	(-19.5, 20.5)	(-10.1, 29.2)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		9.1 (14.53)
95% C.I.		(-19.6, 37.8)
Corrected Hedges' g Statistic		0.32
95% C.I.		(-0.74, 1.37)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Dyspnoea Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 34		
n [1]	12	25
n [2]	6	6
LS Mean (SE)	17.1 (10.97)	34.4 (11.04)
95% C.I.	(-4.6, 38.8)	(12.6, 56.2)
LS Mean Change from Baseline (SE)	-0.9 (10.97)	16.4 (11.04)
95% C.I.	(-22.6, 20.8)	(-5.4, 38.2)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		17.3 (16.37)
95% C.I.		(-15.0, 49.6)
Corrected Hedges' g Statistic		0.59
95% C.I.		(-0.56, 1.75)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Dyspnoea Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 37		
n [1]	12	25
n [2]	4	6
LS Mean (SE)	26.0 (12.03)	21.6 (11.93)
95% C.I.	(2.3, 49.7)	(-1.9, 45.2)
LS Mean Change from Baseline (SE)	8.0 (12.03)	3.6 (11.93)
95% C.I.	(-15.7, 31.7)	(-19.9, 27.2)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-4.4 (17.23)
95% C.I.		(-38.4, 29.7)
Corrected Hedges' g Statistic		-0.14
95% C.I.		(-1.41, 1.12)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Dyspnoea Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 40		
n [1]	12	25
n [2]	4	6
LS Mean (SE)	36.7 (11.95)	35.7 (13.73)
95% C.I.	(13.1, 60.3)	(8.6, 62.7)
LS Mean Change from Baseline (SE)	18.7 (11.95)	17.7 (13.73)
95% C.I.	(-4.8, 42.3)	(-9.4, 44.7)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-1.1 (18.50)
95% C.I.		(-37.5, 35.4)
Corrected Hedges' g Statistic		-0.03
95% C.I.		(-1.30, 1.23)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Dyspnoea Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 43		
n [1]	12	25
n [2]	6	4
LS Mean (SE)	37.4 (10.65)	21.5 (12.81)
95% C.I.	(16.4, 58.5)	(-3.7, 46.7)
LS Mean Change from Baseline (SE)	19.4 (10.65)	3.5 (12.81)
95% C.I.	(-1.6, 40.5)	(-21.7, 28.7)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-15.9 (18.02)
95% C.I.		(-51.4, 19.6)
Corrected Hedges' g Statistic		-0.55
95% C.I.		(-1.84, 0.73)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Dyspnoea Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 46		
n [1]	12	25
n [2]	4	4

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Dyspnoea Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 49		
n [1]	12	25
n [2]	4	4

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Dyspnoea Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 52		
n [1]	12	25
n [2]	3	6

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Dyspnoea Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 55		
n [1]	12	25
n [2]	4	3

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Dyspnoea Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 58		
n [1]	12	25
n [2]	2	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Dyspnoea Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 61		
n [1]	12	25
n [2]	2	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Dyspnoea Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 64		
n [1]	12	25
n [2]	3	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Dyspnoea Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 67		
n [1]	12	25
n [2]	2	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Dyspnoea Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 70		
n [1]	12	25
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Dyspnoea Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 73		
n [1]	12	25
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Dyspnoea Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 76		
n [1]	12	25
n [2]	2	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Dyspnoea Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 79		
n [1]	12	25
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Dyspnoea Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 82		
n [1]	12	25
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Dyspnoea Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 85		
n [1]	12	25
n [2]	1	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Dyspnoea Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 88		
n [1]	12	25
n [2]	1	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Dyspnoea Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 91		
n [1]	12	25
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Dyspnoea Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 94		
n [1]	12	25
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Dyspnoea Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 97		
n [1]	12	25
n [2]	1	0

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Dyspnoea Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 100		
n [1]	12	25
n [2]	0	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Dyspnoea Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
End of Treatment		
n [1]	12	25
n [2]	9	11
LS Mean (SE)	28.4 (8.87)	21.0 (8.34)
95% C.I.	(10.8, 46.0)	(4.5, 37.5)
LS Mean Change from Baseline (SE)	10.4 (8.87)	3.0 (8.34)
95% C.I.	(-7.2, 28.0)	(-13.5, 19.5)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-7.4 (12.01)
95% C.I.		(-31.2, 16.4)
Corrected Hedges' g Statistic		-0.26
95% C.I.		(-1.14, 0.62)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Dyspnoea Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 1		
n [1]	12	25
n [2]	2	4

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Dyspnoea Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 2		
n [1]	12	25
n [2]	2	3

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Dyspnoea Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 4		
n [1]	12	25
n [2]	0	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Dyspnoea Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
PFS Follow-Up 2		
n [1]	12	25
n [2]	1	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Dyspnoea Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
PFS Follow-Up 4		
n [1]	12	25
n [2]	0	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Insomnia Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 4		
n [1]	11	24
n [2]	11	22
LS Mean (SE)	28.7 (8.00)	28.2 (5.55)
95% C.I.	(12.8, 44.5)	(17.2, 39.1)
LS Mean Change from Baseline (SE)	1.0 (8.00)	0.5 (5.55)
95% C.I.	(-14.8, 16.9)	(-10.4, 11.5)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-0.5 (9.79)
95% C.I.		(-19.9, 18.9)
Corrected Hedges' g Statistic		-0.02
95% C.I.		(-0.74, 0.71)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Insomnia Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 7		
n [1]	11	24
n [2]	10	20
LS Mean (SE)	30.5 (8.18)	35.4 (5.76)
95% C.I.	(14.4, 46.7)	(24.0, 46.7)
LS Mean Change from Baseline (SE)	2.9 (8.18)	7.7 (5.76)
95% C.I.	(-13.3, 19.1)	(-3.7, 19.1)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		4.8 (10.04)
95% C.I.		(-15.0, 24.7)
Corrected Hedges' g Statistic		0.18
95% C.I.		(-0.58, 0.94)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Insomnia Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 10		
n [1]	11	24
n [2]	11	11
LS Mean (SE)	20.9 (8.04)	24.2 (7.37)
95% C.I.	(4.9, 36.8)	(9.6, 38.7)
LS Mean Change from Baseline (SE)	-6.8 (8.04)	-3.5 (7.37)
95% C.I.	(-22.7, 9.2)	(-18.0, 11.1)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		3.3 (11.04)
95% C.I.		(-18.5, 25.1)
Corrected Hedges' g Statistic		0.12
95% C.I.		(-0.71, 0.96)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Insomnia Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 13		
n [1]	11	24
n [2]	11	9
LS Mean (SE)	22.8 (8.06)	23.6 (8.13)
95% C.I.	(6.8, 38.7)	(7.6, 39.7)
LS Mean Change from Baseline (SE)	-4.9 (8.06)	-4.0 (8.13)
95% C.I.	(-20.8, 11.1)	(-20.1, 12.0)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		0.8 (11.45)
95% C.I.		(-21.8, 23.5)
Corrected Hedges' g Statistic		0.03
95% C.I.		(-0.85, 0.91)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Insomnia Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 16		
n [1]	11	24
n [2]	10	9
LS Mean (SE)	16.2 (8.27)	26.9 (8.25)
95% C.I.	(-0.2, 32.5)	(10.6, 43.2)
LS Mean Change from Baseline (SE)	-11.5 (8.27)	-0.7 (8.25)
95% C.I.	(-27.8, 4.9)	(-17.0, 15.6)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		10.8 (11.68)
95% C.I.		(-12.3, 33.8)
Corrected Hedges' g Statistic		0.40
95% C.I.		(-0.51, 1.31)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Insomnia Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 19		
n [1]	11	24
n [2]	11	8
LS Mean (SE)	11.8 (8.06)	25.8 (8.70)
95% C.I.	(-4.2, 27.7)	(8.6, 43.0)
LS Mean Change from Baseline (SE)	-15.8 (8.06)	-1.8 (8.70)
95% C.I.	(-31.8, 0.1)	(-19.0, 15.3)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		14.0 (11.93)
95% C.I.		(-9.6, 37.6)
Corrected Hedges' g Statistic		0.52
95% C.I.		(-0.41, 1.44)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Insomnia Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 22		
n [1]	11	24
n [2]	7	7
LS Mean (SE)	24.8 (9.26)	18.1 (9.54)
95% C.I.	(6.5, 43.1)	(-0.8, 36.9)
LS Mean Change from Baseline (SE)	-2.8 (9.26)	-9.6 (9.54)
95% C.I.	(-21.1, 15.5)	(-28.4, 9.3)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-6.8 (13.37)
95% C.I.		(-33.2, 19.6)
Corrected Hedges' g Statistic		-0.25
95% C.I.		(-1.31, 0.80)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Insomnia Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 25		
n [1]	11	24
n [2]	8	8
LS Mean (SE)	28.6 (9.10)	20.5 (9.32)
95% C.I.	(10.6, 46.5)	(2.1, 38.9)
LS Mean Change from Baseline (SE)	0.9 (9.10)	-7.1 (9.32)
95% C.I.	(-17.1, 18.9)	(-25.5, 11.3)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-8.1 (13.11)
95% C.I.		(-34.0, 17.8)
Corrected Hedges' g Statistic		-0.29
95% C.I.		(-1.28, 0.69)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Insomnia Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 28		
n [1]	11	24
n [2]	6	7
LS Mean (SE)	22.0 (10.71)	12.6 (9.46)
95% C.I.	(0.8, 43.1)	(-6.1, 31.2)
LS Mean Change from Baseline (SE)	-5.6 (10.71)	-15.1 (9.46)
95% C.I.	(-26.8, 15.5)	(-33.8, 3.6)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-9.4 (14.30)
95% C.I.		(-37.7, 18.8)
Corrected Hedges' g Statistic		-0.34
95% C.I.		(-1.44, 0.76)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Insomnia Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 31		
n [1]	11	24
n [2]	6	7
LS Mean (SE)	10.9 (11.06)	21.0 (9.95)
95% C.I.	(-11.0, 32.7)	(1.3, 40.6)
LS Mean Change from Baseline (SE)	-16.8 (11.06)	-6.7 (9.95)
95% C.I.	(-38.6, 5.1)	(-26.3, 13.0)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		10.1 (14.31)
95% C.I.		(-18.2, 38.4)
Corrected Hedges' g Statistic		0.35
95% C.I.		(-0.75, 1.45)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Insomnia Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 34		
n [1]	11	24
n [2]	5	6
LS Mean (SE)	17.6 (11.15)	6.6 (10.39)
95% C.I.	(-4.4, 39.6)	(-13.9, 27.1)
LS Mean Change from Baseline (SE)	-10.0 (11.15)	-21.0 (10.39)
95% C.I.	(-32.0, 12.0)	(-41.6, -0.5)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-11.0 (14.93)
95% C.I.		(-40.5, 18.4)
Corrected Hedges' g Statistic		-0.40
95% C.I.		(-1.60, 0.80)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Insomnia Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 37		
n [1]	11	24
n [2]	3	6

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Insomnia Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 40		
n [1]	11	24
n [2]	3	6

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Insomnia Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 43		
n [1]	11	24
n [2]	5	4

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Insomnia Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 46		
n [1]	11	24
n [2]	3	4

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Insomnia Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 49		
n [1]	11	24
n [2]	4	4

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Insomnia Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 52		
n [1]	11	24
n [2]	3	5

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Insomnia Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 55		
n [1]	11	24
n [2]	4	3

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Insomnia Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 58		
n [1]	11	24
n [2]	2	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Insomnia Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 61		
n [1]	11	24
n [2]	2	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Insomnia Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 64		
n [1]	11	24
n [2]	3	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Insomnia Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 67		
n [1]	11	24
n [2]	2	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Insomnia Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 70		
n [1]	11	24
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Insomnia Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 73		
n [1]	11	24
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Insomnia Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 76		
n [1]	11	24
n [2]	2	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Insomnia Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 79		
n [1]	11	24
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Insomnia Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 82		
n [1]	11	24
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Insomnia Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 85		
n [1]	11	24
n [2]	1	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Insomnia Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 88		
n [1]	11	24
n [2]	1	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Insomnia Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 91		
n [1]	11	24
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Insomnia Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 94		
n [1]	11	24
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Insomnia Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 97		
n [1]	11	24
n [2]	1	0

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Insomnia Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 100		
n [1]	11	24
n [2]	0	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Insomnia Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
End of Treatment		
n [1]	11	24
n [2]	8	10
LS Mean (SE)	21.0 (9.29)	20.2 (8.18)
95% C.I.	(2.6, 39.4)	(4.0, 36.4)
LS Mean Change from Baseline (SE)	-6.6 (9.29)	-7.4 (8.18)
95% C.I.	(-25.0, 11.7)	(-23.6, 8.7)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-0.8 (12.30)
95% C.I.		(-25.1, 23.5)
Corrected Hedges' g Statistic		-0.03
95% C.I.		(-0.96, 0.90)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Insomnia Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 1		
n [1]	11	24
n [2]	2	5

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Insomnia Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 2		
n [1]	11	24
n [2]	2	3

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Insomnia Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 4		
n [1]	11	24
n [2]	0	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Insomnia Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
PFS Follow-Up 2		
n [1]	11	24
n [2]	1	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Insomnia Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
PFS Follow-Up 4		
n [1]	11	24
n [2]	0	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Appetite Loss Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 4		
n [1]	12	24
n [2]	12	22
LS Mean (SE)	15.8 (6.02)	27.6 (4.61)
95% C.I.	(3.9, 27.7)	(18.5, 36.7)
LS Mean Change from Baseline (SE)	-3.5 (6.02)	8.3 (4.61)
95% C.I.	(-15.4, 8.4)	(-0.9, 17.4)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		11.8 (7.64)
95% C.I.		(-3.3, 26.9)
Corrected Hedges' g Statistic		0.54
95% C.I.		(-0.18, 1.25)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Appetite Loss Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 7		
n [1]	12	24
n [2]	11	20
LS Mean (SE)	9.6 (6.18)	28.2 (4.74)
95% C.I.	(-2.6, 21.8)	(18.8, 37.6)
LS Mean Change from Baseline (SE)	-9.7 (6.18)	8.9 (4.74)
95% C.I.	(-21.9, 2.5)	(-0.5, 18.3)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		18.6 (7.82)
95% C.I.		(3.1, 34.0)
Corrected Hedges' g Statistic		0.86
95% C.I.		(0.10, 1.63)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Appetite Loss Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 10		
n [1]	12	24
n [2]	12	11
LS Mean (SE)	12.4 (6.03)	25.0 (6.13)
95% C.I.	(0.5, 24.3)	(12.9, 37.1)
LS Mean Change from Baseline (SE)	-6.9 (6.03)	5.7 (6.13)
95% C.I.	(-18.8, 5.0)	(-6.4, 17.8)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		12.6 (8.67)
95% C.I.		(-4.5, 29.7)
Corrected Hedges' g Statistic		0.59
95% C.I.		(-0.25, 1.42)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Appetite Loss Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 13		
n [1]	12	24
n [2]	12	9
LS Mean (SE)	0.6 (6.03)	20.1 (6.77)
95% C.I.	(-11.3, 12.5)	(6.8, 33.5)
LS Mean Change from Baseline (SE)	-18.7 (6.03)	0.8 (6.77)
95% C.I.	(-30.6, -6.8)	(-12.5, 14.2)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		19.5 (9.14)
95% C.I.		(1.5, 37.5)
Corrected Hedges' g Statistic		0.91
95% C.I.		(0.00, 1.81)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Appetite Loss Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 16		
n [1]	12	24
n [2]	11	9
LS Mean (SE)	5.7 (6.18)	13.7 (6.69)
95% C.I.	(-6.5, 17.9)	(0.6, 26.9)
LS Mean Change from Baseline (SE)	-13.6 (6.18)	-5.6 (6.69)
95% C.I.	(-25.8, -1.4)	(-18.8, 7.6)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		8.0 (9.14)
95% C.I.		(-10.0, 26.1)
Corrected Hedges' g Statistic		0.38
95% C.I.		(-0.51, 1.27)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Appetite Loss Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 19		
n [1]	12	24
n [2]	12	8
LS Mean (SE)	6.2 (6.03)	22.7 (7.01)
95% C.I.	(-5.7, 18.2)	(8.8, 36.5)
LS Mean Change from Baseline (SE)	-13.1 (6.03)	3.4 (7.01)
95% C.I.	(-25.0, -1.1)	(-10.5, 17.2)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		16.4 (9.29)
95% C.I.		(-1.9, 34.8)
Corrected Hedges' g Statistic		0.77
95% C.I.		(-0.16, 1.69)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Appetite Loss Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 22		
n [1]	12	24
n [2]	8	7
LS Mean (SE)	6.6 (6.96)	17.7 (7.48)
95% C.I.	(-7.1, 20.4)	(3.0, 32.5)
LS Mean Change from Baseline (SE)	-12.7 (6.96)	-1.6 (7.48)
95% C.I.	(-26.4, 1.0)	(-16.3, 13.2)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		11.1 (10.24)
95% C.I.		(-9.1, 31.3)
Corrected Hedges' g Statistic		0.53
95% C.I.		(-0.50, 1.56)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Appetite Loss Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 25		
n [1]	12	24
n [2]	9	8
LS Mean (SE)	5.7 (6.91)	13.2 (7.18)
95% C.I.	(-7.9, 19.4)	(-0.9, 27.4)
LS Mean Change from Baseline (SE)	-13.6 (6.91)	-6.1 (7.18)
95% C.I.	(-27.2, 0.1)	(-20.2, 8.1)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		7.5 (9.90)
95% C.I.		(-12.0, 27.1)
Corrected Hedges' g Statistic		0.35
95% C.I.		(-0.61, 1.31)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Appetite Loss Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 28		
n [1]	12	24
n [2]	7	7
LS Mean (SE)	7.2 (8.03)	9.5 (7.89)
95% C.I.	(-8.6, 23.1)	(-6.1, 25.0)
LS Mean Change from Baseline (SE)	-12.1 (8.03)	-9.9 (7.89)
95% C.I.	(-27.9, 3.8)	(-25.4, 5.7)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		2.2 (10.75)
95% C.I.		(-19.0, 23.5)
Corrected Hedges' g Statistic		0.10
95% C.I.		(-0.95, 1.15)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Appetite Loss Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 31		
n [1]	12	24
n [2]	7	7
LS Mean (SE)	15.0 (8.27)	23.2 (7.86)
95% C.I.	(-1.3, 31.3)	(7.7, 38.8)
LS Mean Change from Baseline (SE)	-4.3 (8.27)	3.9 (7.86)
95% C.I.	(-20.6, 12.0)	(-11.6, 19.4)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		8.2 (11.07)
95% C.I.		(-13.6, 30.1)
Corrected Hedges' g Statistic		0.36
95% C.I.		(-0.70, 1.42)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Appetite Loss Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 34		
n [1]	12	24
n [2]	6	6
LS Mean (SE)	15.4 (8.71)	20.3 (8.59)
95% C.I.	(-1.8, 32.6)	(3.3, 37.3)
LS Mean Change from Baseline (SE)	-3.9 (8.71)	1.0 (8.59)
95% C.I.	(-21.1, 13.3)	(-16.0, 18.0)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		4.9 (11.81)
95% C.I.		(-18.4, 28.2)
Corrected Hedges' g Statistic		0.21
95% C.I.		(-0.92, 1.35)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Appetite Loss Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 37		
n [1]	12	24
n [2]	4	6
LS Mean (SE)	10.7 (13.36)	11.3 (9.16)
95% C.I.	(-15.6, 37.0)	(-6.7, 29.4)
LS Mean Change from Baseline (SE)	-8.6 (13.36)	-8.0 (9.16)
95% C.I.	(-34.9, 17.7)	(-26.0, 10.1)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		0.6 (14.02)
95% C.I.		(-27.0, 28.3)
Corrected Hedges' g Statistic		0.02
95% C.I.		(-1.24, 1.29)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Appetite Loss Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 40		
n [1]	12	24
n [2]	4	6
LS Mean (SE)	34.7 (13.56)	18.7 (9.16)
95% C.I.	(7.9, 61.4)	(0.6, 36.7)
LS Mean Change from Baseline (SE)	15.4 (13.56)	-0.7 (9.16)
95% C.I.	(-11.4, 42.1)	(-18.7, 17.4)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-16.0 (14.10)
95% C.I.		(-43.8, 11.8)
Corrected Hedges' g Statistic		-0.60
95% C.I.		(-1.89, 0.70)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Appetite Loss Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 43		
n [1]	12	24
n [2]	6	4
LS Mean (SE)	5.6 (8.38)	12.6 (10.18)
95% C.I.	(-10.9, 22.1)	(-7.4, 32.7)
LS Mean Change from Baseline (SE)	-13.7 (8.38)	-6.7 (10.18)
95% C.I.	(-30.3, 2.8)	(-26.7, 13.4)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		7.0 (12.69)
95% C.I.		(-18.0, 32.1)
Corrected Hedges' g Statistic		0.31
95% C.I.		(-0.96, 1.58)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Appetite Loss Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 46		
n [1]	12	24
n [2]	4	4

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Appetite Loss Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 49		
n [1]	12	24
n [2]	4	4

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Appetite Loss Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 52		
n [1]	12	24
n [2]	3	6

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Appetite Loss Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 55		
n [1]	12	24
n [2]	4	3

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Appetite Loss Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 58		
n [1]	12	24
n [2]	2	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Appetite Loss Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 61		
n [1]	12	24
n [2]	2	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Appetite Loss Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 64		
n [1]	12	24
n [2]	3	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Appetite Loss Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 67		
n [1]	12	24
n [2]	2	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Protocol: 207495 Page 452 of 585
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Appetite Loss Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 70		
n [1]	12	24
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Appetite Loss Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 73		
n [1]	12	24
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Appetite Loss Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 76		
n [1]	12	24
n [2]	2	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Appetite Loss Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 79		
n [1]	12	24
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Appetite Loss Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 82		
n [1]	12	24
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Appetite Loss Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 85		
n [1]	12	24
n [2]	1	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Appetite Loss Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 88		
n [1]	12	24
n [2]	1	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Appetite Loss Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 91		
n [1]	12	24
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Appetite Loss Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 94		
n [1]	12	24
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Appetite Loss Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 97		
n [1]	12	24
n [2]	1	0

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Appetite Loss Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 100		
n [1]	12	24
n [2]	0	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Appetite Loss Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
End of Treatment		
n [1]	12	24
n [2]	9	11
LS Mean (SE)	11.2 (6.84)	29.3 (6.33)
95% C.I.	(-2.3, 24.7)	(16.7, 41.8)
LS Mean Change from Baseline (SE)	-8.1 (6.84)	9.9 (6.33)
95% C.I.	(-21.6, 5.4)	(-2.6, 22.5)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		18.1 (9.28)
95% C.I.		(-0.3, 36.4)
Corrected Hedges' g Statistic		0.83
95% C.I.		(-0.09, 1.75)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Appetite Loss Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 1		
n [1]	12	24
n [2]	2	5

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Appetite Loss Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 2		
n [1]	12	24
n [2]	2	3

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Appetite Loss Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 4		
n [1]	12	24
n [2]	0	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Protocol: 207495 Page 467 of 585
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Appetite Loss Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
PFS Follow-Up 2		
n [1]	12	24
n [2]	1	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Appetite Loss Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
PFS Follow-Up 4		
n [1]	12	24
n [2]	0	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Constipation Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 4		
n [1]	12	24
n [2]	12	22
LS Mean (SE)	26.9 (7.93)	14.9 (6.23)
95% C.I.	(11.2, 42.7)	(2.6, 27.3)
LS Mean Change from Baseline (SE)	17.7 (7.93)	5.7 (6.23)
95% C.I.	(1.9, 33.4)	(-6.7, 18.1)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-12.0 (10.39)
95% C.I.		(-32.6, 8.7)
Corrected Hedges' g Statistic		-0.41
95% C.I.		(-1.12, 0.30)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Constipation Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 7		
n [1]	12	24
n [2]	11	20
LS Mean (SE)	25.8 (8.04)	18.4 (6.33)
95% C.I.	(9.8, 41.7)	(5.9, 31.0)
LS Mean Change from Baseline (SE)	16.5 (8.04)	9.2 (6.33)
95% C.I.	(0.6, 32.5)	(-3.3, 21.8)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-7.3 (10.56)
95% C.I.		(-28.3, 13.6)
Corrected Hedges' g Statistic		-0.26
95% C.I.		(-1.00, 0.48)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Constipation Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 10		
n [1]	12	24
n [2]	12	11
LS Mean (SE)	23.8 (7.98)	18.9 (7.35)
95% C.I.	(7.9, 39.6)	(4.3, 33.4)
LS Mean Change from Baseline (SE)	14.5 (7.98)	9.6 (7.35)
95% C.I.	(-1.3, 30.4)	(-4.9, 24.2)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-4.9 (11.23)
95% C.I.		(-27.1, 17.3)
Corrected Hedges' g Statistic		-0.18
95% C.I.		(-1.00, 0.64)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Constipation Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 13		
n [1]	12	24
n [2]	12	9
LS Mean (SE)	26.6 (8.02)	17.7 (8.05)
95% C.I.	(10.6, 42.5)	(1.8, 33.6)
LS Mean Change from Baseline (SE)	17.3 (8.02)	8.5 (8.05)
95% C.I.	(1.4, 33.3)	(-7.4, 24.3)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-8.9 (11.80)
95% C.I.		(-32.2, 14.5)
Corrected Hedges' g Statistic		-0.32
95% C.I.		(-1.19, 0.55)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Constipation Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 16		
n [1]	12	24
n [2]	11	9
LS Mean (SE)	30.5 (8.16)	20.6 (7.94)
95% C.I.	(14.3, 46.7)	(4.9, 36.3)
LS Mean Change from Baseline (SE)	21.2 (8.16)	11.4 (7.94)
95% C.I.	(5.0, 37.4)	(-4.3, 27.1)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-9.9 (11.58)
95% C.I.		(-32.8, 13.1)
Corrected Hedges' g Statistic		-0.37
95% C.I.		(-1.26, 0.52)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Constipation Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 19		
n [1]	12	24
n [2]	12	8
LS Mean (SE)	25.9 (8.10)	23.9 (8.46)
95% C.I.	(9.8, 42.0)	(7.2, 40.6)
LS Mean Change from Baseline (SE)	16.7 (8.10)	14.7 (8.46)
95% C.I.	(0.6, 32.7)	(-2.0, 31.4)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-2.0 (12.08)
95% C.I.		(-25.9, 21.9)
Corrected Hedges' g Statistic		-0.07
95% C.I.		(-0.97, 0.82)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Constipation Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 22		
n [1]	12	24
n [2]	8	7
LS Mean (SE)	13.6 (8.78)	12.0 (9.04)
95% C.I.	(-3.7, 31.0)	(-5.8, 29.9)
LS Mean Change from Baseline (SE)	4.4 (8.78)	2.8 (9.04)
95% C.I.	(-13.0, 21.8)	(-15.0, 20.7)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-1.6 (12.63)
95% C.I.		(-26.6, 23.4)
Corrected Hedges' g Statistic		-0.06
95% C.I.		(-1.08, 0.95)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Constipation Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 25		
n [1]	12	24
n [2]	9	8
LS Mean (SE)	17.6 (8.78)	15.2 (8.92)
95% C.I.	(0.2, 35.0)	(-2.4, 32.9)
LS Mean Change from Baseline (SE)	8.3 (8.78)	6.0 (8.92)
95% C.I.	(-9.0, 25.7)	(-11.6, 23.6)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-2.3 (12.85)
95% C.I.		(-27.8, 23.1)
Corrected Hedges' g Statistic		-0.09
95% C.I.		(-1.04, 0.87)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Constipation Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 28		
n [1]	12	24
n [2]	7	7
LS Mean (SE)	16.3 (9.58)	4.6 (9.35)
95% C.I.	(-2.6, 35.3)	(-13.9, 23.1)
LS Mean Change from Baseline (SE)	7.1 (9.58)	-4.6 (9.35)
95% C.I.	(-11.9, 26.1)	(-23.1, 13.9)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-11.7 (13.30)
95% C.I.		(-38.0, 14.6)
Corrected Hedges' g Statistic		-0.44
95% C.I.		(-1.50, 0.62)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Constipation Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 31		
n [1]	12	24
n [2]	7	7
LS Mean (SE)	12.4 (9.99)	7.3 (9.71)
95% C.I.	(-7.4, 32.1)	(-11.9, 26.5)
LS Mean Change from Baseline (SE)	3.1 (9.99)	-1.9 (9.71)
95% C.I.	(-16.6, 22.9)	(-21.1, 17.3)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-5.1 (13.67)
95% C.I.		(-32.1, 22.0)
Corrected Hedges' g Statistic		-0.18
95% C.I.		(-1.23, 0.87)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Constipation Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 34		
n [1]	12	24
n [2]	6	6
LS Mean (SE)	9.0 (11.52)	7.7 (10.28)
95% C.I.	(-13.7, 31.7)	(-12.6, 28.0)
LS Mean Change from Baseline (SE)	-0.2 (11.52)	-1.5 (10.28)
95% C.I.	(-23.0, 22.5)	(-21.8, 18.8)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-1.3 (14.84)
95% C.I.		(-30.6, 28.0)
Corrected Hedges' g Statistic		-0.04
95% C.I.		(-1.18, 1.09)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Constipation Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 37		
n [1]	12	24
n [2]	4	6
LS Mean (SE)	38.1 (12.79)	8.7 (10.29)
95% C.I.	(12.8, 63.3)	(-11.6, 29.0)
LS Mean Change from Baseline (SE)	28.8 (12.79)	-0.6 (10.29)
95% C.I.	(3.6, 54.1)	(-20.9, 19.8)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-29.4 (16.06)
95% C.I.		(-61.1, 2.3)
Corrected Hedges' g Statistic		-1.05
95% C.I.		(-2.39, 0.30)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Constipation Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 40		
n [1]	12	24
n [2]	4	6
LS Mean (SE)	16.9 (12.42)	10.2 (10.15)
95% C.I.	(-7.6, 41.4)	(-9.8, 30.3)
LS Mean Change from Baseline (SE)	7.7 (12.42)	1.0 (10.15)
95% C.I.	(-16.8, 32.2)	(-19.1, 21.1)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-6.7 (16.68)
95% C.I.		(-39.6, 26.3)
Corrected Hedges' g Statistic		-0.24
95% C.I.		(-1.51, 1.03)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Constipation Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 43		
n [1]	12	24
n [2]	6	4
LS Mean (SE)	18.5 (11.36)	10.3 (11.20)
95% C.I.	(-3.9, 40.9)	(-11.8, 32.4)
LS Mean Change from Baseline (SE)	9.3 (11.36)	1.1 (11.20)
95% C.I.	(-13.2, 31.7)	(-21.1, 23.2)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-8.2 (16.92)
95% C.I.		(-41.6, 25.2)
Corrected Hedges' g Statistic		-0.29
95% C.I.		(-1.56, 0.99)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Constipation Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 46		
n [1]	12	24
n [2]	4	4

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Constipation Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 49		
n [1]	12	24
n [2]	4	4

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Constipation Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 52		
n [1]	12	24
n [2]	3	6

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Constipation Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 55		
n [1]	12	24
n [2]	4	3

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Constipation Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 58		
n [1]	12	24
n [2]	2	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Constipation Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 61		
n [1]	12	24
n [2]	2	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Constipation Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 64		
n [1]	12	24
n [2]	3	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Constipation Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 67		
n [1]	12	24
n [2]	2	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Constipation Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 70		
n [1]	12	24
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Constipation Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 73		
n [1]	12	24
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Constipation Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 76		
n [1]	12	24
n [2]	2	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Constipation Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 79		
n [1]	12	24
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Constipation Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 82		
n [1]	12	24
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Constipation Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 85		
n [1]	12	24
n [2]	1	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Constipation Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 88		
n [1]	12	24
n [2]	1	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Constipation Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 91		
n [1]	12	24
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Constipation Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 94		
n [1]	12	24
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Constipation Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 97		
n [1]	12	24
n [2]	1	0

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Constipation Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 100		
n [1]	12	24
n [2]	0	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Constipation Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
End of Treatment		
n [1]	12	24
n [2]	9	11
LS Mean (SE)	11.2 (8.84)	21.6 (8.70)
95% C.I.	(-6.4, 28.7)	(4.3, 38.9)
LS Mean Change from Baseline (SE)	1.9 (8.84)	12.4 (8.70)
95% C.I.	(-15.6, 19.5)	(-4.9, 29.6)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		10.4 (12.88)
95% C.I.		(-15.1, 36.0)
Corrected Hedges' g Statistic		0.36
95% C.I.		(-0.53, 1.25)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Constipation Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 1		
n [1]	12	24
n [2]	2	5

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Constipation Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 2		
n [1]	12	24
n [2]	2	3

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Constipation Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 4		
n [1]	12	24
n [2]	0	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Constipation Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
PFS Follow-Up 2		
n [1]	12	24
n [2]	1	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Protocol: 207495 Page 507 of 585
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Constipation Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
PFS Follow-Up 4		
n [1]	12	24
n [2]	0	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Diarrhoea Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 4		
n [1]	12	24
n [2]	12	22
LS Mean (SE)	8.5 (6.35)	17.4 (4.59)
95% C.I.	(-4.1, 21.1)	(8.3, 26.5)
LS Mean Change from Baseline (SE)	-8.9 (6.35)	0.0 (4.59)
95% C.I.	(-21.5, 3.7)	(-9.1, 9.1)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		9.0 (7.83)
95% C.I.		(-6.6, 24.5)
Corrected Hedges' g Statistic		0.40
95% C.I.		(-0.31, 1.11)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Diarrhoea Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 7		
n [1]	12	24
n [2]	10	21
LS Mean (SE)	-0.8 (6.53)	22.6 (4.65)
95% C.I.	(-13.8, 12.1)	(13.4, 31.8)
LS Mean Change from Baseline (SE)	-18.2 (6.53)	5.2 (4.65)
95% C.I.	(-31.2, -5.3)	(-4.0, 14.4)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		23.4 (8.02)
95% C.I.		(7.5, 39.3)
Corrected Hedges' g Statistic		1.08
95% C.I.		(0.28, 1.88)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Diarrhoea Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 10		
n [1]	12	24
n [2]	12	12
LS Mean (SE)	0.4 (6.35)	13.4 (5.39)
95% C.I.	(-12.2, 13.1)	(2.7, 24.0)
LS Mean Change from Baseline (SE)	-16.9 (6.35)	-4.0 (5.39)
95% C.I.	(-29.6, -4.3)	(-14.7, 6.6)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		12.9 (8.32)
95% C.I.		(-3.6, 29.4)
Corrected Hedges' g Statistic		0.61
95% C.I.		(-0.21, 1.43)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Diarrhoea Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 13		
n [1]	12	24
n [2]	12	10
LS Mean (SE)	6.0 (6.35)	11.7 (5.87)
95% C.I.	(-6.6, 18.6)	(0.1, 23.3)
LS Mean Change from Baseline (SE)	-11.4 (6.35)	-5.7 (5.87)
95% C.I.	(-24.0, 1.2)	(-17.3, 5.9)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		5.7 (8.64)
95% C.I.		(-11.4, 22.8)
Corrected Hedges' g Statistic		0.27
95% C.I.		(-0.58, 1.11)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Diarrhoea Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 16		
n [1]	12	24
n [2]	10	10
LS Mean (SE)	8.8 (6.53)	13.5 (6.03)
95% C.I.	(-4.1, 21.7)	(1.6, 25.4)
LS Mean Change from Baseline (SE)	-8.6 (6.53)	-3.9 (6.03)
95% C.I.	(-21.5, 4.3)	(-15.8, 8.0)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		4.7 (8.88)
95% C.I.		(-12.9, 22.3)
Corrected Hedges' g Statistic		0.23
95% C.I.		(-0.65, 1.11)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Diarrhoea Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 19		
n [1]	12	24
n [2]	12	9
LS Mean (SE)	8.7 (6.35)	10.1 (6.29)
95% C.I.	(-3.9, 21.3)	(-2.3, 22.5)
LS Mean Change from Baseline (SE)	-8.7 (6.35)	-7.3 (6.29)
95% C.I.	(-21.3, 3.9)	(-19.7, 5.1)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		1.4 (8.94)
95% C.I.		(-16.3, 19.1)
Corrected Hedges' g Statistic		0.07
95% C.I.		(-0.80, 0.93)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Diarrhoea Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 22		
n [1]	12	24
n [2]	8	8
LS Mean (SE)	3.7 (6.88)	17.1 (6.65)
95% C.I.	(-9.9, 17.4)	(3.9, 30.2)
LS Mean Change from Baseline (SE)	-13.7 (6.88)	-0.3 (6.65)
95% C.I.	(-27.3, 0.0)	(-13.4, 12.8)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		13.3 (9.55)
95% C.I.		(-5.5, 32.2)
Corrected Hedges' g Statistic		0.66
95% C.I.		(-0.35, 1.67)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Diarrhoea Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 25		
n [1]	12	24
n [2]	9	8
LS Mean (SE)	3.6 (6.94)	17.4 (6.86)
95% C.I.	(-10.2, 17.3)	(3.9, 30.9)
LS Mean Change from Baseline (SE)	-13.8 (6.94)	0.0 (6.86)
95% C.I.	(-27.6, -0.1)	(-13.5, 13.5)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		13.8 (9.75)
95% C.I.		(-5.5, 33.1)
Corrected Hedges' g Statistic		0.65
95% C.I.		(-0.33, 1.63)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Diarrhoea Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 28		
n [1]	12	24
n [2]	7	7
LS Mean (SE)	3.3 (7.56)	10.4 (7.35)
95% C.I.	(-11.7, 18.2)	(-4.1, 24.9)
LS Mean Change from Baseline (SE)	-14.1 (7.56)	-7.0 (7.35)
95% C.I.	(-29.1, 0.8)	(-21.5, 7.5)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		7.2 (10.52)
95% C.I.		(-13.6, 27.9)
Corrected Hedges' g Statistic		0.34
95% C.I.		(-0.72, 1.39)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Diarrhoea Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 31		
n [1]	12	24
n [2]	7	7
LS Mean (SE)	7.2 (7.87)	16.8 (7.67)
95% C.I.	(-8.4, 22.7)	(1.6, 31.9)
LS Mean Change from Baseline (SE)	-10.2 (7.87)	-0.6 (7.67)
95% C.I.	(-25.8, 5.3)	(-15.8, 14.5)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		9.6 (10.96)
95% C.I.		(-12.0, 31.3)
Corrected Hedges' g Statistic		0.44
95% C.I.		(-0.62, 1.50)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Diarrhoea Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 34		
n [1]	12	24
n [2]	6	6
LS Mean (SE)	0.0 (8.33)	26.1 (8.12)
95% C.I.	(-16.4, 16.5)	(10.1, 42.2)
LS Mean Change from Baseline (SE)	-17.4 (8.33)	8.7 (8.12)
95% C.I.	(-33.8, -0.9)	(-7.3, 24.8)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		26.1 (11.59)
95% C.I.		(3.2, 49.0)
Corrected Hedges' g Statistic		1.20
95% C.I.		(-0.03, 2.42)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Diarrhoea Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 37		
n [1]	12	24
n [2]	4	6
LS Mean (SE)	10.4 (9.39)	26.2 (8.17)
95% C.I.	(-8.1, 28.9)	(10.1, 42.3)
LS Mean Change from Baseline (SE)	-7.0 (9.39)	8.8 (8.17)
95% C.I.	(-25.5, 11.5)	(-7.3, 24.9)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		15.8 (12.50)
95% C.I.		(-8.9, 40.5)
Corrected Hedges' g Statistic		0.73
95% C.I.		(-0.58, 2.03)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Diarrhoea Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 40		
n [1]	12	24
n [2]	4	6
LS Mean (SE)	1.8 (9.35)	20.4 (8.17)
95% C.I.	(-16.7, 20.2)	(4.2, 36.5)
LS Mean Change from Baseline (SE)	-15.6 (9.35)	3.0 (8.17)
95% C.I.	(-34.1, 2.8)	(-13.2, 19.1)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		18.6 (12.37)
95% C.I.		(-5.8, 43.0)
Corrected Hedges' g Statistic		0.86
95% C.I.		(-0.46, 2.18)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Diarrhoea Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 43		
n [1]	12	24
n [2]	6	4
LS Mean (SE)	12.4 (8.01)	18.8 (8.91)
95% C.I.	(-3.4, 28.3)	(1.2, 36.4)
LS Mean Change from Baseline (SE)	-4.9 (8.01)	1.4 (8.91)
95% C.I.	(-20.8, 10.9)	(-16.2, 19.0)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		6.4 (12.13)
95% C.I.		(-17.6, 30.3)
Corrected Hedges' g Statistic		0.30
95% C.I.		(-0.97, 1.58)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Diarrhoea Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 46		
n [1]	12	24
n [2]	4	4

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Diarrhoea Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 49		
n [1]	12	24
n [2]	4	4

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Diarrhoea Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 52		
n [1]	12	24
n [2]	3	6

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Diarrhoea Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 55		
n [1]	12	24
n [2]	4	3

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Diarrhoea Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 58		
n [1]	12	24
n [2]	2	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Diarrhoea Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 61		
n [1]	12	24
n [2]	2	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Diarrhoea Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 64		
n [1]	12	24
n [2]	3	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Diarrhoea Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 67		
n [1]	12	24
n [2]	2	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Diarrhoea Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 70		
n [1]	12	24
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Diarrhoea Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 73		
n [1]	12	24
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Diarrhoea Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 76		
n [1]	12	24
n [2]	2	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Diarrhoea Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 79		
n [1]	12	24
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Diarrhoea Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 82		
n [1]	12	24
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Diarrhoea Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 85		
n [1]	12	24
n [2]	1	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Diarrhoea Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 88		
n [1]	12	24
n [2]	1	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Diarrhoea Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 91		
n [1]	12	24
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Diarrhoea Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 94		
n [1]	12	24
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Diarrhoea Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 97		
n [1]	12	24
n [2]	1	0

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Diarrhoea Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 100		
n [1]	12	24
n [2]	0	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Diarrhoea Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
End of Treatment		
n [1]	12	24
n [2]	9	10
LS Mean (SE)	10.5 (7.11)	13.8 (6.74)
95% C.I.	(-3.6, 24.6)	(0.4, 27.1)
LS Mean Change from Baseline (SE)	-6.9 (7.11)	-3.6 (6.74)
95% C.I.	(-21.0, 7.2)	(-17.0, 9.7)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		3.3 (9.94)
95% C.I.		(-16.4, 22.9)
Corrected Hedges' g Statistic		0.15
95% C.I.		(-0.76, 1.05)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Diarrhoea Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 1		
n [1]	12	24
n [2]	2	5

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Diarrhoea Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 2		
n [1]	12	24
n [2]	2	3

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Diarrhoea Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 4		
n [1]	12	24
n [2]	0	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Diarrhoea Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
PFS Follow-Up 2		
n [1]	12	24
n [2]	1	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Diarrhoea Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
PFS Follow-Up 4		
n [1]	12	24
n [2]	0	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Financial Difficulties Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 4		
n [1]	12	25
n [2]	12	23
LS Mean (SE)	22.5 (8.13)	22.5 (5.75)
95% C.I.	(6.4, 38.5)	(11.1, 33.9)
LS Mean Change from Baseline (SE)	-1.5 (8.13)	-1.4 (5.75)
95% C.I.	(-17.6, 14.6)	(-12.8, 9.9)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		0.0 (10.23)
95% C.I.		(-20.2, 20.3)
Corrected Hedges' g Statistic		0.00
95% C.I.		(-0.70, 0.70)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Financial Difficulties Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 7		
n [1]	12	25
n [2]	11	21
LS Mean (SE)	18.8 (8.25)	19.5 (6.03)
95% C.I.	(2.4, 35.1)	(7.6, 31.4)
LS Mean Change from Baseline (SE)	-5.2 (8.25)	-4.4 (6.03)
95% C.I.	(-21.5, 11.2)	(-16.3, 7.5)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		0.8 (10.57)
95% C.I.		(-20.1, 21.7)
Corrected Hedges' g Statistic		0.03
95% C.I.		(-0.70, 0.76)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Financial Difficulties Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 10		
n [1]	12	25
n [2]	12	12
LS Mean (SE)	22.3 (8.18)	26.2 (7.14)
95% C.I.	(6.1, 38.5)	(12.1, 40.3)
LS Mean Change from Baseline (SE)	-1.6 (8.18)	2.3 (7.14)
95% C.I.	(-17.8, 14.6)	(-11.8, 16.4)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		3.9 (11.22)
95% C.I.		(-18.2, 26.1)
Corrected Hedges' g Statistic		0.14
95% C.I.		(-0.66, 0.94)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Financial Difficulties Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 13		
n [1]	12	25
n [2]	12	10
LS Mean (SE)	14.8 (8.19)	20.1 (7.77)
95% C.I.	(-1.5, 31.0)	(4.8, 35.5)
LS Mean Change from Baseline (SE)	-9.2 (8.19)	-3.8 (7.77)
95% C.I.	(-25.4, 7.1)	(-19.1, 11.5)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		5.4 (11.58)
95% C.I.		(-17.5, 28.3)
Corrected Hedges' g Statistic		0.19
95% C.I.		(-0.65, 1.03)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Financial Difficulties Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 16		
n [1]	12	25
n [2]	10	10
LS Mean (SE)	22.4 (8.46)	25.4 (8.15)
95% C.I.	(5.7, 39.2)	(9.3, 41.5)
LS Mean Change from Baseline (SE)	-1.5 (8.46)	1.5 (8.15)
95% C.I.	(-18.2, 15.3)	(-14.6, 17.6)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		3.0 (12.12)
95% C.I.		(-21.0, 26.9)
Corrected Hedges' g Statistic		0.11
95% C.I.		(-0.77, 0.99)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Financial Difficulties Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 19		
n [1]	12	25
n [2]	12	8
LS Mean (SE)	19.7 (8.24)	20.6 (8.69)
95% C.I.	(3.4, 36.0)	(3.4, 37.7)
LS Mean Change from Baseline (SE)	-4.2 (8.24)	-3.3 (8.69)
95% C.I.	(-20.5, 12.1)	(-20.5, 13.8)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		0.9 (12.31)
95% C.I.		(-23.5, 25.2)
Corrected Hedges' g Statistic		0.03
95% C.I.		(-0.86, 0.93)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Financial Difficulties Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 22		
n [1]	12	25
n [2]	8	8
LS Mean (SE)	26.0 (8.99)	27.2 (8.77)
95% C.I.	(8.3, 43.8)	(9.9, 44.5)
LS Mean Change from Baseline (SE)	2.1 (8.99)	3.2 (8.77)
95% C.I.	(-15.6, 19.9)	(-14.1, 20.6)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		1.1 (12.69)
95% C.I.		(-24.0, 26.2)
Corrected Hedges' g Statistic		0.04
95% C.I.		(-0.94, 1.02)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Financial Difficulties Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 25		
n [1]	12	25
n [2]	9	8
LS Mean (SE)	24.9 (9.04)	15.9 (8.93)
95% C.I.	(7.0, 42.7)	(-1.7, 33.5)
LS Mean Change from Baseline (SE)	1.0 (9.04)	-8.0 (8.93)
95% C.I.	(-16.9, 18.8)	(-25.7, 9.6)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-9.0 (12.82)
95% C.I.		(-34.3, 16.4)
Corrected Hedges' g Statistic		-0.32
95% C.I.		(-1.28, 0.63)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Financial Difficulties Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 28		
n [1]	12	25
n [2]	7	7
LS Mean (SE)	16.0 (9.80)	16.9 (9.60)
95% C.I.	(-3.3, 35.4)	(-2.1, 35.8)
LS Mean Change from Baseline (SE)	-7.9 (9.80)	-7.1 (9.60)
95% C.I.	(-27.2, 11.5)	(-26.0, 11.9)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		0.8 (13.92)
95% C.I.		(-26.7, 28.3)
Corrected Hedges' g Statistic		0.03
95% C.I.		(-1.02, 1.08)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Financial Difficulties Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 31		
n [1]	12	25
n [2]	7	7
LS Mean (SE)	16.2 (10.12)	17.8 (9.88)
95% C.I.	(-3.8, 36.2)	(-1.7, 37.4)
LS Mean Change from Baseline (SE)	-7.7 (10.12)	-6.1 (9.88)
95% C.I.	(-27.7, 12.3)	(-25.6, 13.4)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		1.6 (14.28)
95% C.I.		(-26.6, 29.8)
Corrected Hedges' g Statistic		0.06
95% C.I.		(-0.99, 1.10)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Financial Difficulties Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 34		
n [1]	12	25
n [2]	6	6
LS Mean (SE)	22.3 (10.67)	17.5 (10.50)
95% C.I.	(1.3, 43.4)	(-3.2, 38.2)
LS Mean Change from Baseline (SE)	-1.6 (10.67)	-6.4 (10.50)
95% C.I.	(-22.6, 19.5)	(-27.1, 14.3)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-4.8 (15.04)
95% C.I.		(-34.5, 24.9)
Corrected Hedges' g Statistic		-0.17
95% C.I.		(-1.31, 0.96)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Financial Difficulties Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 37		
n [1]	12	25
n [2]	4	6
LS Mean (SE)	23.8 (12.29)	17.2 (10.54)
95% C.I.	(-0.5, 48.0)	(-3.6, 38.0)
LS Mean Change from Baseline (SE)	-0.2 (12.29)	-6.7 (10.54)
95% C.I.	(-24.4, 24.1)	(-27.5, 14.1)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-6.6 (16.17)
95% C.I.		(-38.5, 25.3)
Corrected Hedges' g Statistic		-0.23
95% C.I.		(-1.50, 1.04)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Financial Difficulties Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 40		
n [1]	12	25
n [2]	4	6
LS Mean (SE)	25.2 (12.18)	18.3 (10.47)
95% C.I.	(1.2, 49.2)	(-2.3, 39.0)
LS Mean Change from Baseline (SE)	1.3 (12.18)	-5.6 (10.47)
95% C.I.	(-22.7, 25.3)	(-26.3, 15.1)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-6.9 (16.13)
95% C.I.		(-38.7, 24.9)
Corrected Hedges' g Statistic		-0.25
95% C.I.		(-1.52, 1.02)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Financial Difficulties Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 43		
n [1]	12	25
n [2]	6	4
LS Mean (SE)	24.9 (10.19)	27.5 (11.87)
95% C.I.	(4.8, 45.0)	(4.1, 50.9)
LS Mean Change from Baseline (SE)	1.0 (10.19)	3.5 (11.87)
95% C.I.	(-19.2, 21.1)	(-19.9, 26.9)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		2.6 (15.80)
95% C.I.		(-28.6, 33.8)
Corrected Hedges' g Statistic		0.10
95% C.I.		(-1.17, 1.36)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Financial Difficulties Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 46		
n [1]	12	25
n [2]	4	4

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Financial Difficulties Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 49		
n [1]	12	25
n [2]	4	4

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Financial Difficulties Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 52		
n [1]	12	25
n [2]	3	6

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Financial Difficulties Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 55		
n [1]	12	25
n [2]	4	3

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Financial Difficulties Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 58		
n [1]	12	25
n [2]	2	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Financial Difficulties Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 61		
n [1]	12	25
n [2]	2	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Financial Difficulties Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 64		
n [1]	12	25
n [2]	3	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Financial Difficulties Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 67		
n [1]	12	25
n [2]	2	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Financial Difficulties Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 70		
n [1]	12	25
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Financial Difficulties Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 73		
n [1]	12	25
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Financial Difficulties Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 76		
n [1]	12	25
n [2]	2	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Financial Difficulties Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 79		
n [1]	12	25
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Financial Difficulties Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 82		
n [1]	12	25
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Financial Difficulties Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 85		
n [1]	12	25
n [2]	1	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Financial Difficulties Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 88		
n [1]	12	25
n [2]	1	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Financial Difficulties Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 91		
n [1]	12	25
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Financial Difficulties Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 94		
n [1]	12	25
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Financial Difficulties Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 97		
n [1]	12	25
n [2]	1	0

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Financial Difficulties Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 100		
n [1]	12	25
n [2]	0	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Financial Difficulties Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
End of Treatment		
n [1]	12	25
n [2]	9	11
LS Mean (SE)	21.8 (9.08)	31.8 (8.21)
95% C.I.	(3.9, 39.8)	(15.6, 48.1)
LS Mean Change from Baseline (SE)	-2.1 (9.08)	7.9 (8.21)
95% C.I.	(-20.0, 15.9)	(-8.3, 24.2)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		10.0 (12.58)
95% C.I.		(-14.9, 34.9)
Corrected Hedges' g Statistic		0.35
95% C.I.		(-0.54, 1.24)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Financial Difficulties Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 1		
n [1]	12	25
n [2]	2	4

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Financial Difficulties Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 2		
n [1]	12	25
n [2]	2	3

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Financial Difficulties Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 4		
n [1]	12	25
n [2]	0	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Financial Difficulties Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
PFS Follow-Up 2		
n [1]	12	25
n [2]	1	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_c30_dom.sas 14MAR2023 06:05

Table 4.003110
Analysis of EORTC QLQ-C30 Domain Scores based on
Mixed Model for Repeated Measures (MMRM)

Domain: Financial Difficulties Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
PFS Follow-Up 4		
n [1]	12	25
n [2]	0	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

Protocol: 207495 Page 1 of 15
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.056110
Summary of EORTC QLQ-C30 Time to first Improvement
(Up to and including Last Follow-Up)

Item Score: Global Health Status Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Improved (event)	8 (53%)	10 (34%)
Censored, follow-up ended	4 (27%)	12 (41%)
Censored, follow-up ongoing	3 (20%)	7 (24%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	1.5 (0.7, 2.9)	1.0 (0.7, 2.4)
Median (95% CI)	3.6 (0.7, -)	- (1.0, -)
3rd Quartile (95% CI)	- (2.9, -)	- (-, -)
Log-Rank P-value [2]		0.9858
Inverse Hazard Ratio (95% CI) [3]		1.00 (0.27, 3.67)
P-value [3]		0.9995

Note: If a subject has not improved, they are censored at the latest assessment or at randomization if no assessments.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Inverse hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. Inverse hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_eortc_tfi.sas 13MAR2023 14:00

Table 4.056110
Summary of EORTC QLQ-C30 Time to first Improvement
(Up to and including Last Follow-Up)

Item Score: Physical Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Improved (event)	7 (47%)	10 (34%)
Censored, follow-up ended	5 (33%)	12 (41%)
Censored, follow-up ongoing	3 (20%)	7 (24%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	1.9 (0.7, 3.5)	1.4 (0.7, 5.7)
Median (95% CI)	4.5 (0.8, -)	5.7 (1.4, -)
3rd Quartile (95% CI)	- (3.5, -)	- (5.7, -)
Log-Rank P-value [2]		0.4893
Inverse Hazard Ratio (95% CI) [3]		0.62 (0.16, 2.50)
P-value [3]		0.5046

Note: If a subject has not improved, they are censored at the latest assessment or at randomization if no assessments.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Inverse hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. Inverse hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_eortc_tfi.sas 13MAR2023 14:00

Table 4.056110
Summary of EORTC QLQ-C30 Time to first Improvement
(Up to and including Last Follow-Up)

Item Score: Role Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Improved (event)	9 (60%)	5 (17%)
Censored, follow-up ended	4 (27%)	15 (52%)
Censored, follow-up ongoing	2 (13%)	9 (31%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	0.8 (0.8, 2.1)	- (0.7, -)
Median (95% CI)	2.5 (0.8, 4.4)	- (-, -)
3rd Quartile (95% CI)	4.4 (2.1, -)	- (-, -)
Log-Rank P-value [2]		0.7267
Inverse Hazard Ratio (95% CI) [3]		1.28 (0.33, 4.94)
P-value [3]		0.7215

Note: If a subject has not improved, they are censored at the latest assessment or at randomization if no assessments.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Inverse hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. Inverse hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_eortc_tfi.sas 13MAR2023 14:00

Table 4.056110
Summary of EORTC QLQ-C30 Time to first Improvement
(Up to and including Last Follow-Up)

Item Score: Emotional Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Improved (event)	8 (53%)	10 (34%)
Censored, follow-up ended	4 (27%)	10 (34%)
Censored, follow-up ongoing	3 (20%)	9 (31%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	0.7 (0.7, 2.2)	1.4 (0.7, 3.0)
Median (95% CI)	2.6 (0.7, -)	5.0 (1.7, -)
3rd Quartile (95% CI)	- (2.2, -)	- (5.0, -)
Log-Rank P-value [2]		0.7448
Inverse Hazard Ratio (95% CI) [3]		0.78 (0.19, 3.26)
P-value [3]		0.7323

Note: If a subject has not improved, they are censored at the latest assessment or at randomization if no assessments.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Inverse hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. Inverse hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_eortc_tfi.sas 13MAR2023 14:00

Table 4.056110
Summary of EORTC QLQ-C30 Time to first Improvement
(Up to and including Last Follow-Up)

Item Score: Cognitive Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Improved (event)	6 (40%)	12 (41%)
Censored, follow-up ended	5 (33%)	11 (38%)
Censored, follow-up ongoing	4 (27%)	6 (21%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	0.8 (0.7, 2.1)	1.0 (0.7, 1.4)
Median (95% CI)	- (0.7, -)	6.2 (1.0, -)
3rd Quartile (95% CI)	- (2.1, -)	- (6.2, -)
Log-Rank P-value [2]		0.2401
Inverse Hazard Ratio (95% CI) [3]		0.46 (0.12, 1.84)
P-value [3]		0.2743

Note: If a subject has not improved, they are censored at the latest assessment or at randomization if no assessments.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Inverse hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. Inverse hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_eortc_tfi.sas 13MAR2023 14:00

Table 4.056110
Summary of EORTC QLQ-C30 Time to first Improvement
(Up to and including Last Follow-Up)

Item Score: Social Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Improved (event)	8 (53%)	10 (34%)
Censored, follow-up ended	4 (27%)	11 (38%)
Censored, follow-up ongoing	3 (20%)	8 (28%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	1.1 (0.7, 2.2)	1.4 (0.7, 4.0)
Median (95% CI)	2.5 (0.7, -)	4.0 (1.4, -)
3rd Quartile (95% CI)	- (2.2, -)	- (-, -)
Log-Rank P-value [2]		0.2777
Inverse Hazard Ratio (95% CI) [3]		2.08 (0.54, 8.02)
P-value [3]		0.2869

Note: If a subject has not improved, they are censored at the latest assessment or at randomization if no assessments.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Inverse hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. Inverse hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_eortc_tfi.sas 13MAR2023 14:00

Table 4.056110
Summary of EORTC QLQ-C30 Time to first Improvement
(Up to and including Last Follow-Up)

Item Score: Fatigue Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Improved (event)	8 (53%)	13 (45%)
Censored, follow-up ended	5 (33%)	11 (38%)
Censored, follow-up ongoing	2 (13%)	5 (17%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	0.8 (0.7, 1.4)	0.8 (0.7, 1.9)
Median (95% CI)	1.4 (0.8, -)	2.0 (0.8, -)
3rd Quartile (95% CI)	4.2 (0.9, -)	9.9 (2.0, -)
Log-Rank P-value [2]		0.7622
Inverse Hazard Ratio (95% CI) [3]		0.81 (0.23, 2.84)
P-value [3]		0.7437

Note: If a subject has not improved, they are censored at the latest assessment or at randomization if no assessments.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Inverse hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. Inverse hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_eortc_tfi.sas 13MAR2023 14:00

Protocol: 207495 Page 8 of 15
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.056110
Summary of EORTC QLQ-C30 Time to first Improvement
(Up to and including Last Follow-Up)

Item Score: Nausea and vomiting Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Improved (event)	2 (13%)	3 (10%)
Censored, follow-up ended	5 (33%)	14 (48%)
Censored, follow-up ongoing	8 (53%)	12 (41%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (0.7, -)	- (0.8, -)
Median (95% CI)	- (1.1, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		0.9338
Inverse Hazard Ratio (95% CI) [3]		1.08 (0.17, 7.04)
P-value [3]		0.9338

Note: If a subject has not improved, they are censored at the latest assessment or at randomization if no assessments.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Inverse hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. Inverse hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_eortc_tfi.sas 13MAR2023 14:00

Table 4.056110
Summary of EORTC QLQ-C30 Time to first Improvement
(Up to and including Last Follow-Up)

Item Score: Pain Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Improved (event)	9 (60%)	13 (45%)
Censored, follow-up ended	4 (27%)	11 (38%)
Censored, follow-up ongoing	2 (13%)	5 (17%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	0.8 (0.7, 1.4)	0.8 (0.7, 1.6)
Median (95% CI)	1.4 (0.7, 6.3)	2.7 (1.4, -)
3rd Quartile (95% CI)	6.3 (1.4, -)	- (2.8, -)
Log-Rank P-value [2]		0.5094
Inverse Hazard Ratio (95% CI) [3]		1.44 (0.47, 4.39)
P-value [3]		0.5256

Note: If a subject has not improved, they are censored at the latest assessment or at randomization if no assessments.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Inverse hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. Inverse hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_eortc_tfi.sas 13MAR2023 14:00

Table 4.056110
Summary of EORTC QLQ-C30 Time to first Improvement
(Up to and including Last Follow-Up)

Item Score: Dyspnoea Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Improved (event)	4 (27%)	7 (24%)
Censored, follow-up ended	6 (40%)	10 (34%)
Censored, follow-up ongoing	5 (33%)	12 (41%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	0.8 (0.7, -)	1.7 (0.8, -)
Median (95% CI)	- (0.8, -)	- (1.7, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		0.2789
Inverse Hazard Ratio (95% CI) [3]		0.42 (0.08, 2.20)
P-value [3]		0.3075

Note: If a subject has not improved, they are censored at the latest assessment or at randomization if no assessments.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Inverse hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. Inverse hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.

Protocol: 207495 Page 11 of 15
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.056110
Summary of EORTC QLQ-C30 Time to first Improvement
(Up to and including Last Follow-Up)

Item Score: Insomnia Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Improved (event)	7 (47%)	6 (21%)
Censored, follow-up ended	5 (33%)	13 (45%)
Censored, follow-up ongoing	3 (20%)	10 (34%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	0.8 (0.7, 1.7)	1.1 (0.7, -)
Median (95% CI)	1.7 (0.7, -)	- (1.1, -)
3rd Quartile (95% CI)	- (1.5, -)	- (-, -)
Log-Rank P-value [2]		0.4467
Inverse Hazard Ratio (95% CI) [3]		1.74 (0.41, 7.36)
P-value [3]		0.4512

Note: If a subject has not improved, they are censored at the latest assessment or at randomization if no assessments.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Inverse hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. Inverse hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_eortc_tfi.sas 13MAR2023 14:00

Protocol: 207495 Page 12 of 15
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.056110
Summary of EORTC QLQ-C30 Time to first Improvement
(Up to and including Last Follow-Up)

Item Score: Appetite Loss Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Improved (event)	4 (27%)	7 (24%)
Censored, follow-up ended	6 (40%)	14 (48%)
Censored, follow-up ongoing	5 (33%)	8 (28%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	1.1 (0.7, -)	2.8 (0.7, -)
Median (95% CI)	- (0.7, -)	- (2.8, -)
3rd Quartile (95% CI)	- (-, -)	- (12.0, -)
Log-Rank P-value [2]		0.6819
Inverse Hazard Ratio (95% CI) [3]		1.33 (0.34, 5.14)
P-value [3]		0.6827

Note: If a subject has not improved, they are censored at the latest assessment or at randomization if no assessments.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Inverse hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. Inverse hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_eortc_tfi.sas 13MAR2023 14:00

Table 4.056110
Summary of EORTC QLQ-C30 Time to first Improvement
(Up to and including Last Follow-Up)

Item Score: Constipation Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Improved (event)	1 (7%)	8 (28%)
Censored, follow-up ended	5 (33%)	12 (41%)
Censored, follow-up ongoing	9 (60%)	9 (31%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (1.4, -)	1.4 (0.7, -)
Median (95% CI)	- (-, -)	- (1.4, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		0.2143
Inverse Hazard Ratio (95% CI) [3]		0.28 (0.03, 2.37)
P-value [3]		0.2440

Note: If a subject has not improved, they are censored at the latest assessment or at randomization if no assessments.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Inverse hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. Inverse hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_eortc_tfi.sas 13MAR2023 14:00

Protocol: 207495 Page 14 of 15
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.056110
Summary of EORTC QLQ-C30 Time to first Improvement
(Up to and including Last Follow-Up)

Item Score: Diarrhoea Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Improved (event)	5 (33%)	6 (21%)
Censored, follow-up ended	5 (33%)	14 (48%)
Censored, follow-up ongoing	5 (33%)	9 (31%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	1.1 (0.8, -)	6.4 (0.8, -)
Median (95% CI)	- (0.8, -)	- (6.4, -)
3rd Quartile (95% CI)	- (-, -)	- (12.3, -)
Log-Rank P-value [2]		0.8285
Inverse Hazard Ratio (95% CI) [3]		0.82 (0.16, 4.25)
P-value [3]		0.8151

Note: If a subject has not improved, they are censored at the latest assessment or at randomization if no assessments.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Inverse hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. Inverse hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_eortc_tfi.sas 13MAR2023 14:00

Protocol: 207495 Page 15 of 15
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.056110
Summary of EORTC QLQ-C30 Time to first Improvement
(Up to and including Last Follow-Up)

Item Score: Financial Difficulties Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Improved (event)	3 (20%)	13 (45%)
Censored, follow-up ended	5 (33%)	11 (38%)
Censored, follow-up ongoing	7 (47%)	5 (17%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	12.4 (0.8, -)	1.0 (0.7, 1.4)
Median (95% CI)	- (0.8, -)	1.5 (1.0, -)
3rd Quartile (95% CI)	- (12.4, -)	- (1.6, -)
Log-Rank P-value [2]		0.0665
Inverse Hazard Ratio (95% CI) [3]		0.17 (0.02, 1.41)
P-value [3]		0.1004

Note: If a subject has not improved, they are censored at the latest assessment or at randomization if no assessments.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Inverse hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. Inverse hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_eortc_tfi.sas 13MAR2023 14:00

Protocol: 207495 Page 1 of 15
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.053110
Summary of EORTC QLQ-C30 Time to first Deterioration 1
(Up to and including Last Follow-Up)

Item Score: Global Health Status Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated or Died (event)	12 (80%)	23 (79%)
Censored, follow-up ended	1 (7%)	0
Censored, follow-up ongoing	2 (13%)	6 (21%)
Event Summary		
Deterioration	9 (60%)	16 (55%)
Death	3 (20%)	7 (24%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	0.8 (0.8, 2.1)	1.0 (0.8, 1.4)
Median (95% CI)	2.1 (0.8, 8.2)	1.7 (1.1, 3.6)
3rd Quartile (95% CI)	8.2 (1.6, 13.5)	5.7 (2.3, 9.5)
Log-Rank P-value [2]		0.8635
Hazard Ratio (95% CI) [3]		1.09 (0.43, 2.75)
P-value [3]		0.8543

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessments.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_eortc_tfd1.sas 13MAR2023 14:00

Table 4.053110
Summary of EORTC QLQ-C30 Time to first Deterioration 1
(Up to and including Last Follow-Up)

Item Score: Physical Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated or Died (event)	9 (60%)	22 (76%)
Censored, follow-up ended	1 (7%)	0
Censored, follow-up ongoing	5 (33%)	7 (24%)
Event Summary		
Deterioration	8 (53%)	14 (48%)
Death	1 (7%)	8 (28%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	1.1 (0.8, 2.4)	1.1 (0.8, 1.7)
Median (95% CI)	2.4 (0.8, -)	2.3 (1.2, 5.1)
3rd Quartile (95% CI)	- (2.3, -)	5.7 (4.0, -)
Log-Rank P-value [2]		0.5566
Hazard Ratio (95% CI) [3]		0.75 (0.29, 1.96)
P-value [3]		0.5576

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessments.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_eortc_tfd1.sas 13MAR2023 14:00

Table 4.053110
Summary of EORTC QLQ-C30 Time to first Deterioration 1
(Up to and including Last Follow-Up)

Item Score: Role Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated or Died (event)	9 (60%)	22 (76%)
Censored, follow-up ended	1 (7%)	0
Censored, follow-up ongoing	5 (33%)	7 (24%)
Event Summary		
Deterioration	8 (53%)	13 (45%)
Death	1 (7%)	9 (31%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	0.8 (0.7, 1.4)	1.0 (0.7, 1.4)
Median (95% CI)	1.4 (0.8, -)	1.6 (1.1, 3.6)
3rd Quartile (95% CI)	- (1.1, -)	9.5 (2.1, 18.7)
Log-Rank P-value [2]		0.4033
Hazard Ratio (95% CI) [3]		0.63 (0.22, 1.81)
P-value [3]		0.3961

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessments.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_eortc_tfd1.sas 13MAR2023 14:00

Protocol: 207495 Page 4 of 15
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.053110
Summary of EORTC QLQ-C30 Time to first Deterioration 1
(Up to and including Last Follow-Up)

Item Score: Emotional Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated or Died (event)	7 (47%)	25 (86%)
Censored, follow-up ended	1 (7%)	0
Censored, follow-up ongoing	7 (47%)	4 (14%)
Event Summary		
Deterioration	5 (33%)	15 (52%)
Death	2 (13%)	10 (34%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	1.4 (0.7, 13.5)	1.1 (0.8, 1.6)
Median (95% CI)	13.5 (1.1, -)	2.1 (1.3, 5.1)
3rd Quartile (95% CI)	- (2.9, -)	5.7 (3.5, 13.0)
Log-Rank P-value [2]		0.8270
Hazard Ratio (95% CI) [3]		1.13 (0.37, 3.53)
P-value [3]		0.8271

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessments.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_eortc_tfd1.sas 13MAR2023 14:00

Protocol: 207495 Page 5 of 15
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.053110
Summary of EORTC QLQ-C30 Time to first Deterioration 1
(Up to and including Last Follow-Up)

Item Score: Cognitive Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated or Died (event)	8 (53%)	21 (72%)
Censored, follow-up ended	1 (7%)	0
Censored, follow-up ongoing	6 (40%)	8 (28%)
Event Summary		
Deterioration	7 (47%)	11 (38%)
Death	1 (7%)	10 (34%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	1.1 (0.7, 4.2)	1.1 (0.7, 1.5)
Median (95% CI)	4.2 (0.8, -)	1.7 (1.2, 7.1)
3rd Quartile (95% CI)	- (1.4, -)	9.5 (4.9, -)
Log-Rank P-value [2]		0.6437
Hazard Ratio (95% CI) [3]		0.79 (0.27, 2.29)
P-value [3]		0.6648

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessments.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_eortc_tfd1.sas 13MAR2023 14:00

Protocol: 207495 Page 6 of 15
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.053110
Summary of EORTC QLQ-C30 Time to first Deterioration 1
(Up to and including Last Follow-Up)

Item Score: Social Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated or Died (event)	10 (67%)	23 (79%)
Censored, follow-up ended	1 (7%)	0
Censored, follow-up ongoing	4 (27%)	6 (21%)
Event Summary		
Deterioration	7 (47%)	14 (48%)
Death	3 (20%)	9 (31%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	1.1 (0.7, 2.1)	1.1 (0.8, 1.6)
Median (95% CI)	2.1 (0.8, 13.5)	2.0 (1.1, 5.1)
3rd Quartile (95% CI)	13.5 (1.6, -)	5.7 (2.3, -)
Log-Rank P-value [2]		0.9477
Hazard Ratio (95% CI) [3]		0.97 (0.38, 2.48)
P-value [3]		0.9562

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessments.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_eortc_tfd1.sas 13MAR2023 14:00

Protocol: 207495 Page 7 of 15
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.053110
Summary of EORTC QLQ-C30 Time to first Deterioration 1
(Up to and including Last Follow-Up)

Item Score: Fatigue Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated or Died (event)	9 (60%)	25 (86%)
Censored, follow-up ended	1 (7%)	0
Censored, follow-up ongoing	5 (33%)	4 (14%)
Event Summary		
Deterioration	7 (47%)	18 (62%)
Death	2 (13%)	7 (24%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	1.1 (0.7, 2.1)	0.9 (0.7, 1.2)
Median (95% CI)	2.1 (0.8, -)	1.5 (1.0, 2.8)
3rd Quartile (95% CI)	13.5 (1.4, -)	4.9 (1.7, 18.7)
Log-Rank P-value [2]		0.7055
Hazard Ratio (95% CI) [3]		0.83 (0.31, 2.23)
P-value [3]		0.7058

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessments.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_eortc_tfd1.sas 13MAR2023 14:00

Table 4.053110
Summary of EORTC QLQ-C30 Time to first Deterioration 1
(Up to and including Last Follow-Up)

Item Score: Nausea and vomiting Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated or Died (event)	8 (53%)	19 (66%)
Censored, follow-up ended	2 (13%)	0
Censored, follow-up ongoing	5 (33%)	10 (34%)
Event Summary		
Deterioration	5 (33%)	7 (24%)
Death	3 (20%)	12 (41%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	1.1 (0.7, 9.1)	1.1 (0.9, 4.2)
Median (95% CI)	9.1 (0.8, -)	5.1 (1.2, 9.5)
3rd Quartile (95% CI)	13.5 (9.1, -)	18.7 (5.7, -)
Log-Rank P-value [2]		0.1391
Hazard Ratio (95% CI) [3]		0.41 (0.12, 1.39)
P-value [3]		0.1503

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessments.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_eortc_tfd1.sas 13MAR2023 14:00

Table 4.053110
Summary of EORTC QLQ-C30 Time to first Deterioration 1
(Up to and including Last Follow-Up)

Item Score: Pain Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated or Died (event)	8 (53%)	21 (72%)
Censored, follow-up ended	2 (13%)	0
Censored, follow-up ongoing	5 (33%)	8 (28%)
Event Summary		
Deterioration	6 (40%)	11 (38%)
Death	2 (13%)	10 (34%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	1.1 (0.7, 7.0)	1.0 (0.9, 1.4)
Median (95% CI)	7.0 (0.8, -)	2.2 (1.1, 5.1)
3rd Quartile (95% CI)	9.1 (7.0, -)	9.5 (2.7, -)
Log-Rank P-value [2]		0.6540
Hazard Ratio (95% CI) [3]		0.78 (0.26, 2.32)
P-value [3]		0.6547

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessments.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_eortc_tfd1.sas 13MAR2023 14:00

Protocol: 207495 Page 10 of 15
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.053110
Summary of EORTC QLQ-C30 Time to first Deterioration 1
(Up to and including Last Follow-Up)

Item Score: Dyspnoea Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated or Died (event)	8 (53%)	21 (72%)
Censored, follow-up ended	1 (7%)	0
Censored, follow-up ongoing	6 (40%)	8 (28%)
Event Summary		
Deterioration	7 (47%)	10 (34%)
Death	1 (7%)	11 (38%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	1.1 (0.7, 4.2)	1.1 (0.7, 2.9)
Median (95% CI)	4.2 (0.8, -)	4.9 (1.2, 5.7)
3rd Quartile (95% CI)	- (2.9, -)	9.5 (5.1, -)
Log-Rank P-value [2]		0.3947
Hazard Ratio (95% CI) [3]		0.64 (0.23, 1.79)
P-value [3]		0.3974

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessments.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_eortc_tfd1.sas 13MAR2023 14:00

Protocol: 207495 Page 11 of 15
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.053110
Summary of EORTC QLQ-C30 Time to first Deterioration 1
(Up to and including Last Follow-Up)

Item Score: Insomnia Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated or Died (event)	7 (47%)	24 (83%)
Censored, follow-up ended	2 (13%)	0
Censored, follow-up ongoing	6 (40%)	5 (17%)
Event Summary		
Deterioration	5 (33%)	13 (45%)
Death	2 (13%)	11 (38%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	1.5 (0.7, 13.5)	1.1 (0.8, 1.4)
Median (95% CI)	13.5 (1.1, -)	1.7 (1.2, 5.7)
3rd Quartile (95% CI)	- (4.2, -)	6.6 (2.9, 22.9)
Log-Rank P-value [2]		0.9591
Hazard Ratio (95% CI) [3]		0.97 (0.33, 2.81)
P-value [3]		0.9501

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessments.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_eortc_tfd1.sas 13MAR2023 14:00

Protocol: 207495 Page 12 of 15
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.053110
Summary of EORTC QLQ-C30 Time to first Deterioration 1
(Up to and including Last Follow-Up)

Item Score: Appetite Loss Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated or Died (event)	7 (47%)	22 (76%)
Censored, follow-up ended	2 (13%)	0
Censored, follow-up ongoing	6 (40%)	7 (24%)
Event Summary		
Deterioration	4 (27%)	11 (38%)
Death	3 (20%)	11 (38%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	4.2 (0.7, 9.5)	1.0 (0.8, 1.6)
Median (95% CI)	9.5 (1.1, -)	2.8 (1.1, 6.8)
3rd Quartile (95% CI)	13.5 (9.1, -)	7.6 (5.5, -)
Log-Rank P-value [2]		0.4100
Hazard Ratio (95% CI) [3]		1.59 (0.53, 4.78)
P-value [3]		0.4133

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessments.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_eortc_tfd1.sas 13MAR2023 14:00

Protocol: 207495 Page 13 of 15
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.053110
Summary of EORTC QLQ-C30 Time to first Deterioration 1
(Up to and including Last Follow-Up)

Item Score: Constipation Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated or Died (event)	10 (67%)	18 (62%)
Censored, follow-up ended	1 (7%)	0
Censored, follow-up ongoing	4 (27%)	11 (38%)
Event Summary		
Deterioration	9 (60%)	6 (21%)
Death	1 (7%)	12 (41%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	1.1 (0.7, 1.6)	1.1 (0.9, 4.5)
Median (95% CI)	1.6 (0.9, 4.2)	5.7 (1.7, 18.7)
3rd Quartile (95% CI)	4.2 (1.5, -)	18.7 (5.7, -)
Log-Rank P-value [2]		0.2089
Hazard Ratio (95% CI) [3]		0.50 (0.17, 1.49)
P-value [3]		0.2149

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessments.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_eortc_tfd1.sas 13MAR2023 14:00

Protocol: 207495 Page 14 of 15
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.053110
Summary of EORTC QLQ-C30 Time to first Deterioration 1
(Up to and including Last Follow-Up)

Item Score: Diarrhoea Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated or Died (event)	5 (33%)	20 (69%)
Censored, follow-up ended	2 (13%)	0
Censored, follow-up ongoing	8 (53%)	9 (31%)
Event Summary		
Deterioration	2 (13%)	8 (28%)
Death	3 (20%)	12 (41%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	9.5 (0.7, -)	1.2 (0.7, 2.1)
Median (95% CI)	13.5 (2.9, -)	5.0 (1.6, 6.6)
3rd Quartile (95% CI)	- (13.5, -)	9.5 (5.1, -)
Log-Rank P-value [2]		0.0510
Hazard Ratio (95% CI) [3]		4.25 (0.90, 20.19)
P-value [3]		0.0685

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessments.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_eortc_tfd1.sas 13MAR2023 14:00

Protocol: 207495 Page 15 of 15
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.053110
Summary of EORTC QLQ-C30 Time to first Deterioration 1
(Up to and including Last Follow-Up)

Item Score: Financial Difficulties Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated or Died (event)	9 (60%)	19 (66%)
Censored, follow-up ended	1 (7%)	0
Censored, follow-up ongoing	5 (33%)	10 (34%)
Event Summary		
Deterioration	6 (40%)	7 (24%)
Death	3 (20%)	12 (41%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	1.5 (0.7, 7.8)	1.3 (0.8, 2.9)
Median (95% CI)	7.8 (1.1, 13.5)	5.1 (1.6, 9.5)
3rd Quartile (95% CI)	13.5 (4.2, -)	18.7 (5.1, -)
Log-Rank P-value [2]		0.9732
Hazard Ratio (95% CI) [3]		1.02 (0.35, 2.98)
P-value [3]		0.9733

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessments.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_eortc_tfd1.sas 13MAR2023 14:00

Table 4.054110
Summary of EORTC QLQ-C30 Time to first Deterioration 2
(Up to and including Last Follow-Up)

Item Score: Global Health Status Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated (event)	9 (60%)	16 (55%)
Censored, follow-up ended	4 (27%)	7 (24%)
Censored, follow-up ongoing	2 (13%)	6 (21%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	0.8 (0.8, 2.1)	1.0 (0.7, 1.7)
Median (95% CI)	2.5 (0.8, 9.1)	2.3 (1.0, 9.1)
3rd Quartile (95% CI)	9.1 (2.1, -)	9.1 (2.7, -)
Log-Rank P-value [2]		0.9694
Hazard Ratio (95% CI) [3]		0.99 (0.34, 2.89)
P-value [3]		0.9815

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessments.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_eortc_tfd2.sas 13MAR2023 14:00

Table 4.054110
Summary of EORTC QLQ-C30 Time to first Deterioration 2
(Up to and including Last Follow-Up)

Item Score: Physical Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated (event)	8 (53%)	14 (48%)
Censored, follow-up ended	2 (13%)	8 (28%)
Censored, follow-up ongoing	5 (33%)	7 (24%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	0.9 (0.8, 2.4)	1.4 (0.7, 2.3)
Median (95% CI)	3.6 (0.8, -)	4.0 (1.4, -)
3rd Quartile (95% CI)	- (2.4, -)	- (4.0, -)
Log-Rank P-value [2]		0.3813
Hazard Ratio (95% CI) [3]		0.61 (0.20, 1.88)
P-value [3]		0.3852

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessments.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_eortc_tfd2.sas 13MAR2023 14:00

Table 4.054110
Summary of EORTC QLQ-C30 Time to first Deterioration 2
(Up to and including Last Follow-Up)

Item Score: Role Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated (event)	8 (53%)	13 (45%)
Censored, follow-up ended	2 (13%)	9 (31%)
Censored, follow-up ongoing	5 (33%)	7 (24%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	0.8 (0.7, 1.4)	1.0 (0.7, 1.6)
Median (95% CI)	1.5 (0.7, -)	2.3 (1.1, -)
3rd Quartile (95% CI)	- (1.4, -)	- (2.3, -)
Log-Rank P-value [2]		0.4577
Hazard Ratio (95% CI) [3]		0.65 (0.22, 1.96)
P-value [3]		0.4486

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessments.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_eortc_tfd2.sas 13MAR2023 14:00

Table 4.054110
Summary of EORTC QLQ-C30 Time to first Deterioration 2
(Up to and including Last Follow-Up)

Item Score: Emotional Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated (event)	5 (33%)	15 (52%)
Censored, follow-up ended	3 (20%)	10 (34%)
Censored, follow-up ongoing	7 (47%)	4 (14%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	1.8 (0.7, -)	1.4 (0.8, 2.4)
Median (95% CI)	- (0.8, -)	3.5 (1.5, 13.0)
3rd Quartile (95% CI)	- (-, -)	13.0 (4.9, 15.2)
Log-Rank P-value [2]		0.3018
Hazard Ratio (95% CI) [3]		0.48 (0.12, 1.98)
P-value [3]		0.3115

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessments.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_eortc_tfd2.sas 13MAR2023 14:00

Table 4.054110
Summary of EORTC QLQ-C30 Time to first Deterioration 2
(Up to and including Last Follow-Up)

Item Score: Cognitive Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated (event)	7 (47%)	11 (38%)
Censored, follow-up ended	2 (13%)	10 (34%)
Censored, follow-up ongoing	6 (40%)	8 (28%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	0.9 (0.7, 4.2)	1.4 (0.7, 1.7)
Median (95% CI)	4.5 (0.8, -)	7.1 (1.4, -)
3rd Quartile (95% CI)	- (4.2, -)	- (7.1, -)
Log-Rank P-value [2]		0.3618
Hazard Ratio (95% CI) [3]		0.59 (0.18, 1.95)
P-value [3]		0.3905

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessments.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_eortc_tfd2.sas 13MAR2023 14:00

Table 4.054110
Summary of EORTC QLQ-C30 Time to first Deterioration 2
(Up to and including Last Follow-Up)

Item Score: Social Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated (event)	7 (47%)	14 (48%)
Censored, follow-up ended	4 (27%)	9 (31%)
Censored, follow-up ongoing	4 (27%)	6 (21%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	1.2 (0.7, 2.1)	1.1 (0.7, 1.7)
Median (95% CI)	5.2 (0.8, -)	2.3 (1.1, -)
3rd Quartile (95% CI)	- (2.1, -)	- (2.3, -)
Log-Rank P-value [2]		0.5786
Hazard Ratio (95% CI) [3]		0.74 (0.24, 2.26)
P-value [3]		0.5931

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessments.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_eortc_tfd2.sas 13MAR2023 14:00

Protocol: 207495 Page 7 of 15
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.054110
Summary of EORTC QLQ-C30 Time to first Deterioration 2
(Up to and including Last Follow-Up)

Item Score: Fatigue Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated (event)	7 (47%)	18 (62%)
Censored, follow-up ended	3 (20%)	7 (24%)
Censored, follow-up ongoing	5 (33%)	4 (14%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	0.8 (0.7, 2.1)	1.0 (0.7, 1.4)
Median (95% CI)	2.1 (0.7, -)	1.7 (1.0, 4.2)
3rd Quartile (95% CI)	- (1.4, -)	6.8 (2.3, -)
Log-Rank P-value [2]		0.3620
Hazard Ratio (95% CI) [3]		0.56 (0.16, 1.97)
P-value [3]		0.3667

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessments.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_eortc_tfd2.sas 13MAR2023 14:00

Table 4.054110
Summary of EORTC QLQ-C30 Time to first Deterioration 2
(Up to and including Last Follow-Up)

Item Score: Nausea and vomiting Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated (event)	5 (33%)	7 (24%)
Censored, follow-up ended	5 (33%)	12 (41%)
Censored, follow-up ongoing	5 (33%)	10 (34%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	2.5 (0.7, -)	1.5 (0.7, -)
Median (95% CI)	9.1 (0.7, -)	- (1.5, -)
3rd Quartile (95% CI)	- (9.1, -)	- (-, -)
Log-Rank P-value [2]		0.1113
Hazard Ratio (95% CI) [3]		0.31 (0.07, 1.41)
P-value [3]		0.1314

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessments.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_eortc_tfd2.sas 13MAR2023 14:00

Table 4.054110
Summary of EORTC QLQ-C30 Time to first Deterioration 2
(Up to and including Last Follow-Up)

Item Score: Pain Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated (event)	6 (40%)	11 (38%)
Censored, follow-up ended	4 (27%)	10 (34%)
Censored, follow-up ongoing	5 (33%)	8 (28%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	1.2 (0.7, 9.1)	1.1 (0.8, 2.7)
Median (95% CI)	8.0 (0.7, -)	4.3 (1.1, -)
3rd Quartile (95% CI)	- (7.0, -)	- (4.3, -)
Log-Rank P-value [2]		0.3265
Hazard Ratio (95% CI) [3]		0.54 (0.15, 1.88)
P-value [3]		0.3337

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessments.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_eortc_tfd2.sas 13MAR2023 14:00

Table 4.054110
Summary of EORTC QLQ-C30 Time to first Deterioration 2
(Up to and including Last Follow-Up)

Item Score: Dyspnoea Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated (event)	7 (47%)	10 (34%)
Censored, follow-up ended	2 (13%)	11 (38%)
Censored, follow-up ongoing	6 (40%)	8 (28%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	0.9 (0.7, 4.2)	1.4 (0.7, 9.0)
Median (95% CI)	6.7 (0.8, -)	9.0 (1.4, -)
3rd Quartile (95% CI)	- (4.2, -)	- (9.0, -)
Log-Rank P-value [2]		0.2425
Hazard Ratio (95% CI) [3]		0.52 (0.17, 1.59)
P-value [3]		0.2497

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessments.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_eortc_tfd2.sas 13MAR2023 14:00

Table 4.054110
Summary of EORTC QLQ-C30 Time to first Deterioration 2
(Up to and including Last Follow-Up)

Item Score: Insomnia Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated (event)	5 (33%)	13 (45%)
Censored, follow-up ended	4 (27%)	11 (38%)
Censored, follow-up ongoing	6 (40%)	5 (17%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	1.5 (0.7, -)	1.3 (0.7, 1.7)
Median (95% CI)	- (0.8, -)	2.8 (1.3, 22.9)
3rd Quartile (95% CI)	- (4.2, -)	22.9 (2.8, 22.9)
Log-Rank P-value [2]		0.8619
Hazard Ratio (95% CI) [3]		0.88 (0.25, 3.15)
P-value [3]		0.8444

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessments.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_eortc_tfd2.sas 13MAR2023 14:00

Table 4.054110
Summary of EORTC QLQ-C30 Time to first Deterioration 2
(Up to and including Last Follow-Up)

Item Score: Appetite Loss Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated (event)	4 (27%)	11 (38%)
Censored, follow-up ended	5 (33%)	11 (38%)
Censored, follow-up ongoing	6 (40%)	7 (24%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	4.2 (0.7, -)	1.1 (0.8, 2.8)
Median (95% CI)	- (0.8, -)	6.8 (1.1, -)
3rd Quartile (95% CI)	- (9.1, -)	- (6.8, -)
Log-Rank P-value [2]		0.4363
Hazard Ratio (95% CI) [3]		1.72 (0.43, 6.90)
P-value [3]		0.4413

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessments.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_eortc_tfd2.sas 13MAR2023 14:00

Protocol: 207495 Page 13 of 15
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.054110
Summary of EORTC QLQ-C30 Time to first Deterioration 2
(Up to and including Last Follow-Up)

Item Score: Constipation Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated (event)	9 (60%)	6 (21%)
Censored, follow-up ended	2 (13%)	12 (41%)
Censored, follow-up ongoing	4 (27%)	11 (38%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	1.0 (0.7, 1.6)	4.2 (0.9, -)
Median (95% CI)	2.2 (0.8, -)	- (4.2, -)
3rd Quartile (95% CI)	- (1.6, -)	- (-, -)
Log-Rank P-value [2]		0.0541
Hazard Ratio (95% CI) [3]		0.29 (0.08, 1.09)
P-value [3]		0.0664

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessments.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_eortc_tfd2.sas 13MAR2023 14:00

Table 4.054110
Summary of EORTC QLQ-C30 Time to first Deterioration 2
(Up to and including Last Follow-Up)

Item Score: Diarrhoea Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated (event)	2 (13%)	8 (28%)
Censored, follow-up ended	5 (33%)	12 (41%)
Censored, follow-up ongoing	8 (53%)	9 (31%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (0.7, -)	1.7 (0.7, 9.0)
Median (95% CI)	- (2.9, -)	9.0 (1.6, -)
3rd Quartile (95% CI)	- (-, -)	- (9.0, -)
Log-Rank P-value [2]		0.1364
Hazard Ratio (95% CI) [3]		4.46 (0.52, 38.01)
P-value [3]		0.1710

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessments.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_eortc_tfd2.sas 13MAR2023 14:00

Protocol: 207495 Page 15 of 15
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.054110
Summary of EORTC QLQ-C30 Time to first Deterioration 2
(Up to and including Last Follow-Up)

Item Score: Financial Difficulties Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated (event)	6 (40%)	7 (24%)
Censored, follow-up ended	4 (27%)	12 (41%)
Censored, follow-up ongoing	5 (33%)	10 (34%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	1.6 (0.7, 7.8)	1.7 (0.8, -)
Median (95% CI)	7.8 (0.8, -)	- (1.7, -)
3rd Quartile (95% CI)	- (7.8, -)	- (-, -)
Log-Rank P-value [2]		0.2777
Hazard Ratio (95% CI) [3]		0.43 (0.09, 2.04)
P-value [3]		0.2890

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessments.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_eortc_tfd2.sas 13MAR2023 14:00

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.057110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 1
(Up to and including End of Treatment)

Item Score: Global Health Status Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated or Died (event)	5 (33%)	9 (31%)
Censored, follow-up ended	4 (27%)	7 (24%)
Censored, follow-up ongoing	6 (40%)	13 (45%)
Event Summary		
Deterioration	4 (27%)	1 (3%)
Death	1 (7%)	8 (28%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	5.6 (0.8, 20.7)	3.0 (1.0, 9.5)
Median (95% CI)	20.7 (4.9, -)	- (3.0, -)
3rd Quartile (95% CI)	- (20.7, -)	- (9.5, -)
Log-Rank P-value [2]		0.4847
Hazard Ratio (95% CI) [3]		1.85 (0.32, 10.68)
P-value [3]		0.4893

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd1_c30_eot.sas 14MAR2023 15:56

Protocol: 207495 Page 2 of 30
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.057110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 1
(Up to and including End of Treatment)

Item Score: Global Health Status Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of subsequent visits with confirmation for subjects who permanently deteriorated or died		
n	5	9
0	1 / 5 (20%)	8 / 9 (89%)
1	0 / 5	0 / 9
2	1 / 5 (20%)	0 / 9
3	0 / 5	1 / 9 (11%)
>=4	3 / 5 (60%)	0 / 9
Number of subsequent visits with confirmation for subjects who deteriorated towards end of observation period [4]		
n	3	9
0	2 / 3 (67%)	3 / 9 (33%)
1	1 / 3 (33%)	6 / 9 (67%)

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd1_c30_eot.sas 14MAR2023 15:56

Table 4.057110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 1
(Up to and including End of Treatment)

Item Score: Physical Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated or Died (event)	3 (20%)	9 (31%)
Censored, follow-up ended	3 (20%)	7 (24%)
Censored, follow-up ongoing	9 (60%)	13 (45%)
Event Summary		
Deterioration	2 (13%)	0
Death	1 (7%)	9 (31%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (1.1, -)	5.1 (1.0, 9.5)
Median (95% CI)	- (2.4, -)	9.5 (5.1, -)
3rd Quartile (95% CI)	- (-, -)	- (9.5, -)
Log-Rank P-value [2]		0.4273
Hazard Ratio (95% CI) [3]		2.00 (0.35, 11.30)
P-value [3]		0.4339

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

Protocol: 207495 Page 4 of 30
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.057110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 1
(Up to and including End of Treatment)

Item Score: Physical Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of subsequent visits with confirmation for subjects who permanently deteriorated or died		
n	3	9
0	1 / 3 (33%)	9 / 9 (100%)
1	0 / 3	0 / 9
2	1 / 3 (33%)	0 / 9
3	1 / 3 (33%)	0 / 9
>=4	0 / 3	0 / 9
Number of subsequent visits with confirmation for subjects who deteriorated towards end of observation period [4]		
n	1	5
0	1 / 1 (100%)	2 / 5 (40%)
1	0 / 1	3 / 5 (60%)

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd1_c30_eot.sas 14MAR2023 15:56

Table 4.057110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 1
(Up to and including End of Treatment)

Item Score: Role Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated or Died (event)	4 (27%)	11 (38%)
Censored, follow-up ended	3 (20%)	7 (24%)
Censored, follow-up ongoing	8 (53%)	11 (38%)
Event Summary		
Deterioration	3 (20%)	3 (10%)
Death	1 (7%)	8 (28%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	20.7 (1.1, -)	2.1 (1.0, 5.1)
Median (95% CI)	20.7 (2.1, -)	9.5 (3.6, -)
3rd Quartile (95% CI)	- (20.7, -)	- (9.5, -)
Log-Rank P-value [2]		0.2144
Hazard Ratio (95% CI) [3]		2.74 (0.53, 14.11)
P-value [3]		0.2293

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

Protocol: 207495 Page 6 of 30
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.057110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 1
(Up to and including End of Treatment)

Item Score: Role Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of subsequent visits with confirmation for subjects who permanently deteriorated or died		
n	4	11
0	1 / 4 (25%)	8 / 11 (73%)
1	0 / 4	0 / 11
2	1 / 4 (25%)	2 / 11 (18%)
3	2 / 4 (50%)	0 / 11
>=4	0 / 4	1 / 11 (9%)
Number of subsequent visits with confirmation for subjects who deteriorated towards end of observation period [4]		
n	1	5
0	1 / 1 (100%)	0 / 5
1	0 / 1	5 / 5 (100%)

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd1_c30_eot.sas 14MAR2023 15:56

Table 4.057110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 1
(Up to and including End of Treatment)

Item Score: Emotional Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated or Died (event)	2 (13%)	10 (34%)
Censored, follow-up ended	5 (33%)	7 (24%)
Censored, follow-up ongoing	8 (53%)	12 (41%)
Event Summary		
Deterioration	1 (7%)	1 (3%)
Death	1 (7%)	9 (31%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	20.7 (1.1, -)	2.1 (1.0, 9.5)
Median (95% CI)	20.7 (20.7, -)	9.5 (5.1, -)
3rd Quartile (95% CI)	- (20.7, -)	- (9.5, -)
Log-Rank P-value [2]		0.1174
Hazard Ratio (95% CI) [3]		5.11 (0.56, 46.58)
P-value [3]		0.1480

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

Protocol: 207495 Page 8 of 30
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.057110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 1
(Up to and including End of Treatment)

Item Score: Emotional Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of subsequent visits with confirmation for subjects who permanently deteriorated or died		
n	2	10
0	1 / 2 (50%)	9 / 10 (90%)
1	0 / 2	0 / 10
2	1 / 2 (50%)	1 / 10 (10%)
3	0 / 2	0 / 10
>=4	0 / 2	0 / 10
Number of subsequent visits with confirmation for subjects who deteriorated towards end of observation period [4]		
n	2	7
0	0 / 2	5 / 7 (71%)
1	2 / 2 (100%)	2 / 7 (29%)

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd1_c30_eot.sas 14MAR2023 15:56

Protocol: 207495 Page 9 of 30
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.057110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 1
(Up to and including End of Treatment)

Item Score: Cognitive Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated or Died (event)	3 (20%)	10 (34%)
Censored, follow-up ended	4 (27%)	6 (21%)
Censored, follow-up ongoing	8 (53%)	13 (45%)
Event Summary		
Deterioration	2 (13%)	2 (7%)
Death	1 (7%)	8 (28%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (1.1, -)	2.1 (0.9, 9.5)
Median (95% CI)	- (5.0, -)	9.5 (3.6, -)
3rd Quartile (95% CI)	- (-, -)	- (9.5, -)
Log-Rank P-value [2]		0.5462
Hazard Ratio (95% CI) [3]		1.56 (0.37, 6.66)
P-value [3]		0.5488

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd1_c30_eot.sas 14MAR2023 15:56

Protocol: 207495 Page 10 of 30
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.057110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 1
(Up to and including End of Treatment)

Item Score: Cognitive Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of subsequent visits with confirmation for subjects who permanently deteriorated or died		
n	3	10
0	1 / 3 (33%)	8 / 10 (80%)
1	0 / 3	0 / 10
2	1 / 3 (33%)	1 / 10 (10%)
3	0 / 3	0 / 10
>=4	1 / 3 (33%)	1 / 10 (10%)
Number of subsequent visits with confirmation for subjects who deteriorated towards end of observation period [4]		
n	2	3
0	2 / 2 (100%)	1 / 3 (33%)
1	0 / 2	2 / 3 (67%)

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd1_c30_eot.sas 14MAR2023 15:56

Protocol: 207495 Page 11 of 30
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.057110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 1
(Up to and including End of Treatment)

Item Score: Social Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated or Died (event)	2 (13%)	10 (34%)
Censored, follow-up ended	4 (27%)	7 (24%)
Censored, follow-up ongoing	9 (60%)	12 (41%)
Event Summary		
Deterioration	1 (7%)	1 (3%)
Death	1 (7%)	9 (31%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (1.1, -)	2.1 (0.9, 9.5)
Median (95% CI)	- (-, -)	9.5 (5.1, -)
3rd Quartile (95% CI)	- (-, -)	- (9.5, -)
Log-Rank P-value [2]		0.3165
Hazard Ratio (95% CI) [3]		2.32 (0.43, 12.49)
P-value [3]		0.3269

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd1_c30_eot.sas 14MAR2023 15:56

Protocol: 207495 Page 12 of 30
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.057110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 1
(Up to and including End of Treatment)

Item Score: Social Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of subsequent visits with confirmation for subjects who permanently deteriorated or died		
n	2	10
0	1 / 2 (50%)	9 / 10 (90%)
1	0 / 2	0 / 10
2	0 / 2	0 / 10
3	1 / 2 (50%)	1 / 10 (10%)
>=4	0 / 2	0 / 10
Number of subsequent visits with confirmation for subjects who deteriorated towards end of observation period [4]		
n	2	6
0	1 / 2 (50%)	3 / 6 (50%)
1	1 / 2 (50%)	3 / 6 (50%)

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd1_c30_eot.sas 14MAR2023 15:56

Table 4.057110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 1
(Up to and including End of Treatment)

Item Score: Fatigue Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated or Died (event)	5 (33%)	9 (31%)
Censored, follow-up ended	3 (20%)	7 (24%)
Censored, follow-up ongoing	7 (47%)	13 (45%)
Event Summary		
Deterioration	4 (27%)	0
Death	1 (7%)	9 (31%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	1.6 (0.7, 20.7)	5.1 (1.0, 9.5)
Median (95% CI)	20.7 (0.8, -)	9.5 (5.1, -)
3rd Quartile (95% CI)	- (20.7, -)	- (9.5, -)
Log-Rank P-value [2]		0.6846
Hazard Ratio (95% CI) [3]		1.37 (0.30, 6.39)
P-value [3]		0.6854

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

Protocol: 207495 Page 14 of 30
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.057110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 1
(Up to and including End of Treatment)

Item Score: Fatigue Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of subsequent visits with confirmation for subjects who permanently deteriorated or died		
n	5	9
0	1 / 5 (20%)	9 / 9 (100%)
1	0 / 5	0 / 9
2	1 / 5 (20%)	0 / 9
3	1 / 5 (20%)	0 / 9
>=4	2 / 5 (40%)	0 / 9
Number of subsequent visits with confirmation for subjects who deteriorated towards end of observation period [4]		
n	0	8
0	0	4 / 8 (50%)
1	0	4 / 8 (50%)

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd1_c30_eot.sas 14MAR2023 15:56

Protocol: 207495 Page 15 of 30
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.057110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 1
(Up to and including End of Treatment)

Item Score: Nausea and Vomiting Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated or Died (event)	2 (13%)	9 (31%)
Censored, follow-up ended	5 (33%)	7 (24%)
Censored, follow-up ongoing	8 (53%)	13 (45%)
Event Summary		
Deterioration	1 (7%)	0
Death	1 (7%)	9 (31%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	20.7 (1.1, -)	5.1 (1.0, 9.5)
Median (95% CI)	20.7 (20.7, -)	9.5 (5.1, -)
3rd Quartile (95% CI)	- (20.7, -)	- (9.5, -)
Log-Rank P-value [2]		0.1558
Hazard Ratio (95% CI) [3]		4.58 (0.48, 43.50)
P-value [3]		0.1847

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd1_c30_eot.sas 14MAR2023 15:56

Protocol: 207495 Page 16 of 30
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.057110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 1
(Up to and including End of Treatment)

Item Score: Nausea and Vomiting Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of subsequent visits with confirmation for subjects who permanently deteriorated or died		
n	2	9
0	1 / 2 (50%)	9 / 9 (100%)
1	0 / 2	0 / 9
2	1 / 2 (50%)	0 / 9
3	0 / 2	0 / 9
>=4	0 / 2	0 / 9
Number of subsequent visits with confirmation for subjects who deteriorated towards end of observation period [4]		
n	1	2
0	1 / 1 (100%)	1 / 2 (50%)
1	0 / 1	1 / 2 (50%)

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd1_c30_eot.sas 14MAR2023 15:56

Protocol: 207495 Page 17 of 30
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.057110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 1
(Up to and including End of Treatment)

Item Score: Pain Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated or Died (event)	1 (7%)	10 (34%)
Censored, follow-up ended	5 (33%)	7 (24%)
Censored, follow-up ongoing	9 (60%)	12 (41%)
Event Summary		
Deterioration	0	1 (3%)
Death	1 (7%)	9 (31%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (1.1, -)	2.1 (0.9, 9.5)
Median (95% CI)	- (-, -)	9.5 (5.1, -)
3rd Quartile (95% CI)	- (-, -)	- (9.5, -)
Log-Rank P-value [2]		0.1174
Hazard Ratio (95% CI) [3]		5.11 (0.56, 46.58)
P-value [3]		0.1480

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd1_c30_eot.sas 14MAR2023 15:56

Protocol: 207495 Page 18 of 30
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.057110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 1
(Up to and including End of Treatment)

Item Score: Pain Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of subsequent visits with confirmation for subjects who permanently deteriorated or died		
n	1	10
0	1 / 1 (100%)	9 / 10 (90%)
1	0 / 1	0 / 10
2	0 / 1	0 / 10
3	0 / 1	0 / 10
>=4	0 / 1	1 / 10 (10%)
Number of subsequent visits with confirmation for subjects who deteriorated towards end of observation period [4]		
n	0	4
0	0	1 / 4 (25%)
1	0	3 / 4 (75%)

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd1_c30_eot.sas 14MAR2023 15:56

Table 4.057110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 1
(Up to and including End of Treatment)

Item Score: Dyspnoea Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated or Died (event)	3 (20%)	11 (38%)
Censored, follow-up ended	4 (27%)	6 (21%)
Censored, follow-up ongoing	8 (53%)	12 (41%)
Event Summary		
Deterioration	2 (13%)	2 (7%)
Death	1 (7%)	9 (31%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	20.7 (1.1, -)	2.1 (0.9, 7.0)
Median (95% CI)	20.7 (20.7, -)	7.0 (5.1, -)
3rd Quartile (95% CI)	- (20.7, -)	- (7.0, -)
Log-Rank P-value [2]		0.3165
Hazard Ratio (95% CI) [3]		2.32 (0.43, 12.49)
P-value [3]		0.3269

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

Protocol: 207495 Page 20 of 30
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.057110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 1
(Up to and including End of Treatment)

Item Score: Dyspnoea Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of subsequent visits with confirmation for subjects who permanently deteriorated or died		
n	3	11
0	1 / 3 (33%)	9 / 11 (82%)
1	0 / 3	0 / 11
2	1 / 3 (33%)	0 / 11
3	1 / 3 (33%)	0 / 11
>=4	0 / 3	2 / 11 (18%)
Number of subsequent visits with confirmation for subjects who deteriorated towards end of observation period [4]		
n	2	3
0	0 / 2	2 / 3 (67%)
1	2 / 2 (100%)	1 / 3 (33%)

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd1_c30_eot.sas 14MAR2023 15:56

Protocol: 207495 Page 21 of 30
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.057110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 1
(Up to and including End of Treatment)

Item Score: Insomnia Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated or Died (event)	1 (7%)	9 (31%)
Censored, follow-up ended	5 (33%)	7 (24%)
Censored, follow-up ongoing	9 (60%)	13 (45%)
Event Summary		
Deterioration	0	0
Death	1 (7%)	9 (31%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (1.1, -)	5.1 (1.0, 9.5)
Median (95% CI)	- (-, -)	9.5 (5.1, -)
3rd Quartile (95% CI)	- (-, -)	- (9.5, -)
Log-Rank P-value [2]		0.1659
Hazard Ratio (95% CI) [3]		4.47 (0.47, 42.78)
P-value [3]		0.1938

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd1_c30_eot.sas 14MAR2023 15:56

Protocol: 207495 Page 22 of 30
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.057110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 1
(Up to and including End of Treatment)

Item Score: Insomnia Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of subsequent visits with confirmation for subjects who permanently deteriorated or died		
n	1	9
0	1 / 1 (100%)	9 / 9 (100%)
1	0 / 1	0 / 9
2	0 / 1	0 / 9
3	0 / 1	0 / 9
>=4	0 / 1	0 / 9
Number of subsequent visits with confirmation for subjects who deteriorated towards end of observation period [4]		
n	2	3
0	2 / 2 (100%)	3 / 3 (100%)
1	0 / 2	0 / 3

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd1_c30_eot.sas 14MAR2023 15:56

Protocol: 207495 Page 23 of 30
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.057110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 1
(Up to and including End of Treatment)

Item Score: Appetite Loss Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated or Died (event)	1 (7%)	9 (31%)
Censored, follow-up ended	5 (33%)	7 (24%)
Censored, follow-up ongoing	9 (60%)	13 (45%)
Event Summary		
Deterioration	0	0
Death	1 (7%)	9 (31%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (1.1, -)	5.1 (1.0, 9.5)
Median (95% CI)	- (-, -)	9.5 (5.1, -)
3rd Quartile (95% CI)	- (-, -)	- (9.5, -)
Log-Rank P-value [2]		0.1558
Hazard Ratio (95% CI) [3]		4.58 (0.48, 43.50)
P-value [3]		0.1847

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd1_c30_eot.sas 14MAR2023 15:56

Protocol: 207495 Page 24 of 30
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.057110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 1
(Up to and including End of Treatment)

Item Score: Appetite Loss Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of subsequent visits with confirmation for subjects who permanently deteriorated or died		
n	1	9
0	1 / 1 (100%)	9 / 9 (100%)
1	0 / 1	0 / 9
2	0 / 1	0 / 9
3	0 / 1	0 / 9
>=4	0 / 1	0 / 9
Number of subsequent visits with confirmation for subjects who deteriorated towards end of observation period [4]		
n	1	3
0	1 / 1 (100%)	2 / 3 (67%)
1	0 / 1	1 / 3 (33%)

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd1_c30_eot.sas 14MAR2023 15:56

Protocol: 207495 Page 25 of 30
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.057110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 1
(Up to and including End of Treatment)

Item Score: Constipation Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated or Died (event)	3 (20%)	9 (31%)
Censored, follow-up ended	4 (27%)	7 (24%)
Censored, follow-up ongoing	8 (53%)	13 (45%)
Event Summary		
Deterioration	2 (13%)	0
Death	1 (7%)	9 (31%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	20.6 (1.1, -)	5.1 (1.0, 9.5)
Median (95% CI)	20.6 (20.6, -)	9.5 (5.1, -)
3rd Quartile (95% CI)	- (20.6, -)	- (9.5, -)
Log-Rank P-value [2]		0.4273
Hazard Ratio (95% CI) [3]		2.00 (0.35, 11.30)
P-value [3]		0.4339

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd1_c30_eot.sas 14MAR2023 15:56

Protocol: 207495 Page 26 of 30
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.057110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 1
(Up to and including End of Treatment)

Item Score: Constipation Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of subsequent visits with confirmation for subjects who permanently deteriorated or died		
n	3	9
0	1 / 3 (33%)	9 / 9 (100%)
1	0 / 3	0 / 9
2	1 / 3 (33%)	0 / 9
3	1 / 3 (33%)	0 / 9
>=4	0 / 3	0 / 9
Number of subsequent visits with confirmation for subjects who deteriorated towards end of observation period [4]		
n	2	3
0	2 / 2 (100%)	0 / 3
1	0 / 2	3 / 3 (100%)

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd1_c30_eot.sas 14MAR2023 15:56

Protocol: 207495 Page 27 of 30
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.057110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 1
(Up to and including End of Treatment)

Item Score: Diarrhoea Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated or Died (event)	1 (7%)	9 (31%)
Censored, follow-up ended	5 (33%)	7 (24%)
Censored, follow-up ongoing	9 (60%)	13 (45%)
Event Summary		
Deterioration	0	0
Death	1 (7%)	9 (31%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (1.1, -)	5.1 (1.0, 9.5)
Median (95% CI)	- (-, -)	9.5 (5.1, -)
3rd Quartile (95% CI)	- (-, -)	- (9.5, -)
Log-Rank P-value [2]		0.1558
Hazard Ratio (95% CI) [3]		4.58 (0.48, 43.50)
P-value [3]		0.1847

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd1_c30_eot.sas 14MAR2023 15:56

Protocol: 207495 Page 28 of 30
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.057110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 1
(Up to and including End of Treatment)

Item Score: Diarrhoea Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of subsequent visits with confirmation for subjects who permanently deteriorated or died		
n	1	9
0	1 / 1 (100%)	9 / 9 (100%)
1	0 / 1	0 / 9
2	0 / 1	0 / 9
3	0 / 1	0 / 9
>=4	0 / 1	0 / 9
Number of subsequent visits with confirmation for subjects who deteriorated towards end of observation period [4]		
n	1	1
0	0 / 1	1 / 1 (100%)
1	1 / 1 (100%)	0 / 1

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd1_c30_eot.sas 14MAR2023 15:56

Protocol: 207495 Page 29 of 30
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.057110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 1
(Up to and including End of Treatment)

Item Score: Financial Difficulties Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated or Died (event)	1 (7%)	10 (34%)
Censored, follow-up ended	5 (33%)	7 (24%)
Censored, follow-up ongoing	9 (60%)	12 (41%)
Event Summary		
Deterioration	0	1 (3%)
Death	1 (7%)	9 (31%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (1.1, -)	2.3 (1.0, 9.5)
Median (95% CI)	- (-, -)	9.5 (2.3, -)
3rd Quartile (95% CI)	- (-, -)	- (9.5, -)
Log-Rank P-value [2]		0.1093
Hazard Ratio (95% CI) [3]		5.24 (0.58, 47.52)
P-value [3]		0.1407

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd1_c30_eot.sas 14MAR2023 15:56

Protocol: 207495 Page 30 of 30
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.057110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 1
(Up to and including End of Treatment)

Item Score: Financial Difficulties Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of subsequent visits with confirmation for subjects who permanently deteriorated or died		
n	1	10
0	1 / 1 (100%)	9 / 10 (90%)
1	0 / 1	0 / 10
2	0 / 1	0 / 10
3	0 / 1	0 / 10
>=4	0 / 1	1 / 10 (10%)
Number of subsequent visits with confirmation for subjects who deteriorated towards end of observation period [4]		
n	4	3
0	2 / 4 (50%)	3 / 3 (100%)
1	2 / 4 (50%)	0 / 3

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd1_c30_eot.sas 14MAR2023 15:56

Table 4.058110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 2
(Up to and including End of Treatment)

Item Score: Global Health Status Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated (event)	4 (27%)	1 (3%)
Censored, follow-up ended	5 (33%)	15 (52%)
Censored, follow-up ongoing	6 (40%)	13 (45%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	5.6 (0.8, -)	- (3.0, -)
Median (95% CI)	20.7 (4.9, -)	- (3.0, -)
3rd Quartile (95% CI)	- (20.7, -)	- (-, -)
Log-Rank P-value [2]		0.1336
Hazard Ratio (95% CI) [3]		<0.01 (<0.01, -)
P-value [3]		0.9986

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd2_c30_eot.sas 14MAR2023 17:00

Table 4.058110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 2
(Up to and including End of Treatment)

Item Score: Global Health Status Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of subsequent visits with confirmation for subjects who permanently deteriorated		
n	4	1
0	0 / 4	0 / 1
1	0 / 4	0 / 1
2	1 / 4 (25%)	0 / 1
3	0 / 4	1 / 1 (100%)
>=4	3 / 4 (75%)	0 / 1
Number of subsequent visits with confirmation for subjects who deteriorated towards end of observation period [4]		
n	3	11
0	2 / 3 (67%)	5 / 11 (45%)
1	1 / 3 (33%)	6 / 11 (55%)

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

Table 4.058110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 2
(Up to and including End of Treatment)

Item Score: Physical Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated (event)	2 (13%)	0
Censored, follow-up ended	4 (27%)	16 (55%)
Censored, follow-up ongoing	9 (60%)	13 (45%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (2.1, -)	- (-, -)
Median (95% CI)	- (2.4, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		0.1859
Hazard Ratio (95% CI) [3]		<0.01 (<0.01, -)
P-value [3]		0.9984

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd2_c30_eot.sas 14MAR2023 17:00

Table 4.058110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 2
(Up to and including End of Treatment)

Item Score: Physical Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of subsequent visits with confirmation for subjects who permanently deteriorated		
n	2	0
0	0 / 2	0
1	0 / 2	0
2	1 / 2 (50%)	0
3	1 / 2 (50%)	0
>=4	0 / 2	0
Number of subsequent visits with confirmation for subjects who deteriorated towards end of observation period [4]		
n	1	7
0	1 / 1 (100%)	4 / 7 (57%)
1	0 / 1	3 / 7 (43%)

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

Table 4.058110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 2
(Up to and including End of Treatment)

Item Score: Role Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated (event)	3 (20%)	3 (10%)
Censored, follow-up ended	4 (27%)	15 (52%)
Censored, follow-up ongoing	8 (53%)	11 (38%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	20.7 (1.5, -)	5.1 (1.4, -)
Median (95% CI)	20.7 (2.1, -)	- (5.1, -)
3rd Quartile (95% CI)	- (20.7, -)	- (-, -)
Log-Rank P-value [2]		0.8704
Hazard Ratio (95% CI) [3]		1.22 (0.11, 13.65)
P-value [3]		0.8706

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

Table 4.058110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 2
(Up to and including End of Treatment)

Item Score: Role Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of subsequent visits with confirmation for subjects who permanently deteriorated		
n	3	3
0	0 / 3	0 / 3
1	0 / 3	0 / 3
2	1 / 3 (33%)	2 / 3 (67%)
3	2 / 3 (67%)	0 / 3
>=4	0 / 3	1 / 3 (33%)
Number of subsequent visits with confirmation for subjects who deteriorated towards end of observation period [4]		
n	1	6
0	1 / 1 (100%)	1 / 6 (17%)
1	0 / 1	5 / 6 (83%)

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

Table 4.058110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 2
(Up to and including End of Treatment)

Item Score: Emotional Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated (event)	1 (7%)	1 (3%)
Censored, follow-up ended	6 (40%)	16 (55%)
Censored, follow-up ongoing	8 (53%)	12 (41%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	20.7 (20.7, -)	- (1.6, -)
Median (95% CI)	- (20.7, -)	- (-, -)
3rd Quartile (95% CI)	- (20.7, -)	- (-, -)
Log-Rank P-value [2]		0.5050
Hazard Ratio (95% CI) [3]		>999.99 (<0.01, -)
P-value [3]		0.9986

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd2_c30_eot.sas 14MAR2023 17:00

Table 4.058110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 2
(Up to and including End of Treatment)

Item Score: Emotional Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of subsequent visits with confirmation for subjects who permanently deteriorated		
n	1	1
0	0 / 1	0 / 1
1	0 / 1	0 / 1
2	1 / 1 (100%)	1 / 1 (100%)
3	0 / 1	0 / 1
>=4	0 / 1	0 / 1
Number of subsequent visits with confirmation for subjects who deteriorated towards end of observation period [4]		
n	2	8
0	0 / 2	6 / 8 (75%)
1	2 / 2 (100%)	2 / 8 (25%)

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

Table 4.058110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 2
(Up to and including End of Treatment)

Item Score: Cognitive Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated (event)	2 (13%)	2 (7%)
Censored, follow-up ended	5 (33%)	14 (48%)
Censored, follow-up ongoing	8 (53%)	13 (45%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (2.9, -)	- (0.7, -)
Median (95% CI)	- (5.0, -)	- (3.6, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		0.3640
Hazard Ratio (95% CI) [3]		0.34 (0.03, 3.87)
P-value [3]		0.3851

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

Table 4.058110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 2
(Up to and including End of Treatment)

Item Score: Cognitive Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of subsequent visits with confirmation for subjects who permanently deteriorated		
n	2	2
0	0 / 2	0 / 2
1	0 / 2	0 / 2
2	1 / 2 (50%)	1 / 2 (50%)
3	0 / 2	0 / 2
>=4	1 / 2 (50%)	1 / 2 (50%)
Number of subsequent visits with confirmation for subjects who deteriorated towards end of observation period [4]		
n	2	6
0	2 / 2 (100%)	3 / 6 (50%)
1	0 / 2	3 / 6 (50%)

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

Protocol: 207495 Page 11 of 30
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.058110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 2
(Up to and including End of Treatment)

Item Score: Social Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated (event)	1 (7%)	1 (3%)
Censored, follow-up ended	5 (33%)	16 (55%)
Censored, follow-up ongoing	9 (60%)	12 (41%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (2.1, -)	- (0.8, -)
Median (95% CI)	- (-, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		0.6641
Hazard Ratio (95% CI) [3]		0.54 (0.03, 8.83)
P-value [3]		0.6688

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd2_c30_eot.sas 14MAR2023 17:00

Protocol: 207495 Page 12 of 30
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.058110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 2
(Up to and including End of Treatment)

Item Score: Social Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of subsequent visits with confirmation for subjects who permanently deteriorated		
n	1	1
0	0 / 1	0 / 1
1	0 / 1	0 / 1
2	0 / 1	0 / 1
3	1 / 1 (100%)	1 / 1 (100%)
>=4	0 / 1	0 / 1
Number of subsequent visits with confirmation for subjects who deteriorated towards end of observation period [4]		
n	2	9
0	1 / 2 (50%)	6 / 9 (67%)
1	1 / 2 (50%)	3 / 9 (33%)

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd2_c30_eot.sas 14MAR2023 17:00

Table 4.058110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 2
(Up to and including End of Treatment)

Item Score: Fatigue Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated (event)	4 (27%)	0
Censored, follow-up ended	4 (27%)	16 (55%)
Censored, follow-up ongoing	7 (47%)	13 (45%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	2.1 (0.7, -)	- (-, -)
Median (95% CI)	20.7 (0.8, -)	- (-, -)
3rd Quartile (95% CI)	- (20.7, -)	- (-, -)
Log-Rank P-value [2]		0.1160
Hazard Ratio (95% CI) [3]		<0.01 (<0.01, -)
P-value [3]		0.9978

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd2_c30_eot.sas 14MAR2023 17:00

Table 4.058110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 2
(Up to and including End of Treatment)

Item Score: Fatigue Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of subsequent visits with confirmation for subjects who permanently deteriorated		
n	4	0
0	0 / 4	0
1	0 / 4	0
2	1 / 4 (25%)	0
3	1 / 4 (25%)	0
>=4	2 / 4 (50%)	0
Number of subsequent visits with confirmation for subjects who deteriorated towards end of observation period [4]		
n	0	11
0	0	7 / 11 (64%)
1	0	4 / 11 (36%)

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

Table 4.058110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 2
(Up to and including End of Treatment)

Item Score: Nausea and Vomiting Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated (event)	1 (7%)	0
Censored, follow-up ended	6 (40%)	16 (55%)
Censored, follow-up ongoing	8 (53%)	13 (45%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	20.7 (20.7, -)	- (-, -)
Median (95% CI)	- (20.7, -)	- (-, -)
3rd Quartile (95% CI)	- (20.7, -)	- (-, -)
Log-Rank P-value [2]		-
Hazard Ratio (95% CI) [3]		- (-, -)
P-value [3]		-

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

Protocol: 207495 Page 16 of 30
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.058110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 2
(Up to and including End of Treatment)

Item Score: Nausea and Vomiting Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of subsequent visits with confirmation for subjects who permanently deteriorated		
n	1	0
0	0 / 1	0
1	0 / 1	0
2	1 / 1 (100%)	0
3	0 / 1	0
>=4	0 / 1	0
Number of subsequent visits with confirmation for subjects who deteriorated towards end of observation period [4]		
n	1	3
0	1 / 1 (100%)	1 / 3 (33%)
1	0 / 1	2 / 3 (67%)

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd2_c30_eot.sas 14MAR2023 17:00

Protocol: 207495 Page 17 of 30
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.058110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 2
(Up to and including End of Treatment)

Item Score: Pain Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated (event)	0	1 (3%)
Censored, follow-up ended	6 (40%)	16 (55%)
Censored, follow-up ongoing	9 (60%)	12 (41%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (-, -)	- (0.9, -)
Median (95% CI)	- (-, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		0.5050
Hazard Ratio (95% CI) [3]		>999.99 (<0.01, -)
P-value [3]		0.9986

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd2_c30_eot.sas 14MAR2023 17:00

Table 4.058110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 2
(Up to and including End of Treatment)

Item Score: Pain Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of subsequent visits with confirmation for subjects who permanently deteriorated		
n	0	1
0	0	0 / 1
1	0	0 / 1
2	0	0 / 1
3	0	0 / 1
>=4	0	1 / 1 (100%)
Number of subsequent visits with confirmation for subjects who deteriorated towards end of observation period [4]		
n	0	5
0	0	1 / 5 (20%)
1	0	4 / 5 (80%)

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

Table 4.058110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 2
(Up to and including End of Treatment)

Item Score: Dyspnoea Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated (event)	2 (13%)	2 (7%)
Censored, follow-up ended	5 (33%)	15 (52%)
Censored, follow-up ongoing	8 (53%)	12 (41%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	20.7 (2.1, -)	- (0.7, -)
Median (95% CI)	20.7 (20.7, -)	- (7.0, -)
3rd Quartile (95% CI)	- (20.7, -)	- (-, -)
Log-Rank P-value [2]		0.6641
Hazard Ratio (95% CI) [3]		0.54 (0.03, 8.83)
P-value [3]		0.6688

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

Table 4.058110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 2
(Up to and including End of Treatment)

Item Score: Dyspnoea Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of subsequent visits with confirmation for subjects who permanently deteriorated		
n	2	2
0	0 / 2	0 / 2
1	0 / 2	0 / 2
2	1 / 2 (50%)	0 / 2
3	1 / 2 (50%)	0 / 2
>=4	0 / 2	2 / 2 (100%)
Number of subsequent visits with confirmation for subjects who deteriorated towards end of observation period [4]		
n	2	5
0	0 / 2	4 / 5 (80%)
1	2 / 2 (100%)	1 / 5 (20%)

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

Table 4.058110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 2
(Up to and including End of Treatment)

Item Score: Insomnia Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated (event)	0	0
Censored, follow-up ended	6 (40%)	16 (55%)
Censored, follow-up ongoing	9 (60%)	13 (45%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (-, -)	- (-, -)
Median (95% CI)	- (-, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		-
Hazard Ratio (95% CI) [3]		- (-, -)
P-value [3]		-

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

Table 4.058110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 2
(Up to and including End of Treatment)

Item Score: Insomnia Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of subsequent visits with confirmation for subjects who permanently deteriorated		
n	0	0
0	0	0
1	0	0
2	0	0
3	0	0
>=4	0	0
Number of subsequent visits with confirmation for subjects who deteriorated towards end of observation period [4]		
n	2	6
0	2 / 2 (100%)	6 / 6 (100%)
1	0 / 2	0 / 6

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

Protocol: 207495 Page 23 of 30
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.058110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 2
(Up to and including End of Treatment)

Item Score: Appetite Loss Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated (event)	0	0
Censored, follow-up ended	6 (40%)	16 (55%)
Censored, follow-up ongoing	9 (60%)	13 (45%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (-, -)	- (-, -)
Median (95% CI)	- (-, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		-
Hazard Ratio (95% CI) [3]		- (-, -)
P-value [3]		-

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd2_c30_eot.sas 14MAR2023 17:00

Table 4.058110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 2
(Up to and including End of Treatment)

Item Score: Appetite Loss Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of subsequent visits with confirmation for subjects who permanently deteriorated		
n	0	0
0	0	0
1	0	0
2	0	0
3	0	0
>=4	0	0
Number of subsequent visits with confirmation for subjects who deteriorated towards end of observation period [4]		
n	1	5
0	1 / 1 (100%)	3 / 5 (60%)
1	0 / 1	2 / 5 (40%)

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

Protocol: 207495 Page 25 of 30
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.058110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 2
(Up to and including End of Treatment)

Item Score: Constipation Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated (event)	2 (13%)	0
Censored, follow-up ended	5 (33%)	16 (55%)
Censored, follow-up ongoing	8 (53%)	13 (45%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	20.6 (2.1, -)	- (-, -)
Median (95% CI)	20.6 (20.6, -)	- (-, -)
3rd Quartile (95% CI)	- (20.6, -)	- (-, -)
Log-Rank P-value [2]		0.1859
Hazard Ratio (95% CI) [3]		<0.01 (<0.01, -)
P-value [3]		0.9984

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd2_c30_eot.sas 14MAR2023 17:00

Protocol: 207495 Page 26 of 30
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.058110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 2
(Up to and including End of Treatment)

Item Score: Constipation Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of subsequent visits with confirmation for subjects who permanently deteriorated		
n	2	0
0	0 / 2	0
1	0 / 2	0
2	1 / 2 (50%)	0
3	1 / 2 (50%)	0
>=4	0 / 2	0
Number of subsequent visits with confirmation for subjects who deteriorated towards end of observation period [4]		
n	2	4
0	2 / 2 (100%)	1 / 4 (25%)
1	0 / 2	3 / 4 (75%)

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd2_c30_eot.sas 14MAR2023 17:00

Table 4.058110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 2
(Up to and including End of Treatment)

Item Score: Diarrhoea Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated (event)	0	0
Censored, follow-up ended	6 (40%)	16 (55%)
Censored, follow-up ongoing	9 (60%)	13 (45%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (-, -)	- (-, -)
Median (95% CI)	- (-, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		-
Hazard Ratio (95% CI) [3]		- (-, -)
P-value [3]		-

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

Protocol: 207495 Page 28 of 30
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.058110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 2
(Up to and including End of Treatment)

Item Score: Diarrhoea Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of subsequent visits with confirmation for subjects who permanently deteriorated		
n	0	0
0	0	0
1	0	0
2	0	0
3	0	0
>=4	0	0
Number of subsequent visits with confirmation for subjects who deteriorated towards end of observation period [4]		
n	1	2
0	0 / 1	2 / 2 (100%)
1	1 / 1 (100%)	0 / 2

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd2_c30_eot.sas 14MAR2023 17:00

Protocol: 207495 Page 29 of 30
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.058110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 2
(Up to and including End of Treatment)

Item Score: Financial Difficulties Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated (event)	0	1 (3%)
Censored, follow-up ended	6 (40%)	16 (55%)
Censored, follow-up ongoing	9 (60%)	12 (41%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (-, -)	- (2.3, -)
Median (95% CI)	- (-, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		0.4497
Hazard Ratio (95% CI) [3]		>999.99 (<0.01, -)
P-value [3]		0.9985

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd2_c30_eot.sas 14MAR2023 17:00

Protocol: 207495 Page 30 of 30
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.058110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 2
(Up to and including End of Treatment)

Item Score: Financial Difficulties Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of subsequent visits with confirmation for subjects who permanently deteriorated		
n	0	1
0	0	0 / 1
1	0	0 / 1
2	0	0 / 1
3	0	0 / 1
>=4	0	1 / 1 (100%)
Number of subsequent visits with confirmation for subjects who deteriorated towards end of observation period [4]		
n	4	4
0	2 / 4 (50%)	4 / 4 (100%)
1	2 / 4 (50%)	0 / 4

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd2_c30_eot.sas 14MAR2023 17:00

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.059110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 1
(Up to and including Last Follow-Up)

Item Score: Global Health Status Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated or Died (event)	7 (47%)	16 (55%)
Censored, follow-up ended	2 (13%)	0
Censored, follow-up ongoing	6 (40%)	13 (45%)
Event Summary		
Deterioration	4 (27%)	2 (7%)
Death	3 (20%)	14 (48%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	5.6 (0.8, 13.5)	2.1 (1.0, 5.1)
Median (95% CI)	13.5 (4.9, -)	5.7 (2.9, -)
3rd Quartile (95% CI)	20.7 (8.0, -)	18.7 (6.6, -)
Log-Rank P-value [2]		0.4171
Hazard Ratio (95% CI) [3]		1.65 (0.49, 5.57)
P-value [3]		0.4209

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd1_c30_lf.sas 14MAR2023 15:56

Protocol: 207495 Page 2 of 30
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.059110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 1
(Up to and including Last Follow-Up)

Item Score: Global Health Status Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of subsequent visits with confirmation for subjects who permanently deteriorated or died		
n	7	16
0	3 / 7 (43%)	14 / 16 (88%)
1	0 / 7	0 / 16
2	1 / 7 (14%)	1 / 16 (6%)
3	0 / 7	1 / 16 (6%)
>=4	3 / 7 (43%)	0 / 16
Number of subsequent visits with confirmation for subjects who deteriorated towards end of observation period [4]		
n	3	3
0	2 / 3 (67%)	2 / 3 (67%)
1	1 / 3 (33%)	1 / 3 (33%)

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd1_c30_lf.sas 14MAR2023 15:56

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.059110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 1
(Up to and including Last Follow-Up)

Item Score: Physical Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated or Died (event)	5 (33%)	17 (59%)
Censored, follow-up ended	1 (7%)	0
Censored, follow-up ongoing	9 (60%)	12 (41%)
Event Summary		
Deterioration	2 (13%)	1 (3%)
Death	3 (20%)	16 (55%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	9.5 (1.1, -)	2.3 (1.0, 5.1)
Median (95% CI)	13.5 (2.4, -)	5.7 (2.9, 18.7)
3rd Quartile (95% CI)	- (13.5, -)	18.7 (5.7, -)
Log-Rank P-value [2]		0.1061
Hazard Ratio (95% CI) [3]		2.83 (0.76, 10.51)
P-value [3]		0.1191

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd1_c30_lf.sas 14MAR2023 15:56

Protocol: 207495 Page 4 of 30
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.059110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 1
(Up to and including Last Follow-Up)

Item Score: Physical Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of subsequent visits with confirmation for subjects who permanently deteriorated or died		
n	5	17
0	3 / 5 (60%)	16 / 17 (94%)
1	0 / 5	0 / 17
2	1 / 5 (20%)	0 / 17
3	1 / 5 (20%)	1 / 17 (6%)
>=4	0 / 5	0 / 17
Number of subsequent visits with confirmation for subjects who deteriorated towards end of observation period [4]		
n	0	2
0	0	1 / 2 (50%)
1	0	1 / 2 (50%)

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd1_c30_lf.sas 14MAR2023 15:56

Protocol: 207495 Page 5 of 30
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.059110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 1
(Up to and including Last Follow-Up)

Item Score: Role Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated or Died (event)	6 (40%)	17 (59%)
Censored, follow-up ended	1 (7%)	0
Censored, follow-up ongoing	8 (53%)	12 (41%)
Event Summary		
Deterioration	3 (20%)	3 (10%)
Death	3 (20%)	14 (48%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	9.5 (1.1, 20.7)	2.1 (1.0, 5.1)
Median (95% CI)	13.5 (2.1, -)	5.1 (2.9, 18.7)
3rd Quartile (95% CI)	20.7 (13.5, -)	18.7 (6.6, -)
Log-Rank P-value [2]		0.1266
Hazard Ratio (95% CI) [3]		2.70 (0.73, 10.01)
P-value [3]		0.1384

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd1_c30_lf.sas 14MAR2023 15:56

Protocol: 207495 Page 6 of 30
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.059110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 1
(Up to and including Last Follow-Up)

Item Score: Role Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of subsequent visits with confirmation for subjects who permanently deteriorated or died		
n	6	17
0	3 / 6 (50%)	14 / 17 (82%)
1	0 / 6	0 / 17
2	1 / 6 (17%)	2 / 17 (12%)
3	2 / 6 (33%)	0 / 17
>=4	0 / 6	1 / 17 (6%)
Number of subsequent visits with confirmation for subjects who deteriorated towards end of observation period [4]		
n	0	2
0	0	1 / 2 (50%)
1	0	1 / 2 (50%)

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd1_c30_lf.sas 14MAR2023 15:56

Protocol: 207495 Page 7 of 30
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.059110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 1
(Up to and including Last Follow-Up)

Item Score: Emotional Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated or Died (event)	5 (33%)	16 (55%)
Censored, follow-up ended	2 (13%)	0
Censored, follow-up ongoing	8 (53%)	13 (45%)
Event Summary		
Deterioration	1 (7%)	0
Death	4 (27%)	16 (55%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	9.5 (1.1, 20.7)	2.9 (1.0, 5.5)
Median (95% CI)	20.7 (8.0, -)	5.7 (4.9, -)
3rd Quartile (95% CI)	- (13.5, -)	18.7 (6.6, -)
Log-Rank P-value [2]		0.0532
Hazard Ratio (95% CI) [3]		4.20 (0.89, 19.91)
P-value [3]		0.0709

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd1_c30_lf.sas 14MAR2023 15:56

Protocol: 207495 Page 8 of 30
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.059110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 1
(Up to and including Last Follow-Up)

Item Score: Emotional Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of subsequent visits with confirmation for subjects who permanently deteriorated or died		
n	5	16
0	4 / 5 (80%)	16 / 16 (100%)
1	0 / 5	0 / 16
2	1 / 5 (20%)	0 / 16
3	0 / 5	0 / 16
>=4	0 / 5	0 / 16
Number of subsequent visits with confirmation for subjects who deteriorated towards end of observation period [4]		
n	1	2
0	0 / 1	2 / 2 (100%)
1	1 / 1 (100%)	0 / 2

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd1_c30_lf.sas 14MAR2023 15:56

Protocol: 207495 Page 9 of 30
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.059110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 1
(Up to and including Last Follow-Up)

Item Score: Cognitive Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated or Died (event)	6 (40%)	16 (55%)
Censored, follow-up ended	1 (7%)	0
Censored, follow-up ongoing	8 (53%)	13 (45%)
Event Summary		
Deterioration	2 (13%)	2 (7%)
Death	4 (27%)	14 (48%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	8.0 (1.1, 13.5)	2.1 (0.9, 5.1)
Median (95% CI)	13.5 (5.0, -)	5.5 (2.9, -)
3rd Quartile (95% CI)	- (9.5, -)	18.7 (9.5, -)
Log-Rank P-value [2]		0.2958
Hazard Ratio (95% CI) [3]		1.87 (0.57, 6.16)
P-value [3]		0.3020

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd1_c30_lf.sas 14MAR2023 15:56

Table 4.059110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 1
(Up to and including Last Follow-Up)

Item Score: Cognitive Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of subsequent visits with confirmation for subjects who permanently deteriorated or died		
n	6	16
0	4 / 6 (67%)	14 / 16 (88%)
1	0 / 6	0 / 16
2	1 / 6 (17%)	1 / 16 (6%)
3	0 / 6	0 / 16
>=4	1 / 6 (17%)	1 / 16 (6%)
Number of subsequent visits with confirmation for subjects who deteriorated towards end of observation period [4]		
n	1	1
0	1 / 1 (100%)	0 / 1
1	0 / 1	1 / 1 (100%)

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

Table 4.059110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 1
(Up to and including Last Follow-Up)

Item Score: Social Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated or Died (event)	5 (33%)	16 (55%)
Censored, follow-up ended	1 (7%)	0
Censored, follow-up ongoing	9 (60%)	13 (45%)
Event Summary		
Deterioration	1 (7%)	0
Death	4 (27%)	16 (55%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	8.0 (1.1, -)	2.9 (1.0, 5.5)
Median (95% CI)	13.5 (8.0, -)	5.7 (4.9, -)
3rd Quartile (95% CI)	- (13.5, -)	18.7 (6.6, -)
Log-Rank P-value [2]		0.1379
Hazard Ratio (95% CI) [3]		2.64 (0.70, 9.95)
P-value [3]		0.1504

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

Protocol: 207495 Page 12 of 30
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.059110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 1
(Up to and including Last Follow-Up)

Item Score: Social Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of subsequent visits with confirmation for subjects who permanently deteriorated or died		
n	5	16
0	4 / 5 (80%)	16 / 16 (100%)
1	0 / 5	0 / 16
2	0 / 5	0 / 16
3	1 / 5 (20%)	0 / 16
>=4	0 / 5	0 / 16
Number of subsequent visits with confirmation for subjects who deteriorated towards end of observation period [4]		
n	1	2
0	1 / 1 (100%)	2 / 2 (100%)
1	0 / 1	0 / 2

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd1_c30_lf.sas 14MAR2023 15:56

Table 4.059110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 1
(Up to and including Last Follow-Up)

Item Score: Fatigue Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated or Died (event)	7 (47%)	16 (55%)
Censored, follow-up ended	1 (7%)	0
Censored, follow-up ongoing	7 (47%)	13 (45%)
Event Summary		
Deterioration	4 (27%)	1 (3%)
Death	3 (20%)	15 (52%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	2.1 (0.7, 13.5)	2.1 (1.0, 5.1)
Median (95% CI)	13.5 (1.1, -)	5.7 (2.9, -)
3rd Quartile (95% CI)	20.7 (13.5, -)	18.7 (6.6, -)
Log-Rank P-value [2]		0.2448
Hazard Ratio (95% CI) [3]		2.02 (0.61, 6.68)
P-value [3]		0.2520

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

Protocol: 207495 Page 14 of 30
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.059110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 1
(Up to and including Last Follow-Up)

Item Score: Fatigue Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of subsequent visits with confirmation for subjects who permanently deteriorated or died		
n	7	16
0	3 / 7 (43%)	15 / 16 (94%)
1	0 / 7	0 / 16
2	1 / 7 (14%)	1 / 16 (6%)
3	1 / 7 (14%)	0 / 16
>=4	2 / 7 (29%)	0 / 16
Number of subsequent visits with confirmation for subjects who deteriorated towards end of observation period [4]		
n	1	6
0	1 / 1 (100%)	5 / 6 (83%)
1	0 / 1	1 / 6 (17%)

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd1_c30_lf.sas 14MAR2023 15:56

Protocol: 207495 Page 15 of 30
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.059110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 1
(Up to and including Last Follow-Up)

Item Score: Nausea and Vomiting Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated or Died (event)	5 (33%)	16 (55%)
Censored, follow-up ended	2 (13%)	0
Censored, follow-up ongoing	8 (53%)	13 (45%)
Event Summary		
Deterioration	1 (7%)	0
Death	4 (27%)	16 (55%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	9.5 (1.1, 20.7)	2.9 (1.0, 5.5)
Median (95% CI)	20.7 (8.0, -)	5.7 (4.9, -)
3rd Quartile (95% CI)	- (13.5, -)	18.7 (6.6, -)
Log-Rank P-value [2]		0.0532
Hazard Ratio (95% CI) [3]		4.20 (0.89, 19.91)
P-value [3]		0.0709

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd1_c30_lf.sas 14MAR2023 15:56

Protocol: 207495 Page 16 of 30
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.059110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 1
(Up to and including Last Follow-Up)

Item Score: Nausea and Vomiting Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of subsequent visits with confirmation for subjects who permanently deteriorated or died		
n	5	16
0	4 / 5 (80%)	16 / 16 (100%)
1	0 / 5	0 / 16
2	1 / 5 (20%)	0 / 16
3	0 / 5	0 / 16
>=4	0 / 5	0 / 16
Number of subsequent visits with confirmation for subjects who deteriorated towards end of observation period [4]		
n	0	1
0	0	1 / 1 (100%)
1	0	0 / 1

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd1_c30_lf.sas 14MAR2023 15:56

Protocol: 207495 Page 17 of 30
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.059110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 1
(Up to and including Last Follow-Up)

Item Score: Pain Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated or Died (event)	4 (27%)	17 (59%)
Censored, follow-up ended	2 (13%)	0
Censored, follow-up ongoing	9 (60%)	12 (41%)
Event Summary		
Deterioration	0	2 (7%)
Death	4 (27%)	15 (52%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	9.5 (1.1, -)	1.7 (0.9, 5.1)
Median (95% CI)	- (8.0, -)	5.7 (2.9, 18.7)
3rd Quartile (95% CI)	- (13.5, -)	18.7 (6.6, -)
Log-Rank P-value [2]		0.0475
Hazard Ratio (95% CI) [3]		4.29 (0.91, 20.10)
P-value [3]		0.0648

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd1_c30_lf.sas 14MAR2023 15:56

Protocol: 207495 Page 18 of 30
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.059110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 1
(Up to and including Last Follow-Up)

Item Score: Pom/Dex Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of subsequent visits with confirmation for subjects who permanently deteriorated or died		
n	4	17
0	4 / 4 (100%)	15 / 17 (88%)
1	0 / 4	0 / 17
2	0 / 4	1 / 17 (6%)
3	0 / 4	0 / 17
>=4	0 / 4	1 / 17 (6%)
Number of subsequent visits with confirmation for subjects who deteriorated towards end of observation period [4]		
n	0	2
0	0	2 / 2 (100%)
1	0	0 / 2

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd1_c30_lf.sas 14MAR2023 15:56

Protocol: 207495 Page 19 of 30
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.059110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 1
(Up to and including Last Follow-Up)

Item Score: Dyspnoea Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated or Died (event)	7 (47%)	18 (62%)
Censored, follow-up ended	1 (7%)	0
Censored, follow-up ongoing	7 (47%)	11 (38%)
Event Summary		
Deterioration	3 (20%)	3 (10%)
Death	4 (27%)	15 (52%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	7.0 (1.1, 13.5)	2.1 (0.9, 5.1)
Median (95% CI)	13.5 (7.0, -)	5.5 (2.6, 9.5)
3rd Quartile (95% CI)	20.7 (9.5, -)	18.7 (6.6, -)
Log-Rank P-value [2]		0.2075
Hazard Ratio (95% CI) [3]		2.09 (0.65, 6.75)
P-value [3]		0.2160

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd1_c30_lf.sas 14MAR2023 15:56

Protocol: 207495 Page 20 of 30
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.059110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 1
(Up to and including Last Follow-Up)

Item Score: Dyspnoea Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of subsequent visits with confirmation for subjects who permanently deteriorated or died		
n	7	18
0	4 / 7 (57%)	15 / 18 (83%)
1	0 / 7	0 / 18
2	1 / 7 (14%)	1 / 18 (6%)
3	2 / 7 (29%)	0 / 18
>=4	0 / 7	2 / 18 (11%)
Number of subsequent visits with confirmation for subjects who deteriorated towards end of observation period [4]		
n	0	2
0	0	2 / 2 (100%)
1	0	0 / 2

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd1_c30_lf.sas 14MAR2023 15:56

Table 4.059110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 1
(Up to and including Last Follow-Up)

Item Score: Insomnia Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated or Died (event)	4 (27%)	16 (55%)
Censored, follow-up ended	2 (13%)	0
Censored, follow-up ongoing	9 (60%)	13 (45%)
Event Summary		
Deterioration	0	0
Death	4 (27%)	16 (55%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	9.5 (1.1, -)	2.9 (1.0, 5.5)
Median (95% CI)	- (8.0, -)	5.7 (4.9, -)
3rd Quartile (95% CI)	- (13.5, -)	18.7 (6.6, -)
Log-Rank P-value [2]		0.0532
Hazard Ratio (95% CI) [3]		4.20 (0.89, 19.91)
P-value [3]		0.0709

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

Protocol: 207495 Page 22 of 30
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.059110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 1
(Up to and including Last Follow-Up)

Item Score: Insomnia Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of subsequent visits with confirmation for subjects who permanently deteriorated or died		
n	4	16
0	4 / 4 (100%)	16 / 16 (100%)
1	0 / 4	0 / 16
2	0 / 4	0 / 16
3	0 / 4	0 / 16
>=4	0 / 4	0 / 16
Number of subsequent visits with confirmation for subjects who deteriorated towards end of observation period [4]		
n	1	4
0	1 / 1 (100%)	4 / 4 (100%)
1	0 / 1	0 / 4

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd1_c30_lf.sas 14MAR2023 15:56

Table 4.059110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 1
(Up to and including Last Follow-Up)

Item Score: Appetite Loss Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated or Died (event)	4 (27%)	16 (55%)
Censored, follow-up ended	2 (13%)	0
Censored, follow-up ongoing	9 (60%)	13 (45%)
Event Summary		
Deterioration	0	0
Death	4 (27%)	16 (55%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	9.5 (1.1, -)	2.9 (1.0, 5.5)
Median (95% CI)	- (8.0, -)	5.7 (4.9, -)
3rd Quartile (95% CI)	- (13.5, -)	18.7 (6.6, -)
Log-Rank P-value [2]		0.0532
Hazard Ratio (95% CI) [3]		4.20 (0.89, 19.91)
P-value [3]		0.0709

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

Protocol: 207495 Page 24 of 30
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.059110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 1
(Up to and including Last Follow-Up)

Item Score: Appetite Loss Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of subsequent visits with confirmation for subjects who permanently deteriorated or died		
n	4	16
0	4 / 4 (100%)	16 / 16 (100%)
1	0 / 4	0 / 16
2	0 / 4	0 / 16
3	0 / 4	0 / 16
>=4	0 / 4	0 / 16
Number of subsequent visits with confirmation for subjects who deteriorated towards end of observation period [4]		
n	0	1
0	0	1 / 1 (100%)
1	0	0 / 1

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd1_c30_lf.sas 14MAR2023 15:56

Protocol: 207495 Page 25 of 30
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.059110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 1
(Up to and including Last Follow-Up)

Item Score: Constipation Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated or Died (event)	7 (47%)	16 (55%)
Censored, follow-up ended	1 (7%)	0
Censored, follow-up ongoing	7 (47%)	13 (45%)
Event Summary		
Deterioration	3 (20%)	1 (3%)
Death	4 (27%)	15 (52%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	8.0 (1.1, 13.5)	2.1 (1.0, 5.1)
Median (95% CI)	13.5 (8.0, -)	5.7 (2.9, -)
3rd Quartile (95% CI)	20.6 (11.3, -)	18.7 (6.6, -)
Log-Rank P-value [2]		0.1630
Hazard Ratio (95% CI) [3]		2.51 (0.66, 9.44)
P-value [3]		0.1748

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd1_c30_lf.sas 14MAR2023 15:56

Protocol: 207495 Page 26 of 30
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.059110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 1
(Up to and including Last Follow-Up)

Item Score: Constipation Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of subsequent visits with confirmation for subjects who permanently deteriorated or died		
n	7	16
0	4 / 7 (57%)	15 / 16 (94%)
1	0 / 7	0 / 16
2	2 / 7 (29%)	1 / 16 (6%)
3	1 / 7 (14%)	0 / 16
>=4	0 / 7	0 / 16
Number of subsequent visits with confirmation for subjects who deteriorated towards end of observation period [4]		
n	1	1
0	1 / 1 (100%)	1 / 1 (100%)
1	0 / 1	0 / 1

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd1_c30_lf.sas 14MAR2023 15:56

Protocol: 207495 Page 27 of 30
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.059110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 1
(Up to and including Last Follow-Up)

Item Score: Diarrhoea Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated or Died (event)	4 (27%)	16 (55%)
Censored, follow-up ended	2 (13%)	0
Censored, follow-up ongoing	9 (60%)	13 (45%)
Event Summary		
Deterioration	0	0
Death	4 (27%)	16 (55%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	9.5 (1.1, -)	2.9 (1.0, 5.5)
Median (95% CI)	- (8.0, -)	5.7 (4.9, -)
3rd Quartile (95% CI)	- (13.5, -)	18.7 (6.6, -)
Log-Rank P-value [2]		0.0532
Hazard Ratio (95% CI) [3]		4.20 (0.89, 19.91)
P-value [3]		0.0709

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd1_c30_lf.sas 14MAR2023 15:56

Protocol: 207495 Page 28 of 30
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.059110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 1
(Up to and including Last Follow-Up)

Item Score: Diarrhoea Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of subsequent visits with confirmation for subjects who permanently deteriorated or died		
n	4	16
0	4 / 4 (100%)	16 / 16 (100%)
1	0 / 4	0 / 16
2	0 / 4	0 / 16
3	0 / 4	0 / 16
>=4	0 / 4	0 / 16
Number of subsequent visits with confirmation for subjects who deteriorated towards end of observation period [4]		
n	0	1
0	0	0 / 1
1	0	1 / 1 (100%)

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd1_c30_lf.sas 14MAR2023 15:56

Protocol: 207495 Page 29 of 30
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.059110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 1
(Up to and including Last Follow-Up)

Item Score: Financial Difficulties Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated or Died (event)	5 (33%)	17 (59%)
Censored, follow-up ended	2 (13%)	0
Censored, follow-up ongoing	8 (53%)	12 (41%)
Event Summary		
Deterioration	1 (7%)	1 (3%)
Death	4 (27%)	16 (55%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	9.5 (1.1, 13.5)	2.3 (1.0, 5.1)
Median (95% CI)	13.5 (8.0, -)	5.7 (2.9, 18.7)
3rd Quartile (95% CI)	- (11.3, -)	18.7 (5.7, -)
Log-Rank P-value [2]		0.0376
Hazard Ratio (95% CI) [3]		4.54 (0.97, 21.22)
P-value [3]		0.0543

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd1_c30_lf.sas 14MAR2023 15:56

Protocol: 207495 Page 30 of 30
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.059110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 1
(Up to and including Last Follow-Up)

Item Score: Financial Difficulties Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of subsequent visits with confirmation for subjects who permanently deteriorated or died		
n	5	17
0	4 / 5 (80%)	16 / 17 (94%)
1	0 / 5	0 / 17
2	1 / 5 (20%)	0 / 17
3	0 / 5	0 / 17
>=4	0 / 5	1 / 17 (6%)
Number of subsequent visits with confirmation for subjects who deteriorated towards end of observation period [4]		
n	2	1
0	2 / 2 (100%)	1 / 1 (100%)
1	0 / 2	0 / 1

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd1_c30_lf.sas 14MAR2023 15:56

Protocol: 207495 Page 1 of 30
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.060110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 2
(Up to and including Last Follow-Up)

Item Score: Global Health Status Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated (event)	4 (27%)	2 (7%)
Censored, follow-up ended	5 (33%)	14 (48%)
Censored, follow-up ongoing	6 (40%)	13 (45%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	5.6 (0.8, -)	- (1.4, -)
Median (95% CI)	20.7 (4.9, -)	- (-, -)
3rd Quartile (95% CI)	- (20.7, -)	- (-, -)
Log-Rank P-value [2]		0.4846
Hazard Ratio (95% CI) [3]		0.38 (0.02, 6.20)
P-value [3]		0.5007

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd2_c30_lf.sas 14MAR2023 17:06

Protocol: 207495 Page 2 of 30
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.060110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 2
(Up to and including Last Follow-Up)

Item Score: Global Health Status Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of subsequent visits with confirmation for subjects who permanently deteriorated		
n	4	2
0	0 / 4	0 / 2
1	0 / 4	0 / 2
2	1 / 4 (25%)	1 / 2 (50%)
3	0 / 4	1 / 2 (50%)
>=4	3 / 4 (75%)	0 / 2
Number of subsequent visits with confirmation for subjects who deteriorated towards end of observation period [4]		
n	3	9
0	2 / 3 (67%)	4 / 9 (44%)
1	1 / 3 (33%)	5 / 9 (56%)

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd2_c30_lf.sas 14MAR2023 17:06

Table 4.060110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 2
(Up to and including Last Follow-Up)

Item Score: Physical Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated (event)	2 (13%)	1 (3%)
Censored, follow-up ended	4 (27%)	16 (55%)
Censored, follow-up ongoing	9 (60%)	12 (41%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (2.1, -)	- (2.3, -)
Median (95% CI)	- (2.4, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		0.5436
Hazard Ratio (95% CI) [3]		0.43 (0.03, 6.97)
P-value [3]		0.5551

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

Protocol: 207495 Page 4 of 30
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.060110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 2
(Up to and including Last Follow-Up)

Item Score: Physical Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of subsequent visits with confirmation for subjects who permanently deteriorated		
n	2	1
0	0 / 2	0 / 1
1	0 / 2	0 / 1
2	1 / 2 (50%)	0 / 1
3	1 / 2 (50%)	1 / 1 (100%)
>=4	0 / 2	0 / 1
Number of subsequent visits with confirmation for subjects who deteriorated towards end of observation period [4]		
n	1	8
0	1 / 1 (100%)	5 / 8 (63%)
1	0 / 1	3 / 8 (38%)

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd2_c30_lf.sas 14MAR2023 17:06

Table 4.060110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 2
(Up to and including Last Follow-Up)

Item Score: Role Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated (event)	3 (20%)	3 (10%)
Censored, follow-up ended	4 (27%)	14 (48%)
Censored, follow-up ongoing	8 (53%)	12 (41%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	20.7 (1.5, -)	- (1.0, -)
Median (95% CI)	20.7 (2.1, -)	- (5.1, -)
3rd Quartile (95% CI)	- (20.7, -)	- (-, -)
Log-Rank P-value [2]		0.9706
Hazard Ratio (95% CI) [3]		1.05 (0.09, 11.54)
P-value [3]		0.9708

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

Protocol: 207495 Page 6 of 30
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.060110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 2
(Up to and including Last Follow-Up)

Item Score: Role Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of subsequent visits with confirmation for subjects who permanently deteriorated		
n	3	3
0	0 / 3	0 / 3
1	0 / 3	0 / 3
2	1 / 3 (33%)	2 / 3 (67%)
3	2 / 3 (67%)	0 / 3
>=4	0 / 3	1 / 3 (33%)
Number of subsequent visits with confirmation for subjects who deteriorated towards end of observation period [4]		
n	1	5
0	1 / 1 (100%)	2 / 5 (40%)
1	0 / 1	3 / 5 (60%)

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd2_c30_lf.sas 14MAR2023 17:06

Table 4.060110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 2
(Up to and including Last Follow-Up)

Item Score: Emotional Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated (event)	1 (7%)	0
Censored, follow-up ended	6 (40%)	16 (55%)
Censored, follow-up ongoing	8 (53%)	13 (45%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	20.7 (20.7, -)	- (-, -)
Median (95% CI)	- (20.7, -)	- (-, -)
3rd Quartile (95% CI)	- (20.7, -)	- (-, -)
Log-Rank P-value [2]		-
Hazard Ratio (95% CI) [3]		- (-, -)
P-value [3]		-

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

Protocol: 207495 Page 8 of 30
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.060110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 2
(Up to and including Last Follow-Up)

Item Score: Emotional Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of subsequent visits with confirmation for subjects who permanently deteriorated		
n	1	0
0	0 / 1	0
1	0 / 1	0
2	1 / 1 (100%)	0
3	0 / 1	0
>=4	0 / 1	0
Number of subsequent visits with confirmation for subjects who deteriorated towards end of observation period [4]		
n	2	5
0	0 / 2	5 / 5 (100%)
1	2 / 2 (100%)	0 / 5

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd2_c30_lf.sas 14MAR2023 17:06

Table 4.060110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 2
(Up to and including Last Follow-Up)

Item Score: Cognitive Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated (event)	2 (13%)	2 (7%)
Censored, follow-up ended	5 (33%)	14 (48%)
Censored, follow-up ongoing	8 (53%)	13 (45%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (2.9, -)	- (0.7, -)
Median (95% CI)	- (5.0, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		0.2228
Hazard Ratio (95% CI) [3]		0.25 (0.02, 2.77)
P-value [3]		0.2594

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

Table 4.060110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 2
(Up to and including Last Follow-Up)

Item Score: Cognitive Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of subsequent visits with confirmation for subjects who permanently deteriorated		
n	2	2
0	0 / 2	0 / 2
1	0 / 2	0 / 2
2	1 / 2 (50%)	1 / 2 (50%)
3	0 / 2	0 / 2
>=4	1 / 2 (50%)	1 / 2 (50%)
Number of subsequent visits with confirmation for subjects who deteriorated towards end of observation period [4]		
n	2	4
0	2 / 2 (100%)	2 / 4 (50%)
1	0 / 2	2 / 4 (50%)

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

Table 4.060110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 2
(Up to and including Last Follow-Up)

Item Score: Social Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated (event)	1 (7%)	0
Censored, follow-up ended	5 (33%)	16 (55%)
Censored, follow-up ongoing	9 (60%)	13 (45%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (2.1, -)	- (-, -)
Median (95% CI)	- (-, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		0.1859
Hazard Ratio (95% CI) [3]		<0.01 (<0.01, -)
P-value [3]		0.9984

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

Table 4.060110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 2
(Up to and including Last Follow-Up)

Item Score: Social Functioning Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of subsequent visits with confirmation for subjects who permanently deteriorated		
n	1	0
0	0 / 1	0
1	0 / 1	0
2	0 / 1	0
3	1 / 1 (100%)	0
>=4	0 / 1	0
Number of subsequent visits with confirmation for subjects who deteriorated towards end of observation period [4]		
n	2	9
0	1 / 2 (50%)	7 / 9 (78%)
1	1 / 2 (50%)	2 / 9 (22%)

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

Protocol: 207495 Page 13 of 30
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.060110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 2
(Up to and including Last Follow-Up)

Item Score: Fatigue Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated (event)	4 (27%)	1 (3%)
Censored, follow-up ended	4 (27%)	15 (52%)
Censored, follow-up ongoing	7 (47%)	13 (45%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	2.1 (0.7, -)	- (1.0, -)
Median (95% CI)	20.7 (0.8, -)	- (-, -)
3rd Quartile (95% CI)	- (20.7, -)	- (-, -)
Log-Rank P-value [2]		0.3643
Hazard Ratio (95% CI) [3]		0.33 (0.03, 4.02)
P-value [3]		0.3821

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd2_c30_lf.sas 14MAR2023 17:06

Protocol: 207495 Page 14 of 30
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.060110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 2
(Up to and including Last Follow-Up)

Item Score: Fatigue Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of subsequent visits with confirmation for subjects who permanently deteriorated		
n	4	1
0	0 / 4	0 / 1
1	0 / 4	0 / 1
2	1 / 4 (25%)	1 / 1 (100%)
3	1 / 4 (25%)	0 / 1
>=4	2 / 4 (50%)	0 / 1
Number of subsequent visits with confirmation for subjects who deteriorated towards end of observation period [4]		
n	1	12
0	1 / 1 (100%)	9 / 12 (75%)
1	0 / 1	3 / 12 (25%)

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd2_c30_lf.sas 14MAR2023 17:06

Table 4.060110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 2
(Up to and including Last Follow-Up)

Item Score: Nausea and Vomiting Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated (event)	1 (7%)	0
Censored, follow-up ended	6 (40%)	16 (55%)
Censored, follow-up ongoing	8 (53%)	13 (45%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	20.7 (20.7, -)	- (-, -)
Median (95% CI)	- (20.7, -)	- (-, -)
3rd Quartile (95% CI)	- (20.7, -)	- (-, -)
Log-Rank P-value [2]		-
Hazard Ratio (95% CI) [3]		- (-, -)
P-value [3]		-

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

Table 4.060110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 2
(Up to and including Last Follow-Up)

Item Score: Nausea and Vomiting Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of subsequent visits with confirmation for subjects who permanently deteriorated		
n	1	0
0	0 / 1	0
1	0 / 1	0
2	1 / 1 (100%)	0
3	0 / 1	0
>=4	0 / 1	0
Number of subsequent visits with confirmation for subjects who deteriorated towards end of observation period [4]		
n	1	4
0	1 / 1 (100%)	2 / 4 (50%)
1	0 / 1	2 / 4 (50%)

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

Table 4.060110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 2
(Up to and including Last Follow-Up)

Item Score: Pain Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated (event)	0	2 (7%)
Censored, follow-up ended	6 (40%)	15 (52%)
Censored, follow-up ongoing	9 (60%)	12 (41%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (-, -)	- (0.9, -)
Median (95% CI)	- (-, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		0.3312
Hazard Ratio (95% CI) [3]		>999.99 (<0.01, -)
P-value [3]		0.9980

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

Protocol: 207495 Page 18 of 30
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.060110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 2
(Up to and including Last Follow-Up)

Item Score: Pain Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of subsequent visits with confirmation for subjects who permanently deteriorated		
n	0	2
0	0	0 / 2
1	0	0 / 2
2	0	1 / 2 (50%)
3	0	0 / 2
>=4	0	1 / 2 (50%)
Number of subsequent visits with confirmation for subjects who deteriorated towards end of observation period [4]		
n	0	4
0	0	2 / 4 (50%)
1	0	2 / 4 (50%)

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd2_c30_lf.sas 14MAR2023 17:06

Table 4.060110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 2
(Up to and including Last Follow-Up)

Item Score: Dyspnoea Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated (event)	3 (20%)	3 (10%)
Censored, follow-up ended	5 (33%)	15 (52%)
Censored, follow-up ongoing	7 (47%)	11 (38%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	20.7 (2.1, -)	- (0.7, -)
Median (95% CI)	20.7 (7.0, -)	- (7.0, -)
3rd Quartile (95% CI)	- (20.7, -)	- (-, -)
Log-Rank P-value [2]		0.5403
Hazard Ratio (95% CI) [3]		0.55 (0.08, 3.90)
P-value [3]		0.5464

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

Protocol: 207495 Page 20 of 30
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.060110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 2
(Up to and including Last Follow-Up)

Item Score: Dyspnoea Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of subsequent visits with confirmation for subjects who permanently deteriorated		
n	3	3
0	0 / 3	0 / 3
1	0 / 3	0 / 3
2	1 / 3 (33%)	1 / 3 (33%)
3	2 / 3 (67%)	0 / 3
>=4	0 / 3	2 / 3 (67%)
Number of subsequent visits with confirmation for subjects who deteriorated towards end of observation period [4]		
n	1	5
0	0 / 1	4 / 5 (80%)
1	1 / 1 (100%)	1 / 5 (20%)

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd2_c30_lf.sas 14MAR2023 17:06

Table 4.060110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 2
(Up to and including Last Follow-Up)

Item Score: Insomnia Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated (event)	0	0
Censored, follow-up ended	6 (40%)	16 (55%)
Censored, follow-up ongoing	9 (60%)	13 (45%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (-, -)	- (-, -)
Median (95% CI)	- (-, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		-
Hazard Ratio (95% CI) [3]		- (-, -)
P-value [3]		-

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

Protocol: 207495 Page 22 of 30
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.060110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 2
(Up to and including Last Follow-Up)

Item Score: Insomnia Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of subsequent visits with confirmation for subjects who permanently deteriorated		
n	0	0
0	0	0
1	0	0
2	0	0
3	0	0
>=4	0	0
Number of subsequent visits with confirmation for subjects who deteriorated towards end of observation period [4]		
n	2	8
0	2 / 2 (100%)	8 / 8 (100%)
1	0 / 2	0 / 8

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd2_c30_lf.sas 14MAR2023 17:06

Table 4.060110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 2
(Up to and including Last Follow-Up)

Item Score: Appetite Loss Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated (event)	0	0
Censored, follow-up ended	6 (40%)	16 (55%)
Censored, follow-up ongoing	9 (60%)	13 (45%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (-, -)	- (-, -)
Median (95% CI)	- (-, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		-
Hazard Ratio (95% CI) [3]		- (-, -)
P-value [3]		-

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

Protocol: 207495 Page 24 of 30
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.060110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 2
(Up to and including Last Follow-Up)

Item Score: Appetite Loss Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of subsequent visits with confirmation for subjects who permanently deteriorated		
n	0	0
0	0	0
1	0	0
2	0	0
3	0	0
>=4	0	0
Number of subsequent visits with confirmation for subjects who deteriorated towards end of observation period [4]		
n	1	6
0	1 / 1 (100%)	3 / 6 (50%)
1	0 / 1	3 / 6 (50%)

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd2_c30_lf.sas 14MAR2023 17:06

Table 4.060110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 2
(Up to and including Last Follow-Up)

Item Score: Constipation Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated (event)	3 (20%)	1 (3%)
Censored, follow-up ended	5 (33%)	15 (52%)
Censored, follow-up ongoing	7 (47%)	13 (45%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	11.3 (2.1, -)	- (1.0, -)
Median (95% CI)	20.6 (11.3, -)	- (-, -)
3rd Quartile (95% CI)	- (11.3, -)	- (-, -)
Log-Rank P-value [2]		0.6171
Hazard Ratio (95% CI) [3]		0.50 (0.03, 7.99)
P-value [3]		0.6241

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

Protocol: 207495 Page 26 of 30
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.060110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 2
(Up to and including Last Follow-Up)

Item Score: Constipation Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of subsequent visits with confirmation for subjects who permanently deteriorated		
n	3	1
0	0 / 3	0 / 1
1	0 / 3	0 / 1
2	2 / 3 (67%)	1 / 1 (100%)
3	1 / 3 (33%)	0 / 1
>=4	0 / 3	0 / 1
Number of subsequent visits with confirmation for subjects who deteriorated towards end of observation period [4]		
n	1	4
0	1 / 1 (100%)	3 / 4 (75%)
1	0 / 1	1 / 4 (25%)

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd2_c30_lf.sas 14MAR2023 17:06

Protocol: 207495 Page 27 of 30
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.060110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 2
(Up to and including Last Follow-Up)

Item Score: Diarrhoea Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated (event)	0	0
Censored, follow-up ended	6 (40%)	16 (55%)
Censored, follow-up ongoing	9 (60%)	13 (45%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (-, -)	- (-, -)
Median (95% CI)	- (-, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		-
Hazard Ratio (95% CI) [3]		- (-, -)
P-value [3]		-

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd2_c30_lf.sas 14MAR2023 17:06

Protocol: 207495 Page 28 of 30
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.060110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 2
(Up to and including Last Follow-Up)

Item Score: Diarrhoea Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of subsequent visits with confirmation for subjects who permanently deteriorated		
n	0	0
0	0	0
1	0	0
2	0	0
3	0	0
>=4	0	0
Number of subsequent visits with confirmation for subjects who deteriorated towards end of observation period [4]		
n	1	3
0	0 / 1	2 / 3 (67%)
1	1 / 1 (100%)	1 / 3 (33%)

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd2_c30_lf.sas 14MAR2023 17:06

Protocol: 207495 Page 29 of 30
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.060110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 2
(Up to and including Last Follow-Up)

Item Score: Financial Difficulties Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated (event)	1 (7%)	1 (3%)
Censored, follow-up ended	6 (40%)	16 (55%)
Censored, follow-up ongoing	8 (53%)	12 (41%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (11.3, -)	- (2.3, -)
Median (95% CI)	- (11.3, -)	- (-, -)
3rd Quartile (95% CI)	- (11.3, -)	- (-, -)
Log-Rank P-value [2]		0.4497
Hazard Ratio (95% CI) [3]		>999.99 (<0.01, -)
P-value [3]		0.9985

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd2_c30_lf.sas 14MAR2023 17:06

Protocol: 207495 Page 30 of 30
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.060110
Summary of EORTC QLQ-C30 Time to permanent Deterioration 2
(Up to and including Last Follow-Up)

Item Score: Financial Difficulties Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of subsequent visits with confirmation for subjects who permanently deteriorated		
n	1	1
0	0 / 1	0 / 1
1	0 / 1	0 / 1
2	1 / 1 (100%)	0 / 1
3	0 / 1	0 / 1
>=4	0 / 1	1 / 1 (100%)
Number of subsequent visits with confirmation for subjects who deteriorated towards end of observation period [4]		
n	3	4
0	2 / 3 (67%)	3 / 4 (75%)
1	1 / 3 (33%)	1 / 4 (25%)

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd2_c30_lf.sas 14MAR2023 17:06

Protocol: 207495 Page 1 of 168
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Future Perspective Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Baseline	Actual Score	n	2	4
		Mean	55.56	52.78
		SD	0.000	36.712
		Median	55.56	66.67
		Min.	55.6	0.0
		Max.	55.6	77.8

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_m20_dom.sas 10MAR2023 13:00

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Future Perspective Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 4	Actual Score	n	2	4
		Mean	72.22	50.00
		SD	7.857	37.952
		Median	72.22	55.56
		Min.	66.7	0.0
		Max.	77.8	88.9
	Change from Baseline	n	2	4
		Mean	16.67	-2.78
		SD	7.857	10.638
		Median	16.67	-5.56
		Min.	11.1	-11.1
		Max.	22.2	11.1
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	2 (100%)	1 (25%)
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	2 (100%)	1 (25%)
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	2 (50%)
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	2 (50%)

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Future Perspective Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 7	Actual Score	n	3	4
		Mean	44.44	50.00
		SD	38.490	41.076
		Median	66.67	55.56
		Min.	0.0	0.0
		Max.	66.7	88.9
	Change from Baseline	n	2	4
		Mean	11.11	-2.78
		SD	0.000	13.981
		Median	11.11	0.00
		Min.	11.1	-22.2
		Max.	11.1	11.1
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	2 (100%)	1 (25%)
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	2 (100%)	1 (25%)
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	1 (25%)
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	1 (25%)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_m20_dom.sas 10MAR2023 13:00

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Future Perspective Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 10	Actual Score	n	3	4
		Mean	51.85	58.33
		SD	44.905	39.933
		Median	77.78	72.22
		Min.	0.0	0.0
		Max.	77.8	88.9
	Change from Baseline	n	2	4
		Mean	22.22	5.56
		SD	0.000	6.415
		Median	22.22	5.56
		Min.	22.2	0.0
		Max.	22.2	11.1
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	2 (100%)	2 (50%)
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	2 (100%)	2 (50%)
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Future Perspective Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 13	Actual Score	n	3	3
		Mean	55.56	81.48
		SD	48.432	12.830
		Median	77.78	88.89
		Min.	0.0	66.7
		Max.	88.9	88.9
	Change from Baseline	n	2	3
		Mean	27.78	11.11
		SD	7.857	22.222
		Median	27.78	11.11
		Min.	22.2	-11.1
		Max.	33.3	33.3
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	2 (100%)	2 (67%)
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	2 (100%)	2 (67%)
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	1 (33%)
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	1 (33%)

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Future Perspective Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 16	Actual Score	n	3	3
		Mean	66.67	74.07
		SD	57.735	27.962
		Median	100.00	77.78
		Min.	0.0	44.4
		Max.	100.0	100.0
	Change from Baseline	n	2	3
		Mean	44.44	3.70
		SD	0.000	32.075
		Median	44.44	22.22
		Min.	44.4	-33.3
		Max.	44.4	22.2
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	2 (100%)	2 (67%)
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	2 (100%)	2 (67%)
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	1 (33%)
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	1 (33%)

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Future Perspective Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 19	Actual Score	n	3	3
		Mean	66.67	74.07
		SD	57.735	6.415
		Median	100.00	77.78
		Min.	0.0	66.7
		Max.	100.0	77.8
	Change from Baseline	n	2	3
		Mean	44.44	3.70
		SD	0.000	6.415
		Median	44.44	0.00
		Min.	44.4	0.0
		Max.	44.4	11.1
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	2 (100%)	1 (33%)
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	2 (100%)	1 (33%)
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Future Perspective Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 22	Actual Score	n	1	3
		Mean	11.11	70.37
		SD		6.415
		Median	11.11	66.67
		Min.	11.1	66.7
		Max.	11.1	77.8
	Change from Baseline	n	1	3
		Mean	-44.44	0.00
		SD		11.111
		Median	-44.44	0.00
		Min.	-44.4	-11.1
		Max.	-44.4	11.1
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	1 (33%)
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	1 (33%)
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	1 (100%)	1 (33%)
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	1 (100%)	1 (33%)

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Future Perspective Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 25	Actual Score	n	0	3
		Mean		66.67
		SD		0.000
		Median		66.67
		Min.		66.7
		Max.		66.7
	Change from Baseline	n	0	3
		Mean		-3.70
		SD		12.830
		Median		-11.11
		Min.		-11.1
		Max.		11.1
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	1 (33%)
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	1 (33%)
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	2 (67%)
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	2 (67%)

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Future Perspective Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 28	Actual Score	n	0	3
		Mean		70.37
		SD		6.415
		Median		66.67
		Min.		66.7
		Max.		77.8
	Change from Baseline	n	0	3
		Mean		0.00
		SD		11.111
		Median		0.00
		Min.		-11.1
		Max.		11.1
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	1 (33%)
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	1 (33%)
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	1 (33%)
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	1 (33%)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_m20_dom.sas 10MAR2023 13:00

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Future Perspective Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 31	Actual Score	n	0	3
		Mean		62.96
		SD		16.973
		Median		66.67
		Min.		44.4
		Max.		77.8
	Change from Baseline	n	0	3
		Mean		-7.41
		SD		6.415
		Median		-11.11
		Min.		-11.1
		Max.		0.0
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	2 (67%)
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	2 (67%)

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Future Perspective Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 34	Actual Score	n	0	3
		Mean		66.67
		SD		11.111
		Median		66.67
		Min.		55.6
		Max.		77.8
	Change from Baseline	n	0	3
		Mean		-3.70
		SD		6.415
		Median		0.00
		Min.		-11.1
		Max.		0.0
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	1 (33%)
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	1 (33%)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_m20_dom.sas 10MAR2023 13:00

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Future Perspective Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 37	Actual Score	n	0	3
		Mean		74.07
		SD		6.415
		Median		77.78
		Min.		66.7
		Max.		77.8
	Change from Baseline	n	0	3
		Mean		3.70
		SD		16.973
		Median		0.00
		Min.		-11.1
		Max.		22.2
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	1 (33%)
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	1 (33%)
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	1 (33%)
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	1 (33%)

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Future Perspective Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 40	Actual Score	n	0	2
		Mean		61.11
		SD		23.570
		Median		61.11
		Min.		44.4
		Max.		77.8
	Change from Baseline	n	0	2
		Mean		-5.56
		SD		7.857
		Median		-5.56
		Min.		-11.1
		Max.		0.0
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	1 (50%)
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	1 (50%)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_m20_dom.sas 10MAR2023 13:00

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Future Perspective Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 43	Actual Score	n	0	1
		Mean		55.56
		SD		
		Median		55.56
		Min.		55.6
		Max.		55.6
	Change from Baseline	n	0	1
		Mean		0.00
		SD		
		Median		0.00
		Min.		0.0
		Max.		0.0
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_m20_dom.sas 10MAR2023 13:00

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Future Perspective Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 46	Actual Score	n	0	1
		Mean		55.56
		SD		
		Median		55.56
		Min.		55.6
		Max.		55.6
	Change from Baseline	n	0	1
		Mean		0.00
		SD		
		Median		0.00
		Min.		0.0
		Max.		0.0
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_m20_dom.sas 10MAR2023 13:00

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Future Perspective Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 49	Actual Score	n	0	1
		Mean		77.78
		SD		
		Median		77.78
		Min.		77.8
		Max.		77.8
	Change from Baseline	n	0	1
		Mean		22.22
		SD		
		Median		22.22
		Min.		22.2
		Max.		22.2
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	1 (100%)
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	1 (100%)
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Future Perspective Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 52	Actual Score	n	0	1
		Mean		44.44
		SD		
		Median		44.44
		Min.		44.4
		Max.		44.4
	Change from Baseline	n	0	1
		Mean		-11.11
		SD		
		Median		-11.11
		Min.		-11.1
		Max.		-11.1
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	1 (100%)
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	1 (100%)

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Future Perspective Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 55	Actual Score	n	0	1
		Mean		55.56
		SD		
		Median		55.56
		Min.		55.6
		Max.		55.6
	Change from Baseline	n	0	1
		Mean		0.00
		SD		
		Median		0.00
		Min.		0.0
		Max.		0.0
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_m20_dom.sas 10MAR2023 13:00

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Future Perspective Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 58	Actual Score	n	0	1
		Mean		33.33
		SD		
		Median		33.33
		Min.		33.3
		Max.		33.3
	Change from Baseline	n	0	1
		Mean		-22.22
		SD		
		Median		-22.22
		Min.		-22.2
		Max.		-22.2
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	1 (100%)
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	1 (100%)

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Future Perspective Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 61	Actual Score	n	0	1
		Mean		44.44
		SD		
		Median		44.44
		Min.		44.4
		Max.		44.4
	Change from Baseline	n	0	1
		Mean		-11.11
		SD		
		Median		-11.11
		Min.		-11.1
		Max.		-11.1
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	1 (100%)
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	1 (100%)

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Future Perspective Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 64	Actual Score	n	0	1
		Mean		44.44
		SD		
		Median		44.44
		Min.		44.4
		Max.		44.4
	Change from Baseline	n	0	1
		Mean		-11.11
		SD		
		Median		-11.11
		Min.		-11.1
		Max.		-11.1
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	1 (100%)
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	1 (100%)

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Future Perspective Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 67	Actual Score	n	0	1
		Mean		33.33
		SD		
		Median		33.33
		Min.		33.3
		Max.		33.3
	Change from Baseline	n	0	1
		Mean		-22.22
		SD		
		Median		-22.22
		Min.		-22.2
		Max.		-22.2
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	1 (100%)
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	1 (100%)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_m20_dom.sas 10MAR2023 13:00

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Future Perspective Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 70	Actual Score	n	0	0
		Mean		
		SD		
		Median		
		Min.		
		Max.		
	Change from Baseline	n	0	0
		Mean		
		SD		
		Median		
		Min.		
		Max.		
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Future Perspective Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 73	Actual Score	n	0	0
		Mean		
		SD		
		Median		
		Min.		
		Max.		
	Change from Baseline	n	0	0
		Mean		
		SD		
		Median		
		Min.		
		Max.		
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Future Perspective Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 76	Actual Score	n	0	0
		Mean		
		SD		
		Median		
		Min.		
		Max.		
	Change from Baseline	n	0	0
		Mean		
		SD		
		Median		
		Min.		
		Max.		
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Future Perspective Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 79	Actual Score	n	0	0
		Mean		
		SD		
		Median		
		Min.		
		Max.		
	Change from Baseline	n	0	0
		Mean		
		SD		
		Median		
		Min.		
		Max.		
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Future Perspective Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 82	Actual Score	n	0	0
		Mean		
		SD		
		Median		
		Min.		
		Max.		
	Change from Baseline	n	0	0
		Mean		
		SD		
		Median		
		Min.		
		Max.		
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Future Perspective Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 85	Actual Score	n	0	0
		Mean		
		SD		
		Median		
		Min.		
		Max.		
	Change from Baseline	n	0	0
		Mean		
		SD		
		Median		
		Min.		
		Max.		
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Future Perspective Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 88	Actual Score	n	0	0
		Mean		
		SD		
		Median		
		Min.		
		Max.		
	Change from Baseline	n	0	0
		Mean		
		SD		
		Median		
		Min.		
		Max.		
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Future Perspective Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 91	Actual Score	n	0	0
		Mean		
		SD		
		Median		
		Min.		
		Max.		
	Change from Baseline	n	0	0
		Mean		
		SD		
		Median		
		Min.		
		Max.		
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Future Perspective Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 94	Actual Score	n	0	0
		Mean		
		SD		
		Median		
		Min.		
		Max.		
	Change from Baseline	n	0	0
		Mean		
		SD		
		Median		
		Min.		
		Max.		
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Future Perspective Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 97	Actual Score	n	0	0
		Mean		
		SD		
		Median		
		Min.		
		Max.		
	Change from Baseline	n	0	0
		Mean		
		SD		
		Median		
		Min.		
		Max.		
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Future Perspective Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 100	Actual Score	n	0	0
		Mean		
		SD		
		Median		
		Min.		
		Max.		
	Change from Baseline	n	0	0
		Mean		
		SD		
		Median		
		Min.		
		Max.		
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Future Perspective Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
End of Treatment	Actual Score	n	3	1
		Mean	40.74	0.00
		SD	35.717	
		Median	55.56	0.00
		Min.	0.0	0.0
		Max.	66.7	0.0
	Change from Baseline	n	2	1
		Mean	5.56	0.00
		SD	7.857	
		Median	5.56	0.00
		Min.	0.0	0.0
		Max.	11.1	0.0
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	1 (50%)	0
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_m20_dom.sas 10MAR2023 13:00

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Future Perspective Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 1	Actual Score	n	1	1
		Mean	0.00	0.00
		SD		
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Change from Baseline	n	0	1
		Mean		0.00
		SD		
		Median		0.00
		Min.		0.0
		Max.		0.0
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_m20_dom.sas 10MAR2023 13:00

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Future Perspective Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 2	Actual Score	n	1	1
		Mean	0.00	0.00
		SD		
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Change from Baseline	n	0	1
		Mean		0.00
		SD		
		Median		0.00
		Min.		0.0
		Max.		0.0
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_m20_dom.sas 10MAR2023 13:00

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Future Perspective Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 4	Actual Score	n	0	0
		Mean		
		SD		
		Median		
		Min.		
		Max.		
	Change from Baseline	n	0	0
		Mean		
		SD		
		Median		
		Min.		
		Max.		
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Future Perspective Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
PFS Follow-Up 2	Actual Score	n	0	0
		Mean		
		SD		
		Median		
		Min.		
		Max.		
	Change from Baseline	n	0	0
		Mean		
		SD		
		Median		
		Min.		
		Max.		
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Future Perspective Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
PFS Follow-Up 4	Actual Score	n	0	0
		Mean		
		SD		
		Median		
		Min.		
		Max.		
	Change from Baseline	n	0	0
		Mean		
		SD		
		Median		
		Min.		
		Max.		
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Future Perspective Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Last Follow-up	Actual Score	n	1	1
		Mean	0.00	0.00
		SD		
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Change from Baseline	n	0	1
		Mean		0.00
		SD		
		Median		0.00
		Min.		0.0
		Max.		0.0
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_m20_dom.sas 10MAR2023 13:00

Protocol: 207495 Page 42 of 168
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Future Perspective Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Worst Case Post-Baseline	Actual Score	n	3	4
		Mean	25.93	36.11
		SD	35.717	27.778
		Median	11.11	38.89
		Min.	0.0	0.0
		Max.	66.7	66.7
	Change from Baseline	n	2	4
		Mean	-16.67	-16.67
		SD	39.284	14.344
		Median	-16.67	-16.67
		Min.	-44.4	-33.3
		Max.	11.1	0.0
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	1 (50%)	0
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	1 (50%)	3 (75%)
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	1 (50%)	3 (75%)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_m20_dom.sas 10MAR2023 13:00

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Body Image Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Baseline	Actual Score	n	2	4
		Mean	66.67	66.67
		SD	0.000	47.140
		Median	66.67	83.33
		Min.	66.7	0.0
		Max.	66.7	100.0

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Body Image Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 4	Actual Score	n	2	4
		Mean	83.33	66.67
		SD	23.570	47.140
		Median	83.33	83.33
		Min.	66.7	0.0
		Max.	100.0	100.0
	Change from Baseline	n	2	4
		Mean	16.67	0.00
		SD	23.570	27.217
		Median	16.67	0.00
		Min.	0.0	-33.3
		Max.	33.3	33.3
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	1 (50%)	1 (25%)
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	1 (50%)	1 (25%)
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	1 (25%)
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	1 (25%)

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Body Image Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 7	Actual Score	n	3	4
		Mean	55.56	50.00
		SD	50.918	43.033
		Median	66.67	50.00
		Min.	0.0	0.0
		Max.	100.0	100.0
	Change from Baseline	n	2	4
		Mean	16.67	-16.67
		SD	23.570	43.033
		Median	16.67	-16.67
		Min.	0.0	-66.7
		Max.	33.3	33.3
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	1 (50%)	1 (25%)
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	1 (50%)	1 (25%)
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	2 (50%)
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	2 (50%)

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Body Image Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 10	Actual Score	n	3	4
		Mean	55.56	66.67
		SD	50.918	47.140
		Median	66.67	83.33
		Min.	0.0	0.0
		Max.	100.0	100.0
	Change from Baseline	n	2	4
		Mean	16.67	0.00
		SD	23.570	27.217
		Median	16.67	0.00
		Min.	0.0	-33.3
		Max.	33.3	33.3
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	1 (50%)	1 (25%)
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	1 (50%)	1 (25%)
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	1 (25%)
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	1 (25%)

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Body Image Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 13	Actual Score	n	3	3
		Mean	55.56	100.00
		SD	50.918	0.000
		Median	66.67	100.00
		Min.	0.0	100.0
		Max.	100.0	100.0
	Change from Baseline	n	2	3
		Mean	16.67	11.11
		SD	23.570	19.245
		Median	16.67	0.00
		Min.	0.0	0.0
		Max.	33.3	33.3
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	1 (50%)	1 (33%)
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	1 (50%)	1 (33%)
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Body Image Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 16	Actual Score	n	3	3
		Mean	66.67	77.78
		SD	57.735	19.245
		Median	100.00	66.67
		Min.	0.0	66.7
		Max.	100.0	100.0
	Change from Baseline	n	2	3
		Mean	33.33	-11.11
		SD	0.000	38.490
		Median	33.33	-33.33
		Min.	33.3	-33.3
		Max.	33.3	33.3
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	2 (100%)	1 (33%)
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	2 (100%)	1 (33%)
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	2 (67%)
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	2 (67%)

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Body Image Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 19	Actual Score	n	3	3
		Mean	66.67	88.89
		SD	57.735	19.245
		Median	100.00	100.00
		Min.	0.0	66.7
		Max.	100.0	100.0
	Change from Baseline	n	2	3
		Mean	33.33	0.00
		SD	0.000	33.333
		Median	33.33	0.00
		Min.	33.3	-33.3
		Max.	33.3	33.3
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	2 (100%)	1 (33%)
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	2 (100%)	1 (33%)
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	1 (33%)
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	1 (33%)

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Body Image Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 22	Actual Score	n	1	3
		Mean	66.67	100.00
		SD		0.000
		Median	66.67	100.00
		Min.	66.7	100.0
		Max.	66.7	100.0
	Change from Baseline	n	1	3
		Mean	0.00	11.11
		SD		19.245
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	33.3
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	1 (33%)
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	1 (33%)
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Body Image Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 25	Actual Score	n	0	3
		Mean		100.00
		SD		0.000
		Median		100.00
		Min.		100.0
		Max.		100.0
	Change from Baseline	n	0	3
		Mean		11.11
		SD		19.245
		Median		0.00
		Min.		0.0
		Max.		33.3
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	1 (33%)
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	1 (33%)
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Body Image Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 28	Actual Score	n	0	3
		Mean		88.89
		SD		19.245
		Median		100.00
		Min.		66.7
		Max.		100.0
	Change from Baseline	n	0	3
		Mean		0.00
		SD		33.333
		Median		0.00
		Min.		-33.3
		Max.		33.3
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	1 (33%)
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	1 (33%)
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	1 (33%)
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	1 (33%)

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Body Image Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 31	Actual Score	n	0	3
		Mean		88.89
		SD		19.245
		Median		100.00
		Min.		66.7
		Max.		100.0
	Change from Baseline	n	0	3
		Mean		0.00
		SD		33.333
		Median		0.00
		Min.		-33.3
		Max.		33.3
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	1 (33%)
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	1 (33%)
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	1 (33%)
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	1 (33%)

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Body Image Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 34	Actual Score	n	0	3
		Mean		100.00
		SD		0.000
		Median		100.00
		Min.		100.0
		Max.		100.0
	Change from Baseline	n	0	3
		Mean		11.11
		SD		19.245
		Median		0.00
		Min.		0.0
		Max.		33.3
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	1 (33%)
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	1 (33%)
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Body Image Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 37	Actual Score	n	0	3
		Mean		100.00
		SD		0.000
		Median		100.00
		Min.		100.0
		Max.		100.0
	Change from Baseline	n	0	3
		Mean		11.11
		SD		19.245
		Median		0.00
		Min.		0.0
		Max.		33.3
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	1 (33%)
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	1 (33%)
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Body Image Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 40	Actual Score	n	0	2
		Mean		83.33
		SD		23.570
		Median		83.33
		Min.		66.7
		Max.		100.0
	Change from Baseline	n	0	2
		Mean		0.00
		SD		47.140
		Median		0.00
		Min.		-33.3
		Max.		33.3
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	1 (50%)
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	1 (50%)
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	1 (50%)
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	1 (50%)

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Body Image Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 43	Actual Score	n	0	1
		Mean		100.00
		SD		
		Median		100.00
		Min.		100.0
		Max.		100.0
	Change from Baseline	n	0	1
		Mean		0.00
		SD		
		Median		0.00
		Min.		0.0
		Max.		0.0
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Body Image Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 46	Actual Score	n	0	1
		Mean		100.00
		SD		
		Median		100.00
		Min.		100.0
		Max.		100.0
	Change from Baseline	n	0	1
		Mean		0.00
		SD		
		Median		0.00
		Min.		0.0
		Max.		0.0
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_m20_dom.sas 10MAR2023 13:00

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Body Image Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 49	Actual Score	n	0	1
		Mean		100.00
		SD		
		Median		100.00
		Min.		100.0
		Max.		100.0
	Change from Baseline	n	0	1
		Mean		0.00
		SD		
		Median		0.00
		Min.		0.0
		Max.		0.0
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Body Image Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 52	Actual Score	n	0	1
		Mean		66.67
		SD		
		Median		66.67
		Min.		66.7
		Max.		66.7
	Change from Baseline	n	0	1
		Mean		-33.33
		SD		
		Median		-33.33
		Min.		-33.3
		Max.		-33.3
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	1 (100%)
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	1 (100%)

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Body Image Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 55	Actual Score	n	0	1
		Mean		66.67
		SD		
		Median		66.67
		Min.		66.7
		Max.		66.7
	Change from Baseline	n	0	1
		Mean		-33.33
		SD		
		Median		-33.33
		Min.		-33.3
		Max.		-33.3
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	1 (100%)
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	1 (100%)

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Body Image Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 58	Actual Score	n	0	1
		Mean		100.00
		SD		
		Median		100.00
		Min.		100.0
		Max.		100.0
	Change from Baseline	n	0	1
		Mean		0.00
		SD		
		Median		0.00
		Min.		0.0
		Max.		0.0
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_m20_dom.sas 10MAR2023 13:00

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Body Image Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 61	Actual Score	n	0	1
		Mean		100.00
		SD		
		Median		100.00
		Min.		100.0
		Max.		100.0
	Change from Baseline	n	0	1
		Mean		0.00
		SD		
		Median		0.00
		Min.		0.0
		Max.		0.0
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_m20_dom.sas 10MAR2023 13:00

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Body Image Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 64	Actual Score	n	0	1
		Mean		100.00
		SD		
		Median		100.00
		Min.		100.0
		Max.		100.0
	Change from Baseline	n	0	1
		Mean		0.00
		SD		
		Median		0.00
		Min.		0.0
		Max.		0.0
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_m20_dom.sas 10MAR2023 13:00

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Body Image Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 67	Actual Score	n	0	1
		Mean		66.67
		SD		
		Median		66.67
		Min.		66.7
		Max.		66.7
	Change from Baseline	n	0	1
		Mean		-33.33
		SD		
		Median		-33.33
		Min.		-33.3
		Max.		-33.3
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	1 (100%)
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	1 (100%)

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Body Image Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 70	Actual Score	n	0	0
		Mean		
		SD		
		Median		
		Min.		
		Max.		
	Change from Baseline	n	0	0
		Mean		
		SD		
		Median		
		Min.		
		Max.		
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Body Image Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 73	Actual Score	n	0	0
		Mean		
		SD		
		Median		
		Min.		
		Max.		
	Change from Baseline	n	0	0
		Mean		
		SD		
		Median		
		Min.		
		Max.		
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Body Image Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 76	Actual Score	n	0	0
		Mean		
		SD		
		Median		
		Min.		
		Max.		
	Change from Baseline	n	0	0
		Mean		
		SD		
		Median		
		Min.		
		Max.		
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Body Image Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 79	Actual Score	n	0	0
		Mean		
		SD		
		Median		
		Min.		
		Max.		
	Change from Baseline	n	0	0
		Mean		
		SD		
		Median		
		Min.		
		Max.		
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Body Image Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 82	Actual Score	n	0	0
		Mean		
		SD		
		Median		
		Min.		
		Max.		
	Change from Baseline	n	0	0
		Mean		
		SD		
		Median		
		Min.		
		Max.		
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Body Image Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 85	Actual Score	n	0	0
		Mean		
		SD		
		Median		
		Min.		
		Max.		
	Change from Baseline	n	0	0
		Mean		
		SD		
		Median		
		Min.		
		Max.		
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Body Image Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 88	Actual Score	n	0	0
		Mean		
		SD		
		Median		
		Min.		
		Max.		
	Change from Baseline	n	0	0
		Mean		
		SD		
		Median		
		Min.		
		Max.		
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Body Image Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 91	Actual Score	n	0	0
		Mean		
		SD		
		Median		
		Min.		
		Max.		
	Change from Baseline	n	0	0
		Mean		
		SD		
		Median		
		Min.		
		Max.		
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Body Image Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 94	Actual Score	n	0	0
		Mean		
		SD		
		Median		
		Min.		
		Max.		
	Change from Baseline	n	0	0
		Mean		
		SD		
		Median		
		Min.		
		Max.		
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Body Image Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 97	Actual Score	n	0	0
		Mean		
		SD		
		Median		
		Min.		
		Max.		
	Change from Baseline	n	0	0
		Mean		
		SD		
		Median		
		Min.		
		Max.		
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Body Image Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 100	Actual Score	n	0	0
		Mean		
		SD		
		Median		
		Min.		
		Max.		
	Change from Baseline	n	0	0
		Mean		
		SD		
		Median		
		Min.		
		Max.		
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Body Image Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
End of Treatment	Actual Score	n	3	1
		Mean	55.56	0.00
		SD	50.918	
		Median	66.67	0.00
		Min.	0.0	0.0
		Max.	100.0	0.0
	Change from Baseline	n	2	1
		Mean	16.67	0.00
		SD	23.570	
		Median	16.67	0.00
		Min.	0.0	0.0
		Max.	33.3	0.0
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	1 (50%)	0
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_m20_dom.sas 10MAR2023 13:00

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Body Image Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 1	Actual Score	n	1	1
		Mean	0.00	0.00
		SD		
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Change from Baseline	n	0	1
		Mean		0.00
		SD		
		Median		0.00
		Min.		0.0
		Max.		0.0
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Body Image Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 2	Actual Score	n	1	1
		Mean	33.33	0.00
		SD		
		Median	33.33	0.00
		Min.	33.3	0.0
		Max.	33.3	0.0
	Change from Baseline	n	0	1
		Mean		0.00
		SD		
		Median		0.00
		Min.		0.0
		Max.		0.0
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_m20_dom.sas 10MAR2023 13:00

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Body Image Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 4	Actual Score	n	0	0
		Mean		
		SD		
		Median		
		Min.		
		Max.		
	Change from Baseline	n	0	0
		Mean		
		SD		
		Median		
		Min.		
		Max.		
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Body Image Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
PFS Follow-Up 2	Actual Score	n	0	0
		Mean		
		SD		
		Median		
		Min.		
		Max.		
	Change from Baseline	n	0	0
		Mean		
		SD		
		Median		
		Min.		
		Max.		
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Body Image Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
PFS Follow-Up 4	Actual Score	n	0	0
		Mean		
		SD		
		Median		
		Min.		
		Max.		
	Change from Baseline	n	0	0
		Mean		
		SD		
		Median		
		Min.		
		Max.		
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Body Image Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Last Follow-up	Actual Score	n	1	1
		Mean	33.33	0.00
		SD		
		Median	33.33	0.00
		Min.	33.3	0.0
		Max.	33.3	0.0
	Change from Baseline	n	0	1
		Mean		0.00
		SD		
		Median		0.00
		Min.		0.0
		Max.		0.0
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_m20_dom.sas 10MAR2023 13:00

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Body Image Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Worst Case Post-Baseline	Actual Score	n	3	4
		Mean	44.44	50.00
		SD	38.490	43.033
		Median	66.67	50.00
		Min.	0.0	0.0
		Max.	66.7	100.0
	Change from Baseline	n	2	4
		Mean	0.00	-16.67
		SD	0.000	43.033
		Median	0.00	-16.67
		Min.	0.0	-66.7
		Max.	0.0	33.3
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	1 (25%)
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	1 (25%)
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	2 (50%)
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	2 (50%)

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Disease Symptoms Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Baseline	Actual Score	n	13	26
		Mean	37.18	35.68
		SD	29.431	23.474
		Median	33.33	33.33
		Min.	0.0	0.0
		Max.	83.3	83.3

Protocol: 207495 Page 86 of 168
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Disease Symptoms Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 4	Actual Score	n	12	23
		Mean	30.32	35.51
		SD	27.561	29.623
		Median	25.00	27.78
		Min.	0.0	0.0
		Max.	88.9	94.4
	Change from Baseline	n	12	22
		Mean	-4.86	0.25
		SD	11.970	16.127
		Median	-2.78	0.00
		Min.	-22.2	-33.3
		Max.	11.1	33.3
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	6 (50%)	8 (36%)
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	4 (33%)	7 (32%)
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	4 (33%)	10 (45%)
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	1 (8%)	6 (27%)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_m20_dom.sas 10MAR2023 13:00

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Disease Symptoms Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 7	Actual Score	n	12	17
		Mean	30.09	38.24
		SD	21.641	32.148
		Median	25.00	38.89
		Min.	0.0	0.0
		Max.	66.7	88.9
	Change from Baseline	n	11	16
		Mean	-11.62	2.43
		SD	17.822	18.699
		Median	-5.56	-2.78
		Min.	-44.4	-22.2
		Max.	11.1	33.3
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	7 (64%)	8 (50%)
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	5 (45%)	5 (31%)
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	3 (27%)	5 (31%)
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	1 (9%)	5 (31%)

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Disease Symptoms Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 10	Actual Score	n	13	12
		Mean	29.06	34.72
		SD	24.338	27.941
		Median	22.22	30.56
		Min.	0.0	0.0
		Max.	72.2	83.3
	Change from Baseline	n	12	11
		Mean	-9.26	2.53
		SD	12.830	13.914
		Median	-8.33	0.00
		Min.	-33.3	-22.2
		Max.	11.1	33.3
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	8 (67%)	3 (27%)
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	6 (50%)	1 (9%)
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	2 (17%)	4 (36%)
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	1 (8%)	2 (18%)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_m20_dom.sas 10MAR2023 13:00

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Disease Symptoms Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 13	Actual Score	n	13	9
		Mean	29.49	35.19
		SD	27.347	31.549
		Median	27.78	22.22
		Min.	0.0	0.0
		Max.	88.9	77.8
	Change from Baseline	n	12	9
		Mean	-9.26	1.23
		SD	21.625	26.900
		Median	-11.11	0.00
		Min.	-38.9	-38.9
		Max.	22.2	38.9
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	7 (58%)	3 (33%)
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	6 (50%)	3 (33%)
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	4 (33%)	4 (44%)
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	3 (25%)	4 (44%)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_m20_dom.sas 10MAR2023 13:00

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Disease Symptoms Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 16	Actual Score	n	12	8
		Mean	17.59	27.78
		SD	21.033	32.530
		Median	13.89	13.89
		Min.	0.0	0.0
		Max.	72.2	83.3
	Change from Baseline	n	11	8
		Mean	-19.70	-2.08
		SD	22.548	23.745
		Median	-16.67	0.00
		Min.	-66.7	-38.9
		Max.	11.1	33.3
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	8 (73%)	2 (25%)
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	7 (64%)	2 (25%)
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	2 (18%)	3 (38%)
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	1 (9%)	3 (38%)

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Disease Symptoms Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 19	Actual Score	n	12	7
		Mean	18.98	28.57
		SD	18.871	32.934
		Median	16.67	5.56
		Min.	0.0	0.0
		Max.	72.2	72.2
	Change from Baseline	n	11	7
		Mean	-18.18	0.00
		SD	24.481	21.517
		Median	-11.11	0.00
		Min.	-66.7	-44.4
		Max.	5.6	22.2
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	6 (55%)	1 (14%)
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	6 (55%)	1 (14%)
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	3 (27%)	3 (43%)
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	2 (29%)

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Disease Symptoms Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 22	Actual Score	n	7	7
		Mean	24.60	19.05
		SD	23.098	23.972
		Median	22.22	11.11
		Min.	5.6	0.0
		Max.	72.2	66.7
	Change from Baseline	n	7	7
		Mean	-8.73	-3.97
		SD	34.375	21.207
		Median	0.00	0.00
		Min.	-77.8	-44.4
		Max.	22.2	16.7
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	2 (29%)	2 (29%)
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	2 (29%)	2 (29%)
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	3 (43%)	2 (29%)
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	2 (29%)	2 (29%)

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Disease Symptoms Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 25	Actual Score	n	7	7
		Mean	14.29	23.02
		SD	22.189	25.746
		Median	5.56	11.11
		Min.	0.0	0.0
		Max.	61.1	72.2
	Change from Baseline	n	7	6
		Mean	-15.87	-5.56
		SD	22.321	20.488
		Median	-5.56	0.00
		Min.	-55.6	-38.9
		Max.	5.6	22.2
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	4 (57%)	2 (33%)
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	3 (43%)	2 (33%)
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	1 (14%)	1 (17%)
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	1 (17%)

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Disease Symptoms Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 28	Actual Score	n	7	6
		Mean	11.11	20.37
		SD	14.344	28.255
		Median	5.56	8.33
		Min.	0.0	0.0
		Max.	38.9	72.2
	Change from Baseline	n	7	6
		Mean	-19.05	-6.48
		SD	33.465	20.311
		Median	-5.56	-2.78
		Min.	-77.8	-38.9
		Max.	22.2	22.2
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	5 (71%)	3 (50%)
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	3 (43%)	2 (33%)
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	2 (29%)	1 (17%)
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	1 (14%)	1 (17%)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_m20_dom.sas 10MAR2023 13:00

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Disease Symptoms Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 31	Actual Score	n	7	6
		Mean	13.49	21.30
		SD	8.399	31.509
		Median	16.67	5.56
		Min.	0.0	0.0
		Max.	22.2	77.8
	Change from Baseline	n	7	6
		Mean	-16.67	-5.56
		SD	27.027	21.660
		Median	-11.11	-5.56
		Min.	-66.7	-38.9
		Max.	11.1	27.8
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	4 (57%)	3 (50%)
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	4 (57%)	3 (50%)
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	2 (29%)	1 (17%)
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	1 (14%)	1 (17%)

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Disease Symptoms Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 34	Actual Score	n	5	6
		Mean	12.22	18.52
		SD	9.938	28.036
		Median	11.11	2.78
		Min.	0.0	0.0
		Max.	27.8	66.7
	Change from Baseline	n	5	6
		Mean	-12.22	-8.33
		SD	12.044	20.412
		Median	-5.56	-5.56
		Min.	-27.8	-44.4
		Max.	0.0	16.7
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	4 (80%)	3 (50%)
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	2 (40%)	3 (50%)
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	1 (17%)
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	1 (17%)

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Disease Symptoms Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 37	Actual Score	n	4	6
		Mean	20.83	21.30
		SD	19.967	28.850
		Median	13.89	8.33
		Min.	5.6	0.0
		Max.	50.0	72.2
	Change from Baseline	n	4	6
		Mean	4.17	-5.56
		SD	20.972	19.876
		Median	0.00	-2.78
		Min.	-16.7	-38.9
		Max.	33.3	22.2
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	1 (25%)	3 (50%)
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	1 (25%)	2 (33%)
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	1 (25%)	1 (17%)
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	1 (25%)	1 (17%)

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Disease Symptoms Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 40	Actual Score	n	4	5
		Mean	16.67	13.33
		SD	13.608	23.766
		Median	19.44	5.56
		Min.	0.0	0.0
		Max.	27.8	55.6
	Change from Baseline	n	4	5
		Mean	0.00	-8.89
		SD	7.857	20.261
		Median	-2.78	0.00
		Min.	-5.6	-44.4
		Max.	11.1	5.6
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	2 (50%)	2 (40%)
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	1 (20%)
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	1 (25%)	1 (20%)
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	1 (25%)	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_m20_dom.sas 10MAR2023 13:00

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Disease Symptoms Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 43	Actual Score	n	4	4
		Mean	12.50	11.11
		SD	5.319	18.703
		Median	13.89	2.78
		Min.	5.6	0.0
		Max.	16.7	38.9
	Change from Baseline	n	4	4
		Mean	-4.17	-16.67
		SD	8.333	19.245
		Median	0.00	-11.11
		Min.	-16.7	-44.4
		Max.	0.0	0.0
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	1 (25%)	3 (75%)
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	1 (25%)	3 (75%)
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Disease Symptoms Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 46	Actual Score	n	3	4
		Mean	12.96	15.28
		SD	17.859	23.733
		Median	5.56	5.56
		Min.	0.0	0.0
		Max.	33.3	50.0
	Change from Baseline	n	3	4
		Mean	-5.56	-12.50
		SD	25.459	25.000
		Median	0.00	0.00
		Min.	-33.3	-50.0
		Max.	16.7	0.0
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	1 (33%)	1 (25%)
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	1 (33%)	1 (25%)
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	1 (33%)	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	1 (33%)	0

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Disease Symptoms Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 49	Actual Score	n	3	4
		Mean	9.26	19.44
		SD	11.565	28.146
		Median	5.56	8.33
		Min.	0.0	0.0
		Max.	22.2	61.1
	Change from Baseline	n	3	4
		Mean	-9.26	-8.33
		SD	21.033	24.637
		Median	0.00	0.00
		Min.	-33.3	-44.4
		Max.	5.6	11.1
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	1 (33%)	1 (25%)
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	1 (33%)	1 (25%)
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	1 (33%)	1 (25%)
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	1 (25%)

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Disease Symptoms Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 52	Actual Score	n	3	4
		Mean	11.11	18.06
		SD	9.623	25.408
		Median	5.56	8.33
		Min.	5.6	0.0
		Max.	22.2	55.6
	Change from Baseline	n	3	4
		Mean	-7.41	-9.72
		SD	17.859	23.296
		Median	0.00	0.00
		Min.	-27.8	-44.4
		Max.	5.6	5.6
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	1 (33%)	1 (25%)
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	1 (33%)	1 (25%)
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	1 (33%)	1 (25%)
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Disease Symptoms Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 55	Actual Score	n	3	3
		Mean	14.81	3.70
		SD	8.486	6.415
		Median	16.67	0.00
		Min.	5.6	0.0
		Max.	22.2	11.1
	Change from Baseline	n	3	3
		Mean	-3.70	-16.67
		SD	11.565	28.868
		Median	0.00	0.00
		Min.	-16.7	-50.0
		Max.	5.6	0.0
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	1 (33%)	1 (33%)
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	1 (33%)	1 (33%)
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	1 (33%)	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Disease Symptoms Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 58	Actual Score	n	2	2
		Mean	8.33	2.78
		SD	3.928	3.928
		Median	8.33	2.78
		Min.	5.6	0.0
		Max.	11.1	5.6
	Change from Baseline	n	2	2
		Mean	-16.67	-22.22
		SD	7.857	31.427
		Median	-16.67	-22.22
		Min.	-22.2	-44.4
		Max.	-11.1	0.0
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	2 (100%)	1 (50%)
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	2 (100%)	1 (50%)
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Disease Symptoms Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 61	Actual Score	n	2	2
		Mean	38.89	0.00
		SD	23.570	0.000
		Median	38.89	0.00
		Min.	22.2	0.0
		Max.	55.6	0.0
	Change from Baseline	n	2	2
		Mean	13.89	-25.00
		SD	11.785	35.355
		Median	13.89	-25.00
		Min.	5.6	-50.0
		Max.	22.2	0.0
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	1 (50%)
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	1 (50%)
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	2 (100%)	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	1 (50%)	0

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Disease Symptoms Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 64	Actual Score	n	2	2
		Mean	16.67	11.11
		SD	7.857	15.713
		Median	16.67	11.11
		Min.	11.1	0.0
		Max.	22.2	22.2
	Change from Baseline	n	2	2
		Mean	-8.33	-13.89
		SD	19.642	19.642
		Median	-8.33	-13.89
		Min.	-22.2	-27.8
		Max.	5.6	0.0
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	1 (50%)	1 (50%)
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	1 (50%)	1 (50%)
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_m20_dom.sas 10MAR2023 13:00

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Disease Symptoms Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 67	Actual Score	n	2	2
		Mean	11.11	2.78
		SD	15.713	3.928
		Median	11.11	2.78
		Min.	0.0	0.0
		Max.	22.2	5.6
	Change from Baseline	n	2	2
		Mean	-13.89	-22.22
		SD	27.499	31.427
		Median	-13.89	-22.22
		Min.	-33.3	-44.4
		Max.	5.6	0.0
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	1 (50%)	1 (50%)
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	1 (50%)	1 (50%)
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Disease Symptoms Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 70	Actual Score	n	2	1
		Mean	0.00	0.00
		SD	0.000	
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Change from Baseline	n	2	1
		Mean	-25.00	0.00
		SD	11.785	
		Median	-25.00	0.00
		Min.	-33.3	0.0
		Max.	-16.7	0.0
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	2 (100%)	0
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	2 (100%)	0
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Disease Symptoms Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 73	Actual Score	n	1	1
		Mean	55.56	0.00
		SD		
		Median	55.56	0.00
		Min.	55.6	0.0
		Max.	55.6	0.0
	Change from Baseline	n	1	1
		Mean	38.89	0.00
		SD		
		Median	38.89	0.00
		Min.	38.9	0.0
		Max.	38.9	0.0
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	1 (100%)	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	1 (100%)	0

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Disease Symptoms Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 76	Actual Score	n	2	1
		Mean	5.56	0.00
		SD	0.000	
		Median	5.56	0.00
		Min.	5.6	0.0
		Max.	5.6	0.0
	Change from Baseline	n	2	1
		Mean	-19.44	0.00
		SD	11.785	
		Median	-19.44	0.00
		Min.	-27.8	0.0
		Max.	-11.1	0.0
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	2 (100%)	0
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	2 (100%)	0
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Disease Symptoms Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 79	Actual Score	n	2	1
		Mean	5.56	0.00
		SD	0.000	
		Median	5.56	0.00
		Min.	5.6	0.0
		Max.	5.6	0.0
	Change from Baseline	n	2	1
		Mean	-19.44	0.00
		SD	11.785	
		Median	-19.44	0.00
		Min.	-27.8	0.0
		Max.	-11.1	0.0
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	2 (100%)	0
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	2 (100%)	0
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Disease Symptoms Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 82	Actual Score	n	2	1
		Mean	5.56	0.00
		SD	0.000	
		Median	5.56	0.00
		Min.	5.6	0.0
		Max.	5.6	0.0
	Change from Baseline	n	2	1
		Mean	-19.44	0.00
		SD	11.785	
		Median	-19.44	0.00
		Min.	-27.8	0.0
		Max.	-11.1	0.0
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	2 (100%)	0
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	2 (100%)	0
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Disease Symptoms Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 85	Actual Score	n	1	1
		Mean	22.22	0.00
		SD		
		Median	22.22	0.00
		Min.	22.2	0.0
		Max.	22.2	0.0
	Change from Baseline	n	1	1
		Mean	5.56	0.00
		SD		
		Median	5.56	0.00
		Min.	5.6	0.0
		Max.	5.6	0.0
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	1 (100%)	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Disease Symptoms Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 88	Actual Score	n	1	1
		Mean	0.00	0.00
		SD		
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Change from Baseline	n	1	1
		Mean	-33.33	0.00
		SD		
		Median	-33.33	0.00
		Min.	-33.3	0.0
		Max.	-33.3	0.0
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	1 (100%)	0
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	1 (100%)	0
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Disease Symptoms Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 91	Actual Score	n	1	1
		Mean	33.33	0.00
		SD		
		Median	33.33	0.00
		Min.	33.3	0.0
		Max.	33.3	0.0
	Change from Baseline	n	1	1
		Mean	16.67	0.00
		SD		
		Median	16.67	0.00
		Min.	16.7	0.0
		Max.	16.7	0.0
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	1 (100%)	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	1 (100%)	0

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Disease Symptoms Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 94	Actual Score	n	2	1
		Mean	5.56	0.00
		SD	7.857	
		Median	5.56	0.00
		Min.	0.0	0.0
		Max.	11.1	0.0
	Change from Baseline	n	2	1
		Mean	-19.44	0.00
		SD	19.642	
		Median	-19.44	0.00
		Min.	-33.3	0.0
		Max.	-5.6	0.0
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	2 (100%)	0
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Disease Symptoms Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 97	Actual Score	n	1	0
		Mean	11.11	
		SD		
		Median	11.11	
		Min.	11.1	
		Max.	11.1	
	Change from Baseline	n	1	0
		Mean	-5.56	
		SD		
		Median	-5.56	
		Min.	-5.6	
		Max.	-5.6	
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	1 (100%)	0
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_m20_dom.sas 10MAR2023 13:00

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Disease Symptoms Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 100	Actual Score	n	0	1
		Mean		0.00
		SD		
		Median		0.00
		Min.		0.0
		Max.		0.0
	Change from Baseline	n	0	1
		Mean		0.00
		SD		
		Median		0.00
		Min.		0.0
		Max.		0.0
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_m20_dom.sas 10MAR2023 13:00

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Disease Symptoms Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
End of Treatment	Actual Score	n	10	11
		Mean	37.22	40.40
		SD	32.080	26.770
		Median	33.33	27.78
		Min.	0.0	11.1
		Max.	94.4	88.9
	Change from Baseline	n	9	11
		Mean	-10.49	12.12
		SD	29.192	19.692
		Median	0.00	11.11
		Min.	-66.7	-16.7
		Max.	27.8	55.6
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	4 (44%)	2 (18%)
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	4 (44%)	2 (18%)
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	3 (33%)	8 (73%)
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	2 (22%)	6 (55%)

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Disease Symptoms Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 1	Actual Score	n	3	2
		Mean	44.44	27.78
		SD	38.889	7.857
		Median	27.78	27.78
		Min.	16.7	22.2
		Max.	88.9	33.3
	Change from Baseline	n	2	2
		Mean	-47.22	8.33
		SD	27.499	11.785
		Median	-47.22	8.33
		Min.	-66.7	0.0
		Max.	-27.8	16.7
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	2 (100%)	0
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	2 (100%)	0
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	1 (50%)
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	1 (50%)

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Disease Symptoms Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 2	Actual Score	n	3	1
		Mean	37.04	11.11
		SD	46.259	
		Median	22.22	11.11
		Min.	0.0	11.1
		Max.	88.9	11.1
	Change from Baseline	n	2	1
		Mean	-58.33	-5.56
		SD	35.355	
		Median	-58.33	-5.56
		Min.	-83.3	-5.6
		Max.	-33.3	-5.6
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	2 (100%)	1 (100%)
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	2 (100%)	0
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_m20_dom.sas 10MAR2023 13:00

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Disease Symptoms Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 4	Actual Score	n	0	1
		Mean		22.22
		SD		
		Median		22.22
		Min.		22.2
		Max.		22.2
	Change from Baseline	n	0	1
		Mean		0.00
		SD		
		Median		0.00
		Min.		0.0
		Max.		0.0
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_m20_dom.sas 10MAR2023 13:00

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Disease Symptoms Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
PFS Follow-Up 2	Actual Score	n	1	1
		Mean	33.33	22.22
		SD		
		Median	33.33	22.22
		Min.	33.3	22.2
		Max.	33.3	22.2
	Change from Baseline	n	1	1
		Mean	-22.22	0.00
		SD		
		Median	-22.22	0.00
		Min.	-22.2	0.0
		Max.	-22.2	0.0
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	1 (100%)	0
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	1 (100%)	0
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Disease Symptoms Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
PFS Follow-Up 4	Actual Score	n	0	1
		Mean		22.22
		SD		
		Median		22.22
		Min.		22.2
		Max.		22.2
	Change from Baseline	n	0	1
		Mean		0.00
		SD		
		Median		0.00
		Min.		0.0
		Max.		0.0
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Disease Symptoms Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Last Follow-up	Actual Score	n	3	2
		Mean	37.04	16.67
		SD	46.259	7.857
		Median	22.22	16.67
		Min.	0.0	11.1
		Max.	88.9	22.2
	Change from Baseline	n	2	2
		Mean	-58.33	-2.78
		SD	35.355	3.928
		Median	-58.33	-2.78
		Min.	-83.3	-5.6
		Max.	-33.3	0.0
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	2 (100%)	1 (50%)
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	2 (100%)	0
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

Protocol: 207495 Page 126 of 168
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Disease Symptoms Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Worst Case Post-Baseline	Actual Score	n	13	25
		Mean	50.43	52.67
		SD	31.136	27.968
		Median	55.56	50.00
		Min.	5.6	0.0
		Max.	94.4	94.4
	Change from Baseline	n	12	24
		Mean	11.57	16.20
		SD	15.795	16.620
		Median	11.11	16.67
		Min.	-22.2	-22.2
		Max.	38.9	55.6
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	1 (8%)	2 (8%)
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	1 (8%)	1 (4%)
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	9 (75%)	19 (79%)
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	7 (58%)	17 (71%)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_m20_dom.sas 10MAR2023 13:00

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Side Effects of Treatment Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Baseline	Actual Score	n	2	4
		Mean	21.30	20.09
		SD	6.547	18.549
		Median	21.30	15.00
		Min.	16.7	3.7
		Max.	25.9	46.7

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Side Effects of Treatment Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 4	Actual Score	n	2	4
		Mean	19.63	13.61
		SD	8.904	18.198
		Median	19.63	7.22
		Min.	13.3	0.0
		Max.	25.9	40.0
	Change from Baseline	n	2	4
		Mean	-1.67	-6.48
		SD	2.357	2.645
		Median	-1.67	-6.11
		Min.	-3.3	-10.0
		Max.	0.0	-3.7
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	3 (75%)
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	1 (25%)
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_m20_dom.sas 10MAR2023 13:00

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Side Effects of Treatment Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 7	Actual Score	n	3	4
		Mean	23.46	18.80
		SD	26.276	16.406
		Median	18.52	17.59
		Min.	0.0	0.0
		Max.	51.9	40.0
	Change from Baseline	n	2	4
		Mean	-12.04	-1.30
		SD	6.547	4.690
		Median	-12.04	-0.93
		Min.	-16.7	-6.7
		Max.	-7.4	3.3
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	2 (100%)	1 (25%)
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_m20_dom.sas 10MAR2023 13:00

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Side Effects of Treatment Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 10	Actual Score	n	3	4
		Mean	20.74	15.28
		SD	20.648	13.889
		Median	11.11	13.89
		Min.	6.7	0.0
		Max.	44.4	33.3
	Change from Baseline	n	2	4
		Mean	-12.41	-4.81
		SD	3.405	6.849
		Median	-12.41	-4.63
		Min.	-14.8	-13.3
		Max.	-10.0	3.3
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	2 (100%)	2 (50%)
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	2 (100%)	1 (25%)
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Side Effects of Treatment Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 13	Actual Score	n	3	3
		Mean	29.26	1.11
		SD	35.627	1.925
		Median	10.00	0.00
		Min.	7.4	0.0
		Max.	70.4	3.3
	Change from Baseline	n	2	3
		Mean	-12.59	-10.12
		SD	8.381	6.482
		Median	-12.59	-10.00
		Min.	-18.5	-16.7
		Max.	-6.7	-3.7
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	2 (100%)	2 (67%)
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	1 (50%)	2 (67%)
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Side Effects of Treatment Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 16	Actual Score	n	3	3
		Mean	20.99	5.93
		SD	23.811	5.592
		Median	11.11	6.67
		Min.	3.7	0.0
		Max.	48.1	11.1
	Change from Baseline	n	2	3
		Mean	-13.89	-5.31
		SD	1.309	1.497
		Median	-13.89	-5.56
		Min.	-14.8	-6.7
		Max.	-13.0	-3.7
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	2 (100%)	2 (67%)
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	2 (100%)	0
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Side Effects of Treatment Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 19	Actual Score	n	3	3
		Mean	22.96	8.02
		SD	28.226	8.350
		Median	6.67	7.41
		Min.	6.7	0.0
		Max.	55.6	16.7
	Change from Baseline	n	2	3
		Mean	-14.63	-3.21
		SD	6.547	6.311
		Median	-14.63	-3.70
		Min.	-19.3	-9.3
		Max.	-10.0	3.3
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	2 (100%)	1 (33%)
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	2 (100%)	0
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Side Effects of Treatment Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 22	Actual Score	n	1	3
		Mean	22.22	5.80
		SD		5.190
		Median	22.22	7.41
		Min.	22.2	0.0
		Max.	22.2	10.0
	Change from Baseline	n	1	3
		Mean	5.56	-5.43
		SD		3.320
		Median	5.56	-3.70
		Min.	5.6	-9.3
		Max.	5.6	-3.3
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	1 (33%)
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	1 (100%)	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Side Effects of Treatment Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 25	Actual Score	n	0	3
		Mean		6.79
		SD		8.752
		Median		3.70
		Min.		0.0
		Max.		16.7
	Change from Baseline	n	0	3
		Mean		-4.44
		SD		8.173
		Median		-3.70
		Min.		-13.0
		Max.		3.3
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	1 (33%)
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	1 (33%)
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_m20_dom.sas 10MAR2023 13:00

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Side Effects of Treatment Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 28	Actual Score	n	0	3
		Mean		9.26
		SD		8.486
		Median		11.11
		Min.		0.0
		Max.		16.7
	Change from Baseline	n	0	3
		Mean		-1.98
		SD		4.690
		Median		-3.70
		Min.		-5.6
		Max.		3.3
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	1 (33%)
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Side Effects of Treatment Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 31	Actual Score	n	0	3
		Mean		6.91
		SD		6.680
		Median		7.41
		Min.		0.0
		Max.		13.3
	Change from Baseline	n	0	3
		Mean		-4.32
		SD		4.660
		Median		-3.70
		Min.		-9.3
		Max.		0.0
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	1 (33%)
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Side Effects of Treatment Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 34	Actual Score	n	0	3
		Mean		11.73
		SD		10.199
		Median		16.67
		Min.		0.0
		Max.		18.5
	Change from Baseline	n	0	3
		Mean		0.49
		SD		3.710
		Median		1.85
		Min.		-3.7
		Max.		3.3
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Side Effects of Treatment Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 37	Actual Score	n	0	3
		Mean		8.27
		SD		7.557
		Median		10.00
		Min.		0.0
		Max.		14.8
	Change from Baseline	n	0	3
		Mean		-2.96
		SD		0.980
		Median		-3.33
		Min.		-3.7
		Max.		-1.9
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Side Effects of Treatment Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 40	Actual Score	n	0	2
		Mean		5.00
		SD		7.071
		Median		5.00
		Min.		0.0
		Max.		10.0
	Change from Baseline	n	0	2
		Mean		-5.19
		SD		2.095
		Median		-5.19
		Min.		-6.7
		Max.		-3.7
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	1 (50%)
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Side Effects of Treatment Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 43	Actual Score	n	0	1
		Mean		0.00
		SD		
		Median		0.00
		Min.		0.0
		Max.		0.0
	Change from Baseline	n	0	1
		Mean		-16.67
		SD		
		Median		-16.67
		Min.		-16.7
		Max.		-16.7
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	1 (100%)
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	1 (100%)
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Side Effects of Treatment Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 46	Actual Score	n	0	1
		Mean		6.67
		SD		
		Median		6.67
		Min.		6.7
		Max.		6.7
	Change from Baseline	n	0	1
		Mean		-10.00
		SD		
		Median		-10.00
		Min.		-10.0
		Max.		-10.0
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	1 (100%)
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	1 (100%)
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_m20_dom.sas 10MAR2023 13:00

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Side Effects of Treatment Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 49	Actual Score	n	0	1
		Mean		10.00
		SD		
		Median		10.00
		Min.		10.0
		Max.		10.0
	Change from Baseline	n	0	1
		Mean		-6.67
		SD		
		Median		-6.67
		Min.		-6.7
		Max.		-6.7
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	1 (100%)
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_m20_dom.sas 10MAR2023 13:00

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Side Effects of Treatment Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 52	Actual Score	n	0	1
		Mean		6.67
		SD		
		Median		6.67
		Min.		6.7
		Max.		6.7
	Change from Baseline	n	0	1
		Mean		-10.00
		SD		
		Median		-10.00
		Min.		-10.0
		Max.		-10.0
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	1 (100%)
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	1 (100%)
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Side Effects of Treatment Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 55	Actual Score	n	0	1
		Mean		13.33
		SD		
		Median		13.33
		Min.		13.3
		Max.		13.3
	Change from Baseline	n	0	1
		Mean		-3.33
		SD		
		Median		-3.33
		Min.		-3.3
		Max.		-3.3
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_m20_dom.sas 10MAR2023 13:00

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Side Effects of Treatment Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 58	Actual Score	n	0	1
		Mean		16.67
		SD		
		Median		16.67
		Min.		16.7
		Max.		16.7
	Change from Baseline	n	0	1
		Mean		0.00
		SD		
		Median		0.00
		Min.		0.0
		Max.		0.0
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_m20_dom.sas 10MAR2023 13:00

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Side Effects of Treatment Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 61	Actual Score	n	0	1
		Mean		18.52
		SD		
		Median		18.52
		Min.		18.5
		Max.		18.5
	Change from Baseline	n	0	1
		Mean		1.85
		SD		
		Median		1.85
		Min.		1.9
		Max.		1.9
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_m20_dom.sas 10MAR2023 13:00

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Side Effects of Treatment Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 64	Actual Score	n	0	1
		Mean		18.52
		SD		
		Median		18.52
		Min.		18.5
		Max.		18.5
	Change from Baseline	n	0	1
		Mean		1.85
		SD		
		Median		1.85
		Min.		1.9
		Max.		1.9
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_m20_dom.sas 10MAR2023 13:00

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Side Effects of Treatment Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 67	Actual Score	n	0	1
		Mean		16.67
		SD		
		Median		16.67
		Min.		16.7
		Max.		16.7
	Change from Baseline	n	0	1
		Mean		0.00
		SD		
		Median		0.00
		Min.		0.0
		Max.		0.0
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_m20_dom.sas 10MAR2023 13:00

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Side Effects of Treatment Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 70	Actual Score	n	0	0
		Mean		
		SD		
		Median		
		Min.		
		Max.		
	Change from Baseline	n	0	0
		Mean		
		SD		
		Median		
		Min.		
		Max.		
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_m20_dom.sas 10MAR2023 13:00

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Side Effects of Treatment Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 73	Actual Score	n	0	0
		Mean		
		SD		
		Median		
		Min.		
		Max.		
	Change from Baseline	n	0	0
		Mean		
		SD		
		Median		
		Min.		
		Max.		
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_m20_dom.sas 10MAR2023 13:00

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Side Effects of Treatment Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 76	Actual Score	n	0	0
		Mean		
		SD		
		Median		
		Min.		
		Max.		
	Change from Baseline	n	0	0
		Mean		
		SD		
		Median		
		Min.		
		Max.		
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_m20_dom.sas 10MAR2023 13:00

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Side Effects of Treatment Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 79	Actual Score	n	0	0
		Mean		
		SD		
		Median		
		Min.		
		Max.		
	Change from Baseline	n	0	0
		Mean		
		SD		
		Median		
		Min.		
		Max.		
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_m20_dom.sas 10MAR2023 13:00

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Side Effects of Treatment Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 82	Actual Score	n	0	0
		Mean		
		SD		
		Median		
		Min.		
		Max.		
	Change from Baseline	n	0	0
		Mean		
		SD		
		Median		
		Min.		
		Max.		
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_m20_dom.sas 10MAR2023 13:00

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Side Effects of Treatment Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 85	Actual Score	n	0	0
		Mean		
		SD		
		Median		
		Min.		
		Max.		
	Change from Baseline	n	0	0
		Mean		
		SD		
		Median		
		Min.		
		Max.		
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Side Effects of Treatment Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 88	Actual Score	n	0	0
		Mean		
		SD		
		Median		
		Min.		
		Max.		
	Change from Baseline	n	0	0
		Mean		
		SD		
		Median		
		Min.		
		Max.		
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_m20_dom.sas 10MAR2023 13:00

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Side Effects of Treatment Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 91	Actual Score	n	0	0
		Mean		
		SD		
		Median		
		Min.		
		Max.		
	Change from Baseline	n	0	0
		Mean		
		SD		
		Median		
		Min.		
		Max.		
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Side Effects of Treatment Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 94	Actual Score	n	0	0
		Mean		
		SD		
		Median		
		Min.		
		Max.		
	Change from Baseline	n	0	0
		Mean		
		SD		
		Median		
		Min.		
		Max.		
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Side Effects of Treatment Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 97	Actual Score	n	0	0
		Mean		
		SD		
		Median		
		Min.		
		Max.		
	Change from Baseline	n	0	0
		Mean		
		SD		
		Median		
		Min.		
		Max.		
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_m20_dom.sas 10MAR2023 13:00

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Side Effects of Treatment Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 100	Actual Score	n	0	0
		Mean		
		SD		
		Median		
		Min.		
		Max.		
	Change from Baseline	n	0	0
		Mean		
		SD		
		Median		
		Min.		
		Max.		
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_m20_dom.sas 10MAR2023 13:00

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Side Effects of Treatment Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
End of Treatment	Actual Score	n	3	1
		Mean	35.93	43.33
		SD	36.588	
		Median	20.00	43.33
		Min.	10.0	43.3
		Max.	77.8	43.3
	Change from Baseline	n	2	1
		Mean	-6.30	-3.33
		SD	13.618	
		Median	-6.30	-3.33
		Min.	-15.9	-3.3
		Max.	3.3	-3.3
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	1 (50%)	0
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_m20_dom.sas 10MAR2023 13:00

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Side Effects of Treatment Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 1	Actual Score	n	1	1
		Mean	37.04	33.33
		SD		
		Median	37.04	33.33
		Min.	37.0	33.3
		Max.	37.0	33.3
	Change from Baseline	n	0	1
		Mean		-13.33
		SD		
		Median		-13.33
		Min.		-13.3
		Max.		-13.3
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	1 (100%)
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	1 (100%)
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Side Effects of Treatment Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 2	Actual Score	n	1	1
		Mean	48.15	33.33
		SD		
		Median	48.15	33.33
		Min.	48.1	33.3
		Max.	48.1	33.3
	Change from Baseline	n	0	1
		Mean		-13.33
		SD		
		Median		-13.33
		Min.		-13.3
		Max.		-13.3
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	1 (100%)
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	1 (100%)
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_m20_dom.sas 10MAR2023 13:00

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Side Effects of Treatment Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 4	Actual Score	n	0	0
		Mean		
		SD		
		Median		
		Min.		
		Max.		
	Change from Baseline	n	0	0
		Mean		
		SD		
		Median		
		Min.		
		Max.		
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_m20_dom.sas 10MAR2023 13:00

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Side Effects of Treatment Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
PFS Follow-Up 2	Actual Score	n	0	0
		Mean		
		SD		
		Median		
		Min.		
		Max.		
	Change from Baseline	n	0	0
		Mean		
		SD		
		Median		
		Min.		
		Max.		
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Side Effects of Treatment Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
PFS Follow-Up 4	Actual Score	n	0	0
		Mean		
		SD		
		Median		
		Min.		
		Max.		
	Change from Baseline	n	0	0
		Mean		
		SD		
		Median		
		Min.		
		Max.		
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Side Effects of Treatment Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Last Follow-up	Actual Score	n	1	1
		Mean	48.15	33.33
		SD		
		Median	48.15	33.33
		Min.	48.1	33.3
		Max.	48.1	33.3
	Change from Baseline	n	0	1
		Mean		-13.33
		SD		
		Median		-13.33
		Min.		-13.3
		Max.		-13.3
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	1 (100%)
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	1 (100%)
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

Table 4.009110
Summary of Change in EORTC QLQ-MY20 Domain Scores from Baseline

Item Score: Side Effects of Treatment Domain Score

Timepoint			Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Worst Case Post-Baseline	Actual Score	n	3	4
		Mean	41.98	19.63
		SD	31.061	17.862
		Median	25.93	17.59
		Min.	22.2	0.0
		Max.	77.8	43.3
	Change from Baseline	n	2	4
		Mean	2.78	-0.46
		SD	3.928	3.583
		Median	2.78	-0.74
		Min.	0.0	-3.7
		Max.	5.6	3.3
	Improvement in EORTC QLQ-MY20 domain score >=5	n (%)	0	0
	Improvement in EORTC QLQ-MY20 domain score >=10	n (%)	0	0
	Worsening in EORTC QLQ-MY20 domain score >=5	n (%)	1 (50%)	0
	Worsening in EORTC QLQ-MY20 domain score >=10	n (%)	0	0

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Future Perspective Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 4		
n [1]	2	4
n [2]	2	4

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Future Perspective Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 7		
n [1]	2	4
n [2]	2	4

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Future Perspective Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 10		
n [1]	2	4
n [2]	2	4

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Future Perspective Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 13		
n [1]	2	4
n [2]	2	3

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Future Perspective Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 16		
n [1]	2	4
n [2]	2	3

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Future Perspective Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 19		
n [1]	2	4
n [2]	2	3

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Future Perspective Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 22		
n [1]	2	4
n [2]	1	4

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Future Perspective Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 25		
n [1]	2	4
n [2]	2	3

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Future Perspective Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 28		
n [1]	2	4
n [2]	0	3

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Future Perspective Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 31		
n [1]	2	4
n [2]	0	4

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Future Perspective Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 34		
n [1]	2	4
n [2]	0	3

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Future Perspective Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 37		
n [1]	2	4
n [2]	0	3

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Future Perspective Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 40		
n [1]	2	4
n [2]	0	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Future Perspective Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 43		
n [1]	2	4
n [2]	0	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Future Perspective Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 46		
n [1]	2	4
n [2]	0	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Future Perspective Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 49		
n [1]	2	4
n [2]	0	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Future Perspective Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 52		
n [1]	2	4
n [2]	0	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Future Perspective Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 55		
n [1]	2	4
n [2]	0	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Future Perspective Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 58		
n [1]	2	4
n [2]	0	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Future Perspective Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 61		
n [1]	2	4
n [2]	0	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Future Perspective Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 64		
n [1]	2	4
n [2]	0	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Future Perspective Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 67		
n [1]	2	4
n [2]	0	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Future Perspective Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 70		
n [1]	2	4
n [2]	0	0

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Future Perspective Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 73		
n [1]	2	4
n [2]	0	0

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Future Perspective Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 76		
n [1]	2	4
n [2]	0	0

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Future Perspective Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 79		
n [1]	2	4
n [2]	0	0

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Future Perspective Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 82		
n [1]	2	4
n [2]	0	0

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Future Perspective Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 85		
n [1]	2	4
n [2]	0	0

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Future Perspective Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 88		
n [1]	2	4
n [2]	0	0

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Future Perspective Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 91		
n [1]	2	4
n [2]	0	0

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Future Perspective Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 94		
n [1]	2	4
n [2]	0	0

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Future Perspective Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 97		
n [1]	2	4
n [2]	0	0

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Future Perspective Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 100		
n [1]	2	4
n [2]	0	0

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Future Perspective Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
End of Treatment		
n [1]	2	4
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Future Perspective Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 1		
n [1]	2	4
n [2]	0	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Future Perspective Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 2		
n [1]	2	4
n [2]	0	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Future Perspective Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 4		
n [1]	2	4
n [2]	0	0

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Future Perspective Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
PFS Follow-Up 2		
n [1]	2	4
n [2]	0	0

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Future Perspective Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
PFS Follow-Up 4		
n [1]	2	4
n [2]	0	0

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Body Image Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 4		
n [1]	2	4
n [2]	2	4

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Body Image Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 7		
n [1]	2	4
n [2]	2	4

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Body Image Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 10		
n [1]	2	4
n [2]	2	4

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Body Image Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 13		
n [1]	2	4
n [2]	2	3

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Body Image Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 16		
n [1]	2	4
n [2]	2	3

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Body Image Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 19		
n [1]	2	4
n [2]	2	3

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Body Image Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 22		
n [1]	2	4
n [2]	1	4

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Body Image Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 25		
n [1]	2	4
n [2]	2	3

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Body Image Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 28		
n [1]	2	4
n [2]	0	3

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Body Image Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 31		
n [1]	2	4
n [2]	0	4

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Body Image Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 34		
n [1]	2	4
n [2]	0	3

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Body Image Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 37		
n [1]	2	4
n [2]	0	3

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Body Image Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 40		
n [1]	2	4
n [2]	0	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Body Image Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 43		
n [1]	2	4
n [2]	0	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Body Image Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 46		
n [1]	2	4
n [2]	0	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Body Image Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 49		
n [1]	2	4
n [2]	0	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Body Image Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 52		
n [1]	2	4
n [2]	0	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Body Image Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 55		
n [1]	2	4
n [2]	0	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Body Image Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 58		
n [1]	2	4
n [2]	0	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Body Image Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 61		
n [1]	2	4
n [2]	0	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Body Image Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 64		
n [1]	2	4
n [2]	0	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Body Image Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 67		
n [1]	2	4
n [2]	0	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Body Image Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 70		
n [1]	2	4
n [2]	0	0

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Body Image Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 73		
n [1]	2	4
n [2]	0	0

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Body Image Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 76		
n [1]	2	4
n [2]	0	0

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Body Image Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 79		
n [1]	2	4
n [2]	0	0

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Body Image Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 82		
n [1]	2	4
n [2]	0	0

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Body Image Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 85		
n [1]	2	4
n [2]	0	0

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Body Image Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 88		
n [1]	2	4
n [2]	0	0

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Body Image Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 91		
n [1]	2	4
n [2]	0	0

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Body Image Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 94		
n [1]	2	4
n [2]	0	0

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Body Image Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 97		
n [1]	2	4
n [2]	0	0

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Body Image Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 100		
n [1]	2	4
n [2]	0	0

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Body Image Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
End of Treatment		
n [1]	2	4
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Body Image Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 1		
n [1]	2	4
n [2]	0	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Body Image Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 2		
n [1]	2	4
n [2]	0	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Body Image Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 4		
n [1]	2	4
n [2]	0	0

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Body Image Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
PFS Follow-Up 2		
n [1]	2	4
n [2]	0	0

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Body Image Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
PFS Follow-Up 4		
n [1]	2	4
n [2]	0	0

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Disease Symptoms Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 4		
n [1]	12	24
n [2]	12	22
LS Mean (SE)	26.8 (5.55)	34.4 (4.01)
95% C.I.	(15.4, 38.1)	(26.2, 42.6)
LS Mean Change from Baseline (SE)	-4.7 (5.55)	2.9 (4.01)
95% C.I.	(-16.1, 6.6)	(-5.3, 11.1)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		7.7 (6.81)
95% C.I.		(-6.3, 21.6)
Corrected Hedges' g Statistic		0.40
95% C.I.		(-0.31, 1.11)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Disease Symptoms Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 7		
n [1]	12	24
n [2]	11	20
LS Mean (SE)	22.2 (6.50)	40.4 (4.72)
95% C.I.	(8.8, 35.5)	(30.7, 50.1)
LS Mean Change from Baseline (SE)	-9.3 (6.50)	8.9 (4.72)
95% C.I.	(-22.7, 4.0)	(-0.8, 18.6)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		18.2 (8.01)
95% C.I.		(1.8, 34.7)
Corrected Hedges' g Statistic		0.83
95% C.I.		(0.07, 1.60)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Disease Symptoms Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 10		
n [1]	12	24
n [2]	12	11
LS Mean (SE)	22.8 (4.45)	38.6 (3.85)
95% C.I.	(13.6, 32.1)	(30.7, 46.5)
LS Mean Change from Baseline (SE)	-8.7 (4.45)	7.1 (3.85)
95% C.I.	(-17.9, 0.6)	(-0.8, 15.0)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		15.8 (5.88)
95% C.I.		(3.6, 27.9)
Corrected Hedges' g Statistic		1.07
95% C.I.		(0.20, 1.94)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Disease Symptoms Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 13		
n [1]	12	24
n [2]	12	10
LS Mean (SE)	23.4 (6.70)	37.6 (6.34)
95% C.I.	(9.5, 37.2)	(24.6, 50.6)
LS Mean Change from Baseline (SE)	-8.1 (6.70)	6.1 (6.34)
95% C.I.	(-22.0, 5.7)	(-6.9, 19.1)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		14.2 (9.22)
95% C.I.		(-4.8, 33.2)
Corrected Hedges' g Statistic		0.63
95% C.I.		(-0.23, 1.49)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Disease Symptoms Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 16		
n [1]	12	24
n [2]	11	8
LS Mean (SE)	15.3 (5.86)	34.3 (6.01)
95% C.I.	(3.1, 27.5)	(21.9, 46.6)
LS Mean Change from Baseline (SE)	-16.2 (5.86)	2.8 (6.01)
95% C.I.	(-28.4, -4.0)	(-9.6, 15.1)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		19.0 (8.41)
95% C.I.		(1.6, 36.4)
Corrected Hedges' g Statistic		0.98
95% C.I.		(0.02, 1.95)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Disease Symptoms Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 19		
n [1]	12	24
n [2]	12	8
LS Mean (SE)	16.9 (5.74)	35.6 (6.15)
95% C.I.	(5.0, 28.8)	(23.0, 48.2)
LS Mean Change from Baseline (SE)	-14.6 (5.74)	4.1 (6.15)
95% C.I.	(-26.5, -2.7)	(-8.5, 16.7)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		18.8 (8.45)
95% C.I.		(1.4, 36.2)
Corrected Hedges' g Statistic		0.95
95% C.I.		(0.01, 1.89)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Disease Symptoms Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 22		
n [1]	12	24
n [2]	8	8
LS Mean (SE)	22.5 (8.25)	34.3 (8.59)
95% C.I.	(5.1, 39.8)	(16.3, 52.3)
LS Mean Change from Baseline (SE)	-9.0 (8.25)	2.8 (8.59)
95% C.I.	(-26.4, 8.3)	(-15.2, 20.8)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		11.9 (11.97)
95% C.I.		(-13.3, 37.0)
Corrected Hedges' g Statistic		0.47
95% C.I.		(-0.52, 1.46)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Disease Symptoms Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 25		
n [1]	12	24
n [2]	9	7
LS Mean (SE)	20.2 (7.38)	33.7 (7.99)
95% C.I.	(4.8, 35.7)	(17.0, 50.4)
LS Mean Change from Baseline (SE)	-11.3 (7.38)	2.2 (7.99)
95% C.I.	(-26.8, 4.2)	(-14.5, 18.9)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		13.5 (11.00)
95% C.I.		(-9.5, 36.5)
Corrected Hedges' g Statistic		0.59
95% C.I.		(-0.42, 1.60)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Disease Symptoms Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 28		
n [1]	12	24
n [2]	7	6
LS Mean (SE)	15.6 (7.42)	28.9 (7.88)
95% C.I.	(0.0, 31.2)	(12.4, 45.5)
LS Mean Change from Baseline (SE)	-15.9 (7.42)	-2.6 (7.88)
95% C.I.	(-31.5, -0.3)	(-19.1, 14.0)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		13.3 (10.87)
95% C.I.		(-9.5, 36.1)
Corrected Hedges' g Statistic		0.64
95% C.I.		(-0.48, 1.75)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Disease Symptoms Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 31		
n [1]	12	24
n [2]	7	7
LS Mean (SE)	18.2 (6.16)	27.8 (6.29)
95% C.I.	(5.3, 31.0)	(14.8, 40.9)
LS Mean Change from Baseline (SE)	-13.3 (6.16)	-3.7 (6.29)
95% C.I.	(-26.2, -0.5)	(-16.7, 9.4)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		9.7 (8.82)
95% C.I.		(-8.7, 28.0)
Corrected Hedges' g Statistic		0.55
95% C.I.		(-0.52, 1.62)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Disease Symptoms Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 34		
n [1]	12	24
n [2]	6	6
LS Mean (SE)	16.6 (5.33)	24.3 (5.35)
95% C.I.	(5.5, 27.7)	(13.2, 35.4)
LS Mean Change from Baseline (SE)	-14.9 (5.33)	-7.2 (5.35)
95% C.I.	(-26.0, -3.8)	(-18.3, 3.9)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		7.7 (7.57)
95% C.I.		(-8.0, 23.5)
Corrected Hedges' g Statistic		0.55
95% C.I.		(-0.61, 1.70)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Disease Symptoms Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 37		
n [1]	12	24
n [2]	4	6
LS Mean (SE)	30.3 (7.83)	28.5 (6.71)
95% C.I.	(13.8, 46.8)	(14.3, 42.7)
LS Mean Change from Baseline (SE)	-1.2 (7.83)	-3.0 (6.71)
95% C.I.	(-17.7, 15.3)	(-17.2, 11.2)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-1.8 (10.11)
95% C.I.		(-23.1, 19.5)
Corrected Hedges' g Statistic		-0.10
95% C.I.		(-1.37, 1.17)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Disease Symptoms Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 40		
n [1]	12	24
n [2]	4	6
LS Mean (SE)	25.7 (5.55)	22.7 (4.77)
95% C.I.	(14.0, 37.5)	(12.6, 32.8)
LS Mean Change from Baseline (SE)	-5.8 (5.55)	-8.8 (4.77)
95% C.I.	(-17.5, 6.0)	(-18.9, 1.3)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-3.0 (7.06)
95% C.I.		(-18.0, 11.9)
Corrected Hedges' g Statistic		-0.24
95% C.I.		(-1.51, 1.03)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Disease Symptoms Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 43		
n [1]	12	24
n [2]	6	4
LS Mean (SE)	19.1 (3.38)	15.3 (3.81)
95% C.I.	(11.9, 26.3)	(7.1, 23.4)
LS Mean Change from Baseline (SE)	-12.4 (3.38)	-16.2 (3.81)
95% C.I.	(-19.6, -5.2)	(-24.4, -8.1)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-3.9 (5.13)
95% C.I.		(-14.8, 7.1)
Corrected Hedges' g Statistic		-0.43
95% C.I.		(-1.71, 0.85)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Disease Symptoms Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 46		
n [1]	12	24
n [2]	4	4

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Disease Symptoms Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 49		
n [1]	12	24
n [2]	4	4

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Disease Symptoms Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 52		
n [1]	12	24
n [2]	3	4

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Disease Symptoms Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 55		
n [1]	12	24
n [2]	4	3

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Disease Symptoms Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 58		
n [1]	12	24
n [2]	2	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Disease Symptoms Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 61		
n [1]	12	24
n [2]	2	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Disease Symptoms Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 64		
n [1]	12	24
n [2]	3	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Disease Symptoms Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 67		
n [1]	12	24
n [2]	2	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Disease Symptoms Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 70		
n [1]	12	24
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Disease Symptoms Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 73		
n [1]	12	24
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Disease Symptoms Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 76		
n [1]	12	24
n [2]	2	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Disease Symptoms Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 79		
n [1]	12	24
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Disease Symptoms Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 82		
n [1]	12	24
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Disease Symptoms Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 85		
n [1]	12	24
n [2]	1	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Disease Symptoms Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 88		
n [1]	12	24
n [2]	1	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Disease Symptoms Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 91		
n [1]	12	24
n [2]	1	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Disease Symptoms Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 94		
n [1]	12	24
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Disease Symptoms Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 97		
n [1]	12	24
n [2]	1	0

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Disease Symptoms Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 100		
n [1]	12	24
n [2]	0	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Disease Symptoms Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
End of Treatment		
n [1]	12	24
n [2]	9	11
LS Mean (SE)	24.8 (6.72)	41.6 (5.97)
95% C.I.	(10.7, 38.8)	(29.1, 54.1)
LS Mean Change from Baseline (SE)	-6.7 (6.72)	10.1 (5.97)
95% C.I.	(-20.8, 7.3)	(-2.4, 22.6)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		16.8 (9.12)
95% C.I.		(-2.2, 35.9)
Corrected Hedges' g Statistic		0.81
95% C.I.		(-0.11, 1.72)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Disease Symptoms Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 1		
n [1]	12	24
n [2]	2	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Disease Symptoms Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 2		
n [1]	12	24
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Disease Symptoms Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 4		
n [1]	12	24
n [2]	0	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Disease Symptoms Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
PFS Follow-Up 2		
n [1]	12	24
n [2]	1	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Disease Symptoms Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
PFS Follow-Up 4		
n [1]	12	24
n [2]	0	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Side Effects of Treatment Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 4		
n [1]	2	4
n [2]	2	4

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Side Effects of Treatment Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 7		
n [1]	2	4
n [2]	2	4

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Side Effects of Treatment Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 10		
n [1]	2	4
n [2]	2	4

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Side Effects of Treatment Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 13		
n [1]	2	4
n [2]	2	3

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Side Effects of Treatment Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 16		
n [1]	2	4
n [2]	2	3

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Side Effects of Treatment Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 19		
n [1]	2	4
n [2]	2	3

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Side Effects of Treatment Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 22		
n [1]	2	4
n [2]	1	4

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Side Effects of Treatment Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 25		
n [1]	2	4
n [2]	2	3

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Side Effects of Treatment Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 28		
n [1]	2	4
n [2]	0	3

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Side Effects of Treatment Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 31		
n [1]	2	4
n [2]	0	4

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Side Effects of Treatment Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 34		
n [1]	2	4
n [2]	0	3

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Side Effects of Treatment Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 37		
n [1]	2	4
n [2]	0	3

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Side Effects of Treatment Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 40		
n [1]	2	4
n [2]	0	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Side Effects of Treatment Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 43		
n [1]	2	4
n [2]	0	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Side Effects of Treatment Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 46		
n [1]	2	4
n [2]	0	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Side Effects of Treatment Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 49		
n [1]	2	4
n [2]	0	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Side Effects of Treatment Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 52		
n [1]	2	4
n [2]	0	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Side Effects of Treatment Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 55		
n [1]	2	4
n [2]	0	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Side Effects of Treatment Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 58		
n [1]	2	4
n [2]	0	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Side Effects of Treatment Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 61		
n [1]	2	4
n [2]	0	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Side Effects of Treatment Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 64		
n [1]	2	4
n [2]	0	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Side Effects of Treatment Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 67		
n [1]	2	4
n [2]	0	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Side Effects of Treatment Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 70		
n [1]	2	4
n [2]	0	0

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Side Effects of Treatment Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 73		
n [1]	2	4
n [2]	0	0

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Side Effects of Treatment Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 76		
n [1]	2	4
n [2]	0	0

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Side Effects of Treatment Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 79		
n [1]	2	4
n [2]	0	0

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Side Effects of Treatment Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 82		
n [1]	2	4
n [2]	0	0

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Side Effects of Treatment Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 85		
n [1]	2	4
n [2]	0	0

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Side Effects of Treatment Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 88		
n [1]	2	4
n [2]	0	0

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Side Effects of Treatment Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 91		
n [1]	2	4
n [2]	0	0

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Side Effects of Treatment Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 94		
n [1]	2	4
n [2]	0	0

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Side Effects of Treatment Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 97		
n [1]	2	4
n [2]	0	0

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Side Effects of Treatment Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 100		
n [1]	2	4
n [2]	0	0

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Side Effects of Treatment Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
End of Treatment		
n [1]	2	4
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Side Effects of Treatment Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 1		
n [1]	2	4
n [2]	0	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Side Effects of Treatment Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 2		
n [1]	2	4
n [2]	0	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Side Effects of Treatment Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Survival Follow-Up 4		
n [1]	2	4
n [2]	0	0

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Side Effects of Treatment Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
PFS Follow-Up 2		
n [1]	2	4
n [2]	0	0

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Table 4.010110
Analysis of EORTC QLQ-MY20 Domain Scores based on Mixed Model for Repeated Measures (MMRM)

Domain: Side Effects of Treatment Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
PFS Follow-Up 4		
n [1]	2	4
n [2]	0	0

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_m20_dom.sas 10MAR2023 06:02

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.068110
Summary of EORTC QLQ-MY20 Domain Scores Time to first Improvement
(Up to and including Last Follow-Up)

Item Score: Future Perspective Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Improved (event)	2 (13%)	2 (7%)
Censored, follow-up ended	6 (40%)	16 (55%)
Censored, follow-up ongoing	7 (47%)	11 (38%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	0.7 (0.7, 0.8)	1.4 (0.7, -)
Median (95% CI)	0.8 (0.7, 0.8)	- (0.7, -)
3rd Quartile (95% CI)	0.8 (0.7, 0.8)	- (0.7, -)
Log-Rank P-value [2]		0.3173
Inverse Hazard Ratio (95% CI) [3]		>999.99 (-, -)
P-value [3]		0.9990

Note: If a subject has not improved, they are censored at the latest assessment or at randomization if no assessments.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Inverse hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. Inverse hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_m20_tfi.sas 13MAR2023 14:01

Table 4.068110
Summary of EORTC QLQ-MY20 Domain Scores Time to first Improvement
(Up to and including Last Follow-Up)

Item Score: Body Image Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Improved (event)	2 (13%)	1 (3%)
Censored, follow-up ended	6 (40%)	16 (55%)
Censored, follow-up ongoing	7 (47%)	12 (41%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	0.7 (0.7, 2.2)	- (0.7, -)
Median (95% CI)	1.4 (0.7, 2.2)	- (0.7, -)
3rd Quartile (95% CI)	2.2 (0.7, 2.2)	- (0.7, -)
Log-Rank P-value [2]		0.3173
Inverse Hazard Ratio (95% CI) [3]		>999.99 (-, -)
P-value [3]		0.9990

Note: If a subject has not improved, they are censored at the latest assessment or at randomization if no assessments.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Inverse hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. Inverse hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_m20_tfi.sas 13MAR2023 14:01

Protocol: 207495 Page 3 of 4
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.068110
Summary of EORTC QLQ-MY20 Domain Scores Time to first Improvement
(Up to and including Last Follow-Up)

Item Score: Disease Symptoms Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Improved (event)	9 (60%)	11 (38%)
Censored, follow-up ended	4 (27%)	11 (38%)
Censored, follow-up ongoing	2 (13%)	7 (24%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	0.8 (0.7, 1.5)	1.0 (0.7, 1.6)
Median (95% CI)	1.8 (0.7, 4.2)	9.9 (1.0, -)
3rd Quartile (95% CI)	4.2 (1.5, -)	- (9.9, -)
Log-Rank P-value [2]		0.9395
Inverse Hazard Ratio (95% CI) [3]		0.93 (0.29, 2.92)
P-value [3]		0.8963

Note: If a subject has not improved, they are censored at the latest assessment or at randomization if no assessments.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Inverse hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. Inverse hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_m20_tfi.sas 13MAR2023 14:01

Protocol: 207495 Page 4 of 4
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.068110
Summary of EORTC QLQ-MY20 Domain Scores Time to first Improvement
(Up to and including Last Follow-Up)

Item Score: Side Effects of Treatment Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Improved (event)	2 (13%)	2 (7%)
Censored, follow-up ended	6 (40%)	16 (55%)
Censored, follow-up ongoing	7 (47%)	11 (38%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	1.4 (1.4, 2.2)	2.5 (2.3, -)
Median (95% CI)	1.8 (1.4, 2.2)	- (2.3, -)
3rd Quartile (95% CI)	2.2 (1.4, 2.2)	- (2.3, -)
Log-Rank P-value [2]		0.3173
Inverse Hazard Ratio (95% CI) [3]		>999.99 (-, -)
P-value [3]		0.9990

Note: If a subject has not improved, they are censored at the latest assessment or at randomization if no assessments.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Inverse hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. Inverse hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_m20_tfi.sas 13MAR2023 14:01

Protocol: 207495 Page 1 of 4
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.065110
Summary of EORTC QLQ-MY20 Domain Scores Time to first Deterioration 1
(Up to and including Last Follow-Up)

Item Score: Future Perspective Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated or Died (event)	5 (33%)	19 (66%)
Censored, follow-up ended	2 (13%)	0
Censored, follow-up ongoing	8 (53%)	10 (34%)
Event Summary		
Deterioration	1 (7%)	3 (10%)
Death	4 (27%)	16 (55%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	4.8 (1.1, 9.5)	1.1 (0.7, 2.9)
Median (95% CI)	8.0 (1.1, 13.5)	5.0 (1.0, 5.7)
3rd Quartile (95% CI)	9.5 (4.8, 13.5)	6.2 (5.1, 18.7)
Log-Rank P-value [2]		0.2594
Hazard Ratio (95% CI) [3]		2.47 (0.49, 12.43)
P-value [3]		0.2712

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessments.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_m20_tfd1.sas 13MAR2023 14:00

Protocol: 207495 Page 2 of 4
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.065110
Summary of EORTC QLQ-MY20 Domain Scores Time to first Deterioration 1
(Up to and including Last Follow-Up)

Item Score: Body Image Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated or Died (event)	4 (27%)	18 (62%)
Censored, follow-up ended	2 (13%)	0
Censored, follow-up ongoing	9 (60%)	11 (38%)
Event Summary		
Deterioration	0	2 (7%)
Death	4 (27%)	16 (55%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	8.0 (1.1, 9.5)	1.1 (0.7, 2.9)
Median (95% CI)	9.5 (1.1, 13.5)	5.0 (1.1, 5.7)
3rd Quartile (95% CI)	13.5 (8.0, 13.5)	6.2 (5.1, 18.7)
Log-Rank P-value [2]		0.0847
Hazard Ratio (95% CI) [3]		5.51 (0.65, 46.57)
P-value [3]		0.1169

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessments.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_m20_tfd1.sas 13MAR2023 14:00

Protocol: 207495 Page 3 of 4
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.065110
Summary of EORTC QLQ-MY20 Domain Scores Time to first Deterioration 1
(Up to and including Last Follow-Up)

Item Score: Disease Symptoms Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated or Died (event)	8 (53%)	22 (76%)
Censored, follow-up ended	1 (7%)	0
Censored, follow-up ongoing	6 (40%)	7 (24%)
Event Summary		
Deterioration	7 (47%)	17 (59%)
Death	1 (7%)	5 (17%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	2.2 (0.8, 4.8)	1.1 (0.7, 1.6)
Median (95% CI)	4.8 (1.4, -)	1.7 (1.2, 5.0)
3rd Quartile (95% CI)	13.9 (2.9, -)	5.1 (2.1, -)
Log-Rank P-value [2]		0.9720
Hazard Ratio (95% CI) [3]		0.98 (0.35, 2.79)
P-value [3]		0.9720

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessments.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_m20_tfd1.sas 13MAR2023 14:00

Protocol: 207495 Page 4 of 4
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.065110
Summary of EORTC QLQ-MY20 Domain Scores Time to first Deterioration 1
(Up to and including Last Follow-Up)

Item Score: Side Effects of Treatment Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated or Died (event)	4 (27%)	16 (55%)
Censored, follow-up ended	2 (13%)	0
Censored, follow-up ongoing	9 (60%)	13 (45%)
Event Summary		
Deterioration	0	0
Death	4 (27%)	16 (55%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	8.0 (1.1, 9.5)	1.7 (0.9, 5.1)
Median (95% CI)	9.5 (1.1, 13.5)	5.3 (1.2, 9.5)
3rd Quartile (95% CI)	13.5 (8.0, 13.5)	9.5 (5.5, 18.7)
Log-Rank P-value [2]		0.3709
Hazard Ratio (95% CI) [3]		2.11 (0.40, 11.20)
P-value [3]		0.3789

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessments.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_m20_tfd1.sas 13MAR2023 14:00

Protocol: 207495 Page 1 of 4
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.066110
Summary of EORTC QLQ-MY20 Domain Scores Time to first Deterioration 2
(Up to and including Last Follow-Up)

Item Score: Future Perspective Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated (event)	1 (7%)	3 (10%)
Censored, follow-up ended	6 (40%)	16 (55%)
Censored, follow-up ongoing	8 (53%)	10 (34%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	4.8 (4.8, -)	0.7 (0.7, 6.9)
Median (95% CI)	- (4.8, -)	3.8 (0.7, -)
3rd Quartile (95% CI)	- (4.8, -)	- (0.7, -)
Log-Rank P-value [2]		0.3173
Hazard Ratio (95% CI) [3]		>999.99 (<0.01, -)
P-value [3]		0.9984

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessments.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_m20_tfd2.sas 14MAR2023 13:12

Table 4.066110
Summary of EORTC QLQ-MY20 Domain Scores Time to first Deterioration 2
(Up to and including Last Follow-Up)

Item Score: Body Image Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated (event)	0	2 (7%)
Censored, follow-up ended	6 (40%)	16 (55%)
Censored, follow-up ongoing	9 (60%)	11 (38%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (-, -)	1.1 (0.7, -)
Median (95% CI)	- (-, -)	- (0.7, -)
3rd Quartile (95% CI)	- (-, -)	- (0.7, -)
Log-Rank P-value [2]		0.3173
Hazard Ratio (95% CI) [3]		>999.99 (<0.01, -)
P-value [3]		0.9990

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessments.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_m20_tfd2.sas 14MAR2023 13:12

Protocol: 207495 Page 3 of 4
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.066110
Summary of EORTC QLQ-MY20 Domain Scores Time to first Deterioration 2
(Up to and including Last Follow-Up)

Item Score: Disease Symptoms Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated (event)	7 (47%)	17 (59%)
Censored, follow-up ended	2 (13%)	5 (17%)
Censored, follow-up ongoing	6 (40%)	7 (24%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	2.5 (0.8, 4.8)	1.2 (0.7, 1.6)
Median (95% CI)	9.3 (1.4, -)	1.7 (1.3, 5.0)
3rd Quartile (95% CI)	- (4.8, -)	5.0 (1.7, -)
Log-Rank P-value [2]		0.7641
Hazard Ratio (95% CI) [3]		0.84 (0.26, 2.68)
P-value [3]		0.7644

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessments.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_m20_tfd2.sas 14MAR2023 13:12

Protocol: 207495 Page 4 of 4
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.066110
Summary of EORTC QLQ-MY20 Domain Scores Time to first Deterioration 2
(Up to and including Last Follow-Up)

Item Score: Side Effects of Treatment Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated (event)	0	0
Censored, follow-up ended	6 (40%)	16 (55%)
Censored, follow-up ongoing	9 (60%)	13 (45%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (-, -)	- (-, -)
Median (95% CI)	- (-, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		-
Hazard Ratio (95% CI) [3]		- (-, -)
P-value [3]		-

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessments.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_m20_tfd2.sas 14MAR2023 13:12

Protocol: 207495 Page 1 of 8
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.069110
Summary of EORTC QLQ-MY20 Domain Scores Time to permanent Deterioration 1
(Up to and including End of Treatment)

Item Score: Future Perspective Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated or Died (event)	1 (7%)	11 (38%)
Censored, follow-up ended	5 (33%)	7 (24%)
Censored, follow-up ongoing	9 (60%)	11 (38%)
Event Summary		
Deterioration	0	2 (7%)
Death	1 (7%)	9 (31%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	1.1 (1.1, -)	1.1 (0.9, 5.1)
Median (95% CI)	- (1.1, -)	5.1 (1.0, 9.5)
3rd Quartile (95% CI)	- (1.1, -)	9.5 (2.1, 13.1)
Log-Rank P-value [2]		0.4245
Hazard Ratio (95% CI) [3]		2.55 (0.24, 27.13)
P-value [3]		0.4370

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd1_m20_eot.sas 14MAR2023 15:57

Protocol: 207495 Page 2 of 8
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.069110
Summary of EORTC QLQ-MY20 Domain Scores Time to permanent Deterioration 1
(Up to and including End of Treatment)

Item Score: Future Perspective Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of subsequent visits with confirmation for subjects who permanently deteriorated or died		
n	1	11
0	1 / 1 (100%)	9 / 11 (82%)
1	0 / 1	0 / 11
2	0 / 1	0 / 11
3	0 / 1	1 / 11 (9%)
>=4	0 / 1	1 / 11 (9%)
Number of subsequent visits with confirmation for subjects who deteriorated towards end of observation period [4]		
n	0	0
0	0	0
1	0	0

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd1_m20_eot.sas 14MAR2023 15:57

Protocol: 207495 Page 3 of 8
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.069110
Summary of EORTC QLQ-MY20 Domain Scores Time to permanent Deterioration 1
(Up to and including End of Treatment)

Item Score: Body Image Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated or Died (event)	1 (7%)	9 (31%)
Censored, follow-up ended	5 (33%)	7 (24%)
Censored, follow-up ongoing	9 (60%)	13 (45%)
Event Summary		
Deterioration	0	0
Death	1 (7%)	9 (31%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	1.1 (1.1, -)	1.1 (0.9, 5.1)
Median (95% CI)	- (1.1, -)	5.1 (1.0, -)
3rd Quartile (95% CI)	- (1.1, -)	9.5 (2.1, -)
Log-Rank P-value [2]		0.4245
Hazard Ratio (95% CI) [3]		2.55 (0.24, 27.13)
P-value [3]		0.4370

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd1_m20_eot.sas 14MAR2023 15:57

Protocol: 207495 Page 4 of 8
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.069110
Summary of EORTC QLQ-MY20 Domain Scores Time to permanent Deterioration 1
(Up to and including End of Treatment)

Item Score: Body Image Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of subsequent visits with confirmation for subjects who permanently deteriorated or died		
n	1	9
0	1 / 1 (100%)	9 / 9 (100%)
1	0 / 1	0 / 9
2	0 / 1	0 / 9
3	0 / 1	0 / 9
>=4	0 / 1	0 / 9
Number of subsequent visits with confirmation for subjects who deteriorated towards end of observation period [4]		
n	0	1
0	0	1 / 1 (100%)
1	0	0 / 1

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd1_m20_eot.sas 14MAR2023 15:57

Protocol: 207495 Page 5 of 8
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.069110
Summary of EORTC QLQ-MY20 Domain Scores Time to permanent Deterioration 1
(Up to and including End of Treatment)

Item Score: Disease Symptoms Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated or Died (event)	1 (7%)	10 (34%)
Censored, follow-up ended	5 (33%)	6 (21%)
Censored, follow-up ongoing	9 (60%)	13 (45%)
Event Summary		
Deterioration	0	1 (3%)
Death	1 (7%)	9 (31%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (1.1, -)	2.1 (0.9, 9.5)
Median (95% CI)	- (-, -)	9.5 (2.1, -)
3rd Quartile (95% CI)	- (-, -)	- (9.5, -)
Log-Rank P-value [2]		0.1174
Hazard Ratio (95% CI) [3]		5.11 (0.56, 46.58)
P-value [3]		0.1480

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd1_m20_eot.sas 14MAR2023 15:57

Protocol: 207495 Page 6 of 8
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.069110
Summary of EORTC QLQ-MY20 Domain Scores Time to permanent Deterioration 1
(Up to and including End of Treatment)

Item Score: Disease Symptoms Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of subsequent visits with confirmation for subjects who permanently deteriorated or died		
n	1	10
0	1 / 1 (100%)	9 / 10 (90%)
1	0 / 1	0 / 10
2	0 / 1	0 / 10
3	0 / 1	0 / 10
>=4	0 / 1	1 / 10 (10%)
Number of subsequent visits with confirmation for subjects who deteriorated towards end of observation period [4]		
n	2	7
0	0 / 2	5 / 7 (71%)
1	2 / 2 (100%)	2 / 7 (29%)

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd1_m20_eot.sas 14MAR2023 15:57

Protocol: 207495 Page 7 of 8
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.069110
Summary of EORTC QLQ-MY20 Domain Scores Time to permanent Deterioration 1
(Up to and including End of Treatment)

Item Score: Side Effects of Treatment Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated or Died (event)	1 (7%)	9 (31%)
Censored, follow-up ended	5 (33%)	7 (24%)
Censored, follow-up ongoing	9 (60%)	13 (45%)
Event Summary		
Deterioration	0	0
Death	1 (7%)	9 (31%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	1.1 (1.1, -)	1.1 (0.9, 5.1)
Median (95% CI)	- (1.1, -)	5.1 (1.0, -)
3rd Quartile (95% CI)	- (1.1, -)	9.5 (2.1, -)
Log-Rank P-value [2]		0.4245
Hazard Ratio (95% CI) [3]		2.55 (0.24, 27.13)
P-value [3]		0.4370

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd1_m20_eot.sas 14MAR2023 15:57

Protocol: 207495 Page 8 of 8
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.069110
Summary of EORTC QLQ-MY20 Domain Scores Time to permanent Deterioration 1
(Up to and including End of Treatment)

Item Score: Side Effects of Treatment Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of subsequent visits with confirmation for subjects who permanently deteriorated or died		
n	1	9
0	1 / 1 (100%)	9 / 9 (100%)
1	0 / 1	0 / 9
2	0 / 1	0 / 9
3	0 / 1	0 / 9
>=4	0 / 1	0 / 9
Number of subsequent visits with confirmation for subjects who deteriorated towards end of observation period [4]		
n	0	0
0	0	0
1	0	0

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd1_m20_eot.sas 14MAR2023 15:57

Table 4.070110
Summary of EORTC QLQ-MY20 Domain Scores Time to permanent Deterioration 2
(Up to and including End of Treatment)

Item Score: Future Perspective Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated (event)	0	2 (7%)
Censored, follow-up ended	6 (40%)	16 (55%)
Censored, follow-up ongoing	9 (60%)	11 (38%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (-, -)	5.3 (5.3, 13.1)
Median (95% CI)	- (-, -)	13.1 (5.3, 13.1)
3rd Quartile (95% CI)	- (-, -)	13.1 (5.3, 13.1)
Log-Rank P-value [2]		-
Hazard Ratio (95% CI) [3]		- (-, -)
P-value [3]		-

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

Table 4.070110
Summary of EORTC QLQ-MY20 Domain Scores Time to permanent Deterioration 2
(Up to and including End of Treatment)

Item Score: Future Perspective Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of subsequent visits with confirmation for subjects who permanently deteriorated		
n	0	2
0	0	0 / 2
1	0	0 / 2
2	0	0 / 2
3	0	1 / 2 (50%)
>=4	0	1 / 2 (50%)
Number of subsequent visits with confirmation for subjects who deteriorated towards end of observation period [4]		
n	0	0
0	0	0
1	0	0

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

Table 4.070110
Summary of EORTC QLQ-MY20 Domain Scores Time to permanent Deterioration 2
(Up to and including End of Treatment)

Item Score: Body Image Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated (event)	0	0
Censored, follow-up ended	6 (40%)	16 (55%)
Censored, follow-up ongoing	9 (60%)	13 (45%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (-, -)	- (-, -)
Median (95% CI)	- (-, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		-
Hazard Ratio (95% CI) [3]		- (-, -)
P-value [3]		-

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

Protocol: 207495 Page 4 of 8
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.070110
Summary of EORTC QLQ-MY20 Domain Scores Time to permanent Deterioration 2
(Up to and including End of Treatment)

Item Score: Body Image Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of subsequent visits with confirmation for subjects who permanently deteriorated		
n	0	0
0	0	0
1	0	0
2	0	0
3	0	0
>=4	0	0
Number of subsequent visits with confirmation for subjects who deteriorated towards end of observation period [4]		
n	0	1
0	0	1 / 1 (100%)
1	0	0 / 1

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd2_m20_eot.sas 14MAR2023 17:06

Table 4.070110
Summary of EORTC QLQ-MY20 Domain Scores Time to permanent Deterioration 2
(Up to and including End of Treatment)

Item Score: Disease Symptoms Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated (event)	0	1 (3%)
Censored, follow-up ended	6 (40%)	15 (52%)
Censored, follow-up ongoing	9 (60%)	13 (45%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (-, -)	- (0.7, -)
Median (95% CI)	- (-, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		0.5050
Hazard Ratio (95% CI) [3]		>999.99 (<0.01, -)
P-value [3]		0.9986

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

Protocol: 207495 Page 6 of 8
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.070110
Summary of EORTC QLQ-MY20 Domain Scores Time to permanent Deterioration 2
(Up to and including End of Treatment)

Item Score: Disease Symptoms Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of subsequent visits with confirmation for subjects who permanently deteriorated		
n	0	1
0	0	0 / 1
1	0	0 / 1
2	0	0 / 1
3	0	0 / 1
>=4	0	1 / 1 (100%)
Number of subsequent visits with confirmation for subjects who deteriorated towards end of observation period [4]		
n	2	12
0	0 / 2	10 / 12 (83%)
1	2 / 2 (100%)	2 / 12 (17%)

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd2_m20_eot.sas 14MAR2023 17:06

Protocol: 207495 Page 7 of 8
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.070110
Summary of EORTC QLQ-MY20 Domain Scores Time to permanent Deterioration 2
(Up to and including End of Treatment)

Item Score: Side Effects of Treatment Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated (event)	0	0
Censored, follow-up ended	6 (40%)	16 (55%)
Censored, follow-up ongoing	9 (60%)	13 (45%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (-, -)	- (-, -)
Median (95% CI)	- (-, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		-
Hazard Ratio (95% CI) [3]		- (-, -)
P-value [3]		-

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd2_m20_eot.sas 14MAR2023 17:06

Protocol: 207495 Page 8 of 8
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.070110
Summary of EORTC QLQ-MY20 Domain Scores Time to permanent Deterioration 2
(Up to and including End of Treatment)

Item Score: Side Effects of Treatment Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of subsequent visits with confirmation for subjects who permanently deteriorated		
n	0	0
0	0	0
1	0	0
2	0	0
3	0	0
>=4	0	0
Number of subsequent visits with confirmation for subjects who deteriorated towards end of observation period [4]		
n	0	0
0	0	0
1	0	0

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd2_m20_eot.sas 14MAR2023 17:06

Protocol: 207495 Page 1 of 8
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.071110
Summary of EORTC QLQ-MY20 Domain Scores Time to permanent Deterioration 1
(Up to and including Last Follow-Up)

Item Score: Future Perspective Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated or Died (event)	4 (27%)	18 (62%)
Censored, follow-up ended	2 (13%)	0
Censored, follow-up ongoing	9 (60%)	11 (38%)
Event Summary		
Deterioration	0	2 (7%)
Death	4 (27%)	16 (55%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	8.0 (1.1, 9.5)	1.7 (0.9, 5.1)
Median (95% CI)	9.5 (1.1, 13.5)	5.2 (1.2, 6.6)
3rd Quartile (95% CI)	13.5 (8.0, 13.5)	8.0 (5.3, 18.7)
Log-Rank P-value [2]		0.3168
Hazard Ratio (95% CI) [3]		2.27 (0.44, 11.72)
P-value [3]		0.3264

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd1_m20_lf.sas 14MAR2023 15:58

Table 4.071110
Summary of EORTC QLQ-MY20 Domain Scores Time to permanent Deterioration 1
(Up to and including Last Follow-Up)

Item Score: Future Perspective Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of subsequent visits with confirmation for subjects who permanently deteriorated or died		
n	4	18
0	4 / 4 (100%)	16 / 18 (89%)
1	0 / 4	0 / 18
2	0 / 4	0 / 18
3	0 / 4	1 / 18 (6%)
>=4	0 / 4	1 / 18 (6%)
Number of subsequent visits with confirmation for subjects who deteriorated towards end of observation period [4]		
n	0	0
0	0	0
1	0	0

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

Protocol: 207495 Page 3 of 8
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.071110
Summary of EORTC QLQ-MY20 Domain Scores Time to permanent Deterioration 1
(Up to and including Last Follow-Up)

Item Score: Body Image Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated or Died (event)	4 (27%)	16 (55%)
Censored, follow-up ended	2 (13%)	0
Censored, follow-up ongoing	9 (60%)	13 (45%)
Event Summary		
Deterioration	0	0
Death	4 (27%)	16 (55%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	8.0 (1.1, 9.5)	1.7 (0.9, 5.1)
Median (95% CI)	9.5 (1.1, 13.5)	5.3 (1.2, 9.5)
3rd Quartile (95% CI)	13.5 (8.0, 13.5)	9.5 (5.5, 18.7)
Log-Rank P-value [2]		0.3709
Hazard Ratio (95% CI) [3]		2.11 (0.40, 11.20)
P-value [3]		0.3789

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd1_m20_lf.sas 14MAR2023 15:58

Protocol: 207495 Page 4 of 8
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.071110
Summary of EORTC QLQ-MY20 Domain Scores Time to permanent Deterioration 1
(Up to and including Last Follow-Up)

Item Score: Body Image Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of subsequent visits with confirmation for subjects who permanently deteriorated or died		
n	4	16
0	4 / 4 (100%)	16 / 16 (100%)
1	0 / 4	0 / 16
2	0 / 4	0 / 16
3	0 / 4	0 / 16
>=4	0 / 4	0 / 16
Number of subsequent visits with confirmation for subjects who deteriorated towards end of observation period [4]		
n	0	1
0	0	1 / 1 (100%)
1	0	0 / 1

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd1_m20_lf.sas 14MAR2023 15:58

Protocol: 207495 Page 5 of 8
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.071110
Summary of EORTC QLQ-MY20 Domain Scores Time to permanent Deterioration 1
(Up to and including Last Follow-Up)

Item Score: Disease Symptoms Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated or Died (event)	4 (27%)	16 (55%)
Censored, follow-up ended	2 (13%)	0
Censored, follow-up ongoing	9 (60%)	13 (45%)
Event Summary		
Deterioration	0	1 (3%)
Death	4 (27%)	15 (52%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	9.5 (1.1, -)	2.1 (0.9, 5.1)
Median (95% CI)	- (8.0, -)	5.7 (2.9, 18.7)
3rd Quartile (95% CI)	- (13.5, -)	18.7 (6.6, -)
Log-Rank P-value [2]		0.0513
Hazard Ratio (95% CI) [3]		4.23 (0.89, 20.06)
P-value [3]		0.0690

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd1_m20_lf.sas 14MAR2023 15:58

Protocol: 207495 Page 6 of 8
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.071110
Summary of EORTC QLQ-MY20 Domain Scores Time to permanent Deterioration 1
(Up to and including Last Follow-Up)

Item Score: Disease Symptoms Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of subsequent visits with confirmation for subjects who permanently deteriorated or died		
n	4	16
0	4 / 4 (100%)	15 / 16 (94%)
1	0 / 4	0 / 16
2	0 / 4	0 / 16
3	0 / 4	0 / 16
>=4	0 / 4	1 / 16 (6%)
Number of subsequent visits with confirmation for subjects who deteriorated towards end of observation period [4]		
n	1	4
0	0 / 1	3 / 4 (75%)
1	1 / 1 (100%)	1 / 4 (25%)

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd1_m20_lf.sas 14MAR2023 15:58

Protocol: 207495 Page 7 of 8
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.071110
Summary of EORTC QLQ-MY20 Domain Scores Time to permanent Deterioration 1
(Up to and including Last Follow-Up)

Item Score: Side Effects of Treatment Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated or Died (event)	4 (27%)	16 (55%)
Censored, follow-up ended	2 (13%)	0
Censored, follow-up ongoing	9 (60%)	13 (45%)
Event Summary		
Deterioration	0	0
Death	4 (27%)	16 (55%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	8.0 (1.1, 9.5)	1.7 (0.9, 5.1)
Median (95% CI)	9.5 (1.1, 13.5)	5.3 (1.2, 9.5)
3rd Quartile (95% CI)	13.5 (8.0, 13.5)	9.5 (5.5, 18.7)
Log-Rank P-value [2]		0.3709
Hazard Ratio (95% CI) [3]		2.11 (0.40, 11.20)
P-value [3]		0.3789

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd1_m20_lf.sas 14MAR2023 15:58

Protocol: 207495 Page 8 of 8
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.071110
Summary of EORTC QLQ-MY20 Domain Scores Time to permanent Deterioration 1
(Up to and including Last Follow-Up)

Item Score: Side Effects of Treatment Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of subsequent visits with confirmation for subjects who permanently deteriorated or died		
n	4	16
0	4 / 4 (100%)	16 / 16 (100%)
1	0 / 4	0 / 16
2	0 / 4	0 / 16
3	0 / 4	0 / 16
>=4	0 / 4	0 / 16
Number of subsequent visits with confirmation for subjects who deteriorated towards end of observation period [4]		
n	0	0
0	0	0
1	0	0

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd1_m20_lf.sas 14MAR2023 15:58

Protocol: 207495 Page 1 of 8
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.072110
Summary of EORTC QLQ-MY20 Domain Scores Time to permanent Deterioration 2
(Up to and including Last Follow-Up)

Item Score: Future Perspective Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated (event)	0	2 (7%)
Censored, follow-up ended	6 (40%)	16 (55%)
Censored, follow-up ongoing	9 (60%)	11 (38%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (-, -)	9.2 (5.3, 13.1)
Median (95% CI)	- (-, -)	13.1 (5.3, 13.1)
3rd Quartile (95% CI)	- (-, -)	13.1 (5.3, 13.1)
Log-Rank P-value [2]		-
Hazard Ratio (95% CI) [3]		- (-, -)
P-value [3]		-

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd2_m20_lf.sas 14MAR2023 17:07

Table 4.072110
Summary of EORTC QLQ-MY20 Domain Scores Time to permanent Deterioration 2
(Up to and including Last Follow-Up)

Item Score: Future Perspective Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of subsequent visits with confirmation for subjects who permanently deteriorated		
n	0	2
0	0	0 / 2
1	0	0 / 2
2	0	0 / 2
3	0	1 / 2 (50%)
>=4	0	1 / 2 (50%)
Number of subsequent visits with confirmation for subjects who deteriorated towards end of observation period [4]		
n	0	0
0	0	0
1	0	0

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

Table 4.072110
Summary of EORTC QLQ-MY20 Domain Scores Time to permanent Deterioration 2
(Up to and including Last Follow-Up)

Item Score: Body Image Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated (event)	0	0
Censored, follow-up ended	6 (40%)	16 (55%)
Censored, follow-up ongoing	9 (60%)	13 (45%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (-, -)	- (-, -)
Median (95% CI)	- (-, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		-
Hazard Ratio (95% CI) [3]		- (-, -)
P-value [3]		-

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

Protocol: 207495 Page 4 of 8
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.072110
Summary of EORTC QLQ-MY20 Domain Scores Time to permanent Deterioration 2
(Up to and including Last Follow-Up)

Item Score: Body Image Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of subsequent visits with confirmation for subjects who permanently deteriorated		
n	0	0
0	0	0
1	0	0
2	0	0
3	0	0
>=4	0	0
Number of subsequent visits with confirmation for subjects who deteriorated towards end of observation period [4]		
n	0	1
0	0	1 / 1 (100%)
1	0	0 / 1

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd2_m20_lf.sas 14MAR2023 17:07

Protocol: 207495 Page 5 of 8
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.072110
Summary of EORTC QLQ-MY20 Domain Scores Time to permanent Deterioration 2
(Up to and including Last Follow-Up)

Item Score: Disease Symptoms Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated (event)	0	1 (3%)
Censored, follow-up ended	6 (40%)	15 (52%)
Censored, follow-up ongoing	9 (60%)	13 (45%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (-, -)	- (0.7, -)
Median (95% CI)	- (-, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		0.5050
Hazard Ratio (95% CI) [3]		>999.99 (<0.01, -)
P-value [3]		0.9986

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd2_m20_lf.sas 14MAR2023 17:07

Protocol: 207495 Page 6 of 8
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.072110
Summary of EORTC QLQ-MY20 Domain Scores Time to permanent Deterioration 2
(Up to and including Last Follow-Up)

Item Score: Disease Symptoms Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of subsequent visits with confirmation for subjects who permanently deteriorated		
n	0	1
0	0	0 / 1
1	0	0 / 1
2	0	0 / 1
3	0	0 / 1
>=4	0	1 / 1 (100%)
Number of subsequent visits with confirmation for subjects who deteriorated towards end of observation period [4]		
n	2	12
0	0 / 2	10 / 12 (83%)
1	2 / 2 (100%)	2 / 12 (17%)

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd2_m20_lf.sas 14MAR2023 17:07

Protocol: 207495 Page 7 of 8
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.072110
Summary of EORTC QLQ-MY20 Domain Scores Time to permanent Deterioration 2
(Up to and including Last Follow-Up)

Item Score: Side Effects of Treatment Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated (event)	0	0
Censored, follow-up ended	6 (40%)	16 (55%)
Censored, follow-up ongoing	9 (60%)	13 (45%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (-, -)	- (-, -)
Median (95% CI)	- (-, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		-
Hazard Ratio (95% CI) [3]		- (-, -)
P-value [3]		-

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd2_m20_lf.sas 14MAR2023 17:07

Protocol: 207495 Page 8 of 8
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.072110
Summary of EORTC QLQ-MY20 Domain Scores Time to permanent Deterioration 2
(Up to and including Last Follow-Up)

Item Score: Side Effects of Treatment Domain Score

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of subsequent visits with confirmation for subjects who permanently deteriorated		
n	0	0
0	0	0
1	0	0
2	0	0
3	0	0
>=4	0	0
Number of subsequent visits with confirmation for subjects who deteriorated towards end of observation period [4]		
n	0	0
0	0	0
1	0	0

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd2_m20_lf.sas 14MAR2023 17:07

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.050110
Summary of FACT-GP5 scores by Visit

Timepoint	Levels	Pom/Dex (N=14)		Belantamab mafodotin (N=29)	
Baseline	n	13		25	
	0	9	(69%)	13	(52%)
	1	1	(8%)	5	(20%)
	2	2	(15%)	4	(16%)
	3	0		3	(12%)
	4	1	(8%)	0	
	3+4	1	(8%)	3	(12%)
	Any Scale >0	4	(31%)	12	(48%)
Week 4	n	13		23	
	0	6	(46%)	12	(52%)
	1	4	(31%)	1	(4%)
	2	1	(8%)	5	(22%)
	3	1	(8%)	4	(17%)
	4	1	(8%)	1	(4%)
	3+4	2	(15%)	5	(22%)
	Any Scale >0	7	(54%)	11	(48%)
	Worsening in FACT-GP5 score >=1 from Baseline	4/12	(33%)	6/22	(27%)
	Improvement in FACT-GP5 score >=1 from Baseline	3/12	(25%)	4/22	(18%)

Note: 0 = Not at all, 1 = A little bit, 2 = Somewhat, 3 = Quite a bit, 4 = Very much.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t6a_fact_gp5_sf.sas 13MAR2023 06:

Table 4.050110
Summary of FACT-GP5 scores by Visit

Timepoint	Levels	Pom/Dex (N=14)		Belantamab mafodotin (N=29)	
Week 7	n	12		15	
	0	3	(25%)	5	(33%)
	1	4	(33%)	5	(33%)
	2	2	(17%)	4	(27%)
	3	2	(17%)	1	(7%)
	4	1	(8%)	0	
	3+4	3	(25%)	1	(7%)
	Any Scale >0	9	(75%)	10	(67%)
	Worsening in FACT-GP5 score >=1 from Baseline	6/11	(55%)	7/14	(50%)
	Improvement in FACT-GP5 score >=1 from Baseline	3/11	(27%)	3/14	(21%)
Week 10	n	13		12	
	0	4	(31%)	3	(25%)
	1	6	(46%)	6	(50%)
	2	2	(15%)	2	(17%)
	3	0		0	
	4	1	(8%)	1	(8%)
	3+4	1	(8%)	1	(8%)
	Any Scale >0	9	(69%)	9	(75%)
	Worsening in FACT-GP5 score >=1 from Baseline	6/12	(50%)	4/11	(36%)
	Improvement in FACT-GP5 score >=1 from Baseline	2/12	(17%)	2/11	(18%)

Note: 0 = Not at all, 1 = A little bit, 2 = Somewhat, 3 = Quite a bit, 4 = Very much.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t6a_fact_gp5_sf.sas 13MAR2023 06:

Table 4.050110
Summary of FACT-GP5 scores by Visit

Timepoint	Levels	Pom/Dex (N=14)		Belantamab mafodotin (N=29)	
Week 13	n	13		9	
	0	4	(31%)	4	(44%)
	1	7	(54%)	1	(11%)
	2	0		3	(33%)
	3	0		1	(11%)
	4	2	(15%)	0	
	3+4	2	(15%)	1	(11%)
	Any Scale >0	9	(69%)	5	(56%)
	Worsening in FACT-GP5 score >=1 from Baseline	5/12	(42%)	2/ 9	(22%)
	Improvement in FACT-GP5 score >=1 from Baseline	1/12	(8%)	1/ 9	(11%)
Week 16	n	12		8	
	0	7	(58%)	4	(50%)
	1	3	(25%)	2	(25%)
	2	0		2	(25%)
	3	2	(17%)	0	
	4	0		0	
	3+4	2	(17%)	0	
	Any Scale >0	5	(42%)	4	(50%)
	Worsening in FACT-GP5 score >=1 from Baseline	3/11	(27%)	2/ 8	(25%)
	Improvement in FACT-GP5 score >=1 from Baseline	3/11	(27%)	1/ 8	(13%)

Note: 0 = Not at all, 1 = A little bit, 2 = Somewhat, 3 = Quite a bit, 4 = Very much.

Table 4.050110
Summary of FACT-GP5 scores by Visit

Timepoint	Levels	Pom/Dex (N=14)		Belantamab mafodotin (N=29)	
Week 19	n	12		7	
	0	8	(67%)	3	(43%)
	1	1	(8%)	3	(43%)
	2	1	(8%)	1	(14%)
	3	0		0	
	4	2	(17%)	0	
	3+4	2	(17%)	0	
	Any Scale >0	4	(33%)	4	(57%)
	Worsening in FACT-GP5 score >=1 from Baseline	3/11	(27%)	2/ 7	(29%)
	Improvement in FACT-GP5 score >=1 from Baseline	3/11	(27%)	1/ 7	(14%)
Week 22	n	7		7	
	0	4	(57%)	3	(43%)
	1	1	(14%)	3	(43%)
	2	2	(29%)	1	(14%)
	3	0		0	
	4	0		0	
	3+4	0		0	
	Any Scale >0	3	(43%)	4	(57%)
	Worsening in FACT-GP5 score >=1 from Baseline	2/ 7	(29%)	2/ 7	(29%)
	Improvement in FACT-GP5 score >=1 from Baseline	2/ 7	(29%)	1/ 7	(14%)

Note: 0 = Not at all, 1 = A little bit, 2 = Somewhat, 3 = Quite a bit, 4 = Very much.

Table 4.050110
Summary of FACT-GP5 scores by Visit

Timepoint	Levels	Pom/Dex (N=14)		Belantamab mafodotin (N=29)	
Week 25	n	7		7	
	0	2	(29%)	4	(57%)
	1	2	(29%)	2	(29%)
	2	1	(14%)	1	(14%)
	3	2	(29%)	0	
	4	0		0	
	3+4	2	(29%)	0	
	Any Scale >0	5	(71%)	3	(43%)
	Worsening in FACT-GP5 score >=1 from Baseline	4/ 7	(57%)	1/ 6	(17%)
	Improvement in FACT-GP5 score >=1 from Baseline	2/ 7	(29%)	1/ 6	(17%)
Week 28	n	7		6	
	0	4	(57%)	3	(50%)
	1	1	(14%)	2	(33%)
	2	0		0	
	3	2	(29%)	1	(17%)
	4	0		0	
	3+4	2	(29%)	1	(17%)
	Any Scale >0	3	(43%)	3	(50%)
	Worsening in FACT-GP5 score >=1 from Baseline	2/ 7	(29%)	2/ 6	(33%)
	Improvement in FACT-GP5 score >=1 from Baseline	2/ 7	(29%)	1/ 6	(17%)

Note: 0 = Not at all, 1 = A little bit, 2 = Somewhat, 3 = Quite a bit, 4 = Very much.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t6a_fact_gp5_sf.sas 13MAR2023 06:

Table 4.050110
Summary of FACT-GP5 scores by Visit

Timepoint	Levels	Pom/Dex (N=14)		Belantamab mafodotin (N=29)	
Week 31	n	7		6	
	0	4	(57%)	3	(50%)
	1	3	(43%)	0	
	2	0		2	(33%)
	3	0		1	(17%)
	4	0		0	
	3+4	0		1	(17%)
	Any Scale >0	3	(43%)	3	(50%)
	Worsening in FACT-GP5 score >=1 from Baseline	2/ 7	(29%)	2/ 6	(33%)
	Improvement in FACT-GP5 score >=1 from Baseline	2/ 7	(29%)	1/ 6	(17%)
Week 34	n	5		6	
	0	4	(80%)	3	(50%)
	1	1	(20%)	2	(33%)
	2	0		1	(17%)
	3	0		0	
	4	0		0	
	3+4	0		0	
	Any Scale >0	1	(20%)	3	(50%)
	Worsening in FACT-GP5 score >=1 from Baseline	1/ 5	(20%)	2/ 6	(33%)
	Improvement in FACT-GP5 score >=1 from Baseline	1/ 5	(20%)	1/ 6	(17%)

Note: 0 = Not at all, 1 = A little bit, 2 = Somewhat, 3 = Quite a bit, 4 = Very much.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t6a_fact_gp5_sf.sas 13MAR2023 06:

Table 4.050110
Summary of FACT-GP5 scores by Visit

Timepoint	Levels	Pom/Dex (N=14)		Belantamab mafodotin (N=29)	
Week 37	n	4		6	
	0	3	(75%)	3	(50%)
	1	0		2	(33%)
	2	0		1	(17%)
	3	1	(25%)	0	
	4	0		0	
	3+4	1	(25%)	0	
	Any Scale >0	1	(25%)	3	(50%)
	Worsening in FACT-GP5 score >=1 from Baseline	1/ 4	(25%)	2/ 6	(33%)
	Improvement in FACT-GP5 score >=1 from Baseline	1/ 4	(25%)	1/ 6	(17%)
Week 40	n	4		5	
	0	3	(75%)	4	(80%)
	1	0		0	
	2	0		1	(20%)
	3	0		0	
	4	1	(25%)	0	
	3+4	1	(25%)	0	
	Any Scale >0	1	(25%)	1	(20%)
	Worsening in FACT-GP5 score >=1 from Baseline	1/ 4	(25%)	1/ 5	(20%)
	Improvement in FACT-GP5 score >=1 from Baseline	1/ 4	(25%)	0/ 5	

Note: 0 = Not at all, 1 = A little bit, 2 = Somewhat, 3 = Quite a bit, 4 = Very much.

Table 4.050110
Summary of FACT-GP5 scores by Visit

Timepoint	Levels	Pom/Dex (N=14)		Belantamab mafodotin (N=29)	
Week 43	n	4		4	
	0	2	(50%)	2	(50%)
	1	1	(25%)	1	(25%)
	2	0		1	(25%)
	3	0		0	
	4	1	(25%)	0	
	3+4	1	(25%)	0	
	Any Scale >0	2	(50%)	2	(50%)
	Worsening in FACT-GP5 score >=1 from Baseline	2/ 4	(50%)	2/ 4	(50%)
	Improvement in FACT-GP5 score >=1 from Baseline	1/ 4	(25%)	0/ 4	
Week 46	n	3		4	
	0	1	(33%)	2	(50%)
	1	2	(67%)	1	(25%)
	2	0		1	(25%)
	3	0		0	
	4	0		0	
	3+4	0		0	
	Any Scale >0	2	(67%)	2	(50%)
	Worsening in FACT-GP5 score >=1 from Baseline	2/ 3	(67%)	2/ 4	(50%)
	Improvement in FACT-GP5 score >=1 from Baseline	0/ 3		0/ 4	

Note: 0 = Not at all, 1 = A little bit, 2 = Somewhat, 3 = Quite a bit, 4 = Very much.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t6a_fact_gp5_sf.sas 13MAR2023 06:

Table 4.050110
Summary of FACT-GP5 scores by Visit

Timepoint	Levels	Pom/Dex (N=14)		Belantamab mafodotin (N=29)	
Week 49	n	3		4	
	0	1	(33%)	2	(50%)
	1	1	(33%)	1	(25%)
	2	1	(33%)	1	(25%)
	3	0		0	
	4	0		0	
	3+4	0		0	
	Any Scale >0	2	(67%)	2	(50%)
	Worsening in FACT-GP5 score >=1 from Baseline	2/ 3	(67%)	2/ 4	(50%)
	Improvement in FACT-GP5 score >=1 from Baseline	0/ 3		0/ 4	
Week 52	n	3		4	
	0	1	(33%)	2	(50%)
	1	1	(33%)	1	(25%)
	2	0		1	(25%)
	3	1	(33%)	0	
	4	0		0	
	3+4	1	(33%)	0	
	Any Scale >0	2	(67%)	2	(50%)
	Worsening in FACT-GP5 score >=1 from Baseline	2/ 3	(67%)	2/ 4	(50%)
	Improvement in FACT-GP5 score >=1 from Baseline	0/ 3		0/ 4	

Note: 0 = Not at all, 1 = A little bit, 2 = Somewhat, 3 = Quite a bit, 4 = Very much.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t6a_fact_gp5_sf.sas 13MAR2023 06:

Table 4.050110
Summary of FACT-GP5 scores by Visit

Timepoint	Levels	Pom/Dex (N=14)		Belantamab mafodotin (N=29)	
Week 55	n	3		3	
	0	2	(67%)	2	(67%)
	1	0		0	
	2	1	(33%)	1	(33%)
	3	0		0	
	4	0		0	
	3+4	0		0	
	Any Scale >0	1	(33%)	1	(33%)
	Worsening in FACT-GP5 score >=1 from Baseline	1/ 3	(33%)	1/ 3	(33%)
	Improvement in FACT-GP5 score >=1 from Baseline	0/ 3		0/ 3	
Week 58	n	2		2	
	0	1	(50%)	1	(50%)
	1	1	(50%)	0	
	2	0		1	(50%)
	3	0		0	
	4	0		0	
	3+4	0		0	
	Any Scale >0	1	(50%)	1	(50%)
	Worsening in FACT-GP5 score >=1 from Baseline	1/ 2	(50%)	1/ 2	(50%)
	Improvement in FACT-GP5 score >=1 from Baseline	0/ 2		0/ 2	

Note: 0 = Not at all, 1 = A little bit, 2 = Somewhat, 3 = Quite a bit, 4 = Very much.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t6a_fact_gp5_sf.sas 13MAR2023 06:

Table 4.050110
Summary of FACT-GP5 scores by Visit

Timepoint	Levels	Pom/Dex (N=14)		Belantamab mafodotin (N=29)	
Week 61	n	2		2	
	0	1	(50%)	1	(50%)
	1	0		0	
	2	1	(50%)	1	(50%)
	3	0		0	
	4	0		0	
	3+4	0		0	
	Any Scale >0	1	(50%)	1	(50%)
	Worsening in FACT-GP5 score >=1 from Baseline	1/ 2	(50%)	1/ 2	(50%)
	Improvement in FACT-GP5 score >=1 from Baseline	0/ 2		0/ 2	
Week 64	n	2		2	
	0	1	(50%)	1	(50%)
	1	0		0	
	2	0		1	(50%)
	3	1	(50%)	0	
	4	0		0	
	3+4	1	(50%)	0	
	Any Scale >0	1	(50%)	1	(50%)
	Worsening in FACT-GP5 score >=1 from Baseline	1/ 2	(50%)	1/ 2	(50%)
	Improvement in FACT-GP5 score >=1 from Baseline	0/ 2		0/ 2	

Note: 0 = Not at all, 1 = A little bit, 2 = Somewhat, 3 = Quite a bit, 4 = Very much.

Table 4.050110
Summary of FACT-GP5 scores by Visit

Timepoint	Levels	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 67	n	2	2
	0	2 (100%)	1 (50%)
	1	0	0
	2	0	1 (50%)
	3	0	0
	4	0	0
	3+4	0	0
	Any Scale >0	0	1 (50%)
	Worsening in FACT-GP5 score >=1 from Baseline	0/ 2	1/ 2 (50%)
	Improvement in FACT-GP5 score >=1 from Baseline	0/ 2	0/ 2
Week 70	n	2	1
	0	1 (50%)	1 (100%)
	1	0	0
	2	1 (50%)	0
	3	0	0
	4	0	0
	3+4	0	0
	Any Scale >0	1 (50%)	0
	Worsening in FACT-GP5 score >=1 from Baseline	1/ 2 (50%)	0/ 1
	Improvement in FACT-GP5 score >=1 from Baseline	0/ 2	0/ 1

Note: 0 = Not at all, 1 = A little bit, 2 = Somewhat, 3 = Quite a bit, 4 = Very much.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t6a_fact_gp5_sf.sas 13MAR2023 06:

Table 4.050110
Summary of FACT-GP5 scores by Visit

Timepoint	Levels	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 73	n	1	1
	0	0	1 (100%)
	1	1 (100%)	0
	2	0	0
	3	0	0
	4	0	0
	3+4	0	0
	Any Scale >0	1 (100%)	0
	Worsening in FACT-GP5 score >=1 from Baseline	1/ 1 (100%)	0/ 1
	Improvement in FACT-GP5 score >=1 from Baseline	0/ 1	0/ 1
Week 76	n	2	1
	0	2 (100%)	1 (100%)
	1	0	0
	2	0	0
	3	0	0
	4	0	0
	3+4	0	0
	Any Scale >0	0	0
	Worsening in FACT-GP5 score >=1 from Baseline	0/ 2	0/ 1
	Improvement in FACT-GP5 score >=1 from Baseline	0/ 2	0/ 1

Note: 0 = Not at all, 1 = A little bit, 2 = Somewhat, 3 = Quite a bit, 4 = Very much.

Table 4.050110
Summary of FACT-GP5 scores by Visit

Timepoint	Levels	Pom/Dex (N=14)		Belantamab mafodotin (N=29)	
Week 79	n	2		1	
	0	2	(100%)	1	(100%)
	1	0		0	
	2	0		0	
	3	0		0	
	4	0		0	
	3+4	0		0	
	Any Scale >0	0		0	
	Worsening in FACT-GP5 score >=1 from Baseline	0/ 2		0/ 1	
	Improvement in FACT-GP5 score >=1 from Baseline	0/ 2		0/ 1	
Week 82	n	2		1	
	0	2	(100%)	1	(100%)
	1	0		0	
	2	0		0	
	3	0		0	
	4	0		0	
	3+4	0		0	
	Any Scale >0	0		0	
	Worsening in FACT-GP5 score >=1 from Baseline	0/ 2		0/ 1	
	Improvement in FACT-GP5 score >=1 from Baseline	0/ 2		0/ 1	

Note: 0 = Not at all, 1 = A little bit, 2 = Somewhat, 3 = Quite a bit, 4 = Very much.

Table 4.050110
Summary of FACT-GP5 scores by Visit

Timepoint	Levels	Pom/Dex (N=14)		Belantamab mafodotin (N=29)	
Week 85	n	1		1	
	0	1	(100%)	1	(100%)
	1	0		0	
	2	0		0	
	3	0		0	
	4	0		0	
	3+4	0		0	
	Any Scale >0	0		0	
	Worsening in FACT-GP5 score >=1 from Baseline	0/ 1		0/ 1	
	Improvement in FACT-GP5 score >=1 from Baseline	0/ 1		0/ 1	
Week 88	n	1		1	
	0	1	(100%)	1	(100%)
	1	0		0	
	2	0		0	
	3	0		0	
	4	0		0	
	3+4	0		0	
	Any Scale >0	0		0	
	Worsening in FACT-GP5 score >=1 from Baseline	0/ 1		0/ 1	
	Improvement in FACT-GP5 score >=1 from Baseline	0/ 1		0/ 1	

Note: 0 = Not at all, 1 = A little bit, 2 = Somewhat, 3 = Quite a bit, 4 = Very much.

Table 4.050110
Summary of FACT-GP5 scores by Visit

Timepoint	Levels	Pom/Dex (N=14)		Belantamab mafodotin (N=29)	
Week 91	n	1		1	
	0	1	(100%)	1	(100%)
	1	0		0	
	2	0		0	
	3	0		0	
	4	0		0	
	3+4	0		0	
	Any Scale >0	0		0	
	Worsening in FACT-GP5 score >=1 from Baseline	0/ 1		0/ 1	
	Improvement in FACT-GP5 score >=1 from Baseline	0/ 1		0/ 1	
Week 94	n	2		1	
	0	1	(50%)	1	(100%)
	1	1	(50%)	0	
	2	0		0	
	3	0		0	
	4	0		0	
	3+4	0		0	
	Any Scale >0	1	(50%)	0	
	Worsening in FACT-GP5 score >=1 from Baseline	1/ 2	(50%)	0/ 1	
	Improvement in FACT-GP5 score >=1 from Baseline	0/ 2		0/ 1	

Note: 0 = Not at all, 1 = A little bit, 2 = Somewhat, 3 = Quite a bit, 4 = Very much.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t6a_fact_gp5_sf.sas 13MAR2023 06:

Table 4.050110
Summary of FACT-GP5 scores by Visit

Timepoint	Levels	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 97	n	1	0
	0	0	0
	1	0	0
	2	1 (100%)	0
	3	0	0
	4	0	0
	3+4	0	0
	Any Scale >0	1 (100%)	0
	Worsening in FACT-GP5 score >=1 from Baseline	1/ 1 (100%)	0
	Improvement in FACT-GP5 score >=1 from Baseline	0/ 1	0
Week 100	n	0	1
	0	0	1 (100%)
	1	0	0
	2	0	0
	3	0	0
	4	0	0
	3+4	0	0
	Any Scale >0	0	0
	Worsening in FACT-GP5 score >=1 from Baseline	0	0/ 1
	Improvement in FACT-GP5 score >=1 from Baseline	0	0/ 1

Note: 0 = Not at all, 1 = A little bit, 2 = Somewhat, 3 = Quite a bit, 4 = Very much.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t6a_fact_gp5_sf.sas 13MAR2023 06:

Table 4.050110
Summary of FACT-GP5 scores by Visit

Timepoint	Levels	Pom/Dex (N=14)		Belantamab mafodotin (N=29)	
End of Treatment	n	10		11	
	0	6	(60%)	3	(27%)
	1	1	(10%)	2	(18%)
	2	2	(20%)	2	(18%)
	3	0		0	
	4	1	(10%)	4	(36%)
	3+4	1	(10%)	4	(36%)
	Any Scale >0	4	(40%)	8	(73%)
	Worsening in FACT-GP5 score >=1 from Baseline	1/ 9	(11%)	7/11	(64%)
	Improvement in FACT-GP5 score >=1 from Baseline	2/ 9	(22%)	1/11	(9%)
Worst Case Post-Baseline	n	13		24	
	0	0		4	(17%)
	1	5	(38%)	3	(13%)
	2	2	(15%)	10	(42%)
	3	2	(15%)	3	(13%)
	4	4	(31%)	4	(17%)
	3+4	6	(46%)	7	(29%)
	Any Scale >0	13	(100%)	20	(83%)
	Worsening in FACT-GP5 score >=1 from Baseline	9/12	(75%)	13/23	(57%)
	Improvement in FACT-GP5 score >=1 from Baseline	0/12		2/23	(9%)

Note: 0 = Not at all, 1 = A little bit, 2 = Somewhat, 3 = Quite a bit, 4 = Very much.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t6a_fact_gp5_sf.sas 13MAR2023 06:

Table 4.026110
Analysis of FACT-GP5 scores based on Generalized Estimating Equations (GEE)

Timepoint: Week 4

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
n	13	23
Bothered	7 (54%)	11 (48%)
Not Bothered	6 (46%)	12 (52%)
Adjusted OR (95% CI) [1] vs. Pom/Dex		0.79 (0.20,3.07)
P-value [1]		0.7288

GEE=Generalized Estimating Equations, OR=Odds Ratio.
Note: Percentages based on number of subjects at the current visit in each treatment arm.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: End of Treatment is analysed as its collected visit and its "Week X" visit per assessment date.
[1] Adjusted Odds Ratio (95% CI) and associated p-value are from a GEE model for the comparison between Belantamab mafodotin and Pom/Dex with covariates treatment group, visit, and treatment by visit interaction.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_gee_gp5.sas 17MAR2023 11:57

Table 4.026110
Analysis of FACT-GP5 scores based on Generalized Estimating Equations (GEE)

Timepoint: Week 7

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
n	12	19
Bothered	9 (75%)	13 (68%)
Not Bothered	3 (25%)	6 (32%)
Adjusted OR (95% CI) [1] vs. Pom/Dex		0.72 (0.14,3.67)
P-value [1]		0.6948

GEE=Generalized Estimating Equations, OR=Odds Ratio.
Note: Percentages based on number of subjects at the current visit in each treatment arm.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: End of Treatment is analysed as its collected visit and its "Week X" visit per assessment date.
[1] Adjusted Odds Ratio (95% CI) and associated p-value are from a GEE model for the comparison between Belantamab mafodotin and Pom/Dex with covariates treatment group, visit, and treatment by visit interaction.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_gee_gp5.sas 17MAR2023 11:57

Table 4.026110
Analysis of FACT-GP5 scores based on Generalized Estimating Equations (GEE)

Timepoint: Week 10

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
n	13	12
Bothered	9 (69%)	9 (75%)
Not Bothered	4 (31%)	3 (25%)
Adjusted OR (95% CI) [1] vs. Pom/Dex		1.33 (0.23,7.74)
P-value [1]		0.7486

GEE=Generalized Estimating Equations, OR=Odds Ratio.
Note: Percentages based on number of subjects at the current visit in each treatment arm.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: End of Treatment is analysed as its collected visit and its "Week X" visit per assessment date.
[1] Adjusted Odds Ratio (95% CI) and associated p-value are from a GEE model for the comparison between Belantamab mafodotin and Pom/Dex with covariates treatment group, visit, and treatment by visit interaction.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_gee_gp5.sas 17MAR2023 11:57

Table 4.026110
Analysis of FACT-GP5 scores based on Generalized Estimating Equations (GEE)

Timepoint: Week 13

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
n	13	10
Bothered	9 (69%)	6 (60%)
Not Bothered	4 (31%)	4 (40%)
Adjusted OR (95% CI) [1] vs. Pom/Dex		0.67 (0.12,3.75)
P-value [1]		0.6457

GEE=Generalized Estimating Equations, OR=Odds Ratio.
Note: Percentages based on number of subjects at the current visit in each treatment arm.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: End of Treatment is analysed as its collected visit and its "Week X" visit per assessment date.
[1] Adjusted Odds Ratio (95% CI) and associated p-value are from a GEE model for the comparison between Belantamab mafodotin and Pom/Dex with covariates treatment group, visit, and treatment by visit interaction.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_gee_gp5.sas 17MAR2023 11:57

Table 4.026110
Analysis of FACT-GP5 scores based on Generalized Estimating Equations (GEE)

Timepoint: Week 16

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
n	12	8
Bothered	5 (42%)	5 (63%)
Not Bothered	7 (58%)	3 (38%)
Adjusted OR (95% CI) [1] vs. Pom/Dex		2.33 (0.37,14.61)
P-value [1]		0.3654

GEE=Generalized Estimating Equations, OR=Odds Ratio.
Note: Percentages based on number of subjects at the current visit in each treatment arm.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: End of Treatment is analysed as its collected visit and its "Week X" visit per assessment date.
[1] Adjusted Odds Ratio (95% CI) and associated p-value are from a GEE model for the comparison between Belantamab mafodotin and Pom/Dex with covariates treatment group, visit, and treatment by visit interaction.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_gee_gp5.sas 17MAR2023 11:57

Table 4.026110
Analysis of FACT-GP5 scores based on Generalized Estimating Equations (GEE)

Timepoint: Week 19

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
n	13	7
Bothered	4 (31%)	4 (57%)
Not Bothered	9 (69%)	3 (43%)
Adjusted OR (95% CI) [1] vs. Pom/Dex		3.00 (0.45,20.15)
P-value [1]		0.2583

GEE=Generalized Estimating Equations, OR=Odds Ratio.
Note: Percentages based on number of subjects at the current visit in each treatment arm.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: End of Treatment is analysed as its collected visit and its "Week X" visit per assessment date.
[1] Adjusted Odds Ratio (95% CI) and associated p-value are from a GEE model for the comparison between Belantamab mafodotin and Pom/Dex with covariates treatment group, visit, and treatment by visit interaction.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_gee_gp5.sas 17MAR2023 11:57

Table 4.026110
Analysis of FACT-GP5 scores based on Generalized Estimating Equations (GEE)

Timepoint: Week 22

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
n	8	7
Bothered	4 (50%)	4 (57%)
Not Bothered	4 (50%)	3 (43%)
Adjusted OR (95% CI) [1] vs. Pom/Dex		1.33 (0.17,10.25)
P-value [1]		0.7822

GEE=Generalized Estimating Equations, OR=Odds Ratio.
Note: Percentages based on number of subjects at the current visit in each treatment arm.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: End of Treatment is analysed as its collected visit and its "Week X" visit per assessment date.
[1] Adjusted Odds Ratio (95% CI) and associated p-value are from a GEE model for the comparison between Belantamab mafodotin and Pom/Dex with covariates treatment group, visit, and treatment by visit interaction.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_gee_gp5.sas 17MAR2023 11:57

Table 4.026110
Analysis of FACT-GP5 scores based on Generalized Estimating Equations (GEE)

Timepoint: Week 25

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
n	9	7
Bothered	5 (56%)	3 (43%)
Not Bothered	4 (44%)	4 (57%)
Adjusted OR (95% CI) [1] vs. Pom/Dex		0.60 (0.08,4.40)
P-value [1]		0.6153

GEE=Generalized Estimating Equations, OR=Odds Ratio.
Note: Percentages based on number of subjects at the current visit in each treatment arm.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: End of Treatment is analysed as its collected visit and its "Week X" visit per assessment date.
[1] Adjusted Odds Ratio (95% CI) and associated p-value are from a GEE model for the comparison between Belantamab mafodotin and Pom/Dex with covariates treatment group, visit, and treatment by visit interaction.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_gee_gp5.sas 17MAR2023 11:57

Table 4.026110
Analysis of FACT-GP5 scores based on Generalized Estimating Equations (GEE)

Timepoint: Week 28

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
n	7	6
Bothered	3 (43%)	3 (50%)
Not Bothered	4 (57%)	3 (50%)
Adjusted OR (95% CI) [1] vs. Pom/Dex		1.33 (0.15,11.93)
P-value [1]		0.7969

GEE=Generalized Estimating Equations, OR=Odds Ratio.
Note: Percentages based on number of subjects at the current visit in each treatment arm.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: End of Treatment is analysed as its collected visit and its "Week X" visit per assessment date.
[1] Adjusted Odds Ratio (95% CI) and associated p-value are from a GEE model for the comparison between Belantamab mafodotin and Pom/Dex with covariates treatment group, visit, and treatment by visit interaction.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_gee_gp5.sas 17MAR2023 11:57

Table 4.026110
Analysis of FACT-GP5 scores based on Generalized Estimating Equations (GEE)

Timepoint: Week 31

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
n	7	6
Bothered	3 (43%)	3 (50%)
Not Bothered	4 (57%)	3 (50%)
Adjusted OR (95% CI) [1] vs. Pom/Dex		1.33 (0.15,11.93)
P-value [1]		0.7969

GEE=Generalized Estimating Equations, OR=Odds Ratio.
Note: Percentages based on number of subjects at the current visit in each treatment arm.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: End of Treatment is analysed as its collected visit and its "Week X" visit per assessment date.
[1] Adjusted Odds Ratio (95% CI) and associated p-value are from a GEE model for the comparison between Belantamab mafodotin and Pom/Dex with covariates treatment group, visit, and treatment by visit interaction.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_gee_gp5.sas 17MAR2023 11:57

Table 4.026110
Analysis of FACT-GP5 scores based on Generalized Estimating Equations (GEE)

Timepoint: Week 34

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
n	6	6
Bothered	2 (33%)	3 (50%)
Not Bothered	4 (67%)	3 (50%)
Adjusted OR (95% CI) [1] vs. Pom/Dex		2.00 (0.19,20.61)
P-value [1]		0.5603

GEE=Generalized Estimating Equations, OR=Odds Ratio.
Note: Percentages based on number of subjects at the current visit in each treatment arm.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: End of Treatment is analysed as its collected visit and its "Week X" visit per assessment date.
[1] Adjusted Odds Ratio (95% CI) and associated p-value are from a GEE model for the comparison between Belantamab mafodotin and Pom/Dex with covariates treatment group, visit, and treatment by visit interaction.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_gee_gp5.sas 17MAR2023 11:57

Table 4.026110
Analysis of FACT-GP5 scores based on Generalized Estimating Equations (GEE)

Timepoint: Week 37

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
n	4	6
Bothered	1 (25%)	3 (50%)
Not Bothered	3 (75%)	3 (50%)
Adjusted OR (95% CI) [1] vs. Pom/Dex		3.00 (0.19,47.96)
P-value [1]		0.4373

GEE=Generalized Estimating Equations, OR=Odds Ratio.
Note: Percentages based on number of subjects at the current visit in each treatment arm.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: End of Treatment is analysed as its collected visit and its "Week X" visit per assessment date.
[1] Adjusted Odds Ratio (95% CI) and associated p-value are from a GEE model for the comparison between Belantamab mafodotin and Pom/Dex with covariates treatment group, visit, and treatment by visit interaction.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_gee_gp5.sas 17MAR2023 11:57

Table 4.026110
Analysis of FACT-GP5 scores based on Generalized Estimating Equations (GEE)

Timepoint: Week 40

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
n	4	5
Bothered	1 (25%)	1 (20%)
Not Bothered	3 (75%)	4 (80%)
Adjusted OR (95% CI) [1] vs. Pom/Dex		- (-, -)
P-value [1]		-

GEE=Generalized Estimating Equations, OR=Odds Ratio.
Note: Percentages based on number of subjects at the current visit in each treatment arm.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: End of Treatment is analysed as its collected visit and its "Week X" visit per assessment date.
[1] Adjusted Odds Ratio (95% CI) and associated p-value are from a GEE model for the comparison between Belantamab mafodotin and Pom/Dex with covariates treatment group, visit, and treatment by visit interaction.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_gee_gp5.sas 17MAR2023 11:57

Table 4.026110
Analysis of FACT-GP5 scores based on Generalized Estimating Equations (GEE)

Timepoint: Week 43

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
n	5	4
Bothered	2 (40%)	2 (50%)
Not Bothered	3 (60%)	2 (50%)
Adjusted OR (95% CI) [1] vs. Pom/Dex		- (-, -)
P-value [1]		-

GEE=Generalized Estimating Equations, OR=Odds Ratio.
Note: Percentages based on number of subjects at the current visit in each treatment arm.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: End of Treatment is analysed as its collected visit and its "Week X" visit per assessment date.
[1] Adjusted Odds Ratio (95% CI) and associated p-value are from a GEE model for the comparison between Belantamab mafodotin and Pom/Dex with covariates treatment group, visit, and treatment by visit interaction.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_gee_gp5.sas 17MAR2023 11:57

Protocol: 207495 Page 15 of 34
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.026110
Analysis of FACT-GP5 scores based on Generalized Estimating Equations (GEE)

Timepoint: Week 46

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
n	4	4
Bothered	2 (50%)	2 (50%)
Not Bothered	2 (50%)	2 (50%)
Adjusted OR (95% CI) [1] vs. Pom/Dex		- (-, -)
P-value [1]		-

GEE=Generalized Estimating Equations, OR=Odds Ratio.
Note: Percentages based on number of subjects at the current visit in each treatment arm.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: End of Treatment is analysed as its collected visit and its "Week X" visit per assessment date.
[1] Adjusted Odds Ratio (95% CI) and associated p-value are from a GEE model for the comparison between Belantamab mafodotin and Pom/Dex with covariates treatment group, visit, and treatment by visit interaction.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_gee_gp5.sas 17MAR2023 11:57

Table 4.026110
Analysis of FACT-GP5 scores based on Generalized Estimating Equations (GEE)

Timepoint: Week 49

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
n	3	4
Bothered	2 (67%)	2 (50%)
Not Bothered	1 (33%)	2 (50%)
Adjusted OR (95% CI) [1] vs. Pom/Dex		- (-, -)
P-value [1]		-

GEE=Generalized Estimating Equations, OR=Odds Ratio.
Note: Percentages based on number of subjects at the current visit in each treatment arm.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: End of Treatment is analysed as its collected visit and its "Week X" visit per assessment date.
[1] Adjusted Odds Ratio (95% CI) and associated p-value are from a GEE model for the comparison between Belantamab mafodotin and Pom/Dex with covariates treatment group, visit, and treatment by visit interaction.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_gee_gp5.sas 17MAR2023 11:57

Table 4.026110
Analysis of FACT-GP5 scores based on Generalized Estimating Equations (GEE)

Timepoint: Week 52

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
n	4	4
Bothered	3 (75%)	2 (50%)
Not Bothered	1 (25%)	2 (50%)
Adjusted OR (95% CI) [1] vs. Pom/Dex		- (-, -)
P-value [1]		-

GEE=Generalized Estimating Equations, OR=Odds Ratio.
Note: Percentages based on number of subjects at the current visit in each treatment arm.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: End of Treatment is analysed as its collected visit and its "Week X" visit per assessment date.
[1] Adjusted Odds Ratio (95% CI) and associated p-value are from a GEE model for the comparison between Belantamab mafodotin and Pom/Dex with covariates treatment group, visit, and treatment by visit interaction.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_gee_gp5.sas 17MAR2023 11:57

Table 4.026110
Analysis of FACT-GP5 scores based on Generalized Estimating Equations (GEE)

Timepoint: Week 55

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
n	3	3
Bothered	1 (33%)	1 (33%)
Not Bothered	2 (67%)	2 (67%)
Adjusted OR (95% CI) [1] vs. Pom/Dex		- (-, -)
P-value [1]		-

GEE=Generalized Estimating Equations, OR=Odds Ratio.
Note: Percentages based on number of subjects at the current visit in each treatment arm.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: End of Treatment is analysed as its collected visit and its "Week X" visit per assessment date.
[1] Adjusted Odds Ratio (95% CI) and associated p-value are from a GEE model for the comparison between Belantamab mafodotin and Pom/Dex with covariates treatment group, visit, and treatment by visit interaction.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_gee_gp5.sas 17MAR2023 11:57

Protocol: 207495 Page 19 of 34
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.026110
Analysis of FACT-GP5 scores based on Generalized Estimating Equations (GEE)

Timepoint: Week 58

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
n	2	2
Bothered	1 (50%)	1 (50%)
Not Bothered	1 (50%)	1 (50%)
Adjusted OR (95% CI) [1] vs. Pom/Dex		- (-, -)
P-value [1]		-

GEE=Generalized Estimating Equations, OR=Odds Ratio.
Note: Percentages based on number of subjects at the current visit in each treatment arm.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: End of Treatment is analysed as its collected visit and its "Week X" visit per assessment date.
[1] Adjusted Odds Ratio (95% CI) and associated p-value are from a GEE model for the comparison between Belantamab mafodotin and Pom/Dex with covariates treatment group, visit, and treatment by visit interaction.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_gee_gp5.sas 17MAR2023 11:57

Table 4.026110
Analysis of FACT-GP5 scores based on Generalized Estimating Equations (GEE)

Timepoint: Week 61

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
n	2	2
Bothered	1 (50%)	1 (50%)
Not Bothered	1 (50%)	1 (50%)
Adjusted OR (95% CI) [1] vs. Pom/Dex		- (-, -)
P-value [1]		-

GEE=Generalized Estimating Equations, OR=Odds Ratio.
Note: Percentages based on number of subjects at the current visit in each treatment arm.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: End of Treatment is analysed as its collected visit and its "Week X" visit per assessment date.
[1] Adjusted Odds Ratio (95% CI) and associated p-value are from a GEE model for the comparison between Belantamab mafodotin and Pom/Dex with covariates treatment group, visit, and treatment by visit interaction.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_gee_gp5.sas 17MAR2023 11:57

Protocol: 207495 Page 21 of 34
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.026110
Analysis of FACT-GP5 scores based on Generalized Estimating Equations (GEE)

Timepoint: Week 64

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
n	2	2
Bothered	1 (50%)	1 (50%)
Not Bothered	1 (50%)	1 (50%)
Adjusted OR (95% CI) [1] vs. Pom/Dex		- (-, -)
P-value [1]		-

GEE=Generalized Estimating Equations, OR=Odds Ratio.
Note: Percentages based on number of subjects at the current visit in each treatment arm.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: End of Treatment is analysed as its collected visit and its "Week X" visit per assessment date.
[1] Adjusted Odds Ratio (95% CI) and associated p-value are from a GEE model for the comparison between Belantamab mafodotin and Pom/Dex with covariates treatment group, visit, and treatment by visit interaction.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_gee_gp5.sas 17MAR2023 11:57

Table 4.026110
Analysis of FACT-GP5 scores based on Generalized Estimating Equations (GEE)

Timepoint: Week 67

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
n	2	2
Bothered	0	1 (50%)
Not Bothered	2 (100%)	1 (50%)
Adjusted OR (95% CI) [1] vs. Pom/Dex		- (-, -)
P-value [1]		-

GEE=Generalized Estimating Equations, OR=Odds Ratio.
Note: Percentages based on number of subjects at the current visit in each treatment arm.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: End of Treatment is analysed as its collected visit and its "Week X" visit per assessment date.
[1] Adjusted Odds Ratio (95% CI) and associated p-value are from a GEE model for the comparison between Belantamab mafodotin and Pom/Dex with covariates treatment group, visit, and treatment by visit interaction.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_gee_gp5.sas 17MAR2023 11:57

Table 4.026110
Analysis of FACT-GP5 scores based on Generalized Estimating Equations (GEE)

Timepoint: Week 70

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
n	2	1
Bothered	1 (50%)	0
Not Bothered	1 (50%)	1 (100%)
Adjusted OR (95% CI) [1] vs. Pom/Dex		- (-, -)
P-value [1]		-

GEE=Generalized Estimating Equations, OR=Odds Ratio.
Note: Percentages based on number of subjects at the current visit in each treatment arm.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: End of Treatment is analysed as its collected visit and its "Week X" visit per assessment date.
[1] Adjusted Odds Ratio (95% CI) and associated p-value are from a GEE model for the comparison between Belantamab mafodotin and Pom/Dex with covariates treatment group, visit, and treatment by visit interaction.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_gee_gp5.sas 17MAR2023 11:57

Table 4.026110
Analysis of FACT-GP5 scores based on Generalized Estimating Equations (GEE)

Timepoint: Week 73

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
n	1	1
Bothered	1 (100%)	0
Not Bothered	0	1 (100%)
Adjusted OR (95% CI) [1] vs. Pom/Dex		- (-, -)
P-value [1]		-

GEE=Generalized Estimating Equations, OR=Odds Ratio.
Note: Percentages based on number of subjects at the current visit in each treatment arm.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: End of Treatment is analysed as its collected visit and its "Week X" visit per assessment date.
[1] Adjusted Odds Ratio (95% CI) and associated p-value are from a GEE model for the comparison between Belantamab mafodotin and Pom/Dex with covariates treatment group, visit, and treatment by visit interaction.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_gee_gp5.sas 17MAR2023 11:57

Table 4.026110
Analysis of FACT-GP5 scores based on Generalized Estimating Equations (GEE)

Timepoint: Week 76

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
n	2	1
Bothered	0	0
Not Bothered	2 (100%)	1 (100%)
Adjusted OR (95% CI) [1] vs. Pom/Dex		- (-, -)
P-value [1]		-

GEE=Generalized Estimating Equations, OR=Odds Ratio.
Note: Percentages based on number of subjects at the current visit in each treatment arm.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: End of Treatment is analysed as its collected visit and its "Week X" visit per assessment date.
[1] Adjusted Odds Ratio (95% CI) and associated p-value are from a GEE model for the comparison between Belantamab mafodotin and Pom/Dex with covariates treatment group, visit, and treatment by visit interaction.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_gee_gp5.sas 17MAR2023 11:57

Table 4.026110
Analysis of FACT-GP5 scores based on Generalized Estimating Equations (GEE)

Timepoint: Week 79

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
n	2	1
Bothered	0	0
Not Bothered	2 (100%)	1 (100%)
Adjusted OR (95% CI) [1] vs. Pom/Dex		- (-, -)
P-value [1]		-

GEE=Generalized Estimating Equations, OR=Odds Ratio.
Note: Percentages based on number of subjects at the current visit in each treatment arm.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: End of Treatment is analysed as its collected visit and its "Week X" visit per assessment date.
[1] Adjusted Odds Ratio (95% CI) and associated p-value are from a GEE model for the comparison between Belantamab mafodotin and Pom/Dex with covariates treatment group, visit, and treatment by visit interaction.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_gee_gp5.sas 17MAR2023 11:57

Table 4.026110
Analysis of FACT-GP5 scores based on Generalized Estimating Equations (GEE)

Timepoint: Week 82

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
n	2	1
Bothered	0	0
Not Bothered	2 (100%)	1 (100%)
Adjusted OR (95% CI) [1] vs. Pom/Dex		- (-, -)
P-value [1]		-

GEE=Generalized Estimating Equations, OR=Odds Ratio.
Note: Percentages based on number of subjects at the current visit in each treatment arm.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: End of Treatment is analysed as its collected visit and its "Week X" visit per assessment date.
[1] Adjusted Odds Ratio (95% CI) and associated p-value are from a GEE model for the comparison between Belantamab mafodotin and Pom/Dex with covariates treatment group, visit, and treatment by visit interaction.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_gee_gp5.sas 17MAR2023 11:57

Table 4.026110
Analysis of FACT-GP5 scores based on Generalized Estimating Equations (GEE)

Timepoint: Week 85

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
n	1	1
Bothered	0	0
Not Bothered	1 (100%)	1 (100%)
Adjusted OR (95% CI) [1] vs. Pom/Dex		- (-, -)
P-value [1]		-

GEE=Generalized Estimating Equations, OR=Odds Ratio.
Note: Percentages based on number of subjects at the current visit in each treatment arm.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: End of Treatment is analysed as its collected visit and its "Week X" visit per assessment date.
[1] Adjusted Odds Ratio (95% CI) and associated p-value are from a GEE model for the comparison between Belantamab mafodotin and Pom/Dex with covariates treatment group, visit, and treatment by visit interaction.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_gee_gp5.sas 17MAR2023 11:57

Table 4.026110
Analysis of FACT-GP5 scores based on Generalized Estimating Equations (GEE)

Timepoint: Week 88

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
n	1	1
Bothered	0	0
Not Bothered	1 (100%)	1 (100%)
Adjusted OR (95% CI) [1] vs. Pom/Dex		- (-, -)
P-value [1]		-

GEE=Generalized Estimating Equations, OR=Odds Ratio.
Note: Percentages based on number of subjects at the current visit in each treatment arm.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: End of Treatment is analysed as its collected visit and its "Week X" visit per assessment date.
[1] Adjusted Odds Ratio (95% CI) and associated p-value are from a GEE model for the comparison between Belantamab mafodotin and Pom/Dex with covariates treatment group, visit, and treatment by visit interaction.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_gee_gp5.sas 17MAR2023 11:57

Table 4.026110
Analysis of FACT-GP5 scores based on Generalized Estimating Equations (GEE)

Timepoint: Week 91

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
n	1	1
Bothered	0	0
Not Bothered	1 (100%)	1 (100%)
Adjusted OR (95% CI) [1] vs. Pom/Dex		- (-, -)
P-value [1]		-

GEE=Generalized Estimating Equations, OR=Odds Ratio.
Note: Percentages based on number of subjects at the current visit in each treatment arm.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: End of Treatment is analysed as its collected visit and its "Week X" visit per assessment date.
[1] Adjusted Odds Ratio (95% CI) and associated p-value are from a GEE model for the comparison between Belantamab mafodotin and Pom/Dex with covariates treatment group, visit, and treatment by visit interaction.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_gee_gp5.sas 17MAR2023 11:57

Table 4.026110
Analysis of FACT-GP5 scores based on Generalized Estimating Equations (GEE)

Timepoint: Week 94

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
n	2	1
Bothered	1 (50%)	0
Not Bothered	1 (50%)	1 (100%)
Adjusted OR (95% CI) [1] vs. Pom/Dex		- (-, -)
P-value [1]		-

GEE=Generalized Estimating Equations, OR=Odds Ratio.
Note: Percentages based on number of subjects at the current visit in each treatment arm.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: End of Treatment is analysed as its collected visit and its "Week X" visit per assessment date.
[1] Adjusted Odds Ratio (95% CI) and associated p-value are from a GEE model for the comparison between Belantamab mafodotin and Pom/Dex with covariates treatment group, visit, and treatment by visit interaction.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_gee_gp5.sas 17MAR2023 11:57

Table 4.026110
Analysis of FACT-GP5 scores based on Generalized Estimating Equations (GEE)

Timepoint: Week 97

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
n	1	0
Bothered	1 (100%)	0
Not Bothered	0	0
Adjusted OR (95% CI) [1] vs. Pom/Dex		- (-, -)
P-value [1]		-

GEE=Generalized Estimating Equations, OR=Odds Ratio.
Note: Percentages based on number of subjects at the current visit in each treatment arm.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: End of Treatment is analysed as its collected visit and its "Week X" visit per assessment date.
[1] Adjusted Odds Ratio (95% CI) and associated p-value are from a GEE model for the comparison between Belantamab mafodotin and Pom/Dex with covariates treatment group, visit, and treatment by visit interaction.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_gee_gp5.sas 17MAR2023 11:57

Table 4.026110
Analysis of FACT-GP5 scores based on Generalized Estimating Equations (GEE)

Timepoint: Week 100

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
n	0	1
Bothered	0	0
Not Bothered	0	1 (100%)
Adjusted OR (95% CI) [1] vs. Pom/Dex		- (-, -)
P-value [1]		-

GEE=Generalized Estimating Equations, OR=Odds Ratio.
Note: Percentages based on number of subjects at the current visit in each treatment arm.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: End of Treatment is analysed as its collected visit and its "Week X" visit per assessment date.
[1] Adjusted Odds Ratio (95% CI) and associated p-value are from a GEE model for the comparison between Belantamab mafodotin and Pom/Dex with covariates treatment group, visit, and treatment by visit interaction.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_gee_gp5.sas 17MAR2023 11:57

Protocol: 207495 Page 34 of 34
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.026110
Analysis of FACT-GP5 scores based on Generalized Estimating Equations (GEE)

Timepoint: End of Treatment

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
n	10	11
Bothered	4 (40%)	8 (73%)
Not Bothered	6 (60%)	3 (27%)
Adjusted OR (95% CI) [1] vs. Pom/Dex		4.00 (0.64,25.02)
P-value [1]		0.1383

GEE=Generalized Estimating Equations, OR=Odds Ratio.
Note: Percentages based on number of subjects at the current visit in each treatment arm.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: End of Treatment is analysed as its collected visit and its "Week X" visit per assessment date.
[1] Adjusted Odds Ratio (95% CI) and associated p-value are from a GEE model for the comparison between Belantamab mafodotin and Pom/Dex with covariates treatment group, visit, and treatment by visit interaction.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_gee_gp5.sas 17MAR2023 11:57

Protocol: 207495 Page 1 of 1
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.089110
Summary of FACT-GP5 Time to first Deterioration 1

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated or Died (event)	11 (79%)	22 (76%)
Censored, follow-up ended	0	0
Censored, follow-up ongoing	3 (21%)	7 (24%)
Event Summary		
Deterioration	9 (64%)	13 (45%)
Death	2 (14%)	9 (31%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	1.1 (0.7, 1.5)	1.0 (0.8, 1.2)
Median (95% CI)	1.5 (0.8, 5.6)	1.4 (1.0, 5.1)
3rd Quartile (95% CI)	5.6 (1.5, 13.5)	5.1 (1.5, 18.7)
Log-Rank P-value [2]		0.2861
Hazard Ratio (95% CI) [3]		0.54 (0.17, 1.69)
P-value [3]		0.2918

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessments.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_gp5_tfd1.sas 17MAR2023 11:47

Protocol: 207495 Page 1 of 1
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.090110
Summary of FACT-GP5 Time to first Deterioration 2

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated (event)	9 (64%)	13 (45%)
Censored, follow-up ended	2 (14%)	9 (31%)
Censored, follow-up ongoing	3 (21%)	7 (24%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	0.9 (0.7, 1.5)	1.1 (0.7, 1.4)
Median (95% CI)	1.5 (0.7, 5.6)	1.5 (1.1, -)
3rd Quartile (95% CI)	5.6 (1.5, -)	- (1.5, -)
Log-Rank P-value [2]		0.2937
Hazard Ratio (95% CI) [3]		0.49 (0.13, 1.89)
P-value [3]		0.3025

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessments.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_gp5_tfd2.sas 17MAR2023 11:48

Table 4.047110
Summary of PGIS Scores by Visit

Timepoint	Severity	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Baseline	n	13	25
	0	1 (8%)	1 (4%)
	1	4 (31%)	8 (32%)
	2	5 (38%)	11 (44%)
	3	3 (23%)	4 (16%)
	4	0	1 (4%)
	3+4	3 (23%)	5 (20%)
	Any Scale > 0	12 (92%)	24 (96%)
Week 4	n	0	1
	0	0	0
	1	0	1 (100%)
	2	0	0
	3	0	0
	4	0	0
	3+4	0	0
	Any Scale > 0	0	1 (100%)
	Worsening in PGIS score >=1 from Baseline	0	0/ 1
	Improvement in PGIS score >=1 from Baseline	0	1/ 1 (100%)

Note: 0 = No symptoms, 1 = Mild, 2 = Moderate, 3 = Severe, 4 = Very Severe.

Table 4.047110
Summary of PGIS Scores by Visit

Timepoint	Severity	Pom/Dex (N=15)		Belantamab mafodotin (N=29)	
Week 7	n	12		14	
	0	2	(17%)	0	
	1	4	(33%)	6	(43%)
	2	5	(42%)	6	(43%)
	3	1	(8%)	1	(7%)
	4	0		1	(7%)
	3+4	1	(8%)	2	(14%)
	Any Scale > 0	10	(83%)	14	(100%)
	Worsening in PGIS score >=1 from Baseline	1/11	(9%)	2/13	(15%)
	Improvement in PGIS score >=1 from Baseline	4/11	(36%)	3/13	(23%)
Week 10	n	0		2	
	0	0		0	
	1	0		1	(50%)
	2	0		0	
	3	0		1	(50%)
	4	0		0	
	3+4	0		1	(50%)
	Any Scale > 0	0		2	(100%)
	Worsening in PGIS score >=1 from Baseline	0		0/ 2	
	Improvement in PGIS score >=1 from Baseline	0		1/ 2	(50%)

Note: 0 = No symptoms, 1 = Mild, 2 = Moderate, 3 = Severe, 4 = Very Severe.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pgis_sc_vis.sas 14MAR2023 08:23

Table 4.047110
Summary of PGIS Scores by Visit

Timepoint	Severity	Pom/Dex (N=15)		Belantamab mafodotin (N=29)	
Week 13	n	13		7	
	0	2	(15%)	1	(14%)
	1	5	(38%)	3	(43%)
	2	5	(38%)	2	(29%)
	3	1	(8%)	1	(14%)
	4	0		0	
	3+4	1	(8%)	1	(14%)
	Any Scale > 0	11	(85%)	6	(86%)
	Worsening in PGIS score >=1 from Baseline	2/12	(17%)	1/ 7	(14%)
	Improvement in PGIS score >=1 from Baseline	5/12	(42%)	3/ 7	(43%)
Week 16	n	0		1	
	0	0		0	
	1	0		1	(100%)
	2	0		0	
	3	0		0	
	4	0		0	
	3+4	0		0	
	Any Scale > 0	0		1	(100%)
	Worsening in PGIS score >=1 from Baseline	0		0/ 1	
	Improvement in PGIS score >=1 from Baseline	0		1/ 1	(100%)

Note: 0 = No symptoms, 1 = Mild, 2 = Moderate, 3 = Severe, 4 = Very Severe.

Table 4.047110
Summary of PGIS Scores by Visit

Timepoint	Severity	Pom/Dex (N=15)		Belantamab mafodotin (N=29)	
Week 19	n	12		7	
	0	4	(33%)	1	(14%)
	1	2	(17%)	4	(57%)
	2	4	(33%)	0	
	3	2	(17%)	2	(29%)
	4	0		0	
	3+4	2	(17%)	2	(29%)
	Any Scale > 0	8	(67%)	6	(86%)
	Worsening in PGIS score >=1 from Baseline	4/11	(36%)	1/ 7	(14%)
	Improvement in PGIS score >=1 from Baseline	6/11	(55%)	3/ 7	(43%)
Week 22	n	0		2	
	0	0		1	(50%)
	1	0		1	(50%)
	2	0		0	
	3	0		0	
	4	0		0	
	3+4	0		0	
	Any Scale > 0	0		1	(50%)
	Worsening in PGIS score >=1 from Baseline	0		0/ 2	
	Improvement in PGIS score >=1 from Baseline	0		1/ 2	(50%)

Note: 0 = No symptoms, 1 = Mild, 2 = Moderate, 3 = Severe, 4 = Very Severe.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pgis_sc_vis.sas 14MAR2023 08:23

Table 4.047110
Summary of PGIS Scores by Visit

Timepoint	Severity	Pom/Dex (N=15)		Belantamab mafodotin (N=29)	
Week 25	n	6		6	
	0	2	(33%)	3	(50%)
	1	1	(17%)	0	
	2	2	(33%)	2	(33%)
	3	1	(17%)	1	(17%)
	4	0		0	
	3+4	1	(17%)	1	(17%)
	Any Scale > 0	4	(67%)	3	(50%)
	Worsening in PGIS score >=1 from Baseline	1/ 6	(17%)	2/ 5	(40%)
	Improvement in PGIS score >=1 from Baseline	1/ 6	(17%)	2/ 5	(40%)
Week 28	n	0		1	
	0	0		0	
	1	0		0	
	2	0		1	(100%)
	3	0		0	
	4	0		0	
	3+4	0		0	
	Any Scale > 0	0		1	(100%)
	Worsening in PGIS score >=1 from Baseline	0		0/ 1	
	Improvement in PGIS score >=1 from Baseline	0		0/ 1	

Note: 0 = No symptoms, 1 = Mild, 2 = Moderate, 3 = Severe, 4 = Very Severe.

Table 4.047110
Summary of PGIS Scores by Visit

Timepoint	Severity	Pom/Dex (N=15)		Belantamab mafodotin (N=29)	
Week 31	n	7		6	
	0	1	(14%)	2	(33%)
	1	3	(43%)	2	(33%)
	2	3	(43%)	2	(33%)
	3	0		0	
	4	0		0	
	3+4	0		0	
	Any Scale > 0	6	(86%)	4	(67%)
	Worsening in PGIS score >=1 from Baseline	2/ 7	(29%)	1/ 6	(17%)
	Improvement in PGIS score >=1 from Baseline	2/ 7	(29%)	2/ 6	(33%)
Week 34	n	0		1	
	0	0		0	
	1	0		1	(100%)
	2	0		0	
	3	0		0	
	4	0		0	
	3+4	0		0	
	Any Scale > 0	0		1	(100%)
	Worsening in PGIS score >=1 from Baseline	0		0/ 1	
	Improvement in PGIS score >=1 from Baseline	0		1/ 1	(100%)

Note: 0 = No symptoms, 1 = Mild, 2 = Moderate, 3 = Severe, 4 = Very Severe.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pgis_sc_vis.sas 14MAR2023 08:23

Table 4.047110
Summary of PGIS Scores by Visit

Timepoint	Severity	Pom/Dex (N=15)		Belantamab mafodotin (N=29)	
Week 37	n	4		6	
	0	1	(25%)	1	(17%)
	1	2	(50%)	3	(50%)
	2	0		2	(33%)
	3	1	(25%)	0	
	4	0		0	
	3+4	1	(25%)	0	
	Any Scale > 0	3	(75%)	5	(83%)
	Worsening in PGIS score >=1 from Baseline	1/ 4	(25%)	1/ 6	(17%)
	Improvement in PGIS score >=1 from Baseline	1/ 4	(25%)	1/ 6	(17%)
Week 43	n	4		4	
	0	2	(50%)	3	(75%)
	1	1	(25%)	1	(25%)
	2	0		0	
	3	1	(25%)	0	
	4	0		0	
	3+4	1	(25%)	0	
	Any Scale > 0	2	(50%)	1	(25%)
	Worsening in PGIS score >=1 from Baseline	1/ 4	(25%)	0/ 4	
	Improvement in PGIS score >=1 from Baseline	1/ 4	(25%)	3/ 4	(75%)

Note: 0 = No symptoms, 1 = Mild, 2 = Moderate, 3 = Severe, 4 = Very Severe.

Table 4.047110
Summary of PGIS Scores by Visit

Timepoint	Severity	Pom/Dex (N=15)		Belantamab mafodotin (N=29)	
Week 49	n	3		4	
	0	1	(33%)	3	(75%)
	1	1	(33%)	1	(25%)
	2	1	(33%)	0	
	3	0		0	
	4	0		0	
	3+4	0		0	
	Any Scale > 0	2	(67%)	1	(25%)
	Worsening in PGIS score >=1 from Baseline	0/ 3		0/ 4	
	Improvement in PGIS score >=1 from Baseline	0/ 3		3/ 4	(75%)
Week 55	n	3		3	
	0	1	(33%)	2	(67%)
	1	2	(67%)	1	(33%)
	2	0		0	
	3	0		0	
	4	0		0	
	3+4	0		0	
	Any Scale > 0	2	(67%)	1	(33%)
	Worsening in PGIS score >=1 from Baseline	0/ 3		1/ 3	(33%)
	Improvement in PGIS score >=1 from Baseline	1/ 3	(33%)	2/ 3	(67%)

Note: 0 = No symptoms, 1 = Mild, 2 = Moderate, 3 = Severe, 4 = Very Severe.

Table 4.047110
Summary of PGIS Scores by Visit

Timepoint	Severity	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 61	n	2	2
	0	0	1 (50%)
	1	0	1 (50%)
	2	2 (100%)	0
	3	0	0
	4	0	0
	3+4	0	0
	Any Scale > 0	2 (100%)	1 (50%)
	Worsening in PGIS score >=1 from Baseline	1/ 2 (50%)	0/ 2
	Improvement in PGIS score >=1 from Baseline	0/ 2	1/ 2 (50%)
Week 67	n	2	2
	0	0	1 (50%)
	1	1 (50%)	1 (50%)
	2	1 (50%)	0
	3	0	0
	4	0	0
	3+4	0	0
	Any Scale > 0	2 (100%)	1 (50%)
	Worsening in PGIS score >=1 from Baseline	0/ 2	0/ 2
	Improvement in PGIS score >=1 from Baseline	0/ 2	1/ 2 (50%)

Note: 0 = No symptoms, 1 = Mild, 2 = Moderate, 3 = Severe, 4 = Very Severe.

Protocol: 207495 Page 10 of 14
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.047110
Summary of PGIS Scores by Visit

Timepoint	Severity	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 73	n	1	1
	0	0	1 (100%)
	1	0	0
	2	1 (100%)	0
	3	0	0
	4	0	0
	3+4	0	0
	Any Scale > 0	1 (100%)	0
	Worsening in PGIS score >=1 from Baseline	0/ 1	0/ 1
	Improvement in PGIS score >=1 from Baseline	0/ 1	1/ 1 (100%)
Week 79	n	2	1
	0	0	1 (100%)
	1	1 (50%)	0
	2	0	0
	3	1 (50%)	0
	4	0	0
	3+4	1 (50%)	0
	Any Scale > 0	2 (100%)	0
	Worsening in PGIS score >=1 from Baseline	1/ 2 (50%)	0/ 1
	Improvement in PGIS score >=1 from Baseline	0/ 2	1/ 1 (100%)

Note: 0 = No symptoms, 1 = Mild, 2 = Moderate, 3 = Severe, 4 = Very Severe.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pgis_sc_vis.sas 14MAR2023 08:23

Table 4.047110
Summary of PGIS Scores by Visit

Timepoint	Severity	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 85	n	1	1
	0	0	1 (100%)
	1	1 (100%)	0
	2	0	0
	3	0	0
	4	0	0
	3+4	0	0
	Any Scale > 0	1 (100%)	0
	Worsening in PGIS score >=1 from Baseline	0/ 1	0/ 1
	Improvement in PGIS score >=1 from Baseline	1/ 1 (100%)	1/ 1 (100%)
Week 91	n	1	1
	0	0	1 (100%)
	1	0	0
	2	1 (100%)	0
	3	0	0
	4	0	0
	3+4	0	0
	Any Scale > 0	1 (100%)	0
	Worsening in PGIS score >=1 from Baseline	0/ 1	0/ 1
	Improvement in PGIS score >=1 from Baseline	0/ 1	1/ 1 (100%)

Note: 0 = No symptoms, 1 = Mild, 2 = Moderate, 3 = Severe, 4 = Very Severe.

Protocol: 207495 Page 12 of 14
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.047110
Summary of PGIS Scores by Visit

Timepoint	Severity	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 97	n	1	0
	0	0	0
	1	1 (100%)	0
	2	0	0
	3	0	0
	4	0	0
	3+4	0	0
	Any Scale > 0	1 (100%)	0
	Worsening in PGIS score >=1 from Baseline	0/ 1	0
	Improvement in PGIS score >=1 from Baseline	1/ 1 (100%)	0
End of Treatment	n	10	11
	0	2 (20%)	1 (9%)
	1	3 (30%)	5 (45%)
	2	3 (30%)	1 (9%)
	3	2 (20%)	3 (27%)
	4	0	1 (9%)
	3+4	2 (20%)	4 (36%)
	Any Scale > 0	8 (80%)	10 (91%)
	Worsening in PGIS score >=1 from Baseline	3/ 9 (33%)	2/11 (18%)
	Improvement in PGIS score >=1 from Baseline	4/ 9 (44%)	2/11 (18%)

Note: 0 = No symptoms, 1 = Mild, 2 = Moderate, 3 = Severe, 4 = Very Severe.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pgis_sc_vis.sas 14MAR2023 08:23

Protocol: 207495 Page 13 of 14
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.047110
Summary of PGIS Scores by Visit

Timepoint	Severity	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
PFS Follow-Up 2	n	1	1
	0	0	0
	1	0	1 (100%)
	2	1 (100%)	0
	3	0	0
	4	0	0
	3+4	0	0
	Any Scale > 0	1 (100%)	1 (100%)
	Worsening in PGIS score >=1 from Baseline	1/ 1 (100%)	0/ 1
	Improvement in PGIS score >=1 from Baseline	0/ 1	0/ 1
PFS Follow-Up 4	n	0	1
	0	0	0
	1	0	1 (100%)
	2	0	0
	3	0	0
	4	0	0
	3+4	0	0
	Any Scale > 0	0	1 (100%)
	Worsening in PGIS score >=1 from Baseline	0	0/ 1
	Improvement in PGIS score >=1 from Baseline	0	0/ 1

Note: 0 = No symptoms, 1 = Mild, 2 = Moderate, 3 = Severe, 4 = Very Severe.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pgis_sc_vis.sas 14MAR2023 08:23

Protocol: 207495 Page 14 of 14
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.047110
Summary of PGIS Scores by Visit

Timepoint	Severity	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Last Follow-up	n	1	1
	0	0	0
	1	0	1 (100%)
	2	1 (100%)	0
	3	0	0
	4	0	0
	3+4	0	0
	Any Scale > 0	1 (100%)	1 (100%)
	Worsening in PGIS score >=1 from Baseline	1/ 1 (100%)	0/ 1
	Improvement in PGIS score >=1 from Baseline	0/ 1	0/ 1
Worst Case Post-Baseline	n	13	21
	0	1 (8%)	0
	1	1 (8%)	7 (33%)
	2	7 (54%)	5 (24%)
	3	3 (23%)	7 (33%)
	4	1 (8%)	2 (10%)
	3+4	4 (31%)	9 (43%)
	Any Scale > 0	12 (92%)	21 (100%)
	Worsening in PGIS score >=1 from Baseline	6/12 (50%)	7/20 (35%)
	Improvement in PGIS score >=1 from Baseline	2/12 (17%)	2/20 (10%)

Note: 0 = No symptoms, 1 = Mild, 2 = Moderate, 3 = Severe, 4 = Very Severe.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pgis_sc_vis.sas 14MAR2023 08:23

Table 4.040110
Analysis of PGIS Score based on Generalized Estimating Equations (GEE)

Timepoint: Week 7

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
n	12	20
Symptoms	10 (83%)	20 (100%)
No Symptoms	2 (17%)	0
Adjusted OR (95% CI) [1] vs. Pom/Dex		- (-, -)
P-value [1]		-

GEE=Generalized Estimating Equations, OR=Odds Ratio.
Note: Percentages based on number of subjects at the current visit in each treatment arm.
Note: Assessments that are recorded at visits that are outside of the scheduled visits for PGI (e.g. Week 4, Week 10 etc.) are slotted into the scheduled visits for PGI (e.g. Week 7, Week 13 etc.) per assessment date. Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
[1] Adjusted Odds Ratio (95% CI) and associated p-value are from a GEE model for the comparison between Belantamab mafodotin and Pom/Dex with covariates treatment group, visit, and treatment by visit interaction.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_gee_pgis.sas 15MAR2023 12:27

Table 4.040110
Analysis of PGIS Score based on Generalized Estimating Equations (GEE)

Timepoint: Week 13

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
n	13	9
Symptoms	11 (85%)	8 (89%)
No Symptoms	2 (15%)	1 (11%)
Adjusted OR (95% CI) [1] vs. Pom/Dex		1.45 (0.11,18.96)
P-value [1]		0.7748

GEE=Generalized Estimating Equations, OR=Odds Ratio.
Note: Percentages based on number of subjects at the current visit in each treatment arm.
Note: Assessments that are recorded at visits that are outside of the scheduled visits for PGI (e.g. Week 4, Week 10 etc.) are slotted into the scheduled visits for PGI (e.g. Week 7, Week 13 etc.) per assessment date. Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
[1] Adjusted Odds Ratio (95% CI) and associated p-value are from a GEE model for the comparison between Belantamab mafodotin and Pom/Dex with covariates treatment group, visit, and treatment by visit interaction.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_gee_pgis.sas 15MAR2023 12:27

Table 4.040110
Analysis of PGIS Score based on Generalized Estimating Equations (GEE)

Timepoint: Week 19

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
n	13	10
Symptoms	10 (77%)	8 (80%)
No Symptoms	3 (23%)	2 (20%)
Adjusted OR (95% CI) [1] vs. Pom/Dex		1.20 (0.16,9.01)
P-value [1]		0.8593

GEE=Generalized Estimating Equations, OR=Odds Ratio.
Note: Percentages based on number of subjects at the current visit in each treatment arm.
Note: Assessments that are recorded at visits that are outside of the scheduled visits for PGI (e.g. Week 4, Week 10 etc.) are slotted into the scheduled visits for PGI (e.g. Week 7, Week 13 etc.) per assessment date. Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
[1] Adjusted Odds Ratio (95% CI) and associated p-value are from a GEE model for the comparison between Belantamab mafodotin and Pom/Dex with covariates treatment group, visit, and treatment by visit interaction.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_gee_pgis.sas 15MAR2023 12:27

Table 4.040110
Analysis of PGIS Score based on Generalized Estimating Equations (GEE)

Timepoint: Week 25

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
n	8	8
Symptoms	5 (63%)	5 (63%)
No Symptoms	3 (38%)	3 (38%)
Adjusted OR (95% CI) [1] vs. Pom/Dex		1.00 (0.13,7.57)
P-value [1]		>0.9999

GEE=Generalized Estimating Equations, OR=Odds Ratio.
Note: Percentages based on number of subjects at the current visit in each treatment arm.
Note: Assessments that are recorded at visits that are outside of the scheduled visits for PGI (e.g. Week 4, Week 10 etc.) are slotted into the scheduled visits for PGI (e.g. Week 7, Week 13 etc.) per assessment date. Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
[1] Adjusted Odds Ratio (95% CI) and associated p-value are from a GEE model for the comparison between Belantamab mafodotin and Pom/Dex with covariates treatment group, visit, and treatment by visit interaction.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_gee_pgis.sas 15MAR2023 12:27

Table 4.040110
Analysis of PGIS Score based on Generalized Estimating Equations (GEE)

Timepoint: Week 31

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
n	7	6
Symptoms	6 (86%)	4 (67%)
No Symptoms	1 (14%)	2 (33%)
Adjusted OR (95% CI) [1] vs. Pom/Dex		0.33 (0.02,5.03)
P-value [1]		0.4275

GEE=Generalized Estimating Equations, OR=Odds Ratio.
Note: Percentages based on number of subjects at the current visit in each treatment arm.
Note: Assessments that are recorded at visits that are outside of the scheduled visits for PGI (e.g. Week 4, Week 10 etc.) are slotted into the scheduled visits for PGI (e.g. Week 7, Week 13 etc.) per assessment date. Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
[1] Adjusted Odds Ratio (95% CI) and associated p-value are from a GEE model for the comparison between Belantamab mafodotin and Pom/Dex with covariates treatment group, visit, and treatment by visit interaction.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_gee_pgis.sas 15MAR2023 12:27

Table 4.040110
Analysis of PGIS Score based on Generalized Estimating Equations (GEE)

Timepoint: Week 37

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
n	4	6
Symptoms	3 (75%)	5 (83%)
No Symptoms	1 (25%)	1 (17%)
Adjusted OR (95% CI) [1] vs. Pom/Dex		1.67 (0.07,37.73)
P-value [1]		0.7483

GEE=Generalized Estimating Equations, OR=Odds Ratio.
Note: Percentages based on number of subjects at the current visit in each treatment arm.
Note: Assessments that are recorded at visits that are outside of the scheduled visits for PGI (e.g. Week 4, Week 10 etc.) are slotted into the scheduled visits for PGI (e.g. Week 7, Week 13 etc.) per assessment date. Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
[1] Adjusted Odds Ratio (95% CI) and associated p-value are from a GEE model for the comparison between Belantamab mafodotin and Pom/Dex with covariates treatment group, visit, and treatment by visit interaction.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_gee_pgis.sas 15MAR2023 12:27

Table 4.040110
Analysis of PGIS Score based on Generalized Estimating Equations (GEE)

Timepoint: Week 43

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
n	5	4
Symptoms	4 (80%)	1 (25%)
No Symptoms	1 (20%)	3 (75%)
Adjusted OR (95% CI) [1] vs. Pom/Dex		- (-, -)
P-value [1]		-

GEE=Generalized Estimating Equations, OR=Odds Ratio.
Note: Percentages based on number of subjects at the current visit in each treatment arm.
Note: Assessments that are recorded at visits that are outside of the scheduled visits for PGI (e.g. Week 4, Week 10 etc.) are slotted into the scheduled visits for PGI (e.g. Week 7, Week 13 etc.) per assessment date. Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
[1] Adjusted Odds Ratio (95% CI) and associated p-value are from a GEE model for the comparison between Belantamab mafodotin and Pom/Dex with covariates treatment group, visit, and treatment by visit interaction.

Table 4.040110
Analysis of PGIS Score based on Generalized Estimating Equations (GEE)

Timepoint: Week 49

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
n	4	4
Symptoms	3 (75%)	1 (25%)
No Symptoms	1 (25%)	3 (75%)
Adjusted OR (95% CI) [1] vs. Pom/Dex		- (-, -)
P-value [1]		-

GEE=Generalized Estimating Equations, OR=Odds Ratio.
Note: Percentages based on number of subjects at the current visit in each treatment arm.
Note: Assessments that are recorded at visits that are outside of the scheduled visits for PGI (e.g. Week 4, Week 10 etc.) are slotted into the scheduled visits for PGI (e.g. Week 7, Week 13 etc.) per assessment date. Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
[1] Adjusted Odds Ratio (95% CI) and associated p-value are from a GEE model for the comparison between Belantamab mafodotin and Pom/Dex with covariates treatment group, visit, and treatment by visit interaction.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_gee_pgis.sas 15MAR2023 12:27

Table 4.040110
Analysis of PGIS Score based on Generalized Estimating Equations (GEE)

Timepoint: Week 55

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
n	4	3
Symptoms	3 (75%)	1 (33%)
No Symptoms	1 (25%)	2 (67%)
Adjusted OR (95% CI) [1] vs. Pom/Dex		- (-, -)
P-value [1]		-

GEE=Generalized Estimating Equations, OR=Odds Ratio.
Note: Percentages based on number of subjects at the current visit in each treatment arm.
Note: Assessments that are recorded at visits that are outside of the scheduled visits for PGI (e.g. Week 4, Week 10 etc.) are slotted into the scheduled visits for PGI (e.g. Week 7, Week 13 etc.) per assessment date. Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
[1] Adjusted Odds Ratio (95% CI) and associated p-value are from a GEE model for the comparison between Belantamab mafodotin and Pom/Dex with covariates treatment group, visit, and treatment by visit interaction.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_gee_pgis.sas 15MAR2023 12:27

Table 4.040110
Analysis of PGIS Score based on Generalized Estimating Equations (GEE)

Timepoint: Week 61

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
n	2	2
Symptoms	2 (100%)	1 (50%)
No Symptoms	0	1 (50%)
Adjusted OR (95% CI) [1] vs. Pom/Dex		- (-, -)
P-value [1]		-

GEE=Generalized Estimating Equations, OR=Odds Ratio.
Note: Percentages based on number of subjects at the current visit in each treatment arm.
Note: Assessments that are recorded at visits that are outside of the scheduled visits for PGI (e.g. Week 4, Week 10 etc.) are slotted into the scheduled visits for PGI (e.g. Week 7, Week 13 etc.) per assessment date. Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
[1] Adjusted Odds Ratio (95% CI) and associated p-value are from a GEE model for the comparison between Belantamab mafodotin and Pom/Dex with covariates treatment group, visit, and treatment by visit interaction.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_gee_pgis.sas 15MAR2023 12:27

Table 4.040110
Analysis of PGIS Score based on Generalized Estimating Equations (GEE)

Timepoint: Week 67

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
n	2	2
Symptoms	2 (100%)	1 (50%)
No Symptoms	0	1 (50%)
Adjusted OR (95% CI) [1] vs. Pom/Dex		- (-, -)
P-value [1]		-

GEE=Generalized Estimating Equations, OR=Odds Ratio.
Note: Percentages based on number of subjects at the current visit in each treatment arm.
Note: Assessments that are recorded at visits that are outside of the scheduled visits for PGI (e.g. Week 4, Week 10 etc.) are slotted into the scheduled visits for PGI (e.g. Week 7, Week 13 etc.) per assessment date. Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
[1] Adjusted Odds Ratio (95% CI) and associated p-value are from a GEE model for the comparison between Belantamab mafodotin and Pom/Dex with covariates treatment group, visit, and treatment by visit interaction.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_gee_pgis.sas 15MAR2023 12:27

Protocol: 207495 Page 12 of 19
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.040110
Analysis of PGIS Score based on Generalized Estimating Equations (GEE)

Timepoint: Week 73

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
n	1	1
Symptoms	1 (100%)	0
No Symptoms	0	1 (100%)
Adjusted OR (95% CI) [1] vs. Pom/Dex		- (-, -)
P-value [1]		-

GEE=Generalized Estimating Equations, OR=Odds Ratio.
Note: Percentages based on number of subjects at the current visit in each treatment arm.
Note: Assessments that are recorded at visits that are outside of the scheduled visits for PGI (e.g. Week 4, Week 10 etc.) are slotted into the scheduled visits for PGI (e.g. Week 7, Week 13 etc.) per assessment date. Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
[1] Adjusted Odds Ratio (95% CI) and associated p-value are from a GEE model for the comparison between Belantamab mafodotin and Pom/Dex with covariates treatment group, visit, and treatment by visit interaction.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_gee_pgis.sas 15MAR2023 12:27

Table 4.040110
Analysis of PGIS Score based on Generalized Estimating Equations (GEE)

Timepoint: Week 79

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
n	2	1
Symptoms	2 (100%)	0
No Symptoms	0	1 (100%)
Adjusted OR (95% CI) [1] vs. Pom/Dex		- (-, -)
P-value [1]		-

GEE=Generalized Estimating Equations, OR=Odds Ratio.
Note: Percentages based on number of subjects at the current visit in each treatment arm.
Note: Assessments that are recorded at visits that are outside of the scheduled visits for PGI (e.g. Week 4, Week 10 etc.) are slotted into the scheduled visits for PGI (e.g. Week 7, Week 13 etc.) per assessment date. Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
[1] Adjusted Odds Ratio (95% CI) and associated p-value are from a GEE model for the comparison between Belantamab mafodotin and Pom/Dex with covariates treatment group, visit, and treatment by visit interaction.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_gee_pgis.sas 15MAR2023 12:27

Protocol: 207495 Page 14 of 19
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.040110
Analysis of PGIS Score based on Generalized Estimating Equations (GEE)

Timepoint: Week 85

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
n	1	1
Symptoms	1 (100%)	0
No Symptoms	0	1 (100%)
Adjusted OR (95% CI) [1] vs. Pom/Dex		- (-, -)
P-value [1]		-

GEE=Generalized Estimating Equations, OR=Odds Ratio.
Note: Percentages based on number of subjects at the current visit in each treatment arm.
Note: Assessments that are recorded at visits that are outside of the scheduled visits for PGI (e.g. Week 4, Week 10 etc.) are slotted into the scheduled visits for PGI (e.g. Week 7, Week 13 etc.) per assessment date. Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
[1] Adjusted Odds Ratio (95% CI) and associated p-value are from a GEE model for the comparison between Belantamab mafodotin and Pom/Dex with covariates treatment group, visit, and treatment by visit interaction.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_gee_pgis.sas 15MAR2023 12:27

Protocol: 207495 Page 15 of 19
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.040110
Analysis of PGIS Score based on Generalized Estimating Equations (GEE)

Timepoint: Week 91

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
n	1	1
Symptoms	1 (100%)	0
No Symptoms	0	1 (100%)
Adjusted OR (95% CI) [1] vs. Pom/Dex		- (-, -)
P-value [1]		-

GEE=Generalized Estimating Equations, OR=Odds Ratio.
Note: Percentages based on number of subjects at the current visit in each treatment arm.
Note: Assessments that are recorded at visits that are outside of the scheduled visits for PGI (e.g. Week 4, Week 10 etc.) are slotted into the scheduled visits for PGI (e.g. Week 7, Week 13 etc.) per assessment date. Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
[1] Adjusted Odds Ratio (95% CI) and associated p-value are from a GEE model for the comparison between Belantamab mafodotin and Pom/Dex with covariates treatment group, visit, and treatment by visit interaction.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_gee_pgis.sas 15MAR2023 12:27

Table 4.040110
Analysis of PGIS Score based on Generalized Estimating Equations (GEE)

Timepoint: Week 97

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
n	1	0
Symptoms	1 (100%)	0
No Symptoms	0	0
Adjusted OR (95% CI) [1] vs. Pom/Dex		- (-, -)
P-value [1]		-

GEE=Generalized Estimating Equations, OR=Odds Ratio.
Note: Percentages based on number of subjects at the current visit in each treatment arm.
Note: Assessments that are recorded at visits that are outside of the scheduled visits for PGI (e.g. Week 4, Week 10 etc.) are slotted into the scheduled visits for PGI (e.g. Week 7, Week 13 etc.) per assessment date. Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
[1] Adjusted Odds Ratio (95% CI) and associated p-value are from a GEE model for the comparison between Belantamab mafodotin and Pom/Dex with covariates treatment group, visit, and treatment by visit interaction.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_gee_pgis.sas 15MAR2023 12:27

Table 4.040110
Analysis of PGIS Score based on Generalized Estimating Equations (GEE)

Timepoint: End of Treatment

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
n	10	11
Symptoms	8 (80%)	10 (91%)
No Symptoms	2 (20%)	1 (9%)
Adjusted OR (95% CI) [1] vs. Pom/Dex		2.50 (0.19,32.80)
P-value [1]		0.4854

GEE=Generalized Estimating Equations, OR=Odds Ratio.
Note: Percentages based on number of subjects at the current visit in each treatment arm.
Note: Assessments that are recorded at visits that are outside of the scheduled visits for PGI (e.g. Week 4, Week 10 etc.) are slotted into the scheduled visits for PGI (e.g. Week 7, Week 13 etc.) per assessment date. Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
[1] Adjusted Odds Ratio (95% CI) and associated p-value are from a GEE model for the comparison between Belantamab mafodotin and Pom/Dex with covariates treatment group, visit, and treatment by visit interaction.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_gee_pgis.sas 15MAR2023 12:27

Table 4.040110
Analysis of PGIS Score based on Generalized Estimating Equations (GEE)

Timepoint: PFS Follow-Up 2

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
n	1	1
Symptoms	1 (100%)	1 (100%)
No Symptoms	0	0
Adjusted OR (95% CI) [1] vs. Pom/Dex		- (-, -)
P-value [1]		-

GEE=Generalized Estimating Equations, OR=Odds Ratio.
Note: Percentages based on number of subjects at the current visit in each treatment arm.
Note: Assessments that are recorded at visits that are outside of the scheduled visits for PGI (e.g. Week 4, Week 10 etc.) are slotted into the scheduled visits for PGI (e.g. Week 7, Week 13 etc.) per assessment date. Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
[1] Adjusted Odds Ratio (95% CI) and associated p-value are from a GEE model for the comparison between Belantamab mafodotin and Pom/Dex with covariates treatment group, visit, and treatment by visit interaction.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_gee_pgis.sas 15MAR2023 12:27

Protocol: 207495 Page 19 of 19
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.040110
Analysis of PGIS Score based on Generalized Estimating Equations (GEE)

Timepoint: PFS Follow-Up 4

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
n	0	1
Symptoms	0	1 (100%)
No Symptoms	0	0
Adjusted OR (95% CI) [1] vs. Pom/Dex		- (-, -)
P-value [1]		-

GEE=Generalized Estimating Equations, OR=Odds Ratio.
Note: Percentages based on number of subjects at the current visit in each treatment arm.
Note: Assessments that are recorded at visits that are outside of the scheduled visits for PGI (e.g. Week 4, Week 10 etc.) are slotted into the scheduled visits for PGI (e.g. Week 7, Week 13 etc.) per assessment date. Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
[1] Adjusted Odds Ratio (95% CI) and associated p-value are from a GEE model for the comparison between Belantamab mafodotin and Pom/Dex with covariates treatment group, visit, and treatment by visit interaction.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_gee_pgis.sas 15MAR2023 12:27

Protocol: 207495 Page 1 of 1
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.108110
Summary of PGIS Time to first Improvement
(Up to and including Last Follow-Up)

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Improved (event)	9 (60%)	8 (28%)
Censored, follow-up ended	3 (20%)	14 (48%)
Censored, follow-up ongoing	3 (20%)	7 (24%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	1.6 (1.4, 3.0)	2.8 (0.8, 4.4)
Median (95% CI)	3.0 (1.5, 12.4)	4.4 (2.8, -)
3rd Quartile (95% CI)	12.4 (3.0, -)	- (4.4, -)
Log-Rank P-value [2]		0.7899
Inverse Hazard Ratio (95% CI) [3]		1.18 (0.35, 4.02)
P-value [3]		0.7901

Note: If a subject has not improved, they are censored at the latest assessment or at randomization if no assessments.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Inverse hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. Inverse hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pgs_tfi.sas 13MAR2023 14:23

Protocol: 207495 Page 1 of 1
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.105110
Summary of PGIS Time to first Deterioration 1
(Up to and including Last Follow-Up)

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated or Died (event)	8 (53%)	18 (62%)
Censored, follow-up ended	1 (7%)	0
Censored, follow-up ongoing	6 (40%)	11 (38%)
Event Summary		
Deterioration	6 (40%)	7 (24%)
Death	2 (13%)	11 (38%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	2.9 (1.1, 13.5)	1.4 (1.0, 2.8)
Median (95% CI)	13.5 (2.9, 13.9)	4.9 (1.5, 5.7)
3rd Quartile (95% CI)	13.9 (4.3, 13.9)	9.5 (4.9, -)
Log-Rank P-value [2]		0.2703
Hazard Ratio (95% CI) [3]		1.96 (0.58, 6.57)
P-value [3]		0.2772

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessments.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pgs_tfd1.sas 13MAR2023 14:23

Protocol: 207495 Page 1 of 1
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.106110
Summary of PGIS Time to first Deterioration 2
(Up to and including Last Follow-Up)

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated (event)	6 (40%)	7 (24%)
Censored, follow-up ended	3 (20%)	11 (38%)
Censored, follow-up ongoing	6 (40%)	11 (38%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	3.5 (1.4, 13.9)	2.8 (1.4, 12.4)
Median (95% CI)	13.9 (2.9, 13.9)	12.4 (1.7, -)
3rd Quartile (95% CI)	13.9 (-, -)	- (5.7, -)
Log-Rank P-value [2]		0.5881
Hazard Ratio (95% CI) [3]		1.60 (0.29, 8.86)
P-value [3]		0.5914

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessments.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pgs_tfd2.sas 13MAR2023 14:23

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.109110
Summary of PGIS Time to permanent Deterioration 1
(Up to and including End of Treatment)

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated or Died (event)	2 (13%)	10 (34%)
Censored, follow-up ended	4 (27%)	7 (24%)
Censored, follow-up ongoing	9 (60%)	12 (41%)
Event Summary		
Deterioration	1 (7%)	1 (3%)
Death	1 (7%)	9 (31%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (1.1, -)	5.1 (1.0, 6.9)
Median (95% CI)	- (4.2, -)	9.5 (5.1, -)
3rd Quartile (95% CI)	- (-, -)	- (6.9, -)
Log-Rank P-value [2]		0.0996
Hazard Ratio (95% CI) [3]		5.42 (0.60, 48.88)
P-value [3]		0.1317

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd1_pgs_eot.sas 14MAR2023 16:05

Protocol: 207495 Page 2 of 2
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.109110
Summary of PGIS Time to permanent Deterioration 1
(Up to and including End of Treatment)

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of subsequent visits with confirmation for subjects who permanently deteriorated or died		
n	2	10
0	1 / 2 (50%)	9 / 10 (90%)
1	0 / 2	0 / 10
2	0 / 2	1 / 10 (10%)
3	1 / 2 (50%)	0 / 10
>=4	0 / 2	0 / 10
Number of subsequent visits with confirmation for subjects who deteriorated towards end of observation period [4]		
n	3	2
0	0 / 3	2 / 2 (100%)
1	3 / 3 (100%)	0 / 2

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd1_pgs_eot.sas 14MAR2023 16:05

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.110110
Summary of PGIS Time to permanent Deterioration 2
(Up to and including End of Treatment)

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated (event)	1 (7%)	1 (3%)
Censored, follow-up ended	5 (33%)	16 (55%)
Censored, follow-up ongoing	9 (60%)	12 (41%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (4.2, -)	- (6.9, -)
Median (95% CI)	- (-, -)	- (6.9, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		0.3865
Hazard Ratio (95% CI) [3]		>999.99 (<0.01, -)
P-value [3]		0.9984
Number of subsequent visits with confirmation for subjects who permanently deteriorated		
n	1	1
0	0 / 1	0 / 1
1	0 / 1	0 / 1
2	0 / 1	1 / 1 (100%)
3	1 / 1 (100%)	0 / 1
>=4	0 / 1	0 / 1

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd2_pgs_eot.sas 14MAR2023 17:08

Protocol: 207495 Page 2 of 2
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.110110
Summary of PGIS Time to permanent Deterioration 2
(Up to and including End of Treatment)

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of subsequent visits with confirmation for subjects who deteriorated towards end of observation period [4]		
n	3	3
0	0 / 3	3 / 3 (100%)
1	3 / 3 (100%)	0 / 3

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd2_pgs_eot.sas 14MAR2023 17:08

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.111110
Summary of PGIS Time to permanent Deterioration 1
(Up to and including Last Follow-Up)

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated or Died (event)	4 (27%)	17 (59%)
Censored, follow-up ended	2 (13%)	0
Censored, follow-up ongoing	9 (60%)	12 (41%)
Event Summary		
Deterioration	1 (7%)	1 (3%)
Death	3 (20%)	16 (55%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	8.0 (1.1, -)	2.9 (1.0, 5.1)
Median (95% CI)	13.5 (4.2, -)	5.7 (2.9, 9.5)
3rd Quartile (95% CI)	- (13.5, -)	18.7 (5.7, -)
Log-Rank P-value [2]		0.1446
Hazard Ratio (95% CI) [3]		2.65 (0.69, 10.20)
P-value [3]		0.1567

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd1_pgs_lf.sas 14MAR2023 16:05

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.111110
Summary of PGIS Time to permanent Deterioration 1
(Up to and including Last Follow-Up)

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of subsequent visits with confirmation for subjects who permanently deteriorated or died		
n	4	17
0	3 / 4 (75%)	16 / 17 (94%)
1	0 / 4	0 / 17
2	0 / 4	1 / 17 (6%)
3	1 / 4 (25%)	0 / 17
>=4	0 / 4	0 / 17
Number of subsequent visits with confirmation for subjects who deteriorated towards end of observation period [4]		
n	2	0
0	1 / 2 (50%)	0
1	1 / 2 (50%)	0

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

Protocol: 207495 Page 1 of 2
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.112110
Summary of PGIS Time to permanent Deterioration 2
(Up to and including Last Follow-Up)

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated (event)	1 (7%)	1 (3%)
Censored, follow-up ended	5 (33%)	16 (55%)
Censored, follow-up ongoing	9 (60%)	12 (41%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (4.2, -)	- (6.9, -)
Median (95% CI)	- (-, -)	- (6.9, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		0.3865
Hazard Ratio (95% CI) [3]		>999.99 (<0.01, -)
P-value [3]		0.9984
Number of subsequent visits with confirmation for subjects who permanently deteriorated		
n	1	1
0	0 / 1	0 / 1
1	0 / 1	0 / 1
2	0 / 1	1 / 1 (100%)
3	1 / 1 (100%)	0 / 1
>=4	0 / 1	0 / 1

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd2_pgs_lf.sas 14MAR2023 17:08

Table 4.112110
Summary of PGIS Time to permanent Deterioration 2
(Up to and including Last Follow-Up)

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of subsequent visits with confirmation for subjects who deteriorated towards end of observation period [4]		
n	3	3
0	1 / 3 (33%)	3 / 3 (100%)
1	2 / 3 (67%)	0 / 3

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

Protocol: 207495 Page 1 of 7
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.048110
Summary of PGIC Scores by Visit

Timepoint	Change	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 4	n	0	1
	1	0	0
	2	0	1 (100%)
	3	0	0
	4	0	0
	5	0	0
	4+5	0	0
Week 7	n	12	14
	1	3 (25%)	2 (14%)
	2	8 (67%)	4 (29%)
	3	1 (8%)	6 (43%)
	4	0	2 (14%)
	5	0	0
	4+5	0	2 (14%)
Week 10	n	0	2
	1	0	1 (50%)
	2	0	0
	3	0	0
	4	0	0
	5	0	1 (50%)
	4+5	0	1 (50%)
Week 13	n	13	7
	1	4 (31%)	1 (14%)
	2	5 (38%)	5 (71%)
	3	3 (23%)	0
	4	1 (8%)	0
	5	0	1 (14%)
	4+5	1 (8%)	1 (14%)

Note: 1 = Much Better, 2 = A little better, 3 = No change, 4 = A little worse, 5 = Much worse.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pgic_sc_vis.sas 21FEB2023 08:41

Table 4.048110
Summary of PGIC Scores by Visit

Timepoint	Change	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 16	n	0	1
	1	0	0
	2	0	1 (100%)
	3	0	0
	4	0	0
	5	0	0
	4+5	0	0
Week 19	n	12	7
	1	5 (42%)	4 (57%)
	2	4 (33%)	1 (14%)
	3	1 (8%)	1 (14%)
	4	1 (8%)	1 (14%)
	5	1 (8%)	0
	4+5	2 (17%)	1 (14%)
Week 22	n	0	1
	1	0	1 (100%)
	2	0	0
	3	0	0
	4	0	0
	5	0	0
	4+5	0	0
Week 25	n	6	6
	1	2 (33%)	4 (67%)
	2	1 (17%)	2 (33%)
	3	2 (33%)	0
	4	1 (17%)	0
	5	0	0
	4+5	1 (17%)	0

Note: 1 = Much Better, 2 = A little better, 3 = No change, 4 = A little worse, 5 = Much worse.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pgic_sc_vis.sas 21FEB2023 08:41

Table 4.048110
Summary of PGIC Scores by Visit

Timepoint	Change	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 28	n	0	1
	1	0	0
	2	0	0
	3	0	0
	4	0	1 (100%)
	5	0	0
	4+5	0	1 (100%)
Week 31	n	7	6
	1	4 (57%)	4 (67%)
	2	1 (14%)	2 (33%)
	3	2 (29%)	0
	4	0	0
	5	0	0
	4+5	0	0
Week 34	n	0	1
	1	0	1 (100%)
	2	0	0
	3	0	0
	4	0	0
	5	0	0
	4+5	0	0
Week 37	n	4	6
	1	2 (50%)	5 (83%)
	2	2 (50%)	1 (17%)
	3	0	0
	4	0	0
	5	0	0
	4+5	0	0

Note: 1 = Much Better, 2 = A little better, 3 = No change, 4 = A little worse, 5 = Much worse.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pgic_sc_vis.sas 21FEB2023 08:41

Protocol: 207495 Page 4 of 7
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.048110
Summary of PGIC Scores by Visit

Timepoint	Change	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 43	n	4	4
	1	3 (75%)	4 (100%)
	2	1 (25%)	0
	3	0	0
	4	0	0
	5	0	0
	4+5	0	0
Week 49	n	3	4
	1	2 (67%)	4 (100%)
	2	1 (33%)	0
	3	0	0
	4	0	0
	5	0	0
	4+5	0	0
Week 55	n	3	3
	1	2 (67%)	2 (67%)
	2	0	0
	3	1 (33%)	1 (33%)
	4	0	0
	5	0	0
	4+5	0	0
Week 61	n	2	2
	1	0	2 (100%)
	2	1 (50%)	0
	3	1 (50%)	0
	4	0	0
	5	0	0
	4+5	0	0

Note: 1 = Much Better, 2 = A little better, 3 = No change, 4 = A little worse, 5 = Much worse.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pgic_sc_vis.sas 21FEB2023 08:41

Protocol: 207495 Page 5 of 7
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.048110
Summary of PGIC Scores by Visit

Timepoint	Change	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 67	n	2	2
	1	1 (50%)	2 (100%)
	2	1 (50%)	0
	3	0	0
	4	0	0
	5	0	0
	4+5	0	0
Week 73	n	1	1
	1	0	1 (100%)
	2	1 (100%)	0
	3	0	0
	4	0	0
	5	0	0
	4+5	0	0
Week 79	n	2	1
	1	1 (50%)	1 (100%)
	2	1 (50%)	0
	3	0	0
	4	0	0
	5	0	0
	4+5	0	0
Week 85	n	1	1
	1	0	1 (100%)
	2	0	0
	3	1 (100%)	0
	4	0	0
	5	0	0
	4+5	0	0

Note: 1 = Much Better, 2 = A little better, 3 = No change, 4 = A little worse, 5 = Much worse.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pgic_sc_vis.sas 21FEB2023 08:41

Protocol: 207495 Page 6 of 7
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.048110
Summary of PGIC Scores by Visit

Timepoint	Change	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 91	n	1	1
	1	0	1 (100%)
	2	1 (100%)	0
	3	0	0
	4	0	0
	5	0	0
	4+5	0	0
Week 97	n	1	0
	1	0	0
	2	0	0
	3	1 (100%)	0
	4	0	0
	5	0	0
	4+5	0	0
End of Treatment	n	10	11
	1	2 (20%)	1 (9%)
	2	4 (40%)	1 (9%)
	3	3 (30%)	3 (27%)
	4	1 (10%)	3 (27%)
	5	0	3 (27%)
	4+5	1 (10%)	6 (55%)
PFS Follow-Up 2	n	1	1
	1	0	0
	2	0	1 (100%)
	3	1 (100%)	0
	4	0	0
	5	0	0
	4+5	0	0

Note: 1 = Much Better, 2 = A little better, 3 = No change, 4 = A little worse, 5 = Much worse.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pgic_sc_vis.sas 21FEB2023 08:41

Table 4.048110
Summary of PGIC Scores by Visit

Timepoint	Change	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
PFS Follow-Up 4	n	0	1
	1	0	0
	2	0	1 (100%)
	3	0	0
	4	0	0
	5	0	0
	4+5	0	0
Last Follow-up	n	1	1
	1	0	0
	2	0	1 (100%)
	3	1 (100%)	0
	4	0	0
	5	0	0
	4+5	0	0

Note: 1 = Much Better, 2 = A little better, 3 = No change, 4 = A little worse, 5 = Much worse.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pgic_sc_vis.sas 21FEB2023 08:41

Table 4.036110
Analysis of PGIC Negative Responder Summary

Timepoint		Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 7	n	12	14
	Negative Responder	0	2 (14%)
	OR (95% CI) [1] vs. Pom/Dex		>999.99 (<0.01, >999.99)
	P-value [1]		0.9455
	RR (95% CI) vs. Pom/Dex		4.33 (0.23, 82.31)
	ARD (95% CI) vs. Pom/Dex		0.13 (-0.09, 0.34)
	P-value [2]		0.4831

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Subjects who have a response of "A little worse" or "Much worse" are considered negative responders.
Note: n is the number of analysable subjects at the specified timepoint, percentages are based on this.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.

Table 4.036110
Analysis of PGIC Negative Responder Summary

Timepoint		Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 13	n	13	7
	Negative Responder	1 (8%)	1 (14%)
	OR (95% CI) [1] vs. Pom/Dex		2.00 (0.11, 37.83)
	P-value [1]		0.6440
	RR (95% CI) vs. Pom/Dex		1.86 (0.14, 25.38)
	ARD (95% CI) vs. Pom/Dex		0.07 (-0.23, 0.36)
	P-value [2]		>0.9999

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Subjects who have a response of "A little worse" or "Much worse" are considered negative responders.
Note: n is the number of analysable subjects at the specified timepoint, percentages are based on this.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.

Table 4.036110
Analysis of PGIC Negative Responder Summary

Timepoint		Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 19	n	12	7
	Negative Responder	2 (17%)	1 (14%)
	OR (95% CI) [1] vs. Pom/Dex		0.83 (0.06, 11.28)
	P-value [1]		0.8909
	RR (95% CI) vs. Pom/Dex		0.86 (0.09, 7.83)
	ARD (95% CI) vs. Pom/Dex		-0.02 (-0.36, 0.31)
	P-value [2]		>0.9999

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Subjects who have a response of "A little worse" or "Much worse" are considered negative responders.
Note: n is the number of analysable subjects at the specified timepoint, percentages are based on this.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.

Table 4.036110
Analysis of PGIC Negative Responder Summary

Timepoint		Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 25	n	6	6
	Negative Responder	1 (17%)	0
	OR (95% CI) [1] vs. Pom/Dex		<0.01 (<0.01, >999.99)
	P-value [1]		0.9595
	RR (95% CI) vs. Pom/Dex		0.33 (0.02, 6.86)
	ARD (95% CI) vs. Pom/Dex		-0.14 (-0.50, 0.22)
	P-value [2]		>0.9999

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Subjects who have a response of "A little worse" or "Much worse" are considered negative responders.
Note: n is the number of analysable subjects at the specified timepoint, percentages are based on this.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.

Table 4.036110
Analysis of PGIC Negative Responder Summary

Timepoint		Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 31	n	7	6
	Negative Responder	0	0
	OR (95% CI) [1] vs. Pom/Dex		- (-,-)
	P-value [1]		-
	RR (95% CI) vs. Pom/Dex		- (-,-)
	ARD (95% CI) vs. Pom/Dex		0.00 (0.00, 0.00)
	P-value [2]		-

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Subjects who have a response of "A little worse" or "Much worse" are considered negative responders.
Note: n is the number of analysable subjects at the specified timepoint, percentages are based on this.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.

Table 4.036110
Analysis of PGIC Negative Responder Summary

Timepoint		Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 37	n	4	6
	Negative Responder	0	0
	OR (95% CI) [1] vs. Pom/Dex		- (-,-)
	P-value [1]		-
	RR (95% CI) vs. Pom/Dex		- (-,-)
	ARD (95% CI) vs. Pom/Dex		0.00 (0.00, 0.00)
	P-value [2]		-

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Subjects who have a response of "A little worse" or "Much worse" are considered negative responders.
Note: n is the number of analysable subjects at the specified timepoint, percentages are based on this.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.

Table 4.036110
Analysis of PGIC Negative Responder Summary

Timepoint		Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 43	n	4	4
	Negative Responder	0	0
	OR (95% CI) [1] vs. Pom/Dex		- (-,-)
	P-value [1]		-
	RR (95% CI) vs. Pom/Dex		- (-,-)
	ARD (95% CI) vs. Pom/Dex		0.00 (0.00, 0.00)
	P-value [2]		-

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Subjects who have a response of "A little worse" or "Much worse" are considered negative responders.
Note: n is the number of analysable subjects at the specified timepoint, percentages are based on this.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.

Table 4.036110
Analysis of PGIC Negative Responder Summary

Timepoint		Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 49	n	3	4
	Negative Responder	0	0
	OR (95% CI) [1] vs. Pom/Dex		- (-,-)
	P-value [1]		-
	RR (95% CI) vs. Pom/Dex		- (-,-)
	ARD (95% CI) vs. Pom/Dex		0.00 (0.00, 0.00)
	P-value [2]		-

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Subjects who have a response of "A little worse" or "Much worse" are considered negative responders.
Note: n is the number of analysable subjects at the specified timepoint, percentages are based on this.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.

Table 4.036110
Analysis of PGIC Negative Responder Summary

Timepoint		Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 55	n	3	3
	Negative Responder	0	0
	OR (95% CI) [1] vs. Pom/Dex		- (-,-)
	P-value [1]		-
	RR (95% CI) vs. Pom/Dex		- (-,-)
	ARD (95% CI) vs. Pom/Dex		0.00 (0.00, 0.00)
	P-value [2]		-

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Subjects who have a response of "A little worse" or "Much worse" are considered negative responders.
Note: n is the number of analysable subjects at the specified timepoint, percentages are based on this.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.

Table 4.036110
Analysis of PGIC Negative Responder Summary

Timepoint		Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 61	n	2	2
	Negative Responder	0	0
	OR (95% CI) [1] vs. Pom/Dex		- (-,-)
	P-value [1]		-
	RR (95% CI) vs. Pom/Dex		- (-,-)
	ARD (95% CI) vs. Pom/Dex		0.00 (0.00, 0.00)
	P-value [2]		-

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Subjects who have a response of "A little worse" or "Much worse" are considered negative responders.
Note: n is the number of analysable subjects at the specified timepoint, percentages are based on this.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.

Table 4.036110
Analysis of PGIC Negative Responder Summary

Timepoint		Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 67	n	2	2
	Negative Responder	0	0
	OR (95% CI) [1] vs. Pom/Dex		- (-,-)
	P-value [1]		-
	RR (95% CI) vs. Pom/Dex		- (-,-)
	ARD (95% CI) vs. Pom/Dex		0.00 (0.00, 0.00)
	P-value [2]		-

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Subjects who have a response of "A little worse" or "Much worse" are considered negative responders.
Note: n is the number of analysable subjects at the specified timepoint, percentages are based on this.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.

Table 4.036110
Analysis of PGIC Negative Responder Summary

Timepoint		Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 73	n	1	1
	Negative Responder	0	0
	OR (95% CI) [1] vs. Pom/Dex		- (-,-)
	P-value [1]		-
	RR (95% CI) vs. Pom/Dex		- (-,-)
	ARD (95% CI) vs. Pom/Dex		0.00 (0.00, 0.00)
	P-value [2]		-

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Subjects who have a response of "A little worse" or "Much worse" are considered negative responders.
Note: n is the number of analysable subjects at the specified timepoint, percentages are based on this.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.

Table 4.036110
Analysis of PGIC Negative Responder Summary

Timepoint		Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 79	n	2	1
	Negative Responder	0	0
	OR (95% CI) [1] vs. Pom/Dex		- (-,-)
	P-value [1]		-
	RR (95% CI) vs. Pom/Dex		- (-,-)
	ARD (95% CI) vs. Pom/Dex		0.00 (0.00, 0.00)
	P-value [2]		-

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Subjects who have a response of "A little worse" or "Much worse" are considered negative responders.
Note: n is the number of analysable subjects at the specified timepoint, percentages are based on this.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.

Table 4.036110
Analysis of PGIC Negative Responder Summary

Timepoint		Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 85	n	1	1
	Negative Responder	0	0
	OR (95% CI) [1] vs. Pom/Dex		- (-,-)
	P-value [1]		-
	RR (95% CI) vs. Pom/Dex		- (-,-)
	ARD (95% CI) vs. Pom/Dex		0.00 (0.00, 0.00)
	P-value [2]		-

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Subjects who have a response of "A little worse" or "Much worse" are considered negative responders.
Note: n is the number of analysable subjects at the specified timepoint, percentages are based on this.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.

Table 4.036110
Analysis of PGIC Negative Responder Summary

Timepoint		Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 91	n	1	1
	Negative Responder	0	0
	OR (95% CI) [1] vs. Pom/Dex		- (-,-)
	P-value [1]		-
	RR (95% CI) vs. Pom/Dex		- (-,-)
	ARD (95% CI) vs. Pom/Dex		0.00 (0.00, 0.00)
	P-value [2]		-

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Subjects who have a response of "A little worse" or "Much worse" are considered negative responders.
Note: n is the number of analysable subjects at the specified timepoint, percentages are based on this.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.

Table 4.036110
Analysis of PGIC Negative Responder Summary

Timepoint		Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 97	n	1	0
	Negative Responder	0	0
	OR (95% CI) [1] vs. Pom/Dex		- (-,-)
	P-value [1]		-
	RR (95% CI) vs. Pom/Dex		- (-,-)
	ARD (95% CI) vs. Pom/Dex		- (-,-)
	P-value [2]		-

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Subjects who have a response of "A little worse" or "Much worse" are considered negative responders.
Note: n is the number of analysable subjects at the specified timepoint, percentages are based on this.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.

Table 4.036110
Analysis of PGIC Negative Responder Summary

Timepoint		Pom/Dex (N=15)	Belantamab mafodotin (N=29)
End of Treatment	n	10	11
	Negative Responder	1 (10%)	6 (55%)
	OR (95% CI) [1] vs. Pom/Dex		10.80 (1.00, 117.00)
	P-value [1]		0.0503
	RR (95% CI) vs. Pom/Dex		5.45 (0.79, 37.81)
	ARD (95% CI) vs. Pom/Dex		0.45 (0.10, 0.79)
	P-value [2]		0.0635

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Subjects who have a response of "A little worse" or "Much worse" are considered negative responders.
Note: n is the number of analysable subjects at the specified timepoint, percentages are based on this.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.

Table 4.036110
Analysis of PGIC Negative Responder Summary

Timepoint		Pom/Dex (N=15)	Belantamab mafodotin (N=29)
PFS Follow-Up 2	n	1	1
	Negative Responder	0	0
	OR (95% CI) [1] vs. Pom/Dex		- (-,-)
	P-value [1]		-
	RR (95% CI) vs. Pom/Dex		- (-,-)
	ARD (95% CI) vs. Pom/Dex		0.00 (0.00, 0.00)
	P-value [2]		-

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Subjects who have a response of "A little worse" or "Much worse" are considered negative responders.
Note: n is the number of analysable subjects at the specified timepoint, percentages are based on this.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.

Table 4.036110
Analysis of PGIC Negative Responder Summary

Timepoint		Pom/Dex (N=15)	Belantamab mafodotin (N=29)
PFS Follow-Up 4	n	0	1
	Negative Responder	0	0
	OR (95% CI) [1] vs. Pom/Dex		- (-,-)
	P-value [1]		-
	RR (95% CI) vs. Pom/Dex		- (-,-)
	ARD (95% CI) vs. Pom/Dex		- (-,-)
	P-value [2]		-

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Subjects who have a response of "A little worse" or "Much worse" are considered negative responders.
Note: n is the number of analysable subjects at the specified timepoint, percentages are based on this.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.

Table 4.037110
Analysis of PGIC Positive Responder Summary

Timepoint		Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 7	n	12	14
	Positive Responder	11 (92%)	6 (43%)
	Inverse OR (95% CI) [1] vs. Pom/Dex		14.67 (1.46, 146.96)
	P-value [1]		0.0224
	Inverse RR (95% CI) vs. Pom/Dex		2.14 (1.14, 4.01)
	ARD (95% CI) vs. Pom/Dex		-0.49 (-0.79, -0.19)
	P-value [2]		0.0145

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Subjects who have a response of "Much Better" or "A little better" are considered positive responders.
Note: n is the number of analysable subjects at the specified timepoint, percentages are based on this.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.

Table 4.037110
Analysis of PGIC Positive Responder Summary

Timepoint		Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 13	n	13	7
	Positive Responder	9 (69%)	6 (86%)
	Inverse OR (95% CI) [1] vs. Pom/Dex		0.38 (0.03, 4.23)
	P-value [1]		0.4275
	Inverse RR (95% CI) vs. Pom/Dex		0.81 (0.50, 1.29)
	ARD (95% CI) vs. Pom/Dex		0.16 (-0.20, 0.53)
	P-value [2]		0.6126

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Subjects who have a response of "Much Better" or "A little better" are considered positive responders.
Note: n is the number of analysable subjects at the specified timepoint, percentages are based on this.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.

Table 4.037110
Analysis of PGIC Positive Responder Summary

Timepoint		Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 19	n	12	7
	Positive Responder	9 (75%)	5 (71%)
	Inverse OR (95% CI) [1] vs. Pom/Dex		1.20 (0.15, 9.77)
	P-value [1]		0.8647
	Inverse RR (95% CI) vs. Pom/Dex		1.05 (0.59, 1.86)
	ARD (95% CI) vs. Pom/Dex		-0.04 (-0.45, 0.38)
	P-value [2]		>0.9999

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Subjects who have a response of "Much Better" or "A little better" are considered positive responders.
Note: n is the number of analysable subjects at the specified timepoint, percentages are based on this.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.

Table 4.037110
Analysis of PGIC Positive Responder Summary

Timepoint		Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 25	n	6	6
	Positive Responder	3 (50%)	6 (100%)
	Inverse OR (95% CI) [1] vs. Pom/Dex		<0.01 (<0.01, >999.99)
	P-value [1]		0.9542
	Inverse RR (95% CI) vs. Pom/Dex		0.54 (0.25, 1.16)
	ARD (95% CI) vs. Pom/Dex		0.43 (0.01, 0.85)
	P-value [2]		0.1818

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Subjects who have a response of "Much Better" or "A little better" are considered positive responders.
Note: n is the number of analysable subjects at the specified timepoint, percentages are based on this.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.

Table 4.037110
Analysis of PGIC Positive Responder Summary

Timepoint		Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 31	n	7	6
	Positive Responder	5 (71%)	6 (100%)
	Inverse OR (95% CI) [1] vs. Pom/Dex		<0.01 (<0.01, >999.99)
	P-value [1]		0.9457
	Inverse RR (95% CI) vs. Pom/Dex		0.74 (0.44, 1.23)
	ARD (95% CI) vs. Pom/Dex		0.24 (-0.13, 0.61)
	P-value [2]		0.4615

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Subjects who have a response of "Much Better" or "A little better" are considered positive responders.
Note: n is the number of analysable subjects at the specified timepoint, percentages are based on this.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.

Table 4.037110
Analysis of PGIC Positive Responder Summary

Timepoint		Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 37	n	4	6
	Positive Responder	4 (100%)	6 (100%)
	Inverse OR (95% CI) [1] vs. Pom/Dex		- (-,-)
	P-value [1]		-
	Inverse RR (95% CI) vs. Pom/Dex		- (-,-)
	ARD (95% CI) vs. Pom/Dex		0.00 (0.00, 0.00)
	P-value [2]		-

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Subjects who have a response of "Much Better" or "A little better" are considered positive responders.
Note: n is the number of analysable subjects at the specified timepoint, percentages are based on this.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.

Table 4.037110
Analysis of PGIC Positive Responder Summary

Timepoint		Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 43	n	4	4
	Positive Responder	4 (100%)	4 (100%)
	Inverse OR (95% CI) [1] vs. Pom/Dex		- (-,-)
	P-value [1]		-
	Inverse RR (95% CI) vs. Pom/Dex		- (-,-)
	ARD (95% CI) vs. Pom/Dex		0.00 (0.00, 0.00)
	P-value [2]		-

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Subjects who have a response of "Much Better" or "A little better" are considered positive responders.
Note: n is the number of analysable subjects at the specified timepoint, percentages are based on this.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.

Table 4.037110
Analysis of PGIC Positive Responder Summary

Timepoint		Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 49	n	3	4
	Positive Responder	3 (100%)	4 (100%)
	Inverse OR (95% CI) [1] vs. Pom/Dex		- (-,-)
	P-value [1]		-
	Inverse RR (95% CI) vs. Pom/Dex		- (-,-)
	ARD (95% CI) vs. Pom/Dex		0.00 (0.00, 0.00)
	P-value [2]		-

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Subjects who have a response of "Much Better" or "A little better" are considered positive responders.
Note: n is the number of analysable subjects at the specified timepoint, percentages are based on this.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.

Table 4.037110
Analysis of PGIC Positive Responder Summary

Timepoint		Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 55	n	3	3
	Positive Responder	2 (67%)	2 (67%)
	Inverse OR (95% CI) [1] vs. Pom/Dex		1.00 (0.03, 29.81)
	P-value [1]		>0.9999
	Inverse RR (95% CI) vs. Pom/Dex		1.00 (0.32, 3.10)
	ARD (95% CI) vs. Pom/Dex		0.00 (-0.75, 0.75)
	P-value [2]		>0.9999

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Subjects who have a response of "Much Better" or "A little better" are considered positive responders.
Note: n is the number of analysable subjects at the specified timepoint, percentages are based on this.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.

Table 4.037110
Analysis of PGIC Positive Responder Summary

Timepoint		Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 61	n	2	2
	Positive Responder	1 (50%)	2 (100%)
	Inverse OR (95% CI) [1] vs. Pom/Dex		<0.01 (<0.01, >999.99)
	P-value [1]		0.9395
	Inverse RR (95% CI) vs. Pom/Dex		0.60 (0.17, 2.07)
	ARD (95% CI) vs. Pom/Dex		0.33 (-0.37, 1.00)
	P-value [2]		>0.9999

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Subjects who have a response of "Much Better" or "A little better" are considered positive responders.
Note: n is the number of analysable subjects at the specified timepoint, percentages are based on this.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.

Table 4.037110
Analysis of PGIC Positive Responder Summary

Timepoint		Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 67	n	2	2
	Positive Responder	2 (100%)	2 (100%)
	Inverse OR (95% CI) [1] vs. Pom/Dex		- (-,-)
	P-value [1]		-
	Inverse RR (95% CI) vs. Pom/Dex		- (-,-)
	ARD (95% CI) vs. Pom/Dex		0.00 (0.00, 0.00)
	P-value [2]		-

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Subjects who have a response of "Much Better" or "A little better" are considered positive responders.
Note: n is the number of analysable subjects at the specified timepoint, percentages are based on this.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.

Table 4.037110
Analysis of PGIC Positive Responder Summary

Timepoint		Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 73	n	1	1
	Positive Responder	1 (100%)	1 (100%)
	Inverse OR (95% CI) [1] vs. Pom/Dex		- (-,-)
	P-value [1]		-
	Inverse RR (95% CI) vs. Pom/Dex		- (-,-)
	ARD (95% CI) vs. Pom/Dex		0.00 (0.00, 0.00)
	P-value [2]		-

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Subjects who have a response of "Much Better" or "A little better" are considered positive responders.
Note: n is the number of analysable subjects at the specified timepoint, percentages are based on this.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.

Table 4.037110
Analysis of PGIC Positive Responder Summary

Timepoint		Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 79	n	2	1
	Positive Responder	2 (100%)	1 (100%)
	Inverse OR (95% CI) [1] vs. Pom/Dex		- (-,-)
	P-value [1]		-
	Inverse RR (95% CI) vs. Pom/Dex		- (-,-)
	ARD (95% CI) vs. Pom/Dex		0.00 (0.00, 0.00)
	P-value [2]		-

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Subjects who have a response of "Much Better" or "A little better" are considered positive responders.
Note: n is the number of analysable subjects at the specified timepoint, percentages are based on this.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.

Table 4.037110
Analysis of PGIC Positive Responder Summary

Timepoint		Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 85	n	1	1
	Positive Responder	0	1 (100%)
	Inverse OR (95% CI) [1] vs. Pom/Dex		- (-,-)
	P-value [1]		-
	Inverse RR (95% CI) vs. Pom/Dex		- (-,-)
	ARD (95% CI) vs. Pom/Dex		1.00 (1.00, 1.00)
	P-value [2]		-

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Subjects who have a response of "Much Better" or "A little better" are considered positive responders.
Note: n is the number of analysable subjects at the specified timepoint, percentages are based on this.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.

Table 4.037110
Analysis of PGIC Positive Responder Summary

Timepoint		Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 91	n	1	1
	Positive Responder	1 (100%)	1 (100%)
	Inverse OR (95% CI) [1] vs. Pom/Dex		- (-,-)
	P-value [1]		-
	Inverse RR (95% CI) vs. Pom/Dex		- (-,-)
	ARD (95% CI) vs. Pom/Dex		0.00 (0.00, 0.00)
	P-value [2]		-

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Subjects who have a response of "Much Better" or "A little better" are considered positive responders.
Note: n is the number of analysable subjects at the specified timepoint, percentages are based on this.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.

Table 4.037110
Analysis of PGIC Positive Responder Summary

Timepoint		Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Week 97	n	1	0
	Positive Responder	0	0
	Inverse OR (95% CI) [1] vs. Pom/Dex		- (-,-)
	P-value [1]		-
	Inverse RR (95% CI) vs. Pom/Dex		- (-,-)
	ARD (95% CI) vs. Pom/Dex		- (-,-)
	P-value [2]		-

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Subjects who have a response of "Much Better" or "A little better" are considered positive responders.
Note: n is the number of analysable subjects at the specified timepoint, percentages are based on this.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.

Table 4.037110
Analysis of PGIC Positive Responder Summary

Timepoint		Pom/Dex (N=15)	Belantamab mafodotin (N=29)
End of Treatment	n	10	11
	Positive Responder	6 (60%)	2 (18%)
	Inverse OR (95% CI) [1] vs. Pom/Dex		6.75 (0.93, 49.23)
	P-value [1]		0.0596
	Inverse RR (95% CI) vs. Pom/Dex		3.30 (0.85, 12.75)
	ARD (95% CI) vs. Pom/Dex		-0.42 (-0.80, -0.04)
	P-value [2]		0.0805

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Subjects who have a response of "Much Better" or "A little better" are considered positive responders.
Note: n is the number of analysable subjects at the specified timepoint, percentages are based on this.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.

Table 4.037110
Analysis of PGIC Positive Responder Summary

Timepoint		Pom/Dex (N=15)	Belantamab mafodotin (N=29)
PFS Follow-Up 2	n	1	1
	Positive Responder	0	1 (100%)
	Inverse OR (95% CI) [1] vs. Pom/Dex		- (-,-)
	P-value [1]		-
	Inverse RR (95% CI) vs. Pom/Dex		- (-,-)
	ARD (95% CI) vs. Pom/Dex		1.00 (1.00, 1.00)
	P-value [2]		-

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Subjects who have a response of "Much Better" or "A little better" are considered positive responders.
Note: n is the number of analysable subjects at the specified timepoint, percentages are based on this.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.

Table 4.037110
Analysis of PGIC Positive Responder Summary

Timepoint		Pom/Dex (N=15)	Belantamab mafodotin (N=29)
PFS Follow-Up 4	n	0	1
	Positive Responder	0	1 (100%)
	Inverse OR (95% CI) [1] vs. Pom/Dex		- (-,-)
	P-value [1]		-
	Inverse RR (95% CI) vs. Pom/Dex		- (-,-)
	ARD (95% CI) vs. Pom/Dex		- (-,-)
	P-value [2]		-

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Subjects who have a response of "Much Better" or "A little better" are considered positive responders.
Note: n is the number of analysable subjects at the specified timepoint, percentages are based on this.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.

Protocol: 207495 Page 1 of 1
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.038110
Summary of PGIC Time to First Positive Responder

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	13 (87%)	10 (34%)
Censored	2 (13%)	19 (66%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	1.5 (1.4, 1.6)	1.5 (0.8, 4.3)
Median (95% CI)	1.6 (1.4, 1.7)	4.3 (1.4, 5.7)
3rd Quartile (95% CI)	1.7 (1.5, 7.9)	4.8 (2.8, 5.7)
Log-Rank P-value [2]		0.6533
Inverse Hazard Ratio (95% CI) [3]		1.30 (0.42, 3.99)
P-value [3]		0.6506

Note: Subjects are censored at their latest assessment.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Inverse hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. Inverse hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pgic_ttfpr.sas 13MAR2023 09:12

Protocol: 207495 Page 1 of 1
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.039110
Summary of PGIC Time to First Negative Responder

	Pom/Dex (N=15)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	4 (27%)	10 (34%)
Censored	11 (73%)	19 (66%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	5.7 (2.8, -)	1.7 (1.4, 3.0)
Median (95% CI)	- (4.2, -)	4.4 (1.7, -)
3rd Quartile (95% CI)	- (-, -)	- (4.4, -)
Log-Rank P-value [2]		0.7299
Hazard Ratio (95% CI) [3]		1.28 (0.32, 5.18)
P-value [3]		0.7305

Note: Subjects are censored at their latest assessment.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pgic_ttfnr.sas 13MAR2023 09:12

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.001110
Adverse Event Overview

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Any AE	13 (93%)	28 (97%)
AEs related to study treatment	11 (79%)	20 (69%)
AEs related to study Pom	10 (71%)	
AEs related to study Dex	9 (64%)	
AEs related to study Pom and Dex	5 (36%)	
AEs leading to permanent discontinuation of study treatment	2 (14%)	1 (3%)
AEs leading to permanent discontinuation of study Pom	2 (14%)	
AEs leading to permanent discontinuation of study Dex	2 (14%)	
AEs leading to permanent discontinuation of study Pom and Dex	2 (14%)	
AEs leading to dose reduction	6 (43%)	5 (17%)
AEs leading to dose reduction of Pom	1 (7%)	
AEs leading to dose reduction of Dex	6 (43%)	
AEs leading to dose reduction of Pom and Dex	1 (7%)	
AEs leading to dose interruption/delay	8 (57%)	12 (41%)
AEs leading to dose interruption/delay of Pom	8 (57%)	
AEs leading to dose interruption/delay of Dex	7 (50%)	
AEs leading to dose interruption/delay of Pom and Dex	7 (50%)	
AEs related to study treatment and leading to permanent discontinuation of study treatment	1 (7%)	1 (3%)
Grade 3 or 4 AEs	11 (79%)	20 (69%)
Grade 3 or 4 AEs related to study treatment	10 (71%)	12 (41%)

Note: Summary only includes treatment emergent adverse events.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae13_ov.sas 20DEC2022 09:48

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.001110
Adverse Event Overview

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Any SAE	5 (36%)	13 (45%)
SAEs related to study treatment	3 (21%)	2 (7%)
SAEs related to study Pom	3 (21%)	
SAEs related to study Dex	3 (21%)	
SAEs related to study Pom and Dex	3 (21%)	
Fatal SAEs	1 (7%)	2 (7%)
Fatal SAEs related to study treatment	0	0
Fatal SAEs related to study Pom	0	
Fatal SAEs related to study Dex	0	
Fatal SAEs related to study Pom and Dex	0	

Note: Summary only includes treatment emergent adverse events.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae13_ov.sas 20DEC2022 09:48

Protocol: 207495 Page 1 of 7
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.002110
Summary of All Adverse Events by System Organ Class and Preferred Term

System Organ Class Preferred Term	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
ANY EVENT	13 (93%)	28 (97%)
Blood and lymphatic system disorders		
Any event	7 (50%)	14 (48%)
Thrombocytopenia	6 (43%)	10 (34%)
Anaemia	4 (29%)	8 (28%)
Neutropenia	4 (29%)	1 (3%)
Lymphopenia	1 (7%)	1 (3%)
Bone marrow failure	0	1 (3%)
Leukocytosis	0	1 (3%)
Eye disorders		
Any event	5 (36%)	15 (52%)
Cataract	3 (21%)	4 (14%)
Vision blurred	1 (7%)	4 (14%)
Dry eye	0	3 (10%)
Foreign body sensation in eyes	0	3 (10%)
Photophobia	0	3 (10%)
Visual acuity reduced	1 (7%)	2 (7%)
Visual impairment	0	3 (10%)
Astigmatism	0	1 (3%)
Cataract cortical	0	1 (3%)
Cataract nuclear	0	1 (3%)
Cataract subcapsular	0	1 (3%)
Choroidal neovascularisation	1 (7%)	0
Conjunctival haemorrhage	0	1 (3%)
Corneal epithelial microcysts	0	1 (3%)
Corneal epithelium defect	0	1 (3%)
Corneal opacity	0	1 (3%)
Diplopia	0	1 (3%)
Eye irritation	0	1 (3%)
Eye pain	0	1 (3%)

Note: Summary only includes treatment emergent adverse events.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae1.sas 20DEC2022 09:51

Table 3.002110
Summary of All Adverse Events by System Organ Class and Preferred Term

System Organ Class Preferred Term	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Eye swelling	0	1 (3%)
Keratitis	0	1 (3%)
Keratopathy	0	1 (3%)
Lacrimation increased	0	1 (3%)
Punctate keratitis	0	1 (3%)
Retinal haemorrhage	0	1 (3%)
Infections and infestations		
Any event	9 (64%)	11 (38%)
COVID-19	4 (29%)	3 (10%)
Pneumonia	2 (14%)	2 (7%)
Burn infection	1 (7%)	0
COVID-19 pneumonia	1 (7%)	0
Campylobacter gastroenteritis	0	1 (3%)
Cellulitis	1 (7%)	0
Cystitis	0	1 (3%)
Eye infection	1 (7%)	0
Herpes zoster	1 (7%)	0
Lower respiratory tract infection	1 (7%)	0
Oral candidiasis	0	1 (3%)
Periodontitis	1 (7%)	0
Pulmonary nocardiosis	1 (7%)	0
Sepsis	0	1 (3%)
Septic shock	0	1 (3%)
Spontaneous bacterial peritonitis	0	1 (3%)
Tinea pedis	1 (7%)	0
Upper respiratory tract infection	1 (7%)	0
Urinary tract infection	0	1 (3%)
Investigations		
Any event	7 (50%)	11 (38%)
Aspartate aminotransferase increased	1 (7%)	3 (10%)

Note: Summary only includes treatment emergent adverse events.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae1.sas 20DEC2022 09:51

Protocol: 207495 Page 3 of 7
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.002110
Summary of All Adverse Events by System Organ Class and Preferred Term

System Organ Class Preferred Term	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Neutrophil count decreased	3 (21%)	0
Alanine aminotransferase increased	2 (14%)	0
Blood creatinine increased	2 (14%)	0
Blood lactate dehydrogenase increased	0	2 (7%)
Gamma-glutamyltransferase increased	0	2 (7%)
Albumin urine present	0	1 (3%)
Blood alkaline phosphatase increased	1 (7%)	0
Blood creatine phosphokinase increased	0	1 (3%)
Glomerular filtration rate decreased	0	1 (3%)
Haemoglobin decreased	1 (7%)	0
Hepatic enzyme increased	0	1 (3%)
Intraocular pressure increased	0	1 (3%)
Lymphocyte count decreased	0	1 (3%)
Platelet count decreased	0	1 (3%)
Gastrointestinal disorders		
Any event	5 (36%)	11 (38%)
Constipation	2 (14%)	2 (7%)
Nausea	1 (7%)	2 (7%)
Diarrhoea	0	2 (7%)
Vomiting	0	2 (7%)
Abdominal compartment syndrome	0	1 (3%)
Abdominal pain	0	1 (3%)
Abdominal pain upper	1 (7%)	0
Colitis	0	1 (3%)
Dental caries	1 (7%)	0
Dyspepsia	1 (7%)	0
Haemorrhoids	1 (7%)	0
Mouth haemorrhage	0	1 (3%)
Stomatitis	1 (7%)	0
Toothache	0	1 (3%)

Note: Summary only includes treatment emergent adverse events.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae1.sas 20DEC2022 09:51

Protocol: 207495 Page 4 of 7
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.002110
Summary of All Adverse Events by System Organ Class and Preferred Term

System Organ Class Preferred Term	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Musculoskeletal and connective tissue disorders		
Any event	7 (50%)	9 (31%)
Arthralgia	1 (7%)	3 (10%)
Bone pain	1 (7%)	3 (10%)
Back pain	2 (14%)	1 (3%)
Muscular weakness	2 (14%)	0
Musculoskeletal chest pain	1 (7%)	1 (3%)
Pathological fracture	1 (7%)	1 (3%)
Joint effusion	0	1 (3%)
Muscle spasms	1 (7%)	0
Musculoskeletal pain	1 (7%)	0
Myalgia	0	1 (3%)
Myopathy	1 (7%)	0
Osteonecrosis of jaw	1 (7%)	0
Pain in extremity	0	1 (3%)
Pain in jaw	1 (7%)	0
General disorders and administration site conditions		
Any event	7 (50%)	4 (14%)
Fatigue	2 (14%)	2 (7%)
Oedema peripheral	3 (21%)	1 (3%)
Pyrexia	1 (7%)	2 (7%)
Chills	0	2 (7%)
Asthenia	1 (7%)	0
Oedema	1 (7%)	0
Sensation of foreign body	1 (7%)	0
Metabolism and nutrition disorders		
Any event	3 (21%)	8 (28%)
Hypercalcaemia	1 (7%)	1 (3%)

Note: Summary only includes treatment emergent adverse events.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae1.sas 20DEC2022 09:51

Table 3.002110
Summary of All Adverse Events by System Organ Class and Preferred Term

System Organ Class Preferred Term	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Hyperglycaemia	1 (7%)	1 (3%)
Hypokalaemia	0	2 (7%)
Hypomagnesaemia	0	2 (7%)
Diabetes mellitus	0	1 (3%)
Hyperchloraemia	0	1 (3%)
Hypercholesterolaemia	0	1 (3%)
Steroid diabetes	1 (7%)	0
Tumour lysis syndrome	0	1 (3%)
Nervous system disorders		
Any event	4 (29%)	3 (10%)
Tremor	2 (14%)	0
Cauda equina syndrome	0	1 (3%)
Dysgeusia	1 (7%)	0
Epilepsy	0	1 (3%)
Hypoaesthesia	1 (7%)	0
Neuropathy peripheral	1 (7%)	0
Peripheral motor neuropathy	0	1 (3%)
Peripheral sensory neuropathy	1 (7%)	0
Polyneuropathy	1 (7%)	0
Radicular pain	0	1 (3%)
Respiratory, thoracic and mediastinal disorders		
Any event	4 (29%)	3 (10%)
Epistaxis	0	3 (10%)
Dyspnoea	1 (7%)	1 (3%)
Hiccups	2 (14%)	0
Dyspnoea exertional	1 (7%)	0
Pleural effusion	0	1 (3%)

Note: Summary only includes treatment emergent adverse events.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae1.sas 20DEC2022 09:51

Table 3.002110
Summary of All Adverse Events by System Organ Class and Preferred Term

System Organ Class Preferred Term	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Injury, poisoning and procedural complications		
Any event	2 (14%)	4 (14%)
Infusion related reaction	0	2 (7%)
Allergic transfusion reaction	0	1 (3%)
Burns second degree	1 (7%)	0
Humerus fracture	1 (7%)	0
Ligament rupture	0	1 (3%)
Stoma site haemorrhage	0	1 (3%)
Renal and urinary disorders		
Any event	1 (7%)	3 (10%)
Acute kidney injury	0	2 (7%)
Glycosuria	0	1 (3%)
Proteinuria	0	1 (3%)
Urinary incontinence	1 (7%)	0
Cardiac disorders		
Any event	1 (7%)	2 (7%)
Acute myocardial infarction	1 (7%)	0
Atrioventricular block first degree	0	1 (3%)
Cardiac failure	0	1 (3%)
Tachycardia	0	1 (3%)
Ventricular extrasystoles	0	1 (3%)
Skin and subcutaneous tissue disorders		
Any event	3 (21%)	0
Rash	2 (14%)	0
Pruritus	1 (7%)	0
Psychiatric disorders		
Any event	1 (7%)	1 (3%)

Note: Summary only includes treatment emergent adverse events.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae1.sas 20DEC2022 09:51

Table 3.002110
Summary of All Adverse Events by System Organ Class and Preferred Term

System Organ Class Preferred Term	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Confusional state	0	1 (3%)
Insomnia	1 (7%)	0
Immune system disorders		
Any event	1 (7%)	0
Serum sickness	1 (7%)	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		
Any event	0	1 (3%)
Plasma cell myeloma	0	1 (3%)

Note: Summary only includes treatment emergent adverse events.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae1.sas 20DEC2022 09:51

Protocol: 207495 Page 1 of 4
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.104110
Summary of All Adverse Events of Max Grade 3 or Higher by System Organ Class and Preferred Term

System Organ Class Preferred Term	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
ANY EVENT	12 (86%)	20 (69%)
Blood and lymphatic system disorders		
Any event	4 (29%)	10 (34%)
Thrombocytopenia	2 (14%)	7 (24%)
Anaemia	0	5 (17%)
Neutropenia	4 (29%)	1 (3%)
Lymphopenia	1 (7%)	1 (3%)
Bone marrow failure	0	1 (3%)
Eye disorders		
Any event	1 (7%)	6 (21%)
Visual impairment	0	3 (10%)
Cataract	1 (7%)	0
Cataract subcapsular	0	1 (3%)
Corneal opacity	0	1 (3%)
Diplopia	0	1 (3%)
Dry eye	0	1 (3%)
Punctate keratitis	0	1 (3%)
Infections and infestations		
Any event	4 (29%)	2 (7%)
Pneumonia	2 (14%)	1 (3%)
COVID-19	1 (7%)	0
Pulmonary nocardiosis	1 (7%)	0
Septic shock	0	1 (3%)
Spontaneous bacterial peritonitis	0	1 (3%)
Musculoskeletal and connective tissue disorders		
Any event	2 (14%)	4 (14%)
Bone pain	1 (7%)	2 (7%)

Note: Summary only includes treatment emergent adverse events.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae1_gr3.sas 16FEB2023 08:15

Table 3.104110

Summary of All Adverse Events of Max Grade 3 or Higher by System Organ Class and Preferred Term

System Organ Class Preferred Term	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Arthralgia	0	1 (3%)
Back pain	0	1 (3%)
Osteonecrosis of jaw	1 (7%)	0
Pathological fracture	0	1 (3%)
Investigations		
Any event	2 (14%)	3 (10%)
Neutrophil count decreased	2 (14%)	0
Glomerular filtration rate decreased	0	1 (3%)
Lymphocyte count decreased	0	1 (3%)
Platelet count decreased	0	1 (3%)
Metabolism and nutrition disorders		
Any event	1 (7%)	4 (14%)
Hypercalcaemia	1 (7%)	1 (3%)
Hypokalaemia	0	2 (7%)
Hypomagnesaemia	0	1 (3%)
Tumour lysis syndrome	0	1 (3%)
Nervous system disorders		
Any event	0	3 (10%)
Cauda equina syndrome	0	1 (3%)
Epilepsy	0	1 (3%)
Peripheral motor neuropathy	0	1 (3%)
Radicular pain	0	1 (3%)
Renal and urinary disorders		
Any event	0	3 (10%)
Acute kidney injury	0	2 (7%)
Proteinuria	0	1 (3%)

Note: Summary only includes treatment emergent adverse events.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae1_gr3.sas 16FEB2023 08:15

Table 3.104110
Summary of All Adverse Events of Max Grade 3 or Higher by System Organ Class and Preferred Term

System Organ Class Preferred Term	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Cardiac disorders		
Any event	1 (7%)	1 (3%)
Acute myocardial infarction	1 (7%)	0
Cardiac failure	0	1 (3%)
Gastrointestinal disorders		
Any event	0	2 (7%)
Abdominal compartment syndrome	0	1 (3%)
Colitis	0	1 (3%)
Respiratory, thoracic and mediastinal disorders		
Any event	1 (7%)	1 (3%)
Epistaxis	0	1 (3%)
Hiccups	1 (7%)	0
General disorders and administration site conditions		
Any event	1 (7%)	0
Fatigue	1 (7%)	0
Injury, poisoning and procedural complications		
Any event	0	1 (3%)
Infusion related reaction	0	1 (3%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		
Any event	0	1 (3%)
Plasma cell myeloma	0	1 (3%)

Note: Summary only includes treatment emergent adverse events.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae1_gr3.sas 16FEB2023 08:15

Table 3.104110

Summary of All Adverse Events of Max Grade 3 or Higher by System Organ Class and Preferred Term

System Organ Class Preferred Term	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Psychiatric disorders		
Any event	1 (7%)	0
Insomnia	1 (7%)	0

Note: Summary only includes treatment emergent adverse events.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae1_gr3.sas 16FEB2023 08:15

Protocol: 207495 Page 1 of 2
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.008110
Summary of Serious Adverse Events by System Organ Class and Preferred Term

System Organ Class Preferred Term	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
ANY EVENT	5 (36%)	13 (45%)
Infections and infestations		
Any event	5 (36%)	3 (10%)
Pneumonia	2 (14%)	2 (7%)
COVID-19	1 (7%)	0
COVID-19 pneumonia	1 (7%)	0
Pulmonary nocardiosis	1 (7%)	0
Septic shock	0	1 (3%)
Spontaneous bacterial peritonitis	0	1 (3%)
Musculoskeletal and connective tissue disorders		
Any event	0	4 (14%)
Bone pain	0	2 (7%)
Back pain	0	1 (3%)
Pathological fracture	0	1 (3%)
Gastrointestinal disorders		
Any event	0	3 (10%)
Abdominal compartment syndrome	0	1 (3%)
Colitis	0	1 (3%)
Vomiting	0	1 (3%)
Nervous system disorders		
Any event	0	3 (10%)
Cauda equina syndrome	0	1 (3%)
Epilepsy	0	1 (3%)
Peripheral motor neuropathy	0	1 (3%)
Radicular pain	0	1 (3%)

Note: Summary only includes treatment emergent adverse events.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae1_sae.sas 20DEC2022 10:11

Table 3.008110
Summary of Serious Adverse Events by System Organ Class and Preferred Term

System Organ Class Preferred Term	Pom/Dex (N=14)		Belantamab mafodotin (N=29)	
Cardiac disorders				
Any event	1	(7%)	1	(3%)
Acute myocardial infarction	1	(7%)	0	
Cardiac failure	0		1	(3%)
Investigations				
Any event	1	(7%)	1	(3%)
Neutrophil count decreased	1	(7%)	0	
Platelet count decreased	0		1	(3%)
Blood and lymphatic system disorders				
Any event	0		1	(3%)
Anaemia	0		1	(3%)
Injury, poisoning and procedural complications				
Any event	0		1	(3%)
Infusion related reaction	0		1	(3%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)				
Any event	0		1	(3%)
Plasma cell myeloma	0		1	(3%)
Renal and urinary disorders				
Any event	0		1	(3%)
Acute kidney injury	0		1	(3%)

Note: Summary only includes treatment emergent adverse events.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae1_sae.sas 20DEC2022 10:11

Table 3.009110
Summary of Serious Adverse Events by System Organ Class and Preferred Term
(Number of Subjects and Occurrences)

System Organ Class / Preferred Term		Pom/Dex (N=14)	Belantamab mafodotin (N=29)
ANY EVENT	Number of Subjects with SAEs	5 (36%)	13 (45%)
	Number of SAEs	9	22
	Number of Drug-related SAEs	7	2
	Number of Fatal SAEs	1	2
	Number of Drug-related Fatal SAEs	0	0
Infections and infestations			
Pneumonia	Number of Subjects with SAEs	2 (14%)	2 (7%)
	Number of SAEs	4	2
	Number of Drug-related SAEs	4	0
	Number of Fatal SAEs	0	0
	Number of Drug-related Fatal SAEs	0	0
COVID-19	Number of Subjects with SAEs	1 (7%)	0
	Number of SAEs	1	0
	Number of Drug-related SAEs	0	0
	Number of Fatal SAEs	1	0
	Number of Drug-related Fatal SAEs	0	0
COVID-19 pneumonia	Number of Subjects with SAEs	1 (7%)	0
	Number of SAEs	1	0
	Number of Drug-related SAEs	0	0
	Number of Fatal SAEs	0	0
	Number of Drug-related Fatal SAEs	0	0

Note: Drug-related includes responses of 'Yes' and missing responses to the question 'Is this event related to study treatment?'.
Note: Summary only includes treatment emergent adverse events.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae16_sae.sas 20DEC2022 10:21

Table 3.009110
Summary of Serious Adverse Events by System Organ Class and Preferred Term
(Number of Subjects and Occurrences)

System Organ Class Preferred Term		Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Pulmonary nocardiosis	Number of Subjects with SAEs	1 (7%)	0
	Number of SAEs	1	0
	Number of Drug-related SAEs	1	0
	Number of Fatal SAEs	0	0
	Number of Drug-related Fatal SAEs	0	0
Septic shock	Number of Subjects with SAEs	0	1 (3%)
	Number of SAEs	0	1
	Number of Drug-related SAEs	0	0
	Number of Fatal SAEs	0	0
	Number of Drug-related Fatal SAEs	0	0
Spontaneous bacterial peritonitis	Number of Subjects with SAEs	0	1 (3%)
	Number of SAEs	0	1
	Number of Drug-related SAEs	0	0
	Number of Fatal SAEs	0	0
	Number of Drug-related Fatal SAEs	0	0
Musculoskeletal and connective tissue disorders			
Bone pain	Number of Subjects with SAEs	0	2 (7%)
	Number of SAEs	0	2
	Number of Drug-related SAEs	0	0
	Number of Fatal SAEs	0	0
	Number of Drug-related Fatal SAEs	0	0

Note: Drug-related includes responses of 'Yes' and missing responses to the question 'Is this event related to study treatment?'.
Note: Summary only includes treatment emergent adverse events.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae16_sae.sas 20DEC2022 10:21

Table 3.009110
Summary of Serious Adverse Events by System Organ Class and Preferred Term
(Number of Subjects and Occurrences)

System Organ Class Preferred Term		Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Back pain	Number of Subjects with SAEs	0	1 (3%)
	Number of SAEs	0	2
	Number of Drug-related SAEs	0	0
	Number of Fatal SAEs	0	0
	Number of Drug-related Fatal SAEs	0	0
Pathological fracture	Number of Subjects with SAEs	0	1 (3%)
	Number of SAEs	0	1
	Number of Drug-related SAEs	0	0
	Number of Fatal SAEs	0	0
	Number of Drug-related Fatal SAEs	0	0
Gastrointestinal disorders			
Abdominal compartment syndrome	Number of Subjects with SAEs	0	1 (3%)
	Number of SAEs	0	1
	Number of Drug-related SAEs	0	0
	Number of Fatal SAEs	0	1
	Number of Drug-related Fatal SAEs	0	0
Colitis	Number of Subjects with SAEs	0	1 (3%)
	Number of SAEs	0	1
	Number of Drug-related SAEs	0	0
	Number of Fatal SAEs	0	0
	Number of Drug-related Fatal SAEs	0	0

Note: Drug-related includes responses of 'Yes' and missing responses to the question 'Is this event related to study treatment?'.
Note: Summary only includes treatment emergent adverse events.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae16_sae.sas 20DEC2022 10:21

Table 3.009110
Summary of Serious Adverse Events by System Organ Class and Preferred Term
(Number of Subjects and Occurrences)

System Organ Class / Preferred Term		Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Vomiting	Number of Subjects with SAEs	0	1 (3%)
	Number of SAEs	0	1
	Number of Drug-related SAEs	0	0
	Number of Fatal SAEs	0	0
	Number of Drug-related Fatal SAEs	0	0
Nervous system disorders			
Cauda equina syndrome	Number of Subjects with SAEs	0	1 (3%)
	Number of SAEs	0	1
	Number of Drug-related SAEs	0	0
	Number of Fatal SAEs	0	0
	Number of Drug-related Fatal SAEs	0	0
Epilepsy	Number of Subjects with SAEs	0	1 (3%)
	Number of SAEs	0	1
	Number of Drug-related SAEs	0	0
	Number of Fatal SAEs	0	0
	Number of Drug-related Fatal SAEs	0	0
Peripheral motor neuropathy	Number of Subjects with SAEs	0	1 (3%)
	Number of SAEs	0	1
	Number of Drug-related SAEs	0	0
	Number of Fatal SAEs	0	0
	Number of Drug-related Fatal SAEs	0	0

Note: Drug-related includes responses of 'Yes' and missing responses to the question 'Is this event related to study treatment?'.
Note: Summary only includes treatment emergent adverse events.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae16_sae.sas 20DEC2022 10:21

Table 3.009110
Summary of Serious Adverse Events by System Organ Class and Preferred Term
(Number of Subjects and Occurrences)

System Organ Class / Preferred Term		Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Radicular pain	Number of Subjects with SAEs	0	1 (3%)
	Number of SAEs	0	1
	Number of Drug-related SAEs	0	0
	Number of Fatal SAEs	0	0
	Number of Drug-related Fatal SAEs	0	0
Cardiac disorders			
Acute myocardial infarction	Number of Subjects with SAEs	1 (7%)	0
	Number of SAEs	1	0
	Number of Drug-related SAEs	1	0
	Number of Fatal SAEs	0	0
	Number of Drug-related Fatal SAEs	0	0
Cardiac failure	Number of Subjects with SAEs	0	1 (3%)
	Number of SAEs	0	1
	Number of Drug-related SAEs	0	0
	Number of Fatal SAEs	0	0
	Number of Drug-related Fatal SAEs	0	0
Investigations			
Neutrophil count decreased	Number of Subjects with SAEs	1 (7%)	0
	Number of SAEs	1	0
	Number of Drug-related SAEs	1	0
	Number of Fatal SAEs	0	0
	Number of Drug-related Fatal SAEs	0	0

Note: Drug-related includes responses of 'Yes' and missing responses to the question 'Is this event related to study treatment?'.
Note: Summary only includes treatment emergent adverse events.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae16_sae.sas 20DEC2022 10:21

Table 3.009110
Summary of Serious Adverse Events by System Organ Class and Preferred Term
(Number of Subjects and Occurrences)

System Organ Class / Preferred Term		Pom/Dex (N=14)	Belantamab mafodotin (N=29)	
Platelet count decreased	Number of Subjects with SAEs	0	1	(3%)
	Number of SAEs	0	1	
	Number of Drug-related SAEs	0	1	
	Number of Fatal SAEs	0	0	
	Number of Drug-related Fatal SAEs	0	0	
Blood and lymphatic system disorders				
Anaemia	Number of Subjects with SAEs	0	1	(3%)
	Number of SAEs	0	1	
	Number of Drug-related SAEs	0	0	
	Number of Fatal SAEs	0	0	
	Number of Drug-related Fatal SAEs	0	0	
Injury, poisoning and procedural complications				
Infusion related reaction	Number of Subjects with SAEs	0	1	(3%)
	Number of SAEs	0	1	
	Number of Drug-related SAEs	0	1	
	Number of Fatal SAEs	0	0	
	Number of Drug-related Fatal SAEs	0	0	

Note: Drug-related includes responses of 'Yes' and missing responses to the question 'Is this event related to study treatment?'.
Note: Summary only includes treatment emergent adverse events.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae16_sae.sas 20DEC2022 10:21

Table 3.009110
Summary of Serious Adverse Events by System Organ Class and Preferred Term
(Number of Subjects and Occurrences)

System Organ Class / Preferred Term		Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Plasma cell myeloma	Number of Subjects with SAEs	0	1 (3%)
	Number of SAEs	0	1
	Number of Drug-related SAEs	0	0
	Number of Fatal SAEs	0	1
	Number of Drug-related Fatal SAEs	0	0
Renal and urinary disorders			
Acute kidney injury	Number of Subjects with SAEs	0	1 (3%)
	Number of SAEs	0	1
	Number of Drug-related SAEs	0	0
	Number of Fatal SAEs	0	0
	Number of Drug-related Fatal SAEs	0	0

Note: Drug-related includes responses of 'Yes' and missing responses to the question 'Is this event related to study treatment?'.
Note: Summary only includes treatment emergent adverse events.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae16_sae.sas 20DEC2022 10:21

Protocol: 207495 Page 1 of 1
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.012110
Summary of Deaths

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Subject Status		
Dead	4 (29%)	16 (55%)
Alive at last contact, follow-up ended	1 (7%)	0
Alive at last contact, follow-up ongoing	9 (64%)	13 (45%)
Primary Cause of Death		
Cancer	2 (14%)	11 (38%)
Equivocally due to disease under study	1 (7%)	5 (17%)
Unequivocally due to disease under study	1 (7%)	6 (21%)
Other cancer	0	0
Cardiac Arrhythmia	0	0
Haemorrhage	0	0
Heart Failure	0	0
Myocardial Infarction	0	0
Other Cardiovascular Cause	0	1 (3%)
Pulmonary Embolism (PE)	0	0
Sepsis	0	0
Stroke	0	0
Suicide	0	0
Trauma	0	0
Other Non-Cardiovascular Cause	2 (14%)	4 (14%)
Unknown	0	0
Time from Last Dose to Death		
<=30 Days	1 (7%)	6 (21%)
>30 Days	3 (21%)	10 (34%)
Unknown	0	0

PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_deaths.sas 21DEC2022 05:40

Protocol: 207495 Page 1 of 1
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.010110
Summary of Adverse Events Leading to Dose Reduction by Preferred Term

Preferred Term	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
ANY EVENT	6 (43%)	5 (17%)
Vision blurred	0	3 (10%)
Dry eye	0	2 (7%)
Muscular weakness	2 (14%)	0
Visual impairment	0	2 (7%)
Cataract	1 (7%)	0
Corneal opacity	0	1 (3%)
Eye irritation	0	1 (3%)
Eye pain	0	1 (3%)
Foreign body sensation in eyes	0	1 (3%)
Hiccups	1 (7%)	0
Insomnia	1 (7%)	0
Lacrimation increased	0	1 (3%)
Photophobia	0	1 (3%)
Pneumonia	1 (7%)	0
Punctate keratitis	0	1 (3%)
Steroid diabetes	1 (7%)	0
Visual acuity reduced	0	1 (3%)

Note: Summary only includes treatment emergent adverse events.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae3_actred.sas 21DEC2022 05:38

Protocol: 207495 Page 1 of 1
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.011110
Summary of Adverse Events Leading to Dose Interruption/Delay by Preferred Term

Preferred Term	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
ANY EVENT	8 (57%)	12 (41%)
COVID-19	3 (21%)	1 (3%)
Neutropenia	3 (21%)	1 (3%)
Vision blurred	0	4 (14%)
Photophobia	0	3 (10%)
Thrombocytopenia	1 (7%)	2 (7%)
Visual impairment	0	3 (10%)
Dry eye	0	2 (7%)
Foreign body sensation in eyes	0	2 (7%)
Neutrophil count decreased	2 (14%)	0
Pneumonia	2 (14%)	0
Acute kidney injury	0	1 (3%)
Arthralgia	0	1 (3%)
Astigmatism	0	1 (3%)
Cataract subcapsular	0	1 (3%)
Colitis	0	1 (3%)
Corneal epithelial microcysts	0	1 (3%)
Corneal opacity	0	1 (3%)
Eye pain	0	1 (3%)
Intraocular pressure increased	0	1 (3%)
Lacrimation increased	0	1 (3%)
Lower respiratory tract infection	1 (7%)	0
Musculoskeletal chest pain	0	1 (3%)
Osteonecrosis of jaw	1 (7%)	0
Pain in jaw	1 (7%)	0
Pathological fracture	0	1 (3%)
Punctate keratitis	0	1 (3%)
Visual acuity reduced	0	1 (3%)

Note: Summary only includes treatment emergent adverse events.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae3_actint.sas 21DEC2022 05:38

Protocol: 207495 Page 1 of 1
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.105110
Summary of AESI by Preferred Term

Preferred Term	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
ANY EVENT	7 (50%)	19 (66%)
Thrombocytopenia	6 (43%)	10 (34%)
Vision blurred	1 (7%)	4 (14%)
Dry eye	0	3 (10%)
Foreign body sensation in eyes	0	3 (10%)
Photophobia	0	3 (10%)
Visual acuity reduced	1 (7%)	2 (7%)
Visual impairment	0	3 (10%)
Chills	0	2 (7%)
Epistaxis	0	2 (7%)
Infusion related reaction	0	2 (7%)
Astigmatism	0	1 (3%)
Corneal epithelial microcysts	0	1 (3%)
Corneal epithelium defect	0	1 (3%)
Corneal opacity	0	1 (3%)
Diplopia	0	1 (3%)
Eye irritation	0	1 (3%)
Eye pain	0	1 (3%)
Eye swelling	0	1 (3%)
Keratitis	0	1 (3%)
Keratopathy	0	1 (3%)
Lacrimation increased	0	1 (3%)
Mouth haemorrhage	0	1 (3%)
Nausea	0	1 (3%)
Platelet count decreased	0	1 (3%)
Punctate keratitis	0	1 (3%)
Pyrexia	0	1 (3%)
Retinal haemorrhage	0	1 (3%)
Stoma site haemorrhage	0	1 (3%)

Note: Summary only includes treatment emergent adverse events.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae3_aesi.sas 17FEB2023 12:39

Protocol: 207495 Page 1 of 1
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.106110
Summary of Corneal Events by Preferred Term

Preferred Term	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
ANY EVENT	2 (14%)	12 (41%)
Vision blurred	1 (7%)	4 (14%)
Dry eye	0	3 (10%)
Foreign body sensation in eyes	0	3 (10%)
Photophobia	0	3 (10%)
Visual acuity reduced	1 (7%)	2 (7%)
Visual impairment	0	3 (10%)
Astigmatism	0	1 (3%)
Corneal epithelial microcysts	0	1 (3%)
Corneal epithelium defect	0	1 (3%)
Corneal opacity	0	1 (3%)
Diplopia	0	1 (3%)
Eye irritation	0	1 (3%)
Eye pain	0	1 (3%)
Eye swelling	0	1 (3%)
Keratitis	0	1 (3%)
Keratopathy	0	1 (3%)
Lacrimation increased	0	1 (3%)
Punctate keratitis	0	1 (3%)

Note: Summary only includes treatment emergent adverse events.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae3_cor.sas 17FEB2023 12:55

Table 3.005110
Summary of Characteristics of Corneal Adverse Events

	Pom/Dex (N=14)		Belantamab mafodotin (N=29)	
Number of Subjects with Event	2	(14%)	12	(41%)
Number of Events	2		51	
Event Characteristics (% based on all subjects) [1]				
Serious	0/14		0/29	
Resulting in hospitalization	0/14		0/29	
Related to study treatment	0/14		12/29	(41%)
Event Characteristics (% based on subjects with the Event) [1]				
Serious	0/ 2		0/12	
Resulting in hospitalization	0/ 2		0/12	
Related to study treatment	0/ 2		12/12	(100%)

[1] Subjects may be included in more than one category for 'Event Characteristics'.
[2] Outcome worst case hierarchy: FATAL > ONGOING > RECOVERING/RESOLVING > RECOVERED/RESOLVED WITH SEQUELAE > RECOVERED/RESOLVED.
[3] Subjects are counted once under each action that was taken.
Note: Corneal Adverse Events are based on a hybrid of terms identified in eCRF, and list of terms identified by GSK internal review.
Note: 'Study treatment related' includes responses of 'Yes' and missing responses to the question 'Is this event related to study treatment?'
Note: Summary only includes treatment emergent adverse events.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_char_cor.sas 06JAN2023 11:31

Table 3.005110
Summary of Characteristics of Corneal Adverse Events

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of occurrences (% based on all subjects)		
One	2/14 (14%)	11/29 (38%)
Two	0/14	1/29 (3%)
Three or more	0/14	0/29
Number of occurrences (% based on subjects with the Event)		
One	2/ 2 (100%)	11/12 (92%)
Two	0/ 2	1/12 (8%)
Three or more	0/ 2	0/12

[1] Subjects may be included in more than one category for 'Event Characteristics'.
[2] Outcome worst case hierarchy: FATAL > ONGOING > RECOVERING/RESOLVING > RECOVERED/RESOLVED WITH SEQUELAE > RECOVERED/RESOLVED.
[3] Subjects are counted once under each action that was taken.
Note: Corneal Adverse Events are based on a hybrid of terms identified in eCRF, and list of terms identified by GSK internal review.
Note: 'Study treatment related' includes responses of 'Yes' and missing responses to the question 'Is this event related to study treatment?'
Note: Summary only includes treatment emergent adverse events.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_char_cor.sas 06JAN2023 11:31

Table 3.005110
Summary of Characteristics of Corneal Adverse Events

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Outcome (% based on all subjects) [2]		
Recovered/Resolved	2/14 (14%)	6/29 (21%)
Recovered/Resolved With Sequelae	0/14	0/29
Recovering/Resolving	0/14	2/29 (7%)
Ongoing	0/14	4/29 (14%)
Fatal	0/14	0/29
Outcome (% based on subjects with the Event) [2]		
Recovered/Resolved	2/ 2 (100%)	6/12 (50%)
Recovered/Resolved With Sequelae	0/ 2	0/12
Recovering/Resolving	0/ 2	2/12 (17%)
Ongoing	0/ 2	4/12 (33%)
Fatal	0/ 2	0/12

[1] Subjects may be included in more than one category for 'Event Characteristics'.
[2] Outcome worst case hierarchy: FATAL > ONGOING > RECOVERING/RESOLVING
> RECOVERED/RESOLVED WITH SEQUELAE > RECOVERED/RESOLVED.
[3] Subjects are counted once under each action that was taken.
Note: Corneal Adverse Events are based on a hybrid of terms identified in eCRF, and list of terms identified by GSK internal review.
Note: 'Study treatment related' includes responses of 'Yes' and missing responses to the question 'Is this event related to study treatment?'
Note: Summary only includes treatment emergent adverse events.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_char_cor.sas 06JAN2023 11:31

Table 3.005110
Summary of Characteristics of Corneal Adverse Events

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Maximum Grade (% based on all subjects)		
Grade 1	2/14 (14%)	5/29 (17%)
Grade 2	0/14	1/29 (3%)
Grade 3	0/14	6/29 (21%)
Grade 4	0/14	0/29
Grade 5	0/14	0/29
Maximum Grade (% based on subjects with the Event)		
Grade 1	2/ 2 (100%)	5/12 (42%)
Grade 2	0/ 2	1/12 (8%)
Grade 3	0/ 2	6/12 (50%)
Grade 4	0/ 2	0/12
Grade 5	0/ 2	0/12

[1] Subjects may be included in more than one category for 'Event Characteristics'.
[2] Outcome worst case hierarchy: FATAL > ONGOING > RECOVERING/RESOLVING > RECOVERED/RESOLVED WITH SEQUELAE > RECOVERED/RESOLVED.
[3] Subjects are counted once under each action that was taken.
Note: Corneal Adverse Events are based on a hybrid of terms identified in eCRF, and list of terms identified by GSK internal review.
Note: 'Study treatment related' includes responses of 'Yes' and missing responses to the question 'Is this event related to study treatment?'
Note: Summary only includes treatment emergent adverse events.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_char_cor.sas 06JAN2023 11:31

Table 3.005110
Summary of Characteristics of Corneal Adverse Events

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Maximum Grade for Events Related to Study Treatment (% based on all subjects)		
Grade 1	0/14	6/29 (21%)
Grade 2	0/14	1/29 (3%)
Grade 3	0/14	5/29 (17%)
Grade 4	0/14	0/29
Grade 5	0/14	0/29
Maximum Grade for Events Related to Study Treatment (% based on subjects with a Study Treatment Related Event)		
Grade 1	0/ 0	6/12 (50%)
Grade 2	0/ 0	1/12 (8%)
Grade 3	0/ 0	5/12 (42%)
Grade 4	0/ 0	0/12
Grade 5	0/ 0	0/12

[1] Subjects may be included in more than one category for 'Event Characteristics'.
[2] Outcome worst case hierarchy: FATAL > ONGOING > RECOVERING/RESOLVING > RECOVERED/RESOLVED WITH SEQUELAE > RECOVERED/RESOLVED.
[3] Subjects are counted once under each action that was taken.
Note: Corneal Adverse Events are based on a hybrid of terms identified in eCRF, and list of terms identified by GSK internal review.
Note: 'Study treatment related' includes responses of 'Yes' and missing responses to the question 'Is this event related to study treatment?'
Note: Summary only includes treatment emergent adverse events.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_char_cor.sas 06JAN2023 11:31

Protocol: 207495 Page 6 of 6
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.005110
Summary of Characteristics of Corneal Adverse Events

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Action Taken (% based on all subjects) [3]		
Drug withdrawn	0/14	1/29 (3%)
Dose reduced	0/14	5/29 (17%)
Dose increased	0/14	0/29
Dose not changed	2/14 (14%)	7/29 (24%)
Dose interrupted/delayed	0/14	7/29 (24%)
Dose reduced or interrupted/delayed	0/14	7/29 (24%)
Infusion interrupted but completed		0/29
Infusion stopped early and not completed		0/29
Not applicable	0/14	0/29
Action Taken (% based on subjects with the Event) [3]		
Drug withdrawn	0/ 2	1/12 (8%)
Dose reduced	0/ 2	5/12 (42%)
Dose increased	0/ 2	0/12
Dose not changed	2/ 2 (100%)	7/12 (58%)
Dose interrupted/delayed	0/ 2	7/12 (58%)
Dose reduced or interrupted/delayed	0/ 2	7/12 (58%)
Infusion interrupted but completed		0/12
Infusion stopped early and not completed		0/12
Not applicable	0/ 2	0/12

[1] Subjects may be included in more than one category for 'Event Characteristics'.
[2] Outcome worst case hierarchy: FATAL > ONGOING > RECOVERING/RESOLVING > RECOVERED/RESOLVED WITH SEQUELAE > RECOVERED/RESOLVED.
[3] Subjects are counted once under each action that was taken.
Note: Corneal Adverse Events are based on a hybrid of terms identified in eCRF, and list of terms identified by GSK internal review.
Note: 'Study treatment related' includes responses of 'Yes' and missing responses to the question 'Is this event related to study treatment?'
Note: Summary only includes treatment emergent adverse events.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_char_cor.sas 06JAN2023 11:31

Protocol: 207495 Page 1 of 2
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.006110
Summary of Characteristics II of Corneal Adverse Events

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Outcome of first occurrence [1]	2	12
Resolved prior to end of treatment exposure	2 (100%)	2 (17%)
With dose delay and reduction	0	0
With dose delay but no reduction	0	0
With dose reduction but no delay	0	0
Without dose delay or reduction	2 (100%)	2 (17%)
Resolved post end of treatment exposure	0	4 (33%)
Ongoing	0	6 (50%)
Not discontinued	0	2 (17%)
Discontinued, follow-up ongoing	0	1 (8%)
Discontinued, follow-up ended	0	3 (25%)
Number of subjects with ongoing Event at the end of treatment exposure, or with event onset post treatment exposure.		
Outcome post treatment exposure [2]	0	10
Resolved	0	4 (40%)
Ongoing, follow-up ongoing	0	3 (30%)
Ongoing, follow-up ended	0	3 (30%)
Time to resolution from event start post treatment exposure, days		
n	0	4
Mean		164.0
SD		118.02
Median		130.0
Min.		64
Max.		332

[1] The duration is defined as time from onset of any corneal adverse event to the first time the subject is free of any such event. It requires at least one day gap between the resolution of all events from first occurrence to the onset of second occurrence.
[2] The end of treatment exposure is defined as last study treatment dose date +20 days.
[3] The lost to follow up refers to those who were under survival follow up but have confirmed not coming back to site for further examination.

PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_char2_cor.sas 10JAN2023 05:14

Table 3.006110
Summary of Characteristics II of Corneal Adverse Events

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Outcome of last event	2	12
Resolved	2 (100%)	6 (50%)
Ongoing, not discontinued	0	2 (17%)
Ongoing, follow-up ongoing	0	1 (8%)
Ongoing, follow-up ended	0	3 (25%)
Time to resolution from event start for subjects who resolved for last event, days		
n	2	6
Mean	79.0	116.5
SD	8.49	117.36
Median	79.0	84.5
Min.	73	21
Max.	85	332
Outcome of last event in subjects who discontinued from study treatment	2	10
Resolved	2 (100%)	6 (60%)
Ongoing, follow-up ongoing	0	1 (10%)
Ongoing, died	0	3 (30%)
Ongoing, withdrawn from study	0	0
Ongoing, lost to follow-up [3]	0	0

[1] The duration is defined as time from onset of any corneal adverse event to the first time the subject is free of any such event. It requires at least one day gap between the resolution of all events from first occurrence to the onset of second occurrence.
[2] The end of treatment exposure is defined as last study treatment dose date +20 days.
[3] The lost to follow up refers to those who were under survival follow up but have confirmed not coming back to site for further examination.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_char2_cor.sas 10JAN2023 05:14

Protocol: 207495 Page 1 of 1
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.007110
Summary of Onset and Duration of the First Occurrence of Corneal Events

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects Experiencing Corneal Adverse Events	2 (14%)	12 (41%)
Time of onset, days		
n	2	12
1-21	0	2 (17%)
22-42	0	7 (58%)
43-63	0	3 (25%)
>63	2 (100%)	0
Mean	104.5	31.0
SD	28.99	15.79
Median	104.5	22.0
Min.	84	15
Max.	125	62
Duration, days		
n	2	6
1-21	0	1 (17%)
22-42	0	1 (17%)
43-63	0	0
64-84	1 (50%)	1 (17%)
85-105	1 (50%)	1 (17%)
>105	0	2 (33%)
Mean	79.0	116.5
SD	8.49	117.36
Median	79.0	84.5
Min.	73	21
Max.	85	332

Note: Corneal Adverse Events are based on a hybrid of terms identified in eCRF, and list of terms identified by GSK internal review.
Note: Time of onset assessed only for those subjects experiencing Corneal Adverse Events.
Note: Summary only includes treatment emergent adverse events.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_onset_cor.sas 10JAN2023 06:09

Protocol: 207495 Page 1 of 1
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.107110
Summary of Thrombocytopenia by Preferred Term

Preferred Term	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
ANY EVENT	6 (43%)	11 (38%)
Thrombocytopenia	6 (43%)	10 (34%)
Epistaxis	0	2 (7%)
Mouth haemorrhage	0	1 (3%)
Platelet count decreased	0	1 (3%)
Retinal haemorrhage	0	1 (3%)
Stoma site haemorrhage	0	1 (3%)

Note: Summary only includes treatment emergent adverse events.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae3_thro.sas 17FEB2023 12:59

Protocol: 207495 Page 1 of 6
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.003110
Summary of Characteristics of Thrombocytopenia

	Pom/Dex (N=14)		Belantamab mafodotin (N=29)	
Number of Subjects with Event	6	(43%)	11	(38%)
Number of Events	12		17	
Event Characteristics (% based on all subjects) [1]				
Serious	0/14		1/29	(3%)
Resulting in hospitalization	0/14		1/29	(3%)
Related to study treatment	5/14	(36%)	7/29	(24%)
Event Characteristics (% based on subjects with the Event) [1]				
Serious	0/ 6		1/11	(9%)
Resulting in hospitalization	0/ 6		1/11	(9%)
Related to study treatment	5/ 6	(83%)	7/11	(64%)

[1] Subjects may be included in more than one category for 'Event Characteristics'.
[2] Outcome worst case hierarchy: FATAL > ONGOING > RECOVERING/RESOLVING > RECOVERED/RESOLVED WITH SEQUELAE > RECOVERED/RESOLVED.
[3] Subjects are counted once under each action that was taken.
Note: Thrombocytopenia is based on a hybrid of terms identified in eCRF, and list of terms identified by GSK internal review.
Note: 'Study treatment related' includes responses of 'Yes' and missing responses to the question 'Is this event related to study treatment?'
Note: Summary only includes treatment emergent adverse events.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_char_thro.sas 06JAN2023 11:30

Table 3.003110
Summary of Characteristics of Thrombocytopenia

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of occurrences (% based on all subjects)		
One	2/14 (14%)	11/29 (38%)
Two	2/14 (14%)	0/29
Three or more	2/14 (14%)	0/29
Number of occurrences (% based on subjects with the Event)		
One	2/ 6 (33%)	11/11 (100%)
Two	2/ 6 (33%)	0/11
Three or more	2/ 6 (33%)	0/11

[1] Subjects may be included in more than one category for 'Event Characteristics'.
[2] Outcome worst case hierarchy: FATAL > ONGOING > RECOVERING/RESOLVING > RECOVERED/RESOLVED WITH SEQUELAE > RECOVERED/RESOLVED.
[3] Subjects are counted once under each action that was taken.
Note: Thrombocytopenia is based on a hybrid of terms identified in eCRF, and list of terms identified by GSK internal review.
Note: 'Study treatment related' includes responses of 'Yes' and missing responses to the question 'Is this event related to study treatment?'
Note: Summary only includes treatment emergent adverse events.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_char_thro.sas 06JAN2023 11:30

Table 3.003110
Summary of Characteristics of Thrombocytopenia

	Pom/Dex (N=14)		Belantamab mafodotin (N=29)	
Outcome (% based on all subjects) [2]				
Recovered/Resolved	4/14	(29%)	4/29	(14%)
Recovered/Resolved With Sequelae	0/14		0/29	
Recovering/Resolving	1/14	(7%)	0/29	
Ongoing	1/14	(7%)	7/29	(24%)
Fatal	0/14		0/29	
Outcome (% based on subjects with the Event) [2]				
Recovered/Resolved	4/ 6	(67%)	4/11	(36%)
Recovered/Resolved With Sequelae	0/ 6		0/11	
Recovering/Resolving	1/ 6	(17%)	0/11	
Ongoing	1/ 6	(17%)	7/11	(64%)
Fatal	0/ 6		0/11	

[1] Subjects may be included in more than one category for 'Event Characteristics'.
[2] Outcome worst case hierarchy: FATAL > ONGOING > RECOVERING/RESOLVING > RECOVERED/RESOLVED WITH SEQUELAE > RECOVERED/RESOLVED.
[3] Subjects are counted once under each action that was taken.
Note: Thrombocytopenia is based on a hybrid of terms identified in eCRF, and list of terms identified by GSK internal review.
Note: 'Study treatment related' includes responses of 'Yes' and missing responses to the question 'Is this event related to study treatment?'
Note: Summary only includes treatment emergent adverse events.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_char_thro.sas 06JAN2023 11:30

Table 3.003110
Summary of Characteristics of Thrombocytopenia

	Pom/Dex (N=14)		Belantamab mafodotin (N=29)	
Maximum Grade (% based on all subjects)				
Grade 1	3/14	(21%)	1/29	(3%)
Grade 2	1/14	(7%)	2/29	(7%)
Grade 3	0/14		2/29	(7%)
Grade 4	2/14	(14%)	6/29	(21%)
Grade 5	0/14		0/29	
Maximum Grade (% based on subjects with the Event)				
Grade 1	3/ 6	(50%)	1/11	(9%)
Grade 2	1/ 6	(17%)	2/11	(18%)
Grade 3	0/ 6		2/11	(18%)
Grade 4	2/ 6	(33%)	6/11	(55%)
Grade 5	0/ 6		0/11	

[1] Subjects may be included in more than one category for 'Event Characteristics'.
[2] Outcome worst case hierarchy: FATAL > ONGOING > RECOVERING/RESOLVING > RECOVERED/RESOLVED WITH SEQUELAE > RECOVERED/RESOLVED.
[3] Subjects are counted once under each action that was taken.
Note: Thrombocytopenia is based on a hybrid of terms identified in eCRF, and list of terms identified by GSK internal review.
Note: 'Study treatment related' includes responses of 'Yes' and missing responses to the question 'Is this event related to study treatment?'
Note: Summary only includes treatment emergent adverse events.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_char_thro.sas 06JAN2023 11:30

Table 3.003110
Summary of Characteristics of Thrombocytopenia

	Pom/Dex (N=14)		Belantamab mafodotin (N=29)	
Maximum Grade for Events Related to Study Treatment (% based on all subjects)				
Grade 1	3/14	(21%)	0/29	
Grade 2	1/14	(7%)	1/29	(3%)
Grade 3	0/14		1/29	(3%)
Grade 4	1/14	(7%)	5/29	(17%)
Grade 5	0/14		0/29	
Maximum Grade for Events Related to Study Treatment (% based on subjects with a Study Treatment Related Event)				
Grade 1	3/ 5	(60%)	0/ 7	
Grade 2	1/ 5	(20%)	1/ 7	(14%)
Grade 3	0/ 5		1/ 7	(14%)
Grade 4	1/ 5	(20%)	5/ 7	(71%)
Grade 5	0/ 5		0/ 7	

[1] Subjects may be included in more than one category for 'Event Characteristics'.
[2] Outcome worst case hierarchy: FATAL > ONGOING > RECOVERING/RESOLVING > RECOVERED/RESOLVED WITH SEQUELAE > RECOVERED/RESOLVED.
[3] Subjects are counted once under each action that was taken.
Note: Thrombocytopenia is based on a hybrid of terms identified in eCRF, and list of terms identified by GSK internal review.
Note: 'Study treatment related' includes responses of 'Yes' and missing responses to the question 'Is this event related to study treatment?'
Note: Summary only includes treatment emergent adverse events.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_char_thro.sas 06JAN2023 11:30

Protocol: 207495 Page 6 of 6
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.003110
Summary of Characteristics of Thrombocytopenia

	Pom/Dex (N=14)		Belantamab mafodotin (N=29)	
Action Taken (% based on all subjects) [3]				
Drug withdrawn	0/14		0/29	
Dose reduced	0/14		0/29	
Dose increased	0/14		0/29	
Dose not changed	6/14	(43%)	9/29	(31%)
Dose interrupted/delayed	1/14	(7%)	2/29	(7%)
Dose reduced or interrupted/delayed	1/14	(7%)	2/29	(7%)
Infusion interrupted but completed			0/29	
Infusion stopped early and not completed			0/29	
Not applicable	0/14		1/29	(3%)
Action Taken (% based on subjects with the Event) [3]				
Drug withdrawn	0/ 6		0/11	
Dose reduced	0/ 6		0/11	
Dose increased	0/ 6		0/11	
Dose not changed	6/ 6	(100%)	9/11	(82%)
Dose interrupted/delayed	1/ 6	(17%)	2/11	(18%)
Dose reduced or interrupted/delayed	1/ 6	(17%)	2/11	(18%)
Infusion interrupted but completed			0/11	
Infusion stopped early and not completed			0/11	
Not applicable	0/ 6		1/11	(9%)

[1] Subjects may be included in more than one category for 'Event Characteristics'.
[2] Outcome worst case hierarchy: FATAL > ONGOING > RECOVERING/RESOLVING > RECOVERED/RESOLVED WITH SEQUELAE > RECOVERED/RESOLVED.
[3] Subjects are counted once under each action that was taken.
Note: Thrombocytopenia is based on a hybrid of terms identified in eCRF, and list of terms identified by GSK internal review.
Note: 'Study treatment related' includes responses of 'Yes' and missing responses to the question 'Is this event related to study treatment?'
Note: Summary only includes treatment emergent adverse events.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_char_thro.sas 06JAN2023 11:30

Protocol: 207495 Page 1 of 1
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.108110
Summary of Infusion-Related Reactions by Preferred Term

Preferred Term	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
ANY EVENT	0	4 (14%)
Chills	0	2 (7%)
Infusion related reaction	0	2 (7%)
Nausea	0	1 (3%)
Pyrexia	0	1 (3%)

Note: Summary only includes treatment emergent adverse events.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae3_irr.sas 17FEB2023 13:00

Table 3.004110
Summary of Characteristics of Infusion-Related Reactions

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)	
Number of Subjects with Event	0	4	(14%)
Number of Events	0	7	
Event Characteristics (% based on all subjects) [1]			
Serious	0/14	1/29	(3%)
Resulting in hospitalization	0/14	1/29	(3%)
Related to study treatment	0/14	4/29	(14%)
Event Characteristics (% based on subjects with the Event) [1]			
Serious	0/ 0	1/ 4	(25%)
Resulting in hospitalization	0/ 0	1/ 4	(25%)
Related to study treatment	0/ 0	4/ 4	(100%)

[1] Subjects may be included in more than one category for 'Event Characteristics'.
[2] Outcome worst case hierarchy: FATAL > ONGOING > RECOVERING/RESOLVING > RECOVERED/RESOLVED WITH SEQUELAE > RECOVERED/RESOLVED.
[3] Subjects are counted once under each action that was taken.
Note: Infusion-Related Reactions are based on a hybrid of terms identified in eCRF, and list of terms identified by GSK internal review and start within 24 hours of infusion.
Note: 'Study treatment related' includes responses of 'Yes' and missing responses to the question 'Is this event related to study treatment?'
Note: Summary only includes treatment emergent adverse events.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_char_irr.sas 06JAN2023 11:31

Table 3.004110
Summary of Characteristics of Infusion-Related Reactions

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of occurrences (% based on all subjects)		
One	0/14	3/29 (10%)
Two	0/14	1/29 (3%)
Three or more	0/14	0/29
Number of occurrences (% based on subjects with the Event)		
One	0/ 0	3/ 4 (75%)
Two	0/ 0	1/ 4 (25%)
Three or more	0/ 0	0/ 4

[1] Subjects may be included in more than one category for 'Event Characteristics'.
[2] Outcome worst case hierarchy: FATAL > ONGOING > RECOVERING/RESOLVING > RECOVERED/RESOLVED WITH SEQUELAE > RECOVERED/RESOLVED.
[3] Subjects are counted once under each action that was taken.
Note: Infusion-Related Reactions are based on a hybrid of terms identified in eCRF, and list of terms identified by GSK internal review and start within 24 hours of infusion.
Note: 'Study treatment related' includes responses of 'Yes' and missing responses to the question 'Is this event related to study treatment?'
Note: Summary only includes treatment emergent adverse events.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_char_irr.sas 06JAN2023 11:31

Table 3.004110
Summary of Characteristics of Infusion-Related Reactions

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Outcome (% based on all subjects) [2]		
Recovered/Resolved	0/14	3/29 (10%)
Recovered/Resolved With Sequelae	0/14	1/29 (3%)
Recovering/Resolving	0/14	0/29
Ongoing	0/14	0/29
Fatal	0/14	0/29
Outcome (% based on subjects with the Event) [2]		
Recovered/Resolved	0/ 0	3/ 4 (75%)
Recovered/Resolved With Sequelae	0/ 0	1/ 4 (25%)
Recovering/Resolving	0/ 0	0/ 4
Ongoing	0/ 0	0/ 4
Fatal	0/ 0	0/ 4

[1] Subjects may be included in more than one category for 'Event Characteristics'.
[2] Outcome worst case hierarchy: FATAL > ONGOING > RECOVERING/RESOLVING
> RECOVERED/RESOLVED WITH SEQUELAE > RECOVERED/RESOLVED.
[3] Subjects are counted once under each action that was taken.
Note: Infusion-Related Reactions are based on a hybrid of terms identified in eCRF, and list of terms identified by GSK internal review and start within 24 hours of infusion.
Note: 'Study treatment related' includes responses of 'Yes' and missing responses to the question 'Is this event related to study treatment?'
Note: Summary only includes treatment emergent adverse events.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_char_irr.sas 06JAN2023 11:31

Table 3.004110
Summary of Characteristics of Infusion-Related Reactions

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Maximum Grade (% based on all subjects)		
Grade 1	0/14	3/29 (10%)
Grade 2	0/14	0/29
Grade 3	0/14	1/29 (3%)
Grade 4	0/14	0/29
Grade 5	0/14	0/29
Maximum Grade (% based on subjects with the Event)		
Grade 1	0/ 0	3/ 4 (75%)
Grade 2	0/ 0	0/ 4
Grade 3	0/ 0	1/ 4 (25%)
Grade 4	0/ 0	0/ 4
Grade 5	0/ 0	0/ 4

[1] Subjects may be included in more than one category for 'Event Characteristics'.
[2] Outcome worst case hierarchy: FATAL > ONGOING > RECOVERING/RESOLVING
> RECOVERED/RESOLVED WITH SEQUELAE > RECOVERED/RESOLVED.
[3] Subjects are counted once under each action that was taken.
Note: Infusion-Related Reactions are based on a hybrid of terms identified in eCRF, and list of terms identified by GSK internal review and start within 24 hours of infusion.
Note: 'Study treatment related' includes responses of 'Yes' and missing responses to the question 'Is this event related to study treatment?'
Note: Summary only includes treatment emergent adverse events.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_char_irr.sas 06JAN2023 11:31

Table 3.004110
Summary of Characteristics of Infusion-Related Reactions

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Maximum Grade for Events Related to Study Treatment (% based on all subjects)		
Grade 1	0/14	3/29 (10%)
Grade 2	0/14	0/29
Grade 3	0/14	1/29 (3%)
Grade 4	0/14	0/29
Grade 5	0/14	0/29
Maximum Grade for Events Related to Study Treatment (% based on subjects with a Study Treatment Related Event)		
Grade 1	0/ 0	3/ 4 (75%)
Grade 2	0/ 0	0/ 4
Grade 3	0/ 0	1/ 4 (25%)
Grade 4	0/ 0	0/ 4
Grade 5	0/ 0	0/ 4

[1] Subjects may be included in more than one category for 'Event Characteristics'.
[2] Outcome worst case hierarchy: FATAL > ONGOING > RECOVERING/RESOLVING > RECOVERED/RESOLVED WITH SEQUELAE > RECOVERED/RESOLVED.
[3] Subjects are counted once under each action that was taken.
Note: Infusion-Related Reactions are based on a hybrid of terms identified in eCRF, and list of terms identified by GSK internal review and start within 24 hours of infusion.
Note: 'Study treatment related' includes responses of 'Yes' and missing responses to the question 'Is this event related to study treatment?'
Note: Summary only includes treatment emergent adverse events.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_char_irr.sas 06JAN2023 11:31

Protocol: 207495 Page 6 of 6
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.004110
Summary of Characteristics of Infusion-Related Reactions

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Action Taken (% based on all subjects) [3]		
Drug withdrawn	0/14	0/29
Dose reduced	0/14	0/29
Dose increased	0/14	0/29
Dose not changed	0/14	4/29 (14%)
Dose interrupted/delayed	0/14	0/29
Dose reduced or interrupted/delayed	0/14	0/29
Infusion interrupted but completed		0/29
Infusion stopped early and not completed		0/29
Not applicable	0/14	0/29
Action Taken (% based on subjects with the Event) [3]		
Drug withdrawn	0/ 0	0/ 4
Dose reduced	0/ 0	0/ 4
Dose increased	0/ 0	0/ 4
Dose not changed	0/ 0	4/ 4 (100%)
Dose interrupted/delayed	0/ 0	0/ 4
Dose reduced or interrupted/delayed	0/ 0	0/ 4
Infusion interrupted but completed		0/ 4
Infusion stopped early and not completed		0/ 4
Not applicable	0/ 0	0/ 4

[1] Subjects may be included in more than one category for 'Event Characteristics'.
[2] Outcome worst case hierarchy: FATAL > ONGOING > RECOVERING/RESOLVING > RECOVERED/RESOLVED WITH SEQUELAE > RECOVERED/RESOLVED.
[3] Subjects are counted once under each action that was taken.
Note: Infusion-Related Reactions are based on a hybrid of terms identified in eCRF, and list of terms identified by GSK internal review and start within 24 hours of infusion.
Note: 'Study treatment related' includes responses of 'Yes' and missing responses to the question 'Is this event related to study treatment?'
Note: Summary only includes treatment emergent adverse events.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_char_irr.sas 06JAN2023 11:31

Protocol: 207495 Page 1 of 1
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.035110
Adverse Event Summary

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	13 (93%)	28 (97%)
OR (95% CI) [1] vs. Pom/Dex		2.15 (0.12, 37.19)
P-value [1]		0.5976
RR (95% CI) vs. Pom/Dex		1.04 (0.89, 1.22)
ARD (95% CI) vs. Pom/Dex		0.04 (-0.11, 0.19)
P-value [2]		>0.9999

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes treatment emergent adverse events.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae_summ.sas 03FEB2023 07:06

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.038110
Time to First Adverse Event

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	13 (93%)	28 (97%)
Censored	1 (7%)	1 (3%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	0.1 (0.1, 0.5)	0.2 (0.1, 0.3)
Median (95% CI)	0.6 (0.1, 1.4)	0.6 (0.2, 0.8)
3rd Quartile (95% CI)	1.4 (0.5, -)	1.1 (0.7, 5.3)
Log-Rank P-value [2]		0.9971
Hazard Ratio (95% CI) [3]		0.99 (0.51, 1.93)
P-value [3]		0.9851

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte_ae.sas 09FEB2023 06:24

Protocol: 207495 Page 1 of 1
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.053110
Adverse Event Summary of Max Grade 3 or higher

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	12 (86%)	20 (69%)
OR (95% CI) [1] vs. Pom/Dex		0.37 (0.07, 2.01)
P-value [1]		0.2497
RR (95% CI) vs. Pom/Dex		0.80 (0.58, 1.11)
ARD (95% CI) vs. Pom/Dex		-0.17 (-0.42, 0.08)
P-value [2]		0.2914

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes treatment emergent adverse events.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae_mg3.sas 03FEB2023 07:16

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.056110
Time to First Adverse Event of Max Grade 3 or higher

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	12 (86%)	20 (69%)
Censored	2 (14%)	9 (31%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	0.7 (0.1, 0.8)	0.5 (0.2, 0.7)
Median (95% CI)	0.9 (0.7, 3.5)	1.1 (0.6, 4.0)
3rd Quartile (95% CI)	3.5 (0.8, 8.2)	- (1.4, -)
Log-Rank P-value [2]		0.7634
Hazard Ratio (95% CI) [3]		0.90 (0.44, 1.85)
P-value [3]		0.7736

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte_ae_gr3.sas 09FEB2023 06:24

Protocol: 207495 Page 1 of 1
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.059110
Adverse Event Summary of Serious AEs

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	5 (36%)	13 (45%)
OR (95% CI) [1] vs. Pom/Dex		1.46 (0.39, 5.45)
P-value [1]		0.5712
RR (95% CI) vs. Pom/Dex		1.26 (0.56, 2.82)
ARD (95% CI) vs. Pom/Dex		0.09 (-0.22, 0.40)
P-value [2]		0.7438

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes treatment emergent adverse events.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_aes_summ.sas 03FEB2023 08:31

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.062110
Time to First Serious Adverse Event

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	5 (36%)	13 (45%)
Censored	9 (64%)	16 (55%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	8.2 (0.5, 19.5)	0.8 (0.3, 4.0)
Median (95% CI)	19.5 (5.5, -)	4.1 (0.9, -)
3rd Quartile (95% CI)	- (19.5, -)	- (4.1, -)
Log-Rank P-value [2]		0.1402
Hazard Ratio (95% CI) [3]		2.18 (0.76, 6.29)
P-value [3]		0.1479

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte_ae_ser.sas 09FEB2023 06:24

Protocol: 207495 Page 1 of 1
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.041110
Fatal Adverse Event Summary

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	1 (7%)	2 (7%)
OR (95% CI) [1] vs. Pom/Dex		0.96 (0.08, 11.61)
P-value [1]		0.9762
RR (95% CI) vs. Pom/Dex		0.97 (0.10, 9.77)
ARD (95% CI) vs. Pom/Dex		0.00 (-0.17, 0.16)
P-value [2]		>0.9999

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes treatment emergent adverse events.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_aef_summ.sas 14FEB2023 03:40

Protocol: 207495 Page 1 of 1
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.044110
Time to Fatal Adverse Event

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	1 (7%)	2 (7%)
Censored	13 (93%)	27 (93%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (0.5, -)	- (0.9, -)
Median (95% CI)	- (-, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		0.9606
Hazard Ratio (95% CI) [3]		0.94 (0.09, 10.38)
P-value [3]		0.9606

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte_aef.sas 14FEB2023 03:40

Protocol: 207495 Page 1 of 1
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.047110
Adverse Event Leading to Discontinuation of Study Treatment Summary

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	2 (14%)	1 (3%)
OR (95% CI) [1] vs. Pom/Dex		0.21 (0.02, 2.59)
P-value [1]		0.2260
RR (95% CI) vs. Pom/Dex		0.24 (0.02, 2.44)
ARD (95% CI) vs. Pom/Dex		-0.11 (-0.30, 0.09)
P-value [2]		0.2433

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes treatment emergent adverse events.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_aed_summ.sas 03FEB2023 07:12

Protocol: 207495 Page 1 of 1
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.050110
Time to first Adverse Event Leading to Discontinuation of Study Treatment

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	2 (14%)	1 (3%)
Censored	12 (86%)	28 (97%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (0.5, -)	- (-, -)
Median (95% CI)	- (8.2, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		0.3169
Hazard Ratio (95% CI) [3]		0.31 (0.03, 3.52)
P-value [3]		0.3416

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte_ae_dis.sas 09FEB2023 06:24

Protocol: 207495 Page 1 of 1
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.012112
Adverse Events Leading to Dose Reduction Summary

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	6 (43%)	5 (17%)
OR (95% CI) [1] vs. Pom/Dex		0.28 (0.07, 1.16)
P-value [1]		0.0794
RR (95% CI) vs. Pom/Dex		0.40 (0.15, 1.09)
ARD (95% CI) vs. Pom/Dex		-0.26 (-0.55, 0.04)
P-value [2]		0.1330

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes treatment emergent adverse events.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae_dosred.sas 20MAR2023 05:39

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.014112
Time to First Adverse Event Leading to Dose Reduction

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	6 (43%)	5 (17%)
Censored	8 (57%)	24 (83%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	2.8 (0.7, 18.4)	9.5 (0.8, -)
Median (95% CI)	18.4 (0.9, 18.4)	- (4.8, -)
3rd Quartile (95% CI)	18.4 (-, -)	- (9.5, -)
Log-Rank P-value [2]		0.2809
Hazard Ratio (95% CI) [3]		0.52 (0.16, 1.73)
P-value [3]		0.2882

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte_ae_dosred.sas 20MAR2023 05:19

Table 3.013112
Adverse Events Leading to Dose Interruption/Delay Summary

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	8 (57%)	12 (41%)
OR (95% CI) [1] vs. Pom/Dex		0.53 (0.15, 1.93)
P-value [1]		0.3342
RR (95% CI) vs. Pom/Dex		0.72 (0.39, 1.36)
ARD (95% CI) vs. Pom/Dex		-0.16 (-0.47, 0.16)
P-value [2]		0.5151

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes treatment emergent adverse events.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae_dosdel.sas 20MAR2023 06:04

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.015112
Time to First Adverse Event Leading to Dose Interruption/Delay

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	8 (57%)	12 (41%)
Censored	6 (43%)	17 (59%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	2.3 (0.5, 8.8)	0.9 (0.7, 2.1)
Median (95% CI)	8.8 (1.7, 13.1)	22.0 (1.4, 22.0)
3rd Quartile (95% CI)	13.1 (8.8, 13.1)	22.0 (-, -)
Log-Rank P-value [2]		0.9655
Hazard Ratio (95% CI) [3]		1.03 (0.41, 2.61)
P-value [3]		0.9528

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte_ae_dosdel.sas 20MAR2023 05:20

Table 3.036110
Adverse Event Summary by SOC

System Organ Class: Blood and lymphatic system disorders

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	7 (50%)	14 (48%)
OR (95% CI) [1] vs. Pom/Dex		0.93 (0.26, 3.34)
P-value [1]		0.9156
RR (95% CI) vs. Pom/Dex		0.97 (0.51, 1.84)
ARD (95% CI) vs. Pom/Dex		−0.02 (−0.34, 0.30)
P-value [2]		>0.9999

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes treatment emergent adverse events for SOCs occurring in [at least 10% of patients] in any treatment arm OR in [at least 10 patients AND at least 1% of patients] in any treatment arm.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae_summ_soc.sas 10FEB2023 06:39

Table 3.036110
Adverse Event Summary by SOC

System Organ Class: Eye disorders

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	5 (36%)	15 (52%)
OR (95% CI) [1] vs. Pom/Dex		1.93 (0.52, 7.17)
P-value [1]		0.3271
RR (95% CI) vs. Pom/Dex		1.45 (0.66, 3.18)
ARD (95% CI) vs. Pom/Dex		0.16 (-0.15, 0.47)
P-value [2]		0.3528

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes treatment emergent adverse events for SOCs occurring in [at least 10% of patients] in any treatment arm OR in [at least 10 patients AND at least 1% of patients] in any treatment arm.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae_summ_soc.sas 10FEB2023 06:39

Table 3.036110
Adverse Event Summary by SOC

System Organ Class: Gastrointestinal disorders

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	5 (36%)	11 (38%)
OR (95% CI) [1] vs. Pom/Dex		1.10 (0.29, 4.14)
P-value [1]		0.8879
RR (95% CI) vs. Pom/Dex		1.06 (0.46, 2.47)
ARD (95% CI) vs. Pom/Dex		0.02 (-0.28, 0.33)
P-value [2]		>0.9999

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes treatment emergent adverse events for SOCs occurring in [at least 10% of patients] in any treatment arm OR in [at least 10 patients AND at least 1% of patients] in any treatment arm.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae_summ_soc.sas 10FEB2023 06:39

Table 3.036110
Adverse Event Summary by SOC

System Organ Class: General disorders and administration site conditions

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	7 (50%)	4 (14%)
OR (95% CI) [1] vs. Pom/Dex		0.16 (0.04, 0.71)
P-value [1]		0.0157
RR (95% CI) vs. Pom/Dex		0.28 (0.10, 0.79)
ARD (95% CI) vs. Pom/Dex		-0.36 (-0.65, -0.07)
P-value [2]		0.0222

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes treatment emergent adverse events for SOCs occurring in [at least 10% of patients] in any treatment arm OR in [at least 10 patients AND at least 1% of patients] in any treatment arm.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae_summ_soc.sas 10FEB2023 06:39

Table 3.036110
Adverse Event Summary by SOC

System Organ Class: Infections and infestations

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	9 (64%)	11 (38%)
OR (95% CI) [1] vs. Pom/Dex		0.34 (0.09, 1.28)
P-value [1]		0.1103
RR (95% CI) vs. Pom/Dex		0.59 (0.32, 1.08)
ARD (95% CI) vs. Pom/Dex		-0.26 (-0.57, 0.04)
P-value [2]		0.1912

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes treatment emergent adverse events for SOCs occurring in [at least 10% of patients] in any treatment arm OR in [at least 10 patients AND at least 1% of patients] in any treatment arm.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae_summ_soc.sas 10FEB2023 06:39

Table 3.036110
Adverse Event Summary by SOC

System Organ Class: Injury, poisoning and procedural complications

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	2 (14%)	4 (14%)
OR (95% CI) [1] vs. Pom/Dex		0.96 (0.15, 5.99)
P-value [1]		0.9650
RR (95% CI) vs. Pom/Dex		0.97 (0.20, 4.65)
ARD (95% CI) vs. Pom/Dex		0.00 (-0.23, 0.22)
P-value [2]		>0.9999

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes treatment emergent adverse events for SOCs occurring in [at least 10% of patients] in any treatment arm OR in [at least 10 patients AND at least 1% of patients] in any treatment arm.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae_summ_soc.sas 10FEB2023 06:39

Table 3.036110
Adverse Event Summary by SOC

System Organ Class: Investigations

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	7 (50%)	11 (38%)
OR (95% CI) [1] vs. Pom/Dex		0.61 (0.17, 2.22)
P-value [1]		0.4538
RR (95% CI) vs. Pom/Dex		0.76 (0.38, 1.53)
ARD (95% CI) vs. Pom/Dex		-0.12 (-0.44, 0.20)
P-value [2]		0.5205

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes treatment emergent adverse events for SOCs occurring in [at least 10% of patients] in any treatment arm OR in [at least 10 patients AND at least 1% of patients] in any treatment arm.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae_summ_soc.sas 10FEB2023 06:39

Table 3.036110
Adverse Event Summary by SOC

System Organ Class: Metabolism and nutrition disorders

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	3 (21%)	8 (28%)
OR (95% CI) [1] vs. Pom/Dex		1.40 (0.31, 6.35)
P-value [1]		0.6654
RR (95% CI) vs. Pom/Dex		1.29 (0.40, 4.12)
ARD (95% CI) vs. Pom/Dex		0.06 (-0.21, 0.33)
P-value [2]		>0.9999

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes treatment emergent adverse events for SOCs occurring in [at least 10% of patients] in any treatment arm OR in [at least 10 patients AND at least 1% of patients] in any treatment arm.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae_summ_soc.sas 10FEB2023 06:39

Table 3.036110
Adverse Event Summary by SOC

System Organ Class: Musculoskeletal and connective tissue disorders

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	7 (50%)	9 (31%)
OR (95% CI) [1] vs. Pom/Dex		0.45 (0.12, 1.67)
P-value [1]		0.2323
RR (95% CI) vs. Pom/Dex		0.62 (0.29, 1.32)
ARD (95% CI) vs. Pom/Dex		-0.19 (-0.50, 0.12)
P-value [2]		0.3161

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes treatment emergent adverse events for SOCs occurring in [at least 10% of patients] in any treatment arm OR in [at least 10 patients AND at least 1% of patients] in any treatment arm.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae_summ_soc.sas 10FEB2023 06:39

Table 3.036110
Adverse Event Summary by SOC

System Organ Class: Nervous system disorders

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	4 (29%)	3 (10%)
OR (95% CI) [1] vs. Pom/Dex		0.29 (0.05, 1.52)
P-value [1]		0.1434
RR (95% CI) vs. Pom/Dex		0.36 (0.09, 1.40)
ARD (95% CI) vs. Pom/Dex		−0.18 (−0.44, 0.08)
P-value [2]		0.1900

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes treatment emergent adverse events for SOCs occurring in [at least 10% of patients] in any treatment arm OR in [at least 10 patients AND at least 1% of patients] in any treatment arm.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae_summ_soc.sas 10FEB2023 06:39

Table 3.036110
Adverse Event Summary by SOC

System Organ Class: Renal and urinary disorders

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	1 (7%)	3 (10%)
OR (95% CI) [1] vs. Pom/Dex		1.50 (0.14, 15.87)
P-value [1]		0.7362
RR (95% CI) vs. Pom/Dex		1.45 (0.17, 12.70)
ARD (95% CI) vs. Pom/Dex		0.03 (-0.14, 0.21)
P-value [2]		>0.9999

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes treatment emergent adverse events for SOCs occurring in [at least 10% of patients] in any treatment arm OR in [at least 10 patients AND at least 1% of patients] in any treatment arm.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae_summ_soc.sas 10FEB2023 06:39

Table 3.036110
Adverse Event Summary by SOC

System Organ Class: Respiratory, thoracic and mediastinal disorders

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	4 (29%)	3 (10%)
OR (95% CI) [1] vs. Pom/Dex		0.29 (0.05, 1.52)
P-value [1]		0.1434
RR (95% CI) vs. Pom/Dex		0.36 (0.09, 1.40)
ARD (95% CI) vs. Pom/Dex		−0.18 (−0.44, 0.08)
P-value [2]		0.1900

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes treatment emergent adverse events for SOCs occurring in [at least 10% of patients] in any treatment arm OR in [at least 10 patients AND at least 1% of patients] in any treatment arm.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae_summ_soc.sas 10FEB2023 06:39

Table 3.036110
Adverse Event Summary by SOC

System Organ Class: Skin and subcutaneous tissue disorders

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	3 (21%)	0
OR (95% CI) [1] vs. Pom/Dex		<0.01 (<0.01, >999.99)
P-value [1]		0.9437
RR (95% CI) vs. Pom/Dex		0.07 (0.00, 1.30)
ARD (95% CI) vs. Pom/Dex		−0.22 (−0.44, 0.00)
P-value [2]		0.0295

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes treatment emergent adverse events for SOCs occurring in [at least 10% of patients] in any treatment arm OR in [at least 10 patients AND at least 1% of patients] in any treatment arm.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae_summ_soc.sas 10FEB2023 06:39

Protocol: 207495 Page 1 of 13
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.039110
Time to First Adverse Event by SOC

System Organ Class: Blood and lymphatic system disorders

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	7 (50%)	14 (48%)
Censored	7 (50%)	15 (52%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	0.8 (0.1, 4.7)	1.0 (0.2, 2.7)
Median (95% CI)	4.7 (0.7, -)	5.3 (1.1, -)
3rd Quartile (95% CI)	- (4.7, -)	- (5.3, -)
Log-Rank P-value [2]		0.8932
Hazard Ratio (95% CI) [3]		1.06 (0.42, 2.67)
P-value [3]		0.8933

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
Note: If zero events in at least one treatment arm then hazard ratio and p-values not calculated.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte2_ae_soc.sas 09FEB2023 04:04

Table 3.039110
Time to First Adverse Event by SOC

System Organ Class: Eye disorders

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	5 (36%)	15 (52%)
Censored	9 (64%)	14 (48%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	4.1 (0.7, -)	1.0 (0.7, 2.0)
Median (95% CI)	- (3.0, -)	2.1 (1.0, -)
3rd Quartile (95% CI)	- (-, -)	- (2.1, -)
Log-Rank P-value [2]		0.0464
Hazard Ratio (95% CI) [3]		2.80 (0.98, 8.01)
P-value [3]		0.0556

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
Note: If zero events in at least one treatment arm then hazard ratio and p-values not calculated.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte2_ae_soc.sas 09FEB2023 04:04

Protocol: 207495 Page 3 of 13
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.039110
Time to First Adverse Event by SOC

System Organ Class: Gastrointestinal disorders

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	5 (36%)	11 (38%)
Censored	9 (64%)	18 (62%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	2.7 (0.3, -)	1.7 (0.2, 2.6)
Median (95% CI)	- (1.8, -)	- (1.7, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		0.5136
Hazard Ratio (95% CI) [3]		1.42 (0.49, 4.13)
P-value [3]		0.5156

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
Note: If zero events in at least one treatment arm then hazard ratio and p-values not calculated.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte2_ae_soc.sas 09FEB2023 04:04

Protocol: 207495 Page 4 of 13
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.039110
Time to First Adverse Event by SOC

System Organ Class: General disorders and administration site conditions

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	7 (50%)	4 (14%)
Censored	7 (50%)	25 (86%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	2.8 (0.1, 6.2)	- (0.3, -)
Median (95% CI)	6.2 (0.8, -)	- (-, -)
3rd Quartile (95% CI)	- (4.8, -)	- (-, -)
Log-Rank P-value [2]		0.0567
Hazard Ratio (95% CI) [3]		0.32 (0.09, 1.10)
P-value [3]		0.0706

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
Note: If zero events in at least one treatment arm then hazard ratio and p-values not calculated.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte2_ae_soc.sas 09FEB2023 04:04

Protocol: 207495 Page 5 of 13
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.039110
Time to First Adverse Event by SOC

System Organ Class: Infections and infestations

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	9 (64%)	11 (38%)
Censored	5 (36%)	18 (62%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	2.3 (0.1, 6.8)	2.7 (0.3, 9.7)
Median (95% CI)	6.8 (1.5, 8.8)	9.7 (2.7, 22.0)
3rd Quartile (95% CI)	8.8 (6.8, -)	22.0 (8.5, 22.0)
Log-Rank P-value [2]		0.4006
Hazard Ratio (95% CI) [3]		0.68 (0.27, 1.70)
P-value [3]		0.4057

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
Note: If zero events in at least one treatment arm then hazard ratio and p-values not calculated.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte2_ae_soc.sas 09FEB2023 04:04

Protocol: 207495 Page 6 of 13
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.039110
Time to First Adverse Event by SOC

System Organ Class: Injury, poisoning and procedural complications

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	2 (14%)	4 (14%)
Censored	12 (86%)	25 (86%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (1.0, -)	9.2 (0.3, -)
Median (95% CI)	- (-, -)	- (9.2, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		0.8715
Hazard Ratio (95% CI) [3]		1.16 (0.21, 6.36)
P-value [3]		0.8670

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
Note: If zero events in at least one treatment arm then hazard ratio and p-values not calculated.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte2_ae_soc.sas 09FEB2023 04:04

Protocol: 207495 Page 7 of 13
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.039110
Time to First Adverse Event by SOC

System Organ Class: Investigations

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	7 (50%)	11 (38%)
Censored	7 (50%)	18 (62%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	2.9 (0.5, 8.5)	2.1 (0.7, 4.2)
Median (95% CI)	8.5 (0.7, 13.9)	8.3 (2.1, -)
3rd Quartile (95% CI)	13.9 (8.5, 13.9)	- (8.3, -)
Log-Rank P-value [2]		0.8135
Hazard Ratio (95% CI) [3]		1.13 (0.41, 3.12)
P-value [3]		0.8121

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
Note: If zero events in at least one treatment arm then hazard ratio and p-values not calculated.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte2_ae_soc.sas 09FEB2023 04:04

Table 3.039110
Time to First Adverse Event by SOC

System Organ Class: Metabolism and nutrition disorders

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	3 (21%)	8 (28%)
Censored	11 (79%)	21 (72%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (0.9, -)	1.4 (0.8, -)
Median (95% CI)	- (5.6, -)	- (5.5, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		0.3175
Hazard Ratio (95% CI) [3]		1.98 (0.51, 7.69)
P-value [3]		0.3255

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
Note: If zero events in at least one treatment arm then hazard ratio and p-values not calculated.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte2_ae_soc.sas 09FEB2023 04:04

Protocol: 207495 Page 9 of 13
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.039110
Time to First Adverse Event by SOC

System Organ Class: Musculoskeletal and connective tissue disorders

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	7 (50%)	9 (31%)
Censored	7 (50%)	20 (69%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	3.4 (0.1, 5.8)	1.2 (0.5, -)
Median (95% CI)	5.8 (2.1, -)	- (1.4, -)
3rd Quartile (95% CI)	- (5.8, -)	- (-, -)
Log-Rank P-value [2]		0.7607
Hazard Ratio (95% CI) [3]		0.86 (0.31, 2.33)
P-value [3]		0.7631

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
Note: If zero events in at least one treatment arm then hazard ratio and p-values not calculated.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte2_ae_soc.sas 09FEB2023 04:04

Protocol: 207495 Page 10 of 13
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.039110
Time to First Adverse Event by SOC

System Organ Class: Nervous system disorders

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	4 (29%)	3 (10%)
Censored	10 (71%)	26 (90%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	4.1 (0.3, -)	- (1.4, -)
Median (95% CI)	- (0.8, -)	- (4.1, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		0.2663
Hazard Ratio (95% CI) [3]		0.43 (0.09, 1.98)
P-value [3]		0.2787

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
Note: If zero events in at least one treatment arm then hazard ratio and p-values not calculated.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte2_ae_soc.sas 09FEB2023 04:04

Protocol: 207495 Page 11 of 13
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.039110
Time to First Adverse Event by SOC

System Organ Class: Renal and urinary disorders

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	1 (7%)	3 (10%)
Censored	13 (93%)	26 (90%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (4.1, -)	- (0.9, -)
Median (95% CI)	- (-, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		0.4977
Hazard Ratio (95% CI) [3]		2.20 (0.21, 22.56)
P-value [3]		0.5068

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
Note: If zero events in at least one treatment arm then hazard ratio and p-values not calculated.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte2_ae_soc.sas 09FEB2023 04:04

Protocol: 207495 Page 12 of 13
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.039110
Time to First Adverse Event by SOC

System Organ Class: Respiratory, thoracic and mediastinal disorders

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	4 (29%)	3 (10%)
Censored	10 (71%)	26 (90%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	20.7 (0.3, -)	- (0.6, -)
Median (95% CI)	20.7 (3.0, -)	- (-, -)
3rd Quartile (95% CI)	- (20.7, -)	- (-, -)
Log-Rank P-value [2]		0.3098
Hazard Ratio (95% CI) [3]		0.46 (0.10, 2.13)
P-value [3]		0.3201

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
Note: If zero events in at least one treatment arm then hazard ratio and p-values not calculated.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte2_ae_soc.sas 09FEB2023 04:04

Protocol: 207495 Page 13 of 13
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.039110
Time to First Adverse Event by SOC

System Organ Class: Skin and subcutaneous tissue disorders

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	3 (21%)	0
Censored	11 (79%)	29 (100%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (0.1, -)	- (-, -)
Median (95% CI)	- (0.3, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		-
Hazard Ratio (95% CI) [3]		- (-, -)
P-value [3]		-

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
Note: If zero events in at least one treatment arm then hazard ratio and p-values not calculated.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte2_ae_soc.sas 09FEB2023 04:04

Table 3.037110
Adverse Event Summary by SOC and PT

System Organ Class: Blood and lymphatic system disorders
Preferred Term: Anaemia

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	4 (29%)	8 (28%)
OR (95% CI) [1] vs. Pom/Dex		0.95 (0.23, 3.93)
P-value [1]		0.9460
RR (95% CI) vs. Pom/Dex		0.97 (0.35, 2.67)
ARD (95% CI) vs. Pom/Dex		-0.01 (-0.30, 0.28)
P-value [2]		>0.9999

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes treatment emergent adverse events for PTs occurring in [at least 10% of patients] in any treatment arm OR in [at least 10 patients AND at least 1% of patients] in any treatment arm.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae_summ_spt.sas 10FEB2023 06:39

Table 3.037110
Adverse Event Summary by SOC and PT

System Organ Class: Blood and lymphatic system disorders
Preferred Term: Neutropenia

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	4 (29%)	1 (3%)
OR (95% CI) [1] vs. Pom/Dex		0.09 (<0.01, 0.90)
P-value [1]		0.0401
RR (95% CI) vs. Pom/Dex		0.12 (0.01, 0.98)
ARD (95% CI) vs. Pom/Dex		-0.25 (-0.50, -0.01)
P-value [2]		0.0322

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes treatment emergent adverse events for PTs occurring in [at least 10% of patients] in any treatment arm OR in [at least 10 patients AND at least 1% of patients] in any treatment arm.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae_summ_spt.sas 10FEB2023 06:39

Table 3.037110
Adverse Event Summary by SOC and PT

System Organ Class: Blood and lymphatic system disorders
Preferred Term: Thrombocytopenia

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	6 (43%)	10 (34%)
OR (95% CI) [1] vs. Pom/Dex		0.70 (0.19, 2.59)
P-value [1]		0.5952
RR (95% CI) vs. Pom/Dex		0.80 (0.37, 1.77)
ARD (95% CI) vs. Pom/Dex		-0.08 (-0.40, 0.23)
P-value [2]		0.7388

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes treatment emergent adverse events for PTs occurring in [at least 10% of patients] in any treatment arm OR in [at least 10 patients AND at least 1% of patients] in any treatment arm.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae_summ_spt.sas 10FEB2023 06:39

Table 3.037110
Adverse Event Summary by SOC and PT

System Organ Class: Eye disorders
Preferred Term: Cataract

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	3 (21%)	4 (14%)
OR (95% CI) [1] vs. Pom/Dex		0.59 (0.11, 3.07)
P-value [1]		0.5280
RR (95% CI) vs. Pom/Dex		0.64 (0.17, 2.49)
ARD (95% CI) vs. Pom/Dex		-0.08 (-0.33, 0.17)
P-value [2]		0.6646

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes treatment emergent adverse events for PTs occurring in [at least 10% of patients] in any treatment arm OR in [at least 10 patients AND at least 1% of patients] in any treatment arm.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae_summ_spt.sas 10FEB2023 06:39

Table 3.037110
Adverse Event Summary by SOC and PT

System Organ Class: Eye disorders
Preferred Term: Dry eye

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	0	3 (10%)
OR (95% CI) [1] vs. Pom/Dex		>999.99 (<0.01, >999.99)
P-value [1]		0.9452
RR (95% CI) vs. Pom/Dex		3.50 (0.19, 63.46)
ARD (95% CI) vs. Pom/Dex		0.08 (-0.06, 0.23)
P-value [2]		0.5394

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes treatment emergent adverse events for PTs occurring in [at least 10% of patients] in any treatment arm OR in [at least 10 patients AND at least 1% of patients] in any treatment arm.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae_summ_spt.sas 10FEB2023 06:39

Table 3.037110
Adverse Event Summary by SOC and PT

System Organ Class: Eye disorders
Preferred Term: Foreign body sensation in eyes

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	0	3 (10%)
OR (95% CI) [1] vs. Pom/Dex		>999.99 (<0.01, >999.99)
P-value [1]		0.9452
RR (95% CI) vs. Pom/Dex		3.50 (0.19, 63.46)
ARD (95% CI) vs. Pom/Dex		0.08 (-0.06, 0.23)
P-value [2]		0.5394

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes treatment emergent adverse events for PTs occurring in [at least 10% of patients] in any treatment arm OR in [at least 10 patients AND at least 1% of patients] in any treatment arm.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae_summ_spt.sas 10FEB2023 06:39

Table 3.037110
Adverse Event Summary by SOC and PT

System Organ Class: Eye disorders
Preferred Term: Photophobia

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	0	3 (10%)
OR (95% CI) [1] vs. Pom/Dex		>999.99 (<0.01, >999.99)
P-value [1]		0.9452
RR (95% CI) vs. Pom/Dex		3.50 (0.19, 63.46)
ARD (95% CI) vs. Pom/Dex		0.08 (-0.06, 0.23)
P-value [2]		0.5394

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes treatment emergent adverse events for PTs occurring in [at least 10% of patients] in any treatment arm OR in [at least 10 patients AND at least 1% of patients] in any treatment arm.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae_summ_spt.sas 10FEB2023 06:39

Table 3.037110
Adverse Event Summary by SOC and PT

System Organ Class: Eye disorders
Preferred Term: Vision blurred

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	1 (7%)	4 (14%)
OR (95% CI) [1] vs. Pom/Dex		2.08 (0.21, 20.57)
P-value [1]		0.5311
RR (95% CI) vs. Pom/Dex		1.93 (0.24, 15.71)
ARD (95% CI) vs. Pom/Dex		0.07 (-0.12, 0.25)
P-value [2]		>0.9999

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes treatment emergent adverse events for PTs occurring in [at least 10% of patients] in any treatment arm OR in [at least 10 patients AND at least 1% of patients] in any treatment arm.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae_summ_spt.sas 10FEB2023 06:39

Table 3.037110
Adverse Event Summary by SOC and PT

System Organ Class: Eye disorders
Preferred Term: Visual impairment

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	0	3 (10%)
OR (95% CI) [1] vs. Pom/Dex		>999.99 (<0.01, >999.99)
P-value [1]		0.9452
RR (95% CI) vs. Pom/Dex		3.50 (0.19, 63.46)
ARD (95% CI) vs. Pom/Dex		0.08 (-0.06, 0.23)
P-value [2]		0.5394

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes treatment emergent adverse events for PTs occurring in [at least 10% of patients] in any treatment arm OR in [at least 10 patients AND at least 1% of patients] in any treatment arm.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae_summ_spt.sas 10FEB2023 06:39

Table 3.037110
Adverse Event Summary by SOC and PT

System Organ Class: Gastrointestinal disorders
Preferred Term: Constipation

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	2 (14%)	2 (7%)
OR (95% CI) [1] vs. Pom/Dex		0.44 (0.06, 3.54)
P-value [1]		0.4436
RR (95% CI) vs. Pom/Dex		0.48 (0.08, 3.08)
ARD (95% CI) vs. Pom/Dex		-0.07 (-0.28, 0.13)
P-value [2]		0.5855

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes treatment emergent adverse events for PTs occurring in [at least 10% of patients] in any treatment arm OR in [at least 10 patients AND at least 1% of patients] in any treatment arm.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae_summ_spt.sas 10FEB2023 06:39

Table 3.037110
Adverse Event Summary by SOC and PT

System Organ Class: General disorders and administration site conditions
Preferred Term: Fatigue

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	2 (14%)	2 (7%)
OR (95% CI) [1] vs. Pom/Dex		0.44 (0.06, 3.54)
P-value [1]		0.4436
RR (95% CI) vs. Pom/Dex		0.48 (0.08, 3.08)
ARD (95% CI) vs. Pom/Dex		-0.07 (-0.28, 0.13)
P-value [2]		0.5855

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes treatment emergent adverse events for PTs occurring in [at least 10% of patients] in any treatment arm OR in [at least 10 patients AND at least 1% of patients] in any treatment arm.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae_summ_spt.sas 10FEB2023 06:39

Table 3.037110
Adverse Event Summary by SOC and PT

System Organ Class: General disorders and administration site conditions
Preferred Term: Oedema peripheral

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	3 (21%)	1 (3%)
OR (95% CI) [1] vs. Pom/Dex		0.13 (0.01, 1.40)
P-value [1]		0.0925
RR (95% CI) vs. Pom/Dex		0.16 (0.02, 1.41)
ARD (95% CI) vs. Pom/Dex		-0.18 (-0.40, 0.05)
P-value [2]		0.0936

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes treatment emergent adverse events for PTs occurring in [at least 10% of patients] in any treatment arm OR in [at least 10 patients AND at least 1% of patients] in any treatment arm.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae_summ_spt.sas 10FEB2023 06:39

Table 3.037110
Adverse Event Summary by SOC and PT

System Organ Class: Infections and infestations
Preferred Term: COVID-19

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	4 (29%)	3 (10%)
OR (95% CI) [1] vs. Pom/Dex		0.29 (0.05, 1.52)
P-value [1]		0.1434
RR (95% CI) vs. Pom/Dex		0.36 (0.09, 1.40)
ARD (95% CI) vs. Pom/Dex		-0.18 (-0.44, 0.08)
P-value [2]		0.1900

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes treatment emergent adverse events for PTs occurring in [at least 10% of patients] in any treatment arm OR in [at least 10 patients AND at least 1% of patients] in any treatment arm.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae_summ_spt.sas 10FEB2023 06:39

Table 3.037110
Adverse Event Summary by SOC and PT

System Organ Class: Infections and infestations
Preferred Term: Pneumonia

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	2 (14%)	2 (7%)
OR (95% CI) [1] vs. Pom/Dex		0.44 (0.06, 3.54)
P-value [1]		0.4436
RR (95% CI) vs. Pom/Dex		0.48 (0.08, 3.08)
ARD (95% CI) vs. Pom/Dex		-0.07 (-0.28, 0.13)
P-value [2]		0.5855

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes treatment emergent adverse events for PTs occurring in [at least 10% of patients] in any treatment arm OR in [at least 10 patients AND at least 1% of patients] in any treatment arm.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae_summ_spt.sas 10FEB2023 06:39

Table 3.037110
Adverse Event Summary by SOC and PT

System Organ Class: Investigations
Preferred Term: Alanine aminotransferase increased

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	2 (14%)	0
OR (95% CI) [1] vs. Pom/Dex		<0.01 (<0.01, >999.99)
P-value [1]		0.9541
RR (95% CI) vs. Pom/Dex		0.10 (0.01, 1.95)
ARD (95% CI) vs. Pom/Dex		-0.15 (-0.34, 0.04)
P-value [2]		0.1008

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes treatment emergent adverse events for PTs occurring in [at least 10% of patients] in any treatment arm OR in [at least 10 patients AND at least 1% of patients] in any treatment arm.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae_summ_spt.sas 10FEB2023 06:39

Table 3.037110
Adverse Event Summary by SOC and PT

System Organ Class: Investigations
Preferred Term: Aspartate aminotransferase increased

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	1 (7%)	3 (10%)
OR (95% CI) [1] vs. Pom/Dex		1.50 (0.14, 15.87)
P-value [1]		0.7362
RR (95% CI) vs. Pom/Dex		1.45 (0.17, 12.70)
ARD (95% CI) vs. Pom/Dex		0.03 (-0.14, 0.21)
P-value [2]		>0.9999

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes treatment emergent adverse events for PTs occurring in [at least 10% of patients] in any treatment arm OR in [at least 10 patients AND at least 1% of patients] in any treatment arm.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae_summ_spt.sas 10FEB2023 06:39

Table 3.037110
Adverse Event Summary by SOC and PT

System Organ Class: Investigations
Preferred Term: Blood creatinine increased

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	2 (14%)	0
OR (95% CI) [1] vs. Pom/Dex		<0.01 (<0.01, >999.99)
P-value [1]		0.9541
RR (95% CI) vs. Pom/Dex		0.10 (0.01, 1.95)
ARD (95% CI) vs. Pom/Dex		-0.15 (-0.34, 0.04)
P-value [2]		0.1008

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes treatment emergent adverse events for PTs occurring in [at least 10% of patients] in any treatment arm OR in [at least 10 patients AND at least 1% of patients] in any treatment arm.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae_summ_spt.sas 10FEB2023 06:39

Table 3.037110
Adverse Event Summary by SOC and PT

System Organ Class: Investigations
Preferred Term: Neutrophil count decreased

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	3 (21%)	0
OR (95% CI) [1] vs. Pom/Dex		<0.01 (<0.01, >999.99)
P-value [1]		0.9437
RR (95% CI) vs. Pom/Dex		0.07 (0.00, 1.30)
ARD (95% CI) vs. Pom/Dex		-0.22 (-0.44, 0.00)
P-value [2]		0.0295

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes treatment emergent adverse events for PTs occurring in [at least 10% of patients] in any treatment arm OR in [at least 10 patients AND at least 1% of patients] in any treatment arm.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae_summ_spt.sas 10FEB2023 06:39

Table 3.037110
Adverse Event Summary by SOC and PT

System Organ Class: Musculoskeletal and connective tissue disorders
Preferred Term: Arthralgia

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	1 (7%)	3 (10%)
OR (95% CI) [1] vs. Pom/Dex		1.50 (0.14, 15.87)
P-value [1]		0.7362
RR (95% CI) vs. Pom/Dex		1.45 (0.17, 12.70)
ARD (95% CI) vs. Pom/Dex		0.03 (-0.14, 0.21)
P-value [2]		>0.9999

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes treatment emergent adverse events for PTs occurring in [at least 10% of patients] in any treatment arm OR in [at least 10 patients AND at least 1% of patients] in any treatment arm.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae_summ_spt.sas 10FEB2023 06:39

Protocol: 207495 Page 20 of 26
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.037110
Adverse Event Summary by SOC and PT

System Organ Class: Musculoskeletal and connective tissue disorders
Preferred Term: Back pain

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	2 (14%)	1 (3%)
OR (95% CI) [1] vs. Pom/Dex		0.21 (0.02, 2.59)
P-value [1]		0.2260
RR (95% CI) vs. Pom/Dex		0.24 (0.02, 2.44)
ARD (95% CI) vs. Pom/Dex		-0.11 (-0.30, 0.09)
P-value [2]		0.2433

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes treatment emergent adverse events for PTs occurring in [at least 10% of patients] in any treatment arm OR in [at least 10 patients AND at least 1% of patients] in any treatment arm.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae_summ_spt.sas 10FEB2023 06:39

Table 3.037110
Adverse Event Summary by SOC and PT

System Organ Class: Musculoskeletal and connective tissue disorders
Preferred Term: Bone pain

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	1 (7%)	3 (10%)
OR (95% CI) [1] vs. Pom/Dex		1.50 (0.14, 15.87)
P-value [1]		0.7362
RR (95% CI) vs. Pom/Dex		1.45 (0.17, 12.70)
ARD (95% CI) vs. Pom/Dex		0.03 (-0.14, 0.21)
P-value [2]		>0.9999

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes treatment emergent adverse events for PTs occurring in [at least 10% of patients] in any treatment arm OR in [at least 10 patients AND at least 1% of patients] in any treatment arm.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae_summ_spt.sas 10FEB2023 06:39

Table 3.037110
Adverse Event Summary by SOC and PT

System Organ Class: Musculoskeletal and connective tissue disorders
Preferred Term: Muscular weakness

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	2 (14%)	0
OR (95% CI) [1] vs. Pom/Dex		<0.01 (<0.01, >999.99)
P-value [1]		0.9541
RR (95% CI) vs. Pom/Dex		0.10 (0.01, 1.95)
ARD (95% CI) vs. Pom/Dex		-0.15 (-0.34, 0.04)
P-value [2]		0.1008

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes treatment emergent adverse events for PTs occurring in [at least 10% of patients] in any treatment arm OR in [at least 10 patients AND at least 1% of patients] in any treatment arm.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae_summ_spt.sas 10FEB2023 06:39

Table 3.037110
Adverse Event Summary by SOC and PT

System Organ Class: Nervous system disorders
Preferred Term: Tremor

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	2 (14%)	0
OR (95% CI) [1] vs. Pom/Dex		<0.01 (<0.01, >999.99)
P-value [1]		0.9541
RR (95% CI) vs. Pom/Dex		0.10 (0.01, 1.95)
ARD (95% CI) vs. Pom/Dex		-0.15 (-0.34, 0.04)
P-value [2]		0.1008

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes treatment emergent adverse events for PTs occurring in [at least 10% of patients] in any treatment arm OR in [at least 10 patients AND at least 1% of patients] in any treatment arm.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae_summ_spt.sas 10FEB2023 06:39

Table 3.037110
Adverse Event Summary by SOC and PT

System Organ Class: Respiratory, thoracic and mediastinal disorders
Preferred Term: Epistaxis

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	0	3 (10%)
OR (95% CI) [1] vs. Pom/Dex		>999.99 (<0.01, >999.99)
P-value [1]		0.9452
RR (95% CI) vs. Pom/Dex		3.50 (0.19, 63.46)
ARD (95% CI) vs. Pom/Dex		0.08 (-0.06, 0.23)
P-value [2]		0.5394

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes treatment emergent adverse events for PTs occurring in [at least 10% of patients] in any treatment arm OR in [at least 10 patients AND at least 1% of patients] in any treatment arm.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae_summ_spt.sas 10FEB2023 06:39

Protocol: 207495 Page 25 of 26
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.037110
Adverse Event Summary by SOC and PT

System Organ Class: Respiratory, thoracic and mediastinal disorders
Preferred Term: Hiccups

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	2 (14%)	0
OR (95% CI) [1] vs. Pom/Dex		<0.01 (<0.01, >999.99)
P-value [1]		0.9541
RR (95% CI) vs. Pom/Dex		0.10 (0.01, 1.95)
ARD (95% CI) vs. Pom/Dex		-0.15 (-0.34, 0.04)
P-value [2]		0.1008

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes treatment emergent adverse events for PTs occurring in [at least 10% of patients] in any treatment arm OR in [at least 10 patients AND at least 1% of patients] in any treatment arm.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae_summ_spt.sas 10FEB2023 06:39

Table 3.037110
Adverse Event Summary by SOC and PT

System Organ Class: Skin and subcutaneous tissue disorders
Preferred Term: Rash

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	2 (14%)	0
OR (95% CI) [1] vs. Pom/Dex		<0.01 (<0.01, >999.99)
P-value [1]		0.9541
RR (95% CI) vs. Pom/Dex		0.10 (0.01, 1.95)
ARD (95% CI) vs. Pom/Dex		-0.15 (-0.34, 0.04)
P-value [2]		0.1008

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes treatment emergent adverse events for PTs occurring in [at least 10% of patients] in any treatment arm OR in [at least 10 patients AND at least 1% of patients] in any treatment arm.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae_summ_spt.sas 10FEB2023 06:39

Protocol: 207495 Page 1 of 26
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.040110
Time to First Adverse Event by SOC and PT

System Organ Class: Blood and lymphatic system disorders
Preferred Term: Anaemia

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	4 (29%)	8 (28%)
Censored	10 (71%)	21 (72%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	8.5 (3.3, –)	2.7 (0.7, –)
Median (95% CI)	17.7 (8.5, –)	– (5.3, –)
3rd Quartile (95% CI)	– (8.5, –)	– (–, –)
Log-Rank P-value [2]		0.4185
Hazard Ratio (95% CI) [3]		1.65 (0.48, 5.65)
P-value [3]		0.4212

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
Note: If zero events in at least one treatment arm then hazard ratio and p-values not calculated.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte2_ae_spt.sas 09FEB2023 04:04

Table 3.040110
Time to First Adverse Event by SOC and PT

System Organ Class: Blood and lymphatic system disorders
Preferred Term: Neutropenia

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	4 (29%)	1 (3%)
Censored	10 (71%)	28 (97%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	3.5 (0.8, -)	- (1.4, -)
Median (95% CI)	- (1.0, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		0.0271
Hazard Ratio (95% CI) [3]		0.12 (0.01, 1.11)
P-value [3]		0.0623

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
Note: If zero events in at least one treatment arm then hazard ratio and p-values not calculated.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte2_ae_spt.sas 09FEB2023 04:04

Protocol: 207495 Page 3 of 26
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.040110
Time to First Adverse Event by SOC and PT

System Organ Class: Blood and lymphatic system disorders
Preferred Term: Thrombocytopenia

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	6 (43%)	10 (34%)
Censored	8 (57%)	19 (66%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	0.8 (0.3, -)	1.4 (0.3, -)
Median (95% CI)	- (0.7, -)	- (2.1, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		0.8255
Hazard Ratio (95% CI) [3]		0.89 (0.32, 2.48)
P-value [3]		0.8242

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
Note: If zero events in at least one treatment arm then hazard ratio and p-values not calculated.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte2_ae_spt.sas 09FEB2023 04:04

Protocol: 207495 Page 4 of 26
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.040110
Time to First Adverse Event by SOC and PT

System Organ Class: Eye disorders
Preferred Term: Cataract

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	3 (21%)	4 (14%)
Censored	11 (79%)	25 (86%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	6.3 (0.7, -)	- (1.4, -)
Median (95% CI)	- (6.3, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		0.9689
Hazard Ratio (95% CI) [3]		1.03 (0.22, 4.80)
P-value [3]		0.9690

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
Note: If zero events in at least one treatment arm then hazard ratio and p-values not calculated.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte2_ae_spt.sas 09FEB2023 04:04

Protocol: 207495 Page 5 of 26
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.040110
Time to First Adverse Event by SOC and PT

System Organ Class: Eye disorders
Preferred Term: Dry eye

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	0	3 (10%)
Censored	14 (100%)	26 (90%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (-, -)	- (1.4, -)
Median (95% CI)	- (-, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		-
Hazard Ratio (95% CI) [3]		- (-, -)
P-value [3]		-

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
Note: If zero events in at least one treatment arm then hazard ratio and p-values not calculated.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte2_ae_spt.sas 09FEB2023 04:04

Protocol: 207495 Page 6 of 26
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.040110
Time to First Adverse Event by SOC and PT

System Organ Class: Eye disorders
Preferred Term: Foreign body sensation in eyes

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	0	3 (10%)
Censored	14 (100%)	26 (90%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (-, -)	- (1.4, -)
Median (95% CI)	- (-, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		-
Hazard Ratio (95% CI) [3]		- (-, -)
P-value [3]		-

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
Note: If zero events in at least one treatment arm then hazard ratio and p-values not calculated.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte2_ae_spt.sas 09FEB2023 04:04

Protocol: 207495 Page 7 of 26
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.040110
Time to First Adverse Event by SOC and PT

System Organ Class: Eye disorders
Preferred Term: Photophobia

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	0	3 (10%)
Censored	14 (100%)	26 (90%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (-, -)	- (2.3, -)
Median (95% CI)	- (-, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		-
Hazard Ratio (95% CI) [3]		- (-, -)
P-value [3]		-

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
Note: If zero events in at least one treatment arm then hazard ratio and p-values not calculated.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte2_ae_spt.sas 09FEB2023 04:04

Protocol: 207495 Page 8 of 26
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.040110
Time to First Adverse Event by SOC and PT

System Organ Class: Eye disorders
Preferred Term: Vision blurred

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	1 (7%)	4 (14%)
Censored	13 (93%)	25 (86%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (4.1, -)	- (0.9, -)
Median (95% CI)	- (-, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		0.2674
Hazard Ratio (95% CI) [3]		3.45 (0.35, 34.17)
P-value [3]		0.2895

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
Note: If zero events in at least one treatment arm then hazard ratio and p-values not calculated.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte2_ae_spt.sas 09FEB2023 04:04

Protocol: 207495 Page 9 of 26
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.040110
Time to First Adverse Event by SOC and PT

System Organ Class: Eye disorders
Preferred Term: Visual impairment

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	0	3 (10%)
Censored	14 (100%)	26 (90%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (-, -)	- (0.8, -)
Median (95% CI)	- (-, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		-
Hazard Ratio (95% CI) [3]		- (-, -)
P-value [3]		-

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
Note: If zero events in at least one treatment arm then hazard ratio and p-values not calculated.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte2_ae_spt.sas 09FEB2023 04:04

Protocol: 207495 Page 10 of 26
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.040110
Time to First Adverse Event by SOC and PT

System Organ Class: Gastrointestinal disorders
Preferred Term: Constipation

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	2 (14%)	2 (7%)
Censored	12 (86%)	27 (93%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	11.0 (0.3, -)	- (1.9, -)
Median (95% CI)	- (11.0, -)	- (-, -)
3rd Quartile (95% CI)	- (11.0, -)	- (-, -)
Log-Rank P-value [2]		0.7706
Hazard Ratio (95% CI) [3]		0.74 (0.10, 5.47)
P-value [3]		0.7713

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
Note: If zero events in at least one treatment arm then hazard ratio and p-values not calculated.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte2_ae_spt.sas 09FEB2023 04:04

Protocol: 207495 Page 11 of 26
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.040110
Time to First Adverse Event by SOC and PT

System Organ Class: General disorders and administration site conditions
Preferred Term: Fatigue

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	2 (14%)	2 (7%)
Censored	12 (86%)	27 (93%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (0.3, -)	- (1.9, -)
Median (95% CI)	- (-, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		0.5261
Hazard Ratio (95% CI) [3]		0.53 (0.07, 3.82)
P-value [3]		0.5327

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
Note: If zero events in at least one treatment arm then hazard ratio and p-values not calculated.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte2_ae_spt.sas 09FEB2023 04:04

Protocol: 207495 Page 12 of 26
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.040110
Time to First Adverse Event by SOC and PT

System Organ Class: General disorders and administration site conditions
Preferred Term: Oedema peripheral

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	3 (21%)	1 (3%)
Censored	11 (79%)	28 (97%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (0.1, -)	- (-, -)
Median (95% CI)	- (6.2, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		0.1639
Hazard Ratio (95% CI) [3]		0.22 (0.02, 2.22)
P-value [3]		0.1998

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
Note: If zero events in at least one treatment arm then hazard ratio and p-values not calculated.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte2_ae_spt.sas 09FEB2023 04:04

Table 3.040110
Time to First Adverse Event by SOC and PT

System Organ Class: Infections and infestations
Preferred Term: COVID-19

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	4 (29%)	3 (10%)
Censored	10 (71%)	26 (90%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	19.3 (0.5, 21.6)	9.7 (8.5, 22.0)
Median (95% CI)	19.3 (19.3, 21.6)	22.0 (8.5, 22.0)
3rd Quartile (95% CI)	21.6 (19.3, 21.6)	22.0 (9.7, 22.0)
Log-Rank P-value [2]		0.4382
Hazard Ratio (95% CI) [3]		0.51 (0.09, 2.88)
P-value [3]		0.4459

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
Note: If zero events in at least one treatment arm then hazard ratio and p-values not calculated.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte2_ae_spt.sas 09FEB2023 04:04

Protocol: 207495 Page 14 of 26
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.040110
Time to First Adverse Event by SOC and PT

System Organ Class: Infections and infestations
Preferred Term: Pneumonia

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	2 (14%)	2 (7%)
Censored	12 (86%)	27 (93%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	19.5 (2.3, -)	- (-, -)
Median (95% CI)	19.5 (19.5, -)	- (-, -)
3rd Quartile (95% CI)	- (19.5, -)	- (-, -)
Log-Rank P-value [2]		0.8127
Hazard Ratio (95% CI) [3]		0.78 (0.10, 6.00)
P-value [3]		0.8131

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
Note: If zero events in at least one treatment arm then hazard ratio and p-values not calculated.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte2_ae_spt.sas 09FEB2023 04:04

Protocol: 207495 Page 15 of 26
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.040110
Time to First Adverse Event by SOC and PT

System Organ Class: Investigations
Preferred Term: Alanine aminotransferase increased

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	2 (14%)	0
Censored	12 (86%)	29 (100%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (0.7, -)	- (-, -)
Median (95% CI)	- (-, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		-
Hazard Ratio (95% CI) [3]		- (-, -)
P-value [3]		-

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
Note: If zero events in at least one treatment arm then hazard ratio and p-values not calculated.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte2_ae_spt.sas 09FEB2023 04:04

Protocol: 207495 Page 16 of 26
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.040110
Time to First Adverse Event by SOC and PT

System Organ Class: Investigations
Preferred Term: Aspartate aminotransferase increased

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	1 (7%)	3 (10%)
Censored	13 (93%)	26 (90%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (6.2, -)	- (1.6, -)
Median (95% CI)	- (-, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		0.3355
Hazard Ratio (95% CI) [3]		2.97 (0.30, 29.89)
P-value [3]		0.3546

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
Note: If zero events in at least one treatment arm then hazard ratio and p-values not calculated.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte2_ae_spt.sas 09FEB2023 04:04

Protocol: 207495 Page 17 of 26
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.040110
Time to First Adverse Event by SOC and PT

System Organ Class: Investigations
Preferred Term: Blood creatinine increased

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	2 (14%)	0
Censored	12 (86%)	29 (100%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	8.5 (2.9, -)	- (-, -)
Median (95% CI)	- (8.5, -)	- (-, -)
3rd Quartile (95% CI)	- (8.5, -)	- (-, -)
Log-Rank P-value [2]		-
Hazard Ratio (95% CI) [3]		- (-, -)
P-value [3]		-

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
Note: If zero events in at least one treatment arm then hazard ratio and p-values not calculated.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte2_ae_spt.sas 09FEB2023 04:04

Protocol: 207495 Page 18 of 26
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.040110
Time to First Adverse Event by SOC and PT

System Organ Class: Investigations
Preferred Term: Neutrophil count decreased

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	3 (21%)	0
Censored	11 (79%)	29 (100%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (0.5, -)	- (-, -)
Median (95% CI)	- (4.4, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		-
Hazard Ratio (95% CI) [3]		- (-, -)
P-value [3]		-

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
Note: If zero events in at least one treatment arm then hazard ratio and p-values not calculated.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte2_ae_spt.sas 09FEB2023 04:04

Protocol: 207495 Page 19 of 26
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.040110
Time to First Adverse Event by SOC and PT

System Organ Class: Musculoskeletal and connective tissue disorders
Preferred Term: Arthralgia

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	1 (7%)	3 (10%)
Censored	13 (93%)	26 (90%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	13.7 (13.7, -)	- (0.8, -)
Median (95% CI)	- (13.7, -)	- (-, -)
3rd Quartile (95% CI)	- (13.7, -)	- (-, -)
Log-Rank P-value [2]		0.4793
Hazard Ratio (95% CI) [3]		2.30 (0.22, 24.45)
P-value [3]		0.4886

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
Note: If zero events in at least one treatment arm then hazard ratio and p-values not calculated.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte2_ae_spt.sas 09FEB2023 04:04

Protocol: 207495 Page 20 of 26
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.040110
Time to First Adverse Event by SOC and PT

System Organ Class: Musculoskeletal and connective tissue disorders
Preferred Term: Back pain

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	2 (14%)	1 (3%)
Censored	12 (86%)	28 (97%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (2.1, -)	- (2.6, -)
Median (95% CI)	- (-, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		0.4382
Hazard Ratio (95% CI) [3]		0.40 (0.04, 4.42)
P-value [3]		0.4538

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
Note: If zero events in at least one treatment arm then hazard ratio and p-values not calculated.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte2_ae_spt.sas 09FEB2023 04:04

Protocol: 207495 Page 21 of 26
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.040110
Time to First Adverse Event by SOC and PT

System Organ Class: Musculoskeletal and connective tissue disorders
Preferred Term: Bone pain

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	1 (7%)	3 (10%)
Censored	13 (93%)	26 (90%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (0.8, -)	- (1.2, -)
Median (95% CI)	- (-, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		0.7129
Hazard Ratio (95% CI) [3]		1.53 (0.16, 14.75)
P-value [3]		0.7111

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
Note: If zero events in at least one treatment arm then hazard ratio and p-values not calculated.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte2_ae_spt.sas 09FEB2023 04:04

Protocol: 207495 Page 22 of 26
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.040110
Time to First Adverse Event by SOC and PT

System Organ Class: Musculoskeletal and connective tissue disorders
Preferred Term: Muscular weakness

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	2 (14%)	0
Censored	12 (86%)	29 (100%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	18.4 (0.8, -)	- (-, -)
Median (95% CI)	18.4 (18.4, -)	- (-, -)
3rd Quartile (95% CI)	- (18.4, -)	- (-, -)
Log-Rank P-value [2]		-
Hazard Ratio (95% CI) [3]		- (-, -)
P-value [3]		-

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
Note: If zero events in at least one treatment arm then hazard ratio and p-values not calculated.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte2_ae_spt.sas 09FEB2023 04:04

Protocol: 207495 Page 23 of 26
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.040110
Time to First Adverse Event by SOC and PT

System Organ Class: Nervous system disorders
Preferred Term: Tremor

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	2 (14%)	0
Censored	12 (86%)	29 (100%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (1.0, -)	- (-, -)
Median (95% CI)	- (-, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		-
Hazard Ratio (95% CI) [3]		- (-, -)
P-value [3]		-

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
Note: If zero events in at least one treatment arm then hazard ratio and p-values not calculated.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte2_ae_spt.sas 09FEB2023 04:04

Protocol: 207495 Page 24 of 26
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.040110
Time to First Adverse Event by SOC and PT

System Organ Class: Respiratory, thoracic and mediastinal disorders
Preferred Term: Epistaxis

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	0	3 (10%)
Censored	14 (100%)	26 (90%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (-, -)	- (0.6, -)
Median (95% CI)	- (-, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		-
Hazard Ratio (95% CI) [3]		- (-, -)
P-value [3]		-

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
Note: If zero events in at least one treatment arm then hazard ratio and p-values not calculated.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte2_ae_spt.sas 09FEB2023 04:04

Protocol: 207495 Page 25 of 26
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.040110
Time to First Adverse Event by SOC and PT

System Organ Class: Respiratory, thoracic and mediastinal disorders
Preferred Term: Hiccups

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	2 (14%)	0
Censored	12 (86%)	29 (100%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (0.3, -)	- (-, -)
Median (95% CI)	- (-, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		-
Hazard Ratio (95% CI) [3]		- (-, -)
P-value [3]		-

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
Note: If zero events in at least one treatment arm then hazard ratio and p-values not calculated.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte2_ae_spt.sas 09FEB2023 04:04

Protocol: 207495 Page 26 of 26
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.040110
Time to First Adverse Event by SOC and PT

System Organ Class: Skin and subcutaneous tissue disorders
Preferred Term: Rash

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	2 (14%)	0
Censored	12 (86%)	29 (100%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (0.1, -)	- (-, -)
Median (95% CI)	- (-, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		-
Hazard Ratio (95% CI) [3]		- (-, -)
P-value [3]		-

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
Note: If zero events in at least one treatment arm then hazard ratio and p-values not calculated.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte2_ae_spt.sas 09FEB2023 04:04

Table 3.054110
Adverse Event Summary of Max Grade 3 or Higher by SOC

System Organ Class: Blood and lymphatic system disorders

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	4 (29%)	10 (34%)
OR (95% CI) [1] vs. Pom/Dex		1.32 (0.33, 5.28)
P-value [1]		0.6987
RR (95% CI) vs. Pom/Dex		1.21 (0.46, 3.18)
ARD (95% CI) vs. Pom/Dex		0.06 (-0.23, 0.35)
P-value [2]		>0.9999

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes grade >=3 treatment emergent adverse events for SOCs occurring in [at least 5% of patients] in any treatment arm OR in [at least 10 patients AND at least 1% of patients] in any treatment arm.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae3_summ_soc.sas 10FEB2023 06:39

Table 3.054110
Adverse Event Summary of Max Grade 3 or Higher by SOC

System Organ Class: Cardiac disorders

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	1 (7%)	1 (3%)
OR (95% CI) [1] vs. Pom/Dex		0.46 (0.03, 8.02)
P-value [1]		0.5976
RR (95% CI) vs. Pom/Dex		0.48 (0.03, 7.16)
ARD (95% CI) vs. Pom/Dex		-0.04 (-0.19, 0.11)
P-value [2]		>0.9999

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes grade >=3 treatment emergent adverse events for SOCs occurring in [at least 5% of patients] in any treatment arm OR in [at least 10 patients AND at least 1% of patients] in any treatment arm.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae3_summ_soc.sas 10FEB2023 06:39

Table 3.054110
Adverse Event Summary of Max Grade 3 or Higher by SOC

System Organ Class: Eye disorders

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	1 (7%)	6 (21%)
OR (95% CI) [1] vs. Pom/Dex		3.39 (0.37, 31.32)
P-value [1]		0.2818
RR (95% CI) vs. Pom/Dex		2.90 (0.38, 21.81)
ARD (95% CI) vs. Pom/Dex		0.14 (-0.06, 0.34)
P-value [2]		0.3964

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes grade >=3 treatment emergent adverse events for SOCs occurring in [at least 5% of patients] in any treatment arm OR in [at least 10 patients AND at least 1% of patients] in any treatment arm.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae3_summ_soc.sas 10FEB2023 06:39

Table 3.054110
Adverse Event Summary of Max Grade 3 or Higher by SOC

System Organ Class: Gastrointestinal disorders

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	0	2 (7%)
OR (95% CI) [1] vs. Pom/Dex		>999.99 (<0.01, >999.99)
P-value [1]		0.9551
RR (95% CI) vs. Pom/Dex		2.50 (0.13, 48.85)
ARD (95% CI) vs. Pom/Dex		0.05 (-0.08, 0.18)
P-value [2]		>0.9999

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes grade >=3 treatment emergent adverse events for SOCs occurring in [at least 5% of patients] in any treatment arm OR in [at least 10 patients AND at least 1% of patients] in any treatment arm.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae3_summ_soc.sas 10FEB2023 06:39

Table 3.054110
Adverse Event Summary of Max Grade 3 or Higher by SOC

System Organ Class: General disorders and administration site conditions

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	1 (7%)	0
OR (95% CI) [1] vs. Pom/Dex		<0.01 (<0.01, >999.99)
P-value [1]		0.9509
RR (95% CI) vs. Pom/Dex		0.17 (0.01, 3.85)
ARD (95% CI) vs. Pom/Dex		-0.08 (-0.24, 0.08)
P-value [2]		0.3256

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes grade >=3 treatment emergent adverse events for SOCs occurring in [at least 5% of patients] in any treatment arm OR in [at least 10 patients AND at least 1% of patients] in any treatment arm.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae3_summ_soc.sas 10FEB2023 06:39

Table 3.054110
Adverse Event Summary of Max Grade 3 or Higher by SOC

System Organ Class: Infections and infestations

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	4 (29%)	2 (7%)
OR (95% CI) [1] vs. Pom/Dex		0.19 (0.03, 1.17)
P-value [1]		0.0734
RR (95% CI) vs. Pom/Dex		0.24 (0.05, 1.16)
ARD (95% CI) vs. Pom/Dex		-0.22 (-0.47, 0.04)
P-value [2]		0.0767

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes grade >=3 treatment emergent adverse events for SOCs occurring in [at least 5% of patients] in any treatment arm OR in [at least 10 patients AND at least 1% of patients] in any treatment arm.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae3_summ_soc.sas 10FEB2023 06:39

Table 3.054110
Adverse Event Summary of Max Grade 3 or Higher by SOC

System Organ Class: Investigations

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	2 (14%)	3 (10%)
OR (95% CI) [1] vs. Pom/Dex		0.69 (0.10, 4.70)
P-value [1]		0.7066
RR (95% CI) vs. Pom/Dex		0.72 (0.14, 3.85)
ARD (95% CI) vs. Pom/Dex		-0.04 (-0.25, 0.17)
P-value [2]		>0.9999

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes grade >=3 treatment emergent adverse events for SOCs occurring in [at least 5% of patients] in any treatment arm OR in [at least 10 patients AND at least 1% of patients] in any treatment arm.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae3_summ_soc.sas 10FEB2023 06:39

Table 3.054110
Adverse Event Summary of Max Grade 3 or Higher by SOC

System Organ Class: Metabolism and nutrition disorders

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	1 (7%)	4 (14%)
OR (95% CI) [1] vs. Pom/Dex		2.08 (0.21, 20.57)
P-value [1]		0.5311
RR (95% CI) vs. Pom/Dex		1.93 (0.24, 15.71)
ARD (95% CI) vs. Pom/Dex		0.07 (-0.12, 0.25)
P-value [2]		>0.9999

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes grade >=3 treatment emergent adverse events for SOCs occurring in [at least 5% of patients] in any treatment arm OR in [at least 10 patients AND at least 1% of patients] in any treatment arm.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae3_summ_soc.sas 10FEB2023 06:39

Table 3.054110
Adverse Event Summary of Max Grade 3 or Higher by SOC

System Organ Class: Musculoskeletal and connective tissue disorders

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	2 (14%)	4 (14%)
OR (95% CI) [1] vs. Pom/Dex		0.96 (0.15, 5.99)
P-value [1]		0.9650
RR (95% CI) vs. Pom/Dex		0.97 (0.20, 4.65)
ARD (95% CI) vs. Pom/Dex		0.00 (-0.23, 0.22)
P-value [2]		>0.9999

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes grade >=3 treatment emergent adverse events for SOCs occurring in [at least 5% of patients] in any treatment arm OR in [at least 10 patients AND at least 1% of patients] in any treatment arm.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae3_summ_soc.sas 10FEB2023 06:39

Table 3.054110
Adverse Event Summary of Max Grade 3 or Higher by SOC

System Organ Class: Nervous system disorders

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	0	3 (10%)
OR (95% CI) [1] vs. Pom/Dex		>999.99 (<0.01, >999.99)
P-value [1]		0.9452
RR (95% CI) vs. Pom/Dex		3.50 (0.19, 63.46)
ARD (95% CI) vs. Pom/Dex		0.08 (-0.06, 0.23)
P-value [2]		0.5394

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes grade >=3 treatment emergent adverse events for SOCs occurring in [at least 5% of patients] in any treatment arm OR in [at least 10 patients AND at least 1% of patients] in any treatment arm.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae3_summ_soc.sas 10FEB2023 06:39

Table 3.054110
Adverse Event Summary of Max Grade 3 or Higher by SOC

System Organ Class: Psychiatric disorders

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	1 (7%)	0
OR (95% CI) [1] vs. Pom/Dex		<0.01 (<0.01, >999.99)
P-value [1]		0.9509
RR (95% CI) vs. Pom/Dex		0.17 (0.01, 3.85)
ARD (95% CI) vs. Pom/Dex		−0.08 (−0.24, 0.08)
P-value [2]		0.3256

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes grade >=3 treatment emergent adverse events for SOCs occurring in [at least 5% of patients] in any treatment arm OR in [at least 10 patients AND at least 1% of patients] in any treatment arm.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae3_summ_soc.sas 10FEB2023 06:39

Table 3.054110
Adverse Event Summary of Max Grade 3 or Higher by SOC

System Organ Class: Renal and urinary disorders

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	0	3 (10%)
OR (95% CI) [1] vs. Pom/Dex		>999.99 (<0.01, >999.99)
P-value [1]		0.9452
RR (95% CI) vs. Pom/Dex		3.50 (0.19, 63.46)
ARD (95% CI) vs. Pom/Dex		0.08 (-0.06, 0.23)
P-value [2]		0.5394

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes grade >=3 treatment emergent adverse events for SOCs occurring in [at least 5% of patients] in any treatment arm OR in [at least 10 patients AND at least 1% of patients] in any treatment arm.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae3_summ_soc.sas 10FEB2023 06:39

Table 3.054110
Adverse Event Summary of Max Grade 3 or Higher by SOC

System Organ Class: Respiratory, thoracic and mediastinal disorders

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	1 (7%)	1 (3%)
OR (95% CI) [1] vs. Pom/Dex		0.46 (0.03, 8.02)
P-value [1]		0.5976
RR (95% CI) vs. Pom/Dex		0.48 (0.03, 7.16)
ARD (95% CI) vs. Pom/Dex		-0.04 (-0.19, 0.11)
P-value [2]		>0.9999

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes grade >=3 treatment emergent adverse events for SOCs occurring in [at least 5% of patients] in any treatment arm OR in [at least 10 patients AND at least 1% of patients] in any treatment arm.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae3_summ_soc.sas 10FEB2023 06:39

Table 3.057110
Time to First Adverse Event of Max Grade 3 or higher by SOC

System Organ Class: Blood and lymphatic system disorders

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	4 (29%)	10 (34%)
Censored	10 (71%)	19 (66%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	1.0 (0.1, -)	1.1 (0.4, -)
Median (95% CI)	- (0.8, -)	- (1.4, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		0.6739
Hazard Ratio (95% CI) [3]		1.28 (0.40, 4.09)
P-value [3]		0.6744

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
Note: If zero events in at least one treatment arm then hazard ratio and p-values not calculated.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte2_ae3_soc.sas 09FEB2023 04:13

Protocol: 207495 Page 2 of 13
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.057110
Time to First Adverse Event of Max Grade 3 or higher by SOC

System Organ Class: Cardiac disorders

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	1 (7%)	1 (3%)
Censored	13 (93%)	28 (97%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (8.5, -)	- (-, -)
Median (95% CI)	- (8.5, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		0.7991
Hazard Ratio (95% CI) [3]		0.69 (0.04, 11.63)
P-value [3]		0.8001

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
Note: If zero events in at least one treatment arm then hazard ratio and p-values not calculated.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte2_ae3_soc.sas 09FEB2023 04:13

Protocol: 207495 Page 3 of 13
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.057110
Time to First Adverse Event of Max Grade 3 or higher by SOC

System Organ Class: Eye disorders

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	1 (7%)	6 (21%)
Censored	13 (93%)	23 (79%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (6.3, -)	4.8 (0.8, -)
Median (95% CI)	- (-, -)	- (4.8, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		0.1001
Hazard Ratio (95% CI) [3]		5.26 (0.60, 46.16)
P-value [3]		0.1339

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
Note: If zero events in at least one treatment arm then hazard ratio and p-values not calculated.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte2_ae3_soc.sas 09FEB2023 04:13

Table 3.057110
Time to First Adverse Event of Max Grade 3 or higher by SOC

System Organ Class: Gastrointestinal disorders

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	0	2 (7%)
Censored	14 (100%)	27 (93%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (-, -)	- (4.0, -)
Median (95% CI)	- (-, -)	- (4.0, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		-
Hazard Ratio (95% CI) [3]		- (-, -)
P-value [3]		-

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
Note: If zero events in at least one treatment arm then hazard ratio and p-values not calculated.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte2_ae3_soc.sas 09FEB2023 04:13

Table 3.057110
Time to First Adverse Event of Max Grade 3 or higher by SOC

System Organ Class: General disorders and administration site conditions

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	1 (7%)	0
Censored	13 (93%)	29 (100%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (0.8, -)	- (-, -)
Median (95% CI)	- (-, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		-
Hazard Ratio (95% CI) [3]		- (-, -)
P-value [3]		-

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
Note: If zero events in at least one treatment arm then hazard ratio and p-values not calculated.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte2_ae3_soc.sas 09FEB2023 04:13

Table 3.057110
Time to First Adverse Event of Max Grade 3 or higher by SOC

System Organ Class: Infections and infestations

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	4 (29%)	2 (7%)
Censored	10 (71%)	27 (93%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	8.2 (0.5, -)	- (-, -)
Median (95% CI)	19.5 (8.2, -)	- (-, -)
3rd Quartile (95% CI)	- (19.5, -)	- (-, -)
Log-Rank P-value [2]		0.2248
Hazard Ratio (95% CI) [3]		0.35 (0.06, 2.02)
P-value [3]		0.2425

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
Note: If zero events in at least one treatment arm then hazard ratio and p-values not calculated.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte2_ae3_soc.sas 09FEB2023 04:13

Table 3.057110
Time to First Adverse Event of Max Grade 3 or higher by SOC

System Organ Class: Investigations

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	2 (14%)	3 (10%)
Censored	12 (86%)	26 (90%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (0.7, -)	- (1.0, -)
Median (95% CI)	- (4.4, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		0.8924
Hazard Ratio (95% CI) [3]		0.88 (0.14, 5.46)
P-value [3]		0.8925

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
Note: If zero events in at least one treatment arm then hazard ratio and p-values not calculated.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte2_ae3_soc.sas 09FEB2023 04:13

Table 3.057110
Time to First Adverse Event of Max Grade 3 or higher by SOC

System Organ Class: Metabolism and nutrition disorders

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	1 (7%)	4 (14%)
Censored	13 (93%)	25 (86%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (3.5, -)	- (0.8, -)
Median (95% CI)	- (-, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		0.3954
Hazard Ratio (95% CI) [3]		2.53 (0.28, 23.24)
P-value [3]		0.4110

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
Note: If zero events in at least one treatment arm then hazard ratio and p-values not calculated.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte2_ae3_soc.sas 09FEB2023 04:13

Protocol: 207495 Page 9 of 13
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.057110
Time to First Adverse Event of Max Grade 3 or higher by SOC

System Organ Class: Musculoskeletal and connective tissue disorders

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	2 (14%)	4 (14%)
Censored	12 (86%)	25 (86%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (0.8, -)	- (0.8, -)
Median (95% CI)	- (5.8, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		0.7173
Hazard Ratio (95% CI) [3]		1.38 (0.24, 7.86)
P-value [3]		0.7182

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
Note: If zero events in at least one treatment arm then hazard ratio and p-values not calculated.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte2_ae3_soc.sas 09FEB2023 04:13

Table 3.057110
Time to First Adverse Event of Max Grade 3 or higher by SOC

System Organ Class: Nervous system disorders

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	0	3 (10%)
Censored	14 (100%)	26 (90%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (-, -)	- (1.4, -)
Median (95% CI)	- (-, -)	- (4.1, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		-
Hazard Ratio (95% CI) [3]		- (-, -)
P-value [3]		-

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
Note: If zero events in at least one treatment arm then hazard ratio and p-values not calculated.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte2_ae3_soc.sas 09FEB2023 04:13

Protocol: 207495 Page 11 of 13
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.057110
Time to First Adverse Event of Max Grade 3 or higher by SOC

System Organ Class: Psychiatric disorders

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	1 (7%)	0
Censored	13 (93%)	29 (100%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (2.8, -)	- (-, -)
Median (95% CI)	- (-, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		-
Hazard Ratio (95% CI) [3]		- (-, -)
P-value [3]		-

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
Note: If zero events in at least one treatment arm then hazard ratio and p-values not calculated.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte2_ae3_soc.sas 09FEB2023 04:13

Table 3.057110
Time to First Adverse Event of Max Grade 3 or higher by SOC

System Organ Class: Renal and urinary disorders

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	0	3 (10%)
Censored	14 (100%)	26 (90%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (-, -)	- (0.9, -)
Median (95% CI)	- (-, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		-
Hazard Ratio (95% CI) [3]		- (-, -)
P-value [3]		-

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
Note: If zero events in at least one treatment arm then hazard ratio and p-values not calculated.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte2_ae3_soc.sas 09FEB2023 04:13

Protocol: 207495 Page 13 of 13
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.057110
Time to First Adverse Event of Max Grade 3 or higher by SOC

System Organ Class: Respiratory, thoracic and mediastinal disorders

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	1 (7%)	1 (3%)
Censored	13 (93%)	28 (97%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (0.7, -)	- (-, -)
Median (95% CI)	- (-, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		0.6078
Hazard Ratio (95% CI) [3]		0.49 (0.03, 7.86)
P-value [3]		0.6153

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
Note: If zero events in at least one treatment arm then hazard ratio and p-values not calculated.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte2_ae3_soc.sas 09FEB2023 04:13

Table 3.055110
Adverse Event Summary of Max Grade 3 or Higher by SOC and PT

System Organ Class: Blood and lymphatic system disorders
Preferred Term: Anaemia

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	0	5 (17%)
OR (95% CI) [1] vs. Pom/Dex		>999.99 (<0.01, >999.99)
P-value [1]		0.9533
RR (95% CI) vs. Pom/Dex		5.50 (0.33, 93.01)
ARD (95% CI) vs. Pom/Dex		0.15 (-0.02, 0.32)
P-value [2]		0.1556

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes grade >=3 treatment emergent adverse events for PTs occurring in [at least 5% of patients] in any treatment arm OR in [at least 10 patients AND at least 1% of patients] in any treatment arm.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae3_summ_spt.sas 10FEB2023 06:39

Table 3.055110
Adverse Event Summary of Max Grade 3 or Higher by SOC and PT

System Organ Class: Blood and lymphatic system disorders
Preferred Term: Lymphopenia

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	1 (7%)	1 (3%)
OR (95% CI) [1] vs. Pom/Dex		0.46 (0.03, 8.02)
P-value [1]		0.5976
RR (95% CI) vs. Pom/Dex		0.48 (0.03, 7.16)
ARD (95% CI) vs. Pom/Dex		-0.04 (-0.19, 0.11)
P-value [2]		>0.9999

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes grade >=3 treatment emergent adverse events for PTs occurring in [at least 5% of patients] in any treatment arm OR in [at least 10 patients AND at least 1% of patients] in any treatment arm.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae3_summ_spt.sas 10FEB2023 06:39

Table 3.055110
Adverse Event Summary of Max Grade 3 or Higher by SOC and PT

System Organ Class: Blood and lymphatic system disorders
Preferred Term: Neutropenia

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	4 (29%)	1 (3%)
OR (95% CI) [1] vs. Pom/Dex		0.09 (<0.01, 0.90)
P-value [1]		0.0401
RR (95% CI) vs. Pom/Dex		0.12 (0.01, 0.98)
ARD (95% CI) vs. Pom/Dex		-0.25 (-0.50, -0.01)
P-value [2]		0.0322

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes grade >=3 treatment emergent adverse events for PTs occurring in [at least 5% of patients] in any treatment arm OR in [at least 10 patients AND at least 1% of patients] in any treatment arm.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae3_summ_spt.sas 10FEB2023 06:39

Table 3.055110
Adverse Event Summary of Max Grade 3 or Higher by SOC and PT

System Organ Class: Blood and lymphatic system disorders
Preferred Term: Thrombocytopenia

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	2 (14%)	7 (24%)
OR (95% CI) [1] vs. Pom/Dex		1.91 (0.34, 10.68)
P-value [1]		0.4617
RR (95% CI) vs. Pom/Dex		1.69 (0.40, 7.10)
ARD (95% CI) vs. Pom/Dex		0.10 (-0.14, 0.34)
P-value [2]		0.6934

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes grade >=3 treatment emergent adverse events for PTs occurring in [at least 5% of patients] in any treatment arm OR in [at least 10 patients AND at least 1% of patients] in any treatment arm.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae3_summ_spt.sas 10FEB2023 06:39

Table 3.055110
Adverse Event Summary of Max Grade 3 or Higher by SOC and PT

System Organ Class: Cardiac disorders
Preferred Term: Acute myocardial infarction

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	1 (7%)	0
OR (95% CI) [1] vs. Pom/Dex		<0.01 (<0.01, >999.99)
P-value [1]		0.9509
RR (95% CI) vs. Pom/Dex		0.17 (0.01, 3.85)
ARD (95% CI) vs. Pom/Dex		-0.08 (-0.24, 0.08)
P-value [2]		0.3256

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes grade >=3 treatment emergent adverse events for PTs occurring in [at least 5% of patients] in any treatment arm OR in [at least 10 patients AND at least 1% of patients] in any treatment arm.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae3_summ_spt.sas 10FEB2023 06:39

Table 3.055110
Adverse Event Summary of Max Grade 3 or Higher by SOC and PT

System Organ Class: Eye disorders
Preferred Term: Cataract

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	1 (7%)	0
OR (95% CI) [1] vs. Pom/Dex		<0.01 (<0.01, >999.99)
P-value [1]		0.9509
RR (95% CI) vs. Pom/Dex		0.17 (0.01, 3.85)
ARD (95% CI) vs. Pom/Dex		-0.08 (-0.24, 0.08)
P-value [2]		0.3256

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes grade >=3 treatment emergent adverse events for PTs occurring in [at least 5% of patients] in any treatment arm OR in [at least 10 patients AND at least 1% of patients] in any treatment arm.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae3_summ_spt.sas 10FEB2023 06:39

Table 3.055110
Adverse Event Summary of Max Grade 3 or Higher by SOC and PT

System Organ Class: Eye disorders
Preferred Term: Visual impairment

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	0	3 (10%)
OR (95% CI) [1] vs. Pom/Dex		>999.99 (<0.01, >999.99)
P-value [1]		0.9452
RR (95% CI) vs. Pom/Dex		3.50 (0.19, 63.46)
ARD (95% CI) vs. Pom/Dex		0.08 (-0.06, 0.23)
P-value [2]		0.5394

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes grade >=3 treatment emergent adverse events for PTs occurring in [at least 5% of patients] in any treatment arm OR in [at least 10 patients AND at least 1% of patients] in any treatment arm.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae3_summ_spt.sas 10FEB2023 06:39

Table 3.055110
Adverse Event Summary of Max Grade 3 or Higher by SOC and PT

System Organ Class: General disorders and administration site conditions
Preferred Term: Fatigue

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	1 (7%)	0
OR (95% CI) [1] vs. Pom/Dex		<0.01 (<0.01, >999.99)
P-value [1]		0.9509
RR (95% CI) vs. Pom/Dex		0.17 (0.01, 3.85)
ARD (95% CI) vs. Pom/Dex		-0.08 (-0.24, 0.08)
P-value [2]		0.3256

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes grade >=3 treatment emergent adverse events for PTs occurring in [at least 5% of patients] in any treatment arm OR in [at least 10 patients AND at least 1% of patients] in any treatment arm.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae3_summ_spt.sas 10FEB2023 06:39

Table 3.055110
Adverse Event Summary of Max Grade 3 or Higher by SOC and PT

System Organ Class: Infections and infestations
Preferred Term: COVID-19

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	1 (7%)	0
OR (95% CI) [1] vs. Pom/Dex		<0.01 (<0.01, >999.99)
P-value [1]		0.9509
RR (95% CI) vs. Pom/Dex		0.17 (0.01, 3.85)
ARD (95% CI) vs. Pom/Dex		-0.08 (-0.24, 0.08)
P-value [2]		0.3256

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes grade >=3 treatment emergent adverse events for PTs occurring in [at least 5% of patients] in any treatment arm OR in [at least 10 patients AND at least 1% of patients] in any treatment arm.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae3_summ_spt.sas 10FEB2023 06:39

Table 3.055110
Adverse Event Summary of Max Grade 3 or Higher by SOC and PT

System Organ Class: Infections and infestations
Preferred Term: Pneumonia

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	2 (14%)	1 (3%)
OR (95% CI) [1] vs. Pom/Dex		0.21 (0.02, 2.59)
P-value [1]		0.2260
RR (95% CI) vs. Pom/Dex		0.24 (0.02, 2.44)
ARD (95% CI) vs. Pom/Dex		-0.11 (-0.30, 0.09)
P-value [2]		0.2433

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes grade >=3 treatment emergent adverse events for PTs occurring in [at least 5% of patients] in any treatment arm OR in [at least 10 patients AND at least 1% of patients] in any treatment arm.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae3_summ_spt.sas 10FEB2023 06:39

Table 3.055110
Adverse Event Summary of Max Grade 3 or Higher by SOC and PT

System Organ Class: Infections and infestations
Preferred Term: Pulmonary nocardiosis

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	1 (7%)	0
OR (95% CI) [1] vs. Pom/Dex		<0.01 (<0.01, >999.99)
P-value [1]		0.9509
RR (95% CI) vs. Pom/Dex		0.17 (0.01, 3.85)
ARD (95% CI) vs. Pom/Dex		-0.08 (-0.24, 0.08)
P-value [2]		0.3256

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes grade >=3 treatment emergent adverse events for PTs occurring in [at least 5% of patients] in any treatment arm OR in [at least 10 patients AND at least 1% of patients] in any treatment arm.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae3_summ_spt.sas 10FEB2023 06:39

Table 3.055110
Adverse Event Summary of Max Grade 3 or Higher by SOC and PT

System Organ Class: Investigations
Preferred Term: Neutrophil count decreased

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	2 (14%)	0
OR (95% CI) [1] vs. Pom/Dex		<0.01 (<0.01, >999.99)
P-value [1]		0.9541
RR (95% CI) vs. Pom/Dex		0.10 (0.01, 1.95)
ARD (95% CI) vs. Pom/Dex		-0.15 (-0.34, 0.04)
P-value [2]		0.1008

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes grade >=3 treatment emergent adverse events for PTs occurring in [at least 5% of patients] in any treatment arm OR in [at least 10 patients AND at least 1% of patients] in any treatment arm.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae3_summ_spt.sas 10FEB2023 06:39

Table 3.055110
Adverse Event Summary of Max Grade 3 or Higher by SOC and PT

System Organ Class: Metabolism and nutrition disorders
Preferred Term: Hypercalcaemia

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	1 (7%)	1 (3%)
OR (95% CI) [1] vs. Pom/Dex		0.46 (0.03, 8.02)
P-value [1]		0.5976
RR (95% CI) vs. Pom/Dex		0.48 (0.03, 7.16)
ARD (95% CI) vs. Pom/Dex		-0.04 (-0.19, 0.11)
P-value [2]		>0.9999

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes grade >=3 treatment emergent adverse events for PTs occurring in [at least 5% of patients] in any treatment arm OR in [at least 10 patients AND at least 1% of patients] in any treatment arm.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae3_summ_spt.sas 10FEB2023 06:39

Table 3.055110
Adverse Event Summary of Max Grade 3 or Higher by SOC and PT

System Organ Class: Metabolism and nutrition disorders
Preferred Term: Hypokalaemia

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	0	2 (7%)
OR (95% CI) [1] vs. Pom/Dex		>999.99 (<0.01, >999.99)
P-value [1]		0.9551
RR (95% CI) vs. Pom/Dex		2.50 (0.13, 48.85)
ARD (95% CI) vs. Pom/Dex		0.05 (-0.08, 0.18)
P-value [2]		>0.9999

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes grade >=3 treatment emergent adverse events for PTs occurring in [at least 5% of patients] in any treatment arm OR in [at least 10 patients AND at least 1% of patients] in any treatment arm.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae3_summ_spt.sas 10FEB2023 06:39

Table 3.055110
Adverse Event Summary of Max Grade 3 or Higher by SOC and PT

System Organ Class: Musculoskeletal and connective tissue disorders
Preferred Term: Bone pain

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	1 (7%)	2 (7%)
OR (95% CI) [1] vs. Pom/Dex		0.96 (0.08, 11.61)
P-value [1]		0.9762
RR (95% CI) vs. Pom/Dex		0.97 (0.10, 9.77)
ARD (95% CI) vs. Pom/Dex		0.00 (-0.17, 0.16)
P-value [2]		>0.9999

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes grade >=3 treatment emergent adverse events for PTs occurring in [at least 5% of patients] in any treatment arm OR in [at least 10 patients AND at least 1% of patients] in any treatment arm.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae3_summ_spt.sas 10FEB2023 06:39

Table 3.055110
Adverse Event Summary of Max Grade 3 or Higher by SOC and PT

System Organ Class: Musculoskeletal and connective tissue disorders
Preferred Term: Osteonecrosis of jaw

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	1 (7%)	0
OR (95% CI) [1] vs. Pom/Dex		<0.01 (<0.01, >999.99)
P-value [1]		0.9509
RR (95% CI) vs. Pom/Dex		0.17 (0.01, 3.85)
ARD (95% CI) vs. Pom/Dex		-0.08 (-0.24, 0.08)
P-value [2]		0.3256

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes grade >=3 treatment emergent adverse events for PTs occurring in [at least 5% of patients] in any treatment arm OR in [at least 10 patients AND at least 1% of patients] in any treatment arm.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae3_summ_spt.sas 10FEB2023 06:39

Table 3.055110
Adverse Event Summary of Max Grade 3 or Higher by SOC and PT

System Organ Class: Psychiatric disorders
Preferred Term: Insomnia

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	1 (7%)	0
OR (95% CI) [1] vs. Pom/Dex		<0.01 (<0.01, >999.99)
P-value [1]		0.9509
RR (95% CI) vs. Pom/Dex		0.17 (0.01, 3.85)
ARD (95% CI) vs. Pom/Dex		-0.08 (-0.24, 0.08)
P-value [2]		0.3256

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes grade >=3 treatment emergent adverse events for PTs occurring in [at least 5% of patients] in any treatment arm OR in [at least 10 patients AND at least 1% of patients] in any treatment arm.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae3_summ_spt.sas 10FEB2023 06:39

Table 3.055110
Adverse Event Summary of Max Grade 3 or Higher by SOC and PT

System Organ Class: Renal and urinary disorders
Preferred Term: Acute kidney injury

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	0	2 (7%)
OR (95% CI) [1] vs. Pom/Dex		>999.99 (<0.01, >999.99)
P-value [1]		0.9551
RR (95% CI) vs. Pom/Dex		2.50 (0.13, 48.85)
ARD (95% CI) vs. Pom/Dex		0.05 (-0.08, 0.18)
P-value [2]		>0.9999

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes grade >=3 treatment emergent adverse events for PTs occurring in [at least 5% of patients] in any treatment arm OR in [at least 10 patients AND at least 1% of patients] in any treatment arm.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae3_summ_spt.sas 10FEB2023 06:39

Table 3.055110
Adverse Event Summary of Max Grade 3 or Higher by SOC and PT

System Organ Class: Respiratory, thoracic and mediastinal disorders
Preferred Term: Hiccups

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	1 (7%)	0
OR (95% CI) [1] vs. Pom/Dex		<0.01 (<0.01, >999.99)
P-value [1]		0.9509
RR (95% CI) vs. Pom/Dex		0.17 (0.01, 3.85)
ARD (95% CI) vs. Pom/Dex		-0.08 (-0.24, 0.08)
P-value [2]		0.3256

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes grade >=3 treatment emergent adverse events for PTs occurring in [at least 5% of patients] in any treatment arm OR in [at least 10 patients AND at least 1% of patients] in any treatment arm.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae3_summ_spt.sas 10FEB2023 06:39

Protocol: 207495 Page 1 of 19
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.058110
Time to First Adverse Event of Max Grade 3 or higher by SOC and PT

System Organ Class: Blood and lymphatic system disorders
Preferred Term: Anaemia

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	0	5 (17%)
Censored	14 (100%)	24 (83%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (-, -)	- (1.0, -)
Median (95% CI)	- (-, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		-
Hazard Ratio (95% CI) [3]		- (-, -)
P-value [3]		-

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
Note: If zero events in at least one treatment arm then hazard ratio and p-values not calculated.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte2_ae3_spt.sas 09FEB2023 04:14

Table 3.058110
Time to First Adverse Event of Max Grade 3 or higher by SOC and PT

System Organ Class: Blood and lymphatic system disorders
Preferred Term: Lymphopenia

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	1 (7%)	1 (3%)
Censored	13 (93%)	28 (97%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (0.1, -)	- (-, -)
Median (95% CI)	- (-, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		0.5793
Hazard Ratio (95% CI) [3]		0.47 (0.03, 7.44)
P-value [3]		0.5885

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
Note: If zero events in at least one treatment arm then hazard ratio and p-values not calculated.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte2_ae3_spt.sas 09FEB2023 04:14

Protocol: 207495 Page 3 of 19
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.058110
Time to First Adverse Event of Max Grade 3 or higher by SOC and PT

System Organ Class: Blood and lymphatic system disorders
Preferred Term: Neutropenia

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	4 (29%)	1 (3%)
Censored	10 (71%)	28 (97%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	5.6 (0.8, -)	- (1.4, -)
Median (95% CI)	- (1.0, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		0.0350
Hazard Ratio (95% CI) [3]		0.13 (0.01, 1.19)
P-value [3]		0.0708

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
Note: If zero events in at least one treatment arm then hazard ratio and p-values not calculated.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte2_ae3_spt.sas 09FEB2023 04:14

Protocol: 207495 Page 4 of 19
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.058110
Time to First Adverse Event of Max Grade 3 or higher by SOC and PT

System Organ Class: Blood and lymphatic system disorders
Preferred Term: Thrombocytopenia

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	2 (14%)	7 (24%)
Censored	12 (86%)	22 (76%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (0.3, -)	1.4 (0.4, -)
Median (95% CI)	- (-, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		0.4414
Hazard Ratio (95% CI) [3]		1.83 (0.38, 8.82)
P-value [3]		0.4510

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
Note: If zero events in at least one treatment arm then hazard ratio and p-values not calculated.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte2_ae3_spt.sas 09FEB2023 04:14

Protocol: 207495 Page 5 of 19
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.058110
Time to First Adverse Event of Max Grade 3 or higher by SOC and PT

System Organ Class: Cardiac disorders
Preferred Term: Acute myocardial infarction

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	1 (7%)	0
Censored	13 (93%)	29 (100%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (8.5, -)	- (-, -)
Median (95% CI)	- (8.5, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		-
Hazard Ratio (95% CI) [3]		- (-, -)
P-value [3]		-

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
Note: If zero events in at least one treatment arm then hazard ratio and p-values not calculated.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte2_ae3_spt.sas 09FEB2023 04:14

Protocol: 207495 Page 6 of 19
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.058110
Time to First Adverse Event of Max Grade 3 or higher by SOC and PT

System Organ Class: Eye disorders
Preferred Term: Cataract

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	1 (7%)	0
Censored	13 (93%)	29 (100%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (6.3, -)	- (-, -)
Median (95% CI)	- (-, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		-
Hazard Ratio (95% CI) [3]		- (-, -)
P-value [3]		-

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
Note: If zero events in at least one treatment arm then hazard ratio and p-values not calculated.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte2_ae3_spt.sas 09FEB2023 04:14

Protocol: 207495 Page 7 of 19
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.058110
Time to First Adverse Event of Max Grade 3 or higher by SOC and PT

System Organ Class: Eye disorders
Preferred Term: Visual impairment

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	0	3 (10%)
Censored	14 (100%)	26 (90%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (-, -)	- (0.8, -)
Median (95% CI)	- (-, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		-
Hazard Ratio (95% CI) [3]		- (-, -)
P-value [3]		-

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
Note: If zero events in at least one treatment arm then hazard ratio and p-values not calculated.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte2_ae3_spt.sas 09FEB2023 04:14

Protocol: 207495 Page 8 of 19
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.058110
Time to First Adverse Event of Max Grade 3 or higher by SOC and PT

System Organ Class: General disorders and administration site conditions
Preferred Term: Fatigue

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	1 (7%)	0
Censored	13 (93%)	29 (100%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (0.8, -)	- (-, -)
Median (95% CI)	- (-, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		-
Hazard Ratio (95% CI) [3]		- (-, -)
P-value [3]		-

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
Note: If zero events in at least one treatment arm then hazard ratio and p-values not calculated.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte2_ae3_spt.sas 09FEB2023 04:14

Protocol: 207495 Page 9 of 19
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.058110
Time to First Adverse Event of Max Grade 3 or higher by SOC and PT

System Organ Class: Infections and infestations
Preferred Term: COVID-19

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	1 (7%)	0
Censored	13 (93%)	29 (100%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (0.5, -)	- (-, -)
Median (95% CI)	- (-, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		-
Hazard Ratio (95% CI) [3]		- (-, -)
P-value [3]		-

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
Note: If zero events in at least one treatment arm then hazard ratio and p-values not calculated.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte2_ae3_spt.sas 09FEB2023 04:14

Table 3.058110
Time to First Adverse Event of Max Grade 3 or higher by SOC and PT

System Organ Class: Infections and infestations
Preferred Term: Pneumonia

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	2 (14%)	1 (3%)
Censored	12 (86%)	28 (97%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	19.5 (2.3, -)	- (-, -)
Median (95% CI)	19.5 (19.5, -)	- (-, -)
3rd Quartile (95% CI)	- (19.5, -)	- (-, -)
Log-Rank P-value [2]		0.4884
Hazard Ratio (95% CI) [3]		0.42 (0.04, 5.09)
P-value [3]		0.4989

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
Note: If zero events in at least one treatment arm then hazard ratio and p-values not calculated.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte2_ae3_spt.sas 09FEB2023 04:14

Protocol: 207495 Page 11 of 19
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.058110
Time to First Adverse Event of Max Grade 3 or higher by SOC and PT

System Organ Class: Infections and infestations
Preferred Term: Pulmonary nocardiosis

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	1 (7%)	0
Censored	13 (93%)	29 (100%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (8.2, -)	- (-, -)
Median (95% CI)	- (8.2, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		-
Hazard Ratio (95% CI) [3]		- (-, -)
P-value [3]		-

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
Note: If zero events in at least one treatment arm then hazard ratio and p-values not calculated.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte2_ae3_spt.sas 09FEB2023 04:14

Protocol: 207495 Page 12 of 19
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.058110
Time to First Adverse Event of Max Grade 3 or higher by SOC and PT

System Organ Class: Investigations
Preferred Term: Neutrophil count decreased

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	2 (14%)	0
Censored	12 (86%)	29 (100%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (0.7, -)	- (-, -)
Median (95% CI)	- (4.4, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		-
Hazard Ratio (95% CI) [3]		- (-, -)
P-value [3]		-

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
Note: If zero events in at least one treatment arm then hazard ratio and p-values not calculated.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte2_ae3_spt.sas 09FEB2023 04:14

Protocol: 207495 Page 13 of 19
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.058110
Time to First Adverse Event of Max Grade 3 or higher by SOC and PT

System Organ Class: Metabolism and nutrition disorders
Preferred Term: Hypercalcaemia

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	1 (7%)	1 (3%)
Censored	13 (93%)	28 (97%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (3.5, -)	- (-, -)
Median (95% CI)	- (-, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		0.7991
Hazard Ratio (95% CI) [3]		0.69 (0.04, 11.63)
P-value [3]		0.8001

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
Note: If zero events in at least one treatment arm then hazard ratio and p-values not calculated.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte2_ae3_spt.sas 09FEB2023 04:14

Protocol: 207495 Page 14 of 19
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.058110
Time to First Adverse Event of Max Grade 3 or higher by SOC and PT

System Organ Class: Metabolism and nutrition disorders
Preferred Term: Hypokalaemia

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	0	2 (7%)
Censored	14 (100%)	27 (93%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (-, -)	10.4 (1.1, -)
Median (95% CI)	- (-, -)	- (10.4, -)
3rd Quartile (95% CI)	- (-, -)	- (10.4, -)
Log-Rank P-value [2]		-
Hazard Ratio (95% CI) [3]		- (-, -)
P-value [3]		-

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
Note: If zero events in at least one treatment arm then hazard ratio and p-values not calculated.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte2_ae3_spt.sas 09FEB2023 04:14

Protocol: 207495 Page 15 of 19
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.058110
Time to First Adverse Event of Max Grade 3 or higher by SOC and PT

System Organ Class: Musculoskeletal and connective tissue disorders
Preferred Term: Bone pain

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	1 (7%)	2 (7%)
Censored	13 (93%)	27 (93%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (0.8, -)	- (-, -)
Median (95% CI)	- (-, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		0.9927
Hazard Ratio (95% CI) [3]		1.00 (0.09, 11.04)
P-value [3]		0.9996

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
Note: If zero events in at least one treatment arm then hazard ratio and p-values not calculated.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte2_ae3_spt.sas 09FEB2023 04:14

Protocol: 207495 Page 16 of 19
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.058110
Time to First Adverse Event of Max Grade 3 or higher by SOC and PT

System Organ Class: Musculoskeletal and connective tissue disorders
Preferred Term: Osteonecrosis of jaw

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	1 (7%)	0
Censored	13 (93%)	29 (100%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (5.8, -)	- (-, -)
Median (95% CI)	- (-, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		-
Hazard Ratio (95% CI) [3]		- (-, -)
P-value [3]		-

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
Note: If zero events in at least one treatment arm then hazard ratio and p-values not calculated.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte2_ae3_spt.sas 09FEB2023 04:14

Protocol: 207495 Page 17 of 19
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.058110
Time to First Adverse Event of Max Grade 3 or higher by SOC and PT

System Organ Class: Psychiatric disorders
Preferred Term: Insomnia

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	1 (7%)	0
Censored	13 (93%)	29 (100%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (2.8, -)	- (-, -)
Median (95% CI)	- (-, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		-
Hazard Ratio (95% CI) [3]		- (-, -)
P-value [3]		-

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
Note: If zero events in at least one treatment arm then hazard ratio and p-values not calculated.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte2_ae3_spt.sas 09FEB2023 04:14

Protocol: 207495 Page 18 of 19
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.058110
Time to First Adverse Event of Max Grade 3 or higher by SOC and PT

System Organ Class: Renal and urinary disorders
Preferred Term: Acute kidney injury

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	0	2 (7%)
Censored	14 (100%)	27 (93%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (-, -)	- (0.9, -)
Median (95% CI)	- (-, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		-
Hazard Ratio (95% CI) [3]		- (-, -)
P-value [3]		-

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
Note: If zero events in at least one treatment arm then hazard ratio and p-values not calculated.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte2_ae3_spt.sas 09FEB2023 04:14

Protocol: 207495 Page 19 of 19
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.058110
Time to First Adverse Event of Max Grade 3 or higher by SOC and PT

System Organ Class: Respiratory, thoracic and mediastinal disorders
Preferred Term: Hiccups

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	1 (7%)	0
Censored	13 (93%)	29 (100%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (0.7, -)	- (-, -)
Median (95% CI)	- (-, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		-
Hazard Ratio (95% CI) [3]		- (-, -)
P-value [3]		-

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
Note: If zero events in at least one treatment arm then hazard ratio and p-values not calculated.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte2_ae3_spt.sas 09FEB2023 04:14

Table 3.060110
Adverse Event Summary of Serious AEs by SOC

System Organ Class: Cardiac disorders

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	1 (7%)	1 (3%)
OR (95% CI) [1] vs. Pom/Dex		0.46 (0.03, 8.02)
P-value [1]		0.5976
RR (95% CI) vs. Pom/Dex		0.48 (0.03, 7.16)
ARD (95% CI) vs. Pom/Dex		-0.04 (-0.19, 0.11)
P-value [2]		>0.9999

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes serious treatment emergent adverse events for SOCs occurring in [at least 5% of patients] in any treatment arm OR in [at least 10 patients AND at least 1% of patients] in any treatment arm.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_aes_summ_soc.sas 10FEB2023 06:39

Table 3.060110
Adverse Event Summary of Serious AEs by SOC

System Organ Class: Gastrointestinal disorders

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	0	3 (10%)
OR (95% CI) [1] vs. Pom/Dex		>999.99 (<0.01, >999.99)
P-value [1]		0.9452
RR (95% CI) vs. Pom/Dex		3.50 (0.19, 63.46)
ARD (95% CI) vs. Pom/Dex		0.08 (-0.06, 0.23)
P-value [2]		0.5394

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes serious treatment emergent adverse events for SOCs occurring in [at least 5% of patients] in any treatment arm OR in [at least 10 patients AND at least 1% of patients] in any treatment arm.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_aes_summ_soc.sas 10FEB2023 06:39

Table 3.060110
Adverse Event Summary of Serious AEs by SOC

System Organ Class: Infections and infestations

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	5 (36%)	3 (10%)
OR (95% CI) [1] vs. Pom/Dex		0.21 (0.04, 1.05)
P-value [1]		0.0572
RR (95% CI) vs. Pom/Dex		0.29 (0.08, 1.04)
ARD (95% CI) vs. Pom/Dex		-0.25 (-0.53, 0.02)
P-value [2]		0.0892

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes serious treatment emergent adverse events for SOCs occurring in [at least 5% of patients] in any treatment arm OR in [at least 10 patients AND at least 1% of patients] in any treatment arm.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_aes_summ_soc.sas 10FEB2023 06:39

Table 3.060110
Adverse Event Summary of Serious AEs by SOC

System Organ Class: Investigations

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	1 (7%)	1 (3%)
OR (95% CI) [1] vs. Pom/Dex		0.46 (0.03, 8.02)
P-value [1]		0.5976
RR (95% CI) vs. Pom/Dex		0.48 (0.03, 7.16)
ARD (95% CI) vs. Pom/Dex		-0.04 (-0.19, 0.11)
P-value [2]		>0.9999

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes serious treatment emergent adverse events for SOCs occurring in [at least 5% of patients] in any treatment arm OR in [at least 10 patients AND at least 1% of patients] in any treatment arm.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_aes_summ_soc.sas 10FEB2023 06:39

Table 3.060110
Adverse Event Summary of Serious AEs by SOC

System Organ Class: Musculoskeletal and connective tissue disorders

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	0	4 (14%)
OR (95% CI) [1] vs. Pom/Dex		>999.99 (<0.01, >999.99)
P-value [1]		0.9581
RR (95% CI) vs. Pom/Dex		4.50 (0.26, 78.20)
ARD (95% CI) vs. Pom/Dex		0.12 (-0.04, 0.27)
P-value [2]		0.2861

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes serious treatment emergent adverse events for SOCs occurring in [at least 5% of patients] in any treatment arm OR in [at least 10 patients AND at least 1% of patients] in any treatment arm.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_aes_summ_soc.sas 10FEB2023 06:39

Table 3.060110
Adverse Event Summary of Serious AEs by SOC

System Organ Class: Nervous system disorders

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	0	3 (10%)
OR (95% CI) [1] vs. Pom/Dex		>999.99 (<0.01, >999.99)
P-value [1]		0.9452
RR (95% CI) vs. Pom/Dex		3.50 (0.19, 63.46)
ARD (95% CI) vs. Pom/Dex		0.08 (-0.06, 0.23)
P-value [2]		0.5394

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes serious treatment emergent adverse events for SOCs occurring in [at least 5% of patients] in any treatment arm OR in [at least 10 patients AND at least 1% of patients] in any treatment arm.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_aes_summ_soc.sas 10FEB2023 06:39

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.063110
Time to First Serious Adverse Event by SOC

System Organ Class: Cardiac disorders

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	1 (7%)	1 (3%)
Censored	13 (93%)	28 (97%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (8.5, -)	- (-, -)
Median (95% CI)	- (8.5, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		0.7991
Hazard Ratio (95% CI) [3]		0.69 (0.04, 11.63)
P-value [3]		0.8001

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
Note: If zero events in at least one treatment arm then hazard ratio and p-values not calculated.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte2_aes_soc.sas 09FEB2023 04:19

Table 3.063110
Time to First Serious Adverse Event by SOC

System Organ Class: Gastrointestinal disorders

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	0	3 (10%)
Censored	14 (100%)	26 (90%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (-, -)	4.8 (4.0, -)
Median (95% CI)	- (-, -)	- (4.0, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		-
Hazard Ratio (95% CI) [3]		- (-, -)
P-value [3]		-

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
Note: If zero events in at least one treatment arm then hazard ratio and p-values not calculated.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte2_aes_soc.sas 09FEB2023 04:19

Table 3.063110
Time to First Serious Adverse Event by SOC

System Organ Class: Infections and infestations

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	5 (36%)	3 (10%)
Censored	9 (64%)	26 (90%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	8.2 (0.5, 19.5)	- (0.6, -)
Median (95% CI)	19.5 (5.5, -)	- (-, -)
3rd Quartile (95% CI)	- (19.5, -)	- (-, -)
Log-Rank P-value [2]		0.2790
Hazard Ratio (95% CI) [3]		0.45 (0.10, 1.97)
P-value [3]		0.2896

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
Note: If zero events in at least one treatment arm then hazard ratio and p-values not calculated.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte2_aes_soc.sas 09FEB2023 04:19

Protocol: 207495 Page 4 of 6
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.063110
Time to First Serious Adverse Event by SOC

System Organ Class: Investigations

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	1 (7%)	1 (3%)
Censored	13 (93%)	28 (97%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (4.4, -)	- (-, -)
Median (95% CI)	- (-, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		0.8885
Hazard Ratio (95% CI) [3]		0.81 (0.05, 14.33)
P-value [3]		0.8886

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
Note: If zero events in at least one treatment arm then hazard ratio and p-values not calculated.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte2_aes_soc.sas 09FEB2023 04:19

Table 3.063110
Time to First Serious Adverse Event by SOC

System Organ Class: Musculoskeletal and connective tissue disorders

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	0	4 (14%)
Censored	14 (100%)	25 (86%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (-, -)	- (1.9, -)
Median (95% CI)	- (-, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		-
Hazard Ratio (95% CI) [3]		- (-, -)
P-value [3]		-

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
Note: If zero events in at least one treatment arm then hazard ratio and p-values not calculated.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte2_aes_soc.sas 09FEB2023 04:19

Table 3.063110
Time to First Serious Adverse Event by SOC

System Organ Class: Nervous system disorders

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	0	3 (10%)
Censored	14 (100%)	26 (90%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (-, -)	- (1.4, -)
Median (95% CI)	- (-, -)	- (4.1, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		-
Hazard Ratio (95% CI) [3]		- (-, -)
P-value [3]		-

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
Note: If zero events in at least one treatment arm then hazard ratio and p-values not calculated.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte2_aes_soc.sas 09FEB2023 04:19

Table 3.061110
Adverse Event Summary of Serious AEs by SOC and PT

System Organ Class: Cardiac disorders
Preferred Term: Acute myocardial infarction

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	1 (7%)	0
OR (95% CI) [1] vs. Pom/Dex		<0.01 (<0.01, >999.99)
P-value [1]		0.9509
RR (95% CI) vs. Pom/Dex		0.17 (0.01, 3.85)
ARD (95% CI) vs. Pom/Dex		-0.08 (-0.24, 0.08)
P-value [2]		0.3256

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes serious treatment emergent adverse events for PTs occurring in [at least 5% of patients] in any treatment arm OR in [at least 10 patients AND at least 1% of patients] in any treatment arm.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_aes_summ_spt.sas 10FEB2023 06:39

Table 3.061110
Adverse Event Summary of Serious AEs by SOC and PT

System Organ Class: Infections and infestations
Preferred Term: COVID-19

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	1 (7%)	0
OR (95% CI) [1] vs. Pom/Dex		<0.01 (<0.01, >999.99)
P-value [1]		0.9509
RR (95% CI) vs. Pom/Dex		0.17 (0.01, 3.85)
ARD (95% CI) vs. Pom/Dex		-0.08 (-0.24, 0.08)
P-value [2]		0.3256

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes serious treatment emergent adverse events for PTs occurring in [at least 5% of patients] in any treatment arm OR in [at least 10 patients AND at least 1% of patients] in any treatment arm.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_aes_summ_spt.sas 10FEB2023 06:39

Table 3.061110
Adverse Event Summary of Serious AEs by SOC and PT

System Organ Class: Infections and infestations
Preferred Term: COVID-19 pneumonia

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	1 (7%)	0
OR (95% CI) [1] vs. Pom/Dex		<0.01 (<0.01, >999.99)
P-value [1]		0.9509
RR (95% CI) vs. Pom/Dex		0.17 (0.01, 3.85)
ARD (95% CI) vs. Pom/Dex		-0.08 (-0.24, 0.08)
P-value [2]		0.3256

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes serious treatment emergent adverse events for PTs occurring in [at least 5% of patients] in any treatment arm OR in [at least 10 patients AND at least 1% of patients] in any treatment arm.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_aes_summ_spt.sas 10FEB2023 06:39

Table 3.061110
Adverse Event Summary of Serious AEs by SOC and PT

System Organ Class: Infections and infestations
Preferred Term: Pneumonia

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	2 (14%)	2 (7%)
OR (95% CI) [1] vs. Pom/Dex		0.44 (0.06, 3.54)
P-value [1]		0.4436
RR (95% CI) vs. Pom/Dex		0.48 (0.08, 3.08)
ARD (95% CI) vs. Pom/Dex		-0.07 (-0.28, 0.13)
P-value [2]		0.5855

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes serious treatment emergent adverse events for PTs occurring in [at least 5% of patients] in any treatment arm OR in [at least 10 patients AND at least 1% of patients] in any treatment arm.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_aes_summ_spt.sas 10FEB2023 06:39

Table 3.061110
Adverse Event Summary of Serious AEs by SOC and PT

System Organ Class: Infections and infestations
Preferred Term: Pulmonary nocardiosis

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	1 (7%)	0
OR (95% CI) [1] vs. Pom/Dex		<0.01 (<0.01, >999.99)
P-value [1]		0.9509
RR (95% CI) vs. Pom/Dex		0.17 (0.01, 3.85)
ARD (95% CI) vs. Pom/Dex		-0.08 (-0.24, 0.08)
P-value [2]		0.3256

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes serious treatment emergent adverse events for PTs occurring in [at least 5% of patients] in any treatment arm OR in [at least 10 patients AND at least 1% of patients] in any treatment arm.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_aes_summ_spt.sas 10FEB2023 06:39

Table 3.061110
Adverse Event Summary of Serious AEs by SOC and PT

System Organ Class: Investigations
Preferred Term: Neutrophil count decreased

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	1 (7%)	0
OR (95% CI) [1] vs. Pom/Dex		<0.01 (<0.01, >999.99)
P-value [1]		0.9509
RR (95% CI) vs. Pom/Dex		0.17 (0.01, 3.85)
ARD (95% CI) vs. Pom/Dex		-0.08 (-0.24, 0.08)
P-value [2]		0.3256

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes serious treatment emergent adverse events for PTs occurring in [at least 5% of patients] in any treatment arm OR in [at least 10 patients AND at least 1% of patients] in any treatment arm.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_aes_summ_spt.sas 10FEB2023 06:39

Table 3.061110
Adverse Event Summary of Serious AEs by SOC and PT

System Organ Class: Musculoskeletal and connective tissue disorders
Preferred Term: Bone pain

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	0	2 (7%)
OR (95% CI) [1] vs. Pom/Dex		>999.99 (<0.01, >999.99)
P-value [1]		0.9551
RR (95% CI) vs. Pom/Dex		2.50 (0.13, 48.85)
ARD (95% CI) vs. Pom/Dex		0.05 (-0.08, 0.18)
P-value [2]		>0.9999

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes serious treatment emergent adverse events for PTs occurring in [at least 5% of patients] in any treatment arm OR in [at least 10 patients AND at least 1% of patients] in any treatment arm.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_aes_summ_spt.sas 10FEB2023 06:39

Protocol: 207495 Page 1 of 7
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.064110
Time to First Serious Adverse Event by SOC and PT

System Organ Class: Cardiac disorders
Preferred Term: Acute myocardial infarction

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	1 (7%)	0
Censored	13 (93%)	29 (100%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (8.5, -)	- (-, -)
Median (95% CI)	- (8.5, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		-
Hazard Ratio (95% CI) [3]		- (-, -)
P-value [3]		-

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
Note: If zero events in at least one treatment arm then hazard ratio and p-values not calculated.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte2_aes_spt.sas 09FEB2023 04:19

Table 3.064110
Time to First Serious Adverse Event by SOC and PT

System Organ Class: Infections and infestations
Preferred Term: COVID-19

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	1 (7%)	0
Censored	13 (93%)	29 (100%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (0.5, -)	- (-, -)
Median (95% CI)	- (-, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		-
Hazard Ratio (95% CI) [3]		- (-, -)
P-value [3]		-

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
Note: If zero events in at least one treatment arm then hazard ratio and p-values not calculated.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte2_aes_spt.sas 09FEB2023 04:19

Table 3.064110
Time to First Serious Adverse Event by SOC and PT

System Organ Class: Infections and infestations
Preferred Term: COVID-19 pneumonia

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	1 (7%)	0
Censored	13 (93%)	29 (100%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (5.5, -)	- (-, -)
Median (95% CI)	- (-, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		-
Hazard Ratio (95% CI) [3]		- (-, -)
P-value [3]		-

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
Note: If zero events in at least one treatment arm then hazard ratio and p-values not calculated.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte2_aes_spt.sas 09FEB2023 04:19

Protocol: 207495 Page 4 of 7
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.064110
Time to First Serious Adverse Event by SOC and PT

System Organ Class: Infections and infestations
Preferred Term: Pneumonia

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	2 (14%)	2 (7%)
Censored	12 (86%)	27 (93%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	19.5 (2.3, -)	- (-, -)
Median (95% CI)	19.5 (19.5, -)	- (-, -)
3rd Quartile (95% CI)	- (19.5, -)	- (-, -)
Log-Rank P-value [2]		0.8127
Hazard Ratio (95% CI) [3]		0.78 (0.10, 6.00)
P-value [3]		0.8131

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
Note: If zero events in at least one treatment arm then hazard ratio and p-values not calculated.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte2_aes_spt.sas 09FEB2023 04:19

Protocol: 207495 Page 5 of 7
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.064110
Time to First Serious Adverse Event by SOC and PT

System Organ Class: Infections and infestations
Preferred Term: Pulmonary nocardiosis

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	1 (7%)	0
Censored	13 (93%)	29 (100%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (8.2, -)	- (-, -)
Median (95% CI)	- (8.2, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		-
Hazard Ratio (95% CI) [3]		- (-, -)
P-value [3]		-

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
Note: If zero events in at least one treatment arm then hazard ratio and p-values not calculated.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte2_aes_spt.sas 09FEB2023 04:19

Protocol: 207495 Page 6 of 7
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.064110
Time to First Serious Adverse Event by SOC and PT

System Organ Class: Investigations
Preferred Term: Neutrophil count decreased

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	1 (7%)	0
Censored	13 (93%)	29 (100%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (4.4, -)	- (-, -)
Median (95% CI)	- (-, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		-
Hazard Ratio (95% CI) [3]		- (-, -)
P-value [3]		-

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
Note: If zero events in at least one treatment arm then hazard ratio and p-values not calculated.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte2_aes_spt.sas 09FEB2023 04:19

Protocol: 207495 Page 7 of 7
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.064110
Time to First Serious Adverse Event by SOC and PT

System Organ Class: Musculoskeletal and connective tissue disorders
Preferred Term: Bone pain

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	0	2 (7%)
Censored	14 (100%)	27 (93%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (-, -)	- (-, -)
Median (95% CI)	- (-, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		-
Hazard Ratio (95% CI) [3]		- (-, -)
P-value [3]		-

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
Note: If zero events in at least one treatment arm then hazard ratio and p-values not calculated.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte2_aes_spt.sas 09FEB2023 04:19

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.065110
Non-fatal Serious Adverse Event Summary

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	4 (29%)	11 (38%)
OR (95% CI) [1] vs. Pom/Dex		1.53 (0.38, 6.08)
P-value [1]		0.5475
RR (95% CI) vs. Pom/Dex		1.33 (0.51, 3.43)
ARD (95% CI) vs. Pom/Dex		0.09 (-0.20, 0.39)
P-value [2]		0.7354

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes treatment emergent adverse events.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_aenf_summ.sas 14FEB2023 03:40

Protocol: 207495 Page 1 of 1
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.068110
Time to First Non-Fatal Serious Adverse Event

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	4 (29%)	11 (38%)
Censored	10 (71%)	18 (62%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	8.2 (2.3, -)	1.4 (0.3, 4.1)
Median (95% CI)	19.5 (5.5, -)	- (1.9, -)
3rd Quartile (95% CI)	- (19.5, -)	- (4.1, -)
Log-Rank P-value [2]		0.1182
Hazard Ratio (95% CI) [3]		2.49 (0.77, 8.04)
P-value [3]		0.1284

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte_ae_nfs.sas 14FEB2023 03:41

Table 3.066110
Non-fatal Serious Adverse Event Summary by SOC

System Organ Class: Cardiac disorders

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	1 (7%)	1 (3%)
OR (95% CI) [1] vs. Pom/Dex		0.46 (0.03, 8.02)
P-value [1]		0.5976
RR (95% CI) vs. Pom/Dex		0.48 (0.03, 7.16)
ARD (95% CI) vs. Pom/Dex		-0.04 (-0.19, 0.11)
P-value [2]		>0.9999

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes non-fatal serious treatment emergent adverse events for SOCs occurring in [at least 5% of patients] in any treatment arm OR in [at least 10 patients AND at least 1% of patients] in any treatment arm.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.

Table 3.066110
Non-fatal Serious Adverse Event Summary by SOC

System Organ Class: Gastrointestinal disorders

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	0	2 (7%)
OR (95% CI) [1] vs. Pom/Dex		>999.99 (<0.01, >999.99)
P-value [1]		0.9551
RR (95% CI) vs. Pom/Dex		2.50 (0.13, 48.85)
ARD (95% CI) vs. Pom/Dex		0.05 (-0.08, 0.18)
P-value [2]		>0.9999

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes non-fatal serious treatment emergent adverse events for SOCs occurring in [at least 5% of patients] in any treatment arm OR in [at least 10 patients AND at least 1% of patients] in any treatment arm.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.

Table 3.066110
Non-fatal Serious Adverse Event Summary by SOC

System Organ Class: Infections and infestations

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	4 (29%)	2 (7%)
OR (95% CI) [1] vs. Pom/Dex		0.19 (0.03, 1.17)
P-value [1]		0.0734
RR (95% CI) vs. Pom/Dex		0.24 (0.05, 1.16)
ARD (95% CI) vs. Pom/Dex		-0.22 (-0.47, 0.04)
P-value [2]		0.0767

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes non-fatal serious treatment emergent adverse events for SOCs occurring in [at least 5% of patients] in any treatment arm OR in [at least 10 patients AND at least 1% of patients] in any treatment arm.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.

Table 3.066110
Non-fatal Serious Adverse Event Summary by SOC

System Organ Class: Investigations

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	1 (7%)	1 (3%)
OR (95% CI) [1] vs. Pom/Dex		0.46 (0.03, 8.02)
P-value [1]		0.5976
RR (95% CI) vs. Pom/Dex		0.48 (0.03, 7.16)
ARD (95% CI) vs. Pom/Dex		-0.04 (-0.19, 0.11)
P-value [2]		>0.9999

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes non-fatal serious treatment emergent adverse events for SOCs occurring in [at least 5% of patients] in any treatment arm OR in [at least 10 patients AND at least 1% of patients] in any treatment arm.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.

Table 3.066110
Non-fatal Serious Adverse Event Summary by SOC

System Organ Class: Musculoskeletal and connective tissue disorders

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	0	4 (14%)
OR (95% CI) [1] vs. Pom/Dex		>999.99 (<0.01, >999.99)
P-value [1]		0.9581
RR (95% CI) vs. Pom/Dex		4.50 (0.26, 78.20)
ARD (95% CI) vs. Pom/Dex		0.12 (-0.04, 0.27)
P-value [2]		0.2861

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes non-fatal serious treatment emergent adverse events for SOCs occurring in [at least 5% of patients] in any treatment arm OR in [at least 10 patients AND at least 1% of patients] in any treatment arm.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.

Table 3.066110
Non-fatal Serious Adverse Event Summary by SOC

System Organ Class: Nervous system disorders

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	0	3 (10%)
OR (95% CI) [1] vs. Pom/Dex		>999.99 (<0.01, >999.99)
P-value [1]		0.9452
RR (95% CI) vs. Pom/Dex		3.50 (0.19, 63.46)
ARD (95% CI) vs. Pom/Dex		0.08 (-0.06, 0.23)
P-value [2]		0.5394

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes non-fatal serious treatment emergent adverse events for SOCs occurring in [at least 5% of patients] in any treatment arm OR in [at least 10 patients AND at least 1% of patients] in any treatment arm.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.

Protocol: 207495 Page 1 of 6
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.069110
Time to First Non-Fatal Serious Adverse Event by SOC

System Organ Class: Cardiac disorders

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	1 (7%)	1 (3%)
Censored	13 (93%)	28 (97%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (8.5, -)	- (-, -)
Median (95% CI)	- (8.5, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		0.7991
Hazard Ratio (95% CI) [3]		0.69 (0.04, 11.63)
P-value [3]		0.8001

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
Note: If zero events in at least one treatment arm then hazard ratio and p-values not calculated.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte2_aenfs_soc.sas 13FEB2023 09:27

Table 3.069110
Time to First Non-Fatal Serious Adverse Event by SOC

System Organ Class: Gastrointestinal disorders

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	0	2 (7%)
Censored	14 (100%)	27 (93%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (-, -)	- (4.0, -)
Median (95% CI)	- (-, -)	- (4.0, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		-
Hazard Ratio (95% CI) [3]		- (-, -)
P-value [3]		-

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
Note: If zero events in at least one treatment arm then hazard ratio and p-values not calculated.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.

Table 3.069110
Time to First Non-Fatal Serious Adverse Event by SOC

System Organ Class: Infections and infestations

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	4 (29%)	2 (7%)
Censored	10 (71%)	27 (93%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	8.2 (2.3, -)	- (-, -)
Median (95% CI)	19.5 (5.5, -)	- (-, -)
3rd Quartile (95% CI)	- (19.5, -)	- (-, -)
Log-Rank P-value [2]		0.3368
Hazard Ratio (95% CI) [3]		0.43 (0.08, 2.49)
P-value [3]		0.3485

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
Note: If zero events in at least one treatment arm then hazard ratio and p-values not calculated.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.

Protocol: 207495 Page 4 of 6
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.069110
Time to First Non-Fatal Serious Adverse Event by SOC

System Organ Class: Investigations

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	1 (7%)	1 (3%)
Censored	13 (93%)	28 (97%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (4.4, -)	- (-, -)
Median (95% CI)	- (-, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		0.8885
Hazard Ratio (95% CI) [3]		0.81 (0.05, 14.33)
P-value [3]		0.8886

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
Note: If zero events in at least one treatment arm then hazard ratio and p-values not calculated.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte2_aenfs_soc.sas 13FEB2023 09:27

Protocol: 207495 Page 5 of 6
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.069110
Time to First Non-Fatal Serious Adverse Event by SOC

System Organ Class: Musculoskeletal and connective tissue disorders

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	0	4 (14%)
Censored	14 (100%)	25 (86%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (-, -)	- (1.9, -)
Median (95% CI)	- (-, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		-
Hazard Ratio (95% CI) [3]		- (-, -)
P-value [3]		-

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
Note: If zero events in at least one treatment arm then hazard ratio and p-values not calculated.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte2_aenfs_soc.sas 13FEB2023 09:27

Protocol: 207495 Page 6 of 6
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.069110
Time to First Non-Fatal Serious Adverse Event by SOC

System Organ Class: Nervous system disorders

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	0	3 (10%)
Censored	14 (100%)	26 (90%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (-, -)	- (1.4, -)
Median (95% CI)	- (-, -)	- (4.1, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		-
Hazard Ratio (95% CI) [3]		- (-, -)
P-value [3]		-

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
Note: If zero events in at least one treatment arm then hazard ratio and p-values not calculated.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte2_aenfs_soc.sas 13FEB2023 09:27

Table 3.067110
Non-fatal Serious Adverse Event Summary by SOC and PT

System Organ Class: Cardiac disorders
Preferred Term: Acute myocardial infarction

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	1 (7%)	0
OR (95% CI) [1] vs. Pom/Dex		<0.01 (<0.01, >999.99)
P-value [1]		0.9509
RR (95% CI) vs. Pom/Dex		0.17 (0.01, 3.85)
ARD (95% CI) vs. Pom/Dex		-0.08 (-0.24, 0.08)
P-value [2]		0.3256

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes non-fatal serious treatment emergent adverse events for PTs occurring in [at least 5% of patients] in any treatment arm OR in [at least 10 patients AND at least 1% of patients] in any treatment arm.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_aenf_summ_spt.sas 13FEB2023 09:18

Table 3.067110
Non-fatal Serious Adverse Event Summary by SOC and PT

System Organ Class: Infections and infestations
Preferred Term: COVID-19 pneumonia

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	1 (7%)	0
OR (95% CI) [1] vs. Pom/Dex		<0.01 (<0.01, >999.99)
P-value [1]		0.9509
RR (95% CI) vs. Pom/Dex		0.17 (0.01, 3.85)
ARD (95% CI) vs. Pom/Dex		-0.08 (-0.24, 0.08)
P-value [2]		0.3256

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes non-fatal serious treatment emergent adverse events for PTs occurring in [at least 5% of patients] in any treatment arm OR in [at least 10 patients AND at least 1% of patients] in any treatment arm.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_aenf_summ_spt.sas 13FEB2023 09:18

Table 3.067110
Non-fatal Serious Adverse Event Summary by SOC and PT

System Organ Class: Infections and infestations
Preferred Term: Pneumonia

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	2 (14%)	2 (7%)
OR (95% CI) [1] vs. Pom/Dex		0.44 (0.06, 3.54)
P-value [1]		0.4436
RR (95% CI) vs. Pom/Dex		0.48 (0.08, 3.08)
ARD (95% CI) vs. Pom/Dex		-0.07 (-0.28, 0.13)
P-value [2]		0.5855

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes non-fatal serious treatment emergent adverse events for PTs occurring in [at least 5% of patients] in any treatment arm OR in [at least 10 patients AND at least 1% of patients] in any treatment arm.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_aenf_summ_spt.sas 13FEB2023 09:18

Table 3.067110
Non-fatal Serious Adverse Event Summary by SOC and PT

System Organ Class: Infections and infestations
Preferred Term: Pulmonary nocardiosis

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	1 (7%)	0
OR (95% CI) [1] vs. Pom/Dex		<0.01 (<0.01, >999.99)
P-value [1]		0.9509
RR (95% CI) vs. Pom/Dex		0.17 (0.01, 3.85)
ARD (95% CI) vs. Pom/Dex		-0.08 (-0.24, 0.08)
P-value [2]		0.3256

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes non-fatal serious treatment emergent adverse events for PTs occurring in [at least 5% of patients] in any treatment arm OR in [at least 10 patients AND at least 1% of patients] in any treatment arm.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_aenf_summ_spt.sas 13FEB2023 09:18

Table 3.067110
Non-fatal Serious Adverse Event Summary by SOC and PT

System Organ Class: Investigations
Preferred Term: Neutrophil count decreased

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	1 (7%)	0
OR (95% CI) [1] vs. Pom/Dex		<0.01 (<0.01, >999.99)
P-value [1]		0.9509
RR (95% CI) vs. Pom/Dex		0.17 (0.01, 3.85)
ARD (95% CI) vs. Pom/Dex		-0.08 (-0.24, 0.08)
P-value [2]		0.3256

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes non-fatal serious treatment emergent adverse events for PTs occurring in [at least 5% of patients] in any treatment arm OR in [at least 10 patients AND at least 1% of patients] in any treatment arm.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_aenf_summ_spt.sas 13FEB2023 09:18

Table 3.067110
Non-fatal Serious Adverse Event Summary by SOC and PT

System Organ Class: Musculoskeletal and connective tissue disorders
Preferred Term: Bone pain

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	0	2 (7%)
OR (95% CI) [1] vs. Pom/Dex		>999.99 (<0.01, >999.99)
P-value [1]		0.9551
RR (95% CI) vs. Pom/Dex		2.50 (0.13, 48.85)
ARD (95% CI) vs. Pom/Dex		0.05 (-0.08, 0.18)
P-value [2]		>0.9999

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes non-fatal serious treatment emergent adverse events for PTs occurring in [at least 5% of patients] in any treatment arm OR in [at least 10 patients AND at least 1% of patients] in any treatment arm.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_aenf_summ_spt.sas 13FEB2023 09:18

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.070110
Time to First Non-Fatal Serious Adverse Event by SOC and PT

System Organ Class: Cardiac disorders
Preferred Term: Acute myocardial infarction

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	1 (7%)	0
Censored	13 (93%)	29 (100%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (8.5, -)	- (-, -)
Median (95% CI)	- (8.5, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		-
Hazard Ratio (95% CI) [3]		- (-, -)
P-value [3]		-

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
Note: If zero events in at least one treatment arm then hazard ratio and p-values not calculated.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte2_aenfs_spt.sas 13FEB2023 09:27

Table 3.070110
Time to First Non-Fatal Serious Adverse Event by SOC and PT

System Organ Class: Infections and infestations
Preferred Term: COVID-19 pneumonia

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	1 (7%)	0
Censored	13 (93%)	29 (100%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (5.5, -)	- (-, -)
Median (95% CI)	- (-, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		-
Hazard Ratio (95% CI) [3]		- (-, -)
P-value [3]		-

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
Note: If zero events in at least one treatment arm then hazard ratio and p-values not calculated.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.

Protocol: 207495 Page 3 of 6
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.070110
Time to First Non-Fatal Serious Adverse Event by SOC and PT

System Organ Class: Infections and infestations
Preferred Term: Pneumonia

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	2 (14%)	2 (7%)
Censored	12 (86%)	27 (93%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	19.5 (2.3, -)	- (-, -)
Median (95% CI)	19.5 (19.5, -)	- (-, -)
3rd Quartile (95% CI)	- (19.5, -)	- (-, -)
Log-Rank P-value [2]		0.8127
Hazard Ratio (95% CI) [3]		0.78 (0.10, 6.00)
P-value [3]		0.8131

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
Note: If zero events in at least one treatment arm then hazard ratio and p-values not calculated.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte2_aenfs_spt.sas 13FEB2023 09:27

Protocol: 207495 Page 4 of 6
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.070110
Time to First Non-Fatal Serious Adverse Event by SOC and PT

System Organ Class: Infections and infestations
Preferred Term: Pulmonary nocardiosis

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	1 (7%)	0
Censored	13 (93%)	29 (100%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (8.2, -)	- (-, -)
Median (95% CI)	- (8.2, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		-
Hazard Ratio (95% CI) [3]		- (-, -)
P-value [3]		-

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
Note: If zero events in at least one treatment arm then hazard ratio and p-values not calculated.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte2_aenfs_spt.sas 13FEB2023 09:27

Protocol: 207495 Page 5 of 6
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.070110
Time to First Non-Fatal Serious Adverse Event by SOC and PT

System Organ Class: Investigations
Preferred Term: Neutrophil count decreased

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	1 (7%)	0
Censored	13 (93%)	29 (100%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (4.4, -)	- (-, -)
Median (95% CI)	- (-, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		-
Hazard Ratio (95% CI) [3]		- (-, -)
P-value [3]		-

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
Note: If zero events in at least one treatment arm then hazard ratio and p-values not calculated.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte2_aenfs_spt.sas 13FEB2023 09:27

Protocol: 207495 Page 6 of 6
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.070110
Time to First Non-Fatal Serious Adverse Event by SOC and PT

System Organ Class: Musculoskeletal and connective tissue disorders
Preferred Term: Bone pain

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	0	2 (7%)
Censored	14 (100%)	27 (93%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (-, -)	- (-, -)
Median (95% CI)	- (-, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		-
Hazard Ratio (95% CI) [3]		- (-, -)
P-value [3]		-

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
Note: If zero events in at least one treatment arm then hazard ratio and p-values not calculated.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte2_aenfs_spt.sas 13FEB2023 09:27

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.042110
Fatal Adverse Event Summary by SOC

System Organ Class: Infections and infestations

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	1 (7%)	1 (3%)
OR (95% CI) [1] vs. Pom/Dex		0.46 (0.03, 8.02)
P-value [1]		0.5976
RR (95% CI) vs. Pom/Dex		0.48 (0.03, 7.16)
ARD (95% CI) vs. Pom/Dex		-0.04 (-0.19, 0.11)
P-value [2]		>0.9999

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes fatal treatment emergent adverse events for SOCs occurring in [at least 5% of patients] in any treatment arm OR in [at least 10 patients AND at least 1% of patients] in any treatment arm.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_aef_summ_soc.sas 13FEB2023 09:04

Protocol: 207495 Page 1 of 1
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.045110
Time to Fatal Adverse Event by SOC

System Organ Class: Infections and infestations

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	1 (7%)	1 (3%)
Censored	13 (93%)	28 (97%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (0.5, -)	- (-, -)
Median (95% CI)	- (-, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		0.5793
Hazard Ratio (95% CI) [3]		0.47 (0.03, 7.44)
P-value [3]		0.5885

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
Note: If zero events in at least one treatment arm then hazard ratio and p-values not calculated.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte2_aef_soc.sas 13FEB2023 10:31

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.043110
Fatal Adverse Event Summary by SOC and PT

System Organ Class: Infections and infestations
Preferred Term: COVID-19

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	1 (7%)	0
OR (95% CI) [1] vs. Pom/Dex		<0.01 (<0.01, >999.99)
P-value [1]		0.9509
RR (95% CI) vs. Pom/Dex		0.17 (0.01, 3.85)
ARD (95% CI) vs. Pom/Dex		-0.08 (-0.24, 0.08)
P-value [2]		0.3256

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes fatal treatment emergent adverse events for PTs occurring in [at least 5% of patients] in any treatment arm OR in [at least 10 patients AND at least 1% of patients] in any treatment arm.
Note: If there is a zero count in one treatment arm then the correction is applied as per the rules in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_aef_summ_spt.sas 13FEB2023 09:05

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.046110
Time to Fatal Adverse Event by SOC and PT

System Organ Class: Infections and infestations
Preferred Term: COVID-19

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	1 (7%)	0
Censored	13 (93%)	29 (100%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (0.5, -)	- (-, -)
Median (95% CI)	- (-, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		-
Hazard Ratio (95% CI) [3]		- (-, -)
P-value [3]		-

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
Note: If zero events in at least one treatment arm then hazard ratio and p-values not calculated.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte2_aef_spt.sas 13FEB2023 09:26

Protocol: 207495 Page 1 of 1
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.048110
Adverse Event Leading to Discontinuation of Study Treatment Summary by SOC

System Organ Class	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
ANY EVENT	2 (14%)	1 (3%)
Infections and infestations	2 (14%)	0
Eye disorders	0	1 (3%)

Note: Summary only includes treatment emergent adverse events.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_aed_soc.sas 08FEB2023 12:13

Protocol: 207495 Page 1 of 1
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.049110
Adverse Event Leading to Discontinuation of Study Treatment Summary by SOC and PT

System Organ Class Preferred Term	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
ANY EVENT	2 (14%)	1 (3%)
Infections and infestations		
Any event	2 (14%)	0
COVID-19	1 (7%)	0
Pulmonary nocardiosis	1 (7%)	0
Eye disorders		
Any event	0	1 (3%)
Dry eye	0	1 (3%)
Lacrimation increased	0	1 (3%)
Photophobia	0	1 (3%)
Punctate keratitis	0	1 (3%)
Vision blurred	0	1 (3%)
Visual impairment	0	1 (3%)

Note: Summary only includes treatment emergent adverse events.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_aed_soc_pt.sas 09FEB2023 09:26

Protocol: 207495 Page 1 of 1
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.103110
AESI Adverse Event Summary

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	7 (50%)	19 (66%)
OR (95% CI) [1] vs. Pom/Dex		1.90 (0.52, 6.96)
P-value [1]		0.3323
RR (95% CI) vs. Pom/Dex		1.31 (0.73, 2.36)
ARD (95% CI) vs. Pom/Dex		0.16 (-0.16, 0.47)
P-value [2]		0.5066

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes treatment emergent adverse events.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae_aesi.sas 15FEB2023 09:40

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.094110
Time to First AESI

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	7 (50%)	19 (66%)
Censored	7 (50%)	10 (34%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	0.8 (0.3, 4.7)	0.5 (0.2, 0.9)
Median (95% CI)	4.7 (0.7, -)	1.4 (0.7, 5.6)
3rd Quartile (95% CI)	- (4.7, -)	- (2.0, -)
Log-Rank P-value [2]		0.1657
Hazard Ratio (95% CI) [3]		1.85 (0.77, 4.48)
P-value [3]		0.1702

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte_ae_si.sas 09FEB2023 06:48

Protocol: 207495 Page 1 of 1
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.095110
AESI of Max Grade 2 or less Adverse Event Summary

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	5 (36%)	15 (52%)
OR (95% CI) [1] vs. Pom/Dex		1.93 (0.52, 7.17)
P-value [1]		0.3271
RR (95% CI) vs. Pom/Dex		1.45 (0.66, 3.18)
ARD (95% CI) vs. Pom/Dex		0.16 (-0.15, 0.47)
P-value [2]		0.3528

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes treatment emergent adverse events.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae_simg2.sas 09FEB2023 05:06

Protocol: 207495 Page 1 of 1
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.096110
Time to First AESI of Max Grade 2 or less Adverse Event

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	5 (36%)	15 (52%)
Censored	9 (64%)	14 (48%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	4.1 (0.3, -)	0.7 (0.2, 1.4)
Median (95% CI)	- (0.8, -)	2.1 (0.8, -)
3rd Quartile (95% CI)	- (-, -)	- (5.6, -)
Log-Rank P-value [2]		0.1481
Hazard Ratio (95% CI) [3]		2.11 (0.75, 5.93)
P-value [3]		0.1559

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte_ae_si2.sas 09FEB2023 06:48

Protocol: 207495 Page 1 of 1
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.097110
AESI of Max Grade 3 or higher Adverse Event Summary

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	2 (14%)	11 (38%)
OR (95% CI) [1] vs. Pom/Dex		3.67 (0.69, 19.56)
P-value [1]		0.1283
RR (95% CI) vs. Pom/Dex		2.66 (0.68, 10.40)
ARD (95% CI) vs. Pom/Dex		0.24 (-0.02, 0.49)
P-value [2]		0.1635

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes treatment emergent adverse events.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae_simg3.sas 09FEB2023 05:07

Protocol: 207495 Page 1 of 1
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.098110
Time to First AESI of Max Grade 3 or higher Adverse Event

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	2 (14%)	11 (38%)
Censored	12 (86%)	18 (62%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (0.3, -)	1.1 (0.3, 4.8)
Median (95% CI)	- (-, -)	- (1.4, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		0.0936
Hazard Ratio (95% CI) [3]		3.41 (0.74, 15.64)
P-value [3]		0.1139

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte_ae_si3.sas 09FEB2023 06:48

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.099110
Serious AESI Adverse Event Summary

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	0	2 (7%)
OR (95% CI) [1] vs. Pom/Dex		>999.99 (<0.01, >999.99)
P-value [1]		0.9551
RR (95% CI) vs. Pom/Dex		2.50 (0.13, 48.85)
ARD (95% CI) vs. Pom/Dex		0.05 (-0.08, 0.18)
P-value [2]		>0.9999

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes treatment emergent adverse events.
Note: RR, ARD and their 95% CI have had the zero-count corrected applied here as one treatment arm has a zero-count and the other arm satisfies the zero-count criteria stated in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae_ssi.sas 09FEB2023 05:01

Protocol: 207495 Page 1 of 1
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.100110
Time to First Serious AESI

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	0	2 (7%)
Censored	14 (100%)	27 (93%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (-, -)	- (-, -)
Median (95% CI)	- (-, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		-
Hazard Ratio (95% CI) [3]		- (-, -)
P-value [3]		-

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
Note: Hazard ratio and p-values not calculated due to zero events in at least one treatment arm.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte_ae_sis.sas 09FEB2023 06:48

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.083110
Corneal Events Adverse Event Summary

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	2 (14%)	12 (41%)
OR (95% CI) [1] vs. Pom/Dex		4.23 (0.80, 22.48)
P-value [1]		0.0902
RR (95% CI) vs. Pom/Dex		2.90 (0.75, 11.22)
ARD (95% CI) vs. Pom/Dex		0.27 (0.01, 0.53)
P-value [2]		0.0949

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes treatment emergent adverse events.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_aec_summ.sas 03FEB2023 09:10

Protocol: 207495 Page 1 of 1
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.084110
Time to First Corneal Events Adverse Event

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	2 (14%)	12 (41%)
Censored	12 (86%)	17 (59%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (3.0, -)	1.0 (0.7, 2.0)
Median (95% CI)	- (-, -)	- (1.4, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		0.0198
Hazard Ratio (95% CI) [3]		5.19 (1.13, 23.86)
P-value [3]		0.0344

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte_ae_ce.sas 09FEB2023 06:36

Table 3.071110
Corneal Events of Max Grade 2 or less Adverse Event Summary

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	2 (14%)	11 (38%)
OR (95% CI) [1] vs. Pom/Dex		3.67 (0.69, 19.56)
P-value [1]		0.1283
RR (95% CI) vs. Pom/Dex		2.66 (0.68, 10.40)
ARD (95% CI) vs. Pom/Dex		0.24 (-0.02, 0.49)
P-value [2]		0.1635

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes treatment emergent adverse events.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae_cmg2.sas 03FEB2023 08:46

Protocol: 207495 Page 1 of 1
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.072110
Time to first Corneal Events of Max Grade 2 or Less Adverse Event

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	2 (14%)	11 (38%)
Censored	12 (86%)	18 (62%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (3.0, -)	1.4 (0.7, 2.1)
Median (95% CI)	- (-, -)	- (1.4, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		0.0313
Hazard Ratio (95% CI) [3]		4.72 (1.01, 21.99)
P-value [3]		0.0480

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte_ae_ce2.sas 09FEB2023 06:24

Table 3.077110
Corneal Events of Max Grade 3 or higher Adverse Event Summary

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	0	6 (21%)
OR (95% CI) [1] vs. Pom/Dex		>999.99 (<0.01, >999.99)
P-value [1]		0.9490
RR (95% CI) vs. Pom/Dex		6.50 (0.39, 107.84)
ARD (95% CI) vs. Pom/Dex		0.18 (0.01, 0.36)
P-value [2]		0.1546

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes treatment emergent adverse events.
Note: RR, ARD and their 95% CI have had the zero-count corrected applied here as one treatment arm has a zero-count and the other arm satisfies the zero-count criteria stated in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae_cmg3.sas 09FEB2023 04:39

Protocol: 207495 Page 1 of 1
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.078110
Time to First Corneal Events of Max Grade 3 or higher Adverse Event

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	0	6 (21%)
Censored	14 (100%)	23 (79%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (-, -)	4.8 (0.8, -)
Median (95% CI)	- (-, -)	- (4.8, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		-
Hazard Ratio (95% CI) [3]		- (-, -)
P-value [3]		-

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
Note: Hazard ratio and p-values not calculated due to zero events in at least one treatment arm.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte_ae_ce3.sas 09FEB2023 06:28

Table 3.087110
Corneal Events Serious Adverse Event Summary

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	0	0
OR (95% CI) [1] vs. Pom/Dex		- (-, -)
P-value [1]		-
RR (95% CI) vs. Pom/Dex		- (-, -)
ARD (95% CI) vs. Pom/Dex		0.00 (0.00, 0.00)
P-value [2]		-

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes treatment emergent adverse events.
Note: Only ARD and 95% CI are calculated here as both treatment arms have zero events.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_aesc_summ.sas 09FEB2023 04:47

Protocol: 207495 Page 1 of 1
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.088110
Time to First Corneal Events Serious Adverse Event

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	0	0
Censored	14 (100%)	29 (100%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (-, -)	- (-, -)
Median (95% CI)	- (-, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		-
Hazard Ratio (95% CI) [3]		- (-, -)
P-value [3]		-

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
Note: Hazard ratio and p-values not calculated due to zero events in at least one treatment arm.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte_ae_ces.sas 09FEB2023 06:36

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.102110
Thrombocytopenia Adverse Event Summary

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	6 (43%)	11 (38%)
OR (95% CI) [1] vs. Pom/Dex		0.81 (0.22, 2.98)
P-value [1]		0.7570
RR (95% CI) vs. Pom/Dex		0.89 (0.41, 1.90)
ARD (95% CI) vs. Pom/Dex		-0.05 (-0.36, 0.26)
P-value [2]		>0.9999

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes treatment emergent adverse events.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae_thr_summ.sas 10FEB2023 09:44

Protocol: 207495 Page 1 of 1
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.093110
Time to First Thrombocytopenia Adverse Event

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	6 (43%)	11 (38%)
Censored	8 (57%)	18 (62%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	0.8 (0.3, -)	1.1 (0.3, 5.6)
Median (95% CI)	- (0.7, -)	- (1.4, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		0.9819
Hazard Ratio (95% CI) [3]		0.99 (0.36, 2.70)
P-value [3]		0.9802

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte_ae_th.sas 09FEB2023 06:42

Protocol: 207495 Page 1 of 1
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.075110
Thrombocytopenia of Max Grade 2 or less Adverse Event Summary

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	4 (29%)	5 (17%)
OR (95% CI) [1] vs. Pom/Dex		0.52 (0.12, 2.35)
P-value [1]		0.3964
RR (95% CI) vs. Pom/Dex		0.60 (0.19, 1.91)
ARD (95% CI) vs. Pom/Dex		-0.11 (-0.39, 0.16)
P-value [2]		0.4415

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes treatment emergent adverse events.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae_tmg2.sas 03FEB2023 08:52

Protocol: 207495 Page 1 of 1
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.076110
Time to First Thrombocytopenia of Max Grade 2 or less Adverse Event

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	4 (29%)	5 (17%)
Censored	10 (71%)	24 (83%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	4.7 (0.3, -)	5.6 (0.6, -)
Median (95% CI)	- (0.8, -)	- (5.6, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		0.6760
Hazard Ratio (95% CI) [3]		0.75 (0.20, 2.87)
P-value [3]		0.6770

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte_ae_th2.sas 09FEB2023 06:24

Protocol: 207495 Page 1 of 1
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.081110
Thrombocytopenia of Max Grade 3 or higher Adverse Event Summary

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	2 (14%)	8 (28%)
OR (95% CI) [1] vs. Pom/Dex		2.29 (0.42, 12.56)
P-value [1]		0.3417
RR (95% CI) vs. Pom/Dex		1.93 (0.47, 7.93)
ARD (95% CI) vs. Pom/Dex		0.13 (-0.11, 0.38)
P-value [2]		0.4557

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes treatment emergent adverse events.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae_tmg3.sas 03FEB2023 09:03

Protocol: 207495 Page 1 of 1
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.082110
Time to First Thrombocytopenia of Max Grade 3 or higher Adverse Event

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	2 (14%)	8 (28%)
Censored	12 (86%)	21 (72%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (0.3, -)	1.4 (0.4, -)
Median (95% CI)	- (-, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		0.3316
Hazard Ratio (95% CI) [3]		2.11 (0.45, 9.94)
P-value [3]		0.3451

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte_ae_th3.sas 09FEB2023 06:28

Table 3.091110
Thrombocytopenia Serious Adverse Event Summary

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	0	1 (3%)
OR (95% CI) [1] vs. Pom/Dex		>999.99 (<0.01, >999.99)
P-value [1]		0.9526
RR (95% CI) vs. Pom/Dex		- (-, -)
ARD (95% CI) vs. Pom/Dex		0.03 (-0.03, 0.10)
P-value [2]		-

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes treatment emergent adverse events.
Note: RR and Fisher's Exact test not calculated here as one treatment arm has a zero-count and the other arm does not satisfy the zero-count criteria stated in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_aest_summ.sas 09FEB2023 04:56

Protocol: 207495 Page 1 of 1
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.092110
Time to First Thrombocytopenia Serious Adverse Event

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	0	1 (3%)
Censored	14 (100%)	28 (97%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (-, -)	- (-, -)
Median (95% CI)	- (-, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		-
Hazard Ratio (95% CI) [3]		- (-, -)
P-value [3]		-

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
Note: Hazard ratio and p-values not calculated due to zero events in at least one treatment arm.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte_ae_ths.sas 09FEB2023 06:42

Table 3.085110
Infusion-Related Reactions Adverse Event Summary

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	0	4 (14%)
OR (95% CI) [1] vs. Pom/Dex		>999.99 (<0.01, >999.99)
P-value [1]		0.9581
RR (95% CI) vs. Pom/Dex		4.50 (0.26, 78.20)
ARD (95% CI) vs. Pom/Dex		0.12 (-0.04, 0.27)
P-value [2]		0.2861

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes treatment emergent adverse events.
Note: RR, ARD and their 95% CI have had the zero-count corrected applied here as one treatment arm has a zero-count and the other arm satisfies the zero-count criteria stated in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_aeirr_summ.sas 09FEB2023 04:47

Protocol: 207495 Page 1 of 1
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.086110
Time to First Infusion-Related Reactions Adverse Event

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	0	4 (14%)
Censored	14 (100%)	25 (86%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (-, -)	- (0.2, -)
Median (95% CI)	- (-, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		-
Hazard Ratio (95% CI) [3]		- (-, -)
P-value [3]		-

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
Note: Hazard ratio and p-values not calculated due to zero events in at least one treatment arm.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte_ae_ir.sas 09FEB2023 06:36

Table 3.073110
Infusion-Related Reactions of Max Grade 2 or less Adverse Event Summary

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	0	4 (14%)
OR (95% CI) [1] vs. Pom/Dex		>999.99 (<0.01, >999.99)
P-value [1]		0.9581
RR (95% CI) vs. Pom/Dex		4.50 (0.26, 78.20)
ARD (95% CI) vs. Pom/Dex		0.12 (-0.04, 0.27)
P-value [2]		0.2861

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes treatment emergent adverse events.
Note: RR, ARD and their 95% CI have had the zero-count corrected applied here as one treatment arm has a zero-count and the other arm satisfies the zero-count criteria stated in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae_irrmg2.sas 09FEB2023 04:34

Protocol: 207495 Page 1 of 1
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.074110
Time to First Infusion-Related Reactions of Max Grade 2 or less Adverse Event

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	0	4 (14%)
Censored	14 (100%)	25 (86%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (-, -)	- (0.3, -)
Median (95% CI)	- (-, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		-
Hazard Ratio (95% CI) [3]		- (-, -)
P-value [3]		-

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
Note: Hazard ratio and p-values not calculated due to zero events in at least one treatment arm.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte_ae_ir2.sas 09FEB2023 06:24

Protocol: 207495 Page 1 of 1
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.079110
Infusion-Related Reactions of Max Grade 3 or higher Adverse Event Summary

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	0	1 (3%)
OR (95% CI) [1] vs. Pom/Dex		>999.99 (<0.01, >999.99)
P-value [1]		0.9526
RR (95% CI) vs. Pom/Dex		- (-, -)
ARD (95% CI) vs. Pom/Dex		0.03 (-0.03, 0.10)
P-value [2]		-

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes treatment emergent adverse events.
Note: RR and Fisher's Exact test not calculated here as one treatment arm has a zero-count and the other arm does not satisfy the zero-count criteria stated in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_ae_irrmg3.sas 09FEB2023 04:43

Protocol: 207495 Page 1 of 1
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.080110
Time to First Infusion-Related Reactions of Max Grade 3 or higher Adverse Event

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	0	1 (3%)
Censored	14 (100%)	28 (97%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (-, -)	- (-, -)
Median (95% CI)	- (-, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		-
Hazard Ratio (95% CI) [3]		- (-, -)
P-value [3]		-

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
Note: Hazard ratio and p-values not calculated due to zero events in at least one treatment arm.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte_ae_ir3.sas 09FEB2023 06:28

Protocol: 207495 Page 1 of 1
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.089110
Infusion-Related Reactions Serious Adverse Event Summary

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number with at least 1 event, n (%)	0	1 (3%)
OR (95% CI) [1] vs. Pom/Dex		>999.99 (<0.01, >999.99)
P-value [1]		0.9526
RR (95% CI) vs. Pom/Dex		- (-, -)
ARD (95% CI) vs. Pom/Dex		0.03 (-0.03, 0.10)
P-value [2]		-

OR=Odds Ratio, RR=Relative Risk, ARD=Absolute Risk Difference.
Note: Analysis only includes treatment emergent adverse events.
Note: RR and Fisher's Exact test not calculated here as one treatment arm has a zero-count and the other arm does not satisfy the zero-count criteria stated in the sSAP.
[1] Odds Ratio (95% CI) and associated p-value are from a logistic regression model for the comparison between Belantamab mafodotin and Pom/Dex with no other covariates.
[2] P-value obtained from Fisher's Exact test.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_aes_irr.sas 09FEB2023 04:56

Protocol: 207495 Page 1 of 1
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 3.090110
Time to First Infusion-Related Reactions Serious Adverse Event

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Event	0	1 (3%)
Censored	14 (100%)	28 (97%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (-, -)	- (-, -)
Median (95% CI)	- (-, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		-
Hazard Ratio (95% CI) [3]		- (-, -)
P-value [3]		-

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
Note: Hazard ratio and p-values not calculated due to zero events in at least one treatment arm.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from non-stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the un-stratified Cox Proportional Hazards with treatment arm as the only covariate. A hazard ratio <1 indicates a lower risk with this treatment compared with Pom/Dex.
PPD : /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_s_tte_ae_irs.sas 09FEB2023 06:42

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.045110
Summary of Maximum Post-Baseline PRO-CTCAE Score

	Pom/Dex (N=14)			Belantamab mafodotin (N=29)		
	Frequency	Severity	Interference	Frequency	Severity	Interference
Blurred Vision						
n	13	10		25	18	
0	3 (23%)	0		7 (28%)	2 (11%)	
1	3 (23%)	3 (30%)		7 (28%)	6 (33%)	
2	3 (23%)	4 (40%)		3 (12%)	4 (22%)	
3	2 (15%)	2 (20%)		6 (24%)	2 (11%)	
4	2 (15%)	1 (10%)		2 (8%)	4 (22%)	
3+4	4 (31%)	3 (30%)		8 (32%)	6 (33%)	
Any Scale >0	10 (77%)	10 (100%)		18 (72%)	16 (89%)	
Constipation						
n	13			25		
0	3 (23%)			10 (40%)		
1	2 (15%)			6 (24%)		
2	2 (15%)			1 (4%)		
3	5 (38%)			7 (28%)		
4	1 (8%)			1 (4%)		
3+4	6 (46%)			8 (32%)		
Any Scale >0	10 (77%)			15 (60%)		

Note: Frequency levels: 0-Never, 1-Rarely, 2-Occasionally, 3-Frequently, 4-Almost Constantly;
Severity levels: 0-None, 1-Mild, 2-Moderate, 3-Severe, 4-Very severe;
Interference levels: 0-Not at all, 1-A little bit, 2-Somewhat, 3-Quite a bit, 4-Very much.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t3_ctcae_max.sas 04JAN2023 07:05

Table 4.045110
Summary of Maximum Post-Baseline PRO-CTCAE Score

	Pom/Dex (N=14)			Belantamab mafodotin (N=29)		
	Frequency	Severity	Interference	Frequency	Severity	Interference
Cough						
n	13	5		25	10	
0	8 (62%)	1 (20%)		15 (60%)	6 (60%)	
1	1 (8%)	0		7 (28%)	3 (30%)	
2	2 (15%)	2 (40%)		3 (12%)	1 (10%)	
3	1 (8%)	2 (40%)		0	0	
4	1 (8%)	0		0	0	
3+4	2 (15%)	2 (40%)		0	0	
Any Scale >0	5 (38%)	4 (80%)		10 (40%)	4 (40%)	
Decreased Appetite						
n	13	8		25	19	
0	5 (38%)	2 (25%)		6 (24%)	7 (37%)	
1	3 (23%)	4 (50%)		8 (32%)	5 (26%)	
2	3 (23%)	1 (13%)		6 (24%)	3 (16%)	
3	1 (8%)	0		5 (20%)	4 (21%)	
4	1 (8%)	1 (13%)		0	0	
3+4	2 (15%)	1 (13%)		5 (20%)	4 (21%)	
Any Scale >0	8 (62%)	6 (75%)		19 (76%)	12 (63%)	

Note: Frequency levels: 0-Never, 1-Rarely, 2-Occasionally, 3-Frequently, 4-Almost Constantly;
Severity levels: 0-None, 1-Mild, 2-Moderate, 3-Severe, 4-Very severe;
Interference levels: 0-Not at all, 1-A little bit, 2-Somewhat, 3-Quite a bit, 4-Very much.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t3_ctcae_max.sas 04JAN2023 07:05

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.045110
Summary of Maximum Post-Baseline PRO-CTCAE Score

	Pom/Dex (N=14)			Belantamab mafodotin (N=29)		
	Frequency	Severity	Interference	Frequency	Severity	Interference
Fatigue						
n	13	13		25	25	
0	0	1 (8%)		0	3 (12%)	
1	1 (8%)	1 (8%)		7 (28%)	8 (32%)	
2	5 (38%)	5 (38%)		6 (24%)	2 (8%)	
3	5 (38%)	4 (31%)		7 (28%)	6 (24%)	
4	2 (15%)	2 (15%)		5 (20%)	6 (24%)	
3+4	7 (54%)	6 (46%)		12 (48%)	12 (48%)	
Any Scale >0	13 (100%)	12 (92%)		25 (100%)	22 (88%)	
General Pain						
n	13	8	8	25	11	10
0	5 (38%)	0	4 (50%)	14 (56%)	1 (9%)	1 (10%)
1	5 (38%)	6 (75%)	2 (25%)	6 (24%)	4 (36%)	4 (40%)
2	2 (15%)	2 (25%)	2 (25%)	4 (16%)	6 (55%)	3 (30%)
3	1 (8%)	0	0	1 (4%)	0	2 (20%)
4	0	0	0	0	0	0
3+4	1 (8%)	0	0	1 (4%)	0	2 (20%)
Any Scale >0	8 (62%)	8 (100%)	4 (50%)	11 (44%)	10 (91%)	9 (90%)

Note: Frequency levels: 0-Never, 1-Rarely, 2-Occasionally, 3-Frequently, 4-Almost Constantly;
Severity levels: 0-None, 1-Mild, 2-Moderate, 3-Severe, 4-Very severe;
Interference levels: 0-Not at all, 1-A little bit, 2-Somewhat, 3-Quite a bit, 4-Very much.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t3_ctcae_max.sas 04JAN2023 07:05

Protocol: 207495 Page 4 of 9
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.045110
Summary of Maximum Post-Baseline PRO-CTCAE Score

	Pom/Dex (N=14)			Belantamab mafodotin (N=29)		
	Frequency	Severity	Interference	Frequency	Severity	Interference
Itchy						
n	13			25		
0	7 (54%)			15 (60%)		
1	2 (15%)			8 (32%)		
2	3 (23%)			2 (8%)		
3	1 (8%)			0		
4	0			0		
3+4	1 (8%)			0		
Any Scale >0	6 (46%)			10 (40%)		
Loose/Watery Stools						
n	13			25		
0	6 (46%)			14 (56%)		
1	4 (31%)			6 (24%)		
2	1 (8%)			3 (12%)		
3	2 (15%)			1 (4%)		
4	0			1 (4%)		
3+4	2 (15%)			2 (8%)		
Any Scale >0	7 (54%)			11 (44%)		

Note: Frequency levels: 0-Never, 1-Rarely, 2-Occasionally, 3-Frequently, 4-Almost Constantly;
Severity levels: 0-None, 1-Mild, 2-Moderate, 3-Severe, 4-Very severe;
Interference levels: 0-Not at all, 1-A little bit, 2-Somewhat, 3-Quite a bit, 4-Very much.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t3_ctcae_max.sas 04JAN2023 07:05

Protocol: 207495 Page 5 of 9
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.045110
Summary of Maximum Post-Baseline PRO-CTCAE Score

	Pom/Dex (N=14)						Belantamab mafodotin (N=29)					
	Frequency		Severity		Interference		Frequency		Severity		Interference	
Mouth/Throat Sores												
n	13		6				25		4			
0	7	(54%)	3	(50%)			21	(84%)	1	(25%)		
1	3	(23%)	1	(17%)			2	(8%)	1	(25%)		
2	1	(8%)	1	(17%)			1	(4%)	1	(25%)		
3	1	(8%)	0				0		0			
4	1	(8%)	1	(17%)			1	(4%)	1	(25%)		
3+4	2	(15%)	1	(17%)			1	(4%)	1	(25%)		
Any Scale >0	6	(46%)	3	(50%)			4	(16%)	3	(75%)		
Nausea												
n	13		4				25		9			
0	9	(69%)	0				16	(64%)	0			
1	1	(8%)	1	(25%)			5	(20%)	5	(56%)		
2	2	(15%)	3	(75%)			2	(8%)	1	(11%)		
3	1	(8%)	0				1	(4%)	3	(33%)		
4	0		0				1	(4%)	0			
3+4	1	(8%)	0				2	(8%)	3	(33%)		
Any Scale >0	4	(31%)	4	(100%)			9	(36%)	9	(100%)		

Note: Frequency levels: 0-Never, 1-Rarely, 2-Occasionally, 3-Frequently, 4-Almost Constantly;
Severity levels: 0-None, 1-Mild, 2-Moderate, 3-Severe, 4-Very severe;
Interference levels: 0-Not at all, 1-A little bit, 2-Somewhat, 3-Quite a bit, 4-Very much.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t3_ctcae_max.sas 04JAN2023 07:05

Table 4.045110
Summary of Maximum Post-Baseline PRO-CTCAE Score

	Pom/Dex (N=14)			Belantamab mafodotin (N=29)		
	Frequency	Severity	Interference	Frequency	Severity	Interference
Nosebleeds						
n	13	1		25	10	
0	12 (92%)	0		15 (60%)	1 (10%)	
1	1 (8%)	1 (100%)		5 (20%)	3 (30%)	
2	0	0		1 (4%)	3 (30%)	
3	0	0		3 (12%)	1 (10%)	
4	0	0		1 (4%)	2 (20%)	
3+4	0	0		4 (16%)	3 (30%)	
Any Scale >0	1 (8%)	1 (100%)		10 (40%)	9 (90%)	
Numb/Tingling Hands/Feet						
n	13	13		25	16	
0	0	1 (8%)		9 (36%)	2 (13%)	
1	1 (8%)	2 (15%)		7 (28%)	7 (44%)	
2	8 (62%)	6 (46%)		4 (16%)	4 (25%)	
3	4 (31%)	3 (23%)		3 (12%)	1 (6%)	
4	0	1 (8%)		2 (8%)	2 (13%)	
3+4	4 (31%)	4 (31%)		5 (20%)	3 (19%)	
Any Scale >0	13 (100%)	12 (92%)		16 (64%)	14 (88%)	

Note: Frequency levels: 0-Never, 1-Rarely, 2-Occasionally, 3-Frequently, 4-Almost Constantly;
Severity levels: 0-None, 1-Mild, 2-Moderate, 3-Severe, 4-Very severe;
Interference levels: 0-Not at all, 1-A little bit, 2-Somewhat, 3-Quite a bit, 4-Very much.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t3_ctcae_max.sas 04JAN2023 07:05

Table 4.045110
Summary of Maximum Post-Baseline PRO-CTCAE Score

	Pom/Dex (N=14)			Belantamab mafodotin (N=29)		
	Frequency	Severity	Interference	Frequency	Severity	Interference
Pain/Burning Urination						
n	13			25		
0	11	(85%)		19	(76%)	
1	0			5	(20%)	
2	2	(15%)		1	(4%)	
3	0			0		
4	0			0		
3+4	0			0		
Any Scale >0	2	(15%)		6	(24%)	
Problems Tasting Food/Drink						
n	13			25		
0	7	(54%)		15	(60%)	
1	3	(23%)		5	(20%)	
2	2	(15%)		2	(8%)	
3	0			2	(8%)	
4	1	(8%)		1	(4%)	
3+4	1	(8%)		3	(12%)	
Any Scale >0	6	(46%)		10	(40%)	

Note: Frequency levels: 0-Never, 1-Rarely, 2-Occasionally, 3-Frequently, 4-Almost Constantly;
Severity levels: 0-None, 1-Mild, 2-Moderate, 3-Severe, 4-Very severe;
Interference levels: 0-Not at all, 1-A little bit, 2-Somewhat, 3-Quite a bit, 4-Very much.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t3_ctcae_max.sas 04JAN2023 07:05

Table 4.045110
Summary of Maximum Post-Baseline PRO-CTCAE Score

	Pom/Dex (N=14)			Belantamab mafodotin (N=29)		
	Frequency	Severity	Interference	Frequency	Severity	Interference
Shivering/Shaking Chills						
n	13	7		25	13	
0	6 (46%)	0		12 (48%)	0	
1	3 (23%)	4 (57%)		5 (20%)	8 (62%)	
2	1 (8%)	1 (14%)		8 (32%)	5 (38%)	
3	2 (15%)	2 (29%)		0	0	
4	1 (8%)	0		0	0	
3+4	3 (23%)	2 (29%)		0	0	
Any Scale >0	7 (54%)	7 (100%)		13 (52%)	13 (100%)	
Shortness of Breath						
n	13	11		25	15	
0	2 (15%)	1 (9%)		10 (40%)	1 (7%)	
1	4 (31%)	3 (27%)		5 (20%)	4 (27%)	
2	4 (31%)	2 (18%)		5 (20%)	5 (33%)	
3	1 (8%)	3 (27%)		3 (12%)	3 (20%)	
4	2 (15%)	2 (18%)		2 (8%)	2 (13%)	
3+4	3 (23%)	5 (45%)		5 (20%)	5 (33%)	
Any Scale >0	11 (85%)	10 (91%)		15 (60%)	14 (93%)	

Note: Frequency levels: 0-Never, 1-Rarely, 2-Occasionally, 3-Frequently, 4-Almost Constantly;
Severity levels: 0-None, 1-Mild, 2-Moderate, 3-Severe, 4-Very severe;
Interference levels: 0-Not at all, 1-A little bit, 2-Somewhat, 3-Quite a bit, 4-Very much.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t3_ctcae_max.sas 04JAN2023 07:05

Protocol: 207495 Page 9 of 9
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.045110
Summary of Maximum Post-Baseline PRO-CTCAE Score

	Pom/Dex (N=14)			Belantamab mafodotin (N=29)		
	Frequency	Severity	Interference	Frequency	Severity	Interference
Vomiting						
n	13	1		25	5	
0	12 (92%)	0		20 (80%)	1 (20%)	
1	1 (8%)	0		5 (20%)	4 (80%)	
2	0	1 (100%)		0	0	
3	0	0		0	0	
4	0	0		0	0	
3+4	0	0		0	0	
Any Scale >0	1 (8%)	1 (100%)		5 (20%)	4 (80%)	
Watery Eyes						
n	13	6		25	14	
0	7 (54%)	0		11 (44%)	2 (14%)	
1	1 (8%)	2 (33%)		7 (28%)	7 (50%)	
2	3 (23%)	2 (33%)		5 (20%)	3 (21%)	
3	2 (15%)	1 (17%)		2 (8%)	1 (7%)	
4	0	1 (17%)		0	1 (7%)	
3+4	2 (15%)	2 (33%)		2 (8%)	2 (14%)	
Any Scale >0	6 (46%)	6 (100%)		14 (56%)	12 (86%)	

Note: Frequency levels: 0-Never, 1-Rarely, 2-Occasionally, 3-Frequently, 4-Almost Constantly;
Severity levels: 0-None, 1-Mild, 2-Moderate, 3-Severe, 4-Very severe;
Interference levels: 0-Not at all, 1-A little bit, 2-Somewhat, 3-Quite a bit, 4-Very much.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t3_ctcae_max.sas 04JAN2023 07:05

Table 4.029110
Summary of Change in OSDI Total Scores from Baseline

Item Score: Total Score

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Baseline	Actual Score	n	13	25
		Mean	11.83	15.65
		SD	14.724	21.303
		Median	6.82	6.25
		Min.	0.0	0.0
		Max.	41.7	72.2
Week 4	Actual Score	n	13	23
		Mean	16.84	16.68
		SD	23.376	20.399
		Median	3.57	9.09
		Min.	0.0	0.0
		Max.	79.2	64.6
	Change from Baseline	n	12	22
		Mean	-1.18	1.60
		SD	14.006	20.053
		Median	0.00	0.00
		Min.	-37.5	-42.7
		Max.	16.9	60.4
	Worsening Score of >=15 from Baseline	n (%)	2 (17%)	2 (9%)
	Improvement Score of >=15 from Baseline	n (%)	1 (8%)	2 (9%)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_osdi_tot.sas 10MAR2023 09:21

Table 4.029110
Summary of Change in OSDI Total Scores from Baseline

Item Score: Total Score

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 7	Actual Score	n	12	15
		Mean	23.18	31.34
		SD	29.690	32.467
		Median	10.61	22.50
		Min.	0.0	0.0
		Max.	85.4	91.7
	Change from Baseline	n	11	14
		Mean	5.72	19.62
		SD	18.389	31.895
		Median	0.00	3.54
		Min.	-20.8	-17.1
		Max.	43.8	89.6
	Worsening Score of >=15 from Baseline	n (%)	3 (27%)	5 (36%)
	Improvement Score of >=15 from Baseline	n (%)	1 (9%)	1 (7%)

Table 4.029110
Summary of Change in OSDI Total Scores from Baseline

Item Score: Total Score

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 10	Actual Score	n	13	12
		Mean	24.34	27.50
		SD	27.423	34.238
		Median	12.50	16.67
		Min.	0.0	0.0
		Max.	79.2	88.9
	Change from Baseline	n	12	11
		Mean	6.95	13.78
		SD	15.828	33.297
		Median	1.56	2.08
		Min.	-12.5	-22.9
		Max.	34.6	85.4
	Worsening Score of >=15 from Baseline	n (%)	4 (33%)	4 (36%)
	Improvement Score of >=15 from Baseline	n (%)	0	2 (18%)

Table 4.029110
Summary of Change in OSDI Total Scores from Baseline

Item Score: Total Score

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 13	Actual Score	n	13	9
		Mean	25.25	20.34
		SD	29.823	19.667
		Median	15.00	12.50
		Min.	0.0	0.0
		Max.	93.8	56.3
	Change from Baseline	n	12	9
		Mean	6.72	6.52
		SD	16.147	25.858
		Median	0.00	4.55
		Min.	-15.3	-32.2
		Max.	30.0	54.2
	Worsening Score of >=15 from Baseline	n (%)	4 (33%)	2 (22%)
	Improvement Score of >=15 from Baseline	n (%)	1 (8%)	2 (22%)

Table 4.029110
Summary of Change in OSDI Total Scores from Baseline

Item Score: Total Score

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 16	Actual Score	n	12	8
		Mean	23.84	12.31
		SD	32.177	20.541
		Median	9.90	4.58
		Min.	0.0	0.0
		Max.	91.7	60.0
	Change from Baseline	n	11	8
		Mean	6.46	1.72
		SD	21.848	9.315
		Median	0.00	1.04
		Min.	-29.2	-12.2
		Max.	52.1	20.1
	Worsening Score of >=15 from Baseline	n (%)	2 (18%)	1 (13%)
	Improvement Score of >=15 from Baseline	n (%)	1 (9%)	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_osdi_tot.sas 10MAR2023 09:21

Table 4.029110
Summary of Change in OSDI Total Scores from Baseline

Item Score: Total Score

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 19	Actual Score	n	12	7
		Mean	26.36	20.13
		SD	31.618	16.478
		Median	18.25	15.91
		Min.	0.0	0.0
		Max.	100.0	42.5
	Change from Baseline	n	11	7
		Mean	8.45	8.62
		SD	23.228	21.623
		Median	3.87	6.25
		Min.	-37.5	-29.7
		Max.	50.0	40.0
	Worsening Score of >=15 from Baseline	n (%)	5 (45%)	3 (43%)
	Improvement Score of >=15 from Baseline	n (%)	1 (9%)	1 (14%)

Table 4.029110
Summary of Change in OSDI Total Scores from Baseline

Item Score: Total Score

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 22	Actual Score	n	7	7
		Mean	19.55	12.50
		SD	26.401	8.793
		Median	13.89	16.67
		Min.	0.0	0.0
		Max.	75.0	22.2
	Change from Baseline	n	7	7
		Mean	9.83	11.31
		SD	15.684	8.185
		Median	8.89	12.50
		Min.	-7.9	0.0
		Max.	33.3	22.2
	Worsening Score of >=15 from Baseline	n (%)	3 (43%)	2 (29%)
	Improvement Score of >=15 from Baseline	n (%)	0	0

Table 4.029110
Summary of Change in OSDI Total Scores from Baseline

Item Score: Total Score

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 25	Actual Score	n	7	7
		Mean	19.44	10.36
		SD	21.420	10.482
		Median	17.50	9.38
		Min.	0.0	0.0
		Max.	56.3	27.5
	Change from Baseline	n	7	6
		Mean	9.71	10.69
		SD	15.293	10.696
		Median	14.58	6.77
		Min.	-10.4	0.0
		Max.	32.5	27.5
	Worsening Score of >=15 from Baseline	n (%)	3 (43%)	2 (33%)
	Improvement Score of >=15 from Baseline	n (%)	0	0

Table 4.029110
Summary of Change in OSDI Total Scores from Baseline

Item Score: Total Score

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 28	Actual Score	n	7	6
		Mean	20.29	22.41
		SD	28.753	23.163
		Median	10.00	18.23
		Min.	0.0	0.0
		Max.	81.3	59.4
	Change from Baseline	n	7	6
		Mean	10.56	21.02
		SD	17.053	22.716
		Median	6.11	15.10
		Min.	-6.8	0.0
		Max.	39.6	57.3
	Worsening Score of >=15 from Baseline	n (%)	2 (29%)	3 (50%)
	Improvement Score of >=15 from Baseline	n (%)	0	0

Table 4.029110
Summary of Change in OSDI Total Scores from Baseline

Item Score: Total Score

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 31	Actual Score	n	7	6
		Mean	15.00	17.17
		SD	24.213	18.091
		Median	7.50	12.50
		Min.	0.0	0.0
		Max.	68.8	41.7
	Change from Baseline	n	7	6
		Mean	5.27	15.78
		SD	11.410	17.734
		Median	5.42	9.38
		Min.	-7.3	0.0
		Max.	27.1	39.6
	Worsening Score of >=15 from Baseline	n (%)	1 (14%)	2 (33%)
	Improvement Score of >=15 from Baseline	n (%)	0	0

Table 4.029110
Summary of Change in OSDI Total Scores from Baseline

Item Score: Total Score

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 34	Actual Score	n	5	6
		Mean	15.91	21.27
		SD	29.668	21.463
		Median	4.55	17.26
		Min.	0.0	0.0
		Max.	68.8	53.1
	Change from Baseline	n	5	6
		Mean	3.71	19.89
		SD	13.551	21.260
		Median	0.00	14.14
		Min.	-6.8	0.0
		Max.	27.1	51.0
	Worsening Score of >=15 from Baseline	n (%)	1 (20%)	3 (50%)
	Improvement Score of >=15 from Baseline	n (%)	0	0

Table 4.029110
Summary of Change in OSDI Total Scores from Baseline

Item Score: Total Score

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 37	Actual Score	n	4	6
		Mean	4.99	13.38
		SD	8.637	15.375
		Median	1.04	8.33
		Min.	0.0	0.0
		Max.	17.9	38.6
	Change from Baseline	n	4	6
		Mean	0.16	11.99
		SD	11.025	15.675
		Median	−3.41	5.21
		Min.	−8.3	0.0
		Max.	15.8	38.6
	Worsening Score of >=15 from Baseline	n (%)	1 (25%)	2 (33%)
	Improvement Score of >=15 from Baseline	n (%)	0	0

Table 4.029110
Summary of Change in OSDI Total Scores from Baseline

Item Score: Total Score

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 40	Actual Score	n	4	5
		Mean	0.57	14.17
		SD	1.136	16.806
		Median	0.00	9.38
		Min.	0.0	0.0
		Max.	2.3	39.6
	Change from Baseline	n	4	5
		Mean	-4.26	13.75
		SD	4.504	16.592
		Median	-3.31	9.38
		Min.	-10.4	0.0
		Max.	0.0	39.6
	Worsening Score of >=15 from Baseline	n (%)	0	2 (40%)
	Improvement Score of >=15 from Baseline	n (%)	0	0

Table 4.029110
Summary of Change in OSDI Total Scores from Baseline

Item Score: Total Score

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 43	Actual Score	n	4	4
		Mean	2.70	13.98
		SD	3.193	12.069
		Median	2.27	13.37
		Min.	0.0	0.0
		Max.	6.3	29.2
	Change from Baseline	n	4	4
		Mean	-2.13	13.45
		SD	6.134	12.019
		Median	-1.14	12.33
		Min.	-10.4	0.0
		Max.	4.2	29.2
	Worsening Score of >=15 from Baseline	n (%)	0	1 (25%)
	Improvement Score of >=15 from Baseline	n (%)	0	0

Table 4.029110
Summary of Change in OSDI Total Scores from Baseline

Item Score: Total Score

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 46	Actual Score	n	3	4
		Mean	6.28	22.05
		SD	7.299	24.179
		Median	4.55	15.97
		Min.	0.0	0.0
		Max.	14.3	56.3
	Change from Baseline	n	3	4
		Mean	3.31	21.53
		SD	7.785	23.199
		Median	0.00	15.97
		Min.	-2.3	0.0
		Max.	12.2	54.2
	Worsening Score of >=15 from Baseline	n (%)	0	2 (50%)
	Improvement Score of >=15 from Baseline	n (%)	0	0

Table 4.029110
Summary of Change in OSDI Total Scores from Baseline

Item Score: Total Score

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 49	Actual Score	n	3	4
		Mean	3.66	22.81
		SD	3.437	30.227
		Median	4.17	12.81
		Min.	0.0	0.0
		Max.	6.8	65.6
	Change from Baseline	n	3	4
		Mean	0.69	22.29
		SD	1.203	29.245
		Median	0.00	12.81
		Min.	0.0	0.0
		Max.	2.1	63.5
	Worsening Score of >=15 from Baseline	n (%)	0	2 (50%)
	Improvement Score of >=15 from Baseline	n (%)	0	0

Table 4.029110
Summary of Change in OSDI Total Scores from Baseline

Item Score: Total Score

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 52	Actual Score	n	3	4
		Mean	3.24	20.67
		SD	2.891	24.917
		Median	4.17	14.77
		Min.	0.0	0.0
		Max.	5.6	53.1
	Change from Baseline	n	3	4
		Mean	0.27	20.15
		SD	1.690	24.018
		Median	0.00	14.77
		Min.	-1.3	0.0
		Max.	2.1	51.0
	Worsening Score of >=15 from Baseline	n (%)	0	2 (50%)
	Improvement Score of >=15 from Baseline	n (%)	0	0

Table 4.029110
Summary of Change in OSDI Total Scores from Baseline

Item Score: Total Score

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 55	Actual Score	n	3	3
		Mean	2.90	9.85
		SD	2.522	17.058
		Median	4.17	0.00
		Min.	0.0	0.0
		Max.	4.5	29.5
	Change from Baseline	n	3	3
		Mean	-0.06	9.85
		SD	2.179	17.058
		Median	0.00	0.00
		Min.	-2.3	0.0
		Max.	2.1	29.5
	Worsening Score of >=15 from Baseline	n (%)	0	1 (33%)
	Improvement Score of >=15 from Baseline	n (%)	0	0

Table 4.029110
Summary of Change in OSDI Total Scores from Baseline

Item Score: Total Score

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 58	Actual Score	n	2	2
		Mean	4.17	18.18
		SD	5.893	25.713
		Median	4.17	18.18
		Min.	0.0	0.0
		Max.	8.3	36.4
	Change from Baseline	n	2	2
		Mean	3.13	18.18
		SD	4.419	25.713
		Median	3.13	18.18
		Min.	0.0	0.0
		Max.	6.3	36.4
	Worsening Score of >=15 from Baseline	n (%)	0	1 (50%)
	Improvement Score of >=15 from Baseline	n (%)	0	0

Table 4.029110
Summary of Change in OSDI Total Scores from Baseline

Item Score: Total Score

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 61	Actual Score	n	2	2
		Mean	10.42	17.50
		SD	14.731	24.749
		Median	10.42	17.50
		Min.	0.0	0.0
		Max.	20.8	35.0
	Change from Baseline	n	2	2
		Mean	9.38	17.50
		SD	13.258	24.749
		Median	9.38	17.50
		Min.	0.0	0.0
		Max.	18.8	35.0
	Worsening Score of >=15 from Baseline	n (%)	1 (50%)	1 (50%)
	Improvement Score of >=15 from Baseline	n (%)	0	0

Table 4.029110
Summary of Change in OSDI Total Scores from Baseline

Item Score: Total Score

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 64	Actual Score	n	2	2
		Mean	10.42	17.05
		SD	14.731	24.106
		Median	10.42	17.05
		Min.	0.0	0.0
		Max.	20.8	34.1
	Change from Baseline	n	2	2
		Mean	9.38	17.05
		SD	13.258	24.106
		Median	9.38	17.05
		Min.	0.0	0.0
		Max.	18.8	34.1
	Worsening Score of >=15 from Baseline	n (%)	1 (50%)	1 (50%)
	Improvement Score of >=15 from Baseline	n (%)	0	0

Table 4.029110
Summary of Change in OSDI Total Scores from Baseline

Item Score: Total Score

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 67	Actual Score	n	2	2
		Mean	8.93	12.50
		SD	12.627	17.678
		Median	8.93	12.50
		Min.	0.0	0.0
		Max.	17.9	25.0
	Change from Baseline	n	2	2
		Mean	7.89	12.50
		SD	11.154	17.678
		Median	7.89	12.50
		Min.	0.0	0.0
		Max.	15.8	25.0
	Worsening Score of >=15 from Baseline	n (%)	1 (50%)	1 (50%)
	Improvement Score of >=15 from Baseline	n (%)	0	0

Table 4.029110
Summary of Change in OSDI Total Scores from Baseline

Item Score: Total Score

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 70	Actual Score	n	2	1
		Mean	3.13	0.00
		SD	4.419	
		Median	3.13	0.00
		Min.	0.0	0.0
		Max.	6.3	0.0
	Change from Baseline	n	2	1
		Mean	2.08	0.00
		SD	2.946	
		Median	2.08	0.00
		Min.	0.0	0.0
		Max.	4.2	0.0
	Worsening Score of >=15 from Baseline	n (%)	0	0
	Improvement Score of >=15 from Baseline	n (%)	0	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_osdi_tot.sas 10MAR2023 09:21

Table 4.029110
Summary of Change in OSDI Total Scores from Baseline

Item Score: Total Score

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 73	Actual Score	n	1	1
		Mean	4.55	0.00
		SD		
		Median	4.55	0.00
		Min.	4.5	0.0
		Max.	4.5	0.0
	Change from Baseline	n	1	1
		Mean	2.46	0.00
		SD		
		Median	2.46	0.00
		Min.	2.5	0.0
		Max.	2.5	0.0
	Worsening Score of >=15 from Baseline	n (%)	0	0
	Improvement Score of >=15 from Baseline	n (%)	0	0

Table 4.029110
Summary of Change in OSDI Total Scores from Baseline

Item Score: Total Score

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 76	Actual Score	n	2	1
		Mean	6.25	0.00
		SD	8.839	
		Median	6.25	0.00
		Min.	0.0	0.0
		Max.	12.5	0.0
	Change from Baseline	n	2	1
		Mean	5.21	0.00
		SD	7.366	
		Median	5.21	0.00
		Min.	0.0	0.0
		Max.	10.4	0.0
	Worsening Score of >=15 from Baseline	n (%)	0	0
	Improvement Score of >=15 from Baseline	n (%)	0	0

Table 4.029110
Summary of Change in OSDI Total Scores from Baseline

Item Score: Total Score

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 79	Actual Score	n	2	1
		Mean	7.64	0.00
		SD	6.875	
		Median	7.64	0.00
		Min.	2.8	0.0
		Max.	12.5	0.0
	Change from Baseline	n	2	1
		Mean	6.60	0.00
		SD	5.402	
		Median	6.60	0.00
		Min.	2.8	0.0
		Max.	10.4	0.0
	Worsening Score of >=15 from Baseline	n (%)	0	0
	Improvement Score of >=15 from Baseline	n (%)	0	0

Table 4.029110
Summary of Change in OSDI Total Scores from Baseline

Item Score: Total Score

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 82	Actual Score	n	2	1
		Mean	6.25	0.00
		SD	8.839	
		Median	6.25	0.00
		Min.	0.0	0.0
		Max.	12.5	0.0
	Change from Baseline	n	2	1
		Mean	5.21	0.00
		SD	7.366	
		Median	5.21	0.00
		Min.	0.0	0.0
		Max.	10.4	0.0
	Worsening Score of >=15 from Baseline	n (%)	0	0
	Improvement Score of >=15 from Baseline	n (%)	0	0

Table 4.029110
Summary of Change in OSDI Total Scores from Baseline

Item Score: Total Score

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 85	Actual Score	n	1	1
		Mean	2.08	0.00
		SD		
		Median	2.08	0.00
		Min.	2.1	0.0
		Max.	2.1	0.0
	Change from Baseline	n	1	1
		Mean	0.00	0.00
		SD		
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Worsening Score of >=15 from Baseline	n (%)	0	0
	Improvement Score of >=15 from Baseline	n (%)	0	0

Table 4.029110
Summary of Change in OSDI Total Scores from Baseline

Item Score: Total Score

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 88	Actual Score	n	1	1
		Mean	0.00	0.00
		SD		
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Change from Baseline	n	1	1
		Mean	0.00	0.00
		SD		
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Worsening Score of >=15 from Baseline	n (%)	0	0
	Improvement Score of >=15 from Baseline	n (%)	0	0

Table 4.029110
Summary of Change in OSDI Total Scores from Baseline

Item Score: Total Score

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 91	Actual Score	n	1	1
		Mean	4.17	0.00
		SD		
		Median	4.17	0.00
		Min.	4.2	0.0
		Max.	4.2	0.0
	Change from Baseline	n	1	1
		Mean	2.08	0.00
		SD		
		Median	2.08	0.00
		Min.	2.1	0.0
		Max.	2.1	0.0
	Worsening Score of >=15 from Baseline	n (%)	0	0
	Improvement Score of >=15 from Baseline	n (%)	0	0

Table 4.029110
Summary of Change in OSDI Total Scores from Baseline

Item Score: Total Score

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 94	Actual Score	n	2	1
		Mean	0.00	0.00
		SD	0.000	
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Change from Baseline	n	2	1
		Mean	-1.04	0.00
		SD	1.473	
		Median	-1.04	0.00
		Min.	-2.1	0.0
		Max.	0.0	0.0
	Worsening Score of >=15 from Baseline	n (%)	0	0
	Improvement Score of >=15 from Baseline	n (%)	0	0

Table 4.029110
Summary of Change in OSDI Total Scores from Baseline

Item Score: Total Score

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 97	Actual Score	n	1	0
		Mean	12.50	
		SD		
		Median	12.50	
		Min.	12.5	
		Max.	12.5	
	Change from Baseline	n	1	0
		Mean	10.42	
		SD		
		Median	10.42	
		Min.	10.4	
		Max.	10.4	
	Worsening Score of >=15 from Baseline	n (%)	0	0
	Improvement Score of >=15 from Baseline	n (%)	0	0

Table 4.029110
Summary of Change in OSDI Total Scores from Baseline

Item Score: Total Score

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 100	Actual Score	n	0	1
		Mean		0.00
		SD		
		Median		0.00
		Min.		0.0
		Max.		0.0
	Change from Baseline	n	0	1
		Mean		0.00
		SD		
		Median		0.00
		Min.		0.0
		Max.		0.0
	Worsening Score of >=15 from Baseline	n (%)	0	0
	Improvement Score of >=15 from Baseline	n (%)	0	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_osdi_tot.sas 10MAR2023 09:21

Table 4.029110
Summary of Change in OSDI Total Scores from Baseline

Item Score: Total Score

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
End of Treatment	Actual Score	n	9	11
		Mean	23.66	35.90
		SD	26.133	33.982
		Median	10.00	45.00
		Min.	0.0	0.0
		Max.	71.4	87.5
	Change from Baseline	n	9	11
		Mean	7.84	12.74
		SD	24.418	35.774
		Median	1.82	-4.17
		Min.	-27.5	-27.2
		Max.	63.1	85.4
	Worsening Score of >=15 from Baseline	n (%)	2 (22%)	3 (27%)
	Improvement Score of >=15 from Baseline	n (%)	1 (11%)	1 (9%)

Table 4.029110
Summary of Change in OSDI Total Scores from Baseline

Item Score: Total Score

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Survival Follow-Up 1	Actual Score	n	0	5
		Mean		28.38
		SD		20.595
		Median		25.00
		Min.		0.0
		Max.		50.0
	Change from Baseline	n	0	5
		Mean		12.47
		SD		19.161
		Median		3.33
		Min.		-2.1
		Max.		42.3
	Worsening Score of >=15 from Baseline	n (%)	0	2 (40%)
	Improvement Score of >=15 from Baseline	n (%)	0	0

Table 4.029110
Summary of Change in OSDI Total Scores from Baseline

Item Score: Total Score

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Survival Follow-Up 2	Actual Score	n	0	3
		Mean		34.38
		SD		32.924
		Median		37.50
		Min.		0.0
		Max.		65.6
	Change from Baseline	n	0	3
		Mean		14.93
		SD		17.749
		Median		13.54
		Min.		-2.1
		Max.		33.3
	Worsening Score of >=15 from Baseline	n (%)	0	1 (33%)
	Improvement Score of >=15 from Baseline	n (%)	0	0

Table 4.029110
Summary of Change in OSDI Total Scores from Baseline

Item Score: Total Score

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Survival Follow-Up 4	Actual Score	n	0	1
		Mean		75.00
		SD		
		Median		75.00
		Min.		75.0
		Max.		75.0
	Change from Baseline	n	0	1
		Mean		70.83
		SD		
		Median		70.83
		Min.		70.8
		Max.		70.8
	Worsening Score of >=15 from Baseline	n (%)	0	1 (100%)
	Improvement Score of >=15 from Baseline	n (%)	0	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_osdi_tot.sas 10MAR2023 09:21

Table 4.029110
Summary of Change in OSDI Total Scores from Baseline

Item Score: Total Score

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
PFS Follow-Up 2 Actual Score		n	0	1
		Mean		100.00
		SD		
		Median		100.00
		Min.		100.0
		Max.		100.0
	Change from Baseline	n	0	1
		Mean		97.92
		SD		
		Median		97.92
		Min.		97.9
		Max.		97.9
	Worsening Score of >=15 from Baseline	n (%)	0	1 (100%)
	Improvement Score of >=15 from Baseline	n (%)	0	0

Table 4.029110
Summary of Change in OSDI Total Scores from Baseline

Item Score: Total Score

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
PFS Follow-Up 4 Actual Score		n	0	1
		Mean		63.89
		SD		
		Median		63.89
		Min.		63.9
		Max.		63.9
	Change from Baseline	n	0	1
		Mean		61.81
		SD		
		Median		61.81
		Min.		61.8
		Max.		61.8
	Worsening Score of >=15 from Baseline	n (%)	0	1 (100%)
	Improvement Score of >=15 from Baseline	n (%)	0	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_osdi_tot.sas 10MAR2023 09:21

Table 4.029110
Summary of Change in OSDI Total Scores from Baseline

Item Score: Total Score

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Last Follow-up	Actual Score	n	0	5
		Mean		41.50
		SD		31.296
		Median		46.88
		Min.		0.0
		Max.		75.0
	Change from Baseline	n	0	5
		Mean		25.59
		SD		30.551
		Median		13.54
		Min.		-2.1
		Max.		70.8
	Worsening Score of >=15 from Baseline	n (%)	0	2 (40%)
	Improvement Score of >=15 from Baseline	n (%)	0	0

Table 4.029110
Summary of Change in OSDI Total Scores from Baseline

Item Score: Total Score

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Worst Case Post-Baseline	Actual Score	n	13	24
		Mean	41.70	38.66
		SD	29.699	29.678
		Median	35.42	33.54
		Min.	2.5	2.1
		Max.	100.0	100.0
	Change from Baseline	n	12	23
		Mean	24.02	23.47
		SD	22.910	30.787
		Median	24.72	13.54
		Min.	-12.5	-17.1
		Max.	63.1	97.9
	Worsening Score of >=15 from Baseline	n (%)	8 (67%)	11 (48%)
	Improvement Score of >=15 from Baseline	n (%)	0	1 (4%)

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Ocular Symptom

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Baseline	Actual Score	n	13	25
		Mean	8.97	11.67
		SD	14.216	18.942
		Median	0.00	8.33
		Min.	0.0	0.0
		Max.	33.3	75.0
Week 4	Actual Score	n	13	23
		Mean	10.26	14.86
		SD	16.720	21.608
		Median	0.00	8.33
		Min.	0.0	0.0
		Max.	41.7	83.3
	Change from Baseline	n	12	22
		Mean	-2.08	3.79
		SD	10.734	20.530
		Median	0.00	0.00
		Min.	-33.3	-25.0
		Max.	8.3	83.3
	Worsening Score of >=16.67 from Baseline	n (%)	0	2 (9%)
	Improvement Score of >=16.67 from Baseline	n (%)	1 (8%)	1 (5%)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_osdi_sub.sas 10MAR2023 09:21

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Ocular Symptom

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 7	Actual Score	n	12	15
		Mean	17.36	25.56
		SD	21.455	28.254
		Median	8.33	16.67
		Min.	0.0	0.0
		Max.	58.3	75.0
	Change from Baseline	n	11	14
		Mean	4.55	15.48
		SD	14.124	28.468
		Median	0.00	4.17
		Min.	-25.0	-25.0
		Max.	25.0	75.0
	Worsening Score of >=16.67 from Baseline	n (%)	2 (18%)	3 (21%)
	Improvement Score of >=16.67 from Baseline	n (%)	1 (9%)	1 (7%)

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Ocular Symptom

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 10	Actual Score	n	13	12
		Mean	15.38	20.83
		SD	19.498	27.178
		Median	8.33	8.33
		Min.	0.0	0.0
		Max.	50.0	75.0
	Change from Baseline	n	12	11
		Mean	3.47	9.09
		SD	10.334	27.247
		Median	0.00	0.00
		Min.	-16.7	-33.3
		Max.	16.7	75.0
	Worsening Score of >=16.67 from Baseline	n (%)	0	2 (18%)
	Improvement Score of >=16.67 from Baseline	n (%)	0	1 (9%)

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Ocular Symptom

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 13	Actual Score	n	13	9
		Mean	16.67	12.96
		SD	26.352	14.500
		Median	0.00	16.67
		Min.	0.0	0.0
		Max.	75.0	41.7
	Change from Baseline	n	12	9
		Mean	2.08	1.85
		SD	12.873	16.017
		Median	0.00	0.00
		Min.	-25.0	-16.7
		Max.	25.0	33.3
	Worsening Score of >=16.67 from Baseline	n (%)	1 (8%)	1 (11%)
	Improvement Score of >=16.67 from Baseline	n (%)	1 (8%)	0

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Ocular Symptom

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 16	Actual Score	n	12	8
		Mean	17.36	11.46
		SD	24.989	16.629
		Median	8.33	8.33
		Min.	0.0	0.0
		Max.	66.7	50.0
	Change from Baseline	n	11	8
		Mean	5.30	3.13
		SD	17.189	6.200
		Median	0.00	4.17
		Min.	-25.0	-8.3
		Max.	33.3	8.3
	Worsening Score of >=16.67 from Baseline	n (%)	2 (18%)	0
	Improvement Score of >=16.67 from Baseline	n (%)	1 (9%)	0

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Ocular Symptom

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 19	Actual Score	n	12	7
		Mean	22.22	14.29
		SD	30.011	14.203
		Median	8.33	16.67
		Min.	0.0	0.0
		Max.	100.0	33.3
	Change from Baseline	n	11	7
		Mean	7.58	5.95
		SD	19.880	14.996
		Median	0.00	0.00
		Min.	-33.3	-16.7
		Max.	41.7	25.0
	Worsening Score of >=16.67 from Baseline	n (%)	2 (18%)	2 (29%)
	Improvement Score of >=16.67 from Baseline	n (%)	1 (9%)	0

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Ocular Symptom

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 22	Actual Score	n	7	7
		Mean	15.48	9.52
		SD	20.654	10.125
		Median	8.33	8.33
		Min.	0.0	0.0
		Max.	58.3	25.0
	Change from Baseline	n	7	7
		Mean	8.33	7.14
		SD	12.729	7.498
		Median	8.33	8.33
		Min.	-8.3	0.0
		Max.	25.0	16.7
	Worsening Score of >=16.67 from Baseline	n (%)	2 (29%)	0
	Improvement Score of >=16.67 from Baseline	n (%)	0	0

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Ocular Symptom

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 25	Actual Score	n	7	7
		Mean	19.05	14.29
		SD	17.817	15.749
		Median	25.00	16.67
		Min.	0.0	0.0
		Max.	50.0	41.7
	Change from Baseline	n	7	6
		Mean	11.90	13.89
		SD	14.319	13.608
		Median	16.67	12.50
		Min.	-8.3	0.0
		Max.	25.0	33.3
	Worsening Score of >=16.67 from Baseline	n (%)	3 (43%)	2 (33%)
	Improvement Score of >=16.67 from Baseline	n (%)	0	0

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Ocular Symptom

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 28	Actual Score	n	7	6
		Mean	16.67	15.28
		SD	28.464	15.290
		Median	0.00	12.50
		Min.	0.0	0.0
		Max.	75.0	33.3
	Change from Baseline	n	7	6
		Mean	9.52	12.50
		SD	19.501	13.693
		Median	0.00	8.33
		Min.	-8.3	0.0
		Max.	41.7	33.3
	Worsening Score of >=16.67 from Baseline	n (%)	2 (29%)	2 (33%)
	Improvement Score of >=16.67 from Baseline	n (%)	0	0

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Ocular Symptom

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 31	Actual Score	n	7	6
		Mean	16.67	19.44
		SD	26.352	18.758
		Median	8.33	20.83
		Min.	0.0	0.0
		Max.	75.0	50.0
	Change from Baseline	n	7	6
		Mean	9.52	16.67
		SD	15.537	18.257
		Median	0.00	16.67
		Min.	0.0	0.0
		Max.	41.7	50.0
	Worsening Score of >=16.67 from Baseline	n (%)	1 (14%)	1 (17%)
	Improvement Score of >=16.67 from Baseline	n (%)	0	0

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Ocular Symptom

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 34	Actual Score	n	5	6
		Mean	16.67	20.83
		SD	28.868	20.917
		Median	0.00	16.67
		Min.	0.0	0.0
		Max.	66.7	50.0
	Change from Baseline	n	5	6
		Mean	6.67	18.06
		SD	16.029	20.012
		Median	0.00	12.50
		Min.	-8.3	0.0
		Max.	33.3	50.0
	Worsening Score of >=16.67 from Baseline	n (%)	1 (20%)	2 (33%)
	Improvement Score of >=16.67 from Baseline	n (%)	0	0

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Ocular Symptom

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 37	Actual Score	n	4	6
		Mean	6.25	13.89
		SD	7.979	15.516
		Median	4.17	12.50
		Min.	0.0	0.0
		Max.	16.7	41.7
	Change from Baseline	n	4	6
		Mean	2.08	11.11
		SD	10.486	15.516
		Median	0.00	8.33
		Min.	-8.3	0.0
		Max.	16.7	41.7
	Worsening Score of >=16.67 from Baseline	n (%)	0	1 (17%)
	Improvement Score of >=16.67 from Baseline	n (%)	0	0

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Ocular Symptom

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 40	Actual Score	n	4	5
		Mean	2.08	15.00
		SD	4.167	17.078
		Median	0.00	16.67
		Min.	0.0	0.0
		Max.	8.3	41.7
	Change from Baseline	n	4	5
		Mean	-2.08	13.33
		SD	4.167	17.280
		Median	0.00	8.33
		Min.	-8.3	0.0
		Max.	0.0	41.7
	Worsening Score of >=16.67 from Baseline	n (%)	0	1 (20%)
	Improvement Score of >=16.67 from Baseline	n (%)	0	0

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Ocular Symptom

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 43	Actual Score	n	4	4
		Mean	0.00	20.83
		SD	0.000	20.972
		Median	0.00	16.67
		Min.	0.0	0.0
		Max.	0.0	50.0
	Change from Baseline	n	4	4
		Mean	-4.17	18.75
		SD	4.811	21.916
		Median	-4.17	12.50
		Min.	-8.3	0.0
		Max.	0.0	50.0
	Worsening Score of >=16.67 from Baseline	n (%)	0	1 (25%)
	Improvement Score of >=16.67 from Baseline	n (%)	0	0

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Ocular Symptom

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 46	Actual Score	n	3	4
		Mean	2.78	14.58
		SD	4.811	10.486
		Median	0.00	16.67
		Min.	0.0	0.0
		Max.	8.3	25.0
	Change from Baseline	n	3	4
		Mean	0.00	12.50
		SD	8.333	8.333
		Median	0.00	16.67
		Min.	-8.3	0.0
		Max.	8.3	16.7
	Worsening Score of >=16.67 from Baseline	n (%)	0	0
	Improvement Score of >=16.67 from Baseline	n (%)	0	0

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Ocular Symptom

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 49	Actual Score	n	3	4
		Mean	0.00	14.58
		SD	0.000	14.232
		Median	0.00	12.50
		Min.	0.0	0.0
		Max.	0.0	33.3
	Change from Baseline	n	3	4
		Mean	-2.78	12.50
		SD	4.811	10.758
		Median	0.00	12.50
		Min.	-8.3	0.0
		Max.	0.0	25.0
	Worsening Score of >=16.67 from Baseline	n (%)	0	1 (25%)
	Improvement Score of >=16.67 from Baseline	n (%)	0	0

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Ocular Symptom

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 52	Actual Score	n	3	4
		Mean	0.00	16.67
		SD	0.000	19.245
		Median	0.00	16.67
		Min.	0.0	0.0
		Max.	0.0	33.3
	Change from Baseline	n	3	4
		Mean	-2.78	14.58
		SD	4.811	17.180
		Median	0.00	12.50
		Min.	-8.3	0.0
		Max.	0.0	33.3
	Worsening Score of >=16.67 from Baseline	n (%)	0	2 (50%)
	Improvement Score of >=16.67 from Baseline	n (%)	0	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_osdi_sub.sas 10MAR2023 09:21

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Ocular Symptom

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 55	Actual Score	n	3	3
		Mean	0.00	8.33
		SD	0.000	14.434
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	25.0
	Change from Baseline	n	3	3
		Mean	-2.78	8.33
		SD	4.811	14.434
		Median	0.00	0.00
		Min.	-8.3	0.0
		Max.	0.0	25.0
	Worsening Score of >=16.67 from Baseline	n (%)	0	1 (33%)
	Improvement Score of >=16.67 from Baseline	n (%)	0	0

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Ocular Symptom

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 58	Actual Score	n	2	2
		Mean	8.33	25.00
		SD	11.785	35.355
		Median	8.33	25.00
		Min.	0.0	0.0
		Max.	16.7	50.0
	Change from Baseline	n	2	2
		Mean	8.33	25.00
		SD	11.785	35.355
		Median	8.33	25.00
		Min.	0.0	0.0
		Max.	16.7	50.0
	Worsening Score of >=16.67 from Baseline	n (%)	0	1 (50%)
	Improvement Score of >=16.67 from Baseline	n (%)	0	0

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Ocular Symptom

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 61	Actual Score	n	2	2
		Mean	4.17	20.83
		SD	5.893	29.463
		Median	4.17	20.83
		Min.	0.0	0.0
		Max.	8.3	41.7
	Change from Baseline	n	2	2
		Mean	4.17	20.83
		SD	5.893	29.463
		Median	4.17	20.83
		Min.	0.0	0.0
		Max.	8.3	41.7
	Worsening Score of >=16.67 from Baseline	n (%)	0	1 (50%)
	Improvement Score of >=16.67 from Baseline	n (%)	0	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_osdi_sub.sas 10MAR2023 09:21

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Ocular Symptom

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 64	Actual Score	n	2	2
		Mean	4.17	20.83
		SD	5.893	29.463
		Median	4.17	20.83
		Min.	0.0	0.0
		Max.	8.3	41.7
	Change from Baseline	n	2	2
		Mean	4.17	20.83
		SD	5.893	29.463
		Median	4.17	20.83
		Min.	0.0	0.0
		Max.	8.3	41.7
	Worsening Score of >=16.67 from Baseline	n (%)	0	1 (50%)
	Improvement Score of >=16.67 from Baseline	n (%)	0	0

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Ocular Symptom

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 67	Actual Score	n	2	2
		Mean	4.17	12.50
		SD	5.893	17.678
		Median	4.17	12.50
		Min.	0.0	0.0
		Max.	8.3	25.0
	Change from Baseline	n	2	2
		Mean	4.17	12.50
		SD	5.893	17.678
		Median	4.17	12.50
		Min.	0.0	0.0
		Max.	8.3	25.0
	Worsening Score of >=16.67 from Baseline	n (%)	0	1 (50%)
	Improvement Score of >=16.67 from Baseline	n (%)	0	0

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Ocular Symptom

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 70	Actual Score	n	2	1
		Mean	0.00	0.00
		SD	0.000	
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Change from Baseline	n	2	1
		Mean	0.00	0.00
		SD	0.000	
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Worsening Score of >=16.67 from Baseline	n (%)	0	0
	Improvement Score of >=16.67 from Baseline	n (%)	0	0

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Ocular Symptom

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 73	Actual Score	n	1	1
		Mean	0.00	0.00
		SD		
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Change from Baseline	n	1	1
		Mean	0.00	0.00
		SD		
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Worsening Score of >=16.67 from Baseline	n (%)	0	0
	Improvement Score of >=16.67 from Baseline	n (%)	0	0

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Ocular Symptom

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 76	Actual Score	n	2	1
		Mean	4.17	0.00
		SD	5.893	
		Median	4.17	0.00
		Min.	0.0	0.0
		Max.	8.3	0.0
	Change from Baseline	n	2	1
		Mean	4.17	0.00
		SD	5.893	
		Median	4.17	0.00
		Min.	0.0	0.0
		Max.	8.3	0.0
	Worsening Score of >=16.67 from Baseline	n (%)	0	0
	Improvement Score of >=16.67 from Baseline	n (%)	0	0

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Ocular Symptom

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 79	Actual Score	n	2	1
		Mean	4.17	0.00
		SD	5.893	
		Median	4.17	0.00
		Min.	0.0	0.0
		Max.	8.3	0.0
	Change from Baseline	n	2	1
		Mean	4.17	0.00
		SD	5.893	
		Median	4.17	0.00
		Min.	0.0	0.0
		Max.	8.3	0.0
	Worsening Score of >=16.67 from Baseline	n (%)	0	0
	Improvement Score of >=16.67 from Baseline	n (%)	0	0

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Ocular Symptom

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 82	Actual Score	n	2	1
		Mean	4.17	0.00
		SD	5.893	
		Median	4.17	0.00
		Min.	0.0	0.0
		Max.	8.3	0.0
	Change from Baseline	n	2	1
		Mean	4.17	0.00
		SD	5.893	
		Median	4.17	0.00
		Min.	0.0	0.0
		Max.	8.3	0.0
	Worsening Score of >=16.67 from Baseline	n (%)	0	0
	Improvement Score of >=16.67 from Baseline	n (%)	0	0

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Ocular Symptom

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 85	Actual Score	n	1	1
		Mean	0.00	0.00
		SD		
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Change from Baseline	n	1	1
		Mean	0.00	0.00
		SD		
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Worsening Score of >=16.67 from Baseline	n (%)	0	0
	Improvement Score of >=16.67 from Baseline	n (%)	0	0

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Ocular Symptom

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 88	Actual Score	n	1	1
		Mean	0.00	0.00
		SD		
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Change from Baseline	n	1	1
		Mean	0.00	0.00
		SD		
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Worsening Score of >=16.67 from Baseline	n (%)	0	0
	Improvement Score of >=16.67 from Baseline	n (%)	0	0

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Ocular Symptom

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 91	Actual Score	n	1	1
		Mean	0.00	0.00
		SD		
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Change from Baseline	n	1	1
		Mean	0.00	0.00
		SD		
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Worsening Score of >=16.67 from Baseline	n (%)	0	0
	Improvement Score of >=16.67 from Baseline	n (%)	0	0

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Ocular Symptom

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 94	Actual Score	n	2	1
		Mean	0.00	0.00
		SD	0.000	
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Change from Baseline	n	2	1
		Mean	0.00	0.00
		SD	0.000	
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Worsening Score of >=16.67 from Baseline	n (%)	0	0
	Improvement Score of >=16.67 from Baseline	n (%)	0	0

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Ocular Symptom

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 97	Actual Score	n	1	0
		Mean	8.33	
		SD		
		Median	8.33	
		Min.	8.3	
		Max.	8.3	
	Change from Baseline	n	1	0
		Mean	8.33	
		SD		
		Median	8.33	
		Min.	8.3	
		Max.	8.3	
	Worsening Score of >=16.67 from Baseline	n (%)	0	0
	Improvement Score of >=16.67 from Baseline	n (%)	0	0

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Ocular Symptom

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 100	Actual Score	n	0	1
		Mean		0.00
		SD		
		Median		0.00
		Min.		0.0
		Max.		0.0
	Change from Baseline	n	0	1
		Mean		0.00
		SD		
		Median		0.00
		Min.		0.0
		Max.		0.0
	Worsening Score of >=16.67 from Baseline	n (%)	0	0
	Improvement Score of >=16.67 from Baseline	n (%)	0	0

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Ocular Symptom

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
End of Treatment	Actual Score	n	9	11
		Mean	25.93	31.82
		SD	32.661	32.450
		Median	16.67	33.33
		Min.	0.0	0.0
		Max.	100.0	91.7
	Change from Baseline	n	9	11
		Mean	12.96	14.39
		SD	35.627	33.971
		Median	0.00	0.00
		Min.	-25.0	-16.7
		Max.	100.0	91.7
	Worsening Score of >=16.67 from Baseline	n (%)	2 (22%)	3 (27%)
	Improvement Score of >=16.67 from Baseline	n (%)	1 (11%)	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_osdi_sub.sas 10MAR2023 09:21

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Ocular Symptom

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Survival Follow-Up 1	Actual Score	n	0	5
		Mean		31.67
		SD		30.277
		Median		16.67
		Min.		0.0
		Max.		75.0
	Change from Baseline	n	0	5
		Mean		20.00
		SD		31.513
		Median		8.33
		Min.		0.0
		Max.		75.0
	Worsening Score of >=16.67 from Baseline	n (%)	0	1 (20%)
	Improvement Score of >=16.67 from Baseline	n (%)	0	0

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Ocular Symptom

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Survival Follow-Up 2	Actual Score	n	0	3
		Mean		22.22
		SD		25.459
		Median		16.67
		Min.		0.0
		Max.		50.0
	Change from Baseline	n	0	3
		Mean		2.78
		SD		4.811
		Median		0.00
		Min.		0.0
		Max.		8.3
	Worsening Score of >=16.67 from Baseline	n (%)	0	0
	Improvement Score of >=16.67 from Baseline	n (%)	0	0

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Ocular Symptom

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Survival Follow-Up 4	Actual Score	n	0	1
		Mean		50.00
		SD		
		Median		50.00
		Min.		50.0
		Max.		50.0
	Change from Baseline	n	0	1
		Mean		41.67
		SD		
		Median		41.67
		Min.		41.7
		Max.		41.7
	Worsening Score of >=16.67 from Baseline	n (%)	0	1 (100%)
	Improvement Score of >=16.67 from Baseline	n (%)	0	0

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Ocular Symptom

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
PFS Follow-Up 2 Actual Score		n	0	1
		Mean		100.00
		SD		
		Median		100.00
		Min.		100.0
		Max.		100.0
	Change from Baseline	n	0	1
		Mean		100.00
		SD		
		Median		100.00
		Min.		100.0
		Max.		100.0
	Worsening Score of >=16.67 from Baseline	n (%)	0	1 (100%)
	Improvement Score of >=16.67 from Baseline	n (%)	0	0

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Ocular Symptom

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
PFS Follow-Up 4 Actual Score		n	0	1
		Mean		66.67
		SD		
		Median		66.67
		Min.		66.7
		Max.		66.7
	Change from Baseline	n	0	1
		Mean		66.67
		SD		
		Median		66.67
		Min.		66.7
		Max.		66.7
	Worsening Score of >=16.67 from Baseline	n (%)	0	1 (100%)
	Improvement Score of >=16.67 from Baseline	n (%)	0	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_osdi_sub.sas 10MAR2023 09:21

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Ocular Symptom

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Last Follow-up	Actual Score	n	0	5
		Mean		38.33
		SD		29.814
		Median		50.00
		Min.		0.0
		Max.		75.0
	Change from Baseline	n	0	5
		Mean		26.67
		SD		31.950
		Median		16.67
		Min.		0.0
		Max.		75.0
	Worsening Score of >=16.67 from Baseline	n (%)	0	2 (40%)
	Improvement Score of >=16.67 from Baseline	n (%)	0	0

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Ocular Symptom

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Worst Case Post-Baseline	Actual Score	n	13	24
		Mean	39.74	33.68
		SD	33.011	29.229
		Median	33.33	25.00
		Min.	0.0	0.0
		Max.	100.0	100.0
	Change from Baseline	n	12	23
		Mean	25.00	22.46
		SD	29.516	31.123
		Median	20.83	8.33
		Min.	-16.7	-16.7
		Max.	100.0	100.0
	Worsening Score of >=16.67 from Baseline	n (%)	6 (50%)	9 (39%)
	Improvement Score of >=16.67 from Baseline	n (%)	0	0

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Vision-Related Function

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Baseline	Actual Score	n	13	25
		Mean	13.43	19.77
		SD	15.727	25.122
		Median	10.00	8.33
		Min.	0.0	0.0
		Max.	50.0	81.3
Week 4	Actual Score	n	13	23
		Mean	20.00	18.75
		SD	28.325	25.466
		Median	6.25	8.33
		Min.	0.0	0.0
		Max.	100.0	100.0
	Change from Baseline	n	12	22
		Mean	-1.22	-1.31
		SD	21.027	27.216
		Median	-2.08	0.00
		Min.	-50.0	-56.3
		Max.	29.2	100.0
	Worsening Score of >=15 from Baseline	n (%)	3 (25%)	2 (9%)
	Improvement Score of >=15 from Baseline	n (%)	1 (8%)	4 (18%)

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Vision-Related Function

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 7	Actual Score	n	12	15
		Mean	26.94	36.53
		SD	36.110	37.433
		Median	10.83	20.83
		Min.	0.0	0.0
		Max.	100.0	100.0
	Change from Baseline	n	11	14
		Mean	4.43	22.95
		SD	24.915	35.888
		Median	0.00	7.29
		Min.	-33.3	-14.6
		Max.	58.3	100.0
	Worsening Score of >=15 from Baseline	n (%)	3 (27%)	6 (43%)
	Improvement Score of >=15 from Baseline	n (%)	2 (18%)	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_osdi_sub.sas 10MAR2023 09:21

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Vision-Related Function

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 10	Actual Score	n	13	12
		Mean	27.69	30.76
		SD	31.876	39.403
		Median	25.00	18.33
		Min.	0.0	0.0
		Max.	100.0	100.0
	Change from Baseline	n	12	11
		Mean	7.12	15.57
		SD	21.125	41.386
		Median	0.00	4.17
		Min.	-16.7	-45.8
		Max.	41.7	95.0
	Worsening Score of >=15 from Baseline	n (%)	4 (33%)	4 (36%)
	Improvement Score of >=15 from Baseline	n (%)	1 (8%)	1 (9%)

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Vision-Related Function

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 13	Actual Score	n	13	9
		Mean	32.12	30.28
		SD	32.613	33.899
		Median	37.50	16.67
		Min.	0.0	0.0
		Max.	100.0	87.5
	Change from Baseline	n	12	9
		Mean	11.91	16.16
		SD	23.661	40.038
		Median	2.50	4.17
		Min.	-16.7	-31.3
		Max.	60.0	87.5
	Worsening Score of >=15 from Baseline	n (%)	4 (33%)	2 (22%)
	Improvement Score of >=15 from Baseline	n (%)	1 (8%)	1 (11%)

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Vision-Related Function

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 16	Actual Score	n	12	8
		Mean	26.74	15.36
		SD	32.101	25.563
		Median	16.67	5.21
		Min.	0.0	0.0
		Max.	100.0	75.0
	Change from Baseline	n	11	8
		Mean	7.05	3.65
		SD	24.055	10.608
		Median	0.00	0.00
		Min.	-33.3	-6.3
		Max.	50.0	25.0
	Worsening Score of >=15 from Baseline	n (%)	3 (27%)	1 (13%)
	Improvement Score of >=15 from Baseline	n (%)	2 (18%)	0

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Vision-Related Function

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 19	Actual Score	n	12	7
		Mean	30.56	31.85
		SD	34.179	34.668
		Median	18.75	16.67
		Min.	0.0	0.0
		Max.	100.0	100.0
	Change from Baseline	n	11	7
		Mean	11.21	19.05
		SD	31.858	38.779
		Median	6.25	12.50
		Min.	-50.0	-25.0
		Max.	62.5	100.0
	Worsening Score of >=15 from Baseline	n (%)	5 (45%)	3 (43%)
	Improvement Score of >=15 from Baseline	n (%)	2 (18%)	1 (14%)

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Vision-Related Function

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 22	Actual Score	n	7	7
		Mean	24.52	15.60
		SD	29.918	9.739
		Median	25.00	16.67
		Min.	0.0	0.0
		Max.	83.3	30.0
	Change from Baseline	n	7	7
		Mean	13.57	14.40
		SD	22.370	9.498
		Median	20.83	12.50
		Min.	-12.5	0.0
		Max.	50.0	30.0
	Worsening Score of >=15 from Baseline	n (%)	4 (57%)	3 (43%)
	Improvement Score of >=15 from Baseline	n (%)	0	0

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Vision-Related Function

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 25	Actual Score	n	7	7
		Mean	21.43	12.32
		SD	22.493	16.000
		Median	25.00	5.00
		Min.	0.0	0.0
		Max.	50.0	37.5
	Change from Baseline	n	7	6
		Mean	10.48	12.99
		SD	18.439	17.815
		Median	16.67	5.63
		Min.	-12.5	-4.2
		Max.	37.5	37.5
	Worsening Score of >=15 from Baseline	n (%)	4 (57%)	2 (33%)
	Improvement Score of >=15 from Baseline	n (%)	0	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_osdi_sub.sas 10MAR2023 09:21

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Vision-Related Function

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 28	Actual Score	n	7	6
		Mean	25.36	27.71
		SD	25.612	32.706
		Median	25.00	17.71
		Min.	0.0	0.0
		Max.	75.0	85.0
	Change from Baseline	n	7	6
		Mean	14.40	26.32
		SD	17.715	33.438
		Median	20.83	13.54
		Min.	-10.0	0.0
		Max.	41.7	85.0
	Worsening Score of >=15 from Baseline	n (%)	4 (57%)	3 (50%)
	Improvement Score of >=15 from Baseline	n (%)	0	0

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Vision-Related Function

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 31	Actual Score	n	7	6
		Mean	16.07	19.03
		SD	22.202	23.514
		Median	12.50	10.42
		Min.	0.0	0.0
		Max.	62.5	60.0
	Change from Baseline	n	7	6
		Mean	5.12	17.64
		SD	14.403	24.212
		Median	6.25	6.25
		Min.	-12.5	0.0
		Max.	29.2	60.0
	Worsening Score of >=15 from Baseline	n (%)	1 (14%)	2 (33%)
	Improvement Score of >=15 from Baseline	n (%)	0	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_osdi_sub.sas 10MAR2023 09:21

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Vision-Related Function

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 34	Actual Score	n	5	6
		Mean	15.33	22.99
		SD	29.021	29.745
		Median	0.00	11.46
		Min.	0.0	0.0
		Max.	66.7	75.0
	Change from Baseline	n	5	6
		Mean	3.33	21.60
		SD	18.343	30.969
		Median	0.00	9.38
		Min.	-12.5	-4.2
		Max.	33.3	75.0
	Worsening Score of >=15 from Baseline	n (%)	1 (20%)	3 (50%)
	Improvement Score of >=15 from Baseline	n (%)	0	0

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Vision-Related Function

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 37	Actual Score	n	4	6
		Mean	4.17	14.24
		SD	8.333	17.796
		Median	0.00	6.25
		Min.	0.0	0.0
		Max.	16.7	41.7
	Change from Baseline	n	4	6
		Mean	-2.50	12.85
		SD	11.365	19.022
		Median	-5.00	4.17
		Min.	-12.5	-4.2
		Max.	12.5	41.7
	Worsening Score of >=15 from Baseline	n (%)	0	2 (33%)
	Improvement Score of >=15 from Baseline	n (%)	0	0

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Vision-Related Function

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 40	Actual Score	n	4	5
		Mean	0.00	14.17
		SD	0.000	20.750
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	45.8
	Change from Baseline	n	4	5
		Mean	-6.67	14.17
		SD	5.652	20.750
		Median	-7.08	0.00
		Min.	-12.5	0.0
		Max.	0.0	45.8
	Worsening Score of >=15 from Baseline	n (%)	0	2 (40%)
	Improvement Score of >=15 from Baseline	n (%)	0	0

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Vision-Related Function

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 43	Actual Score	n	4	4
		Mean	5.63	8.96
		SD	6.575	10.615
		Median	5.00	7.50
		Min.	0.0	0.0
		Max.	12.5	20.8
	Change from Baseline	n	4	4
		Mean	-1.04	8.96
		SD	8.590	10.615
		Median	0.00	7.50
		Min.	-12.5	0.0
		Max.	8.3	20.8
	Worsening Score of >=15 from Baseline	n (%)	0	2 (50%)
	Improvement Score of >=15 from Baseline	n (%)	0	0

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Vision-Related Function

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 46	Actual Score	n	3	4
		Mean	9.58	26.04
		SD	9.382	33.398
		Median	10.00	14.58
		Min.	0.0	0.0
		Max.	18.8	75.0
	Change from Baseline	n	3	4
		Mean	4.86	26.04
		SD	8.420	33.398
		Median	0.00	14.58
		Min.	0.0	0.0
		Max.	14.6	75.0
	Worsening Score of >=15 from Baseline	n (%)	0	2 (50%)
	Improvement Score of >=15 from Baseline	n (%)	0	0

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Vision-Related Function

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 49	Actual Score	n	3	4
		Mean	7.78	27.50
		SD	7.515	40.104
		Median	8.33	12.50
		Min.	0.0	0.0
		Max.	15.0	85.0
	Change from Baseline	n	3	4
		Mean	3.06	27.50
		SD	2.679	40.104
		Median	4.17	12.50
		Min.	0.0	0.0
		Max.	5.0	85.0
	Worsening Score of >=15 from Baseline	n (%)	0	2 (50%)
	Improvement Score of >=15 from Baseline	n (%)	0	0

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Vision-Related Function

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 52	Actual Score	n	3	4
		Mean	6.11	22.50
		SD	5.358	30.687
		Median	8.33	12.50
		Min.	0.0	0.0
		Max.	10.0	65.0
	Change from Baseline	n	3	4
		Mean	1.39	22.50
		SD	2.406	30.687
		Median	0.00	12.50
		Min.	0.0	0.0
		Max.	4.2	65.0
	Worsening Score of >=15 from Baseline	n (%)	0	2 (50%)
	Improvement Score of >=15 from Baseline	n (%)	0	0

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Vision-Related Function

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 55	Actual Score	n	3	3
		Mean	6.11	11.11
		SD	5.358	19.245
		Median	8.33	0.00
		Min.	0.0	0.0
		Max.	10.0	33.3
	Change from Baseline	n	3	3
		Mean	1.39	11.11
		SD	2.406	19.245
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	4.2	33.3
	Worsening Score of >=15 from Baseline	n (%)	0	1 (33%)
	Improvement Score of >=15 from Baseline	n (%)	0	0

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Vision-Related Function

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 58	Actual Score	n	2	2
		Mean	4.17	16.67
		SD	5.893	23.570
		Median	4.17	16.67
		Min.	0.0	0.0
		Max.	8.3	33.3
	Change from Baseline	n	2	2
		Mean	2.08	16.67
		SD	2.946	23.570
		Median	2.08	16.67
		Min.	0.0	0.0
		Max.	4.2	33.3
	Worsening Score of >=15 from Baseline	n (%)	0	1 (50%)
	Improvement Score of >=15 from Baseline	n (%)	0	0

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Vision-Related Function

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 61	Actual Score	n	2	2
		Mean	18.75	17.50
		SD	26.517	24.749
		Median	18.75	17.50
		Min.	0.0	0.0
		Max.	37.5	35.0
	Change from Baseline	n	2	2
		Mean	16.67	17.50
		SD	23.570	24.749
		Median	16.67	17.50
		Min.	0.0	0.0
		Max.	33.3	35.0
	Worsening Score of >=15 from Baseline	n (%)	1 (50%)	1 (50%)
	Improvement Score of >=15 from Baseline	n (%)	0	0

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Vision-Related Function

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 64	Actual Score	n	2	2
		Mean	18.75	16.67
		SD	26.517	23.570
		Median	18.75	16.67
		Min.	0.0	0.0
		Max.	37.5	33.3
	Change from Baseline	n	2	2
		Mean	16.67	16.67
		SD	23.570	23.570
		Median	16.67	16.67
		Min.	0.0	0.0
		Max.	33.3	33.3
	Worsening Score of >=15 from Baseline	n (%)	1 (50%)	1 (50%)
	Improvement Score of >=15 from Baseline	n (%)	0	0

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Vision-Related Function

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 67	Actual Score	n	2	2
		Mean	12.50	12.50
		SD	17.678	17.678
		Median	12.50	12.50
		Min.	0.0	0.0
		Max.	25.0	25.0
	Change from Baseline	n	2	2
		Mean	10.42	12.50
		SD	14.731	17.678
		Median	10.42	12.50
		Min.	0.0	0.0
		Max.	20.8	25.0
	Worsening Score of >=15 from Baseline	n (%)	1 (50%)	1 (50%)
	Improvement Score of >=15 from Baseline	n (%)	0	0

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Vision-Related Function

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 70	Actual Score	n	2	1
		Mean	6.25	0.00
		SD	8.839	
		Median	6.25	0.00
		Min.	0.0	0.0
		Max.	12.5	0.0
	Change from Baseline	n	2	1
		Mean	4.17	0.00
		SD	5.893	
		Median	4.17	0.00
		Min.	0.0	0.0
		Max.	8.3	0.0
	Worsening Score of >=15 from Baseline	n (%)	0	0
	Improvement Score of >=15 from Baseline	n (%)	0	0

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Vision-Related Function

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 73	Actual Score	n	1	1
		Mean	10.00	0.00
		SD		
		Median	10.00	0.00
		Min.	10.0	0.0
		Max.	10.0	0.0
	Change from Baseline	n	1	1
		Mean	5.83	0.00
		SD		
		Median	5.83	0.00
		Min.	5.8	0.0
		Max.	5.8	0.0
	Worsening Score of >=15 from Baseline	n (%)	0	0
	Improvement Score of >=15 from Baseline	n (%)	0	0

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Vision-Related Function

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 76	Actual Score	n	2	1
		Mean	10.42	0.00
		SD	14.731	
		Median	10.42	0.00
		Min.	0.0	0.0
		Max.	20.8	0.0
	Change from Baseline	n	2	1
		Mean	8.33	0.00
		SD	11.785	
		Median	8.33	0.00
		Min.	0.0	0.0
		Max.	16.7	0.0
	Worsening Score of >=15 from Baseline	n (%)	1 (50%)	0
	Improvement Score of >=15 from Baseline	n (%)	0	0

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Vision-Related Function

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 79	Actual Score	n	2	1
		Mean	12.50	0.00
		SD	11.785	
		Median	12.50	0.00
		Min.	4.2	0.0
		Max.	20.8	0.0
	Change from Baseline	n	2	1
		Mean	10.42	0.00
		SD	8.839	
		Median	10.42	0.00
		Min.	4.2	0.0
		Max.	16.7	0.0
	Worsening Score of >=15 from Baseline	n (%)	1 (50%)	0
	Improvement Score of >=15 from Baseline	n (%)	0	0

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Vision-Related Function

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 82	Actual Score	n	2	1
		Mean	10.42	0.00
		SD	14.731	
		Median	10.42	0.00
		Min.	0.0	0.0
		Max.	20.8	0.0
	Change from Baseline	n	2	1
		Mean	8.33	0.00
		SD	11.785	
		Median	8.33	0.00
		Min.	0.0	0.0
		Max.	16.7	0.0
	Worsening Score of >=15 from Baseline	n (%)	1 (50%)	0
	Improvement Score of >=15 from Baseline	n (%)	0	0

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Vision-Related Function

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 85	Actual Score	n	1	1
		Mean	4.17	0.00
		SD		
		Median	4.17	0.00
		Min.	4.2	0.0
		Max.	4.2	0.0
	Change from Baseline	n	1	1
		Mean	0.00	0.00
		SD		
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Worsening Score of >=15 from Baseline	n (%)	0	0
	Improvement Score of >=15 from Baseline	n (%)	0	0

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Vision-Related Function

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 88	Actual Score	n	1	1
		Mean	0.00	0.00
		SD		
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Change from Baseline	n	1	1
		Mean	0.00	0.00
		SD		
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Worsening Score of >=15 from Baseline	n (%)	0	0
	Improvement Score of >=15 from Baseline	n (%)	0	0

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Vision-Related Function

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 91	Actual Score	n	1	1
		Mean	8.33	0.00
		SD		
		Median	8.33	0.00
		Min.	8.3	0.0
		Max.	8.3	0.0
	Change from Baseline	n	1	1
		Mean	4.17	0.00
		SD		
		Median	4.17	0.00
		Min.	4.2	0.0
		Max.	4.2	0.0
	Worsening Score of >=15 from Baseline	n (%)	0	0
	Improvement Score of >=15 from Baseline	n (%)	0	0

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Vision-Related Function

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 94	Actual Score	n	2	1
		Mean	0.00	0.00
		SD	0.000	
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Change from Baseline	n	2	1
		Mean	-2.08	0.00
		SD	2.946	
		Median	-2.08	0.00
		Min.	-4.2	0.0
		Max.	0.0	0.0
	Worsening Score of >=15 from Baseline	n (%)	0	0
	Improvement Score of >=15 from Baseline	n (%)	0	0

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Vision-Related Function

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 97	Actual Score	n	1	0
		Mean	18.75	
		SD		
		Median	18.75	
		Min.	18.8	
		Max.	18.8	
	Change from Baseline	n	1	0
		Mean	14.58	
		SD		
		Median	14.58	
		Min.	14.6	
		Max.	14.6	
	Worsening Score of >=15 from Baseline	n (%)	0	0
	Improvement Score of >=15 from Baseline	n (%)	0	0

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Vision-Related Function

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 100	Actual Score	n	0	1
		Mean		0.00
		SD		
		Median		0.00
		Min.		0.0
		Max.		0.0
	Change from Baseline	n	0	1
		Mean		0.00
		SD		
		Median		0.00
		Min.		0.0
		Max.		0.0
	Worsening Score of >=15 from Baseline	n (%)	0	0
	Improvement Score of >=15 from Baseline	n (%)	0	0

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Vision-Related Function

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
End of Treatment	Actual Score	n	9	11
		Mean	21.53	43.30
		SD	17.965	41.916
		Median	18.75	50.00
		Min.	0.0	0.0
		Max.	50.0	100.0
	Change from Baseline	n	9	11
		Mean	2.59	14.47
		SD	17.944	45.488
		Median	2.50	-4.17
		Min.	-31.3	-31.3
		Max.	33.3	100.0
	Worsening Score of >=15 from Baseline	n (%)	2 (22%)	3 (27%)
	Improvement Score of >=15 from Baseline	n (%)	1 (11%)	2 (18%)

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Vision-Related Function

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Survival Follow-Up 1	Actual Score	n	0	5
		Mean		35.83
		SD		29.107
		Median		37.50
		Min.		0.0
		Max.		75.0
	Change from Baseline	n	0	5
		Mean		13.00
		SD		32.051
		Median		4.17
		Min.		-20.8
		Max.		65.0
	Worsening Score of >=15 from Baseline	n (%)	0	2 (40%)
	Improvement Score of >=15 from Baseline	n (%)	0	1 (20%)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_osdi_sub.sas 10MAR2023 09:21

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Vision-Related Function

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Survival Follow-Up 2	Actual Score	n	0	3
		Mean		36.81
		SD		34.632
		Median		41.67
		Min.		0.0
		Max.		68.8
	Change from Baseline	n	0	3
		Mean		13.19
		SD		24.680
		Median		0.00
		Min.		-2.1
		Max.		41.7
	Worsening Score of >=15 from Baseline	n (%)	0	1 (33%)
	Improvement Score of >=15 from Baseline	n (%)	0	0

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Vision-Related Function

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Survival Follow-Up 4	Actual Score	n	0	1
		Mean		100.00
		SD		
		Median		100.00
		Min.		100.0
		Max.		100.0
	Change from Baseline	n	0	1
		Mean		100.00
		SD		
		Median		100.00
		Min.		100.0
		Max.		100.0
	Worsening Score of >=15 from Baseline	n (%)	0	1 (100%)
	Improvement Score of >=15 from Baseline	n (%)	0	0

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Vision-Related Function

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
PFS Follow-Up 2	Actual Score	n	0	1
		Mean		100.00
		SD		
		Median		100.00
		Min.		100.0
		Max.		100.0
	Change from Baseline	n	0	1
		Mean		100.00
		SD		
		Median		100.00
		Min.		100.0
		Max.		100.0
	Worsening Score of >=15 from Baseline	n (%)	0	1 (100%)
	Improvement Score of >=15 from Baseline	n (%)	0	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_osdi_sub.sas 10MAR2023 09:21

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Vision-Related Function

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
PFS Follow-Up 4	Actual Score	n	0	1
		Mean		55.00
		SD		
		Median		55.00
		Min.		55.0
		Max.		55.0
	Change from Baseline	n	0	1
		Mean		55.00
		SD		
		Median		55.00
		Min.		55.0
		Max.		55.0
	Worsening Score of >=15 from Baseline	n (%)	0	1 (100%)
	Improvement Score of >=15 from Baseline	n (%)	0	0

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Vision-Related Function

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Last Follow-up	Actual Score	n	0	5
		Mean		56.25
		SD		38.528
		Median		68.75
		Min.		0.0
		Max.		100.0
	Change from Baseline	n	0	5
		Mean		33.42
		SD		46.539
		Median		4.17
		Min.		-2.1
		Max.		100.0
	Worsening Score of >=15 from Baseline	n (%)	0	2 (40%)
	Improvement Score of >=15 from Baseline	n (%)	0	0

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Vision-Related Function

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Worst Case Post-Baseline	Actual Score	n	13	24
		Mean	48.08	50.12
		SD	28.794	35.391
		Median	50.00	45.83
		Min.	0.0	4.2
		Max.	100.0	100.0
	Change from Baseline	n	12	23
		Mean	29.20	30.85
		SD	24.815	40.133
		Median	29.17	12.50
		Min.	-6.3	-22.5
		Max.	62.5	100.0
	Worsening Score of >=15 from Baseline	n (%)	8 (67%)	11 (48%)
	Improvement Score of >=15 from Baseline	n (%)	0	1 (4%)

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Environmental Triggers

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Baseline	Actual Score	n	11	24
		Mean	13.64	12.85
		SD	20.841	25.771
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	66.7	100.0
Week 4	Actual Score	n	11	20
		Mean	20.45	16.25
		SD	29.194	22.250
		Median	0.00	4.17
		Min.	0.0	0.0
		Max.	75.0	75.0
	Change from Baseline	n	10	19
		Mean	0.00	3.95
		SD	12.423	26.149
		Median	0.00	0.00
		Min.	-25.0	-66.7
		Max.	25.0	66.7
	Worsening Score of >=15 from Baseline	n (%)	1 (10%)	5 (26%)
	Improvement Score of >=15 from Baseline	n (%)	1 (10%)	3 (16%)

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Environmental Triggers

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 7	Actual Score	n	10	11
		Mean	25.42	29.55
		SD	30.835	37.521
		Median	25.00	8.33
		Min.	0.0	0.0
		Max.	100.0	100.0
	Change from Baseline	n	8	11
		Mean	7.81	12.88
		SD	14.509	36.394
		Median	0.00	0.00
		Min.	-8.3	-25.0
		Max.	33.3	91.7
	Worsening Score of >=15 from Baseline	n (%)	2 (25%)	2 (18%)
	Improvement Score of >=15 from Baseline	n (%)	0	2 (18%)

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Environmental Triggers

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 10	Actual Score	n	11	8
		Mean	31.06	30.73
		SD	37.098	40.393
		Median	16.67	16.67
		Min.	0.0	0.0
		Max.	100.0	100.0
	Change from Baseline	n	9	8
		Mean	7.41	9.90
		SD	26.169	32.270
		Median	0.00	0.00
		Min.	-8.3	-33.3
		Max.	75.0	79.2
	Worsening Score of >=15 from Baseline	n (%)	1 (11%)	2 (25%)
	Improvement Score of >=15 from Baseline	n (%)	0	1 (13%)

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Environmental Triggers

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 13	Actual Score	n	12	8
		Mean	23.96	14.58
		SD	35.539	16.517
		Median	0.00	12.50
		Min.	0.0	0.0
		Max.	100.0	41.7
	Change from Baseline	n	10	8
		Mean	3.75	-5.21
		SD	17.174	28.150
		Median	0.00	0.00
		Min.	-25.0	-58.3
		Max.	37.5	25.0
	Worsening Score of >=15 from Baseline	n (%)	2 (20%)	2 (25%)
	Improvement Score of >=15 from Baseline	n (%)	1 (10%)	2 (25%)

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Environmental Triggers

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 16	Actual Score	n	11	6
		Mean	28.03	8.33
		SD	42.044	20.412
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	100.0	50.0
	Change from Baseline	n	9	6
		Mean	8.33	-8.33
		SD	29.167	20.412
		Median	0.00	0.00
		Min.	-25.0	-50.0
		Max.	75.0	0.0
	Worsening Score of >=15 from Baseline	n (%)	2 (22%)	0
	Improvement Score of >=15 from Baseline	n (%)	1 (11%)	1 (17%)

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Environmental Triggers

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 19	Actual Score	n	10	5
		Mean	27.50	8.33
		SD	39.878	18.634
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	100.0	41.7
	Change from Baseline	n	8	5
		Mean	7.29	-11.67
		SD	29.017	26.087
		Median	0.00	0.00
		Min.	-25.0	-58.3
		Max.	75.0	0.0
	Worsening Score of >=15 from Baseline	n (%)	1 (13%)	0
	Improvement Score of >=15 from Baseline	n (%)	1 (13%)	1 (20%)

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Environmental Triggers

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 22	Actual Score	n	7	4
		Mean	16.07	8.33
		SD	27.683	11.785
		Median	0.00	4.17
		Min.	0.0	0.0
		Max.	75.0	25.0
	Change from Baseline	n	6	4
		Mean	6.25	8.33
		SD	11.711	11.785
		Median	4.17	4.17
		Min.	-8.3	0.0
		Max.	25.0	25.0
	Worsening Score of >=15 from Baseline	n (%)	1 (17%)	1 (25%)
	Improvement Score of >=15 from Baseline	n (%)	0	0

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Environmental Triggers

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 25	Actual Score	n	7	6
		Mean	16.07	0.00
		SD	27.683	0.000
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	75.0	0.0
	Change from Baseline	n	6	5
		Mean	2.08	0.00
		SD	7.336	0.000
		Median	0.00	0.00
		Min.	-8.3	0.0
		Max.	12.5	0.0
	Worsening Score of >=15 from Baseline	n (%)	0	0
	Improvement Score of >=15 from Baseline	n (%)	0	0

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Environmental Triggers

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 28	Actual Score	n	6	5
		Mean	16.67	13.33
		SD	40.825	12.638
		Median	0.00	16.67
		Min.	0.0	0.0
		Max.	100.0	25.0
	Change from Baseline	n	5	5
		Mean	5.00	13.33
		SD	16.245	12.638
		Median	0.00	16.67
		Min.	-8.3	0.0
		Max.	33.3	25.0
	Worsening Score of >=15 from Baseline	n (%)	1 (20%)	3 (60%)
	Improvement Score of >=15 from Baseline	n (%)	0	0

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Environmental Triggers

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 31	Actual Score	n	6	6
		Mean	13.89	6.94
		SD	30.123	11.076
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	75.0	25.0
	Change from Baseline	n	5	6
		Mean	1.67	6.94
		SD	3.727	11.076
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	8.3	25.0
	Worsening Score of >=15 from Baseline	n (%)	0	2 (33%)
	Improvement Score of >=15 from Baseline	n (%)	0	0

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Environmental Triggers

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 34	Actual Score	n	5	4
		Mean	15.00	10.42
		SD	33.541	12.500
		Median	0.00	8.33
		Min.	0.0	0.0
		Max.	75.0	25.0
	Change from Baseline	n	5	4
		Mean	0.00	10.42
		SD	5.893	12.500
		Median	0.00	8.33
		Min.	-8.3	0.0
		Max.	8.3	25.0
	Worsening Score of >=15 from Baseline	n (%)	0	2 (50%)
	Improvement Score of >=15 from Baseline	n (%)	0	0

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Environmental Triggers

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 37	Actual Score	n	4	5
		Mean	6.25	8.33
		SD	12.500	10.206
		Median	0.00	8.33
		Min.	0.0	0.0
		Max.	25.0	25.0
	Change from Baseline	n	4	5
		Mean	4.17	8.33
		SD	14.434	10.206
		Median	0.00	8.33
		Min.	-8.3	0.0
		Max.	25.0	25.0
	Worsening Score of >=15 from Baseline	n (%)	1 (25%)	1 (20%)
	Improvement Score of >=15 from Baseline	n (%)	0	0

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Environmental Triggers

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 40	Actual Score	n	4	4
		Mean	0.00	12.50
		SD	0.000	14.434
		Median	0.00	12.50
		Min.	0.0	0.0
		Max.	0.0	25.0
	Change from Baseline	n	4	4
		Mean	-2.08	12.50
		SD	4.167	14.434
		Median	0.00	12.50
		Min.	-8.3	0.0
		Max.	0.0	25.0
	Worsening Score of >=15 from Baseline	n (%)	0	2 (50%)
	Improvement Score of >=15 from Baseline	n (%)	0	0

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Environmental Triggers

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 43	Actual Score	n	4	3
		Mean	0.00	16.67
		SD	0.000	14.434
		Median	0.00	25.00
		Min.	0.0	0.0
		Max.	0.0	25.0
	Change from Baseline	n	4	3
		Mean	-2.08	16.67
		SD	4.167	14.434
		Median	0.00	25.00
		Min.	-8.3	0.0
		Max.	0.0	25.0
	Worsening Score of >=15 from Baseline	n (%)	0	2 (67%)
	Improvement Score of >=15 from Baseline	n (%)	0	0

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Environmental Triggers

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 46	Actual Score	n	2	3
		Mean	0.00	8.33
		SD	0.000	14.434
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	25.0
	Change from Baseline	n	2	3
		Mean	0.00	8.33
		SD	0.000	14.434
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	25.0
	Worsening Score of >=15 from Baseline	n (%)	0	1 (33%)
	Improvement Score of >=15 from Baseline	n (%)	0	0

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Environmental Triggers

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 49	Actual Score	n	3	3
		Mean	0.00	8.33
		SD	0.000	14.434
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	25.0
	Change from Baseline	n	3	3
		Mean	0.00	8.33
		SD	0.000	14.434
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	25.0
	Worsening Score of >=15 from Baseline	n (%)	0	1 (33%)
	Improvement Score of >=15 from Baseline	n (%)	0	0

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Environmental Triggers

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 52	Actual Score	n	3	3
		Mean	0.00	11.11
		SD	0.000	12.729
		Median	0.00	8.33
		Min.	0.0	0.0
		Max.	0.0	25.0
	Change from Baseline	n	3	3
		Mean	0.00	11.11
		SD	0.000	12.729
		Median	0.00	8.33
		Min.	0.0	0.0
		Max.	0.0	25.0
	Worsening Score of >=15 from Baseline	n (%)	0	1 (33%)
	Improvement Score of >=15 from Baseline	n (%)	0	0

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Environmental Triggers

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 55	Actual Score	n	3	2
		Mean	0.00	12.50
		SD	0.000	17.678
		Median	0.00	12.50
		Min.	0.0	0.0
		Max.	0.0	25.0
	Change from Baseline	n	3	2
		Mean	0.00	12.50
		SD	0.000	17.678
		Median	0.00	12.50
		Min.	0.0	0.0
		Max.	0.0	25.0
	Worsening Score of >=15 from Baseline	n (%)	0	1 (50%)
	Improvement Score of >=15 from Baseline	n (%)	0	0

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Environmental Triggers

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 58	Actual Score	n	2	2
		Mean	0.00	12.50
		SD	0.000	17.678
		Median	0.00	12.50
		Min.	0.0	0.0
		Max.	0.0	25.0
	Change from Baseline	n	2	2
		Mean	0.00	12.50
		SD	0.000	17.678
		Median	0.00	12.50
		Min.	0.0	0.0
		Max.	0.0	25.0
	Worsening Score of >=15 from Baseline	n (%)	0	1 (50%)
	Improvement Score of >=15 from Baseline	n (%)	0	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_osdi_sub.sas 10MAR2023 09:21

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Environmental Triggers

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 61	Actual Score	n	2	2
		Mean	0.00	12.50
		SD	0.000	17.678
		Median	0.00	12.50
		Min.	0.0	0.0
		Max.	0.0	25.0
	Change from Baseline	n	2	2
		Mean	0.00	12.50
		SD	0.000	17.678
		Median	0.00	12.50
		Min.	0.0	0.0
		Max.	0.0	25.0
	Worsening Score of >=15 from Baseline	n (%)	0	1 (50%)
	Improvement Score of >=15 from Baseline	n (%)	0	0

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Environmental Triggers

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 64	Actual Score	n	2	2
		Mean	0.00	12.50
		SD	0.000	17.678
		Median	0.00	12.50
		Min.	0.0	0.0
		Max.	0.0	25.0
	Change from Baseline	n	2	2
		Mean	0.00	12.50
		SD	0.000	17.678
		Median	0.00	12.50
		Min.	0.0	0.0
		Max.	0.0	25.0
	Worsening Score of >=15 from Baseline	n (%)	0	1 (50%)
	Improvement Score of >=15 from Baseline	n (%)	0	0

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_osdi_sub.sas 10MAR2023 09:21

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Environmental Triggers

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 67	Actual Score	n	1	2
		Mean	0.00	12.50
		SD		17.678
		Median	0.00	12.50
		Min.	0.0	0.0
		Max.	0.0	25.0
	Change from Baseline	n	1	2
		Mean	0.00	12.50
		SD		17.678
		Median	0.00	12.50
		Min.	0.0	0.0
		Max.	0.0	25.0
	Worsening Score of >=15 from Baseline	n (%)	0	1 (50%)
	Improvement Score of >=15 from Baseline	n (%)	0	0

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Environmental Triggers

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 70	Actual Score	n	2	1
		Mean	0.00	0.00
		SD	0.000	
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Change from Baseline	n	2	1
		Mean	0.00	0.00
		SD	0.000	
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Worsening Score of >=15 from Baseline	n (%)	0	0
	Improvement Score of >=15 from Baseline	n (%)	0	0

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Environmental Triggers

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 73	Actual Score	n	1	1
		Mean	0.00	0.00
		SD		
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Change from Baseline	n	1	1
		Mean	0.00	0.00
		SD		
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Worsening Score of >=15 from Baseline	n (%)	0	0
	Improvement Score of >=15 from Baseline	n (%)	0	0

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Environmental Triggers

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 76	Actual Score	n	1	1
		Mean	0.00	0.00
		SD		
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Change from Baseline	n	1	1
		Mean	0.00	0.00
		SD		
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Worsening Score of >=15 from Baseline	n (%)	0	0
	Improvement Score of >=15 from Baseline	n (%)	0	0

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Environmental Triggers

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 79	Actual Score	n	1	1
		Mean	0.00	0.00
		SD		
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Change from Baseline	n	1	1
		Mean	0.00	0.00
		SD		
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Worsening Score of >=15 from Baseline	n (%)	0	0
	Improvement Score of >=15 from Baseline	n (%)	0	0

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Environmental Triggers

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 82	Actual Score	n	2	1
		Mean	0.00	0.00
		SD	0.000	
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Change from Baseline	n	2	1
		Mean	0.00	0.00
		SD	0.000	
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Worsening Score of >=15 from Baseline	n (%)	0	0
	Improvement Score of >=15 from Baseline	n (%)	0	0

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Environmental Triggers

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 85	Actual Score	n	1	1
		Mean	0.00	0.00
		SD		
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Change from Baseline	n	1	1
		Mean	0.00	0.00
		SD		
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Worsening Score of >=15 from Baseline	n (%)	0	0
	Improvement Score of >=15 from Baseline	n (%)	0	0

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Environmental Triggers

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 88	Actual Score	n	1	1
		Mean	0.00	0.00
		SD		
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Change from Baseline	n	1	1
		Mean	0.00	0.00
		SD		
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Worsening Score of >=15 from Baseline	n (%)	0	0
	Improvement Score of >=15 from Baseline	n (%)	0	0

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Environmental Triggers

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 91	Actual Score	n	1	1
		Mean	0.00	0.00
		SD		
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Change from Baseline	n	1	1
		Mean	0.00	0.00
		SD		
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Worsening Score of >=15 from Baseline	n (%)	0	0
	Improvement Score of >=15 from Baseline	n (%)	0	0

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Environmental Triggers

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 94	Actual Score	n	2	1
		Mean	0.00	0.00
		SD	0.000	
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Change from Baseline	n	2	1
		Mean	0.00	0.00
		SD	0.000	
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	0.0
	Worsening Score of >=15 from Baseline	n (%)	0	0
	Improvement Score of >=15 from Baseline	n (%)	0	0

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Environmental Triggers

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 97	Actual Score	n	1	0
		Mean	0.00	
		SD		
		Median	0.00	
		Min.	0.0	
		Max.	0.0	
	Change from Baseline	n	1	0
		Mean	0.00	
		SD		
		Median	0.00	
		Min.	0.0	
		Max.	0.0	
	Worsening Score of >=15 from Baseline	n (%)	0	0
	Improvement Score of >=15 from Baseline	n (%)	0	0

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Environmental Triggers

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 100	Actual Score	n	0	1
		Mean		0.00
		SD		
		Median		0.00
		Min.		0.0
		Max.		0.0
	Change from Baseline	n	0	1
		Mean		0.00
		SD		
		Median		0.00
		Min.		0.0
		Max.		0.0
	Worsening Score of >=15 from Baseline	n (%)	0	0
	Improvement Score of >=15 from Baseline	n (%)	0	0

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Environmental Triggers

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
End of Treatment	Actual Score	n	7	9
		Mean	21.43	32.41
		SD	39.340	35.219
		Median	0.00	25.00
		Min.	0.0	0.0
		Max.	100.0	100.0
	Change from Baseline	n	6	9
		Mean	5.56	7.41
		SD	20.861	40.278
		Median	0.00	0.00
		Min.	-25.0	-58.3
		Max.	33.3	91.7
	Worsening Score of >=15 from Baseline	n (%)	2 (33%)	3 (33%)
	Improvement Score of >=15 from Baseline	n (%)	1 (17%)	2 (22%)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t1_osdi_sub.sas 10MAR2023 09:21

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Environmental Triggers

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Survival Follow-Up 1	Actual Score	n	0	5
		Mean		20.00
		SD		27.386
		Median		0.00
		Min.		0.0
		Max.		50.0
	Change from Baseline	n	0	5
		Mean		13.33
		SD		22.515
		Median		0.00
		Min.		-8.3
		Max.		41.7
	Worsening Score of >=15 from Baseline	n (%)	0	2 (40%)
	Improvement Score of >=15 from Baseline	n (%)	0	0

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Environmental Triggers

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Survival Follow-Up 2	Actual Score	n	0	3
		Mean		50.00
		SD		50.000
		Median		50.00
		Min.		0.0
		Max.		100.0
	Change from Baseline	n	0	3
		Mean		38.89
		SD		45.896
		Median		41.67
		Min.		-8.3
		Max.		83.3
	Worsening Score of >=15 from Baseline	n (%)	0	2 (67%)
	Improvement Score of >=15 from Baseline	n (%)	0	0

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Environmental Triggers

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Survival Follow-Up 4	Actual Score	n	0	1
		Mean		50.00
		SD		
		Median		50.00
		Min.		50.0
		Max.		50.0
	Change from Baseline	n	0	1
		Mean		41.67
		SD		
		Median		41.67
		Min.		41.7
		Max.		41.7
	Worsening Score of >=15 from Baseline	n (%)	0	1 (100%)
	Improvement Score of >=15 from Baseline	n (%)	0	0

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Environmental Triggers

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
PFS Follow-Up 2 Actual Score		n	0	1
		Mean		100.00
		SD		
		Median		100.00
		Min.		100.0
		Max.		100.0
	Change from Baseline	n	0	1
		Mean		91.67
		SD		
		Median		91.67
		Min.		91.7
		Max.		91.7
	Worsening Score of >=15 from Baseline	n (%)	0	1 (100%)
	Improvement Score of >=15 from Baseline	n (%)	0	0

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Environmental Triggers

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
PFS Follow-Up 4 Actual Score		n	0	1
		Mean		100.00
		SD		
		Median		100.00
		Min.		100.0
		Max.		100.0
	Change from Baseline	n	0	1
		Mean		91.67
		SD		
		Median		91.67
		Min.		91.7
		Max.		91.7
	Worsening Score of >=15 from Baseline	n (%)	0	1 (100%)
	Improvement Score of >=15 from Baseline	n (%)	0	0

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Environmental Triggers

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Last Follow-up	Actual Score	n	0	5
		Mean		30.00
		SD		44.721
		Median		0.00
		Min.		0.0
		Max.		100.0
	Change from Baseline	n	0	5
		Mean		23.33
		SD		38.819
		Median		0.00
		Min.		-8.3
		Max.		83.3
	Worsening Score of >=15 from Baseline	n (%)	0	2 (40%)
	Improvement Score of >=15 from Baseline	n (%)	0	0

Table 4.028110
Summary of Change in OSDI Subscale Scores from Baseline

Item Score: Environmental Triggers

Timepoint			Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Worst Case Post-Baseline	Actual Score	n	12	23
		Mean	41.67	29.71
		SD	41.742	35.540
		Median	25.00	16.67
		Min.	0.0	0.0
		Max.	100.0	100.0
	Change from Baseline	n	10	22
		Mean	20.00	17.05
		SD	31.720	30.939
		Median	0.00	0.00
		Min.	-8.3	-16.7
		Max.	75.0	91.7
	Worsening Score of >=15 from Baseline	n (%)	4 (40%)	9 (41%)
	Improvement Score of >=15 from Baseline	n (%)	0	2 (9%)

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Ocular Symptom

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 4		
n [1]	12	23
n [2]	12	22
LS Mean (SE)	7.2 (5.72)	13.2 (4.23)
95% C.I.	(-4.5, 18.8)	(4.5, 21.8)
LS Mean Change from Baseline (SE)	-1.8 (5.72)	4.3 (4.23)
95% C.I.	(-13.4, 9.9)	(-4.4, 12.9)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		6.0 (7.10)
95% C.I.		(-8.5, 20.5)
Corrected Hedges' g Statistic		0.30
95% C.I.		(-0.41, 1.00)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Ocular Symptom

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 7		
n [1]	12	23
n [2]	11	18
LS Mean (SE)	13.5 (7.95)	26.2 (6.07)
95% C.I.	(-2.7, 29.7)	(13.8, 38.5)
LS Mean Change from Baseline (SE)	4.6 (7.95)	17.3 (6.07)
95% C.I.	(-11.6, 20.8)	(4.9, 29.6)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		12.7 (9.98)
95% C.I.		(-7.7, 33.0)
Corrected Hedges' g Statistic		0.47
95% C.I.		(-0.29, 1.23)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Ocular Symptom

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 10		
n [1]	12	23
n [2]	12	11
LS Mean (SE)	12.5 (5.57)	17.9 (5.06)
95% C.I.	(1.2, 23.9)	(7.6, 28.2)
LS Mean Change from Baseline (SE)	3.6 (5.57)	9.0 (5.06)
95% C.I.	(-7.7, 15.0)	(-1.3, 19.3)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		5.3 (7.50)
95% C.I.		(-9.9, 20.6)
Corrected Hedges' g Statistic		0.28
95% C.I.		(-0.54, 1.11)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Ocular Symptom

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 13		
n [1]	12	23
n [2]	12	10
LS Mean (SE)	11.3 (5.64)	19.3 (5.41)
95% C.I.	(-0.2, 22.8)	(8.3, 30.3)
LS Mean Change from Baseline (SE)	2.4 (5.64)	10.4 (5.41)
95% C.I.	(-9.1, 13.9)	(-0.6, 21.4)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		8.0 (7.81)
95% C.I.		(-7.9, 23.8)
Corrected Hedges' g Statistic		0.41
95% C.I.		(-0.43, 1.26)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Ocular Symptom

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 16		
n [1]	12	23
n [2]	11	10
LS Mean (SE)	15.2 (4.59)	18.2 (4.42)
95% C.I.	(5.7, 24.7)	(9.1, 27.3)
LS Mean Change from Baseline (SE)	6.3 (4.59)	9.3 (4.42)
95% C.I.	(-3.2, 15.8)	(0.2, 18.4)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		3.0 (6.37)
95% C.I.		(-10.1, 16.2)
Corrected Hedges' g Statistic		0.20
95% C.I.		(-0.66, 1.06)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Ocular Symptom

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 19		
n [1]	12	23
n [2]	12	9
LS Mean (SE)	16.5 (6.49)	27.7 (6.67)
95% C.I.	(3.2, 29.8)	(14.1, 41.3)
LS Mean Change from Baseline (SE)	7.6 (6.49)	18.8 (6.67)
95% C.I.	(-5.7, 20.9)	(5.2, 32.4)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		11.2 (9.32)
95% C.I.		(-7.8, 30.2)
Corrected Hedges' g Statistic		0.50
95% C.I.		(-0.38, 1.38)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Ocular Symptom

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 22		
n [1]	12	23
n [2]	8	8
LS Mean (SE)	16.2 (4.69)	19.5 (4.68)
95% C.I.	(6.3, 26.0)	(9.7, 29.4)
LS Mean Change from Baseline (SE)	7.3 (4.69)	10.6 (4.68)
95% C.I.	(-2.6, 17.1)	(0.8, 20.5)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		3.4 (6.63)
95% C.I.		(-10.5, 17.3)
Corrected Hedges' g Statistic		0.24
95% C.I.		(-0.74, 1.22)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Ocular Symptom

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 25		
n [1]	12	23
n [2]	9	7
LS Mean (SE)	23.1 (8.92)	17.0 (9.84)
95% C.I.	(4.5, 41.8)	(-3.6, 37.6)
LS Mean Change from Baseline (SE)	14.2 (8.92)	8.1 (9.84)
95% C.I.	(-4.4, 32.9)	(-12.5, 28.7)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-6.1 (12.77)
95% C.I.		(-32.9, 20.6)
Corrected Hedges' g Statistic		-0.22
95% C.I.		(-1.21, 0.77)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Ocular Symptom

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 28		
n [1]	12	23
n [2]	7	7
LS Mean (SE)	21.0 (6.60)	20.7 (6.79)
95% C.I.	(6.9, 35.1)	(6.2, 35.1)
LS Mean Change from Baseline (SE)	12.1 (6.60)	11.7 (6.79)
95% C.I.	(-2.0, 26.2)	(-2.7, 26.2)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-0.3 (9.27)
95% C.I.		(-20.1, 19.4)
Corrected Hedges' g Statistic		-0.02
95% C.I.		(-1.07, 1.03)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Ocular Symptom

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 31		
n [1]	12	23
n [2]	7	7
LS Mean (SE)	21.5 (6.18)	22.6 (6.02)
95% C.I.	(8.5, 34.5)	(9.9, 35.3)
LS Mean Change from Baseline (SE)	12.6 (6.18)	13.7 (6.02)
95% C.I.	(-0.4, 25.6)	(1.0, 26.4)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		1.1 (8.64)
95% C.I.		(-17.1, 19.3)
Corrected Hedges' g Statistic		0.06
95% C.I.		(-0.98, 1.11)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Ocular Symptom

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 34		
n [1]	12	23
n [2]	6	6
LS Mean (SE)	16.9 (5.59)	25.9 (5.88)
95% C.I.	(5.0, 28.7)	(13.5, 38.4)
LS Mean Change from Baseline (SE)	8.0 (5.59)	17.0 (5.88)
95% C.I.	(-3.9, 19.8)	(4.6, 29.5)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		9.1 (8.09)
95% C.I.		(-8.1, 26.2)
Corrected Hedges' g Statistic		0.60
95% C.I.		(-0.56, 1.75)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Ocular Symptom

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 37		
n [1]	12	23
n [2]	4	6
LS Mean (SE)	12.0 (6.22)	12.2 (6.60)
95% C.I.	(-1.4, 25.3)	(-1.9, 26.4)
LS Mean Change from Baseline (SE)	3.1 (6.22)	3.3 (6.60)
95% C.I.	(-10.3, 16.4)	(-10.8, 17.5)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		0.3 (7.42)
95% C.I.		(-15.7, 16.3)
Corrected Hedges' g Statistic		0.02
95% C.I.		(-1.25, 1.28)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Ocular Symptom

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 40		
n [1]	12	23
n [2]	4	6
LS Mean (SE)	10.9 (7.57)	16.2 (9.59)
95% C.I.	(-6.3, 28.1)	(-5.6, 38.0)
LS Mean Change from Baseline (SE)	2.0 (7.57)	7.3 (9.59)
95% C.I.	(-15.2, 19.2)	(-14.5, 29.1)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		5.3 (9.17)
95% C.I.		(-15.5, 26.2)
Corrected Hedges' g Statistic		0.23
95% C.I.		(-1.04, 1.50)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Ocular Symptom

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 43		
n [1]	12	23
n [2]	5	4

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Ocular Symptom

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 46		
n [1]	12	23
n [2]	4	4

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Ocular Symptom

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 49		
n [1]	12	23
n [2]	3	4

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Ocular Symptom

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 52		
n [1]	12	23
n [2]	3	6

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Ocular Symptom

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 55		
n [1]	12	23
n [2]	3	3

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Ocular Symptom

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 58		
n [1]	12	23
n [2]	2	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Ocular Symptom

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 61		
n [1]	12	23
n [2]	2	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Ocular Symptom

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 64		
n [1]	12	23
n [2]	2	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Ocular Symptom

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 67		
n [1]	12	23
n [2]	2	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Ocular Symptom

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 70		
n [1]	12	23
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Ocular Symptom

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 73		
n [1]	12	23
n [2]	1	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Ocular Symptom

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 76		
n [1]	12	23
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Ocular Symptom

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 79		
n [1]	12	23
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Ocular Symptom

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 82		
n [1]	12	23
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Ocular Symptom

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 85		
n [1]	12	23
n [2]	1	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Ocular Symptom

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 88		
n [1]	12	23
n [2]	1	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Ocular Symptom

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 91		
n [1]	12	23
n [2]	1	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Ocular Symptom

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 94		
n [1]	12	23
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Ocular Symptom

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 97		
n [1]	12	23
n [2]	1	0

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Ocular Symptom

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 100		
n [1]	12	23
n [2]	0	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Ocular Symptom

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
End of Treatment		
n [1]	12	23
n [2]	9	11
LS Mean (SE)	24.1 (12.62)	32.7 (11.50)
95% C.I.	(-2.7, 50.8)	(8.4, 57.1)
LS Mean Change from Baseline (SE)	15.2 (12.62)	23.8 (11.50)
95% C.I.	(-11.6, 41.9)	(-0.6, 48.2)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		8.6 (16.92)
95% C.I.		(-27.2, 44.5)
Corrected Hedges' g Statistic		0.22
95% C.I.		(-0.67, 1.10)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Ocular Symptom

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Survival Follow-Up 1		
n [1]	12	23
n [2]	0	5

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Ocular Symptom

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Survival Follow-Up 2		
n [1]	12	23
n [2]	0	3

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Ocular Symptom

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Survival Follow-Up 4		
n [1]	12	23
n [2]	0	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Ocular Symptom

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
PFS Follow-Up 2		
n [1]	12	23
n [2]	0	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Ocular Symptom

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
PFS Follow-Up 4		
n [1]	12	23
n [2]	0	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Vision-Related Function

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 4		
n [1]	12	23
n [2]	12	22
LS Mean (SE)	12.9 (6.63)	15.4 (4.99)
95% C.I.	(-0.6, 26.3)	(5.3, 25.5)
LS Mean Change from Baseline (SE)	-0.5 (6.63)	2.1 (4.99)
95% C.I.	(-14.0, 13.0)	(-8.1, 12.2)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		2.5 (8.27)
95% C.I.		(-14.3, 19.3)
Corrected Hedges' g Statistic		0.11
95% C.I.		(-0.60, 0.81)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Vision-Related Function

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 7		
n [1]	12	23
n [2]	11	18
LS Mean (SE)	20.3 (10.52)	41.5 (8.13)
95% C.I.	(-1.1, 41.7)	(25.0, 58.0)
LS Mean Change from Baseline (SE)	6.9 (10.52)	28.2 (8.13)
95% C.I.	(-14.5, 28.3)	(11.6, 44.7)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		21.2 (13.24)
95% C.I.		(-5.7, 48.1)
Corrected Hedges' g Statistic		0.60
95% C.I.		(-0.17, 1.36)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Vision-Related Function

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 10		
n [1]	12	23
n [2]	12	11
LS Mean (SE)	20.8 (9.19)	30.3 (8.43)
95% C.I.	(1.8, 39.7)	(13.1, 47.6)
LS Mean Change from Baseline (SE)	7.4 (9.19)	17.0 (8.43)
95% C.I.	(-11.5, 26.3)	(-0.2, 34.2)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		9.6 (12.44)
95% C.I.		(-15.9, 35.1)
Corrected Hedges' g Statistic		0.31
95% C.I.		(-0.52, 1.13)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Vision-Related Function

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 13		
n [1]	12	23
n [2]	12	10
LS Mean (SE)	26.1 (10.05)	31.6 (9.76)
95% C.I.	(5.3, 46.9)	(11.5, 51.6)
LS Mean Change from Baseline (SE)	12.8 (10.05)	18.2 (9.76)
95% C.I.	(-8.0, 33.6)	(-1.9, 38.3)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		5.4 (14.00)
95% C.I.		(-23.4, 34.3)
Corrected Hedges' g Statistic		0.16
95% C.I.		(-0.68, 1.00)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Vision-Related Function

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 16		
n [1]	12	23
n [2]	11	10
LS Mean (SE)	20.9 (6.37)	17.9 (6.20)
95% C.I.	(7.7, 34.2)	(5.1, 30.8)
LS Mean Change from Baseline (SE)	7.6 (6.37)	4.6 (6.20)
95% C.I.	(-5.7, 20.8)	(-8.2, 17.4)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-3.0 (8.89)
95% C.I.		(-21.4, 15.5)
Corrected Hedges' g Statistic		-0.14
95% C.I.		(-1.00, 0.72)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Vision-Related Function

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 19		
n [1]	12	23
n [2]	12	9
LS Mean (SE)	25.3 (10.39)	38.1 (10.80)
95% C.I.	(3.8, 46.9)	(15.8, 60.4)
LS Mean Change from Baseline (SE)	12.0 (10.39)	24.8 (10.80)
95% C.I.	(-9.6, 33.5)	(2.5, 47.1)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		12.8 (15.00)
95% C.I.		(-18.2, 43.8)
Corrected Hedges' g Statistic		0.36
95% C.I.		(-0.51, 1.23)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Vision-Related Function

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 22		
n [1]	12	23
n [2]	8	8
LS Mean (SE)	21.3 (6.89)	27.4 (7.01)
95% C.I.	(6.8, 35.8)	(12.7, 42.1)
LS Mean Change from Baseline (SE)	8.0 (6.89)	14.1 (7.01)
95% C.I.	(-6.5, 22.4)	(-0.6, 28.8)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		6.1 (9.88)
95% C.I.		(-14.6, 26.9)
Corrected Hedges' g Statistic		0.29
95% C.I.		(-0.69, 1.28)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Vision-Related Function

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 25		
n [1]	12	23
n [2]	9	7
LS Mean (SE)	20.4 (7.46)	18.5 (10.07)
95% C.I.	(4.7, 36.1)	(-2.6, 39.6)
LS Mean Change from Baseline (SE)	7.1 (7.46)	5.2 (10.07)
95% C.I.	(-8.6, 22.8)	(-15.9, 26.3)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-1.9 (11.73)
95% C.I.		(-26.5, 22.7)
Corrected Hedges' g Statistic		-0.07
95% C.I.		(-1.06, 0.91)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Vision-Related Function

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 28		
n [1]	12	23
n [2]	7	7
LS Mean (SE)	26.3 (8.60)	37.7 (10.95)
95% C.I.	(8.3, 44.3)	(14.8, 60.5)
LS Mean Change from Baseline (SE)	13.0 (8.60)	24.3 (10.95)
95% C.I.	(-5.0, 31.0)	(1.5, 47.2)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		11.3 (13.15)
95% C.I.		(-16.1, 38.8)
Corrected Hedges' g Statistic		0.41
95% C.I.		(-0.65, 1.47)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Vision-Related Function

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 31		
n [1]	12	23
n [2]	7	7
LS Mean (SE)	18.4 (5.41)	28.2 (5.31)
95% C.I.	(7.3, 29.6)	(17.2, 39.2)
LS Mean Change from Baseline (SE)	5.1 (5.41)	14.9 (5.31)
95% C.I.	(-6.1, 16.3)	(3.9, 25.8)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		9.8 (7.55)
95% C.I.		(-5.8, 25.4)
Corrected Hedges' g Statistic		0.64
95% C.I.		(-0.43, 1.72)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Vision-Related Function

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 34		
n [1]	12	23
n [2]	6	6
LS Mean (SE)	17.5 (7.05)	33.1 (9.04)
95% C.I.	(2.8, 32.1)	(14.3, 51.9)
LS Mean Change from Baseline (SE)	4.1 (7.05)	19.8 (9.04)
95% C.I.	(-10.6, 18.8)	(0.9, 38.6)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		15.7 (11.18)
95% C.I.		(-7.6, 38.9)
Corrected Hedges' g Statistic		0.73
95% C.I.		(-0.44, 1.90)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Vision-Related Function

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 37		
n [1]	12	23
n [2]	4	6
LS Mean (SE)	10.4 (6.93)	15.8 (10.02)
95% C.I.	(-4.4, 25.1)	(-5.5, 37.2)
LS Mean Change from Baseline (SE)	-3.0 (6.93)	2.5 (10.02)
95% C.I.	(-17.7, 11.8)	(-18.9, 23.8)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		5.4 (8.44)
95% C.I.		(-12.5, 23.4)
Corrected Hedges' g Statistic		0.23
95% C.I.		(-1.04, 1.50)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Vision-Related Function

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 40		
n [1]	12	23
n [2]	4	6
LS Mean (SE)	8.2 (8.68)	17.0 (15.34)
95% C.I.	(-11.0, 27.4)	(-16.9, 50.9)
LS Mean Change from Baseline (SE)	-5.1 (8.68)	3.7 (15.34)
95% C.I.	(-24.3, 14.1)	(-30.2, 37.6)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		8.8 (11.34)
95% C.I.		(-16.2, 33.8)
Corrected Hedges' g Statistic		0.25
95% C.I.		(-1.02, 1.52)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Vision-Related Function

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 43		
n [1]	12	23
n [2]	5	4

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Vision-Related Function

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 46		
n [1]	12	23
n [2]	4	4

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Vision-Related Function

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 49		
n [1]	12	23
n [2]	3	4

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Vision-Related Function

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 52		
n [1]	12	23
n [2]	3	6

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Vision-Related Function

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 55		
n [1]	12	23
n [2]	3	3

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Vision-Related Function

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 58		
n [1]	12	23
n [2]	2	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Vision-Related Function

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 61		
n [1]	12	23
n [2]	2	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Vision-Related Function

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 64		
n [1]	12	23
n [2]	2	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Vision-Related Function

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 67		
n [1]	12	23
n [2]	2	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Vision-Related Function

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 70		
n [1]	12	23
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Vision-Related Function

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 73		
n [1]	12	23
n [2]	1	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Vision-Related Function

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 76		
n [1]	12	23
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Vision-Related Function

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 79		
n [1]	12	23
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Vision-Related Function

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 82		
n [1]	12	23
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Vision-Related Function

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 85		
n [1]	12	23
n [2]	1	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Vision-Related Function

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 88		
n [1]	12	23
n [2]	1	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Vision-Related Function

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 91		
n [1]	12	23
n [2]	1	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Vision-Related Function

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 94		
n [1]	12	23
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Vision-Related Function

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 97		
n [1]	12	23
n [2]	1	0

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Vision-Related Function

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 100		
n [1]	12	23
n [2]	0	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Vision-Related Function

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
End of Treatment		
n [1]	12	23
n [2]	9	11
LS Mean (SE)	20.0 (11.76)	44.7 (11.06)
95% C.I.	(-4.8, 44.8)	(21.4, 68.0)
LS Mean Change from Baseline (SE)	6.7 (11.76)	31.3 (11.06)
95% C.I.	(-18.1, 31.5)	(8.0, 54.7)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		24.7 (15.73)
95% C.I.		(-8.5, 57.8)
Corrected Hedges' g Statistic		0.66
95% C.I.		(-0.25, 1.56)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Vision-Related Function

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Survival Follow-Up 1		
n [1]	12	23
n [2]	0	5

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Vision-Related Function

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Survival Follow-Up 2		
n [1]	12	23
n [2]	0	3

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Vision-Related Function

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Survival Follow-Up 4		
n [1]	12	23
n [2]	0	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Vision-Related Function

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
PFS Follow-Up 2		
n [1]	12	23
n [2]	0	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Vision-Related Function

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
PFS Follow-Up 4		
n [1]	12	23
n [2]	0	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Environmental Triggers

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 4		
n [1]	10	22
n [2]	10	19
LS Mean (SE)	14.5 (7.92)	16.8 (5.54)
95% C.I.	(-1.9, 30.8)	(5.3, 28.2)
LS Mean Change from Baseline (SE)	0.5 (7.92)	2.8 (5.54)
95% C.I.	(-15.9, 16.9)	(-8.6, 14.2)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		2.3 (9.67)
95% C.I.		(-17.7, 22.3)
Corrected Hedges' g Statistic		0.09
95% C.I.		(-0.67, 0.86)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Environmental Triggers

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 7		
n [1]	10	22
n [2]	8	15
LS Mean (SE)	20.5 (11.32)	23.1 (8.03)
95% C.I.	(-2.9, 44.0)	(6.6, 39.7)
LS Mean Change from Baseline (SE)	6.5 (11.32)	9.2 (8.03)
95% C.I.	(-16.9, 30.0)	(-7.4, 25.7)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		2.6 (13.88)
95% C.I.		(-26.1, 31.3)
Corrected Hedges' g Statistic		0.08
95% C.I.		(-0.78, 0.94)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Environmental Triggers

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 10		
n [1]	10	22
n [2]	9	9
LS Mean (SE)	23.3 (9.99)	22.1 (8.03)
95% C.I.	(2.6, 44.1)	(5.7, 38.6)
LS Mean Change from Baseline (SE)	9.4 (9.99)	8.2 (8.03)
95% C.I.	(-11.4, 30.1)	(-8.3, 24.6)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-1.2 (12.80)
95% C.I.		(-27.6, 25.2)
Corrected Hedges' g Statistic		-0.04
95% C.I.		(-0.97, 0.88)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Environmental Triggers

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 13		
n [1]	10	22
n [2]	10	9
LS Mean (SE)	18.2 (8.13)	20.8 (6.85)
95% C.I.	(1.4, 35.0)	(6.8, 34.8)
LS Mean Change from Baseline (SE)	4.2 (8.13)	6.9 (6.85)
95% C.I.	(-12.5, 21.0)	(-7.1, 20.8)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		2.6 (10.63)
95% C.I.		(-19.2, 24.4)
Corrected Hedges' g Statistic		0.11
95% C.I.		(-0.79, 1.01)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Environmental Triggers

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 16		
n [1]	10	22
n [2]	9	8
LS Mean (SE)	26.1 (9.41)	20.2 (8.22)
95% C.I.	(6.5, 45.7)	(3.3, 37.1)
LS Mean Change from Baseline (SE)	12.1 (9.41)	6.2 (8.22)
95% C.I.	(-7.5, 31.7)	(-10.7, 23.1)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-5.9 (12.50)
95% C.I.		(-31.8, 20.0)
Corrected Hedges' g Statistic		-0.22
95% C.I.		(-1.17, 0.74)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Environmental Triggers

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 19		
n [1]	10	22
n [2]	9	7
LS Mean (SE)	22.1 (8.11)	17.9 (7.52)
95% C.I.	(5.5, 38.7)	(2.7, 33.2)
LS Mean Change from Baseline (SE)	8.1 (8.11)	4.0 (7.52)
95% C.I.	(-8.5, 24.7)	(-11.3, 19.2)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-4.1 (11.06)
95% C.I.		(-26.7, 18.4)
Corrected Hedges' g Statistic		-0.17
95% C.I.		(-1.16, 0.82)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Environmental Triggers

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 22		
n [1]	10	22
n [2]	7	5
LS Mean (SE)	16.9 (6.27)	27.4 (6.42)
95% C.I.	(3.5, 30.2)	(13.9, 40.9)
LS Mean Change from Baseline (SE)	2.9 (6.27)	13.4 (6.42)
95% C.I.	(-10.4, 16.2)	(-0.1, 26.9)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		10.5 (8.97)
95% C.I.		(-8.5, 29.4)
Corrected Hedges' g Statistic		0.62
95% C.I.		(-0.56, 1.79)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Environmental Triggers

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 25		
n [1]	10	22
n [2]	7	6
LS Mean (SE)	13.6 (7.02)	22.9 (7.02)
95% C.I.	(-0.9, 28.2)	(8.4, 37.4)
LS Mean Change from Baseline (SE)	-0.3 (7.02)	8.9 (7.02)
95% C.I.	(-14.9, 14.2)	(-5.6, 23.4)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		9.2 (9.79)
95% C.I.		(-11.0, 29.5)
Corrected Hedges' g Statistic		0.48
95% C.I.		(-0.63, 1.58)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Environmental Triggers

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 28		
n [1]	10	22
n [2]	5	6
LS Mean (SE)	17.3 (7.69)	40.8 (7.27)
95% C.I.	(-0.1, 34.7)	(24.6, 57.1)
LS Mean Change from Baseline (SE)	3.3 (7.69)	26.9 (7.27)
95% C.I.	(-14.1, 20.7)	(10.6, 43.2)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		23.5 (10.59)
95% C.I.		(-0.3, 47.4)
Corrected Hedges' g Statistic		1.23
95% C.I.		(-0.07, 2.52)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Environmental Triggers

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 31		
n [1]	10	22
n [2]	5	7
LS Mean (SE)	9.0 (11.89)	32.7 (10.60)
95% C.I.	(-17.0, 34.9)	(9.7, 55.7)
LS Mean Change from Baseline (SE)	-5.0 (11.89)	18.7 (10.60)
95% C.I.	(-30.9, 20.9)	(-4.3, 41.7)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		23.7 (15.96)
95% C.I.		(-11.0, 58.5)
Corrected Hedges' g Statistic		0.80
95% C.I.		(-0.39, 1.99)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Environmental Triggers

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 34		
n [1]	10	22
n [2]	5	4

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Environmental Triggers

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 37		
n [1]	10	22
n [2]	4	5

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Environmental Triggers

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 40		
n [1]	10	22
n [2]	4	5

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Environmental Triggers

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 43		
n [1]	10	22
n [2]	5	3

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Environmental Triggers

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 46		
n [1]	10	22
n [2]	2	3

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Environmental Triggers

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 49		
n [1]	10	22
n [2]	3	3

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Environmental Triggers

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 52		
n [1]	10	22
n [2]	3	5

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Environmental Triggers

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 55		
n [1]	10	22
n [2]	3	3

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Environmental Triggers

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 58		
n [1]	10	22
n [2]	2	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Environmental Triggers

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 61		
n [1]	10	22
n [2]	2	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Environmental Triggers

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 64		
n [1]	10	22
n [2]	2	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Environmental Triggers

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 67		
n [1]	10	22
n [2]	1	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Environmental Triggers

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 70		
n [1]	10	22
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Environmental Triggers

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 73		
n [1]	10	22
n [2]	1	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Environmental Triggers

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 76		
n [1]	10	22
n [2]	1	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Environmental Triggers

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 79		
n [1]	10	22
n [2]	1	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Environmental Triggers

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 82		
n [1]	10	22
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Environmental Triggers

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 85		
n [1]	10	22
n [2]	1	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Environmental Triggers

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 88		
n [1]	10	22
n [2]	1	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Environmental Triggers

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 91		
n [1]	10	22
n [2]	1	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Environmental Triggers

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 94		
n [1]	10	22
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Environmental Triggers

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 97		
n [1]	10	22
n [2]	1	0

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Environmental Triggers

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 100		
n [1]	10	22
n [2]	0	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Environmental Triggers

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
End of Treatment		
n [1]	10	22
n [2]	6	9
LS Mean (SE)	18.6 (9.25)	15.6 (7.64)
95% C.I.	(-0.7, 38.0)	(-0.4, 31.6)
LS Mean Change from Baseline (SE)	4.7 (9.25)	1.7 (7.64)
95% C.I.	(-14.7, 24.0)	(-14.3, 17.7)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-3.0 (11.89)
95% C.I.		(-27.9, 21.9)
Corrected Hedges' g Statistic		-0.12
95% C.I.		(-1.16, 0.91)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Environmental Triggers

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Survival Follow-Up 1		
n [1]	10	22
n [2]	0	5

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Environmental Triggers

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Survival Follow-Up 2		
n [1]	10	22
n [2]	0	3

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Environmental Triggers

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Survival Follow-Up 4		
n [1]	10	22
n [2]	0	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Environmental Triggers

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
PFS Follow-Up 2		
n [1]	10	22
n [2]	0	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Environmental Triggers

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
PFS Follow-Up 4		
n [1]	10	22
n [2]	0	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Total Score

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 4		
n [1]	12	23
n [2]	12	22
LS Mean (SE)	10.8 (5.33)	14.3 (3.96)
95% C.I.	(0.0, 21.7)	(6.3, 22.4)
LS Mean Change from Baseline (SE)	-0.4 (5.33)	3.1 (3.96)
95% C.I.	(-11.3, 10.4)	(-5.0, 11.1)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		3.5 (6.61)
95% C.I.		(-10.0, 16.9)
Corrected Hedges' g Statistic		0.18
95% C.I.		(-0.52, 0.89)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Total Score

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 7		
n [1]	12	23
n [2]	11	18
LS Mean (SE)	17.6 (8.71)	33.0 (6.65)
95% C.I.	(-0.1, 35.3)	(19.5, 46.5)
LS Mean Change from Baseline (SE)	6.3 (8.71)	21.7 (6.65)
95% C.I.	(-11.4, 24.0)	(8.2, 35.2)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		15.4 (10.92)
95% C.I.		(-6.8, 37.6)
Corrected Hedges' g Statistic		0.53
95% C.I.		(-0.24, 1.29)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Total Score

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 10		
n [1]	12	23
n [2]	12	11
LS Mean (SE)	18.4 (7.06)	24.2 (6.26)
95% C.I.	(4.0, 32.8)	(11.5, 36.9)
LS Mean Change from Baseline (SE)	7.1 (7.06)	12.9 (6.26)
95% C.I.	(-7.3, 21.5)	(0.2, 25.6)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		5.8 (9.40)
95% C.I.		(-13.4, 24.9)
Corrected Hedges' g Statistic		0.24
95% C.I.		(-0.58, 1.07)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Total Score

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 13		
n [1]	12	23
n [2]	12	10
LS Mean (SE)	18.8 (6.39)	23.4 (5.99)
95% C.I.	(5.8, 31.9)	(11.3, 35.5)
LS Mean Change from Baseline (SE)	7.6 (6.39)	12.1 (5.99)
95% C.I.	(-5.5, 20.6)	(0.0, 24.3)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		4.6 (8.74)
95% C.I.		(-13.2, 22.3)
Corrected Hedges' g Statistic		0.21
95% C.I.		(-0.63, 1.05)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Total Score

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 16		
n [1]	12	23
n [2]	11	10
LS Mean (SE)	19.0 (5.55)	16.9 (5.25)
95% C.I.	(7.6, 30.5)	(6.1, 27.6)
LS Mean Change from Baseline (SE)	7.8 (5.55)	5.6 (5.25)
95% C.I.	(-3.6, 19.2)	(-5.1, 16.3)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-2.2 (7.64)
95% C.I.		(-17.8, 13.5)
Corrected Hedges' g Statistic		-0.12
95% C.I.		(-0.98, 0.74)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Total Score

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 19		
n [1]	12	23
n [2]	12	9
LS Mean (SE)	20.9 (6.46)	28.1 (6.48)
95% C.I.	(7.7, 34.1)	(14.9, 41.3)
LS Mean Change from Baseline (SE)	9.6 (6.46)	16.8 (6.48)
95% C.I.	(-3.6, 22.8)	(3.7, 30.0)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		7.2 (9.15)
95% C.I.		(-11.4, 25.9)
Corrected Hedges' g Statistic		0.33
95% C.I.		(-0.54, 1.20)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Total Score

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 22		
n [1]	12	23
n [2]	8	8
LS Mean (SE)	17.9 (5.10)	24.7 (5.11)
95% C.I.	(7.3, 28.5)	(14.1, 35.3)
LS Mean Change from Baseline (SE)	6.6 (5.10)	13.4 (5.11)
95% C.I.	(-4.0, 17.2)	(2.8, 24.1)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		6.8 (7.24)
95% C.I.		(-8.2, 21.9)
Corrected Hedges' g Statistic		0.45
95% C.I.		(-0.54, 1.44)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Total Score

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 25		
n [1]	12	23
n [2]	9	7
LS Mean (SE)	21.2 (7.30)	15.4 (8.41)
95% C.I.	(5.9, 36.4)	(-2.1, 33.0)
LS Mean Change from Baseline (SE)	9.9 (7.30)	4.2 (8.41)
95% C.I.	(-5.4, 25.2)	(-13.4, 21.7)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-5.7 (10.78)
95% C.I.		(-28.2, 16.8)
Corrected Hedges' g Statistic		-0.25
95% C.I.		(-1.24, 0.75)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Total Score

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 28		
n [1]	12	23
n [2]	7	7
LS Mean (SE)	23.2 (6.80)	32.7 (7.38)
95% C.I.	(8.9, 37.5)	(17.3, 48.2)
LS Mean Change from Baseline (SE)	11.9 (6.80)	21.5 (7.38)
95% C.I.	(-2.3, 26.2)	(6.0, 36.9)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		9.6 (9.82)
95% C.I.		(-11.0, 30.1)
Corrected Hedges' g Statistic		0.48
95% C.I.		(-0.59, 1.54)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Total Score

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 31		
n [1]	12	23
n [2]	7	7
LS Mean (SE)	18.1 (4.26)	26.6 (4.17)
95% C.I.	(9.3, 26.9)	(18.0, 35.2)
LS Mean Change from Baseline (SE)	6.8 (4.26)	15.3 (4.17)
95% C.I.	(-2.0, 15.7)	(6.7, 24.0)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		8.5 (5.94)
95% C.I.		(-3.8, 20.8)
Corrected Hedges' g Statistic		0.71
95% C.I.		(-0.37, 1.79)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Total Score

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 34		
n [1]	12	23
n [2]	6	6
LS Mean (SE)	16.5 (5.02)	30.2 (5.49)
95% C.I.	(6.0, 27.0)	(18.8, 41.6)
LS Mean Change from Baseline (SE)	5.2 (5.02)	18.9 (5.49)
95% C.I.	(-5.2, 15.7)	(7.5, 30.4)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		13.7 (7.43)
95% C.I.		(-1.8, 29.2)
Corrected Hedges' g Statistic		0.98
95% C.I.		(-0.22, 2.18)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Total Score

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 37		
n [1]	12	23
n [2]	4	6
LS Mean (SE)	8.2 (6.72)	7.5 (8.79)
95% C.I.	(-6.1, 22.5)	(-11.1, 26.2)
LS Mean Change from Baseline (SE)	-3.1 (6.72)	-3.7 (8.79)
95% C.I.	(-17.3, 11.2)	(-22.4, 14.9)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		-0.7 (7.24)
95% C.I.		(-16.0, 14.7)
Corrected Hedges' g Statistic		-0.03
95% C.I.		(-1.30, 1.23)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Total Score

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 40		
n [1]	12	23
n [2]	4	6
LS Mean (SE)	3.9 (8.23)	4.8 (12.43)
95% C.I.	(-14.5, 22.2)	(-22.9, 32.5)
LS Mean Change from Baseline (SE)	-7.4 (8.23)	-6.5 (12.43)
95% C.I.	(-25.7, 10.9)	(-34.2, 21.2)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		0.9 (8.92)
95% C.I.		(-19.0, 20.8)
Corrected Hedges' g Statistic		0.03
95% C.I.		(-1.23, 1.30)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Total Score

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 43		
n [1]	12	23
n [2]	5	4

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Total Score

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 46		
n [1]	12	23
n [2]	4	4

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Total Score

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 49		
n [1]	12	23
n [2]	3	4

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Total Score

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 52		
n [1]	12	23
n [2]	3	6

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Total Score

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 55		
n [1]	12	23
n [2]	3	3

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Total Score

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 58		
n [1]	12	23
n [2]	2	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Total Score

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 61		
n [1]	12	23
n [2]	2	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Total Score

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 64		
n [1]	12	23
n [2]	2	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Total Score

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 67		
n [1]	12	23
n [2]	2	2

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Total Score

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 70		
n [1]	12	23
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Total Score

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 73		
n [1]	12	23
n [2]	1	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Total Score

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 76		
n [1]	12	23
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Total Score

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 79		
n [1]	12	23
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Total Score

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 82		
n [1]	12	23
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Total Score

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 85		
n [1]	12	23
n [2]	1	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Total Score

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 88		
n [1]	12	23
n [2]	1	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Total Score

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 91		
n [1]	12	23
n [2]	1	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Total Score

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 94		
n [1]	12	23
n [2]	2	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Total Score

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 97		
n [1]	12	23
n [2]	1	0

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Total Score

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Week 100		
n [1]	12	23
n [2]	0	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Total Score

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
End of Treatment		
n [1]	12	23
n [2]	9	11
LS Mean (SE)	19.2 (11.76)	36.9 (10.80)
95% C.I.	(-5.7, 44.0)	(14.1, 59.8)
LS Mean Change from Baseline (SE)	7.9 (11.76)	25.7 (10.80)
95% C.I.	(-17.0, 32.8)	(2.8, 48.5)
Belantamab mafodotin vs. Pom/Dex		
Difference (SE)		17.8 (15.64)
95% C.I.		(-15.3, 50.9)
Corrected Hedges' g Statistic		0.48
95% C.I.		(-0.42, 1.37)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Total Score

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Survival Follow-Up 1		
n [1]	12	23
n [2]	0	5

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Total Score

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Survival Follow-Up 2		
n [1]	12	23
n [2]	0	3

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Total Score

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Survival Follow-Up 4		
n [1]	12	23
n [2]	0	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_t5_osdi_dom.sas 10MAR2023 06:03

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Total Score

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
PFS Follow-Up 2		
n [1]	12	23
n [2]	0	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

Table 4.031110
Analysis of OSDI Domain Score based on Mixed Model for Repeated Measures (MMRM)

Item Score: Total Score

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
PFS Follow-Up 4		
n [1]	12	23
n [2]	0	1

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the current time point.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions. End of Treatment and Follow-up assessments are analysed as their collected visits and their "Week X" visit per assessment date.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
Note: Corrected Hedges' g Statistic and 95% C.I. are derived from the Change from Baseline LS Means and associated SEs.

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.096110
Summary of OSDI Time to first Improvement
(Up to and including Last Follow-Up)

Item Score: Total Score

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Improved (event)	1 (7%)	4 (14%)
Censored, follow-up ended	5 (36%)	14 (48%)
Censored, follow-up ongoing	8 (57%)	11 (38%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (0.7, -)	- (0.7, -)
Median (95% CI)	- (-, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		0.6789
Inverse Hazard Ratio (95% CI) [3]		0.59 (0.05, 7.38)
P-value [3]		0.6814

Note: If a subject has not improved, they are censored at the latest assessment or at randomization if no assessments.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Inverse hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. Inverse hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_os_tfi.sas 13MAR2023 14:16

Table 4.096110
Summary of OSDI Time to first Improvement
(Up to and including Last Follow-Up)

Item Score: Ocular Symptoms

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Improved (event)	1 (7%)	2 (7%)
Censored, follow-up ended	5 (36%)	15 (52%)
Censored, follow-up ongoing	8 (57%)	12 (41%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (0.7, -)	- (1.1, -)
Median (95% CI)	- (-, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		0.4795
Inverse Hazard Ratio (95% CI) [3]		>999.99 (-, -)
P-value [3]		0.9985

Note: If a subject has not improved, they are censored at the latest assessment or at randomization if no assessments.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Inverse hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. Inverse hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_os_tfi.sas 13MAR2023 14:16

Table 4.096110
Summary of OSDI Time to first Improvement
(Up to and including Last Follow-Up)

Item Score: Vision-related Function

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Improved (event)	2 (14%)	4 (14%)
Censored, follow-up ended	5 (36%)	14 (48%)
Censored, follow-up ongoing	7 (50%)	11 (38%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (0.7, -)	- (0.7, -)
Median (95% CI)	- (1.5, -)	- (-, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		0.8892
Inverse Hazard Ratio (95% CI) [3]		0.86 (0.13, 5.51)
P-value [3]		0.8725

Note: If a subject has not improved, they are censored at the latest assessment or at randomization if no assessments.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Inverse hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. Inverse hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_os_tfi.sas 13MAR2023 14:16

Protocol: 207495 Page 4 of 4
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.096110
Summary of OSDI Time to first Improvement
(Up to and including Last Follow-Up)

Item Score: Environmental Triggers

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Improved (event)	1 (7%)	5 (17%)
Censored, follow-up ended	5 (36%)	12 (41%)
Censored, follow-up ongoing	8 (57%)	12 (41%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (0.7, -)	1.6 (0.7, -)
Median (95% CI)	- (0.7, -)	- (1.6, -)
3rd Quartile (95% CI)	- (-, -)	- (-, -)
Log-Rank P-value [2]		0.9183
Inverse Hazard Ratio (95% CI) [3]		0.88 (0.08, 10.26)
P-value [3]		0.9183

Note: If a subject has not improved, they are censored at the latest assessment or at randomization if no assessments.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Inverse hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. Inverse hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_os_tfi.sas 13MAR2023 14:16

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.093110
Summary of OSDI Time to first Deterioration 1
(Up to and including Last Follow-Up)

Item Score: Total Score

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated or Died (event)	10 (71%)	21 (72%)
Censored, follow-up ended	0	0
Censored, follow-up ongoing	4 (29%)	8 (28%)
Event Summary		
Deterioration	8 (57%)	11 (38%)
Death	2 (14%)	10 (34%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	1.5 (0.8, 4.1)	1.2 (0.8, 1.6)
Median (95% CI)	4.1 (1.1, 13.5)	2.1 (1.4, 4.8)
3rd Quartile (95% CI)	13.5 (2.8, 13.5)	5.1 (2.9, -)
Log-Rank P-value [2]		0.6348
Hazard Ratio (95% CI) [3]		1.28 (0.46, 3.52)
P-value [3]		0.6354

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessments.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_os_tfd1.sas 13MAR2023 14:16

Table 4.093110
Summary of OSDI Time to first Deterioration 1
(Up to and including Last Follow-Up)

Item Score: Ocular Symptoms

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated or Died (event)	9 (64%)	21 (72%)
Censored, follow-up ended	0	0
Censored, follow-up ongoing	5 (36%)	8 (28%)
Event Summary		
Deterioration	6 (43%)	9 (31%)
Death	3 (21%)	12 (41%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	4.2 (1.1, 5.9)	1.2 (0.8, 2.1)
Median (95% CI)	5.9 (1.6, 13.5)	2.9 (1.4, 6.1)
3rd Quartile (95% CI)	13.5 (5.7, -)	6.6 (4.2, -)
Log-Rank P-value [2]		0.2906
Hazard Ratio (95% CI) [3]		1.71 (0.63, 4.69)
P-value [3]		0.2953

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessments.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.

Table 4.093110
Summary of OSDI Time to first Deterioration 1
(Up to and including Last Follow-Up)

Item Score: Vision-related Function

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated or Died (event)	10 (71%)	21 (72%)
Censored, follow-up ended	0	0
Censored, follow-up ongoing	4 (29%)	8 (28%)
Event Summary		
Deterioration	8 (57%)	11 (38%)
Death	2 (14%)	10 (34%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	1.1 (0.8, 2.8)	1.2 (0.8, 1.4)
Median (95% CI)	2.8 (1.1, 13.5)	2.1 (1.4, 4.8)
3rd Quartile (95% CI)	13.5 (1.6, 13.5)	5.1 (2.9, -)
Log-Rank P-value [2]		0.8244
Hazard Ratio (95% CI) [3]		1.12 (0.40, 3.12)
P-value [3]		0.8245

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessments.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.093110
Summary of OSDI Time to first Deterioration 1
(Up to and including Last Follow-Up)

Item Score: Environmental Triggers

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated or Died (event)	6 (43%)	23 (79%)
Censored, follow-up ended	1 (7%)	0
Censored, follow-up ongoing	7 (50%)	6 (21%)
Event Summary		
Deterioration	4 (29%)	9 (31%)
Death	2 (14%)	14 (48%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	1.6 (0.8, 13.5)	1.0 (0.7, 2.1)
Median (95% CI)	8.2 (1.1, -)	4.9 (1.1, 5.7)
3rd Quartile (95% CI)	13.5 (8.2, -)	6.2 (5.1, 9.5)
Log-Rank P-value [2]		0.0714
Hazard Ratio (95% CI) [3]		3.05 (0.86, 10.84)
P-value [3]		0.0846

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessments.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_os_tfd1.sas 13MAR2023 14:16

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.094110
Summary of OSDI Time to first Deterioration 2
(Up to and including Last Follow-Up)

Item Score: Total Score

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated (event)	8 (57%)	11 (38%)
Censored, follow-up ended	2 (14%)	10 (34%)
Censored, follow-up ongoing	4 (29%)	8 (28%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	1.5 (0.8, 4.1)	1.4 (0.8, 2.1)
Median (95% CI)	4.2 (0.8, -)	3.0 (1.4, -)
3rd Quartile (95% CI)	- (4.1, -)	- (3.0, -)
Log-Rank P-value [2]		0.9169
Hazard Ratio (95% CI) [3]		1.07 (0.31, 3.67)
P-value [3]		0.9169

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessments.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_os_tfd2.sas 13MAR2023 14:16

Table 4.094110
Summary of OSDI Time to first Deterioration 2
(Up to and including Last Follow-Up)

Item Score: Ocular Symptoms

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated (event)	6 (43%)	9 (31%)
Censored, follow-up ended	3 (21%)	12 (41%)
Censored, follow-up ongoing	5 (36%)	8 (28%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	4.5 (1.4, 5.9)	1.7 (0.8, 4.2)
Median (95% CI)	5.9 (1.6, -)	4.2 (1.7, -)
3rd Quartile (95% CI)	- (5.7, -)	- (4.2, -)
Log-Rank P-value [2]		0.4499
Hazard Ratio (95% CI) [3]		1.69 (0.43, 6.74)
P-value [3]		0.4546

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessments.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_os_tfd2.sas 13MAR2023 14:16

Protocol: 207495 Page 3 of 4
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.094110
Summary of OSDI Time to first Deterioration 2
(Up to and including Last Follow-Up)

Item Score: Vision-related Function

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated (event)	8 (57%)	11 (38%)
Censored, follow-up ended	2 (14%)	10 (34%)
Censored, follow-up ongoing	4 (29%)	8 (28%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	1.3 (0.8, 2.8)	1.4 (0.8, 1.7)
Median (95% CI)	3.5 (0.8, -)	3.0 (1.4, -)
3rd Quartile (95% CI)	- (2.8, -)	- (3.0, -)
Log-Rank P-value [2]		0.8661
Hazard Ratio (95% CI) [3]		0.90 (0.26, 3.11)
P-value [3]		0.8661

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessments.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_os_tfd2.sas 13MAR2023 14:16

Protocol: 207495 Page 4 of 4
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.094110
Summary of OSDI Time to first Deterioration 2
(Up to and including Last Follow-Up)

Item Score: Environmental Triggers

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated (event)	4 (29%)	9 (31%)
Censored, follow-up ended	3 (21%)	14 (48%)
Censored, follow-up ongoing	7 (50%)	6 (21%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	2.4 (0.8, -)	1.4 (0.7, 6.2)
Median (95% CI)	- (0.8, -)	6.2 (1.4, -)
3rd Quartile (95% CI)	- (8.2, -)	- (6.2, -)
Log-Rank P-value [2]		0.1162
Hazard Ratio (95% CI) [3]		4.63 (0.57, 37.63)
P-value [3]		0.1515

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessments.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_os_tfd2.sas 13MAR2023 14:16

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.097110
Summary of OSDI Time to permanent Deterioration 1
(Up to and including End of Treatment)

Item Score: Total Score

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated or Died (event)	2 (14%)	12 (41%)
Censored, follow-up ended	4 (29%)	7 (24%)
Censored, follow-up ongoing	8 (57%)	10 (34%)
Event Summary		
Deterioration	1 (7%)	3 (10%)
Death	1 (7%)	9 (31%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (1.1, -)	2.1 (0.9, 9.5)
Median (95% CI)	- (6.4, -)	9.5 (2.1, -)
3rd Quartile (95% CI)	- (-, -)	11.1 (9.5, -)
Log-Rank P-value [2]		0.0863
Hazard Ratio (95% CI) [3]		5.68 (0.64, 50.16)
P-value [3]		0.1178

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd1_os_eot.sas 14MAR2023 16:03

Protocol: 207495 Page 2 of 8
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.097110
Summary of OSDI Time to permanent Deterioration 1
(Up to and including End of Treatment)

Item Score: Total Score

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of subsequent visits with confirmation for subjects who permanently deteriorated or died		
n	2	12
0	1 / 2 (50%)	9 / 12 (75%)
1	0 / 2	0 / 12
2	0 / 2	1 / 12 (8%)
3	1 / 2 (50%)	1 / 12 (8%)
>=4	0 / 2	1 / 12 (8%)
Number of subsequent visits with confirmation for subjects who deteriorated towards end of observation period [4]		
n	2	2
0	2 / 2 (100%)	1 / 2 (50%)
1	0 / 2	1 / 2 (50%)

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd1_os_eot.sas 14MAR2023 16:03

Table 4.097110
Summary of OSDI Time to permanent Deterioration 1
(Up to and including End of Treatment)

Item Score: Ocular Symptoms

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated or Died (event)	1 (7%)	11 (38%)
Censored, follow-up ended	4 (29%)	7 (24%)
Censored, follow-up ongoing	9 (64%)	11 (38%)
Event Summary		
Deterioration	0	2 (7%)
Death	1 (7%)	9 (31%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (1.1, -)	2.1 (0.9, 9.5)
Median (95% CI)	- (-, -)	9.5 (2.1, -)
3rd Quartile (95% CI)	- (-, -)	- (9.5, -)
Log-Rank P-value [2]		0.1174
Hazard Ratio (95% CI) [3]		5.11 (0.56, 46.58)
P-value [3]		0.1480

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

Protocol: 207495 Page 4 of 8
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.097110
Summary of OSDI Time to permanent Deterioration 1
(Up to and including End of Treatment)

Item Score: Ocular Symptoms

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of subsequent visits with confirmation for subjects who permanently deteriorated or died		
n	1	11
0	1 / 1 (100%)	9 / 11 (82%)
1	0 / 1	0 / 11
2	0 / 1	0 / 11
3	0 / 1	1 / 11 (9%)
>=4	0 / 1	1 / 11 (9%)
Number of subsequent visits with confirmation for subjects who deteriorated towards end of observation period [4]		
n	3	3
0	3 / 3 (100%)	1 / 3 (33%)
1	0 / 3	2 / 3 (67%)

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd1_os_eot.sas 14MAR2023 16:03

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.097110
Summary of OSDI Time to permanent Deterioration 1
(Up to and including End of Treatment)

Item Score: Vision-related Function

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated or Died (event)	1 (7%)	12 (41%)
Censored, follow-up ended	4 (29%)	7 (24%)
Censored, follow-up ongoing	9 (64%)	10 (34%)
Event Summary		
Deterioration	0	3 (10%)
Death	1 (7%)	9 (31%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (1.1, -)	2.1 (0.9, 6.4)
Median (95% CI)	- (-, -)	6.4 (2.1, -)
3rd Quartile (95% CI)	- (-, -)	11.1 (6.4, -)
Log-Rank P-value [2]		0.0758
Hazard Ratio (95% CI) [3]		5.94 (0.68, 52.01)
P-value [3]		0.1078

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd1_os_eot.sas 14MAR2023 16:03

Protocol: 207495 Page 6 of 8
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.097110
Summary of OSDI Time to permanent Deterioration 1
(Up to and including End of Treatment)

Item Score: Vision-related Function

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of subsequent visits with confirmation for subjects who permanently deteriorated or died		
n	1	12
0	1 / 1 (100%)	9 / 12 (75%)
1	0 / 1	0 / 12
2	0 / 1	0 / 12
3	0 / 1	1 / 12 (8%)
>=4	0 / 1	2 / 12 (17%)
Number of subsequent visits with confirmation for subjects who deteriorated towards end of observation period [4]		
n	3	2
0	2 / 3 (67%)	1 / 2 (50%)
1	1 / 3 (33%)	1 / 2 (50%)

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd1_os_eot.sas 14MAR2023 16:03

Protocol: 207495 Page 7 of 8
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.097110
Summary of OSDI Time to permanent Deterioration 1
(Up to and including End of Treatment)

Item Score: Environmental Triggers

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated or Died (event)	2 (14%)	11 (38%)
Censored, follow-up ended	3 (21%)	7 (24%)
Censored, follow-up ongoing	9 (64%)	11 (38%)
Event Summary		
Deterioration	1 (7%)	2 (7%)
Death	1 (7%)	9 (31%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (1.1, -)	2.1 (0.9, 9.5)
Median (95% CI)	- (2.4, -)	9.5 (2.1, -)
3rd Quartile (95% CI)	- (-, -)	- (9.5, -)
Log-Rank P-value [2]		0.1502
Hazard Ratio (95% CI) [3]		4.42 (0.50, 39.09)
P-value [3]		0.1812

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd1_os_eot.sas 14MAR2023 16:03

Protocol: 207495 Page 8 of 8
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.097110
Summary of OSDI Time to permanent Deterioration 1
(Up to and including End of Treatment)

Item Score: Environmental Triggers

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of subsequent visits with confirmation for subjects who permanently deteriorated or died		
n	2	11
0	1 / 2 (50%)	9 / 11 (82%)
1	0 / 2	0 / 11
2	1 / 2 (50%)	0 / 11
3	0 / 2	1 / 11 (9%)
>=4	0 / 2	1 / 11 (9%)
Number of subsequent visits with confirmation for subjects who deteriorated towards end of observation period [4]		
n	1	2
0	1 / 1 (100%)	1 / 2 (50%)
1	0 / 1	1 / 2 (50%)

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd1_os_eot.sas 14MAR2023 16:03

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.098110
Summary of OSDI Time to permanent Deterioration 2
(Up to and including End of Treatment)

Item Score: Total Score

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated (event)	1 (7%)	3 (10%)
Censored, follow-up ended	5 (36%)	16 (55%)
Censored, follow-up ongoing	8 (57%)	10 (34%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (6.4, -)	10.6 (0.8, -)
Median (95% CI)	- (6.4, -)	11.1 (10.6, -)
3rd Quartile (95% CI)	- (-, -)	- (10.6, -)
Log-Rank P-value [2]		0.3312
Hazard Ratio (95% CI) [3]		>999.99 (<0.01, -)
P-value [3]		0.9980

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd2_os_eot.sas 14MAR2023 17:07

Table 4.098110
Summary of OSDI Time to permanent Deterioration 2
(Up to and including End of Treatment)

Item Score: Total Score

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of subsequent visits with confirmation for subjects who permanently deteriorated		
n	1	3
0	0 / 1	0 / 3
1	0 / 1	0 / 3
2	0 / 1	1 / 3 (33%)
3	1 / 1 (100%)	1 / 3 (33%)
>=4	0 / 1	1 / 3 (33%)
Number of subsequent visits with confirmation for subjects who deteriorated towards end of observation period [4]		
n	2	2
0	2 / 2 (100%)	1 / 2 (50%)
1	0 / 2	1 / 2 (50%)

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

Table 4.098110
Summary of OSDI Time to permanent Deterioration 2
(Up to and including End of Treatment)

Item Score: Ocular Symptoms

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated (event)	0	2 (7%)
Censored, follow-up ended	5 (36%)	16 (55%)
Censored, follow-up ongoing	9 (64%)	11 (38%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (-, -)	11.8 (0.8, -)
Median (95% CI)	- (-, -)	- (11.8, -)
3rd Quartile (95% CI)	- (-, -)	- (11.8, -)
Log-Rank P-value [2]		0.5050
Hazard Ratio (95% CI) [3]		>999.99 (<0.01, -)
P-value [3]		0.9986

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.098110
Summary of OSDI Time to permanent Deterioration 2
(Up to and including End of Treatment)

Item Score: Ocular Symptoms

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of subsequent visits with confirmation for subjects who permanently deteriorated		
n	0	2
0	0	0 / 2
1	0	0 / 2
2	0	0 / 2
3	0	1 / 2 (50%)
>=4	0	1 / 2 (50%)
Number of subsequent visits with confirmation for subjects who deteriorated towards end of observation period [4]		
n	3	3
0	3 / 3 (100%)	1 / 3 (33%)
1	0 / 3	2 / 3 (67%)

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

Table 4.098110
Summary of OSDI Time to permanent Deterioration 2
(Up to and including End of Treatment)

Item Score: Vision-related Function

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated (event)	0	3 (10%)
Censored, follow-up ended	5 (36%)	16 (55%)
Censored, follow-up ongoing	9 (64%)	10 (34%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (-, -)	11.1 (0.8, -)
Median (95% CI)	- (-, -)	- (6.4, -)
3rd Quartile (95% CI)	- (-, -)	- (11.1, -)
Log-Rank P-value [2]		0.2766
Hazard Ratio (95% CI) [3]		>999.99 (<0.01, -)
P-value [3]		0.9979

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

Protocol: 207495 Page 6 of 8
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.098110
Summary of OSDI Time to permanent Deterioration 2
(Up to and including End of Treatment)

Item Score: Vision-related Function

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of subsequent visits with confirmation for subjects who permanently deteriorated		
n	0	3
0	0	0 / 3
1	0	0 / 3
2	0	0 / 3
3	0	1 / 3 (33%)
>=4	0	2 / 3 (67%)
Number of subsequent visits with confirmation for subjects who deteriorated towards end of observation period [4]		
n	3	2
0	2 / 3 (67%)	1 / 2 (50%)
1	1 / 3 (33%)	1 / 2 (50%)

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd2_os_eot.sas 14MAR2023 17:07

Protocol: 207495 Page 7 of 8
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.098110
Summary of OSDI Time to permanent Deterioration 2
(Up to and including End of Treatment)

Item Score: Environmental Triggers

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated (event)	1 (7%)	2 (7%)
Censored, follow-up ended	4 (29%)	16 (55%)
Censored, follow-up ongoing	9 (64%)	11 (38%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (2.4, -)	11.1 (0.8, -)
Median (95% CI)	- (2.4, -)	- (11.1, -)
3rd Quartile (95% CI)	- (-, -)	- (11.1, -)
Log-Rank P-value [2]		0.5403
Hazard Ratio (95% CI) [3]		>999.99 (<0.01, -)
P-value [3]		0.9979

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd2_os_eot.sas 14MAR2023 17:07

Protocol: 207495 Page 8 of 8
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.098110
Summary of OSDI Time to permanent Deterioration 2
(Up to and including End of Treatment)

Item Score: Environmental Triggers

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of subsequent visits with confirmation for subjects who permanently deteriorated		
n	1	2
0	0 / 1	0 / 2
1	0 / 1	0 / 2
2	1 / 1 (100%)	0 / 2
3	0 / 1	1 / 2 (50%)
>=4	0 / 1	1 / 2 (50%)
Number of subsequent visits with confirmation for subjects who deteriorated towards end of observation period [4]		
n	1	3
0	1 / 1 (100%)	2 / 3 (67%)
1	0 / 1	1 / 3 (33%)

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd2_os_eot.sas 14MAR2023 17:07

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.099110
Summary of OSDI Time to permanent Deterioration 1
(Up to and including Last Follow-Up)

Item Score: Total Score

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated or Died (event)	5 (36%)	18 (62%)
Censored, follow-up ended	1 (7%)	0
Censored, follow-up ongoing	8 (57%)	11 (38%)
Event Summary		
Deterioration	1 (7%)	2 (7%)
Death	4 (29%)	16 (55%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	8.0 (1.1, 13.5)	2.9 (1.0, 5.5)
Median (95% CI)	13.5 (6.4, -)	5.7 (4.9, 11.1)
3rd Quartile (95% CI)	- (9.5, -)	11.1 (6.6, -)
Log-Rank P-value [2]		0.0286
Hazard Ratio (95% CI) [3]		4.92 (1.05, 23.13)
P-value [3]		0.0437

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd1_os_lf.sas 14MAR2023 16:04

Protocol: 207495 Page 2 of 8
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.099110
Summary of OSDI Time to permanent Deterioration 1
(Up to and including Last Follow-Up)

Item Score: Total Score

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of subsequent visits with confirmation for subjects who permanently deteriorated or died		
n	5	18
0	4 / 5 (80%)	16 / 18 (89%)
1	0 / 5	0 / 18
2	0 / 5	1 / 18 (6%)
3	1 / 5 (20%)	0 / 18
>=4	0 / 5	1 / 18 (6%)
Number of subsequent visits with confirmation for subjects who deteriorated towards end of observation period [4]		
n	2	1
0	2 / 2 (100%)	1 / 1 (100%)
1	0 / 2	0 / 1

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd1_os_lf.sas 14MAR2023 16:04

Table 4.099110
Summary of OSDI Time to permanent Deterioration 1
(Up to and including Last Follow-Up)

Item Score: Ocular Symptoms

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated or Died (event)	4 (29%)	17 (59%)
Censored, follow-up ended	1 (7%)	0
Censored, follow-up ongoing	9 (64%)	12 (41%)
Event Summary		
Deterioration	0	1 (3%)
Death	4 (29%)	16 (55%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	9.5 (1.1, -)	2.9 (1.0, 5.5)
Median (95% CI)	13.5 (8.0, -)	5.7 (4.9, 18.7)
3rd Quartile (95% CI)	- (13.5, -)	18.7 (6.6, -)
Log-Rank P-value [2]		0.0412
Hazard Ratio (95% CI) [3]		4.55 (0.95, 21.74)
P-value [3]		0.0575

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

Protocol: 207495 Page 4 of 8
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.099110
Summary of OSDI Time to permanent Deterioration 1
(Up to and including Last Follow-Up)

Item Score: Ocular Symptoms

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of subsequent visits with confirmation for subjects who permanently deteriorated or died		
n	4	17
0	4 / 4 (100%)	16 / 17 (94%)
1	0 / 4	0 / 17
2	0 / 4	0 / 17
3	0 / 4	0 / 17
>=4	0 / 4	1 / 17 (6%)
Number of subsequent visits with confirmation for subjects who deteriorated towards end of observation period [4]		
n	2	2
0	2 / 2 (100%)	1 / 2 (50%)
1	0 / 2	1 / 2 (50%)

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd1_os_lf.sas 14MAR2023 16:04

Protocol: 207495 Page 5 of 8
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.099110
Summary of OSDI Time to permanent Deterioration 1
(Up to and including Last Follow-Up)

Item Score: Vision-related Function

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated or Died (event)	4 (29%)	18 (62%)
Censored, follow-up ended	1 (7%)	0
Censored, follow-up ongoing	9 (64%)	11 (38%)
Event Summary		
Deterioration	0	2 (7%)
Death	4 (29%)	16 (55%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	9.5 (1.1, -)	2.9 (1.0, 5.5)
Median (95% CI)	13.5 (8.0, -)	5.7 (4.9, 11.1)
3rd Quartile (95% CI)	- (13.5, -)	18.7 (6.4, -)
Log-Rank P-value [2]		0.0310
Hazard Ratio (95% CI) [3]		4.84 (1.03, 22.79)
P-value [3]		0.0463

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd1_os_lf.sas 14MAR2023 16:04

Protocol: 207495 Page 6 of 8
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.099110
Summary of OSDI Time to permanent Deterioration 1
(Up to and including Last Follow-Up)

Item Score: Vision-related Function

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of subsequent visits with confirmation for subjects who permanently deteriorated or died		
n	4	18
0	4 / 4 (100%)	16 / 18 (89%)
1	0 / 4	0 / 18
2	0 / 4	0 / 18
3	0 / 4	0 / 18
>=4	0 / 4	2 / 18 (11%)
Number of subsequent visits with confirmation for subjects who deteriorated towards end of observation period [4]		
n	2	1
0	1 / 2 (50%)	1 / 1 (100%)
1	1 / 2 (50%)	0 / 1

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd1_os_lf.sas 14MAR2023 16:04

Protocol: 207495 Page 7 of 8
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.099110
Summary of OSDI Time to permanent Deterioration 1
(Up to and including Last Follow-Up)

Item Score: Environmental Triggers

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated or Died (event)	4 (29%)	18 (62%)
Censored, follow-up ended	1 (7%)	0
Censored, follow-up ongoing	9 (64%)	11 (38%)
Event Summary		
Deterioration	1 (7%)	2 (7%)
Death	3 (21%)	16 (55%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	9.5 (1.1, -)	2.6 (1.0, 5.1)
Median (95% CI)	13.5 (2.4, -)	5.7 (2.9, 11.1)
3rd Quartile (95% CI)	- (13.5, -)	18.7 (5.7, -)
Log-Rank P-value [2]		0.0448
Hazard Ratio (95% CI) [3]		4.36 (0.93, 20.39)
P-value [3]		0.0617

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd1_os_lf.sas 14MAR2023 16:04

Protocol: 207495 Page 8 of 8
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.099110
Summary of OSDI Time to permanent Deterioration 1
(Up to and including Last Follow-Up)

Item Score: Environmental Triggers

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of subsequent visits with confirmation for subjects who permanently deteriorated or died		
n	4	18
0	3 / 4 (75%)	16 / 18 (89%)
1	0 / 4	0 / 18
2	1 / 4 (25%)	1 / 18 (6%)
3	0 / 4	0 / 18
>=4	0 / 4	1 / 18 (6%)
Number of subsequent visits with confirmation for subjects who deteriorated towards end of observation period [4]		
n	1	1
0	1 / 1 (100%)	1 / 1 (100%)
1	0 / 1	0 / 1

Note: If a subject has not died or deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd1_os_lf.sas 14MAR2023 16:04

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.100110
Summary of OSDI Time to permanent Deterioration 2
(Up to and including Last Follow-Up)

Item Score: Total Score

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated (event)	1 (7%)	2 (7%)
Censored, follow-up ended	5 (36%)	16 (55%)
Censored, follow-up ongoing	8 (57%)	11 (38%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (6.4, -)	11.1 (10.6, -)
Median (95% CI)	- (6.4, -)	- (10.6, -)
3rd Quartile (95% CI)	- (-, -)	- (11.1, -)
Log-Rank P-value [2]		0.5637
Hazard Ratio (95% CI) [3]		>999.99 (<0.01, -)
P-value [3]		0.9987

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd2_os_lf.sas 14MAR2023 17:07

Table 4.100110
Summary of OSDI Time to permanent Deterioration 2
(Up to and including Last Follow-Up)

Item Score: Total Score

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of subsequent visits with confirmation for subjects who permanently deteriorated		
n	1	2
0	0 / 1	0 / 2
1	0 / 1	0 / 2
2	0 / 1	1 / 2 (50%)
3	1 / 1 (100%)	0 / 2
>=4	0 / 1	1 / 2 (50%)
Number of subsequent visits with confirmation for subjects who deteriorated towards end of observation period [4]		
n	2	2
0	2 / 2 (100%)	2 / 2 (100%)
1	0 / 2	0 / 2

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.100110
Summary of OSDI Time to permanent Deterioration 2
(Up to and including Last Follow-Up)

Item Score: Ocular Symptoms

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated (event)	0	1 (3%)
Censored, follow-up ended	5 (36%)	16 (55%)
Censored, follow-up ongoing	9 (64%)	12 (41%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (-, -)	- (11.8, -)
Median (95% CI)	- (-, -)	- (11.8, -)
3rd Quartile (95% CI)	- (-, -)	- (11.8, -)
Log-Rank P-value [2]		-
Hazard Ratio (95% CI) [3]		- (-, -)
P-value [3]		-

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd2_os_lf.sas 14MAR2023 17:07

Table 4.100110
Summary of OSDI Time to permanent Deterioration 2
(Up to and including Last Follow-Up)

Item Score: Ocular Symptoms

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of subsequent visits with confirmation for subjects who permanently deteriorated		
n	0	1
0	0	0 / 1
1	0	0 / 1
2	0	0 / 1
3	0	0 / 1
>=4	0	1 / 1 (100%)
Number of subsequent visits with confirmation for subjects who deteriorated towards end of observation period [4]		
n	3	3
0	3 / 3 (100%)	2 / 3 (67%)
1	0 / 3	1 / 3 (33%)

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

Protocol: 207495 Page 5 of 8
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.100110
Summary of OSDI Time to permanent Deterioration 2
(Up to and including Last Follow-Up)

Item Score: Vision-related Function

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated (event)	0	2 (7%)
Censored, follow-up ended	5 (36%)	16 (55%)
Censored, follow-up ongoing	9 (64%)	11 (38%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (-, -)	11.1 (6.4, -)
Median (95% CI)	- (-, -)	- (6.4, -)
3rd Quartile (95% CI)	- (-, -)	- (11.1, -)
Log-Rank P-value [2]		0.4795
Hazard Ratio (95% CI) [3]		>999.99 (<0.01, -)
P-value [3]		0.9985

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd2_os_lf.sas 14MAR2023 17:07

Protocol: 207495 Page 6 of 8
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.100110
Summary of OSDI Time to permanent Deterioration 2
(Up to and including Last Follow-Up)

Item Score: Vision-related Function

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of subsequent visits with confirmation for subjects who permanently deteriorated		
n	0	2
0	0	0 / 2
1	0	0 / 2
2	0	0 / 2
3	0	0 / 2
>=4	0	2 / 2 (100%)
Number of subsequent visits with confirmation for subjects who deteriorated towards end of observation period [4]		
n	3	2
0	2 / 3 (67%)	2 / 2 (100%)
1	1 / 3 (33%)	0 / 2

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd2_os_lf.sas 14MAR2023 17:07

Protocol: 207495 Page 7 of 8
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.100110
Summary of OSDI Time to permanent Deterioration 2
(Up to and including Last Follow-Up)

Item Score: Environmental Triggers

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of Subjects		
Deteriorated (event)	1 (7%)	2 (7%)
Censored, follow-up ended	4 (29%)	16 (55%)
Censored, follow-up ongoing	9 (64%)	11 (38%)
Estimates for Time Variable (Months) [1]		
1st Quartile (95% CI)	- (2.4, -)	11.1 (2.6, -)
Median (95% CI)	- (2.4, -)	- (11.1, -)
3rd Quartile (95% CI)	- (-, -)	- (11.1, -)
Log-Rank P-value [2]		0.5403
Hazard Ratio (95% CI) [3]		>999.99 (<0.01, -)
P-value [3]		0.9979

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd2_os_lf.sas 14MAR2023 17:07

Protocol: 207495 Page 8 of 8
Population: Safety (Fifth Line (5L+) plus TCR) Data as of 12SEP2022

Table 4.100110
Summary of OSDI Time to permanent Deterioration 2
(Up to and including Last Follow-Up)

Item Score: Environmental Triggers

	Pom/Dex (N=14)	Belantamab mafodotin (N=29)
Number of subsequent visits with confirmation for subjects who permanently deteriorated		
n	1	2
0	0 / 1	0 / 2
1	0 / 1	0 / 2
2	1 / 1 (100%)	1 / 2 (50%)
3	0 / 1	0 / 2
>=4	0 / 1	1 / 2 (50%)
Number of subsequent visits with confirmation for subjects who deteriorated towards end of observation period [4]		
n	1	2
0	1 / 1 (100%)	2 / 2 (100%)
1	0 / 1	0 / 2

Note: If a subject has not deteriorated, they are censored at the latest assessment or at randomization if no assessement.
[1] Confidence intervals for time variables are estimated using the Brookmeyer-Crowley method.
[2] Two-sided p-value obtained from stratified log-rank test.
[3] Hazard ratio and associated p-value are estimated using the Cox Proportional Hazards stratified by previous treatment with anti-CD38 (yes, no), ISS staging (I/II, III) and number of prior lines of therapy for Fifth Line plus sub-population (4, 5, 6, ...) all CRF reported with treatment arm as the only covariate. A hazard ratio <1 indicates a benefit with this treatment compared with Pom/Dex.
[4] Towards end of observation period is defined as the penultimate or last visit for a subject.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/t_pro_pd2_os_lf.sas 14MAR2023 17:07

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR)

Data as of 12SEP2022

Figure 2.003110
Graph of Kaplan-Meier Curves of Overall Survival



Number at Risk (Number of Events)

Pom/Dex	15(0)	14(0)	13(1)	13(1)	13(1)	12(1)	12(1)	12(1)	11(2)	10(2)	9(3)	9(3)	9(3)	7(3)	6(4)	5(4)	4(4)	4(4)	2(4)	2(4)	2(4)	2(4)	1(4)	1(4)	1(4)	0(4)
Belamaf	29(0)	26(3)	24(5)	22(7)	22(7)	21(8)	16(13)	15(14)	15(14)	15(14)	13(15)	12(15)	10(15)	10(15)	10(15)	9(15)	7(15)	7(15)	6(15)	3(16)	3(16)	3(16)	2(16)	0(16)	0(16)	0(16)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_e_os.sas 13FEB2023 10:46

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 2.001112
Graph of Kaplan-Meier Curves of Overall Survival by Response Category (based on Investigator-Assessed Response with Confirmation) and Treatment Arm
Treatment: Pom/Dex



Number at Risk (Number of Events)

PR or better	9(0)	9(0)	9(0)	9(0)	9(0)	9(0)	9(0)	9(0)	9(0)	9(0)	8(1)	8(1)	8(1)	6(1)	5(2)	4(2)	3(2)	3(2)	1(2)	1(2)	1(2)	1(2)	0(2)	0(2)	0(2)	0(2)	
MR or better	9(0)	9(0)	9(0)	9(0)	9(0)	9(0)	9(0)	9(0)	9(0)	9(0)	8(1)	8(1)	8(1)	6(1)	5(2)	4(2)	3(2)	3(2)	1(2)	1(2)	1(2)	1(2)	0(2)	0(2)	0(2)	0(2)	
SD	4(0)	4(0)	4(0)	4(0)	4(0)	3(0)	3(0)	3(0)	2(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	0(1)	
PD or NE	2(0)	1(0)	0(1)	0(1)	0(1)	0(1)	0(1)	0(1)	0(1)	0(1)	0(1)	0(1)	0(1)	0(1)	0(1)	0(1)	0(1)	0(1)	0(1)	0(1)	0(1)	0(1)	0(1)	0(1)	0(1)	0(1)	

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_e_os_rsp_irc.sas 03MAR2023 11:55

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 2.001112
Graph of Kaplan-Meier Curves of Overall Survival by Response Category (based on Investigator-Assessed Response with Confirmation) and Treatment Arm
Treatment: Belantamab mafodotin



Number at Risk (Number of Events)

PR or better	6(0)	6(0)	6(0)	6(0)	6(0)	5(1)	5(1)	5(1)	5(1)	5(1)	4(1)	4(1)	3(1)	3(1)	3(1)	3(1)	2(1)	2(1)	2(1)	1(2)	1(2)	1(2)	1(2)	0(2)	0(2)	0(2)
MR or better	8(0)	8(0)	8(0)	8(0)	8(0)	7(1)	7(1)	7(1)	7(1)	7(1)	6(1)	6(1)	5(1)	5(1)	5(1)	5(1)	4(1)	4(1)	4(1)	1(2)	1(2)	1(2)	1(2)	0(2)	0(2)	0(2)
SD	13(0)	13(0)	12(1)	11(2)	11(2)	11(2)	7(6)	7(6)	7(6)	7(6)	6(7)	5(7)	5(7)	5(7)	5(7)	4(7)	3(7)	3(7)	2(7)	2(7)	2(7)	2(7)	1(7)	0(7)	0(7)	0(7)
PD or NE	8(0)	5(3)	4(4)	3(5)	3(5)	3(5)	2(6)	1(7)	1(7)	1(7)	1(7)	1(7)	0(7)	0(7)	0(7)	0(7)	0(7)	0(7)	0(7)	0(7)	0(7)	0(7)	0(7)	0(7)	0(7)	0(7)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_e_os_rsp_irc.sas 03MAR2023 11:55

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR)

Data as of 12SEP2022

Figure 2.011110
Graph of Kaplan-Meier Curves of Time to Response Based on Investigator-Assessed Response



Number at Risk
(Number of Events)

Pom/Dex	9(0)	5(4)	2(7)	1(8)	0(9)	0(9)	0(9)	0(9)	0(9)	0(9)	0(9)	0(9)	0(9)
Belamaf	6(0)	2(4)	2(4)	2(4)	2(4)	2(4)	1(5)	1(5)	1(5)	1(5)	1(5)	1(5)	0(6)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_e_resp_inv.sas 15FEB2023 10:10

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR)

Data as of 12SEP2022

Figure 2.009110
Graph of Kaplan-Meier Curves of Time to Best Response Based on Investigator-Assessed Response



Number at Risk (Number of Events)														
Pom/Dex	9(0)	6(3)	3(6)	2(7)	1(8)	1(8)	1(8)	0(9)	0(9)	0(9)	0(9)	0(9)	0(9)	0(9)
Belamaf	6(0)	4(2)	4(2)	2(4)	2(4)	2(4)	1(5)	1(5)	1(5)	1(5)	1(5)	1(5)	1(5)	0(6)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_e_br_inv.sas 15FEB2023 10:09

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR)

Data as of 12SEP2022

Figure 2.001110
Graph of Kaplan-Meier Curves of Duration of Response Based on Investigator-Assessed Response



Number at Risk (Number of Events)

Pom/Dex	9(0)	9(0)	9(0)	7(2)	7(2)	5(3)	5(3)	4(3)	4(3)	2(5)	2(5)	1(5)	1(5)	1(5)	1(5)	1(5)	1(5)	1(5)	1(5)	1(5)	0(5)
Belamaf	6(0)	6(0)	6(0)	5(1)	4(1)	4(1)	4(1)	4(1)	4(1)	4(1)	3(2)	2(2)	1(2)	1(2)	1(2)	0(2)	0(2)	0(2)	0(2)	0(2)	0(2)	0(2)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_e_dor_inv.sas 13FEB2023 10:46

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR)

Data as of 12SEP2022

Figure 2.007110
Graph of Kaplan-Meier Curves of Progression-Free Survival Based on Investigator-Assessed Response and Primary Censoring Rule



Number at Risk (Number of Events)

Pom/Dex	15(0)	14(0)	13(1)	12(2)	9(4)	8(5)	7(5)	6(6)	5(6)	5(6)	4(7)	4(7)	3(8)	2(8)	2(8)	2(8)	2(8)	2(8)	2(8)	2(8)	2(8)	1(8)	1(8)	0(8)
Belamaf	29(0)	22(6)	14(12)	10(15)	9(16)	9(16)	7(18)	7(18)	6(19)	6(19)	5(19)	3(20)	2(20)	2(20)	2(20)	2(20)	1(20)	1(20)	1(20)	1(20)	1(20)	1(20)	0(20)	0(20)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_e_pfs_inv.sas 13FEB2023 10:47

Protocol: 207495

Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 2.006110
Graph of Restricted Mean Survival Time Curves of Progression-Free Survival Based on Investigator-Assessed Response and Primary Censoring Rule



Note: The RMST is the expected survival time restricted to a specific time horizon t*. The cutoff t* for determining the RMST is the smallest value among the largest observed time across study interventions.
Note: 95% Confidence Intervals are included in the plot.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_e_rmst_pfs.sas 23FEB2023 05:34

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 2.002112
Graph of Kaplan-Meier Curves of Progression-Free Survival by Response Category (based on Investigator-Assessed Response with Confirmation) and Treatment Arm
Treatment: Pom/Dex



Number at Risk (Number of Events)																									
PR or better	9(0)	9(0)	9(0)	8(1)	7(2)	7(2)	6(2)	5(3)	4(3)	4(3)	3(4)	3(4)	2(5)	1(5)	1(5)	1(5)	1(5)	1(5)	1(5)	1(5)	1(5)	1(5)	0(5)	0(5)	0(5)
MR or better	9(0)	9(0)	9(0)	8(1)	7(2)	7(2)	6(2)	5(3)	4(3)	4(3)	3(4)	3(4)	2(5)	1(5)	1(5)	1(5)	1(5)	1(5)	1(5)	1(5)	1(5)	1(5)	0(5)	0(5)	0(5)
SD	4(0)	4(0)	4(0)	4(0)	2(1)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	0(2)
PD or NE	2(0)	1(0)	0(1)	0(1)	0(1)	0(1)	0(1)	0(1)	0(1)	0(1)	0(1)	0(1)	0(1)	0(1)	0(1)	0(1)	0(1)	0(1)	0(1)	0(1)	0(1)	0(1)	0(1)	0(1)	0(1)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_e_pfs_rsp_irc.sas 03MAR2023 11:55

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR)

Data as of 12SEP2022

Figure 2.002112
Graph of Kaplan-Meier Curves of Progression-Free Survival by Response Category (based on Investigator-Assessed Response with Confirmation) and Treatment Arm
Treatment: Belantamab mafodotin



Number at Risk (Number of Events)

PR or better	6(0)	6(0)	6(0)	5(1)	5(1)	5(1)	5(1)	5(1)	5(1)	5(1)	4(1)	3(2)	2(2)	2(2)	2(2)	2(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	0(2)	0(2)
MR or better	8(0)	8(0)	8(0)	7(1)	7(1)	7(1)	6(2)	6(2)	5(3)	5(3)	4(3)	3(4)	2(4)	2(4)	2(4)	2(4)	1(4)	1(4)	1(4)	1(4)	1(4)	1(4)	1(4)	0(4)	0(4)
SD	13(0)	13(0)	6(5)	3(7)	2(8)	2(8)	1(9)	1(9)	1(9)	1(9)	1(9)	0(9)	0(9)	0(9)	0(9)	0(9)	0(9)	0(9)	0(9)	0(9)	0(9)	0(9)	0(9)	0(9)	0(9)
PD or NE	8(0)	1(6)	0(7)	0(7)	0(7)	0(7)	0(7)	0(7)	0(7)	0(7)	0(7)	0(7)	0(7)	0(7)	0(7)	0(7)	0(7)	0(7)	0(7)	0(7)	0(7)	0(7)	0(7)	0(7)	0(7)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_e_pfs_rsp_irc.sas 03MAR2023 11:55

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR)

Data as of 12SEP2022

Figure 2.008110
Graph of Kaplan-Meier Curves of Progression-Free Survival 2 Based on Investigator-Assessed Response



Number at Risk (Number of Events)

Pom/Dex	15(0)	14(0)	13(1)	13(1)	13(1)	12(1)	12(1)	12(1)	11(2)	8(4)	7(5)	6(6)	6(6)	5(6)	4(7)	3(7)	3(7)	3(7)	2(7)	2(7)	2(7)	2(7)	1(7)	1(7)	1(7)	0(7)
Belamaf	29(0)	26(3)	23(6)	21(8)	18(11)	17(12)	13(16)	13(16)	12(17)	12(17)	11(17)	10(17)	9(17)	9(17)	7(19)	6(19)	5(19)	4(20)	3(20)	2(21)	2(21)	2(21)	2(21)	0(21)	0(21)	0(21)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_e_pfs2_inv.sas 13FEB2023 05:59

Protocol: 207495

Population: Intent-to-treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.042110

Plot of Least Squares Mean (95% CI) of EQ-5D-3L VAS Subscale Scores

Domain: EQ VAS Score



Pom/Dex - n	11	12	12	8	7	4	6	9
Belamaf - n	18	10	12	6	8	7	4	11

Note: EOT = "End of Treatment".
Note: Interval shown represents 95% confidence limits around mean at each planned time.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_f3_vas_dom.sas 13MAR2023 10:26

Protocol: 207495

Population: Intent-to-treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.043110

Plot of Least Squares Mean (95% CI) Change from Baseline of EQ-5D-3L VAS Subscale Scores

Domain: EQ VAS Score



Pom/Dex - n	11	12	12	8	7	4	6	9
Belamaf - n	18	10	12	6	8	7	4	11

Note: EOT = "End of Treatment".
Note: Interval shown represents 95% confidence limits around mean at each planned time.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_f3_vas_cfb.sas 13MAR2023 10:26

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR)

Data as of 12SEP2022

Figure 4.080110
Graph of Kaplan-Meier Curves of EQ-5D-3L VAS Time to first Improvement
(Up to and including Last Follow-Up)



Number at Risk
(Number of Events)

Pom/Dex	15(0)	12(0)	11(1)	8(4)	8(4)	5(6)	4(6)	4(6)	3(6)	3(6)	2(7)	2(7)	2(7)	1(7)	1(7)	1(7)	1(7)	1(7)	0(7)	0(7)	0(7)	0(7)
Belamaf	29(0)	20(0)	14(1)	13(2)	11(2)	8(2)	8(2)	6(4)	5(4)	5(4)	4(4)	4(4)	3(4)	2(4)	2(4)	2(4)	2(4)	2(4)	1(4)	1(4)	1(4)	0(4)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_vas_tfi.sas 14MAR2023 06:08

Protocol: 207495

Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.077110
Graph of Kaplan-Meier Curves of EQ-5D-3L VAS Time to first Deterioration 1
(Up to and including Last Follow-Up)



Number at Risk
(Number of Events)

Pom/Dex	15(0)	13(0)	11(2)	9(4)	9(4)	9(4)	6(4)	6(4)	6(4)	6(4)	6(4)	5(5)	5(5)	4(5)	1(7)	1(7)	1(7)	1(7)	1(7)	1(7)	1(7)	1(7)	0(7)
Belamaf	29(0)	24(3)	12(12)	11(13)	11(13)	10(14)	8(16)	8(16)	8(16)	7(16)	5(17)	5(17)	4(17)	4(17)	4(17)	4(17)	3(17)	3(17)	2(17)	1(18)	1(18)	0(19)	0(19)	0(19)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_vas_tfd1.sas 14MAR2023 06:08

Protocol: 207495

Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.078110
Graph of Kaplan-Meier Curves of EQ-5D-3L VAS Time to first Deterioration 2
(Up to and including Last Follow-Up)

Number at Risk
(Number of Events)

Pom/Dex	15(0)	12(0)	11(1)	9(3)	9(3)	9(3)	6(3)	6(3)	6(3)	6(3)	6(3)	4(4)	4(4)	3(4)	1(5)	1(5)	1(5)	1(5)	1(5)	1(5)	1(5)	1(5)	0(5)
Belamaf	29(0)	20(0)	9(7)	9(7)	8(7)	7(7)	7(7)	7(7)	7(7)	6(7)	5(7)	5(7)	4(7)	4(7)	3(7)	3(7)	2(7)	2(7)	1(7)	1(7)	1(7)	0(8)	0(8)	0(8)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_vas_tfd2.sas 14MAR2023 06:08

Protocol: 207495

Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.081110
Graph of Kaplan-Meier Curves of EQ-5D-3L VAS Time to permanent Deterioration 1
(Up to and including End of Treatment)



Number at Risk
(Number of Events)

Pom/Dex	15(0)	13(0)	12(1)	12(1)	12(1)	10(1)	6(2)	6(2)	5(2)	5(2)	5(2)	3(2)	3(2)	2(2)	2(2)	2(2)	2(2)	2(2)	2(2)	1(2)	1(2)	1(2)	1(2)	0(2)
Belamaf	29(0)	24(3)	14(5)	11(6)	10(6)	9(6)	7(8)	7(8)	7(8)	6(8)	4(9)	4(9)	3(9)	3(9)	2(9)	2(9)	1(9)	1(9)	1(9)	1(9)	1(9)	0(9)	0(9)	0(9)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_vas_pd1_eot.sas 14MAR2023 13:25

Protocol: 207495

Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.082110
Graph of Kaplan-Meier Curves of EQ-5D-3L VAS Time to permanent Deterioration 2
(Up to and including End of Treatment)



Number at Risk
(Number of Events)

Pom/Dex	15(0)	12(0)	12(0)	12(0)	12(0)	10(0)	6(1)	6(1)	5(1)	5(1)	5(1)	3(1)	3(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	1(1)	1(1)	1(1)	1(1)	0(1)
Belamaf	29(0)	20(0)	11(0)	9(0)	8(0)	6(0)	6(0)	6(0)	6(0)	5(0)	4(0)	4(0)	3(0)	3(0)	2(0)	2(0)	1(0)	1(0)	1(0)	1(0)	1(0)	0(0)	0(0)	0(0)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_vas_pd2_eot.sas 14MAR2023 13:27

Protocol: 207495

Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.083110
Graph of Kaplan-Meier Curves of EQ-5D-3L VAS Time to permanent Deterioration 1
(Up to and including Last Follow-Up)



Number at Risk
(Number of Events)

Pom/Dex	15(0)	13(0)	12(1)	12(1)	12(1)	11(1)	7(2)	7(2)	6(3)	6(3)	6(3)	6(3)	6(3)	5(3)	3(4)	3(4)	3(4)	3(4)	2(4)	1(4)	1(4)	1(4)	1(4)	0(4)
Belamaf	29(0)	24(3)	19(5)	17(7)	17(7)	16(8)	11(13)	10(14)	9(14)	8(14)	6(15)	6(15)	5(15)	4(15)	4(15)	4(15)	3(15)	3(15)	2(15)	1(16)	1(16)	0(16)	0(16)	0(16)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_vas_pd1_lf.sas 14MAR2023 13:25

Protocol: 207495

Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.084110
Graph of Kaplan-Meier Curves of EQ-5D-3L VAS Time to permanent Deterioration 2
(Up to and including Last Follow-Up)



Number at Risk
(Number of Events)

Pom/Dex	15(0)	12(0)	12(0)	12(0)	12(0)	10(0)	6(1)	6(1)	6(1)	6(1)	6(1)	5(1)	5(1)	4(1)	3(1)	3(1)	3(1)	3(1)	2(1)	1(1)	1(1)	1(1)	1(1)	0(1)
Belamaf	29(0)	20(0)	14(0)	14(0)	12(0)	9(0)	9(0)	9(0)	8(0)	7(0)	6(0)	6(0)	5(0)	4(0)	3(0)	3(0)	2(0)	2(0)	1(0)	1(0)	1(0)	0(0)	0(0)	0(0)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_vas_pd2_lf.sas 14MAR2023 13:27

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.005110
Plot of Least Squares Mean (95% CI) of EORTC QLQ-C30 Domain Scores
Domain: Global Health Status Domain Score



	WK 4	WK 7	WK 10	WK 13	WK 16	WK 19	WK 22	WK 25	WK 28	WK 31	WK 34	WK 37	WK 40	WK 43	EOT
Pom/Dex - n	12	11	12	12	11	12	8	9	7	7	6	4	4	6	9
Belamaf - n	23	21	12	10	10	9	8	8	7	7	6	6	6	4	11

Note: Interval shown represents 95% confidence limits around mean at each planned time.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_f3_c30_dom.sas 14MAR2023 08:22

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.005110
Plot of Least Squares Mean (95% CI) of EORTC QLQ-C30 Domain Scores
Domain: Physical Functioning Domain Score



	WK 4	WK 7	WK 10	WK 13	WK 16	WK 19	WK 22	WK 25	WK 28	WK 31	WK 34	WK 37	WK 40	WK 43	EOT
Pom/Dex - n	12	11	12	12	11	12	8	9	7	7	6	4	4	6	9
Belamaf - n	23	21	12	10	10	9	8	8	7	7	6	6	6	4	11

Note: Interval shown represents 95% confidence limits around mean at each planned time.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_f3_c30_dom.sas 14MAR2023 08:22

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.005110
Plot of Least Squares Mean (95% CI) of EORTC QLQ-C30 Domain Scores
Domain: Role Functioning Domain Score



Pom/Dex - n	12	10	12	12	11	12	8	9	7	7	6	4	4	6	9
Belamaf - n	23	21	12	10	10	8	8	8	7	7	6	6	6	4	11

Note: Interval shown represents 95% confidence limits around mean at each planned time.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_f3_c30_dom.sas 14MAR2023 08:22

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.005110
Plot of Least Squares Mean (95% CI) of EORTC QLQ-C30 Domain Scores
Domain: Emotional Functioning Domain Score



Pom/Dex - n	12	11	12	12	11	12	8	9	7	7	6	4	4	6	9
Belamaf - n	23	21	12	10	10	9	8	8	7	7	6	6	6	4	11

Note: Interval shown represents 95% confidence limits around mean at each planned time.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_f3_c30_dom.sas 14MAR2023 08:22

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.005110
Plot of Least Squares Mean (95% CI) of EORTC QLQ-C30 Domain Scores
Domain: Cognitive Functioning Domain Score



	WK 4	WK 7	WK 10	WK 13	WK 16	WK 19	WK 22	WK 25	WK 28	WK 31	WK 34	WK 37	WK 40	WK 43	EOT
Pom/Dex - n	12	11	12	12	11	12	8	9	7	7	6	4	4	6	9
Belamaf - n	23	21	12	10	10	9	8	8	7	7	6	6	6	4	11

Note: Interval shown represents 95% confidence limits around mean at each planned time.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_f3_c30_dom.sas 14MAR2023 08:22

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.005110
Plot of Least Squares Mean (95% CI) of EORTC QLQ-C30 Domain Scores
Domain: Social Functioning Domain Score



	WK 4	WK 7	WK 10	WK 13	WK 16	WK 19	WK 22	WK 25	WK 28	WK 31	WK 34	WK 37	WK 40	WK 43	EOT
Pom/Dex - n	12	11	12	12	10	12	8	9	7	7	6	4	4	6	9
Belamaf - n	23	21	12	10	10	8	8	8	7	7	6	6	6	4	11

Note: Interval shown represents 95% confidence limits around mean at each planned time.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_f3_c30_dom.sas 14MAR2023 08:22

Protocol: 207495

Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.005110

Plot of Least Squares Mean (95% CI) of EORTC QLQ-C30 Domain Scores

Domain: Fatigue Domain Score



	WK 4	WK 7	WK 10	WK 13	WK 16	WK 19	WK 22	WK 25	WK 28	WK 31	WK 34	WK 37	WK 40	WK 43	EOT
Pom/Dex - n	11	10	11	11	10	11	7	8	6	6	5	0	0	0	8
Belamaf - n	23	21	12	10	10	9	8	8	7	7	6	0	0	0	10

Note: Interval shown represents 95% confidence limits around mean at each planned time.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_f3_c30_dom.sas 14MAR2023 08:22

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.005110
Plot of Least Squares Mean (95% CI) of EORTC QLQ-C30 Domain Scores
Domain: Nausea and vomiting Domain Score



Pom/Dex - n	12	11	12	12	11	12	8	9	7	7	6	4	4	6	9
Belamaf - n	22	20	11	9	9	8	7	8	7	7	6	6	6	4	11

Note: Interval shown represents 95% confidence limits around mean at each planned time.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_f3_c30_dom.sas 14MAR2023 08:22

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.005110
Plot of Least Squares Mean (95% CI) of EORTC QLQ-C30 Domain Scores
Domain: Pain Domain Score



	WK 4	WK 7	WK 10	WK 13	WK 16	WK 19	WK 22	WK 25	WK 28	WK 31	WK 34	WK 37	WK 40	WK 43	EOT
Pom/Dex - n	12	11	12	12	11	12	8	9	7	7	6	4	4	6	9
Belamaf - n	23	21	12	10	10	9	8	8	7	7	6	6	6	4	10

Note: Interval shown represents 95% confidence limits around mean at each planned time.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_f3_c30_dom.sas 14MAR2023 08:22

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.005110
Plot of Least Squares Mean (95% CI) of EORTC QLQ-C30 Domain Scores
Domain: Dyspnoea Domain Score



Pom/Dex - n	12	10	12	12	11	12	8	9	7	7	6	4	4	6	9
Belamaf - n	23	21	12	10	10	8	8	8	7	7	6	6	6	4	11

Note: Interval shown represents 95% confidence limits around mean at each planned time.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_f3_c30_dom.sas 14MAR2023 08:22

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.005110
Plot of Least Squares Mean (95% CI) of EORTC QLQ-C30 Domain Scores
Domain: Insomnia Domain Score



	WK 4	WK 7	WK 10	WK 13	WK 16	WK 19	WK 22	WK 25	WK 28	WK 31	WK 34	WK 37	WK 40	WK 43	EOT
Pom/Dex - n	11	10	11	11	10	11	7	8	6	6	5	0	0	0	8
Belamaf - n	22	20	11	9	9	8	7	8	7	7	6	0	0	0	10

Note: Interval shown represents 95% confidence limits around mean at each planned time.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_f3_c30_dom.sas 14MAR2023 08:22

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.005110
Plot of Least Squares Mean (95% CI) of EORTC QLQ-C30 Domain Scores
Domain: Appetite Loss Domain Score



Pom/Dex - n	12	11	12	12	11	12	8	9	7	7	6	4	4	6	9
Belamaf - n	22	20	11	9	9	8	7	8	7	7	6	6	6	4	11

Note: Interval shown represents 95% confidence limits around mean at each planned time.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_f3_c30_dom.sas 14MAR2023 08:22

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.005110
Plot of Least Squares Mean (95% CI) of EORTC QLQ-C30 Domain Scores
Domain: Constipation Domain Score



	WK 4	WK 7	WK 10	WK 13	WK 16	WK 19	WK 22	WK 25	WK 28	WK 31	WK 34	WK 37	WK 40	WK 43	EOT
Pom/Dex - n	12	11	12	12	11	12	8	9	7	7	6	4	4	6	9
Belamaf - n	22	20	11	9	9	8	7	8	7	7	6	6	6	4	11

Note: Interval shown represents 95% confidence limits around mean at each planned time.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_f3_c30_dom.sas 14MAR2023 08:22

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.005110
Plot of Least Squares Mean (95% CI) of EORTC QLQ-C30 Domain Scores
Domain: Diarrhoea Domain Score



	WK 4	WK 7	WK 10	WK 13	WK 16	WK 19	WK 22	WK 25	WK 28	WK 31	WK 34	WK 37	WK 40	WK 43	EOT
Pom/Dex - n	12	10	12	12	10	12	8	9	7	7	6	4	4	6	9
Belamaf - n	22	21	12	10	10	9	8	8	7	7	6	6	6	4	10

Note: Interval shown represents 95% confidence limits around mean at each planned time.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_f3_c30_dom.sas 14MAR2023 08:22

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.005110
Plot of Least Squares Mean (95% CI) of EORTC QLQ-C30 Domain Scores
Domain: Financial Difficulties Domain Score



	WK 4	WK 7	WK 10	WK 13	WK 16	WK 19	WK 22	WK 25	WK 28	WK 31	WK 34	WK 37	WK 40	WK 43	EOT
Pom/Dex - n	12	11	12	12	10	12	8	9	7	7	6	4	4	6	9
Belamaf - n	23	21	12	10	10	8	8	8	7	7	6	6	6	4	11

Note: Interval shown represents 95% confidence limits around mean at each planned time.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_f3_c30_dom.sas 14MAR2023 08:22

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.006110
Plot of Least Squares Mean (95% CI) Change from Baseline of EORTC QLQ-C30 Domain Scores
Domain: Global Health Status Domain Score



	WK 4	WK 7	WK 10	WK 13	WK 16	WK 19	WK 22	WK 25	WK 28	WK 31	WK 34	WK 37	WK 40	WK 43	EOT
Pom/Dex - n	12	11	12	12	11	12	8	9	7	7	6	4	4	6	9
Belamaf - n	23	21	12	10	10	9	8	8	7	7	6	6	6	4	11

Note: Interval shown represents 95% confidence limits around mean at each planned time.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_f3_c30_dom_cfb.sas 14MAR2023 08:23

Protocol: 207495

Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.006110

Plot of Least Squares Mean (95% CI) Change from Baseline of EORTC QLQ-C30 Domain Scores

Domain: Physical Functioning Domain Score



Pom/Dex - n	12	11	12	12	11	12	8	9	7	7	6	4	4	6	9
Belamaf - n	23	21	12	10	10	9	8	8	7	7	6	6	6	4	11

Note: Interval shown represents 95% confidence limits around mean at each planned time.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_f3_c30_dom_cfb.sas 14MAR2023 08:23

Protocol: 207495

Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.006110

Plot of Least Squares Mean (95% CI) Change from Baseline of EORTC QLQ-C30 Domain Scores

Domain: Role Functioning Domain Score



Pom/Dex - n	12	10	12	12	11	12	8	9	7	7	6	4	4	6	9
Belamaf - n	23	21	12	10	10	8	8	8	7	7	6	6	6	4	11

Note: Interval shown represents 95% confidence limits around mean at each planned time.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_f3_c30_dom_cfb.sas 14MAR2023 08:23

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.006110
Plot of Least Squares Mean (95% CI) Change from Baseline of EORTC QLQ-C30 Domain Scores
Domain: Emotional Functioning Domain Score



	WK 4	WK 7	WK 10	WK 13	WK 16	WK 19	WK 22	WK 25	WK 28	WK 31	WK 34	WK 37	WK 40	WK 43	EOT
Pom/Dex - n	12	11	12	12	11	12	8	9	7	7	6	4	4	6	9
Belamaf - n	23	21	12	10	10	9	8	8	7	7	6	6	6	4	11

Note: Interval shown represents 95% confidence limits around mean at each planned time.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_f3_c30_dom_cfb.sas 14MAR2023 08:23

Protocol: 207495

Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.006110

Plot of Least Squares Mean (95% CI) Change from Baseline of EORTC QLQ-C30 Domain Scores

Domain: Cognitive Functioning Domain Score



	WK 4	WK 7	WK 10	WK 13	WK 16	WK 19	WK 22	WK 25	WK 28	WK 31	WK 34	WK 37	WK 40	WK 43	EOT
Pom/Dex - n	12	11	12	12	11	12	8	9	7	7	6	4	4	6	9
Belamaf - n	23	21	12	10	10	9	8	8	7	7	6	6	6	4	11

Note: Interval shown represents 95% confidence limits around mean at each planned time.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_f3_c30_dom_cfb.sas 14MAR2023 08:23

Protocol: 207495

Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.006110

Plot of Least Squares Mean (95% CI) Change from Baseline of EORTC QLQ-C30 Domain Scores

Domain: Social Functioning Domain Score



	WK 4	WK 7	WK 10	WK 13	WK 16	WK 19	WK 22	WK 25	WK 28	WK 31	WK 34	WK 37	WK 40	WK 43	EOT
Pom/Dex - n	12	11	12	12	10	12	8	9	7	7	6	4	4	6	9
Belamaf - n	23	21	12	10	10	8	8	8	7	7	6	6	6	4	11

Note: Interval shown represents 95% confidence limits around mean at each planned time.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_f3_c30_dom_cfb.sas 14MAR2023 08:23

Protocol: 207495

Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.006110

Plot of Least Squares Mean (95% CI) Change from Baseline of EORTC QLQ-C30 Domain Scores

Domain: Fatigue Domain Score



	WK 4	WK 7	WK 10	WK 13	WK 16	WK 19	WK 22	WK 25	WK 28	WK 31	WK 34	WK 37	WK 40	WK 43	EOT
Pom/Dex - n	11	10	11	11	10	11	7	8	6	6	5	0	0	0	8
Belamaf - n	23	21	12	10	10	9	8	8	7	7	6	0	0	0	10

Note: Interval shown represents 95% confidence limits around mean at each planned time.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_f3_c30_dom_cfb.sas 14MAR2023 08:23

Protocol: 207495

Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.006110

Plot of Least Squares Mean (95% CI) Change from Baseline of EORTC QLQ-C30 Domain Scores

Domain: Nausea and vomiting Domain Score



	WK 4	WK 7	WK 10	WK 13	WK 16	WK 19	WK 22	WK 25	WK 28	WK 31	WK 34	WK 37	WK 40	WK 43	EOT
Pom/Dex - n	12	11	12	12	11	12	8	9	7	7	6	4	4	6	9
Belamaf - n	22	20	11	9	9	8	7	8	7	7	6	6	6	4	11

Note: Interval shown represents 95% confidence limits around mean at each planned time.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_f3_c30_dom_cfb.sas 14MAR2023 08:23

Protocol: 207495

Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.006110

Plot of Least Squares Mean (95% CI) Change from Baseline of EORTC QLQ-C30 Domain Scores

Domain: Pain Domain Score



Pom/Dex - n	12	11	12	12	11	12	8	9	7	7	6	4	4	6	9
Belamaf - n	23	21	12	10	10	9	8	8	7	7	6	6	6	4	10

Note: Interval shown represents 95% confidence limits around mean at each planned time.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_f3_c30_dom_cfb.sas 14MAR2023 08:23

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.006110
Plot of Least Squares Mean (95% CI) Change from Baseline of EORTC QLQ-C30 Domain Scores
Domain: Dyspnoea Domain Score



Pom/Dex - n	12	10	12	12	11	12	8	9	7	7	6	4	4	6	9
Belamaf - n	23	21	12	10	10	8	8	8	7	7	6	6	6	4	11

Note: Interval shown represents 95% confidence limits around mean at each planned time.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_f3_c30_dom_cfb.sas 14MAR2023 08:23

Protocol: 207495

Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.006110

Plot of Least Squares Mean (95% CI) Change from Baseline of EORTC QLQ-C30 Domain Scores

Domain: Insomnia Domain Score



	WK 4	WK 7	WK 10	WK 13	WK 16	WK 19	WK 22	WK 25	WK 28	WK 31	WK 34	WK 37	WK 40	WK 43	EOT
Pom/Dex - n	11	10	11	11	10	11	7	8	6	6	5	0	0	0	8
Belamaf - n	22	20	11	9	9	8	7	8	7	7	6	0	0	0	10

Note: Interval shown represents 95% confidence limits around mean at each planned time.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_f3_c30_dom_cfb.sas 14MAR2023 08:23

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.006110
Plot of Least Squares Mean (95% CI) Change from Baseline of EORTC QLQ-C30 Domain Scores
Domain: Appetite Loss Domain Score



Pom/Dex - n	12	11	12	12	11	12	8	9	7	7	6	4	4	6	9
Belamaf - n	22	20	11	9	9	8	7	8	7	7	6	6	6	4	11

Note: Interval shown represents 95% confidence limits around mean at each planned time.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_f3_c30_dom_cfb.sas 14MAR2023 08:23

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.006110
Plot of Least Squares Mean (95% CI) Change from Baseline of EORTC QLQ-C30 Domain Scores
Domain: Constipation Domain Score



	WK 4	WK 7	WK 10	WK 13	WK 16	WK 19	WK 22	WK 25	WK 28	WK 31	WK 34	WK 37	WK 40	WK 43	EOT
Pom/Dex - n	12	11	12	12	11	12	8	9	7	7	6	4	4	6	9
Belamaf - n	22	20	11	9	9	8	7	8	7	7	6	6	6	4	11

Note: Interval shown represents 95% confidence limits around mean at each planned time.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_f3_c30_dom_cfb.sas 14MAR2023 08:23

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.006110
Plot of Least Squares Mean (95% CI) Change from Baseline of EORTC QLQ-C30 Domain Scores
Domain: Diarrhoea Domain Score



Pom/Dex - n	12	10	12	12	10	12	8	9	7	7	6	4	4	6	9
Belamaf - n	22	21	12	10	10	9	8	8	7	7	6	6	6	4	10

Note: Interval shown represents 95% confidence limits around mean at each planned time.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_f3_c30_dom_cfb.sas 14MAR2023 08:23

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.006110
Plot of Least Squares Mean (95% CI) Change from Baseline of EORTC QLQ-C30 Domain Scores
Domain: Financial Difficulties Domain Score



	WK 4	WK 7	WK 10	WK 13	WK 16	WK 19	WK 22	WK 25	WK 28	WK 31	WK 34	WK 37	WK 40	WK 43	EOT
Pom/Dex - n	12	11	12	12	10	12	8	9	7	7	6	4	4	6	9
Belamaf - n	23	21	12	10	10	8	8	8	7	7	6	6	6	4	11

Note: Interval shown represents 95% confidence limits around mean at each planned time.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_f3_c30_dom_cfb.sas 14MAR2023 08:23

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.056110
Graph of Kaplan-Meier Curves of EORTC QLQ-C30 Time to first Improvement
(Up to and including Last Follow-Up)
Item Score: Global Health Status Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	9(3)	9(3)	6(6)	6(6)	4(7)	4(7)	4(7)	3(7)	3(7)	3(7)	2(8)	2(8)	1(8)	0(8)	0(8)	0(8)	0(8)	0(8)	0(8)	0(8)	0(8)	0(8)
Belamaf	29(0)	15(7)	10(8)	8(10)	7(10)	6(10)	6(10)	6(10)	6(10)	6(10)	5(10)	5(10)	4(10)	3(10)	2(10)	2(10)	2(10)	2(10)	1(10)	1(10)	1(10)	1(10)	1(10)	0(10)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_c30_tfi.sas 10MAR2023 10:09

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.056110
Graph of Kaplan-Meier Curves of EORTC QLQ-C30 Time to first Improvement
(Up to and including Last Follow-Up)
Item Score: Physical Functioning Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	9(3)	9(3)	7(5)	6(6)	4(6)	3(7)	3(7)	3(7)	3(7)	3(7)	2(7)	2(7)	1(7)	1(7)	1(7)	1(7)	1(7)	1(7)	1(7)	1(7)	0(7)
Belamaf	29(0)	17(5)	10(8)	9(9)	8(9)	6(9)	5(10)	5(10)	4(10)	4(10)	3(10)	3(10)	2(10)	1(10)	1(10)	1(10)	1(10)	1(10)	1(10)	1(10)	1(10)	0(10)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_c30_tfi.sas 10MAR2023 10:09

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR)

Data as of 12SEP2022

Figure 4.056110
Graph of Kaplan-Meier Curves of EORTC QLQ-C30 Time to first Improvement
(Up to and including Last Follow-Up)
Item Score: Role Functioning Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	8(4)	7(5)	5(7)	4(8)	1(9)	1(9)	1(9)	1(9)	1(9)	1(9)	1(9)	1(9)	1(9)	1(9)	1(9)	1(9)	1(9)	1(9)	1(9)	1(9)	1(9)	0(9)
Belamaf	29(0)	18(4)	10(5)	9(5)	7(5)	6(5)	4(5)	4(5)	4(5)	4(5)	3(5)	3(5)	3(5)	2(5)	2(5)	2(5)	2(5)	2(5)	1(5)	1(5)	1(5)	1(5)	1(5)	0(5)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_c30_tfi.sas 10MAR2023 10:09

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.056110
Graph of Kaplan-Meier Curves of EORTC QLQ-C30 Time to first Improvement
(Up to and including Last Follow-Up)
Item Score: Emotional Functioning Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	7(5)	7(5)	5(7)	5(7)	4(7)	3(8)	3(8)	3(8)	3(8)	3(8)	2(8)	2(8)	2(8)	2(8)	2(8)	2(8)	2(8)	2(8)	2(8)	2(8)	1(8)	0(8)
Belamaf	29(0)	17(5)	11(7)	9(9)	8(9)	8(9)	6(10)	6(10)	6(10)	6(10)	5(10)	5(10)	4(10)	3(10)	2(10)	2(10)	2(10)	2(10)	1(10)	1(10)	1(10)	1(10)	1(10)	0(10)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_c30_tfi.sas 10MAR2023 10:09

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR)

Data as of 12SEP2022

Figure 4.056110
Graph of Kaplan-Meier Curves of EORTC QLQ-C30 Time to first Improvement
(Up to and including Last Follow-Up)
Item Score: Cognitive Functioning Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	8(4)	7(5)	6(6)	6(6)	5(6)	5(6)	5(6)	4(6)	4(6)	4(6)	3(6)	3(6)	2(6)	1(6)	1(6)	1(6)	1(6)	1(6)	1(6)	1(6)	1(6)	0(6)
Belamaf	29(0)	16(7)	9(10)	9(10)	7(11)	6(11)	5(11)	4(12)	4(12)	3(12)	2(12)	2(12)	1(12)	1(12)	1(12)	1(12)	1(12)	1(12)	1(12)	1(12)	1(12)	1(12)	0(12)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_c30_tfi.sas 10MAR2023 10:09

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.056110
Graph of Kaplan-Meier Curves of EORTC QLQ-C30 Time to first Improvement
(Up to and including Last Follow-Up)
Item Score: Social Functioning Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	9(3)	7(5)	5(7)	5(7)	2(8)	2(8)	2(8)	2(8)	2(8)	2(8)	2(8)	2(8)	1(8)	1(8)	1(8)	1(8)	1(8)	1(8)	1(8)	1(8)	0(8)	0(8)
Belamaf	29(0)	18(4)	9(9)	8(9)	6(10)	6(10)	5(10)	5(10)	4(10)	3(10)	2(10)	2(10)	2(10)	2(10)	1(10)	1(10)	1(10)	1(10)	0(10)	0(10)	0(10)	0(10)	0(10)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_c30_tfi.sas 10MAR2023 10:09

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.056110
Graph of Kaplan-Meier Curves of EORTC QLQ-C30 Time to first Improvement
(Up to and including Last Follow-Up)
Item Score: Fatigue Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	6(5)	5(6)	4(7)	4(7)	1(8)	0(8)	0(8)	0(8)	0(8)	0(8)	0(8)	0(8)	0(8)	0(8)	0(8)	0(8)	0(8)	0(8)	0(8)	0(8)	0(8)	0(8)
Belamaf	29(0)	14(8)	6(11)	6(11)	4(12)	4(12)	3(12)	3(12)	3(12)	3(12)	1(13)	1(13)	1(13)	1(13)	1(13)	1(13)	1(13)	1(13)	1(13)	1(13)	1(13)	1(13)	0(13)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_c30_tfi.sas 10MAR2023 10:09

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.056110
Graph of Kaplan-Meier Curves of EORTC QLQ-C30 Time to first Improvement
(Up to and including Last Follow-Up)
Item Score: Nausea and vomiting Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	11(1)	10(2)	10(2)	10(2)	9(2)	7(2)	7(2)	6(2)	6(2)	6(2)	5(2)	5(2)	4(2)	3(2)	3(2)	3(2)	3(2)	2(2)	2(2)	2(2)	2(2)	1(2)	0(2)
Belamaf	29(0)	19(2)	12(3)	11(3)	10(3)	9(3)	8(3)	8(3)	7(3)	6(3)	5(3)	5(3)	4(3)	3(3)	2(3)	2(3)	1(3)	1(3)	1(3)	1(3)	1(3)	1(3)	1(3)	0(3)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_c30_tfi.sas 10MAR2023 10:09

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.056110
Graph of Kaplan-Meier Curves of EORTC QLQ-C30 Time to first Improvement
(Up to and including Last Follow-Up)
Item Score: Pain Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	7(5)	5(7)	4(8)	4(8)	3(8)	3(8)	2(9)	2(9)	2(9)	2(9)	1(9)	1(9)	0(9)	0(9)	0(9)	0(9)	0(9)	0(9)	0(9)	0(9)	0(9)	0(9)
Belamaf	29(0)	16(6)	9(10)	7(12)	6(12)	5(13)	4(13)	4(13)	3(13)	3(13)	2(13)	2(13)	1(13)	1(13)	1(13)	1(13)	1(13)	1(13)	1(13)	1(13)	1(13)	1(13)	0(13)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_c30_tfi.sas 10MAR2023 10:09

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.056110
Graph of Kaplan-Meier Curves of EORTC QLQ-C30 Time to first Improvement
(Up to and including Last Follow-Up)
Item Score: Dyspnoea Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	8(4)	8(4)	8(4)	8(4)	6(4)	4(4)	4(4)	3(4)	3(4)	3(4)	2(4)	2(4)	2(4)	1(4)	1(4)	1(4)	1(4)	1(4)	1(4)	1(4)	1(4)	0(4)
Belamaf	29(0)	18(4)	12(6)	11(6)	10(7)	9(7)	8(7)	8(7)	7(7)	7(7)	6(7)	6(7)	5(7)	4(7)	3(7)	3(7)	2(7)	2(7)	1(7)	1(7)	1(7)	1(7)	0(7)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_c30_tfi.sas 10MAR2023 10:09

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.056110
Graph of Kaplan-Meier Curves of EORTC QLQ-C30 Time to first Improvement
(Up to and including Last Follow-Up)
Item Score: Insomnia Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	7(4)	5(6)	5(6)	4(7)	3(7)	3(7)	3(7)	2(7)	2(7)	2(7)	2(7)	2(7)	2(7)	2(7)	2(7)	2(7)	2(7)	2(7)	2(7)	2(7)	1(7)	0(7)
Belamaf	29(0)	16(5)	10(6)	9(6)	7(6)	6(6)	5(6)	5(6)	4(6)	4(6)	3(6)	3(6)	3(6)	3(6)	3(6)	3(6)	2(6)	2(6)	1(6)	1(6)	1(6)	1(6)	1(6)	0(6)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_c30_tfi.sas 10MAR2023 10:09

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR)

Data as of 12SEP2022

Figure 4.056110
Graph of Kaplan-Meier Curves of EORTC QLQ-C30 Time to first Improvement
(Up to and including Last Follow-Up)
Item Score: Appetite Loss Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	9(3)	8(4)	8(4)	8(4)	6(4)	6(4)	6(4)	5(4)	5(4)	5(4)	4(4)	4(4)	3(4)	3(4)	3(4)	3(4)	3(4)	2(4)	2(4)	2(4)	2(4)	1(4)	0(4)
Belamaf	29(0)	18(3)	11(4)	10(5)	9(5)	8(5)	7(6)	7(6)	6(6)	6(6)	5(6)	5(6)	4(7)	3(7)	2(7)	2(7)	1(7)	1(7)	1(7)	1(7)	1(7)	1(7)	1(7)	0(7)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_c30_tfi.sas 10MAR2023 10:09

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.056110
Graph of Kaplan-Meier Curves of EORTC QLQ-C30 Time to first Improvement
(Up to and including Last Follow-Up)
Item Score: Constipation Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	12(0)	11(1)	11(1)	11(1)	9(1)	6(1)	6(1)	6(1)	6(1)	6(1)	5(1)	5(1)	4(1)	3(1)	3(1)	3(1)	3(1)	2(1)	2(1)	2(1)	2(1)	1(1)	0(1)
Belamaf	29(0)	16(5)	10(7)	9(8)	7(8)	7(8)	7(8)	7(8)	6(8)	5(8)	4(8)	4(8)	3(8)	2(8)	2(8)	2(8)	1(8)	1(8)	1(8)	1(8)	1(8)	1(8)	1(8)	0(8)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_c30_tfi.sas 10MAR2023 10:09

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.056110
Graph of Kaplan-Meier Curves of EORTC QLQ-C30 Time to first Improvement
(Up to and including Last Follow-Up)
Item Score: Diarrhoea Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	9(3)	7(5)	7(5)	7(5)	6(5)	4(5)	4(5)	3(5)	3(5)	3(5)	2(5)	2(5)	2(5)	2(5)	2(5)	2(5)	2(5)	2(5)	2(5)	2(5)	1(5)	0(5)
Belamaf	29(0)	18(4)	14(4)	13(4)	11(4)	10(4)	8(4)	7(5)	6(5)	6(5)	5(5)	5(5)	5(5)	4(6)	3(6)	3(6)	2(6)	2(6)	1(6)	1(6)	1(6)	1(6)	1(6)	0(6)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_c30_tfi.sas 10MAR2023 10:09

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.056110
Graph of Kaplan-Meier Curves of EORTC QLQ-C30 Time to first Improvement
(Up to and including Last Follow-Up)
Item Score: Financial Difficulties Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	10(2)	10(2)	10(2)	10(2)	8(2)	5(2)	5(2)	4(2)	4(2)	4(2)	4(2)	4(2)	3(3)	2(3)	2(3)	2(3)	2(3)	1(3)	1(3)	1(3)	1(3)	0(3)	0(3)
Belamaf	29(0)	16(7)	6(13)	6(13)	5(13)	5(13)	4(13)	4(13)	4(13)	4(13)	3(13)	3(13)	2(13)	2(13)	1(13)	1(13)	1(13)	1(13)	0(13)	0(13)	0(13)	0(13)	0(13)	0(13)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_c30_tfi.sas 10MAR2023 10:09

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.053110
Graph of Kaplan-Meier Curves of EORTC QLQ-C30 Time to first Deterioration 1
(Up to and including Last Follow-Up)
Item Score: Global Health Status Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	9(4)	7(6)	5(8)	5(8)	5(8)	4(8)	4(8)	3(9)	2(10)	1(11)	1(11)	1(11)	1(11)	0(12)	0(12)	0(12)	0(12)	0(12)	0(12)	0(12)	0(12)	0(12)
Belamaf	29(0)	20(8)	13(14)	8(18)	7(19)	7(19)	4(21)	4(21)	3(21)	3(21)	1(23)	1(23)	1(23)	1(23)	1(23)	1(23)	0(23)	0(23)	0(23)	0(23)	0(23)	0(23)	0(23)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_c30_tfd1.sas 10MAR2023 10:08

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.053110
Graph of Kaplan-Meier Curves of EORTC QLQ-C30 Time to first Deterioration 1
(Up to and including Last Follow-Up)
Item Score: Physical Functioning Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	10(3)	8(5)	6(7)	6(7)	5(8)	4(8)	4(8)	4(8)	4(8)	3(9)	3(9)	3(9)	2(9)	1(9)	1(9)	1(9)	1(9)	0(9)	0(9)	0(9)	0(9)	0(9)	0(9)
Belamaf	29(0)	22(6)	15(12)	12(14)	10(16)	8(18)	6(20)	6(20)	6(20)	6(20)	4(21)	4(21)	4(21)	4(21)	4(21)	4(21)	3(21)	3(21)	2(21)	1(22)	1(22)	1(22)	1(22)	0(22)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_c30_tfd1.sas 10MAR2023 10:08

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.053110
Graph of Kaplan-Meier Curves of EORTC QLQ-C30 Time to first Deterioration 1
(Up to and including Last Follow-Up)
Item Score: Role Functioning Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	9(4)	5(8)	5(8)	5(8)	5(8)	4(8)	4(8)	4(8)	4(8)	3(9)	3(9)	3(9)	2(9)	1(9)	1(9)	1(9)	1(9)	0(9)	0(9)	0(9)	0(9)	0(9)	0(9)
Belamaf	29(0)	20(8)	13(14)	8(18)	7(19)	7(19)	5(20)	5(20)	5(20)	4(20)	2(21)	2(21)	2(21)	2(21)	2(21)	2(21)	1(21)	1(21)	1(21)	0(22)	0(22)	0(22)	0(22)	0(22)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_c30_tfd1.sas 10MAR2023 10:08

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.053110
Graph of Kaplan-Meier Curves of EORTC QLQ-C30 Time to first Deterioration 1
(Up to and including Last Follow-Up)
Item Score: Emotional Functioning Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	11(2)	9(4)	7(6)	7(6)	7(6)	4(6)	4(6)	4(6)	4(6)	4(6)	4(6)	4(6)	3(6)	1(7)	1(7)	1(7)	1(7)	0(7)	0(7)	0(7)	0(7)	0(7)	0(7)
Belamaf	29(0)	22(6)	14(13)	12(15)	11(16)	10(17)	6(21)	6(21)	6(21)	4(22)	2(23)	2(23)	2(23)	2(23)	1(24)	1(24)	0(25)	0(25)	0(25)	0(25)	0(25)	0(25)	0(25)	0(25)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_c30_tfd1.sas 10MAR2023 10:08

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.053110
Graph of Kaplan-Meier Curves of EORTC QLQ-C30 Time to first Deterioration 1
(Up to and including Last Follow-Up)
Item Score: Cognitive Functioning Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	10(3)	7(6)	7(6)	7(6)	5(8)	3(8)	3(8)	3(8)	3(8)	3(8)	3(8)	3(8)	2(8)	2(8)	2(8)	2(8)	2(8)	1(8)	1(8)	1(8)	1(8)	0(8)	0(8)
Belamaf	29(0)	21(7)	13(14)	11(15)	11(15)	10(16)	8(17)	7(18)	5(19)	5(19)	3(20)	3(20)	3(20)	3(20)	3(20)	3(20)	2(20)	2(20)	2(20)	1(21)	1(21)	1(21)	1(21)	0(21)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_c30_tfd1.sas 10MAR2023 10:08

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.053110
Graph of Kaplan-Meier Curves of EORTC QLQ-C30 Time to first Deterioration 1
(Up to and including Last Follow-Up)
Item Score: Social Functioning Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	10(3)	7(6)	6(7)	6(7)	6(7)	5(7)	5(7)	5(7)	4(8)	3(9)	3(9)	3(9)	2(9)	1(10)	1(10)	1(10)	1(10)	0(10)	0(10)	0(10)	0(10)	0(10)	0(10)
Belamaf	29(0)	21(7)	13(14)	9(18)	9(18)	9(18)	5(21)	5(21)	5(21)	5(21)	3(22)	3(22)	3(22)	3(22)	3(22)	3(22)	2(22)	2(22)	2(22)	1(23)	1(23)	1(23)	1(23)	0(23)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_c30_tfd1.sas 10MAR2023 10:08

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.053110
Graph of Kaplan-Meier Curves of EORTC QLQ-C30 Time to first Deterioration 1
(Up to and including Last Follow-Up)
Item Score: Fatigue Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	10(3)	7(6)	5(8)	5(8)	5(8)	3(8)	3(8)	3(8)	3(8)	3(8)	3(8)	3(8)	2(8)	1(9)	1(9)	1(9)	1(9)	0(9)	0(9)	0(9)	0(9)	0(9)	0(9)
Belamaf	29(0)	18(10)	12(16)	9(19)	8(20)	7(21)	6(22)	5(23)	5(23)	4(23)	3(24)	3(24)	3(24)	3(24)	3(24)	3(24)	2(24)	2(24)	1(24)	0(25)	0(25)	0(25)	0(25)	0(25)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_c30_tfd1.sas 10MAR2023 10:08

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.053110
Graph of Kaplan-Meier Curves of EORTC QLQ-C30 Time to first Deterioration 1
(Up to and including Last Follow-Up)
Item Score: Nausea and vomiting Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	10(3)	9(4)	9(4)	9(4)	7(5)	5(5)	5(5)	5(5)	5(5)	3(7)	3(7)	3(7)	2(7)	1(8)	1(8)	1(8)	1(8)	0(8)	0(8)	0(8)	0(8)	0(8)	0(8)
Belamaf	29(0)	21(7)	15(11)	15(11)	15(11)	13(13)	10(16)	9(17)	9(17)	8(17)	6(18)	6(18)	5(18)	4(18)	4(18)	4(18)	3(18)	3(18)	2(18)	1(19)	1(19)	1(19)	1(19)	0(19)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_c30_tfd1.sas 10MAR2023 10:08

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.053110
Graph of Kaplan-Meier Curves of EORTC QLQ-C30 Time to first Deterioration 1
(Up to and including Last Follow-Up)
Item Score: Pain Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	10(3)	8(5)	8(5)	8(5)	7(5)	5(5)	4(6)	3(7)	3(7)	2(8)	2(8)	2(8)	2(8)	1(8)	1(8)	1(8)	1(8)	0(8)	0(8)	0(8)	0(8)	0(8)	0(8)
Belamaf	29(0)	20(8)	15(13)	11(16)	11(16)	10(17)	6(20)	6(20)	6(20)	6(20)	4(21)	4(21)	4(21)	3(21)	3(21)	3(21)	2(21)	2(21)	1(21)	1(21)	1(21)	1(21)	1(21)	0(21)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_c30_tfd1.sas 10MAR2023 10:08

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.053110
Graph of Kaplan-Meier Curves of EORTC QLQ-C30 Time to first Deterioration 1
(Up to and including Last Follow-Up)
Item Score: Dyspnoea Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	10(3)	8(5)	7(6)	7(6)	6(7)	3(7)	3(7)	3(7)	3(7)	2(8)	2(8)	2(8)	1(8)	1(8)	1(8)	1(8)	1(8)	0(8)	0(8)	0(8)	0(8)	0(8)	0(8)
Belamaf	29(0)	22(6)	16(10)	13(12)	12(13)	11(14)	7(18)	7(18)	7(18)	7(18)	4(20)	4(20)	3(20)	2(20)	2(20)	2(20)	2(20)	2(20)	2(20)	1(21)	1(21)	1(21)	1(21)	0(21)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_c30_tfd1.sas 10MAR2023 10:08

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.053110
Graph of Kaplan-Meier Curves of EORTC QLQ-C30 Time to first Deterioration 1
(Up to and including Last Follow-Up)
Item Score: Insomnia Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	11(2)	9(4)	8(5)	8(5)	6(6)	3(6)	3(6)	3(6)	3(6)	3(6)	3(6)	3(6)	2(6)	1(7)	1(7)	1(7)	1(7)	0(7)	0(7)	0(7)	0(7)	0(7)	0(7)
Belamaf	29(0)	21(7)	13(14)	11(16)	10(17)	10(17)	7(20)	6(21)	6(21)	6(21)	4(22)	4(22)	3(22)	2(22)	2(22)	2(22)	2(22)	2(22)	2(22)	1(23)	1(23)	1(23)	1(23)	0(24)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_c30_tfd1.sas 10MAR2023 10:08

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.053110
Graph of Kaplan-Meier Curves of EORTC QLQ-C30 Time to first Deterioration 1
(Up to and including Last Follow-Up)
Item Score: Appetite Loss Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	11(2)	10(3)	10(3)	10(3)	8(4)	6(4)	6(4)	6(4)	6(4)	4(6)	4(6)	4(6)	3(6)	1(7)	1(7)	1(7)	1(7)	0(7)	0(7)	0(7)	0(7)	0(7)	0(7)
Belamaf	29(0)	20(8)	14(13)	12(14)	12(14)	11(15)	8(18)	7(19)	6(20)	5(20)	3(21)	3(21)	3(21)	3(21)	3(21)	3(21)	3(21)	3(21)	2(21)	1(22)	1(22)	1(22)	1(22)	0(22)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_c30_tfd1.sas 10MAR2023 10:08

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.053110
Graph of Kaplan-Meier Curves of EORTC QLQ-C30 Time to first Deterioration 1
(Up to and including Last Follow-Up)
Item Score: Constipation Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	10(3)	6(7)	4(9)	4(9)	3(10)	1(10)	1(10)	1(10)	1(10)	1(10)	1(10)	1(10)	1(10)	0(10)	0(10)	0(10)	0(10)	0(10)	0(10)	0(10)	0(10)	0(10)
Belamaf	29(0)	22(6)	17(9)	15(10)	15(10)	12(13)	9(15)	8(16)	8(16)	8(16)	6(17)	6(17)	5(17)	4(17)	4(17)	4(17)	3(17)	3(17)	2(17)	1(18)	1(18)	1(18)	1(18)	0(18)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_c30_tfd1.sas 10MAR2023 10:08

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.053110
Graph of Kaplan-Meier Curves of EORTC QLQ-C30 Time to first Deterioration 1
(Up to and including Last Follow-Up)
Item Score: Diarrhoea Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	12(1)	11(2)	10(3)	10(3)	9(3)	6(3)	6(3)	6(3)	6(3)	5(4)	5(4)	5(4)	4(4)	2(5)	2(5)	2(5)	2(5)	1(5)	1(5)	1(5)	1(5)	0(5)	0(5)
Belamaf	29(0)	23(5)	15(11)	14(12)	14(12)	13(13)	8(17)	7(18)	7(18)	6(18)	3(20)	3(20)	3(20)	2(20)	2(20)	2(20)	1(20)	1(20)	1(20)	1(20)	1(20)	1(20)	1(20)	0(20)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_c30_tfd1.sas 10MAR2023 10:08

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.053110
Graph of Kaplan-Meier Curves of EORTC QLQ-C30 Time to first Deterioration 1
(Up to and including Last Follow-Up)
Item Score: Financial Difficulties Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	11(2)	8(5)	8(5)	8(5)	7(6)	5(6)	5(6)	4(7)	4(7)	3(8)	3(8)	3(8)	2(8)	1(9)	1(9)	1(9)	1(9)	1(9)	1(9)	1(9)	0(9)	0(9)
Belamaf	29(0)	23(5)	17(10)	14(12)	13(13)	13(13)	10(16)	9(17)	8(17)	7(17)	5(18)	5(18)	5(18)	4(18)	4(18)	4(18)	3(18)	3(18)	2(18)	1(19)	1(19)	1(19)	1(19)	0(19)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_c30_tfd1.sas 10MAR2023 10:08

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.054110
Graph of Kaplan-Meier Curves of EORTC QLQ-C30 Time to first Deterioration 2
(Up to and including Last Follow-Up)
Item Score: Global Health Status Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	8(4)	7(5)	5(7)	5(7)	4(7)	3(7)	3(7)	3(7)	2(8)	1(9)	0(9)	0(9)	0(9)	0(9)	0(9)	0(9)	0(9)	0(9)	0(9)	0(9)	0(9)	0(9)
Belamaf	29(0)	17(7)	10(11)	6(14)	5(15)	4(15)	3(15)	3(15)	2(15)	2(15)	1(16)	1(16)	1(16)	1(16)	1(16)	1(16)	0(16)	0(16)	0(16)	0(16)	0(16)	0(16)	0(16)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_c30_tfd2.sas 10MAR2023 10:09

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.054110
Graph of Kaplan-Meier Curves of EORTC QLQ-C30 Time to first Deterioration 2
(Up to and including Last Follow-Up)
Item Score: Physical Functioning Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	9(3)	8(4)	6(6)	6(6)	5(7)	4(7)	4(7)	4(7)	4(7)	3(8)	3(8)	3(8)	2(8)	1(8)	1(8)	1(8)	1(8)	0(8)	0(8)	0(8)	0(8)	0(8)	0(8)
Belamaf	29(0)	19(5)	12(9)	10(10)	8(12)	5(14)	5(14)	5(14)	5(14)	5(14)	4(14)	4(14)	4(14)	4(14)	3(14)	3(14)	2(14)	2(14)	1(14)	1(14)	1(14)	1(14)	1(14)	0(14)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_c30_tfd2.sas 10MAR2023 10:09

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.054110
Graph of Kaplan-Meier Curves of EORTC QLQ-C30 Time to first Deterioration 2
(Up to and including Last Follow-Up)
Item Score: Role Functioning Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	8(4)	5(7)	5(7)	5(7)	5(7)	4(7)	4(7)	4(7)	4(7)	3(8)	3(8)	3(8)	2(8)	1(8)	1(8)	1(8)	1(8)	0(8)	0(8)	0(8)	0(8)	0(8)	0(8)
Belamaf	29(0)	17(6)	9(10)	6(12)	5(13)	5(13)	4(13)	4(13)	4(13)	3(13)	2(13)	2(13)	2(13)	2(13)	1(13)	1(13)	0(13)	0(13)	0(13)	0(13)	0(13)	0(13)	0(13)	0(13)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_c30_tfd2.sas 10MAR2023 10:09

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.054110
Graph of Kaplan-Meier Curves of EORTC QLQ-C30 Time to first Deterioration 2
(Up to and including Last Follow-Up)
Item Score: Emotional Functioning Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	10(2)	9(3)	7(5)	7(5)	7(5)	4(5)	4(5)	4(5)	4(5)	4(5)	3(5)	3(5)	2(5)	1(5)	1(5)	1(5)	1(5)	0(5)	0(5)	0(5)	0(5)	0(5)	0(5)
Belamaf	29(0)	19(4)	11(9)	10(10)	9(11)	6(12)	5(12)	5(12)	5(12)	3(13)	2(13)	2(13)	2(13)	2(13)	1(14)	1(14)	0(15)	0(15)	0(15)	0(15)	0(15)	0(15)	0(15)	0(15)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_c30_tfd2.sas 10MAR2023 10:09

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.054110
Graph of Kaplan-Meier Curves of EORTC QLQ-C30 Time to first Deterioration 2
(Up to and including Last Follow-Up)
Item Score: Cognitive Functioning Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	9(3)	7(5)	7(5)	7(5)	5(7)	3(7)	3(7)	3(7)	3(7)	3(7)	3(7)	3(7)	2(7)	2(7)	2(7)	2(7)	2(7)	1(7)	1(7)	1(7)	1(7)	0(7)	0(7)
Belamaf	29(0)	18(5)	10(10)	9(10)	8(10)	7(10)	6(10)	6(10)	4(11)	4(11)	3(11)	3(11)	3(11)	3(11)	2(11)	2(11)	1(11)	1(11)	1(11)	1(11)	1(11)	1(11)	1(11)	0(11)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_c30_tfd2.sas 10MAR2023 10:09

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.054110
Graph of Kaplan-Meier Curves of EORTC QLQ-C30 Time to first Deterioration 2
(Up to and including Last Follow-Up)
Item Score: Social Functioning Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	9(3)	7(5)	6(6)	6(6)	6(6)	5(6)	5(6)	4(6)	3(7)	3(7)	2(7)	2(7)	1(7)	1(7)	1(7)	1(7)	1(7)	0(7)	0(7)	0(7)	0(7)	0(7)	0(7)
Belamaf	29(0)	18(6)	9(11)	6(14)	6(14)	5(14)	4(14)	4(14)	4(14)	4(14)	3(14)	3(14)	3(14)	3(14)	2(14)	2(14)	1(14)	1(14)	1(14)	1(14)	1(14)	1(14)	1(14)	0(14)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_c30_tfd2.sas 10MAR2023 10:09

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.054110
Graph of Kaplan-Meier Curves of EORTC QLQ-C30 Time to first Deterioration 2
(Up to and including Last Follow-Up)
Item Score: Fatigue Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	8(3)	6(5)	4(7)	4(7)	4(7)	2(7)	2(7)	2(7)	2(7)	2(7)	2(7)	2(7)	1(7)	1(7)	1(7)	1(7)	1(7)	0(7)	0(7)	0(7)	0(7)	0(7)	0(7)
Belamaf	29(0)	16(8)	10(13)	8(15)	7(16)	5(17)	5(17)	4(18)	4(18)	3(18)	3(18)	3(18)	3(18)	3(18)	2(18)	2(18)	1(18)	1(18)	0(18)	0(18)	0(18)	0(18)	0(18)	0(18)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_c30_tfd2.sas 10MAR2023 10:09

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.054110
Graph of Kaplan-Meier Curves of EORTC QLQ-C30 Time to first Deterioration 2
(Up to and including Last Follow-Up)
Item Score: Nausea and vomiting Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	9(3)	9(3)	9(3)	9(3)	7(4)	5(4)	5(4)	4(4)	4(4)	3(5)	2(5)	2(5)	1(5)	1(5)	1(5)	1(5)	1(5)	0(5)	0(5)	0(5)	0(5)	0(5)	0(5)
Belamaf	29(0)	17(4)	11(6)	11(6)	9(6)	8(7)	8(7)	8(7)	8(7)	7(7)	6(7)	6(7)	5(7)	4(7)	3(7)	3(7)	2(7)	2(7)	1(7)	1(7)	1(7)	1(7)	1(7)	0(7)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_c30_tfd2.sas 10MAR2023 10:09

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.054110
Graph of Kaplan-Meier Curves of EORTC QLQ-C30 Time to first Deterioration 2
(Up to and including Last Follow-Up)
Item Score: Pain Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	9(3)	8(4)	8(4)	8(4)	6(4)	4(4)	3(5)	3(5)	3(5)	2(6)	2(6)	2(6)	2(6)	1(6)	1(6)	1(6)	1(6)	0(6)	0(6)	0(6)	0(6)	0(6)	0(6)
Belamaf	29(0)	17(5)	12(8)	9(10)	9(10)	6(11)	5(11)	5(11)	5(11)	5(11)	4(11)	4(11)	4(11)	3(11)	3(11)	3(11)	2(11)	2(11)	1(11)	1(11)	1(11)	1(11)	1(11)	0(11)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_c30_tfd2.sas 10MAR2023 10:09

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.054110
Graph of Kaplan-Meier Curves of EORTC QLQ-C30 Time to first Deterioration 2
(Up to and including Last Follow-Up)
Item Score: Dyspnoea Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	9(3)	8(4)	7(5)	7(5)	6(6)	3(6)	3(6)	3(6)	3(6)	2(7)	2(7)	2(7)	1(7)	1(7)	1(7)	1(7)	1(7)	0(7)	0(7)	0(7)	0(7)	0(7)	0(7)
Belamaf	29(0)	19(5)	12(7)	10(8)	7(9)	7(9)	6(9)	6(9)	6(9)	6(9)	4(10)	4(10)	3(10)	2(10)	1(10)	1(10)	1(10)	1(10)	1(10)	1(10)	1(10)	1(10)	1(10)	0(10)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_c30_tfd2.sas 10MAR2023 10:09

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.054110
Graph of Kaplan-Meier Curves of EORTC QLQ-C30 Time to first Deterioration 2
(Up to and including Last Follow-Up)
Item Score: Insomnia Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	9(2)	8(3)	7(4)	7(4)	5(5)	2(5)	2(5)	2(5)	2(5)	2(5)	2(5)	2(5)	1(5)	1(5)	1(5)	1(5)	1(5)	0(5)	0(5)	0(5)	0(5)	0(5)	0(5)
Belamaf	29(0)	17(5)	9(10)	8(11)	7(12)	5(12)	5(12)	5(12)	5(12)	5(12)	4(12)	4(12)	3(12)	2(12)	1(12)	1(12)	1(12)	1(12)	1(12)	1(12)	1(12)	1(12)	1(12)	0(13)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_c30_tfd2.sas 10MAR2023 10:09

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.054110
Graph of Kaplan-Meier Curves of EORTC QLQ-C30 Time to first Deterioration 2
(Up to and including Last Follow-Up)
Item Score: Appetite Loss Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	10(2)	10(2)	10(2)	10(2)	8(3)	6(3)	6(3)	5(3)	5(3)	4(4)	3(4)	3(4)	2(4)	1(4)	1(4)	1(4)	1(4)	0(4)	0(4)	0(4)	0(4)	0(4)	0(4)
Belamaf	29(0)	16(5)	12(8)	10(9)	8(9)	7(9)	7(9)	6(10)	5(11)	4(11)	3(11)	3(11)	3(11)	3(11)	2(11)	2(11)	2(11)	2(11)	1(11)	1(11)	1(11)	1(11)	1(11)	0(11)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_c30_tfd2.sas 10MAR2023 10:09

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.054110
Graph of Kaplan-Meier Curves of EORTC QLQ-C30 Time to first Deterioration 2
(Up to and including Last Follow-Up)
Item Score: Constipation Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	9(3)	6(6)	4(8)	4(8)	3(9)	1(9)	1(9)	1(9)	1(9)	1(9)	1(9)	1(9)	1(9)	0(9)	0(9)	0(9)	0(9)	0(9)	0(9)	0(9)	0(9)	0(9)
Belamaf	29(0)	18(3)	13(4)	12(4)	11(4)	8(6)	7(6)	7(6)	7(6)	7(6)	6(6)	6(6)	5(6)	4(6)	3(6)	3(6)	2(6)	2(6)	1(6)	1(6)	1(6)	1(6)	0(6)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_c30_tfd2.sas 10MAR2023 10:09

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.054110
Graph of Kaplan-Meier Curves of EORTC QLQ-C30 Time to first Deterioration 2
(Up to and including Last Follow-Up)
Item Score: Diarrhoea Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	11(1)	11(1)	10(2)	10(2)	9(2)	6(2)	6(2)	5(2)	5(2)	5(2)	4(2)	4(2)	3(2)	2(2)	2(2)	2(2)	2(2)	1(2)	1(2)	1(2)	1(2)	0(2)	0(2)
Belamaf	29(0)	20(2)	12(6)	12(6)	10(6)	9(6)	6(7)	6(7)	6(7)	5(7)	3(8)	3(8)	3(8)	2(8)	2(8)	2(8)	1(8)	1(8)	1(8)	1(8)	1(8)	1(8)	1(8)	0(8)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_c30_tfd2.sas 10MAR2023 10:09

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.054110
Graph of Kaplan-Meier Curves of EORTC QLQ-C30 Time to first Deterioration 2
(Up to and including Last Follow-Up)
Item Score: Financial Difficulties Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	10(2)	8(4)	8(4)	8(4)	7(5)	5(5)	5(5)	3(6)	3(6)	3(6)	2(6)	2(6)	1(6)	1(6)	1(6)	1(6)	1(6)	1(6)	1(6)	1(6)	0(6)	0(6)
Belamaf	29(0)	20(3)	11(6)	10(6)	9(7)	8(7)	8(7)	8(7)	7(7)	6(7)	5(7)	5(7)	5(7)	4(7)	3(7)	3(7)	2(7)	2(7)	1(7)	1(7)	1(7)	1(7)	1(7)	0(7)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_c30_tfd2.sas 10MAR2023 10:09

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.057110
Graph of Kaplan-Meier Curves of EORTC QLQ-C30 Time to permanent Deterioration 1
(Up to and including End of Treatment)
Item Score: Global Health Status Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	12(1)	11(2)	11(2)	11(2)	8(3)	4(4)	4(4)	4(4)	4(4)	4(4)	2(4)	2(4)	2(4)	2(4)	2(4)	2(4)	2(4)	2(4)	2(4)	2(4)	1(5)	0(5)	0(5)
Belamaf	29(0)	25(3)	16(5)	11(7)	10(7)	9(7)	7(8)	7(8)	7(8)	6(8)	4(9)	4(9)	3(9)	3(9)	2(9)	2(9)	1(9)	1(9)	1(9)	1(9)	1(9)	1(9)	1(9)	0(9)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_c30_pd1_eot.sas 14MAR2023 11:00

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.057110
Graph of Kaplan-Meier Curves of EORTC QLQ-C30 Time to permanent Deterioration 1
(Up to and including End of Treatment)
Item Score: Physical Functioning Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	13(0)	12(1)	10(3)	10(3)	10(3)	7(3)	7(3)	5(3)	5(3)	5(3)	3(3)	3(3)	2(3)	2(3)	2(3)	2(3)	2(3)	2(3)	2(3)	2(3)	1(3)	0(3)
Belamaf	29(0)	25(3)	16(5)	12(6)	11(6)	10(6)	7(8)	7(8)	7(8)	6(8)	4(9)	4(9)	3(9)	3(9)	2(9)	2(9)	1(9)	1(9)	1(9)	1(9)	1(9)	1(9)	0(9)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_c30_pd1_eot.sas 14MAR2023 11:00

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.057110
Graph of Kaplan-Meier Curves of EORTC QLQ-C30 Time to permanent Deterioration 1
(Up to and including End of Treatment)
Item Score: Role Functioning Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	13(0)	11(2)	10(3)	10(3)	10(3)	7(3)	7(3)	5(3)	5(3)	5(3)	3(3)	3(3)	2(3)	2(3)	2(3)	2(3)	2(3)	2(3)	2(3)	1(4)	0(4)	0(4)
Belamaf	29(0)	25(3)	15(6)	12(7)	10(8)	9(8)	6(10)	6(10)	6(10)	5(10)	3(11)	3(11)	3(11)	3(11)	2(11)	2(11)	1(11)	1(11)	1(11)	1(11)	1(11)	1(11)	0(11)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_c30_pd1_eot.sas 14MAR2023 11:00

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.057110
Graph of Kaplan-Meier Curves of EORTC QLQ-C30 Time to permanent Deterioration 1
(Up to and including End of Treatment)
Item Score: Emotional Functioning Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	13(0)	12(1)	12(1)	12(1)	10(1)	7(1)	7(1)	5(1)	5(1)	5(1)	3(1)	3(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	1(2)	0(2)	0(2)
Belamaf	29(0)	25(3)	15(6)	12(7)	11(7)	10(7)	7(9)	7(9)	7(9)	6(9)	4(10)	4(10)	3(10)	3(10)	2(10)	2(10)	1(10)	1(10)	1(10)	1(10)	1(10)	1(10)	0(10)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_c30_pd1_eot.sas 14MAR2023 11:00

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.057110
Graph of Kaplan-Meier Curves of EORTC QLQ-C30 Time to permanent Deterioration 1
(Up to and including End of Treatment)
Item Score: Cognitive Functioning Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	13(0)	12(1)	11(2)	11(2)	9(3)	6(3)	6(3)	5(3)	5(3)	5(3)	3(3)	3(3)	2(3)	2(3)	2(3)	2(3)	2(3)	2(3)	2(3)	2(3)	1(3)	0(3)
Belamaf	29(0)	24(4)	15(6)	11(7)	9(8)	9(8)	7(9)	7(9)	7(9)	6(9)	4(10)	4(10)	3(10)	3(10)	2(10)	2(10)	1(10)	1(10)	1(10)	1(10)	1(10)	1(10)	0(10)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_c30_pd1_eot.sas 14MAR2023 11:00

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.057110
Graph of Kaplan-Meier Curves of EORTC QLQ-C30 Time to permanent Deterioration 1
(Up to and including End of Treatment)
Item Score: Social Functioning Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	13(0)	12(1)	11(2)	11(2)	10(2)	7(2)	7(2)	5(2)	5(2)	5(2)	3(2)	3(2)	2(2)	2(2)	2(2)	2(2)	2(2)	2(2)	2(2)	2(2)	1(2)	0(2)
Belamaf	29(0)	24(4)	15(6)	12(7)	11(7)	10(7)	7(9)	7(9)	7(9)	6(9)	4(10)	4(10)	3(10)	3(10)	2(10)	2(10)	1(10)	1(10)	1(10)	1(10)	1(10)	1(10)	0(10)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_c30_pd1_eot.sas 14MAR2023 11:00

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.057110
Graph of Kaplan-Meier Curves of EORTC QLQ-C30 Time to permanent Deterioration 1
(Up to and including End of Treatment)
Item Score: Fatigue Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	10(2)	9(3)	8(4)	8(4)	8(4)	6(4)	6(4)	4(4)	4(4)	4(4)	3(4)	3(4)	2(4)	2(4)	2(4)	2(4)	2(4)	2(4)	2(4)	1(5)	0(5)	0(5)
Belamaf	29(0)	25(3)	16(5)	12(6)	11(6)	10(6)	7(8)	7(8)	7(8)	6(8)	4(9)	4(9)	3(9)	3(9)	2(9)	2(9)	1(9)	1(9)	1(9)	1(9)	1(9)	1(9)	0(9)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_c30_pd1_eot.sas 14MAR2023 11:00

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.057110
Graph of Kaplan-Meier Curves of EORTC QLQ-C30 Time to permanent Deterioration 1
(Up to and including End of Treatment)
Item Score: Nausea and Vomiting Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	13(0)	12(1)	12(1)	12(1)	10(1)	7(1)	7(1)	5(1)	5(1)	5(1)	3(1)	3(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	1(2)	0(2)	0(2)
Belamaf	29(0)	25(3)	16(5)	12(6)	11(6)	10(6)	7(8)	7(8)	7(8)	6(8)	4(9)	4(9)	3(9)	3(9)	2(9)	2(9)	1(9)	1(9)	1(9)	1(9)	1(9)	1(9)	0(9)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_c30_pd1_eot.sas 14MAR2023 11:00

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.057110
Graph of Kaplan-Meier Curves of EORTC QLQ-C30 Time to permanent Deterioration 1
(Up to and including End of Treatment)
Item Score: Pain Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	13(0)	12(1)	12(1)	12(1)	10(1)	7(1)	7(1)	5(1)	5(1)	5(1)	3(1)	3(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	1(1)	0(1)
Belamaf	29(0)	24(4)	15(6)	11(7)	10(7)	9(7)	6(9)	6(9)	6(9)	5(9)	3(10)	3(10)	3(10)	3(10)	2(10)	2(10)	1(10)	1(10)	1(10)	1(10)	1(10)	1(10)	0(10)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_c30_pd1_eot.sas 14MAR2023 11:00

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.057110
Graph of Kaplan-Meier Curves of EORTC QLQ-C30 Time to permanent Deterioration 1
(Up to and including End of Treatment)
Item Score: Dyspnoea Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	13(0)	12(1)	11(2)	11(2)	10(2)	7(2)	7(2)	5(2)	5(2)	5(2)	3(2)	3(2)	2(2)	2(2)	2(2)	2(2)	2(2)	2(2)	2(2)	2(2)	1(3)	0(3)	0(3)
Belamaf	29(0)	24(4)	15(6)	11(7)	10(7)	10(7)	7(9)	6(10)	6(10)	5(10)	3(11)	3(11)	2(11)	2(11)	1(11)	1(11)	1(11)	1(11)	1(11)	1(11)	1(11)	1(11)	1(11)	0(11)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_c30_pd1_eot.sas 14MAR2023 11:00

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.057110
Graph of Kaplan-Meier Curves of EORTC QLQ-C30 Time to permanent Deterioration 1
(Up to and including End of Treatment)
Item Score: Insomnia Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	12(0)	11(1)	11(1)	11(1)	9(1)	6(1)	6(1)	4(1)	4(1)	4(1)	3(1)	3(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	1(1)	0(1)
Belamaf	29(0)	25(3)	16(5)	12(6)	11(6)	10(6)	7(8)	7(8)	7(8)	6(8)	4(9)	4(9)	3(9)	3(9)	2(9)	2(9)	1(9)	1(9)	1(9)	1(9)	1(9)	1(9)	0(9)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_c30_pd1_eot.sas 14MAR2023 11:00

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.057110
Graph of Kaplan-Meier Curves of EORTC QLQ-C30 Time to permanent Deterioration 1
(Up to and including End of Treatment)
Item Score: Appetite Loss Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	13(0)	12(1)	12(1)	12(1)	10(1)	7(1)	7(1)	5(1)	5(1)	5(1)	3(1)	3(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	1(1)	0(1)
Belamaf	29(0)	25(3)	16(5)	12(6)	11(6)	10(6)	7(8)	7(8)	7(8)	6(8)	4(9)	4(9)	3(9)	3(9)	2(9)	2(9)	1(9)	1(9)	1(9)	1(9)	1(9)	1(9)	0(9)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_c30_pd1_eot.sas 14MAR2023 11:00

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.057110
Graph of Kaplan-Meier Curves of EORTC QLQ-C30 Time to permanent Deterioration 1
(Up to and including End of Treatment)
Item Score: Constipation Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	13(0)	12(1)	11(2)	11(2)	10(2)	7(2)	7(2)	5(2)	5(2)	5(2)	3(2)	3(2)	2(2)	2(2)	2(2)	2(2)	2(2)	2(2)	2(2)	1(3)	1(3)	0(3)
Belamaf	29(0)	25(3)	16(5)	12(6)	11(6)	10(6)	7(8)	7(8)	7(8)	6(8)	4(9)	4(9)	3(9)	3(9)	2(9)	2(9)	1(9)	1(9)	1(9)	1(9)	1(9)	1(9)	0(9)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_c30_pd1_eot.sas 14MAR2023 11:00

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.057110
Graph of Kaplan-Meier Curves of EORTC QLQ-C30 Time to permanent Deterioration 1
(Up to and including End of Treatment)
Item Score: Diarrhoea Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	13(0)	12(1)	12(1)	12(1)	10(1)	7(1)	7(1)	5(1)	5(1)	5(1)	3(1)	3(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	1(1)	0(1)
Belamaf	29(0)	25(3)	16(5)	12(6)	11(6)	10(6)	7(8)	7(8)	7(8)	6(8)	4(9)	4(9)	3(9)	3(9)	2(9)	2(9)	1(9)	1(9)	1(9)	1(9)	1(9)	1(9)	0(9)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_c30_pd1_eot.sas 14MAR2023 11:00

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.057110
Graph of Kaplan-Meier Curves of EORTC QLQ-C30 Time to permanent Deterioration 1
(Up to and including End of Treatment)
Item Score: Financial Difficulties Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	13(0)	12(1)	12(1)	12(1)	10(1)	7(1)	7(1)	5(1)	5(1)	5(1)	3(1)	3(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	1(1)	0(1)
Belamaf	29(0)	25(3)	16(5)	11(7)	10(7)	9(7)	6(9)	6(9)	6(9)	5(9)	3(10)	3(10)	3(10)	3(10)	2(10)	2(10)	1(10)	1(10)	1(10)	1(10)	1(10)	1(10)	0(10)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_c30_pd1_eot.sas 14MAR2023 11:00

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.058110
Graph of Kaplan-Meier Curves of EORTC QLQ-C30 Time to permanent Deterioration 2
(Up to and including End of Treatment)
Item Score: Global Health Status Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	11(1)	11(1)	11(1)	11(1)	8(2)	4(3)	4(3)	4(3)	4(3)	4(3)	2(3)	2(3)	2(3)	2(3)	2(3)	2(3)	2(3)	2(3)	2(3)	1(4)	0(4)	0(4)
Belamaf	29(0)	22(0)	13(0)	9(1)	8(1)	7(1)	6(1)	6(1)	6(1)	5(1)	4(1)	4(1)	3(1)	3(1)	2(1)	2(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	0(1)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_c30_pd2_eot.sas 14MAR2023 11:15

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.058110
Graph of Kaplan-Meier Curves of EORTC QLQ-C30 Time to permanent Deterioration 2
(Up to and including End of Treatment)
Item Score: Physical Functioning Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	12(0)	12(0)	10(2)	10(2)	10(2)	7(2)	7(2)	5(2)	5(2)	5(2)	3(2)	3(2)	2(2)	2(2)	2(2)	2(2)	2(2)	2(2)	2(2)	2(2)	1(2)	0(2)
Belamaf	29(0)	22(0)	13(0)	10(0)	9(0)	8(0)	6(0)	6(0)	6(0)	5(0)	4(0)	4(0)	3(0)	3(0)	2(0)	2(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	0(0)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_c30_pd2_eot.sas 14MAR2023 11:15

Protocol: 207495

Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.058110
Graph of Kaplan-Meier Curves of EORTC QLQ-C30 Time to permanent Deterioration 2
(Up to and including End of Treatment)
Item Score: Role Functioning Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	12(0)	11(1)	10(2)	10(2)	10(2)	7(2)	7(2)	5(2)	5(2)	5(2)	3(2)	3(2)	2(2)	2(2)	2(2)	2(2)	2(2)	2(2)	2(2)	1(3)	0(3)	0(3)
Belamaf	29(0)	22(0)	12(1)	10(1)	8(2)	7(2)	5(3)	5(3)	5(3)	4(3)	3(3)	3(3)	3(3)	3(3)	2(3)	2(3)	1(3)	1(3)	1(3)	1(3)	1(3)	1(3)	0(3)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_c30_pd2_eot.sas 14MAR2023 11:15

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.058110
Graph of Kaplan-Meier Curves of EORTC QLQ-C30 Time to permanent Deterioration 2
(Up to and including End of Treatment)
Item Score: Emotional Functioning Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	12(0)	12(0)	12(0)	12(0)	10(0)	7(0)	7(0)	5(0)	5(0)	5(0)	3(0)	3(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	1(1)	0(1)	0(1)
Belamaf	29(0)	22(0)	12(1)	10(1)	9(1)	8(1)	6(1)	6(1)	6(1)	5(1)	4(1)	4(1)	3(1)	3(1)	2(1)	2(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	0(1)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_c30_pd2_eot.sas 14MAR2023 11:15

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.058110
Graph of Kaplan-Meier Curves of EORTC QLQ-C30 Time to permanent Deterioration 2
(Up to and including End of Treatment)
Item Score: Cognitive Functioning Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	12(0)	12(0)	11(1)	11(1)	9(2)	6(2)	6(2)	5(2)	5(2)	5(2)	3(2)	3(2)	2(2)	2(2)	2(2)	2(2)	2(2)	2(2)	2(2)	2(2)	1(2)	0(2)
Belamaf	29(0)	21(1)	12(1)	9(1)	7(2)	7(2)	6(2)	6(2)	6(2)	5(2)	4(2)	4(2)	3(2)	3(2)	2(2)	2(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	0(2)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_c30_pd2_eot.sas 14MAR2023 11:15

Protocol: 207495

Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.058110
Graph of Kaplan-Meier Curves of EORTC QLQ-C30 Time to permanent Deterioration 2
(Up to and including End of Treatment)
Item Score: Social Functioning Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	12(0)	12(0)	11(1)	11(1)	10(1)	7(1)	7(1)	5(1)	5(1)	5(1)	3(1)	3(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	1(1)	0(1)
Belamaf	29(0)	21(1)	12(1)	10(1)	9(1)	8(1)	6(1)	6(1)	6(1)	5(1)	4(1)	4(1)	3(1)	3(1)	2(1)	2(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	0(1)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_c30_pd2_eot.sas 14MAR2023 11:15

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.058110
Graph of Kaplan-Meier Curves of EORTC QLQ-C30 Time to permanent Deterioration 2
(Up to and including End of Treatment)
Item Score: Fatigue Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	9(2)	9(2)	8(3)	8(3)	8(3)	6(3)	6(3)	4(3)	4(3)	4(3)	3(3)	3(3)	2(3)	2(3)	2(3)	2(3)	2(3)	2(3)	2(3)	1(4)	0(4)	0(4)
Belamaf	29(0)	22(0)	13(0)	10(0)	9(0)	8(0)	6(0)	6(0)	6(0)	5(0)	4(0)	4(0)	3(0)	3(0)	2(0)	2(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	0(0)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_c30_pd2_eot.sas 14MAR2023 11:15

Protocol: 207495

Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.058110
Graph of Kaplan-Meier Curves of EORTC QLQ-C30 Time to permanent Deterioration 2
(Up to and including End of Treatment)
Item Score: Nausea and Vomiting Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	12(0)	12(0)	12(0)	12(0)	10(0)	7(0)	7(0)	5(0)	5(0)	5(0)	3(0)	3(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	1(1)	0(1)	0(1)
Belamaf	29(0)	21(0)	12(0)	9(0)	8(0)	7(0)	6(0)	6(0)	6(0)	5(0)	4(0)	4(0)	3(0)	3(0)	2(0)	2(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	0(0)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_c30_pd2_eot.sas 14MAR2023 11:15

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.058110
Graph of Kaplan-Meier Curves of EORTC QLQ-C30 Time to permanent Deterioration 2
(Up to and including End of Treatment)
Item Score: Pain Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	12(0)	12(0)	12(0)	12(0)	10(0)	7(0)	7(0)	5(0)	5(0)	5(0)	3(0)	3(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	1(0)	0(0)
Belamaf	29(0)	21(1)	12(1)	9(1)	8(1)	7(1)	5(1)	5(1)	5(1)	4(1)	3(1)	3(1)	3(1)	3(1)	2(1)	2(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	0(1)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_c30_pd2_eot.sas 14MAR2023 11:15

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.058110
Graph of Kaplan-Meier Curves of EORTC QLQ-C30 Time to permanent Deterioration 2
(Up to and including End of Treatment)
Item Score: Dyspnoea Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	12(0)	12(0)	11(1)	11(1)	10(1)	7(1)	7(1)	5(1)	5(1)	5(1)	3(1)	3(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	1(2)	0(2)	0(2)
Belamaf	29(0)	21(1)	12(1)	9(1)	8(1)	8(1)	6(1)	5(2)	5(2)	4(2)	3(2)	3(2)	2(2)	2(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	0(2)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_c30_pd2_eot.sas 14MAR2023 11:15

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.058110
Graph of Kaplan-Meier Curves of EORTC QLQ-C30 Time to permanent Deterioration 2
(Up to and including End of Treatment)
Item Score: Insomnia Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	11(0)	11(0)	11(0)	11(0)	9(0)	6(0)	6(0)	4(0)	4(0)	4(0)	3(0)	3(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	1(0)	0(0)
Belamaf	29(0)	21(0)	12(0)	9(0)	8(0)	7(0)	6(0)	6(0)	6(0)	5(0)	4(0)	4(0)	3(0)	3(0)	2(0)	2(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	0(0)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_c30_pd2_eot.sas 14MAR2023 11:15

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.058110
Graph of Kaplan-Meier Curves of EORTC QLQ-C30 Time to permanent Deterioration 2
(Up to and including End of Treatment)
Item Score: Appetite Loss Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	12(0)	12(0)	12(0)	12(0)	10(0)	7(0)	7(0)	5(0)	5(0)	5(0)	3(0)	3(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	1(0)	0(0)
Belamaf	29(0)	21(0)	12(0)	9(0)	8(0)	7(0)	6(0)	6(0)	6(0)	5(0)	4(0)	4(0)	3(0)	3(0)	2(0)	2(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	0(0)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_c30_pd2_eot.sas 14MAR2023 11:15

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.058110
Graph of Kaplan-Meier Curves of EORTC QLQ-C30 Time to permanent Deterioration 2
(Up to and including End of Treatment)
Item Score: Constipation Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	12(0)	12(0)	11(1)	11(1)	10(1)	7(1)	7(1)	5(1)	5(1)	5(1)	3(1)	3(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	1(2)	1(2)	0(2)
Belamaf	29(0)	21(0)	12(0)	9(0)	8(0)	7(0)	6(0)	6(0)	6(0)	5(0)	4(0)	4(0)	3(0)	3(0)	2(0)	2(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	0(0)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_c30_pd2_eot.sas 14MAR2023 11:15

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.058110
Graph of Kaplan-Meier Curves of EORTC QLQ-C30 Time to permanent Deterioration 2
(Up to and including End of Treatment)
Item Score: Diarrhoea Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	12(0)	12(0)	12(0)	12(0)	10(0)	7(0)	7(0)	5(0)	5(0)	5(0)	3(0)	3(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	1(0)	0(0)
Belamaf	29(0)	22(0)	13(0)	10(0)	9(0)	8(0)	6(0)	6(0)	6(0)	5(0)	4(0)	4(0)	3(0)	3(0)	2(0)	2(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	0(0)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_c30_pd2_eot.sas 14MAR2023 11:15

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.058110
Graph of Kaplan-Meier Curves of EORTC QLQ-C30 Time to permanent Deterioration 2
(Up to and including End of Treatment)
Item Score: Financial Difficulties Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	12(0)	12(0)	12(0)	12(0)	10(0)	7(0)	7(0)	5(0)	5(0)	5(0)	3(0)	3(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	1(0)	0(0)
Belamaf	29(0)	22(0)	13(0)	9(1)	8(1)	7(1)	5(1)	5(1)	5(1)	4(1)	3(1)	3(1)	3(1)	3(1)	2(1)	2(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	0(1)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_c30_pd2_eot.sas 14MAR2023 11:15

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.059110
Graph of Kaplan-Meier Curves of EORTC QLQ-C30 Time to permanent Deterioration 1
(Up to and including Last Follow-Up)
Item Score: Global Health Status Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	12(1)	11(2)	11(2)	11(2)	9(3)	5(4)	5(4)	4(5)	4(5)	4(5)	4(5)	4(5)	4(5)	3(6)	3(6)	3(6)	3(6)	2(6)	2(6)	2(6)	1(7)	0(7)	0(7)
Belamaf	29(0)	25(3)	20(6)	16(9)	16(9)	15(10)	11(13)	10(14)	9(14)	8(14)	6(15)	6(15)	5(15)	4(15)	4(15)	4(15)	3(15)	3(15)	2(15)	1(16)	1(16)	1(16)	1(16)	0(16)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_c30_pd1_lf.sas 14MAR2023 11:10

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.059110
Graph of Kaplan-Meier Curves of EORTC QLQ-C30 Time to permanent Deterioration 1
(Up to and including Last Follow-Up)
Item Score: Physical Functioning Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	13(0)	12(1)	10(3)	10(3)	10(3)	7(3)	7(3)	7(3)	7(3)	6(4)	6(4)	6(4)	5(4)	3(5)	3(5)	3(5)	3(5)	2(5)	2(5)	2(5)	2(5)	1(5)	0(5)
Belamaf	29(0)	25(3)	21(5)	17(8)	17(8)	16(9)	10(14)	9(15)	9(15)	8(15)	6(16)	6(16)	5(16)	4(16)	4(16)	4(16)	3(16)	3(16)	2(16)	1(17)	1(17)	1(17)	1(17)	0(17)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_c30_pd1_lf.sas 14MAR2023 11:10

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR)

Data as of 12SEP2022

Figure 4.059110
Graph of Kaplan-Meier Curves of EORTC QLQ-C30 Time to permanent Deterioration 1
(Up to and including Last Follow-Up)
Item Score: Role Functioning Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	13(0)	11(2)	10(3)	10(3)	10(3)	7(3)	7(3)	7(3)	7(3)	6(4)	6(4)	6(4)	5(4)	3(5)	3(5)	3(5)	3(5)	2(5)	2(5)	2(5)	1(6)	0(6)	0(6)
Belamaf	29(0)	24(4)	20(6)	17(8)	16(9)	15(10)	10(14)	9(15)	8(15)	7(15)	5(16)	5(16)	5(16)	4(16)	4(16)	4(16)	3(16)	3(16)	2(16)	1(17)	1(17)	1(17)	1(17)	0(17)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_c30_pd1_lf.sas 14MAR2023 11:10

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.059110
Graph of Kaplan-Meier Curves of EORTC QLQ-C30 Time to permanent Deterioration 1
(Up to and including Last Follow-Up)
Item Score: Emotional Functioning Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	13(0)	12(1)	12(1)	12(1)	11(1)	8(1)	8(1)	7(2)	7(2)	6(3)	6(3)	6(3)	5(3)	3(4)	3(4)	3(4)	3(4)	2(4)	2(4)	2(4)	1(5)	0(5)	0(5)
Belamaf	29(0)	25(3)	21(5)	18(7)	18(7)	17(8)	11(13)	10(14)	9(14)	8(14)	6(15)	6(15)	5(15)	4(15)	4(15)	4(15)	3(15)	3(15)	2(15)	1(16)	1(16)	1(16)	1(16)	0(16)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_c30_pd1_lf.sas 14MAR2023 11:10

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.059110
Graph of Kaplan-Meier Curves of EORTC QLQ-C30 Time to permanent Deterioration 1
(Up to and including Last Follow-Up)
Item Score: Cognitive Functioning Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	13(0)	12(1)	11(2)	11(2)	10(3)	7(3)	7(3)	6(4)	6(4)	5(5)	5(5)	5(5)	4(5)	3(6)	3(6)	3(6)	3(6)	2(6)	2(6)	2(6)	2(6)	1(6)	0(6)
Belamaf	29(0)	24(4)	20(6)	17(8)	16(9)	15(10)	11(13)	10(14)	9(14)	8(14)	6(15)	6(15)	5(15)	4(15)	4(15)	4(15)	3(15)	3(15)	2(15)	1(16)	1(16)	1(16)	1(16)	0(16)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_c30_pd1_lf.sas 14MAR2023 11:10

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.059110
Graph of Kaplan-Meier Curves of EORTC QLQ-C30 Time to permanent Deterioration 1
(Up to and including Last Follow-Up)
Item Score: Social Functioning Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	13(0)	12(1)	11(2)	11(2)	11(2)	8(2)	8(2)	7(3)	7(3)	6(4)	6(4)	6(4)	5(4)	3(5)	3(5)	3(5)	3(5)	2(5)	2(5)	2(5)	2(5)	1(5)	0(5)
Belamaf	29(0)	25(3)	21(5)	18(7)	18(7)	17(8)	11(13)	10(14)	9(14)	8(14)	6(15)	6(15)	5(15)	4(15)	4(15)	4(15)	3(15)	3(15)	2(15)	1(16)	1(16)	1(16)	1(16)	0(16)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_c30_pd1_lf.sas 14MAR2023 11:10

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.059110
Graph of Kaplan-Meier Curves of EORTC QLQ-C30 Time to permanent Deterioration 1
(Up to and including Last Follow-Up)
Item Score: Fatigue Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	11(2)	10(3)	9(4)	9(4)	9(4)	7(4)	7(4)	7(4)	7(4)	6(5)	6(5)	6(5)	5(5)	3(6)	3(6)	3(6)	3(6)	2(6)	2(6)	2(6)	1(7)	0(7)	0(7)
Belamaf	29(0)	24(4)	20(6)	17(8)	17(8)	16(9)	11(13)	10(14)	9(14)	8(14)	6(15)	6(15)	5(15)	4(15)	4(15)	4(15)	3(15)	3(15)	2(15)	1(16)	1(16)	1(16)	1(16)	0(16)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_c30_pd1_lf.sas 14MAR2023 11:10

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.059110
Graph of Kaplan-Meier Curves of EORTC QLQ-C30 Time to permanent Deterioration 1
(Up to and including Last Follow-Up)
Item Score: Nausea and Vomiting Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	13(0)	12(1)	12(1)	12(1)	11(1)	8(1)	8(1)	7(2)	7(2)	6(3)	6(3)	6(3)	5(3)	3(4)	3(4)	3(4)	3(4)	2(4)	2(4)	2(4)	1(5)	0(5)	0(5)
Belamaf	29(0)	25(3)	21(5)	18(7)	18(7)	17(8)	11(13)	10(14)	9(14)	8(14)	6(15)	6(15)	5(15)	4(15)	4(15)	4(15)	3(15)	3(15)	2(15)	1(16)	1(16)	1(16)	1(16)	0(16)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_c30_pd1_lf.sas 14MAR2023 11:10

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.059110
Graph of Kaplan-Meier Curves of EORTC QLQ-C30 Time to permanent Deterioration 1
(Up to and including Last Follow-Up)
Item Score: Pain Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	13(0)	12(1)	12(1)	12(1)	11(1)	8(1)	8(1)	7(2)	7(2)	6(3)	6(3)	6(3)	5(3)	3(4)	3(4)	3(4)	3(4)	2(4)	2(4)	2(4)	2(4)	1(4)	0(4)
Belamaf	29(0)	23(5)	19(7)	16(9)	16(9)	15(10)	10(14)	9(15)	8(15)	7(15)	5(16)	5(16)	5(16)	4(16)	4(16)	4(16)	3(16)	3(16)	2(16)	1(17)	1(17)	1(17)	1(17)	0(17)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_c30_pd1_lf.sas 14MAR2023 11:10

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.059110
Graph of Kaplan-Meier Curves of EORTC QLQ-C30 Time to permanent Deterioration 1
(Up to and including Last Follow-Up)
Item Score: Dyspnoea Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	13(0)	12(1)	11(2)	11(2)	11(2)	8(2)	8(2)	6(4)	6(4)	5(5)	5(5)	5(5)	4(5)	3(6)	3(6)	3(6)	3(6)	2(6)	2(6)	2(6)	1(7)	0(7)	0(7)
Belamaf	29(0)	24(4)	20(6)	16(9)	16(9)	15(10)	10(14)	8(16)	8(16)	7(16)	5(17)	5(17)	4(17)	3(17)	3(17)	3(17)	3(17)	3(17)	2(17)	1(18)	1(18)	1(18)	1(18)	0(18)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_c30_pd1_lf.sas 14MAR2023 11:10

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.059110
Graph of Kaplan-Meier Curves of EORTC QLQ-C30 Time to permanent Deterioration 1
(Up to and including Last Follow-Up)
Item Score: Insomnia Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	13(0)	12(1)	12(1)	12(1)	11(1)	8(1)	8(1)	7(2)	7(2)	6(3)	6(3)	6(3)	5(3)	3(4)	3(4)	3(4)	3(4)	2(4)	2(4)	2(4)	2(4)	1(4)	0(4)
Belamaf	29(0)	25(3)	21(5)	18(7)	18(7)	17(8)	11(13)	10(14)	9(14)	8(14)	6(15)	6(15)	5(15)	4(15)	4(15)	4(15)	3(15)	3(15)	2(15)	1(16)	1(16)	1(16)	1(16)	0(16)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_c30_pd1_lf.sas 14MAR2023 11:10

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.059110
Graph of Kaplan-Meier Curves of EORTC QLQ-C30 Time to permanent Deterioration 1
(Up to and including Last Follow-Up)
Item Score: Appetite Loss Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	13(0)	12(1)	12(1)	12(1)	11(1)	8(1)	8(1)	7(2)	7(2)	6(3)	6(3)	6(3)	5(3)	3(4)	3(4)	3(4)	3(4)	2(4)	2(4)	2(4)	2(4)	1(4)	0(4)
Belamaf	29(0)	25(3)	21(5)	18(7)	18(7)	17(8)	11(13)	10(14)	9(14)	8(14)	6(15)	6(15)	5(15)	4(15)	4(15)	4(15)	3(15)	3(15)	2(15)	1(16)	1(16)	1(16)	1(16)	0(16)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_c30_pd1_lf.sas 14MAR2023 11:10

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.059110
Graph of Kaplan-Meier Curves of EORTC QLQ-C30 Time to permanent Deterioration 1
(Up to and including Last Follow-Up)
Item Score: Constipation Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	13(0)	12(1)	11(2)	11(2)	11(2)	8(2)	8(2)	7(3)	7(3)	6(4)	6(4)	5(5)	4(5)	2(6)	2(6)	2(6)	2(6)	2(6)	2(6)	2(6)	1(7)	1(7)	0(7)
Belamaf	29(0)	24(4)	20(6)	17(8)	17(8)	16(9)	11(13)	10(14)	9(14)	8(14)	6(15)	6(15)	5(15)	4(15)	4(15)	4(15)	3(15)	3(15)	2(15)	1(16)	1(16)	1(16)	1(16)	0(16)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_c30_pd1_lf.sas 14MAR2023 11:10

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.059110
Graph of Kaplan-Meier Curves of EORTC QLQ-C30 Time to permanent Deterioration 1
(Up to and including Last Follow-Up)
Item Score: Diarrhoea Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	13(0)	12(1)	12(1)	12(1)	11(1)	8(1)	8(1)	7(2)	7(2)	6(3)	6(3)	6(3)	5(3)	3(4)	3(4)	3(4)	3(4)	2(4)	2(4)	2(4)	2(4)	1(4)	0(4)
Belamaf	29(0)	25(3)	21(5)	18(7)	18(7)	17(8)	11(13)	10(14)	9(14)	8(14)	6(15)	6(15)	5(15)	4(15)	4(15)	4(15)	3(15)	3(15)	2(15)	1(16)	1(16)	1(16)	1(16)	0(16)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_c30_pd1_lf.sas 14MAR2023 11:10

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.059110
Graph of Kaplan-Meier Curves of EORTC QLQ-C30 Time to permanent Deterioration 1
(Up to and including Last Follow-Up)
Item Score: Financial Difficulties Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	13(0)	12(1)	12(1)	12(1)	11(1)	8(1)	8(1)	7(2)	7(2)	6(3)	6(3)	5(4)	4(4)	2(5)	2(5)	2(5)	2(5)	2(5)	2(5)	2(5)	1(5)	0(5)
Belamaf	29(0)	25(3)	21(5)	17(8)	17(8)	16(9)	10(14)	9(15)	8(15)	7(15)	5(16)	5(16)	5(16)	4(16)	4(16)	4(16)	3(16)	3(16)	2(16)	1(17)	1(17)	1(17)	1(17)	0(17)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_c30_pd1_lf.sas 14MAR2023 11:10

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.060110
Graph of Kaplan-Meier Curves of EORTC QLQ-C30 Time to permanent Deterioration 2
(Up to and including Last Follow-Up)
Item Score: Global Health Status Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	11(1)	11(1)	11(1)	11(1)	8(2)	4(3)	4(3)	4(3)	4(3)	4(3)	3(3)	3(3)	3(3)	3(3)	3(3)	3(3)	3(3)	2(3)	2(3)	2(3)	1(4)	0(4)	0(4)
Belamaf	29(0)	22(0)	15(1)	13(2)	11(2)	10(2)	9(2)	9(2)	8(2)	7(2)	6(2)	6(2)	5(2)	4(2)	3(2)	3(2)	2(2)	2(2)	1(2)	1(2)	1(2)	1(2)	1(2)	0(2)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_c30_pd2_lf.sas 14MAR2023 11:20

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.060110
Graph of Kaplan-Meier Curves of EORTC QLQ-C30 Time to permanent Deterioration 2
(Up to and including Last Follow-Up)
Item Score: Physical Functioning Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	12(0)	12(0)	10(2)	10(2)	10(2)	7(2)	7(2)	6(2)	6(2)	6(2)	5(2)	5(2)	4(2)	3(2)	3(2)	3(2)	3(2)	2(2)	2(2)	2(2)	2(2)	1(2)	0(2)
Belamaf	29(0)	22(0)	16(0)	14(1)	12(1)	10(1)	8(1)	8(1)	8(1)	7(1)	6(1)	6(1)	5(1)	4(1)	3(1)	3(1)	2(1)	2(1)	1(1)	1(1)	1(1)	1(1)	1(1)	0(1)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_c30_pd2_lf.sas 14MAR2023 11:20

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.060110
Graph of Kaplan-Meier Curves of EORTC QLQ-C30 Time to permanent Deterioration 2
(Up to and including Last Follow-Up)
Item Score: Role Functioning Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	12(0)	11(1)	10(2)	10(2)	10(2)	7(2)	7(2)	6(2)	6(2)	6(2)	5(2)	5(2)	4(2)	3(2)	3(2)	3(2)	3(2)	2(2)	2(2)	2(2)	1(3)	0(3)	0(3)
Belamaf	29(0)	21(1)	14(1)	13(1)	11(2)	10(2)	8(3)	8(3)	7(3)	6(3)	5(3)	5(3)	5(3)	4(3)	3(3)	3(3)	2(3)	2(3)	1(3)	1(3)	1(3)	1(3)	1(3)	0(3)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_c30_pd2_lf.sas 14MAR2023 11:20

Protocol: 207495

Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.060110
Graph of Kaplan-Meier Curves of EORTC QLQ-C30 Time to permanent Deterioration 2
(Up to and including Last Follow-Up)
Item Score: Emotional Functioning Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	12(0)	12(0)	12(0)	12(0)	10(0)	7(0)	7(0)	6(0)	6(0)	6(0)	5(0)	5(0)	4(0)	3(0)	3(0)	3(0)	3(0)	2(0)	2(0)	2(0)	1(1)	0(1)	0(1)
Belamaf	29(0)	22(0)	16(0)	15(0)	13(0)	11(0)	9(0)	9(0)	8(0)	7(0)	6(0)	6(0)	5(0)	4(0)	3(0)	3(0)	2(0)	2(0)	1(0)	1(0)	1(0)	1(0)	1(0)	0(0)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_c30_pd2_lf.sas 14MAR2023 11:20

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.060110
Graph of Kaplan-Meier Curves of EORTC QLQ-C30 Time to permanent Deterioration 2
(Up to and including Last Follow-Up)
Item Score: Cognitive Functioning Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	12(0)	12(0)	11(1)	11(1)	9(2)	6(2)	6(2)	5(2)	5(2)	5(2)	4(2)	4(2)	3(2)	3(2)	3(2)	3(2)	3(2)	2(2)	2(2)	2(2)	2(2)	1(2)	0(2)
Belamaf	29(0)	21(1)	15(1)	14(1)	11(2)	10(2)	9(2)	9(2)	8(2)	7(2)	6(2)	6(2)	5(2)	4(2)	3(2)	3(2)	2(2)	2(2)	1(2)	1(2)	1(2)	1(2)	1(2)	0(2)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_c30_pd2_lf.sas 14MAR2023 11:20

Protocol: 207495

Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.060110
Graph of Kaplan-Meier Curves of EORTC QLQ-C30 Time to permanent Deterioration 2
(Up to and including Last Follow-Up)
Item Score: Social Functioning Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	12(0)	12(0)	11(1)	11(1)	10(1)	7(1)	7(1)	6(1)	6(1)	6(1)	5(1)	5(1)	4(1)	3(1)	3(1)	3(1)	3(1)	2(1)	2(1)	2(1)	2(1)	1(1)	0(1)
Belamaf	29(0)	22(0)	15(0)	14(0)	12(0)	11(0)	9(0)	9(0)	8(0)	7(0)	6(0)	6(0)	5(0)	4(0)	3(0)	3(0)	2(0)	2(0)	1(0)	1(0)	1(0)	1(0)	1(0)	0(0)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_c30_pd2_lf.sas 14MAR2023 11:20

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.060110
Graph of Kaplan-Meier Curves of EORTC QLQ-C30 Time to permanent Deterioration 2
(Up to and including Last Follow-Up)
Item Score: Fatigue Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	9(2)	9(2)	8(3)	8(3)	8(3)	6(3)	6(3)	5(3)	5(3)	5(3)	5(3)	5(3)	4(3)	3(3)	3(3)	3(3)	3(3)	2(3)	2(3)	2(3)	1(4)	0(4)	0(4)
Belamaf	29(0)	21(1)	15(1)	14(1)	13(1)	11(1)	9(1)	9(1)	8(1)	7(1)	6(1)	6(1)	5(1)	4(1)	3(1)	3(1)	2(1)	2(1)	1(1)	1(1)	1(1)	1(1)	1(1)	0(1)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_c30_pd2_lf.sas 14MAR2023 11:20

Protocol: 207495

Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.060110
Graph of Kaplan-Meier Curves of EORTC QLQ-C30 Time to permanent Deterioration 2
(Up to and including Last Follow-Up)
Item Score: Nausea and Vomiting Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	12(0)	12(0)	12(0)	12(0)	10(0)	7(0)	7(0)	6(0)	6(0)	6(0)	5(0)	5(0)	4(0)	3(0)	3(0)	3(0)	3(0)	2(0)	2(0)	2(0)	1(1)	0(1)	0(1)
Belamaf	29(0)	21(0)	15(0)	14(0)	12(0)	10(0)	9(0)	9(0)	8(0)	7(0)	6(0)	6(0)	5(0)	4(0)	3(0)	3(0)	2(0)	2(0)	1(0)	1(0)	1(0)	1(0)	1(0)	0(0)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_c30_pd2_lf.sas 14MAR2023 11:20

Protocol: 207495

Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.060110
Graph of Kaplan-Meier Curves of EORTC QLQ-C30 Time to permanent Deterioration 2
(Up to and including Last Follow-Up)
Item Score: Pain Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	12(0)	12(0)	12(0)	12(0)	10(0)	7(0)	7(0)	6(0)	6(0)	6(0)	5(0)	5(0)	4(0)	3(0)	3(0)	3(0)	3(0)	2(0)	2(0)	2(0)	2(0)	1(0)	0(0)
Belamaf	29(0)	20(2)	14(2)	13(2)	12(2)	10(2)	8(2)	8(2)	7(2)	6(2)	5(2)	5(2)	5(2)	4(2)	3(2)	3(2)	2(2)	2(2)	1(2)	1(2)	1(2)	1(2)	1(2)	0(2)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_c30_pd2_lf.sas 14MAR2023 11:20

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.060110
Graph of Kaplan-Meier Curves of EORTC QLQ-C30 Time to permanent Deterioration 2
(Up to and including Last Follow-Up)
Item Score: Dyspnoea Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	12(0)	12(0)	11(1)	11(1)	10(1)	7(1)	7(1)	5(2)	5(2)	5(2)	4(2)	4(2)	3(2)	3(2)	3(2)	3(2)	3(2)	2(2)	2(2)	2(2)	1(3)	0(3)	0(3)
Belamaf	29(0)	21(1)	14(1)	12(2)	10(2)	10(2)	8(2)	7(3)	7(3)	6(3)	5(3)	5(3)	4(3)	3(3)	2(3)	2(3)	2(3)	2(3)	1(3)	1(3)	1(3)	1(3)	1(3)	0(3)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_c30_pd2_lf.sas 14MAR2023 11:20

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.060110
Graph of Kaplan-Meier Curves of EORTC QLQ-C30 Time to permanent Deterioration 2
(Up to and including Last Follow-Up)
Item Score: Insomnia Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	11(0)	11(0)	11(0)	11(0)	9(0)	6(0)	6(0)	5(0)	5(0)	5(0)	5(0)	5(0)	4(0)	3(0)	3(0)	3(0)	3(0)	2(0)	2(0)	2(0)	2(0)	1(0)	0(0)
Belamaf	29(0)	21(0)	15(0)	14(0)	12(0)	10(0)	9(0)	9(0)	8(0)	7(0)	6(0)	6(0)	5(0)	4(0)	3(0)	3(0)	2(0)	2(0)	1(0)	1(0)	1(0)	1(0)	1(0)	0(0)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_c30_pd2_lf.sas 14MAR2023 11:20

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.060110
Graph of Kaplan-Meier Curves of EORTC QLQ-C30 Time to permanent Deterioration 2
(Up to and including Last Follow-Up)
Item Score: Appetite Loss Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	12(0)	12(0)	12(0)	12(0)	10(0)	7(0)	7(0)	6(0)	6(0)	6(0)	5(0)	5(0)	4(0)	3(0)	3(0)	3(0)	3(0)	2(0)	2(0)	2(0)	2(0)	1(0)	0(0)
Belamaf	29(0)	21(0)	15(0)	14(0)	12(0)	10(0)	9(0)	9(0)	8(0)	7(0)	6(0)	6(0)	5(0)	4(0)	3(0)	3(0)	2(0)	2(0)	1(0)	1(0)	1(0)	1(0)	1(0)	0(0)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_c30_pd2_lf.sas 14MAR2023 11:20

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.060110
Graph of Kaplan-Meier Curves of EORTC QLQ-C30 Time to permanent Deterioration 2
(Up to and including Last Follow-Up)
Item Score: Constipation Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	12(0)	12(0)	11(1)	11(1)	10(1)	7(1)	7(1)	6(1)	6(1)	6(1)	5(1)	4(2)	3(2)	2(2)	2(2)	2(2)	2(2)	2(2)	2(2)	1(3)	1(3)	0(3)
Belamaf	29(0)	20(1)	14(1)	13(1)	12(1)	10(1)	9(1)	9(1)	8(1)	7(1)	6(1)	6(1)	5(1)	4(1)	3(1)	3(1)	2(1)	2(1)	1(1)	1(1)	1(1)	1(1)	1(1)	0(1)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_c30_pd2_lf.sas 14MAR2023 11:20

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.060110
Graph of Kaplan-Meier Curves of EORTC QLQ-C30 Time to permanent Deterioration 2
(Up to and including Last Follow-Up)
Item Score: Diarrhoea Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	12(0)	12(0)	12(0)	12(0)	10(0)	7(0)	7(0)	6(0)	6(0)	6(0)	5(0)	5(0)	4(0)	3(0)	3(0)	3(0)	3(0)	2(0)	2(0)	2(0)	2(0)	1(0)	0(0)
Belamaf	29(0)	22(0)	16(0)	15(0)	13(0)	11(0)	9(0)	9(0)	8(0)	7(0)	6(0)	6(0)	5(0)	4(0)	3(0)	3(0)	2(0)	2(0)	1(0)	1(0)	1(0)	1(0)	1(0)	0(0)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_c30_pd2_lf.sas 14MAR2023 11:20

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.060110
Graph of Kaplan-Meier Curves of EORTC QLQ-C30 Time to permanent Deterioration 2
(Up to and including Last Follow-Up)
Item Score: Financial Difficulties Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	12(0)	12(0)	12(0)	12(0)	10(0)	7(0)	7(0)	6(0)	6(0)	6(0)	5(0)	4(1)	3(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	1(1)	0(1)
Belamaf	29(0)	22(0)	15(0)	13(1)	11(1)	10(1)	8(1)	8(1)	7(1)	6(1)	5(1)	5(1)	5(1)	4(1)	3(1)	3(1)	2(1)	2(1)	1(1)	1(1)	1(1)	1(1)	1(1)	0(1)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_c30_pd2_lf.sas 14MAR2023 11:20

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.041110
Plot of Least Squares Mean (95% CI) of EORTC QLQ-MY20 Domain Scores
Domain: Disease Symptoms Domain Score



	WK 4	WK 7	WK 10	WK 13	WK 16	WK 19	WK 22	WK 25	WK 28	WK 31	WK 34	WK 37	WK 40	WK 43	EOT
Pom/Dex - n	12	11	12	12	11	12	8	9	7	7	6	4	4	6	9
Belamaf - n	22	20	11	10	8	8	8	7	6	7	6	6	6	4	11

Note: EOT = "End of Treatment".
Note: Interval shown represents 95% confidence limits around mean at each planned time.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_f3_m20_dom.sas 14MAR2023 05:55

Protocol: 207495

Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.040110

Plot of Least Squares Mean (95% CI) Change from Baseline of EORTC QLQ-MY20 Domain Scores

Domain: Disease Symptoms Domain Score



Pom/Dex - n	12	11	12	12	11	12	8	9	7	7	6	4	4	6	9
Belamaf - n	22	20	11	10	8	8	8	7	6	7	6	6	6	4	11

Note: EOT = "End of Treatment".
Note: Interval shown represents 95% confidence limits around mean at each planned time.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_f3_m20_dom_cfb.sas 14MAR2023 05:54

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.068110
Graph of Kaplan-Meier Curves of EORTC QLQ-MY20 Domain Scores Time to first Improvement (Up to and including Last Follow-Up)
Item Score: Future Perspective Domain Score



Number at Risk (Number of Events)

Pom/Dex	15(0)	0(2)	0(2)	0(2)	0(2)	0(2)	0(2)	0(2)	0(2)	0(2)	0(2)	0(2)	0(2)	0(2)	0(2)	0(2)	0(2)	0(2)	0(2)	0(2)	0(2)	0(2)	0(2)
Belamaf	29(0)	3(1)	3(1)	2(2)	2(2)	2(2)	2(2)	2(2)	1(2)	0(2)	0(2)	0(2)	0(2)	0(2)	0(2)	0(2)	0(2)	0(2)	0(2)	0(2)	0(2)	0(2)	0(2)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_m20_tfi.sas 14MAR2023 08:08

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.068110
Graph of Kaplan-Meier Curves of EORTC QLQ-MY20 Domain Scores Time to first Improvement (Up to and including Last Follow-Up)
Item Score: Body Image Domain Score



Number at Risk (Number of Events)

Pom/Dex	15(0)	1(1)	1(1)	0(2)	0(2)	0(2)	0(2)	0(2)	0(2)	0(2)	0(2)	0(2)	0(2)	0(2)	0(2)	0(2)	0(2)	0(2)	0(2)	0(2)	0(2)	0(2)	0(2)
Belamaf	29(0)	3(1)	3(1)	3(1)	3(1)	3(1)	3(1)	3(1)	2(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	0(1)	0(1)	0(1)	0(1)	0(1)	0(1)	0(1)	0(1)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_m20_tfi.sas 14MAR2023 08:08

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.068110
Graph of Kaplan-Meier Curves of EORTC QLQ-MY20 Domain Scores Time to first Improvement (Up to and including Last Follow-Up)
Item Score: Disease Symptoms Domain Score



Number at Risk (Number of Events)

Pom/Dex	15(0)	8(4)	6(6)	5(7)	4(8)	2(9)	2(9)	2(9)	1(9)	1(9)	1(9)	1(9)	1(9)	0(9)	0(9)	0(9)	0(9)	0(9)	0(9)	0(9)	0(9)	0(9)	0(9)
Belamaf	29(0)	14(7)	6(10)	5(10)	5(10)	4(10)	3(10)	3(10)	3(10)	3(10)	1(11)	1(11)	1(11)	1(11)	1(11)	1(11)	1(11)	1(11)	1(11)	1(11)	1(11)	1(11)	0(11)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_m20_tfi.sas 14MAR2023 08:08

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.068110
Graph of Kaplan-Meier Curves of EORTC QLQ-MY20 Domain Scores Time to first Improvement
(Up to and including Last Follow-Up)
Item Score: Side Effects of Treatment Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	2(0)	1(1)	0(2)	0(2)	0(2)	0(2)	0(2)	0(2)	0(2)	0(2)	0(2)	0(2)	0(2)	0(2)	0(2)	0(2)	0(2)	0(2)	0(2)	0(2)	0(2)	0(2)
Belamaf	29(0)	4(0)	4(0)	2(2)	2(2)	2(2)	2(2)	2(2)	2(2)	1(2)	0(2)	0(2)	0(2)	0(2)	0(2)	0(2)	0(2)	0(2)	0(2)	0(2)	0(2)	0(2)	0(2)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_m20_tfi.sas 14MAR2023 08:08

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.065110
Graph of Kaplan-Meier Curves of EORTC QLQ-MY20 Domain Scores Time to first Deterioration 1
(Up to and including Last Follow-Up)
Item Score: Future Perspective Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	6(0)	5(1)	5(1)	5(1)	4(2)	3(2)	3(2)	2(3)	2(3)	1(4)	1(4)	1(4)	1(4)	0(5)	0(5)	0(5)	0(5)	0(5)	0(5)	0(5)	0(5)	0(5)	0(5)
Belamaf	29(0)	15(5)	13(7)	11(9)	11(9)	10(10)	5(15)	3(17)	2(17)	2(17)	1(18)	1(18)	1(18)	1(18)	1(18)	1(18)	1(18)	1(18)	1(18)	0(19)	0(19)	0(19)	0(19)	0(19)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_m20_tfd1.sas 14MAR2023 08:07

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.065110
Graph of Kaplan-Meier Curves of EORTC QLQ-MY20 Domain Scores Time to first Deterioration 1
(Up to and including Last Follow-Up)
Item Score: Body Image Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	6(0)	5(1)	5(1)	5(1)	5(1)	3(1)	3(1)	2(2)	2(2)	1(3)	1(3)	1(3)	1(3)	0(4)	0(4)	0(4)	0(4)	0(4)	0(4)	0(4)	0(4)	0(4)
Belamaf	29(0)	16(4)	13(7)	11(9)	11(9)	10(10)	5(15)	4(16)	3(16)	3(16)	1(17)	1(17)	1(17)	1(17)	1(17)	1(17)	1(17)	1(17)	1(17)	0(18)	0(18)	0(18)	0(18)	0(18)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_m20_tfd1.sas 14MAR2023 08:07

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.065110
Graph of Kaplan-Meier Curves of EORTC QLQ-MY20 Domain Scores Time to first Deterioration 1
(Up to and including Last Follow-Up)
Item Score: Disease Symptoms Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	12(1)	10(3)	7(6)	7(6)	6(7)	4(7)	4(7)	4(7)	4(7)	4(7)	4(7)	4(7)	3(7)	1(8)	1(8)	1(8)	1(8)	0(8)	0(8)	0(8)	0(8)	0(8)	0(8)
Belamaf	29(0)	21(6)	12(15)	10(17)	9(18)	9(18)	6(21)	6(21)	6(21)	5(21)	3(22)	3(22)	3(22)	3(22)	3(22)	3(22)	2(22)	2(22)	1(22)	1(22)	1(22)	1(22)	1(22)	0(22)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_m20_tfd1.sas 14MAR2023 08:07

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.065110
Graph of Kaplan-Meier Curves of EORTC QLQ-MY20 Domain Scores Time to first Deterioration 1
(Up to and including Last Follow-Up)
Item Score: Side Effects of Treatment Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	6(0)	5(1)	5(1)	5(1)	5(1)	3(1)	3(1)	2(2)	2(2)	1(3)	1(3)	1(3)	1(3)	0(4)	0(4)	0(4)	0(4)	0(4)	0(4)	0(4)	0(4)	0(4)	0(4)
Belamaf	29(0)	17(3)	15(5)	13(7)	13(7)	12(8)	7(13)	6(14)	5(14)	4(14)	2(15)	2(15)	2(15)	2(15)	2(15)	2(15)	1(15)	1(15)	1(15)	0(16)	0(16)	0(16)	0(16)	0(16)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_m20_tfd1.sas 14MAR2023 08:07

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.066110
Graph of Kaplan-Meier Curves of EORTC QLQ-MY20 Domain Scores Time to first Deterioration 2
(Up to and including Last Follow-Up)
Item Score: Future Perspective Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	2(0)	2(0)	2(0)	2(0)	1(1)	0(1)	0(1)	0(1)	0(1)	0(1)	0(1)	0(1)	0(1)	0(1)	0(1)	0(1)	0(1)	0(1)	0(1)	0(1)	0(1)	0(1)
Belamaf	29(0)	2(2)	2(2)	2(2)	2(2)	2(2)	2(2)	1(3)	0(3)	0(3)	0(3)	0(3)	0(3)	0(3)	0(3)	0(3)	0(3)	0(3)	0(3)	0(3)	0(3)	0(3)	0(3)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_m20_tfd2.sas 14MAR2023 08:07

Protocol: 207495

Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.066110
Graph of Kaplan-Meier Curves of EORTC QLQ-MY20 Domain Scores Time to first Deterioration 2
(Up to and including Last Follow-Up)
Item Score: Body Image Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	2(0)	2(0)	2(0)	2(0)	2(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)
Belamaf	29(0)	3(1)	2(2)	2(2)	2(2)	2(2)	2(2)	2(2)	1(2)	1(2)	0(2)	0(2)	0(2)	0(2)	0(2)	0(2)	0(2)	0(2)	0(2)	0(2)	0(2)	0(2)	0(2)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_m20_tfd2.sas 14MAR2023 08:07

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.066110
Graph of Kaplan-Meier Curves of EORTC QLQ-MY20 Domain Scores Time to first Deterioration 2
(Up to and including Last Follow-Up)
Item Score: Disease Symptoms Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	11(1)	10(2)	7(5)	7(5)	6(6)	4(6)	4(6)	4(6)	4(6)	4(6)	4(6)	4(6)	3(6)	1(7)	1(7)	1(7)	1(7)	0(7)	0(7)	0(7)	0(7)	0(7)	0(7)
Belamaf	29(0)	19(5)	9(13)	8(14)	7(15)	7(15)	5(17)	5(17)	5(17)	4(17)	3(17)	3(17)	3(17)	3(17)	3(17)	3(17)	2(17)	2(17)	1(17)	1(17)	1(17)	1(17)	1(17)	0(17)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_m20_tfd2.sas 14MAR2023 08:07

Protocol: 207495

Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.066110
Graph of Kaplan-Meier Curves of EORTC QLQ-MY20 Domain Scores Time to first Deterioration 2
(Up to and including Last Follow-Up)
Item Score: Side Effects of Treatment Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	2(0)	2(0)	2(0)	2(0)	2(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)
Belamaf	29(0)	4(0)	4(0)	4(0)	4(0)	4(0)	4(0)	4(0)	3(0)	2(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_m20_tfd2.sas 14MAR2023 08:07

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.069110
Graph of Kaplan-Meier Curves of EORTC QLQ-MY20 Domain Scores Time to permanent Deterioration 1 (Up to and including End of Treatment)
Item Score: Future Perspective Domain Score



Number at Risk (Number of Events)

Pom/Dex	15(0)	3(0)	2(1)	2(1)	2(1)	2(1)	0(1)	0(1)	0(1)	0(1)	0(1)	0(1)	0(1)	0(1)	0(1)	0(1)	0(1)	0(1)	0(1)	0(1)	0(1)	0(1)	0(1)
Belamaf	29(0)	10(3)	8(5)	6(6)	6(6)	6(6)	3(9)	3(9)	3(9)	3(9)	1(10)	1(10)	1(10)	1(10)	0(11)	0(11)	0(11)	0(11)	0(11)	0(11)	0(11)	0(11)	0(11)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_m20_pd1_eot.sas 14MAR2023 12:15

Protocol: 207495

Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.069110
Graph of Kaplan-Meier Curves of EORTC QLQ-MY20 Domain Scores Time to permanent Deterioration 1 (Up to and including End of Treatment)
Item Score: Body Image Domain Score



Number at Risk (Number of Events)

Pom/Dex	15(0)	3(0)	2(1)	2(1)	2(1)	2(1)	0(1)	0(1)	0(1)	0(1)	0(1)	0(1)	0(1)	0(1)	0(1)	0(1)	0(1)	0(1)	0(1)	0(1)	0(1)	0(1)	0(1)
Belamaf	29(0)	10(3)	8(5)	6(6)	6(6)	6(6)	4(8)	4(8)	4(8)	3(8)	1(9)	1(9)	1(9)	1(9)	1(9)	1(9)	0(9)	0(9)	0(9)	0(9)	0(9)	0(9)	0(9)	0(9)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_m20_pd1_eot.sas 14MAR2023 12:15

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.069110
Graph of Kaplan-Meier Curves of EORTC QLQ-MY20 Domain Scores Time to permanent Deterioration 1 (Up to and including End of Treatment)
Item Score: Disease Symptoms Domain Score



Number at Risk (Number of Events)

Pom/Dex	15(0)	13(0)	12(1)	12(1)	12(1)	10(1)	7(1)	7(1)	5(1)	5(1)	5(1)	3(1)	3(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	1(1)	0(1)
Belamaf	29(0)	23(4)	14(6)	10(7)	9(7)	9(7)	7(9)	7(9)	7(9)	6(9)	4(10)	4(10)	3(10)	3(10)	2(10)	2(10)	1(10)	1(10)	1(10)	1(10)	1(10)	1(10)	0(10)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_m20_pd1_eot.sas 14MAR2023 12:15

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.069110
Graph of Kaplan-Meier Curves of EORTC QLQ-MY20 Domain Scores Time to permanent Deterioration 1
(Up to and including End of Treatment)
Item Score: Side Effects of Treatment Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	3(0)	2(1)	2(1)	2(1)	2(1)	0(1)	0(1)	0(1)	0(1)	0(1)	0(1)	0(1)	0(1)	0(1)	0(1)	0(1)	0(1)	0(1)	0(1)	0(1)	0(1)	0(1)
Belamaf	29(0)	10(3)	8(5)	6(6)	6(6)	6(6)	4(8)	4(8)	4(8)	3(8)	1(9)	1(9)	1(9)	1(9)	1(9)	1(9)	0(9)	0(9)	0(9)	0(9)	0(9)	0(9)	0(9)	0(9)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_m20_pd1_eot.sas 14MAR2023 12:15

Protocol: 207495

Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.070110

Graph of Kaplan-Meier Curves of EORTC QLQ-MY20 Domain Scores Time to permanent Deterioration 2 (Up to and including End of Treatment)

Item Score: Future Perspective Domain Score



Number at Risk (Number of Events)

Pom/Dex	15(0)	2(0)	2(0)	2(0)	2(0)	2(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)
Belamaf	29(0)	4(0)	4(0)	3(0)	3(0)	3(0)	2(1)	2(1)	2(1)	2(1)	1(1)	1(1)	1(1)	1(1)	0(2)	0(2)	0(2)	0(2)	0(2)	0(2)	0(2)	0(2)	0(2)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_m20_pd2_eot.sas 14MAR2023 12:15

Protocol: 207495

Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.070110
Graph of Kaplan-Meier Curves of EORTC QLQ-MY20 Domain Scores Time to permanent Deterioration 2
(Up to and including End of Treatment)
Item Score: Body Image Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	2(0)	2(0)	2(0)	2(0)	2(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)
Belamaf	29(0)	4(0)	4(0)	3(0)	3(0)	3(0)	3(0)	3(0)	3(0)	2(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_m20_pd2_eot.sas 14MAR2023 12:15

Protocol: 207495

Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.070110

Graph of Kaplan-Meier Curves of EORTC QLQ-MY20 Domain Scores Time to permanent Deterioration 2 (Up to and including End of Treatment)

Item Score: Disease Symptoms Domain Score



Number at Risk (Number of Events)

Pom/Dex	15(0)	12(0)	12(0)	12(0)	12(0)	10(0)	7(0)	7(0)	5(0)	5(0)	5(0)	3(0)	3(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	1(0)	0(0)
Belamaf	29(0)	20(1)	11(1)	8(1)	7(1)	7(1)	6(1)	6(1)	6(1)	5(1)	4(1)	4(1)	3(1)	3(1)	2(1)	2(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	0(1)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_m20_pd2_eot.sas 14MAR2023 12:15

Protocol: 207495

Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.070110

Graph of Kaplan-Meier Curves of EORTC QLQ-MY20 Domain Scores Time to permanent Deterioration 2 (Up to and including End of Treatment)

Item Score: Side Effects of Treatment Domain Score



Number at Risk (Number of Events)

Pom/Dex	15(0)	2(0)	2(0)	2(0)	2(0)	2(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)
Belamaf	29(0)	4(0)	4(0)	3(0)	3(0)	3(0)	3(0)	3(0)	3(0)	2(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_m20_pd2_eot.sas 14MAR2023 12:15

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.071110
Graph of Kaplan-Meier Curves of EORTC QLQ-MY20 Domain Scores Time to permanent Deterioration 1 (Up to and including Last Follow-Up)
Item Score: Future Perspective Domain Score



Number at Risk (Number of Events)

Pom/Dex	15(0)	6(0)	5(1)	5(1)	5(1)	5(1)	3(1)	3(1)	2(2)	2(2)	1(3)	1(3)	1(3)	1(3)	0(4)	0(4)	0(4)	0(4)	0(4)	0(4)	0(4)	0(4)	0(4)
Belamaf	29(0)	17(3)	15(5)	13(7)	13(7)	12(8)	6(14)	5(15)	4(15)	4(15)	2(16)	2(16)	2(16)	2(16)	1(17)	1(17)	1(17)	1(17)	1(17)	0(18)	0(18)	0(18)	0(18)	0(18)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_m20_pd1_lf.sas 14MAR2023 12:16

Protocol: 207495

Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.071110
Graph of Kaplan-Meier Curves of EORTC QLQ-MY20 Domain Scores Time to permanent Deterioration 1 (Up to and including Last Follow-Up)
Item Score: Body Image Domain Score



Number at Risk (Number of Events)

Pom/Dex	15(0)	6(0)	5(1)	5(1)	5(1)	5(1)	3(1)	3(1)	2(2)	2(2)	1(3)	1(3)	1(3)	1(3)	0(4)	0(4)	0(4)	0(4)	0(4)	0(4)	0(4)	0(4)	0(4)
Belamaf	29(0)	17(3)	15(5)	13(7)	13(7)	12(8)	7(13)	6(14)	5(14)	4(14)	2(15)	2(15)	2(15)	2(15)	2(15)	2(15)	1(15)	1(15)	1(15)	0(16)	0(16)	0(16)	0(16)	0(16)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_m20_pd1_lf.sas 14MAR2023 12:16

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.071110
Graph of Kaplan-Meier Curves of EORTC QLQ-MY20 Domain Scores Time to permanent Deterioration 1 (Up to and including Last Follow-Up)
Item Score: Disease Symptoms Domain Score



Number at Risk (Number of Events)

Pom/Dex	15(0)	13(0)	12(1)	12(1)	12(1)	11(1)	8(1)	8(1)	7(2)	7(2)	6(3)	6(3)	6(3)	5(3)	3(4)	3(4)	3(4)	3(4)	2(4)	2(4)	2(4)	2(4)	1(4)	0(4)
Belamaf	29(0)	23(4)	18(6)	15(8)	15(8)	14(9)	10(13)	9(14)	8(14)	7(14)	5(15)	5(15)	4(15)	4(15)	4(15)	4(15)	3(15)	3(15)	2(15)	1(16)	1(16)	1(16)	1(16)	0(16)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_m20_pd1_lf.sas 14MAR2023 12:16

Protocol: 207495

Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.071110
Graph of Kaplan-Meier Curves of EORTC QLQ-MY20 Domain Scores Time to permanent Deterioration 1 (Up to and including Last Follow-Up)
Item Score: Side Effects of Treatment Domain Score



Number at Risk (Number of Events)

Pom/Dex	15(0)	6(0)	5(1)	5(1)	5(1)	5(1)	3(1)	3(1)	2(2)	2(2)	1(3)	1(3)	1(3)	1(3)	0(4)	0(4)	0(4)	0(4)	0(4)	0(4)	0(4)	0(4)	0(4)
Belamaf	29(0)	17(3)	15(5)	13(7)	13(7)	12(8)	7(13)	6(14)	5(14)	4(14)	2(15)	2(15)	2(15)	2(15)	2(15)	2(15)	1(15)	1(15)	1(15)	0(16)	0(16)	0(16)	0(16)	0(16)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_m20_pd1_lf.sas 14MAR2023 12:16

Protocol: 207495

Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.072110

Graph of Kaplan-Meier Curves of EORTC QLQ-MY20 Domain Scores Time to permanent Deterioration 2 (Up to and including Last Follow-Up)

Item Score: Future Perspective Domain Score



Number at Risk (Number of Events)

Pom/Dex	15(0)	2(0)	2(0)	2(0)	2(0)	2(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)
Belamaf	29(0)	4(0)	4(0)	4(0)	4(0)	4(0)	3(1)	3(1)	2(1)	2(1)	1(1)	1(1)	1(1)	1(1)	0(2)	0(2)	0(2)	0(2)	0(2)	0(2)	0(2)	0(2)	0(2)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_m20_pd2_lf.sas 14MAR2023 12:16

Protocol: 207495

Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.072110
Graph of Kaplan-Meier Curves of EORTC QLQ-MY20 Domain Scores Time to permanent Deterioration 2
(Up to and including Last Follow-Up)
Item Score: Body Image Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	2(0)	2(0)	2(0)	2(0)	2(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)
Belamaf	29(0)	4(0)	4(0)	4(0)	4(0)	4(0)	4(0)	4(0)	3(0)	2(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_m20_pd2_lf.sas 14MAR2023 12:16

Protocol: 207495

Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.072110
Graph of Kaplan-Meier Curves of EORTC QLQ-MY20 Domain Scores Time to permanent Deterioration 2 (Up to and including Last Follow-Up)
Item Score: Disease Symptoms Domain Score



Number at Risk (Number of Events)

Pom/Dex	15(0)	12(0)	12(0)	12(0)	12(0)	10(0)	7(0)	7(0)	6(0)	6(0)	6(0)	5(0)	5(0)	4(0)	3(0)	3(0)	3(0)	3(0)	2(0)	2(0)	2(0)	2(0)	1(0)	0(0)
Belamaf	29(0)	20(1)	11(1)	10(1)	9(1)	9(1)	8(1)	8(1)	7(1)	6(1)	5(1)	5(1)	4(1)	4(1)	3(1)	3(1)	2(1)	2(1)	1(1)	1(1)	1(1)	1(1)	1(1)	0(1)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_m20_pd2_lf.sas 14MAR2023 12:16

Protocol: 207495

Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.072110
Graph of Kaplan-Meier Curves of EORTC QLQ-MY20 Domain Scores Time to permanent Deterioration 2
(Up to and including Last Follow-Up)
Item Score: Side Effects of Treatment Domain Score



Number at Risk
(Number of Events)

Pom/Dex	15(0)	2(0)	2(0)	2(0)	2(0)	2(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)
Belamaf	29(0)	4(0)	4(0)	4(0)	4(0)	4(0)	4(0)	4(0)	3(0)	2(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_m20_pd2_lf.sas 14MAR2023 12:16

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR)

Data as of 12SEP2022

Figure 4.022110
Stacked Bar Chart of FACT-GP5 Score by Attributes and Visit
Parameter: Bothered By Treatment Side Effect



PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_f1_gp5.sas 13MAR2023 09:29

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR)

Data as of 12SEP2022

Figure 4.089110
Graph of Kaplan-Meier Curves of FACT-GP5 Time to first Deterioration 1



Number at Risk
(Number of Events)

Pom/Dex	14(0)	10(3)	5(8)	5(8)	5(8)	5(8)	2(10)	2(10)	1(10)	1(10)	1(10)	1(10)	1(10)	1(10)	0(11)	0(11)	0(11)	0(11)	0(11)	0(11)
Belamaf	29(0)	19(8)	8(18)	6(18)	6(18)	6(18)	4(20)	4(20)	4(20)	3(20)	1(21)	1(21)	1(21)	1(21)	1(21)	1(21)	1(21)	1(21)	1(21)	0(22)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_gp5_tfd1.sas 17MAR2023 11:49

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR)

Data as of 12SEP2022

Figure 4.090110
Graph of Kaplan-Meier Curves of FACT-GP5 Time to first Deterioration 2

Number at Risk
(Number of Events)

Pom/Dex	14(0)	9(3)	5(7)	5(7)	5(7)	5(7)	2(9)	2(9)	1(9)	1(9)	1(9)	0(9)	0(9)	0(9)	0(9)
Belamaf	29(0)	15(5)	5(13)	3(13)	3(13)	3(13)	3(13)	3(13)	3(13)	2(13)	1(13)	1(13)	1(13)	1(13)	0(13)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_gp5_tfd2.sas 17MAR2023 11:50

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR)

Data as of 12SEP2022

Figure 4.032110
Stacked Bar Chart of PGIS Score by Attributes and Visit
Parameter: Severity



PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_f1_pgis.sas 13MAR2023 09:30

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR)

Data as of 12SEP2022

Figure 4.108110
Graph of Kaplan-Meier Curves of PGIS Time to first Improvement
(Up to and including Last Follow-Up)



Number at Risk
(Number of Events)

Pom/Dex	15(0)	12(0)	8(4)	6(6)	5(7)	3(8)	3(8)	3(8)	3(8)	3(8)	3(8)	3(8)	2(8)	0(9)	0(9)
Belamaf	29(0)	19(1)	8(4)	6(6)	6(6)	4(7)	2(8)	2(8)	2(8)	2(8)	1(8)	1(8)	1(8)	1(8)	0(8)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_pgs_tfi.sas 14MAR2023 06:09

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR)

Data as of 12SEP2022

Figure 4.105110
Graph of Kaplan-Meier Curves of PGIS Time to first Deterioration 1
(Up to and including Last Follow-Up)



Number at Risk
(Number of Events)

Pom/Dex	15(0)	13(0)	11(2)	9(4)	9(4)	7(6)	4(6)	4(6)	3(6)	3(6)	3(6)	3(6)	3(6)	2(6)	0(8)	0(8)	0(8)	0(8)	0(8)	0(8)	0(8)
Belamaf	29(0)	24(3)	14(9)	10(12)	10(12)	9(13)	5(16)	5(16)	5(16)	4(16)	3(17)	3(17)	3(17)	2(18)	2(18)	2(18)	1(18)	1(18)	1(18)	1(18)	1(18)	0(18)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_pgs_tfd1.sas 14MAR2023 06:08

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR)

Data as of 12SEP2022

Figure 4.106110
Graph of Kaplan-Meier Curves of PGIS Time to first Deterioration 2
(Up to and including Last Follow-Up)



Number at Risk
(Number of Events)

Pom/Dex	15(0)	12(0)	11(1)	9(3)	9(3)	7(5)	4(5)	4(5)	3(5)	3(5)	3(5)	2(5)	2(5)	1(5)	0(6)	0(6)	0(6)	0(6)	0(6)	0(6)	0(6)
Belamaf	29(0)	20(0)	10(4)	8(5)	7(5)	6(5)	4(6)	4(6)	4(6)	3(6)	3(6)	3(6)	3(6)	2(7)	2(7)	2(7)	1(7)	1(7)	1(7)	1(7)	0(7)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_pgs_tfd2.sas 14MAR2023 06:08

Protocol: 207495

Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.109110
Graph of Kaplan-Meier Curves of PGIS Time to permanent Deterioration 1
(Up to and including End of Treatment)



Number at Risk
(Number of Events)

Pom/Dex	15(0)	13(0)	12(1)	12(1)	12(1)	9(2)	6(2)	6(2)	5(2)	5(2)	5(2)	3(2)	3(2)	2(2)	2(2)	2(2)	2(2)	2(2)	2(2)	1(2)	1(2)	1(2)	1(2)	0(2)
Belamaf	29(0)	24(3)	14(5)	11(6)	10(6)	9(6)	7(8)	6(9)	6(9)	5(9)	4(10)	4(10)	3(10)	3(10)	2(10)	2(10)	1(10)	1(10)	1(10)	1(10)	1(10)	0(10)	0(10)	0(10)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_pgs_pd1_eot.sas 14MAR2023 13:29

Protocol: 207495

Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.110110
Graph of Kaplan-Meier Curves of PGIS Time to permanent Deterioration 2
(Up to and including End of Treatment)



Number at Risk
(Number of Events)

Pom/Dex	15(0)	12(0)	12(0)	12(0)	12(0)	9(1)	6(1)	6(1)	5(1)	5(1)	5(1)	3(1)	3(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	1(1)	1(1)	1(1)	1(1)	0(1)
Belamaf	29(0)	20(0)	11(0)	9(0)	8(0)	6(0)	6(0)	5(1)	5(1)	4(1)	4(1)	4(1)	3(1)	3(1)	2(1)	2(1)	1(1)	1(1)	1(1)	1(1)	1(1)	0(1)	0(1)	0(1)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_pgs_pd2_eot.sas 14MAR2023 13:33

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR)

Data as of 12SEP2022

Figure 4.111110
Graph of Kaplan-Meier Curves of PGIS Time to permanent Deterioration 1
(Up to and including Last Follow-Up)



Number at Risk
(Number of Events)

Pom/Dex	15(0)	13(0)	12(1)	12(1)	12(1)	10(2)	7(2)	7(2)	5(3)	5(3)	5(3)	5(3)	4(3)	3(3)	2(4)	2(4)	2(4)	2(4)	2(4)	1(4)	1(4)	1(4)	1(4)	0(4)
Belamaf	29(0)	24(3)	18(5)	15(7)	15(7)	14(8)	8(13)	6(15)	6(15)	5(15)	4(16)	4(16)	3(16)	3(16)	3(16)	3(16)	2(16)	2(16)	2(16)	1(17)	1(17)	0(17)	0(17)	0(17)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_pgs_pd1_lf.sas 14MAR2023 13:30

Protocol: 207495

Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.112110
Graph of Kaplan-Meier Curves of PGIS Time to permanent Deterioration 2
(Up to and including Last Follow-Up)



Number at Risk
(Number of Events)

Pom/Dex	15(0)	12(0)	12(0)	12(0)	12(0)	9(1)	6(1)	6(1)	5(1)	5(1)	5(1)	4(1)	3(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	1(1)	1(1)	1(1)	1(1)	0(1)
Belamaf	29(0)	20(0)	11(0)	10(0)	9(0)	7(0)	6(0)	5(1)	5(1)	4(1)	4(1)	4(1)	3(1)	3(1)	2(1)	2(1)	1(1)	1(1)	1(1)	1(1)	1(1)	0(1)	0(1)	0(1)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_pgs_pd2_lf.sas 14MAR2023 13:33

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR)

Data as of 12SEP2022

Figure 4.031110
Stacked Bar Chart of PGIC Score by Attributes and Visit
Parameter: Change



PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_f1_pgic.sas 13MAR2023 09:30

Protocol: 207495
Population: Intent-to-Treat (Fifth Line (5L+) plus TCR)

Data as of 12SEP2022

Figure 4.046110
Graph of Kaplan-Meier Curves of Time to first Positive Response PGIC



Number at Risk
(Number of Events)

Pom/Dex	15(0)	13(0)	3(10)	2(11)	2(11)	1(12)	1(12)	1(12)	0(13)
Belamaf	29(0)	20(1)	6(6)	4(7)	4(7)	1(9)	0(10)	0(10)	0(10)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_km_pr.sas 07MAR2023 06:17

Protocol: 207495

Population: Intent-to-Treat (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.047110

Graph of Kaplan-Meier Curves of Time to first Negative Response PGIC



Number at Risk (Number of Events)

Pom/Dex	15(0)	13(0)	13(0)	12(1)	12(1)	9(3)	5(4)	5(4)	5(4)	5(4)	5(4)	4(4)	3(4)	1(4)	1(4)	1(4)	1(4)	1(4)	1(4)	0(4)	0(4)	0(4)
Belamaf	29(0)	21(0)	11(6)	9(8)	8(8)	7(9)	6(9)	5(10)	5(10)	5(10)	4(10)	4(10)	3(10)	3(10)	2(10)	2(10)	1(10)	1(10)	1(10)	1(10)	1(10)	0(10)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_km_nr.sas 07MAR2023 06:17

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR)

Data as of 12SEP2022

Figure 3.001110
Graph of Kaplan-Meier Curves of Time to first Adverse Event



Number at Risk (Number of Events)										
Pom/Dex	14(0)	4(10)	2(12)	2(12)	2(12)	2(12)	1(13)	0(13)	0(13)	0(13)
Belamaf	29(0)	8(21)	5(24)	3(25)	3(25)	3(25)	1(27)	1(27)	1(27)	0(28)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte_ae.sas 15FEB2023 04:52

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.008110
Graph of Kaplan-Meier Curves of Time to first Max Grade 3 or higher Adverse Event



Number at Risk (Number of Events)

Pom/Dex	14(0)	6(8)	6(8)	4(10)	3(11)	3(11)	3(11)	1(11)	1(11)	0(12)	0(12)	0(12)	0(12)	0(12)	0(12)	0(12)	0(12)	0(12)	0(12)	0(12)	0(12)	0(12)	0(12)
Belamaf	29(0)	15(14)	9(18)	6(19)	4(20)	4(20)	4(20)	4(20)	4(20)	4(20)	3(20)	2(20)	1(20)	1(20)	1(20)	1(20)	1(20)	1(20)	1(20)	1(20)	1(20)	1(20)	0(20)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte_ae3.sas 16FEB2023 11:43

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR)

Data as of 12SEP2022

Figure 3.011110
Graph of Kaplan-Meier Curves of Time to first Serious Adverse Event



Number at Risk (Number of Events)	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23
Pom/Dex	14(0)	13(1)	13(1)	12(2)	12(2)	10(2)	9(3)	8(3)	6(3)	4(4)	4(4)	4(4)	4(4)	2(4)	2(4)	2(4)	2(4)	2(4)	2(4)	2(4)	1(5)	1(5)	0(5)	0(5)
Belamaf	29(0)	19(9)	13(11)	10(11)	7(12)	6(13)	5(13)	5(13)	5(13)	5(13)	4(13)	3(13)	2(13)	2(13)	1(13)	1(13)	1(13)	1(13)	1(13)	1(13)	1(13)	1(13)	1(13)	0(13)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte_aes.sas 15FEB2023 04:53

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.004110
Graph of Kaplan-Meier Curves of Time to Fatal Adverse Event



Number at Risk (Number of Events)	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
Pom/Dex	14(0)	13(1)	13(1)	13(1)	13(1)	11(1)	11(1)	9(1)	7(1)	5(1)	5(1)	4(1)	4(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	1(1)	1(1)	0(1)
Belamaf	29(0)	24(2)	19(2)	14(2)	9(2)	8(2)	7(2)	7(2)	7(2)	6(2)	5(2)	3(2)	2(2)	2(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	0(2)	0(2)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte_aef.sas 15FEB2023 04:52

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR)

Data as of 12SEP2022

Figure 3.007110
Graph of Kaplan-Meier Curves of Time to first Adverse Event Leading to Discontinuation of Study Treatment



Number at Risk (Number of Events)	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
Pom/Dex	14(0)	13(1)	13(1)	13(1)	13(1)	11(1)	11(1)	9(1)	7(1)	4(2)	4(2)	4(2)	4(2)	2(2)	2(2)	2(2)	2(2)	2(2)	2(2)	2(2)	2(2)	2(2)	1(2)	1(2)	0(2)
Belamaf	29(0)	25(1)	18(1)	13(1)	9(1)	8(1)	7(1)	7(1)	7(1)	6(1)	5(1)	3(1)	2(1)	2(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	0(1)	0(1)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte_aed.sas 15FEB2023 04:53

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR)

Data as of 12SEP2022

Figure 3.001112
Graph of Kaplan-Meier Curves of Time to First Adverse Event Leading to Dose Reduction



Number at Risk (Number of Events)	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23
Pom/Dex	14(0)	11(3)	10(3)	9(4)	9(4)	6(5)	6(5)	4(5)	4(5)	3(5)	3(5)	3(5)	3(5)	1(5)	1(5)	1(5)	1(5)	1(5)	1(5)	0(6)	0(6)	0(6)	0(6)	0(6)
Belamaf	29(0)	23(3)	16(3)	12(3)	8(3)	6(4)	5(4)	5(4)	5(4)	4(4)	2(5)	1(5)	1(5)	1(5)	1(5)	1(5)	1(5)	1(5)	1(5)	1(5)	1(5)	1(5)	1(5)	0(5)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte_ae_dosred.sas 17MAR2023 12:37

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.002112
Graph of Kaplan-Meier Curves of Time to First Adverse Event Leading to Dose Interruption/Delay



Number at Risk (Number of Events)	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23
Pom/Dex	14(0)	12(2)	11(3)	10(4)	9(5)	7(6)	7(6)	5(6)	4(6)	2(7)	2(7)	1(7)	1(7)	1(7)	0(8)	0(8)	0(8)	0(8)	0(8)	0(8)	0(8)	0(8)	0(8)	0(8)
Belamaf	29(0)	18(8)	11(10)	7(11)	5(11)	4(11)	4(11)	4(11)	4(11)	3(11)	2(11)	1(11)	1(11)	1(11)	1(11)	1(11)	1(11)	1(11)	1(11)	1(11)	1(11)	1(11)	1(11)	0(12)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte_ae_dosdel.sas 17MAR2023 12:37

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.002110
Graph of Kaplan-Meier Curves of Time to first Adverse Event by SOC
(if prerequisites are met)
System Organ Class: Blood and lymphatic system disorders



Number at Risk (Number of Events)

	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
Pom/Dex	14(0)	8(6)	7(6)	7(6)	7(6)	6(7)	6(7)	4(7)	2(7)	1(7)	1(7)	1(7)	1(7)	1(7)	1(7)	1(7)	1(7)	1(7)	1(7)	1(7)	1(7)	1(7)	1(7)	1(7)	0(7)
Belamaf	29(0)	20(8)	14(10)	10(12)	7(12)	6(12)	4(14)	4(14)	4(14)	3(14)	3(14)	3(14)	2(14)	2(14)	1(14)	1(14)	1(14)	1(14)	1(14)	1(14)	1(14)	1(14)	1(14)	0(14)	0(14)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte2_ae.sas 15FEB2023 10:39

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.002110
Graph of Kaplan-Meier Curves of Time to first Adverse Event by SOC
(if prerequisites are met)
System Organ Class: Eye disorders



Number at Risk (Number of Events)

Pom/Dex	14(0)	13(1)	11(2)	10(3)	10(3)	7(4)	7(4)	4(5)	3(5)	3(5)	3(5)	3(5)	3(5)	1(5)	1(5)	1(5)	1(5)	1(5)	1(5)	1(5)	1(5)	0(5)	0(5)	0(5)
Belamaf	29(0)	17(9)	10(12)	4(15)	3(15)	3(15)	3(15)	3(15)	3(15)	3(15)	2(15)	1(15)	1(15)	1(15)	1(15)	1(15)	1(15)	1(15)	1(15)	1(15)	1(15)	1(15)	0(15)	0(15)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte2_ae.sas 15FEB2023 10:39

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.002110
Graph of Kaplan-Meier Curves of Time to first Adverse Event by SOC
(if prerequisites are met)
System Organ Class: Gastrointestinal disorders



Number at Risk (Number of Events)

	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
Pom/Dex	14(0)	12(2)	10(3)	9(4)	8(5)	8(5)	8(5)	6(5)	4(5)	2(5)	2(5)	2(5)	2(5)	0(5)	0(5)	0(5)	0(5)	0(5)	0(5)	0(5)	0(5)	0(5)	0(5)	0(5)	0(5)
Belamaf	29(0)	19(7)	14(9)	9(11)	7(11)	6(11)	5(11)	5(11)	5(11)	5(11)	4(11)	3(11)	2(11)	2(11)	1(11)	1(11)	1(11)	1(11)	1(11)	1(11)	1(11)	1(11)	1(11)	0(11)	0(11)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte2_ae.sas 15FEB2023 10:39

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.002110
Graph of Kaplan-Meier Curves of Time to first Adverse Event by SOC
(if prerequisites are met)
System Organ Class: General disorders and administration site conditions



Number at Risk (Number of Events)

	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
Pom/Dex	14(0)	11(3)	10(3)	9(4)	8(5)	5(6)	5(6)	2(7)	1(7)	1(7)	1(7)	1(7)	1(7)	1(7)	1(7)	1(7)	1(7)	1(7)	1(7)	1(7)	1(7)	1(7)	0(7)	0(7)	0(7)
Belamaf	29(0)	23(3)	18(3)	13(4)	9(4)	8(4)	7(4)	7(4)	7(4)	6(4)	5(4)	3(4)	2(4)	2(4)	1(4)	1(4)	1(4)	1(4)	1(4)	1(4)	1(4)	1(4)	1(4)	0(4)	0(4)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte2_ae.sas 15FEB2023 10:39

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.002110
Graph of Kaplan-Meier Curves of Time to first Adverse Event by SOC
(if prerequisites are met)
System Organ Class: Infections and infestations



Number at Risk (Number of Events)	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
Pom/Dex	14(0)	12(2)	11(3)	10(4)	9(5)	8(5)	7(6)	5(7)	3(7)	1(9)	1(9)	1(9)	1(9)	0(9)	0(9)	0(9)	0(9)	0(9)	0(9)	0(9)	0(9)	0(9)	0(9)	0(9)	0(9)
Belamaf	29(0)	21(6)	15(6)	9(8)	7(8)	6(8)	5(8)	5(8)	5(8)	4(9)	3(10)	2(10)	1(10)	1(10)	1(10)	1(10)	1(10)	1(10)	1(10)	1(10)	1(10)	1(10)	1(10)	0(11)	0(11)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte2_ae.sas 15FEB2023 10:39

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.002110
Graph of Kaplan-Meier Curves of Time to first Adverse Event by SOC
(if prerequisites are met)
System Organ Class: Injury, poisoning and procedural complications



Number at Risk (Number of Events)

	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
Pom/Dex	14(0)	14(0)	11(2)	11(2)	11(2)	11(2)	11(2)	9(2)	7(2)	5(2)	5(2)	4(2)	4(2)	2(2)	2(2)	2(2)	2(2)	2(2)	2(2)	2(2)	2(2)	2(2)	1(2)	1(2)	0(2)
Belamaf	29(0)	23(3)	17(3)	13(3)	9(3)	8(3)	7(3)	7(3)	7(3)	6(3)	4(4)	2(4)	2(4)	2(4)	1(4)	1(4)	1(4)	1(4)	1(4)	1(4)	1(4)	1(4)	1(4)	0(4)	0(4)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte2_ae.sas 15FEB2023 10:39

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.002110
Graph of Kaplan-Meier Curves of Time to first Adverse Event by SOC
(if prerequisites are met)
System Organ Class: Investigations



Number at Risk (Number of Events)

Pom/Dex	14(0)	11(3)	10(3)	9(4)	9(4)	7(5)	7(5)	5(5)	3(5)	2(6)	2(6)	2(6)	2(6)	1(6)	0(7)	0(7)	0(7)	0(7)	0(7)	0(7)	0(7)	0(7)	0(7)	0(7)
Belamaf	29(0)	24(5)	17(7)	11(8)	6(9)	5(10)	5(10)	5(10)	5(10)	4(11)	3(11)	1(11)	0(11)	0(11)	0(11)	0(11)	0(11)	0(11)	0(11)	0(11)	0(11)	0(11)	0(11)	0(11)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte2_ae.sas 15FEB2023 10:39

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.002110
Graph of Kaplan-Meier Curves of Time to first Adverse Event by SOC
(if prerequisites are met)
System Organ Class: Metabolism and nutrition disorders



Number at Risk (Number of Events)

	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
Pom/Dex	14(0)	13(1)	12(1)	12(1)	11(2)	10(2)	9(3)	7(3)	5(3)	3(3)	3(3)	3(3)	3(3)	2(3)	2(3)	2(3)	2(3)	2(3)	2(3)	2(3)	2(3)	2(3)	1(3)	1(3)	0(3)
Belamaf	29(0)	24(4)	14(7)	9(7)	7(7)	7(7)	5(8)	5(8)	5(8)	4(8)	3(8)	2(8)	1(8)	1(8)	1(8)	1(8)	1(8)	1(8)	1(8)	1(8)	1(8)	1(8)	1(8)	0(8)	0(8)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte2_ae.sas 15FEB2023 10:39

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.002110
Graph of Kaplan-Meier Curves of Time to first Adverse Event by SOC
(if prerequisites are met)
System Organ Class: Musculoskeletal and connective tissue disorders



Number at Risk (Number of Events)

Pom/Dex	14(0)	12(2)	11(2)	10(3)	7(6)	6(6)	5(7)	3(7)	3(7)	2(7)	2(7)	1(7)	1(7)	0(7)	0(7)	0(7)	0(7)	0(7)	0(7)	0(7)	0(7)	0(7)	0(7)	0(7)
Belamaf	29(0)	20(6)	12(8)	9(9)	6(9)	6(9)	5(9)	5(9)	5(9)	5(9)	4(9)	2(9)	2(9)	2(9)	1(9)	1(9)	1(9)	1(9)	1(9)	1(9)	1(9)	1(9)	1(9)	0(9)	0(9)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte2_ae.sas 15FEB2023 10:39

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.002110
Graph of Kaplan-Meier Curves of Time to first Adverse Event by SOC
(if prerequisites are met)
System Organ Class: Nervous system disorders



Number at Risk (Number of Events)

Pom/Dex	14(0)	11(3)	10(3)	10(3)	10(3)	7(4)	7(4)	5(4)	4(4)	3(4)	3(4)	3(4)	3(4)	1(4)	1(4)	1(4)	1(4)	1(4)	1(4)	1(4)	1(4)	1(4)	0(4)	0(4)	0(4)
Belamaf	29(0)	25(1)	18(2)	13(2)	9(2)	8(3)	7(3)	7(3)	7(3)	6(3)	5(3)	3(3)	2(3)	2(3)	1(3)	1(3)	1(3)	1(3)	1(3)	1(3)	1(3)	1(3)	1(3)	0(3)	0(3)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte2_ae.sas 15FEB2023 10:39

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.002110
Graph of Kaplan-Meier Curves of Time to first Adverse Event by SOC
(if prerequisites are met)
System Organ Class: Renal and urinary disorders



Number at Risk (Number of Events)	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
Pom/Dex	14(0)	14(0)	13(0)	13(0)	13(0)	11(1)	11(1)	9(1)	7(1)	5(1)	5(1)	4(1)	4(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	1(1)	1(1)	0(1)
Belamaf	29(0)	24(2)	17(3)	12(3)	8(3)	8(3)	7(3)	7(3)	7(3)	6(3)	5(3)	3(3)	2(3)	2(3)	1(3)	1(3)	1(3)	1(3)	1(3)	1(3)	1(3)	1(3)	1(3)	0(3)	0(3)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte2_ae.sas 15FEB2023 10:39

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.002110
Graph of Kaplan-Meier Curves of Time to first Adverse Event by SOC
(if prerequisites are met)
System Organ Class: Respiratory, thoracic and mediastinal disorders



Number at Risk (Number of Events)	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
Pom/Dex	14(0)	12(2)	11(2)	10(3)	10(3)	8(3)	8(3)	6(3)	5(3)	4(3)	4(3)	4(3)	4(3)	2(3)	2(3)	2(3)	2(3)	2(3)	2(3)	2(3)	2(3)	1(4)	0(4)	0(4)	0(4)
Belamaf	29(0)	24(3)	18(3)	13(3)	9(3)	8(3)	7(3)	7(3)	7(3)	6(3)	5(3)	3(3)	2(3)	2(3)	1(3)	1(3)	1(3)	1(3)	1(3)	1(3)	1(3)	1(3)	1(3)	0(3)	0(3)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte2_ae.sas 15FEB2023 10:39

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.002110
Graph of Kaplan-Meier Curves of Time to first Adverse Event by SOC
(if prerequisites are met)
System Organ Class: Skin and subcutaneous tissue disorders



Number at Risk (Number of Events)	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
Pom/Dex	14(0)	11(3)	10(3)	10(3)	10(3)	10(3)	10(3)	8(3)	6(3)	4(3)	4(3)	4(3)	4(3)	2(3)	2(3)	2(3)	2(3)	2(3)	2(3)	2(3)	2(3)	2(3)	1(3)	1(3)	0(3)
Belamaf	29(0)	26(0)	19(0)	14(0)	9(0)	8(0)	7(0)	7(0)	7(0)	6(0)	5(0)	3(0)	2(0)	2(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	0(0)	0(0)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte2_ae.sas 15FEB2023 10:39

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.003110
Graph of Kaplan-Meier Curves of Time to first Adverse Event by SOC and PT
(if prerequisites are met)
System Organ Class: Blood and lymphatic system disorders
Preferred Term: Anaemia



Number at Risk (Number of Events)	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
Time since Randomization (Months)																									
Pom/Dex	14(0)	14(0)	13(0)	13(0)	11(2)	10(2)	10(2)	8(2)	6(2)	3(3)	3(3)	3(3)	3(3)	2(3)	2(3)	2(3)	2(3)	2(3)	1(4)	1(4)	1(4)	1(4)	1(4)	1(4)	0(4)
Belamaf	29(0)	23(5)	16(6)	12(7)	9(7)	8(7)	6(8)	6(8)	6(8)	5(8)	4(8)	3(8)	2(8)	2(8)	1(8)	1(8)	1(8)	1(8)	1(8)	1(8)	1(8)	1(8)	1(8)	0(8)	0(8)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte2_pt_ae.sas 16FEB2023 11:26

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.003110
Graph of Kaplan-Meier Curves of Time to first Adverse Event by SOC and PT
(if prerequisites are met)
System Organ Class: Blood and lymphatic system disorders
Preferred Term: Neutropenia



Number at Risk (Number of Events)	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
Time since Randomization (Months)																									
Pom/Dex	14(0)	11(3)	10(3)	10(3)	9(4)	8(4)	8(4)	6(4)	4(4)	3(4)	3(4)	2(4)	2(4)	2(4)	2(4)	2(4)	2(4)	2(4)	2(4)	2(4)	2(4)	2(4)	1(4)	1(4)	0(4)
Belamaf	29(0)	26(0)	18(1)	13(1)	8(1)	7(1)	7(1)	7(1)	7(1)	6(1)	5(1)	3(1)	2(1)	2(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	0(1)	0(1)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte2_pt_ae.sas 16FEB2023 11:26

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.003110
Graph of Kaplan-Meier Curves of Time to first Adverse Event by SOC and PT
(if prerequisites are met)
System Organ Class: Blood and lymphatic system disorders
Preferred Term: Thrombocytopenia



Number at Risk (Number of Events)

	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
Pom/Dex	14(0)	9(5)	8(5)	8(5)	8(5)	7(6)	7(6)	5(6)	3(6)	2(6)	2(6)	2(6)	2(6)	1(6)	1(6)	1(6)	1(6)	1(6)	1(6)	1(6)	1(6)	1(6)	1(6)	1(6)	0(6)
Belamaf	29(0)	21(6)	15(8)	11(9)	7(9)	6(9)	5(10)	5(10)	5(10)	4(10)	4(10)	3(10)	2(10)	2(10)	1(10)	1(10)	1(10)	1(10)	1(10)	1(10)	1(10)	1(10)	1(10)	0(10)	0(10)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte2_pt_ae.sas 16FEB2023 11:26

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.003110
Graph of Kaplan-Meier Curves of Time to first Adverse Event by SOC and PT
(if prerequisites are met)
System Organ Class: Eye disorders
Preferred Term: Cataract



Number at Risk (Number of Events)	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
Pom/Dex	14(0)	13(1)	12(1)	12(1)	12(1)	10(1)	10(1)	6(3)	5(3)	5(3)	5(3)	4(3)	4(3)	2(3)	2(3)	2(3)	2(3)	2(3)	2(3)	2(3)	2(3)	2(3)	1(3)	1(3)	0(3)
Belamaf	29(0)	25(1)	17(2)	10(4)	6(4)	6(4)	6(4)	6(4)	6(4)	6(4)	5(4)	3(4)	2(4)	2(4)	1(4)	1(4)	1(4)	1(4)	1(4)	1(4)	1(4)	1(4)	1(4)	0(4)	0(4)

Time since Randomization (Months)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte2_pt_ae.sas 16FEB2023 11:26

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.003110
Graph of Kaplan-Meier Curves of Time to first Adverse Event by SOC and PT
(if prerequisites are met)
System Organ Class: Eye disorders
Preferred Term: Dry eye



Number at Risk (Number of Events)	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
Pom/Dex	14(0)	14(0)	13(0)	13(0)	13(0)	11(0)	11(0)	9(0)	7(0)	5(0)	5(0)	4(0)	4(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	1(0)	1(0)	0(0)
Belamaf	29(0)	25(1)	17(2)	11(3)	7(3)	7(3)	6(3)	6(3)	6(3)	5(3)	4(3)	2(3)	1(3)	1(3)	1(3)	1(3)	1(3)	1(3)	1(3)	1(3)	1(3)	1(3)	1(3)	0(3)	0(3)

Time since Randomization (Months)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte2_pt_ae.sas 16FEB2023 11:26

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.003110
Graph of Kaplan-Meier Curves of Time to first Adverse Event by SOC and PT
(if prerequisites are met)
System Organ Class: Eye disorders
Preferred Term: Foreign body sensation in eyes



Number at Risk (Number of Events)	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
Pom/Dex	14(0)	14(0)	13(0)	13(0)	13(0)	11(0)	11(0)	9(0)	7(0)	5(0)	5(0)	4(0)	4(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	1(0)	1(0)	0(0)
Belamaf	29(0)	26(0)	18(1)	12(2)	6(3)	6(3)	5(3)	5(3)	5(3)	4(3)	3(3)	1(3)	1(3)	1(3)	1(3)	1(3)	1(3)	1(3)	1(3)	1(3)	1(3)	1(3)	1(3)	0(3)	0(3)

Time since Randomization (Months)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte2_pt_ae.sas 16FEB2023 11:26

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.003110
Graph of Kaplan-Meier Curves of Time to first Adverse Event by SOC and PT
(if prerequisites are met)
System Organ Class: Eye disorders
Preferred Term: Photophobia



Number at Risk (Number of Events)

	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
Pom/Dex	14(0)	14(0)	13(0)	13(0)	13(0)	11(0)	11(0)	9(0)	7(0)	5(0)	5(0)	4(0)	4(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	1(0)	1(0)	0(0)
Belamaf	29(0)	24(2)	18(2)	12(3)	8(3)	7(3)	6(3)	6(3)	6(3)	5(3)	4(3)	2(3)	2(3)	2(3)	1(3)	1(3)	1(3)	1(3)	1(3)	1(3)	1(3)	1(3)	1(3)	0(3)	0(3)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte2_pt_ae.sas 16FEB2023 11:26

Figure 3.003110
Graph of Kaplan-Meier Curves of Time to first Adverse Event by SOC and PT
(if prerequisites are met)
System Organ Class: Eye disorders
Preferred Term: Vision blurred



Number at Risk (Number of Events)	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
Pom/Dex	14(0)	14(0)	13(0)	13(0)	13(0)	10(1)	10(1)	8(1)	6(1)	4(1)	4(1)	3(1)	3(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	0(1)	0(1)	0(1)
Belamaf	29(0)	23(3)	16(3)	10(4)	6(4)	5(4)	4(4)	4(4)	4(4)	3(4)	2(4)	1(4)	1(4)	1(4)	1(4)	1(4)	1(4)	1(4)	1(4)	1(4)	1(4)	1(4)	1(4)	0(4)	0(4)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte2_pt_ae.sas 16FEB2023 11:26

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.003110
Graph of Kaplan-Meier Curves of Time to first Adverse Event by SOC and PT
(if prerequisites are met)
System Organ Class: Eye disorders
Preferred Term: Visual impairment



Number at Risk (Number of Events)

Pom/Dex	14(0)	14(0)	13(0)	13(0)	13(0)	11(0)	11(0)	9(0)	7(0)	5(0)	5(0)	4(0)	4(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	1(0)	1(0)	0(0)
Belamaf	29(0)	23(3)	16(3)	13(3)	9(3)	8(3)	7(3)	7(3)	7(3)	6(3)	5(3)	3(3)	2(3)	2(3)	1(3)	1(3)	1(3)	1(3)	1(3)	1(3)	1(3)	1(3)	0(3)	0(3)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte2_pt_ae.sas 16FEB2023 11:26

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.003110
Graph of Kaplan-Meier Curves of Time to first Adverse Event by SOC and PT
(if prerequisites are met)
System Organ Class: Gastrointestinal disorders
Preferred Term: Constipation



Number at Risk (Number of Events)	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
Time since Randomization (Months)																									
Pom/Dex	14(0)	13(1)	12(1)	12(1)	12(1)	10(1)	10(1)	8(1)	6(1)	4(1)	4(1)	4(1)	3(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	0(2)	0(2)	0(2)
Belamaf	29(0)	26(0)	18(1)	12(2)	8(2)	7(2)	6(2)	6(2)	6(2)	6(2)	5(2)	3(2)	2(2)	2(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	0(2)	0(2)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte2_pt_ae.sas 16FEB2023 11:26

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.003110
Graph of Kaplan-Meier Curves of Time to first Adverse Event by SOC and PT
(if prerequisites are met)
System Organ Class: General disorders and administration site conditions
Preferred Term: Fatigue



Number at Risk (Number of Events)

Pom/Dex	14(0)	12(2)	11(2)	11(2)	11(2)	9(2)	9(2)	7(2)	6(2)	4(2)	4(2)	4(2)	4(2)	2(2)	2(2)	2(2)	2(2)	2(2)	2(2)	2(2)	2(2)	2(2)	1(2)	1(2)	0(2)
Belamaf	29(0)	26(0)	19(1)	13(2)	9(2)	8(2)	7(2)	7(2)	7(2)	6(2)	5(2)	3(2)	2(2)	2(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	0(2)	0(2)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte2_pt_ae.sas 16FEB2023 11:26

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.003110
Graph of Kaplan-Meier Curves of Time to first Adverse Event by SOC and PT
(if prerequisites are met)
System Organ Class: General disorders and administration site conditions
Preferred Term: Oedema peripheral



Number at Risk (Number of Events)

Pom/Dex	14(0)	13(1)	12(1)	12(1)	11(2)	9(2)	9(2)	6(3)	4(3)	4(3)	4(3)	3(3)	3(3)	2(3)	2(3)	2(3)	2(3)	2(3)	2(3)	2(3)	2(3)	2(3)	1(3)	1(3)	0(3)
Belamaf	29(0)	25(1)	19(1)	14(1)	9(1)	8(1)	7(1)	7(1)	7(1)	6(1)	5(1)	3(1)	2(1)	2(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	0(1)	0(1)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte2_pt_ae.sas 16FEB2023 11:26

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.003110
Graph of Kaplan-Meier Curves of Time to first Adverse Event by SOC and PT
(if prerequisites are met)
System Organ Class: Infections and infestations
Preferred Term: COVID-19



Number at Risk (Number of Events)

Pom/Dex	14(0)	13(1)	13(1)	13(1)	13(1)	11(1)	10(2)	9(2)	7(2)	5(2)	5(2)	4(2)	4(2)	2(2)	2(2)	2(2)	2(2)	2(2)	2(2)	2(2)	1(3)	1(3)	0(4)	0(4)	0(4)
Belamaf	29(0)	26(0)	19(0)	14(0)	9(0)	8(0)	7(0)	7(0)	7(0)	5(1)	4(2)	2(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	0(3)	0(3)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte2_pt_ae.sas 16FEB2023 11:26

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.003110
Graph of Kaplan-Meier Curves of Time to first Adverse Event by SOC and PT
(if prerequisites are met)
System Organ Class: Infections and infestations
Preferred Term: Pneumonia



Number at Risk (Number of Events)	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
Pom/Dex	14(0)	14(0)	13(0)	12(1)	12(1)	10(1)	10(1)	8(1)	6(1)	5(1)	5(1)	4(1)	4(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	1(2)	1(2)	0(2)	0(2)	0(2)
Belamaf	29(0)	25(2)	18(2)	13(2)	8(2)	7(2)	6(2)	6(2)	6(2)	6(2)	5(2)	3(2)	2(2)	2(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	0(2)	0(2)

Time since Randomization (Months)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte2_pt_ae.sas 16FEB2023 11:26

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.003110
Graph of Kaplan-Meier Curves of Time to first Adverse Event by SOC and PT
(if prerequisites are met)
System Organ Class: Investigations
Preferred Term: Alanine aminotransferase increased



Number at Risk (Number of Events)

	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
Pom/Dex	14(0)	12(2)	11(2)	11(2)	11(2)	10(2)	10(2)	8(2)	6(2)	4(2)	4(2)	3(2)	3(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	0(2)	0(2)	0(2)
Belamaf	29(0)	26(0)	19(0)	14(0)	9(0)	8(0)	7(0)	7(0)	7(0)	6(0)	5(0)	3(0)	2(0)	2(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	0(0)	0(0)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte2_pt_ae.sas 16FEB2023 11:26

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.003110
Graph of Kaplan-Meier Curves of Time to first Adverse Event by SOC and PT
(if prerequisites are met)
System Organ Class: Investigations
Preferred Term: Aspartate aminotransferase increased



Number at Risk (Number of Events)	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
Time since Randomization (Months)																									
Pom/Dex	14(0)	14(0)	13(0)	13(0)	13(0)	11(0)	11(0)	8(1)	6(1)	4(1)	4(1)	3(1)	3(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	0(1)	0(1)	0(1)
Belamaf	29(0)	26(0)	18(2)	13(2)	7(3)	6(3)	6(3)	6(3)	6(3)	6(3)	5(3)	3(3)	2(3)	2(3)	1(3)	1(3)	1(3)	1(3)	1(3)	1(3)	1(3)	1(3)	1(3)	0(3)	0(3)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte2_pt_ae.sas 16FEB2023 11:26

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.003110
Graph of Kaplan-Meier Curves of Time to first Adverse Event by SOC and PT
(if prerequisites are met)
System Organ Class: Investigations
Preferred Term: Blood creatinine increased



Number at Risk (Number of Events)	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
Pom/Dex	14(0)	14(0)	13(0)	12(1)	12(1)	10(1)	10(1)	8(1)	6(1)	3(2)	3(2)	3(2)	3(2)	2(2)	2(2)	2(2)	2(2)	2(2)	2(2)	2(2)	2(2)	2(2)	1(2)	1(2)	0(2)
Belamaf	29(0)	26(0)	19(0)	14(0)	9(0)	8(0)	7(0)	7(0)	7(0)	6(0)	5(0)	3(0)	2(0)	2(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	0(0)	0(0)

Time since Randomization (Months)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte2_pt_ae.sas 16FEB2023 11:26

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.003110
Graph of Kaplan-Meier Curves of Time to first Adverse Event by SOC and PT
(if prerequisites are met)
System Organ Class: Investigations
Preferred Term: Neutrophil count decreased



Number at Risk (Number of Events)

Pom/Dex	14(0)	12(2)	11(2)	11(2)	11(2)	8(3)	8(3)	6(3)	4(3)	4(3)	4(3)	3(3)	3(3)	1(3)	1(3)	1(3)	1(3)	1(3)	1(3)	1(3)	1(3)	1(3)	0(3)	0(3)	0(3)
Belamaf	29(0)	26(0)	19(0)	14(0)	9(0)	8(0)	7(0)	7(0)	7(0)	6(0)	5(0)	3(0)	2(0)	2(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	0(0)	0(0)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte2_pt_ae.sas 16FEB2023 11:26

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.003110
Graph of Kaplan-Meier Curves of Time to first Adverse Event by SOC and PT
(if prerequisites are met)
System Organ Class: Musculoskeletal and connective tissue disorders
Preferred Term: Arthralgia



Number at Risk (Number of Events)	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
Time since Randomization (Months)																									
Pom/Dex	14(0)	14(0)	13(0)	13(0)	13(0)	11(0)	11(0)	9(0)	7(0)	5(0)	5(0)	4(0)	4(0)	2(0)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	0(1)
Belamaf	29(0)	23(3)	17(3)	13(3)	8(3)	7(3)	6(3)	6(3)	6(3)	5(3)	4(3)	2(3)	2(3)	2(3)	1(3)	1(3)	1(3)	1(3)	1(3)	1(3)	1(3)	1(3)	1(3)	0(3)	0(3)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte2_pt_ae.sas 16FEB2023 11:26

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.003110
Graph of Kaplan-Meier Curves of Time to first Adverse Event by SOC and PT
(if prerequisites are met)
System Organ Class: Musculoskeletal and connective tissue disorders
Preferred Term: Back pain



Number at Risk (Number of Events)	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
Pom/Dex	14(0)	14(0)	13(0)	12(1)	11(2)	9(2)	9(2)	7(2)	5(2)	4(2)	4(2)	3(2)	3(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	0(2)	0(2)	0(2)
Belamaf	29(0)	26(0)	19(0)	13(1)	8(1)	7(1)	6(1)	6(1)	6(1)	6(1)	5(1)	3(1)	2(1)	2(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	0(1)	0(1)

Time since Randomization (Months)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte2_pt_ae.sas 16FEB2023 11:26

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.003110
Graph of Kaplan-Meier Curves of Time to first Adverse Event by SOC and PT
(if prerequisites are met)
System Organ Class: Musculoskeletal and connective tissue disorders
Preferred Term: Bone pain



Number at Risk (Number of Events)	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
Pom/Dex	14(0)	13(1)	12(1)	12(1)	12(1)	10(1)	10(1)	8(1)	7(1)	5(1)	5(1)	4(1)	4(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	1(1)	1(1)	0(1)
Belamaf	29(0)	24(2)	16(3)	12(3)	9(3)	8(3)	7(3)	7(3)	7(3)	6(3)	5(3)	3(3)	2(3)	2(3)	1(3)	1(3)	1(3)	1(3)	1(3)	1(3)	1(3)	1(3)	1(3)	0(3)	0(3)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte2_pt_ae.sas 16FEB2023 11:26

Figure 3.003110
Graph of Kaplan-Meier Curves of Time to first Adverse Event by SOC and PT
(if prerequisites are met)
System Organ Class: Musculoskeletal and connective tissue disorders
Preferred Term: Muscular weakness



Number at Risk (Number of Events)

	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
Pom/Dex	14(0)	13(1)	12(1)	12(1)	12(1)	10(1)	10(1)	8(1)	7(1)	5(1)	5(1)	4(1)	4(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	1(2)	1(2)	1(2)	0(2)	0(2)	0(2)
Belamaf	29(0)	26(0)	19(0)	14(0)	9(0)	8(0)	7(0)	7(0)	7(0)	6(0)	5(0)	3(0)	2(0)	2(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	0(0)	0(0)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte2_pt_ae.sas 16FEB2023 11:26

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.003110
Graph of Kaplan-Meier Curves of Time to first Adverse Event by SOC and PT
(if prerequisites are met)
System Organ Class: Nervous system disorders
Preferred Term: Tremor



Number at Risk (Number of Events)	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
Time since Randomization (Months)																									
Pom/Dex	14(0)	13(1)	12(1)	12(1)	12(1)	9(2)	9(2)	7(2)	5(2)	4(2)	4(2)	3(2)	3(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	0(2)	0(2)	0(2)
Belamaf	29(0)	26(0)	19(0)	14(0)	9(0)	8(0)	7(0)	7(0)	7(0)	6(0)	5(0)	3(0)	2(0)	2(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	0(0)	0(0)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte2_pt_ae.sas 16FEB2023 11:26

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.003110
Graph of Kaplan-Meier Curves of Time to first Adverse Event by SOC and PT
(if prerequisites are met)
System Organ Class: Respiratory, thoracic and mediastinal disorders
Preferred Term: Epistaxis



Number at Risk (Number of Events)	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
Pom/Dex	14(0)	14(0)	13(0)	13(0)	13(0)	11(0)	11(0)	9(0)	7(0)	5(0)	5(0)	4(0)	4(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	1(0)	1(0)	0(0)
Belamaf	29(0)	24(3)	18(3)	13(3)	9(3)	8(3)	7(3)	7(3)	7(3)	6(3)	5(3)	3(3)	2(3)	2(3)	1(3)	1(3)	1(3)	1(3)	1(3)	1(3)	1(3)	1(3)	1(3)	0(3)	0(3)

Time since Randomization (Months)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte2_pt_ae.sas 16FEB2023 11:26

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.003110
Graph of Kaplan-Meier Curves of Time to first Adverse Event by SOC and PT
(if prerequisites are met)
System Organ Class: Respiratory, thoracic and mediastinal disorders
Preferred Term: Hiccups



Number at Risk (Number of Events)

Pom/Dex	14(0)	12(2)	11(2)	11(2)	11(2)	9(2)	9(2)	7(2)	6(2)	4(2)	4(2)	4(2)	4(2)	2(2)	2(2)	2(2)	2(2)	2(2)	2(2)	2(2)	2(2)	2(2)	1(2)	1(2)	0(2)
Belamaf	29(0)	26(0)	19(0)	14(0)	9(0)	8(0)	7(0)	7(0)	7(0)	6(0)	5(0)	3(0)	2(0)	2(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	0(0)	0(0)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte2_pt_ae.sas 16FEB2023 11:26

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.003110
Graph of Kaplan-Meier Curves of Time to first Adverse Event by SOC and PT
(if prerequisites are met)
System Organ Class: Skin and subcutaneous tissue disorders
Preferred Term: Rash



Number at Risk (Number of Events)

Pom/Dex	14(0)	12(2)	11(2)	11(2)	11(2)	11(2)	11(2)	9(2)	7(2)	5(2)	5(2)	4(2)	4(2)	2(2)	2(2)	2(2)	2(2)	2(2)	2(2)	2(2)	2(2)	2(2)	1(2)	1(2)	0(2)
Belamaf	29(0)	26(0)	19(0)	14(0)	9(0)	8(0)	7(0)	7(0)	7(0)	6(0)	5(0)	3(0)	2(0)	2(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	0(0)	0(0)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte2_pt_ae.sas 16FEB2023 11:26

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.009110
Graph of Kaplan-Meier Curves of Time to first Max Grade 3 or higher Adverse Event by SOC (if prerequisites are met)
System Organ Class: Blood and lymphatic system disorders



Number at Risk (Number of Events)	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
Pom/Dex	14(0)	10(4)	9(4)	9(4)	9(4)	8(4)	8(4)	6(4)	4(4)	3(4)	3(4)	2(4)	2(4)	2(4)	2(4)	2(4)	2(4)	2(4)	2(4)	2(4)	2(4)	2(4)	1(4)	1(4)	0(4)
Belamaf	29(0)	20(7)	14(9)	11(10)	8(10)	7(10)	7(10)	7(10)	7(10)	6(10)	5(10)	3(10)	2(10)	2(10)	1(10)	1(10)	1(10)	1(10)	1(10)	1(10)	1(10)	1(10)	1(10)	0(10)	0(10)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte2_ae3.sas 15FEB2023 10:40

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.009110
Graph of Kaplan-Meier Curves of Time to first Max Grade 3 or higher Adverse Event by SOC (if prerequisites are met)
System Organ Class: Cardiac disorders



Number at Risk (Number of Events)	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
Pom/Dex	14(0)	14(0)	13(0)	13(0)	13(0)	11(0)	11(0)	9(0)	7(0)	4(1)	4(1)	4(1)	4(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	1(1)	1(1)	0(1)
Belamaf	29(0)	25(1)	18(1)	13(1)	9(1)	8(1)	7(1)	7(1)	7(1)	6(1)	5(1)	3(1)	2(1)	2(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	0(1)	0(1)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte2_ae3.sas 15FEB2023 10:40

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.009110
Graph of Kaplan-Meier Curves of Time to first Max Grade 3 or higher Adverse Event by SOC (if prerequisites are met)
System Organ Class: Eye disorders



Number at Risk (Number of Events)	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
Pom/Dex	14(0)	14(0)	13(0)	13(0)	13(0)	11(0)	11(0)	8(1)	6(1)	5(1)	5(1)	4(1)	4(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	1(1)	1(1)	0(1)
Belamaf	29(0)	23(3)	15(5)	12(5)	8(5)	6(6)	5(6)	5(6)	5(6)	4(6)	3(6)	2(6)	1(6)	1(6)	1(6)	1(6)	1(6)	1(6)	1(6)	1(6)	1(6)	1(6)	1(6)	0(6)	0(6)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte2_ae3.sas 15FEB2023 10:40

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.009110
Graph of Kaplan-Meier Curves of Time to first Max Grade 3 or higher Adverse Event by SOC (if prerequisites are met)
System Organ Class: Gastrointestinal disorders



Number at Risk (Number of Events)	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
Pom/Dex	14(0)	14(0)	13(0)	13(0)	13(0)	11(0)	11(0)	9(0)	7(0)	5(0)	5(0)	4(0)	4(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	1(0)	1(0)	0(0)
Belamaf	29(0)	25(1)	19(1)	14(1)	8(2)	7(2)	6(2)	6(2)	6(2)	5(2)	4(2)	3(2)	2(2)	2(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	0(2)	0(2)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte2_ae3.sas 15FEB2023 10:40

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.009110
Graph of Kaplan-Meier Curves of Time to first Max Grade 3 or higher Adverse Event by SOC (if prerequisites are met)
System Organ Class: General disorders and administration site conditions



Number at Risk (Number of Events)	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
Pom/Dex	14(0)	13(1)	12(1)	12(1)	12(1)	10(1)	10(1)	8(1)	7(1)	5(1)	5(1)	4(1)	4(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	1(1)	1(1)	0(1)
Belamaf	29(0)	26(0)	19(0)	14(0)	9(0)	8(0)	7(0)	7(0)	7(0)	6(0)	5(0)	3(0)	2(0)	2(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	0(0)	0(0)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte2_ae3.sas 15FEB2023 10:40

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.009110
Graph of Kaplan-Meier Curves of Time to first Max Grade 3 or higher Adverse Event by SOC (if prerequisites are met)
System Organ Class: Infections and infestations



Number at Risk (Number of Events)

Pom/Dex	14(0)	13(1)	13(1)	12(2)	12(2)	10(2)	10(2)	8(2)	6(2)	4(3)	4(3)	4(3)	4(3)	2(3)	2(3)	2(3)	2(3)	2(3)	2(3)	2(3)	1(4)	1(4)	0(4)	0(4)	0(4)
Belamaf	29(0)	25(2)	19(2)	14(2)	9(2)	8(2)	7(2)	7(2)	7(2)	6(2)	5(2)	3(2)	2(2)	2(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	0(2)	0(2)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte2_ae3.sas 15FEB2023 10:40

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.009110
Graph of Kaplan-Meier Curves of Time to first Max Grade 3 or higher Adverse Event by SOC (if prerequisites are met)
System Organ Class: Investigations



Number at Risk (Number of Events)	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
Pom/Dex	14(0)	13(1)	12(1)	12(1)	12(1)	9(2)	9(2)	7(2)	5(2)	4(2)	4(2)	3(2)	3(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	0(2)	0(2)	0(2)
Belamaf	29(0)	26(3)	19(3)	14(3)	9(3)	8(3)	7(3)	7(3)	7(3)	6(3)	5(3)	3(3)	2(3)	2(3)	1(3)	1(3)	1(3)	1(3)	1(3)	1(3)	1(3)	1(3)	1(3)	0(3)	0(3)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte2_ae3.sas 15FEB2023 10:40

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.009110
Graph of Kaplan-Meier Curves of Time to first Max Grade 3 or higher Adverse Event by SOC (if prerequisites are met)
System Organ Class: Metabolism and nutrition disorders



Number at Risk (Number of Events)

Pom/Dex	14(0)	14(0)	13(0)	13(0)	12(1)	11(1)	11(1)	9(1)	7(1)	5(1)	5(1)	4(1)	4(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	1(1)	1(1)	0(1)
Belamaf	29(0)	25(3)	17(4)	12(4)	8(4)	7(4)	6(4)	6(4)	6(4)	5(4)	4(4)	2(4)	1(4)	1(4)	1(4)	1(4)	1(4)	1(4)	1(4)	1(4)	1(4)	1(4)	1(4)	0(4)	0(4)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte2_ae3.sas 15FEB2023 10:40

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.009110
Graph of Kaplan-Meier Curves of Time to first Max Grade 3 or higher Adverse Event by SOC (if prerequisites are met)
System Organ Class: Musculoskeletal and connective tissue disorders



Number at Risk (Number of Events)	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
Pom/Dex	14(0)	13(1)	12(1)	12(1)	12(1)	10(1)	9(2)	7(2)	6(2)	4(2)	4(2)	3(2)	3(2)	2(2)	2(2)	2(2)	2(2)	2(2)	2(2)	2(2)	2(2)	2(2)	1(2)	1(2)	0(2)
Belamaf	29(0)	23(3)	16(3)	12(4)	8(4)	7(4)	6(4)	6(4)	6(4)	6(4)	5(4)	3(4)	2(4)	2(4)	1(4)	1(4)	1(4)	1(4)	1(4)	1(4)	1(4)	1(4)	1(4)	0(4)	0(4)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte2_ae3.sas 15FEB2023 10:40

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.009110
Graph of Kaplan-Meier Curves of Time to first Max Grade 3 or higher Adverse Event by SOC (if prerequisites are met)
System Organ Class: Nervous system disorders



Number at Risk (Number of Events)

	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
Pom/Dex	14(0)	14(0)	13(0)	13(0)	13(0)	11(0)	11(0)	9(0)	7(0)	5(0)	5(0)	4(0)	4(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	1(0)	1(0)	0(0)
Belamaf	29(0)	25(1)	18(2)	13(2)	9(2)	8(3)	7(3)	7(3)	7(3)	6(3)	5(3)	3(3)	2(3)	2(3)	1(3)	1(3)	1(3)	1(3)	1(3)	1(3)	1(3)	1(3)	1(3)	0(3)	0(3)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte2_ae3.sas 15FEB2023 10:40

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.009110
Graph of Kaplan-Meier Curves of Time to first Max Grade 3 or higher Adverse Event by SOC (if prerequisites are met)
System Organ Class: Psychiatric disorders



Number at Risk (Number of Events)	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
Pom/Dex	14(0)	14(0)	13(0)	12(1)	12(1)	10(1)	10(1)	8(1)	6(1)	4(1)	4(1)	3(1)	3(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	0(1)
Belamaf	29(0)	26(0)	19(0)	14(0)	9(0)	8(0)	7(0)	7(0)	7(0)	6(0)	5(0)	3(0)	2(0)	2(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	0(0)	0(0)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte2_ae3.sas 15FEB2023 10:40

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.009110
Graph of Kaplan-Meier Curves of Time to first Max Grade 3 or higher Adverse Event by SOC (if prerequisites are met)
System Organ Class: Renal and urinary disorders



Number at Risk (Number of Events)

	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
Pom/Dex	14(0)	14(0)	13(0)	13(0)	13(0)	11(0)	11(0)	9(0)	7(0)	5(0)	5(0)	4(0)	4(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	1(0)	1(0)	0(0)
Belamaf	29(0)	24(2)	17(3)	12(3)	8(3)	8(3)	7(3)	7(3)	7(3)	6(3)	5(3)	3(3)	2(3)	2(3)	1(3)	1(3)	1(3)	1(3)	1(3)	1(3)	1(3)	1(3)	1(3)	0(3)	0(3)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte2_ae3.sas 15FEB2023 10:40

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.009110
Graph of Kaplan-Meier Curves of Time to first Max Grade 3 or higher Adverse Event by SOC (if prerequisites are met)
System Organ Class: Respiratory, thoracic and mediastinal disorders



Number at Risk (Number of Events)	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
Pom/Dex	14(0)	13(1)	12(1)	12(1)	12(1)	10(1)	10(1)	8(1)	7(1)	5(1)	5(1)	4(1)	4(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	1(1)	1(1)	0(1)
Belamaf	29(0)	26(1)	19(1)	14(1)	9(1)	8(1)	7(1)	7(1)	7(1)	6(1)	5(1)	3(1)	2(1)	2(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	0(1)	0(1)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte2_ae3.sas 15FEB2023 10:40

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.010110
Graph of Kaplan-Meier Curves of Time to first Max Grade 3 or higher Adverse Event by SOC and PT (if prerequisites are met)
System Organ Class: Blood and lymphatic system disorders
Preferred Term: Anaemia



Number at Risk (Number of Events)	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
Pom/Dex	14(0)	14(0)	13(0)	13(0)	13(0)	11(0)	11(0)	9(0)	7(0)	5(0)	5(0)	4(0)	4(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	1(0)	1(0)	0(0)
Belamaf	29(0)	24(3)	17(4)	12(5)	9(5)	8(5)	7(5)	7(5)	7(5)	6(5)	5(5)	3(5)	2(5)	2(5)	1(5)	1(5)	1(5)	1(5)	1(5)	1(5)	1(5)	1(5)	1(5)	0(5)	0(5)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte2_pt_ae3.sas 16FEB2023 11:38

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.010110
Graph of Kaplan-Meier Curves of Time to first Max Grade 3 or higher Adverse Event by SOC and PT (if prerequisites are met)
System Organ Class: Blood and lymphatic system disorders
Preferred Term: Lymphopenia



Number at Risk (Number of Events)

	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
Pom/Dex	14(0)	13(1)	12(1)	12(1)	12(1)	10(1)	10(1)	8(1)	6(1)	5(1)	5(1)	4(1)	4(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	1(1)	1(1)	0(1)
Belamaf	29(0)	25(1)	19(1)	14(1)	9(1)	8(1)	7(1)	7(1)	7(1)	6(1)	5(1)	3(1)	2(1)	2(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	0(1)	0(1)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte2_pt_ae3.sas 16FEB2023 11:38

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.010110
Graph of Kaplan-Meier Curves of Time to first Max Grade 3 or higher Adverse Event by SOC and PT (if prerequisites are met)
System Organ Class: Blood and lymphatic system disorders
Preferred Term: Neutropenia



Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte2_pt_ae3.sas 16FEB2023 11:38

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.010110
Graph of Kaplan-Meier Curves of Time to first Max Grade 3 or higher Adverse Event by SOC and PT (if prerequisites are met)
System Organ Class: Blood and lymphatic system disorders
Preferred Term: Thrombocytopenia



Number at Risk (Number of Events)

Pom/Dex	14(0)	12(2)	11(2)	11(2)	11(2)	10(2)	10(2)	8(2)	6(2)	5(2)	5(2)	4(2)	4(2)	2(2)	2(2)	2(2)	2(2)	2(2)	2(2)	2(2)	2(2)	2(2)	1(2)	1(2)	0(2)
Belamaf	29(0)	21(5)	15(7)	12(7)	8(7)	7(7)	7(7)	7(7)	7(7)	6(7)	5(7)	3(7)	2(7)	2(7)	1(7)	1(7)	1(7)	1(7)	1(7)	1(7)	1(7)	1(7)	1(7)	0(7)	0(7)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte2_pt_ae3.sas 16FEB2023 11:38

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.010110
Graph of Kaplan-Meier Curves of Time to first Max Grade 3 or higher Adverse Event by SOC and PT (if prerequisites are met)
System Organ Class: Cardiac disorders
Preferred Term: Acute myocardial infarction



Number at Risk (Number of Events)

	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
Pom/Dex	14(0)	14(0)	13(0)	13(0)	13(0)	11(0)	11(0)	9(0)	7(0)	4(1)	4(1)	4(1)	4(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	1(1)	1(1)	0(1)
Belamaf	29(0)	26(0)	19(0)	14(0)	9(0)	8(0)	7(0)	7(0)	7(0)	6(0)	5(0)	3(0)	2(0)	2(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	0(0)	0(0)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte2_pt_ae3.sas 16FEB2023 11:38

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.010110
Graph of Kaplan-Meier Curves of Time to first Max Grade 3 or higher Adverse Event by SOC and PT (if prerequisites are met)
System Organ Class: Eye disorders
Preferred Term: Cataract



Number at Risk (Number of Events)

	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
Pom/Dex	14(0)	14(0)	13(0)	13(0)	13(0)	11(0)	11(0)	8(1)	6(1)	5(1)	5(1)	4(1)	4(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	1(1)	1(1)	0(1)
Belamaf	29(0)	26(0)	19(0)	14(0)	9(0)	8(0)	7(0)	7(0)	7(0)	6(0)	5(0)	3(0)	2(0)	2(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	0(0)	0(0)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte2_pt_ae3.sas 16FEB2023 11:38

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.010110
Graph of Kaplan-Meier Curves of Time to first Max Grade 3 or higher Adverse Event by SOC and PT (if prerequisites are met)
System Organ Class: Eye disorders
Preferred Term: Visual impairment



Number at Risk (Number of Events)	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
Pom/Dex	14(0)	14(0)	13(0)	13(0)	13(0)	11(0)	11(0)	9(0)	7(0)	5(0)	5(0)	4(0)	4(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	1(0)	1(0)	0(0)
Belamaf	29(0)	23(3)	16(3)	13(3)	9(3)	8(3)	7(3)	7(3)	7(3)	6(3)	5(3)	3(3)	2(3)	2(3)	1(3)	1(3)	1(3)	1(3)	1(3)	1(3)	1(3)	1(3)	1(3)	0(3)	0(3)

Time since Randomization (Months)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte2_pt_ae3.sas 16FEB2023 11:38

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.010110
Graph of Kaplan-Meier Curves of Time to first Max Grade 3 or higher Adverse Event by SOC and PT (if prerequisites are met)
System Organ Class: General disorders and administration site conditions
Preferred Term: Fatigue



Number at Risk (Number of Events)

	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
Pom/Dex	14(0)	13(1)	12(1)	12(1)	12(1)	10(1)	10(1)	8(1)	7(1)	5(1)	5(1)	4(1)	4(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	1(1)	1(1)	0(1)
Belamaf	29(0)	26(0)	19(0)	14(0)	9(0)	8(0)	7(0)	7(0)	7(0)	6(0)	5(0)	3(0)	2(0)	2(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	0(0)	0(0)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte2_pt_ae3.sas 16FEB2023 11:38

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.010110
Graph of Kaplan-Meier Curves of Time to first Max Grade 3 or higher Adverse Event by SOC and PT (if prerequisites are met)
System Organ Class: Infections and infestations
Preferred Term: COVID-19



Number at Risk (Number of Events)

Pom/Dex	14(0)	13(1)	13(1)	13(1)	13(1)	11(1)	11(1)	9(1)	7(1)	5(1)	5(1)	4(1)	4(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	1(1)	1(1)	0(1)
Belamaf	29(0)	26(0)	19(0)	14(0)	9(0)	8(0)	7(0)	7(0)	7(0)	6(0)	5(0)	3(0)	2(0)	2(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	0(0)	0(0)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte2_pt_ae3.sas 16FEB2023 11:38

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.010110
Graph of Kaplan-Meier Curves of Time to first Max Grade 3 or higher Adverse Event by SOC and PT (if prerequisites are met)
System Organ Class: Infections and infestations
Preferred Term: Pneumonia



Number at Risk (Number of Events)	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
	Time since Randomization (Months)																								
Pom/Dex	14(0)	14(0)	13(0)	12(1)	12(1)	10(1)	10(1)	8(1)	6(1)	5(1)	5(1)	4(1)	4(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	1(2)	1(2)	0(2)	0(2)	0(2)
Belamaf	29(0)	26(1)	19(1)	14(1)	9(1)	8(1)	7(1)	7(1)	7(1)	6(1)	5(1)	3(1)	2(1)	2(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	0(1)	0(1)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte2_pt_ae3.sas 16FEB2023 11:38

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.010110
Graph of Kaplan-Meier Curves of Time to first Max Grade 3 or higher Adverse Event by SOC and PT (if prerequisites are met)
System Organ Class: Infections and infestations
Preferred Term: Pulmonary nocardiosis



Number at Risk (Number of Events)

	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
Pom/Dex	14(0)	14(0)	13(0)	13(0)	13(0)	11(0)	11(0)	9(0)	7(0)	4(1)	4(1)	4(1)	4(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	1(1)	1(1)	0(1)
Belamaf	29(0)	26(0)	19(0)	14(0)	9(0)	8(0)	7(0)	7(0)	7(0)	6(0)	5(0)	3(0)	2(0)	2(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	0(0)	0(0)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte2_pt_ae3.sas 16FEB2023 11:38

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.010110
Graph of Kaplan-Meier Curves of Time to first Max Grade 3 or higher Adverse Event by SOC and PT (if prerequisites are met)
System Organ Class: Investigations
Preferred Term: Neutrophil count decreased



Number at Risk (Number of Events)

	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
Pom/Dex	14(0)	13(1)	12(1)	12(1)	12(1)	9(2)	9(2)	7(2)	5(2)	4(2)	4(2)	3(2)	3(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	0(2)	0(2)	0(2)
Belamaf	29(0)	26(0)	19(0)	14(0)	9(0)	8(0)	7(0)	7(0)	7(0)	6(0)	5(0)	3(0)	2(0)	2(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	0(0)	0(0)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte2_pt_ae3.sas 16FEB2023 11:38

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.010110
Graph of Kaplan-Meier Curves of Time to first Max Grade 3 or higher Adverse Event by SOC and PT (if prerequisites are met)
System Organ Class: Metabolism and nutrition disorders
Preferred Term: Hypercalcaemia



Number at Risk (Number of Events)

Pom/Dex	14(0)	14(0)	13(0)	13(0)	12(1)	11(1)	11(1)	9(1)	7(1)	5(1)	5(1)	4(1)	4(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	1(1)	1(1)	0(1)
Belamaf	29(0)	26(1)	19(1)	14(1)	9(1)	8(1)	7(1)	7(1)	7(1)	6(1)	5(1)	3(1)	2(1)	2(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	0(1)	0(1)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte2_pt_ae3.sas 16FEB2023 11:38

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.010110
Graph of Kaplan-Meier Curves of Time to first Max Grade 3 or higher Adverse Event by SOC and PT (if prerequisites are met)
System Organ Class: Metabolism and nutrition disorders
Preferred Term: Hypokalaemia



Number at Risk (Number of Events)

	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
Pom/Dex	14(0)	14(0)	13(0)	13(0)	13(0)	11(0)	11(0)	9(0)	7(0)	5(0)	5(0)	4(0)	4(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	1(0)	1(0)	0(0)
Belamaf	29(0)	26(0)	18(1)	13(1)	9(1)	8(1)	7(1)	7(1)	7(1)	6(1)	5(1)	2(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	0(2)	0(2)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte2_pt_ae3.sas 16FEB2023 11:38

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.010110
Graph of Kaplan-Meier Curves of Time to first Max Grade 3 or higher Adverse Event by SOC and PT (if prerequisites are met)
System Organ Class: Musculoskeletal and connective tissue disorders
Preferred Term: Bone pain



Number at Risk (Number of Events)

Pom/Dex	14(0)	13(1)	12(1)	12(1)	12(1)	10(1)	10(1)	8(1)	7(1)	5(1)	5(1)	4(1)	4(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	1(1)	1(1)	0(1)
Belamaf	29(0)	24(2)	17(2)	13(2)	9(2)	8(2)	7(2)	7(2)	7(2)	6(2)	5(2)	3(2)	2(2)	2(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	0(2)	0(2)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte2_pt_ae3.sas 16FEB2023 11:38

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.010110
Graph of Kaplan-Meier Curves of Time to first Max Grade 3 or higher Adverse Event by SOC and PT (if prerequisites are met)
System Organ Class: Musculoskeletal and connective tissue disorders
Preferred Term: Osteonecrosis of jaw



Number at Risk (Number of Events)

	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
Pom/Dex	14(0)	14(0)	13(0)	13(0)	13(0)	11(0)	10(1)	8(1)	6(1)	4(1)	4(1)	3(1)	3(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	1(1)	1(1)	0(1)
Belamaf	29(0)	26(0)	19(0)	14(0)	9(0)	8(0)	7(0)	7(0)	7(0)	6(0)	5(0)	3(0)	2(0)	2(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	0(0)	0(0)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte2_pt_ae3.sas 16FEB2023 11:38

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.010110
Graph of Kaplan-Meier Curves of Time to first Max Grade 3 or higher Adverse Event by SOC and PT (if prerequisites are met)
System Organ Class: Psychiatric disorders
Preferred Term: Insomnia



Number at Risk (Number of Events)

	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
Pom/Dex	14(0)	14(0)	13(0)	12(1)	12(1)	10(1)	10(1)	8(1)	6(1)	4(1)	4(1)	3(1)	3(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	0(1)
Belamaf	29(0)	26(0)	19(0)	14(0)	9(0)	8(0)	7(0)	7(0)	7(0)	6(0)	5(0)	3(0)	2(0)	2(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	0(0)	0(0)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte2_pt_ae3.sas 16FEB2023 11:38

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.010110
Graph of Kaplan-Meier Curves of Time to first Max Grade 3 or higher Adverse Event by SOC and PT (if prerequisites are met)
System Organ Class: Renal and urinary disorders
Preferred Term: Acute kidney injury



Number at Risk (Number of Events)

Pom/Dex	14(0)	14(0)	13(0)	13(0)	13(0)	11(0)	11(0)	9(0)	7(0)	5(0)	5(0)	4(0)	4(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	1(0)	1(0)	0(0)
Belamaf	29(0)	24(2)	18(2)	13(2)	9(2)	8(2)	7(2)	7(2)	7(2)	6(2)	5(2)	3(2)	2(2)	2(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	0(2)	0(2)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte2_pt_ae3.sas 16FEB2023 11:38

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.010110
Graph of Kaplan-Meier Curves of Time to first Max Grade 3 or higher Adverse Event by SOC and PT (if prerequisites are met)
System Organ Class: Respiratory, thoracic and mediastinal disorders
Preferred Term: Hiccups



Number at Risk (Number of Events)

	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
Pom/Dex	14(0)	13(1)	12(1)	12(1)	12(1)	10(1)	10(1)	8(1)	7(1)	5(1)	5(1)	4(1)	4(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	1(1)	1(1)	0(1)
Belamaf	29(0)	26(0)	19(0)	14(0)	9(0)	8(0)	7(0)	7(0)	7(0)	6(0)	5(0)	3(0)	2(0)	2(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	0(0)	0(0)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte2_pt_ae3.sas 16FEB2023 11:38

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.012110
Graph of Kaplan-Meier Curves of Time to first Serious Adverse Event by SOC
(if prerequisites are met)
System Organ Class: Cardiac disorders



Number at Risk (Number of Events)	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
Pom/Dex	14(0)	14(0)	13(0)	13(0)	13(0)	11(0)	11(0)	9(0)	7(0)	4(1)	4(1)	4(1)	4(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	1(1)	1(1)	0(1)
Belamaf	29(0)	25(1)	18(1)	13(1)	9(1)	8(1)	7(1)	7(1)	7(1)	6(1)	5(1)	3(1)	2(1)	2(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	0(1)	0(1)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte2_aes.sas 17FEB2023 08:38

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.012110
Graph of Kaplan-Meier Curves of Time to first Serious Adverse Event by SOC
(if prerequisites are met)
System Organ Class: Gastrointestinal disorders



Number at Risk (Number of Events)

	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
Pom/Dex	14(0)	14(0)	13(0)	13(0)	13(0)	11(0)	11(0)	9(0)	7(0)	5(0)	5(0)	4(0)	4(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	1(0)	1(0)	0(0)
Belamaf	29(0)	25(1)	19(1)	14(1)	8(2)	6(3)	5(3)	5(3)	5(3)	5(3)	4(3)	3(3)	2(3)	2(3)	1(3)	1(3)	1(3)	1(3)	1(3)	1(3)	1(3)	1(3)	1(3)	0(3)	0(3)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte2_aes.sas 17FEB2023 08:38

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.012110
Graph of Kaplan-Meier Curves of Time to first Serious Adverse Event by SOC
(if prerequisites are met)
System Organ Class: Infections and infestations



Number at Risk (Number of Events)																								
Pom/Dex	14(0)	13(1)	13(1)	12(2)	12(2)	10(2)	9(3)	8(3)	6(3)	4(4)	4(4)	4(4)	4(4)	2(4)	2(4)	2(4)	2(4)	2(4)	2(4)	2(4)	1(5)	1(5)	0(5)	0(5)	0(5)
Belamaf	29(0)	24(3)	18(3)	13(3)	8(3)	7(3)	6(3)	6(3)	6(3)	6(3)	5(3)	3(3)	2(3)	2(3)	1(3)	1(3)	1(3)	1(3)	1(3)	1(3)	1(3)	1(3)	1(3)	0(3)	0(3)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte2_aes.sas 17FEB2023 08:38

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.012110
Graph of Kaplan-Meier Curves of Time to first Serious Adverse Event by SOC
(if prerequisites are met)
System Organ Class: Investigations



Number at Risk (Number of Events)

Pom/Dex	14(0)	14(0)	13(0)	13(0)	13(0)	10(1)	10(1)	8(1)	6(1)	5(1)	5(1)	4(1)	4(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	1(1)	1(1)	0(1)
Belamaf	29(0)	26(1)	19(1)	14(1)	9(1)	8(1)	7(1)	7(1)	7(1)	6(1)	5(1)	3(1)	2(1)	2(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	0(1)	0(1)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte2_aes.sas 17FEB2023 08:38

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.012110
Graph of Kaplan-Meier Curves of Time to first Serious Adverse Event by SOC
(if prerequisites are met)
System Organ Class: Musculoskeletal and connective tissue disorders



Number at Risk
(Number of Events)

	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
Pom/Dex	14(0)	14(0)	13(0)	13(0)	13(0)	11(0)	11(0)	9(0)	7(0)	5(0)	5(0)	4(0)	4(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	1(0)	1(0)	0(0)
Belamaf	29(0)	24(2)	16(3)	12(4)	8(4)	7(4)	6(4)	6(4)	6(4)	6(4)	5(4)	3(4)	2(4)	2(4)	1(4)	1(4)	1(4)	1(4)	1(4)	1(4)	1(4)	1(4)	1(4)	0(4)	0(4)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte2_aes.sas 17FEB2023 08:38

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.012110
Graph of Kaplan-Meier Curves of Time to first Serious Adverse Event by SOC
(if prerequisites are met)
System Organ Class: Nervous system disorders



Number at Risk (Number of Events)	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
Pom/Dex	14(0)	14(0)	13(0)	13(0)	13(0)	11(0)	11(0)	9(0)	7(0)	5(0)	5(0)	4(0)	4(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	1(0)	1(0)	0(0)
Belamaf	29(0)	25(1)	18(2)	13(2)	9(2)	8(3)	7(3)	7(3)	7(3)	6(3)	5(3)	3(3)	2(3)	2(3)	1(3)	1(3)	1(3)	1(3)	1(3)	1(3)	1(3)	1(3)	1(3)	0(3)	0(3)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte2_aes.sas 17FEB2023 08:38

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.013110
Graph of Kaplan-Meier Curves of Time to first Serious Adverse Event by SOC and PT
(if prerequisites are met)
System Organ Class: Cardiac disorders
Preferred Term: Acute myocardial infarction



Number at Risk (Number of Events)	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
Time since Randomization (Months)																									
Pom/Dex	14(0)	14(0)	13(0)	13(0)	13(0)	11(0)	11(0)	9(0)	7(0)	4(1)	4(1)	4(1)	4(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	1(1)	1(1)	0(1)
Belamaf	29(0)	26(0)	19(0)	14(0)	9(0)	8(0)	7(0)	7(0)	7(0)	6(0)	5(0)	3(0)	2(0)	2(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	0(0)	0(0)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte2_pt_aes.sas 16FEB2023 11:39

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.013110
Graph of Kaplan-Meier Curves of Time to first Serious Adverse Event by SOC and PT
(if prerequisites are met)
System Organ Class: Infections and infestations
Preferred Term: COVID-19



Number at Risk (Number of Events)

	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
Pom/Dex	14(0)	13(1)	13(1)	13(1)	13(1)	11(1)	11(1)	9(1)	7(1)	5(1)	5(1)	4(1)	4(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	1(1)	1(1)	0(1)
Belamaf	29(0)	26(0)	19(0)	14(0)	9(0)	8(0)	7(0)	7(0)	7(0)	6(0)	5(0)	3(0)	2(0)	2(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	0(0)	0(0)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte2_pt_aes.sas 16FEB2023 11:39

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.013110
Graph of Kaplan-Meier Curves of Time to first Serious Adverse Event by SOC and PT
(if prerequisites are met)
System Organ Class: Infections and infestations
Preferred Term: COVID-19 pneumonia



Number at Risk (Number of Events)

	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
Pom/Dex	14(0)	14(0)	13(0)	13(0)	13(0)	11(0)	10(1)	9(1)	7(1)	5(1)	5(1)	4(1)	4(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	1(1)	1(1)	0(1)
Belamaf	29(0)	26(0)	19(0)	14(0)	9(0)	8(0)	7(0)	7(0)	7(0)	6(0)	5(0)	3(0)	2(0)	2(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	0(0)	0(0)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte2_pt_aes.sas 16FEB2023 11:39

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.013110
Graph of Kaplan-Meier Curves of Time to first Serious Adverse Event by SOC and PT
(if prerequisites are met)
System Organ Class: Infections and infestations
Preferred Term: Pneumonia



Number at Risk (Number of Events)	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
	Time since Randomization (Months)																								
Pom/Dex	14(0)	14(0)	13(0)	12(1)	12(1)	10(1)	10(1)	8(1)	6(1)	5(1)	5(1)	4(1)	4(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	1(2)	1(2)	0(2)	0(2)	0(2)
Belamaf	29(0)	25(2)	18(2)	13(2)	8(2)	7(2)	6(2)	6(2)	6(2)	6(2)	5(2)	3(2)	2(2)	2(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	0(2)	0(2)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte2_pt_aes.sas 16FEB2023 11:39

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.013110
Graph of Kaplan-Meier Curves of Time to first Serious Adverse Event by SOC and PT
(if prerequisites are met)
System Organ Class: Infections and infestations
Preferred Term: Pulmonary nocardiosis



Number at Risk (Number of Events)	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
Time since Randomization (Months)																									
Pom/Dex	14(0)	14(0)	13(0)	13(0)	13(0)	11(0)	11(0)	9(0)	7(0)	4(1)	4(1)	4(1)	4(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	1(1)	1(1)	0(1)
Belamaf	29(0)	26(0)	19(0)	14(0)	9(0)	8(0)	7(0)	7(0)	7(0)	6(0)	5(0)	3(0)	2(0)	2(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	0(0)	0(0)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte2_pt_aes.sas 16FEB2023 11:39

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.013110
Graph of Kaplan-Meier Curves of Time to first Serious Adverse Event by SOC and PT
(if prerequisites are met)
System Organ Class: Investigations
Preferred Term: Neutrophil count decreased



Number at Risk (Number of Events)	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
Pom/Dex	14(0)	14(0)	13(0)	13(0)	13(0)	10(1)	10(1)	8(1)	6(1)	5(1)	5(1)	4(1)	4(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	1(1)	1(1)	0(1)
Belamaf	29(0)	26(0)	19(0)	14(0)	9(0)	8(0)	7(0)	7(0)	7(0)	6(0)	5(0)	3(0)	2(0)	2(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	0(0)	0(0)

Time since Randomization (Months)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte2_pt_aes.sas 16FEB2023 11:39

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.013110
Graph of Kaplan-Meier Curves of Time to first Serious Adverse Event by SOC and PT
(if prerequisites are met)
System Organ Class: Musculoskeletal and connective tissue disorders
Preferred Term: Bone pain



Number at Risk (Number of Events)	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
Pom/Dex	14(0)	14(0)	13(0)	13(0)	13(0)	11(0)	11(0)	9(0)	7(0)	5(0)	5(0)	4(0)	4(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	1(0)	1(0)	0(0)
Belamaf	29(0)	24(2)	17(2)	13(2)	9(2)	8(2)	7(2)	7(2)	7(2)	6(2)	5(2)	3(2)	2(2)	2(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	0(2)	0(2)

Time since Randomization (Months)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte2_pt_aes.sas 16FEB2023 11:39

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.030110
Graph of Kaplan-Meier Curves of Time to first Non-Fatal Serious Adverse Event



Number at Risk (Number of Events)

Pom/Dex	14(0)	14(0)	13(0)	12(1)	12(1)	10(1)	9(2)	8(2)	6(2)	4(3)	4(3)	4(3)	4(3)	2(3)	2(3)	2(3)	2(3)	2(3)	2(3)	2(3)	1(4)	1(4)	0(4)	0(4)
Belamaf	29(0)	21(7)	13(9)	10(9)	7(10)	6(11)	5(11)	5(11)	5(11)	5(11)	4(11)	3(11)	2(11)	2(11)	1(11)	1(11)	1(11)	1(11)	1(11)	1(11)	1(11)	1(11)	1(11)	0(11)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte_aenfs.sas 17FEB2023 09:23

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.031110
Graph of Kaplan-Meier Curves of Time to first Non-Fatal Serious Adverse Event by SOC (if prerequisites are met)
System Organ Class: Cardiac disorders



Number at Risk (Number of Events)	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
Pom/Dex	14(0)	14(0)	13(0)	13(0)	13(0)	11(0)	11(0)	9(0)	7(0)	4(1)	4(1)	4(1)	4(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	1(1)	1(1)	0(1)
Belamaf	29(0)	25(1)	18(1)	13(1)	9(1)	8(1)	7(1)	7(1)	7(1)	6(1)	5(1)	3(1)	2(1)	2(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	0(1)	0(1)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte2_aenfs.sas 17FEB2023 09:28

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.031110
Graph of Kaplan-Meier Curves of Time to first Non-Fatal Serious Adverse Event by SOC (if prerequisites are met)
System Organ Class: Gastrointestinal disorders



Number at Risk (Number of Events)	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
Pom/Dex	14(0)	14(0)	13(0)	13(0)	13(0)	11(0)	11(0)	9(0)	7(0)	5(0)	5(0)	4(0)	4(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	1(0)	1(0)	0(0)
Belamaf	29(0)	26(0)	19(0)	14(0)	8(1)	6(2)	5(2)	5(2)	5(2)	5(2)	4(2)	3(2)	2(2)	2(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	0(2)	0(2)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte2_aenfs.sas 17FEB2023 09:28

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.031110
Graph of Kaplan-Meier Curves of Time to first Non-Fatal Serious Adverse Event by SOC (if prerequisites are met)
System Organ Class: Infections and infestations



Number at Risk (Number of Events)	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
Pom/Dex	14(0)	14(0)	13(0)	12(1)	12(1)	10(1)	9(2)	8(2)	6(2)	4(3)	4(3)	4(3)	4(3)	2(3)	2(3)	2(3)	2(3)	2(3)	2(3)	2(3)	1(4)	1(4)	0(4)	0(4)	0(4)
Belamaf	29(0)	25(2)	18(2)	13(2)	8(2)	7(2)	6(2)	6(2)	6(2)	6(2)	5(2)	3(2)	2(2)	2(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	0(2)	0(2)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte2_aenfs.sas 17FEB2023 09:28

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.031110
Graph of Kaplan-Meier Curves of Time to first Non-Fatal Serious Adverse Event by SOC
(if prerequisites are met)
System Organ Class: Investigations



Number at Risk (Number of Events)	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
Pom/Dex	14(0)	14(0)	13(0)	13(0)	13(0)	10(1)	10(1)	8(1)	6(1)	5(1)	5(1)	4(1)	4(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	1(1)	1(1)	0(1)
Belamaf	29(0)	26(1)	19(1)	14(1)	9(1)	8(1)	7(1)	7(1)	7(1)	6(1)	5(1)	3(1)	2(1)	2(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	0(1)	0(1)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte2_aenfs.sas 17FEB2023 09:28

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.031110
Graph of Kaplan-Meier Curves of Time to first Non-Fatal Serious Adverse Event by SOC (if prerequisites are met)
System Organ Class: Musculoskeletal and connective tissue disorders



Number at Risk (Number of Events)	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
Pom/Dex	14(0)	14(0)	13(0)	13(0)	13(0)	11(0)	11(0)	9(0)	7(0)	5(0)	5(0)	4(0)	4(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	1(0)	1(0)	0(0)
Belamaf	29(0)	24(2)	16(3)	12(4)	8(4)	7(4)	6(4)	6(4)	6(4)	6(4)	5(4)	3(4)	2(4)	2(4)	1(4)	1(4)	1(4)	1(4)	1(4)	1(4)	1(4)	1(4)	1(4)	0(4)	0(4)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte2_aenfs.sas 17FEB2023 09:28

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.031110
Graph of Kaplan-Meier Curves of Time to first Non-Fatal Serious Adverse Event by SOC (if prerequisites are met)
System Organ Class: Nervous system disorders



Number at Risk (Number of Events)	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
Pom/Dex	14(0)	14(0)	13(0)	13(0)	13(0)	11(0)	11(0)	9(0)	7(0)	5(0)	5(0)	4(0)	4(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	1(0)	1(0)	0(0)
Belamaf	29(0)	25(1)	18(2)	13(2)	9(2)	8(3)	7(3)	7(3)	7(3)	6(3)	5(3)	3(3)	2(3)	2(3)	1(3)	1(3)	1(3)	1(3)	1(3)	1(3)	1(3)	1(3)	1(3)	0(3)	0(3)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte2_aenfs.sas 17FEB2023 09:28

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.032110
Graph of Kaplan-Meier Curves of Time to first Non-Fatal Serious Adverse Event by SOC and PT (if prerequisites are met)
System Organ Class: Cardiac disorders
Preferred Term: Acute myocardial infarction



Number at Risk (Number of Events)

	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
Pom/Dex	14(0)	14(0)	13(0)	13(0)	13(0)	11(0)	11(0)	9(0)	7(0)	4(1)	4(1)	4(1)	4(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	1(1)	1(1)	0(1)
Belamaf	29(0)	26(0)	19(0)	14(0)	9(0)	8(0)	7(0)	7(0)	7(0)	6(0)	5(0)	3(0)	2(0)	2(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	0(0)	0(0)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte2_pt_aenfs.sas 17FEB2023 09:28

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.032110
Graph of Kaplan-Meier Curves of Time to first Non-Fatal Serious Adverse Event by SOC and PT (if prerequisites are met)
System Organ Class: Infections and infestations
Preferred Term: COVID-19 pneumonia



Number at Risk (Number of Events)	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
Pom/Dex	14(0)	14(0)	13(0)	13(0)	13(0)	11(0)	10(1)	9(1)	7(1)	5(1)	5(1)	4(1)	4(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	1(1)	1(1)	0(1)
Belamaf	29(0)	26(0)	19(0)	14(0)	9(0)	8(0)	7(0)	7(0)	7(0)	6(0)	5(0)	3(0)	2(0)	2(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	0(0)	0(0)

Time since Randomization (Months)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte2_pt_aenfs.sas 17FEB2023 09:28

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.032110
Graph of Kaplan-Meier Curves of Time to first Non-Fatal Serious Adverse Event by SOC and PT (if prerequisites are met)
System Organ Class: Infections and infestations
Preferred Term: Pneumonia



Number at Risk (Number of Events)	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
Time since Randomization (Months)																									
Pom/Dex	14(0)	14(0)	13(0)	12(1)	12(1)	10(1)	10(1)	8(1)	6(1)	5(1)	5(1)	4(1)	4(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	1(2)	1(2)	0(2)	0(2)	0(2)
Belamaf	29(0)	25(2)	18(2)	13(2)	8(2)	7(2)	6(2)	6(2)	6(2)	6(2)	5(2)	3(2)	2(2)	2(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	0(2)	0(2)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte2_pt_aenfs.sas 17FEB2023 09:28

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.032110
Graph of Kaplan-Meier Curves of Time to first Non-Fatal Serious Adverse Event by SOC and PT (if prerequisites are met)
System Organ Class: Infections and infestations
Preferred Term: Pulmonary nocardiosis



Number at Risk (Number of Events)

	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
Pom/Dex	14(0)	14(0)	13(0)	13(0)	13(0)	11(0)	11(0)	9(0)	7(0)	4(1)	4(1)	4(1)	4(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	1(1)	1(1)	0(1)
Belamaf	29(0)	26(0)	19(0)	14(0)	9(0)	8(0)	7(0)	7(0)	7(0)	6(0)	5(0)	3(0)	2(0)	2(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	0(0)	0(0)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte2_pt_aenfs.sas 17FEB2023 09:28

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.032110
Graph of Kaplan-Meier Curves of Time to first Non-Fatal Serious Adverse Event by SOC and PT (if prerequisites are met)
System Organ Class: Investigations
Preferred Term: Neutrophil count decreased



Number at Risk (Number of Events)	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
Time since Randomization (Months)																									
Pom/Dex	14(0)	14(0)	13(0)	13(0)	13(0)	10(1)	10(1)	8(1)	6(1)	5(1)	5(1)	4(1)	4(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	1(1)	1(1)	0(1)
Belamaf	29(0)	26(0)	19(0)	14(0)	9(0)	8(0)	7(0)	7(0)	7(0)	6(0)	5(0)	3(0)	2(0)	2(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	0(0)	0(0)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte2_pt_aenfs.sas 17FEB2023 09:28

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.032110
Graph of Kaplan-Meier Curves of Time to first Non-Fatal Serious Adverse Event by SOC and PT (if prerequisites are met)
System Organ Class: Musculoskeletal and connective tissue disorders
Preferred Term: Bone pain



Number at Risk (Number of Events)

	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
Pom/Dex	14(0)	14(0)	13(0)	13(0)	13(0)	11(0)	11(0)	9(0)	7(0)	5(0)	5(0)	4(0)	4(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	1(0)	1(0)	0(0)
Belamaf	29(0)	24(2)	17(2)	13(2)	9(2)	8(2)	7(2)	7(2)	7(2)	6(2)	5(2)	3(2)	2(2)	2(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	0(2)	0(2)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte2_pt_aenfs.sas 17FEB2023 09:28

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.005110
Graph of Kaplan-Meier Curves of Time to Fatal Adverse Event by SOC
(if prerequisites are met)
System Organ Class: Infections and infestations



Number at Risk (Number of Events)	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
Pom/Dex	14(0)	13(1)	13(1)	13(1)	13(1)	11(1)	11(1)	9(1)	7(1)	5(1)	5(1)	4(1)	4(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	1(1)	1(1)	0(1)
Belamaf	29(0)	25(1)	19(1)	14(1)	9(1)	8(1)	7(1)	7(1)	7(1)	6(1)	5(1)	3(1)	2(1)	2(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	0(1)	0(1)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte2_aef.sas 15FEB2023 10:39

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.006110
Graph of Kaplan-Meier Curves of Time to Fatal Adverse Event by SOC and PT
(if prerequisites are met)
System Organ Class: Infections and infestations
Preferred Term: COVID-19



Number at Risk (Number of Events)

Pom/Dex	14(0)	13(1)	13(1)	13(1)	13(1)	11(1)	11(1)	9(1)	7(1)	5(1)	5(1)	4(1)	4(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	1(1)	1(1)	0(1)
Belamaf	29(0)	26(0)	19(0)	14(0)	9(0)	8(0)	7(0)	7(0)	7(0)	6(0)	5(0)	3(0)	2(0)	2(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	0(0)	0(0)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte2_pt_aef.sas 16FEB2023 11:38

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR)

Data as of 12SEP2022

Figure 3.026110
Graph of Kaplan-Meier Curves of Time to first AESI



Number at Risk (Number of Events)	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23
Pom/Dex	14(0)	9(5)	8(5)	8(5)	8(5)	6(7)	6(7)	4(7)	2(7)	1(7)	1(7)	1(7)	1(7)	0(7)	0(7)	0(7)	0(7)	0(7)	0(7)	0(7)	0(7)	0(7)	0(7)	0(7)
Belamaf	29(0)	15(13)	9(17)	6(18)	4(18)	4(18)	3(19)	3(19)	3(19)	2(19)	2(19)	1(19)	1(19)	1(19)	1(19)	1(19)	1(19)	1(19)	1(19)	1(19)	1(19)	1(19)	1(19)	0(19)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte_aesi.sas 15FEB2023 05:42

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR)

Data as of 12SEP2022

Figure 3.028110
Graph of Kaplan-Meier Curves of Time to first AESI of Max Grade 2 or less



Number at Risk (Number of Events)	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23
Pom/Dex	14(0)	11(3)	10(3)	10(3)	10(3)	7(5)	7(5)	5(5)	3(5)	1(5)	1(5)	1(5)	1(5)	0(5)	0(5)	0(5)	0(5)	0(5)	0(5)	0(5)	0(5)	0(5)	0(5)	0(5)
Belamaf	29(0)	16(11)	11(13)	7(14)	5(14)	5(14)	3(15)	3(15)	3(15)	2(15)	2(15)	1(15)	1(15)	1(15)	1(15)	1(15)	1(15)	1(15)	1(15)	1(15)	1(15)	1(15)	1(15)	0(15)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte_aesi2.sas 15FEB2023 05:42

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.027110
Graph of Kaplan-Meier Curves of Time to first AESI of Max Grade 3 or higher



Number at Risk (Number of Events)

	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
Pom/Dex	14(0)	12(2)	11(2)	11(2)	11(2)	10(2)	10(2)	8(2)	6(2)	5(2)	5(2)	4(2)	4(2)	2(2)	2(2)	2(2)	2(2)	2(2)	2(2)	2(2)	2(2)	2(2)	1(2)	1(2)	0(2)
Belamaf	29(0)	20(7)	13(10)	10(10)	7(10)	5(11)	5(11)	5(11)	5(11)	4(11)	3(11)	2(11)	1(11)	1(11)	1(11)	1(11)	1(11)	1(11)	1(11)	1(11)	1(11)	1(11)	1(11)	0(11)	0(11)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte_aesi3.sas 15FEB2023 05:42

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR)

Data as of 12SEP2022

Figure 3.029110
Graph of Kaplan-Meier Curves of Time to first Serious AESI



Number at Risk (Number of Events)	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
Pom/Dex	14(0)	14(0)	13(0)	13(0)	13(0)	11(0)	11(0)	9(0)	7(0)	5(0)	5(0)	4(0)	4(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	1(0)	1(0)	0(0)
Belamaf	29(0)	25(2)	18(2)	13(2)	9(2)	8(2)	7(2)	7(2)	7(2)	6(2)	5(2)	3(2)	2(2)	2(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	0(2)	0(2)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte_aesis.sas 17FEB2023 09:11

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR)

Data as of 12SEP2022

Figure 3.014110
Graph of Kaplan-Meier Curves of Time to first Corneal Events Adverse Event



Number at Risk (Number of Events)

	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23
Pom/Dex	14(0)	14(0)	13(0)	12(1)	12(1)	9(2)	9(2)	7(2)	5(2)	3(2)	3(2)	3(2)	3(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	0(2)	0(2)
Belamaf	29(0)	18(8)	11(11)	7(12)	5(12)	5(12)	4(12)	4(12)	4(12)	3(12)	2(12)	1(12)	1(12)	1(12)	1(12)	1(12)	1(12)	1(12)	1(12)	1(12)	1(12)	1(12)	1(12)	0(12)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte_aec.sas 15FEB2023 05:13

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR)

Data as of 12SEP2022

Figure 3.015110
Graph of Kaplan-Meier Curves of Time to first Corneal Events of Max Grade 2 or less Adverse Event



Number at Risk (Number of Events)

Pom/Dex	14(0)	14(0)	13(0)	12(1)	12(1)	9(2)	9(2)	7(2)	5(2)	3(2)	3(2)	3(2)	3(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	0(2)	0(2)
Belamaf	29(0)	19(7)	12(10)	7(11)	5(11)	5(11)	4(11)	4(11)	4(11)	3(11)	2(11)	1(11)	1(11)	1(11)	1(11)	1(11)	1(11)	1(11)	1(11)	1(11)	1(11)	1(11)	0(11)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte_aec2.sas 15FEB2023 05:13

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.016110
Graph of Kaplan-Meier Curves of Time to first Corneal Events of Max Grade 3 or higher Adverse Event



Number at Risk (Number of Events)	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
Pom/Dex	14(0)	14(0)	13(0)	13(0)	13(0)	11(0)	11(0)	9(0)	7(0)	5(0)	5(0)	4(0)	4(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	1(0)	1(0)	0(0)
Belamaf	29(0)	23(3)	15(5)	12(5)	8(5)	6(6)	5(6)	5(6)	5(6)	4(6)	3(6)	2(6)	1(6)	1(6)	1(6)	1(6)	1(6)	1(6)	1(6)	1(6)	1(6)	1(6)	1(6)	0(6)	0(6)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte_aec3.sas 15FEB2023 05:14

Protocol: 207495

Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.017110

Graph of Kaplan-Meier Curves of Time to first Corneal Events Serious Adverse Event



Number at Risk (Number of Events)

	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
Pom/Dex	14(0)	14(0)	13(0)	13(0)	13(0)	11(0)	11(0)	9(0)	7(0)	5(0)	5(0)	4(0)	4(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	1(0)	1(0)	0(0)
Belamaf	29(0)	26(0)	19(0)	14(0)	9(0)	8(0)	7(0)	7(0)	7(0)	6(0)	5(0)	3(0)	2(0)	2(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	1(0)	0(0)	0(0)

Note: Analysis only includes treatment emergent adverse events.

Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte_aesc.sas 15FEB2023 05:14

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.022110
Graph of Kaplan-Meier Curves of Time to first Thrombocytopenia Adverse Event



Number at Risk (Number of Events)	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
Pom/Dex	14(0)	9(5)	8(5)	8(5)	8(5)	7(6)	7(6)	5(6)	3(6)	2(6)	2(6)	2(6)	2(6)	1(6)	1(6)	1(6)	1(6)	1(6)	1(6)	1(6)	1(6)	1(6)	1(6)	1(6)	0(6)
Belamaf	29(0)	21(7)	15(9)	11(10)	7(10)	6(10)	5(11)	5(11)	5(11)	4(11)	4(11)	3(11)	2(11)	2(11)	1(11)	1(11)	1(11)	1(11)	1(11)	1(11)	1(11)	1(11)	1(11)	0(11)	0(11)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte_aeth.sas 15FEB2023 05:23

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.023110
Graph of Kaplan-Meier Curves of Time to first Thrombocytopenia of Max Grade 2 or less Adverse Event



Number at Risk (Number of Events)

Pom/Dex	14(0)	11(3)	10(3)	10(3)	10(3)	8(4)	8(4)	6(4)	4(4)	2(4)	2(4)	2(4)	2(4)	1(4)	1(4)	1(4)	1(4)	1(4)	1(4)	1(4)	1(4)	1(4)	1(4)	0(4)
Belamaf	29(0)	24(3)	18(3)	12(4)	8(4)	7(4)	5(5)	5(5)	5(5)	4(5)	4(5)	3(5)	2(5)	2(5)	1(5)	1(5)	1(5)	1(5)	1(5)	1(5)	1(5)	1(5)	1(5)	0(5)	0(5)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte_aeth2.sas 15FEB2023 05:23

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR)

Data as of 12SEP2022

Figure 3.024110
Graph of Kaplan-Meier Curves of Time to first Thrombocytopenia of Max Grade 3 or higher Adverse Event



Number at Risk (Number of Events)	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
Pom/Dex	14(0)	12(2)	11(2)	11(2)	11(2)	10(2)	10(2)	8(2)	6(2)	5(2)	5(2)	4(2)	4(2)	2(2)	2(2)	2(2)	2(2)	2(2)	2(2)	2(2)	2(2)	2(2)	1(2)	1(2)	0(2)
Belamaf	29(0)	21(6)	15(8)	12(8)	8(8)	7(8)	7(8)	7(8)	7(8)	6(8)	5(8)	3(8)	2(8)	2(8)	1(8)	1(8)	1(8)	1(8)	1(8)	1(8)	1(8)	1(8)	1(8)	0(8)	0(8)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte_aeth3.sas 15FEB2023 05:23

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.025110
Graph of Kaplan-Meier Curves of Time to first Thrombocytopenia Serious Adverse Event



Number at Risk (Number of Events)	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
Pom/Dex	14(0)	14(0)	13(0)	13(0)	13(0)	11(0)	11(0)	9(0)	7(0)	5(0)	5(0)	4(0)	4(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	1(0)	1(0)	0(0)
Belamaf	29(0)	26(1)	19(1)	14(1)	9(1)	8(1)	7(1)	7(1)	7(1)	6(1)	5(1)	3(1)	2(1)	2(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	0(1)	0(1)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte_aesth.sas 15FEB2023 05:45

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.018110
Graph of Kaplan-Meier Curves of Time to first Infusion-Related Reactions Adverse Event



Number at Risk (Number of Events)	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
Pom/Dex	14(0)	14(0)	13(0)	13(0)	13(0)	11(0)	11(0)	9(0)	7(0)	5(0)	5(0)	4(0)	4(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	1(0)	1(0)	0(0)
Belamaf	29(0)	22(4)	17(4)	13(4)	9(4)	8(4)	7(4)	7(4)	7(4)	6(4)	5(4)	3(4)	2(4)	2(4)	1(4)	1(4)	1(4)	1(4)	1(4)	1(4)	1(4)	1(4)	1(4)	0(4)	0(4)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte_aeir.sas 17FEB2023 05:13

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.019110
Graph of Kaplan-Meier Curves of Time to first Infusion-Related Reactions of Max Grade 2 or less Adverse Event



Number at Risk (Number of Events)	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
Pom/Dex	14(0)	14(0)	13(0)	13(0)	13(0)	11(0)	11(0)	9(0)	7(0)	5(0)	5(0)	4(0)	4(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	1(0)	1(0)	0(0)
Belamaf	29(0)	23(3)	17(4)	13(4)	9(4)	8(4)	7(4)	7(4)	7(4)	6(4)	5(4)	3(4)	2(4)	2(4)	1(4)	1(4)	1(4)	1(4)	1(4)	1(4)	1(4)	1(4)	1(4)	0(4)	0(4)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte_aeir2.sas 17FEB2023 05:13

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.020110
Graph of Kaplan-Meier Curves of Time to first Infusion-Related Reactions of Max Grade 3 or higher Adverse Event



Number at Risk (Number of Events)

	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
Pom/Dex	14(0)	14(0)	13(0)	13(0)	13(0)	11(0)	11(0)	9(0)	7(0)	5(0)	5(0)	4(0)	4(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	1(0)	1(0)	0(0)
Belamaf	29(0)	25(1)	18(1)	13(1)	9(1)	8(1)	7(1)	7(1)	7(1)	6(1)	5(1)	3(1)	2(1)	2(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	0(1)	0(1)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte_aeir3.sas 17FEB2023 05:13

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 3.021110
Graph of Kaplan-Meier Curves of Time to first Infusion-Related Reactions Serious Adverse Event



Number at Risk (Number of Events)	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
Pom/Dex	14(0)	14(0)	13(0)	13(0)	13(0)	11(0)	11(0)	9(0)	7(0)	5(0)	5(0)	4(0)	4(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	1(0)	1(0)	0(0)
Belamaf	29(0)	25(1)	18(1)	13(1)	9(1)	8(1)	7(1)	7(1)	7(1)	6(1)	5(1)	3(1)	2(1)	2(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	0(1)	0(1)

Note: Analysis only includes treatment emergent adverse events.
Note: Subjects are censored at the earliest date out of the following: Treatment end date + 70 days, new anti-cancer therapy date and last contact date.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_s_tte_aeirs.sas 17FEB2023 05:13

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR)

Data as of 12SEP2022

Figure 4.001110
Stacked Bar Chart of PRO-CTCAE Score by Attributes and Visit
Parameter: Abdominal Pain - Frequency Scale



PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_f1_ctcae.sas 15MAR2023 04:46

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR)

Data as of 12SEP2022

Figure 4.001110
Stacked Bar Chart of PRO-CTCAE Score by Attributes and Visit
Parameter: Abdominal Pain - Interference Scale



PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_f1_ctcae.sas 15MAR2023 04:46

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR)

Data as of 12SEP2022

Figure 4.001110
Stacked Bar Chart of PRO-CTCAE Score by Attributes and Visit
Parameter: Abdominal Pain - Severity Scale



PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_f1_ctcae.sas 15MAR2023 04:46

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR)

Data as of 12SEP2022

Figure 4.001110
Stacked Bar Chart of PRO-CTCAE Score by Attributes and Visit
Parameter: Blurred Vision - Interference Scale



PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_f1_ctcae.sas 15MAR2023 04:46

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR)

Data as of 12SEP2022

Figure 4.001110
Stacked Bar Chart of PRO-CTCAE Score by Attributes and Visit
Parameter: Blurred Vision - Severity Scale



PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_f1_ctcae.sas 15MAR2023 04:46

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR)

Data as of 12SEP2022

Figure 4.001110
Stacked Bar Chart of PRO-CTCAE Score by Attributes and Visit
Parameter: Constipation - Severity Scale



PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_f1_ctcae.sas 15MAR2023 04:46

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR)

Data as of 12SEP2022

Figure 4.001110
Stacked Bar Chart of PRO-CTCAE Score by Attributes and Visit
Parameter: Cough - Interference Scale



PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_f1_ctcae.sas 15MAR2023 04:46

Figure 4.001110
Stacked Bar Chart of PRO-CTCAE Score by Attributes and Visit
Parameter: Cough - Severity Scale



PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_f1_ctcae.sas 15MAR2023 04:46

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR)

Data as of 12SEP2022

Figure 4.001110
Stacked Bar Chart of PRO-CTCAE Score by Attributes and Visit
Parameter: Decreased Appetite - Interference Scale



PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_f1_ctcae.sas 15MAR2023 04:46

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR)

Data as of 12SEP2022

Figure 4.001110
Stacked Bar Chart of PRO-CTCAE Score by Attributes and Visit
Parameter: Decreased Appetite - Severity Scale



PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_f1_ctcae.sas 15MAR2023 04:46

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR)

Data as of 12SEP2022

Figure 4.001110
Stacked Bar Chart of PRO-CTCAE Score by Attributes and Visit
Parameter: Fatigue - Interference Scale



PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_f1_ctcae.sas 15MAR2023 04:46

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR)

Data as of 12SEP2022

Figure 4.001110
Stacked Bar Chart of PRO-CTCAE Score by Attributes and Visit
Parameter: Fatigue - Severity Scale



PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_f1_ctcae.sas 15MAR2023 04:46

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR)

Data as of 12SEP2022

Figure 4.001110
Stacked Bar Chart of PRO-CTCAE Score by Attributes and Visit
Parameter: Itchy - Severity Scale



PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_f1_ctcae.sas 15MAR2023 04:46

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR)

Data as of 12SEP2022

Figure 4.001110
Stacked Bar Chart of PRO-CTCAE Score by Attributes and Visit
Parameter: Loose/Watery Stools - Frequency Scale



PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_f1_ctcae.sas 15MAR2023 04:46

Figure 4.001110
Stacked Bar Chart of PRO-CTCAE Score by Attributes and Visit
Parameter: Mouth/Throat Sores - Interference Scale



PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_f1_ctcae.sas 15MAR2023 04:46

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR)

Data as of 12SEP2022

Figure 4.001110
Stacked Bar Chart of PRO-CTCAE Score by Attributes and Visit
Parameter: Mouth/Throat Sores - Severity Scale



PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_f1_ctcae.sas 15MAR2023 04:46

Figure 4.001110
Stacked Bar Chart of PRO-CTCAE Score by Attributes and Visit
Parameter: Nausea - Frequency Scale



PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_f1_ctcae.sas 15MAR2023 04:46

Figure 4.001110
Stacked Bar Chart of PRO-CTCAE Score by Attributes and Visit
Parameter: Nausea - Severity Scale



PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_f1_ctcae.sas 15MAR2023 04:46

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR)

Data as of 12SEP2022

Figure 4.001110
Stacked Bar Chart of PRO-CTCAE Score by Attributes and Visit
Parameter: Nosebleeds - Frequency Scale



PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_f1_ctcae.sas 15MAR2023 04:46

Figure 4.001110
Stacked Bar Chart of PRO-CTCAE Score by Attributes and Visit
Parameter: Nosebleeds - Severity Scale



PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_f1_ctcae.sas 15MAR2023 04:46

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR)

Data as of 12SEP2022

Figure 4.001110
Stacked Bar Chart of PRO-CTCAE Score by Attributes and Visit
Parameter: Numb/Tingling Hands/Feet - Interference Scale



PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_f1_ctcae.sas 15MAR2023 04:46

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR)

Data as of 12SEP2022

Figure 4.001110
Stacked Bar Chart of PRO-CTCAE Score by Attributes and Visit
Parameter: Numb/Tingling Hands/Feet - Severity Scale



PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_f1_ctcae.sas 15MAR2023 04:46

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR)

Data as of 12SEP2022

Figure 4.001110
Stacked Bar Chart of PRO-CTCAE Score by Attributes and Visit
Parameter: Pain/Burning Urination - Severity Scale

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_f1_ctcae.sas 15MAR2023 04:46

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR)

Data as of 12SEP2022

Figure 4.001110
Stacked Bar Chart of PRO-CTCAE Score by Attributes and Visit
Parameter: Problems Tasting Food/Drink - Severity Scale



PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_f1_ctcae.sas 15MAR2023 04:46

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR)

Data as of 12SEP2022

Figure 4.001110
Stacked Bar Chart of PRO-CTCAE Score by Attributes and Visit
Parameter: Shivering/Shaking Chills - Frequency Scale



PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_f1_ctcae.sas 15MAR2023 04:46

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR)

Data as of 12SEP2022

Figure 4.001110
Stacked Bar Chart of PRO-CTCAE Score by Attributes and Visit
Parameter: Shivering/Shaking Chills - Severity Scale



PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_f1_ctcae.sas 15MAR2023 04:46

Figure 4.001110
Stacked Bar Chart of PRO-CTCAE Score by Attributes and Visit
Parameter: Shortness Of Breath - Interference Scale



PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_f1_ctcae.sas 15MAR2023 04:46

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR)

Data as of 12SEP2022

Figure 4.001110
Stacked Bar Chart of PRO-CTCAE Score by Attributes and Visit
Parameter: Shortness Of Breath - Severity Scale



PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_f1_ctcae.sas 15MAR2023 04:46

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR)

Data as of 12SEP2022

Figure 4.001110
Stacked Bar Chart of PRO-CTCAE Score by Attributes and Visit
Parameter: Vomiting - Frequency Scale



PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_f1_ctcae.sas 15MAR2023 04:46

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR)

Data as of 12SEP2022

Figure 4.001110
Stacked Bar Chart of PRO-CTCAE Score by Attributes and Visit
Parameter: Vomiting - Severity Scale



PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_f1_ctcae.sas 15MAR2023 04:46

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR)

Data as of 12SEP2022

Figure 4.001110
Stacked Bar Chart of PRO-CTCAE Score by Attributes and Visit
Parameter: Watery Eyes - Interference Scale



PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_f1_ctcae.sas 15MAR2023 04:46

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR)

Data as of 12SEP2022

Figure 4.001110
Stacked Bar Chart of PRO-CTCAE Score by Attributes and Visit
Parameter: Watery Eyes - Severity Scale



PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_f1_ctcae.sas 15MAR2023 04:46

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.044110
Plot of Least Squares Mean (95% CI) of OSDI Scores
Domain: Environmental Triggers



Pom/Dex - n	10	8	9	10	9	9	7	7	5	5	0	0	0	6
Belamaf - n	19	15	9	9	8	7	5	6	6	7	0	0	0	9

Note: EOT = "End of Treatment".
Note: Interval shown represents 95% confidence limits around mean at each planned time.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_f3_osdi_dom.sas 13MAR2023 10:14

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.044110
Plot of Least Squares Mean (95% CI) of OSDI Scores

Domain: Ocular Symptom



Pom/Dex - n	12	11	12	12	11	12	8	9	7	7	6	4	4	9
Belamaf - n	22	18	11	10	10	9	8	7	7	7	6	6	6	11

Note: EOT = "End of Treatment".
Note: Interval shown represents 95% confidence limits around mean at each planned time.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_f3_osdi_dom.sas 13MAR2023 10:14

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.044110
Plot of Least Squares Mean (95% CI) of OSDI Scores

Domain: Total Score



Pom/Dex - n	12	11	12	12	11	12	8	9	7	7	6	4	4	9
Belamaf - n	22	18	11	10	10	9	8	7	7	7	6	6	6	11

Note: EOT = "End of Treatment".
Note: Interval shown represents 95% confidence limits around mean at each planned time.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_f3_osdi_dom.sas 13MAR2023 10:14

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.044110
Plot of Least Squares Mean (95% CI) of OSDI Scores
Domain: Vision-Related Function



Pom/Dex - n	12	11	12	12	11	12	8	9	7	7	6	4	4	9
Belamaf - n	22	18	11	10	10	9	8	7	7	7	6	6	6	11

Note: EOT = "End of Treatment".
Note: Interval shown represents 95% confidence limits around mean at each planned time.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_f3_osdi_dom.sas 13MAR2023 10:14

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.045110
Plot of Least Squares Mean (95% CI) Change from Baseline of OSDI Scores
Domain: Environmental Triggers



	WK 4	WK 7	WK 10	WK 13	WK 16	WK 19	WK 22	WK 25	WK 28	WK 31	WK 34	WK 37	WK 40	EOT
Pom/Dex - n	10	8	9	10	9	9	7	7	5	5	0	0	0	6
Belamaf - n	19	15	9	9	8	7	5	6	6	7	0	0	0	9

Note: EOT = "End of Treatment".
Note: Interval shown represents 95% confidence limits around mean at each planned time.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_f3_osdi_dom_cfb.sas 13MAR2023 10:14

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.045110
Plot of Least Squares Mean (95% CI) Change from Baseline of OSDI Scores
Domain: Ocular Symptom



	WK 4	WK 7	WK 10	WK 13	WK 16	WK 19	WK 22	WK 25	WK 28	WK 31	WK 34	WK 37	WK 40	EOT
Pom/Dex - n	12	11	12	12	11	12	8	9	7	7	6	4	4	9
Belamaf - n	22	18	11	10	10	9	8	7	7	7	6	6	6	11

Note: EOT = "End of Treatment".
Note: Interval shown represents 95% confidence limits around mean at each planned time.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.
PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_f3_osdi_dom_cfb.sas 13MAR2023 10:14

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.045110
Plot of Least Squares Mean (95% CI) Change from Baseline of OSDI Scores
Domain: Total Score



Pom/Dex - n	12	11	12	12	11	12	8	9	7	7	6	4	4	9
Belamaf - n	22	18	11	10	10	9	8	7	7	7	6	6	6	11

Note: EOT = "End of Treatment".
Note: Interval shown represents 95% confidence limits around mean at each planned time.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_f3_osdi_dom_cfb.sas 13MAR2023 10:14

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.045110
Plot of Least Squares Mean (95% CI) Change from Baseline of OSDI Scores
Domain: Vision-Related Function



	WK 4	WK 7	WK 10	WK 13	WK 16	WK 19	WK 22	WK 25	WK 28	WK 31	WK 34	WK 37	WK 40	EOT
Pom/Dex - n	12	11	12	12	11	12	8	9	7	7	6	4	4	9
Belamaf - n	22	18	11	10	10	9	8	7	7	7	6	6	6	11

Note: EOT = "End of Treatment".
Note: Interval shown represents 95% confidence limits around mean at each planned time.
Note: Analysis performed using a repeated measures model with covariates of treatment group, visit, baseline value, treatment by visit interactions and baseline value by visit interactions.
Note: Statistics are only calculated if the number of subjects with analysable data at the current time point is >= 10 in total across both treatments.

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_f3_osdi_dom_cfb.sas 13MAR2023 10:14

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR)

Data as of 12SEP2022

Figure 4.096110
Graph of Kaplan-Meier Curves of OSDI Time to first Improvement
(Up to and including Last Follow-Up)
Item Score: Total Score



Number at Risk
(Number of Events)

Pom/Dex	14(0)	11(1)	11(1)	11(1)	11(1)	9(1)	7(1)	7(1)	5(1)	5(1)	5(1)	3(1)	3(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	1(1)	0(1)
Belamaf	29(0)	19(1)	13(3)	12(4)	10(4)	9(4)	8(4)	8(4)	8(4)	7(4)	6(4)	6(4)	4(4)	3(4)	2(4)	2(4)	1(4)	1(4)	1(4)	1(4)	1(4)	1(4)	0(4)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_os_tfi.sas 13MAR2023 10:05

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR)

Data as of 12SEP2022

Figure 4.096110
Graph of Kaplan-Meier Curves of OSDI Time to first Improvement
(Up to and including Last Follow-Up)
Item Score: Ocular Symptoms



Number at Risk
(Number of Events)

Pom/Dex	14(0)	11(1)	11(1)	11(1)	11(1)	9(1)	7(1)	7(1)	5(1)	5(1)	5(1)	3(1)	3(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	1(1)	0(1)
Belamaf	29(0)	20(0)	14(2)	14(2)	12(2)	10(2)	9(2)	9(2)	8(2)	7(2)	6(2)	6(2)	4(2)	3(2)	2(2)	2(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	0(2)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_os_tfi.sas 13MAR2023 10:05

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR)

Data as of 12SEP2022

Figure 4.096110
Graph of Kaplan-Meier Curves of OSDI Time to first Improvement
(Up to and including Last Follow-Up)
Item Score: Vision-related Function



Number at Risk
(Number of Events)

Pom/Dex	14(0)	11(1)	10(2)	10(2)	10(2)	8(2)	7(2)	7(2)	5(2)	5(2)	5(2)	3(2)	3(2)	2(2)	2(2)	2(2)	2(2)	2(2)	2(2)	2(2)	2(2)	1(2)	0(2)
Belamaf	29(0)	17(3)	13(4)	12(4)	10(4)	9(4)	8(4)	8(4)	8(4)	7(4)	6(4)	6(4)	4(4)	3(4)	2(4)	2(4)	1(4)	1(4)	1(4)	1(4)	1(4)	1(4)	0(4)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_os_tfi.sas 13MAR2023 10:05

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR)

Data as of 12SEP2022

Figure 4.096110
Graph of Kaplan-Meier Curves of OSDI Time to first Improvement
(Up to and including Last Follow-Up)
Item Score: Environmental Triggers



Number at Risk
(Number of Events)

Pom/Dex	14(0)	9(1)	9(1)	9(1)	9(1)	7(1)	6(1)	6(1)	5(1)	5(1)	4(1)	3(1)	3(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	1(1)	0(1)
Belamaf	29(0)	18(2)	12(5)	12(5)	10(5)	9(5)	9(5)	9(5)	7(5)	6(5)	5(5)	5(5)	4(5)	3(5)	2(5)	2(5)	1(5)	1(5)	1(5)	1(5)	1(5)	1(5)	0(5)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_os_tfi.sas 13MAR2023 10:05

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR)

Data as of 12SEP2022

Figure 4.093110
Graph of Kaplan-Meier Curves of OSDI Time to first Deterioration 1
(Up to and including Last Follow-Up)
Item Score: Total Score



Number at Risk
(Number of Events)

Pom/Dex	14(0)	11(2)	8(5)	7(6)	7(6)	5(8)	2(9)	2(9)	2(9)	2(9)	2(9)	2(9)	2(9)	1(9)	0(10)	0(10)	0(10)	0(10)	0(10)	0(10)	0(10)	0(10)	0(10)
Belamaf	29(0)	22(5)	13(12)	8(16)	8(16)	6(18)	5(19)	4(20)	3(20)	3(20)	1(21)	1(21)	1(21)	1(21)	1(21)	1(21)	1(21)	1(21)	1(21)	1(21)	1(21)	1(21)	0(21)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_os_tfd1.sas 13MAR2023 10:04

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR)

Data as of 12SEP2022

Figure 4.093110
Graph of Kaplan-Meier Curves of OSDI Time to first Deterioration 1
(Up to and including Last Follow-Up)
Item Score: Ocular Symptoms



Number at Risk
(Number of Events)

Pom/Dex	14(0)	13(0)	10(3)	10(3)	10(3)	8(5)	4(7)	4(7)	3(8)	3(8)	3(8)	3(8)	3(8)	2(8)	1(9)	1(9)	1(9)	1(9)	1(9)	1(9)	1(9)	0(9)	0(9)
Belamaf	29(0)	22(5)	15(10)	10(14)	10(14)	9(15)	7(17)	5(19)	4(19)	4(19)	2(20)	2(20)	2(20)	2(20)	2(20)	2(20)	2(20)	2(20)	2(20)	1(21)	1(21)	1(21)	0(21)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_os_tfd1.sas 13MAR2023 10:04

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR)

Data as of 12SEP2022

Figure 4.093110
Graph of Kaplan-Meier Curves of OSDI Time to first Deterioration 1
(Up to and including Last Follow-Up)
Item Score: Vision-related Function



Number at Risk
(Number of Events)

Pom/Dex	14(0)	11(2)	7(6)	6(7)	6(7)	5(8)	2(9)	2(9)	2(9)	2(9)	2(9)	2(9)	2(9)	1(9)	0(10)	0(10)	0(10)	0(10)	0(10)	0(10)	0(10)	0(10)	0(10)
Belamaf	29(0)	22(5)	12(13)	8(16)	8(16)	6(18)	5(19)	4(20)	3(20)	3(20)	1(21)	1(21)	1(21)	1(21)	1(21)	1(21)	1(21)	1(21)	1(21)	1(21)	1(21)	1(21)	0(21)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_os_tfd1.sas 13MAR2023 10:04

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR)

Data as of 12SEP2022

Figure 4.093110
Graph of Kaplan-Meier Curves of OSDI Time to first Deterioration 1
(Up to and including Last Follow-Up)
Item Score: Environmental Triggers



Number at Risk
(Number of Events)

Pom/Dex	14(0)	10(1)	8(3)	7(4)	7(4)	6(4)	4(4)	4(4)	4(4)	3(5)	3(5)	3(5)	3(5)	2(5)	1(6)	1(6)	1(6)	1(6)	1(6)	1(6)	1(6)	0(6)	0(6)
Belamaf	29(0)	20(7)	16(10)	12(13)	12(13)	11(14)	6(19)	3(22)	3(22)	3(22)	1(23)	1(23)	1(23)	1(23)	1(23)	1(23)	1(23)	1(23)	1(23)	1(23)	1(23)	1(23)	0(23)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_os_tfd1.sas 13MAR2023 10:04

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR)

Data as of 12SEP2022

Figure 4.094110
Graph of Kaplan-Meier Curves of OSDI Time to first Deterioration 2
(Up to and including Last Follow-Up)
Item Score: Total Score



Number at Risk
(Number of Events)

Pom/Dex	14(0)	10(2)	8(4)	7(5)	7(5)	5(7)	2(8)	2(8)	2(8)	2(8)	2(8)	1(8)	1(8)	0(8)	0(8)	0(8)	0(8)	0(8)	0(8)	0(8)	0(8)	0(8)	0(8)
Belamaf	29(0)	18(2)	8(7)	5(9)	5(9)	3(11)	3(11)	3(11)	2(11)	2(11)	1(11)	1(11)	1(11)	1(11)	1(11)	1(11)	1(11)	1(11)	1(11)	1(11)	1(11)	1(11)	0(11)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_os_tfd2.sas 13MAR2023 10:04

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR)

Data as of 12SEP2022

Figure 4.094110
Graph of Kaplan-Meier Curves of OSDI Time to first Deterioration 2
(Up to and including Last Follow-Up)
Item Score: Ocular Symptoms



Number at Risk
(Number of Events)

Pom/Dex	14(0)	12(0)	10(2)	10(2)	10(2)	7(4)	3(6)	3(6)	3(6)	3(6)	3(6)	2(6)	2(6)	1(6)	1(6)	1(6)	1(6)	1(6)	1(6)	1(6)	1(6)	0(6)	0(6)
Belamaf	29(0)	18(2)	10(5)	7(7)	7(7)	6(8)	5(8)	4(9)	3(9)	3(9)	2(9)	2(9)	2(9)	2(9)	1(9)	1(9)	1(9)	1(9)	1(9)	1(9)	1(9)	1(9)	0(9)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_os_tfd2.sas 13MAR2023 10:04

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR)

Data as of 12SEP2022

Figure 4.094110
Graph of Kaplan-Meier Curves of OSDI Time to first Deterioration 2
(Up to and including Last Follow-Up)
Item Score: Vision-related Function



Number at Risk
(Number of Events)

Pom/Dex	14(0)	10(2)	7(5)	6(6)	6(6)	5(7)	2(8)	2(8)	2(8)	2(8)	2(8)	1(8)	1(8)	0(8)	0(8)	0(8)	0(8)	0(8)	0(8)	0(8)	0(8)	0(8)	0(8)
Belamaf	29(0)	18(2)	7(8)	5(9)	5(9)	3(11)	3(11)	3(11)	2(11)	2(11)	1(11)	1(11)	1(11)	1(11)	1(11)	1(11)	1(11)	1(11)	1(11)	1(11)	1(11)	1(11)	0(11)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_os_tfd2.sas 13MAR2023 10:04

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR)

Data as of 12SEP2022

Figure 4.094110
Graph of Kaplan-Meier Curves of OSDI Time to first Deterioration 2
(Up to and including Last Follow-Up)
Item Score: Environmental Triggers



Number at Risk
(Number of Events)

Pom/Dex	14(0)	9(1)	8(2)	7(3)	7(3)	6(3)	4(3)	4(3)	4(3)	3(4)	2(4)	2(4)	2(4)	1(4)	1(4)	1(4)	1(4)	1(4)	1(4)	1(4)	1(4)	0(4)	0(4)
Belamaf	29(0)	15(5)	10(6)	8(7)	6(7)	4(7)	4(7)	2(9)	2(9)	2(9)	1(9)	1(9)	1(9)	1(9)	1(9)	1(9)	1(9)	1(9)	1(9)	1(9)	1(9)	1(9)	0(9)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_os_tfd2.sas 13MAR2023 10:04

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR)

Data as of 12SEP2022

Figure 4.097110
Graph of Kaplan-Meier Curves of OSDI Time to permanent Deterioration 1
(Up to and including End of Treatment)
Item Score: Total Score



Number at Risk
(Number of Events)

Pom/Dex	14(0)	13(0)	12(1)	12(1)	12(1)	10(1)	7(1)	6(2)	4(2)	4(2)	4(2)	3(2)	3(2)	2(2)	2(2)	2(2)	2(2)	2(2)	2(2)	2(2)	2(2)	1(2)	0(2)
Belamaf	29(0)	23(4)	14(6)	11(7)	10(7)	9(7)	7(9)	7(9)	7(9)	6(9)	4(10)	3(11)	2(12)	2(12)	1(12)	1(12)	1(12)	1(12)	1(12)	1(12)	1(12)	1(12)	0(12)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_os_pd1_eot.sas 14MAR2023 13:20

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR)

Data as of 12SEP2022

Figure 4.097110
Graph of Kaplan-Meier Curves of OSDI Time to permanent Deterioration 1
(Up to and including End of Treatment)
Item Score: Ocular Symptoms



Number at Risk
(Number of Events)

Pom/Dex	14(0)	13(0)	12(1)	12(1)	12(1)	10(1)	7(1)	7(1)	5(1)	5(1)	5(1)	3(1)	3(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	1(1)	0(1)
Belamaf	29(0)	23(4)	14(6)	11(7)	10(7)	9(7)	7(9)	7(9)	7(9)	6(9)	4(10)	4(10)	2(11)	2(11)	1(11)	1(11)	1(11)	1(11)	1(11)	1(11)	1(11)	1(11)	1(11)	0(11)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_os_pd1_eot.sas 14MAR2023 13:20

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR)

Data as of 12SEP2022

Figure 4.097110
Graph of Kaplan-Meier Curves of OSDI Time to permanent Deterioration 1
(Up to and including End of Treatment)
Item Score: Vision-related Function



Number at Risk
(Number of Events)

Pom/Dex	14(0)	13(0)	12(1)	12(1)	12(1)	10(1)	7(1)	7(1)	5(1)	5(1)	5(1)	3(1)	3(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	1(1)	0(1)
Belamaf	29(0)	23(4)	14(6)	11(7)	10(7)	9(7)	7(9)	6(10)	6(10)	5(10)	3(11)	3(11)	2(12)	2(12)	1(12)	1(12)	1(12)	1(12)	1(12)	1(12)	1(12)	1(12)	1(12)	0(12)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_os_pd1_eot.sas 14MAR2023 13:20

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR)

Data as of 12SEP2022

Figure 4.097110
Graph of Kaplan-Meier Curves of OSDI Time to permanent Deterioration 1
(Up to and including End of Treatment)
Item Score: Environmental Triggers



Number at Risk
(Number of Events)

Pom/Dex	14(0)	11(0)	10(1)	9(2)	9(2)	8(2)	6(2)	6(2)	5(2)	5(2)	4(2)	3(2)	3(2)	2(2)	2(2)	2(2)	2(2)	2(2)	2(2)	2(2)	2(2)	1(2)	0(2)
Belamaf	29(0)	22(4)	14(6)	11(7)	10(7)	9(7)	7(9)	7(9)	6(9)	5(9)	3(10)	3(10)	2(11)	2(11)	1(11)	1(11)	1(11)	1(11)	1(11)	1(11)	1(11)	1(11)	0(11)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_os_pd1_eot.sas 14MAR2023 13:20

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR)

Data as of 12SEP2022

Figure 4.098110
Graph of Kaplan-Meier Curves of OSDI Time to permanent Deterioration 2
(Up to and including End of Treatment)
Item Score: Total Score



Number at Risk
(Number of Events)

Pom/Dex	14(0)	12(0)	12(0)	12(0)	12(0)	10(0)	7(0)	6(1)	4(1)	4(1)	4(1)	3(1)	3(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	1(1)	0(1)
Belamaf	29(0)	19(1)	11(1)	9(1)	8(1)	7(1)	6(1)	6(1)	6(1)	5(1)	4(1)	3(2)	2(3)	2(3)	1(3)	1(3)	1(3)	1(3)	1(3)	1(3)	1(3)	1(3)	0(3)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_os_pd2_eot.sas 14MAR2023 13:20

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.098110
Graph of Kaplan-Meier Curves of OSDI Time to permanent Deterioration 2
(Up to and including End of Treatment)
Item Score: Ocular Symptoms



Number at Risk
(Number of Events)

Pom/Dex	14(0)	12(0)	12(0)	12(0)	12(0)	10(0)	7(0)	7(0)	5(0)	5(0)	5(0)	3(0)	3(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	1(0)	0(0)
Belamaf	29(0)	19(1)	11(1)	9(1)	8(1)	7(1)	6(1)	6(1)	6(1)	5(1)	4(1)	4(1)	2(2)	2(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	0(2)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_os_pd2_eot.sas 14MAR2023 13:20

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.098110
Graph of Kaplan-Meier Curves of OSDI Time to permanent Deterioration 2
(Up to and including End of Treatment)
Item Score: Vision-related Function



Number at Risk
(Number of Events)

Pom/Dex	14(0)	12(0)	12(0)	12(0)	12(0)	10(0)	7(0)	7(0)	5(0)	5(0)	5(0)	3(0)	3(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	1(0)	0(0)
Belamaf	29(0)	19(1)	11(1)	9(1)	8(1)	7(1)	6(1)	5(2)	5(2)	4(2)	3(2)	3(2)	2(3)	2(3)	1(3)	1(3)	1(3)	1(3)	1(3)	1(3)	1(3)	1(3)	0(3)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_os_pd2_eot.sas 14MAR2023 13:20

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.098110
Graph of Kaplan-Meier Curves of OSDI Time to permanent Deterioration 2
(Up to and including End of Treatment)
Item Score: Environmental Triggers



Number at Risk
(Number of Events)

Pom/Dex	14(0)	10(0)	10(0)	9(1)	9(1)	8(1)	6(1)	6(1)	5(1)	5(1)	4(1)	3(1)	3(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	1(1)	0(1)
Belamaf	29(0)	17(1)	10(1)	8(1)	7(1)	6(1)	6(1)	6(1)	5(1)	4(1)	3(1)	3(1)	2(2)	2(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	0(2)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_os_pd2_eot.sas 14MAR2023 13:20

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR)

Data as of 12SEP2022

Figure 4.099110
Graph of Kaplan-Meier Curves of OSDI Time to permanent Deterioration 1
(Up to and including Last Follow-Up)
Item Score: Total Score



Number at Risk
(Number of Events)

Pom/Dex	14(0)	13(0)	12(1)	12(1)	12(1)	11(1)	8(1)	7(2)	5(3)	5(3)	4(4)	4(4)	4(4)	3(4)	2(5)	2(5)	2(5)	2(5)	2(5)	2(5)	2(5)	1(5)	0(5)
Belamaf	29(0)	24(3)	20(5)	17(7)	17(7)	16(8)	11(13)	10(14)	9(14)	8(14)	6(15)	5(16)	3(17)	2(17)	2(17)	2(17)	2(17)	2(17)	2(17)	1(18)	1(18)	1(18)	0(18)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_os_pd1_lf.sas 14MAR2023 13:20

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR)

Data as of 12SEP2022

Figure 4.099110
Graph of Kaplan-Meier Curves of OSDI Time to permanent Deterioration 1
(Up to and including Last Follow-Up)
Item Score: Ocular Symptoms



Number at Risk
(Number of Events)

Pom/Dex	14(0)	13(0)	12(1)	12(1)	12(1)	11(1)	8(1)	8(1)	6(2)	6(2)	5(3)	4(3)	4(3)	3(3)	2(4)	2(4)	2(4)	2(4)	2(4)	2(4)	2(4)	2(4)	1(4)	0(4)
Belamaf	29(0)	24(3)	20(5)	17(7)	17(7)	16(8)	11(13)	10(14)	9(14)	8(14)	6(15)	6(15)	3(16)	2(16)	2(16)	2(16)	2(16)	2(16)	2(16)	1(17)	1(17)	1(17)	1(17)	0(17)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_os_pd1_lf.sas 14MAR2023 13:20

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR)

Data as of 12SEP2022

Figure 4.099110
Graph of Kaplan-Meier Curves of OSDI Time to permanent Deterioration 1
(Up to and including Last Follow-Up)
Item Score: Vision-related Function



Number at Risk
(Number of Events)

Pom/Dex	14(0)	13(0)	12(1)	12(1)	12(1)	11(1)	8(1)	8(1)	6(2)	6(2)	5(3)	4(3)	4(3)	3(3)	2(4)	2(4)	2(4)	2(4)	2(4)	2(4)	2(4)	2(4)	1(4)	0(4)
Belamaf	29(0)	24(3)	20(5)	17(7)	17(7)	16(8)	11(13)	9(15)	8(15)	7(15)	5(16)	5(16)	3(17)	2(17)	2(17)	2(17)	2(17)	2(17)	2(17)	1(18)	1(18)	1(18)	1(18)	0(18)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_os_pd1_lf.sas 14MAR2023 13:20

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR)

Data as of 12SEP2022

Figure 4.099110
Graph of Kaplan-Meier Curves of OSDI Time to permanent Deterioration 1
(Up to and including Last Follow-Up)
Item Score: Environmental Triggers



Number at Risk
(Number of Events)

Pom/Dex	14(0)	11(0)	10(1)	9(2)	9(2)	8(2)	6(2)	6(2)	6(2)	6(2)	5(3)	4(3)	4(3)	3(3)	2(4)	2(4)	2(4)	2(4)	2(4)	2(4)	2(4)	1(4)	0(4)
Belamaf	29(0)	24(3)	20(5)	16(8)	16(8)	15(9)	10(14)	9(15)	8(15)	7(15)	5(16)	5(16)	3(17)	2(17)	2(17)	2(17)	2(17)	2(17)	2(17)	1(18)	1(18)	1(18)	1(18)	0(18)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_os_pd1_lf.sas 14MAR2023 13:20

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR)

Data as of 12SEP2022

Figure 4.100110
Graph of Kaplan-Meier Curves of OSDI Time to permanent Deterioration 2
(Up to and including Last Follow-Up)
Item Score: Total Score



Number at Risk
(Number of Events)

Pom/Dex	14(0)	12(0)	12(0)	12(0)	12(0)	10(0)	7(0)	6(1)	4(1)	4(1)	4(1)	3(1)	3(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	1(1)	0(1)
Belamaf	29(0)	20(0)	15(0)	14(0)	12(0)	10(0)	9(0)	9(0)	8(0)	7(0)	6(0)	5(1)	3(2)	2(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	0(2)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_os_pd2_lf.sas 14MAR2023 13:21

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.100110
Graph of Kaplan-Meier Curves of OSDI Time to permanent Deterioration 2
(Up to and including Last Follow-Up)
Item Score: Ocular Symptoms



Number at Risk
(Number of Events)

Pom/Dex	14(0)	12(0)	12(0)	12(0)	12(0)	10(0)	7(0)	7(0)	5(0)	5(0)	5(0)	3(0)	3(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	1(0)	0(0)
Belamaf	29(0)	20(0)	15(0)	14(0)	12(0)	10(0)	9(0)	9(0)	8(0)	7(0)	6(0)	6(0)	3(1)	2(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	1(1)	0(1)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_os_pd2_lf.sas 14MAR2023 13:21

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR) **Data as of 12SEP2022**

Figure 4.100110
Graph of Kaplan-Meier Curves of OSDI Time to permanent Deterioration 2
(Up to and including Last Follow-Up)
Item Score: Vision-related Function



Number at Risk
(Number of Events)

Pom/Dex	14(0)	12(0)	12(0)	12(0)	12(0)	10(0)	7(0)	7(0)	5(0)	5(0)	5(0)	3(0)	3(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	2(0)	1(0)	0(0)
Belamaf	29(0)	20(0)	15(0)	14(0)	12(0)	10(0)	9(0)	8(1)	7(1)	6(1)	5(1)	5(1)	3(2)	2(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	0(2)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_os_pd2_lf.sas 14MAR2023 13:21

Protocol: 207495
Population: Safety (Fifth Line (5L+) plus TCR)

Data as of 12SEP2022

Figure 4.100110
Graph of Kaplan-Meier Curves of OSDI Time to permanent Deterioration 2
(Up to and including Last Follow-Up)
Item Score: Environmental Triggers



Number at Risk
(Number of Events)

Pom/Dex	14(0)	10(0)	10(0)	9(1)	9(1)	8(1)	6(1)	6(1)	5(1)	5(1)	4(1)	3(1)	3(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	2(1)	1(1)	0(1)
Belamaf	29(0)	19(0)	14(0)	12(1)	10(1)	8(1)	8(1)	8(1)	7(1)	6(1)	5(1)	5(1)	3(2)	2(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	1(2)	0(2)

PPD /arenv/arprod/gsk2857916/mid207495/postcsr_2022_01/drivers/f_pro_os_pd2_lf.sas 14MAR2023 13:21